{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "%matplotlib inline\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import gensim \n",
    "import sys\n",
    "from parse import *\n",
    "from prep_data import read_aact\n",
    "import re\n",
    "from collections import OrderedDict\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Christine: gender; location; medication\n",
    "# Charity: age; race; condition"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Approach 1:\n",
    "\n",
    "Leverages regexes (modified from `nlp.custom_tasks.RaceFinderTask`)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def compile_gender_regex():\n",
    "    \n",
    "    str_sep = r'(\\s-\\s|-\\s|\\s-|\\s)'\n",
    "    str_word = r'\\b[-a-z.\\d]+'\n",
    "    str_punct = r'[,.\\s]*'\n",
    "    str_words = r'(' + str_word + str_punct + r'){0,6}'\n",
    "    str_category = r'\\b(woman|women|female|girl'                      +\\\n",
    "               r'man|men|male|boy)'\n",
    "    \n",
    "    str_gender1 = r'(\\brace:?\\s*)' + r'(?P<category>' + str_category + r')'\n",
    "    regex_gender1 = re.compile(str_gender1, re.IGNORECASE)\n",
    "    str_gender2 = r'(?P<category>' + str_category + r')' + str_punct    +\\\n",
    "            str_words \n",
    "    regex_gender2 = re.compile(str_gender2, re.IGNORECASE)\n",
    "    str_gender3 =  str_punct + str_words + r'(?P<category>' +\\\n",
    "            str_category + r')'\n",
    "    regex_gender3 = re.compile(str_gender3, re.IGNORECASE)\n",
    "    REGEXES = [regex_gender1, regex_gender2, regex_gender3]\n",
    "\n",
    "    return REGEXES\n",
    "     "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(0, 12, 25, 'men')"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def find_gender(gender_regexes, sentence_list):\n",
    "\n",
    "    result_list = []\n",
    "\n",
    "    found_match = False\n",
    "    for i in range(len(sentence_list)):\n",
    "        s = sentence_list[i]\n",
    "        for regex in gender_regexes:\n",
    "            match = regex.search(s)\n",
    "            if match:\n",
    "                match_text = match.group('category')\n",
    "        \n",
    "                start = match.start()\n",
    "                end   = match.end()\n",
    "                result = (i, start, end, match_text)\n",
    "                result_list.append(result)\n",
    "                found_match = True\n",
    "\n",
    "    if len(result_list) > 0:\n",
    "        return result_list[0]\n",
    "    else:\n",
    "        return ''\n",
    "\n",
    "\n",
    "gender_regexes = compile_gender_regex()\n",
    "find_gender(gender_regexes, [\"15 year old men and women\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Approach 2:\n",
    "\n",
    "Leverages substring search "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1, 0, 1]"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def find_gender(single_study_inclusion_criteria):\n",
    "    \n",
    "    male_terms = [\"man\", \"men\", \"male\", \"boy\", \"boys\"]\n",
    "    female_terms = [\"woman\", \"women\", \"female\", \"girl\", \"girls\", \"pregnant\", \"menopausal\", \"postmenopausal\"]\n",
    "\n",
    "    contains_female_term = False\n",
    "    contains_male_term = False\n",
    "    \n",
    "    male_results = OrderedDict()\n",
    "    female_results = OrderedDict()\n",
    "    \n",
    "    results = OrderedDict({\"male_results\":{}, \"female_results\":{}, \"gender_boolean\":{}})\n",
    "    \n",
    "    for i, criteria in enumerate(single_study_inclusion_criteria.split(\"\\n\")): \n",
    "           \n",
    "        criteria = criteria.lower().replace(\"human\", \"person\")\n",
    "        \n",
    "        male_results[i]  = {\"term\":[], \"start_index\":[]}\n",
    "        female_results[i]  = {\"term\":[], \"start_index\":[]}\n",
    "        \n",
    "        male_results[i][\"term\"] = [male_term for male_term in male_terms for word in criteria.split() if len(word) <= len(male_term)]\n",
    "        male_results[i][\"start_index\"] = [word.find(male_term) for male_term in male_terms for word in criteria.split() if len(word) <= len(male_term)]\n",
    "        \n",
    "        \n",
    "        #print(male_results[i])\n",
    "        \n",
    "        female_results[i][\"term\"] = [female_term for female_term in female_terms for word in criteria.split() if len(word) <= len(female_term)]\n",
    "        female_results[i][\"start_index\"] = [word.find(female_term) for female_term in female_terms for word in criteria.split() if len(word) <= len(female_term)]\n",
    "        \n",
    "        male_results[i][\"male_boolean\"] = 1 if 0 in male_results[i]['start_index']  else 0\n",
    "        female_results[i][\"female_boolean\"] = 1 if 0 in female_results[i]['start_index']  else 0\n",
    " \n",
    "    \n",
    "    contains_male_term = int(np.any([male_results[x][\"male_boolean\"] for x in male_results.keys()]))\n",
    "    contains_female_term = int(np.any([female_results[x][\"female_boolean\"] for x in female_results.keys()]))\n",
    "    any_gender_mention = int(contains_male_term or contains_female_term)\n",
    "    \n",
    "    return [contains_male_term, contains_female_term, any_gender_mention]\n",
    "    \n",
    "    #return  male_results, female_results, contains_male_term, contains_female_term, any_gender_mention\n",
    "\n",
    "\n",
    "def find_gender_boolean(single_study_inclusion_criteria):\n",
    "    mr, fr, cm, cf, gm = find_gender(single_study_inclusion_criteria)\n",
    "    return gm \n",
    "\n",
    "def find_male_boolean(single_study_inclusion_criteria):\n",
    "    mr, fr, cm, cf, gm = find_gender(single_study_inclusion_criteria)\n",
    "    return cm\n",
    "\n",
    "def find_female_boolean(single_study_inclusion_criteria):\n",
    "    mr, fr, cm, cf, gm = find_gender(single_study_inclusion_criteria)\n",
    "    return cf\n",
    "    \n",
    "result = find_gender(\"Inclusion Criteria:\\n\" + \\\n",
    "\"Patients must have a diagnosis of cancer of any histologic type.\\n\" +\\\n",
    "          \"Patients must have a Karnofsky performance status great or equal to 70%.\\n\" +\\\n",
    "        \"All patients must sign informed consent approved by the Committee on the Use of man human\\n\" +\\\n",
    "             \"Subjects at the University of Minnesota\")\n",
    "\n",
    "\n",
    "result"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Goal 1: \n",
    "\n",
    "Develop a query and a model for each primitive; output = {0,1} whether the inclusion criteria statement in question mentions (and, by extension, restricts on) the primitive in question. Note that a single clinical trial will generally include > 1 criteria statement. Run against MIMIC. Use either manual review and/or regex-based queries as ground truth to train model(s) on. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6795\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>study_id</th>\n",
       "      <th>inclusion</th>\n",
       "      <th>exclusion</th>\n",
       "      <th>gender</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00000105</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients mus...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  Pregnant or ...</td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>N/A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00000106</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients are...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>65 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00000107</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Resting bloo...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>17 Years</td>\n",
       "      <td>60 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00000108</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Postmenopaus...</td>\n",
       "      <td></td>\n",
       "      <td>Female</td>\n",
       "      <td>50 Years</td>\n",
       "      <td>65 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00000102</td>\n",
       "      <td>Inclusion Criteria:\\n          -  diagnosed wi...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  history of l...</td>\n",
       "      <td>Both</td>\n",
       "      <td>14 Years</td>\n",
       "      <td>35 Years</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      study_id                                          inclusion  \\\n",
       "0  NCT00000105  Inclusion Criteria:\\n          -  Patients mus...   \n",
       "1  NCT00000106  Inclusion Criteria:\\n          -  Patients are...   \n",
       "2  NCT00000107  Inclusion Criteria:\\n          -  Resting bloo...   \n",
       "3  NCT00000108  Inclusion Criteria:\\n          -  Postmenopaus...   \n",
       "4  NCT00000102  Inclusion Criteria:\\n          -  diagnosed wi...   \n",
       "\n",
       "                                           exclusion  gender   age_min  \\\n",
       "0  Exclusion Criteria:\\n          -  Pregnant or ...    Both  18 Years   \n",
       "1                                                       Both  18 Years   \n",
       "2                                                       Both  17 Years   \n",
       "3                                                     Female  50 Years   \n",
       "4  Exclusion Criteria:\\n          -  history of l...    Both  14 Years   \n",
       "\n",
       "    age_max  \n",
       "0       N/A  \n",
       "1  65 Years  \n",
       "2  60 Years  \n",
       "3  65 Years  \n",
       "4  35 Years  "
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = read_aact()\n",
    "df = pd.DataFrame(data)\n",
    "df.columns = ['study_id', 'inclusion', 'exclusion', 'gender', 'age_min', 'age_max']\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 313,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>study_id</th>\n",
       "      <th>inclusion</th>\n",
       "      <th>exclusion</th>\n",
       "      <th>gender</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "      <th>ic_mentions_gender</th>\n",
       "      <th>gender_regex_bool</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00000105</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients mus...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  Pregnant or ...</td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>N/A</td>\n",
       "      <td>1</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00000106</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients are...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>65 Years</td>\n",
       "      <td>1</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00000107</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Resting bloo...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>17 Years</td>\n",
       "      <td>60 Years</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00000108</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Postmenopaus...</td>\n",
       "      <td></td>\n",
       "      <td>Female</td>\n",
       "      <td>50 Years</td>\n",
       "      <td>65 Years</td>\n",
       "      <td>1</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00000102</td>\n",
       "      <td>Inclusion Criteria:\\n          -  diagnosed wi...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  history of l...</td>\n",
       "      <td>Both</td>\n",
       "      <td>14 Years</td>\n",
       "      <td>35 Years</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      study_id                                          inclusion  \\\n",
       "0  NCT00000105  Inclusion Criteria:\\n          -  Patients mus...   \n",
       "1  NCT00000106  Inclusion Criteria:\\n          -  Patients are...   \n",
       "2  NCT00000107  Inclusion Criteria:\\n          -  Resting bloo...   \n",
       "3  NCT00000108  Inclusion Criteria:\\n          -  Postmenopaus...   \n",
       "4  NCT00000102  Inclusion Criteria:\\n          -  diagnosed wi...   \n",
       "\n",
       "                                           exclusion  gender   age_min  \\\n",
       "0  Exclusion Criteria:\\n          -  Pregnant or ...    Both  18 Years   \n",
       "1                                                       Both  18 Years   \n",
       "2                                                       Both  17 Years   \n",
       "3                                                     Female  50 Years   \n",
       "4  Exclusion Criteria:\\n          -  history of l...    Both  14 Years   \n",
       "\n",
       "    age_max  ic_mentions_gender gender_regex_bool  \n",
       "0       N/A                   1                    \n",
       "1  65 Years                   1                    \n",
       "2  60 Years                   0                    \n",
       "3  65 Years                   1                    \n",
       "4  35 Years                   0                    "
      ]
     },
     "execution_count": 313,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Apply regex-based function\n",
    "df['gender_regex_bool'] = df['inclusion'].apply(lambda x: find_gender(gender_regexes,[criteria for criteria in x.split(\"\\n\")]))\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>study_id</th>\n",
       "      <th>inclusion</th>\n",
       "      <th>exclusion</th>\n",
       "      <th>gender</th>\n",
       "      <th>age_min</th>\n",
       "      <th>age_max</th>\n",
       "      <th>ic_mentions_male</th>\n",
       "      <th>ic_mentions_female</th>\n",
       "      <th>ic_mentions_gender</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00000105</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients mus...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  Pregnant or ...</td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>N/A</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00000106</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Patients are...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>65 Years</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00000107</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Resting bloo...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>17 Years</td>\n",
       "      <td>60 Years</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00000108</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Postmenopaus...</td>\n",
       "      <td></td>\n",
       "      <td>Female</td>\n",
       "      <td>50 Years</td>\n",
       "      <td>65 Years</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00000102</td>\n",
       "      <td>Inclusion Criteria:\\n          -  diagnosed wi...</td>\n",
       "      <td>Exclusion Criteria:\\n          -  history of l...</td>\n",
       "      <td>Both</td>\n",
       "      <td>14 Years</td>\n",
       "      <td>35 Years</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT00000104</td>\n",
       "      <td>Inclusion Criteria:\\n          -  Pregnant mot...</td>\n",
       "      <td></td>\n",
       "      <td>Female</td>\n",
       "      <td>N/A</td>\n",
       "      <td>N/A</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00000117</td>\n",
       "      <td>To be eligible, patients must have a history o...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>N/A</td>\n",
       "      <td>50 Years</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00000118</td>\n",
       "      <td>All patients must have had AIDS as defined by ...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>N/A</td>\n",
       "      <td>N/A</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT00000119</td>\n",
       "      <td>Women and men 18 years or older with a documen...</td>\n",
       "      <td>Exclusion criteria include corneal pathology o...</td>\n",
       "      <td>Both</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>N/A</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00000120</td>\n",
       "      <td>The study included male and female infants del...</td>\n",
       "      <td></td>\n",
       "      <td>Both</td>\n",
       "      <td>N/A</td>\n",
       "      <td>1 Year</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      study_id                                          inclusion  \\\n",
       "0  NCT00000105  Inclusion Criteria:\\n          -  Patients mus...   \n",
       "1  NCT00000106  Inclusion Criteria:\\n          -  Patients are...   \n",
       "2  NCT00000107  Inclusion Criteria:\\n          -  Resting bloo...   \n",
       "3  NCT00000108  Inclusion Criteria:\\n          -  Postmenopaus...   \n",
       "4  NCT00000102  Inclusion Criteria:\\n          -  diagnosed wi...   \n",
       "5  NCT00000104  Inclusion Criteria:\\n          -  Pregnant mot...   \n",
       "6  NCT00000117  To be eligible, patients must have a history o...   \n",
       "7  NCT00000118  All patients must have had AIDS as defined by ...   \n",
       "8  NCT00000119  Women and men 18 years or older with a documen...   \n",
       "9  NCT00000120  The study included male and female infants del...   \n",
       "\n",
       "                                           exclusion  gender   age_min  \\\n",
       "0  Exclusion Criteria:\\n          -  Pregnant or ...    Both  18 Years   \n",
       "1                                                       Both  18 Years   \n",
       "2                                                       Both  17 Years   \n",
       "3                                                     Female  50 Years   \n",
       "4  Exclusion Criteria:\\n          -  history of l...    Both  14 Years   \n",
       "5                                                     Female       N/A   \n",
       "6                                                       Both       N/A   \n",
       "7                                                       Both       N/A   \n",
       "8  Exclusion criteria include corneal pathology o...    Both  18 Years   \n",
       "9                                                       Both       N/A   \n",
       "\n",
       "    age_max  ic_mentions_male  ic_mentions_female  ic_mentions_gender  \n",
       "0       N/A                 0                   0                   0  \n",
       "1  65 Years                 0                   0                   0  \n",
       "2  60 Years                 0                   0                   0  \n",
       "3  65 Years                 0                   1                   1  \n",
       "4  35 Years                 0                   0                   0  \n",
       "5       N/A                 0                   1                   1  \n",
       "6  50 Years                 0                   0                   0  \n",
       "7       N/A                 0                   0                   0  \n",
       "8       N/A                 1                   1                   1  \n",
       "9    1 Year                 1                   1                   1  "
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Apply string search-based function\n",
    "df[['ic_mentions_male', 'ic_mentions_female','ic_mentions_gender']] = df.apply(lambda row: pd.Series(find_gender(row['inclusion'])), axis=1)\n",
    "df.head(n=10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "24\n",
      "An eligible male or female must have been age 3 years or older (adults were included) and\n",
      "        must have had esotropia that occurred at age 6 months or older, with no history of\n",
      "        previous eye muscle surgery.\n",
      "25\n",
      "Men and women with uncontrolled intraocular pressure greater than 21 mm Hg in one or both\n",
      "        eyes despite maximal tolerated therapy and who were aphakic or had undergone previous\n",
      "        filtering surgery were eligible to participate.\n",
      "27\n",
      "Men and women eligible for the study must be age 21 or older, have primary choroidal\n",
      "        melanoma in only one eye, and have no evidence of metastatic disease. Accurate estimation\n",
      "        of tumor thickness by echography must also be possible.\n",
      "28\n",
      "Men and nonpregnant women between the ages of 40 and 80 with IOP greater than or equal to\n",
      "        24 mm Hg but less than or equal to 32 mm Hg in at least one eye and IOP greater than or\n",
      "        equal to 21 but less than or equal to 32 mm Hg in the fellow eye, as well as normal visual\n",
      "        fields and optic discs are eligible for the trial. Patients presenting with best-corrected\n",
      "        visual acuity worse than 20/40 in either eye, previous intraocular surgery, a\n",
      "        life-threatening or debilitating disease, secondary causes of elevated IOP, angle-closure\n",
      "        glaucoma or anatomically narrow angles, other diseases that can cause visual field loss,\n",
      "        background diabetic retinopathy, optic disc abnormalities that can produce visual field\n",
      "        loss or obscure the interpretation of the optic disc, or unwillingness to undergo random\n",
      "        assignment are excluded from the trial.\n",
      "30\n",
      "Men and women age 50 years or older, with acute NAION and visual symptoms for 14 days or\n",
      "        less since the onset of symptoms, and visual acuity worse than or equal to 20/64 were\n",
      "        eligible for randomization.\n",
      "31\n",
      "Boys must have been between 6 and 12 years of age; girls between 6 and 11 years of age.\n",
      "        All children must have had at least 0.5 diopters of myopia in both eyes, near-point\n",
      "        esophoria, at least 20/25 acuity in each eye, and 40 seconds of stereopsis and must have\n",
      "        been free of ocular disease or systemic disease that may have altered refraction. All\n",
      "        subjects were willing to wear bifocal spectacle lenses for 30 months.\n",
      "32\n",
      "All men and women had 2 to 8 diopters of simple myopia and were correctable to 20/20 or\n",
      "        better with glasses or contact lenses. All patients had the stability of their myopia\n",
      "        documented by previous records. Patients were at least 21 years of age and lived in the\n",
      "        metropolitan area of the study centers. Each patient agreed to have surgery on one eye and\n",
      "        to wait 1 year for surgery on the other eye. Patients with systemic diseases that might\n",
      "        affect corneal wound healing and patients with high corneal astigmatism were excluded from\n",
      "        the study.\n",
      "35\n",
      "Inclusion Criteria:\n",
      "          -  Memory complaints and memory difficulties which are verified by an informant.\n",
      "          -  Abnormal memory function documented by scoring below the education adjusted cutoff on\n",
      "             the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory\n",
      "             Scale - Revised (the maximum score is 25): a) less than or equal to 8 for 16 or more\n",
      "             years of education, b) less than or equal to 4 for 8-15 years of education, c) less\n",
      "             than or equal to 2 for 0-7 years of education.\n",
      "          -  Mini-Mental Exam score between 24 and 30 (inclusive) (Exceptions may be made for\n",
      "             subjects with less than 8 years of education at the discretion of the project\n",
      "             director.).\n",
      "          -  Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5.\n",
      "          -  General cognition and functional performance sufficiently preserved such that a\n",
      "             diagnosis of Alzheimer's disease cannot be made by the site physician at the time of\n",
      "             the screening visit.\n",
      "          -  No significant cerebrovascular disease: Modified Hachinski score of less than or\n",
      "             equal to 4.\n",
      "          -  Age between 55 and 90 (inclusive).\n",
      "          -  Permitted medications stable for at least 1 month prior to screening. In particular:\n",
      "             a) Subjects may take stable doses of antidepressants lacking significant\n",
      "             anticholinergic side effects (if they are not currently depressed and do not have a\n",
      "             history of major depression within the past 2 years). b) Estrogen replacement therapy\n",
      "             is permissible. c) Ginkgo biloba is permissible, but discouraged.\n",
      "          -  Hamilton Depression rating scale score of less than or equal to 12 on the 17-item\n",
      "             scale.\n",
      "          -  Informant is available who has frequent contact with the subject (e.g. an average of\n",
      "             10 hours per week or more), agrees to monitor administration of study drug, observe\n",
      "             for adverse events, and accompany the subject to all clinic visits for the duration\n",
      "             of the protocol.\n",
      "          -  CT or MRI scans within 12 months prior to screening without evidence of infection,\n",
      "             infarction, or other focal lesions and without clinical symptoms suggestive of\n",
      "             intervening neurological disease. A lacune in a non-critical brain area which is not\n",
      "             believed to contribute to the subject's cognitive impairment is permissible.\n",
      "          -  Adequate visual and auditory acuity to allow neuropsychological testing.\n",
      "          -  Good general health with no additional diseases expected to interfere with the study.\n",
      "          -  Normal B12, RPR, and Thyroid Function Tests or without any clinically significant\n",
      "             abnormalities that would be expected to interfere with the study.\n",
      "          -  ECG without clinically significant abnormalities that would be expected to interfere\n",
      "             with the study.\n",
      "          -  Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be\n",
      "             two years post-menopausal or surgically sterile).\n",
      "          -  Agreement not to take other vitamin supplements (including Vitamin E), multivitamins,\n",
      "             other than those provided by the study.\n",
      "        \n",
      "36\n",
      "Inclusion Criteria:\n",
      "          -  Are aged 55-85 years, inclusive. Subjects older than 85 years may be eligible to\n",
      "             participate, with approval of the designated study medical monitor.\n",
      "          -  Are male or female without child-bearing potential (i.e., surgically sterilized [via\n",
      "             bilateral tubal ligation,bilateral oophorectomy, or hysterectomy], at least one year\n",
      "             postmenopausal, or using adequate birth control).\n",
      "          -  Are cooperative, able to ingest oral medication, and willing to complete all aspects\n",
      "             of the study.\n",
      "          -  Will provide written informed consent prior to their participation in the study.\n",
      "          -  Show evidence of mild cognitive impairment (MCI) by meeting all of the following\n",
      "             criteria: Global CDR score = 0.5, NYU Delayed Paragraph Recall less than 9, 17-item\n",
      "             HAM-D score less than 13, and HAM-D Item 1 (depressed mood) score =1.\n",
      "          -  Have a friend or family member who is willing to participate in the study as an\n",
      "             informant. The informant must see the subject at least once a week for several hours\n",
      "             and be available to accompany the subject to the screening and baseline visits, and\n",
      "             at a minimum, be accessible by telephone for other scheduled visits.\n",
      "        \n",
      "43\n",
      "Inclusion criteria:\n",
      "          -  Age 13 years or older\n",
      "          -  Diagnosis of AIDS according to current Centers for Disease Control and Prevention\n",
      "             (CDC) definition\n",
      "          -  Diagnosis of active CMV retinitis by a SOCA-certified ophthalmologist (involvement of\n",
      "             any zone or amount of retina is allowed)\n",
      "          -  Best corrected visual acuity of 20/100 or better in at least one eye\n",
      "          -  At least one lesion 750 cells/µL or greater\n",
      "          -  Platelet count 50,000 cells/µL or greater\n",
      "          -  Willingness and ability, with the assistance of a caregiver if necessary to comply\n",
      "             with treatment and follow up procedures\n",
      "          -  Willingness of all men and women of childbearing potential to practice adequate birth\n",
      "             control to prevent pregnancies during the study and for 3 months afterwards\n",
      "          -  Collection of all baseline data within 5 days prior to randomization\n",
      "          -  Signed consent statement\n",
      "        \n",
      "47\n",
      "Men and women between the ages of 35 and 80 with open-angle glaucoma that was not\n",
      "        successfully controlled by medication were eligible for enrollment.\n",
      "48\n",
      "Men and women eligible for the SRT had diabetes for 1 to 15 years and were between ages 18\n",
      "        and 56 at the time of enrollment. They had begun taking insulin before their 41st\n",
      "        birthday. Their hemoglobin A1c value was within the diabetic range. On retinal\n",
      "        examination, they showed no evidence of or only very mild retinopathy, with no more than\n",
      "        five microaneurysms per eye. Women were postmenopausal, sterile, or had an IUD in place.\n",
      "50\n",
      "Women's Health Study:\n",
      "        A participant must have met all of the following criteria:\n",
      "        (a) female; (b) aged 45 years or older; (c) postmenopausal or with no intention of\n",
      "        becoming pregnant; (d) no reported personal history of cardiovascular disease, cancer\n",
      "        (other than non-melanoma skin cancer), gout, peptic ulcer, chronic renal or liver disease,\n",
      "        or other serious illness precluding participation; (e) no reported history of serious side\n",
      "        effects to the study treatments; (f) not currently taking aspirin, aspirin containing\n",
      "        medication, or nonsteroidal anti-inflammatory drugs (NSAIDs) more than 1 day per week or,\n",
      "        if so doing, willing to forego use of these medications; (g) not currently taking\n",
      "        individual supplements of vitamin E or beta carotene more than 1 day per week; (h) not\n",
      "        currently taking anticoagulants or corticosteroids.\n",
      "        Women's Antioxidant Cardiovascular Study:\n",
      "        Potentially eligible female health professionals for WACS were identified from the pool of\n",
      "        respondents to the Women's Health Study initial mailing and must have met the following\n",
      "        criteria:\n",
      "        (a) female; (b) date of birth before January 1, 1955; (c) a reported history of myocardial\n",
      "        infarction (MI), stroke (CVA), angina pectoris (AP), coronary artery bypass grafting\n",
      "        (CABG), percutaneous transluminal angioplasty (PCTA), transient ischemic attack (TIA),\n",
      "        carotid endarterectomy (CEA), or peripheral artery surgery (PAS); (d) no history of cancer\n",
      "        (except non-melanoma skin cancer) within the past 10 years and no active liver disease or\n",
      "        cirrhosis; (e) pregnancy physiologically impossible due to menopause (natural or surgical)\n",
      "        or tubal ligation, or the participant does not intend to become pregnant in the future as\n",
      "        indicated on the initial WHS questionnaire; (f) no current use of a vitamin K-depleting\n",
      "        anticoagulant agent (e.g., Coumadin). Individuals taking aspirin or other NSAIDs were not\n",
      "        excluded.\n",
      "52\n",
      "Patients eligible for CAPT can be either male or female and meet the following criteria:\n",
      "        Age at least 50 years old\n",
      "        Vision in each eye must measure 20/40 or better.\n",
      "        At least 10 large drusen in each eye\n",
      "        Available for follow-up examinations for 5 years after enrollment\n",
      "        Final eligibility is determined through a detailed eye examination by a CAPT-certified\n",
      "        ophthalmologist.\n",
      "53\n",
      "Men and women between the ages of 18 and 70 years with moderate or severe nonproliferative\n",
      "        diabetic retinopathy or mild proliferative retinopathy in both eyes, with no previous\n",
      "        photocoagulation treatment, and with visual acuity of 20/40 or better (20/200 or better if\n",
      "        macular edema is present) were eligible for this study.\n",
      "55\n",
      "Men and women ages 18 through 79 diagnosed with diabetes mellitus and who had\n",
      "        neovascularization on the optic nerve head (NVD) were eligible. NVD in one or both eyes of\n",
      "        each patient had to be greater than or equal to DRS Standard Photograph 10A. NVD was\n",
      "        defined as new vessels on the surface of the retina, further forward in the vitreous\n",
      "        cavity over the disc, or within one disc diameter of the disc in any direction. Patient's\n",
      "        ocular media must have been clear enough for fundus photography, which allowed the extent\n",
      "        of neovascularization on the optic nerve head to be assessed. (If vitreous hemorrhage or\n",
      "        other media opacity prevented adequate visualization of the neovascularization, it would\n",
      "        greatly impair the ability to assess the effect of photocoagulation.) Another requirement\n",
      "        for patient eligibility was the presence of an area of at least three quadrants of the\n",
      "        retina in which full argon or krypton laser panretinal photocoagulation could be placed.\n",
      "        (Vitreous hemorrhage and/or traction retinal detachment that interfered with treatment was\n",
      "        less than one quadrant in extent.)\n",
      "56\n",
      "Men and women eligible for the vitreous hemorrhage group had at least one eye with recent\n",
      "        severe vitreous hemorrhage (within 5 months) and visual acuity of 5/200 or less. Patients\n",
      "        eligible for the \"very severe proliferative retinopathy with useful vision\" group had\n",
      "        extensive active fibrovascular proliferations and visual acuity of 10/200 or better.\n",
      "60\n",
      "Common Eligibility Criteria for the Argon, Krypton, and Foveal Studies:\n",
      "        To be eligible, men and women must have been experiencing visual symptoms attributable to\n",
      "        the macular lesion, such as decreased visual acuity or Amsler grid distortion, at the time\n",
      "        of entry into the study. They also must have had visible, well-demarcated\n",
      "        hyperfluorescence characteristic of classic choroidal neovascularization on fluorescein\n",
      "        angiography. AMD patients were 50 years of age or older and had drusen visible in the\n",
      "        macula of at least one eye. POH patients were at least 18 years old and had at least one\n",
      "        characteristic histo spot in one or both eyes. INVM patients were at least 18 years old\n",
      "        and had no evidence of AMD, POH, angioid streaks, high myopia, diabetic retinopathy, or\n",
      "        any other condition that could be the cause of the neovascularization. In particular, INVM\n",
      "        patients had neither drusen greater than MPS Standard Photograph No. 1.1 nor histo spots\n",
      "        in either eye.\n",
      "        Additional Patient Eligibility Criteria for the Argon Study:\n",
      "        Each patient had a visible serous detachment of the sensory retina with a diffuse area of\n",
      "        leakage, discrete choroidal neovascularization outside the fovea (200-2,500 microns from\n",
      "        the center of the FAZ), and visual acuity of 20/100 or better in the study eye.\n",
      "        Additional Patient Eligibility Criteria for the Krypton Study:\n",
      "        All patients had a neovascular lesion consisting of neovascularization and possibly blood\n",
      "        and/or pigment that extended into the FAZ. The posterior border of CNV could extend as\n",
      "        close as 1 micron to the FAZ center. Visual acuity of the study eye was 20/400 or better.\n",
      "        Additional Patient Eligibility Criteria for the Foveal Study:\n",
      "        Only patients with AMD were eligible for this study. Fluorescein angiography of the\n",
      "        eligible eye had to show evidence of a leaking choroidal neovascular membrane, some part\n",
      "        of which extended under the center of the FAZ, or a neovascular lesion consisting of an\n",
      "        old laser treatment scar and contiguous leaking neovascularization within 150 microns of\n",
      "        the center of the FAZ. New, never-treated subfoveal lesions were less than four disc areas\n",
      "        in size. Recurrent lesions were less than six disc areas in size, including the old\n",
      "        treatment scar and new neovascularization. Best-corrected visual acuity was no better than\n",
      "        20/40 and no worse than 20/320.\n",
      "61\n",
      "Inclusion Criteria:\n",
      "          -  Women and men aged 65-90 who have not received hormone replacement for the last three\n",
      "             months.\n",
      "        \n",
      "62\n",
      "Inclusion Criteria:\n",
      "          -  Healthy women 65 or older with a family history of memory problems not currently on\n",
      "             estrogen.\n",
      "        \n",
      "69\n",
      "Inclusion Criteria:\n",
      "          -  Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen\n",
      "             replacement therapy, who have had a hysterectomy, and who are in stable general\n",
      "             health.\n",
      "        \n",
      "79\n",
      "Inclusion Criteria:\n",
      "        Male or female subjects, aged 21-45 yrs inclusive, with a smoking history of at least 1\n",
      "        pack of cigarettes daily for at least 1 year. Subject must be in good health as verified\n",
      "        by medical history, screening exam, and screening laboratory tests. Subject must provide\n",
      "        written informed consent to participate in the study and be motivated to stop smoking for\n",
      "        a short term.\n",
      "        \n",
      "80\n",
      "Inclusion Criteria:\n",
      "        Males/Females between the ages of 20-40. History of smoked cocaine use on the avg. of at\n",
      "        least 2 times/week over a 6 month period. Have currently used at least 1 g of cocaine\n",
      "        within a 4-6 hr period. Current history of good health, normal serum albumin levels and\n",
      "        normal QTc intervals. Nonreactive for HIV. No participation in any of our studies for the\n",
      "        past 6 months. For females: not pregnant as determined by pregnancy screening nor breat\n",
      "        feeding, and using acceptable birth control methods (e.g. birth control pills, diaphragm,\n",
      "        condoms plus foam).\n",
      "        \n",
      "81\n",
      "Inclusion Criteria:\n",
      "        Male/Female between 20 and 55. History of smoked or intravenous cocaine use on the average\n",
      "        of at least once a week over a 6 month period. current history of good health and normal\n",
      "        EKG. Not pregnant as determined by pregnancy screening nor breast feeding, using\n",
      "        acceptable birth control methods (e.g. birth control pills diaphragm, condoms plus foam)\n",
      "        \n",
      "82\n",
      "Inclusion Criteria:\n",
      "        Male/Female ages 20-55. History of smoked or intravenous cocaine use on the average of at\n",
      "        least once a week over a six month period. Current history of good health and normal EKG.\n",
      "        Not pregnant as determined by pregnancy screening nor breat feeding and using acceptable\n",
      "        birth control methods (e.g. birth control pills diaphragm, condoms, plus foam) during the\n",
      "        study.\n",
      "        \n",
      "88\n",
      "Inclusion Criteria- Subject must:\n",
      "          -  Exhibit cocaine and opiate dependence through a DSM-IV diagnosis as determined by\n",
      "             SCID.\n",
      "          -  Be between 18 and 45 years old\n",
      "          -  Women must agree to use contraception\n",
      "          -  Have an EKG that has been confirmed by a cardiologist\n",
      "          -  Give a cocaine positive urine during screening - Present with evidence of opiate\n",
      "             withdrawal\n",
      "        \n",
      "94\n",
      "Inclusion Criteria:\n",
      "        Female subjects aged 21-45 years with a smoking history of at least 20 cigarettes daily\n",
      "        for at least 1 year. In good health as verified by medical history, screening examination,\n",
      "        and screening laboratory tests. Not pregnant as determined by pregnancy screening nor\n",
      "        breast feeding, and using acceptable birth control methods other than hormonal\n",
      "        contraceptives.\n",
      "        \n",
      "136\n",
      "Inclusion Criteria:\n",
      "          -  Have sensorineural (nerve/inner ear) hearing loss of at least 30 dB in each ear,\n",
      "             which has rapidly progressed.\n",
      "          -  Are in good general health.\n",
      "          -  Are sterile or use contraception (if a woman of child-bearing age).\n",
      "          -  Are able to speak and understand English or Spanish.\n",
      "        \n",
      "140\n",
      "Men and women between 1 and 11 years post-CABG. Patients had two completely independent\n",
      "        saphenous vein grafts that were patent. Patients had an LDL-cholesterol between 130 and\n",
      "        175 with plasma triglycerides below 300 mg/dl.\n",
      "141\n",
      "Men and women with ventricular fibrillation who had survived an out-of-hospital cardiac\n",
      "        arrest not associated with a Q-wave acute myocardial infarction.\n",
      "142\n",
      "Men and women with multivessel coronary artery disease whose symptoms were refractory to\n",
      "        medical treatment.\n",
      "150\n",
      "Inclusion Criteria:\n",
      "          -  Women at least 60 years of age.\n",
      "          -  Good general health.\n",
      "          -  Willingness to participate in this 3.5 year study.\n",
      "          -  Ability to give informed consent.\n",
      "          -  Ability to live independently and travel to the research center for visits (we will\n",
      "             provide transportation on a limited basis).\n",
      "          -  Spine bone mineral density (BMD) (L1-4) T-score between -1.0 and -2.5, or a hip\n",
      "             T-score between -1.0 and -2.5. A T-score of -1.0 is equal to a bone mass of one\n",
      "             standard deviation below the mean peak bone mass in healthy young adult women.\n",
      "        \n",
      "157\n",
      "Men and women with coronary heart disease in the native coronary arteries. Patients were\n",
      "        symptomatic or had 50 percent or greater stenosis as defined by coronary angiography.\n",
      "        Patients had not undergone prior angioplasty.\n",
      "158\n",
      "Men and women with a diastolic blood pressure of 80 to 89 mm Hg and alcohol intake of 21\n",
      "        drinks or more per week.\n",
      "159\n",
      "Pregnant women with chronic hypertension.\n",
      "160\n",
      "Men and women with higher than optimal diastolic blood pressure or with Stage 1 (mild)\n",
      "        hypertension.\n",
      "161\n",
      "Men and women over the age of 18 who have stable, documented coronary artery disease\n",
      "        (CAD). Evidence of CAD was by any one of: history of MI; greater than 50% stenosis in any\n",
      "        coronary artery; or history of coronary revascularization procedure.\n",
      "164\n",
      "Men and women with controlled hypertension.\n",
      "165\n",
      "Women over the age of 18 who have suspected ischemic heart disease.\n",
      "166\n",
      "Postmenopausal women, up to age 86, with angiographically documented coronary artery\n",
      "        disease of at least 15 percent, but no more than 75 percent occlusion.\n",
      "167\n",
      "Men and women patients with known or suspected sites of serious infection if core\n",
      "        temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers,\n",
      "        respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o\n",
      "169\n",
      "Men and women suspected of having a pulmonary embolism and who met the criteria to undergo\n",
      "        angiography.\n",
      "170\n",
      "Boy and girl infants weighing less than 2000 g. who required mechanical ventilation within\n",
      "        24 hours of birth and had been treated for less than 12 hours with conventional mechanical\n",
      "        ventilation before randomization.\n",
      "176\n",
      "Men and women with clinical heart failure, sinus rhythm, and an ejection fraction less\n",
      "        than or equal to 45 percent.\n",
      "177\n",
      "Men and women who were cigarette smokers and between the ages of 35 and 60.\n",
      "180\n",
      "Premature boy and girl infants with birth weight less than 1,251 grams, gestational age\n",
      "        less than 33 weeks, and postnatal age three to fourteen days, who continue to require\n",
      "        mechanical ventilation with an emphasis on enrollment at three days.\n",
      "182\n",
      "Boys and girls who met the CDC criteria for Kawasaki Syndrome. Subjects were excluded if\n",
      "        they presented themselves to the participating centers after the tenth day of illness.\n",
      "183\n",
      "Men and women with low HDL and/or high triglyceride levels and/or high insulin levels.\n",
      "184\n",
      "Men and women who had recently undergone carotid endarterectomy.\n",
      "189\n",
      "Men and women coronary heart disease/myocardial infarction patients, hospitalized for\n",
      "        enzyme-documented MI and who are depressed and/or have low social support. Patients must\n",
      "        be enrolled with 28 days of the index MI.\n",
      "195\n",
      "Men and women hypertensive patients, ages 55 and above. A total of 36 percent were\n",
      "        diabetics.\n",
      "198\n",
      "Boy and girl premature infants with patent ductus arteriosus. Birth weight of 1,750 grams\n",
      "        or less. Admitted to participating institution within first 24 hours of life.\n",
      "202\n",
      "Men and women with myocardial infarction and cardiogenic shock.\n",
      "204\n",
      "Cohort of pre-adolescent American Indian boys and girls followed in grades 3-5.\n",
      "208\n",
      "Men and women with documented ventricular tachycardia and those resuscitated from sudden\n",
      "        death.\n",
      "216\n",
      "Postmenopausal women, ages 45 to 64. One third of the subjects had had a hysterectomy.\n",
      "218\n",
      "Men and women with symptomatic or asymptomatic peripheral arterial disease.\n",
      "221\n",
      "Postmenopausal women with established coronary atherosclerosis.\n",
      "222\n",
      "Men and women with acute MI or unstable angina.\n",
      "224\n",
      "Inclusion Criteria:\n",
      "          -  Patients must have:\n",
      "        HIV infection. Ability to give informed consent. Ability to participate in an outpatient\n",
      "        study.\n",
      "          -  Allowed: Short course antimicrobials.\n",
      "          -  Not breast-feeding\n",
      "          -  Abstinence or agree to use barrier methods of birth control / contraception during\n",
      "             the study\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  CD4 100 to 500 cells/mm3 (100 - 200 - 300 - 400 - 500).\n",
      "          -  Creatinine > 1.6 mg/dl\n",
      "          -  Hemoglobin >= 12 g/dl\n",
      "          -  Platelet Count >= 100000 /mm3\n",
      "        \n",
      "232\n",
      "Boy and girl preterm infants 24-29 weeks of gestational age and 500-1400 grams\n",
      "        birthweight.\n",
      "233\n",
      "Men aand women with angiographically documented coronary artery disease, ischemia on both\n",
      "        stress (exercise) testing and 48-hour ambulatory electrocardiogram monitoring, and who\n",
      "        were amenable to revascularization.\n",
      "234\n",
      "Inclusion Criteria:\n",
      "          -  Healthy women\n",
      "          -  No previous history of cardiovascular disease or cancer\n",
      "          -  No contraindications to aspirin or vitamin E\n",
      "235\n",
      "Men and women patients with documented coronary artery disease, ejection fraction less\n",
      "        than or equal to 40 percent, and nonsustained asymptomatic ventricular tachycardia.\n",
      "238\n",
      "Men and women under age 76. Patients had acute myocardial infarction.\n",
      "240\n",
      "Boy and girl infants, birth to 3 years, born to mothers who were hepatitis B surface\n",
      "        antigen carriers.\n",
      "241\n",
      "Men & women with VF, VT with syncope, or VT without syncope, but with ejection fraction\n",
      "        less than or equal to .40 & systolic blood pressure less than 80 mm Hg, chest pain , or\n",
      "        near syncope.\n",
      "246\n",
      "Male and female fetuses and infants; pregnant women with anticipated premature delivery\n",
      "        and gestational age between 26 and 37 weeks.\n",
      "247\n",
      "Men and women with hypertension. Diastolic blood pressure equal to or above 95 mm Hg and\n",
      "        90 mm Hg, respectively for home and clinic readings.\n",
      "249\n",
      "Boy and girl pediatric oncology patients, at least two years off treatment, with some\n",
      "        cardiac dysfunction, but not congestive heart failure, after receiving anthracyclines.\n",
      "        Patients were not on digoxin, diuretics, or vasodilators for heart failure.\n",
      "250\n",
      "Men and women with acute respiratory distress syndrome.\n",
      "        Inclusion Criteria: ECMO ENTRY CRITERIA (PaO2 < 50 mm Hg -REPEATED THREE TIMES):\n",
      "        Rapid entry: 2 hours at fraFIO2=1.00 and PEEP>5 cm H2O with PaCO2=30-45 mmHg\n",
      "        Slow entry: 12 hours at fraction of inspired oxygen (FIO2)>0.60 and positive\n",
      "        end-expiratory pressure (PEEP)>5 cm H2O with PaCO2=30-45 mmHg and right to Left shunt\n",
      "        fraction >0.30\n",
      "        \n",
      "251\n",
      "Men and women with uncomplicated stable chronic obstructive pulmonary disease.\n",
      "255\n",
      "Inclusion Criteria:\n",
      "          -  Limited to early problem drinkers (i.e., those with no more than mild alcohol\n",
      "             dependence).\n",
      "          -  Have an average weekly alcohol consumption of greater than or equal to 24 standard\n",
      "             drinks for men and 18 standard drinks for women.\n",
      "          -  Able to read English at the eighth grade or higher level and show no evidence of\n",
      "             significant cognitive impairment.\n",
      "          -  Willing to provide a collateral informant for interviews regarding the patient's\n",
      "             drinking during the study.\n",
      "          -  A woman of child-bearing potential must be non-lactating, practicing a reliable\n",
      "             method of birth control, and have a negative pregnancy test prior to initiation of\n",
      "             treatment.\n",
      "          -  Willing to provide a signed informed consent to participate in the study.\n",
      "        \n",
      "258\n",
      "Sedentary men and women, ages 50 to 65. Women were postmenopausal and not taking hormone\n",
      "        replacement therapy. All subjects were free from, but at increased risk for, coronary\n",
      "        heart disease.\n",
      "263\n",
      "Men and women patients at least 50 years of age with coronary heart disease documented by\n",
      "        angiography and a left ventricular ejection fraction of 40 percent or more.\n",
      "265\n",
      "Men and women myocardial infarction patients.\n",
      "266\n",
      "Nulliparous, normotensive, pregnant women.\n",
      "267\n",
      "Men and women with low HDL cholesterol, with at least one 50% stenotic coronary lesion or\n",
      "        three 30% stenotic coronary lesions. Women range in age from 35 to less than 68 and men\n",
      "        from 35 to less than 63.\n",
      "272\n",
      "Postmenopausal women with angiographically-documented coronary disease. Approximately 70\n",
      "        percent minority\n",
      "274\n",
      "Men and women with sick sinus syndrome.\n",
      "275\n",
      "Asthmatic pregnant women.\n",
      "280\n",
      "Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary\n",
      "        artery lumen as revealed by angiography. (Cholesterol-Lowering Agent Trial).\n",
      "        Men and women with angiographically-documented coronary heart disease (Fish Oil Tr\n",
      "282\n",
      "Inclusion Criteria:\n",
      "          -  Men and women\n",
      "          -  13 years of age or older\n",
      "          -  ARDS or risk factors for ARDS (patients will be considered at risk if they are\n",
      "             critically ill and have trauma, sepsis, shock, pneumonia, inhalation injury, drug\n",
      "             overdose, pancreatitis, or hypertransfusion)\n",
      "284\n",
      "Women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66\n",
      "        percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or\n",
      "        more, breast examination and mammogram without evidence of cancer, no hormonal therapy\n",
      "        within three months prior to randomization, and no history of deep venous thrombosis or\n",
      "        pulmonary embolism. .\n",
      "285\n",
      "Men and women with documented primary or secondary Raynaud's syndrome.\n",
      "289\n",
      "Postmenopausal women, aged 50 to 69 years, who consumed 38 percent or more of total\n",
      "        calories as fat at baseline.\n",
      "290\n",
      "Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol\n",
      "        between the 60th and 90th percentiles.\n",
      "293\n",
      "Inclusion Criteria:\n",
      "          -  Women in good health\n",
      "          -  Dietary calcium-to-protein ratio (in mg:g, as assessed by 7-day food diary) does not\n",
      "             exceed 13\n",
      "        \n",
      "296\n",
      "Boy and girl infants, up to three months of age, with transposition of the great arteries\n",
      "        with or without septal defect.\n",
      "304\n",
      "Inclusion Criteria:\n",
      "          -  Women 45-64 years of age.\n",
      "          -  Upper tertile of sex-, age- and race-adjusted norms for body mass index.\n",
      "          -  Unilateral knee OA at baseline.\n",
      "          -  Postmenopausal status or otherwise incapable of childbearing.\n",
      "          -  Ability to ambulate (move about) independently without assistive devices.\n",
      "          -  Ability to read and write in English or Spanish and give informed consent.\n",
      "        \n",
      "306\n",
      "Inclusion Criteria:\n",
      "          -  Apparently healthy boys and girls\n",
      "          -  BMI < 30kg/m2\n",
      "        \n",
      "308\n",
      "Inclusion Criteria:\n",
      "          -  9- and 10-year-old premenarchal girls (girls who have not started their periods).\n",
      "        \n",
      "327\n",
      "Inclusion Criteria:\n",
      "          -  Female\n",
      "          -  Able to visit Seattle based clinic 9 times\n",
      "          -  Meet ACR criteria for FMS\n",
      "        \n",
      "341\n",
      "Inclusion Criteria:\n",
      "          -  Female\n",
      "          -  Unequivocal diagnosis of SLE\n",
      "          -  Inactive disease or stable on 0.5 mg/kg/day or less of prednisone\n",
      "          -  Chemical evidence of menopause or have stopped periods for at least 6 months\n",
      "        \n",
      "349\n",
      "Inclusion Criteria:\n",
      "          -  History of either opportunistic infection and/or Kaposi's sarcoma, and/or serologic\n",
      "             evidence of past infection with HIV. Ability to give informed consent.\n",
      "          -  Allowed but discouraged: Antiretroviral medication. Immunomodulating medication.\n",
      "             Psychoactive medication.\n",
      "          -  Not breast-feeding\n",
      "          -  Abstinence or agree to use barrier methods of birth control / contraception during\n",
      "             the study\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  CD4 >= 200 cells/mm3 (200 - 300 - 400 - 500 - 600 - 700 - 800 plus).\n",
      "          -  Creatinine <= 1.6 mg/dl\n",
      "          -  Hemoglobin >= 12 g/dl\n",
      "          -  Platelet Count >= 100000 /mm3\n",
      "        \n",
      "352\n",
      "Men and women with ventricular premature depolarization six days to two years after the\n",
      "        start of myocardial infarction.\n",
      "356\n",
      "Men and women, ages 35 to 71, with chest pain of between 15 minutes and 6 hours duration,\n",
      "        systolic blood pressure of more than 80 mm Hg and less than 200 mm Hg, and a diastolic\n",
      "        blood pressure of less than 120 mm Hg. (Phase I).\n",
      "        Men and women with m\n",
      "362\n",
      "Inclusion Criteria:\n",
      "          -  Lumbar spine or hip BMD T-score less than or equal to minus 2.0\n",
      "          -  Postmenopausal at least 5 years\n",
      "          -  Fully ambulatory\n",
      "          -  Able to give informed consent\n",
      "        \n",
      "364\n",
      "Inclusion Criteria:\n",
      "          -  Female\n",
      "          -  Unequivocal diagnosis of SLE\n",
      "          -  Inactive disease or be stable on 0.5 mg/kg/day or less of predisone\n",
      "          -  Must be between 18 and 39 years old if non-smoker\n",
      "          -  Must be between 18 and 35 years old if smoker\n",
      "        \n",
      "365\n",
      "Men and women with a systolic blood pressure of less than 145 mm Hg and diastolic blood\n",
      "        pressure of less than 85 mm Hg on single-drug therapy.\n",
      "366\n",
      "Elderly men and women with atrial fibrillation and other risk factors for stroke.\n",
      "369\n",
      "Inclusion Criteria\n",
      "          1. Men and women with Class III and Class IV congestive heart failure\n",
      "          2. Between the ages of 18 and 72\n",
      "        \n",
      "415\n",
      "Men and women with angiographically demonstrated coronary artery disease.\n",
      "434\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  FDA-approved anti-pneumocystis and antifungal prophylactic or suppressive regimens.\n",
      "          -  Acyclovir for up to 3 weeks intermittently.\n",
      "        Patients must:\n",
      "          -  Meet current guidelines for receiving prescription zidovudine.\n",
      "          -  Have written informed consent from both subject and parent or guardian if under 18.\n",
      "             Be capable of understanding and giving informed consent. Women and minorities are\n",
      "             actively encouraged to participate.\n",
      "        \n",
      "437\n",
      "Male and female thrombocytopenic patients, ages 15 and over, newly diagnosed with acute\n",
      "        myelogenous leukemia (AML) and undergoing chemotherapy.\n",
      "456\n",
      "HIV-positive, asymptomatic, pregnant women with CD4 concentrations of 500 or less and\n",
      "        their infants.\n",
      "462\n",
      "Study 1: Approximately 12 to 18 adult men and non-pregnant women with iron-loading anemias\n",
      "        in the United States and 12 to 18 similar patients in Thailand each year.\n",
      "        Study 2: Approximately 6 to 12 well-chelated patients with transfusion-dependence.\n",
      "474\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication: Strongly recommended:\n",
      "          -  Pyrimethamine (50 mg) and folinic acid (15 mg) weekly in patients receiving dapsone\n",
      "             who have CD4 count < 100 cells/mm3 and are toxoplasmosis seropositive.\n",
      "        Patients must have:\n",
      "          -  Working diagnosis of HIV infection.\n",
      "          -  CD4 count <= 200 cells/mm3 or <= 15 percent of total lymphocyte count at any time in\n",
      "             the past OR a history of PCP.\n",
      "          -  History of intolerance of trimethoprim and/or sulfonamides that required permanent\n",
      "             discontinuation.\n",
      "        NOTE:\n",
      "          -  Pregnant patients are eligible at the clinician's discretion.\n",
      "        Prior Medication:\n",
      "        Allowed:\n",
      "          -  Prior PCP prophylaxis.\n",
      "        \n",
      "477\n",
      "Postmenopausal women who had undergone coronary artery bypass graft.\n",
      "478\n",
      "Men and women with end-stage emphysema.\n",
      "485\n",
      "Postmenopausal women with unstable angina.\n",
      "494\n",
      "Men and women with moderate or acute, severe, aplastic anemia.\n",
      "495\n",
      "Men with with LDL-cholesterol of 125-189 mg/dL and HDL-cholesterol below or equal to 44\n",
      "        mg/dL, and postmenopausal women, age 45 to 64, with LDL-cholesterol of 125 to 209 mg/dL\n",
      "        and HDL-cholesterol below or equal to 59 mg/dL.\n",
      "501\n",
      "1. Men and women > 45 years.\n",
      "          2. Women of child-bearing potential must agree to use two forms of contraception or\n",
      "             abstinence, and undergo monthly pregnancy testing.\n",
      "          3. No inhaled nicotine for >= 6 months and cotinine < 20 ng/mL.\n",
      "          4. Best FEV1 >= 25% of predicted and <= 80% of predicted on initial screening, using\n",
      "             Hankinson's predicted values.\n",
      "          5. DLCO <= 80% predicted on initial screening, using Crapo's predicted values (corrected\n",
      "             for hemoglobin).\n",
      "          6. Spiral CT scan evidence of emphysema: visual impression of at least 10% emphysema on\n",
      "             a fixed section of the total lung, and at least 10% of the lung with < -910 HU.\n",
      "          7. PCO2 < 45 mm Hg, and willingness to undergo bronchoscopy if FEV1 >= 30% of predicted.\n",
      "508\n",
      "Postmenopausal women, ages 45 to 74.\n",
      "514\n",
      "Postmenopausal women ages 50 to 79.\n",
      "531\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed if clinically indicated:\n",
      "          -  Recombinant erythropoietin (rEPO) and G-CSF.\n",
      "        Allowed for symptomatic treatment of mild study drug toxicity:\n",
      "          -  Antipyretics and analgesics (ibuprofen).\n",
      "          -  Antihistamines (diphenhydramine HCl).\n",
      "          -  Terfenadine or astemizole (but not allowed with concomitant antifungal or macrolide\n",
      "             use).\n",
      "          -  Systemic steroids.\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count <= 250 cells/mm3 OR history or presence of thrush.\n",
      "          -  No history of confirmed or probable pneumocystosis.\n",
      "        NOTE:\n",
      "          -  Pregnant women are not excluded, but safety issues should be discussed with patient\n",
      "             prior to enrollment.\n",
      "          -  This study is appropriate for prisoner participation.\n",
      "          -  Coenrollment in ongoing ACTG antiretroviral studies is permitted provided no new\n",
      "             study drugs are added to the patient's drug regimen for 4 weeks before or after\n",
      "             initiation of SMX/TMP.\n",
      "        Prior Medication:\n",
      "        Allowed:\n",
      "          -  Prior aerosolized pentamidine and dapsone for primary PCP prophylaxis.\n",
      "        \n",
      "553\n",
      "Inclusion Criteria\n",
      "        Women may be eligible for this study if they:\n",
      "          -  Are HIV-positive.\n",
      "          -  Are at least 13 years old (need consent of parent or guardian if under 18).\n",
      "          -  Are unable to or refuse to take ZDV or the woman's doctor says that she should take\n",
      "             d4T.\n",
      "          -  Are 14 to 34 weeks pregnant.\n",
      "        \n",
      "559\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed for occasional use (chronic use is permitted only if clinician deems that\n",
      "        medication can be discontinued in the event of overlapping toxicity):\n",
      "          -  CNS active agents, such as alcohol, narcotics (i.e., morphine, codeine, meperidine),\n",
      "             barbiturates, benzodiazepines, tricyclic antidepressants, phenothiazines, sedating\n",
      "             antihistamines, or over-the-counter sleeping aids.\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count 200 - 500 cells/mm3.\n",
      "          -  No active opportunistic infection requiring systemic therapy within the past 14 days.\n",
      "          -  NOTE: Women must be post-menopausal or provide written documentation of surgical\n",
      "             sterilization, and sexually active men must use a barrier method of contraception,\n",
      "             beginning 4 weeks prior to study entry and continuing until 4 weeks following end of\n",
      "             treatment.\n",
      "        PER AMENDMENT 8/2/96:\n",
      "          -  Been on stable licensed antiretroviral treatment for 60 days prior to study entry or\n",
      "             must not have received any antiretroviral medications for 60 days prior to study\n",
      "             entry.\n",
      "        Prior Medication:\n",
      "        Required:\n",
      "          -  Patients must have been on stable licensed antiretroviral treatment for 60 days prior\n",
      "             to study entry or must not have received any antiretroviral medications for 60 days\n",
      "             prior to study entry.\n",
      "        \n",
      "563\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  PCP prophylaxis with pentamidine, TMP/SMX, or dapsone (if appropriate).\n",
      "          -  Clotrimazole troches or nystatin oral suspension for oral candidiasis.\n",
      "          -  Acyclovir (up to 1000 mg/day) for herpes lesions.\n",
      "          -  Supportive care as deemed necessary for toxicities .\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count <= 500 cells/mm3.\n",
      "          -  No active opportunistic infections.\n",
      "          -  Consent of parent, guardian, or person with power of attorney, if less than 18 years\n",
      "             of age.\n",
      "        NOTE:\n",
      "          -  Participation of women in the study is encouraged.\n",
      "        \n",
      "587\n",
      "Inclusion Criteria\n",
      "        A woman may be eligible for this study if:\n",
      "          -  She is HIV-positive.\n",
      "          -  She is at least 34 weeks pregnant.\n",
      "          -  She has a history of at least 4 weeks of continuous oral ZDV during her current\n",
      "             pregnancy and tolerated it well.\n",
      "          -  She has given consent for her newborn to participate in this study. (The father must\n",
      "             also give consent if he is available after reasonable attempts to contact him. A\n",
      "             woman under 18 needs the consent of a parent or legal guardian for her and her infant\n",
      "             to participate.)\n",
      "        \n",
      "592\n",
      "Inclusion Criteria:\n",
      "        You may be eligible for this study if you:\n",
      "          -  Are between 18 and 65 years of age.\n",
      "          -  Are a resident of Long Island or greater NY metropolitan area.\n",
      "          -  Are fluent in English.\n",
      "          -  Have a history of Lyme Disease.\n",
      "          -  Have completed antibiotic treatment for Lyme Disease 6 or more months before starting\n",
      "             the study.\n",
      "          -  Have severe fatigue.\n",
      "          -  Are not pregnant or planning to be pregnant.\n",
      "        \n",
      "594\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Antiretroviral therapy.\n",
      "          -  Coenrollment in a therapeutic protocol if begun at least 30 days following the week\n",
      "             20 immunization.\n",
      "          -  Routine immunizations if given more than 1 week before or after study vaccine.\n",
      "        Patients must be:\n",
      "          -  > 37 weeks gestation and < 72 hours of age born to HIV-infected women.\n",
      "          -  NOT born to women who received either passive or active immunotherapy during\n",
      "             pregnancy.\n",
      "          -  NOT breast-fed.\n",
      "          -  NOT born to women who are hepatitis B surface antigen positive.\n",
      "          -  Receiving AZT at study entry (except infants enrolled in ACTG 076).\n",
      "        NOTE:\n",
      "          -  Parent or guardian must provide informed consent and be willing to comply with study\n",
      "             requirements.\n",
      "        \n",
      "598\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Stable maintenance or prophylaxis therapy for opportunistic infection, if such\n",
      "             therapy was administered for at least 30 days prior to study entry.\n",
      "          -  Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis.\n",
      "          -  Fluconazole for mucosal candidiasis or cryptococcosis.\n",
      "          -  Acyclovir (up to 1.0 g/day).\n",
      "          -  Dapsone.\n",
      "          -  Ketoconazole.\n",
      "          -  Quinolones.\n",
      "          -  Tetracycline.\n",
      "          -  Vitamins and herbal therapies.\n",
      "          -  Antibiotics as clinically indicated.\n",
      "          -  Systemic corticosteroids for < 21 days for acute problems.\n",
      "          -  Regularly prescribed medications.\n",
      "        Patients must have:\n",
      "          -  HIV positivity by ELISA confirmed by Western blot.\n",
      "          -  CD4 count < 500 cells/mm3 within 30 days prior to study entry.\n",
      "          -  No active opportunistic infections requiring treatment (patients on stable\n",
      "             maintenance and prophylaxis therapy for opportunistic infections for at least 30 days\n",
      "             are permitted).\n",
      "        NOTE:\n",
      "          -  Enrollment of women is encouraged.\n",
      "        Prior Medication:\n",
      "        Allowed:\n",
      "          -  Prior stable maintenance or prophylaxis therapy for opportunistic infection, if\n",
      "             administered for at least 30 days prior to study entry.\n",
      "        \n",
      "602\n",
      "Participants must meet the following criteria:\n",
      "          -  HIV-negative, sexually active women living in social and sexual proximity to men at\n",
      "             high risk for acquiring HIV infection.\n",
      "          -  Able to speak English, Spanish, or Creole.\n",
      "          -  Living in the geographic area surrounding Kings County Hospital in Brooklyn, New\n",
      "             York. (Hospital-based and community-based recruitment sites will be utilized.)\n",
      "        Personal history of parenteral drug use by self-report or urine test. Heterosexual contact\n",
      "        with men at high risk for HIV infection.\n",
      "607\n",
      "Inclusion Criteria\n",
      "        You may be eligible for this study if you:\n",
      "          -  Are an HIV-positive woman over 13 years old (need consent if under 18).\n",
      "          -  Have lost weight over the past 12 months.\n",
      "          -  Are able to eat almost enough to maintain your current weight.\n",
      "          -  Agree to practice abstinence or use effective methods of birth control.\n",
      "          -  Are on a stable anti-HIV drug regimen or have not been on any anti-HIV drug regimen\n",
      "             for the past 30 days.\n",
      "        \n",
      "619\n",
      "Inclusion Criteria\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count <= 200 cells/mm3 OR a history of prior PCP.\n",
      "          -  No active pneumocystosis. Patients or their guardians must sign informed consent.\n",
      "             Pregnant patients are eligible at the clinician's discretion. Patients who do not\n",
      "             meet required laboratory values may be eligible at the discretion of the clinician.\n",
      "        \n",
      "633\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Antiretroviral therapy.\n",
      "          -  Intermittent acetaminophen, aspirin, and ibuprofen.\n",
      "        Patients must have:\n",
      "          -  CD4 count >= 250 cells/mm3 within 3 months prior to study entry.\n",
      "          -  Received a stable dose of methadone for a minimum of 30 days prior to study entry.\n",
      "          -  Negative urine toxicology screen (except for methadone or methadone metabolites)\n",
      "             within 14 days prior to study entry.\n",
      "          -  Reasonably good health.\n",
      "          -  Life expectancy of at least 6 months.\n",
      "          -  Ability and willingness to comply with protocol requirements.\n",
      "        NOTE:\n",
      "          -  Patients will be recruited from the methadone maintenance treatment program currently\n",
      "             administered by Addiction Research and Treatment Corporation. Enrollment of women is\n",
      "             encouraged.\n",
      "        NOTE:\n",
      "          -  Patients who are currently enrolled in CPCRA treatment and prophylaxis trials are\n",
      "             eligible for this study provided they have been permanently removed from study drug\n",
      "             on the other protocol.\n",
      "        Prior Medication:\n",
      "        Required:\n",
      "          -  Stable dose of methadone for a minimum of 30 days prior to study entry.\n",
      "        Allowed:\n",
      "          -  Prior antiretroviral therapy (dose should be stable for 14 days prior to study\n",
      "             entry).\n",
      "        \n",
      "645\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Women - Medications as required for obstetrical management of HIV infection (e.g.,\n",
      "             acyclovir, ketoconazole, isoniazid, antibiotics, or other antiretroviral therapy if\n",
      "             intolerant or failing on AZT), unless specifically excluded.\n",
      "          -  Infants - Drug treatment for signs of drug withdrawal (phenobarbital, chlorpromazine,\n",
      "             tincture of opium, paregoric or Valium).\n",
      "          -  Infants - Medications as indicated for management of an HIV-exposed infant (e.g.,\n",
      "             hepatitis B vaccine, syphilis treatment, Pneumocystis carinii pneumonia prophylaxis).\n",
      "        Patients must have:\n",
      "          -  Documented HIV infection.\n",
      "          -  Been receiving AZT during current pregnancy for medical indications.\n",
      "          -  Gestational age between 20 and 30 weeks.\n",
      "          -  Intention to carry pregnancy to term.\n",
      "          -  Available venous access (placement of central line or Hickman catheter not indicated\n",
      "             for study purposes).\n",
      "          -  Willingness to be followed by a participating site for study duration.\n",
      "        NOTE:\n",
      "          -  Father of fetus (if available after a reasonable attempt to contact him) must also\n",
      "             provide informed consent.\n",
      "        \n",
      "649\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed in all patients:\n",
      "          -  Antacids if administered more than 2 hours before or after study drug.\n",
      "        Allowed in isoniazid patients:\n",
      "          -  Anticonvulsant therapy if blood levels are monitored.\n",
      "        Allowed in levofloxacin patients:\n",
      "          -  Acceptable medications other than antacids if administered at least 2 hours before or\n",
      "             1 hour after study drug.\n",
      "          -  Anticonvulsant therapy, theophylline, or warfarin if doses are monitored.\n",
      "        Patients must have:\n",
      "          -  Presumptive active pulmonary TB.\n",
      "          -  No clinical evidence of central nervous system or miliary tuberculosis.\n",
      "        NOTE:\n",
      "          -  Both HIV-positive and HIV-negative patients are eligible.\n",
      "        NOTE:\n",
      "          -  Pregnant women may be enrolled in the isoniazid cohort only.\n",
      "        \n",
      "650\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed for infants:\n",
      "          -  Treatment for signs of drug withdrawal (e.g., phenobarbital, chlorpromazine, tincture\n",
      "             of opium, paregoric, or Valium).\n",
      "          -  Treatment for nonserious conditions (e.g., syphilis treatment, hepatitis B vaccine).\n",
      "          -  All essential supportive treatment for conditions that are nonlife threatening as\n",
      "             deemed by the on-site pediatrician.\n",
      "          -  Acetaminophen.\n",
      "          -  Standard immunizations.\n",
      "          -  Allowed for women:\n",
      "          -  All medications/treatments as required for normal OB care of HIV+ women, except as\n",
      "             noted under exclusions.\n",
      "          -  Pneumocystis prophylaxis as indicated.\n",
      "          -  Topical steroids. Parenteral and oral steroids for 6 or fewer days.\n",
      "        Concurrent Treatment:\n",
      "        Allowed for pregnant woman:\n",
      "        Blood transfusion for anemia (hemoglobin less than 7 g/dl).\n",
      "        Allowed for infant:\n",
      "        - Blood transfusions for anemia except if attributed to study drug.\n",
      "        Patients must:\n",
      "          -  Have HIV infection.\n",
      "          -  Intend to carry pregnancy to term.\n",
      "          -  Be willing to be followed by a participating ACTG center for duration of the study.\n",
      "          -  Be able to provide informed consent (if available, father of the fetus must also\n",
      "             provide informed consent).\n",
      "          -  Infants may enroll simultaneously in other pediatric protocols after completing the\n",
      "             initial 6 weeks of study treatment.\n",
      "          -  Inclusion age for women is 13 years old or more or IRB local age of consent.\n",
      "          -  Inclusion age for infants is 0 to 20 months.\n",
      "        \n",
      "673\n",
      "Inclusion Criteria\n",
      "        Men and women may be eligible for this study if they:\n",
      "          -  Are HIV positive.\n",
      "        Women may be eligible for this study if they:\n",
      "          -  Have regular periods and a normal gynecological exam, (including a Pap smear and\n",
      "             mammogram).\n",
      "          -  Enter the study between Days 10 and 18 of the first day of their last period.\n",
      "          -  Are willing to use either the Pill or Depo-Provera as birth control.\n",
      "          -  Have a negative pregnancy test within 14 days prior to study.\n",
      "        \n",
      "682\n",
      "INCLUSION CRITERIA\n",
      "        Women of any age with clinical stage II breast cancer who met the following criteria:\n",
      "        Patients with stage II breast cancer will include primary tumor less than or equal to 5 cm\n",
      "        in size with axillary lymph nodes which are clinically ([N0 or N1] [T1N1, T2N0, T2N1]).\n",
      "        Patients will be staged according to the 1986 AJCC TMM classification.\n",
      "        Patients with bilateral breast cancer will be eligible provided at least one tumor is\n",
      "        invasive and classified as stage I or II, and neither breast is stage III.\n",
      "        Histologic sections of the breast tumor must be classified as an invasive primary breast\n",
      "        neoplasm of epithelial origin.\n",
      "        Patients must be geographically accessible for follow-up and willing to return for the\n",
      "        follow-up at the NCI.\n",
      "        Patients must be mentally competent to understand and give informed consent for the\n",
      "        protocol.\n",
      "        Estrogen receptor (ER) status can include ER positive, negative, or unknown.\n",
      "        Patients with prior cancers may be eligible as long as they have received curative therapy\n",
      "        and have had no evidence of recurrence for greater than or equal to 10 years.\n",
      "        \n",
      "711\n",
      "All stage III or clinical T3N0 or TxN2 patients must have a histologically documented\n",
      "        diagnosis of breast carcinoma and evaluate disease in the breast or axilla.\n",
      "        Patients with stage III must enter this protocol within 12 weeks of the initial diagnosis.\n",
      "        Patients with Stage IV (metastatic) breast cancer must have histologically proven\n",
      "        diagnosis and must have evaluate disease. Patients with bone-only disease may be\n",
      "        considered eligible after discussion with Dr. Kenneth Cowan.\n",
      "        For Stage III disease, there must be no history of prior cytotoxic therapy.\n",
      "        Stage IV patients will be eligible if they have had prior adjuvant chemotherapy and/or\n",
      "        hormonal therapy provided the regimen did not included adriamycin. Patients will also be\n",
      "        eligible if they have been treated with one prior Phase I or II single chemotherapy agent\n",
      "        on a Medicine branch protocol. Patients who have had prior radiation therapy may be\n",
      "        eligible providing there was not extensive radiation to the cardiac area.\n",
      "        There must be no history of previous malignancy except for cured non-melanoma skin cancer\n",
      "        (basal cell carcinoma) and cervical cancer in situ.\n",
      "        Performance status (Karnofsky scale) must be greater than 70.\n",
      "        WBC count greater than 4000/mm3 and platelet count 100,000/mm3, unless there is evidence\n",
      "        of bone marrow involvement with tumor.\n",
      "        Liver function tests (SGOT, Alk. Phosph., and T. Bilil) should be less than 1.5 times the\n",
      "        upper limits of normal, and serum creatinine should be less than 1.7 or creatinine\n",
      "        clearance should be greater than 45 ml/min unless these abnormalities are due to tumor\n",
      "        involvement.\n",
      "        The patient must give informed consent.\n",
      "        No pregnant patients may be entered on this study; all patients should be informed about\n",
      "        the need for contraception.\n",
      "        No history of other malignant neoplasms except for curatively treated basal cell skin\n",
      "        cancer or surgically cured carcinoma of the cervix in situ.\n",
      "        Patients must not be in poor medical or psychiatric risks because of nonmalignant systemic\n",
      "        disease which would preclude them being subjected to any treatments in this protocol.\n",
      "        Patients with a history of cardiac disease must have a normal ejection fraction by MUGA\n",
      "        Scan and have no angina.\n",
      "        Must not have evidence of CNS metastasis.\n",
      "718\n",
      "Inclusion Criteria\n",
      "        Subjects must have:\n",
      "          -  Normal history and physical exam.\n",
      "          -  HIV negativity by ELISA.\n",
      "          -  CD4 count >= 400 cells/mm3.\n",
      "          -  No clinically significant medical disease.\n",
      "          -  No history of immunodeficiency, autoimmune disease, or use of immunosuppressive\n",
      "             medication.\n",
      "          -  No prior HIV vaccines.\n",
      "          -  Classification in one of the eligible risk groups defined in the Disease Status\n",
      "             field.\n",
      "        Eligible higher risk groups:\n",
      "          -  Heterosexual teenagers and young adults (ages 16-28 permitted) who have attended a\n",
      "             clinic for sexually transmitted diseases in the last 3 months or have higher risk\n",
      "             sexual behavior.\n",
      "          -  Homosexually active males who are practicing higher risk behavior (ages 18-60).\n",
      "          -  Injection drug users active within the past 3 years (ages 18-60).\n",
      "          -  Heterosexual partners of HIV seropositive individuals (ages 18-60).\n",
      "        Eligible lower risk groups:\n",
      "          -  Homosexually active males who are practicing lower risk behavior (ages 18-60).\n",
      "          -  Adult women and heterosexual adult men practicing lower risk sexual behavior (ages\n",
      "             18-60).\n",
      "        \n",
      "720\n",
      "Inclusion Criteria\n",
      "        Women may be eligible for this study if they:\n",
      "          -  Are HIV-positive.\n",
      "          -  Have been pregnant for 14-28 weeks (are in your 1st or 2nd trimester).\n",
      "          -  Have a normal ultrasound exam when they are screened for the study.\n",
      "          -  Are able to drink 6 glasses of water a day throughout the study.\n",
      "          -  Are at least 13 years old (need consent of parent or guardian if under 18).\n",
      "        \n",
      "744\n",
      "Inclusion Criteria\n",
      "        You may be eligible for this study if you:\n",
      "          -  Are an HIV-positive pregnant woman.\n",
      "          -  Have been pregnant for at least 28 weeks.\n",
      "          -  Are at least 13 years of age (consent of parent or guardian is required if under 18).\n",
      "        \n",
      "747\n",
      "Inclusion Criteria\n",
      "        Women may be eligible for this study if they:\n",
      "          -  Are HIV-positive.\n",
      "          -  Are between 14 and 32 weeks pregnant.\n",
      "          -  Are at least 13 years old (consent of parent or guardian required if under 18).\n",
      "          -  Have the consent of the baby's father (if he can be reached).\n",
      "        \n",
      "763\n",
      "Inclusion Criteria\n",
      "        Patients may be eligible for this study if they:\n",
      "          -  Are at least 13 years old (need consent of parent or guardian if under 18).\n",
      "          -  Are HIV-positive.\n",
      "          -  Are in the 2nd or 3rd trimester (14 to 34 weeks pregnant) and are pregnant with one\n",
      "             or two children.\n",
      "          -  Have a normal ultrasound exam.\n",
      "        \n",
      "785\n",
      "Inclusion Criteria\n",
      "        Women may be eligible for this study if they:\n",
      "          -  Are HIV-positive.\n",
      "          -  Are at least 20 weeks pregnant. (This study has been changed. Women no longer have to\n",
      "             be 28 weeks pregnant.)\n",
      "          -  Have consent from the child's father (if available).\n",
      "          -  Are at least 13 years old (consent of parent or guardian required if under 18).\n",
      "        \n",
      "796\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed cancer (including leukemia) that is: Refractory to standard\n",
      "        therapy (objective disease progression required) OR For which no standard therapy exists\n",
      "        and patient is ineligible for potentially curative surgery.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Recovery from the toxic effects of prior therapy required.\n",
      "        Biologic Therapy: Not specified.\n",
      "        Chemotherapy: No prior taxanes. At least 3 weeks since myelosuppressive therapy (6 weeks\n",
      "        since nitrosourea).\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: Prior extensive craniospinal or pelvic irradiation allowed.\n",
      "        Surgery: Ineligible for potential curative surgery.\n",
      "        Other: Prior bone marrow transplant allowed.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: Over 1 to 21;\n",
      "        Performance status: ECOG 0-2;\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        Hematopoietic: (except with leukemia, bone marrow involvement, history of bone marrow\n",
      "        transplantation, or extensive prior radiotherapy).\n",
      "        Absolute granulocyte count at least 1,500/mm(3);\n",
      "        Platelet count at least 100,000/mm(3);\n",
      "        Hemoglobin at least 8.0 g/dL.\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL;\n",
      "        AST less than 2 times normal.\n",
      "        Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL OR;\n",
      "        Creatinine clearance at least 60 mL/min per square meter.\n",
      "        OTHER:\n",
      "        No concurrent anticonvulsant therapy.\n",
      "        No grade 2 or worse neuropathy.\n",
      "        No significant systemic illness (e.g., infection) that could compromise drug excretion or\n",
      "        confuse assessment of toxicity.\n",
      "        Not pregnant or nursing.\n",
      "823\n",
      "Inclusion Criteria\n",
      "        Children may be eligible for this study if they:\n",
      "          -  Are HIV-positive.\n",
      "          -  Are between 8 and 22 years old (consent of parent or guardian required if under 18).\n",
      "          -  Have detectable levels of HIV in the blood within 30 days prior to study entry.\n",
      "          -  Expect to be on the study for at least 1 year. (This study has been changed by adding\n",
      "             this requirement.)\n",
      "          -  Are pregnant and are not taking didanosine/stavudine (ddI/d4T) or EFV as part of\n",
      "             their HAART regimen. (This study has been changed so that pregnant patients may be\n",
      "             eligible if they are not taking ddI/d4T or EFV.)\n",
      "        \n",
      "829\n",
      "Normal Controls:\n",
      "        Males and female subjects from two age ranges: 18-30 and 50-65 years of age.\n",
      "        Individuals with a history of neurological or psychiatric disorder will not be included\n",
      "        nor will individuals currently taking psychoactive medication.\n",
      "        Patients:\n",
      "        Patients with outstanding problems in planning.\n",
      "        Patients must have a diagnosed CNS disorder with lesion localization verified by MRI\n",
      "        scanning available from the referring physician or completed at the NIH Clinical Center.\n",
      "        Patients with unilateral or bilateral lesions that meet the behavioral criteria for\n",
      "        selection (planning disorder).\n",
      "        Patients will be medication free (or taking medication with no known central nervous\n",
      "        system effects) and be able to understand instructions and task demands.\n",
      "845\n",
      "-  INCLUSION CRITERIA:\n",
      "          -  Healthy male or female volunteers from 18 to 70 years old\n",
      "          -  Ability to understand and sign an informed consent document.\n",
      "        \n",
      "864\n",
      "Inclusion Criteria\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count <= 200 cells/mm3 or <= 15 percent of total lymphocytes OR a history of\n",
      "             prior PCP.\n",
      "          -  History of intolerance to trimethoprim and/or sulfonamides.\n",
      "          -  No active pneumocystosis. Patient or guardian must sign informed consent. Pregnant\n",
      "             patients are eligible at the clinician's discretion. Patients who do not meet\n",
      "             required laboratory values may be eligible at the discretion of the clinician.\n",
      "        \n",
      "879\n",
      "Inclusion Criteria\n",
      "        Participant must be HIV-negative at entry and source must be HIV-positive. The source\n",
      "        should be documented to be infected with HIV by one of the following criteria:\n",
      "          -  Clinical diagnosis of AIDS or ARC.\n",
      "          -  Positive test for HIV antibody (both ELISA and Western blot) or presence of HIV p24\n",
      "             antigen in serum.\n",
      "          -  Participant may be enrolled if the source of exposure is suspected of being infected\n",
      "             with HIV (member of risk group, some type of symptom of HIV infection), but the\n",
      "             source must be confirmed to be infected with HIV for the participant to remain in the\n",
      "             study.\n",
      "          -  Significant exposure within 5 days prior to beginning therapy, defined as one of the\n",
      "             following:\n",
      "          -  Research laboratory workers or auxiliary personnel who, during the course of their\n",
      "             work, were exposed to high titers of virus on abraded skin or mucous membranes or\n",
      "             were accidentally inoculated with high titers of cell-associated or free virus\n",
      "             through an exposed wound or puncture.\n",
      "          -  Organ transplant recipients from HIV-positive donor.\n",
      "          -  Recipients of blood or blood products from HIV-positive donor.\n",
      "          -  Women who have been artificially inseminated with semen from HIV-positive donor.\n",
      "          -  Other sources of exposure considered appropriate by the principal investigator and\n",
      "             the sponsor.\n",
      "          -  Persons with poor health (such as renal, hepatic, or bone marrow insufficiency) will\n",
      "             be evaluated on a case-by-case basis.\n",
      "        \n",
      "880\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Recommended in patients with CD4 count <= 200 cells/mm3:\n",
      "          -  Antiretroviral therapy.\n",
      "          -  PCP prophylaxis.\n",
      "        Allowed in all patients:\n",
      "          -  Isoniazid preventive therapy.\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  Evidence of disseminated MAC infection.\n",
      "        NOTE:\n",
      "          -  Pregnant women are permitted to enroll following counseling by their clinician\n",
      "             regarding the potential negative side effects of the study medications. These drugs\n",
      "             should be used in pregnancy only when the potential benefits outweigh the risks.\n",
      "        \n",
      "887\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed adult T-cell leukemia/lymphoma (ATL) or cutaneous T-cell lymphoma\n",
      "        (CTCL).\n",
      "        Reactivity of at least 10% of peripheral blood, lymph node, or dermal malignant cells with\n",
      "        anti-Tac as determined by immunofluorescent staining or soluble IL-2 receptor level\n",
      "        greater than 1,500 U required.\n",
      "        All stages of Tac-expressing T-cell leukemia and lymphoma eligible except Stage I CTCL.\n",
      "        All forms of ATL eligible, including the \"smoldering\" type as well as aggressive disease.\n",
      "        No symptomatic CNS disease other than tropical spastic paraparesis.\n",
      "        Asymptomatic CNS disease with demonstrable malignant cells in the CSF allowed (such\n",
      "        patients receive CNS therapy, e.g., intrathecal methotrexate and/or CNS irradiation, as\n",
      "        appropriate).\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Not specified.\n",
      "        Chemotherapy:\n",
      "        CTCL must have failed initial chemotherapy.\n",
      "        ATL may or may not have had prior chemotherapy.\n",
      "        At least 4 weeks since prior cytotoxic chemotherapy.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy.\n",
      "        Surgery: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: Not specified.\n",
      "        Life expectancy: Greater than 1 month.\n",
      "        Hematopoietic: WBC at least 3,000, Platelets at least 75,000.\n",
      "        Hepatic: Not specified.\n",
      "        Renal: Not specified.\n",
      "        Other:\n",
      "        No pregnant women.\n",
      "        Negative pregnancy test required of fertile women.\n",
      "904\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Chemoprophylaxis for Pneumocystis carinii pneumonia.\n",
      "          -  Antibiotics, antifungals, and antiviral medications, as clinically indicated.\n",
      "          -  Regularly prescribed medication such as antipyretics, analgesics, allergy\n",
      "             medications, antidepressants, sleep medications, oral contraceptives, or any other\n",
      "             medications deemed appropriate by the primary care provider.\n",
      "        Concurrent Treatment:\n",
      "        Allowed:\n",
      "          -  Limited localized radiation therapy to the skin.\n",
      "        Prior Medication: Required:\n",
      "          -  AZT (minimum 300 mg/day) for at least 1 month (uninterrupted) but no more than 2\n",
      "             years immediately prior to study entry.\n",
      "        Patients must have:\n",
      "          -  Asymptomatic HIV infection.\n",
      "          -  CD4 count 300-600 cells/mm3.\n",
      "          -  No plasma/serum PCR for codon 215 mutation at screening.\n",
      "          -  Prior AZT monotherapy.\n",
      "        NOTE:\n",
      "          -  All Department of Defense (DOD)-eligible patients must be at least 18 years of age.\n",
      "             Enrollment of women is encouraged.\n",
      "        AS PER AMENDMENT 04/03/95:\n",
      "          -  DOD female patients must have a negative pregnancy test within 48 hours prior to\n",
      "             study entry.\n",
      "        \n",
      "911\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Recommended:\n",
      "          -  PCP prophylaxis.\n",
      "        Allowed:\n",
      "          -  Acetaminophen if not on a continual basis.\n",
      "        NOTE:\n",
      "          -  Drugs that are metabolized by hepatic glucuronidation or that are associated with\n",
      "             occurrence of pancreatitis are allowed but should be used with caution.\n",
      "        Patients must have at least one of the following:\n",
      "          -  Documented HIV infection.\n",
      "          -  Been born to an HIV-infected woman and receiving AZT.\n",
      "        PER AMENDMENT 4/8/97:\n",
      "          -  Number 2 above no longer required with closure of Part A of study.\n",
      "          -  Patients must have signed, informed consent of parent or legal guardian.\n",
      "        PER 6/20/95 AMENDMENT, patients in Part A must be less than 28 days of age and those in\n",
      "        Part B must be less than 90 days of age.\n",
      "        PER 7/7/94 AMENDMENT, patients in Part A were less than 120 days of age and those in Part\n",
      "        B were less than 180 days of age.\n",
      "        NOTE:\n",
      "          -  All patients must have been more than 34 weeks gestation at birth.\n",
      "        Prior Medication:\n",
      "        Allowed:\n",
      "          -  Prior vaccine therapy.\n",
      "        \n",
      "917\n",
      "-  INCLUSION CRITERIA:\n",
      "        All eligible patients are invited to participate in this protocol. Patients are adults and\n",
      "        minors, aged 16 or higher, with possible idiopathic muscle disease (suspected or\n",
      "        confirmed). Since both men and women are affected with the disease, both sexes will be\n",
      "        studied. All ethnic and racial groups are at risk and will be included. Healthy volunteers\n",
      "        will be eligible only if they are adults aged 18 or older and only if they are willing to\n",
      "        provide informed consent.\n",
      "        EXCLUSION:\n",
      "          -  Children (age less than 16 years) are excluded\n",
      "          -  Subjects with severe active infection (such as requiring intravenous antibiotics) or\n",
      "             other co-morbidities that in the opinion of the investigator would warrant exclusion.\n",
      "          -  Subjects or their legal guardians who are unable or unwilling to give informed\n",
      "             consent/assent.\n",
      "919\n",
      "-  INCLUSION CRITERIA:\n",
      "        Screening:\n",
      "        Age greater than or equal to 13 years old.\n",
      "        Suspect of suffering from Lyme disease.\n",
      "        Post-Treatment Lyme Disease Syndrome (PTLDS): For the purposes of this study, PTLDS is\n",
      "        defined as occurring in male or female patients age 13 and above who have been diagnosed\n",
      "        with confirmed Lyme disease, have received recommended antibiotic therapy and have\n",
      "        persistent or relapsing symptoms and/or signs for at least six months after therapy. They\n",
      "        also should have no other documented explanation for their signs and symptoms and have\n",
      "        positive serum antibodies to B.burgdorferi confirmed by Western blot according to the CDC\n",
      "        criteria (IgG immunoblot is considered positive if five of the following 10 bands are\n",
      "        present: 18 kDa, 21 kDa (OspC), 28 kDa, 30 kDa, 39 kDa, 41 kDa (Fla), 45 kDa, 58 kDa (not\n",
      "        GroEL), 66 kDa, and 93 kDa).\n",
      "        Lyme arthritis controls: For the purposes of this study, Lyme arthritis is defined as\n",
      "        occurring in an otherwise healthy male or female aged 18 and above who have intermittent\n",
      "        episodes of arthritis involving one or few joint, without any other cause being\n",
      "        documented, and have positive serum antibodies to B.burgdorferi confirmed by Western blot\n",
      "        according to the CDC criteria.\n",
      "        Recovered Controls: For the purposes of this study, a recovered control is defined as an\n",
      "        otherwise healthy male or female aged 18 and above who has had Lyme disease, fulfilling\n",
      "        the CDC Lyme Disease National Surveillance Case Definition and who had received accepted\n",
      "        antibiotic treatment for Lyme disease (at least 3 months since the end of antibiotic\n",
      "        therapy before protocol evaluation) and who are currently asymptomatic.\n",
      "        Seropositive Controls: For the purposes of this study, a serpositive control is defined as\n",
      "        an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody\n",
      "        to B.burgdorferi by Western blot according to the CDC criteria and are asymptomatic and\n",
      "        who recall no episodes of disease compatible with Lyme infection and have not received\n",
      "        antibiotic therapy for Lyme disease.\n",
      "        OspA vaccinated control: For the purposes of this study, a OspA vaccinated control is\n",
      "        defined as an otherwise healthy male or female aged 18 and above who has received at least\n",
      "        two doses of the OspA vaccine for Lyme disease (Lymerix [R]). These controls may have a\n",
      "        positive ELISA for B.burgdorferi but a negative (or unreadable) IgG western blot.\n",
      "        Multiple sclerosis controls: For the purposes of this study, a multiple sclerosis control\n",
      "        is defined as an otherwise healthy male or female aged 18 and above with\n",
      "        relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial\n",
      "        Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to\n",
      "        B.burgdorferi as indicate by negative history for Lyme disease and negative Western blot\n",
      "        for B.burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or\n",
      "        Expanded Disability Status Scale (EDSS) between 1 to 5.\n",
      "        Healthy Volunteers: For the purpose of this study, a healthy volunteer is defined as\n",
      "        healthy male or female, age 18 and above, with no history compatible with acute or chronic\n",
      "        Lyme disease and negative western blot to B.burgdorferi in the serum by the CDC criteria.\n",
      "        All study participants must agree to allow their samples to be used for future research.\n",
      "        \n",
      "922\n",
      "-  INCLUSION CRITERIA:\n",
      "               1. Patients ages 2 to 75 years will be considered for therapy. Children under age\n",
      "                  18 will not normally be eligible for use of immunosuppressives other than\n",
      "                  corticosteroids.\n",
      "               2. Patients with proven or likely neurocysticercosis. The diagnosis of\n",
      "                  neurocysticercosis depends on the presence of cysts by MRI or CT scan and/or the\n",
      "                  presence of typical calcifications by CT. Serology is usually, but not always,\n",
      "                  positive and depends on the burden and type of disease.\n",
      "               3. Willing to sign consent and be seen at prescribed intervals\n",
      "               4. Patients who are pregnant will be included, however, they will not be offered\n",
      "                  treatment with albendazole, praziquantel and/or methotrexate and etanercept\n",
      "                  during the pregnancy unless the clinical condition is severe, e.g. life\n",
      "                  threatening, in the opinion of the PI. They may receive corticosteroids.\n",
      "               5. Patients with a positive PPD or quantiferon assay for TB and strongyloidiasis\n",
      "                  will be started/treated for these infections, per standard protocol, and shortly\n",
      "                  thereafter treated for neurocysticercosis.\n",
      "        \n",
      "926\n",
      "Patients greater than 1 year of age with the clinical and pathological diagnosis of WG\n",
      "        whose illness presents a risk of permanent disability or death. Examples of processes that\n",
      "        impart risk of permanent disability or death include: peripheral and central nervous\n",
      "        system disease, cardiac involvement, glomerulonephritis, and vascular comprise of\n",
      "        gastrointestinal organs.\n",
      "        No women who are pregnant or intend to become pregnant.\n",
      "        No patients who have known malignancies.\n",
      "        Patients must be HIV negative.\n",
      "929\n",
      "18 - 65 years of age.\n",
      "        Patients with severe aortic regurgitation and patients with severe mitral regurgitation.\n",
      "        Patients will discontinue medications 48 hours prior to the study.\n",
      "        Women must not be pregnant.\n",
      "        Patients must not have an associated valvular heart disease (i.e., patients with aortic\n",
      "        regurgitation will be excluded if there is coexistent mitral valve disease; patients with\n",
      "        mitral regurgitation will be excluded if there is coexistent aortic valve disease).\n",
      "        Patients must not have any form of cardiomyopathy.\n",
      "        Patients must not have coronary artery disease.\n",
      "        Patients must not have ventricular ectopy during baseline conditions (i.e., couplets,\n",
      "        frequent PVc's [greater than 6/min], early coupling [\"R-on-T\" phenomenon], ventricular\n",
      "        bigeminy) that might potentially predispose the patient for the development of dangerous\n",
      "        dysrhythmia during dobutamine infusion.\n",
      "        Patients must not have a history of cardiac arrest or ventricular tachycardia.\n",
      "        Patients must not have a history of congestive heart failure.\n",
      "        Patients must not have hypotension (i.e., systolic blood pressure less than 100 mmHg).\n",
      "        Patients must not have a systolic blood pressure greater than 200 mmHg.\n",
      "        Patients must not have a left atrial size of greater than 100 mm.\n",
      "        Patients must not have atrial fibrillation.\n",
      "        Patients must not have sinus tachycardia greater than or equal to 100 beats/min.\n",
      "        Patients must not have esophageal disease.\n",
      "        Patients must not have any other medical condition that , at the discretion of the\n",
      "        physician in charge, may increase the risk of the procedure.\n",
      "933\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients (male or female any age) with known or suspected primary hyperparathyroidism or a\n",
      "        related disorder (such as familial multiple endocrine neoplasia type 1 [MEN1]) will be\n",
      "        evaluated.\n",
      "        The vast majority of patients will be greater than age 18.\n",
      "        In the rare occasion where special resources might be appropriate (uremic patient, young\n",
      "        child), the availability of special resources would be confirmed prior to admission.\n",
      "        \n",
      "936\n",
      "INCLUSION CRITERIA:\n",
      "        Patients will include girls and women ages 5-50 yr with the diagnosis of Turner syndrome\n",
      "        based on absence of all or part of one of the X chromosomes.\n",
      "        Control subjects must be within +/- 2SD for height and weight and have normal intelligence\n",
      "        and educational achievement.\n",
      "        Biological parents (both male and female) of TS subjects may be included in this study,\n",
      "        but only to have blood drawn for genetic testing in order to determine the origin of the\n",
      "        X-chromosome of their daughters.\n",
      "        \n",
      "942\n",
      "Adult patients with greater than 50% stenosis in at least one major coronary artery.\n",
      "        No significant valvular heart disease.\n",
      "        No congenital heart disease.\n",
      "        No myocardial disease unrelated to co-existing coronary artery disease.\n",
      "        No severe angina where withdrawal of therapy would be dangerous.\n",
      "        No recent unstable angina or myocardial infarction (less than 1 month).\n",
      "        Not pregnant or breast feeding.\n",
      "        No history of ventricular tachycardia or malignant arrhythmias.\n",
      "        No history of active bronchospastic disease.\n",
      "943\n",
      "-  INCLUSION CRITERIA:\n",
      "        Healthy healthy individual aged between 18 and 60 years.\n",
      "        No active infection or history of recurrent infection.\n",
      "        Normal renal function: creatinine less than 1.5 mg/dl, proteinuria less than 1+.\n",
      "        Normal liver function: bilirubin less than 1.5 mg/dl, transaminase within normal limit.\n",
      "        Normal blood count: WBC 3000 to 10,000/mm(3), granulocytes greater than 1500/mm(3),\n",
      "        platelets greater than 150,000/mm(3), hemoglobin greater than 12.5 g/dl, MCV and MCHC\n",
      "        normal.\n",
      "        Normal cardiovascular function, no history of chest pain, myocardial infarction,\n",
      "        peripheral vascular disease, transient ischemic attack, or stroke.\n",
      "        Healthy female subjects of childbearing age should have a negative serum pregnancy test\n",
      "        within one week of beginning G-CSF administration.\n",
      "        Female subjects should not be lactating.\n",
      "        Subject must be eligible for normal blood donation. He or she must be tested negative for\n",
      "        syphilis (RPR), hepatitis B and C (HBsAg, Anti HBc, Anti HCV), HIV and HTLV 1.\n",
      "        Subject must be able to comprehend the investigational nature of the study and provide\n",
      "        informed consent to participate in the protocol.\n",
      "        Antecubital veins must be adequate for peripheral access during apheresis. Potential\n",
      "        participants must be screened by an apheresis nurse to check venous access before protocol\n",
      "        entry.\n",
      "        \n",
      "949\n",
      "-  INCLUSION CRITERIA:\n",
      "          -  Age 18 or older\n",
      "          -  Male or female\n",
      "          -  Diagnosis of Schizophrenia, Schizoaffective Disorder or Psychosis NOS: Subjects with\n",
      "             other neuropsychiatric disorders may also be admitted and participate in the protocol\n",
      "             if there is sufficient evidence to believe they have an underlying, undiagnosed\n",
      "             schizophrenia, schizoaffective disorder or psychosis NOS.\n",
      "        \n",
      "953\n",
      "-  INCLUSION CRITERIA:\n",
      "        The subjects of this study will be women who meet the criteria for MRMD as described in\n",
      "        Protocol No. 81-M-0126, 'The Phenomenology and Biophysiology of Menstrually-related Mood\n",
      "        and Behavioral Disorders.' In brief, these criteria include:\n",
      "          1. history within the last two years of at least six months with menstrually-related\n",
      "             mood or behavioral disturbances of at least moderate severity--i.e., disturbances\n",
      "             that are distinct in appearance and associated with a notable degree of subjective\n",
      "             distress;\n",
      "          2. symptoms should have a sudden onset and offset;\n",
      "          3. age 18-50;\n",
      "          4. not pregnant and in good medical health;\n",
      "          5. medication free.\n",
      "             All patients participating in this protocol will have already participated in\n",
      "             Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable\n",
      "             relationship between their mood disorder and the premenstrual phase of the menstrual\n",
      "             cycle, i.e., a 30% change in severity of symptom self rating scales, relative to the\n",
      "             range of the scale employed, during the seven days premenstrually compared with the\n",
      "             seven days post-menstrually in two out of three months of study.\n",
      "             The Schedule for Affective Disorders and Schizophrenia will be administered to all\n",
      "             patients prior to study entry. Any patient with a current axis I psychiatric\n",
      "             diagnosis will be excluded from participating in this protocol.\n",
      "             Prior to treatment, a complete physical and neurological examination will have been\n",
      "             performed and the following routine laboratory data obtained:\n",
      "             A. Blood\n",
      "             Complete blood count; thyroid function tests; cortisol; renal function tests, such as\n",
      "             BUN and creatinine; electrolytes; glucose; liver function tests.\n",
      "             B. Urine\n",
      "             Routine urinalysis; urine pregnancy test.\n",
      "             GnRH agonist will not be administered to any subject with significant clinical or\n",
      "             laboratory abnormalities. The blood tests and urinalysis will be repeated 2 weeks\n",
      "             after GnRH agonist administration to rule out any evidence of acute renal, hepatic or\n",
      "             hematologic toxicity.\n",
      "             Results of Pap smear performed within one year of the onset of treatment will be\n",
      "             obtained.\n",
      "             \n",
      "954\n",
      "Patients with Stage IV (metastatic) breast cancer are eligible who have a\n",
      "        histologically-proven diagnosis. Measurable disease is not a prerequisite. Patients with\n",
      "        Stage III disease or Stage ll with 7 or more nodes positive are eligible.\n",
      "        Patients who have had prior adjuvant chemotherapy and/or hormonal therapy are eligible\n",
      "        providing the regimen did not include adriamycin. Patients who have had prior radiation\n",
      "        therapy may be eligible providing there was not extensive radiation to the cardiac area or\n",
      "        to greater than 20% of the bone marrow.\n",
      "        Patients who have received greater than 360mg/m2 of adriamycin as adjuvant therapy are\n",
      "        ineligible.\n",
      "        Patient must be previously untreated with chemotherapy for metastatic disease.\n",
      "        There must be no history of previous malignancy except for cured non-melanoma skin cancer\n",
      "        (basal or squamous cell carcinoma), cervical cancer in situ, or a past malignancy that has\n",
      "        been inactive for over 5 years.\n",
      "        Performance status (Karnofsky scale) must be greater than 70; ECOG 0-2.\n",
      "        Absolute granulocyte count greater than 1500/mm3 and platelet count greater than\n",
      "        100,000/mm3.\n",
      "        Liver function tests (SCOT, Alk, Phosph., and T. Bili) should be less than 1.5 time the\n",
      "        upper limits of normal. Serum creatinine should be less than 1.7 or creatinine clearance\n",
      "        should be greater than 45 ml/min unless these abnormalities are due to tumor involvement.\n",
      "        The patient must be able to give an informed consent, and to return to NCI for treatment\n",
      "        and adequate follow-up for the period the protocol requires.\n",
      "        No pregnant patients may be entered on this study; all patients should be informed about\n",
      "        the need for contraception.\n",
      "        Patients must be greater than or equal to 18 years of age.\n",
      "        No patients who are poor medical or psychiatric risks because of nonmalignant systemic\n",
      "        disease which would preclude them from being subjected to any treatments in this protocol.\n",
      "        No patients with a history of cardiac disease must have a normal ejection fraction by MUGA\n",
      "        Scan and have no angina. Patients who have received prior adriamycin must have a LVEF\n",
      "        greater than 45%.\n",
      "        No history of CNS metastasis, or known seizure disorder.\n",
      "        No allergy to any study medication.\n",
      "        No pregnant or lactacting women.\n",
      "        No patients requiring ongoing therapy for asthma.\n",
      "        No patients with bleeding disorders.\n",
      "957\n",
      "INCLUSION CRITERIA:\n",
      "        Patients are girls aged 1-8 years (on entry to the study) with gonadotropin-independent\n",
      "        precocious puberty. All ethnic groups are included.\n",
      "        \n",
      "962\n",
      "-  INCLUSION CRITERIA:\n",
      "          -  Perimenopausal Subjects:\n",
      "               -  History within the last one year of at least one month with\n",
      "                  perimenopause-related mood or behavioral disturbances of at least moderate\n",
      "                  severity - that is, disturbances that are distinct in appearance and associated\n",
      "                  with a notable degree of functional impairment;\n",
      "               -  Age 40-60;\n",
      "               -  History of the onset of menstrual irregularity during the past six months but\n",
      "                  not greater than one year of amenorrhea (i.e., not postmenopausal);\n",
      "               -  Biological evidence of a deterioration of normal ovarian activity, specifically,\n",
      "                  plasma FSH levels persistently elevated (> 14IU/L) (as recommended by the Stages\n",
      "                  of Reproductive Aging Workshop criteria (106)) drawn at two week intervals over\n",
      "                  a period of eight weeks;\n",
      "               -  No prior estrogen replacement therapy for treatment of perimenopausal physical\n",
      "                  or emotional symptoms within the last six months; and\n",
      "               -  In good medical health;\n",
      "               -  Subjects must be competent to comprehend the purpose of the screening process\n",
      "                  and to provide written informed consent and be willing to participate in NIMH\n",
      "                  IRB approved research protocols.\n",
      "          -  A control group of age-matched perimenopausal women who meet patient selection\n",
      "             criteria with the exception of the presence of mood or behavioral disorders will also\n",
      "             be sought.\n",
      "          -  Premenopausal women will be women who meet the following inclusion criteria for the\n",
      "             longitudinal study participants:\n",
      "               -  Regular menstrual cycle function (21-34 days);\n",
      "               -  Absence of current mood or behavioral disturbance as determined by a structured\n",
      "                  diagnostic interview;\n",
      "               -  Plasma gonadotropin levels in pre-perimenopausal range (< 14 IU/L);\n",
      "               -  In good medical health; and\n",
      "               -  Medication free.\n",
      "        \n",
      "967\n",
      "Male or female; 18 years of age and over.\n",
      "        Women of child bearing potential must have a negative pregnancy test 2 weeks prior to\n",
      "        immunization and must agree to use an active form of birth control during participation.\n",
      "        Men should exercise appropriate contraceptive measures while participating on the study.\n",
      "        Ability and willingness to sign an informed consent.\n",
      "        Adequate venous access as assessed by the Principal or Associate Investigators.\n",
      "        Willingness to comply with the protocol requirements and visit schedule.\n",
      "        HIV-INFECTED PATIENTS:\n",
      "        HIV seropositivity on Elisa, confirmed with Western Blot.\n",
      "        No use or a stable use of an FDA-approved antiviral drug regimen for at least one month.\n",
      "        Life expectancy greater than 6 months.\n",
      "        NORMAL VOLUNTEERS:\n",
      "        Healthy (all clinical and laboratory tests should be in the normal range).\n",
      "        HIV seronegativity.\n",
      "        No signs and/or other laboratory evidence of immunodeficiency. These include a history of\n",
      "        persistent or recurrent infections, infections with unusual organisms or autoimmunity.\n",
      "        No prior immunization with bacteriophage phi X 174.\n",
      "        No current active opportunistic infection.\n",
      "        No use of immune -based therapies or other experimental agents, corticosteroids (at doses\n",
      "        greater than 25 mg/d of prednisone for more than 4 weeks) or any other immunosuppressive\n",
      "        drugs within 6 months prior to enrollment.\n",
      "        No history of severe asthma defined by the need for intermittent or continuous\n",
      "        corticosteroid therapy.\n",
      "975\n",
      "-  INCLUSION CRITERIA:\n",
      "        Inclusion criteria for patients with AAT deficiency include: (1) Diagnosis of AAT with a\n",
      "        confirmed phenotype considered in the high risk category; (2) Clinical phenotype\n",
      "        consistent with potential genetic diseases and other genetic causes of lung diseases (3)\n",
      "        symptoms consistent with pulmonary disease; (4) chest x-ray consistent with pulmonary\n",
      "        disease; (5) pulmonary function tests consistent with pulmonary disease; (6) smokers,\n",
      "        defined as individuals who are current smokers (1 pack per day for at least 2 years) and\n",
      "        nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more\n",
      "        years ago;\n",
      "        Inclusion criteria for individuals with chronic obstructive pulmonary diseases include:\n",
      "          1. symptoms consistent with pulmonary disease\n",
      "          2. chest x-ray consistent with pulmonary disease\n",
      "          3. pulmonary function tests consistent with pulmonary disease;\n",
      "          4. smokers, defined as individuals who are current smokers (1 pack per day for at least\n",
      "             2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked\n",
      "             for three or more years.\n",
      "        Inclusion criteria for patients with cystic fibrosis include a defined genetic mutation\n",
      "        (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic\n",
      "        fibrosis phenotype and clinical features consistent with this disease. Children with\n",
      "        cystic fibrosis over eight years of age may be included.\n",
      "        Patients with established diagnoses of sarcoidosis; mycobacterial infections; TSC\n",
      "        (definite or possible); cystic lung diseases including genetic diseases;\n",
      "        lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of\n",
      "        pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be\n",
      "        included in this protocol. Relatives of patients may also be seen under this protocol.\n",
      "        Children with lymphangiomatosis who are two years of age or older may be included.\n",
      "        Research volunteers in the pulmonary control group are defined as individuals with no\n",
      "        pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease).\n",
      "        Research volunteers in the diabetes control group are defined as individuals with no\n",
      "        history of diabetes, coronary artery disease, or pulmonary disease.\n",
      "        Because radiation exposure is not required, pregnant women are not excluded from the\n",
      "        study.\n",
      "        Patients with abnormalities in ADP-ribosyltransferases, ADP-ribosyl-acceptor hydrolases,\n",
      "        and their substrates. Children who are two years of age or older may be studied if they\n",
      "        have a known defect in ADP-ribosylation, or if they have a family member with a defect in\n",
      "        ADP-ribosylation and may be affected.\n",
      "        \n",
      "976\n",
      "Disease Characteristics:\n",
      "        Histologically proven cancer that is refractory to standard therapy.\n",
      "        Patients with neurofibromatosis having progressive inoperable plexiform neurofibromas with\n",
      "        potential to cause significant morbidity are eligible.\n",
      "        Patients with brainstem gliomas histology may have histology requirements waived.\n",
      "        Patients without prior therapy are eligible if they have diseases with no available\n",
      "        standard therapy.\n",
      "        Patients with evidence of bone marrow involvement by tumor, or a history of either bone\n",
      "        marrow transplantation or extensive radiotherapy will be eligible, but inevaluable for\n",
      "        hematologic toxicities.\n",
      "        Patients with greater than grade 2 neurocortical toxicity will be excluded.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: No concurrent hematopoietic growth factor.\n",
      "        Chemotherapy: No chemotherapy within 3 weeks of study.\n",
      "        No nitrosoursea within 6 weeks of study.\n",
      "        No concurrent chemotherapy allowed.\n",
      "        Must be on stable or decreasing dose of dexamethasone within 2 weeks of study.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: No radiotherapy within 6 weeks of study.\n",
      "        Surgery: Not specified.\n",
      "        Other:\n",
      "        Patient must be recovered from toxic effects of all prior therapy.\n",
      "        Concurrent antibiotic therapy when appropriate.\n",
      "        Patient Characteristics:\n",
      "        Age: 2 to 21.\n",
      "        Performance Status: ECOG 0-2.\n",
      "        Life Expectancy: At least 8 weeks.\n",
      "        Hematopoietic (hematologic requirements below do not apply to patients with histologically\n",
      "        confirmed bone marrow involvement or history of either bone marrow transplantation or\n",
      "        extensive radiotherapy; these patients are inevaluable for hematologic toxicity):\n",
      "        Absolute granulocyte count (AGC) at least 1500/mm3.\n",
      "        Platelet count at least 100,000/mm3.\n",
      "        Hemoglobin at least 8 g/dL.\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 2 mg/Dl.\n",
      "        SGPT less than 2 times normal.\n",
      "        Renal:\n",
      "        Creatinine no greater than 1.5 mg/Dl OR\n",
      "        Creatinine clearance at least 60 Ml/min/square meter.\n",
      "        Other:\n",
      "        No systemic illness.\n",
      "        Not pregnant or nursing.\n",
      "        No amino acidurias or organic acidemias.\n",
      "987\n",
      "INCLUSION CRITERIA\n",
      "        Patients with urticaria of all types, blistering diseases, inflammatory dermatoses and\n",
      "        neoplastic skin diseases.\n",
      "        Patients 18 years of age or older.\n",
      "        No pregnant women.\n",
      "988\n",
      "Male or female greater than 18 years of age.\n",
      "        Patient must have documented hypertension (diastolic BP greater than 90 mmHg or systolic\n",
      "        BP greater than 140 mmHg) for greater than 1 year OR hypercholesterolemia (LDL greater\n",
      "        than 160 or total Chol greater than 240 with a total cholesterol/HDL-Chol ratio more than\n",
      "        1.6 for greater that 1 year OR Diabetes (blood glucose greater than 150 mg/dl requiring\n",
      "        oral antihyperglycemics or insulin dependent) for greater than 1 year OR any combination.\n",
      "        Subgroup eligibility for risk factors with cerebral ischemic events must meet criteria #2\n",
      "        plus documented stroke by physical exam and CT and/or MRI consistent with ischemic\n",
      "        infarction or TIA witnessed and recorded by medical personnel.\n",
      "        Patient will be excluded if enrollment time is within 30 days of a stroke, myocardial\n",
      "        infarction, or surgery. Patient may be enrolled after 30 days of the above events.\n",
      "        No patients on immunosuppressive therapy.\n",
      "        No patients who are unable to follow up for 1 year from the time of enrollment.\n",
      "        No stroke patients with an identifiable cardiac source (including atrial fibrillation,\n",
      "        mural thrombus, valvular disease with vegetation).\n",
      "989\n",
      "Recently diagnosed patients with histologically proven Stage II breast cancer who have 4\n",
      "        or more positive lymph nodes or patients with stage III breast cancer are eligible for\n",
      "        this study.\n",
      "        Patients will be eligible for study either before or after receiving adjuvant radiation\n",
      "        therapy.\n",
      "        Patients with stage III disease will be eligible to receive this regimen as neo-adjuvant\n",
      "        chemotherapy or as adjuvant therapy if surgery was performed prior to patient referral.\n",
      "        Patients must be previously untreated with chemotherapy.\n",
      "        There must be no history of previous malignancy except for cured non-melanoma skin cancer\n",
      "        (basal or squamous cell carcinoma), cervical cancer in situ, or a past malignancy that has\n",
      "        been inactive for over 5 years. Patients with a prior history of lower stage contralateral\n",
      "        breast cancer, treated with surgery, and/or radiation, but not chemotherapy, are eligible\n",
      "        for this study.\n",
      "        Performance status (Karnofsky scale) must be greater than 70; ECOG 0 to 2.\n",
      "        Absolute granulocyte count greater than 1500 per microliter and platelet count greater\n",
      "        than 100,000 per mm(3).\n",
      "        Liver function tests (SGOT, and total bilirubin) should be less than 2X upper limits of\n",
      "        normal. Serum creatinine should be less than 1.7 or creatinine clearance should be greater\n",
      "        than 45 ml per min.\n",
      "        The patient must be able to give an informed consent, and to return to NCI for treatment\n",
      "        and adequate follow-up for the period the protocol requires.\n",
      "        Patients must be greater than or equal to 18 years of age.\n",
      "        Patients and/or their partners must be willing to practice a non-hormonal method of\n",
      "        contraception during therapy and for 6 months following therapy.\n",
      "        Patients who are poor medical or psychiatric risks because of nonmalignant systemic\n",
      "        disease which would preclude them from being subjected to any treatments in this protocol\n",
      "        are excluded.\n",
      "        Patients must have a normal ejection fraction by MUGA scan and have no angina. Patients\n",
      "        should not currently require therapy for cardiac arrhythmias, congestive heart failure, or\n",
      "        coronary artery disease.\n",
      "        No patients with a history of symptomatic CNS disease.\n",
      "        No patients with allergy to any study medication.\n",
      "        No pregnant or lactating women.\n",
      "        Patients with bleeding disorders are ineligible for study entry as are patients requiring\n",
      "        chronic anticoagulation.\n",
      "999\n",
      "PATIENTS:\n",
      "        Patients in chronic phase CML.\n",
      "        Age 10 to 50.\n",
      "        Informed consent given.\n",
      "        Availability of HLA identical or single HLA-locus mismatched family donor.\n",
      "        Females must not be pregnant or lactating.\n",
      "        Must not have ECOG performance status of 3 or more. Must not have a psychiatric disorder\n",
      "        or mental deficiency severe as to make compliance with the BMT treatment unlikely, and\n",
      "        making informed consent impossible.\n",
      "        Must not have major anticipated illness or organ failure incompatible with survival from\n",
      "        PBSC transplant.\n",
      "        Must not have diffusion capacity of carbon monoxide (DLCO) less than 40% predicted.\n",
      "        Must not have left ventricular ejection fraction: less than 30%.\n",
      "        Must not have serum creatinine greater than 50% above normal as defined by age.\n",
      "        Must not have serum bilirubin greater than 4 mg/dl.\n",
      "        Must not have transaminases greater 5 x upper limit of normal.\n",
      "        Must not have other malignant diseases liable to relapse or progress within 5 years.\n",
      "        DONOR:\n",
      "        HLA identical or single HLA-locus mismatched family donor, up to 80 years old.\n",
      "        Informed consent given.\n",
      "        Females must not be pregnant or lactating.\n",
      "        Donor must be fit to receive G-CSF and undergo apheresis. (No controlled hypertension, no\n",
      "        history of congestive heart failure or unstable angina, thrombocytopenia).\n",
      "        Must be HIV negative. Donors who are positive for hepatitis B (HBV), hepatitis C (HBC) or\n",
      "        human T-cell lymphotropic virus (HTLV)-I will be used at the discretion of the\n",
      "        investigator.\n",
      "1004\n",
      "Male and female patients 18 years and older.\n",
      "        Patients admitted to the Clinical Center under other approved research protocols designed\n",
      "        to investigate immune mediated or inflammatory diseases and who have not been immunized to\n",
      "        tetanus toxoid within 6 months.\n",
      "        No pregnant women.\n",
      "1020\n",
      "Patients who are seropositive, documented by a licensed ELISA with a confirmatory Western\n",
      "        blot assay for HIV with greater than or equal to 500 CD4+ cells/mm(3) at the time of\n",
      "        screening who also meet either of the 2 following criteria:\n",
      "        During acute infection there is no lower limit for the CD4 count (acute infection is\n",
      "        defined for this protocol as the 6 month period after diagnosis of HIV seropositivity in a\n",
      "        patient with documented negative HIV serology within the 6 months prior to diagnosis of\n",
      "        HIV seropositivity) OR;\n",
      "        If there is a history of CD4 count less than 300 cells/mm(s) at any point after initial\n",
      "        HIV seropositive diagnosis patient will not be eligible, unless this count was during the\n",
      "        time of acute infection.\n",
      "        Ambulatory status, and ability and willingness to give informed consent.\n",
      "        Must be over 18 years old and have an estimated life expectancy of more than 12 months.\n",
      "        Hgb greater than or equal to 12 g/dl for men and 11 gm/dl for women.\n",
      "        ANC greater than or equal to 1000/mm(3).\n",
      "        Creatinine greater than or equal to 1.5 mg/dl or creatinine clearance greater than 50\n",
      "        ml/min.\n",
      "        LFT: AST and ALT less than or equal to 3x upper limit of normal IU/ml for enrollment.\n",
      "        Alkaline phosphatase less than or equal to 2.5x ULN.\n",
      "        Bilirubin within normal limits, except for known Gilbert's Syndrome or if patient is on\n",
      "        protease inhibitor therapy. For patients on protease inhibitor therapy, direct bilirubin\n",
      "        less than or equal to 0.3 mg/dl and indirect bilirubin less than or equal to 4.5 mg/dl.\n",
      "        Patients must be willing to comply with a medical regimen of highly active antiretroviral\n",
      "        therapy, and must be on a stable antiretroviral regimen for a minimum of 4 weeks prior to\n",
      "        the first vaccination.\n",
      "        Patients should not be receiving antiretroviral therapy or should not have received\n",
      "        antiretroviral therapy within 6 months.\n",
      "        Patients without actual or suspected allergies to any component of vaccine.\n",
      "        No prior vaccines for HIV.\n",
      "        Patients should not have received treatment with the following meds at study entry or\n",
      "        within preceding 3 months - agents with immunomodulating activity, parenteral therapies,\n",
      "        HIV drugs, vaccines, interferons, corticosteroids, any growth factors.\n",
      "        No prior Aids defining OI.\n",
      "        No active life threatening infection.\n",
      "        No severe malabsorption.\n",
      "        No evidence of Kaposi Sarcoma or other tumor - likely to require cytotoxic antitumor\n",
      "        therapy within 6 months of entering study. Must complete acute therapy for infections at\n",
      "        least 14 days prior to entry.\n",
      "        No pregnancy. Female patients of child bearing potential must have a negative pregnancy\n",
      "        test prior to vaccine administration. Males and females must agree to use effective birth\n",
      "        control methods during the course of vaccination.\n",
      "        No patients in whom there is a medical contraindication or potential problems in complying\n",
      "        with the requirements of the protocol.\n",
      "1023\n",
      "-  INCLUSION CRITERIA:\n",
      "        Normal adult volunteers age 18 and over are included.\n",
      "        Only normal volunteers are studied under this protocol. Normal volunteers are recruited\n",
      "        from the NIH volunteer office and the NIH web page. Women and minorities are actively\n",
      "        recruited.\n",
      "1024\n",
      "Patients must be age 18 or older.\n",
      "        Patients male or female must use contraception if of childbearing age. No men and women\n",
      "        actively attempting to conceive a child during the time of drug testing. No pregnant or\n",
      "        nursing women.\n",
      "        Patients must be otherwise healthy, immunocompetent, ambulatory patients with psoriasis\n",
      "        who have more than 5 percent of their body surface area involved with the disease or who\n",
      "        have localized disabling psoriasis.\n",
      "        Have failed one prior topical treatment regimen including topical cortiscosteroids, coat\n",
      "        tar preparations, or ultraviolet light.\n",
      "        An ambulatory performance status of 0,1,2 (ECOG Scale).\n",
      "        Ability to participate in an out -patient study and to provide informed consent.\n",
      "        Creatinine less than 2.0 mg/100ml. Bilirubin less than or equal to 1.5 mg/100ml;\n",
      "        prothrombin time less than or equal to 1.3 times control. WBC greater than 3000/mm(3),\n",
      "        granulocytes greater than 1500/mm(3), platelets greater than 100,000/mm(3).\n",
      "        No clinically significant cardiac disease.\n",
      "        No patients with previously documented serious infectious diseases such as pneumocystis\n",
      "        pneumonia, mycobacterium avium infection, etc. which would suggest clinically evident\n",
      "        immunodeficiency.\n",
      "        No systemic treatment for psoriasis (methotrexate, PUVA, UVB, cyclosporine, etc.) and\n",
      "        topical treatments (corticosteroids, tar, anthralin, etc.) during the four weeks prior to\n",
      "        study entry, and topical treatment during the two weeks prior to study entry.\n",
      "1028\n",
      "Inclusion Criteria\n",
      "        You may be eligible for this study if you:\n",
      "          -  Are an HIV-positive pregnant woman.\n",
      "          -  Have been pregnant for at least 28 weeks.\n",
      "          -  Are at least 13 years of age (consent of parent or guardian is required if under 18).\n",
      "        \n",
      "1039\n",
      "Patients to be studied will be required to have an inflammatory arthritis of less than one\n",
      "        year's duration.\n",
      "        Patients must be greater than 18 years of age.\n",
      "        Pregnant patients may be entered into the study, but they will not undergo percutaneous\n",
      "        needle biopsy or joint radiographs.\n",
      "        No patients with known bacterial septic arthritis, crystal-induced, or degenerative\n",
      "        arthritis.\n",
      "        Synovial biopsies will not be performed if patients have platelet counts less than\n",
      "        70,000/mm(3), other bleeding diathesis in the skin over the joint or sepsis.\n",
      "        Joint MRI: Patient must currently be evaluated at the NIH through protocol 94-AR-0194 or\n",
      "        98-AR-0150.\n",
      "        Joint MRI: Patient must have at least one clinically active arthritic joint that is under\n",
      "        consideration for percutaneous needle synovial biopsy.\n",
      "        Joint MRI: Patients must not have the following: cardiac pacemakers, auto defibrillators,\n",
      "        neural stimulators, aneurysm clips, metallic prostheses, cochlear (ear) implants, any\n",
      "        implanted devices (pumps, infusion devices, etc.), metal fragments in the eye, or shrapnel\n",
      "        injuries.\n",
      "        Joint MRI: Patients must not exceed the size limitations of the MRI scanner.\n",
      "        Joint MRI: Must not suffer from claustrophobia.\n",
      "        Joint MRI: Must not have had a previous anaphylactoid reaction to gadolinium-based\n",
      "        contrast material.\n",
      "        Joint MRI: Must not be pregnant.\n",
      "1043\n",
      "-  INCLUSION CRITERIA:\n",
      "        The subjects of this study will be women who meet the following criteria:\n",
      "          -  history within the last two years of at least six months with menstrually-related\n",
      "             mood or behavioral disturbances of at least moderate severity - that is, disturbances\n",
      "             that are distinct in appearance and associated with a notable degree of subjective\n",
      "             distress;\n",
      "          -  a 30% increase in mean negative mood ratings (relative to the range of the scale\n",
      "             employed) in the premenstrual week compared with the week following the end of menses\n",
      "             in at least two of three cycles;\n",
      "          -  age 18 to 50;\n",
      "          -  not pregnant and in good medical health;\n",
      "          -  regular menses.\n",
      "        Subjects who do not meet the criteria listed above but who do meet diagnostic criteria for\n",
      "        recurrent brief depression will also be studied. The criteria for recurrent brief\n",
      "        depression include the following:\n",
      "          -  dysphoric mood or loss of interest or pleasure;\n",
      "          -  duration less than two weeks;\n",
      "          -  four of the following symptoms: poor appetite or significant weight loss (when not\n",
      "             dieting) or increased appetite or significant weight gain; insomnia or hypersomnia;\n",
      "             psychomotor agitation or retardation; loss of interest or pleasure in usual\n",
      "             activities, or decrease in sexual drive; loss of energy; fatigue; feelings of\n",
      "             worthlessness, self-reproach, or excessive or inappropriate guilt; diminished ability\n",
      "             to think or concentrate, slowed thinking, or indecisiveness;\n",
      "          -  impairment in usual occupational activities;\n",
      "          -  at least one-two episodes per month over one year.\n",
      "        Age-matched women without mood and behavioral disorders will be recruited.\n",
      "        \n",
      "1052\n",
      "Any patient age greater than or equal to 18 with measurable metastatic melanoma who has\n",
      "        failed standard treatment and has an expected survival of greater than three months will\n",
      "        be considered.\n",
      "        Serum creatinine of 2.0 mg/dl or less.\n",
      "        Bilirubin 1.6 mg/dl or less.\n",
      "        WBC 3000/mm(3) or greater.\n",
      "        Platelet count 90,000 mm(3) or greater.\n",
      "        Serum AST/ALT less then two times normal.\n",
      "        ECOG performance status of 0 or 1 or 2.\n",
      "        Patients of both genders must be willing to practice effective birth control during this\n",
      "        trial.\n",
      "        No patients who are undergoing or have undergone in the past 3 weeks any other form of\n",
      "        therapy except surgery for their cancer.\n",
      "        No patients who have active systemic infections, coagulation disorders, autoimmune disease\n",
      "        or other major medical illnesses of the cardiovascular or respiratory systems or any known\n",
      "        immunodeficiency disease. Patients with cardiovascular disease will be eligible to receive\n",
      "        peptide in IFA alone.\n",
      "        No patients who require steroid therapy.\n",
      "        No patients who are pregnant (because of possible side effects on the fetus).\n",
      "        No patients who are known to be positive for hepatitis BsAG or HIV antibody (because of\n",
      "        possible immune effects of these conditions).\n",
      "        No patients who have any form of primary or secondary immunodeficiency. (The experimental\n",
      "        treatment being evaluated in this protocol depends on an intact immune system. Patients\n",
      "        who have decreased immune competence may be less responsive to the experimental treatment\n",
      "        and more susceptible to its toxicities).\n",
      "1053\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed superficial transitional cell carcinoma of the bladder\n",
      "        pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required.\n",
      "        No metastatic disease or muscle invasion.\n",
      "        Clinically useful pretreatment bladder function required.\n",
      "        No significant prostatic obstructive symptoms associated with impaired or incomplete\n",
      "        bladder emptying.\n",
      "        No active urinary tract infection.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        At least 1 course of prior standard intravesical therapy required.\n",
      "        At least 4 weeks since intravesical treatment, with resolution of any local or systemic\n",
      "        toxicity.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0 or 1.\n",
      "        Hematopoietic:\n",
      "        WBC at least 3,300;\n",
      "        Hemoglobin at least 10 g/dL.\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL;\n",
      "        AST and ALT no greater than 2 times normal.\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL.\n",
      "        OTHER:\n",
      "        Medically able to undergo cystoscopy.\n",
      "        No pregnant women.\n",
      "1055\n",
      "Must be 18 years old or greater.\n",
      "        ECOG performance status of 0-1.\n",
      "        Individuals without a history of cancer are eligible, as are those with a history of\n",
      "        cancer. Individuals with a history of cancer (excluding non-melanomatous skin cancer )\n",
      "        will need to submit their pathology slides for review in the Laboratory of Pathology, NCI.\n",
      "        Must be able to understand and give informed consent.\n",
      "        Life expectancy greater than 6 months.\n",
      "        Hgb greater than or equal to 8.0gm/dl, platelets greater than or equal to\n",
      "        100,000/microliters, ANC greater than or equal to 1000/microliters, creatinine less than\n",
      "        or equal to 2.0/mg/dl, SGPT and SGOT less than or equal to 147 and 168 U/L, total\n",
      "        bilirubin less than or equal to 2 mg/dl (patients with a higher level of bilirubin due to\n",
      "        a familial defect in bilirubin metabolism will be considered on an individual basis).\n",
      "        No history of breast cancer.\n",
      "        No pregnant or breast feeding subjects.\n",
      "        Must not be HIV positive.\n",
      "        No history of venous thrombosis within the past year.\n",
      "        No medical conditions, which, in the opinion of the investigators would jeopardize either\n",
      "        the patient or the integrity of the data obtained.\n",
      "        No patients who are currently receiving active therapy for neoplastic disorders. However,\n",
      "        patients with prostate cancer who are on an LHRH agonist (e.g., Lupron or Zoladex), or who\n",
      "        have undergone surgical castration, are eligible for study.\n",
      "        No patients who are on estrogen therapy.\n",
      "        No patients taking hormonal forms of contraception.\n",
      "        No patients with a known soy intolerance.\n",
      "1067\n",
      "The diagnosis of chronic granulomatous disease as indicated by an unusual pattern of\n",
      "        infection in the patient or one pedigree relation, confirmed by both of the following\n",
      "        tests:\n",
      "        Abnormal neutrophil NBT slide test (following PMA stimulation) and neutrophil superoxide\n",
      "        anion production less than or equal to 20 percent normal.\n",
      "        Preserved renal function (creatinine less than or equal to 2.0 mg/100 mL; less than or\n",
      "        equal to 2+ proteinuria).\n",
      "        Preserved hepatic function (bilirubin less than or equal to 1.5 mg/100 mL; prothrombin\n",
      "        time less than or equal to 1.3 x control).\n",
      "        Preserved hematologic function (WBC greater than or equal to 3000/mm3; granulocytes\n",
      "        greater than 1500/mm3; platelets greater than or equal to 100,000/mm3).\n",
      "        A minimum life expectancy of three months.\n",
      "        Patients seropositive for Hepatitis B surface antigen may be entered but serum specimens\n",
      "        for rIFN-y antibody should not be collected.\n",
      "        Patients must not be pregnant or lactating.\n",
      "        Patients of childbearing potential may be entered if using effective contraception.\n",
      "        Full recovery from previous serious infections requiring hospitalization and parenteral\n",
      "        antibiotic therapy. At least two weeks must elapse following the cessation of parenteral\n",
      "        antibiotic therapy before study admission.\n",
      "1068\n",
      "Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary.\n",
      "        Received medical treatment for at least 3 months without improvement.\n",
      "        Preserved renal, hepatic and hematologic function.\n",
      "        Negative pregnancy urine and effective contraceptive.\n",
      "        Age range greater than 5.\n",
      "        No secondary immunodeficiency such as HIV or malignancy.\n",
      "        Not currently receiving cytotoxic therapy within the past 3 months.\n",
      "        Not pregnant or lactating.\n",
      "        No seizure disorders.\n",
      "        No known symptomatic cardiac disease.\n",
      "1069\n",
      "Patients must be over 18 years of age.\n",
      "        Patients must have a definite diagnosis of diabetic neuropathy or post herpetic neuralgia\n",
      "        or a diagnosis of neuropathic pain of various etiologies other than diabetic neuropathy or\n",
      "        post herpetic neuralgia.\n",
      "        Duration of symptoms must be at least 3 months.\n",
      "        Severity of pain must be at least mild, if constant; or at least moderate, if intermittent\n",
      "        and at least 2 hours duration a day.\n",
      "        Patients using tricyclics, narcotics, or antiseizure medications, must keep the drug\n",
      "        dosages constant throughout the study.\n",
      "        No patients with unstable disease process; i.e., angina pectoris, accelerated\n",
      "        hypertension, recent stroke or transient cerebral ischemia, uncontrolled seizures.\n",
      "        No pregnant or lactating women. Women of child bearing potential must use birth control\n",
      "        pills, intrauterine device, or barrier contraceptive devices.\n",
      "        No history of significant drug abuse or PCP use. No history of IV drug abuse, prescription\n",
      "        drug abuse, or alcoholism.\n",
      "        No significant liver or kidney disease.\n",
      "        No MAO inhibitors.\n",
      "        No cognitive impairment or language difficulty as judged by difficulty completing pain\n",
      "        diary, medical history, or telephone conversation.\n",
      "        Patients must not have any other chronic pain condition that gives them pain greater than\n",
      "        the neuropathy pain.\n",
      "1070\n",
      "-  INCLUSION CRITERIA:\n",
      "        A. ALPS Natural History sample size and demographics:\n",
      "        Study size: up to 1000 patients, patients, relatives and normal controls.\n",
      "        Sex Distribution: Male and female\n",
      "        Age range: All ages acceptable\n",
      "        B. Eligibility Criteria for Natural History Study:\n",
      "          1. To be considered as having ALPS, patients must elevated TCR alpha/beta+ CD4-8-\n",
      "             peripheral blood DNT cells (equal to or greater than 1.5 percent of total lymphocytes\n",
      "             or 2.5 percent of CD3+ lymphocytes) in the setting of normal or evalted lymphocyte\n",
      "             counts.\n",
      "          2. A history of chronic (greater than 6 months) non-malignant, non-infectious\n",
      "             lymphadenopathy and/or splenomegaly.\n",
      "          3. Willingness to allow blood, tissue and other samples to be stored.\n",
      "          4. Patients with RALD (RAS associated leukoproliferative disorders) who present with\n",
      "             autoimmunity, lymphadenopathy and/or splenomegaly, with elevated or normal DNT s and\n",
      "             somatic mutations in NRAS and KRAS\n",
      "        C. Eligibility Criteria for Screening potential patients:\n",
      "          1. A history of chronic (greater than 6 months) lymphadenopathy and/or splenomegaly.\n",
      "          2. Willingness to allow blood, tissue and other samples to be stored.\n",
      "        D. Screening criteria for ALPS Relatives:\n",
      "          1. Extended family members of an ALPS patient are eligible for genetic screening to\n",
      "             determine if they carry the mutation found in their family.\n",
      "          2. Willingness to allow blood, tissue and other samples to be stored.\n",
      "        E. 1. Apheresis will be done only on healthy volunteers or patients with ALPS who have\n",
      "        adequate peripheral venous access. Women of childbearing age must have a negative\n",
      "        pregnancy test within 24 hours of the procedure and must not be breast-feeding.\n",
      "        \n",
      "1075\n",
      "INCLUSION CRITERIA:\n",
      "        Patients must be 18 years or older. A negative pregnancy test is required for all female\n",
      "        patients of child-bearing age.\n",
      "        Only patients with first onset acute DVT will be accepted. Acute DVT-LE must be documented\n",
      "        by ultrasonography or venogram and will be defined as thrombosis of a major deep vein\n",
      "        segment above the popliteal vein less than 14 days since onset of symptoms or diagnosis.\n",
      "        Extension of thrombosis from the popliteal vein into calf veins is acceptable, but\n",
      "        isolated calf vein thrombosis will not be treated under this protocol, as the benefits of\n",
      "        thrombolytic therapy do not outweigh the risks.\n",
      "        \n",
      "1081\n",
      "Must be greater than or equal to 18 years of age.\n",
      "        Must not be pregnant or lactating.\n",
      "1085\n",
      "Patients with Stage IV (metastatic) breast cancer who have a histologically-proven\n",
      "        diagnosis. Measurable, evaluable Stage III patients, Stage II patients with 4 or more\n",
      "        nodes positive, and Stage IV NED (no evidence of disease) patients.\n",
      "        Patients who have had prior radiation therapy providing there was not more than 20% of the\n",
      "        bone marrow has been irradiated.\n",
      "        Patients who have received less than or equal to 360mg/m2 of Adriamycin as adjuvant\n",
      "        therapy.\n",
      "        Patients must be previously untreated with chemotherapy for metastatic disease.\n",
      "        There must be no history of previous malignancy except for cured non-melanoma skin cancer\n",
      "        (basal or squamous cell carcinoma), cervical cancer in situ, or a past malignancy that has\n",
      "        been inactive for over 5 years.\n",
      "        Performance status (Karnofsky scale) must be greater than 70; ECOG 0-2.\n",
      "        Absolute granulocyte count greater than 1500 microliters and platelet count greater than\n",
      "        100,000/mm3.\n",
      "        Liver function tests (SGOT, and total bilirubin) should be less than 2X the upper limits\n",
      "        of normal unless there is evidence of hepatic involvement with tumor. Serum creatinine\n",
      "        should be less than 1.7 or creatinine clearance should be greater than 45 ml/min.\n",
      "        Patients must be greater than or equal to 18 years of age.\n",
      "        The patient must be able to give informed consent, and to return to NCI for treatment and\n",
      "        adequate follow-up for the period the protocol requires.\n",
      "        No patients who are poor medical or psychiatric risks because of nonmalignant systemic\n",
      "        disease which would preclude them from being subjected to any treatments in this protocol.\n",
      "        Patients should not currently require therapy for cardiac arrhythmias, congestive heart\n",
      "        failure, or coronary artery disease. Patients who have received prior Adriamycin or have\n",
      "        any history of cardiac disease must have a LVEF greater than 45 percent by MUGA.\n",
      "        No history of CNS metastasis, or know seizure disorder.\n",
      "        No allergy to any study medication.\n",
      "        No pregnant or lactating women.\n",
      "        No patients requiring ongoing therapy for asthma.\n",
      "        No patients with bleeding disorders for study entry as are patients requiring chronic\n",
      "        anticoagulation.\n",
      "        No patients with active infection or are known to be HIV positive.\n",
      "1087\n",
      "-  ELIGIBILITY CRITERIA:\n",
      "        Patients (Patients with a genetically defined PID or clinical history consistent with PID)\n",
      "          1. Patients will have a genetically defined PID or have a clinical history of recurrent\n",
      "             infections or other problems suggestive of PID, must be 2-70 years of age,\n",
      "          2. Is at least 10 kilograms body weight.\n",
      "          3. Some patients may have active bacterial or fungal infection at the time of study\n",
      "             entry.\n",
      "          4. Preserved renal function (creatinine < 2.5 mg/dL; < 3+ proteinuria); preserved\n",
      "             hepatic function (bilirubin < 2.0 mg/dl); preserved hematologic function (WBC greater\n",
      "             than or equal to1000/mm3;granulocytes greater than or equal to 500/mm3; platelets\n",
      "             greater than or equal to 100,000; hematocrit greater than or equal to 25). Of note,\n",
      "             patients with PID often have associated chronic thrombocytopenia. Patients with\n",
      "             stable chronic thrombocytopenia will be eligible for collection, at the investigator\n",
      "             s discretion, with the caveat that patients with platelet count < 40,000 the day\n",
      "             prior to collection will be transfused with platelets on the morning of collection.\n",
      "             Platelets may also be given to these patients following the collection if medically\n",
      "             indicated..\n",
      "          5. Patients of childbearing potential may be entered if using effective contraception\n",
      "             and having a negative serum pregnancy test within one week of beginning G-CSF\n",
      "             administration.\n",
      "          6. Patients may remain on their regimen of prophylactic treatments as deemed necessary\n",
      "             by the investigator.\n",
      "          7. Willingness to allow blood cell samples to be stored\n",
      "          8. Willingness to allow blood and/or bone marrow samples to be modified to iPS cells\n",
      "        Healthy Donors (HLA matched sibling or other related donor of a patient with PID in need\n",
      "        of an allogeneic hematopoietic stem cell transplant)\n",
      "          1. Healthy sibling or other relative of a patient with PID in need of an allogeneic\n",
      "             transplant,\n",
      "             between 2-65 years of age,\n",
      "          2. Is fully or closely HLA tissue matched to the patient with PID that the hematopoietic\n",
      "             stem cell PBSC or bone marrow collection is designated to clinically benefit,\n",
      "          3. Is at least 10 kilograms body weight.\n",
      "          4. Normal renal function (creatinine < 1.5 mg/dL; < 1+ proteinuria); normal hepatic\n",
      "             function (bilirubin < 1.5 mg/dL); normal hematologic function (WBC greater than or\n",
      "             equal to 2500/mm3; granulocytes greater than or equal to 1200/mm3; platelets greater\n",
      "             than or equal to120,000; hematocrit greater than or equal to 38).\n",
      "          5. Normal female donors of childbearing potential may be entered if using effective\n",
      "             contraception and having a negative serum pregnancy test within one week of beginning\n",
      "             G-CSF administration.\n",
      "          6. Willingness to allow blood cell samples to be stored\n",
      "          7. Willingness to allow blood and/or bone marrow samples to be modified to iPS cells\n",
      "        Healthy Volunteers\n",
      "          1. Healthy adults aged 18-65 without active current infection or history of recurrent\n",
      "             infection,\n",
      "          2. Weighs at least 50kg.\n",
      "          3. Normal renal function (creatinine < 1.5 mg/dL; < 1+ proteinuria); normal hepatic\n",
      "             function (bilirubin < 1.5 mg/dL); normal hematologic function (WBC greater than or\n",
      "             equal to 2500/mm3; granulocytes greater than or equal to 1200/mm3; platelets greater\n",
      "             than or equal to 120,000; hematocrit greater than or equal to 38).\n",
      "          4. Normal female volunteers of childbearing potential may be entered if using effective\n",
      "             contraception and having a negative serum pregnancy test within one week of beginning\n",
      "             GCSF administration.\n",
      "          5. Willingness to allow blood cell samples to be stored\n",
      "          6. Willingness to allow blood and/or bone marrow samples to be modified to iPS cells\n",
      "        For PBMCs and grans collections, adult subjects with known genetic mutations may\n",
      "        participate as healthy volunteers for research purposes as long as the other criteria\n",
      "        listed above are fulfilled.\n",
      "        EXCLUSIONS:\n",
      "        Patients\n",
      "          1. Patients who are hemodynamically unstable (systolic or diastolic blood pressure fall\n",
      "             of 20 mm Hg from the stable patient s baseline measurement) or requiring mechanical\n",
      "             respiratory assistance are excluded.\n",
      "          2. Female patients who are pregnant or lactating as determined by history and/or\n",
      "             positive pregnancy test are excluded.\n",
      "          3. Must be negative by routine blood donor eligibility testing criteria including tests\n",
      "             for syphilis (RPR) and TTV Donor Transplant Panel testing (list is modified\n",
      "             periodically, but may include hepatitis B and C, HIV and HTLV, T. cruzi). This does\n",
      "             not apply to leukapheresis patients, as these tests are not required by DTM.\n",
      "               1. XSCID patients do not make antibodies and false positives may occur because they\n",
      "                  receive periodic infusions of pooled donations of IVIG. We have observed\n",
      "                  positive anti-HBc testing in these patients. If this occurs, more specific DNA\n",
      "                  or antigen testing will be done and must be negative.\n",
      "               2. Autologous HSC Transplant patients may be positive for Hepatitis B and C if the\n",
      "                  investigator deems it necessary to be collected and used as a safety back-up\n",
      "        Healthy Volunteers and Healthy Donors\n",
      "          1. Active bacterial, fungal or viral infection as evidenced by history, physical exam\n",
      "             (temperature > 38 (Infinite) C), or WBC > 9000 are excluded.\n",
      "          2. Females who are pregnant or lactating as determined by history and/or pregnancy test\n",
      "             are excluded.\n",
      "          3. Must be negative by routine blood donor eligibility testing criteria, including tests\n",
      "             for syphilis (RPR) and TTV Recipient Transplant Panel (list is modified periodically,\n",
      "             but may include hepatitis B and C, HIV and HTLV, T. cruzi) This does not apply to\n",
      "             leukapheresis patients, as these tests are not required by DTM policy.\n",
      "          4. Someone without peripheral venous access in arm veins adequate for apheresis (healthy\n",
      "             volunteers only).\n",
      "          5. If in the opinion of the investigator participation in this study places the healthy\n",
      "             volunteer or donor at undue risk.\n",
      "        These same \n",
      "1090\n",
      "Patients must have documented HIV infection (ELISA and Western blot positive).\n",
      "        Patients must be 18 years or older.\n",
      "        Patients must have CD4 count greater than 200 cells/mm(3).\n",
      "        Patients must have clinical laboratory values Grade 0 or 1.\n",
      "        Patients must not have therapy with corticosteroids, chemotherapy, or experimental therapy\n",
      "        in the prior 4 weeks.\n",
      "        Patients must have a negative urine pregnancy test (women of childbearing potential).\n",
      "        Patients with prior IL-2 therapy will be excluded.\n",
      "        Patients with malignancy other than Kaposi sarcoma will be excluded. Patients with Kaposi\n",
      "        sarcoma are eligible, but must not have received systemic therapy for KS within 4 weeks\n",
      "        prior to study entry.\n",
      "        Patients with history of prior AIDS-defining opportunistic infection will be excluded.\n",
      "        Patients with active substance abuse which may affect patient safety or compliance will be\n",
      "        excluded.\n",
      "        Patients exhibiting psychiatric disturbance or illness, which in the assessment of the\n",
      "        protocol team may affect patient safety or compliance will be excluded.\n",
      "        Patients with significant cardiac, pulmonary, thyroid, kidney, rheumatologic, or CNS\n",
      "        disease will be excluded.\n",
      "        Patients with hypertension requiring anti-hypersensitive therapy will be excluded.\n",
      "        Pregnant or lactating patients or patients of childbearing potential, will be excluded,\n",
      "        unless they use effective contraception.\n",
      "        Patients unwillingness to comply with current NIH Clinical Center guidelines concerning\n",
      "        appropriate notification by an individual of current or ongoing sexual partners and/or\n",
      "        needle-sharing partners regarding his or her HIV seropositivity and the risk of\n",
      "        transmission of HIV infection will be cause for exclusion.\n",
      "1093\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven, advanced epithelial ovarian cancer.\n",
      "        Histologic confirmation by Pathology Department, NIH, required.\n",
      "        Recurrent disease after paclitaxel and either cisplatin or carboplatin. Combination\n",
      "        platinum/paclitaxel acceptable.\n",
      "        Bidimensionally measurable disease on physical exam, radiographs, or peritoneoscopy.\n",
      "        Repeat peritoneoscopy after 8 courses of therapy required if documentation of disease was\n",
      "        solely by peritoneoscopy.\n",
      "        Laparotomy not required.\n",
      "        No CNS metastasis.\n",
      "        No borderline or mixed histology.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        See Disease Characteristics.\n",
      "        More than 4 weeks since any prior therapy and recovered.\n",
      "        No prior camptothecin analogue-based chemotherapy.\n",
      "        No prior radiotherapy except intraperitoneal 32-P.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Hematopoietic:\n",
      "        WBC greater than 3,000.\n",
      "        AGC greater than 1,500.\n",
      "        Platelets at least 100,000.\n",
      "        Hemoglobin greater than 9 g/dL OR;\n",
      "        Hematocrit greater than 27 g/dL.\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL.\n",
      "        Serum transaminases no greater than 2 times normal.\n",
      "        Renal:\n",
      "        24-hour creatinine clearance greater than 45 mL/min (documented by NCI investigator or\n",
      "        primary care physician).\n",
      "        Cardiovascular:\n",
      "        No myocardial infarction within 12 months.\n",
      "        No active congestive heart failure.\n",
      "        No heart block.\n",
      "        No arrhythmia requiring medication.\n",
      "        OTHER:\n",
      "        No active uncontrolled infection.\n",
      "        No known HIV positivity.\n",
      "        No second malignancy currently under treatment except: Local basal cell carcinoma of the\n",
      "        skin, Cervical carcinoma in situ, Other malignancies (e.g., stage I breast cancer)\n",
      "        eligible at the discretion of the principal or associate investigators.\n",
      "        No pregnant women.\n",
      "1094\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Unresectable primary colorectal adenocarcinoma that is metastatic or recurrent.\n",
      "        Objectively measurable disease required.\n",
      "        No cerebral metastases.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy:\n",
      "        No history of intolerance to interferon alfa (IFN-A).\n",
      "        At least 4 weeks since immunotherapy and recovered.\n",
      "        Chemotherapy: No prior chemotherapy for metastatic or recurrent disease. At least 6 months\n",
      "        since adjuvant chemotherapy with fluorouracil (5-FU) in combination with levamisole,\n",
      "        leucovorin (CF), or IFN-A Interval waived for 5-FU (with or without CF) as a\n",
      "        radiosensitizer only . No dose-limiting toxicity with prior 5-FU.\n",
      "        Endocrine Therapy: Not specified\n",
      "        Radiotherapy: At least 2 weeks since palliative radiotherapy and recovered. Prior\n",
      "        definitive pelvic or whole or upper abdominal radiotherapy allowed in the absence of\n",
      "        current radiation enteritis.\n",
      "        Surgery: Prior surgery allowed with adequate healing/recovery\n",
      "        Patient Characteristics:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0 or 1.\n",
      "        Hematopoietic:\n",
      "        AGC at least 2,000.\n",
      "        Platelets at least 100,000.\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "        No MI within the past year.\n",
      "        No active ischemic heart disease.\n",
      "        No NYHA class III/IV status.\n",
      "        No symptomatic arrhythmia.\n",
      "        OTHER:\n",
      "        No requirement for pharmacologic steroid doses for inflammatory or autoimmune disorders.\n",
      "        Physiologic replacement doses of steroids allowed.\n",
      "        No concurrent cimetidine or oxypurinol.\n",
      "        No HIV antibody.\n",
      "        No history of seizure disorder.\n",
      "        No active infection or other serious concurrent medical illness that would preclude\n",
      "        treatment.\n",
      "        No second malignancy within 3 years except curatively treated: In situ carcinoma of\n",
      "        cervix, Basal cell carcinoma of the skin.\n",
      "        No pregnant or nursing women.\n",
      "        Effective contraception required of fertile patients.\n",
      "1097\n",
      "Selected patients should have CIDP with or without an associated monoclonal gammopathy.\n",
      "        Subjects should have clinical evidence of peripheral neuropathy with muscle weakness and\n",
      "        sensory deficit.\n",
      "        Subjects should have evidence of clinical, histological or family history of another\n",
      "        neuromuscular illness.\n",
      "        Subjects should have elevation of CSF protein during the course of the disease.\n",
      "        Subjects should have demyelination by nerve conduction study and/or nerve biopsy.\n",
      "        Suitable candidates for IVIg should be patients with active, bonefide CIDP who:\n",
      "          1. have been treated with steroids but had: a) no response or incomplete response (as\n",
      "             defined by continued muscle weakness) to high-dose therapy or b) a good response to\n",
      "             steroids but inability to taper the dose without a flare of disease activity or c)\n",
      "             unacceptable steroid side effects such as gastrointestinal hemorrhages,\n",
      "             osteonecrosis, hyperglycemia, extreme weight gain etc. or\n",
      "          2. have been additionally treated with one of the other immunosuppressive agents\n",
      "             considered effective in some CIDP patients, such as azathioprine, chlorambucil,\n",
      "             cyclophosphamide, cyclosporine or plasmapheresis but without benefit or with\n",
      "             unacceptable side effects that had necessitated their discontinuation.\n",
      "        Subjects should not be pregnant or nursing.\n",
      "        Subjects should not be critically ill such as those requiring intravenous pressors for\n",
      "        maintenance of cardiac output, patients with unstable respiratory insufficiency and\n",
      "        patients with such severe muscle weakness requiring help for basic self care (Karnofsky\n",
      "        performance scale less than 50).\n",
      "        No subjects below 18 years of age.\n",
      "        Patients should not have severe renal or hepatic disease and severe COPD or coronary\n",
      "        artery disease.\n",
      "        Patients should not be allergic to IVIg or have a known IgA deficiency.\n",
      "1098\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Biopsy-proven Stage IIIA or IIIAB melanoma (M.D. Anderson staging system) of an extremity,\n",
      "        as follows:\n",
      "        Advanced local disease indicated by 2 or more satellite or in-transit metastases.\n",
      "        Lower limb regional metastases must be distal to the apex of the femoral triangle except\n",
      "        inguinal lymph node metastases.\n",
      "        Upper limb regional metastases must be distal to the deltoid insertion except axillary\n",
      "        lymph node metastases.\n",
      "        No evidence of systemic disease outside the involved extremity.\n",
      "        Recurrent disease subsequent to prior successful limb perfusion allowed.\n",
      "        Bidimensional directly measurable dermal or subcutaneous lesion required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        No prior isolated limb perfusion.\n",
      "        Biologic Therapy: At least 1 month since Biologic Therapy.\n",
      "        At least 3 months since regional therapy of the extremity.\n",
      "        Chemotherapy: At least 1 month since chemotherap.y\n",
      "        At least 3 months since regional therapy of the extremity.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: At least 1 month since radiotherapy.\n",
      "        Surgery: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0 or 1.\n",
      "        Hematopoietic: Platelets greater than 150,000.\n",
      "        Hepatic: Bilirubin less than 1.5 mg/dl; Coagulation profile normal.\n",
      "        Renal: Creatinine less than 2.0 mg/dl.\n",
      "        Cardiovascular: No evidence of peripheral vascular disease, e.g.:\n",
      "        No history of claudication.\n",
      "        OTHER:\n",
      "        HIV negative.\n",
      "        No pregnant or nursing women.\n",
      "1101\n",
      "Biopsy proven advanced cancer, for whom no better therapy exists.\n",
      "        Enrollment of patients with breast cancer, lymphoma, renal cell cancer or ovarian cancer\n",
      "        are encouraged.\n",
      "        Patients with a life expectancy of at least 16 weeks, and a performance status (Karnofsky\n",
      "        Scale) of 70% or greater. No rapidly growing disease.\n",
      "        Patients with prior therapy.\n",
      "        WBC greater than 3,000/mm(3) and AGC greater than 1000/mm(3); platelets greater than\n",
      "        100,000/mm(3).\n",
      "        Creatinine clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than\n",
      "        90 u/L; SGPT less than 100 u/L.\n",
      "        Patients must sign an informed consent and have geographic accessibility to return for\n",
      "        follow up and treatment.\n",
      "        No history of brain metastases.\n",
      "        No patients currently receiving treatment with the following agents or any other agent\n",
      "        known to significantly interact with cyclosporine, and the treatment cannot be\n",
      "        discontinued , or changed to another therapeutically equivalent allowable drug:\n",
      "        acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole,\n",
      "        ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides,\n",
      "        trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.\n",
      "        No patients with a history of coronary artery disease with angina pectoris or history of\n",
      "        congestive heart failure.\n",
      "        No patients with a history of cardiac disease, other than angina pectoris or congestive\n",
      "        heart failure, including patients with arrhythmias or conduction system abnormalities will\n",
      "        be considered on an individual basis.\n",
      "        No patients with symptomatic peripheral neuropathy (grade 2 or greater).\n",
      "        No patients with a positive serology for HIV.\n",
      "        No patients who are pregnant or unwilling to practice adequate contraception.\n",
      "        No patients with prior bone marrow transplantation or extensive irradiation resulting in\n",
      "        compromised bone marrow reserve.\n",
      "1105\n",
      "Diagnosis of HNPCC patient or HNPCC carrier status defined by:\n",
      "        HNPCC patient is an individual with a personal history of RER plus HNPCC related\n",
      "        malignancy AND; meets the Amsterdam criteria or modified Amsterdam criteria (an HNPCC\n",
      "        associated extracolonic cancer may be substituted for one of the three colorectal cases in\n",
      "        one family otherwise required by these criteria) OR; having a definite mutation of one of\n",
      "        the HNPCC - related genes identified by gene sequencing or other method of reliability.\n",
      "        This includes gene status determined through segregation analysis in cases in which\n",
      "        \"direct\" testing yields no alteration.\n",
      "        HNPCC carrier is a relative of an individual meeting the criteria of an \"HNPCC patient\" as\n",
      "        described above and having a mutation of one of the HNPCC-related genes identified by gene\n",
      "        sequencing or other method of equivalent reliability (this includes gene status determined\n",
      "        through segregation analysis in cases in which direct testing yields no alterations, as\n",
      "        above) OR; having an RER plus adenoma.\n",
      "        Age greater than or equal to 18 years.\n",
      "        Voluntary consent documented by a signed and witnessed informed consent.\n",
      "        Willingness to abstain from use of NSAID's (including aspirin), oral\n",
      "        adrenocorticosteroids, and other nonsterodial OTC products for the duration of the study.\n",
      "        If patient is female and of childbearing potential, she must meet all of the following\n",
      "        conditions:\n",
      "        Have been using adequate contraception (e.g., abstinence, condom, IUD, birth control pill,\n",
      "        diaphragm and spermicide gel combination) since her last menses AND;\n",
      "        Be willing to use adequate contraception (as above) during the study AND;\n",
      "        Not be breastfeeding AND;\n",
      "        Have a negative serum pregnancy test within 14 days prior to study drug administration.\n",
      "        Though an individual with prior colorectal surgery is allowed, the subject must have\n",
      "        greater than or equal to 50 percent of the colorectum with documentation describing the\n",
      "        post-surgical anatomy (e.g., operative report).\n",
      "        No use of investigational agent within the last 3 months, or at the discretion of the\n",
      "        medical monitor.\n",
      "        The subject will be allowed to proceed to baseline colonoscopy so long as all of the\n",
      "        following laboratory criteria are met on baseline evaluation: Hgb greater than 10.0 gm/dl,\n",
      "        platelet count greater than 100,000/ul; WBC greater than 3,000/ul; ALT less than 1.5 x\n",
      "        upper limit of normal; AST less than 1.5 x upper limit of normal, alkaline phosphatase\n",
      "        less than 1.5 x upper limit of normal, total bilirubin less than 1.2 x upper limit of\n",
      "        normal, creatinine less than 1.5 x upper limit of normal, negative pregnancy test. For\n",
      "        tests not mentioned specifically, there must be no clinically significant abnormalities\n",
      "        which in the opinion of the PI would preclude a subject's safe participation.\n",
      "        To proceed to randomization, the subject must have all of the following:\n",
      "        An assessable colon or colonic segment (greater than or equal to 50 percent) which was\n",
      "        endoscopically evaluated in its entirety following an adequate preparative procedure AND;\n",
      "        An assessment of aberrant crypt foci via \"enhanced\" endoscopy 10 cm distal to the\n",
      "        ileocecal valve or 10 cm distal to the anastamosis and at the distal most 10 cm from the\n",
      "        rectum AND;\n",
      "        All polyps must have been removed with the exception of small polyps (less than or equal\n",
      "        to 0.6 cm in maximal diameter) amenable to serial endoscopic surveillance AND;\n",
      "        Mucosal sampling via pinch biopsies must have been obtained from normal-appearing mucosa\n",
      "        in standardized areas of the right and left colon (or surrogate regions in the case of\n",
      "        prior surgical resections) and from any areas that are clearly neoplastic or suspicious\n",
      "        for neoplastic pathologies (ACF, adenomas, carcinomas) of interest.\n",
      "        No anticipated colectomy within eighteen months of randomization.\n",
      "        No history of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAID's or salicylates.\n",
      "        No use of NSAID's (including aspirin) or oral adrenocorticosteroids, at any dose at a\n",
      "        frequency averaging greater than 3 times per week during the six months prior to study\n",
      "        entry. Use of such NSAID's or oral adrenocorticosteroids at the above frequency will\n",
      "        require a six-month washout period prior to eligibility, beginning with the time of the\n",
      "        patient's last dose. Use of any dose of NSAID's or oral adrenocorticosteroids, at an\n",
      "        average frequency of 1-3 times per week during the six months prior to study entry will\n",
      "        require a three-month washout period beginning with the time of last dose.\n",
      "        No history in the past year of discrete gastric or duodenal ulcer of size greater than 5\n",
      "        mm, except that patients with a history of Helicobacter pylori-related peptic ulcer\n",
      "        disease may become eligible for study upon successfully completing antibiotic treatment of\n",
      "        Helicobacter pylori.\n",
      "        Ability to participate in the scheduled follow-up tests.\n",
      "        No significant medical or psychiatric problems which would make the patient a poor\n",
      "        protocol candidate, in the opinion of the principal investigator.\n",
      "        No \"unacceptable clinical risk\" to proceed (based upon the subclinical discoveries made\n",
      "        via baseline colonoscopy and biopsies) including a previously-unknown bleeding diathesis,\n",
      "        a new diagnosis of carcinoma, suspicion that the subject may require colectomy (complete\n",
      "        or partial) within eighteen months of randomization.\n",
      "        Patient must not have undergone a colectomy within the past 6 months.\n",
      "        Patient must not have undergone chemotherapy within the past 6 months.\n",
      "        Patient must not have received pelvic radiation.\n",
      "1106\n",
      "-  INCLUSION CRITERIA:\n",
      "        Non-Hodgkin's lymphomas in the following categories: diffuse large B cell to include gray\n",
      "        zone lymphoma and follicular center cell grade IIIB, anaplastic large cell, and aggressive\n",
      "        T-cell lymphomas and Burkitt Lymphoma.\n",
      "        Patients with evidence of an underlying low-grade lymphoma will not be eligible for this\n",
      "        study. This includes patients who have both indolent and aggressive histologies in the\n",
      "        same or different biopsy sites (e.g. large cell lymphoma in a node and follicular center\n",
      "        cell lymphoma in the bone marrow).\n",
      "        Diagnosis confirmed by staff of the Hematopathology Section, Laboratory of Pathology, NCI.\n",
      "        Tissue blocks from patients treated in extramural sites must be forwarded to the NCI for\n",
      "        analysis of bcl-2 by IHC and other markers within 1 month of study entry.\n",
      "        Patients greater than or equal to 12 years old.\n",
      "        Stage and Prognosis of Patients: Stages II, III, IV for all subtypes, and stage I bulky\n",
      "        (greater than 5 cm) primary mediastinal B-cell lymphomas or Burkitt Lymphoma.\n",
      "        No prior systemic chemotherapy. Patients may be entered if they have had prior\n",
      "        limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for\n",
      "        an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava\n",
      "        syndrome).\n",
      "        HIV negative.\n",
      "        Not pregnant or nursing.\n",
      "        Adequate major organ function [in adults: serum creatinine less than or equal to 1.5 mg/dl\n",
      "        or creatinine clearance greater than 60 ml/min; and in children serum CR less than or\n",
      "        equal to age-adjusted normal (age 12 to 15 maximum serum creatinine 1.2 mg/dl and age\n",
      "        greater than 15 maximum serum creatinine 1.5 mg/dl); bilirubin less than 1.5 mg/dl; ANC\n",
      "        greater than 1,000 and platelets greater than 100,000) unless impairment is due to organ\n",
      "        involvement by lymphoma or immune-mediated mechanism caused by lymphoma.\n",
      "        No active symptomatic ischemic heart disease, myocardial infarction or congestive heart\n",
      "        failure within the past year. If MUGA is obtained, the LVEF should exceed 40%.\n",
      "        No other serious concomitant medical illnesses or uncontrolled active infection that would\n",
      "        jeopardize the patient's ability to receive the regimen with reasonable safety.\n",
      "        No history of unrelated (non-lymphomatous) neoplasms within past 5 years other than\n",
      "        non-melanoma skin cancer or in-situ cancer.\n",
      "        Ability to give informed consent.\n",
      "1107\n",
      "Left ventricular ejection fraction by radionuclide angiography of less than or equal to\n",
      "        40%.\n",
      "        New York Heart Association class II, III or IV symptoms on standard heart failure\n",
      "        medications which my include digoxin, diuretics and angiotensin converting enzyme\n",
      "        inhibitors for at least one month prior to enrollment.\n",
      "        Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major\n",
      "        vessel.\n",
      "        Dilated cardiomyopathy-if no coronary disease.\n",
      "        No pregnant or lactating women.\n",
      "        No women of child-bearing age not on proven birth control.\n",
      "        No severe hepatic or renal disease.\n",
      "        No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.\n",
      "        No primary valvular heart disease.\n",
      "        No PTCA or CABG within 3 months of enrollment.\n",
      "        No history of myocardial infarction or unstable angina within past 2 months.\n",
      "        No resting heart rate less than 60 bpm.\n",
      "        No A-V block greater than 1 degree block without pacemaker.\n",
      "        No severe ETOH abuse within 6 months of enrollment.\n",
      "        No severe bronchospasm.\n",
      "1110\n",
      "Patients with AIDS or symptomatic HIV infection who have 10-350 CD4+ T cells per mm(3) and\n",
      "        an estimated life-expectancy of over 3 months.\n",
      "        For the purpose of this study, a patient is defined as having symptomatic HIV infection if\n",
      "        he or she has a history of or has active thrush (oral candidiasis); a history of or active\n",
      "        oral hairy leukoplakia; herpes zoster within the last 3 years; recurrent seborrheic\n",
      "        dermatitis or puritic folliculitis; weight loss of 4.5 kg or 10 percent of body weight not\n",
      "        caused by dieting; unexplained intermittent diarrhea (2 or more liquid stools per day)\n",
      "        within the last 4 months; night sweats; mild cognitive impairment; or fatigue interfering\n",
      "        with activity within the past 6 months.\n",
      "        Lymphadenopathy will not, in itself, be considered as sufficient for being considered as\n",
      "        having symptomatic HIV infection.\n",
      "        All patients must have serum antibodies to HIV, ambulatory status, and capacity to give\n",
      "        informed consent.\n",
      "        No prior use of dideoxynucleoside therapy (including but not restricted to AZT, ddC, or\n",
      "        ddI) for over 3 months. However, preference will be given to patients who have received\n",
      "        them for 1 month or less.\n",
      "        No pregnancy or the possibility of becoming pregnant during drug administration. Female\n",
      "        patients of child-bearing age must have a negative pregnancy test just prior to enrollment\n",
      "        and agree to practice birth control while on the protocol.\n",
      "        No past or present evidence of renal disease (CRC1 estimated or determined to be less than\n",
      "        50 ml/min/1.73 m2).\n",
      "        Patients will be excluded if they have any one of the following hematologic abnormalities:\n",
      "        Hb less than 10.0 gm per dl or transfusion within the last month, or\n",
      "        WBC less than 2000 per mm(3) or\n",
      "        Platelets less than 75,000 per mm(3).\n",
      "        No history of hepatic cirrhosis or present hepatic dysfunction with:\n",
      "        Total bilirubin greater than 3.0 mg per dl (2x the upper limit of normal).\n",
      "        Alkaline phosphatase greater than 372 U per l (3x the upper limit of normal).\n",
      "        AST/GOT greater than 132 U per l (3x the upper limit of normal).\n",
      "        No evidence of severe diarrhea (over 5 stools per day), an underlying severe infection\n",
      "        (including CMV retinitis, colitis, or pneumonitis); or evidence of Kaposi's sarcoma or\n",
      "        other tumor which is likely to require specific anti-tumor therapy within 24 months of\n",
      "        entering the study:\n",
      "        As a practical matter, only patients with Kaposi's sarcoma who have a few cutaneous\n",
      "        lesions with no mucosal or internal lesions will be eligible.\n",
      "        Patients will be ineligible if they have some evidence of active life-threatening\n",
      "        infections with bacterial, viral, fungal, or protozoan pathogens at the time of entry into\n",
      "        the study. In general, patients who have had a fever of 39 degrees Celsius within the past\n",
      "        10 days will in general be ineligible unless it is apparent that this is not the result of\n",
      "        a severe underlying infection.\n",
      "        No known hypersensitivity reactions to or major toxicities from AZT or ddI. (This would\n",
      "        include anaphylaxis reactions, hives, or Stevens Johnson syndrome, but would not include\n",
      "        the minor rash occasionally seen with ddI.)\n",
      "        Patients must be willing to give informed consent, attend the outpatient clinic, and\n",
      "        refrain from unprotected sexual contact or other activities which may result in\n",
      "        re-infection with HIV. Present use of illicit drugs (for example, heroin or cocaine) or\n",
      "        ingestion of substantial alcohol (enough to increase the risk of pancreatitis) will\n",
      "        exclude the patient from the study.\n",
      "        No evidence of underlying cardiac disease, history of pancreatitis, or peripheral\n",
      "        neuropathy.\n",
      "        No treatment within the last 4 months with suramin, treatment within the last 3 months\n",
      "        with ribavirin, or treatment within the past 4 weeks with any anti-retroviral drug,\n",
      "        cytotoxic chemotherapeutic agents, steroids, interferon, or immunomodulating agents.\n",
      "1111\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed adenocarcinoma of the prostate as follows: Unresectable and/or\n",
      "        incurable tumor AND Tumor progression after at least 1 prior hormonal manipulation (i.e.,\n",
      "        LHRH agonist/flutamide or orchiectomy). LHRH agonist may by continued concurrently with\n",
      "        protocol therapy.\n",
      "        New bone or soft tissue lesions OR Serum PSA that has risen on 3 successive evaluations at\n",
      "        least 1 week apart during and/or after hormonal therapy. If PSA is below 4 ng/mL,\n",
      "        measurable disease with positive immunohistochemical stain for PSA is required.\n",
      "        No history of allergy to eggs.\n",
      "        No history of or active CNS metastases.\n",
      "        Symptomatic spinal or other bony metastasis should be irradiated prior to entry.\n",
      "        Bi-dimensionally measurable disease not required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy:\n",
      "        No concurrent Biologic Therapy.\n",
      "        Must fully recover from prior Biologic Therapy.\n",
      "        Chemotherapy:\n",
      "        At least 4 weeks since prior chemotherapy and fully recovered.\n",
      "        No more than 1 prior chemotherapy regimen.\n",
      "        No concurrent chemotherapy.\n",
      "        Endocrine Therapy:\n",
      "        See Disease Characteristics.\n",
      "        At least 4 weeks since prior hormonal therapy and fully recovered.\n",
      "        No concurrent steroids.\n",
      "        Radiotherapy:\n",
      "        At least 4 weeks since prior radiation therapy and fully recovered.\n",
      "        No prior radiotherapy to more than 50% of nodal groups.\n",
      "        No concurrent radiotherapy.\n",
      "        Surgery:\n",
      "        At least 4 weeks since prior surgery, with surgical scar healed.\n",
      "        No prior splenectomy.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: Over 18.\n",
      "        Performance status: Zubrod (ECOG) 0-2.\n",
      "        Hematopoietic:\n",
      "        Absolute granulocyte count greater than 2,000/mm(3);\n",
      "        Platelet count greater than 100,000/mm(3);\n",
      "        Hemoglobin greater than 8.0 g/dL.\n",
      "        Hepatic:\n",
      "        Bilirubin less than 1.6 mg/dL;\n",
      "        AST and ALT less than 4 times normal.\n",
      "        Renal: Creatinine less than 1.6 mg/dL.\n",
      "        Immunologic:\n",
      "        Prior vaccinia (for smallpox immunization) required, with proof of vaccination as follows:\n",
      "        Detectable anti-vaccinia antibodies, Physician certification of prior vaccination, Patient\n",
      "        recollection or appropriate vaccination-site scar sufficient in patients over age 25,\n",
      "        Delayed-type hypersensitivity skin testing (to mumps, Candida, and Trichophyton antigens)\n",
      "        normal Quantitative immunoglobulins normal.\n",
      "        No evidence of immunocompromise, i.e.:\n",
      "        No HIV antibody;\n",
      "        No eczema or atopic dermatitis;\n",
      "        No autoimmune neutropenia, thrombocytopenia, or hemolytic anemia;\n",
      "        No systemic lupus erythematosus, Sjogren syndrome, or scleroderma;\n",
      "        No myasthenia gravis;\n",
      "        No Goodpasture syndrome;\n",
      "        No Addison's disease, Hashimoto's thyroiditis, or active Graves' disease;\n",
      "        No other autoimmune disease or diagnosis of altered immune function.\n",
      "        OTHER:\n",
      "        No active case or history of extensive psoriasis, severe acneiform rash, impetigo,\n",
      "        varicella zoster, burns, or other traumatic or pruritic skin condition.\n",
      "        No active infection requiring antibiotics (including chronic suppressive therapy). At\n",
      "        least 3 days since antibiotic therapy.\n",
      "        No history of seizures, encephalitis, or multiple sclerosis.\n",
      "        No other serious intercurrent illness.\n",
      "        Able to avoid close contact with the following individuals for at least 2 weeks after\n",
      "        vaccination (i.e., no such individuals as household members and no care-giving\n",
      "        responsibilities for such individuals): Children under age 3, Pregnant women, Individuals\n",
      "        with eczema or skin conditions defined above, Leukemia or lymphoma patients, HIV-positive\n",
      "        individuals, Patients receiving immunosuppressive therapy, Any other immunosuppressed\n",
      "        individuals.\n",
      "        No prior malignancy unless curatively treated and patient has been in remission for at\n",
      "        least 2 years (excluding squamous cell or basal cell carcinoma of the skin or carcinoma in\n",
      "        situ of the cervix).\n",
      "        Able and willing to travel to the NIH, NCI-NMOB, or the Lombardi Cancer Center at\n",
      "        Georgetown University for treatment and follow-up.\n",
      "1112\n",
      "Must be over 18 years of age.\n",
      "        Must not have personal history of seizures, loss of consciousness, hypertension,\n",
      "        psychosis, heart conditions or allergies to any of the drugs.\n",
      "        Women must not be nursing or pregnant.\n",
      "        Patients may have amputations, spinal cord injuries, blindness or large hemispheric\n",
      "        lesions from stroke.\n",
      "1113\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven malignancy considered refractory to standard therapy. Objective\n",
      "        evidence of progression on prior therapy required.\n",
      "        No leukemia.\n",
      "        Bone marrow involvement by tumor acceptable. Marrow biopsy required if there is a history\n",
      "        of involvement or peripheral counts are inadequate.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Recovery from toxic effects of prior immunotherapy required.\n",
      "        Chemotherapy: No more than 2 prior chemotherapy regimens and recovered. At least 2 weeks\n",
      "        since myelosuppressive therapy (6 weeks since nitrosoureas).\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy:\n",
      "        No prior central axis irradiation (i.e., skull, spine, ribs, pelvis).\n",
      "        Recovery from toxic effects of prior radiotherapy required.\n",
      "        Surgery: Not specified.\n",
      "        Other: No prior bone marrow transplantation.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 21 and under.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        Hematopoietic:\n",
      "        (unless histologic evidence of bone marrow involvement by tumor).\n",
      "        AGC at least 1,500/mm3.\n",
      "        Platelet count at least 100,000/mm3.\n",
      "        Hemoglobin at least 8.0 g/dL.\n",
      "        Prior transfusion acceptable.\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 2 times normal.\n",
      "        ALT no greater than 2 times normal.\n",
      "        Renal:\n",
      "        Creatinine less than 1.5 mg/dL OR\n",
      "        Creatinine clearance greater than 60 mL/min/1.73 sqm.\n",
      "        Cardiovascular: Not specified.\n",
      "        Pulmonary: Not specified.\n",
      "        OTHER:\n",
      "        No significant accumulation of third space fluid.\n",
      "        No significant systemic illness (e.g., infection).\n",
      "        No pregnant or nursing women.\n",
      "        Pregnancy test required in fertile women.\n",
      "        All patients or their guardians must sign an informed consent.\n",
      "1118\n",
      "18 to 60 years of age, HIV-1 negative by HIV-1 ELISA, HIV PCR and Western Blot analysis.\n",
      "        Subjects in good health with no evidence of underlying disease based on history, physical\n",
      "        exam and laboratory analysis.\n",
      "        Must have normal organ function as characterized by the following:\n",
      "        Hematopoietic: absolute granulocyte count of at least 1500/mm(3); platelet count of at\n",
      "        least 150, 000/mm(3); hematocrit within normal range.\n",
      "        Renal: BUN less than 23 mg/dl; creatine less than 1.6 mg/dl.\n",
      "        Hepatic: serum total bilirubin less than 1.5 mg%.\n",
      "        Metabolic: ALT less than or equal to 1.5 x upper limit of normal range; serum calcium\n",
      "        within normal range; serum lactate within normal range; total serum CPK within normal\n",
      "        range.\n",
      "        Endocrine: serum glucose -- within normal range.\n",
      "        Immunologic: CD4 count greater than or equal to 500 cells/mm(3); total serum\n",
      "        immunoglobulin (IgM, IgG and IgA) levels within normal ranges.\n",
      "        No other clinically significant laboratory abnormalities.\n",
      "        All subjects must understand the basis of transmission of HIV and other common sexual and\n",
      "        blood borne infections and agree to practice abstinence or clinically accepted methods of\n",
      "        prevention, including barrier protection during intercourse for the duration of the study.\n",
      "        Female subjects of child bearing potential must have a negative pregnancy test.\n",
      "        Must be available for active follow-up.\n",
      "        Able to give informed consent by signing the Institutional Review Board (IRB)-approved\n",
      "        consent form(s).\n",
      "        Must not have previous immunization with any experimental vaccine directed against HIV or\n",
      "        receipt of any experimental agent within 30 days prior to enrollment.\n",
      "        Must not receive any blood product or immunoglobulin within 6 months prior to enrollment.\n",
      "        Must not be exposed to potentially infective HIV fluids within the prior 6 months or\n",
      "        tested positive for HIV at any time.\n",
      "        No history of any prior disease or therapy which would affect immune function including:\n",
      "        Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma of the\n",
      "        skin or carcinoma in situ of the cervix;\n",
      "        Radiation therapy or cytotoxic/cancer chemotherapy;\n",
      "        immunodeficiency or auto-immune disease;\n",
      "        Acute infection or a recent (within 6 months) history of chronic infection.\n",
      "        Female subjects must not be nursing a child.\n",
      "        Must not be taking any medication which may affect immune function, with the following\n",
      "        exceptions: subjects may be taking low doses of nonprescription strength NSAIDS (e.g.\n",
      "        ibuprofen or aspirin) or acetaminophen.\n",
      "        No known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as\n",
      "        lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or of any\n",
      "        serious adverse reactions to vaccines.\n",
      "        No evidence of active drug or alcohol abuse or uncontrolled (unstable) psychiatric\n",
      "        disorders which would interfere with study participation.\n",
      "        Must not be engaging in HIV-related high-risk behavior such as unprotected sex, sex with\n",
      "        multiple partners, or intravenous drug use.\n",
      "        No evidence of infection with HBV, HIV-1, HCV or HTLV-1 using standard testing procedures.\n",
      "        Must not have any positive result for anti-DNA antibodies as measured by standard testing\n",
      "        procedures (anti-DNA antibody and anti-nuclear antibody (ANA) assays. This study does\n",
      "        permit enrollment of volunteers with a low positive ANA (less than or equal to 1:160)\n",
      "        titers, if there is no clinical evidence of underlying disorders that are associated with\n",
      "        a positive ANA, if no first degree relative has an autoimmune disease, and if anti-DNA and\n",
      "        ENA are negative.\n",
      "1122\n",
      "Patients age greater than or equal to 18 years.\n",
      "        Patients with histologically proven gastrointestinal adenocarcinoma, mesothelioma, or\n",
      "        sarcoma. By standard staging studies there must be evidence of advanced or metastatic\n",
      "        intraabdominal disease. Patients with minimal extraabdominal metastatic disease and who\n",
      "        have symptoms exclusively referable to advanced intraabdominal malignancy will be\n",
      "        considered for the study. Specifically, patients with gastric cancer and bulky N-2 lymph\n",
      "        node involvement or patients with other primaries and who have malignant ascites or\n",
      "        peritoneal seeding would be considered optimal candidates. If all gross peritoneal disease\n",
      "        is resected (i.e., gross omental implants removed by gastrectomy), patients are still\n",
      "        eligible for treatment.\n",
      "        Patients must have recovered from any toxicity from all prior chemotherapy, immunotherapy,\n",
      "        or radiotherapy (30 days).\n",
      "        Patients must not have any significant systemic illness (e.g., infection, cardiovascular,\n",
      "        or pulmonary) which would preclude them from being an operative candidate.\n",
      "        patients must have a life expectancy of at least 8 weeks.\n",
      "        Performance status should be ECOG level 0, 1, or 2.\n",
      "        Patients must have adequate renal function (i.e., serum creatinine less than or equal to\n",
      "        2.0 or creatinine clearance of greater than or equal to 45 ml/min).\n",
      "        Patients must be HIV negative.\n",
      "        Women of child bearing age must not be pregnant or breast feeding.\n",
      "        Patients with prior CDDP will be eligible if there is no evidence of existing irreversible\n",
      "        CDDP toxicity. Patients suspected of having chronic CDDP toxicity will be further\n",
      "        evaluated as clinically indicated.\n",
      "        Patients may have mild elevations (less than 2.0 times normal) in liver function test if\n",
      "        the abnormalities are consistent with advanced intra-abdominal cancer.\n",
      "        Abnormalities (greater than 1 sec over normal) in PT or PTT or severe thrombocytopenia\n",
      "        (less than 75 K) will render patients ineligible.\n",
      "        A low Hgb secondary to chronic tumor-related, blood loss is acceptable if the patient is\n",
      "        willing and able to have transfusion.\n",
      "        Patients will be ineligible if the WBC is less than 3,000.\n",
      "1124\n",
      "INCLUSION CRITERIA:\n",
      "        Normal Volunteers:\n",
      "        The desired age range is 18 to 55 years.\n",
      "        Subjects will have no history of head injury or other neurological disease and must not be\n",
      "        taking any medication.\n",
      "        Female subjects of childbearing potential will be administered a pregnancy test; these\n",
      "        subjects will not be eligible for the study requiring 2 scans.\n",
      "        All volunteers will read and sign the consent form.\n",
      "        Patients:\n",
      "        Patients will be selected from among those referred to the Clinical Epilepsy Section,\n",
      "        NINDS for evaluation.\n",
      "        \n",
      "1125\n",
      "-  INCLUSION CRITERIA:\n",
      "        Women 18 to 42 years of age with primary ovarian insufficiency who meet the following\n",
      "        requirements were candidates for recruitment to the study: 1) at least a four month\n",
      "        history of oligo-amenorrhea not due to pregnancy, and 2) clearly elevated gonadotropins in\n",
      "        the menopausal range on two separate occasions at least one month apart.\n",
      "        \n",
      "1127\n",
      "-  INCLUSION CRITERIA:\n",
      "               1. 18 to 45 years of age, either male or female\n",
      "               2. Employees or non-employees are eligible\n",
      "               3. Normal screening examination:\n",
      "                    1. history and physical examination, nonsmoker, no concurrent medications\n",
      "                       including aspirin or nonsteroidal anti-inflammatory drugs, no active\n",
      "                       medical problems;\n",
      "                    2. complete blood count with differential and platelet counts;\n",
      "                    3. serum chemistries including creatinine, blood urea nitrogen, glucose, liver\n",
      "                       enzymes and function tests, electrolytes, prothrombin time, partial\n",
      "                       thromboplastin time;\n",
      "                    4. urinalysis;\n",
      "                    5. female subjects must have negative urine pregnancy test within one week of\n",
      "                       participation;\n",
      "                    6. electrocardiogram;\n",
      "                    7. chest radiograph.\n",
      "               4. If age is 40 to 45 years, normal submaximal stress test to screen for\n",
      "                  asymptomatic coronary artery disease.\n",
      "        \n",
      "1129\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Leukemia, lymphoma, or solid tumor with overt meningeal involvement considered refractory\n",
      "        to conventional therapy.\n",
      "        CSF leukemic cell count at least 5 per cubic millimeter with evidence of blast cells on\n",
      "        cytospin or cytology required for leukemia and lymphoma patients.\n",
      "        Tumor cells on cytospin or cytology or measurable meningeal disease on CT or MRI required\n",
      "        for patients with solid tumors.\n",
      "        No clinical evidence of obstructive hydrocephalus or compartmentalization of the CSF flow\n",
      "        as documented by indium-111- or technetium-99-DPTA flow study.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        At least 1 week since CNS therapy.\n",
      "        Biologic Therapy: Recovery from toxic effects of prior immunotherapy required.\n",
      "        Chemotherapy:\n",
      "        Recovery from toxic effects of prior chemotherapy required.\n",
      "        No concomitant therapy to treat meningeal malignancy (intrathecal or systemic).\n",
      "        Concomitant chemotherapy to control systemic disease or bulk CNS disease allowed except:\n",
      "        Investigational agents. Agents that penetrate the CNS (e.g., high-dose methotrexate,\n",
      "        thiotepa, high-dose cytarabine, fluorouracil, intravenous mercaptopurine).\n",
      "        Agents known to have serious unpredictable CNS side effects.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: Recovery from toxic effects of prior radiotherapy required. Patient eligible\n",
      "        if flow restored following focal radiotherapy to the blockage site.\n",
      "        Surgery: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 3 and over (older patients giving consent will be enrolled before the very young, if\n",
      "        possible).\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        Hematopoietic: See Disease Characteristics.\n",
      "        Hepatic: Bilirubin less than 2.0 mg/dL, SGPT less than 3 times normal.\n",
      "        Renal: Creatinine less than 1.5 mg/dL.\n",
      "        Metabolic: Serum electrolytes (including calcium and phosphate) normal.\n",
      "        Other: No significant systemic illness (e.g., infection). Not pregnant or lactating.\n",
      "1136\n",
      "-  INCLUSION CRITERIA:\n",
      "        Volunteers will qualify for inclusion under this protocol if they meet the following\n",
      "        criteria:\n",
      "          1. Good general health. Individuals with renal, hepatic, most endocrinologic (e.g.\n",
      "             hypothyroidism, or Cushing syndrome), or pulmonary disorders (other than mild asthma\n",
      "             not requiring chronic medication) will be excluded.\n",
      "          2. For obese subjects, body mass index for age above the 85th percentile (determined by\n",
      "             NHANES I age-, sex-, and race-special data). For normal weight subjects of obese\n",
      "             parents, body mass index (determined by NHANES I age-, sex-, and race- specific data)\n",
      "             between the 5th and 85th percentile and both parents' current body mass index above\n",
      "             25 kg/m(2), or a history of a body mass index above 25 kg/m(2).\n",
      "          3. No significant psychiatric illness.\n",
      "          4. At initial visit, Tanner I (prepubertal) or Tanner II (early pubertal) pubic hair and\n",
      "             breast stage of development for girls, and Tanner I or Tanner II pubic hair and\n",
      "             testes size (6ml) for boys.\n",
      "          5. Subjects must be able to undergo MRI. Volunteers with metal in their bodies that are\n",
      "             contraindications for MRI will be excluded. These include cardiac pacemakers, neural\n",
      "             pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants,\n",
      "             non-detachable electronic or electromechanical devices (such as infusion pumps, nerve\n",
      "             stimulators, bone growth stimulators, etc.).\n",
      "          6. Age 6 to12 years at the start of the study.\n",
      "          7. For girls who have been followed to an age when they are menstruating (or are of an\n",
      "             age when pregnancy is a possibility), a negative pregnancy test.\n",
      "          8. Race of all 4 grandparents self-identified either as all Caucasian or all African\n",
      "             American.\n",
      "1143\n",
      "Subjects must be at least 18 years of age.\n",
      "        Subjects eligible for this study will be those enrolled in NIDDK protocol 98-DK-0003 and\n",
      "        consequently at increased risk for the development of neuropsychiatric toxicity.\n",
      "        Subjects must be able to provide informed consent.\n",
      "        No individuals who are critically ill or markedly agitated or confused.\n",
      "        No individuals with implanted cardiac pacemakers or autodefibrillators.\n",
      "        No individuals with implanted neural pacemakers.\n",
      "        No individuals with CNS aneurysmal clips.\n",
      "        No individuals with cochlear implants.\n",
      "        No individuals with metallic foreign bodies in the eye or CNS.\n",
      "        No individuals with any form of implanted wire or metal device which may concentrate\n",
      "        radiofrequency fields.\n",
      "        No pregnant women.\n",
      "        No individuals with a history of moderate to severe claustrophobia.\n",
      "1145\n",
      "-  INCLUSION CRITERIA\n",
      "        Participant is 18 years of age or older.\n",
      "        Participant has a diagnosis of sight-threatening, intermediate or posterior uveitis of at\n",
      "        least three months duration prior to orginal enrollment, requiring treatment to control\n",
      "        their intraocular inflammatory disease with at least 20 mg/day of prednisone (or\n",
      "        equivalent) or any combination of two or more anti-inflammatory treatments for uveitis,\n",
      "        including for example prednisone, cyclophosphamide, cyclosporine, azathioprine,\n",
      "        mycophenolate mofetil, methotrexate, etc.\n",
      "        Participant exhibits intolerance to the indicated systemic medications required for their\n",
      "        uveitis or, though their uveitis may be under control, wish to be taken off their present\n",
      "        medications due to potential or actual unacceptable side effects.\n",
      "        Participant has visual acuity in at least one eye of 20/63 or better (ETDRS, logMAR less\n",
      "        than 0.54).\n",
      "        Participant has normal renal or liver function or evidence of no worse than mild\n",
      "        abnormalities as defined by the WHO/NEI criteria.\n",
      "        Participant is not currently pregnant or lactating.\n",
      "        Participant with reproductive potential and who is sexually active agrees to use\n",
      "        acceptable birth control methods throughout the course of the study.\n",
      "        \n",
      "1146\n",
      "-  INCLUSION CRITERIA:\n",
      "        Volunteers participating in this study will be women meeting the following criteria:\n",
      "        Between the ages of 18 and 50 years,\n",
      "        Not pregnant,\n",
      "        In good medical health,\n",
      "        Medication free,\n",
      "        No history of menstrual-related mood or behavioral disturbances.\n",
      "        Additionally, we will recruit a subsample of 20 asymptomatic women who will meet all\n",
      "        inclusion and \n",
      "1150\n",
      "The patient must fall into one of the following diagnostic categories:\n",
      "        Ewing's sarcoma family of tumors (ESF): Includes Ewing's sarcoma (classic, atypical,\n",
      "        extra-osseous), primitive sarcoma of bone, ectomesenchymoma, or peripheral primitive\n",
      "        neuroectodermal tumor (peripheral neuroepithelioma).\n",
      "        Rhabdomyosarcoma: The patient must have either\n",
      "        High-risk arm: Metastatic disease at diagnosis (any site, any histology);\n",
      "        OR\n",
      "        Moderate-risk arm: Incompletely resected ( Clinical Group III) Stage II tumors and ALL\n",
      "        stage III tumors (regardless of degree of surgical resection).\n",
      "        Neuroblastoma: Any patient with metastatic disease at diagnosis (POG stage D or Evans'\n",
      "        stage IV); or, patients with loco-regional metastatic disease (POG stage C) or tumor\n",
      "        infiltrating across the midline (Evans' stage III) IF they have an elevated serum ferritin\n",
      "        (greater than 142 ng/ml), an amplified N-myc copy number (greater than 10 copies on\n",
      "        Southern analysis), or a DNA index of greater than 1.1.\n",
      "        The patient must not have been previously treated with chemotherapy or radiation therapy.\n",
      "        Patients must be greater than or equal to 1 year of age but less than or equal to 25 years\n",
      "        of age. Patients weight must be greater than or equal to 15 kg.\n",
      "        The patient (or his/her guardian if less than 18 years of age) must sign a document\n",
      "        indicating that he/she is aware of the investigational nature of this treatment protocol\n",
      "        and the potential risks and benefits that may be expected.\n",
      "        Potentially fertile female patients must have a documented negative urine or serum\n",
      "        pregnancy test.\n",
      "        Patients must have a documented negative HIV serologic evaluation (Western Blot and/or\n",
      "        ELISA).\n",
      "        Patients must not have abnormal cardiac function (left ventricular ejection fraction less\n",
      "        than 45% as measured by gated equilibrium radionuclide angiography [MUGA scan] and\n",
      "        confirmed by echocardiography).\n",
      "        Patients must not have impaired renal function (serum creatinine greater than or equal to\n",
      "        twice the upper limit of normal for age).\n",
      "        Patients with a total bilirubin of greater than 4.0 mg/dl (or a direct bilirubin of\n",
      "        greater than 2.0 mg/dl) or SGOT/SGPT greater than five times the upper limits of normal\n",
      "        (NOT on the basis of hepatic involvement by tumor) will be excluded.\n",
      "        Patients with a second malignancy following previous therapy will be excluded.\n",
      "        Patients previously treated with chemotherapy or radiation therapy (other than limited,\n",
      "        emergency radiation therapy) will be excluded.\n",
      "        Patients who are HIV-infected will be excluced.\n",
      "1154\n",
      "Volunteers must be healthy individuals between the ages of 18 and 45 years old.\n",
      "        No pregnant women.\n",
      "        No history of menstrually-related mood or behavioral disturbances.\n",
      "        No volunteers with current or past Axis I diagnoses, significant abnormalities on physical\n",
      "        or neurological examination, or significant laboratory abnormalities.\n",
      "        Must be HIV negative.\n",
      "1156\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patient Selection:\n",
      "        Patients with IgG or IgA multiple myeloma who attain at least a PR before transplantation\n",
      "        are eligible for thsi protocol.\n",
      "        Patients may only have received 3-4 courses of VAD, high dose cyclophosphamide and one\n",
      "        autologous transplant before entering the study.\n",
      "        All previous therapy must be completed at least 2 weeks prior to study entry.\n",
      "        Patients should have recovered from all hematologic and non-hematologic toxicity of\n",
      "        previous therapy.\n",
      "        Steroid must be discontinued at least two weeks prior to vaccination.\n",
      "        Only patients less than 60 years are eligible for this protocol.\n",
      "        Patients must meet the following criteria:\n",
      "        A. Karnofsky performance status greater than or equal to 70 percent.\n",
      "        B. Life expectancy greater than 8 weeks and absence of co-existing medical problems which\n",
      "        would significantly increase the risk of the transplant procedure in the judgment of the\n",
      "        bone marrow transplant attending physicians (e.g., the MUGA left ventricular ejection\n",
      "        fraction has to be greater than 50% and DLCO greater thant 50% of the expected value when\n",
      "        corrected for Hb).\n",
      "        Creatinine less than 2x normal and not rising for at least 2-4 weeks before\n",
      "        transplantation. If creatinine is elevated, then creatinine clearance must be greater than\n",
      "        40 ml/min.\n",
      "        Direct bilirubin less than 2 mg/dl, SGOT less than 4x top normal, and none of these\n",
      "        parameters increasing, for at least 2-4 weeks before transplantation.\n",
      "        Patients must be HIV-negative, HBsAg-, and Hepatitis C antibody Negative.\n",
      "        Not pregnant or lactating. Patients of childbearing potential must use an effective method\n",
      "        of contraception.\n",
      "        M-protein concentration in the harvested plasma must be greater than 90 percent of the\n",
      "        total Ig of the corresponding isotype.\n",
      "        Patients must be greater than or equal to 18 years old.\n",
      "        Donor criteria:\n",
      "        Any consenting healthy individual who fulfills the donor criteria will be considered for\n",
      "        the marrow donation.\n",
      "        HLA-identical sibling donors.\n",
      "        HLA, A and B and DR phenotypically identical family donors.\n",
      "        HIV, hepatitis B or C seropositive.\n",
      "        Complete blood count, platelets, and PT, PTT within normal limits.\n",
      "1166\n",
      "-  INCLUSION CRITERIA:\n",
      "        Girls with Turner syndrome will qualify to participate in this study if they meet the\n",
      "        following criteria:\n",
      "        Karyotype diagnosis compatible with Turner syndrome.\n",
      "        No treatment with estrogen, androgen or growth hormone exceeding twelve months, and no\n",
      "        treatment with either of these agents in the preceding 3 months.\n",
      "        Chronological age of 10.0 to 14.9 years.\n",
      "        Bone age less than or equal to 12 years.\n",
      "        \n",
      "1171\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous\n",
      "        Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma,\n",
      "        primitive sarcoma of bone, and ectomesenchymoma.\n",
      "        Confirmed presence of tumor-specific infusion protein by documented RT-PCR which\n",
      "        corresponds to one of the tumor specific peptides available for vaccination.\n",
      "        Measurable tumor.\n",
      "        No prior or current CNS metastases.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Arm A patients:\n",
      "        May be enrolled on the protocol for the first phase in the absence of RT PCR documentation\n",
      "        of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides\n",
      "        available for vaccination. However, RT PCR documentation at the time of tumor recurrence\n",
      "        must occur prior to administration of immunotherapy. At time of initial tumor diagnosis,\n",
      "        prior to any cytoreductive therapy.\n",
      "        Arm B patients:\n",
      "        Tumor recurrence occurring during or after receiving at least first line cytoreductive\n",
      "        therapy for ESFT and AR. No more than two post-recurrence salvage regimens unless\n",
      "        peripheral CD4+T cell number is greater than 400 cells per millimeter cubed.\n",
      "        At least 6 weeks since any treatments and recovered from all acute toxic effects from time\n",
      "        in which immunotherapy will be started for this study.\n",
      "        No concurrent estrogen therapy during immunotherapy section of study.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).\n",
      "        Weight: Greater than 15 kg (at time of apheresis).\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        Hematopoietic:\n",
      "        ANC greater than 100,000/mm3.\n",
      "        Hemoglobin greater than 9.0 g/dL.\n",
      "        Platelet count greater than 50,000/mm3.\n",
      "        Hepatic:\n",
      "        Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).\n",
      "        Transaminases less than 3 times normal (unless related to involvement by tumor).\n",
      "        Renal:\n",
      "        Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.\n",
      "        Cardiovascular:\n",
      "        No major disorder of cardiovascular system.\n",
      "        Cardiac ejection fraction greater than 40%.\n",
      "        Pulmonary:\n",
      "        No major disorder of pulmonary system.\n",
      "        Other:\n",
      "        Not pregnant or nursing.\n",
      "        HIV negative.\n",
      "        Hepatitis B or C negative.\n",
      "        No patients requiring daily oral corticosteroid therapy.\n",
      "        If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre\n",
      "        syndrome, ineligible to receive influenza vaccine.\n",
      "1172\n",
      "POPULATION CHARACTERISTICS:\n",
      "        Women and men at increased risk for the development of breast cancer by at least one of\n",
      "        the following criteria:\n",
      "        Histologically documented ductal carcinoma in situ (DCIS), including DCIS with minimal\n",
      "        invasion or microinvasion.\n",
      "        Histologically documented lobular neoplasia, including lobular hyperplasia and lobular\n",
      "        carcinoma in situ (LCIS).\n",
      "        Histologically documented atypical ductal hyperplasia in postmenopausal women.\n",
      "        Histologically documented atypical ductal hyperplasia in premenopausal women with 1\n",
      "        first-degree relative (mother or sister) diagnosed with breast cancer.\n",
      "        Histologically documented atypical ductal hyperplasia in premenopausal women with 3 or\n",
      "        more relatives diagnosed with breast cancer provided at least 1 is a second-degree\n",
      "        relative.\n",
      "        3 or more first- or second-degree relatives diagnosed with breast or ovarian cancer with\n",
      "        at least 1 diagnosed with breast cancer.\n",
      "        2 or more premenopausal (under age 50) first-degree relatives diagnosed with breast\n",
      "        cancer.\n",
      "        1 or more first-degree relatives diagnosed with breast cancer if at least 1 relative in\n",
      "        the extended pedigree had ovarian cancer.\n",
      "        3 or more relatives with breast cancer with at least 1 first-degree relative diagnosed\n",
      "        with premenopausal breast cancer.\n",
      "        Previously diagnosed Stage I breast cancer with surgery and/or radiotherapy only (without\n",
      "        prior adjuvant chemo- or hormonal therapy).\n",
      "        Positive for the BRCA1/BRCA2 gene.\n",
      "        No history of other invasive breast cancer.\n",
      "        No evidence of malignancy on breast and gynecologic exams.\n",
      "        Participants with a family history of breast cancer will be seen in consultation by the\n",
      "        Family Studies Branch, NCI.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Mastectomy or lumpectomy plus radiotherapy required prior to entry for patients with DCIS.\n",
      "        Patients with DCIS who have participated in protocol NCI-MB-348 eligible.\n",
      "        No participation in any other breast cancer prevention study involving pharmacologic\n",
      "        intervention.\n",
      "        No prior chemotherapy or hormonal therapy for invasive breast cancer.\n",
      "        At least 3 months since estrogen or progesterone replacement therapy or hormonal\n",
      "        contraceptives.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 35 and over.\n",
      "        Performance status: Ambulatory.\n",
      "        Life expectancy: At least 10 years.\n",
      "        Hematopoietic: Complete blood count normal.\n",
      "        Hepatic:\n",
      "        Bilirubin normal.\n",
      "        Alkaline phosphate normal.\n",
      "        AST normal.\n",
      "        PT, PTT normal.\n",
      "        No history of bleeding disorder.\n",
      "        No history of chronic hepatitis or cirrhosis.\n",
      "        Renal:Creatinine less than 1.5 mg/dL.\n",
      "        Cardiovascular:\n",
      "        No history of deep venous thrombosis.\n",
      "        No history of pulmonary embolus.\n",
      "        Other:\n",
      "        No allergy to any study medication.\n",
      "        Capable of tolerating multiple diagnostic procedures.\n",
      "        No history of abnormal vaginal bleeding. Hysterectomy for vaginal bleeding of benign\n",
      "        etiology allowed.\n",
      "        No history of retinal disease, macular degeneration, or night blindness.\n",
      "        No medical or psychiatric risk due to nonmalignant systemic disease that would preclude\n",
      "        study participation.\n",
      "        No history of malignancy except: Curatively treated nonmelanomatous skin cancer.\n",
      "        Curatively treated in situ cervical carcinoma. Hodgkin's disease treated more than 5 years\n",
      "        ago.\n",
      "        No pregnant women.\n",
      "        Adequate contraception required of fertile patients during and for 12 months after\n",
      "        fenretinide and for 2 months after tamoxifen.\n",
      "1173\n",
      "All patients greater than 18 years old who have had a prior resection of colorectal cancer\n",
      "        and are suspected of having recurrent disease.\n",
      "        Rising serum CEA levels greater than 6 on two successive tests.\n",
      "        Resectable residual or recurrent disease. Patients in the occult arm (Arm 1) must have no\n",
      "        visible residual disease in the abdomen at the time of the last surgical exploration. In\n",
      "        addition, there must be no imageable definitive site of recurrent disease using\n",
      "        conventional imaging modalities including; CT scan of chest/ abdomen/ pelvis with\n",
      "        contrast, MRI scan, and chest x-ray. Patients in arm 2 may have a single site of recurrent\n",
      "        or metastatic disease which is resectable but in whom additional sites of disease are not\n",
      "        known and no imageable disease other than a solitary site of potentially resectable\n",
      "        disease is identified.\n",
      "        Patients must have an ECOG performance status of 0-1.\n",
      "        Patients must be willing to return to NIH for follow-up.\n",
      "        Patients must be able to provide informed consent as demonstrated by the signed consent.\n",
      "        Patients must be 2 or more months from abdominal or thoracic surgery.\n",
      "        No patients with medical contraindication to abdominal exploration.\n",
      "        No patients with recurrent disease detected by conventional imaging studies as outlined\n",
      "        above. Metastatic disease localized outside of the abdominal cavity by conventional\n",
      "        imaging studies as outlined above. Patients must weigh less than 136 kgs. which is the\n",
      "        weight limit for the scanner tables.\n",
      "        No patients with previous injection of murine monoclonal antibodies: Human anti-mouse\n",
      "        assay (HAMA) will be performed in patients with prior history of receiving murine\n",
      "        monoclonal antibodies.\n",
      "        No patients that are pregnant or breast feeding.\n",
      "        Patients who are HIV + will be excluded.\n",
      "1180\n",
      "DISEASE CHARACTERISTICS:\n",
      "        All patients must have histologically documented diagnosis of Stage III, or IV breast\n",
      "        carcinoma.\n",
      "        Patients with stage III that has completed chemotherapy: Estrogen receptor (ER) or\n",
      "        progesterone receptor (PR) positive tumor required if premenopausal. Either ER/PR-positive\n",
      "        or -negative tumor allowed if postmenopausal and have received prior chemotherapy.\n",
      "        Patients may have stage IV with ER/PR-positive or -negative tumor.\n",
      "        No CNS metastases, pseudotumor cereri, or seizures.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Patients who have ecovered from the toxic effects of prior therapy will be eligible.\n",
      "        Patients with prior tamoxifen will be allowed to participate. At least 3 weeks must have\n",
      "        elapsed since the last dose of chemotherapy.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Sex: Men and women.\n",
      "        Menopausal status: Any status.\n",
      "        Patients must have a performance status of ECOG 0-2.\n",
      "        Patients must have Hematopoietic criteria of:\n",
      "        ANC at least 1,500/mm(3).\n",
      "        Platelet count at least 90,000/mm(3).\n",
      "        Patients must have Hepatic criteria of:\n",
      "        In the absence of tumor involvement:\n",
      "        Bilirubin no greater than twice normal;\n",
      "        SGOT no greater than twice normal;\n",
      "        Alkaline phosphate no greater than twice normal;\n",
      "        Fasting triglycerides less than 3 times normal.\n",
      "        Patients must have Renal criteria of:\n",
      "        Serum creatinine no greater than 1.5 mg/dL OR;\n",
      "        Creatinine clearance at least 60 mL/min.\n",
      "        Other:\n",
      "        No allergy to study medications.\n",
      "        No nonmalignant systemic disease that would preclude therapy.\n",
      "        No second malignancy within 5 years except: Curatively treated basal cell skin carcinoma.\n",
      "        Cervical carcinoma in situ.\n",
      "        Pregnant women will be excluded.\n",
      "        Negative pregnancy test required within 7 days prior to entry.\n",
      "        Adequate contraception required for 4 weeks prior to, during, and for 1 year after study.\n",
      "        Patients must give informed consent.\n",
      "        Patients who are poor medical or psychiatric risks will be eligible.\n",
      "1182\n",
      "Males or (non-pregnant) females greater than or equal to 12 years of age.\n",
      "        Patients must have one of the following systemic or invasive fungal infections at\n",
      "        baseline: systemic or invasive infection due to a fungal pathogen for which there is\n",
      "        currently no licensed treatment or systemic or invasive fungal infection, with evidence of\n",
      "        failure and/or intolerance/toxicity to treatment with approved systemic antifungal agents.\n",
      "        Definitions of failure to treatment with approved systemic antifungal agents:\n",
      "        For invasive aspergillosis and other invasive fungal infections - lack of clinical\n",
      "        response after at least 7 days of systemic antifungal treatment at adequate doses;\n",
      "        For candida esophagitis only - lack of clinical response after at least 14 days of\n",
      "        fluconazole at a dose of greater than or equal to 200 mg/day.\n",
      "        Definition of intolerance/toxicity to treatment with approved systemic antifungal agents:\n",
      "        Intolerance to the infusion-related toxicities of amphotericin B preparations despite\n",
      "        appropriate supportive therapy, OR;\n",
      "        Nephrotoxicity defined as a serum creatinine that had increased by greater than 1.5 mg/dl\n",
      "        while receiving amphotericin B therapy, OR;\n",
      "        Pre-existing renal impairment defined as a serum creatinine that increased to greater than\n",
      "        2.0 mg/dl due to reasons other than amphotericin B therapy.\n",
      "        The systemic or invasive fungal infection must be present at baseline and documented\n",
      "        within four weeks preceding study entry as follows: positive histopathology with evidence\n",
      "        of tissue invasion by fungal elements or positive serology where diagnostic (CSF\n",
      "        cryptococcal antigen; serum or CSF Coccidioides antibody; serum, CSF or urine Histoplasma\n",
      "        antigen) or positive mycologic culture from a normally sterile site, taken during the\n",
      "        current episode of infection.\n",
      "        Women of child bearing potential (or less than 2 years post-menopausal) must have a\n",
      "        negative serum pregnancy test at baseline, and must agree to use barrier methods of\n",
      "        contraception during the study. Women may not be pregnant or lactating.\n",
      "        Signed written informed consent must be obtained at baseline.\n",
      "        Assent will be obtained from minors capable of understanding.\n",
      "        Subjects may not have previously participated in this trial.\n",
      "        Patients may not be receiving or be unable to discontinue the following drugs at least 24\n",
      "        hours prior to randomization: terfenadine, cisapride and astemizole (due to the\n",
      "        possibility of QTc prolongation).\n",
      "        Patients may not be receiving or be unable to discontinue sulphonylureas at least 24 hours\n",
      "        prior to randomization (as these compounds have a narrow therapeutic window and an\n",
      "        increase in plasma levels may lead to hypoglycemia).\n",
      "        Patients may not have received the following drugs within 14 days prior to randomization:\n",
      "        rifampin, carbamazepine and barbiturates as these are potent inducers of hepatic enzymes\n",
      "        and will result in undetectable levels of voriconazole.\n",
      "        Patients may not be participating in a blinded trial of any investigational drug.\n",
      "        Patients may not have AST, ALT, total bilirubin or alkaline phosphatase greater than 5\n",
      "        times the upper limit normal.\n",
      "        No patients with a serum creatinine greater than 3.5 mg/dl or with end-stage renal disease\n",
      "        requiring chronic dialysis.\n",
      "        Patients may not have allergic bronchopulmonary aspergillosis, aspergilloma, zygomycoses,\n",
      "        isolated candiduria, and/or catheter-or-device-related candidemia.\n",
      "        Patients may not have fungal infections not considered to be invasive or systemic\n",
      "        including dermatophytosis and oropharyngeal candidiasis.\n",
      "        Patients may not be receiving or likely to receive any investigational drug (any\n",
      "        unlicensed new chemical entity), except one of the following classes of medications:\n",
      "        cancer chemotherapeutic agents, antiretrovirals, or other therapies for HIV/AIDS-related\n",
      "        opportunistic infections.\n",
      "        Patients may not be receiving or likely to receive the following medications or treatments\n",
      "        during the study period:\n",
      "        G-CSF or GM-CSF (for other than treatment of granulocytopenia);\n",
      "        Any systemic antifungal medication;\n",
      "        White blood cell transfusions.\n",
      "        Patients may not have hypersensitivity or intolerance to azole antifungal agents including\n",
      "        miconazole, ketocanazole, fluconazole, or itraconazole.\n",
      "        Patients must have a life expectancy greater than 72 hours.\n",
      "        Patients may not have any condition which, in the opinion of the investigator, could\n",
      "        affect subject safety, preclude evaluation of response, or render it unlikely that the\n",
      "        contemplated course of therapy can be completed.\n",
      "1183\n",
      "Patients must have a clinical and oculographic diagnosis of CN, and no other treatment\n",
      "        options.\n",
      "        Patients must have binocular best corrected visual acuity of 20/200 to 20/30.\n",
      "        Patients must be 18 years of age or older for the pilot study (Phase I and for the first 5\n",
      "        patients of Phase II).\n",
      "        Patients must be able to undergo a complete ophthalmic evaluation.\n",
      "        Patients must be able to undergo and cooperate for standard eye movement recordings.\n",
      "        Patients must be able to medically undergo extraocular muscle surgery.\n",
      "        Patients must be available for 1 year of post-surgical follow-up.\n",
      "        Patients must understand and sign an informed consent, or have their legal guardian sign\n",
      "        an informed consent.\n",
      "        Patients must have three oculographic recordings performed within 4 months prior to\n",
      "        surgery.\n",
      "        No previous extraocular muscle surgery.\n",
      "        No plan to have extraocular muscle surgery for strabismus.\n",
      "        Patients must not have a clinically significant null position greater than 15 degrees from\n",
      "        primary position horizontally, 5 degrees vertically, or 5 degrees torsionally.\n",
      "        Patients must not be on systemic medication known to affect ocular oscillations.\n",
      "        No acquired eye disease other than refractive error that is known to decrease visual\n",
      "        acuity (e.g., cataracts, glaucoma, age related macular disease, etc.).\n",
      "        No previous ophthalmic or orbital surgery.\n",
      "        No concurrent medical conditions or known risks which would increase their chance of an\n",
      "        adverse event due to general anesthesia (Greater than an ASA Class 1) or have a family\n",
      "        history of malignant hyperthermia.\n",
      "        Patients must not be pregnant at the time of surgery.\n",
      "        Patients must not be less than or equal to 6 months of age.\n",
      "1184\n",
      "Men and non-pregnant women, between 18-75 years of age, who meet a defined criteria for\n",
      "        the diagnosis of Stiff-man syndrome (SMS) will be screened as inpatients or in the\n",
      "        outpatient clinic.\n",
      "        If the diagnosis is confirmed, the patients will be enrolled into the protocol, provided\n",
      "        their disease remains symptomatic and poorly responsive to benzodiazepines.\n",
      "        Only patients with anti-GAD antibodies will be included.\n",
      "        Patients who have not received IVIg in the past 6 months may be included.\n",
      "        No pregnant or nursing women (confirmed by a pregnancy screening test).\n",
      "        No critically ill patients, such as those with severe cardiomyopathy, and respiratory\n",
      "        insufficiency and severely incapacitated patients that require help for self care.\n",
      "        No patients with severe renal or hepatic disease, COPD or severe coronary artery disease.\n",
      "        No patients with serum IgA level less than 11 mg/dl.\n",
      "1185\n",
      "Subjects fulfill DSM-IV criteria for Bipolar I disorder (BPI), Bipolar II disorder (BPII),\n",
      "        Bipolar disorder not otherwise specified (BPNOS), or schizoaffective disorder bipolar\n",
      "        type.\n",
      "        Subjects must be competent to comprehend the purpose of the study and provide informed\n",
      "        consent.\n",
      "        Subjects must undergo complete psychiatric diagnostic interview (SCID--DSM-IV), medical,\n",
      "        neurological, and Laboratory examinations (including EKG, renal and liver function tests,\n",
      "        serum electrolytes, urinalysis, HIV, hepatitis B, pregnancy testing, and urine drug screen\n",
      "        for the presence of psychoactive drugs and drugs of abuse).\n",
      "        At least 18 years old.\n",
      "        Subjects must have a depression of sufficient severity to rate greater than or equal to 16\n",
      "        on the Inventory of Depressive Symptomatology -Clinician (IDS-C) comparable to greater\n",
      "        than or equal to 12 on the Hamilton Depression Rating Scale) or the clinician must decide\n",
      "        that there is a need to treat with an antidepressant. In addition, patients must be on at\n",
      "        least one mood stabilizer.\n",
      "        Subjects should have no general medical illness that is causing the mood disorder.\n",
      "        Subjects should not have liver, renal, hematological, or neurological disease.\n",
      "        Women participants of childbearing potential must be nongravid, nonnursing, and using an\n",
      "        acceptable method of birth control.\n",
      "        Patients must not have alcohol or substance use or dependence of sufficient magnitude to\n",
      "        require independent, concurrent treatment intervention (excluding self-help groups), i.e.,\n",
      "        hospitalization, day treatment programs, or counselor visits.\n",
      "        No patients taking concomitant medications that would contraindicate the medications under\n",
      "        study, such as chemotherapy.\n",
      "        No history of bulimia or seizure disorder.\n",
      "1187\n",
      "Patients with Wegener's granulomatosis who are scheduled for fiberoptic bronchoscopy.\n",
      "        Patients with cavitary lung diseases who are enrolled in protocols studying patients with\n",
      "        Wegener's granulomatosis, chronic granulomatosis disease, host immune defects,\n",
      "        mycobacterial infections, and Job's syndrome.\n",
      "        Patients with bronchogenic carcinoma, other thoracic malignancies, or metastatic disease\n",
      "        to the thorax.\n",
      "        Patients will be selected from Clinical Center inpatient and outpatient population based\n",
      "        on a clinical suspicion of pulmonary, mediastinal or bronchial disease, and are to have\n",
      "        medically indicated chest CT.\n",
      "        Written informed consent will be obtained from all patients and studies will only be done\n",
      "        with the permission of the patient's attending physician.\n",
      "        Patients will be drawn from the following protocols:\n",
      "        92-I-0186\n",
      "        93-I-0119\n",
      "        94-I-0149\n",
      "        95-I-0091\n",
      "        90-I-0086\n",
      "        76-I-0023\n",
      "        92-I-0255\n",
      "        93-I-0172\n",
      "        95-I-0177\n",
      "        Subjects must not be pregnant and be able to hold their breath for required periods of\n",
      "        time.\n",
      "1189\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed non-small cell lung cancer, including: Squamous cell carcinoma,\n",
      "        Adenocarcinoma, Large cell carcinoma, Mixed histologies in the absence of a predominant\n",
      "        small cell component.\n",
      "        Eligible Stages Include:\n",
      "        Stage IV, Stage IIIA/B ineligible for resection or radiotherapy, Postsurgical recurrence\n",
      "        that is histologically or cytologically proven.\n",
      "        CNS Metastases Allowed Provided:\n",
      "        Radiotherapy completed prior to entry.\n",
      "        No requirement for concurrent steroids.\n",
      "        No carcinomatous meningitis.\n",
      "        No epidural metastases.\n",
      "        Measurable disease not required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Not specified.\n",
      "        Chemotherapy: No prior chemotherapy for lung cancer.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: No prior chest irradiation for lung cancer.\n",
      "        Surgery: Prior surgery allowed.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance Status: ECOG 0-2.\n",
      "        Hematopoietic:\n",
      "        Absolute granulocyte count greater than 2,000.\n",
      "        Platelet count greater than 100,000.\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL.\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL.\n",
      "        Cardiovascular:\n",
      "        No CHF unless fully compensated.\n",
      "        No second- or third-degree heart block.\n",
      "        No uncontrolled, symptomatic atrial dysrhythmia except sinus bradycardia.\n",
      "        No sustained ventricular tachycardia.\n",
      "        No MI within 3 months.\n",
      "        OTHER:\n",
      "        No uncontrolled infection unless due to an obstructed bronchus.\n",
      "        No major psychiatric problems requiring hospitalization.\n",
      "        No psychotropic medications such as phenothiazines.\n",
      "        No contraindication to transfusion, if required.\n",
      "        No second malignancy within 5 years except: Nonmelanomatous skin cancer.\n",
      "        In situ cervical cancer.\n",
      "        No pregnant or nursing women.\n",
      "        Effective contraception required of fertile patients.\n",
      "1191\n",
      "Patients older than 18 years of age with known or suspected coronary artery disease who\n",
      "        agree to undergo stress echocardiography and have undergone or will undergo coronary\n",
      "        angiography within 3 months of the stress echocardiogram.\n",
      "        No pre-menopausal patients who are lactating, are pregnant or potentially pregnant as\n",
      "        judged by history, physical examination, ultrasound or urine pregnancy test.\n",
      "        No unstable angina.\n",
      "        No recent myocardial infarction (less than 1 month).\n",
      "        No ventricular ectopy during baseline conditions (i.e., couplets, frequent PVC's [greater\n",
      "        than 6/min], early coupling [\"R-on-T\" phenomenon], ventricular bigeminy) that might\n",
      "        potentially predispose the patient for the development of dangerous dysrhythmias during\n",
      "        dobutamine infusion.\n",
      "        No congestive heart failure.\n",
      "        No significant hypertension (systolic blood pressure greater than 170 mmHg) or hypotension\n",
      "        (systolic blood pressure less than 100 mmHg).\n",
      "        No sinus tachycardia greater than 100 beats/min.\n",
      "        No other acute medical illness.\n",
      "        No atrial fibrillation, or inadequate two-dimensional echocardiographic windows.\n",
      "1192\n",
      "INCLUSION CRITERIA\n",
      "        Patients must satisfy the following criteria:\n",
      "        The patient must have a biopsy proven diagnosis of carcinoma of the oral cavity,\n",
      "        oropharynx, hypopharynx, nasopharynx, larynx, maxillary sinus. Squamous cell,\n",
      "        lymphoepithelioma, transitional cell and undifferentiated histologies will be included.\n",
      "        We will accept AJCC stages III-IV for all the sites, except base of tongue, nasopharynx,\n",
      "        and maxillary sinus where we will accept stage II patients as well.\n",
      "        Patients must have no surgical option or have refused surgery.\n",
      "        Patients with evidence of distant metastasis not confined to the region of the head and\n",
      "        neck will be excluded.\n",
      "        All patients will be evaluated by either the NIH or National Naval Medical Center (NNMC)\n",
      "        Otolaryngology-head and neck surgery center.\n",
      "        Patients must have had no prior radiotherapy to the head and neck region and no prior\n",
      "        treatment with chemotherapy for their head and neck cancers.\n",
      "        Patients must have a performance status of less then or equal to 2 (ECOG Criteria).\n",
      "        Patients must have an absolute granulocyte count of greater than or equal to 2000/mm(3)\n",
      "        and a platelet count of greater than or equal to 100,000/mm(3).\n",
      "        Patients should have adequate hepatic and renal function as indicated by a serum bilirubin\n",
      "        of less than or equal to 2.0 mg/dl and SGOT of less than or equal to 4.0 times the upper\n",
      "        limit of the institutional norm and a serum creatinine of less than or equal to 1.5 mg/dl.\n",
      "        No other serious concurrent medical or psychiatric illness which would jeopardize the\n",
      "        ability of the patient to receive with reasonable safety the chemotherapy and radiation\n",
      "        therapy outlined in this protocol is allowed.\n",
      "        No other active, concomitant malignancy other than curatively treated carcinoma in situ of\n",
      "        the cervix or basal cell carcinoma of the skin is allowed.\n",
      "        Patients must be at least 18 years old.\n",
      "        Signed informed consent: Each patient must be aware of the neoplastic nature of his/her\n",
      "        disease and willingly consent after being informed of the procedure to be followed, the\n",
      "        experimental nature of the therapy, alternatives, potential benefits, side effects, risks,\n",
      "        and discomforts.\n",
      "        Pregnant women and nursing mothers are ineligible.\n",
      "        Eligible patients of childbearing potential should use contraception.\n",
      "        Patients will be registered on the protocol by telephone. An authorized physician will\n",
      "        telephone information concerning a potential candidate for this protocol to the Orkand\n",
      "        personnel in their Central Clinical Data Management Registration Office at (301) 402-1732\n",
      "        between the hours of 8:30 am to 5:00 pm Monday through Friday.\n",
      "1193\n",
      "Age - six months to 18 years.\n",
      "        PREVIOUSLY UNTREATED OR MINIMALLY TREATED PATIENTS:\n",
      "        Asymptomatic HIV-infected children with an age-corrected absolute CD4 count that renders\n",
      "        them at possible risk for an AIDS-related opportunistic infection, or;\n",
      "        Children with moderate to severe symptomatic HIV infection as defined by the CDC\n",
      "        classification.\n",
      "        Absence of active opportunistic infection requiring acute intervention at the time of\n",
      "        entry.\n",
      "        Prophylaxis for PCP with trimethoprim/sulfamethoxazole or pentamidine at the time of entry\n",
      "        will be allowed.\n",
      "        Availability of a parent or legal guardian to give informed consent and who is deemed\n",
      "        sufficiently reliable to return for the child's follow-up visits.\n",
      "        PREVIOUSLY TREATED PATIENTS WITH REFRACTORY DISEASE OR INTOLERANCE TO PRIOR THERAPY:\n",
      "        HIV-infected patients who have been previously treated with one or more dideoxynucleosides\n",
      "        (zidovudine, didanosine, lamivudine, stavudine, zalcitabine) or another protease inhibitor\n",
      "        (will be analysed separately) and have experienced either a withdrawal grade toxicity or\n",
      "        refractory disease evidenced by progressive clinical immunological deterioration.\n",
      "        Availability of a parent or legal guardian to give informed consent and who is deemed\n",
      "        sufficiently reliable to return for the child's follow-up visits.\n",
      "        ALL CHILDREN:\n",
      "        Must not be critically ill or clinically unstable.\n",
      "        Patients receiving treatment for an acute infection must have been on stable therapy for\n",
      "        at least 7 days prior to entry on study.\n",
      "        MUST NOT HAVE ONE OR MORE OF THE FOLLOWING LABORATORY FINDINGS (WITHIN 2 WEEKS OF ENTRY\n",
      "        AND NOT YET RESOLVED):\n",
      "        Total WBC count less than 1500 cells/mm(3).\n",
      "        Neutrophil plus band count less than 750 cells/mm(3).\n",
      "        Hemoglobin less than 8.0 g/dl (history of recent transfusion is not an exclusion).\n",
      "        Platelet count less than 500,000/mm(3).\n",
      "        Creatinine greater than 2 times the upper limit of normal.\n",
      "        Liver transaminase greater than 3 times the upper limit of normal.\n",
      "        Bilirubin greater than 1.5 mg/dL.\n",
      "        Hematuria.\n",
      "        Because of the possibility for an increased risk of kidney stone formation patients must\n",
      "        not have severe recurrent or persistent diarrhea, or a family history of kidney stones.\n",
      "        Patients must not have received, within 30 days prior to entry, therapy with\n",
      "        immunomodulating agents (interleukin-2, interferons, growth hormone, IGF-1, or other\n",
      "        biological response modifier), cytolytic chemotherapeutic agents, radiation therapy.\n",
      "        Stable (e.g., for greater than 4 weeks prior to entry) corticosteroids therapy for the\n",
      "        treatment of lymphocytic interstitial pneumonitis or an autoimmune process or stable\n",
      "        therapy with G-CSF (Neupogen) at the same dosage for at least 4 weeks are acceptable.\n",
      "        Must not have an active opportunistic infection requiring acute intervention.\n",
      "        Women must not be pregnant or breast feeding.\n",
      "1194\n",
      "INCLUSION CRITERIA:\n",
      "        Men, women and children from across the United States and from around the world who\n",
      "        participate in clinical research at the National Institutes of Health, and who have been\n",
      "        referred to occupational therapy as part of their routine care, are eligible to be\n",
      "        considered for this study.\n",
      "        Patients whose occupational therapy treatment plan recommends the personal computer\n",
      "        intervention will be eligible to participate.\n",
      "1195\n",
      "IL-2 NAIVE PATIENTS:\n",
      "        Documented HIV-1 infection (ELISA and Western blot positive).\n",
      "        18 years or older.\n",
      "        CD4 count greater than or equal to 200 cells per mm(3) and less than or equal to 500\n",
      "        cells/mm(3)\n",
      "        Clinical laboratory values Grade 0 or 1.\n",
      "        No therapy with corticosteroids, chemotherapy, pentoxifylline, thalidomide, or\n",
      "        experimental therapy in the prior 4 weeks.\n",
      "        Negative urine pregnancy test within 2 weeks prior to study entry (for women of\n",
      "        childbearing potential).\n",
      "        Current treatment with a stable regimen or licensed anti-retroviral therapy for at least 2\n",
      "        weeks.\n",
      "        Adequate venous access in the upper extremities for repeated blood drawing and intravenous\n",
      "        catheter placement.\n",
      "        No prior IL-2 therapy.\n",
      "        No malignancy other than Kaposi's sarcoma. Patients with Kaposi's sarcoma are eligible,\n",
      "        but most not have received systemic therapy for KS within 4 weeks prior to study entry.\n",
      "        No history of prior AIDS-defining opportunistic infection other than pulmonary TB or\n",
      "        recurrent pneumonia.\n",
      "        No active substance abuse which may affect patient safety or compliance.\n",
      "        No patients exhibiting psychiatric disturbance or illness which in the assessment of the\n",
      "        protocol team may affect patient safety or compliance.\n",
      "        No patients with significant cardiac, pulmonary, rheumatologic, thyroid, kidney,\n",
      "        gastrointestinal or neurological disease that could either decrease absorption of oral\n",
      "        therapy, prove a cardiovascular risk during the fluid shifts and stresses that occur with\n",
      "        IL-2 therapy, or that could have an inflammatory/immune etiology and thus might be\n",
      "        activated or worsened by IL-2.\n",
      "        No patients with hypertension requiring continuous anti-hypertensive therapy.\n",
      "        No pregnant or lactating patients.\n",
      "        Women of childbearing potential must agree to practice abstinence or use 2 forms of\n",
      "        contraception simultaneously beginning 1 month prior to receiving study medication and\n",
      "        continuing thereafter until 1 month after the last dose of study medication.\n",
      "        Men must agree to practice abstinence or use a condom when engaging in intercourse during\n",
      "        the same time period.\n",
      "        Must be willing to comply with current NIH Clinical Center guidelines concerning\n",
      "        appropriate notification by an individual of current or ongoing sexual partners and/or\n",
      "        needle-sharing partners regarding his or her HIV-1 seropositivity and the risk of\n",
      "        transmission of HIV-1 infection.\n",
      "        No history of hypersensitivity or intolerance to either IL-2 or thalidomide.\n",
      "        PRIOR IL-2 THERAPY PATIENTS:\n",
      "        Active participation in protocols 91-CC-0113 or 93-CC-0143.\n",
      "        Negative urine pregnancy test within 2 weeks prior to study entry (for women of\n",
      "        childbearing potential).\n",
      "        No history of hypersensitivity or intolerance to thalidomide.\n",
      "1198\n",
      "Patients must meet all the following to be eligible for study entry:\n",
      "        Documented HIV infection (ELISA and Western blot positive).\n",
      "        18 years or older.\n",
      "        Karnofsky performance status greater than or equal to 70.\n",
      "        CD4 cell count between 200 and 500 cells/mm(3).\n",
      "        Negative urine or serum pregnancy test within 7 days prior to study entry for women of\n",
      "        childbearing potential.\n",
      "        Patients must be receiving a stable FDA approved antiretroviral regimen for at least 2\n",
      "        weeks prior to study entry.\n",
      "        SGOT less than or equal to 150 u/l.\n",
      "        Total bilirubin less than or equal to 2.0 mg/dl.\n",
      "        Serum creatinine less than or equal to 2.0 mg/dl.\n",
      "        Proteinuria less than or equal to 1+.\n",
      "        Granulocyte count greater than or equal to 1,000/mm(3).\n",
      "        Hemoglobin greater than or equal to 10 gm/dl and platelet count greater than or equal to\n",
      "        75,000.\n",
      "        Patients should have a companion who is willing to monitor the outpatient infusions of\n",
      "        IL-2.\n",
      "        Patient must sign an informed consent conforming to FDA and institutional guidelines.\n",
      "        No prior IL-2 therapy.\n",
      "        No malignancy other than mucocutaneous Kaposi sarcoma.\n",
      "        No history of prior AIDS-defining opportunistic infection.\n",
      "        No current history of alcohol or substance abuse, or dependence that in the opinion of the\n",
      "        screening team may affect patient safety or compliance.\n",
      "        No patients exhibiting psychiatric or cognitive disturbance or illness, which in the\n",
      "        assessment of the protocol team may affect patient safety or compliance.\n",
      "        No clinically significant cardiac, thyroid, pulmonary, kidney or CNS impairment.\n",
      "        No hypertension requiring anti-hypersensitive therapy.\n",
      "        No use of systemic corticosteroids, chemotherapy, or experimental therapy in the prior 4\n",
      "        weeks.\n",
      "        No pregnant or lactating patients.\n",
      "        No patients who are likely to require treatment with G-CSF, GM-CSF, or interferons.\n",
      "        No patients with a history of Crohn's disease or autoimmune diseases with potentially\n",
      "        life-threatening complications.\n",
      "        No patients with avascular necrosis of the bone.\n",
      "        Home - patient must be enrolled and in good standing on a current NIAID protocol involving\n",
      "        the use of IL-2 therapy. The patient must already have undergone at least one year of\n",
      "        treatment on the protocol during with IL-2 therapy has been given, including at least 2\n",
      "        well-tolerated outpatient cycles of scIL-2 at a stable dose.\n",
      "        Home - The patient must have a history of generally tolerable side effects while receiving\n",
      "        IL-2 that did not require frequent medical interventions, intravenous fluid replacement,\n",
      "        and/or IL-2 dose reductions. Conditions generally not suitable for home scIL-2\n",
      "        administration would include (but are not limited to) an unusually heavy requirement for\n",
      "        narcotic usage during a cycle, significant urticaria (hives) or other allergic conditions,\n",
      "        and any history of possible airway compromise due to throat swelling.\n",
      "        Home - Patient must not have experienced any serious (grade 3 or higher) clinical or\n",
      "        laboratory abnormalities of medical significance during days 0-5 of the last 2 outpatient\n",
      "        scIL-2 cycles.\n",
      "        Home -The patient must have a strong relationship with a private physician or health-care\n",
      "        provider at home who has demonstrated close involvement in the patient's care to date and\n",
      "        who would be willing to help supervise a patient's care during each home scIL-2 cycle.\n",
      "        Because of the need to identify a single health-care provider at home who will agree to be\n",
      "        available to render care (if needed) during a patient's scIL-2 cycle, patients who\n",
      "        currently receive their home care from rotating staff members in a general clinic setting\n",
      "        may not be eligible for home scIL-2 administration. A signed written statement\n",
      "        acknowledging willingness to participate in monitoring must be received by the clinic 8\n",
      "        study team from the private physician or health-care provider prior to the first home\n",
      "        scIL-2 cycle. In addition, communication must occur between your clinic 8-study team and\n",
      "        the designated physician or health-care provider prior to each subsequent cycle to confirm\n",
      "        that individual's continued willingness to serve as on-site provider for any serious\n",
      "        medical conditions that might develop during a cycle.\n",
      "        Home - The patient must live at a home address with easy access to a telephone and must\n",
      "        have demonstrated reliability in responding to telephone calls from clinic 8 staff\n",
      "        members. The patient must also be able to provide the study team with reliable contact\n",
      "        information for a close family member or friend who will agree to serve in the capacity of\n",
      "        a \"care-giver\" during each cycle: i.e. someone who will be able to render non-medical\n",
      "        assistance to the patient and be able to check on their condition daily in the event that\n",
      "        emergency medical assistance needs to be summoned. It will become the patient's\n",
      "        responsibility to ensure that the local \"care-giver\" communicates their willingness to\n",
      "        serve in this capacity by telephoning the clinic 8-study team prior to each cycle.\n",
      "        Home -The patient must have \"reasonable\" (i.e. rapid and close) access at home to\n",
      "        emergency medical services and a nearby medical facility in the event of a medical crisis.\n",
      "        The suitability of the at-home situation will be assessed on a case-by-case basis by the\n",
      "        clinic 8-study team.\n",
      "        Home - The patient must have demonstrated reliability and consistency in sterile\n",
      "        technique, the reconstitution of IL-2 vials, and the administration of scIL-2 injections.\n",
      "        Home - The patient must be receiving outpatient scIL-2 cycles at least once every 6 months\n",
      "        as part of their normal protocol participation, except at the discretion of the study\n",
      "        team.\n",
      "        Home - The patient must have access to a reliable home weight scale and be able to weigh\n",
      "        themselves accurately on a daily basis for the purposes of safety monitoring.\n",
      "1200\n",
      "HIV infection previously documented by ELISA test kit and confirmed by either Western\n",
      "        Blot, HIV antigen, HIV culture, or a second antibody test other than ELISA.\n",
      "        Age 18 years or older.\n",
      "        CD4 count of less than or equal to 150 cells/mm(3).\n",
      "        At least one prior episode of health care provider diagnosed oropharyngeal candidiasis in\n",
      "        the 6 months preceding enrollment.\n",
      "        No allergy or intolerance to azoles.\n",
      "        Less than 3 episodes of oropharyngeal candidiasis within the last 3 months.\n",
      "        No history of esophageal candidiasis.\n",
      "        No presence of systemic fungal infection requiring continuous antifungal therapy.\n",
      "        No use of continuous azole treatment (i.e. daily, weekly, every other day, twice weekly\n",
      "        fluconazole, itraconazole, ketoconazole or coltrimazole) for the prevention of fungal\n",
      "        infections greater than or equal to 1 month within the past 6 months.\n",
      "        No severe liver disease (ALT or AST greater than 5 times the upper limit of normal).\n",
      "        No history of poorly responsive mucosal infection (i.e., requiring more than 200 mg of\n",
      "        fluconazole daily or more than 14 days of therapy).\n",
      "        Females may not be pregnant or lactating. Must have a negative pregnancy test within 2\n",
      "        weeks of enrollment.\n",
      "        No one unlikely to survive more than 6 months.\n",
      "        Must have ability to tolerate oral medications.\n",
      "        No presence of active mucosal infection or symptoms of OPC/EC at time of initial\n",
      "        assessment. (Note: Can enroll 2 weeks after resolution of the active episode).\n",
      "        No patients currently being treated with azole for recent mucosal infection. (Note: These\n",
      "        patients can enroll 2 weeks after the completion of azole therapy.)\n",
      "        No presence of severe renal insufficiency as indicated by a serum creatinine greater than\n",
      "        or equal to 3.0.\n",
      "        Women must be taking appropriate birth control measures.\n",
      "1201\n",
      "Depressed patients must have a history of past major depression of at least four months\n",
      "        duration, or a history of two or more briefer episodes. Must be overweight.\n",
      "        Must not need a hospital admission as part of their treatment.\n",
      "        Overweight normal volunteers.\n",
      "        No subjects on chronic medication which cannot be washed out for one month.\n",
      "        No subjects with any serious medical illness.\n",
      "        No women who are pregnant, trying to become pregnant, or sexually active and not using\n",
      "        effective contraception.\n",
      "        No patients with HIV infection.\n",
      "        No subjects who cannot discontinue use of alcohol/tobacco.\n",
      "1206\n",
      "Patients must have a histologic diagnosis of a solid tumor or lymphoma confirmed by the\n",
      "        Laboratory of Pathology, NCI and have failed standard chemotherapy.\n",
      "        No patients with leukemia, brain metastasis, or primary brain tumors.\n",
      "        Patients must be older than 18 years of age .\n",
      "        Must have a SGPT and SGOT less than 2.5 times the upper normal limits.\n",
      "        Liver tumor replacement should be less than 50% total liver surface.\n",
      "        Total bilirubin must be less than 1.5 times the upper limit and measured creatinine\n",
      "        clearance of at least 55 ml/min.\n",
      "        Hemoglobin must be greater than 9.0.\n",
      "        Platelet count must be greater than 100,000, and absolute granulocyte count greater than\n",
      "        1,500.\n",
      "        PT/PTT must be within normal range.\n",
      "        Must have a performance status ECOG of 0-2.\n",
      "        Must have the ability to give informed consent.\n",
      "        Must have reliability to return for follow up and treatment, and to follow instructions.\n",
      "        The patient must not have received radiation therapy of chemotherapy within the past 4\n",
      "        weeks and have recovered from all toxicities prior to starting therapy.\n",
      "        Patients must not have received any nitrosureas, mitomycin C, or bone seeking\n",
      "        radioisotopes within 6 weeks of entry.\n",
      "        Patients with prostate cancer:\n",
      "        Must have had tumor progression following blockade of both testicular and adrenal\n",
      "        androgens.\n",
      "        If taking flutamide or any other anti-androgen, this will have to be discontinued at least\n",
      "        four weeks prior to treatment with evidence of progression of disease following this\n",
      "        maneuver.\n",
      "        Leuprolide or any other GnRh analog should be maintained if the patient has not had an\n",
      "        orchiectomy.\n",
      "        All prostate cancer patients must have a serum testosterone in the castrate range.\n",
      "        Exposure to suramin:\n",
      "        Patients with prior exposure to suramin should be at least 3 months off therapy (from the\n",
      "        last day of infusion) and have undetectable suramin levels.\n",
      "        Patients with breast carcinoma who are taking a hormonal treatment should discontinue this\n",
      "        medication for at least 4 weeks prior to treatment with UCN-01 and have showed further\n",
      "        progression of disease after this maneuver.\n",
      "        Patients may not be treated if any of the following is present:\n",
      "        Active infection, requiring antibiotics within 7 days prior to entry.\n",
      "        Bacterial colonization secondary to percutaneous nephrostomy tube, ileal pouch, or\n",
      "        indwelling urinary catheter.\n",
      "        Positive serology for HIV.\n",
      "        Greater than grade I peripheral neuropathy at study entry.\n",
      "        Prior radiation therapy to greater than or equal to 30% of their bone marrow.\n",
      "        No patients with local complications which require urgent local therapy (e.g.: untreated\n",
      "        hydronephrosis, impending spinal cord compression, severe bone pain unresponsive to\n",
      "        analgesics).\n",
      "        No patients with a history of unstable or newly diagnoses angina pectoris, recent\n",
      "        myocardial infarction (within 6 months of enrollment), class II-IV congestive heart\n",
      "        failure, severe chronic obstructive lung disease (forced vital capacity less than 1000\n",
      "        ml).\n",
      "        No patients with uncontrolled seizure activity, controlled seizure activity but with less\n",
      "        than one year free of seizures.\n",
      "        Patients with a past history of seizures must be seizure free for greater than a year and\n",
      "        not taking any anticonvulsant medications.\n",
      "        No patients with coagulopathy or active renal disease.\n",
      "        No patients receiving steroids for other than physiologic replacement.\n",
      "        Effective June 10, 1998, patients with history of diabetes mellitus within 6 months of\n",
      "        enrollment or fasting glucose greater than or equal to 116/mg/dl or Hemoglobin A1C greater\n",
      "        than 6.5 mg/dl will not be eligible.\n",
      "        If the patient is a premenopausal female she must have a negative pregnancy test (b-HCG)\n",
      "        and be counseled concerning the necessity for effective contraception\n",
      "        No lactating females.\n",
      "        Both male and female patients must practice effective contraception while on study and for\n",
      "        four months following its conclusion.\n",
      "1208\n",
      "-  INCLUSION CRITERIA:\n",
      "        Subjects will be boys with bone ages 2 to 13 years and girls with bone ages 2 to 11 years\n",
      "        with classic 21-hydroxylase.\n",
      "        Subjects must either not yet have undergone pubertal activation of the\n",
      "        hypothalamic-pituitary-gonadal axis, or, if pubertal activation has occurred, must be\n",
      "        receiving an LHRH agonist to suppress secondary central precocious puberty.\n",
      "        Children with a bone age of 1 to 2 years may enroll in the protocol for optimization of\n",
      "        conventional therapy, but will not be randomized to a study arm until the bone age reaches\n",
      "        2.\n",
      "        \n",
      "1212\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed non-small cell lung cancer of the following histologies: Squamous\n",
      "        cell carcinoma, Adenocarcinoma, Large cell carcinoma, No mixed small/non-small cell\n",
      "        carcinoma with predominant small cell component.\n",
      "        Unresectable stage IIIA/B disease confined to thorax including:\n",
      "        Microscopic disease involvement following attempted surgery and limited to anatomic areas\n",
      "        corresponding to stage III disease (N2-3, T3-4).\n",
      "        Surgically treated stage I/II disease with histologic or cytologic proof of relapse and\n",
      "        limited to anatomic areas corresponding to stage III disease (N2-3, T3-4).\n",
      "        T3, N0 tumor extending directly to the chest wall considered resectable and not eligible.\n",
      "        No stage IIIB disease with pleural effusion visible on chest x-ray unless related to a\n",
      "        previous thoracotomy.\n",
      "        No typical carcinoid or mesothelioma.\n",
      "        Measurable disease preferred but not required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        No prior chemotherapy or thoracic radiotherapy.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Hematopoietic:\n",
      "        AGC greater than 2,000.\n",
      "        Platelets greater than 100,000.\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL.\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL.\n",
      "        Cardiovascular:\n",
      "        No symptomatic heart disease including: Less than fully compensated congestive cardiac\n",
      "        failure, Significant arrhythmias e.g.: Greater than first-degree heart block, Uncontrolled\n",
      "        and symptomatic atrial dysrhythmia except sinus, bradycardia or sustained ventricular\n",
      "        tachycardia, Myocardial infarction within 3 months.\n",
      "        Pulmonary: No major uncontrolled active infection (unless due to obstructed bronchus).\n",
      "        OTHER:\n",
      "        No major active psychiatric problem requiring hospitalization or psychotropic medication\n",
      "        such as phenothiazines.\n",
      "        No prior second malignancy within 5 years except: nonmelanomatous skin cancer, In situ\n",
      "        carcinoma of the cervix.\n",
      "        No pregnant or nursing women.\n",
      "1213\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven renal cancer with clear cell component:\n",
      "        Measurable or evaluable disease;\n",
      "        No brain metastases;\n",
      "        No grade 2 or greater peripheral neuropathy or neurologic toxicity symptoms.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Not specified.\n",
      "        Chemotherapy: No prior or concurrent hypersensitivity to PSC 833 or cyclosporine A.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: No prior radiation therapy within 4 weeks of study.\n",
      "        Surgery: No major surgery within 4 weeks of study.\n",
      "        Other: No concurrent treatments that interfere with cyclosporine blood concentrations.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance Status: ECOG 0-2.\n",
      "        Life Expectancy: At least 16 weeks.\n",
      "        Hematopoietic:\n",
      "        ANC greater than or equal to 1500/mm(3);\n",
      "        Platelet count greater than or equal to 100,000/mm(3).\n",
      "        Hepatic:\n",
      "        Bilirubin no greater than 1.5 x normal;\n",
      "        AST no greater than 2.5 x normal.\n",
      "        Renal:\n",
      "        Creatinine no greater than 2.0 mg/dL OR;\n",
      "        Creatinine clearance greater than or equal to 50 mL/min.\n",
      "        Cardiovascular:\n",
      "        No concurrent angina or myocardial infarction that has not been appropriately treated.\n",
      "        Other:\n",
      "        Not pregnant or nursing.\n",
      "        Effective contraceptive required of all fertile patients.\n",
      "        Patients with a history of curatively treated basal cell or squamous cell carcinoma are\n",
      "        eligible.\n",
      "        No HIV seropositivity.\n",
      "        No chronic hepatitis or cirrhosis.\n",
      "        Patients with concurrent reversible conditions such as diabetes, hypercalcemia,\n",
      "        hyperuricemia, hyperviscosity, infection, renal disease, or spinal cord compression are\n",
      "        eligible with appropriate therapy.\n",
      "        Patients must give written informed consent.\n",
      "1215\n",
      "-  INCLUSION CRITERIA:\n",
      "        Healthy volunteers will be in excellent health.\n",
      "        Only women with regular menstrual cycles (every 26-35 days) using mechanical (condoms,\n",
      "        diaphragm) or sterilization methods of contraception will be included.\n",
      "        Only women with a negative pregnancy test, normal physical examination and laboratory\n",
      "        results, and a luteal phase progesterone value of greater than 4 ng/mL will be entered\n",
      "        into this study.\n",
      "        Women with endometriosis will be recruited from those with histologically-proven\n",
      "        endometriosis. Except for this diagnosis they will meet criteria for healthy volunteers as\n",
      "        stated above.\n",
      "        Women may participate in the study on more than one occasion, but biopsies may not be\n",
      "        performed in a \"baseline\" cycle.\n",
      "1217\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous\n",
      "        Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma,\n",
      "        primitive sarcoma of bone, and ectomesenchymoma.\n",
      "        Confirmed presence of tumor-specific infusion protein by documented RT-PCR which\n",
      "        corresponds to one of the tumor specific peptides available for vaccination.\n",
      "        Measurable tumor.\n",
      "        No prior or current CNS metastases.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        ARM A PATIENTS:\n",
      "        May be enrolled on the protocol for the first phase in the absence of RT PCR documentation\n",
      "        of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides\n",
      "        available for vaccination. However, RT PCR documentation at the time of tumor recurrence\n",
      "        must occur prior to administration of immunotherapy. At time of initial tumor diagnosis,\n",
      "        prior to any cytoreductive therapy.\n",
      "        ARM B PATIENTS:\n",
      "        Tumor recurrence occurring during or after receiving at least first line cytoreductive\n",
      "        therapy for ESFT and AR. No more than two post-recurrence salvage regimens unless\n",
      "        peripheral CD4+T cell number is greater than 400 cells per millimeter cubed.\n",
      "        At least 6 weeks since any treatments and recovered from all acute toxic effects from time\n",
      "        in which immunotherapy will be started for this study.\n",
      "        No concurrent estrogen therapy during immunotherapy section of study.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).\n",
      "        Weight: Greater than 15 kg (at time of apheresis).\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        Hematopoietic:\n",
      "        ANC greater than 100,000/mm(3).\n",
      "        Hemoglobin greater than 9.0 g/dL.\n",
      "        Platelet count greater than 50,000/mm(3).\n",
      "        Hepatic:\n",
      "        Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).\n",
      "        Transaminases less than 3 times normal (unless related to involvement by tumor).\n",
      "        Renal:\n",
      "        Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.\n",
      "        Cardiovascular:\n",
      "        No major disorder of cardiovascular system.\n",
      "        Cardiac ejection fraction greater than 40%.\n",
      "        Pulmonary:\n",
      "        No major disorder of pulmonary system.\n",
      "        OTHER:\n",
      "        Not pregnant or nursing.\n",
      "        HIV negative.\n",
      "        Hepatitis B or C negative.\n",
      "        No patients requiring daily oral corticosteroid therapy.\n",
      "        If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre\n",
      "        syndrome, ineligible to receive influenza vaccine.\n",
      "1219\n",
      "Women at high risk for breast cancer, either because they are a member of a high risk\n",
      "        breast or ovarian cancer family, or because of a carcinoma of the opposite breast.\n",
      "        Normal mammogram within past 3 months.\n",
      "        No suspicious breast or axillary lesions on physical examination.\n",
      "        No major cardiopulmonary, hepatic or renal disorders.\n",
      "1221\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Diagnostically proven locally advanced, but unresectable primary or recurrent solid tumors\n",
      "        or lymphoma or metastatic solid tumors that have failed standard therapy or no such\n",
      "        therapy is available.\n",
      "        Objectively measurable disease not required.\n",
      "        No patients with leukemia or primary or metastatic CNS malignancies.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Greater than 4 weeks since prior immunotherapy and recovered from all\n",
      "        toxic effects.\n",
      "        Chemotherapy: Greater than 4 weeks since prior chemotherapy and recovered from all toxic\n",
      "        effects with following exceptions: At least 6 weeks since prior mitomycin C or nitrosourea\n",
      "        therapy. At least 3 months since prior suramin therapy.\n",
      "        Endocrine Therapy: Not specified\n",
      "        Radiotherapy: At least 2 weeks since prior radiotherapy (4 weeks if at least 21% of marrow\n",
      "        irradiated) and recovered from all toxic effects.\n",
      "        Surgery: Recovered from any prior surgery.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0-2\n",
      "        Hematopoietic:\n",
      "        AGC at least 2,000/microL.\n",
      "        Platelet count at least 100,000/microL.\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL.\n",
      "        Renal: Creatinine no greater than 2.0 mg/dL.\n",
      "        OTHER:\n",
      "        No failure of prior gemcitabine therapy.\n",
      "        No concurrent cimetidine (ranitidine and other anti-ulcer agents allowed).\n",
      "        No active infection requiring intravenous antibiotic therapy.\n",
      "        HIV negative.\n",
      "        No other medical contraindication to protocol therapy.\n",
      "        No pregnant or nursing women.\n",
      "        Adequate contraception required of fertile patients.\n",
      "1224\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven solid tumor that has failed standard therapy or for which no such\n",
      "        therapy exists.\n",
      "        Tumor may be locally advanced and unresectable, recurrent and/or metastatic.\n",
      "        Lymphomas with minimal or no involvement of bone marrow are also eligible.\n",
      "        No primary malignancies or metastatic disease of the CNS.\n",
      "        No symptomatic pre-existing peripheral neuropathy.\n",
      "        PRIOR/CURRENT THERAPY:\n",
      "        BIOLOGIC THERAPY:\n",
      "        No immunotherapy within past 4 weeks.\n",
      "        Recovered from toxic effects.\n",
      "        CHEMOTHERAPY:\n",
      "        No chemotherapy within past 4 weeks (6 weeks for nitrosoureas).\n",
      "        No mitomycin within past 12 weeks.\n",
      "        Recovered from toxic effects.\n",
      "        ENDOCRINE THERAPY: Not specified.\n",
      "        RADIOTHERAPY:\n",
      "        No radiotherapy within past 2 weeks (8 weeks for strontium therapy).\n",
      "        Recovered from toxic effects.\n",
      "        SURGERY: Recovered from prior surgery.\n",
      "        OTHER: No concurrent cimetidine.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        AGE: 18 and over.\n",
      "        PERFORMANCE STATUS: ECOG 0-2.\n",
      "        LIFE EXPECTANCY: Not specified.\n",
      "        HEMATOPOIETIC:\n",
      "        Absolute granulocyte count at least 2000/mm(3);\n",
      "        Platelet count at least 100,000/mm(3).\n",
      "        HEPATIC:\n",
      "        Bilirubin no greater than 2 times upper normal limit;\n",
      "        SGOT/SGPT no greater than 4 times upper normal limit.\n",
      "        RENAL:\n",
      "        Creatinine no greater than 1.6 mg/dL;\n",
      "        Creatinine clearance greater than 55 mL/min.\n",
      "        OTHER:\n",
      "        Not pregnant or nursing.\n",
      "        Fertile patients must use effective contraception.\n",
      "        Not HIV positive.\n",
      "        No active infections requiring intravenous antibiotic therapy.\n",
      "        No other serious concurrent illness.\n",
      "        No evidence of hemolytic uremic syndrome.\n",
      "1225\n",
      "Age 18-70.\n",
      "        Patients must have morphologically identifiable hairy cells in peripheral blood and bone\n",
      "        marrow, or tissue biopsies with at least one of the following: 1) Positive stain for the\n",
      "        tartrate-resistant acid phosphatase 2) Electron microscopy compatible with hairy cells.\n",
      "        Patients must be ambulatory with an expected survival greater than 16 weeks and be willing\n",
      "        and able to give written informed consent.\n",
      "        Patients must have a disease that is assessable, defined by: 1) Pancytopenia 2) Bone\n",
      "        marrow leukemic infiltrate 3) Lymphadenopathy, splenomegaly, or hepatomegaly.\n",
      "        Patients must not require palliative chemotherapy, immunotherapy or hormonal therapy other\n",
      "        than the treatment prescribed in this protocol.\n",
      "        Patients must be tested for Hepatitis B surface antigen within one week of entry into this\n",
      "        study.\n",
      "        No pregnant or lactating women. No fertile men and women, unless using effective\n",
      "        contraception.\n",
      "        No patients with unstable angina. Patients with Class III or IV cardiovascular disease may\n",
      "        be entered only after medical clearance by a cardiology consultant.\n",
      "        No patients with severe intercurrent infection or patients having had surgery within the\n",
      "        past four weeks unless fully recovered.\n",
      "        No patients with impaired renal function (serum creatinine greater than 1.8).\n",
      "        No patients with impaired hepatic function (total bilirubin greater than 1.4).\n",
      "        No patients with serum calcium greater than 12 mg/dl.\n",
      "        No patients with a performance status less than or equal to 60% on the Karnofsky scale.\n",
      "        No patients who have had any prior (leukocyte or fibroblast) interferon therapy.\n",
      "        No patients unable to carry out the treatment program.\n",
      "        No patients less than 20,000 per cu mm platelets and clinical bleeding disorder; both must\n",
      "        be present for patient to be excluded.\n",
      "1226\n",
      "Children between the ages of 3 months and 18 years.\n",
      "        Diagnosis of HIV-1 infection as defined by the Centers for Disease Control (CDC)\n",
      "        Definition. Children and adolescents with vertically, transfusion or sexually acquired\n",
      "        HIV-1 infection are eligible.\n",
      "        Availability of a parent or guardian to provide Informed Consent.\n",
      "        ARM A:\n",
      "        Children and adolescents with vertically, transfusion or sexually acquired HIV-1\n",
      "        infection.\n",
      "        No or moderate immune suppression at the time of study entry as defined by the CDC\n",
      "        Classification System, Immune Categories 1 and 2.\n",
      "        No history of or indication for antiretroviral intervention at time of enrollment or not\n",
      "        receiving antiretroviral treatment because: (a) the patient has elected to decline\n",
      "        treatment or (b) in the opinion of the patient's health care provider, antiretroviral\n",
      "        treatment is not currently recommended because of the patient's inability to adhere to\n",
      "        therapy, promoting the development of viral resistance.\n",
      "        Children younger than 24 months of age must not have had plasma HIV-1 RNA levels greater\n",
      "        than 8 X 10(4) copies/ml previously and at the time of initial evaluation, confirmed at\n",
      "        least at two different time points 2 to 4 weeks apart, showing no sign of increase\n",
      "        (increment less than 0.5 log(10). If the child has had plasma HIV-1 RNA levels greater\n",
      "        than 8 X 10(4) copies/ml at some point prior to the initial evaluation, he/she will have\n",
      "        to be placed on antiretroviral treatment and must meet all the criteria for Arm B.\n",
      "        ARM B:\n",
      "        Children and adolescents with vertically, transfusion, or sexually acquired HIV-1\n",
      "        infection, who are on or have received antiretroviral treatment of longer than 7 weeks.\n",
      "        No or moderate immune suppression at the time of study entry as defined by CDC\n",
      "        Classification System, Immune Categories 1 and 2.\n",
      "        Children younger than 24 months or age, who meet all the inclusion criteria for army B\n",
      "        must have plasma HIV-1 RNA levels less than 5 X 10(4) copies/ml while receiving optimal\n",
      "        antiretroviral therapy, confirmed at least two different time points 2 to 4 weeks apart,\n",
      "        showing no sign of increase (increment less than 0.5 log(10). If the child has been\n",
      "        previously treated with antiretroviral drugs for more than 7 weeks (therefore not eligible\n",
      "        for arm A) and is currently off drugs, he/she will have to be placed on optimal\n",
      "        antiretroviral agents and will have to maintain viral RNA levels below 5 X 10(4) copies/ml\n",
      "        prior to the entry.\n",
      "        Each child enrolled in arm B has to be on constant regimen of antiretroviral treatment for\n",
      "        at least 6 weeks-prior to the first inoculation. Children in immune categories 1 and 2 at\n",
      "        the time of study entry will be allowed to enroll.\n",
      "        Not critically ill or clinically unstable or no presence of active infection requiring\n",
      "        on-going (or induction) therapy.\n",
      "        No evidence of severe immune suppression at the time of study entry as defined by CDC\n",
      "        classification system, Immune Category 3.\n",
      "        For children younger than 24 months of age, no plasma HIV-1 RNA levels greater than or\n",
      "        equal to 5 x 10(4) copies/ml despite appropriate antiretroviral treatment, confirmed at\n",
      "        least at two different time points 2 to 4 weeks apart.\n",
      "        No use of tube feeding or intravenous hyperalimentation itself will be allowed as long as\n",
      "        it is a stable regimen.\n",
      "        No administration of chemotherapeutic agents, or use of immunomodulating agents such as\n",
      "        corticosteroids, interferons, G-CSF, EPO, growth hormone (GH) or IVIG within one month of\n",
      "        enrollment.\n",
      "        No abnormalities of laboratory findings within one month of enrollment including the\n",
      "        following: SGPT or SGOT greater than 5 times the normal value; Total bilirubin greater\n",
      "        than 3 times normal; BUN or creatinine greater than 2 times normal; Total WBC greater than\n",
      "        150/mm(3) or ANC greater than 750/mm(3); Hemoglobin greater than 8.0 g/dl (transfusions\n",
      "        are allowed); Platelet count greater than 100,000/mm(3).\n",
      "        Not pregnant or not planning to become pregnant.\n",
      "        No active substance abuse.\n",
      "        Able to comply with the study requirements for scheduled evaluations such as periodic\n",
      "        clinic visits or blood sampling.\n",
      "1229\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients of any age, of both genders, and all racial/ethnic groups with dermatologic\n",
      "        diseases or systemic diseases with cutaneous manifestations.\n",
      "        Women of childbearing potential, or who are pregnant or lactating, will only undergo tests\n",
      "        and procedures, and/or receive medications for which data exists proving minimal risk to\n",
      "        the fetus and/or child. Only tests that are clinically indicated for diagnosis will be\n",
      "        performed.\n",
      "        Patients must be referred by a physician.\n",
      "        \n",
      "1230\n",
      "Male and female subjects.\n",
      "        Must be 18 years of age or older.\n",
      "        Subjects must pass the health criteria for blood donors established by the American\n",
      "        Association of Blood Banks.\n",
      "        No subjects who are pregnant or lactating females.\n",
      "        No subjects with uncontrolled hypertension, heart disease, diabetes, history of allergic\n",
      "        reactions to G-CSF, history of allergic reactions to E. coli, abnormal hemoglobin or white\n",
      "        blood cell counts, a malignancy, asthma, taking prednisone or using an inhalant.\n",
      "        No hemoglobin less than 11.0 or greater than 19.0 gm/dL\n",
      "        No platelet counts less than 140 x 10(9)/L or greater than 500 x 10(9)/L.\n",
      "        No absolute neutrophil count less than 1.5 x 10(9/)/L or greater than 10.0 x 10(9)/L.\n",
      "1231\n",
      "-  INCLUSION CRITERIA - ALL VOLUNTEERS:\n",
      "        Greater than or equal to 18 years old.\n",
      "        Ability to sign informed consent.\n",
      "        For women of child-bearing potential, negative result on a serum or urine pregnancy test\n",
      "        within 1 week prior to the procedure.\n",
      "        Willingness to allow storage of blood or biopsy samples for possible future use to study\n",
      "        HIV/AIDS, related diseases or the immune system; willingness to permit HLA testing.\n",
      "        FOR PATIENTS UNDERGOING BIOPSIES:\n",
      "        No medical contraindication to tonsillar, lymph node, or intestinal biopsy.\n",
      "        For tonsillar biopsy, presence of visible tonsillar tissue; for lymph node biopsy,\n",
      "        palpable lymph nodes.\n",
      "        No aspirin or piroxicam (Feldene) for 10 days prior to the procedure; other non steroidal\n",
      "        anti-inflammatory drugs (e.g. ibuprofen) must be discontinued the day prior to the\n",
      "        procedure. Acetaminophen [Tylenol] is permitted at any time.\n",
      "        FOR PATIENTS UNDERGOING BRONCHOALVEOLAR LAVAGE:\n",
      "        Hematocrit greater than 27 percent, platelets greater than 50,000/ml.\n",
      "        Baseline pulse-oximetry recording of 94 percent or greater unless clinical indication for\n",
      "        bronchoscopy.\n",
      "        No medical contraindication to bronchoscopy.\n",
      "        In addition to the above:\n",
      "        FOR HIV POSITIVE VOLUNTEERS:\n",
      "        HIV infection must be confirmed by ELISA and western blot or dot blot. For patients with\n",
      "        acute HIV infection and negative HIV serology, plasma HIV viral load greater than 10,000\n",
      "        copies/ml.\n",
      "        FOR HEALTHY VOLUNTEERS:\n",
      "        No underlying significant medical problem, especially an immunodeficiency or autoimmune\n",
      "        disease, or an underlying problem requiring immunosuppressive therapy.\n",
      "        Absence of HIV infection as confirmed by negative ELISA and, if indicated, western blot or\n",
      "        dot blot.\n",
      "        FOR ICL PATIENTS:\n",
      "        Patients must meet the definition of ICL according to the CDC criteria: documented\n",
      "        absolute CD4 T lymphocyte count of less than 300 cells per cubic millimeter or of less\n",
      "        than 20 percent of total T cells on more than one occasion usually two to three months\n",
      "        apart, without evidence of HIV infection or any defined immunodeficiency or therapy\n",
      "        associated with depressed levels of CD4 T cells.\n",
      "        Absence of HIV infection as confirmed by negative ELISA and, if indicated, western blot or\n",
      "        dot blot.\n",
      "        \n",
      "1234\n",
      "Histologically or cytologically proven measurable primary or metastatic non-colorectal\n",
      "        cancer limited to the parenchyma of the liver with no evidence of unresectable\n",
      "        extrahepatic disease by preoperative radiological studies.\n",
      "        Limited resectable extrahepatic disease is acceptable.\n",
      "        Patients with colorectal cancer previously treated with intrahepatic arterial infusional\n",
      "        therapy using FUDR, those with aberrant arterial anatomy such that infusional therapy is\n",
      "        not possible, or those with limited extrahepatic disease such that regional therapy is not\n",
      "        indicated will be eligible for this protocol.\n",
      "        Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their\n",
      "        malignancy in the month prior to the liver perfusion and must have recovered from all side\n",
      "        effects.\n",
      "        Patients must have an ECOG performance standard of 0, 1 or 2 on the day prior to\n",
      "        treatment.\n",
      "        Patients must have adequate hepatic function as evidence by bilirubin less than 2.0 and a\n",
      "        PT and PTT that are within 1-2 seconds of the upper normal limit.\n",
      "        No patients with biopsy proven cirrhosis or evidence of significant portal hypertension by\n",
      "        history, endoscopy, or radiologic studies will be included.\n",
      "        No patients with a history of congestive heart failure with an LVEF of equal to or less\n",
      "        than 40% will be included.\n",
      "        No patients with COPD or other chronic pulmonary disease with PFT's less than 50%\n",
      "        predicted for age will be included.\n",
      "        Patients must be 18 years of age or older.\n",
      "        Patients must have a platelet count greater than 100,000, a HCT greater than 27.0, a white\n",
      "        blood count greater than 3000/ micrograms, and a creatinine less than or equal to 1.5 or a\n",
      "        creatinine clearance of greater than 60 ml/min.\n",
      "        No pregnant patients or nursing mothers will be eligible.\n",
      "        Patients must not be taking immunosuppressive drugs or on chronic anticoagulation.\n",
      "        Patients must not have an active infection.\n",
      "        Patients with severe allergic reactions to iodine contrast which can not be controlled by\n",
      "        premedication with antihistamines and steroids are not eligible as a hepatic angiogram is\n",
      "        needed for this procedure.\n",
      "        Patients must not have HIV disease.\n",
      "        Patients must be aware of the neoplastic nature of his/her illness, the experimental\n",
      "        nature of the therapy, alternative treatments, potential benefits, and risks.\n",
      "        The patient must be willing to sign an informed consent.\n",
      "        Patients must not have a history of veno occlusive disease.\n",
      "1239\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Metastatic melanoma that is HLA-A2 positive.\n",
      "        No primary melanoma of ocular or mucosal origin.\n",
      "        Measurable or resected metastatic disease required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        BIOLOGIC THERAPY: No prior (greater than 30 days) or concurrent Biologic Therapy.\n",
      "        CHEMOTHERAPY: No prior (greater than 30 days) or concurrent chemotherapy.\n",
      "        ENDOCRINE THERAPY: No prior (greater than 30 days) or concurrent hormone therapy.\n",
      "        No requirement for steroids.\n",
      "        RADIOTHERAPY: No prior (greater than 30 days) or concurrent radiotherapy.\n",
      "        SURGERY: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance Status: ECOG 0 or 1.\n",
      "        Life Expectancy: More than 3 months.\n",
      "        HEMATOPOIETIC: No coagulation disorder.\n",
      "        HEPATIC:\n",
      "        Bilirubin no greater than 2.0 mg/dL.\n",
      "        No Hepatitis BsAg antibody.\n",
      "        RENAL: Creatinine no greater than 2.0 mg/dL.\n",
      "        CARDIOVASCULAR: No major cardiovascular illness.\n",
      "        PULMONARY: No major respiratory illness.\n",
      "        OTHER:\n",
      "        No previous allergic reaction to incomplete Freund's adjuvant.\n",
      "        HIV negative.\n",
      "        No active systemic infection.\n",
      "        Not pregnant or lactating.\n",
      "1240\n",
      "Patients must be between 18 and 70 years old.\n",
      "        All stages of patients with low-, intermediate- or high-grade non-Hodgkin's lymphomas, or\n",
      "        Hodgkin's disease who have disease following standard chemotherapy.\n",
      "        Stage II-IV patients with previously untreated low-grade lymphoma or untreated low-grade\n",
      "        with progression.\n",
      "        Patients must have received less than or equal to 2 prior combination chemotherapy\n",
      "        regimens, no combination chemotherapy refractory disease, no high-dose chemotherapy with\n",
      "        stem cell rescue, and may not have CNS involvement by lymphoma.\n",
      "        Pathology slides must be reviewed and a diagnosis of lymphoma confirmed by the\n",
      "        Hematopathology Section, Laboratory of Pathology, NCI.\n",
      "        No patients with a history of coronary artery disease with angina pectoris and/or an\n",
      "        ejection fraction less than 42 percent.\n",
      "        Serum creatinine clearance greater than 50 cc/min, bilirubin less than 2.5 u and AST/ALT\n",
      "        less than 2x normal, absolute neutrophil count greater than 1000/mm(3) and platelet count\n",
      "        greater than or equal to 100,000/mm(3) unless due to respective organ involvement by\n",
      "        tumor.\n",
      "        Patients must have an ECOG performance status less than or equal to 2.\n",
      "        Patients must be HIV negative.\n",
      "        Pregnant women will be excluded.\n",
      "        Patients must be able to give informed consent.\n",
      "        Patients who, in the opinion of the principal investigator, are poor psychiatric or\n",
      "        medical risks because of non-malignant systemic disease will be excluded.\n",
      "        A completed eligibility form.\n",
      "1241\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically or cytologically proven unresectable adenocarcinoma of the pancreas or\n",
      "        ampulla of Vater. Surgical consult at NCI confirming unresectability fulfills requirement.\n",
      "        Unresectable disease defined as tumor with: Gross involvement of regional nodes or direct\n",
      "        extension to any of the following sites: Duodenum, Spleen, Bile duct , Colon,\n",
      "        Peripancreatic tissue, Adjacent large vessels, Stomach.\n",
      "        Metastatic disease requiring local radiotherapy allowed. No CNS metastasis.\n",
      "        No lymphomas or neuroendocrine tumors.\n",
      "        No peritoneal carcinomatosis.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: More than 4 weeks since immunotherapy.\n",
      "        Chemotherapy:\n",
      "        No prior chemotherapy for newly diagnosed disease.\n",
      "        More than 4 weeks since chemotherapy for recurrent disease (6 weeks since nitrosoureas,\n",
      "        mitomycin, or suramin).\n",
      "        Endocrine Therapy: More than 4 weeks since hormonal therapy.\n",
      "        Radiotherapy:\n",
      "        No prior radiotherapy for newly diagnosed disease.\n",
      "        No prior abdominal or pelvic radiotherapy.\n",
      "        More than 4 weeks since radiotherapy for recurrent disease. No prior radiotherapy for\n",
      "        locally advanced disease after resection allowed.\n",
      "        Surgery:\n",
      "        Prior resection allowed.\n",
      "        Biliary decompression or gastric bypass allowed.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Hematopoietic:\n",
      "        ANC greater than 2,000/mm(3).\n",
      "        Platelets greater than 100,000/mm(3).\n",
      "        Hepatic: AST/ALT no greater than 2.5 times normal.\n",
      "        Renal:\n",
      "        Creatinine less than 1.5 mg/dL.\n",
      "        Creatinine clearance at least 60 mL/min,\n",
      "        Cardiovascular:\n",
      "        No myocardial infarction within 6 months.\n",
      "        No unstable angina.\n",
      "        No congestive heart failure (NYHA class III/IV).\n",
      "        OTHER:\n",
      "        HIV seronegative.\n",
      "        No medical or psychiatric contraindication to protocol therapy.\n",
      "        No concurrent malignancy other than: Skin cancer, Cervical carcinoma in situ.\n",
      "        No pregnant or nursing women.\n",
      "        Adequate contraception required of fertile patients.\n",
      "1244\n",
      "-  INPATIENT ALCOHOLICS:\n",
      "          -  We will study up to 150 male and 150 female individuals who meet criteria for alcohol\n",
      "             use disorders and are between the age of 18 and 65 years. Inpatient alcoholics will\n",
      "             be recruited from the NIAAA protocol 05-AA-0121, Assessment and treatment of people\n",
      "             with alcohol drinking problems.\n",
      "          -  Inclusion criteria\n",
      "               -  (1) Are physically healthy;\n",
      "               -  (2) Are between 18-65 years of age (since age effects FMRI signal in ways that\n",
      "                  have not yet been well-characterized);\n",
      "               -  (2) Are right handed.\n",
      "          -  \n",
      "1245\n",
      "-  INCLUSION CRITERIA:\n",
      "        Male or female; if concurrent infection is present or there has been recent multiple\n",
      "        relapse of infection with likely potential for additional relapse, then subjects may\n",
      "        include minors 5 to 17 years of age and adults of any age; if no concurrent infection is\n",
      "        present at enrollment then subjects must be adults of any age or minors 16-17 years of\n",
      "        age.\n",
      "        History of severe infections (two infections requiring hospitalization and intravenous\n",
      "        antibiotics).\n",
      "        Confirmed diagnosis of Chronic Granulomatous Disease as defined by less than 2 percent of\n",
      "        normal oxidant production by all circulating neutrophils.\n",
      "        Confirmed CGD genetic subtype of gp91(phox)-deficiency or p47(phox)-deficiency as defined\n",
      "        by the absence or deficiency of the phox subunit protein using an antibody detection assay\n",
      "        (western blot, ELISA, or flow cytometry) of patient granulocytes.\n",
      "        Subjects without current active infection or recent multiple recurrence of infections must\n",
      "        have adequate organ function as defined by renal function (creatinine less than or equal\n",
      "        to 2 mg per dl; less than or equal to 2+ proteinuria); hepatic function (bilirubin less\n",
      "        than or equal to 1.5 mg per dl; prothrombin time less than or equal to 1.3 x control);\n",
      "        hematologic function (WBC greater than or equal to 2500 per mm(3); granulocytes greater\n",
      "        than or equal to 1200 per mm(3); platelet greater than or equal to 100,000; hematocrit\n",
      "        greater than or equal to 26).\n",
      "        Successful mobilization as demonstrated by greater than or equal to 10 CD34+ cells per\n",
      "        microliter in peripheral blood on the day of the planned apheresis.\n",
      "        Must weigh at least 15 kg.\n",
      "        If a female of childbearing potential, then the patient must have a negative serum\n",
      "        pregnancy test within one week of beginning administration of combination flt3L and GM-CSF\n",
      "        or single agent G-CSF. Both male and female must use a barrier or other effective form of\n",
      "        contraception during marrow growth factor administration and for at least three months\n",
      "        following the last reinfusion of the transduced CD34 + PBHP.\n",
      "        Written informed consent, conforming to institutional guidelines obtained from patient\n",
      "        (and/or parent or guardian if a minor).\n",
      "        \n",
      "1247\n",
      "POPULATION CHARACTERISTICS:\n",
      "        Regional advanced postradiation fibrosis of the neck, chest wall, pelvis, or extremities\n",
      "        causing measurable impairment of specific function, i.e.: Decreased range of motion,\n",
      "        Weakness, Sensory deficit, Pain requiring narcotics, Significantly altered activities of\n",
      "        daily living.\n",
      "        None of these conditions present either before or during radiotherapy or attributed to\n",
      "        surgery or chemotherapy.\n",
      "        Patients with prostate cancer allowed if prostate-specific antigen (PSA) is less than 4.0\n",
      "        ng/mL and the last 3 PSA values were stable or decreasing. Abnormal bone scan or film\n",
      "        acceptable if consistent with degenerative disease.\n",
      "        No recurrent or metastatic cancer.\n",
      "        No concurrent second cancer.\n",
      "        PRIOR/CONCURRENT THERAPY: At least 3 months since pentoxifylline.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: Karnofsky 70%-100% (unrelated to postradiation fibrosis).\n",
      "        CARDIOVASCULAR:\n",
      "        No symptomatic coronary artery disease with frequent anginal episodes necessitating any of\n",
      "        the following during past 6 months: Coronary artery bypass, Angioplasty, Pacemaker\n",
      "        placement, Thrombolytic treatment.\n",
      "        No chronic cardiac failure with persistent hemodynamic abnormality and ejection fraction\n",
      "        less than 40%.\n",
      "        No coagulation, platelet, or vascular disorder that threatens to cause bleeding.\n",
      "        OTHER:\n",
      "        No intolerance to pentoxifylline or other xanthines (e.g., caffeine, theophylline,\n",
      "        theobromine).\n",
      "        No seizure disorder.\n",
      "        No peptic ulcer disease.\n",
      "        Willing to undergo serial evaluations (excluding biopsies, laser Doppler, MRI) by NCI\n",
      "        rehabilitation specialist for documentation and grading of functional disability.\n",
      "        No pregnant or nursing women.\n",
      "        Adequate contraception encouraged in fertile women.\n",
      "1248\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Congenital or acquired immunodeficiency (including HIV-1 infection) with a\n",
      "        lymphoproliferative disorder (LPD) of any of the following types:\n",
      "        Severe and/or progressive lymphadenopathy with hypergammaglobulinemia.\n",
      "        Diffuse infiltrative lymphocytosis syndrome.\n",
      "        Clinically symptomatic pulmonary lymphoid hyperplasia/lymphocytic interstitial\n",
      "        pneumonitis.\n",
      "        Polyclonal B-cell LPD.\n",
      "        No patients with malignant lymphoma.\n",
      "        No active opportunistic infection requiring acute intervention at entry.\n",
      "        THERAPY:\n",
      "        Biologic Therapy:\n",
      "        At least 30 days since immunomodulating agents or biological response modifiers, e.g.:\n",
      "        Interleukin-2, Interferons, Growth hormone, Insulin-like growth factor 1.\n",
      "        Requirement waived for intravenous immunoglobulins for hypogammaglobulinemia.\n",
      "        Concurrent post-transplant immunosuppressants allowed. Doses stable for at least 4 weeks\n",
      "        prior to entry.\n",
      "        Chemotherapy: At least 30 days since chemotherapy.\n",
      "        Endocrine Therapy:\n",
      "        Concurrent corticosteroids allowed only for lymphocytic interstitial pneumonitis or an\n",
      "        autoimmune process. Doses stable for more than 4 weeks prior to entry.\n",
      "        Radiotherapy: At least 30 days since radiotherapy.\n",
      "        Surgery: Not specified.\n",
      "        Antiretroviral therapy (in patients with HIV infection):\n",
      "        Approved anti-HIV medication required.\n",
      "        Initiated at least 8 weeks prior to entry.\n",
      "        Continued throughout protocol treatment.\n",
      "        Prophylaxis for Pneumocystis carinii pneumonia and/or Mycobacterium avium-intracellulare\n",
      "        allowed.\n",
      "        Maintenance antifungal or antiviral therapy allowed.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: Under 18.\n",
      "        Performance status: Not specified.\n",
      "        One or more of the following laboratory findings (within 4 weeks of starting retinoic acid\n",
      "        and interferon-alpha , and which have not resolved within 2 weeks of starting):\n",
      "        Creatinine greater than 2 times the upper limit of normal;\n",
      "        Liver transaminases greater than 5 times the upper limit of normal (children with\n",
      "        chronically elevated liver enzymes with a proven etiology can be enrolled, but will not be\n",
      "        evaluable for liver toxicity); or\n",
      "        Bilirubin greater than 3 times the upper limit of normal.\n",
      "        Patients receiving treatment for an acute infection must have completed therapy at least\n",
      "        14 days prior to starting therapy with retinoic acid and interferon-alpha.\n",
      "        OTHER:\n",
      "        Able to swallow capsules.\n",
      "        No requirement for drugs suspected of causing pseudotumor cerebri for which alternatives\n",
      "        cannot be substituted, e.g.: Tetracycline, Nalidixic acid, Nitrofurantoin, Phenytoin,\n",
      "        Lithium, Amiodarone, Vitamin A (except as a multivitamin supplement component).\n",
      "        No critical or clinically unstable illness.\n",
      "        No pregnant or nursing women.\n",
      "        Effective contraception encouraged in fertile patients.\n",
      "        Parent or legal guardian available to give informed consent and deemed sufficiently\n",
      "        reliable to return for followup visits.\n",
      "        No critically ill or critically unstable children.\n",
      "1250\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed brain tumor including but not limited to the following:\n",
      "        Anaplastic astrocytoma, Glioblastoma multiforme, Low-grade glioma, Ependymoma,\n",
      "        Medulloblastoma, Pineal tumors, Chiasmal glioma, Craniopharyngioma, Brain stem glioma\n",
      "        (requirement for histologic diagnosis may be waived).\n",
      "        Disease refractory to standard therapy or no standard chemotherapy exists and ineligible\n",
      "        for potential curative surgery or radiotherapy.\n",
      "        Measurable or evaluable disease on radiographic studies with evidence of progression on\n",
      "        prior chemotherapy or radiotherapy or persistent disease after surgery.\n",
      "        PRIOR/CURRENT THERAPY:\n",
      "        See Disease Characteristics\n",
      "        At least 6 months since carboplatin.\n",
      "        At least 3 weeks since myelosuppressive therapy.\n",
      "        Patients who received stem cell or bone marrow rescue after nitrosourea therapy are\n",
      "        eligible after 3 weeks if they have recovered from hematologic toxicities of their prior\n",
      "        therapy.\n",
      "        Concurrent steroids allowed if dose stable for at least 2 weeks prior to entry.\n",
      "        Recovered from toxic effects of any prior therapy.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 21 and under.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        HEMATOLOGIC:\n",
      "        Absolute granulocyte count greater than 1,500/mm(3).\n",
      "        Platelet count greater than 100,000/mm(3) (at least 75,000/mm(3) in patients with prior\n",
      "        bone marrow transplantation or craniospinal irradiation).\n",
      "        Hemoglobin greater than 8.0 g/dL.\n",
      "        HEPATIC:\n",
      "        Bilirubin no greater than 2 times normal.\n",
      "        ALT no greater than 2 times normal.\n",
      "        RENAL:\n",
      "        Creatinine within normal limits for age as follows:\n",
      "        Age (in years) -- Creatinine (in mg/dL):\n",
      "        Younger than 5 -- no greater than 1.2;\n",
      "        5-10 -- no greater than 1.5;\n",
      "        10-15 -- no greater than 1.8;\n",
      "        Older than 15 -- no greater than 2.4.\n",
      "        OTHER:\n",
      "        No significant systemic illness.\n",
      "        No pregnant or nursing women.\n",
      "        Negative pregnancy test required of fertile women.\n",
      "        Effective contraception required of fertile patients.\n",
      "        Durable power of attorney required of all patients 18-21 years of age.\n",
      "1251\n",
      "Age 5 to 60 at entry to protocol.\n",
      "        History of partial or Complex Partial Epilepsy for two or more years.\n",
      "        Patients should be on a stable anti-convulsant regimen defined as unchanged medicines and\n",
      "        dose modifications lower than 20% in the last month. Blood levels of anti-convulsants will\n",
      "        be measured at the beginning of the study, prior to stimulation and after the study to\n",
      "        assure that the type and dose of medication will remain constant.\n",
      "        Seizures not completely responsive to medical treatment (1 or more seizures per week for\n",
      "        at least 6 months) and patients have failed at least two anti-convulsant regimens in the\n",
      "        past.\n",
      "        The patients have a localized seizure focus.\n",
      "        Epilepsy refractory to medical treatments.\n",
      "        No pregnant women (will be tested with urine pregnancy test).\n",
      "        No severe coronary disease.\n",
      "        No metal anywhere in the cranium except the mouth.\n",
      "        No intracardiac lines.\n",
      "        No increased intracranial pressure as expressed by the presence of papilledema.\n",
      "        No cardiac pacemakers.\n",
      "        Must not be taking neuroleptic or antidepressant medications.\n",
      "        No progressive neurologic disease.\n",
      "1257\n",
      "Patients must be at least 3 years of age.\n",
      "        Must have a biochemically confirmed (enzyme) and/or genetically confirmed diagnosis of\n",
      "        type 1 or type 3 Gaucher disease.\n",
      "        Clinical or laboratory signs suggesting need for therapy which will include at least 2 of\n",
      "        the following: hemoglobin less than 11 gm/dl; platelets less than 90,000/mm(3);\n",
      "        hepatomegaly and/or splenomegaly.\n",
      "        Patient/Guardian must provide written informed consent.\n",
      "        No pregnant or breast feeding women.\n",
      "        No women/men of reproductive potential unless they agree to use an effective contraceptive\n",
      "        method.\n",
      "        No patients treated with alglucerase or imiglucerase during the 6 months prior to study\n",
      "        entry.\n",
      "        No patients with the diagnosis of type 2 Gaucher disease.\n",
      "        No patients who have a life-threatening disease or are gravely ill.\n",
      "        No patients who have rapidly progressing fatal illness or concomitant malignancy.\n",
      "        No patients who have a chronic infectious disease including HIV or hepatitis B.\n",
      "        No patients chronically on other medications which may interfere with the drug's\n",
      "        metabolism or activity.\n",
      "        No patients who received blood transfusion within a month prior to study entry.\n",
      "1258\n",
      "Must have been diagnosed with osteosarcoma by the age of 25 years.\n",
      "        Patient must have a biopsy proven osteosarcoma and either: a) active tumor with no\n",
      "        available standard therapy options; b) metastatic osteosarcoma at diagnosis, has completed\n",
      "        therapy and has no evidence of active disease; or, c) is status-post any surgery for\n",
      "        recurrent osteosarcoma, either local or metastatic recurrence, and is free of disease by\n",
      "        CT scan.\n",
      "        Measurable disease not required.\n",
      "        Patients with serum creatinine &lte; 2.0 mg/dL or creatinine clearance &gte; 40 ml/min per\n",
      "        1.73m(2) (if serum creatinine is &gte; 2.0 mg/dL).\n",
      "        Patients with normal thyroid function.\n",
      "        Patients with total bilirubin, SGOT and SGPT < twice the upper limit of normal.\n",
      "        Patients with normal direct bilirubin only if total direct bilirubin is abnormal.\n",
      "        Patients with bone marrow criteria: ANC>1500/mm(3) and platelet count >100,000/mm(3).\n",
      "        Patients without a history of insulin-dependent diabetes mellitus or current insulin\n",
      "        requirement. Fasting morning blood glucose <150 mg/dL.\n",
      "        Patients with ECOG performance status of 0, 1 or 2 and a life expectancy of at least 8\n",
      "        weeks.\n",
      "        Patients not on chemotherapy or radiation therapy within the past 2 weeks and recovered\n",
      "        from the acute side effects of prior anti-neoplastic therapy.\n",
      "        Patients with documented negative HIV serology within the past 6 months.\n",
      "        Post-menarcheal patients must have documented negative urine and serum pregnancy test\n",
      "        (B-HCG); when indicated, patient must be willing to take oral contraceptives or other\n",
      "        appropriate contraceptives to avoid pregnancy during the period of treatment.\n",
      "        Patient, parent or guardian must give informed consent.\n",
      "        No pregnant or lactating women.\n",
      "        No women of child-bearing potential who are unable or unwilling to use appropriate\n",
      "        contraceptives during the period of treatment.\n",
      "        No patients with uncorrected hypothyroidism.\n",
      "        No patients with insulin-dependent diabetes mellitus or fasting blood glucose &gte; 150\n",
      "        mg/dL.\n",
      "        No patients with HIV infection.\n",
      "        No patients with a history of thromboembolic events who require prophylaxis for\n",
      "        thromboembolic events with anticoagulants once entry into Cohort III has begun.\n",
      "        Patients with a history of symptomatic gallbladder disease must have had a\n",
      "        cholecystectomy.\n",
      "1259\n",
      "-  INCLUSION CRITERIA:\n",
      "        A. Group 1: Women with a history of postpartum depression:\n",
      "          1. A history of DSM-IV major depression or hypomanic/manic episode that occurred within\n",
      "             three months of childbirth (as determined by a SCID interview);\n",
      "          2. has been well for a minimum of one year;\n",
      "          3. a regular menstrual cycle for at least three months;\n",
      "          4. age 18-50;\n",
      "          5. not pregnant, not lactating and in good medical health;\n",
      "          6. medication free (including birth control pills);\n",
      "          7. no history of puerperal suicide attempts or psychotic episodes requiring\n",
      "             hospitalization.\n",
      "        Group 2: Women with a history of Major Depressive Disorder\n",
      "          1. A history of DSM-IV major depression episode(s) occurring outside of pregnancy and\n",
      "             not within three months postpartum;\n",
      "          2. has been well for a minimum of one year;\n",
      "          3. a regular menstrual cycle for at least three months;\n",
      "          4. age 18-50;\n",
      "          5. not pregnant, not lactating and in good medical health;\n",
      "          6. medication free (including birth control pills);\n",
      "          7. no history of suicide attempts or psychotic episodes requiring hospitalization.\n",
      "        Group 3; Normal Controls\n",
      "          1. Controls will meet all criteria specified except they must not have any past or\n",
      "             present Axis I diagnosis or evidence of menstrually related mood disorders.\n",
      "          2. A structured clinical interview for DSM-IV (SCID) will be administered to all women\n",
      "             prior to study entry. Any woman with a current axis I psychiatric diagnosis will be\n",
      "             excluded from participating in this protocol.\n",
      "             \n",
      "1260\n",
      "PRE-CHEMOTHERAPY ELIGIBILITY:\n",
      "        Patients must have a histologically confirmed diagnosis of stage II, III, or IV\n",
      "        infiltrating breast cancer; stage II patients must be considered high risk with greater\n",
      "        than four positive axillary lymph nodes at primary surgery. Patients with metastatic\n",
      "        disease must have their relapse confirmed pathologically. All pathological material must\n",
      "        be reviewed and the diagnosis confirmed by the Department of Pathology at the NIH Clinical\n",
      "        Center prior to acceptance on the protocol.\n",
      "        Patients enrolled on this protocol may receive chemotherapy by one of the following\n",
      "        mechanisms: (1) Any dose intensive chemotherapy regimen given as part of a separate NCI\n",
      "        breast cancer protocol. In such a case, prior approval of the principal investigator for\n",
      "        that study should be obtained. It must be emphasized that no clinical or research\n",
      "        endpoints of the chemotherapy protocol must be compromised by participation in this immune\n",
      "        reconstitution protocol.\n",
      "        (2) In some cases, patients may receive non-experimental chemotherapy from their referring\n",
      "        physicians. Patients may not be enrolled on this study if they are to receive chemotherapy\n",
      "        as part of an experimental study performed outside of the NCI; patients who are receiving\n",
      "        high-dose chemotherapy requiring stem cell support at other institutions are specifically\n",
      "        excluded from participation in this study. The determination of whether non-experimental\n",
      "        chemotherapy qualifies as dose intensive will be made by the principal investigator.\n",
      "        All stage II and III patients must represent a new diagnosis and must have received no\n",
      "        prior chemotherapy.\n",
      "        Patients with metastatic disease can represent a new diagnosis as stage IV, or may have\n",
      "        metastatic disease that represents a relapse after adjuvant therapy for any other stage of\n",
      "        breast cancer. However, a prior of one year must have elapsed since the completion of\n",
      "        adjuvant chemotherapy.\n",
      "        Patient must have a Hct of greater than or equal to 24%, a WBC count of greater than or\n",
      "        equal to 3000 per mm(3), and platelets greater than or equal to 100,000 per mm(3) at the\n",
      "        time of enrollment.\n",
      "        Patients must have no history of abnormal bleeding tendency or predisposition to\n",
      "        infection.\n",
      "        Serum creatinine of less than 1.5 or Crcl of less than 60 cc per min. Higher values may be\n",
      "        allowed if it is determined by the principal investigator that elevated values are due to\n",
      "        tumor impairment of organ function.\n",
      "        AST and ALT less than 3 times the upper limits of normal. Higher values may be allowed if\n",
      "        it is determined by the principal investigator that elevated values are due to tumor\n",
      "        impairment of organ function.\n",
      "        In the presence of known pulmonary disease of symptoms, patients must have a pO2 greater\n",
      "        than 65 and FEV1 and FVC greater than 65% of predicted (unless directly due to tumor\n",
      "        involvement prior to therapy).\n",
      "        LVEF greater than or equal to 45% post-chemotherapy, as measured by MUGA or 2-D\n",
      "        echocardiogram.\n",
      "        All patients must be free of a significant history or active symptomatology of coronary\n",
      "        artery disease, congestive heart failure, neurologic disease, or chronic obstructive\n",
      "        pulmonary disease.\n",
      "        Patients must have a Karnofsky performance score of greater than 70% (ECOG 0 or 1) and a\n",
      "        life expectancy of at least three months.\n",
      "        Patients must be able to give informed consent.\n",
      "        POST-CHEMOTHERAPY ELIGIBILITY:\n",
      "        After completion of dose intensive chemotherapy, patients must continue to meet the\n",
      "        eligibility criteria above. However, for patients who are to receive only autologous T\n",
      "        cells (and no IL-2 therapy), cardiac ejection fraction will not represent a treatment\n",
      "        eligibility criteria. In addition, patients must meet the criteria as outlined below.\n",
      "        To proceed with the protocol after completion of dose intensive chemotherapy, stage II and\n",
      "        III patients must have no evidence of disease. Patients requiring adjuvant radiation\n",
      "        therapy will receive this prior to proceeding with this protocol. Patients with metastatic\n",
      "        disease must have demonstrated a least a partial response to chemotherapy (greater than\n",
      "        50% reduction in measurable disease).\n",
      "        To be eligible to proceed with T cell infusion and/or IL-2 administration after completion\n",
      "        of chemotherapy, patients must have a Hb of greater than or equal to 9, an ANC greater\n",
      "        than or equal to 1000, and a platelet count of greater than or equal to 75,000.\n",
      "        Patients must have recovered from any non-hematologic toxicities of dose-intensive\n",
      "        chemotherapy and radiation therapy prior to receiving T cell infusions or IL-2.\n",
      "        All women will be tested for pregnancy at enrollment and prior to T cell transfer or IL-2\n",
      "        treatment; individuals must not be pregnant.\n",
      "        Patients must not be HIV positive or have Hepatitis B or C infection.\n",
      "        Patients must not have a chronic need to steroid or anti-coagulant therapy. However, for\n",
      "        patients who are to receive only autologous T cells, steroid or anti-coagulant therapy\n",
      "        will not be an \n",
      "1265\n",
      "AGE:\n",
      "        All patients must be less than or equal to 21 years of age.\n",
      "        PERFORMANCE STATUS:\n",
      "        Patients should have an ECOG performance status of 0, 1, or 2, and a life expectancy of at\n",
      "        least 8 weeks.\n",
      "        HISTOLOGIC DIAGNOSIS:\n",
      "        Patients with the following diagnosis, confirmed by appropriate histologic examination,\n",
      "        will be eligible for this study: neuroblastoma and Wilms' tumor.\n",
      "        MEASURABLE DISEASE:\n",
      "        Patients must have measurable disease. Patients with evaluable disease only (i.e., limited\n",
      "        to positive bone scan or bone marrow) are eligible only if the bone involvement is\n",
      "        measurable by alternative imaging modalities (MRI, CT, or plain film).\n",
      "        PROGRESSIVE DISEASE:\n",
      "        Patients must have evidence of progressive disease following or during prior therapy.\n",
      "        HEMATOLOGIC FUNCTION:\n",
      "        Patients do not have to be evaluable for hematologic toxicity to be enrolled onto the\n",
      "        study. Patients without bone marrow involvement by tumor, with no history of BMT, and with\n",
      "        no prior cranio-spinal or pelvic radiation, will be considered evaluable for hematologic\n",
      "        toxicity.\n",
      "        Patients evaluable for hematologic toxicity must have adequate bone marrow function\n",
      "        (defined as peripheral absolute granulocyte count of greater than 1500/mm(3), hemoglobin\n",
      "        greater than 8.0 gm% and platelet count greater than 100,000/mm(3)).\n",
      "        HEPATIC FUNCTION:\n",
      "        Patients must have adequate liver function (bilirubin less than 2.0 mg%; SGPT less than 2\n",
      "        times normal).\n",
      "        RENAL FUNCTION:\n",
      "        Patients must have adequate renal function defined as a creatinine clearance greater than\n",
      "        or equal to 70 ml/min/1.732 or a serum creatinine based on age as follows:\n",
      "        equal to or less than 5 years old: maximum serum creatinine 0.8;\n",
      "        older than 5 but equal to or less than 10: 1.0;\n",
      "        older than 10 but equal to or less than 15: 1.2;\n",
      "        older than 15: 1.5.\n",
      "        RECOVERY FROM PRIOR THERAPY:\n",
      "        Patients must have recovered from the toxic effects of prior therapy, and must be off of\n",
      "        all chemotherapy for a minimum of two weeks prior to entry onto the protocol (a minimum of\n",
      "        six weeks for prior nitrosoureas).\n",
      "        INFORMED CONSENT:\n",
      "        All patients or their legal guardians must sign a document of informed consent indicating\n",
      "        their awareness of the investigational nature and the risks of this study.\n",
      "        No history of CNS malignant disease, hydro-cephalus, or pseudotumor cerebri.\n",
      "        No history of treatment with 13-cis retinoic acid within the prior three months.\n",
      "        Women of childbearing potential must not be pregnant or lactating.\n",
      "1270\n",
      "-  INCLUSION CRITERIA - BLOOD DRAW/ASTHMA:\n",
      "        Age 18-65.\n",
      "        Asthma of greater than one year duration.\n",
      "        Willingness to adhere to effective contraception in women of child bearing age.\n",
      "        Negative HIV test.\n",
      "        \n",
      "1275\n",
      "Patients with known coronary artery disease (obstruction of greater than or equal to 50%\n",
      "        in at least one major coronary artery).\n",
      "        Patients with hypertrophic cardiomyopathy.\n",
      "        Patients with microvascular angina.\n",
      "        No unstable angina.\n",
      "        No hepatic or renal failure.\n",
      "        Infective endocarditis\n",
      "        No primary valvular disease.\n",
      "        No congenital heart disease.\n",
      "        No pregnant or breast feeding women.\n",
      "1277\n",
      "Patients will be drawn from among those referred to the NINDS Epilepsy Research Branch.\n",
      "        No patients with evidence for a progressive neurological disorder.\n",
      "        No subjects with metal hardware in the cranial cavity, cardiac pacemakers, indwelling\n",
      "        medication pumps, cochlear implants, intracardiac lines, significant intracranial masses\n",
      "        or evidence of increased intracranial pressure.\n",
      "        Women must not be pregnant.\n",
      "1278\n",
      "Ability to provide informed consent to all aspects of the study after full information is\n",
      "        provided.\n",
      "        Age equal to or older than 18.\n",
      "        A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised\n",
      "        American College of Rheumatology criteria.\n",
      "        Active RA defined as: 6 or more swollen joints;\n",
      "        6 or more tender joints;\n",
      "        ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45\n",
      "        minutes.\n",
      "        Incomplete response (defined as persistently active disease as described above) to\n",
      "        treatment with at least one of the following regimens for over 3 months:\n",
      "        MTX alone (greater than or equal to 17.5 mg/week);\n",
      "        MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200\n",
      "        mg/day);\n",
      "        MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);\n",
      "        MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);\n",
      "        MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ\n",
      "        (greater than or equal to 200 mg/day);\n",
      "        No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other\n",
      "        immunosuppressive agents required for the control of extraarticular manifestations at the\n",
      "        time of study entry.\n",
      "        No active acute or chronic infections requiring antibiotic therapy, serious viral\n",
      "        infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections.\n",
      "        Patients with a positive PPD who have not received INH or other antituberculous therapy\n",
      "        will be excluded.\n",
      "        No pregnant women, nursing mothers, or patients of childbearing age not practicing birth\n",
      "        control.\n",
      "        No preexisting malignancy other than basal cell carcinoma.\n",
      "        No history of stroke, seizure disorder, or chronic neurologic disease.\n",
      "        No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than\n",
      "        first degree, or a dysrhythmia requiring therapy.\n",
      "        No confounding medical illness that in the judgment of the investigators would pose added\n",
      "        risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone\n",
      "        marrow hypoplasia).\n",
      "        No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic\n",
      "        sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel\n",
      "        disease.\n",
      "        No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is\n",
      "        sustained for at least 1 month.\n",
      "        No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less\n",
      "        than 100,000, or white blood count less than 3,500/dL.\n",
      "        No patients with active lung disease, patients with a chronic and progressive lung\n",
      "        disease, or patients with a chronic but stable lung disease with pulmonary function tests\n",
      "        of less than 70% of predicted (DLCO less than 60%).\n",
      "        No patients with hypogammaglobulinemia (IgG count less than 300).\n",
      "        No patients treated with alkylating agents for over 1 year at any time or treated with a\n",
      "        purine nucleoside analog at any time.\n",
      "1280\n",
      "Patients meeting the diagnostic criteria for von Hippel-Lindau (VHL) disease.\n",
      "        No persons who are pregnant or lactating are eligible for the surgical arm of this\n",
      "        protocol until the pregnancy and/or nursing period has reached completion.\n",
      "        No patients with disorders associated with multiple abnormalities of the middle ear and\n",
      "        inner ear. Specific laboratory abnormalities such as anti-HIV-1, FTA-Abs, serum ANA, and\n",
      "        ANCA have been associated with AIDS, Syphilis, Systemic Lupus Erythematosus, and Wegener's\n",
      "        Granulomatosis, respectively.\n",
      "        No patients currently undergoing chemotherapeutic regimen with ototoxic agents (e.g.,\n",
      "        cisplatin). Other agents will be reviewed on a case-by-case basis for their potential to\n",
      "        cause ototoxicity and thereby interfere with audiologic data interpretation.\n",
      "        Patients with an ELST in an only hearing ear will be excluded from the protocol for\n",
      "        surgical treatment of ELST's (except in cases where other medical indications necessitate\n",
      "        intervention for the welfare of the patient).\n",
      "        Patients with only unilateral vestibular function on the side affected by the ELST, as\n",
      "        documented by caloric ENG testing, will be excluded from the surgical treatment group in\n",
      "        most cases.\n",
      "        No patients with the inability to understand all of the requirements of the study or\n",
      "        inability to give informed consent and/or comply with all aspects of the evaluation.\n",
      "1282\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Recurrent or metastatic cancer, including lymphoma.\n",
      "        No leukemia.\n",
      "        No active CNS disease.\n",
      "        Refractory to all effective therapy OR No effective therapy exists.\n",
      "        Measurable disease not required.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Biologic Therapy: Greater than 4 weeks and recovered from immunotherapy.\n",
      "        Chemotherapy: Greater than 4 weeks and recovered from chemotherapy.\n",
      "        Previous therapy with irinotecan is permitted.\n",
      "        Endocrine Therapy: Not specified.\n",
      "        Radiotherapy: Greater than 4 weeks since radiotherapy.\n",
      "        Surgery: Recovered from prior surgery.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 18 and over.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Hematopoietic: AGC greater than 1,500.\n",
      "        Platelets greater than 100,000.\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL.\n",
      "        AST no greater than 2 times normal.\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL.\n",
      "        OTHER:\n",
      "        HIV negative.\n",
      "        No active infection requiring antibiotics.\n",
      "        No concurrent medical illness that would interfere with chemotherapy.\n",
      "        No pregnant or nursing women.\n",
      "        Adequate contraception required of fertile patients.\n",
      "        Imaging/exams for tumor measurement within 28 days prior to registration.\n",
      "1285\n",
      "Age, 18 or more.\n",
      "        Must have lesions that fulfill clinical and histologic criteria for active CDLE.\n",
      "        Lesions must be of at least 3 months duration and must not have been treated with topical\n",
      "        steroids or retinoids for at least 3 weeks.\n",
      "        Patient must have at least two similar lesions that can accommodate a 2X3 inch dressing.\n",
      "        Patient must be willing to have two 4 mm biopsies prior to onset of therapy and four 4 mm\n",
      "        biopsies at the end of the study period.\n",
      "        In the absence of systemic involvement, the CDLE lesions must not have responded to at\n",
      "        least 3 months of therapy with topical steroids, sunscreens with or without antimalarials\n",
      "        such as hydroxychloroquine.\n",
      "        If CDLE is present in association with systemic involvement, the lesions must not have\n",
      "        responded to 3 months of stable conventional systemic therapy and/or topical steroids and\n",
      "        sunscreens.\n",
      "        If female, the patient must have a negative pregnancy test prior to study entry.\n",
      "        If female, must be postmenopausal surgically sterile, sexually inactive, or practicing\n",
      "        successful contraception with two methods of birth control simultaneously for at least one\n",
      "        month prior to starting on thalidomide and continue use for another month after the last\n",
      "        application of thalidomide.\n",
      "        If male, the patient must be surgically sterilized, sexually inactive, or use a condom\n",
      "        during the study and continue regular use until one month after the last application of\n",
      "        thalidomide.\n",
      "        Patients must have normal cognitive abilities to be able to understand the experimental\n",
      "        nature of the therapy, to be able to follow instructions regarding application of\n",
      "        medication and correct use of contraceptive measures.\n",
      "        Patients must not be pregnant or lactating.\n",
      "        Patients must not have renal disease (serum creatinine greater than 2 times the upper\n",
      "        limit of normal.\n",
      "        Patients must not have hepatic dysfunction (liver function tests greater than 2 times the\n",
      "        upper limit of normal).\n",
      "        Patients must not have unstable systemic lupus erythematosus such that systemic therapy\n",
      "        cannot be maintained at steady doses for the duration of the study.\n",
      "        Patients must not use topical steroids for the duration of the study.\n",
      "        Patients must not be currently receiving systemic thalidomide.\n",
      "        Patients must not be hypersensitive to thalidomide.\n",
      "        Patients must not have presence of polyneuropathy (objective sensory loss or motor\n",
      "        weakness or reflex loss) with the exception of focal nerve entrapment syndromes (such as\n",
      "        carpal tunnel syndrome), or receiving drugs with known or suspected neuropathic side\n",
      "        effects.\n",
      "        Patients must not have any other condition or therapy which in the opinion of the\n",
      "        investigators may pose a risk to the patient or confound the results of the study.\n",
      "1288\n",
      "Diagnosis of Polymyositis or Dermatomyositis.\n",
      "        Baseline muscle weakness score of less than or equal to 139 out of 160 on manual testing\n",
      "        (MMT).\n",
      "        Baseline functional assessment score of less than or equal to 82 out of 91.\n",
      "        Ability to provide informed consent to all aspects of the study after full information is\n",
      "        provided.\n",
      "        Age equal to or older than 18.\n",
      "        A diagnosis of classic or definite polymyositis or dermatomyositis (Critieria A and B plus\n",
      "        at least one of the three other criteria):\n",
      "          1. Symmetrical proximal muscle weakness;\n",
      "          2. Muscle biopsy abnormalities at some time during their disease:\n",
      "        i. degeneration and regeneration of muscle fibers\n",
      "        ii. necrosis\n",
      "        iii. phagocytosis\n",
      "        iv. interstitial mononuclear infiltration;\n",
      "        c. Elevation of serum creatinine phosphokinase (CPK), transaminases, lactic dehydrogenase\n",
      "        (LDH) or aldolase activity;\n",
      "        d. Electromyography (EMG) triad of changes\n",
      "        i. small amplitude, short duration polyphasic motor unit potentials\n",
      "        ii. fibrillations, positive sharp waves, increased insertional irritability\n",
      "        iii. spontaneous bizarre high frequency discharges;\n",
      "        e. Typical skin rash of DM.\n",
      "        Willingness to undergo 2 muscle biopsies.\n",
      "        Evidence of active disease as measured by weakness, and an elevated CK or an active MRI.\n",
      "        Must be tapered to a stable dose of steroid equal to or less than 0.50 mg/kg/day\n",
      "        equivalent of prednisone for one month prior to the study.\n",
      "        If on additional immunosuppressive drugs, the drugs must be maintained at a stable dose\n",
      "        for 1 month prior to the initiation of therapy and will be maintained throughout the\n",
      "        trial.\n",
      "        Women of childbearing potential and men whose partners are of childbearing potential must\n",
      "        practice an acceptable form of contraception. No pregnant females or nursing mothers.\n",
      "        No history of hepatitis or abnormal liver function tests.\n",
      "        No history of prior thyroid disease.\n",
      "        No active acute or chronic infections requiring antimicrobial therapy, or serious viral or\n",
      "        fungal infections.\n",
      "        No preexisting or coexisting malignancy other than basal cell and localized squamous cell\n",
      "        carcinoma of the skin.\n",
      "        No history of cerebrovascular accidents, seizure disorder, aseptic meningitis, transverse\n",
      "        myelitis or central nervous system disease.\n",
      "        No history of documented coronary artery disease, cardiomyopathy, greater than\n",
      "        first-degree heart block, or dysrhythmia requiring therapy.\n",
      "        No confounding medical illness that in the judgement of the investigators would pose added\n",
      "        risk for study participants.\n",
      "        No anemia requiring maintenance blood transfusions; leukoplakia with WBC less than 3,000\n",
      "        micrograms or absolute neutrophil count less than 2,000 micrograms; and platelet count\n",
      "        less than 100,000 micrograms on at least two different occasions.\n",
      "        No history of (or current) autoimmune hemolytic anemia.\n",
      "        No current anticoagulant therapy.\n",
      "1289\n",
      "Healthy volunteers and patients who satisfy DSM-III-R criteria for mood disorders between\n",
      "        ages of 18 and 75 will be invited to participate provided that the following criteria are\n",
      "        fulfilled:\n",
      "        No history of medical illness (including seizures, endocrine, hepatic, renal, cardiac,\n",
      "        allergic, infectious, autoimmune, or neurological disorders) that would contraindicate\n",
      "        participation.\n",
      "        No evidence of co-existing major illness after undergoing complete psychiatric (including\n",
      "        SADS-LA interview), medical, neurological, and laboratory examinations (including EEG,\n",
      "        EKG, renal and liver function tests, serum electrolytes, urinalysis, HIV, hepatitis B,\n",
      "        syphilis).\n",
      "        Negative pregnancy test for women of child bearing potential.\n",
      "        Women must not be breast feeding.\n",
      "        Negative HIV test, as we are studying primary mood and anxiety disorders and not disorders\n",
      "        secondary to HIV infection.\n",
      "        Negative urine comprehensive drug screen and have not had alcohol or substance abuse\n",
      "        problems in last 12 months.\n",
      "1291\n",
      "Personality data and DNA samples will be collected from related individuals, primarily\n",
      "        pairs of male and pairs of female siblings, but also including parents.\n",
      "1292\n",
      "Index subjects as well as male and female first and second degree family members, greater\n",
      "        than 5 years of age, of index subjects with iron overload.\n",
      "        In some cases, more distant family members will also be studied.\n",
      "        No patients less than or equal to 5 years old.\n",
      "1298\n",
      "Patients must be between 18-55 years old; meet the diagnostic criteria for clinical\n",
      "        definite or laboratory supported definite MS with either a relapsing remitting or\n",
      "        secondary progressive course;\n",
      "        Stage I - known by history to have a mean enhancing lesion frequency of 0.3 per month or\n",
      "        greater;\n",
      "        Stage II - known by history to have a mean enhancing lesion frequency of 0.5 per month or\n",
      "        greater;\n",
      "        Ability to comply with protocol requirements;\n",
      "        Provide written informed consent;\n",
      "        If a female patient, not of child bearing potential (surgically sterilized or\n",
      "        post-menopausal) or if of child bearing potential, documented to be nonpregnant by urine\n",
      "        pregnancy test and not lactating with adequate contraception and counseling.\n",
      "        Male patients should also receive adequate counseling and exercise adequate contraception.\n",
      "        No clinically significant abnormalities on the prestudy laboratory evaluations, physical\n",
      "        examination, electrocardiogram (ECG), chest x-ray, mammogram or ophthalmologic exam.\n",
      "        No connective tissue or rheumatic disorder (systemic lupus erythematosus [SLE] ;\n",
      "        rheumatoid arthritis [RA]; progressive systemic sclerosis [PSS]; Sjogren's syndrome [SS]).\n",
      "        Patient may not be HIV (human immunodeficiency virus), HTLV-1 (human T cell leukemia\n",
      "        virus), or HB/C Ag (hepatitis B or C surface antigen) positive.\n",
      "        No history of insulin-producing tumors or reactive hypoglycemia.\n",
      "        No clinically significant medical condition (e.g., within 6 months of screen had\n",
      "        myocardial infarction, angina pectoris, untreated hypertension, and/or congestive heart\n",
      "        failure [CHF] that, in the opinion of the investigator would compromise the safety of the\n",
      "        patient.\n",
      "        Ability to tolerate MRI examinations due to claustrophobia, or have contraindications to\n",
      "        MRI scanning, such as pacemakers, aneurysm clips, or shrapnel fragments. Welders and metal\n",
      "        workers must have radiographic evidence to document lack of foreign bodies in the eyes or\n",
      "        they will be excluded, due to the risk of eye injury while in the MRI machine.\n",
      "        No history of substance use disorder (DSM-IV criteria) within the past two years.\n",
      "        No Type I or Type II diabetes treated with hypoglycemic agents (diet-controlled Type II\n",
      "        diabetes may be included.)\n",
      "        No history of cancer (with the exception of localized skin cancers with no evidence of\n",
      "        metastasis, significant invasion, or recurrence) within three years of screening.\n",
      "        No first or second degree relatives with breast cancer.\n",
      "        Have not used an investigational drug within 30 days of the screen visit.\n",
      "        Have previously received interferon-alpha, interferon-beta, copolymer 1, cyclophosphamide,\n",
      "        intravenous immunoglobulin, oral myelin, or other immunosuppressive drugs within 6 months\n",
      "        of screen.\n",
      "1299\n",
      "Ability to provide informed consent to all aspects of the study after full information is\n",
      "        provided.\n",
      "        Age equal to or older than 18 years.\n",
      "        Psoriatic arthritis of more than 6 months duration defined by the following criteria:\n",
      "        A psoriatic skin lesion (or history of psoriatic skin lesion documented by a physician)\n",
      "        with or without nail involvement.\n",
      "        Peripheral arthritis alone or in combination with sacroiliitis. Patients with chest\n",
      "        expansion less than 2.5 cm or decreased flexion of the cervical and lumbosacral spine\n",
      "        flexion by 50% or more will be excluded.\n",
      "        A negative serum test for rheumatoid factor and absence of subcutaneous nodules.\n",
      "        Radiographic findings (if present) compatible with psoriatic arthritis (\"pencil in cup\n",
      "        lesion,\" osteolysis of the terminal phalanx, asymmetrical sacroiliitis, erosive\n",
      "        oligoarticular arthritis or spinal syndesmophytes).\n",
      "        Criteria a-c are required for diagnosis whereas criterion d is optional.\n",
      "        Active arthritis with 3 or more painful or swollen joints considered capable of responding\n",
      "        to drug therapy and at least 2 of the following:\n",
      "        Tenderness or pain on movement of at least 3 joints (or periarticular areas).\n",
      "        30 minutes of morning stiffness (in peripheral joints or in the spine).\n",
      "        Erythrocyte sedimentation rate (ESR) greater than or equal to 28mm/hour or C-reactive\n",
      "        protein (CRP) greater than 0.8 mg/dl.\n",
      "        Failure to respond or development of intolerable side effects to at least one of the\n",
      "        following treatments: sulfasalazine, gold retinoids, PUVA, methotrexate, azathioprine or\n",
      "        cyclosporin. A waiting period of equal to or greater than 4 weeks after the end of\n",
      "        previous systemic treatment will be required before initiation of fludarabine treatment.\n",
      "        Topical treatment for psoriasis (glucocorticoids, tar, anthralin, etc.) should be\n",
      "        discontinued 2 weeks prior to study entry.\n",
      "        not have seropositive, symmetric polyarthritis.\n",
      "        Must not have the spondylitic form of psoriatic arthritis (spondylitis alone or in\n",
      "        combination with shoulder and hip arthritis).\n",
      "        Must not have arthritis mutilans.\n",
      "        Must not be receiving glucocorticoids in doses greater than 10mg/day of prednisone.\n",
      "        Patients must not have acute or chronic infections requiring antimicrobial therapy or\n",
      "        serious viral (e.g., hepatitis, herpes zoster or HIV infections) or fungal infections.\n",
      "        Patients with a positive PPD who have not received INH or other antituberculous therapy\n",
      "        may be excluded if in the opinion of an infectious disease consultant immunosuppressive\n",
      "        therapy is contraindicated.\n",
      "        Females must not be pregnant or lactating. Females of childbearing age must be practicing\n",
      "        birth control.\n",
      "        No pre-existing malignancy other than basal cell carcinoma. All females must have a\n",
      "        negative Papanicolaou smear within a 3 month period prior to study entry.\n",
      "        No history of cerebrovascular accidents, seizure disorder or chronic neurologic disease.\n",
      "        No history of documented coronary artery disease, cardiomyopathy or dysrhythmia requiring\n",
      "        therapy.\n",
      "        No confounding medical illness that in the judgment of the investigators would pose added\n",
      "        risk for study participants (e.g., chronic hepatic, renal or pulmonary disease (PFTs less\n",
      "        than 70% of predicted value or DLCO less than 60%) or bone marrow hypoplasia (Hb less than\n",
      "        10 mg/dl, platelets less than 100.000/dl or WBC less than 3.400/dl).\n",
      "        No patients who have received alkylating agents for greater than or equal to 1 year.\n",
      "        No patients with creatinine clearance (CrCl) less than 50 ml/min.\n",
      "1303\n",
      "Patients of either sex requiring removal of two impacted mandibular third molars (partial\n",
      "        bony or soft tissue impaction).\n",
      "        16 years of age of older.\n",
      "        Indicates willingness to undergo oral surgery with local anesthesia and intravenous\n",
      "        midazolam only.\n",
      "        Willing to return for the removal of the remaining maxillary third molars at a second\n",
      "        appointment.\n",
      "        Patients with a history of allergy to flurbiprofen, aspirin, or any NSAID will be\n",
      "        excluded.\n",
      "        Those with a history of aspirin or NSAID-induced asthma will be excluded.\n",
      "        Females of childbearing potential who are not practicing adequate contraception will be\n",
      "        excluded.\n",
      "        Pregnant or nursing females will be excluded.\n",
      "        Patients with recent history or present signs of renal, hepatic, endocrine, pulmonary,\n",
      "        cardiac, gastrointestinal, neurologic, or cerebral function impairment will be excluded.\n",
      "        Those with psychiatric disorders will be excluded.\n",
      "        Patients who have taken an investigational drug within 30 days of this study will be\n",
      "        excluded.\n",
      "        Those who have taken another analgesic, steroid, opioid, or NSAID within 24 hours prior to\n",
      "        the study will be excluded.\n",
      "        Those with an absence of bilateral local anesthesia during surgery as evidenced by\n",
      "        anesthesia or paresthesia of the lower lip postoperatively will be excluded.\n",
      "        Patients who use drugs which will interact with NSAID such as aspirin, warfarin,\n",
      "        probenecid, methotrexate, lithium and diuretics will be excluded.\n",
      "1307\n",
      "Patients with essential tremor affecting the upper limbs who are 21 years of age or older.\n",
      "        Patients who are not taking medications for essential tremor or any other medical\n",
      "        condition for at least 2 weeks.\n",
      "        Patients who have not consumed alcohol or cold medications containing alcohol for at least\n",
      "        24 hours prior to the day of the study.\n",
      "        Women must not be pregnant or lactating. Women of childbearing age must use birth control\n",
      "        while participating in this study.\n",
      "        Patients must not have any neurological disease other than tremor (e.g., Parkinson's\n",
      "        disease).\n",
      "        Patients must not have evidence of thyroid, liver, kidney or chronic lung disease.\n",
      "1314\n",
      "Subjects must fulfill DSM-IV criteria for Bipolar I disorder (BPI), Bipolar II disorder\n",
      "        (BPII), Bipolar Disorder not otherwise specified (BPNOS), or schizoaffective disorder\n",
      "        bipolar type.\n",
      "        Subjects must be competent to comprehend the purpose of the study and to provide written\n",
      "        informed consent and be willing to participate in detailed longitudinal follow-up.\n",
      "        Subjects will undergo complete psychiatric diagnostic interview (SCID--DSM-IV), medical,\n",
      "        neurological, and laboratory examinations (as appropriate such as EKG, renal and liver\n",
      "        function tests, serum electrolytes, urinalysis, HIV, hepatitis B, pregnancy testing, and\n",
      "        urine drug screen for the presence of psychoactive drugs and drugs of abuse).\n",
      "        Subjects must be at least 18 years old.\n",
      "        Subjects should have no general medical illness that is primary (i.e. appears to be\n",
      "        causing the mood disorder), or contraindicates the use of conventional and study\n",
      "        medications under other protocols.\n",
      "        Women participants of child bearing potential must be nongravid, nonnursing, and using\n",
      "        acceptable method of birth control such as intrauterine device, diaphragm with\n",
      "        contraceptive foam, or condom with spermicide.\n",
      "        Subjects must not have alcohol or substance use or dependence of sufficient magnitude to\n",
      "        require independent, concurrent treatment intervention (excluding self-help groups), i.e.,\n",
      "        hospitalization, day treatment programs, or counselor visits.\n",
      "1315\n",
      "INCLUSION CRITERIA:\n",
      "        Diagnosis of AIDS as defined by the Centers for Disease Control.\n",
      "        Inactive, non-sight-threatening CMV retinitis. Non sight-threatening CMV retinitis is\n",
      "        defined as CMV retinitis not within 1000 microns from the optic disc or 1000 microns from\n",
      "        the fovea. Exception: patients with CMV retinitis within 1000 microns of the fovea or disc\n",
      "        in only one eye, if visual acuity in that eye is worse than 20/400 without the use of\n",
      "        eccentric fixation, and visual acuity in the other eye is 20/400 or better.\n",
      "        CD4 T cell count greater than 150 cells per microliter.\n",
      "        Patients must be able understand the nature of the study, agree to the provision, and\n",
      "        understand and sign the informed consent form.\n",
      "        Women and men age 18 or older are eligible for enrollment.\n",
      "        Platelets greater than 25,000/microliter.\n",
      "        Hemoglobin greater than 8.5 gms.\n",
      "        Total neutrophil count greater than 750/mm(3).\n",
      "        Karnofsky performance score greater than or equal to 60.\n",
      "        Receiving systemic anti-CMV therapy.\n",
      "        Receiving anti-HIV therapy. If the patient is receiving IL-2, at least one month from last\n",
      "        infusion must elapse prior to assessment for eligibility.\n",
      "        \n",
      "1319\n",
      "-  INCLUSION CRITERIA:\n",
      "             18 years or older.\n",
      "        Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR\n",
      "        positive).\n",
      "        Able to provide informed consent and willing to comply with study requirements and clinic\n",
      "        policies.\n",
      "        Negative urine or serum pregnancy test (for women of childbearing potential). In addition,\n",
      "        women of childbearing potential must agree to practice abstinence or use two methods of\n",
      "        birth control / contraception for 4 weeks prior to and 2 weeks after each BrDU infusion.\n",
      "        Similarly, all men must agree to practice abstinence or use a condom when engaging in\n",
      "        intercourse during the same time period.\n",
      "        Hemoglobin greater than 9 mg/dl; platelets greater than 50,000/mm(3); neutrophils greater\n",
      "        than 750 cells/mm(3).\n",
      "        AST/ALT less than 300 IU/ml.\n",
      "        Less than Grade 2 level toxicity for other laboratory parameters.\n",
      "        \n",
      "1336\n",
      "INCLUSION CRITERIA - ALZHEIMER'S DISEASE:\n",
      "        Study subjects will satisfy NINCDS-ADRDA criteria for probable Alzheimer's disease.\n",
      "        Dementia severity will be mild to moderate range with Mini-Mental Status Examination total\n",
      "        score between 12 and 26, inclusive.\n",
      "        The modified Hachinski Ischemia Score must be less than 4, and brain MRI performed within\n",
      "        15 months of enrollment must be compatible with the diagnosis of Alzheimer's disease.\n",
      "        Dementia must be present historically for at least one year. Baseline electroencephalogram\n",
      "        must not show significant epileptiform features.\n",
      "        INCLUSION CRITERIA - RELATED DEMENTING DISORDERS:\n",
      "        Study subjects will show deficits in at least two cognitive spheres, including memory.\n",
      "        Modified Hachinski Ischemia Score must be less than 4, and Folstein mini-mental status\n",
      "        examination total score must be between 12 and 26.\n",
      "        Cognitive difficulties must e present historically for at least one year.\n",
      "        Brain MRI performed with 15 months of enrollment must be normal or show atrophy.\n",
      "        Baseline electroencephalogram must not show epileptiform features.\n",
      "        In addition, all patients must have acceptable nutritional status.\n",
      "        Patients must be between ages 40 and 85.\n",
      "        Patients must be sterile, post-menopausal, or using an acceptable forms of birth control.\n",
      "        Chest x-ray within 15 months before enrollment must be acceptable for the trial.\n",
      "        Participants in this study will reflect the diversity of those suffering from dementia.\n",
      "        No one will be excluded or discriminated against based on the grounds of race, creed, or\n",
      "        gender.\n",
      "        Every attempt will be made to include women and minorities in the study population.\n",
      "        \n",
      "1354\n",
      "Patients greater than or equal to 18 years of age, with well-differentiated, non-medullary\n",
      "        thyroid cancer, including papillary (including follicular-variant), follicular, and\n",
      "        Hurthle cell.\n",
      "        Patients who recently have undergone a total or near-total thyroidectomy and are scheduled\n",
      "        to undergo initial 131I diagnostic studies and ablation.\n",
      "        Patients must have evidence of residual thyroid tissue after thyroid surgery confirmed by\n",
      "        ultrasound or other imaging technique (e.g., a technetium [Tc 99] pertechnetate or\n",
      "        thallium scan).\n",
      "        Patients who have undergone thyroidectomy or other thyroid surgery at least 6 weeks prior\n",
      "        to enrollment.\n",
      "        All patients who have been sustained on maintenance THST for at least 4 weeks, but not\n",
      "        longer than 12 weeks after thyroidectomy.\n",
      "        All patients who have confirmed serum TSH levels less than or equal to 0.5 mU per liter\n",
      "        within 7 days prior to the first Thyrogen dose, and prior to randomization.\n",
      "        Female patients of childbearing age must have a negative serum human chorionic\n",
      "        gonadotropin (HCG) pregnancy test prior to entering the study and within 5 days of any\n",
      "        131I administration and must be following an approved method of contraception.\n",
      "        Patients who are committed to following the protocol requirements as evidenced by\n",
      "        providing written informed consent.\n",
      "        Patients for whom a 131I scan is currently contraindicated because withdrawal from THST is\n",
      "        not an option due to pituitary dysfunction or other compelling medical reasons are\n",
      "        excluded.\n",
      "        Patients should not have a concurrent major medical disorder (e.g., documented cardiac\n",
      "        disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver\n",
      "        disease or advanced pulmonary disease) who may be too ill to adequately comply with the\n",
      "        requirements of this study.\n",
      "        Patients with non-thyroidal conditions known to effect 131I uptake (e.g., congestive heart\n",
      "        failure, renal failure) are excluded.\n",
      "        Patients should not have undergone any intravenous water soluble radiographic contrast\n",
      "        administration within the previous 4 weeks.\n",
      "        Patients should not have received intrathecal or cholecystographic iodinated contrast\n",
      "        agent administration within 3 months prior to enrollment.\n",
      "        Patients should not be taking drugs that affect thyroid or renal function (e.g., renal\n",
      "        drugs, lithium, or corticosteroids).\n",
      "        Patients should not be participating in another investigational drug study or in such a\n",
      "        study within 30 days of their enrollment in this study.\n",
      "        No patients with a recent history of alcoholism or drug abuse, severe emotional behavioral\n",
      "        or psychiatric problems who, in the opinion of the investigator, would not be able to\n",
      "        comply with the requirements of this study.\n",
      "1355\n",
      "Healthy volunteers between ages 18 and 35 years.\n",
      "        Not pregnant or planning to become pregnant in next six months.\n",
      "        HIV negative.\n",
      "        Hepatitis B Negative.\n",
      "        No chronic Respiratory Tract Infections.\n",
      "        No history of abnormal immune system.\n",
      "        No severe or multiple allergies.\n",
      "1358\n",
      "NORMAL VOLUNTEERS:\n",
      "        Age between 18 and 90 years.\n",
      "        No past or current medical condition that would interfere with brain function.\n",
      "        No history of alcoholism, psychiatric or neurological illness, head trauma with loss of\n",
      "        consciousness, history of exposure to central nervous system toxin; history of central\n",
      "        nervous system infection, metabolic, endocrine, connective tissue disease; hypertension or\n",
      "        other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or\n",
      "        coagulation disease; malignancy; psychopharmacological treatment; neurodegenerative or\n",
      "        neurodevelopmental disorder; stroke; epilepsy; subjects requiring regular medication, and\n",
      "        subjects demonstrated by drug screening to have taken a controlled substance.\n",
      "        No occupational exposure to metal slivers or shavings.\n",
      "        No females who are pregnant or breast feeding.\n",
      "        PATIENTS WITH ALZHEIMER DISEASE:\n",
      "        Age between 18 and 90 years.\n",
      "        Diagnosis of possible or probably Alzheimer Disease according to NINCDS-ADRDA criteria.\n",
      "        Aside from Alzheimer Disease, no past or current medical condition that would interfere\n",
      "        with brain function.\n",
      "        No history of alcoholism, psychiatric or neurological illness, head trauma with loss of\n",
      "        consciousness, history of exposure to central nervous system toxin; history of central\n",
      "        nervous system infection, metabolic, endocrine, connective tissue diseases; hypertension\n",
      "        or other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or\n",
      "        coagulation disease; malignancy; psychopharmacological treatment.\n",
      "        No females who are pregnant or breast feeding.\n",
      "1359\n",
      "INCLUSION CRITERIA\n",
      "        Normal adult volunteers in good health with no history of liver disease or alcohol abuse -\n",
      "        minimum age: 18 years.\n",
      "        Physically able to tolerate lying within the bore of the magnet for 1-2 hours (usual study\n",
      "        is expected to last approximately 1-1.5 hours).\n",
      "        Subjects should not be claustrophobic.\n",
      "        Normotensive: Upper limit of Systolic Blood Pressure 140 mm Hg; Upper limit of Diastolic\n",
      "        Blood Pressure 90 mm Hg.\n",
      "        No known history of vascular disease, including but not limited to the presence of\n",
      "        cardiovascular risk factors such as smoking, or if receiving vasoactive medications such\n",
      "        as for treatment of hypertension.\n",
      "        Weight range: 120 lbs. to 250 lbs.\n",
      "        Not pregnant. If a female subject is in her child bearing years and at risk for pregnancy,\n",
      "        subject must be using a reliable birth control method and must be within two weeks of the\n",
      "        onset of the last menstrual period/\n",
      "        No relative or specific contraindications for MRI exam: including, but not limited to,\n",
      "        metal objects in the body such as pacemakers, aneurysm clips, cochlear implants, metallic\n",
      "        implants (orthopedic appliance, artificial cardiac valve) or shrapnel. Subjects whose\n",
      "        occupation places them at risk of having unsuspected metal fragments in the eye, such as\n",
      "        welders and metal workers, will be excluded,\n",
      "        No known hearing impairment.\n",
      "1370\n",
      "Diagnosis of CS with documented symptoms and signs (as required below) despite\n",
      "        conventional management which may include artificial tears, gels and ointments,\n",
      "        sympathomimetic agents and parasympathomimetic agents:\n",
      "        Schirmer (without anesthesia) less than or equal to 8 mm/5 min in at least one eye;\n",
      "        HOWEVER, if Schirmer (without anesthesia) is zero (0) mm, Schirmer with nasal stimulation\n",
      "        greater than or equal to 3 mm/ 5 min in the same eye, OR;\n",
      "        Schirmer (with anesthesia) less than or equal to 10 mm/ 5 min in at least one eye and sum\n",
      "        of interpalpebral staining greater than or equal to 3+ or corneal staining greater than or\n",
      "        equal to 1+ in the same eye.\n",
      "        Able and willing to provide informed consent.\n",
      "        Willingness and ability to meet followup requirements.\n",
      "        Female patients of childbearing potential must use reliable forms of contraception during\n",
      "        the study.\n",
      "        A negative pregnancy test result in women of childbearing potential.\n",
      "        Normal lid position and closure.\n",
      "        The following topical (creams, ointments or patches) or systemic medications are allowed\n",
      "        as long as the patient has been on a stable dose for at least 90 days before the baseline\n",
      "        visit: Estrogen-progesterone, or other estrogen derivatives.\n",
      "        If using concomitant medications, and the patient's condition is stable, the patient must\n",
      "        agree to remain on a stable dose of his or her concomitant medications throughout the\n",
      "        study period, or if the patient's condition is not stable, then they must agree not to use\n",
      "        concomitant medications.\n",
      "        Review of the instructions for use of concomitant medications during the study, prior to\n",
      "        the eye examination, and agreement from the patient that they will comply with the\n",
      "        instructions. A copy of the instructions must be given to the patient prior to enrollment.\n",
      "        Patient must not have uncontrolled systemic disease (e.g., hypertension, diabetes) or the\n",
      "        presence of any significant illness (e.g., serious gastrointestinal, renal, hepatic,\n",
      "        endocrine, pulmonary, cardiac, neurologic disease, cancer, AIDS, or cerebral dysfunction)\n",
      "        that could, in the judgment of the investigator, interfere with interpretation of the\n",
      "        study results.\n",
      "        Patients must not have used ophthalmic topical or systemic cyclosporine in the past 90\n",
      "        days.\n",
      "        Patients must not have Schirmer readings less than 3 mm/5 min, without anesthesia, in both\n",
      "        eyes after stimulation thereby indicating end stage lacrimal gland disease.\n",
      "        Patient must not have active ocular infection or non-KCS ocular inflammation.\n",
      "        Patient must not have a history of recurrent herpes keratitis or active disease within the\n",
      "        last six months.\n",
      "        Patient must not have corneal disorder or abnormality that effects corneal sensitivity or\n",
      "        normal spreading of the tear film (except SPK).\n",
      "        Patient must not have severe blepharitis or obvious inflammation of the lid margin which\n",
      "        in the judgment of the investigator may interfere with the interpretation of the study\n",
      "        results.\n",
      "        No plug placement (laser, cautery, silicone, or collagen implant) within one month prior\n",
      "        to the screening visit.\n",
      "        No punctal occlusion performed during the study.\n",
      "        Patient must not have a history of anterior segment surgery or trauma which could affect\n",
      "        corneal sensitivity (e.g., cataract surgery or any surgery involving a limbal or corneal\n",
      "        incision within the last 12 months).\n",
      "        Patient must not have KCS secondary to the destruction of conjunctival goblet cells as\n",
      "        occurs with vitamin A deficiency or scarring such as that with cicatricial pemphigoid,\n",
      "        alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation.\n",
      "        Patients must not use Saligan or antihistamines more than 3 times a week.\n",
      "1372\n",
      "-  INCLUSION CRITERIA:\n",
      "        All eligible patients are invited to participate in this protocol. Patients are adults\n",
      "        with possible ectopic Cushing syndrome. Since both men and women are affected with ectopic\n",
      "        Cushing syndrome, both sexes are studied. All ethnic and racial groups are at risk and\n",
      "        will be included. Patients must be willing to return to NIH for follow-up studies.\n",
      "        \n",
      "1375\n",
      "-  INCLUSION CRITERIA-PATIENT:\n",
      "          -  Ages 10 to 55 years.\n",
      "          -  Chronic myelogenous leukemia, any of these categories: chronic phase, accelerated\n",
      "             phase of blast transformation.\n",
      "          -  Acute lymphoblastic leukemia, any of these categories: Adults (greater than 18 years)\n",
      "             in first remission with high risk features (presenting leukocyte count greater than\n",
      "             100,000 per cu mm, Karyotypes t9;22, t4, t19, t11, biphenotypic leukemia). All second\n",
      "             remissions, primary induction failure, partially responding or untreated relapse.\n",
      "          -  Acute myelogenous leukemia (AML): AML in first remission Except AML with good risk\n",
      "             karyotypes: AML M3 (t15;17), AML M4Eo (inv 16), AML t(8;21). All AML in second or\n",
      "             subsequent remission, primary induction failure and resistant relapse.\n",
      "          -  Myelodysplastic syndromes, any of these categories: refractory anemia with excess of\n",
      "             blasts, transformation to acute leukemia, chronic myelomonocytic leukemia.\n",
      "          -  Multiple myeloma following initial disease control with chemotherapy.\n",
      "          -  Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia, in remission or\n",
      "             partial remission following fludarabine treatment. Richter transformation of CLL.\n",
      "          -  No major organ dysfunction precluding transplantation.\n",
      "          -  DLCO greater than 65 percent predicted.\n",
      "          -  Left ventricular ejection fraction: greater than 40 percent predicted.\n",
      "          -  ECOG performance status of 0 or 1.\n",
      "          -  Informed consent given. Informed consent from both parents for minors.\n",
      "          -  Women of childbearing age with a negative pregnancy test may participate.\n",
      "        \n",
      "1376\n",
      "Normal control between the ages of 18 - 70 years of age who are capable of giving informed\n",
      "        consent.\n",
      "        Subjects must not have a condition which would preclude their use for technical\n",
      "        development (e.g. paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.).\n",
      "        Subjects must not have a condition which would present unnecessary risks (e.g. pregnancy,\n",
      "        surgery of uncertain type, symptoms of pheochromocystoma or insulinoma, etc.).\n",
      "        Lactating women and subjects with hemoglobinopathies, asthma, or renal or hepatic disease\n",
      "        will be excluded from studies involving the administration of contrast agents.\n",
      "        Must not have a contraindication to MR scanning such as surgery that involves metal clips\n",
      "        or wires which might be expected to concentrate radiofrequency fields or cause tissue\n",
      "        damage from twisting in a magnetic field. Examples include: aneurysm clip; implanted\n",
      "        neural stimulator; implanted cardiac pacemaker or autodefibrillator; cochlear implant;\n",
      "        ocular foreign body (e.g. metal shavings); insulin pump.\n",
      "1379\n",
      "Must be a candidate for a renal transplant from a living related, living non-related, or\n",
      "        cadaveric donor.\n",
      "        Must be willing and able to give written informed consent.\n",
      "        Aged between 18 and 65 years, inclusive. Subjects over the age of 65 may be considered on\n",
      "        an individual basis based on medical suitability.\n",
      "        Female subjects must be post-menopausal or surgically sterile, or using an acceptable\n",
      "        method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices\n",
      "        are acceptable; condoms used alone are not acceptable).\n",
      "        WBC count must be greater than or equal to 3000/mm(2).\n",
      "        No history of malignancy (except non-metastatic cutaneous squamous or basal cell\n",
      "        carcinomas that have been completely excised without evidence of recurrence for at least 1\n",
      "        year).\n",
      "        No active systemic bacterial, fungal or viral infections (including active zoster or\n",
      "        herpetic lesions).\n",
      "        No serological evidence of HIV, HCV, or HbsAg.\n",
      "        No active peptic ulcer disease.\n",
      "        No condition or circumstance that could potentially interfere with the evaluation of\n",
      "        BG9588.\n",
      "        No contraindication to monoclonal antibody therapies.\n",
      "        No history of Major Thromboembolic event (e.g. stroke, pulmonary embolus).\n",
      "        For the first 5 patients, no patient with a PRA greater than 20%.\n",
      "        No previous participation in the study.\n",
      "        No use of any investigational agent or device within 4 weeks prior to first dose of study\n",
      "        drug.\n",
      "        No Cold Ischemia Time of donor kidney greater than 36 hours.\n",
      "        No uncontrolled non-heart-beating donor status.\n",
      "        No positive T-cell Crossmatch.\n",
      "1387\n",
      "Patient must be over 18 years of age requiring diagnostic cardiac catheterization will\n",
      "        participate.\n",
      "        Women on chronic estrogen therapy are eligible for the study.\n",
      "        Patients investigated for chest pain syndrome with normal coronary arteries with and\n",
      "        without risk factors for atherosclerosis, patients with coronary artery disease, and\n",
      "        patients with heart failure.\n",
      "        No patients with unstable angina; significant left main disease (greater than 50%\n",
      "        stenosis); Recent myocardial infarction (less than 1 month); Pregnancy, lactation; Allergy\n",
      "        to losartan; Renal failure (creatinine greater than 2.5 mg/dl); Inability to withdraw ACE\n",
      "        inhibitors.\n",
      "1390\n",
      "Must meet American College of Rheumatology Criteria for JRA.\n",
      "        Must have active anterior uveitis defined as the presence of inflammatory cells in the\n",
      "        anterior chamber in at least one eye, or the current use of topical corticosteroids.\n",
      "        Must be between 2 and 18 years of age, inclusive.\n",
      "        Must have had previous therapy for uveitis.\n",
      "        Must be able to undergo a slit lamp biomicroscopy for assessment of anterior chamber\n",
      "        cells.\n",
      "        Must not have a media opacity that precludes assessment of anterior chamber inflammation.\n",
      "        Must not have received a periocular injection of corticosteroids within 2 months of\n",
      "        baseline.\n",
      "        Must not be currently receiving DMARD (disease modifying anti-rheumatic) therapy, with the\n",
      "        exception of prednisone at a dose no greater than 1.5-2.0 mg/kg/day, or methotrexate at a\n",
      "        dose no greater than 10 mg/m(2)/week.\n",
      "        Must not have active eye or joint inflammation requiring immediate addition or increase in\n",
      "        systemic anti-inflammatory medications.\n",
      "        Must not have involvement in prior clinical trials of type II collagen.\n",
      "        Must not have exposure within the past year to shark or other collagen preparations found\n",
      "        in health food stores.\n",
      "        Must not have a history of gastrointestinal disease which could affect the presentation of\n",
      "        type II collagen.\n",
      "        Women must not be pregnant or lactating.\n",
      "        Patients currently using Latanoprost, patients who have used Latanoprost within the last 2\n",
      "        weeks, or patients who are likely to need Latanoprost during the course of the study will\n",
      "        be excluded.\n",
      "1392\n",
      "-  Inclusion Criteria:\n",
      "          -  Subjects aged 1-85 with reproductive endocrine related conditions.\n",
      "          -  Young women, women of reproductive age, and older women are the focus of this\n",
      "             protocol.\n",
      "          -  Girls with reproductive disorders under the age of 18 will be studied and their\n",
      "             assent will be obtained if possible along with the consent of their parent/guardian.\n",
      "          -  Reproductive disorders of men will be included.\n",
      "        \n",
      "1396\n",
      "INCLUSION CRITERIA:\n",
      "        Male or female patients, 18 years of age or older.\n",
      "        Newly diagnosed patients with acromegaly, or previously untreated.\n",
      "        Presence of a pituitary tumor greater than 10 mm at greatest diameter (macroadenoma).\n",
      "        Lack of suppression of GH to less than 2.0 ng/mL using a regular GH RIA, or less than one\n",
      "        ng/mL using a two-site immunoradiometric or chemiluminescent GH assay, after oral\n",
      "        administration of 100 g of glucose.\n",
      "        IGF-1 levels above the upper limits of normal (adjusted for age and gender).\n",
      "        Demonstrated tolerance to a test dose of s.c. Sandostatin Injection.\n",
      "        Demonstrated responsiveness to a 100 ug s.c. Sandostatin Injection test dose, as evidenced\n",
      "        by suppression of mean 4HR GH to less than 5 ng/mL, or to greater than 50 % of the\n",
      "        baseline value.\n",
      "        Patients who are able to provide written informed consent.\n",
      "        \n",
      "1400\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically confirmed unresectable sarcoma or intransit melanoma of the upper or lower\n",
      "        extremity.\n",
      "        Extremity sarcoma with no local resection option and would require amputation based upon\n",
      "        abutment or proximity of the tumor to major neurovascular structures or bone or joint\n",
      "        structures.\n",
      "        MELANOMA PATIENTS:\n",
      "        Must have history of two or more satellite intransit metastases of which one may be\n",
      "        excised for diagnosis with the exception of patients with a single, large, deep, locally\n",
      "        recurrent tumor or metastatic tumor (greater than 5 cm) that precludes an excision with\n",
      "        primary closure. Stage IV melanoma must have a significant component (greater than 90%) of\n",
      "        disease distal to the apex of the femoral triangle in the lower limb or distal to the\n",
      "        insertion of the deltoid in the upper limb.\n",
      "        Must have evaluable disease in the extremity. Melanoma must have dermal or subcutaneous\n",
      "        lesion that can be measure directly in two diameters to assess tumor burden. Sarcoma must\n",
      "        have either cutaneous lesions amenable to direct measurement or deeper lesions that can be\n",
      "        measured on CT or MRI scans.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        At least 2 months since any regional therapy to the affected extremity.\n",
      "        BIOLOGIC THERAPY: At least 1 month since Biologic Therapy.\n",
      "        CHEMOTHERAPY: At least 1 month since chemotherapy.\n",
      "        ENDOCRINE THERAPY: Not specified.\n",
      "        RADIOTHERAPY: At least 1 month since radiotherapy.\n",
      "        SURGERY: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        AGE: 18 and over.\n",
      "        PERFORMANCE STATUS: ECOG 0-2.\n",
      "        LIFE EXPECTANCY: At least 6 months.\n",
      "        HEMATOPOIETIC: Platelet count greater than 150,000/mm(3).\n",
      "        HEPATIC: Bilirubin less than 2.0 mg/dL.\n",
      "        RENAL: Creatinine less than 2.0 mg/dL.\n",
      "        CARDIOVASCULAR: No history of congestive heart failure with an LVEF less than 40%.\n",
      "        PULMONARY:\n",
      "        No chronic obstructive pulmonary disease.\n",
      "        No other chronic pulmonary disease with PFTs less than 50% predicted for age.\n",
      "        OTHER:\n",
      "        IF HIV POSITIVE: Must have CD4 cell count greater than 500/mL and, No clinical\n",
      "        manifestations of AIDS. Coagulation parameters no greater than 1-2 seconds within the\n",
      "        upper limit of normal.\n",
      "        No evidence of severe peripheral vascular disease.\n",
      "        No history of claudication or other ischemic vascular disease.\n",
      "        Not pregnant or nursing.\n",
      "1404\n",
      "INCLUSION CRITERIA\n",
      "        Patients of any age, both genders, and all racial/ethnic groups with oral diseases or\n",
      "        systemic diseases with oral manifestations that will help the branch fulfill the\n",
      "        objectives listed in Section 1.0.\n",
      "        Women of childbearing potential, or who are pregnant or lactating, will only undergo tests\n",
      "        and procedures, and/or receive medications for which data exists proving minimal risk to\n",
      "        the fetus and/or child. Only diagnosis without radiographs will be performed.\n",
      "        \n",
      "1408\n",
      "Males and females of greater than 12 years of age with any of the following conditions:\n",
      "        Allogeneic or autologous bone marrow/ peripheral stem cell transplant.\n",
      "        Hematological malignancy (including lymphoma).\n",
      "        Aplastic anemia and myelodysplastic syndromes (currently on immunosuppressive treatment).\n",
      "        Solid organ transplantation.\n",
      "        Solid organ malignancy (after cytotoxic chemotherapy).\n",
      "        HIV infection/AIDS.\n",
      "        High dose prolonged corticosteroid therapy (greater than or equal to 20 mg daily of\n",
      "        prednisone or equivalent for greater than 3 weeks) or prolonged therapy with other\n",
      "        immunosuppressive agents (e.g., azathioprine, methotrexate).\n",
      "        WITH a diagnosis of definite or probable acute invasive aspergillosis.\n",
      "        The fungal infection at baseline should represent a new episode of acute invasive\n",
      "        aspergillosis. Any course of systemic treatment with amphotericin B (conventional or lipid\n",
      "        formulation) or itraconazole should have been completed at least 8 weeks prior to study\n",
      "        entry.\n",
      "        Signed informed consent must be obtained prior to study participation (patient, relative\n",
      "        or legal representative). For patients aged 12-17 years, the written informed consent of\n",
      "        the parents or legal guardian must also be obtained.\n",
      "        Women of child bearing potential must have a negative pregnancy test at entry and must\n",
      "        agree to use barrier methods of contraception throughout the study.\n",
      "        No patients with sarcoidosis, aspergilloma or allergic bronchopulmonary aspergillosis.\n",
      "        No patients with chronic invasive aspergillosis with a duration of symptoms or\n",
      "        radiological findings for more than 4 weeks prior to study entry.\n",
      "        No patients that have received systemic antifungal therapy at doses greater than 0.5\n",
      "        mg/kg/day for conventional or lipid formulations of amphotericin B or greater than 200\n",
      "        mg/day of itraconazole, for more than 96 hours during the two week period prior to study\n",
      "        entry.\n",
      "        No patients with a diagnosis of CMV pneumonia.\n",
      "        No pregnant or lactating females.\n",
      "        No patients with a history of hypersensitivity or intolerance to azole antifungal agents\n",
      "        including miconazole, ketoconazole, fluconazole, or itraconazole.\n",
      "        No patients with a history of hypersensitivity or severe intolerance (despite supportive\n",
      "        therapy) to conventional or a lipid formulation of amphotericin B.\n",
      "        No subjects who are receiving and cannot discontinue the following drugs at least 24 hours\n",
      "        prior to randomization: Terfenadine, cisapride and astemizole (due to the possibility of\n",
      "        QTc prolongation); Sulphonylureas (as these compounds have a narrow therapeutic window and\n",
      "        an increase in plasma levels may lead to hypoglycemia).\n",
      "        No subjects who have received the following drugs within 14 days prior to randomization:\n",
      "        Rifampin, carbamazepine and barbiturates as these are potent inducers of hepatic enzymes\n",
      "        and will result in undetectable levels of voriconazole.\n",
      "        No patients who are receiving or are likely to received any investigational drug (any\n",
      "        unlicensed new chemical entity), except one of the following classes of medications:\n",
      "        cancer chemotherapeutic agents, antiretrovirals, therapies for HIV/AIDS-related\n",
      "        opportunistic infections.\n",
      "        No patients who are receiving the following medications or treatments during the study\n",
      "        period: G-CSF or GM-CSF (for other than of granulocytopenia) any systemic antifungal\n",
      "        medication active against Aspergillus white blood cell transfusions.\n",
      "        No patients with the following abnormalities of liver function tests: AST, ALT greater\n",
      "        than 5x ULN (upper limit normal); alkaline phosphatase, total bilirubin greater than 5x\n",
      "        ULN.\n",
      "        No patients with renal insufficiency that would contraindicate treatment with initial\n",
      "        randomized therapy (serum creatinine greater than 2.5 mg/dl).\n",
      "        No patients with a life expectancy of less than 72 hours.\n",
      "        No patients on artificial ventilation, unlikely to be extubated within 24 hours of study\n",
      "        entry.\n",
      "        No patients for whom written informed consent cannot be obtained.\n",
      "        No patients that have already participated in this trial.\n",
      "        No patients with any condition which, in the opinion of the investigator, could affect\n",
      "        patient safety, preclude evaluation of response, or render it unlikely that the\n",
      "        contemplated course of therapy can be completed.\n",
      "1411\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients will be otherwise healthy women, men, and children, with polyostotic fibrous\n",
      "        dysplasia (PFD)/McCune-Albright Syndrome (MAS).\n",
      "        Children will be greater than 4 years of age.\n",
      "        The diagnosis will be based on evidence of the clinical spectrum of the disease and\n",
      "        confirmed by the presence of typical findings on bone biopsy.\n",
      "        All patients must be actively enrolled in the Screening and Natural History Protocol and\n",
      "        possibly the Bisphosphonate Protocol.\n",
      "        Patients will be enrolled in the study if they have a lytic lesion of the humerus, femur,\n",
      "        or tibia which satisfies at least one of the following criteria: the lesion encompasses at\n",
      "        least 50% of the width of the bone at that point on both AP and lateral radiographs; the\n",
      "        lesion has caused a change in the anatomical shape and contour of the bone; the lesion has\n",
      "        a bone density less than 50% of the density of the contralateral, normal side.\n",
      "        Patients on previous or concomitant therapy are eligible for enrollment.\n",
      "        Patients on the Bisphosphonate Protocol must have received at least one month of treatment\n",
      "        on that protocol before receiving a bone marrow injection in this protocol.\n",
      "        Women in childbearing age will be offered barrier methods of contraception to decrease the\n",
      "        risk of pregnancy for a period of one year following the transplant. Subjects who become\n",
      "        pregnant during year one of the study will be transferred to the inactive participant\n",
      "        group. Pregnancy testing will be performed prior to research procedures and surgery.\n",
      "        Subjects using oral contraceptive agents are included. Women without normal menstrual\n",
      "        cycles will be offered hormone replacement therapy for a period of 3 cycles prior to\n",
      "        treatment.\n",
      "        Subjects must agree to travel to NIH during the first 24 months and remain in the Bethesda\n",
      "        area for the post-operative period as defined by protocol requirements.\n",
      "        \n",
      "1412\n",
      "-  INCLUSION CRITERIA:\n",
      "        Male and female subjects.\n",
      "        All subjects will have first participated in screening protocol 84-D-0056 to confirm their\n",
      "        diagnosis and assess salivary function.\n",
      "        Subjects must have dry mouth symptoms (xerostomia) and a diagnosis of primary or secondary\n",
      "        SS, incomplete SS, or radiation-induced salivary gland dysfunction (as determined in\n",
      "        protocol 84-D-0056).\n",
      "        Diagnostic criteria for SS are the American-European Consensus Group Classification\n",
      "        Criteria: For primary Sjogren s syndrome, any 4 of the 6 criteria, must include item IV\n",
      "        (Histopathology) or VI (Auto-antibodies) or any 3 of the 4 objective criteria (III, IV, V,\n",
      "        VI). For secondary Sjogren s syndrome, must have established connective tissue disease,\n",
      "        one symptom (I or II) plus 2 of the 3 objective criteria (III, IV, VI).\n",
      "        Ocular symptoms (at least one)\n",
      "        Daily persistent dry eyes for greater than 3 months?\n",
      "        Recurrent sensation of sand or gravel in the eyes?\n",
      "        Use of tear substitutes greater than 3 x/day?\n",
      "        Oral symptoms (at least one)\n",
      "        Daily feeling of dry Mouth greater than 3 months\n",
      "        Recurrent or persistently swollen salivary glands as an adult?\n",
      "        Frequently drink liquids to aid in swallowing dry foods?\n",
      "        Ocular signs (at least one)\n",
      "        Schirmer s test, (without anesthesia) greater than or equal to 5mm/5 minutes\n",
      "        Positive vital dye staining (van Bijsterveld greater than or equal to 4)\n",
      "        Histopathology: Lip biopsy showing focal lymphocytic sialadenitis (focus score greater or\n",
      "        equal to 1 per 4mm squared)\n",
      "        Oral signs (at least one)\n",
      "        Unstimulated whole salivary flow (greater or equal to 1.5 ml in 15 minutes)\n",
      "        Abnormal parotid sialography\n",
      "        Abnormal salivary scintigraphy\n",
      "        Auto-antibodies (at least one)\n",
      "        Anti-SSA (Ro) or Anti-SSB (La)\n",
      "        \n",
      "1413\n",
      "-  INCLUSION CRITERIA:\n",
      "        Ethnicity: African Americans\n",
      "        To enroll participants must self-identify as African Americans and be born in the United\n",
      "        States, with American born parents or be born in Africa with African born parents. In the\n",
      "        future, we plan to expand the study to include other groups which self-identify as African\n",
      "        Americans (i.e. AfroCarribeans and Hispanic blacks).\n",
      "        Age: The age range of the participants will be between 18 and 50 years.\n",
      "        Medical History: To participate in the study subjects should identify themselves as\n",
      "        healthy.\n",
      "        Menstrual History: Women must give a history of regular monthly cycles (24-35 days) for at\n",
      "        least one year.\n",
      "        \n",
      "1418\n",
      "INCLUSION:\n",
      "        Healthy research volunteers who are between 21 and 65 years.\n",
      "        EXCLUSION:\n",
      "        Patients with a history of ischemic or valvular heart disease.\n",
      "        Patients with history of chronic pulmonary disease.\n",
      "        Pregnant women.\n",
      "1422\n",
      "Histologically or cytologically proven measurable metastatic colorectal cancer limited to\n",
      "        the parenchyma of the liver with no evidence of unresectable extrahepatic disease by\n",
      "        preoperative radiological studies. Limited resectable extrahepatic disease is acceptable.\n",
      "        Patients must not have been previously treated with intrahepatic artery infusional therapy\n",
      "        using FUDR.\n",
      "        Patients mush have had no chemotherapy, radiotherapy or biologic therapy for their\n",
      "        malignancy in the month prior to the liver perfusion and must have recovered from all side\n",
      "        effects.\n",
      "        Patients must have an ECOG performance standard of 0, 1 or 2 on the day prior to\n",
      "        treatment.\n",
      "        Patients must have adequate hepatic function as evidence by bilirubin less than 2.0 and a\n",
      "        PT and PTT that are within 1-2 seconds of the upper normal limit.\n",
      "        Patients must not have biopsy proven cirrhosis or evidence of significant portal\n",
      "        hypertension by history, endoscopy, or radiologic studies.\n",
      "        Patients must not have a history of congestive heart failure with an LVEF less than 40%.\n",
      "        Patients must not have COPD or other chronic pulmonary disease with PFT's less than 50%\n",
      "        predicted for age.\n",
      "        Patients must be 18 years of age or older.\n",
      "        Patients must have a platelet count greater than 100,000 a Hct greater than 27.0, a white\n",
      "        blood count greater than 3000/micro liters, and a creatinine less than or equal to 1.5 or\n",
      "        a creatinine clearance of greater than 60 ml/min.\n",
      "        Patients must not be pregnant or nursing.\n",
      "        Patients must not be taking immunosuppressive drugs or on chronic anticoagulation.\n",
      "        Patients must not have an active infection.\n",
      "        Patients must not have severe allergic reactions to iodine contrast which can not be\n",
      "        controlled by premedication with antihistamines and steroids.\n",
      "        Patients must not have HIV disease.\n",
      "        Patients must be aware of the neoplastic nature of his/her illness, the experimental\n",
      "        nature of the therapy, alternative treatments, potential benefits, and risks. The patient\n",
      "        must be willing to sign an informed consent.\n",
      "1424\n",
      "-  INCLUSION CRITERIA:\n",
      "        Greater than or equal to 18 years old.\n",
      "        Ability to sign informed consent and willingness to comply with study requirements and\n",
      "        clinic policies.\n",
      "        For women of child-bearing potential, negative result on pregnancy test within one week\n",
      "        prior to initiating therapy.\n",
      "        No medical contraindication to lymph node biopsy.\n",
      "        HIV infection confirmed by ELISA and Western blot.\n",
      "        Two CD4+ T cell counts less than 300/microliters within 3 months of beginning the\n",
      "        protocol, with one of the two counts obtained at a screening history and physical\n",
      "        examination performed 2 weeks prior to initiating therapy.\n",
      "        Plasma HIV-1 RNA levels greater than 8000/ml.\n",
      "        For participants with CD4 T cell counts greater than or equal to 300/microliter,\n",
      "        asymptomatic for significant HIV-related illnesses. For participants with CD4 T cell\n",
      "        counts less than or equal to 300/microliter no active opportunistic infections.\n",
      "        For participants with greater than or equal to 300 CD4 cells/ microliter, no prior receipt\n",
      "        of antiretroviral therapy. For participants with less than or equal to 300 CD4\n",
      "        cells/microliter, no prior use of lamivudine, nevirapine or protease inhibitors.\n",
      "        Three or more palpable lymph nodes.\n",
      "        Willingness to allow storage of samples for future research.\n",
      "        Willingness to allow HLA testing.\n",
      "        \n",
      "1425\n",
      "INCLUSION CRITERIA:\n",
      "          -  Women between the ages of 18 and 45 years, who have their reproductive organs.\n",
      "          -  Excellent health other than a three month history of pelvic pain and documented\n",
      "             endometriosis at laparoscopy. Chronic medications may be acceptable at the discretion\n",
      "             of the internist associate investigator (LN). Use of antidepressants, medications for\n",
      "             migraines and headaches, allergy medications, and treatment of bowel symptoms such as\n",
      "             irritable bowel disease will be allowed.\n",
      "          -  Do not desire pregnancy for the duration of the study.\n",
      "          -  Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of\n",
      "             contraception and are willing to continue using them throughout the study.\n",
      "          -  Willing and able to give informed consent.\n",
      "          -  Willing and able to comply with study requirements.\n",
      "          -  Less than grade III overweight or BMI less than 40 kg/m(2).\n",
      "        \n",
      "1426\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Histologically proven primary CNS malignancy, neuroblastoma or sarcoma that is refractory\n",
      "        to standard therapy or for which no standard therapy exists and disease can not be cured\n",
      "        by surgery.\n",
      "        PRIOR/CONCURRENT THERAPY:\n",
      "        Recovered from toxic affects of all prior therapy.\n",
      "        No investigational agent within past 2 weeks.\n",
      "        BIOLOGY THERAPY: Not specified.\n",
      "        CHEMOTHERAPY:\n",
      "        No myelosuppressive therapy within past 3 weeks.\n",
      "        No nitrosourea within past 6 weeks.\n",
      "        ENDOCRINE THERAPY: If receiving dexamethasone dose must be stable for at least 2 weeks.\n",
      "        RADIOTHERAPY: Not specified.\n",
      "        SURGERY: Not specified.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age: 3 to 21.\n",
      "        Performance status: ECOG 0-2.\n",
      "        Life expectancy: At least 8 weeks.\n",
      "        HEMATOPOIETIC:\n",
      "        AGC greater than 1500/mm(3).\n",
      "        Hemoglobin greater than or equal to 8.0 g/dL percent.\n",
      "        Platelet count greater than 100,000/mm(3).\n",
      "        For patients with bone marrow involvement or history of bone marrow transplantation or\n",
      "        craniospinal radiotherapy: AGC greater than 750/mm(3), Hemoglobin greater than 6.0 g/dL,\n",
      "        Platelet count greater than 50,000/mm(3).\n",
      "        HEPATIC:\n",
      "        SGOT, SGPT or alkaline phosphatase less than 3 times upper limit of normal.\n",
      "        Bilirubin no less than or equal to 1.5 times upper limit of normal.\n",
      "        RENAL:\n",
      "        Ages 3-5 Creatinine no greater than 0.8 mg/dL.\n",
      "        Ages 5-10 Creatinine no greater than 1.0 mg/dL.\n",
      "        Ages 10-15 Creatinine no greater than 1.2 mg/dL.\n",
      "        Ages 16-21 Creatinine no greater than 1.5 mg/dL.\n",
      "        OTHER:\n",
      "        All patients or their legal guardians (if the patient is under 18 years old) must sign a\n",
      "        document of informed consent indicating their understanding of the investigational nature\n",
      "        and the risks of this study.\n",
      "        For patients with brain tumors who are over 18 years of age, a DPA should be signed.\n",
      "        Not pregnant or nursing.\n",
      "        Not allergic to etoposide.\n",
      "        No acute or chronic medical or psychiatric condition or laboratory abnormality that may\n",
      "        increase the risks associated with study participation/study drug administration or may\n",
      "        interfere with the interpretation of study results.\n",
      "1429\n",
      "Male or female greater than or equal to 18 years of age.\n",
      "        Body weight less than or equal to 120 kg.\n",
      "        If female, be surgically sterile for at least one year, be post-menopausal for at least\n",
      "        one year, or test negative on a pregnancy test by urine or blood within 48 hours prior to\n",
      "        MS-325 administration.\n",
      "        Ability to comprehend and a willingness to sign an Informed Consent Form.\n",
      "        Stable medical condition at time of MS-325 administration with no major clinical\n",
      "        cardiovascular events within 30 days of MS-325 administration.\n",
      "        Fasted from liquids and solids for two hours prior to MS-325 administration.\n",
      "        Must have a positive diagnostic quality coronary x-ray angiogram which demonstrated\n",
      "        coronary artery stenosis(es) of at least 50 percent diameter stenosis in at least one\n",
      "        proximal coronary artery vessel between five and 30 days prior to MS-325 administration;\n",
      "        angiographic data must be available for loan to an angiographic core lab in order for the\n",
      "        patient to be included in the trial.\n",
      "        Normal sinus rhythm.\n",
      "        Willing to abstain from alcohol from 24 hours prior to MS-325 administration through 72-96\n",
      "        hours following MS-325 administration.\n",
      "        No prior coronary bypass graft or coronary stent of the target vessel.\n",
      "        No acute or chronic condition which would limit the patient's ability to complete the\n",
      "        study.\n",
      "        No history of claustrophobia.\n",
      "        No receipt of any investigational drug within 30 days prior to\n",
      "        MS-325 administration.\n",
      "        No previous exposure to MS-325; no previous exposure to other contrast agents in other\n",
      "        contrast enhanced MR or x-ray studies within five days prior to MS-325 administration.\n",
      "        No major clinical cardiovascular events, coronary angioplasty, or major surgery within 30\n",
      "        days prior to MS-325 administration.\n",
      "        No scheduled x-ray angiography within five days prior to MS-325 administration.\n",
      "        No supine blood pressure less than 100/60 mm HG with pulse rate less than 50 beats per\n",
      "        minute (bpm), or supine blood pressure greater than 160/100 m HG with pulse rate greater\n",
      "        than 100 bpm, unless deemed not clinically significant by the Principal Investigator.\n",
      "        No history of involuntary motion disorder.\n",
      "        No persons unable to lay on back for 120 minutes.\n",
      "        No persons with known serum creatinine levels greater than 1.5 mg/dL or clinical evidence\n",
      "        of severe renal impairment; serum creatinine levels must be determined at least 72 hours\n",
      "        post-x-ray angiography but prior to MS-325 administration.\n",
      "        No known SGPT (ALT) and SGOT (AST) levels exceeding three times the upper limit of the\n",
      "        study center's normal range; no known serum bilirubin greater than 1.75 mg/dL or clinical\n",
      "        evidence of severe hepatic disease.\n",
      "        No specific magnetic resonance (MR) \n",
      "1435\n",
      "-  INCLUSION CRITERIA:\n",
      "        FOR PATIENTS:\n",
      "        18 years or older.\n",
      "        Able to provide informed consent and willing to comply with study requirements and clinic\n",
      "        policies.\n",
      "        Negative urine pregnancy test (for women of childbearing potential).\n",
      "        Hemoglobin greater than 10 mg/dl.\n",
      "        Adequate venous access in the arms for blood drawing and 5 day infusions, and\n",
      "        lymphapheresis\n",
      "        Willingness to allow stored samples to be used for future studies of HIV infection and/or\n",
      "        immunological function, and willingness to have HLA typing performed. (For previously\n",
      "        enrolled patients, patients would be requested, but not required, to provide permission to\n",
      "        use stored samples in the future, and to permit HLA testing\n",
      "        FOR HIV POSITIVE PATIENTS:\n",
      "        Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR\n",
      "        positive).\n",
      "        FOR HIV NEGATIVE PATIENTS:\n",
      "        Negative ELISA/Western blot.\n",
      "        \n",
      "1436\n",
      "Subjects must be between the ages of 11 and 21 years.\n",
      "        Subjects must be diagnosed with HIV for at least one year (to ensure sufficient\n",
      "        opportunity to experience living with a chronic condition such that adherence level is\n",
      "        unlikely to be the result of skill or knowledge deficits).\n",
      "        Subjects must be prescribed oral medications (e.g., pills, liquids, inhaler) to be taken\n",
      "        on a daily basis.\n",
      "        Subjects must be living with same female caregiver for at least one year.\n",
      "        Subjects must have a telephone number where he/she can be contacted during the two weeks\n",
      "        after recruitment.\n",
      "        The adolescent and mother must be able to provide informed consent.\n",
      "        Adolescents must not have mental retardation or developmental delay that would prevent the\n",
      "        adolescent from reading and comprehending the questionnaire.\n",
      "1440\n",
      "Must have known or suspected coronary artery calcification, including subjects of age\n",
      "        equal to or greater than 55 years (men), or 65 years (women).\n",
      "        Must be at increased risk for CAD. (Chronic hypertension greater than 140/90,\n",
      "        cholesterolemia greater than 130 mg/dl, active cigarette smoker, or diabetes mellitus.)\n",
      "        Must be 18 years of age or older.\n",
      "        Females must not be pregnant or considering pregnancy and must not be lactating.\n",
      "        Must not have any surgical devices which may interfere with imaging: heart valves,\n",
      "        pacemakers, sternal wire sutures, epicardial pacer leads, metallic coronary stents.\n",
      "        Must not have tachycardia greater than 90 bpm at time of scanning, or other fast or\n",
      "        irregular rhythm.\n",
      "        Must not be obese. Patients weighing more than 300 pounds will be excluded since this is\n",
      "        the table weight limit for the EBCT scanner.\n",
      "        Must be able to suspend respiration for 28 seconds at time of scanning.\n",
      "        Must be able to give informed consent.\n",
      "1441\n",
      "Must be a postmenopausal woman 65 years of age or younger.\n",
      "        Time since last date of menses should be at least 12 months, with plasma estradiol less\n",
      "        than 50 pg/ml and FSH greater than 50 pg/ml.\n",
      "        Women must be without clinical evidence of CAD as determined by history, cardiovascular\n",
      "        physical examination, and EKG.\n",
      "        Must not have used hormone replacement therapy within past 6 months.\n",
      "        Must not have used dietary supplements and any medication (over-the-counter or prescribed)\n",
      "        within 1 month. Acetaminophen use is allowed.\n",
      "        Must not have a history of alcoholism or binge-drinking.\n",
      "        Must not have diabetes mellitus or known abnormal glucose intolerance test.\n",
      "        Must not have a history of stroke, angina or myocardial infarction.\n",
      "        Must not have a history of deep venous thrombosis/pulmonary embolism.\n",
      "        Must not have a history of cancer (except for treated squamous cell and basal cell\n",
      "        carcinomas).\n",
      "        Must not have evidence of liver disease (liver function enzymes greater than twice the\n",
      "        upper limit of normal).\n",
      "        Must not have impaired renal function (creatinine greater than 1.6 mg/dl).\n",
      "        Must not have a diagnosis of an autoimmune disease (e.g., systemic lupus erythematosus,\n",
      "        rheumatoid arthritis, thyroiditis, Raynaud's Disease).\n",
      "        Must not have a history of intermittent vaginal bleeding.\n",
      "        Must not have serum triglycerides greater than 400 mg/dL.\n",
      "1450\n",
      "INCLUSION CRITERIA:\n",
      "        Age 18-50 years.\n",
      "        History of asthma for one year or greater.\n",
      "        Asthma symptoms (wheezing, chest tightness, shortness of breath) on exposure to allergen\n",
      "        (by history or challenge).\n",
      "        10-20 mm erythema and/or 5 mm wheal response to one or more panel allergens via prick\n",
      "        testing.\n",
      "        Screening forced expiratory volume (FEV(1)) or the ratio of FEV(1) to forced vial capacity\n",
      "        (FEV(1)/FVC) must be equal to or greater than 70% of the predicted value for age and sex.\n",
      "        Frequency of IL-4 producing allergen specific CD4 T cells must be greater than or equal to\n",
      "        0.01% at time of screening.\n",
      "        Baseline values within the following laboratory ranges:\n",
      "        White blood cell count greater than or equal to 3,300 and less than 10,500 cells/L;\n",
      "        Absolute neutrophil count greater than or equal to 1,500 cells/microliter;\n",
      "        Hemoglobin greater than or equal to 12 g/dL;\n",
      "        Platelet count greater than or equal to 100,000/microliter;\n",
      "        Serum creatinine less than 1.7 mg/dL;\n",
      "        Total bilirubin less than 1.5 mg/dL;\n",
      "        AST, ALT less than 50 U/L;\n",
      "        Urinalysis within normal limits.\n",
      "        Written informed consent\n",
      "        Women of childbearing potential must agree to use adequate contraception (diaphragm with\n",
      "        spermicide, condom with spermicide, intrauterine device (IUD), birth control pills or\n",
      "        Norplant) for the duration of the study.\n",
      "        \n",
      "1454\n",
      "Women must be enrolled in NCI Study 98-C-0123.\n",
      "1456\n",
      "-  INCLUSION CRITERIA:\n",
      "        At least one of the following:\n",
      "        Diagnosis of breast cancer, or DCIS prior to or at 45, or ovarian cancer prior to or at\n",
      "        age 50;\n",
      "        Diagnosis of breast cancer with bilateral disease or multiple primaries or breast cancer\n",
      "        and ovarian cancer in the same individual;\n",
      "        Diagnosis of breast or ovarian cancer and one first or second degree relative with breast\n",
      "        cancer diagnosed prior to or at age 45, or ovarian cancer prior to or at age 50;\n",
      "        Diagnosis of breast or ovarian cancer and three relatives in the same lineage with breast\n",
      "        or ovarian cancer; each affected individual must be a first- or second-degree relative to\n",
      "        another of the affected individuals;\n",
      "        Diagnosis of breast or ovarian cancer and a first or second degree male relative with\n",
      "        breast cancer;\n",
      "        A woman of Ashkenazi Jewish descent who meets any of the above criteria, with specified\n",
      "        ages of onset of 50 for breast cancer and any age for ovarian cancer;\n",
      "        A male with breast cancer diagnosed at any age;\n",
      "        Documented BRCA mutation in the family.\n",
      "        All individuals must be able to give informed consent.\n",
      "        \n",
      "1458\n",
      "-  SUBJECT INCLUSION CRITERIA:\n",
      "        Healthy Volunteers must:\n",
      "          1. Be 18-70 years of age\n",
      "          2. Be healthy\n",
      "          3. Have adequate peripheral venous access\n",
      "          4. Have normal renal function (creatinine less than or equal to 1.5mg/dL; less than or\n",
      "             equal to 1 plus proteinuria)\n",
      "          5. Have normal hepatic function (bilirubin less than or equal to 1.5 mg/dL)\n",
      "          6. Have normal hematologic function (WBC greater than or equal to 3000/mm(3);\n",
      "             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to\n",
      "             175,000; hemoglobin greater than or equal to 12.5 g/dL)\n",
      "        Patients must:\n",
      "          1. Be 18-70 years of age\n",
      "          2. Have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis\n",
      "             (applicable to systemic mastocytosis patients only) or other allergic, hematologic,\n",
      "             or immunologic condition\n",
      "          3. Have adequate peripheral venous access or be willing to have a central line placed.\n",
      "          4. First be admitted as inpatients under an existing NIH protocol\n",
      "          5. Have preserved renal function (creatinine less than or equal to 2 mg/dL; less than or\n",
      "             equal to 2 plus proteinuria)\n",
      "          6. Have preserved hepatic function (bilirubin less than or equal to 1.5 mg/dL)\n",
      "          7. Have preserved hematologic function (WBC greater than or equal to 3000/mm(3);\n",
      "             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to\n",
      "             175,000; hemoglobin greater than or equal to 12.5 g/dL)\n",
      "        All female subjects of childbearing potential:\n",
      "          1. May be enrolled if using effective contraception\n",
      "          2. Have a negative serum or urine pregnancy test determined before beginning Plerixafor\n",
      "             or G-CSF administration\n",
      "        SUBJECT \n",
      "1461\n",
      "Black and white normal volunteers, approximately matched for age and sex, will be included\n",
      "        in the study.\n",
      "        All subjects must be capable of rendering informed consent for all procedures.\n",
      "        Volunteers with a history or evidence of present or past hypertension (BP greater than\n",
      "        140/90), diabetes mellitus, hypercholesterolemia (plasma cholesterol greater than 200\n",
      "        mg/dL), cardiac disease, peripheral vascular disease, coagulopathy, chronic smoking (2\n",
      "        pack-years or more), obesity (20% greater than ideal body weight), hyperhomocysteinemia\n",
      "        (plasma homocysteine greater than 17 umol/1) or any other disease predisposing them to\n",
      "        vasculitis will be excluded from the study.\n",
      "        No pregnant women.\n",
      "        Volunteers who are taking any medication will be excluded.\n",
      "1464\n",
      "-  INCLUSION CRITERIA:\n",
      "               1. Adults greater than or equal to 18 years of age.\n",
      "               2. Patients will provide informed consent.\n",
      "               3. Biopsy proven FSGS.\n",
      "               4. Glomerular filtration rate of at least 25 and no more than 80 ml/minute as\n",
      "                  assessed by the 4 variable Modification of diet in renal disease GFR equation.\n",
      "               5. At least 6 months of renal function data must be available prior to the\n",
      "                  patient's receiving pirfenidone, and renal function must show a rate of decline\n",
      "                  of greater than or equal to 0.4 ml/min/month during this baseline period.\n",
      "               6. Patients must have received no glucocorticoids, cyclophosphamide, mycophenolate\n",
      "                  or other immunosuppressive drugs for at least 2 months prior to the study\n",
      "                  period.\n",
      "               7. Patients must have received no cyclosporin for at least 6 months prior to the\n",
      "                  study period.\n",
      "               8. Patients must have been taking an angiotensin converting enzyme inhibitor (ACEI)\n",
      "                  or angiotensin receptor blocker (ARB) at a stable dose for at least 6 months,\n",
      "                  unless intolerant of both classes of medication.\n",
      "               9. Patients who are HIV seropositive will receive standard care for HIV disease\n",
      "                  (patients receiving immune-modulating therapy will be excluded).\n",
      "              10. Women with child-bearing potential must maintain an effective birth control\n",
      "                  regimen (oral contraceptive, intrauterine device, barrier plus spermicide).\n",
      "              11. Men will be advised that although Ames testing has been negative for any\n",
      "                  evidence of mutagenicity, they should consider use of contraceptives during the\n",
      "                  study period as well.\n",
      "        \n",
      "1467\n",
      "INCLUSION CRITERIA:\n",
      "        PATIENT CRITERIA:\n",
      "        Ages 1 to 55 years\n",
      "        DHR proven Chronic Granulomatous Disease: Includes gp91phox, p47phox, p22phox and p67phox\n",
      "        deficiency.\n",
      "        Free of active infection.\n",
      "        Patient has experienced 2 or more prior infections requiring treatment with intravenous\n",
      "        anti-bacterial or anti-fungal therapy.\n",
      "        HIV negative.\n",
      "        No major organ dysfunction precluding transplantation.\n",
      "        HLA identical sibling or parent compatible at all 6 of the HLA A, B, and DR antigens by\n",
      "        serotyping or DNA typing techniques.\n",
      "        Left ventricular ejection fraction: greater than 40% predicted.\n",
      "        ECOG performance status of 0 or 1.\n",
      "        DONOR CRITERIA:\n",
      "        HLA identical sibling donor or parent donor.\n",
      "        Fit to receive G-CSF and give peripheral blood stem cells (normal blood count,\n",
      "        normotensive, no history of stroke, no history of severe heart disease).\n",
      "        Female x-linked CGD carriers must have greater than 30% normal neutrophils.\n",
      "        \n",
      "1468\n",
      "Male or nonpregnant, non-breastfeeding females age 12-85 years.\n",
      "        Diagnosis of persistent asthma for greater than 1 year and currently being treated with\n",
      "        short acting beta-2 agonist only.\n",
      "        FEV1 50-80% of predicted (must be demonstrated at Day 10 and Day 0). Patients will be\n",
      "        stratified into 50-70% or 71-80% cohort at Day 10.\n",
      "        Increase of greater than or equal to 15% over baseline FEV1 approximately 15-20 minutes\n",
      "        after beta-2 agonist inhalation (2-4 puffs of albuterol via MDI or the nebulized\n",
      "        equivalent) documented at baseline.\n",
      "        Positive prick skin test to at least two allergens (defined as wheal 3 mm greater than\n",
      "        control and erythema greater than control).\n",
      "        History of asthma symptoms (wheezing, shortness of breath, cough, chest tightness, or\n",
      "        nighttime awakening) on least 3 of the last 7 days.\n",
      "        Fulfillment of washout criteria by not using any of the medications listed below for the\n",
      "        specified times prior to Day 0 of the study drug treatment:\n",
      "        Parenteral corticosteroids for 4 weeks;\n",
      "        Oral corticosteroids for 4 weeks;\n",
      "        Inhaled corticosteroids for 4 weeks;\n",
      "        Cromolyn sodium (Intal), nedocromil (Tilade) for 4 weeks;\n",
      "        Theophylline, zileuton (Zyflo), zafirlukast (Accolate), or montelukast (Singulair) for 4\n",
      "        weeks;\n",
      "        Astemizole (Hismanal) for 12 weeks;\n",
      "        Terfenadine (Seldane), or fexofenadine (Allegra) for 6 days;\n",
      "        Cetirizine (Zyrtec) for 6 days;\n",
      "        Hydroxyzine (Atarax, Vistaril) for 6 days;\n",
      "        Azelastine (Astelin) nasal spray for 6 days; and\n",
      "        Salmeterol (Serevent) for 9 days.\n",
      "        No clinically significant abnormality in chemistry, hematology, urinalysis: serum\n",
      "        creatinine less than or equal to 1.7 mg/dL; total bilirubin less than or equal to 1.5\n",
      "        mg/dL; AST (SGOT), ALT (SGPT) less than or equal to 2 times laboratory's upper limit of\n",
      "        normal.\n",
      "        No clinically significant abnormality in EKG within 1 month prior to enrollment.\n",
      "        No clinically significant abnormality in CXR (other than changes consistent with asthma)\n",
      "        within 1 year prior to enrollment.\n",
      "        Nonsmoker, for at least 2 years with a smoking history of no more than 10 pack years\n",
      "        (e.g., one pack per day for 10 years).\n",
      "        Agreement to use medically accepted contraception throughout the study, if sexually\n",
      "        active, except females who are postmenopausal for greater than or equal to 2 years.\n",
      "        Agreement not to donate blood or blood products throughout the study.\n",
      "        Demonstrated ability to follow proper technique in the use of the AERx system.\n",
      "        A written, signed, and witnessed consent form.\n",
      "        No desensitization therapy within 3 months prior to Day 0 of study drug treatment.\n",
      "        No use of any investigational or non-approved drug therapy within 30 days prior to Day 0\n",
      "        of study drug treatment.\n",
      "        No occurrence of acute asthma exacerbation requiring emergency room treatment within 6\n",
      "        weeks of Day 0 of study drug treatment.\n",
      "        No occurrence of acute asthma exacerbation requiring hospitalization within 12 months of\n",
      "        Day 0 of study drug treatment.\n",
      "        No occurrence of respiratory infection which affects asthma within 4 weeks prior to Day 0\n",
      "        of study drug treatment.\n",
      "        No history of endotracheal intubation for asthma-related exacerbation within 15 years\n",
      "        prior to Day 0 of study drug treatment.\n",
      "        No presence of significant medical conditions (including obesity affecting respiratory\n",
      "        function, congestive heart failure, myocardial infarction, unstable angina, uncontrolled\n",
      "        hypertension, severe pulmonary disease, history of cancer [other than resected cutaneous\n",
      "        basal or squamous cell carcinoma], insulin-dependent diabetes, autoimmune disease, or\n",
      "        known HIV infection).\n",
      "        No previous enrollment in a study of soluble IL-4 receptor.\n",
      "        No history of alcohol abuse, drug abuse, or psychiatric illness that would interfere with\n",
      "        ability to comply with protocol requirements or give informed consent.\n",
      "        No patients experiencing hypersensitivity to soluble IL-4R.\n",
      "1471\n",
      "Able to provide informed consent to all aspects of the study after full information is\n",
      "        provided.\n",
      "        Age equal to or between 18 and 65 years.\n",
      "        Moderate-to-severe stable plaque psoriasis of at least 6 months duration as defined by the\n",
      "        following criteria: 1) Classic psoriatic skin lesions with or without nail involvement, 2)\n",
      "        Psoriasis Area and Severity Index score greater than 10(i), 3) Total body surface area\n",
      "        involved greater than 10%.\n",
      "        Weight less than 242 pounds.\n",
      "        Must be able to self-administer medication (subcutaneous injection) or arrange for\n",
      "        administration.\n",
      "        No unstable psoriatic disease, including erythrodermic, pustular, and palmar/plantar\n",
      "        variants.\n",
      "        No use of topical medications for psoriasis (except for bland emollients) during 2 weeks\n",
      "        prior to study entry.\n",
      "        No use of systemic medications for psoriasis during 1 month prior to study entry.\n",
      "        No patients with an ECOG or Zubrod Performance Status Scale greater than 2.\n",
      "        No patients with acute or chronic infections requiring antimicrobial therapy or serious\n",
      "        viral (e.g., hepatitis, herpes zoster, or HIV) or fungal infections as the effects of\n",
      "        IL-10 on the immune system not completely elucidated and treatment could pose additional\n",
      "        risk to the patient. Patients with a positive PPD who have not received antituberculous\n",
      "        therapy may be excluded, if in the opinion of an infectious consultant, IL-10 treatment is\n",
      "        contraindicated.\n",
      "        No patients receiving disease modifying anti-inflammatory drugs (methotrexate,\n",
      "        sulfasalazine, gold, hydroxychloroquine, cyclosporin, azathioprine, cyclophosphamide,\n",
      "        chlorambucil, retinoids, vitamin D). Such drugs will be discontinued at least 4 weeks\n",
      "        prior to randomization.\n",
      "        No pregnant females, nursing mothers, or patients of childbearing age not practicing birth\n",
      "        control, since the risks to the unborn fetus and newborn child are unknown.\n",
      "        No previous history of malignancy or current malignancy other than satisfactorily treated\n",
      "        basal-squamous cell carcinoma or in situ cervical carcinoma.\n",
      "        No confounding medical illness that in the judgment of the investigators would pose added\n",
      "        risk for study participants (e.g., hepatic, hematologic [e.g., hematocrit less than or\n",
      "        equal to 28% or platelet counts less than 100,000/ml], neurologic, renal, or pulmonary\n",
      "        disease).\n",
      "        No patients with serum creatinine greater than 1.8 or creatinine clearance (CrCl) less\n",
      "        than 50 ml/min.\n",
      "        No patients with abnormal liver function tests (e.g., serum glumatic oxalacetic\n",
      "        transaminase, serum glutamic pyruvic transaminase or alkaline phosphatase levels greater\n",
      "        than 2.5x upper limit of normal (UNL) and/or bilirubin levels 1.5x UNL).\n",
      "        No current alcohol or drug abuse.\n",
      "1473\n",
      "Patients must have advanced stage solid tumor with histologically or cytologically proven\n",
      "        evaluable or measurable disease and who are refractory to standard treatment for their\n",
      "        malignancy or for whom no effective standard therapy exists.\n",
      "        Must have the presence of B3 antigen on the surface of greater than 30% of the tumor\n",
      "        cells.\n",
      "        Must be greater than or equal to 18 years old and be able to give informed consent.\n",
      "        Must have an ECOG performance status of 0 or 1 and a minimum life expectancy of 3 months.\n",
      "        Must have normal renal function (Creatinine less than or equal to 1.4 mg/dl), SGOT and\n",
      "        SGPT less than or equal to 2.5 x of the upper limits of normal. Total bilirubin less than\n",
      "        1.5 mg/dL; AGC greater than or equal to 1.5 x 10(3) microliter; platelets greater than\n",
      "        100,000 per mm(3).\n",
      "        Must have recovered from the toxic effects of prior chemotherapy or radiation therapy. At\n",
      "        least 3 weeks must have elapsed since the last dose of chemotherapy, hormonal therapy or\n",
      "        radiation therapy. At least six weeks must have elapsed since the last dose of Mitomycin C\n",
      "        and a nitrosourea.\n",
      "        Must not have serum neutralizing antibodies to LMB-1.\n",
      "        Must not have positive hepatitis B surface antigen, hepatitis C antibody or HIV.\n",
      "        Must not have a history of coronary artery disease, NY class II-IV CHF, arrhythmia\n",
      "        requiring treatment and any contraindication to pressor therapy.\n",
      "        Must not have FEV1 and FVC less than or equal to 65% of the predicted value.\n",
      "        Must not have baseline serum albumin of less than 3.0 g/dl.\n",
      "        Must not have a history of CNS metastasis and/or known seizure disorders, or concurrent\n",
      "        malignancy.\n",
      "        Must not have an acute bacterial infection that requires antibiotic therapy (unless\n",
      "        infection is completely resolved).\n",
      "        Must not have any coexisting medical or psychiatric condition that is likely to interfere\n",
      "        with study procedures and/or results.\n",
      "        Must not be pregnant or breastfeeding. Patients of childbearing potential must agree to\n",
      "        use an effective method of contraception.\n",
      "        Must not have a history of allergic reaction to penicillin.\n",
      "        Must not have lymphoma.\n",
      "1477\n",
      "Patient:\n",
      "        Ages 10-45 years.\n",
      "        Chronic myelogenous leukemia, any of these categories: accelerated phase or blast\n",
      "        transformation.\n",
      "        Acute lymphoblastic leukemia, any of these categories: Adults (greater than 18 years) in\n",
      "        any remission with high-risk features (presenting leukocyte count greater than 100,000/cu\n",
      "        mm, Karyotypes t9; 22, t4, t19, t11, biphenotypic leukemia). All second remissions,\n",
      "        primary induction failure including partial remission, partially responding or untreated\n",
      "        relapse.\n",
      "        Acute myelogenous leukemia (AML): All AML in second or subsequent remission, primary\n",
      "        induction failure or partial remission and resistant relapse.\n",
      "        Myelodysplastic syndromes, any of these categories: refractory anemia with excess of\n",
      "        blasts, transformation to acute leukemia, chronic myelomonocytic leukemia.\n",
      "        Myeloproliferative disorders undergoing transformation to terminal stages.\n",
      "        Chronic lymphocytic leukemia (CLL) in Richter transformation.\n",
      "        High-grade lymphoma, refractory to standard treatment approaches, mantle cell lymphoma.\n",
      "        No major organ dysfunction precluding transplantation.\n",
      "        DLCO greater than 65% predicted.\n",
      "        Left ventricular ejection fraction: greater than 40% predicted.\n",
      "        ECOG performance status of 0 or 1.\n",
      "        Informed consent given. Informed consent from parents for minors.\n",
      "        Women of childbearing age with a negative pregnancy test may participate.\n",
      "        Donor:\n",
      "        Partially HLA matched family donor (3-5/6 matches).\n",
      "        Fit to receive G-CSF and give peripheral blood stem cells (normal blood count,\n",
      "        normotensive, and no history of stroke).\n",
      "        Informed consent given.\n",
      "        Patients or donors must not be pregnant or nursing.\n",
      "        Must not have ECOG performance status of 2 or more.\n",
      "        No severe psychiatric illness in patient or donor: Mental deficiency sufficiently severe\n",
      "        as to make compliance with the BMT treatment unlikely and making informed consent\n",
      "        impossible.\n",
      "        No major anticipated illness or organ failure incompatible with survival from BMT.\n",
      "        DLCO must not be less than 65% predicted.\n",
      "        No left ventricular ejection fraction: less than 40% predicted.\n",
      "        Must not have serum creatinine greater than 3 mg/dl.\n",
      "        Must not have serum bilirubin greater than 4 mg/dl, Transaminases greater than 3 times the\n",
      "        upper limit of normal.\n",
      "        Donor or patient must not be HIV positive.\n",
      "        Must not have history of other malignancies except basal cell or squamous carcinoma of the\n",
      "        skin, positive PAP smear and subsequent negative follow up.\n",
      "        Donor must be fit to receive G-CSF and undergo apheresis.\n",
      "        Must not fail to mobilize adequate numbers of CD34+ cells after two cycles of G-CSF.\n",
      "1479\n",
      "All volunteer subjects will be assessed for study participation, including a\n",
      "        cardiovascular physical examination and resting electrocardiogram. Fasting blood will be\n",
      "        taken for SMAC, CBC, thyroid battery, lipid levels, estradiol and FSH levels under\n",
      "        screening protocol 94-H-0045. A urine pregnancy test will be performed in women with a\n",
      "        uterus and cessation of menses less than 6 months. Aspirin and non-steroidal\n",
      "        anti-inflammatory drugs and steroidal drugs (oral, ointment, drops or inhalation) will be\n",
      "        stopped 10 days prior to starting the study and discontinued throughout the study.\n",
      "        Thirty hypercholesterolemic (LDL greater than 130 mg/dL) postmenopausal women who have not\n",
      "        taken estrogenic hormone, antioxidant vitamins (A, C, E), or lipid-lowering therapy in the\n",
      "        preceding 2 months will be selected to take part in this double-blind, cross-over study.\n",
      "        No subjects with plasma estradiol level greater than 50 pg/ml and FSH less than 50 pg/ml.\n",
      "        No subjects with blood pressure greater than 160/100 mm/Hg (off medication).\n",
      "        No subjects smoking cigarettes within 6 months.\n",
      "        No pregnant subjects.\n",
      "        No subjects with a history of deep venous thrombosis/pulmonary embolus.\n",
      "        No subjects with important chronic medical conditions (cancer, coronary artery disease,\n",
      "        diabetes mellitus, COPD, renal disease) other than hypothyroidism if the subject is\n",
      "        euthyroid on thyroid replacement.\n",
      "        No subjects who refuse to follow nitrate-restricted diet for 3 days prior to each study.\n",
      "1480\n",
      "Ages 18 to 50.\n",
      "        Male and female subjects.\n",
      "        Capable of giving informed consent.\n",
      "        Healthy normal volunteers.\n",
      "        No cardiac pacemaker of implantable defibrillator.\n",
      "        No aneurysm clip.\n",
      "        No neural stimulator (e.g. TENS-unit).\n",
      "        No ear implant of any type.\n",
      "        No metal in the eye (e.g. from machining).\n",
      "        No implanted device (e.g. insulin pump, drug infusion device).\n",
      "        No metallic foreign body, shrapnel, or bullet.\n",
      "1483\n",
      "Informed consent of the patient or legally authorized representative must be obtained\n",
      "        prior to entry.\n",
      "        Verbal assent will be obtained from minors capable of understanding.\n",
      "        Patients may be of either gender. Females of childbearing potential must have a negative\n",
      "        pregnancy test obtained within 14 days prior to the first dose of study drug.\n",
      "        Patients greater than or equal to 6 months of age.\n",
      "        Patients at risk of systemic fungal infections due to their immunocompromised state due to\n",
      "        one of the following:\n",
      "        Patient with a hematologic malignancy undergoing an autologous hematopoietic stem cell\n",
      "        transplant;\n",
      "        Any patient undergoing an allogeneic hematopoietic stem cell transplant.\n",
      "        Patients must have sufficient venous access to permit administration of study drug and\n",
      "        monitoring of safety variables.\n",
      "        No patients who are pregnant or nursing. Females of childbearing potential must avoid\n",
      "        becoming pregnant by abstinence or barrier methods of birth control while receiving\n",
      "        antifungal agents.\n",
      "        No patients with moderate or severe liver disease, as defined by:\n",
      "        AST or ALT greater than 5 times upper limit of normal (ULN), OR;\n",
      "        Total bilirubin greater than 2.5 times ULN.\n",
      "        No patients with evidence of a deeply invasive or disseminated fungal infection at time of\n",
      "        enrollment.\n",
      "        No patients who have received systemic antifungal agents within 72 hours prior to the\n",
      "        first dose of study drug.\n",
      "        No patients receiving an autologous transplant for nonhematologic malignancies.\n",
      "        No patients known to be infected with HIV due to the lack of data on drug interaction\n",
      "        between highly active antiretroviral therapy (HAART) and FK463.\n",
      "        No patients previously randomized in this study.\n",
      "        No patients with a history of anaphylaxis attributed to azole compounds or the\n",
      "        echinocandin class or antifungals.\n",
      "        No patients with a concomitant medical condition, in the opinion of the investigator\n",
      "        and/or medical monitor, whose participation may create an unacceptable additional risk for\n",
      "        the patient.\n",
      "        No patients receiving another investigational drug other than for the treatment of cancer\n",
      "        or supportive care.\n",
      "1484\n",
      "-  INCLUSION CRITERIA:\n",
      "        ASTHMATICS:\n",
      "        Patients will be between 18 and 75 years of age, male or female.\n",
      "        The diagnosis of asthma requires a history of intermittent, reversible expiratory flow\n",
      "        limitation.\n",
      "        In addition, patients will have either an abnormal methacholine challenge or evidence of\n",
      "        ongoing reversible airway obstruction. An abnormal methacholine challenge will be defined\n",
      "        as a decrease in FEV(1) of at least 20% following inhalation of less than or equal to 4\n",
      "        mg/ml of methacholine. Ongoing reversible airway obstruction will be defined as an\n",
      "        improvement of at least 12% and 200 cc in either the FEV(1) or FVC folowing bronchodilator\n",
      "        treatment.\n",
      "        For women of childbearing potential, negative pregnancy test prior to study and\n",
      "        willingness to adhere to reliable birth control methods during the study.\n",
      "        \n",
      "1490\n",
      "INCLUSION CRITERIA:\n",
      "        Boys and girls 9 to 13 years of age.\n",
      "        Right handed subjects only.\n",
      "        Subjects that are off stimulant medications.\n",
      "        Children who undergo a medication washout as a part of a different study or are on a\n",
      "        planned drug holigay will be allowed to enroll in the study once they have bee off the\n",
      "        medications for at least 10 days.\n",
      "        Adult men with a history of ADHD between 18 and 30 years and healthy age-matched normal\n",
      "        volunteers.\n",
      "        \n",
      "1492\n",
      "MDS of RA & RAEB sub-types.\n",
      "        No current treatment and off other treatments for at least two weeks.\n",
      "        ECOG performance status less than or equal to 2.\n",
      "        No MDS of FAB sub-group' refractory anemia with ring sideroblasts' (RARS).\n",
      "        No transforming to acute leukemia (FAB sub-group RAEB-Tie.; greater than 20% blasts in\n",
      "        marrow aspirate).\n",
      "        No hypoplastic marrow without one major or two minor criteria as outlined in table 3 of\n",
      "        the appendix.\n",
      "        No one being treatment with growth factors or cyclosporine within four weeks prior to\n",
      "        entry to protocol.\n",
      "        No previous treatment with ATG.\n",
      "        No ECOG performance status of greater than 2.\n",
      "        No active uncontrolled infection.\n",
      "        No women which current pregnancy, or unwilling to take oral contraceptives if of\n",
      "        childbearing potential.\n",
      "        No patients for whom bone marrow transplant is indicated as primary therapy.\n",
      "        No one age less than 18 years.\n",
      "        Must be able to give informed consent.\n",
      "        No HIV positive patients.\n",
      "        No active malignant disease (excluding basal cell carcinoma).\n",
      "        No one with serum creatine greater than 2mg/dl.\n",
      "        No patients who are moribund or patients with concurrent hepatic, renal, cardiac,\n",
      "        metabolic, or any disease of such severity that death within 7-10 days is likely.\n",
      "1505\n",
      "Characterized as having behavioral manifestations using a standardized neuropsychiatric\n",
      "        scale and interview.\n",
      "        FLD patients' frontal cognitive sysfunctions characterized using a short neurobehavioral\n",
      "        test battery.\n",
      "        Patients must be able to be tested and cooperative with the procedures required in this\n",
      "        protocol.\n",
      "        No contraindications to the use of Sertraline.\n",
      "        No medical conditions that can reasonably be expected to subject the patient to\n",
      "        unwarranted risk (e.g., cancer) or require frequent changes in medication. Well-controlled\n",
      "        medical conditions such as hypertension and diabetes will not be excluded.\n",
      "        Patients must not be pregnant or nursing and must be using effective contraception, if\n",
      "        still at child-bearing age.\n",
      "        No history of prior severe traumatic brain injury or other severe neurologic or\n",
      "        psychiatric condition, such as psychosis, stroke, multiple sclerosis, or spinal cord\n",
      "        injury.\n",
      "        Not using any psychotropic medication which cannot be stopped 4 weeks before the study.\n",
      "1515\n",
      "ASTHMATICS:\n",
      "        Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in\n",
      "        height.\n",
      "        The diagnosis of asthma requires a history of intermittent, reversible expiratory flow\n",
      "        limitation. Patients will have mild-to-moderately severe asthma as defined by a baseline\n",
      "        forced expiratory flow in one second (FEV(1)) greater than 70% of predicted (at least 6\n",
      "        hours after bronchodilator use) and therapy limited to inhaled beta-agonists.\n",
      "        Positive skin prick-puncture test to one or more common aeroallergens.\n",
      "        A positive inhaled methacholine challenge as defined by a decrease in FEV(1) of at least\n",
      "        20% (PC(20)) in response to inhalation of less than 25 mg/ml of methacholine.\n",
      "        A decrease in FEV(1) of at least 20% in response to inhalation of up to 10,000\n",
      "        bioequivalency allergy units (BAU) or allergy units (AU) per ml of a selected common\n",
      "        aeroallergen (house dust mite, cat hair or grasses) or up to 150 Antigen E units per ml of\n",
      "        short ragweed. Asthmatic patients must also demonstrate a late asthmatic response (defined\n",
      "        as a 20% fall from the baseline established following completion of the early asthmatic\n",
      "        response).\n",
      "        Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels\n",
      "        (less than 30 ml of blood will be drawn), normal EKG and chest radiograph without acute\n",
      "        pulmonary infiltrates.\n",
      "        Women of childbearing potential must have a negative pregnancy test within 2 weeks prior\n",
      "        to study and willingness to adhere to reliable birth control methods during the study.\n",
      "        Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic\n",
      "        bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).\n",
      "        Must not have a baseline FEV(1) of less than 70% predicted.\n",
      "        Must not have respiratory tract infection or asthma exacerbation within 4 weeks of\n",
      "        screening.\n",
      "        Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn\n",
      "        sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or\n",
      "        anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing\n",
      "        therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be\n",
      "        excluded. Research subjects can continue therapy with inhaled beta-agonists during the\n",
      "        study.\n",
      "        No history of anaphylaxis or severe allergic response.\n",
      "        No history of adverse reactions to lidocaine or other local anesthetics.\n",
      "        No history of active inhaled or intravenous drug abuse or alcohol abuse.\n",
      "        Must not have an abnormal EKG or evidence of coronary artery disease.\n",
      "        Must not require chronic anti-coagulant therapy.\n",
      "        Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal\n",
      "        anti-inflammatory agents within 2 days of the bronchoscopic study.\n",
      "        No history of cigarette smoking within the past 3 years.\n",
      "        No history of allergy immunotherapy within the past year.\n",
      "        Not allergic to methacholine.\n",
      "        PT or PTT must not be prolonged 2 seconds greater than normal range.\n",
      "        Platelet count must be greater than or equal to 150,000/mm(3).\n",
      "        Must not test positive for human immunodeficiency virus.\n",
      "        RESEARCH VOLUNTEERS:\n",
      "        Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in\n",
      "        height.\n",
      "        A negative inhaled methacholine challenge as defined by the absence of a decrease in\n",
      "        FEV(1) by 20% (PC(20)) in response to inhalation of 25 mg/ml of methacholine.\n",
      "        A negative skin test to a panel of common aeroallergens.\n",
      "        Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels\n",
      "        (less than 30 ml of blood will be drawn). Negative hepatitis serology. Normal EKG and\n",
      "        chest radiograph without acute pulmonary infiltrates.\n",
      "        Women of childbearing potential must have a negative pregnancy test within 2 weeks prior\n",
      "        to study and willingness to adhere to reliable birth control methods during the study.\n",
      "        No history of asthma, allergic rhinitis, or atopic dermatitis.\n",
      "        Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic\n",
      "        bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).\n",
      "        Must not have a baseline FEV(1) of less than 70% predicted.\n",
      "        Must not have respiratory tract infection or asthma exacerbation within 4 weeks of\n",
      "        screening.\n",
      "        Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn\n",
      "        sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or\n",
      "        anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing\n",
      "        therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be\n",
      "        excluded. Research subjects can continue therapy with inhaled beta-agonists during the\n",
      "        study.\n",
      "        No history of anaphylaxis or severe allergic response.\n",
      "        No history of adverse reactions to lidocaine or other local anesthetics.\n",
      "        No history of active inhaled or intravenous drug abuse or alcohol abuse.\n",
      "        Must not have an abnormal EKG or evidence of coronary artery disease.\n",
      "        Must not require chronic anti-coagulant therapy.\n",
      "        Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal\n",
      "        anti-inflammatory agents within 2 days of the bronchoscopic study.\n",
      "        No history of cigarette smoking within the past 3 years.\n",
      "        No history of allergy immunotherapy within the past year.\n",
      "        Not allergic to methacholine.\n",
      "        PT or PTT must not be prolonged 2 seconds greater than normal range.\n",
      "        Platelet count must be greater than or equal to 150,000/mm(3).\n",
      "        Must not test positive for human immunodeficiency virus.\n",
      "1520\n",
      "Patients with clinically definite and/or laboratory-supported definite diagnosis of MS.\n",
      "        Patients must have had a minimum of 6 monthly MRI scans prior to randomization according\n",
      "        to a standardized MRI protocol and fulfill the pre-defined MRI criteria of disease\n",
      "        activity: mean of at least 0.5 total gadolinium-enhancing lesion in the 6 monthly scans\n",
      "        immediately preceding randomization.\n",
      "        No evidence of relapse for at least 30 days prior to entry.\n",
      "        One or more relapses in the 2 years preceding randomization.\n",
      "        Expanded Disability Status Scale (EDSS) score less than or equal to 7.0.\n",
      "        Male or female aged 18 to 55 years.\n",
      "        Females must be either post-menopausal, surgically incapable of bearing children, or\n",
      "        practicing a medically accepted method of birth control.\n",
      "        Patients willing and able to give informed consent according to national legal\n",
      "        requirements.\n",
      "1526\n",
      "Subject age between 18 and 65 years.\n",
      "        Adult hearing offsprings of deaf parents.\n",
      "        Congenitally deaf individuals.\n",
      "        Intact hearing volunteers.\n",
      "        No subjects with personal or family history of seizures or other neurological or\n",
      "        demyelinating disorders.\n",
      "        No pregnant women tested after urine pregnancy test.\n",
      "        No subjects with severe coronary disease.\n",
      "        No subjects with metal in the cranium except mouth.\n",
      "        No subjects with intracardiac lines and implanted medication pumps.\n",
      "        No subjects with increased intracranial pressure as evaluated by clinical means.\n",
      "        No subjects with cardiac pacemakers.\n",
      "        No subjects with an intake of neuroleptics.\n",
      "1528\n",
      "-  INCLUSION CRITERIA:\n",
      "        Good general health. Individuals taking medications for obesity-related comorbid\n",
      "        conditions will not be excluded.\n",
      "        Obesity: body mass index for age and triceps skinfold above the 95th percentile\n",
      "        (determined by NHANES I age-, sex-, and race- specific data). All subjects will be\n",
      "        required to be over 60 kg in body weight.\n",
      "        Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or\n",
      "        diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes,\n",
      "        impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia\n",
      "        (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total\n",
      "        cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting\n",
      "        triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range\n",
      "        with negative hepatitis studies) or sleep apnea documented by a sleep study.\n",
      "        Age 12 to 17 years at the start of the study.\n",
      "        For girls with childbearing potential, a negative pregnancy test before taking and while\n",
      "        taking study medication. Sexually active females must be using an effective form of birth\n",
      "        control. These methods include total abstinence (no sex), oral contraceptives (\"the\n",
      "        pill\"), an intrauterine device (IUD), levonogestrol implants (Norplant), or\n",
      "        medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be\n",
      "        used, contraceptive foam with a condom is recommended.\n",
      "        Race of all four grandparents self-identified as either all Caucasian or all African\n",
      "        American.\n",
      "        \n",
      "1529\n",
      "-  INCLUSION CRITERIA - Patient:\n",
      "        Ages 10-55 years.\n",
      "        Chronic myelogenous leukemia, any of these categories: chronic phase, accelerated phase or\n",
      "        blast transformation.\n",
      "        Acute lymphoblastic leukemia, any of these categories: Adults (greater than 18 years) in\n",
      "        first remission with high-risk features (presenting leukocyte count greater than\n",
      "        100,000/cu mm, karyotypes t9; 22, t4, t11, biphenotypic leukemia) All second or subsequent\n",
      "        remissions, primary induction failure, partially responding or untreated relapse.\n",
      "        Acute myelogenous leukemia (AML): AML in first remission except AML with good risk\n",
      "        karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8;21). All AML in second or\n",
      "        subsequent remission, primary induction failure and resistant relapse.\n",
      "        Myelodysplastic syndromes, any of these categories: refractory anemia with transfusion\n",
      "        dependence, refractory anemia with excess of blasts, transformation to acute leukemia,\n",
      "        chronic myelomonocytic leukemia.\n",
      "        Myeloproliferative disorders (myelofibrosis, polycythemia vera, essential thrombocythemia)\n",
      "        in transformation to acute leukemia.\n",
      "        Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky\n",
      "        progressive disease or with thrombocytopenia (less than or equal to 100,000 / mcl) or\n",
      "        anemia (less than or equal to 10g/dl) not due to recent chemotherapy.\n",
      "        No major organ dysfunction precluding transplantation.\n",
      "        DLCO greater than or equal to 60% predicted.\n",
      "        Left ventricular ejection fraction: greater than or equal to 40% predicted.\n",
      "        ECOG performance status of 0 or 1.\n",
      "        For adults: Written informed consent given by adults. For minors: Written informed consent\n",
      "        from one parent or guardian. Informed oral consent from minors: The process will be\n",
      "        explained to the minor on a level of complexity appropriate for their age and ability to\n",
      "        comprehend.\n",
      "        Women of childbearing age with a negative pregnancy test may participate.\n",
      "        \n",
      "1533\n",
      "-  INCLUSION CRITERIA:\n",
      "        All patients must be concomitantly enrolled in the companion Screening and Natural History\n",
      "        protocol.\n",
      "        Any patient with at least 2 active fibrous dysplastic lesions of either the cranial,\n",
      "        axial, or appendicular skeleton will be eligible for consideration for inclusion in the\n",
      "        study. The diagnosis will be based on evidence typical findings on bone biopsy (performed\n",
      "        during the \"Screening\" protocol). Final consideration for enrollment will depend on\n",
      "        diagnosis at the NIH.\n",
      "        Patients must be at least 6 years old.\n",
      "        Patients may be of child-bearing age, but will be expected to be on a nonhormonal form of\n",
      "        birth control that gives a 95% protection rate. If a patient becomes pregnant during the\n",
      "        course of the study, they must withdraw but will be eligible for re-enrollment upon the\n",
      "        completion of pregnancy and lactation.\n",
      "        Patients on previous of concomitant therapy are eligible for enrollment. However, patients\n",
      "        who have received previous treatment with a bisphosphonate must wait one year from the\n",
      "        completion of the last course before they can be enrolled.\n",
      "        \n",
      "1534\n",
      "Patients must have histologically confirmed malignancy which is metastatic or unresectable\n",
      "        and for which standard curative or palliative measures do not exist or are no longer\n",
      "        effective.\n",
      "        Patients with prior chemotherapy, radiation therapy, hormonal therapy and immunotherapy\n",
      "        are allowed with the exception that patients cannot have had prior treatment with\n",
      "        oxaliplatin.\n",
      "        Patients greater than or equal to 18 years of age.\n",
      "        Patients must have an ECOG performance status less than or equal to 2 (Karnofsky greater\n",
      "        than or equal to 60 percent) and a life expectancy of at least 3 months.\n",
      "        Patients must have adequate organ and marrow function which includes:\n",
      "        Leukocytes must be greater than or equal to 3,000/microliter.\n",
      "        Absolute neutrophil count must be greater than or equal to 1,500/microliter.\n",
      "        Platelet count must be greater than or equal to 100,000/microliter.\n",
      "        Total bilirubin within normal institutional limits.\n",
      "        AST (SGOT)/ALT(SGPT) less than or equal to 1.5 times the upper limit of normal.\n",
      "        Patients with no evidence of clinically significant neuropathy.\n",
      "        Women of child-bearing potential and men must agree to use adequate contraception.\n",
      "        Patients must have the ability to understand and the willingness to sign a written\n",
      "        informed consent document.\n",
      "        Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the\n",
      "        study, or within 6 weeks of prior platinum therapy will be excluded.\n",
      "        Patients undergoing therapy with other investigational agents will be excluded.\n",
      "        Patients with known brain metastaseswill be excluded.\n",
      "        Patients with a history of an allergy to platinum compounds will be excluded.\n",
      "        Patients with uncontrolled intercurrent illness including but not limited to ongoing or\n",
      "        active infection, symptomatic congestive heart failure, or unstable angina pectoris, or\n",
      "        cardiac arrhythmia will be excluded.\n",
      "        Women must not be pregnant or nursing.\n",
      "        Patients must not be HIV-positive or receiving anti-retroviral therapy (HAART).\n",
      "        Patients actively receiving renal dialysis treatments while on the study will be excluded.\n",
      "1536\n",
      "Facial neuralgia, not explained by bone, soft tissue or mucosal lesions.\n",
      "        Experiencing daily moderate pain or daily paroxysms of pain unremitting for at least 3\n",
      "        months.\n",
      "        Previous trial of an antineuralgic medication.\n",
      "        Patients entering the study on other analgesic medications must either continue them as a\n",
      "        stable regimen throughout the study period or discontinue them 2 weeks prior to starting\n",
      "        the initial pain diary.\n",
      "        Adults aged 18 to 89.\n",
      "        Serum laboratory results obtained at study entry:\n",
      "        Liver function tests: ALT/AST less than 1.2 times upper limit of normal;\n",
      "        Creatinine less than 1.5 times upper limit of normal;\n",
      "        Negative serum betaHCG for women of childbearing age.\n",
      "        Adequate birth control (e.g., oral contraceptives, Norplant) for all women of\n",
      "        child-bearing age.\n",
      "        Sufficient cognitive function and English language skills to complete questionnaires and\n",
      "        communicate verbally with the nursing staff to permit titration of the study drugs.\n",
      "        No presence of a painful condition as severe as, but distinct from their orofacial pain\n",
      "        condition.\n",
      "        No pregnant or lactating women.\n",
      "        Patients must not have end-stage renal or hepatic disease.\n",
      "        Patients must not have moderate to severe heart disease (MI within preceding year,\n",
      "        unstable angina or congestive heart failure).\n",
      "        No signs or symptoms of any central neurologic disorder (including seizures).\n",
      "        No psychological/psychiatric disorder as identified by a pre-study entry psychiatric\n",
      "        assessment.\n",
      "        Patients must not have hypersensitivity or intolerance to dextromethorphan, topiramate or\n",
      "        the active placebo.\n",
      "        No chronic substance abuse, including alcoholism.\n",
      "        Patients must have a primary physician.\n",
      "        Subjects must not have received an experimental drug or used and experimental device\n",
      "        within 30 days.\n",
      "1538\n",
      "Patients of either gender, aged 18-75 years, with HCM caused by sarcomeric gene mutations\n",
      "        determined by existing protocols.\n",
      "        LV wall thickness of greater than or equal to 20 mm measured in any LV segment by MRI.\n",
      "        Severe symptoms refractory to medical treatment (New York Heart Association functional\n",
      "        class III or IV).\n",
      "        No LV outflow tract obstruction at rest greater than 30 mm Hg as determined by cardiac\n",
      "        catheterization.\n",
      "        No coronary artery disease (greater than 50% arterial luminal narrowing of a major\n",
      "        epicardial vessel).\n",
      "        No chronic atrial fibrillation.\n",
      "        No bleeding disorder (PTT greater than 35 sec, pro time greater than 14 sec, platelet\n",
      "        count less than 154 k/mm(3).\n",
      "        No anemia (Hb less than 12.7 g/dl in males and less than 11.0 g/dl in females).\n",
      "        No renal impairment (serum creatinine greater than 1.3 mg/dl).\n",
      "        No hepatitis B or C; nor unexplained abnormal LFTs.\n",
      "        No inability to estimate LV wall thickness.\n",
      "        No positive urine pregnancy test.\n",
      "        No pregnant or lactating female patients.\n",
      "        No concurrent use of immunosuppressives or steroids.\n",
      "        No diabetes mellitus.\n",
      "        No history of malignancy other than skin tumors (squamous and basal cell) in the last 5\n",
      "        years.\n",
      "        No condition that excludes the patient from undergoing an MRI test.\n",
      "1544\n",
      "Diagnosis of Wegener's granulomatosis based on clinical characteristics and\n",
      "        histopathological and/or angiographic evidence of vasculitis or the presence of\n",
      "        glomerulonephritis and a positive assay for anti-neutrophil cytoplasmic autoantibodies\n",
      "        (ANCA).\n",
      "        Age between 18 to 65 years.\n",
      "        No change in immunosuppressive drug therapy during the prior 4 weeks and one of the\n",
      "        following:\n",
      "        Persistent disease activity (\"Vasculitis Activity Index\" score of greater than or equal to\n",
      "        3) despite optimal therapy;\n",
      "        Persistent or recurrent disease activity in a patient who cannot tolerate optimal therapy;\n",
      "        Patients not on maximal immunosuppressive therapy but with persistent or recurrent disease\n",
      "        activity that is not, in the judgment of investigators, immediately threatening the\n",
      "        function of a major organ system;\n",
      "        No evidence of active infection.\n",
      "        Patients may not be pregnant or nursing infants. Fertile women must have a negative\n",
      "        pregnancy test within one week prior to study entry and all participants must be using\n",
      "        effective means of birth control.\n",
      "        Serum creatinine is less than 3.5 mg/dL.\n",
      "        Hemocytopenia (platelet count is greater than 100,000/mm(3), leukocyte count is greater\n",
      "        than 3,500/mm(s), hemoglobin is greater than 9 mg/dL).\n",
      "        Liver function test abnormalities is less than 3x upper limits of normal (either serum\n",
      "        GOT, GPT, alkaline phosphatase, and/or bilirubin).\n",
      "        Patients cannot be anti-HIV, anti-HCV, or anti-Hepatitis B surface antigen (HBsAG)\n",
      "        positive.\n",
      "        Weight greater less than 104 Kg (because of SCH 52000 concentration and volume limitations\n",
      "        for subcutaneous injection).\n",
      "        No treatment with any investigational drug within 30 days.\n",
      "        No pre-existing malignancy.\n",
      "        No known allergy to E. coli protein or IL-10.\n",
      "        No history of psychiatric illness that in the opinion of the principal investigator would\n",
      "        preclude entrance into the study.\n",
      "1555\n",
      "Males or (non-pregnant) females must be at least 18 Years of age.\n",
      "        Subjects must have one of the following systemic or invasive fungal infections at\n",
      "        baseline: (1) systemic or invasive infection due to a fungal pathogen for which there is\n",
      "        no currently licensed treatment; (2) systemic or invasive fungal infection, with evidence\n",
      "        of failure and/or intolerance/toxicity to treatment with approved systemic antifungal\n",
      "        agents. Definition of failure to treatment with approved systemic antifungal agents: a)\n",
      "        for invasive aspergillosis and other invasive fungal infections: lack of clinical response\n",
      "        after at least 7 days of systemic antifungal treatment at adequate doses; or b) for\n",
      "        Candida esophagitis only: lack of clinical response after at least 14 days of fluconazole\n",
      "        at a dose of greater than or equal to 200 mg/day. Definition of intolerance/toxicity to\n",
      "        treatment with approved systemic antifungal agents: a) intolerance to the infusion-related\n",
      "        toxicities of amphotericin B preparations despite appropriate supportive therapy; b)\n",
      "        nephrotoxicity defined as a serum creatinine that had increased by greater than or equal\n",
      "        to 1.5 mg/dl while receiving amphotericin B therapy or c) preexisting renal impairment\n",
      "        defined as a serum creatinine that increased to greater than or equal to 2.0 mg/dl due to\n",
      "        reasons other than amphotericin B.\n",
      "        The systemic or invasive fungal infection must be present at baseline and documented\n",
      "        within four weeks preceding study entry as follows: (1) positive histopathology with\n",
      "        evidence of tissue invasion by fungal elements, or (2) positive serology where diagnostic\n",
      "        (CSF cryptococcal antigen; serum or CSF Coccidioides antibody; serum, CSF or urine\n",
      "        Histoplasma antigen), or (3) positive mycologic culture from a normally sterile site,\n",
      "        taken during the current episode of infection.\n",
      "        Women of child bearing potential (or less than 2 years post-menopausal) must have a\n",
      "        negative serum pregnancy test at baseline, and must agree to use barrier methods of\n",
      "        contraception during the study.\n",
      "        Medical history must be obtained at baseline.\n",
      "        Signed written informed consent must be obtained at baseline.\n",
      "        Subjects must not have previously participated in this trial.\n",
      "        Subjects must not be taking and are unable to discontinue the following drugs at least 24\n",
      "        hours prior to randomization: terfenadine, cisapride, astemizole, and sulphonylureas.\n",
      "        Subjects must not have received any of the following drugs within 14 days prior to\n",
      "        randomization: rifampin, carbamazepine, and barbiturates as these are potent inducers of\n",
      "        hepatic enzymes and will result in undetectable levels of voriconazole.\n",
      "        Subjects must not have the following abnormalities of liver function tests (LFT's): AST,\n",
      "        ALT greater than 5 times upper limit normal; alkaline phosphatase, total bilirubin greater\n",
      "        than 5 times upper limit normal.\n",
      "        Subjects must not have a serum creatinine greater than 3.5 mg/dl or end-stage renal\n",
      "        disease requiring chronic dialysis.\n",
      "        Subjects must not have allergic bronchopulmonary aspergillosis, aspergilloma, zygomycoses,\n",
      "        candiduria, and/or catheter- or device-related candidemia.\n",
      "        Subjects must not have fungal infections which are not considered to be invasive or\n",
      "        systemic including dermatophytosis and oropharyngeal candidiasis.\n",
      "        Subjects must not be receiving or are likely to receive any investigational drug (any\n",
      "        unlicensed new chemical entity), except one of the following classes of medications:\n",
      "        Cancer chemotherapeutic agents, antiretrovirals, therapies for HIV/AIDS-related\n",
      "        opportunistic infections.\n",
      "        Subjects must not be receiving or are likely to receive the following medications or\n",
      "        treatments during the study period: G-CSF or GM-CSF (for other than treatment of\n",
      "        granulocytopenia), any systemic antifungal medication or white blood cell transfusions.\n",
      "        Subjects must not have a history of hypersensitivity or intolerance to azole antifungal\n",
      "        agents including miconazole, ketoconazole, fluconazole, or itraconazole.\n",
      "        Subjects must not have a life expectancy of less than 72 hours.\n",
      "        Subjects must not have any condition which, in the opinion of the investigator, could\n",
      "        affect subject safety, preclude evaluation of response, or render it unlikely that the\n",
      "        contemplated course of therapy can be completed.\n",
      "1561\n",
      "INCLUSION\n",
      "        Adults (greater than 18 years) infected with HIV-1.\n",
      "        Plasma viral burden greater than 500 RNA copies/ml by bDNA method at screening visit while\n",
      "        receiving a protease inhibitor as a part of combination therapy.\n",
      "        Treatment with a protease inhibitor or inhibitor(s) for the preceding 20 weeks with no\n",
      "        protease inhibitor drug change or dose interruption for greater than 3 days in the most\n",
      "        recent 12 weeks.\n",
      "        Laboratory values at screen:\n",
      "        hemoglobin greater than 9 g/dl;\n",
      "        granulocyte count greater than 900 cells/microL;\n",
      "        platelet count greater than 80,000 cells/microL;\n",
      "        AST (SGOT) less than 151 U/L;\n",
      "        Creatine less than 2 mg/dL.\n",
      "        Willingness to avoid becoming pregnant or causing a pregnancy by use of effective methods\n",
      "        which include surgical sterilization and barrier methods such as condoms and/or\n",
      "        diaphragms. Hormonal methods of birth control are not acceptable unless barrier methods\n",
      "        are also used because drug interactions may render their concentrations subtherapeutic.\n",
      "        Willing and able to provide written informed consent.\n",
      "        Negative serum or urine pregnancy test on the day of enrollment.\n",
      "        No intolerance of ritonavir or nelfinavir.\n",
      "        EXCLUSION\n",
      "        Treatment with systemic corticosteroids at greater than physiologic replacement doses,\n",
      "        interleukins, interferons, radiation therapy or cytotoxic chemotherapeutic agents within\n",
      "        30 days of study drug administration or an anticipated need for radiation or chemotherapy\n",
      "        treatment within the next 48 weeks (with the exception of local treatment for Kaposi's\n",
      "        sarcoma).\n",
      "        Subjects suffering from serious medical conditions such as diabetes, congestive heart\n",
      "        failure, cardiomyopathy, or other cardiac dysfunction, which, in the opinion of the\n",
      "        investigator, would compromise the safety of the patient.\n",
      "        Current or anticipated therapy with other agents with documented activity against HIV-1 in\n",
      "        vitro (other than stable maintenance dosing of foscarnet begun prior to screening).\n",
      "        Prior exposure to abacavir, amprenavir or efavirenz.\n",
      "        Concomitant therapy at entry with corticosteroids in other than replacement doses,\n",
      "        chemotherapy, or investigational agents.\n",
      "        Active, untreated opportunistic infection or other major illness that would, in the\n",
      "        opinion of the investigator, increase the risk that adverse events might pose to the\n",
      "        patient or might render the patient too ill to return for study visits.\n",
      "        Lymphoma not diagnosed within 5 years of study enrollment.\n",
      "        Significant substance abuse or psychiatric illness that might interfere with assessment or\n",
      "        compliance.\n",
      "        Refusal to employ adequate means of birth control (non-hormonal methods); efavirenz is\n",
      "        potentially teratofenic and conception must be avoided.\n",
      "        Malabsorption or other gastrointestinal dysfunction which, in the opinion of the\n",
      "        investigator, might interfere with drug absorption or render the patient unable to take\n",
      "        oral medication.\n",
      "        History of serious rash (erythema multiforme or Stevens-Johnson syndrome) caused by\n",
      "        nevirapine or delavirdine.\n",
      "        Treatment with phenobarbital, rifampin, rifabutin, midazolam, astemizole, cisapride, or\n",
      "        triazolam unless subject is safely able to discontinue the drug(s) prior to receipt of\n",
      "        study medications.\n",
      "        Pregnancy or lactation.\n",
      "1575\n",
      "INCLUSION CRITERIA\n",
      "        The subjects in this study will be women who meet the following criteria:\n",
      "          1. history of mood and/or behavioral symptoms associated with hormone replacement\n",
      "             therapy;\n",
      "          2. age 40 to 65;\n",
      "          3. in good medical health.\n",
      "        \n",
      "1576\n",
      "Elevated serum ornithine level greater than or equal to 200 micro M, as measured by the\n",
      "        median of three values obtained monthly for two months prior to the screening visit and at\n",
      "        the screening visit.\n",
      "        Absence of OAT activity measured by western blot analysis and isolated enzyme activity in\n",
      "        skin biopsy samples.\n",
      "        Fundus findings indicative of gyrate atrophy as characterized by sharply demarcated\n",
      "        circular patches of chorioretinal atrophy.\n",
      "        Must be at least 18 years of age.\n",
      "        Female patients of child bearing potential must have a pregnancy test done, which\n",
      "        demonstrates a negative result and must agree to practice effective birth control for 12\n",
      "        months following study initiation, or until patch removal, whichever comes first.\n",
      "        Must sign and date the informed consent and is willing and able to follow study\n",
      "        procedures.\n",
      "        Patients demonstrates progression of ocular disease due to grate atrophy evidenced by\n",
      "        reduction in electrophysiologic testing, visual field testing or progression of retinal\n",
      "        findings.\n",
      "        Patient has been offered an arginine-restricted diet and is unable to attain ornithine\n",
      "        levels less than 200 micro M prior to patch placement.\n",
      "        Patient has previously undergone a skin biopsy.\n",
      "        Not currently participating in other experimental protocols or therapeutic trials.\n",
      "        Does not have a known malignancy or chronic infection yielding immunoincompetence.\n",
      "        Patient must be able to maintain follow-up and follow details of the protocol.\n",
      "1577\n",
      "Must give written informed consent prior to any testing under this protocol.\n",
      "        Must be 18 years or older, inclusive, at the time of informed consent.\n",
      "        Must have a renal biopsy showing active WHO Class III, IV, or mixed membranous and\n",
      "        proliferative SLE GN, within the 5 years prior to the first dose of study drug.\n",
      "        Must have proteinuria of greater than or equal to 1.0 g/day at both the Day-27 and day-13\n",
      "        evaluations.\n",
      "        Must fulfill any one the following four criteria, at each of the two screening visits\n",
      "        (i.e., Day-27 and Day-13):\n",
      "        Anti-dsDNA antibody greater than 2x the upper limit of normal (ULN).\n",
      "        C3 complement less than 80 mg/dL.\n",
      "        Hematuria greater than 5 rbc/hpf.\n",
      "        Urinary granular or red blood cell casts.\n",
      "        Must not have any medical disorder, which in the opinion of the investigator, should\n",
      "        exclude the subject from this study.\n",
      "        Must not have prior arterial or venous thrombosis, or history of recurrent abortion (3 or\n",
      "        more), in the presence of anti-cardiolipin antibodies.\n",
      "        Must not have a chest x-ray with evidence of active infection or neoplasm within the 6\n",
      "        months prior to the first dose of study drug.\n",
      "        Must not have rapidly progressive glomerulonephritis, defined as a doubling of serum\n",
      "        creatinine, within the 3 months prior to the first dose of study drug.\n",
      "        Must not have fibrinoid necrosis and/or cellular crescents affecting more than 25 percent\n",
      "        of glomeruli in any renal biopsy performed within the 3 months prior to the first dose of\n",
      "        study drug.\n",
      "        Must not have clinically significant findings for any of the following within the 4 weeks\n",
      "        prior to the first dose of study drug: active psychiatric disease, serum creatinine\n",
      "        greater than 2.0 mg/dL, prothrombin time (PT) greater than 1.3x control (in the absence of\n",
      "        coumadin therapy; abnormal PT values due to anti-coagulation therapy are allowed if within\n",
      "        the therapeutic range), AST or ALT levels greater than 3x normal, other major organ\n",
      "        dysfunction, or serious local or systemic infection (e.g., pneumonia, septicemia).\n",
      "        Must not be positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HVC\n",
      "        Ab), or HIV antibody at the Day-27 evaluation.\n",
      "        Must not have a mean CD4 count less than or equal to 300 microliters (mean of Day-27 and\n",
      "        Day-13 results).\n",
      "        Must not have treatment with an antibody or other investigational drug within the 3 months\n",
      "        prior to the first dose of the study drug.\n",
      "        Must not have any vaccination within the 4 weeks prior to the first dose of the study\n",
      "        drug.\n",
      "        Must not have treatment with IV or oral cyclophosphamide within the 4 weeks prior to the\n",
      "        first dose of the study drug.\n",
      "        Must not have treatment with any of the following medications within the 4 weeks prior to\n",
      "        the first dose of study drug: IV methylprednisolone, cyclosporine or related compound, or\n",
      "        oral prednisone (equivalent oral glucocorticoid) at a dose greater than 0.5 mg/kg/day.\n",
      "        Must not have initiation of treatment with ACE inhibitors within the 4 weeks prior to the\n",
      "        first dose of study drug.\n",
      "        Must not have initiation of treatment with azathioprine, methotrexate or mycophenolate\n",
      "        mofetil within the 4 weeks prior to the first dose of study drug.\n",
      "        Must not have treatment with any new oral or new IV antibiotic within the 2 weeks prior to\n",
      "        the first dose of study drug. Subjects on prophylactic antibiotics are permitted to\n",
      "        continue these during the study.\n",
      "        Female subjects, unless post-menopausal or surgically sterile, must use an adequate method\n",
      "        of contraception.\n",
      "        Women must not be currently breast-feeding.\n",
      "        Must not have a positive pregnancy test in any evaluation prior to the first dose of study\n",
      "        drug.\n",
      "        Must not be currently enrolled in any other study in which the subject is receiving any\n",
      "        type of drug or non-drug therapy.\n",
      "        Must not have been previously dosed with BG9588.\n",
      "1578\n",
      "Any subject suspected of having a stroke based on the NIH Stroke Scale and age 21 years or\n",
      "        over.\n",
      "        Subjects will be enrolled into this protocol only if they are determined intellectually\n",
      "        capable of providing their own informed consent.\n",
      "        No subjects will be included if they have a condition which would preclude their entry\n",
      "        into the scanner (e.g., paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.) or\n",
      "        present unnecessary risks (e.g., surgery of uncertain type, symptoms of pheochromocytoma\n",
      "        or insulinoma, etc.).\n",
      "        No women who are pregnant or lactating.\n",
      "        No subjects with hemoglobinopathies and asthma.\n",
      "        No subjects with renal or hepatic disease.\n",
      "        No subjects who have a contraindication to MR scanning such as surgery that involves metal\n",
      "        clips or wires which might be expected to concentrate radiofrequency fields or cause\n",
      "        tissue damage from twisting in a magnetic field (e.g., aneurysm clip, implanted neural\n",
      "        stimulator, implanted cardiac pacemaker or autodefibrillator, cochlear implant, ocular\n",
      "        foreign body and mechanical pump).\n",
      "1580\n",
      "Documented HIV infection (ELISA and Western blot positive).\n",
      "        18 years or older.\n",
      "        Clinically stable enough to travel to NIH and meet protocol schedule requirements.\n",
      "        Negative urine or serum pregnancy test within 14 days prior to study entry (for women of\n",
      "        childbearing potential).\n",
      "        Patients should be receiving a combination of FDA approved antiretroviral drugs or\n",
      "        expanded access antiretroviral therapy for at least two weeks prior to study entry. The\n",
      "        exception would be that, in the opinion of the primary treating physician, this therapy\n",
      "        would not likely provide benefit.\n",
      "        Greater than or equal to 1 positive blood culture or 1 positive culture from a normally\n",
      "        sterile site (e.g. lymph node, bone marrow, etc.) for MAC within 6 weeks of study. The\n",
      "        initial screening blood culture at the NIH must be positive.\n",
      "        The following lab values must be present at study entry:\n",
      "        Transaminases, alkaline phosphatase, total bilirubin less than or equal to 5x upper limit\n",
      "        of normal range.\n",
      "        Serum creatinine less than or equal to 2.0 mg/ml.\n",
      "        Proteinuria less than or equal to positive 1.\n",
      "        Normal PT/PTT.\n",
      "        Granulocyte count greater than or equal to 750/cubic millimeter.\n",
      "        Hemoglobin greater than or equal to 8 gm/dL and platelet count greater than or equal to\n",
      "        75,000.\n",
      "        Fasting Blood glucose 1.25x upper normal limit (126 g/dl). (In persons with no history of\n",
      "        diabetes.)\n",
      "        No malignancy other than Kaposi sarcoma. Patients with Kaposi sarcoma are eligible, but\n",
      "        must not have received systemic therapy for KS.\n",
      "        No current life threatening AIDS related opportunistic infection other than disseminated\n",
      "        MAC.\n",
      "        No evidence of active substance abuse according to the standard 8th floor clinic substance\n",
      "        abuse assessment, which allows enrollment at the discretion of the principal investigator.\n",
      "        No patients exhibiting psychiatric disturbance or illness, which in the assessment of the\n",
      "        protocol team may affect patient safety or compliance.\n",
      "        No significant cardiac, gastrointestinal, pulmonary, autoimmune, renal, or CNS disease\n",
      "        which could interfere with patient safety.\n",
      "        No hypertension requiring anti-hypertensive therapy.\n",
      "        No pregnant or lactating patients, or any patient with an inability or unwillingness to\n",
      "        use effective contraception.\n",
      "        Willingness to comply with current NIH Clinical Center guidelines concerning appropriate\n",
      "        notification by an individual of current or ongoing sexual partners and/or needle-sharing\n",
      "        partners regarding his or her HIV seropositivity and the risk of transmission of HIV\n",
      "        infection.\n",
      "1584\n",
      "-  INCLUSION CRITERIA\n",
      "          -  Patients must have evaluable metastatic melanoma that is refractory to standard\n",
      "             therapy.\n",
      "          -  Age greater than or equal to 16 years.\n",
      "          -  Patients of both genders must be willing to practice birth control for four months\n",
      "             after receiving the preparative regimen.\n",
      "          -  Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1 at\n",
      "             entry to the trial and at the time of chemotherapy induction.\n",
      "          -  Absolute neutrophil count greater than 1000/mm^3.\n",
      "          -  Platelet count greater than 100,000/mm^3.\n",
      "          -  Hemoglobin greater than 8.0 g/dl.\n",
      "          -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than two\n",
      "             times the upper limit of normal.\n",
      "          -  Serum creatinine less than or equal to 1.6 mg/dl.\n",
      "          -  Total bilirubin less than or equal to 1.6 mg/dl, except for patients with Gilbert's\n",
      "             Syndrome who must have a total bilirubin less than 3.0 mg/dl.\n",
      "          -  More than four weeks must have elapsed since any prior therapy at the time the\n",
      "             patient receives the preparative regimen.\n",
      "          -  Women of child-bearing potential must have a negative pregnancy test because of the\n",
      "             potentially dangerous effects of the preparative chemotherapy on the fetus.\n",
      "          -  Life expectancy of greater than three months.\n",
      "          -  No steroid therapy required.\n",
      "          -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental\n",
      "             treatment being evaluated in this protocol depends on an intact immune system.\n",
      "             Patients who are HIV seropositive can have decreased immune competence and thus be\n",
      "             less responsive to the experimental treatment and more susceptible to its\n",
      "             toxicities.)\n",
      "          -  Seronegative for hepatitis B antigen.\n",
      "          -  Patients to receive high dose interleukin 2 (IL-2) must have no active systemic\n",
      "             infections, coagulation disorders or other major medical illnesses of the\n",
      "             cardiovascular, respiratory or immune system.\n",
      "          -  Patients who will receive high dose IL-2 as part of the phase I portion of this study\n",
      "             or who will be randomized must be eligible to receive high dose IL-2.\n",
      "          -  Any patient receiving IL-2 must sign a durable power of attorney.\n",
      "1600\n",
      "Patients must be HIV seropositive man or women of at least 18 years of age who are\n",
      "        enrolled in the NIAID clinical trial, \"Immunologic and virologic studies of intermittent\n",
      "        versus continuous HAART in the treatment of HIV disease\".\n",
      "        Patients must be able to read and understand standard English.\n",
      "1615\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients will be between 18 and 65 years of age, male or female, and must be at least 5\n",
      "        feet in height.\n",
      "        The diagnosis of asthma requires a history of intermittent, reversible expiratory flow\n",
      "        limitation.\n",
      "        Patients will have mild-to-moderate allergic asthma as defined by a baseline forced\n",
      "        expiratory flow in one second (FEV(1)) greater than 70% of predicted (at least 6 hours\n",
      "        after bronchodilator use) and therapy limited to inhaled beta-agonists.\n",
      "        Patients must be without evidence of an asthma exacerbation or a viral upper respiratory\n",
      "        tract infection for 6 weeks prior to entry into the study.\n",
      "        Positive skin prick-puncture test to one or more common aeroallergens.\n",
      "        A positive inhaled methacholine challenge as defined by a decrease in FEV(1) of at least\n",
      "        20% (PC20) in response to inhalation of less than 25 mg/ml of methacholine.\n",
      "        A decrease in FEV(1) of at least 20% in response to inhalation of up to 10,000\n",
      "        bioequivalency allergy units (BAU) or allergy units (AU) per ml of a selected common\n",
      "        aeroallergen (house dust mite, cat hair or grasses) or up to 150 Antigen E units per ml of\n",
      "        short ragweed. Asthmatic patients must also demonstrate a late asthmatic response (defined\n",
      "        as a 20% fall from the baseline established following completion of the early asthmatic\n",
      "        response).\n",
      "        Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels\n",
      "        (less than 30 ml of blood will be drawn), normal EKG and chest radiograph without acute\n",
      "        pulmonary infiltrates.\n",
      "        For women of childbearing potential, negative pregnancy test with 2 weeks prior to study\n",
      "        and willingness to adhere to reliable birth control methods during the study.\n",
      "        \n",
      "1618\n",
      "-  INCLUSION CRITERIA:\n",
      "        CHILDREN WITH A HISTORY OF PORENCEPHALY OR STROKE:\n",
      "          1. Children less than 18 years of age with a history of porencephaly or cerebral\n",
      "             infarction (stroke).\n",
      "          2. Children less than 18 years of age with a history of spastic hemiplegic or\n",
      "             quadriplegic cerebral palsy (ICD-9 codes 343.1, 343.2, 343.3, 343.4, 343.8 and 343.9)\n",
      "             with radiographic evidence of porencephaly or stroke.\n",
      "          3. A diagnosis of porencephaly as defined by a fluid-filled cavity within the cerebral\n",
      "             hemispheres which may or may not communicate with CSF spaces and confirmed by at\n",
      "             least one imaging method including computed tomography (CT), magnetic resonance (MR)\n",
      "             and or Doppler ultrasonography.\n",
      "          4. A diagnosis of cerebral infarction (stroke) as defined by a new focal neurologic\n",
      "             deficit lasting greater than or equal to 24 hours and presumably due to a vascular\n",
      "             process (ICD-9 codes 430-437) and confirmed by brain imaging, either computed\n",
      "             tomography (CT), magnetic resonance (MR) or Doppler ultrasonography.\n",
      "          5. Informed consent of the parent.\n",
      "          6. Informed assent of the child, when available.\n",
      "        FIRST-DEGREE RELATIVES OF CHILDREN WITH PORENCEPHALY OR STROKE:\n",
      "          1. Full biological first-degree relatives of children with a history of porencephaly or\n",
      "             stroke enrolled in this study.\n",
      "          2. Informed consent of each participant.\n",
      "          3. Informed assent of each participant under 18 years, when available.\n",
      "        HEALTHY CHILDREN:\n",
      "          1. Children less than 18 years of age.\n",
      "          2. Informed consent of the parent.\n",
      "          3. Informed assent of the child when available.\n",
      "        HEALTHY MOTHERS:\n",
      "          1. Women between 18 and 45 years of age.\n",
      "          2. History of full-term pregnancy.\n",
      "          3. Informed consent of the participant.\n",
      "        \n",
      "1619\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Any medication with the exception of other investigational drugs not available under\n",
      "             a treatment IND, expanded access, or parallel track program.\n",
      "        Patients must have:\n",
      "          -  Confirmed HIV infection.\n",
      "          -  CD4 cell counts <= 200 cells/mm3.\n",
      "          -  No evidence of disseminated MAC disease.\n",
      "          -  Informed consent of parent or guardian if 12 to < 18 years of age.\n",
      "        NOTE:\n",
      "          -  Pregnant females may be eligible. There are no studies of the safety or efficacy of\n",
      "             rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the\n",
      "             potential benefit justifies the potential risk to the fetus. In addition, a\n",
      "             risk/benefit decision should consider the likelihood of a woman's developing MAC if\n",
      "             she does not receive prophylaxis. The risk of developing MAC rises substantially for\n",
      "             women with CD4 counts less than 100, although it can also develop in women with\n",
      "             higher CD4 counts. Women of reproductive potential who are not pregnant must use\n",
      "             contraception. They are encouraged to use means other than oral contraceptives.\n",
      "        \n",
      "1624\n",
      "Severe disseminated or pulmonary nontuberculous mycobacterial infection refractory to the\n",
      "        best tolerated conventional therapy in addition to IFN gamma delivered for at least 3\n",
      "        months. This infection must have been proven by culture at some point during the illness.\n",
      "        At the time of enrollment, patients will be eligible if they have negative cultures but\n",
      "        histopathologic, examinable, or radiographic evidence of ongoing infection.\n",
      "        In vitro responsiveness to IL-12 as demonstrated by augmentation of peripheral blood\n",
      "        mononuclear cell (PBMC) phytohemagglutinin (PHA) induced IFN gamma production.\n",
      "        Women of childbearing age must have a negative pregnancy test (urine or serum) at the time\n",
      "        of starting the study and agree to take measures to avoid pregnancy throughout the study\n",
      "        while receiving IL-12. Males will be advised that the effects of IL-12 on sperm are not\n",
      "        well-known, and they should avoid conception during the study period.\n",
      "        Age 18 years or over.\n",
      "        Adequate hematopoietic, renal and hepatic function, defined as:\n",
      "        Absolute neutrophil count greater than or equal to 1000/microL (G-CSF permitted);\n",
      "        Hemoglobin greater than or equal to 9 g/dl (transfusion or erythropoietin permitted);\n",
      "        Platelet count greater than or equal to 100,000/microL;\n",
      "        Creatinine less than or equal to 1.5 X upper limit of normal;\n",
      "        Bilirubin less than or equal to 1.5 X upper limit of normal;\n",
      "        AST/SGOT less than or equal to 2.5 X upper limit of normal;\n",
      "        ALT/SGPT less than or equal to 2.5 X upper limit of normal;\n",
      "        Calculated Creatinine Clearance greater than 60 mL/min.\n",
      "        Karnofsky Performance Status index greater than or equal to 70.\n",
      "        Written signed informed consent.\n",
      "        No HIV infection.\n",
      "        No active malignancy.\n",
      "        No symptomatic cardiac disease or ongoing treatment for same.\n",
      "        No active seizure disorder or ongoing treatment for same.\n",
      "        No pregnancy or lactation.\n",
      "        No surgery during the two weeks prior to the start of IL-12.\n",
      "        No concurrent use of systematic corticosteroids, except for physiologic replacement.\n",
      "        No exposure to any investigational drug within four weeks prior to the start of dosing.\n",
      "        No gastrointestinal bleeding or uncontrolled peptic ulcer disease.\n",
      "        No history of inflammatory bowel disease or autoimmune disease such as rheumatoid\n",
      "        arthritis or systemic lupus erythematosus.\n",
      "        No other major illness which, in the investigator's judgement, will substantially increase\n",
      "        the risk associated with the patient's participation in this study.\n",
      "1629\n",
      "All patients will have parkinsonism of undetermined etiology.\n",
      "        Males and females between the ages of 18 and 85 are eligible for the study.\n",
      "        No presence or history of any medical condition that can reasonably be expected to subject\n",
      "        the patient to unwarranted risks, specifically those who have the following: a history of\n",
      "        convulsive, hepatic, or renal disorders; currently receiving treatment for myocardial\n",
      "        infarction, arrhythmia or cardiac failure; and pregnant women or anyone not practicing an\n",
      "        effective means of birth control.\n",
      "1647\n",
      "Patients must be between 18 and 65 years of age.\n",
      "        Patients must have amputations and phantom pain for at least 12 months.\n",
      "        Patient's pain should be at least moderate and be present at least 8 hours per day or\n",
      "        severe lasting for at least 2 hours per day.\n",
      "        Patients must not have had a previous stroke or brain lesions.\n",
      "        Patients must not have severe depression, poor motivational capacity.\n",
      "        Patients must not have serious cognitive deficits (defined as equivalent to a mini-mental\n",
      "        state exam score of 20 or less).\n",
      "        Patients must not have severe uncontrolled medical problems (e.g. cardiovascular disease,\n",
      "        any kind of end-stage pulmonary or cardiovascular disease, or epilepsy).\n",
      "        Patients must not have a personal history of seizures or other neurological disorders.\n",
      "        Women must not be pregnant.\n",
      "        Patients must not have severe coronary disease.\n",
      "        Patients must not have metal in the cranium except mouth.\n",
      "        Patients must not have intracardiac lines.\n",
      "        Patients must not have increased intracranial pressure as evaluated by clinical means.\n",
      "        Patients must not have cardiac pacemakers.\n",
      "        Patients must not be taking neuroleptics.\n",
      "1652\n",
      "INCLUSION CRITERIA:\n",
      "        Documentation of HIV-1 infection by licensed ELISA test kit and confirmed by a second\n",
      "        method (e.g. Western Blot).\n",
      "        Absolute CD4+ T-cell count of greater than or equal to 300/mm(3) within 30 days before\n",
      "        randomization (For patients who are status post-splenectomy, also CD4+ T-cell greater than\n",
      "        20%). For patients in cohort 2, the lowest documented CD4+ T-cell count must be greater\n",
      "        than or equal to 200 cells/mm(3).\n",
      "        Receiving HAART (at least 2 NRTIs and an NNRTI or a PI) with at least 1 viral load test\n",
      "        below the limit of detection (at least less than 500 copies/ml) greater than or equal to 3\n",
      "        months for cohort 1 and 4 and greater than or equal to 6 months for cohorts 2, 3 and 5\n",
      "        before screening.\n",
      "        A confirmatory viral load of less than 50 copies/ml prior to enrollment.\n",
      "        Age at least 18 years.\n",
      "        For women of childbearing potential, a negative pregnancy test (serum or urine) is\n",
      "        required within 14 days prior to randomization.\n",
      "        Laboratory values (within 30 days prior to randomization):\n",
      "        AST no more than 5 times the upper limit of normal (ULN);\n",
      "        Total or direct bilirubin no more than 2 times the ULN unless there is a pattern\n",
      "        consistent with Gilbert's syndrome or the patient is receiving indinavir;\n",
      "        Creatinine no more than 2.0 mg/dL;\n",
      "        Platelet count at least 50,000 microliters.\n",
      "        Willingness to provide blood samples for storage that may be used in future studies of HIV\n",
      "        infection and/or immunopathogenesis.\n",
      "        \n",
      "1664\n",
      "Female patients with primary affective disorder (major depression n=17).\n",
      "        Controls must not have psychiatric disorders.\n",
      "        Subjects with past or current depression will be studied if bone mineral density in any\n",
      "        site in either hip or spine was assessed by DEXA scan to be equal to or greater than 1 1/2\n",
      "        standard deviation below peak bone density.\n",
      "        Subjects with psychiatric illness can either be drug free or receiving any FDA approved\n",
      "        medication for the treatment of depression, with the exception of valproic acid and\n",
      "        carbamazepine, which are known to interfere with intestinal calcium absorption (and hence,\n",
      "        can influence bone mineral density), and monoamine oxidase inhibitors, which can interact\n",
      "        adversely with fentanyl in the event that it would be given for relief of pain.\n",
      "        During the course of the entire study all subjects must abstain from tobacco and alcohol\n",
      "        and will be instructed to inform the physicians conducting the research about their use of\n",
      "        prescription or non-prescription medication, including birth control pills.\n",
      "        Must not have any serious medical illnesses.\n",
      "        Must not have current or past, prolonged steroid use.\n",
      "        Must not be pregnant.\n",
      "        Must not be on anticoagulant medication.\n",
      "        Must not be allergic to or have shown adverse reactions to tetracyline, benzodiazepines,\n",
      "        fentanyl, or lidocaine.\n",
      "        Must not have used aspirin or other non-steroidal anti-inflammatory agents in the past\n",
      "        week.\n",
      "1674\n",
      "Male or female patients that are 10 years of age or older up to 80 years of age are\n",
      "        included.\n",
      "        Patients must be enrolled in a protocol at the NIH Clinical Center that will result in the\n",
      "        patient receiving an allogeneic stem cell transplant (A-HSCT).\n",
      "        Patients who have not yet received a pre-transplant chemotherapy and radiation therapy\n",
      "        conditioning regimen are eligible.\n",
      "        Patients must not have a negative IgG serologic test for CMV and whose hematopoietic stem\n",
      "        cell donor also has a negative IgG serologic test as reported by the Bone Marrow\n",
      "        Transplant staff.\n",
      "        Patients must not have documentation of prior cytomegalovirus antigenemia or disease prior\n",
      "        to starting the conditioning regimen.\n",
      "1690\n",
      "Male or female patients who are between the ages of 2 and 80 years.\n",
      "        Must be admitted to the Bone Marrow Transplant Unit for a bone marrow transplantation\n",
      "        (BMT), peripheral stem cell transplantation (PSCT) or mini-transplantation (MT).\n",
      "        Must be in the early phase of BMT, PSCT or MT, i.e., receiving conditioning therapy for\n",
      "        the transplant or within the first 30 days of receiving a bone marrow graft or;\n",
      "        Must be greater than 30 days post-engraftment but being treated for Graft vs. Host disease\n",
      "        (GVHD) with a total dose of equal to or greater than 1.5 grams/m(2) of methylprednisolone\n",
      "        (or equivalent dose of steroids) over the first 3 days.\n",
      "        Must have a negative result (at 48 hours) for RSV in the screening respiratory viral\n",
      "        culture.\n",
      "        Less than 8 days have elapsed between meeting eligibility criteria, being contacted by one\n",
      "        of the investigators, and making a decision to join the study.\n",
      "        Patients with signs or symptoms of Upper Respiratory Tract infection or pneumonia will be\n",
      "        excluded until the etiology is established or RSV is ruled-out by the screening culture.\n",
      "        Patients will be excluded if they have any condition that, in the opinion of the\n",
      "        investigator, could affect their safety, preclude evaluation of response, or render\n",
      "        unlikely that the contemplated course of therapy can be completed.\n",
      "1692\n",
      "Patients with known or suspected coronary artery disease.\n",
      "        Adults 18 years of age or older.\n",
      "        No pre-menopausal patients who are lactating, pregnant or potentially pregnant as judged\n",
      "        by history, physical examination, ultrasound or urine pregnancy test.\n",
      "        No unstable angina patients.\n",
      "        No recent myocardial infarction patients (less than 1 month).\n",
      "        No frequent ectopy which precludes adequate image acquisition.\n",
      "        No history of asthma or chronic obstructive pulmonary disease.\n",
      "        No patients receiving aminophylline, theophylline or dipyridamole.\n",
      "        No presence of second and third degree heart block without pacemaker.\n",
      "        No significant hypertension (systolic blood pressure greater than 170 mm Hg) or\n",
      "        hypotension (systolic blood pressure less than 100 mm Hg).\n",
      "        No hypotension: basal sitting systolic arterial pressure less than 100 mm Hg confirmed 30\n",
      "        minutes later.\n",
      "        No sinus tachycardia greater than or equal to 100 beats per min.\n",
      "        No atrial fibrillation.\n",
      "        No inadequate two-dimensional echocardiographic windows.\n",
      "1694\n",
      "Patients with chronic hepatitis C.\n",
      "        Age 18 to 70 years, male or female.\n",
      "        HCV infection indicated by the presence of anti-HCV (by ELISA and recombinant immunoblot\n",
      "        assay [RIBA]).\n",
      "        Written informed consent.\n",
      "        Women must not be pregnant.\n",
      "        Patients must not have significant systemic illnesses other than liver disease, including\n",
      "        congestive heart failure, renal failure, uncontrolled diabetes mellitus.\n",
      "        Patients must not have antiviral or immunosuppressive therapy within the last 6 months.\n",
      "        Patients must not have HIV infection.\n",
      "        Patients must not have contraindications to liver biopsy (mainly clotting abnormality\n",
      "        (coumadin therapy, platelet count less than 50,000/cubic millimeter, prothrombin time more\n",
      "        than 4 seconds beyond control)).\n",
      "1698\n",
      "Men and women whose mandibular molars are either: intact, caries-free, and have no signs\n",
      "        or symptoms of pulpal disease or carious, symptomatic (to hot/cold and percussion), but\n",
      "        have no evidence of pulpal necrosis or infection. At least one intact caries-free\n",
      "        contralateral mandibular molar must be present.\n",
      "        Individuals should be healthy and over the age of 16.\n",
      "        No history of stomach ulcers, asthma, lung problems, or allergy to lidocaine, fentanyl or\n",
      "        any of the standard or test medications.\n",
      "        No body weight which is 30% greater or less than standard height-weight tables.\n",
      "        No pregnant or lactating females. Also, no females who are sexually active and will not\n",
      "        submit to a pregnancy test.\n",
      "        No history of taking any analgesics or antihistamines for 24 hr period prior to study.\n",
      "        No patients taking steroids or other anti-inflammatory drugs.\n",
      "        Willing to accept root canal treatment without parenteral sedation.\n",
      "        Willing to participate in data collection procedures.\n",
      "        No clinically significant medical history or signs of debilitation including patients with\n",
      "        heart, respiratory, renal, or liver dysfunction.\n",
      "        No history of personality disorder, alcohol abuse or drug abuse.\n",
      "        No chronic use of drugs which would confound assessment including barbituates,\n",
      "        anticonvulsants, tranquilizers, antiarrythmics, beta blockers, and antidepressants.\n",
      "        No patients whose mandibular molars are heavily restored (i.e., crowns, large fillings).\n",
      "        No hypersensitivity to drugs used (epinephrine, lidocaine, fentanyl).\n",
      "1699\n",
      "Female gender only, ages 18 to 75.\n",
      "        Patients should have documented primary Sjogren's syndrome as determined by protocol\n",
      "        84-D-0056. The diagnosis of primary Sjogren's syndrome will be based on the presence of\n",
      "        all three of the following:\n",
      "        Salivary gland abnormalities;\n",
      "        Lacrimal gland abnormalities;\n",
      "        Serologic abnormalities.\n",
      "        Controls should have no signs or symptoms of Sjogren's syndrome, and negative serologic\n",
      "        testing reconfirmed within 2 weeks of the OGTT.\n",
      "        Willingness to: a) participate in phase I and II of the protocol; b) follow the guidelines\n",
      "        set to prepare for the OGTT; and c) modify current medical therapy if necessary.\n",
      "        Must be able to comply with protocol procedures.\n",
      "        No patients with \"incomplete\" Sjogren's syndrome, i.e., with less than three positive\n",
      "        findings as described above.\n",
      "        No presence of physical or mental conditions that may interfere with the protocol. These\n",
      "        include the following diseases and conditions:\n",
      "        (Present at time of phase I/II): significant disruption of sleep-wake pattern (i.e., less\n",
      "        than 4 hours of continuous sleep, on the night before the OGTT only), BMI less than 18 or\n",
      "        equal to/greater than 30, anemia with Hgb less than 10 gm/dl, use of tobacco or alcohol;\n",
      "        (Within the past 6 weeks): acute weight change (greater than 5%), use of contraceptives\n",
      "        -BCP-, Depoprovera or Norplant), irregular menstrual cycle, lactation, blood drawing in\n",
      "        excess of 50 ml, use of recreational drugs, modification of estrogen replacement therapy;\n",
      "        (Within the past 6 months): chronic pattern of weight change (greater than 10%), eating\n",
      "        disorders, uncontrolled hypo/hyperthyroidism, breast cancer, lymphoma or other malignancy,\n",
      "        pregnancy, treatment for depression, insulinoma, VIPoma, pheochromocytoma, atrophic\n",
      "        gastritis, active tuberculosis or treatment for it;\n",
      "        (A history of): HIV+, sarcoidosis, secondary Sjogren's syndrome, bleeding diathesis, organ\n",
      "        transplant, severe neuroendocrine, renal, cardiovascular, pulmonary or gastrointestinal\n",
      "        disease (e.g., renal insufficiency, unstable angina, heart failure, severe emphysema,\n",
      "        Crohn's disease), diabetes mellitus, acromegaly and mental retardation.\n",
      "        No contraindications to OGTT. These include:\n",
      "        Hospital inpatient status, acute illness, immobilization, starvation, severe emotional\n",
      "        distress within one week of the OGTT;\n",
      "        Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT;\n",
      "        Pregnancy;\n",
      "        Therapy which impairs glucose tolerance: e.g., niacin, thiazide diuretics, phenytoin,\n",
      "        excess thyroxine or psychotropic drugs within 1 month of phase I, oral contraceptives\n",
      "        within 6 weeks of phase I, glucocorticoid treatment within the past 6 months (or one year\n",
      "        if treatment lasted over 2 weeks), Beta blockers/agonists (e.g., terbutaline) within 2\n",
      "        days of phase I;\n",
      "        Diabetes mellitus;\n",
      "        Glucose intolerance.\n",
      "        Subjects may not take medications that can affect somatostatin levels, such as\n",
      "        antidepressants, benzodiazepines, neuromodulators (e.g., cholinergic, alpha/beta\n",
      "        adrenergic), oral contraceptives (BCP), steroid hormones (with the exception of estrogen\n",
      "        replacement therapy -ERT-, for which subjects will be matched), immunomodulators,\n",
      "        anticonvulsants (e.g., carbamazepine), cimetidine -Tagamet® (Registered Trademark)-,\n",
      "        herbal remedies (because of their variable substance content). Subjects may not take drugs\n",
      "        affecting gastrin secretion: antacids (e.g., Maalox® (Registered Trademark), Mylanta®\n",
      "        (Registered Trademark), H(2) receptor antagonists (e.g., famotidine -Pepcid® (Registered\n",
      "        Trademark)-, ranitidine -Zantac® (Registered Trademark)-), cathecolamines, atropine,\n",
      "        haloperidol. To become eligible, subjects should be able to safely discontinue these\n",
      "        medications at least one month prior to phase I. Antacids, H(2) antagonists and\n",
      "        neuromodulators (e.g., Salagen) may be discontinued 2 days prior to phase I.\n",
      "        Patients cannot have take experimental drugs within 1 month of the beginning of the\n",
      "        protocol.\n",
      "1700\n",
      "Free of concomitant medications and must be willing to take hypericum for a period of two\n",
      "        weeks and a placebo for two weeks.\n",
      "        No subjects with a relevant Axis I or Axis II disorder.\n",
      "        No subjects with concomitant medical or neurological disorders which require ongoing\n",
      "        medication, or which may affect the central nervous system; or taking medication with\n",
      "        which St. John's wort may interact.\n",
      "        Must not be pregnant.\n",
      "        Must not be breastfeeding.\n",
      "        No subjects with a prior reaction to iodine, iodine compounds, or shellfish.\n",
      "        No subjects with a history of thyroid disease or dysfunction.\n",
      "        No subjects with a history of recent substance abuse.\n",
      "        No subjects with metal objects in their bodies.\n",
      "        No subjects with a prior adverse reaction to hypericum extracts.\n",
      "        No women who taking birth control pills.\n",
      "1703\n",
      "All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing.\n",
      "        Patients will have mild to moderate disease with associated significant chorea.\n",
      "        Ability to comply with study requirements and to report on their condition by telephone.\n",
      "        Males and females between the ages of 18 and 82.\n",
      "        No patients with the presence or history of any medical condition that can reasonably be\n",
      "        expected to subject the patient to unwarranted risk.\n",
      "        No patients with renal impairment (serum creatinine exceeding the upper limit of normal).\n",
      "        No patients with a history of intolerance to previous exposure to amantadine.\n",
      "        No patients with an MMSE of less than 18/30.\n",
      "        No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other\n",
      "        anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the\n",
      "        study to be eligible.\n",
      "        No pregnant women.\n",
      "        Patients must practice effective means of birth control.\n",
      "1704\n",
      "All patients will carry a diagnosis of Parkinson's Disease based on the presence of a\n",
      "        characteristic clinical history and neurological findings. Symptom severity will range\n",
      "        from Hoehn & Yahr stage II-IV.\n",
      "        Males and females between the ages 30-76 are eligible for the study.\n",
      "        Initial emphasis will be on patients who are taking few or no other medications than\n",
      "        levodopa for their Parkinson's disease.\n",
      "        No presence or history of any medical condition that can reasonably be expected to subject\n",
      "        the patient to unwarranted risk.\n",
      "        No patients with a history of significant cardiac (myocardial infarction within 12 months\n",
      "        prior to study, dysrhythmia; QTc intervals greater than 440 msec).\n",
      "        No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper\n",
      "        limit of normal values for LFT's and creatinine respectively).\n",
      "        No patients with evidence of other serious medical illness, a history of alcohol or drug\n",
      "        abuse, those who have participated in an investigational trial within 28 days prior to\n",
      "        study, and pregnant or nursing women or anyone not practicing effective means of birth\n",
      "        control.\n",
      "1705\n",
      "-  INCLUSION CRITERIA:\n",
      "             18 years of age or older. If children are evaluated they can be seen under the\n",
      "             general protocol and they may be entered into the present protocol under an\n",
      "             exception.\n",
      "        Likely diagnosis of inactive cysticercosis and present or past seizure activity. Requires\n",
      "        \"a\" and \"b\" plus any one of the remaining criteria:\n",
      "          1. History of seizures or present seizure activity;\n",
      "          2. Previously treated or has inactive disease and declines treatment;\n",
      "          3. Single calcified lesions and positive serology;\n",
      "          4. Multiple calcified lesions;\n",
      "          5. Multiple small enhancing nodular lesions;\n",
      "          6. History of cystic lesions responding to specific chemotherapy.\n",
      "        If female, not pregnant and using effective birth control methods.\n",
      "        \n",
      "1708\n",
      "Male or female patients greater than or equal to 21 years undergoing diagnostic cardiac\n",
      "        catheterization.\n",
      "        Must not have unstable angina.\n",
      "        No significant unprotected left main disease (greater than 50% stenosis).\n",
      "        No recent myocardial infarction (less than 4 weeks).\n",
      "        Females must not be pregnant or lactating.\n",
      "        No chronic atrial fibrillation.\n",
      "        No prosthetic heart valves.\n",
      "        No significant aortic valve pathology (sclerosis or stenosis) which might prevent\n",
      "        retrograde crossing of catheter across the aortic valve.\n",
      "        No left ventricular thrombus seen on echo.\n",
      "        No severe heart failure (NYHA Class 4).\n",
      "        No severe ectopy (greater than 1 every 10 beats) or ventricular tachycardia.\n",
      "        No active infections (fever and elevated white cell count).\n",
      "        Patients will not be considered for this protocol because of contraindications to MRI\n",
      "        scan, as stated below:\n",
      "        Pacemaker\n",
      "        Implanted defibrillator\n",
      "        Cerebral aneurysm clips\n",
      "        Swan Ganz catheter with electrodes for a thermistor\n",
      "        Cochlear implants\n",
      "        Insulin pumps\n",
      "        Neural stimulator\n",
      "1709\n",
      "All volunteer subjects must be between 21 and 75 years of age, in good health, and must\n",
      "        have provided informed, written consent for participation in this study.\n",
      "        No subjects with a history or evidence of present or past hypertension (blood pressure\n",
      "        greater than 145/95 mmHg), hypercholesterolemia (LDL cholesterol greater than 130 mg/dL),\n",
      "        diabetes mellitus (fasting blood glucose greater than 120 mg/dL), smoking within 2 years,\n",
      "        cardiac disease, peripheral vascular disease, coagulopathy, or any other disease\n",
      "        predisposing to vasculitis or Raynaud's phenomenon.\n",
      "        No volunteer subject will be allowed to take any medication (oral contraceptive agents are\n",
      "        allowed) or vitamin supplements for at least one month prior to study and will not be\n",
      "        allowed to take aspirin for one week prior to study.\n",
      "        Pregnancy testing will be required of all women of reproductive age to exclude current\n",
      "        pregnancy.\n",
      "1710\n",
      "All patients will carry a diagnosis of idiopathic Parkinson's Disease based on the\n",
      "        presence of a characteristic clinical history and neurologic findings. Most will have\n",
      "        relatively advanced disease with associated motor response complications.\n",
      "        Males and females between the ages of 18-75.\n",
      "        No presence or history of any medical condition that can reasonably be expected to subject\n",
      "        the patient to unwarranted risk.\n",
      "        No patients with baseline QTc prolongation (greater than 440 msec).\n",
      "        No pregnant women nor those not practicing effective means of birth control.\n",
      "1712\n",
      "Patients undergoing evaluation for CAD who show at least two myocardial segments with wall\n",
      "        motion abnormalities on a baseline echocardiogram will be offered to participate in this\n",
      "        study.\n",
      "        Patients will be adults older than 21 years of age.\n",
      "        No pre-menopausal patients who are lactating, are pregnant or potentially pregnant as\n",
      "        judged by history, physical examination, ultrasound or urine pregnancy test.\n",
      "        No one with unstable angina.\n",
      "        No subjects with recent myocardial infarction (less than 1 month).\n",
      "        No one with frequent ectopy which precludes adequate imaging acquisition.\n",
      "        No subjects with significant hypertension (systolic blood pressure greater than 170 mm\n",
      "        Hg).\n",
      "        No hypotension with basal sitting systolic arterial pressure less than 100 mm HG confirmed\n",
      "        30 minutes later.\n",
      "        No subjects with sinus tachycardia greater than or equal to 100 beats/minute.\n",
      "        No atrial fibrillation.\n",
      "        No inadequate two-dimensional echocardiographic windows.\n",
      "1721\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients with karyotypically normal spontaneous premature ovarian failure (as defined by\n",
      "        screening protocol 91-CH-0127, i.e. women who have at least 4 months of amenorrhea, two\n",
      "        FSH levels above 40 mIU/ml, at least one month apart, and a normal 46, XX karotype,\n",
      "        diagnosed with premature ovarian failure prior to the age of 40) who are between the age\n",
      "        of 18 and 42 years will be candidates.\n",
      "        \n",
      "1725\n",
      "Adults (greater than 18 years) infected with HIV-1.\n",
      "        Plasma viral burden greater than 8,000 and less than 60,000 RNA copies per ml. by bDNA\n",
      "        method at screening.\n",
      "        CD4 cell count above 200 cells per microliter at screen.\n",
      "        No prior treatment with any anti-retroviral agent.\n",
      "        Laboratory values at screen: hemoglobin greater than 9 g per dl; granulocyte count greater\n",
      "        than 900 cells per microliter; platelet count greater than 80,000 cells per microliter;\n",
      "        AST (SGOT) less than 151 U/L; creatinine less than 2 mg/dL.\n",
      "        Must not be pregnant or breast-feeding and willing to avoid pregnancy by the use of\n",
      "        non-hormonal methods of birth control during study participation. Pregnancy test (blood or\n",
      "        urine) must be negative within two weeks prior to dosing with study medications.\n",
      "        Willing and able to provide written informed consent.\n",
      "        No history suggestive of malabsorption.\n",
      "        No chronic diarrhea.\n",
      "        Must not have had treatment with systemic corticosteroids at greater than physiologic\n",
      "        replacement doses, interleukins, interferons, radiation therapy or cytotoxic\n",
      "        chemotherapeutic agents within 30 days of study drug administration or an anticipated need\n",
      "        for radiation or chemotherapy treatment within the next 48 weeks (with the exception of\n",
      "        local treatment of Kaposi's sarcoma).\n",
      "        Must not have current or anticipated therapy with other agents with documented activity\n",
      "        against HIV-1 in vitro.\n",
      "        Must not have active, untreated opportunistic infection or other major illness that would,\n",
      "        in the opinion of the investigator, increase the risk that adverse events might pose to\n",
      "        the patient or might render the patient too ill to return for study visits.\n",
      "        Must not have significant substance abuse or psychiatric illness that might interfere with\n",
      "        assessment or compliance.\n",
      "        Must not have current or anticipated future need for any of the following drugs which are\n",
      "        contraindicated with an amprenavir-ritonavir regimen because of drug-drug interactions:\n",
      "        Terfenadine (Seldane), Astemizole (Hismanal), Cisapride (Propulsid), Triazolam (Halcion),\n",
      "        Bepridil (Vascor), Medazolam (Versed), Rifampin (Rifadin, Rifamate, Rifater),\n",
      "        Ergotamine/Dihydroergotamine containing regimens (Ergomar, Wygraine, Ercaf, DHE,\n",
      "        Migranal), Amiodarone (Cordarone), Flecanaide (Tambocor), Propafenone (Rythmol), Quinidine\n",
      "        (Quinaglute, Cardioquin), and Pimozide (Orap).\n",
      "        Must not have current or anticipated future need for the following anticonvulsants:\n",
      "        phenobarbital, phenytoin, carbamazepine.\n",
      "1728\n",
      "Male or non-pregnant female 18 - 50 years of age at the time of screening and willing to\n",
      "        use effective birth control for one month post vaccination.\n",
      "        Free of obvious health problems as established by medical history and clinical examination\n",
      "        before entering into the study.\n",
      "        Available to participate for the duration of the study (approximately 6 months).\n",
      "        Able to give signed informed consent.\n",
      "        May not have received an investigational leishmania vaccine or skin test, or recombinant\n",
      "        human interleukin-12.\n",
      "        No use of an investigational drug or any vaccine other than the study vaccine within 30\n",
      "        days preceding the dose, or planned use during the study period.\n",
      "        No administration of chronic immunosuppressants (defined as more than 14 days) or other\n",
      "        immune-modifying drugs within six months of vaccination. (For corticosteroids, this will\n",
      "        mean prednisone, or equivalent, greater than 0.5 mg/kg/day. Inhaled and topical steroids\n",
      "        are allowed.)\n",
      "        No history of prior leishmaniasis or of extensive travel to regions endemic for\n",
      "        leishmaniasis, such as southern Mexico, Central and most of South America, the\n",
      "        Mediterranean region and Middle East, Africa, and India.\n",
      "        No confirmed or suspected immunosuppressive or immunodeficient condition, including human\n",
      "        immunodeficiency virus (HIV) infection.\n",
      "        No family history of congenital or hereditary immunodeficiency.\n",
      "        No history of significant allergic disease or reactions likely to be exacerbated by any\n",
      "        component.\n",
      "        No acute disease at the time of enrollment, defined as the presence of a moderate or\n",
      "        severe illness with or without fever.\n",
      "        No acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal\n",
      "        function abnormality, as determined by physical examination or laboratory screening tests.\n",
      "        No pregnant or lactating females.\n",
      "        Must not have suspected or known alcohol or drug abuse.\n",
      "        No other significant finding that, in the opinion of the investigator, would increase the\n",
      "        risk of having an adverse outcome from participating in this study.\n",
      "1741\n",
      "Males or (non-pregnant, lactating and nursing) females equal to or greater than 12 years\n",
      "        of age.\n",
      "        Previous enrollment into and completion of voriconazole therapy in protocol 99-C-0094\n",
      "        investigating the use of voriconazole in the treatment of invasive fungal disease or\n",
      "        empirical treatment of presumed fungal infections and enrolled within three weeks of\n",
      "        completion of 99-C-0094B.\n",
      "        Clinical benefit was derived from previous voriconazole treatment.\n",
      "        Further clinical benefit is expected with extended voriconazole treatment.\n",
      "        Women of child bearing potential (or less than 2 years post- menopausal) must have a\n",
      "        negative serum pregnancy test at baseline, and must agree to use barrier methods of\n",
      "        contraception during the study.\n",
      "        Signed written informed consent must be obtained at protocol entry.\n",
      "        Assent will be obtained from minors capable of understanding.\n",
      "        Subjects must not have either ongoing serious adverse events probably related to\n",
      "        voriconazole therapy or have ongoing adverse events probably related to voriconazole\n",
      "        therapy which may pose a significant risk on continued therapy.\n",
      "        Must not have previously participated in this trial.\n",
      "        If receiving, must be able to discontinue the following drugs at least 24 hours prior to\n",
      "        randomization: terfenadine, cisapride, and astemizole.\n",
      "        If receiving, must be able to discontinue sulphonylureas at least 24 hours prior to\n",
      "        randomization.\n",
      "        Must not have received the following drugs within 14 days prior to randomization:\n",
      "        rifampin, carbamazepine, or barbiturates.\n",
      "        Must not have AST, ALT, greater than 10 (upper limit normal).\n",
      "        Must not have serum creatinine greater than 3.0 mg/dl.\n",
      "1743\n",
      "Age greater than or equal to 18 years.\n",
      "        Histologic or cytologic confirmation of cancer, for which there is no known standard\n",
      "        therapy capable of extending life expectancy.\n",
      "        Performance status ECOG 0-2.\n",
      "        Life expectancy of 3 months or greater.\n",
      "        Platelet count greater than or equal to 90,000/mL.\n",
      "        Absolute granulocyte count (AGC) greater than or equal to 1,000/mL.\n",
      "        Serum creatinine less than or equal to 1.5 mg/dl (or if greater than 1.5, measured\n",
      "        creatinine clearance greater than or equal to 50 mL/min).\n",
      "        SGPT and SGOT less than or equal to 2.5 times normal limit, and bilirubin less than or\n",
      "        equal to 1.5 times normal limit (in patients with clinical evidence of Gilbert's disease,\n",
      "        less than or equal to 3 times normal limit).\n",
      "        2 weeks from prior radiation or chemotherapy and recovery from associated toxicities such\n",
      "        that they meet eligibility criteria. Hormonal therapy may be taken up to the time of\n",
      "        enrollment.\n",
      "        No serious intercurrent medical illness.\n",
      "        Bidimensionally measurable disease by radiographic means or physical examination; or\n",
      "        relevant tumor markers (i.e. CA-125 and PSA greater than or equal to 2 times upper limit\n",
      "        of normal).\n",
      "        The ability to understand and willingness to sign a written informed consent form, and to\n",
      "        comply with the protocol.\n",
      "        No pregnant or nursing women; or women of childbearing potential unless using effective\n",
      "        contraception as determined by the patient's physician.\n",
      "        No history of another malignancy; specifically, no patients with a non-skin malignancy or\n",
      "        with melanoma within the past 5 years; no concomitant malignancy that has not been\n",
      "        curatively treated. However, cancer survivors who have undergone potentially curative\n",
      "        therapy for a prior malignancy at least 5 years before enrollment is considered, and are\n",
      "        deemed at low risk for recurrence by their treating physicians.\n",
      "        No patients with current or a history of CNS metastases.\n",
      "        No patients who are a poor medical risk because of other non malignant systemic disease or\n",
      "        active, uncontrolled infection.\n",
      "        No HIV seropositive patients.\n",
      "        No prior vinorelbine therapy.\n",
      "1744\n",
      "-  INCLUSION CRITERIA:\n",
      "        Patients must have clinically documented partial seizures with consistent EEG evidence as\n",
      "        defined by the 1981 International Classification of Epileptic Seizures, refractory to\n",
      "        standard antiepileptic treatment for at least one year.\n",
      "        Patients will be in age ranges of 18 to 60.\n",
      "        Patients may be male or female. Female patients of child bearing potential will have a\n",
      "        pregnancy test prior to each PET scan to ensure that pregnant patients will not\n",
      "        participate in the study. During the study, woman of child bearing potential must use a\n",
      "        reliable method of birth control.\n",
      "        Three groups of patients will be scanned:\n",
      "          -  50 patients with EEG and clinical evidence for mesial temporal onset with either MRI\n",
      "             findings of mesial temporal sclerosis (MTS) or dysplasia or normal MRI studies.\n",
      "          -  25 patients with apparent neocortical seizure foci.\n",
      "        In addition, patients will be screened for the presence of depression in addition to\n",
      "        epilepsy; at least 15 patients from groups 1 and 2 who currently meet DSM-IV criteria for\n",
      "        the category \"Mood disorder due to epilepsy\" (293.83), and the subtype \"with major\n",
      "        Depressive-Like Episode\" 296.2 Major Depressive Disorder, Single Episode, or 296.3 Major\n",
      "        Depressive Disorder, Recurrent, indicating that subjects meet diagnostic criteria for a\n",
      "        major depressive episode. DSM diagnoses will be based on the Research Version of the\n",
      "        Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I) including the\n",
      "        detailed assessment of the course of both epilepsy and depressive symptoms as well as the\n",
      "        family history of medical and psychiatric conditions.\n",
      "        Twenty healthy normal adults will be included. Controls will be screened in the NINDS\n",
      "        Clinical Epilepsy Section outpatient clinic, with physical examination, CBC urinalysis and\n",
      "        blood chemistries. Controls with chronic illnesses, taking any medications, or who smoke\n",
      "        will be excluded. They will be asked to abstain from alcohol for one week before the\n",
      "        study.\n",
      "        \n",
      "1747\n",
      "DISEASE CHARACTERISTICS: Histologically documented breast adenocarcinoma Clinical or\n",
      "        radiologic evidence of metastatic disease required Histologic confirmation recommended if\n",
      "        evidence is equivocal Bidimensionally measurable disease required, i.e.: Lesion with\n",
      "        clearly defined margins on physical exam or radiologic evaluation with 1 diameter greater\n",
      "        than 0.5 cm Lytic bone metastases only if measurable on bone x-ray/survey Lesion\n",
      "        previously irradiated only if subsequent measurable progression New measurable lesion in\n",
      "        previously irradiated field The following are not considered measurable: Unidimensionally\n",
      "        measurable lesions Palpable nodal disease not measurable on CT Masses with margins not\n",
      "        clearly defined Lesions with both diameters less than 0.5 cm Bone disease other than lytic\n",
      "        bone disease Pleural effusions or ascites Disease identified by bone scan only History of\n",
      "        bilateral breast cancer allowed No brain metastases CT required if clinically indicated No\n",
      "        meningeal carcinomatosis Hormone receptor status: Any status\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Women only Menopausal status: Not specified\n",
      "        Performance status: Zubrod 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute\n",
      "        granulocyte count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin less than 2.0 mg/dL Renal: Creatinine less than 1.5 mg/dL Other: No second\n",
      "        malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer\n",
      "        Adequately treated carcinoma in situ of the cervix Not pregnant or nursing Negative\n",
      "        pregnancy test required of premenopausal women Appropriate contraception required of\n",
      "        fertile women Blood/body fluid analyses to determine eligibility and physical exams for\n",
      "        tumor measurement completed within 7 days prior to registration; imaging studies to\n",
      "        evaluate and document measurable disease completed within 4 weeks prior to registration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1\n",
      "        prior chemotherapy for metastatic disease allowed At least 4 weeks since adjuvant\n",
      "        chemotherapy Endocrine therapy: Prior hormonal therapy allowed At least 4 weeks since\n",
      "        hormonal therapy for patients with partial or complete response to most recent maneuver\n",
      "        Radiotherapy: Prior radiotherapy for metastatic disease allowed At least 4 weeks since\n",
      "        radiotherapy and recovered Surgery: Not specified\n",
      "1750\n",
      "DISEASE CHARACTERISTICS: Histologically documented colorectal cancer that has been\n",
      "        curatively resected, including: Dukes' A/B1 (T1-2, N0, M0) Dukes' B2/C (T3, N0, M0 and any\n",
      "        T, N1, M0) disease-free more than 5 years post-resection Colonoscopy to the cecum (or\n",
      "        small bowel anastomosis) with removal of all polyps required within 4 months of entry\n",
      "        Preparation must be adequate to visualize mucosa and discern the presence of no further\n",
      "        polyps No familial polyposis (more than 100 polyps at time of resection) No history of\n",
      "        inflammatory bowel disease including ulcerative colitis or Crohn's disease\n",
      "        PATIENT CHARACTERISTICS: Age: 30 to under 75 Performance status: Physician's assessment of\n",
      "        good general health required Life expectancy: At least 5 years Hematopoietic: Not\n",
      "        specified Hepatic: Not specified Renal: Not specified Cardiovascular: No NYHA class III/IV\n",
      "        status No history of angina No history of MI No history of stroke or TIAs No peripheral\n",
      "        vascular disease No bleeding diathesis including hemorrhagic stroke No prophylactic\n",
      "        aspirin for cardiovascular disease Other: No documented peptic ulcer disease within past\n",
      "        15 years No aspirin sensitivity including: Aspirin-induced asthma Bronchial\n",
      "        hyper-reactivity Urticaria Angioedema No requirement for sodium warfarin or other\n",
      "        anticoagulant No frequent (greater than 36 times/year) NSAID use within the past 5 years\n",
      "        No recurrent arthritis or other musculoskeletal problems No narcotic or alcohol dependency\n",
      "        (unless there has been at least a 6-month period of abstinence) No prior or concurrent\n",
      "        malignancy within 5 years (including metastases) except nonmelanomatous skin cancer No\n",
      "        pregnant or nursing women Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent enrollment in a colon cancer treatment trial or\n",
      "        other chemoprevention trial Biologic therapy: At least 6 months since immunosuppressive\n",
      "        therapy (i.e., azathioprine, methotrexate, cyclosporine) Chemotherapy: Prior chemotherapy\n",
      "        allowed for patients with Dukes' B2/C colorectal cancer No concurrent chemotherapy\n",
      "        Endocrine therapy: Prior non-immunosuppressive steroid treatment allowed Radiotherapy:\n",
      "        Prior radiotherapy allowed for patients with Dukes' B2/C colorectal cancer No concurrent\n",
      "        radiotherapy Surgery: Curative resection required\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1755\n",
      "Inclusion Criteria:\n",
      "          -  Patients must have a diagnosis of multiple myeloma confirmed by the presence of:\n",
      "               -  Bone marrow plasmacytosis with >= 10% plasma cells or sheets of plasma cells or\n",
      "                  biopsy-proven plasmacytoma\n",
      "               -  In addition, at least 1 of the following ancillary criteria must be documented:\n",
      "                    -  M-protein in the serum\n",
      "                    -  M-protein in the urine\n",
      "                    -  Radiographic evidence of osteolytic lesions (generalized osteoporosis\n",
      "                       qualifies only if the bone marrow aspirate contains >= 20% plasma cells)\n",
      "          -  Patients must have measurable disease; the following will constitute measurable\n",
      "             disease; tests used to document measurable disease must be done within two weeks\n",
      "             prior to registration; a bone marrow biopsy performed =< 6 weeks prior to\n",
      "             registration is acceptable; Note: If present, all of these parameters must be\n",
      "             followed for response\n",
      "          -  Serum M-protein >= 1.0 g/dL by serum protein electrophoresis\n",
      "          -  Urine M-protein (light chain) excretion > 200 mg/24 hours by urine protein\n",
      "             electrophoresis\n",
      "          -  Measurable plasmacytoma(s) of soft tissue (must be biopsy proven)\n",
      "          -  Bone marrow plasmacytosis >= 20%\n",
      "          -  Patients must not have been previously treated with chemotherapy; prior treatment of\n",
      "             hypercalcemia with corticosteroids, bisphosphonates, or other agents does not\n",
      "             disqualify the patient\n",
      "          -  Patients refuses entry or is ineligible for S9321; Note: S9321, \"Standard Dose Versus\n",
      "             Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma\" has\n",
      "             priority over E5A93; patients with previously untreated multiple myeloma should be\n",
      "             entered on S9321; patients who are ineligible for or decline entry to S9321 should be\n",
      "             entered on E5A93 and E3A93 if eligible\n",
      "          -  Patients treated with local radiotherapy to > 15% of the bone marrow area are\n",
      "             ineligible; patients who require concurrent radiotherapy should have entry to the\n",
      "             protocol deferred until the radiotherapy is completed; if, in the physician's\n",
      "             opinion, the delay in systemic therapy would itself pose undue risk, the patient may\n",
      "             be entered and receive concurrent radiotherapy; in this situation, for the first\n",
      "             VBMCP cycle, Melphalan, BCNU and Cyclophosphamide should be given at 75% of the dose\n",
      "          -  Patients with Stages I, II, or III disease according to a modification of the\n",
      "             clinical staging system by Durie and Salmon are eligible; staging should be based on\n",
      "             values obtained at the time of diagnosis unless patient has had a more abnormal value\n",
      "             prior to supportive treatment, transfusion, etc.; include only values obtained prior\n",
      "             to initiation of protocol treatment\n",
      "          -  Pretreatment x-rays must be done within 6 weeks of registration; copies of the bone\n",
      "             x-ray reports are required and must be submitted with on-study forms\n",
      "          -  Bone marrow slides must be submitted\n",
      "          -  Absolute neutrophil count (ANC) >= 1,000/mm^3\n",
      "          -  Platelet count >= 50,000/mm^3\n",
      "          -  Creatinine =< 5.0 mg/dL (NOTE: Patients with creatinine 2.0-5.0 mg/dL may be admitted\n",
      "             to this study but must receive altered doses and schedules of therapy)\n",
      "          -  Patients requiring dialysis are not eligible\n",
      "          -  Bilirubin =< 2.0 mg/dL\n",
      "          -  Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x upper limit of normal\n",
      "          -  Alkaline phosphatase =< 2.5 x upper limit of normal\n",
      "          -  No myocardial infarction within previous 6 months, no significant arrhythmia within\n",
      "             the prior 3 months; if hypertension is present, it should be under control prior to\n",
      "             study entry\n",
      "          -  Patients with a history of congestive heart failure or myocardial infarction must\n",
      "             have a normal myocardial ejection fraction as determined by echogram or multiple gate\n",
      "             acquisition (MUGA) scan\n",
      "          -  No patient with angina requiring nitrates or beta blockers, or with a history of\n",
      "             thrombophlebitis or pulmonary emboli within the previous 6 months and currently\n",
      "             requiring anticoagulants\n",
      "          -  Patients with concurrent reversible conditions, e.g., infection, hyperuricemia, cord\n",
      "             compression, hyperviscosity syndrome, central nervous system (CNS) complications, or\n",
      "             renal disease may be entered into this study after appropriate therapy for these\n",
      "             complications is initiated and the condition is controlled; therapy must be fully\n",
      "             documented and dated on the on-study form; Note: Hypercalcemia patients may be\n",
      "             entered directly on study and may receive corticosteroids, bisphosphonates, or other\n",
      "             agents as needed for control of hypercalcemia; Note: Anemia patients may be entered\n",
      "             directly on study and may receive erythropoietin (epoetin alfa: Procrit, Epogen,\n",
      "             Aranesp, etc.) or other agents as needed for control of anemia\n",
      "          -  No smoldering multiple myeloma, nonsecretory myeloma, localized plasmacytomas,\n",
      "             monoclonal gammopathy of undetermined significance (MGUS), or primary systemic\n",
      "             amyloidosis (AL)\n",
      "          -  No patient with second malignancies except: those treated with surgery alone who are\n",
      "             disease free > 5 years or patients whose only other malignancy is non-melanoma skin\n",
      "             cancer or carcinoma in situ of the cervix\n",
      "          -  Patients >= 70 years must have a performance status of 0-2, and be specifically\n",
      "             evaluated by their physician to determine if they can tolerate either regimen; they\n",
      "             should not enter the study if the physician feels that they would be unable to\n",
      "             tolerate either regimen\n",
      "          -  Female patients of childbearing potential must have a negative pregnancy test\n",
      "             documented before entering this study; these patients must be provided adequate\n",
      "             guidance about birth control measures; lactating women will be ineligible\n",
      "          -  Pre-treatment baseline Eastern Cooperative Oncology Group (ECOG) Performance Status\n",
      "             must be assessed\n",
      "          -  Patients that are known to have acquired immune deficiency syndrome (AIDS) are\n",
      "             excluded from this trial because the safety of the agents on this population has not\n",
      "             been established\n",
      "          -  Participation in E3A93 is mandatory for all patients in E5A93; patients must be\n",
      "             registered separately to each protocol, first to E5A93, then to E3A93; NOTE: Study\n",
      "             participants from South African institutions are exempt from mandatory registration\n",
      "             to E3A93 due to costs and problems associated with international shipping\n",
      "          -  Patients must give written informed consent\n",
      "1768\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage I-IV Hodgkin's lymphoma\n",
      "          -  Must have refractory or relapsed disease, defined by 1 of the following:\n",
      "               -  Failure to achieve a complete remission (CR) after 4 courses of\n",
      "                  conventional-dose front-line chemotherapy\n",
      "               -  Disease in second or greater remission\n",
      "                    -  Patients should be encouraged to undergo transplantation prior to a third\n",
      "                       salvage regimen\n",
      "                    -  Patients previously treated with multiple regimens considered on a\n",
      "                       case-by-case basis\n",
      "          -  No chemoresistant disease, defined as active progression with tumor growth greater\n",
      "             than 25% by volume during first-line chemotherapy\n",
      "               -  Patients who respond to second-line chemotherapy may be eligible\n",
      "          -  Stable residual masses after conventional-dose chemotherapy not considered treatment\n",
      "             failures\n",
      "               -  Active (refractory or relapsed) disease must be proven histologically or\n",
      "                  documented by gallium nitrate uptake\n",
      "          -  Syngeneic marrow transplantation offered to patients with consenting identical twin\n",
      "             donor\n",
      "          -  No CNS involvement by lymphoma\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to 60 (selected patients up to age 70 may be eligible)\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Absolute neutrophil count greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  SGOT and SGPT less than 2 times upper limit of normal\n",
      "          -  Albumin greater than 3.0 g/dL\n",
      "        Renal:\n",
      "          -  Must meet 1 of the following criteria:\n",
      "               -  Creatinine less than 1.8 mg/dL\n",
      "               -  Creatinine clearance greater than 60 mL/min\n",
      "               -  BUN less than 20 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular ejection fraction at least 50%\n",
      "        Pulmonary:\n",
      "          -  DLCO, FEV_1, and FVC greater than 50% of predicted OR\n",
      "          -  Resting pO_2 greater than 70 mm Hg on room air\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No severe neurologic or emotional disorders\n",
      "          -  No active infection\n",
      "          -  No other disease that would limit life expectancy\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Adequate psychosocial support required\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "1769\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary ovarian epithelial cancer Stage\n",
      "        III disease, i.e.: Greater than 1 cm residual intraperitoneal disease following\n",
      "        exploratory laparotomy with maximum debulking Laparoscopic resection alone insufficient\n",
      "        The following histologies are eligible: Serous adenocarcinoma Transitional cell carcinoma\n",
      "        Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed\n",
      "        epithelial carcinoma Adenocarcinoma Endometrioid tumor Adenocarcinoma NOS Malignant\n",
      "        Brenner's tumor No unclassified ovarian cancer (i.e., unexplored tumors thought to be of\n",
      "        ovarian origin or tumors not verified as arising from ovarian stroma) No borderline (grade\n",
      "        0) or \"probably malignant\" carcinoma Measurable disease preferred Patients eligible for\n",
      "        this protocol are also eligible for protocol GOG-136\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: GOG 0-2 Hematopoietic: WBC at\n",
      "        least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no more than 1.5 times normal ALT, AST, and GGT no more\n",
      "        than 3 times normal Alkaline phosphatase no more than 3 times normal LDH no more than 3\n",
      "        times normal Renal: Creatinine no more than 2.0 mg/dL Cardiovascular: No history of\n",
      "        congestive heart failure No myocardial infarction within 6 months No unstable angina\n",
      "        Other: No septicemia or severe infection No acute hepatitis No severe gastrointestinal\n",
      "        bleeding No second malignancy within 5 years except nonmelanomatous skin cancer Not\n",
      "        pregnant or nursing Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        See Disease Characteristics No more than 6 weeks since staging surgery\n",
      "1777\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Chronic myelogenous leukemia (CML) in chronic phase\n",
      "          -  Clonal evolution (i.e., the presence of clones other than the Ph chromosome) allowed\n",
      "             Ph chromosome variants or complex Ph chromosome translocations are not considered\n",
      "             disease acceleration\n",
      "          -  Ineligible for known therapy of higher efficacy or priority\n",
      "          -  Allogeneic bone marrow transplantation should be considered priority therapy for CML\n",
      "             patients with a matched related donor\n",
      "          -  No blastic phase CML (30% or more blasts in peripheral blood or bone marrow)\n",
      "          -  No accelerated phase CML, defined as any of the following: 15% or more peripheral or\n",
      "             marrow blasts or 30% or more blasts and promyelocytes 20% or more peripheral or\n",
      "             marrow basophils\n",
      "          -  Thrombocytopenia (platelets less than 100,000) unrelated to therapy\n",
      "          -  Documented extramedullary disease outside of liver or spleen\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 15 and over\n",
      "          -  Performance status: Zubrod 0-2\n",
      "          -  Life expectancy: Sufficient to fully evaluate the effects of 2 courses of therapy\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  SGOT less than 300\n",
      "          -  Creatinine less than 2.0 mg/dL OR creatinine clearance at least 60 mL/min\n",
      "          -  No severe heart disease (class III/IV)\n",
      "          -  No pregnant or nursing women\n",
      "          -  Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No prior interferon alpha\n",
      "          -  At least 2 weeks since antileukemic therapy, with recovery required\n",
      "          -  Patients who received hydroxyurea within the past 2 weeks and have WBC greater than\n",
      "             50,000 may enter protocol after discussion with the primary investigator\n",
      "1780\n",
      "DISEASE CHARACTERISTICS: Previously diagnosed acute leukemia in one of the following\n",
      "        categories: Acute myelogenous leukemia (any subtype) in first or subsequent remission Ph+\n",
      "        acute lymphoblastic leukemia (ALL) in first or greater remission Ph- ALL in second or\n",
      "        subsequent remission Cellular marrow with no morphologic evidence of residual leukemia\n",
      "        within approximately 2 weeks of cryopreservation Negative CSF cytology required of ALL\n",
      "        patients Allogeneic marrow transplant considered for patients under age 55 with a healthy\n",
      "        HLA-identical family member available\n",
      "        PATIENT CHARACTERISTICS: Age: Over 16 to 65 Performance status: Not specified\n",
      "        Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than 100,000/mm3 Hepatic:\n",
      "        Bilirubin less than 2.0 mg/dl Renal: Creatinine no greater than 1.5 mg/dl OR Creatinine\n",
      "        clearance at least 60 ml/min Cardiovascular: LVEF at least 50% by MUGA or normal on\n",
      "        echocardiogram Pulmonary: DLCO at least 50% of predicted Other: HIV seronegative No\n",
      "        uncontrolled infection Negative pregnancy test required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "1784\n",
      "DISEASE CHARACTERISTICS: Kernohan Grade III/IV primary malignant brain tumor that has\n",
      "        failed conventional surgical resection and radiotherapy Evidence of recurrent tumor on\n",
      "        gadolinium-enhanced MRI following completion of radiotherapy (minimum 5,000 cGy for\n",
      "        adults) required The following histologies are eligible: Anaplastic astrocytoma Anaplastic\n",
      "        oligodendroglioma Glioblastoma multiforme Mixed anaplastic glioma Surgical resection of\n",
      "        progressing brain tumor feasible No evidence of tumor extending across the midline from\n",
      "        one hemisphere to the other No multifocal tumor or leptomeningeal spread\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 2 months Hematopoietic: WBC greater than 2,000 Platelets greater than\n",
      "        100,000 Hct at least 28% Hepatic: Bilirubin less than 1.5 mg/dl Renal: Creatinine less\n",
      "        than 1.5 mg/dl Cardiovascular: No major cardiovascular problems Pulmonary: No major\n",
      "        pulmonary problems Other: Seronegative for HTLV/HIV, syphilis, and hepatitis B and C No\n",
      "        concurrent systemic infection Ability to maintain proper nutrition (orally or\n",
      "        intravenously) during the study period required No pregnant women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: More than 4 weeks\n",
      "        since systemic chemotherapy (6 weeks since carmustine), with the WBC increasing on 2\n",
      "        consecutive determinations at least 3 days apart Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 8 weeks since radiotherapy Surgery: See Disease Characteristics\n",
      "1786\n",
      "DISEASE CHARACTERISTICS: Adenocarcinoma of the breast with 1 or more histologically proven\n",
      "        positive axillary nodes OR Adenocarcinoma of the breast with negative axillary nodes or\n",
      "        adverse prognostic factors such that the patient is at high risk for recurrence and node\n",
      "        negative lesion is characterized by the following features: Tumor at least 1 cm Poorly\n",
      "        differentiated, SBR grade III, or MSBR grade V and/or lymphatic/vascular invasion\n",
      "        Pathologic review by experienced breast pathologist recommended if grade is unspecified\n",
      "        and lymphatic/vascular invasion is absent Disease considered potentially curable and\n",
      "        treated by 1 of the following: Complete surgical removal of the breast plus axillary node\n",
      "        dissection Partial surgical removal of the breast plus axillary node dissection, with the\n",
      "        intention of giving breast irradiation following completion of an adjuvant chemotherapy\n",
      "        regimen Regional nodal or chest wall irradiation not prohibited but strongly discouraged\n",
      "        No evidence of residual tumor in the axilla following dissection No microscopic evidence\n",
      "        of residual tumor at the resection margins following total mastectomy Further excision\n",
      "        highly recommended if there is microscopic residual disease present at partial mastectomy\n",
      "        margins If further excision is not undertaken, a radiotherapy boost to the tumor bed is\n",
      "        required in addition to breast irradiation given following protocol chemotherapy Disease\n",
      "        clinically staged prior to surgery as T1-T3a, N0-2, M0 No clinical T4 disease, i.e.: No\n",
      "        extension to the chest wall No edema (including peau d'orange) No skin ulceration No\n",
      "        satellite skin nodules confined to the same breast No inflammatory carcinoma Disease\n",
      "        pathologically staged following surgery as TNM stage I, II, or III (T0-4; N0-2; M0) T4\n",
      "        allowed only with dermal involvement on pathology assessment No evidence of metastatic\n",
      "        disease beyond the homolateral axillary nodes on pre-chemotherapy chest x-ray, bone scan\n",
      "        (with radiographs of suspicious areas), and abdominal ultrasound (required only if\n",
      "        bilirubin, alkaline phosphatase, or AST/ALT are elevated) Simultaneous bilateral breast\n",
      "        carcinoma allowed Complete tumor resection on both breasts required Axillary dissection on\n",
      "        both sides must meet criteria as above if both sides are clinically node-positive Axillary\n",
      "        dissection on the second side optional if the axilla is clinically negative at the time of\n",
      "        surgery and the other side is node-positive Adjuvant chemotherapy must begin within 14\n",
      "        weeks of initial pathologic diagnosis Hormone receptor status: Any receptor level allowed\n",
      "        (values must be available if biochemical method used; immunocytochemical assay permitted)\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Menopausal status: Pre- or\n",
      "        perimenopausal, i.e., meeting at least 1 of the following criteria: Normal menstruation\n",
      "        Amenorrhea for less than 1 year (up to 3 years in patients under age 52) Biochemical\n",
      "        evidence of ovarian function Hysterectomy without bilateral oophorectomy in patients under\n",
      "        age 56 Premenopausal women no greater than age 50 who were started on replacement hormone\n",
      "        therapy before amenorrhea are eligible Performance status: ECOG 0-2 prior to chemotherapy\n",
      "        Hematopoietic: WBC at least 3,000/mm3 Polymorphs and bands at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: (unless abdominal ultrasound indicates liver\n",
      "        metastasis) Alkaline phosphatase no greater than 2 times normal AST and/or ALT no greater\n",
      "        than 2 times normal Renal: Not specified Other: No history of serious underlying medical\n",
      "        illness or psychiatric or addictive disorder No second malignancy within 5 years except:\n",
      "        Curatively treated nonmelanomatous skin cancer Curatively treated endometrium, colon, or\n",
      "        thyroid cancer or carcinoma in situ of the cervix No plan for pregnancy during the 5-year\n",
      "        study period Fertile women must use effective contraception (other than oral\n",
      "        contraception) Accessible for treatment and follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed (use must\n",
      "        be documented) Chemotherapy: No prior chemotherapy No concurrent other cytotoxic therapy\n",
      "        Endocrine therapy: Adjuvant tamoxifen (20 mg po daily) allowed up to 2 weeks before or\n",
      "        during adjuvant chemotherapy provided drug is discontinued at randomization No long-term\n",
      "        prednisone or other hormones Radiotherapy: See Disease Characteristics Surgery: See\n",
      "        Disease Characteristics\n",
      "1790\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed stage I or IIA breast carcinoma that is\n",
      "             considered operable\n",
      "          -  No prior axillary clearance or biopsy\n",
      "          -  Complete excisional biopsy of primary tumor without axillary clearance or biopsy\n",
      "             allowed\n",
      "          -  Suspicious manifestations of metastatic disease (e.g., hot spots on bone scan or\n",
      "             skeletal pain of unknown cause) must be proven benign\n",
      "          -  No bilateral breast cancer (any mass in contralateral breast must be proven benign by\n",
      "             biopsy)\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  60 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status\n",
      "          -  Postmenopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.1 mg/dL\n",
      "          -  AST less than 60 U/L\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.3 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Normal cardiac function\n",
      "          -  No history of congestive heart failure\n",
      "        Other:\n",
      "          -  No nonmalignant systemic disease that would preclude protocol therapy or prolonged\n",
      "             follow-up\n",
      "          -  No psychiatric or addictive disorder that would preclude protocol therapy or informed\n",
      "             consent\n",
      "          -  No other prior or concurrent malignancy except nonmelanomatous skin cancer or\n",
      "             adequately treated carcinoma in situ of the cervix\n",
      "          -  Geographically accessible for follow-up\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior biologic therapy for breast cancer\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for breast cancer\n",
      "        Endocrine therapy:\n",
      "          -  No prior endocrine therapy for breast cancer\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for breast cancer\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "1791\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed breast cancer with palpable, unilateral,\n",
      "        invasive disease Bilateral mammography required within 1 year prior to randomization TNM\n",
      "        Stage T1-3, N0-1, M0 disease for which adjuvant chemotherapy is considered an essential\n",
      "        part of initial therapy No prior pure in situ carcinoma in either breast No concurrent in\n",
      "        situ carcinoma only No Paget's disease of the nipple without underlying invasion No\n",
      "        evidence of distant disease, e.g.: No ipsilateral supraclavicular node enlargement unless\n",
      "        proven benign Hormone receptor status: Any status\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Sex: Women only Menopausal status: Pre- or\n",
      "        postmenopausal Performance status: Not specified Hematopoietic: Not specified Hepatic: Not\n",
      "        specified Renal: Not specified Other: No serious unrelated illness No prior invasive\n",
      "        malignancy at any other site except adequately treated nonmelanomatous skin cancer No\n",
      "        pregnant or nursing women Adequate contraception required\n",
      "        PRIOR CONCURRENT THERAPY: No prior tamoxifen and not currently receiving tamoxifen\n",
      "1795\n",
      "DISEASE CHARACTERISTICS: Histologically proven, invasive, localized carcinoma of the\n",
      "        breast Stage I/II/IIIA disease, i.e.: Tumor confined to breast on clinical examination\n",
      "        Overlying skin movable with respect to tumor Tumor movable in relation to underlying\n",
      "        muscle and chest wall Bone scan and/or x-ray required to rule out bone metastases in cases\n",
      "        of skeletal pain Tumor size requirements: No greater than 5 cm if lymph nodes are positive\n",
      "        Greater than 1 cm if lymph nodes are negative Tumor definitively treated by one of the\n",
      "        following procedures: Total mastectomy with axillary node dissection Segmental mastectomy\n",
      "        with or without axillary node dissection and/or sentinel node biopsy followed by breast\n",
      "        irradiation, provided: Surgical margins are histologically free of invasive or noninvasive\n",
      "        tumor One additional resection allowed to obtain clear margins Total mastectomy required\n",
      "        if clear margins are not obtained at second resection The following conditions exclude:\n",
      "        Bilateral malignancy or any mass in the contralateral breast unless proven nonmalignant by\n",
      "        biopsy Palpable lymph nodes in the contralateral axilla or probable supraclavicular or\n",
      "        infraclavicular nodal involvement unless proven nonmalignant by biopsy 10 or more positive\n",
      "        lymph nodes Inflammatory breast cancer Ulceration or erythema Infiltration of the skin or\n",
      "        peau d'orange Tethering or dimpling of the skin or nipple inversion should not be\n",
      "        considered skin infiltration Satellite breast nodules Parasternal nodules Edema of the arm\n",
      "        Hormone receptor status: Any estrogen receptor (ER) or progesterone receptor (PR) status\n",
      "        allowed ER assessment required PR assessment recommended Less than 365 days between\n",
      "        definitive surgery and randomization\n",
      "        PATIENT CHARACTERISTICS: Age: 48 to 78 Sex: Female Menopausal status: Postmenopausal\n",
      "        Performance status: Not specified Life expectancy: At least 10 years (excluding breast\n",
      "        cancer) Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL AST no greater than 60 IU/mL (or within 2 times\n",
      "        normal) Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No active cardiac\n",
      "        disease that would preclude doxorubicin in patients assigned to adjuvant chemotherapy with\n",
      "        doxorubicin Other: Baseline caloric intake at least 20% fat Accessible for follow-up and\n",
      "        by telephone Sufficient memory required to provide food recall data Must speak and read\n",
      "        English Medically and nutritionally eligible for either dietary intervention arm No prior\n",
      "        or concomitant malignancy except curatively treated nonmelanoma skin cancer or carcinoma\n",
      "        in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent participation in another adjuvant breast cancer\n",
      "        trial that has disease-free or overall survival as a study endpoint (e.g., a major\n",
      "        cooperative group trial) Biologic therapy: Not specified Chemotherapy: Concurrent adjuvant\n",
      "        cyclophosphamide, methotrexate, fluorouracil (CMF), doxorubicin, cyclophosphamide (AC), AC\n",
      "        followed by paclitaxel, or fluorouracil/doxorubicin/cyclophosphamide (FAC, CAF) allowed If\n",
      "        ER negative, approved chemotherapy regimen and/or tamoxifen required No more than 120 days\n",
      "        between definitive surgery and initiation of adjuvant systemic chemotherapy Endocrine\n",
      "        therapy: Concurrent adjuvant tamoxifen required if ER positive (if ER negative, tamoxifen\n",
      "        and/or an approved chemotherapy regimen required) No more than 180 days between definitive\n",
      "        surgery and initiation of tamoxifen (if receiving tamoxifen alone) If receiving adjuvant\n",
      "        CMF, AC, or FAC, CAF, or AC, paclitaxel, tamoxifen begins after completion of adjuvant\n",
      "        therapy Radiotherapy: Radiotherapy required within 56 days following segmental mastectomy\n",
      "        Surgery: Definitive surgery required Prior oophorectomy for reasons other than malignancy\n",
      "        allowed\n",
      "1805\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following diagnoses:\n",
      "               -  Stage I or II bladder, colorectal, head and neck, lung, or other cancer\n",
      "               -  Stage I-III testicular cancer\n",
      "               -  Stage I-IV breast cancer, prostate cancer, or lymphoma\n",
      "          -  Must have smoked 1 or more cigarettes within the past month or define self as a\n",
      "             smoker\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  19 and over\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No history of recent heart attack\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  No other imminent medical needs requiring referral to a more intensive smoking\n",
      "             cessation regimen\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior participation in the pilot phase study\n",
      "1806\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven relapsed or refractory, stage I-IV, intermediate- or high-grade\n",
      "             non-Hodgkin's lymphoma\n",
      "               -  Eligible subtypes:\n",
      "                    -  Diffuse small cleaved cell\n",
      "                    -  Diffuse mixed (small and large cell)\n",
      "                    -  Diffuse large cell\n",
      "                    -  Large cell immunoblastic\n",
      "                    -  Lymphoblastic\n",
      "                    -  Small noncleaved cell\n",
      "          -  High-grade histology patients should first be considered for Protocol TUHSC-1520\n",
      "          -  Must have chemosensitive disease, defined by 1 of the following conditions:\n",
      "               -  Response to initial chemotherapy without obtaining complete response\n",
      "                  (CR)(refractory lymphoma)\n",
      "               -  Relapse after chemotherapy-induced CR if tumor volume reduced by at least 25%\n",
      "                  for more than 1 month after completion of 1-3 courses of salvage chemotherapy\n",
      "                  (chemosensitive relapse)\n",
      "          -  No chemoresistant disease, defined by the following conditions:\n",
      "               -  Unresponsive or progressive disease during initial chemotherapy\n",
      "               -  Relapse after chemotherapy-induced CR if tumor volume not reduced by at least\n",
      "                  25% after completion of 1-3 courses salvage chemotherapy (chemoresistant\n",
      "                  relapse)\n",
      "          -  No CNS involvement by lymphoma\n",
      "          -  Syngeneic bone marrow transplantation offered to patients with consenting identical\n",
      "             twin donor NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has\n",
      "             been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will\n",
      "             replace the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma.\n",
      "             However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to 60 (physically fit patients up to age 70 may be considered)\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  AST and ALT not persistently greater than 2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.8 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Cardiac ejection fraction at least 45%\n",
      "        Pulmonary:\n",
      "          -  DLCO, FEV_1, and FVC at least 50% predicted\n",
      "          -  Resting pO_2 at least 70 mm Hg\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No other concurrent disease that would limit life expectancy\n",
      "          -  No active infection\n",
      "          -  No severe neurologic or emotional disorders\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Adequate psychological support available\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "1807\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven rhabdomyosarcoma, non-Hodgkin's lymphoma, or other\n",
      "        solid tumor refractory to conventional therapy or for which no effective curative therapy\n",
      "        is known Re-biopsy required if disease recurs more than 2 years after initial diagnosis\n",
      "        recommended if radiographic abnormalities suggest tumor recurrence within 5 months of\n",
      "        completing radiotherapy or chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 21 and under at diagnosis Performance status: Karnofsky\n",
      "        50%-100% Life expectancy: More than 4 weeks Hematopoietic: (unless extensive bone marrow\n",
      "        involvement) ANC greater than 750 Platelets greater than 75,000 Hepatic: Not specified\n",
      "        Renal: Creatinine normal for age OR Glomerular filtration rate at least 50 mL/min per 1.73\n",
      "        square meters Other: Adequate nutritional status No serious uncontrolled infection No\n",
      "        pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: At least 2 weeks since other anticancer therapy and recovered\n",
      "        Prior radiotherapy or surgery for symptomatic lesions allowed provided site of evaluable\n",
      "        disease remains untreated Prior bone marrow or stem cell transplantation allowed No\n",
      "        concurrent anticancer therapy\n",
      "1808\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven metastatic breast cancer of poor prognosis, defined by any of\n",
      "             the following characteristics:\n",
      "               -  Patient aged 35 or under\n",
      "               -  Liver metastases\n",
      "               -  Lung metastases combined with other disease manifestations\n",
      "               -  Lung metastases without other disease manifestations but with a disease free\n",
      "                  interval of no more than 18 months\n",
      "          -  Indication for chemotherapy documented by either:\n",
      "               -  Hormone receptor negativity OR\n",
      "               -  Hormone resistant disease\n",
      "          -  Measurable metastatic disease required\n",
      "               -  Nonmeasurable disease includes:\n",
      "                    -  Metastases verified only histologically\n",
      "                    -  Tumor parameters not precisely measurable (e.g., bone marrow involvement,\n",
      "                       lymphangitic disease)\n",
      "          -  No CNS metastasis or bone marrow carcinomatosis\n",
      "          -  Hormone receptor status:\n",
      "               -  Receptor status known\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  80 and under\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Absolute granulocyte count greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase no greater than 6 times ULN\n",
      "          -  SGOT and/or SGPT no greater than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.15 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No congestive heart failure within the past 6 months\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "        Other:\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No acute or chronic infection\n",
      "          -  No second primary tumor\n",
      "          -  No other serious illness\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for metastatic disease\n",
      "          -  Greater than 1 year since prior adjuvant chemotherapy\n",
      "          -  No prior anthracycline or anthraquinone\n",
      "        Endocrine therapy:\n",
      "          -  Hormone resistant disease required of receptor positive patients\n",
      "          -  No concurrent endocrine therapy\n",
      "        Radiotherapy:\n",
      "          -  No prior mediastinal irradiation\n",
      "          -  Adjuvant irradiation of parasternal nodes eligible\n",
      "          -  No prior irradiation to more than 25% of bone marrow\n",
      "          -  No concurrent irradiation of sole measurable lesion\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent anticoagulant therapy\n",
      "1817\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage I-IV AIDS-related non-Hodgkin's\n",
      "        lymphoma Intermediate- or high-grade disease HIV infection documented by ELISA and\n",
      "        confirmed by Western blot Must have received at least 1 potentially curative chemotherapy\n",
      "        regimen for lymphoma Must be past the hematologic nadir resulting from prior chemotherapy\n",
      "        (generally 2 weeks from onset of prior therapy regardless of filgrastim (G-CSF) use)\n",
      "        Waiting period waived at the discretion of the principal investigator if patient\n",
      "        well-being would be compromised At least 1 site of bidimensionally measurable or evaluable\n",
      "        disease (e.g., bone marrow involvement only) History of leptomeningeal disease associated\n",
      "        with systemic lymphoma allowed No primary CNS non-Hodgkin's lymphoma A new classification\n",
      "        scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of\n",
      "        \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of \"low\",\n",
      "        \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former\n",
      "        terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 6 weeks Hematopoietic: Granulocyte count at least 750/mm3* Platelet count at least\n",
      "        50,000/mm3* Hemoglobin at least 7.5 g/dL* * Unless bone marrow infiltrated by lymphoma\n",
      "        Hepatic: Bilirubin less than 1.25 times upper limit of normal AST no greater than 3.0\n",
      "        times normal Renal: Creatinine clearance greater than 60 mL/min Cardiovascular: No\n",
      "        myocardial infarction within the past 6 months No history of congestive heart failure No\n",
      "        angina No serious arrhythmia requiring treatment Other: No other prior or concurrent\n",
      "        malignancy except: Inactive, nonvisceral Kaposi's sarcoma not requiring chemotherapy\n",
      "        Curatively treated basal cell or squamous cell skin cancer Curatively treated carcinoma in\n",
      "        situ of the cervix No severe, acute opportunistic infection No acute or intermittent\n",
      "        infection (other than oropharyngeal candidiasis) requiring treatment within 2 weeks before\n",
      "        study entry Not pregnant Negative pregnancy test Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Prior biologic\n",
      "        therapy allowed Chemotherapy: See Disease Characteristics No concurrent chemotherapy\n",
      "        Endocrine therapy: No concurrent hormonal therapy Radiotherapy: Prior radiotherapy allowed\n",
      "        No concurrent radiotherapy Surgery: Not specified Other: No concurrent investigational\n",
      "        anticancer or anti-infective therapy No concurrent aminoglycosides, amphotericin B, or\n",
      "        foscarnet Concurrent required supportive care allowed, including: Non-investigational\n",
      "        antiretroviral and antiviral medications Medications for Mycobacterium avium DISEASE\n",
      "        CHARACTERISTICS: Histologically proven stage I-IV AIDS-related non-Hodgkin's lymphoma\n",
      "        Intermediate- or high-grade disease HIV infection documented by ELISA and confirmed by\n",
      "        Western blot Must have received at least 1 potentially curative chemotherapy regimen for\n",
      "        lymphoma Must be past the hematologic nadir resulting from prior chemotherapy (generally 2\n",
      "        weeks from onset of prior therapy regardless of filgrastim (G-CSF) use) Waiting period\n",
      "        waived at the discretion of the principal investigator if patient well-being would be\n",
      "        compromised At least 1 site of bidimensionally measurable or evaluable disease (e.g., bone\n",
      "        marrow involvement only) History of leptomeningeal disease associated with systemic\n",
      "        lymphoma allowed No primary CNS non-Hodgkin's lymphoma A new classification scheme for\n",
      "        adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n",
      "        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n",
      "        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 6 weeks Hematopoietic: Granulocyte count at least 750/mm3* Platelet count at least\n",
      "        50,000/mm3* Hemoglobin at least 7.5 g/dL* * Unless bone marrow infiltrated by lymphoma\n",
      "        Hepatic: Bilirubin less than 1.25 times upper limit of normal AST no greater than 3.0\n",
      "        times normal Renal: Creatinine clearance greater than 60 mL/min Cardiovascular: No\n",
      "        myocardial infarction within the past 6 months No history of congestive heart failure No\n",
      "        angina No serious arrhythmia requiring treatment Other: No other prior or concurrent\n",
      "        malignancy except: Inactive, nonvisceral Kaposi's sarcoma not requiring chemotherapy\n",
      "        Curatively treated basal cell or squamous cell skin cancer Curatively treated carcinoma in\n",
      "        situ of the cervix No severe, acute opportunistic infection No acute or intermittent\n",
      "        infection (other than oropharyngeal candidiasis) requiring treatment within 2 weeks before\n",
      "        study entry Not pregnant Negative pregnancy test Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Prior biologic\n",
      "        therapy allowed Chemotherapy: See Disease Characteristics No concurrent chemotherapy\n",
      "        Endocrine therapy: No concurrent hormonal therapy Radiotherapy: Prior radiotherapy allowed\n",
      "        No concurrent radiotherapy Surgery: Not specified Other: No concurrent investigational\n",
      "        anticancer or anti-infective therapy No concurrent aminoglycosides, amphotericin B, or\n",
      "        foscarnet Concurrent required supportive care allowed, including: Non-investigational\n",
      "        antiretroviral and antiviral medications Medications for Mycobacterium avium\n",
      "        intracellulare infection Medications for cytomegalovirus (CMV) infection or CMV infection\n",
      "        prophylaxis infection Medications for cytomegalovirus (CMV) infection or CMV infection\n",
      "        prophylaxis\n",
      "1818\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Clinical diagnosis of primary adenocarcinoma\n",
      "               -  Involving a single colon segment:\n",
      "                    -  Right colon from the ileocecal valve up to and including the hepatic\n",
      "                       flexure\n",
      "                    -  Left colon from the splenic flexure to the junction of the sigmoid and\n",
      "                       descending colon\n",
      "                    -  Sigmoid colon between the descending colon and the rectum (at least 15 cm\n",
      "                       from the dentate)\n",
      "          -  Diagnosis based on physical exam plus either a proctosigmoidoscopy and barium enema\n",
      "             or a colonoscopy\n",
      "          -  No advanced local disease that renders laparoscopic resection impossible\n",
      "          -  No acutely obstructed or perforated colon cancer requiring urgent surgery\n",
      "          -  No transverse colon cancer (i.e., between distal hepatic flexure and proximal splenic\n",
      "             flexure)\n",
      "          -  No stage IV disease\n",
      "          -  No rectal cancer (i.e., below the peritoneal reflection, lower edge of tumor less\n",
      "             than 15 cm from dentate)\n",
      "          -  No American Society of Anesthesiologists IV/V disease classification\n",
      "          -  No associated gastrointestinal diseases (i.e., Crohn's, chronic ulcerative colitis,\n",
      "             or familial polyposis) that require additional extensive operative evaluation or\n",
      "             intervention\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Other:\n",
      "          -  No other prior or concurrent malignancy within the past 5 years except superficial\n",
      "             squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Surgery:\n",
      "          -  No prohibitive scars/adhesions from prior abdominal surgery\n",
      "        Other:\n",
      "          -  No concurrent investigational treatments or invasive diagnostic procedures within 30\n",
      "             days after surgery\n",
      "1828\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed invasive carcinoma of the breast for which adjuvant systemic\n",
      "             therapy is appropriate\n",
      "               -  Stage I, II, or IIIA\n",
      "               -  Pathologically positive or negative nodes\n",
      "               -  Any size primary tumor\n",
      "          -  No edema, peau d'orange, infiltration of the skin, or direct extension to the chest\n",
      "             wall\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Pre-, peri-, or postmenopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior malignancy except:\n",
      "               -  Basal cell carcinoma\n",
      "               -  Carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior systemic treatment for breast cancer\n",
      "1829\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary non-small cell lung cancer that\n",
      "        is completely resected No mixed small and non-small cell histologies Pathologic T2 N0 or\n",
      "        T1-2 N1 T1 N1 and T2 N1 only for CALGB institutions Removal of all gross disease with\n",
      "        negative resection margins by lobectomy, sleeve resection, bilobectomy, or pneumonectomy\n",
      "        (based on intraoperative findings) No segmentectomy or wedge resection Complete\n",
      "        mediastinal lymph node resection or sampling required at primary tumor resection, with\n",
      "        minimum levels of nodal sampling as follows: Primary in right upper lobe - levels 4, 7, 10\n",
      "        Primary in right middle lobe - levels 4, 7, 10 Primary in right lower lobe - levels 4, 7,\n",
      "        9, 10 Primary in left upper lobe - levels 5, 6, 7, 10 Primary in left lower lobe - levels\n",
      "        7, 9, 10 If complete mediastinal lymph node resection has not been undertaken, any\n",
      "        mediastinal lymph node which measured 1.5 cm or more on presurgical CT scan must have been\n",
      "        biopsied and found to be free of metastatic involvement Disease at nodal station 10\n",
      "        (tracheobronchial angle) is considered N2 disease for this trial and is not eligible No\n",
      "        more than one discrete primary tumor No bronchoalveolar carcinoma with lobar or multilobar\n",
      "        involvement Discrete solitary radiological mass or nodule eligible Snap frozen fresh\n",
      "        primary tumor tissue must be submitted to Lung Cancer Tumor Bank within 14 days after\n",
      "        surgery by selected Canadian centers Others to submit representative paraffin block within\n",
      "        2 months of surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over (lower age limit determined by individual\n",
      "        center) Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic:\n",
      "        Absolute granulocyte count greater than 2,000/mm3 Platelet count greater than 100,000/mm3\n",
      "        Hemoglobin greater than 10.0 g/dL Hepatic: Bilirubin no greater than 1.25 times normal\n",
      "        AST/ALT no greater than 1.25 times normal Alkaline phosphatase no greater than 1.25 times\n",
      "        normal Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No history of\n",
      "        congestive heart failure or other cardiac abnormality that may preclude hydration\n",
      "        necessary for cisplatin administration Other: No active pathologic condition that would\n",
      "        preclude study No active uncontrolled infection No history of psychiatric or neurologic\n",
      "        disorder that would preclude study No prior breast cancer, melanoma, or hypernephroma No\n",
      "        other malignancy within the past 5 years except adequately treated nonmelanomatous skin\n",
      "        cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception Ability to tolerate treatment (based on consultation between\n",
      "        the thoracic surgeon and a medical oncologist or hematologist) and available for follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Complete resection required Randomization between 28 and 40 days\n",
      "        after surgery required\n",
      "1830\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven unifocal or multifocal, supratentorial, pure or mixed\n",
      "             anaplastic oligodendroglioma\n",
      "               -  Prior suspected or proven low-grade glioma allowed if current histologic proof\n",
      "                  of pure or mixed anaplastic oligodendroglioma\n",
      "          -  Tumor must contain an unequivocal (at least 25%) oligodendroglial element and have 2\n",
      "             or more anaplastic features, 1 of which must be frequent mitoses or endothelial\n",
      "             proliferation\n",
      "               -  For mixed tumors, the non-oligodendroglial element must be astrocytic and the\n",
      "                  oligodendroglial or astroglial component may be anaplastic\n",
      "          -  No evidence of spinal drop metastasis or spread to noncontiguous meninges\n",
      "               -  MRI of spine not required for asymptomatic patients and patients not excluded\n",
      "                  based on pathologic evidence of local meningeal infiltration by underlying tumor\n",
      "          -  No tumor that is predominantly located in the posterior fossa (i.e., brainstem or\n",
      "             cerebellum)\n",
      "          -  No spinal cord tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 150,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 times normal\n",
      "          -  Serum glutamate oxaloacetate transaminase (SGOT) no greater than 2 times normal\n",
      "          -  Alkaline phosphatase no greater than 2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times normal\n",
      "        Pulmonary:\n",
      "          -  No chronic lung disease unless diffusion capacity of lung for carbon monoxide (DLCO)\n",
      "             is at least 60% predicted\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent steroids as antiemetics\n",
      "          -  Concurrent steroids allowed to control central nervous system (CNS) symptoms due to\n",
      "             tumor-associated or radiotherapy-associated cerebral edema\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to brain or head/neck\n",
      "        Surgery:\n",
      "          -  Prior surgery allowed\n",
      "1845\n",
      "Inclusion Criteria\n",
      "        Patients must have:\n",
      "          -  Positive AFB smear and/or culture for Mycobacterium tuberculosis, M. avium, or other\n",
      "             mycobacterial infection, with or without documented HIV infection. NOTE:\n",
      "          -  HIV-positive patients must have CD4 count < 500 cells/mm3 and be on antiretroviral\n",
      "             therapy.\n",
      "          -  One of the following manifestations:\n",
      "          -  Temperature over 38 C on at least two occasions in the week prior to study entry.\n",
      "          -  Recent weight loss of more than 5 kilograms.\n",
      "          -  Pulmonary involvement of one or more lobes or involvement of other tissues due to\n",
      "             tuberculosis or other mycobacterial infections, or symptomatic infections related to\n",
      "             HIV status.\n",
      "          -  Night sweats on two or more occasions in the week prior to study entry.\n",
      "        NOTE:\n",
      "          -  Patients must be hospitalized men aged 18-65 and postmenopausal women to age 65.\n",
      "             Anticipated requirement for hospitalization must be at least 10 days.\n",
      "        \n",
      "1854\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Other antimicrobial drugs as long as documented on Case Report Form.\n",
      "        Patients must have:\n",
      "          -  Serious nontuberculous mycobacterial infection.\n",
      "          -  Approval of eligibility from Pfizer Clinical Monitor. Patients below the legal age of\n",
      "             consent must have consent of parent or guardian.\n",
      "        NOTE:\n",
      "          -  Pregnant women, women of childbearing potential, and children will not be\n",
      "             specifically excluded from participation. However, patients and physicians should be\n",
      "             aware that the safety of azithromycin during pregnancy and in long-term use in\n",
      "             children and adults has not been established. The risks and benefits of azithromycin\n",
      "             use in these patients will be considered in consultation with the physician and the\n",
      "             Pfizer Clinical Monitor.\n",
      "        \n",
      "1858\n",
      "Inclusion Criteria:\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  All FDA-approved medications, antiretrovirals, and PCP prophylaxis drugs, with the\n",
      "             exception of warfarin (Coumadin).\n",
      "          -  Other self-prescribed medications available either over the counter or through\n",
      "             buyer's clubs.\n",
      "        Patients must have:\n",
      "        HIV positivity.\n",
      "        NOTE:\n",
      "          -  Patients on an antiviral or immunomodulating drug must have received it for at least\n",
      "             2 months and have no intention to make clinical or therapeutic changes in the first 8\n",
      "             weeks (such as adding a new agent or discontinuing effective viral suppressive\n",
      "             therapy) that may interfere with the study.\n",
      "        NOTE:\n",
      "          -  Patients who become pregnant after enrollment will be permitted to continue on study\n",
      "             drug but must sign an additional informed consent indicating their awareness of the\n",
      "             issues in taking a drug with limited safety data during pregnancy.\n",
      "        Prior Medication:\n",
      "        Allowed:\n",
      "          -  Antiviral and immunomodulating drugs, provided patient has been on such therapy for\n",
      "             at least 2 months prior to study entry.\n",
      "        \n",
      "1868\n",
      "Patients must:\n",
      "          -  Have progressive, symptomatic HIV disease.\n",
      "          -  Have a mean CD4 count <= 99 cells/mm3 for adults and <= 300 cells/mm3 for children\n",
      "             (original design was CD4 count <= 300 cells/mm3 for both adults and children).\n",
      "          -  Be unable to participate in a controlled trial.\n",
      "          -  Be refractory to or unable to tolerate other therapies.\n",
      "          -  Be able to attend clinic on a monthly schedule.\n",
      "          -  Have consent of parent or guardian if under the age of consent.\n",
      "        NOTE:\n",
      "          -  If a pregnant or breast-feeding woman requests enrollment, her physician should\n",
      "             contact Glaxo staff directly to discuss the case.\n",
      "        Practice of unsafe sex.\n",
      "1913\n",
      "Patients must:\n",
      "        Be HIV-uninfected men and women at low or intermediate risk for HIV-1 infection.\n",
      "1920\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed non-Hodgkin's lymphoma\n",
      "          -  Working formulation low-, intermediate-, and high-grade histologies eligible\n",
      "          -  Mantle cell and marginal zone lymphoma eligible\n",
      "          -  Relapse after at least 1 doxorubicin-containing regimen required\n",
      "          -  No more than 2 prior chemotherapy regimens\n",
      "          -  One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed\n",
      "          -  No prior bone marrow transplantation\n",
      "          -  Ineligible for treatment on higher priority protocols\n",
      "          -  Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk\n",
      "          -  Bidimensionally measurable disease required\n",
      "          -  No history of primary or metastatic CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Any age\n",
      "          -  Performance status: Zubrod 0-2\n",
      "          -  Life expectancy: Greater than 12 weeks\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.8 mg/dL\n",
      "          -  Transaminases no greater than 2.5 times normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min\n",
      "          -  No HIV antibody\n",
      "          -  No serious intercurrent illness\n",
      "          -  No pregnant or nursing women\n",
      "          -  Effective contraception required of fertile patients throughout study and for 1 year\n",
      "             thereafter\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        -At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered\n",
      "1926\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary ovarian epithelial cancer or\n",
      "        primary peritoneal cancer Suboptimal residual disease within 6 weeks of laparotomy with\n",
      "        maximum resection Stage III residual retroperitoneal disease greater than 1 cm and no\n",
      "        greater than 1 cm residual intraperitoneal disease OR Stage IV disease The following\n",
      "        histologies are eligible: Serous adenocarcinoma Malignant Brenner's tumor Mucinous\n",
      "        adenocarcinoma Endometrioid adenocarcinoma Undifferentiated carcinoma Clear cell\n",
      "        adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Adenocarcinoma not\n",
      "        otherwise specified Measurable disease not required Cytologic confirmation of malignant\n",
      "        pleural effusion required if sole basis of entry No borderline (low malignant potential)\n",
      "        carcinoma No unclassified ovarian cancer, i.e., thought to be of ovarian origin but\n",
      "        unexplored or unable to verify tumor arising from ovarian stroma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Hematopoietic: WBC\n",
      "        at least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal AST, ALT, and GGT no\n",
      "        greater than 3 times normal Alkaline phosphatase no greater than 3 times normal LDH no\n",
      "        greater than 3 times normal No acute hepatitis Renal: Creatinine no greater than 2 mg/dL\n",
      "        Cardiovascular: No history of congestive heart failure No history of unstable angina No\n",
      "        myocardial infarction within 6 months Other: No severe infection, including septicemia No\n",
      "        severe gastrointestinal bleeding No history of second malignancy within 5 years except\n",
      "        nonmelanomatous skin cancer Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        See Disease Characteristics No more than 6 weeks since staging laparotomy and primary\n",
      "        cytoreductive surgery\n",
      "1927\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following diagnoses:\n",
      "               -  Acute myelogenous leukemia (AML) meeting 1 of the following conditions:\n",
      "                    -  Failed to achieve first remission after an intensive induction regimen\n",
      "                       containing an anthracycline and cytarabine\n",
      "                    -  In second remission and not enrolled in a protocol for autologous bone\n",
      "                       marrow transplantation\n",
      "                    -  Failed to achieve or sustain second remission\n",
      "                    -  In first remission but at high risk of relapse because of 1 of the\n",
      "                       following factors:\n",
      "                         -  High-risk cytogenetic features (monosomy 7,5q-, trisomy 8, or t(9;22))\n",
      "                         -  AML secondary to treatment of a prior malignancy and without good-risk\n",
      "                            cytogenetic features of t(8;21), t(15;17), or inv 16\n",
      "                         -  AML secondary to myelodysplastic disease\n",
      "               -  Acute lymphocytic leukemia (ALL) meeting 1 of the following conditions:\n",
      "                    -  In second remission with initial relapse occurring within 2 years of\n",
      "                       diagnosis\n",
      "                    -  In first complete remission with high-risk cytogenetics (t(9;22) or\n",
      "                       t(4;11))\n",
      "                    -  In third or subsequent remission\n",
      "                    -  Failed to achieve or sustain a second remission\n",
      "               -  Chronic myelogenous leukemia (CML) in first or second chronic phase or\n",
      "                  accelerated phase\n",
      "               -  Stage IV lymphoblastic lymphoma not in first remission or that failed to achieve\n",
      "                  a remission within the first 4 weeks of induction therapy\n",
      "               -  Juvenile CML\n",
      "               -  Myelodysplastic syndrome\n",
      "               -  Severe aplastic anemia unresponsive to anti-thymocyte globulin or cyclosporine\n",
      "          -  No CNS or skin involvement with leukemia\n",
      "          -  No requirement for mediastinal irradiation\n",
      "          -  No healthy, HLA-identical related donor of at least 1 year of age or matched\n",
      "             unrelated donor available within 4-6 months\n",
      "          -  Availability of a healthy, 1-3 HLA-A, -B, and -DR mismatched related donor\n",
      "               -  Willing and able to undergo general anesthesia for marrow donation and a 5-day\n",
      "                  course of filgrastim (G-CSF) with 2 daily leukaphereses\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 50 (50 and over allowed on a case-by-case basis)\n",
      "        Performance status:\n",
      "          -  Age 16 and over:\n",
      "               -  Karnofsky 70-100%\n",
      "          -  Under age 16:\n",
      "               -  Lansky 50-100%\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL (in the absence of liver involvement)\n",
      "          -  AST less than twice normal (in the absence of liver involvement)\n",
      "        Renal:\n",
      "          -  Creatinine normal OR\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Asymptomatic or LVEF greater than 50% at rest, with improvement during exercise\n",
      "        Pulmonary:\n",
      "          -  Asymptomatic or DLCO greater than 50% predicted (corrected for hemoglobin)\n",
      "        Other:\n",
      "          -  No known hypersensitivity to mouse protein or chicken egg products\n",
      "          -  No active viral, bacterial, or fungal infection\n",
      "          -  HIV-1, HIV-2, HTLV-1, and HTLV-2 negative\n",
      "          -  No other concurrent medical condition that would preclude transplantation\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Surgery\n",
      "          -  See Disease Characteristics\n",
      "1929\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of colon cancer, breast cancer, or melanoma with minimal residual disease\n",
      "             (at least 90% of tumor mass resected) after surgical resection\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  20 to 80\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  See Disease Characteristics\n",
      "1934\n",
      "DISEASE CHARACTERISTICS:\n",
      "        -Histologically or cytologically confirmed leukemia refractory to conventional therapy or\n",
      "        for which no effective curative therapy exists\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Under 21\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Adequate platelet count and hemoglobin required (transfusion allowed)\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST or ALT no greater than 2 times normal\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Adequate nutritional status, e.g. higher than third percentile weight for height\n",
      "          -  Albumin at least 3 g/dL\n",
      "          -  No severe uncontrolled infection\n",
      "          -  No pregnant women\n",
      "          -  Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 3 weeks since systemic chemotherapy (6 weeks since nitrosoureas)\n",
      "          -  Recovered at least 3 months since bone marrow transplant (at least 6 months since\n",
      "             total-body irradiation)\n",
      "          -  No concurrent anticancer therapy\n",
      "          -  No concurrent treatment studies\n",
      "1935\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary intracranial low-grade glioma\n",
      "        (i.e., astrocytoma or oligodendroglioma) No more than 2 years since tissue diagnosis\n",
      "        Biopsy not required for intrinsic chiasmatic mass or tumor infiltration along the\n",
      "        posterior optic tracts Evidence of progressive disease by at least one of the following:\n",
      "        Papilledema or other clinical sign of increased intracranial pressure Documented change in\n",
      "        neuroimaging studies, e.g.: Hydrocephalus 25% increase in product of maximum perpendicular\n",
      "        diameters of tumor The following are required in patients with optic pathway gliomas:\n",
      "        Progressive loss of vision documented by an ophthalmologist, i.e.: Doubling of octaves\n",
      "        (e.g., 20/20 to 20/40 or 20/40 to 20/80) on 2 successive visits Loss of visual acuity not\n",
      "        explainable by other causes, e.g., media abnormalities or amblyopia Greater than 3 mm\n",
      "        increase in proptosis At least 2 mm increase in diameter of optic nerve on neuroimaging\n",
      "        Increase in distribution of tumor involving the optic tracts or optic radiations\n",
      "        demonstrated by CT or MRI using T1 (with or without contrast) or T2 imaging\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70%-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: ANC at least 1,500 Platelets at least 100,000\n",
      "        Hemoglobin at least 8.0 g/dL Hepatic: Bilirubin less than 1.5 times normal ALT less than\n",
      "        1.5 times normal Renal: Creatinine less than 1.5 mg/dL Other: Negative pregnancy test\n",
      "        required of fertile women Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: At least 12 weeks since radiotherapy (4 weeks since other\n",
      "        therapy) and recovered Prior chemotherapy allowed with subsequent disease progression\n",
      "1941\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Myelosuppressive or nephrotoxic agents at the discretion of the treating physician.\n",
      "        Patients must have:\n",
      "          -  Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.\n",
      "          -  Serious intolerance and/or resistance to standard therapies (such as\n",
      "             trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of\n",
      "             therapy for the current episode of PCP, or a documented history of such intolerance\n",
      "             during a prior episode.\n",
      "          -  Consent of parent or guardian if less than 18 years of age.\n",
      "        NOTE:\n",
      "          -  Pregnant women may enroll after the physician and patient have discussed the\n",
      "             potential benefit versus risk.\n",
      "        \n",
      "1948\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven primary or metastatic malignant supratentorial anaplastic\n",
      "             glioma\n",
      "               -  Newly diagnosed or recurrent\n",
      "               -  No diffusely infiltrating or multifocal tumor\n",
      "               -  No tumor with subependymal spread\n",
      "          -  Resection of glioma and placement of an intralesional catheter into the surgical\n",
      "             cavity required before study\n",
      "          -  Measurable lesion on enhanced CT scan or MRI\n",
      "               -  No measurable enhancing lesion greater than 1.0 cm beyond cavity margin\n",
      "          -  Neoplastic cell reactivity with tenascin demonstrated by immunohistology with either\n",
      "             a polyclonal rabbit antibody or a monoclonal murine antibody\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  3 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 50-100%\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  AST less than 1.5 times normal\n",
      "          -  Alkaline phosphatase less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior chemotherapy unless unequivocal evidence of tumor\n",
      "             progression\n",
      "        Endocrine therapy:\n",
      "          -  Corticosteroids allowed if at lowest possible dose and dose stable for at least 10\n",
      "             days prior to entry\n",
      "        Radiotherapy:\n",
      "          -  At least 3 months since prior radiotherapy to site of measurable disease unless\n",
      "             unequivocal evidence of tumor progression\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "1950\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage I-IIA Hodgkin's disease No lymphocyte\n",
      "        predominant disease No stage IA high neck presentation (above the top of the larynx) No\n",
      "        mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter on\n",
      "        chest x-ray No constitutional (B) symptoms at diagnosis No more than 1 extranodal site of\n",
      "        disease\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 60 Performance status: Not specified Hematopoietic:\n",
      "        Granulocyte count at least 2,000/mm3 Platelet count at least 150,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 2.5 mg/dL Renal: Creatinine no greater than 2 mg/dL Other: No\n",
      "        other medical condition that would preclude study therapy HIV negative No other prior\n",
      "        malignancy except basal cell skin cancer Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for Hodgkin's disease No other concurrent\n",
      "        antineoplastic therapy No other concurrent investigational drugs\n",
      "1954\n",
      "DISEASE CHARACTERISTICS: Persistent febrile neutropenia associated with 1 of the following\n",
      "        within 3 months prior to entry: Cytotoxic chemotherapy Bone marrow transplantation\n",
      "        Neutropenia defined as either: ANC no greater than 500/mm3 ANC no greater than 1,000/mm3\n",
      "        and expected to decrease to 500/mm3 or less within 2 days after entry Persistent\n",
      "        continuous or spiking fever of at least 38 C No association with administration of\n",
      "        pyrogenic substances No response to at least 72 hours of empiric, broad-spectrum\n",
      "        antibacterial therapy No microbiologically documented source of infection At least 30 days\n",
      "        since documented invasive fungal infection\n",
      "        PATIENT CHARACTERISTICS: Age: 2 and over Performance status: Not specified Life\n",
      "        expectancy: At least 28 days Hematopoietic: Not specified Hepatic: No grade 2 or greater\n",
      "        hepatic impairment Renal: No grade 2 or greater renal impairment No peritoneal dialysis or\n",
      "        hemodialysis Other: No history of severe allergic reaction to polyene antifungal agent No\n",
      "        pregnant or nursing women Negative pregnancy test required of fertile women Effective\n",
      "        contraception required of fertile women during and for 3 months after study\n",
      "        PRIOR CONCURRENT THERAPY: At least 2 weeks since polyene antifungal therapy Concurrent\n",
      "        oral prophylactic antifungal therapy with an azole antifungal agent (e.g., fluconazole,\n",
      "        itraconazole) allowed if patient remains febrile No concurrent azole therapy At least 30\n",
      "        days since other investigational drug or device except investigational formulation of\n",
      "        amphotericin B\n",
      "1955\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically documented Hodgkin's disease (closed to accrual 4/15/2000) OR\n",
      "          -  Histologically documented non-Hodgkin's lymphoma (NHL) of one of the following\n",
      "             International Working Formulation (IWF) histologies:\n",
      "               -  Small lymphocytic (absolute lymphocyte count less than 5,000)\n",
      "               -  IWF A Follicular, predominantly small cleaved cell\n",
      "               -  IWF B Follicular mixed\n",
      "               -  IWF C Follicular large cell\n",
      "               -  IWF D* Diffuse small cleaved cell\n",
      "               -  IWF E* Diffuse mixed\n",
      "               -  IWF F* Diffuse large cell\n",
      "               -  IWF G* Large cell, immunoblastic\n",
      "               -  IWF H* * Accrual of patients with these diagnoses closed 4/15/2000\n",
      "          -  Pathology review required within 60 days of registration\n",
      "          -  Refractory to or relapsed after prior chemotherapy as follows:\n",
      "               -  Low-grade NHL (IWF A-C): 1 or 2 prior therapies\n",
      "               -  Intermediate-grade NHL (IWF D-H): 1 prior therapy (stratum closed 4/15/2000)\n",
      "               -  Hodgkin's disease: 1 or 2 prior therapies (stratum closed 4/15/2000)\n",
      "          -  Treatment with the same drugs on 2 different schedules considered 1 therapy\n",
      "          -  Measurable disease by physical exam or imaging studies\n",
      "          -  Mass larger than 1 x 1 cm\n",
      "          -  Documented progression required of previously irradiated lesions\n",
      "          -  The following are not considered measurable:\n",
      "               -  Ascites or pleural effusion\n",
      "               -  Bone marrow involvement\n",
      "               -  Positive barium studies\n",
      "               -  Bony disease (lytic lesions noted)\n",
      "               -  No mantle cell or transformed lymphoma\n",
      "               -  No parenchymal or leptomeningeal CNS disease\n",
      "          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.\n",
      "             The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: CALGB 0-2\n",
      "          -  Unless hypersplenism or biopsy-proven bone marrow involvement:\n",
      "               -  Absolute granulocyte count at least 1,500/mm3\n",
      "               -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin normal\n",
      "          -  AST no greater than 4 times normal\n",
      "          -  Creatinine normal\n",
      "          -  No suspected HIV infection\n",
      "          -  No second malignancy within past 5 years except:\n",
      "               -  Curatively treated carcinoma of the cervix\n",
      "               -  Curatively treated basal cell skin cancer\n",
      "               -  No uncontrolled infection or other serious medical condition\n",
      "               -  No psychiatric condition that precludes informed consent\n",
      "               -  Not pregnant or nursing\n",
      "               -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No prior allogeneic or autologous bone marrow transplant\n",
      "          -  More than 3 weeks since chemotherapy (6 weeks since nitrosoureas, melphalan, or\n",
      "             mitomycin)\n",
      "          -  No prior camptothecin\n",
      "          -  More than 3 weeks since radiotherapy\n",
      "1962\n",
      "DISEASE CHARACTERISTICS: Histologic evidence of any type of cancer with metastases\n",
      "        Melanoma or renal cell cancer preferred No active brain metastasis Tumor infiltrating\n",
      "        lymphocytes must be available Measurable or evaluable disease preferred\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over (under 75 preferred) Performance status: ECOG\n",
      "        0-3 (ECOG 0 or 1 preferred) Hematopoietic: (preferred) WBC at least 3,000/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hematocrit at least 30% (transfusion allowed) Hepatic:\n",
      "        (preferred) Bilirubin less than 2.0 mg/dL PT/PTT normal Renal: (preferred) Creatinine less\n",
      "        than 2.0 mg/dL Cardiovascular: (preferred) At least 6 months since prior myocardial\n",
      "        infarction No congestive heart failure, cardiac arrhythmia, or hypertension requiring\n",
      "        medication Pulmonary: (preferred) pO2 at least 60 mm Hg Reasonable respiratory reserve No\n",
      "        supplemental oxygen requirement Not dyspneic at rest Other: No chronic auto-coagulation\n",
      "        (preferred) No active infection No chronic underlying immunodeficiency disease (including\n",
      "        HIV, hepatitis B) No known autoimmune disease Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy (7 days since stereotactic radiosurgery) Surgery: At least 4\n",
      "        weeks since prior surgery to control brain metastases No prior organ transplantation\n",
      "1963\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the ovary or papillary serous carcinoma of\n",
      "             extraovarian origin\n",
      "          -  Recurrent or persistent following standard surgery and 1 or 2 chemotherapy regimens\n",
      "             (with or without paclitaxel), i.e.: persistent disease or progression after\n",
      "             chemotherapy with nodules less than the equivalent of 5 x 5 x 5 cm Recurrent\n",
      "             carcinoma (after primary or secondary chemotherapy) detected clinically either by\n",
      "             exam or rising CA 125 and with radiographic evidence of disease no greater than the\n",
      "             equivalent of 5 x 5 x 5 cm nodules\n",
      "          -  Residual disease less than 5 x 5 x 5 cm following reassessment laparotomy\n",
      "          -  Microscopic residual disease on reassessment laparotomy after chemotherapy\n",
      "          -  Tumor TAG-72 positive by immunoperoxidase staining of original or current tumor\n",
      "             blocks\n",
      "          -  At least 85% free flow of fluid in peritoneal cavity demonstrated by technetium-99m\n",
      "             scan or other imaging within 2 weeks prior to treatment\n",
      "          -  No evidence of disease outside the peritoneal cavity other than retroperitoneal\n",
      "             lymphadenopathy\n",
      "          -  No massive ascites\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  WBC at least 3,500/mm3\n",
      "          -  Platelet count at least 125,000/mm3\n",
      "          -  Hemoglobin greater than 9 g/dL\n",
      "          -  No nucleated RBC or significant teardrop RBC morphology\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  AST/ALT less than 4 times normal\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "          -  HIV negative\n",
      "          -  Hepatitis B surface antigen negative\n",
      "          -  No hypersensitivity to paclitaxel, polyoxethylated castor oil, or topotecan\n",
      "          -  No other malignancy in past 5 years except basal cell skin carcinoma\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 3 weeks since prior biologic therapy and recovered\n",
      "          -  No prior monoclonal antibody therapy\n",
      "          -  No concurrent immunotherapy\n",
      "          -  No prior bone marrow or stem cell transplantation\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin)\n",
      "             and recovered\n",
      "          -  No concurrent chemotherapy\n",
      "          -  At least 3 weeks since prior radiotherapy and recovered\n",
      "          -  No prior radiotherapy to the abdominal cavity\n",
      "          -  No concurrent radiotherapy\n",
      "          -  At least 3 weeks since prior major surgery and recovered\n",
      "          -  No prior intraperitoneal therapy\n",
      "1969\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Encouraged:\n",
      "          -  PCP chemoprophylaxis for patients whose CD4 count falls below 200 cells/mm3 or who\n",
      "             develop PCP on study.\n",
      "        Allowed:\n",
      "          -  Secondary prophylaxis with nonexperimental agents in patients who develop TB,\n",
      "             Mycobacterium avium-intracellulare, toxoplasmosis, histoplasmosis, cryptococcosis,\n",
      "             disseminated candidiasis, or cytomegalovirus infection.\n",
      "          -  Acyclovir for 21 days or less for acute treatment.\n",
      "          -  Recombinant erythropoietin and G-CSF for grade 3 or worse anemia and neutropenia,\n",
      "             respectively.\n",
      "        Patients must have:\n",
      "          -  HIV infection.\n",
      "          -  CD4 count 200 - 500 cells/mm3.\n",
      "          -  No prior antiretroviral therapy.\n",
      "          -  Life expectancy of at least 48 weeks.\n",
      "          -  Consent of parent or guardian if less than 18 years of age.\n",
      "        NOTE:\n",
      "          -  Participating centers are encouraged to enroll female patients.\n",
      "        \n",
      "1973\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven prostate cancer or other solid tumor that is refractory to\n",
      "             standard treatment or for which no standard therapy exists\n",
      "          -  Patients with prostate cancer must meet the following conditions:\n",
      "               -  Stage D2 disease\n",
      "               -  Disease progression after orchiectomy or treatment with leuprolide or flutamide\n",
      "               -  If no prior orchiectomy, must continue leuprolide or other antiandrogen\n",
      "                  throughout study\n",
      "          -  No CNS neoplasms or brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: More than 3 months\n",
      "          -  WBC at least 3,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST and ALT no greater than 1.5 times normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 50 mL/min\n",
      "          -  No concurrent medical or psychiatric condition that would preclude study\n",
      "          -  Able to swallow numerous capsules\n",
      "          -  Willing to participate in pharmacokinetic studies\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since prior chemotherapy (more than 8 weeks since prior carmustine,\n",
      "             mitomycin, or other drugs with delayed toxic effects) and recovered\n",
      "          -  No prior suramin\n",
      "          -  At least 4 weeks since prior flutamide\n",
      "          -  No concurrent hydrocortisone or other steroids\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "          -  No concurrent palliative radiotherapy\n",
      "1975\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the\n",
      "        hypopharynx or base of the tongue that is newly diagnosed and considered resectable For\n",
      "        hypopharyngeal cancer, total laryngectomy would be required surgery Disease staged by\n",
      "        clinical exam, endoscopy, and CT or MRI Stage III that is T2-3 N0-1 M0 Stage IV that is\n",
      "        T2-3 N2-3 M0 Measurable or evaluable disease other than pleural effusion, ascites, or\n",
      "        disease documented by indirect evidence Closed to patients with cancer of the base of\n",
      "        tongue as of 11/15/1998\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0 or 1 Hematopoietic: WBC at\n",
      "        least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 2 times normal AST or ALT no greater than 3\n",
      "        times normal Renal: Creatinine no greater than 2 times normal Creatinine clearance at\n",
      "        least 60 mL/min Magnesium normal (supplementation allowed) Other: Average hearing loss in\n",
      "        both ears no greater than 40 dB in 50-2,000 Hz range No second malignancy within 5 years\n",
      "        except: Adequately treated nonmelanomatous skin cancer Carcinoma in situ of the cervix\n",
      "        Stage I/II cancer (other than head/neck) in complete remission Not pregnant or nursing\n",
      "        Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy\n",
      "1976\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell adenocarcinoma\n",
      "        Histologic confirmation of metastases desirable Progression of metastases within 2 months\n",
      "        of study No clinically manifest CNS metastasis Bidimensionally measurable metastases, as\n",
      "        follows: Lung lesion with diameter greater than 2 cm Superficial lymph node or skin or\n",
      "        subcutaneous lesion with diameter greater than 2.5 cm Lymph node in the mediastinum or\n",
      "        retroperitoneal region, liver lesion, or soft tissue lesion visible on CT or ultrasound\n",
      "        with initial diameter greater than 2.5 cm No bone lesion without surrounding, measurable\n",
      "        soft tissue lesion\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: WHO 0 or 1 Life expectancy: At\n",
      "        least 90 days Hematopoietic: WBC greater than 3,000/mm3 OR Absolute granulocyte count\n",
      "        greater than 1,500/mm3 OR Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no\n",
      "        greater than 1.1 mg/dL Lipids no greater than 1.5 times normal Renal: Creatinine no\n",
      "        greater than 1.6 mg/dL Cardiovascular: No congestive heart failure No significant\n",
      "        arrhythmia No complete bundle branch block Pulmonary: No serious concurrent pulmonary\n",
      "        illness Other: No recent uncontrolled bleeding No serous effusion No history of autoimmune\n",
      "        disease No controlled or uncontrolled active infection No seizure disorder or compromised\n",
      "        CNS function No secondary gastrointestinal dysfunction that could interfere with drug\n",
      "        absorption No psychological condition that would preclude participation or consent No\n",
      "        second malignancy except basal cell skin cancer or carcinoma in situ of the cervix Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: No concurrent hormonal therapy Radiotherapy: At least 3\n",
      "        months since irradiation of target lesions Subsequent progression or new lesion required\n",
      "        No concurrent radiotherapy Surgery: Prior nephrectomy required No concurrent surgery\n",
      "        Other: No concurrent tetracyclines or hepatotoxic drugs\n",
      "1981\n",
      "DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the breast with\n",
      "        involvement of 4 or more axillary nodes, including any T N1 M0 Concurrent bilateral breast\n",
      "        cancer allowed Complete resection required Total mastectomy or breast conserving surgery\n",
      "        Adjuvant radiotherapy planned after protocol chemotherapy Clear surgical margins Axillary\n",
      "        dissection yielding at least 9 lymph nodes Entry required within 8 weeks of definitive\n",
      "        surgery Hormone receptor status: Any status\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Not specified Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 80%-100% ECOG 0 or 1 Hematopoietic: Absolute granulocyte\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL\n",
      "        Hepatic: Bilirubin no greater than 1.5 times normal AST no greater than 2 times normal\n",
      "        Alkaline phosphatase no greater than 2 times normal Renal: Creatinine no greater than 1.8\n",
      "        mg/dL OR Creatinine clearance at least 60 mL/min Urinalysis normal Cardiovascular: Left\n",
      "        ventricular ejection fraction normal on MUGA or echocardiogram No congestive heart failure\n",
      "        requiring medical therapy No serious arrhythmia No first-, second-, or third-degree heart\n",
      "        block Other: No abnormal CT of chest or abdomen No uncontrolled infection No serious\n",
      "        medical condition that would prevent treatment No second malignancy except curatively\n",
      "        treated: Nonmelanomatous skin cancer Carcinoma in situ of the cervix Not pregnant Negative\n",
      "        pregnancy test Barrier contraception required of fertile patients before, during, and for\n",
      "        6 months after protocol therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic\n",
      "        chemotherapy Endocrine Therapy: No concurrent hormonal therapy unless unrelated to cancer\n",
      "        Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics Other: No\n",
      "        concurrent medication affecting conduction unless cleared by a cardiologist, e.g.: Beta\n",
      "        blockers Digoxin Antiarrhythmia agents Calcium channel blockers\n",
      "1985\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Unresectable liver metastases secondary to colorectal cancer\n",
      "               -  Less than 70% liver involvement on CT scan or MRI\n",
      "               -  Liver biopsy required before study unless 1 of the following conditions are met:\n",
      "                    -  Carcinoembryonic antigen greater than 30\n",
      "                    -  5 or more liver metastases visible on CT scan or MRI\n",
      "                    -  Greater than 50% to under 70% liver involvement on CT scan or MRI\n",
      "          -  Histologically proven primary colorectal cancer that is resected or appears\n",
      "             resectable on CT scan and physical exam\n",
      "               -  Documentation of previously resected primaries must be based on pathologic\n",
      "                  results of the resected tumor\n",
      "               -  Histological documentation of synchronous disease must be based on 1 of the\n",
      "                  following:\n",
      "                    -  Biopsy of primary colorectal tumor before study\n",
      "                    -  Suspicious lesion on barium enema, colonoscopy, or sigmoidoscopy, and a\n",
      "                       liver biopsy positive for adenocarcinoma consistent with the primary\n",
      "                       colorectal tumor\n",
      "          -  Measurable disease\n",
      "               -  Clearly defined liver mass measuring at least 2 cm or at least 3 liver masses on\n",
      "                  CT scan or MRI\n",
      "          -  No evidence of extrahepatic disease on CT scan and physical exam\n",
      "          -  No portal vein occlusion or ascites\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 times normal\n",
      "        Other:\n",
      "          -  No other malignancy within the past 5 years except inactive nonmelanomatous skin\n",
      "             cancer, carcinoma in situ of the cervix, or grade 1 bladder cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        Chemotherapy:\n",
      "          -  At least 1 year since prior adjuvant chemotherapy comprising fluorouracil (5-FU) and\n",
      "             leucovorin calcium (CF) or 5-FU, CF, and levamisole (LEV)\n",
      "          -  At least 6 months since prior adjuvant chemotherapy comprising 5-FU with or without\n",
      "             LEV\n",
      "          -  No other prior chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy except for nondisease-related conditions, e.g.:\n",
      "               -  Steroids for adrenal failure\n",
      "               -  Insulin for diabetes\n",
      "               -  Intermittent dexamethasone as an antiemetic\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the liver\n",
      "1989\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed supratentorial anaplastic glioma with a\n",
      "        recurrent cyst requiring aspiration for symptom control Measurable cystic lesion confirmed\n",
      "        by contrast-enhanced CT or MRI At least 3 months since radiotherapy to site of measurable\n",
      "        disease unless unequivocal evidence of tumor progression Neoplastic cell reactivity with\n",
      "        tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a\n",
      "        monoclonal murine antibody\n",
      "        PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%\n",
      "        Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 1.5 times normal\n",
      "        Alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL\n",
      "        Other: Negative pregnancy test Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since antineoplastic chemotherapy unless unequivocal evidence of tumor progression\n",
      "        Endocrine therapy: Corticosteroids allowed if at lowest possible dose and dose stable for\n",
      "        at least 10 days prior to entry Radiotherapy: See Disease Characteristics Surgery: Not\n",
      "        specified\n",
      "1992\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage III breast cancer\n",
      "          -  Measurable disease\n",
      "          -  No inflammatory breast cancer\n",
      "          -  No synchronous bilateral breast cancer\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  21 to 75\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-1 OR\n",
      "          -  Zubrod 0-1\n",
      "        Life expectancy:\n",
      "          -  More than 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.25 times upper limit of normal (ULN)\n",
      "          -  AST less than 1.25 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine clearance greater than 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No angina pectoris\n",
      "          -  No significant arrhythmia requiring therapy\n",
      "          -  No bilateral bundle branch block\n",
      "          -  No congestive heart failure\n",
      "          -  No myocardial infarction\n",
      "        Other:\n",
      "          -  No medical or psychiatric disease that would preclude study therapy\n",
      "          -  No other malignancy except adequately treated nonmelanomatous skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No prior surgery except incisional biopsy or fine-needle aspiration\n",
      "        Other:\n",
      "          -  No prior systemic therapy\n",
      "          -  No concurrent caffeine or alcohol\n",
      "1993\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Acute lymphocytic or myeloid leukemia (ALL or AML) in 1 of the following categories:\n",
      "               -  Failed to achieve a complete response (CR) with initial induction regimen\n",
      "               -  First relapse within 1 year of initial CR\n",
      "               -  Failed re-induction therapy at first relapse\n",
      "               -  Second relapse after no more than 2 different induction regimens\n",
      "               -  Relapse defined as more than 10% blasts in marrow or circulating blasts in\n",
      "                  peripheral blood and either:\n",
      "                    -  Symptoms of recurrence (e.g., B symptoms)\n",
      "                    -  Evidence of impending marrow failure (i.e., cytopenias) OR\n",
      "          -  Chronic myelogenous leukemia in accelerated or blastic phase after no more than 1\n",
      "             prior induction regimen\n",
      "          -  No HLA-identical sibling marrow donor or patient ineligible for allogeneic marrow\n",
      "             transplantation\n",
      "          -  No clinical symptoms of CNS leukemia\n",
      "               -  Patients with history of CNS leukemia must have pretreatment lumbar puncture\n",
      "                  demonstrating absence of active CNS disease\n",
      "          -  No active CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 4 weeks\n",
      "        Hematologic:\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure\n",
      "          -  No poorly controlled arrhythmia\n",
      "          -  No myocardial infarction within the past 3 months\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  No other serious medical condition that would prevent compliance\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 24 hours since prior hydroxyurea for impending leukostasis\n",
      "          -  No concurrent hydroxyurea glucocorticoids\n",
      "          -  Recovered from prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 24 hours since prior glucocorticoids for impending leukostasis\n",
      "          -  At least 7 days since prior amphotericin or aminoglycosides\n",
      "          -  No concurrent glucocorticoids\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent aminoglycoside antibiotics\n",
      "1994\n",
      "DISEASE CHARACTERISTICS: Histologically proven high risk neuroblastoma at the completion\n",
      "        of planned primary therapy No rapidly progressing disease Allogeneic transduced cell line\n",
      "        available Demonstrated production of at least 150 picograms of interleukin-2 per 10 to the\n",
      "        6th cells per day\n",
      "        PATIENT CHARACTERISTICS: Age: Under 21 at diagnosis Performance status: ECOG 0-2 Life\n",
      "        expectancy: At least 8 weeks Hematopoietic: (unless marrow replaced by tumor) Absolute\n",
      "        neutrophil count greater than 500/mm3 Platelet count greater than 50,000/mm3 Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL AST no greater than 2 times normal PT normal Renal:\n",
      "        Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 80 mL/min Urinalysis\n",
      "        normal Metabolic: Electrolytes (including calcium, phosphate) normal Glucose normal Weight\n",
      "        greater than 10th percentile for age Albumin greater than 3 g/dL Other: No active\n",
      "        infection HIV negative Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from prior chemotherapy No\n",
      "        concurrent antibiotics except prophylactic trimethoprim/sulfamethoxazole No concurrent\n",
      "        drugs other than analgesics\n",
      "1995\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary or metastatic malignant melanoma\n",
      "        OR Histologically confirmed supratentorial malignant brain tumor Newly diagnosed or\n",
      "        recurrent primary or metastatic tumor Eligible primary histologies, including but not\n",
      "        limited to: Glioblastoma multiforme Mixed anaplastic glioma Anaplastic astrocytoma Other\n",
      "        astrocytoma Gliosarcoma Anaplastic oligodendroglioma The following excluded: Diffusely\n",
      "        infiltrating tumors Multifocal tumors Infratentorial tumors Subependymal spread No\n",
      "        measurable enhancing lesion extending more than 1 cm beyond margins of surgical cavity on\n",
      "        contrast-enhanced CT or MRI performed within 72 hours after resection Intralesional\n",
      "        catheter placed at resection Patency of catheter demonstrated by radiolabeled albumin flow\n",
      "        Reactivity of neoplastic cells with intact Me1-14 IgG2a or Me1-14 F(ab')2 demonstrated by\n",
      "        immunohistology with polyclonal rabbit antibody or monoclonal mouse antibody\n",
      "        PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50%-100%\n",
      "        Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 1.5 times normal\n",
      "        Alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL\n",
      "        Other: Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since antineoplastic chemotherapy unless unequivocal tumor progression Endocrine therapy:\n",
      "        Concurrent corticosteroids allowed at lowest possible dose and stable for at least 10 days\n",
      "        prior to entry Radiotherapy: At least 3 months since radiotherapy to site of measurable\n",
      "        disease within the nervous system unless unequivocal tumor progression Surgery: See\n",
      "        Disease Characteristics\n",
      "1999\n",
      "DISEASE CHARACTERISTICS: Newly diagnosed stage IV neuroblastoma by one of the following:\n",
      "        Histologic verification Demonstration of tumor cell clumps in bone marrow with elevated\n",
      "        urinary catecholamine metabolites Initial presentation with low-stage disease allowed if\n",
      "        followed by progression to stage IV disease\n",
      "        PATIENT CHARACTERISTICS: Age: 1 to 21 Performance status: Not specified Hematopoietic:\n",
      "        (unless bone marrow involvement by tumor) Absolute neutrophil count greater than 1,000/mm3\n",
      "        Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 3.0 mg/dL Renal:\n",
      "        Creatinine less than 1.5 mg/dL Creatinine clearance or radionuclide GFR greater than 60\n",
      "        mL/min Cardiovascular: EKG normal Ejection fraction at least 55% by radionuclide MUGA OR\n",
      "        Fractional shortening at least 28% by echocardiogram Other: No other significant organ\n",
      "        dysfunction that precludes study treatment Body weight at least 10 kg Not pregnant or\n",
      "        nursing Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior systemic chemotherapy No prior radiotherapy except as\n",
      "        emergency treatment\n",
      "2005\n",
      "DISEASE CHARACTERISTICS: Acute myelogenous leukemia (M0-M7) and acute lymphoblastic\n",
      "        leukemia (L1-L2) Refractory or in first or subsequent relapse Circulating blasts present\n",
      "        OR Greater than 5% blasts in bone marrow Acute myelogenous leukemia secondary to\n",
      "        myelodysplastic syndrome or cytotoxic therapy Untreated OR Maximum of 2 intensive\n",
      "        induction regimens Chronic myelogenous leukemia in blastic or lymphoid crisis Untreated OR\n",
      "        Maximum of 2 intensive induction regimens No CNS leukemia\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-3 Life expectancy: At\n",
      "        least 4 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL\n",
      "        AST and ALT less than 3 times normal Alkaline phosphatase less than 3 times normal Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: No myocardial infarction within 6 months No active ischemic cardiac\n",
      "        disease No poorly controlled congestive heart failure No other symptomatic cardiac disease\n",
      "        Left ventricular ejection fraction at least 40% Pulmonary: No symptomatic restrictive or\n",
      "        obstructive lung disease Other: No severe neurologic disease No active infection unless\n",
      "        stable on antimicrobial therapy or fever is tumor related HIV negative Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: At least 2 weeks since prior cytotoxic therapy (except\n",
      "        hydroxyurea and steroids) Biologic therapy: No prior bone marrow transplantation At least\n",
      "        3 days since prior hematopoietic growth factors Chemotherapy: No prior topotecan or\n",
      "        camptothecin analogues Prior etoposide allowed Endocrine therapy: Not specified\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "2006\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically documented and completely resected stage III or stage IV renal cell\n",
      "             carcinoma, clinically staged within 2 months prior to initiation of therapy\n",
      "          -  No evidence of nephrotic syndrome\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 16\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count 50,000/mm3 to 500,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "          -  No hematologic abnormalities\n",
      "        Hepatic:\n",
      "          -  PT no greater than 1.5 times control\n",
      "          -  PTT less than 1.5 times control\n",
      "          -  Hepatitis B surface antigen negative\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 4.0 mg/dL\n",
      "          -  Calcium no greater than 12 mg/dL\n",
      "          -  No symptomatic hypercalcemia\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled or severe cardiac disease, e.g.:\n",
      "               -  No myocardial infarction within 6 months\n",
      "               -  No congestive heart failure\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No significant organ dysfunction\n",
      "          -  No other serious medical illness that would limit life expectancy\n",
      "          -  No significant CNS disease including uncontrolled or untreated psychiatric or seizure\n",
      "             disorders\n",
      "          -  No uncontrolled bacterial, viral, or fungal infection\n",
      "          -  No active peptic or duodenal ulcer\n",
      "          -  Adequate peripheral venous access required\n",
      "          -  No prior malignancy within past 5 years except inactive nonmelanoma skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No other concurrent postnephrectomy adjuvant therapy\n",
      "        Biologic therapy:\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  More than 1 week since prior corticosteroids (except as inhalation therapy for\n",
      "             respiratory ailments or replacement for adrenal insufficiency)\n",
      "          -  No concurrent therapy with the following:\n",
      "               -  Estrogens (except as postmenopausal replacement therapy)\n",
      "               -  Androgens\n",
      "               -  Progestins\n",
      "               -  Antiestrogens\n",
      "               -  Antiandrogens\n",
      "               -  LHRH analogues or antagonists\n",
      "               -  Other hormones\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior solid organ allograft\n",
      "          -  More than 3 weeks since major surgery, including nephrectomy\n",
      "2024\n",
      "DISEASE CHARACTERISTICS: Histologically proven unilateral, invasive breast cancer Stage\n",
      "        T0-3, N0-1, M0 No carcinoma in situ alone, including Paget's disease of the nipple without\n",
      "        underlying invasion No evidence of distant disease, including ipsilateral supraclavicular\n",
      "        node enlargement unless proven benign No history of pure carcinoma in situ in either\n",
      "        breast Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 70 and under Sex: Female Menopausal status: Premenopausal,\n",
      "        defined by 1 of the following criteria: Last menstrual period less than 1 year before\n",
      "        surgery Under age 50 with prior hysterectomy (for nonmalignant reason) without bilateral\n",
      "        oophorectomy Under age 50 and on continuous oral contraception If at variance with the\n",
      "        above definitions, hormonal assays in the premenopausal range take precedence Performance\n",
      "        status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic:\n",
      "        Not specified Renal: Not specified Other: Not pregnant or nursing No other serious illness\n",
      "        No other prior invasive malignancy except adequately treated basal cell or squamous cell\n",
      "        skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2026\n",
      "Eligibility Criteria\n",
      "          -  Histologically proven Hodgkin's Disease. A needle aspirate specimen will not be\n",
      "             considered sufficient for diagnosis.\n",
      "          -  Pathologic material must have been reviewed by a designated local reference\n",
      "             pathologist (LRP) prior to randomization. Histologic subtype determined by the LRP\n",
      "             will be used for patient cohort assignment.\n",
      "          -  Patients must have clinical stage I - IIA disease according to Ann Arbor staging\n",
      "             criteria. Clinical stage must be based on at least one tissue biopsy. The following\n",
      "             aspects are to be considered in determining patient stage:\n",
      "             i) Splenic Enlargement: Splenic enlargement determined by imaging studies only should\n",
      "             not be considered evidence of splenic involvement with Hodgkin's disease. Patients\n",
      "             should be considered as having splenic involvement if the spleen is palpable on\n",
      "             physical examination and enlarged on imaging studies, or imaging studies show focal\n",
      "             abnormalities consistent with Hodgkin's disease. These patients, if presenting with\n",
      "             supradiaphragmatic disease would therefore be assessed as having Stage III disease\n",
      "             and would be ineligible.\n",
      "        ii) Bone Disease: Lytic or blastic lesions seen on plain radiographs or abnormalities on\n",
      "        bone scan consistent with Hodgkin's disease will be considered as bone involvement with\n",
      "        Hodgkin's disease. These patients would therefore be assessed as having Stage IV disease\n",
      "        and would be ineligible.\n",
      "        iii) Pleural Effusion and Ascites: The presence of a pleural effusion or ascites will be\n",
      "        considered as evidence of Hodgkin's disease even if cytological examination is negative.\n",
      "        These patients would be assessed as having probable Stage IV disease and therefore would\n",
      "        be ineligible. Patients assessed on Xray as having pleural thickening or \"blunting\" of the\n",
      "        costophrenic angle only may be eligible. iv) Extra-nodal vs. Stage IV Disease: Patients\n",
      "        with disease involving a single extra-nodal site may be considered as \"limited-stage\"\n",
      "        provided all disease can be included in a standard radiation field. Patients with\n",
      "        extra-nodal disease that cannot be included in such a field (eg, lung, bone) or with\n",
      "        multiple sites of extra-nodal disease are not eligible for this trial.\n",
      "          -  Pulmonary function tests must be done in patients with symptomatic lung disease. FVC,\n",
      "             FEV-1 and DLCO must be ≥ 60% of predicted value. Patients with asthma controlled by\n",
      "             medication are eligible if the above criteria are met.\n",
      "          -  Patient's age is ≥ 16 years. (Note that the lower age limit at each centre will be\n",
      "             determined by that centre's policy regarding the age at which an individual may sign\n",
      "             their own consent.)\n",
      "          -  Patient must not have received previous chemotherapy or radiotherapy.\n",
      "          -  Laboratory requirements:\n",
      "        granulocytes ≥ 1.5 x 109/L (S.I.) or ≥ 1.5 x 103/uL (U.S.) platelets ≥ 125 x 109/L (S.I.)\n",
      "        or ≥ 125 x 103/uL (U.S.) bilirubin ≤ 2.5 x UNL (unless due to hemolytic anemia) serum\n",
      "        creatinine ≤ 2 x UNL\n",
      "          -  Patient must have been seen by both a radiation oncologist and medical oncologist who\n",
      "             agree the patient is able to receive protocol radiation therapy.\n",
      "          -  Patient consent must be obtained according to local Institutional and/or University\n",
      "             Human Experimentation Committee requirements. It will be the responsibility of the\n",
      "             local participating investigators to obtain the necessary local clearance, and to\n",
      "             indicate in writing to the NCIC CTG Clinical Trials Coordinator that such clearance\n",
      "             has been obtained, before the trial can commence in that centre. Because of differing\n",
      "             requirements, a standard consent form for the trial will not be provided but a sample\n",
      "             form is given. The patient must sign the consent form prior to randomization. Please\n",
      "             note that the consent form for this study must contain a statement which gives\n",
      "             permission for the NCICCTG and monitoring agencies to review patient records.\n",
      "          -  Availability of patient for follow-up and quality of life (QoL) assessments. Patients\n",
      "             must be accessible for treatment and follow-up. Investigators must assure themselves\n",
      "             that patients registered on this trial will be available for complete documentation\n",
      "             of the treatment, toxicity and follow-up. Comparison of quality of life is an\n",
      "             end-point of this study. Patients must have completed the pre-randomization quality\n",
      "             of life assessment and be willing to complete future assessments. The only exceptions\n",
      "             will be patients who are unable to read english or french. Patients on study are\n",
      "             expected to complete all the quality of life assessments but, should this not prove\n",
      "             possible, they will be retained in the study for all other analyses.\n",
      "        Ineligibility Criteria\n",
      "          -  Prior or concurrent malignancies, except adequately treated basal cell carcinoma of\n",
      "             the skin. (Patients with prior carcinoma-in-situ of the cervix are not eligible.)\n",
      "          -  Cardiac disease defined as symptomatic congestive heart failure or coronary artery\n",
      "             disease, known valvular (other than asymptomatic mitral valve prolapse) or congenital\n",
      "             heart disease (other than asymptomatic atrial septal defects) or need for cardiac\n",
      "             medications. Hypertension controlled with drug therapy is not an exclusion criterion.\n",
      "          -  Other major medical illness judged likely by the local investigator to preclude safe\n",
      "             administration of protocol treatment or required follow-up.\n",
      "          -  Patients with stage IA disease (who might be treated with involved-field only\n",
      "             irradiation) defined by meeting all of the following criteria:\n",
      "             i) lymphocyte predominant or nodular sclerosing histology ii) disease bulk < 3 cm\n",
      "             iii) erythrocyte sedimentation rate (ESR) < 50 iv) unilateral high - neck only\n",
      "             disease, defined as disease located above the upper border of the thyroid cartilage\n",
      "             or isolated epitrochlear adenopathy\n",
      "          -  Patients with very unfavourable clinical stage I-IIA disease defined as bulky\n",
      "             adenopathy. Bulky adenopathy is defined as a palpable nodal mass greater than 10 cm.\n",
      "             in diameter or a mediastinal mass with a maximum mass diameter measuring greater than\n",
      "             or equal to 1/3 the maximum chest wall diameter (see Appendix III).\n",
      "          -  Patients with intra-abdominal disease. (Patients with pelvic disease: ileofemoral,\n",
      "             inguinal or parailiac nodes are eligible for this study.)\n",
      "          -  Patients with B symptoms.\n",
      "          -  Patients known to have a positive antibody test for the human immunodeficiency virus\n",
      "             (HIV) or who have a clinical diagnosis of acquired immunodeficiency syndrome. HIV\n",
      "             testing is not a requirement for study entry.\n",
      "          -  Patients who have undergone a staging laparotomy.\n",
      "          -  Female patients who are pregnant. Note: men and women of childbearing age must be\n",
      "             advised in the use of adequate contraception.\n",
      "2044\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Newly diagnosed, active multiple myeloma of any stage requiring treatment\n",
      "               -  Smoldering myeloma (Durie-Salmon stage I) must have a 25% or greater increase in\n",
      "                  M component levels and/or Bence-Jones protein excretion or development of\n",
      "                  symptoms\n",
      "          -  Quantifiable M component of IgG, IgA, IgD, IgE, and/or urinary kappa or lambda light\n",
      "             chain (Bence-Jones protein) excretion required\n",
      "               -  Plasmacytosis of at least 30% allowed for non-secretory disease or secretory\n",
      "                  disease without quantifiable protein\n",
      "               -  IgM peaks excluded\n",
      "          -  Evaluation of siblings as potential allogeneic bone marrow transplant donors required\n",
      "             for patients 55 years of age and younger (As of 8/1/97, permanently closed)\n",
      "               -  HLA followed by DR and MLC testing required\n",
      "          -  Renal failure, even on dialysis, eligible provided:\n",
      "               -  Cause is attributed to myeloma (Bence-Jones protein or hypercalcemia)\n",
      "               -  Duration does not exceed 2 months\n",
      "          -  If medically appropriate, the following conditions should be treated prior to\n",
      "             registration:\n",
      "               -  Pathologic fractures\n",
      "               -  Pneumonia at diagnosis\n",
      "               -  Hyperviscosity with shortness of breath\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  70 and under\n",
      "        Performance status:\n",
      "          -  SWOG 0-2 (SWOG 3 or 4 based solely on bone pain allowed)\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  See Disease Characteristics\n",
      "        Cardiovascular:\n",
      "          -  Normal ejection fraction by ECHO or MUGA\n",
      "          -  No myocardial infarction within 6 months\n",
      "          -  No unstable angina\n",
      "          -  No difficult to control congestive heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No difficult to control arrhythmias\n",
      "          -  No history of chronic cerebral vascular accident\n",
      "        Pulmonary:\n",
      "          -  No history of chronic obstructive or restrictive pulmonary disease\n",
      "          -  Pulmonary function studies and DLCO at least 50% of predicted except for demonstrated\n",
      "             myeloma involvement on bronchoscopy and/or open lung biopsy\n",
      "        Other:\n",
      "          -  No uncontrolled diabetes\n",
      "          -  No significant comorbid medical condition\n",
      "          -  No uncontrolled, life-threatening infection\n",
      "          -  No prior malignancy within 5 years except adequately treated nonmelanoma skin cancer\n",
      "             or carcinoma in situ of the cervix\n",
      "          -  No prior malignancy treated with cytotoxic drugs used on this protocol\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy except local radiotherapy provided the following cumulative\n",
      "             dose limits for prior dose plus potential TBI dose on protocol are not exceeded:\n",
      "               -  Less than 5,000 cGy to bone\n",
      "               -  Less than 4,000 cGy to mediastinum, heart, small bowel, brain, and spinal cord\n",
      "               -  Less than 2,000 cGy to the liver\n",
      "               -  Less than 1,500 cGy to the kidney and lungs\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2046\n",
      "DISEASE CHARACTERISTICS: Histologically proven intermediate or high grade non-Hodgkin's\n",
      "        lymphoma of one of the following histologies: Follicular, predominantly large cell\n",
      "        Diffuse, small cleaved cell Diffuse mixed, small and large cell Diffuse, large cell\n",
      "        (cleaved or noncleaved) Immunoblastic, large cell Small noncleaved cell, Burkitt's or\n",
      "        non-Burkitt's No lymphoblastic lymphoma Prior diagnosis of AIDS or HIV positivity required\n",
      "        Confirmation of HIV antibody status by Western blot mandatory Bidimensionally measurable\n",
      "        or evaluable disease No primary CNS lymphoma Concurrent registration on protocol SWOG-8947\n",
      "        (central serum repository) required\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Hematopoietic: Absolute\n",
      "        neutrophil count at least 500/mm3 Platelet count at least 75,000/mm3 Hepatic: AST no\n",
      "        greater than 1.5 times normal Alkaline phosphatase no greater than 1.5 times normal LDH no\n",
      "        greater than 1.5 times normal PT/PTT normal Renal: Creatinine no greater than 2.0 times\n",
      "        normal Creatinine clearance at least 60 mL/min Cardiovascular: No serious abnormalities on\n",
      "        EKG No history of severe coronary artery disease No history of cardiomyopathy, congestive\n",
      "        heart failure, or arrhythmia Other: No active uncontrolled infection No active second\n",
      "        malignancy within 5 years except adequately treated nonmelanoma skin cancer or adequately\n",
      "        treated carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy for lymphoma\n",
      "2052\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven solid tumor\n",
      "          -  Measurable or evaluable disease\n",
      "          -  Measurable disease defined as tumor outside prior radiotherapy fields and\n",
      "             reproducibly measurable in 2 dimensions on physical exam, x-ray, CT, or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: 0 or 1\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  WBC at least 4,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST less than 3 times normal\n",
      "          -  Alkaline phosphatase less than 3 times normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  No poorly controlled angina\n",
      "          -  No history of congestive heart failure\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No concurrent prophylactic hematopoietic growth factors\n",
      "          -  No concurrent medications altering cardiac conduction\n",
      "2070\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven newly diagnosed, stage IIIA (T1-3, N2)\n",
      "             non-small cell lung cancer\n",
      "               -  Eligible subtypes:\n",
      "                    -  Adenocarcinoma\n",
      "                    -  Large cell carcinoma\n",
      "                    -  Squamous cell carcinoma\n",
      "                    -  Nonlobar and nondiffuse bronchoalveolar cell carcinoma\n",
      "          -  Measurable or evaluable disease on chest x-ray and/or contrast CT scan\n",
      "               -  Contrast thoracic CT required to complete staging\n",
      "          -  Single primary bronchogenic tumor (no more than 1 parenchymal lung lesion)\n",
      "          -  Pleural effusions allowed if 1 of the following conditions is met:\n",
      "               -  Negative cytology on thoracentesis if effusions present before mediastinoscopy\n",
      "                  or exploratory thoracotomy\n",
      "               -  Effusion seen on CT scan but not on chest x-ray and deemed too small to tap\n",
      "                  under CT or ultrasound guidance\n",
      "          -  Positive ipsilateral mediastinal node(s) with or without positive ipsilateral hilar\n",
      "             nodes\n",
      "               -  Mediastinal nodes separate from primary lesion on CT scan or surgical\n",
      "                  exploration\n",
      "               -  Histologic or cytologic proof of N2 disease by thoracotomy, mediastinoscopy,\n",
      "                  mediastinotomy, Chamberlain procedure, Wang needle, or fine needle aspiration\n",
      "                  under bronchoscopic or CT guidance\n",
      "               -  Nodal biopsy or aspiration waived if all of the following conditions are met:\n",
      "                    -  Paralyzed left true vocal cord documented by bronchoscopy or indirect\n",
      "                       laryngoscopy\n",
      "                    -  Nodes visible in Level 5 region on CT scan\n",
      "                    -  Distinct primary lesion separate from nodes on CT scan\n",
      "               -  All mediastinal nodal involvement mapped (positive or negative)\n",
      "          -  No positive nodes in contralateral mediastinum (supraclavicular areas and higher) and\n",
      "             neck\n",
      "               -  Mediastinoscopy, mediastinotomy, Chamberlain procedure, or thoracotomy required\n",
      "                  for nodes larger than 1 cm on contrast CT scan\n",
      "               -  Surgery waived if nodes negative or no larger than 1 cm on CT scan\n",
      "          -  Lymphadenopathy allowed if biopsy proof of a benign cause\n",
      "          -  No metastases by contrast CT or MRI scan of the brain, bone scan, CT scan of the\n",
      "             lungs to exclude other ipsilateral or contralateral parenchymal lesions, and contrast\n",
      "             CT scan of the upper abdomen including entire liver and adrenals\n",
      "          -  No hepatomegaly or splenomegaly by physical examination or CT scan unless\n",
      "             documentation of a benign cause\n",
      "          -  No pericardial effusion\n",
      "          -  No superior vena cava syndrome\n",
      "          -  No prior diagnosis of lung cancer\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 90-100% (70-80% allowed if albumin at least 0.85 times lower limit of\n",
      "             normal and weight loss no greater than 10% within 3 months before diagnosis)\n",
      "        Hematopoietic:\n",
      "          -  White blood cell count (WBC) at least 4,000/mm^3 OR\n",
      "          -  Granulocyte count at least 2,000/mm^3\n",
      "          -  Platelet count normal\n",
      "          -  Hemoglobin at least 10.0 g/dL (less than 8.5 g/dL allowed if no marrow involvement\n",
      "             with tumor)\n",
      "        Hepatic:\n",
      "          -  See Performance status\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)*\n",
      "          -  Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate\n",
      "             transaminase (SGPT) no greater than 1.5 times ULN* NOTE: * Unless documentation of a\n",
      "             benign cause\n",
      "        Renal:\n",
      "          -  Creatinine clearance at least 50 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 3 months\n",
      "          -  No active angina\n",
      "          -  No unstable arrhythmia\n",
      "          -  No congestive heart failure\n",
      "        Pulmonary:\n",
      "          -  Forced expiratory volume at one second (FEV1) at least 2.0 liters OR\n",
      "          -  Predicted postresection FEV1 at least 800 mL based on quantitative V/Q scan\n",
      "          -  Diffusion capacity of lung for carbon monoxide (DLCO) at least 50% predicted\n",
      "             (corrected for hemoglobin) if pneumonectomy planned or likely after induction\n",
      "             chemotherapy\n",
      "        Other:\n",
      "          -  No clinically significant hearing loss unless willing to accept the potential of\n",
      "             further loss\n",
      "          -  No symptomatic peripheral neuropathy\n",
      "          -  No peptic ulcer disease under active treatment\n",
      "          -  No other medical illness not controllable by appropriate medical therapy\n",
      "          -  No other malignancy within the past 5 years except adequately treated basal cell or\n",
      "             squamous cell skin cancer, carcinoma in situ of the cervix, or ductal or lobular\n",
      "             carcinoma in situ of the breast\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent colony-stimulating factors\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for lung cancer\n",
      "          -  No concurrent chemotherapy for another condition (such as arthritis)\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for lung cancer\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior resection of primary tumor\n",
      "2071\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage II or III adenocarcinoma of the\n",
      "        rectum Tumor extends through the bowel wall and into perirectal fat or soft tissue (TNM\n",
      "        T3-4, N0, M0) Nodes are involved with tumor (TNM T1-4, N1-3, M0) Tumor completely resected\n",
      "        en bloc with no gross or microscopic evidence of residual disease Circumferential (radial)\n",
      "        margins of resected adherent tumors must be specifically documented free of disease (with\n",
      "        the sole exception of extraperitoneal serosal margins) No evidence of metastasis No\n",
      "        regional nodal metastases (metastases outside of the pelvis) that cannot be resected en\n",
      "        bloc with the primary lesion No distant peritoneal metastases (metastases that are not a\n",
      "        direct extension from the primary tumor) even if grossly resected (direct extension into\n",
      "        another structure permitted) Abdominopelvic CT required unless: Bilirubin, SGOT, and\n",
      "        alkaline phosphatase are within normal limits, AND Operative report describes liver as\n",
      "        normal on exploration No tumors of colonic origin, i.e.: Lower edge of the tumor is below\n",
      "        the peritoneal reflection or a portion of the tumor is retroperitoneally located (usually\n",
      "        posteriorly) as defined by the surgeon at laparotomy OR Lower margin of the tumor is 12 cm\n",
      "        or less from the anal verge by proctoscopic exam No prior history of rectal cancer No\n",
      "        stage II or III cancers of the extrapelvic colon within the past 5 years Complete surgical\n",
      "        resection at least 5 years prior to protocol registration allowed provided no other\n",
      "        therapy was administered Synchronous modified stage I or IIa colorectal cancer (no nodal\n",
      "        involvement or penetration through the muscularis propria) that has been completely\n",
      "        resected allowed Registration between 20 and 70 days after the definitive surgical\n",
      "        procedure required Chemotherapy must begin no later than day 70 following surgery\n",
      "        Concurrent registration on protocol SWOG-9419 allowed for patients with adequate tissue\n",
      "        samples\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Hematopoietic: WBC at\n",
      "        least 4,000/mm3 Platelet count normal Hepatic: Bilirubin no greater than 2 times upper\n",
      "        limit of normal (ULN) SGOT no greater than 2 times ULN Alkaline phosphatase no greater\n",
      "        than 2 times ULN Renal: Not specified Other: No chronic ulcerative colitis No other\n",
      "        serious medical illness that would preclude protocol therapy No psychiatric condition that\n",
      "        would preclude informed consent No noncolorectal malignancy within 5 years except:\n",
      "        Adequately treated nonmelanomatous skin cancer Adequately treated carcinoma in situ of the\n",
      "        cervix Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        See Disease Characteristics Other: No other concurrent antineoplastic therapy\n",
      "2078\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed cancer of the colon or\n",
      "        rectum that is locally advanced or metastatic Primary lesion was or is located in the\n",
      "        large bowel as confirmed by endoscopy, radiology, or surgery Radiologic or clinical\n",
      "        evidence of metastasis subsequent to resection does not require histologic or cytologic\n",
      "        confirmation unless: Interval between primary surgery and development of metastasis is\n",
      "        greater than 5 years OR Primary cancer was Dukes' A or B1 Ineligible for potentially\n",
      "        curative therapy, e.g.: Surgical resection of a limited hepatic or pulmonary metastasis\n",
      "        Irradiation of locally recurrent colon or rectal cancer No or minimal symptoms related to\n",
      "        the cancer, i.e.: No persistent pain requiring regular narcotic analgesia No persistent\n",
      "        fever greater than 38 degrees C No symptomatic bowel obstruction No persistent nausea\n",
      "        requiring medication No weight loss of greater than 5 kg over the previous 3 months unless\n",
      "        clearly not associated with the cancer (e.g., associated with surgery or intercurrent\n",
      "        illness) Symptomatic relapse/metastases rendered asymptomatic by secondary surgery or\n",
      "        radiotherapy are eligible provided the patient remains asymptomatic for at least 6 weeks\n",
      "        following such treatment No CNS metastases No significant ascites, pleural effusion, or\n",
      "        pericardial effusion\n",
      "        PATIENT CHARACTERISTICS: Age: Adult under 80 (i.e., of legal age to sign own informed\n",
      "        consent according to institutional policy) Performance status: Karnofsky 90-100% ECOG 0\n",
      "        Hematopoietic: Granulocytes at least 1,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than upper limit of normal Renal: Creatinine less than 2.26\n",
      "        mg/dL Cardiovascular: No arrhythmia Other: No infection No other medical condition that is\n",
      "        uncontrolled or could be aggravated by the protocol therapy No prior or concurrent second\n",
      "        cancer except: Nonmelanomatous skin cancer In situ cervical cancer No pregnant women\n",
      "        Adequate contraception required of fertile patients Blood/body fluid analyses to determine\n",
      "        eligibility and quality-of-life questionnaire completed within 14 days prior to\n",
      "        randomization; imaging studies of sites of disease completed within 28 days prior to\n",
      "        randomization\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for metastatic disease or local recurrence Prior fluorouracil-based or other\n",
      "        adjuvant therapy allowed At least 6 months required between completion of therapy and\n",
      "        documentation of metastasis or recurrence Endocrine therapy: Not specified Radiotherapy:\n",
      "        Prior radiotherapy allowed Surgery: Prior surgery allowed\n",
      "2095\n",
      "DISEASE CHARACTERISTICS: Histologically proven unilateral, invasive breast cancer Stage\n",
      "        T0-3, N0-1, M0 No evidence of distant disease, including ipsilateral supraclavicular node\n",
      "        enlargement unless proven benign No carcinoma in situ alone, including Paget's disease of\n",
      "        the nipple without underlying invasion No evidence of distant disease, including\n",
      "        ipsilateral supraclavicular node enlargement unless proven benign No history of pure\n",
      "        carcinoma in situ in either breast Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 70 and under Sex: Female Menopausal status: Postmenopausal,\n",
      "        defined by 1 of the following criteria: Last menstrual period more than 1 year before\n",
      "        initial surgery Any age with prior bilateral oophorectomy (for nonmalignant reason) Age 50\n",
      "        and over with prior hysterectomy (for nonmalignant reason) without oophorectomy If at\n",
      "        variance with the above definitions, hormonal assays in postmenopausal range take\n",
      "        precedence Performance status: Not specified Life expectancy: Not specified Hematopoietic:\n",
      "        Not specified Hepatic: Not specified Renal: Not specified Other: No other serious illness\n",
      "        No other prior invasive malignancy except adequately treated basal cell or squamous cell\n",
      "        skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2102\n",
      "Inclusion Criteria\n",
      "        Concurrent Medication:\n",
      "        Allowed:\n",
      "          -  Antimicrobial agents not specifically prohibited.\n",
      "        Concurrent Treatment:\n",
      "        Allowed:\n",
      "          -  Transfusion.\n",
      "        Patients must have:\n",
      "          -  HIV positivity.\n",
      "          -  Prior PCP (histologically confirmed) OR documented CD4 count < 200 cells/mm3 OR\n",
      "             constitutional symptoms such as thrush or unexplained fever (> 100 F) for 2 or more\n",
      "             weeks.\n",
      "          -  No current or suspected active PCP, and no signs of active PCP on chest x-ray.\n",
      "          -  Prior intolerance to TMP/SMX or other trimethoprim or sulfa-containing regimens.\n",
      "          -  Life-expectancy of at least 6 months.\n",
      "        NOTE:\n",
      "          -  Pregnant women are eligible at the discretion of the investigator.\n",
      "        \n",
      "2106\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed nonlobular invasive breast cancer of one\n",
      "        of the following histologies: Ductal Papillary Medullary Colloid (mucinous) Tubular Stage\n",
      "        I/II (T1-2 N0-1 M0) tumor no greater than 3 cm Prior tylectomy and axillary lymph node\n",
      "        dissection required No more than 3 positive axillary lymph nodes and no extracapsular\n",
      "        extension At least 6 lymph nodes sampled OR Negative sentinal node Surgical clips in place\n",
      "        delineating margins of tylectomy cavity Negative, or close but negative, inked histologic\n",
      "        margins of tylectomy or re-excision specimen Negative margins defined as no tumor at least\n",
      "        2 mm away from the inked margins Close but negative margins defined as tumor within 2 mm\n",
      "        of inked margin Positive margins defined as invasive or noninvasive tumor at inked\n",
      "        resection margins Negative post-tylectomy or post-reexcision mammogram required if disease\n",
      "        presented with malignancy-associated microcalcifications No remaining suspicious\n",
      "        microcalcifications If catheters are placed at time of reexcision, the crieria may not be\n",
      "        feasible but a post brachytherapy mammogram should be obtained as soon as possible No\n",
      "        extensive intraductal carcinoma by the Harvard definition, i.e.: More than 25% of tumor is\n",
      "        ductal carcinoma in situ (DCIS) and there is DCIS in adjacent breast tissue OR Intraductal\n",
      "        carcinoma with microinvasion No proven multicentric carcinoma, i.e.: Tumor in different\n",
      "        quadrants of the breast OR Tumor separated by at least 4 cm The following exclude: Skin or\n",
      "        chest wall invasion Matted or fixed axillary adenopathy Metastatic internal mammary or\n",
      "        supraclavicular nodes Paget's disease of the nipple Previously treated contralateral\n",
      "        breast carcinoma or synchronous bilateral breast carcinoma Hormone receptor status: Not\n",
      "        specified\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified\n",
      "        Renal: Not specified Other: No collagen vascular disease with a c-reactive protein level\n",
      "        above normal or with an active skin rash (e.g., systemic lupus erythematosus, scleroderma,\n",
      "        or dermatomyositis) No coexisting medical condition that reduces life expectancy to less\n",
      "        than 2 years No second malignancy within 5 years except nonmelanomatous skin cancer Not\n",
      "        pregnant or nursing Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for breast cancer Planned chemotherapy may begin at least 2 weeks after\n",
      "        removal of brachytherapy catheters Endocrine therapy: Concurrent tamoxifen permitted\n",
      "        Radiotherapy: No prior radiotherapy for breast cancer Surgery: See Disease Characteristics\n",
      "2109\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor that is not\n",
      "        amenable to standard therapy No evidence of brain involvement or leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: ANC at least 2,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.5 mg/dL Transaminases normal\n",
      "        (no greater than 2.5 times normal if liver metastases) Alkaline phosphatase normal (no\n",
      "        greater than 2.5 times normal if liver or bone metastases) No history of chronic liver\n",
      "        disease, e.g., chronic active hepatitis, cirrhosis Renal: Creatinine no greater than 1.4\n",
      "        mg/dL Creatinine clearance at least 60 mL/min Other: No active bacterial infection (e.g.,\n",
      "        abscess) or with fistulae No grade 2 or worse neurotoxicity No concurrent medical\n",
      "        condition that precludes treatment No history of alcoholism, drug addiction, or psychotic\n",
      "        disorder Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed for\n",
      "        specific indications At least 4 weeks since prior biologic therapy, immunotherapy, or\n",
      "        growth factors Chemotherapy: No prior intensive chemotherapy with bone marrow or stem cell\n",
      "        support At least 4 weeks since chemotherapy (6 weeks since nitrosoureas, mitomycin, or\n",
      "        high-dose carboplatin) Endocrine therapy: Not specified Radiotherapy: At least 4 weeks\n",
      "        since radiotherapy Concomitant palliative local radiotherapy allowed for existing lesion\n",
      "        Surgery: Recovered from prior surgery Other: No concurrent investigational drug Concurrent\n",
      "        prophylactic antiemetics allowed after first therapy course\n",
      "2110\n",
      "DISEASE CHARACTERISTICS: Histologically proven previously untreated non-small cell lung\n",
      "        cancer that is not amenable to potentially curative surgery due to the following: Direct\n",
      "        invasion of the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or\n",
      "        carina by tumor (T4) Cytologically positive scalene or supraclavicular nodes Mediastinal\n",
      "        or contralateral hilar nodes 3 cm or greater on CT, with or without pathological\n",
      "        confirmation Pathologically positive mediastinal or contralateral hilar nodes on\n",
      "        mediastinoscopy or Chamberlain procedure (N2 or N3) Medically inoperable stage IIIA\n",
      "        disease (e.g., resection would result in insufficient pulmonary volume) allowed No distant\n",
      "        metastases No pleural effusion (regardless of fluid cytology) Evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-2 Hematopoietic: WBC\n",
      "        normal Platelet count normal Hepatic: Bilirubin no greater than 2 times upper limit of\n",
      "        normal (ULN) Transaminases no greater than 2 times ULN Alkaline phosphatase no greater\n",
      "        than 2 times ULN Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No significant\n",
      "        coronary artery disease No documented myocardial infarction No angina, arrhythmia, or\n",
      "        congestive heart failure requiring medication Pulmonary: FEV1 greater than 1 liter pO2\n",
      "        greater than 55 mm Hg on room air pCO2 less than 45 mm Hg on room air Other: No prior\n",
      "        severe hypersensitivity reaction to products containing Cremaphor EL No clinical evidence\n",
      "        of pre-existing polyneuropathy Not pregnant Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic irradiation\n",
      "        Surgery: See Disease Characteristics Other: No concurrent medications known to alter\n",
      "        cardiac conduction or cause bradycardia (e.g., digoxin, beta blockers, or calcium channel\n",
      "        blockers)\n",
      "2111\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed extragonadal and gonadal germ cell tumor\n",
      "        Seminoma and nonseminoma eligible Recurrent or refractory disease despite adequate\n",
      "        first-line cisplatin- or carboplatin-based chemotherapy and not amenable to surgery and/or\n",
      "        curative radiotherapy Relapse after disease-free interval of 1 or more years ineligible\n",
      "        Measurable or evaluable disease with documented progression within 2 months prior to entry\n",
      "        Elevated beta human chorionic gonadotropin and alpha-fetoprotein considered evaluable if\n",
      "        no other evaluable lesion and provided marker(s): Increased since end of last treatment At\n",
      "        least 10 times upper limit of normal unless due to tumor lysis Rising on 3 successive\n",
      "        occasions at least 2-3 days apart If no tumor markers available, cytology or histology\n",
      "        should be obtained No inadequately treated CNS metastases No pleural or pericardial\n",
      "        effusion and/or ascites\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute granulocyte count at least 2,000/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times normal AST/ALT no\n",
      "        greater than 3 times normal Alkaline phosphatase no greater than 2.5 times normal Renal:\n",
      "        Creatinine no greater than 1.6 mg/dL Creatinine clearance at least 60 mL/min if creatinine\n",
      "        borderline (1.1-1.6 mg/dL) Other: No active infection No severe malnutrition No\n",
      "        pre-existing grade 2 or worse neurotoxicity No pre-existing edema No senility or psychosis\n",
      "        No other expected difficulties for follow-up including geographic considerations No other\n",
      "        malignancy except: Second testicular primary tumor Treated basocellular and planocellular\n",
      "        skin carcinoma Adequately treated carcinoma in situ of the cervix Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No prior high dose chemotherapy with or without stem cell transplant At\n",
      "        least 3 weeks since chemotherapy and past WBC and platelet nadirs Endocrine therapy: Not\n",
      "        specified Radiotherapy: Not amenable to curative radiotherapy At least 3 weeks since\n",
      "        radiotherapy and recovered Surgery: Not amenable to surgery\n",
      "2112\n",
      "DISEASE CHARACTERISTICS: Histologically documented non-Hodgkin's lymphoma Needle or core\n",
      "        biopsy not acceptable as sole means of diagnosis No mantle cell or transformed lymphoma\n",
      "        One of the following International Working Formulation (IWF) histologic subtypes required:\n",
      "        Small lymphocytic with absolute lymphocytic count less than 5,000 (IWF A) Follicular,\n",
      "        predominately small cleaved cell (IWF B) Follicular, mixed (IWF C) Follicular, large cell\n",
      "        (IWF D) Diffuse, small cleaved cell (IWF E) Diffuse, mixed (IWF F) Diffuse, large cell\n",
      "        (IWF G) Large cell, immunoblastic (IWF H) Recurrent or refractory disease treated with no\n",
      "        more than 4 prior chemotherapy regimens Rebiopsy of a node at first relapse recommended\n",
      "        Prior etoposide (oral or intravenous) allowed if given for no more than 5 days every 3\n",
      "        weeks The following are considered 1 prior therapy each: Identical drugs given on 2\n",
      "        different schedules Bone marrow transplant preparative regimen (single cycle of\n",
      "        chemotherapy used solely to mobilize peripheral blood stem cells considered part of\n",
      "        preparative regimen) Ineligible for protocol CLB-9551 (aminocamptothecin) Measurable\n",
      "        disease by physical exam or imaging study required Indicator lesion larger than 1 x 1 cm\n",
      "        No prior radiotherapy to indicator lesion unless progression clearly documented The\n",
      "        following are not considered measurable: Barium study Ascites or pleural effusions Bony\n",
      "        disease Bone marrow involvement No known parenchymal or leptomeningeal CNS disease Lumbar\n",
      "        puncture not required prior to study\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: CALGB 0-2 Hematopoietic:\n",
      "        Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 times normal Renal: Creatinine no greater than 1.5 times\n",
      "        normal Other: HIV negative (testing required for patients at risk) No uncontrolled\n",
      "        infection No other serious medical condition that would interfere with evaluation of study\n",
      "        agent No psychiatric condition that would preclude protocol completion or informed consent\n",
      "        No second malignancy within 5 years except curatively treated: Basal cell skin cancer\n",
      "        Cervical cancer Not pregnant or nursing Adequate contraception required of fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 3 weeks since prior chemotherapy (3 weeks for nitrosoureas,\n",
      "        melphalan, or mitomycin) Endocrine therapy: No concurrent corticosteroids except for\n",
      "        physiologic replacement Radiotherapy: At least 3 weeks since prior radiotherapy Surgery:\n",
      "        Not specified Other: No other concurrent investigational agent\n",
      "2113\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed solid tumor or lymphoma that is progressive\n",
      "             or refractory to conventional therapy or for which no effective therapy is known\n",
      "          -  Priority given to hormone-refractory prostate cancer and melanoma\n",
      "          -  No untreated CNS metastases\n",
      "          -  Head CT not required in the absence of clinical signs or symptoms but recommended for\n",
      "             metastatic melanoma\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: At least 3 months\n",
      "          -  WBC greater than 2,000/mm3 OR absolute neutrophil count greater than 1,500/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  Hemoglobin greater than 9 g/dL\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  AST/ALT less than 1.5 times normal\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "          -  Obstructive uropathy allowed if relieved by nephrostomy or other appropriate device\n",
      "          -  Left ventricular ejection fraction greater than 40% by MUGA or normal by\n",
      "             echocardiogram\n",
      "          -  No history of congestive heart failure\n",
      "          -  No uncontrolled hypertension (diastolic greater than 110 mm Hg)\n",
      "          -  Forced expiratory volume (1 second) greater than 1.5 L/min\n",
      "          -  No active infection, including HIV or viral hepatitis\n",
      "          -  No active seizure disorder\n",
      "          -  No clinical evidence of increased intracranial pressure\n",
      "          -  No baseline dementia (mini-mental exam less than 23)\n",
      "          -  No autoimmune disease, including systemic lupus erythematosus, scleroderma, or other\n",
      "             connective tissue illness\n",
      "          -  No nonmalignant medical or psychiatric problem of sufficient severity to limit full\n",
      "             compliance with study or to pose undue risk\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required of fertile patients for 2 weeks prior to, during, and\n",
      "             for 3 months after study\n",
      "          -  Normal gastrointestinal function with ability to tolerate large intake of oral volume\n",
      "             required for phenylbutyrate administration\n",
      "          -  Patients with persistent nausea or moderate to severe anorexia may not be good\n",
      "             candidates for study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Fully recovered from all prior therapy\n",
      "          -  Prior suramin allowed if serum suramin level less than 50 micrograms/mL at entry\n",
      "          -  At least 28 days since chemotherapy\n",
      "          -  No prior phenylacetate, phenylbutyrate, or antineoplaston therapy\n",
      "          -  The following may be continued during study:\n",
      "          -  Luteinizing hormone-releasing hormone agonist with evidence of tumor progression\n",
      "             (e.g., rising prostate-specific antigen, new lesions on bone scan) despite therapy\n",
      "          -  Adrenal steroid replacement (if needed)\n",
      "          -  Dexamethasone or other steroids\n",
      "          -  At least 4-6 weeks since flutamide with evidence of PSA progression required (if\n",
      "             possible)\n",
      "          -  At least 28 days since radiotherapy\n",
      "          -  At least 28 days since major surgery\n",
      "2115\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed renal cell carcinoma (RCC) that is metastatic or recurrent\n",
      "               -  No central nervous system or major nerve involvement\n",
      "               -  No more than 25% estimated hepatic replacement by tumor on CT or MRI\n",
      "          -  Measurable disease required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 80%-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 3 months\n",
      "        Hematopoietic:\n",
      "          -  Platelet count at least 80,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  AST and ALT no greater than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "        Cardiovascular:\n",
      "          -  Stress cardiac exam normal (exam performed in patients aged 50 and older and in those\n",
      "             with potential cardiac disease suggested by history, physical exam, or EKG)\n",
      "        Pulmonary:\n",
      "          -  FEV1 and VC greater than 65% of predicted (tests performed in patients with\n",
      "             significant smoking history and in those with potential pulmonary disease suggested\n",
      "             by history, physical exam, or x-ray)\n",
      "        Other:\n",
      "          -  No sites of ongoing bleeding\n",
      "          -  No HIV antibody or AIDS\n",
      "          -  No hepatitis B antigen\n",
      "          -  No systemic infection\n",
      "          -  No requirement for steroids\n",
      "          -  No psychiatric disease that precludes informed consent or safe administration of\n",
      "             immunotherapy\n",
      "          -  No second malignancy except:\n",
      "               -  Basal cell carcinoma\n",
      "               -  In situ cervical cancer\n",
      "               -  Other cancer provided all evaluable lesions are documented RCC\n",
      "          -  No pregnant or nursing women\n",
      "          -  Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior interleukin-2 therapy\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  At least 28 days since therapy for RCC\n",
      "2117\n",
      "DISEASE CHARACTERISTICS: Unilateral malignant pleural effusion requiring sclerosis (as\n",
      "        judged by the attending surgeon) At least 3 months since treatment of contralateral\n",
      "        effusion No chylous effusion\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        More than 2 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Able to undergo thoracoscopy under general or local anesthesia (as\n",
      "        determined by the attending surgeon) Not pregnant Tests and observations must be completed\n",
      "        within 1 week prior to randomization (chest x-ray within 1 week prior to procedure)\n",
      "        PRIOR CONCURRENT THERAPY: No prior intrapleural therapy No systemic therapy within 2 weeks\n",
      "        prior to randomization or 2 weeks post pleurodesis Biologic therapy: Not specified\n",
      "        Chemotherapy: No new systemic chemotherapy for 2 weeks prior to and at least 2 weeks after\n",
      "        pleurodesis Endocrine therapy: No new hormonal therapy for 2 weeks prior to and at least 2\n",
      "        weeks after pleurodesis No concurrent steroids used as antiemetics Radiotherapy: Prior\n",
      "        radiotherapy allowed No radiotherapy to entire hemithorax Palliative irradiation of\n",
      "        symptomatic bone lesions allowed on the affected side if field does not include a\n",
      "        significant portion of pleura Surgery: See Disease Characteristics\n",
      "2118\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven primary unresectable non-small cell lung\n",
      "             cancer (NSCLC) by mediastinoscopy, mediastinotomy, thoracotomy, video-assisted\n",
      "             thoracic surgery, or needle biopsy\n",
      "               -  Stage IIIA (N2) disease by chest CT scan\n",
      "               -  Any histologic subtype allowed\n",
      "          -  At least 1 unidimensionally or bidimensionally measurable target lesion on chest CT\n",
      "             scan\n",
      "          -  No N3 or metastatic disease by physical exam, CT scan of thorax, bone scan, and CT\n",
      "             scan or ultrasound of liver and adrenals\n",
      "          -  No pre-existing pleural or pericardial effusion\n",
      "          -  No symptomatic CNS involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No superior vena cava syndrome\n",
      "        Pulmonary:\n",
      "          -  No diffuse interstitial pulmonary fibrosis\n",
      "        Other:\n",
      "          -  No prior melanoma, breast cancer, or hypernephroma\n",
      "          -  No other primary malignancy within the past 5 years except adequately treated basal\n",
      "             cell skin cancer or carcinoma in situ of the cervix\n",
      "          -  No grade 2 or greater pre-existing motor or sensory neurotoxicity\n",
      "          -  No active uncontrolled infection requiring IV antibiotics\n",
      "          -  Must be physically and mentally fit for study therapy\n",
      "          -  No psychological, familial, sociological, or geographical condition that would\n",
      "             preclude study compliance\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for NSCLC\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for NSCLC\n",
      "        Surgery:\n",
      "          -  No prior surgery for NSCLC\n",
      "        Other:\n",
      "          -  No other prior therapy for NSCLC\n",
      "2122\n",
      "DISEASE CHARACTERISTICS: Histologically documented diffuse small noncleaved cell lymphoma\n",
      "        (category J by IWF) of any stage Nodal or abdominal masses with less than 25% lymphoblasts\n",
      "        in marrow are defined as lymphoma OR Histologically documented L3 acute lymphocytic\n",
      "        leukemia (ALL) Greater than 25% lymphoblasts in marrow is defined as ALL, regardless of\n",
      "        presence of bulky nodal disease Lymphoma requirements include: Documentation of\n",
      "        lymphadenopathy, splenomegaly, or hepatomegaly, presence or absence of abdominal masses,\n",
      "        and presence or absence of B symptoms Measurable disease other than ascites and pleural\n",
      "        effusions, bony disease, and CNS lesions Bidimensionally measurable mass on physical exam,\n",
      "        x-ray, or CT, or MRI OR Clearly defined hepatic mass greater than 3.5 cm on CT, MRI, or\n",
      "        ultrasound considered to represent lymphoma OR Histologically documented hepatic lymphoma\n",
      "        with the liver extending more than 5 cm below the costal margin on quiet respiration ALL\n",
      "        requirements include: Documentation of monoclonal surface immunoglobulin by surface\n",
      "        immunophenotyping Lymph node biopsy strongly recommended for patients with obvious marrow\n",
      "        involvement Disease labeled L3 but also manifested by lymphadenopathy must be evaluated as\n",
      "        is lymphoma (see above)\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Any status Life expectancy:\n",
      "        At least 2 years Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times\n",
      "        normal (unless further elevation is directly attributable to malignancy) Renal: Creatinine\n",
      "        no greater than 1.5 times normal (unless further elevation is directly attributable to\n",
      "        malignancy) Cardiovascular: No uncontrolled or severe cardiovascular disease, e.g.: No\n",
      "        myocardial infarction within the past 6 months No congestive heart failure Other: HIV\n",
      "        negative No active, uncontrolled bacterial, viral, or fungal infection No active,\n",
      "        uncontrolled duodenal ulcer No other serious medical illness No serious psychiatric\n",
      "        condition that would preclude informed consent or protocol compliance No second malignancy\n",
      "        within 5 years except: Curatively treated carcinoma in situ of the cervix Curatively\n",
      "        treated basal cell carcinoma Not pregnant Effective contraception required of fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic: No concurrent growth factors Chemotherapy: Not\n",
      "        specified Endocrine therapy: Not specified Radiotherapy: No concurrent palliative\n",
      "        radiotherapy Surgery: Not specified Other: No prior therapy\n",
      "2123\n",
      "DISEASE CHARACTERISTICS: One of the following hematologic malignancies that has failed 1\n",
      "        or 2 prior front-line chemotherapy regimens and is ineligible for treatment of higher\n",
      "        potential efficacy: Histologically confirmed chronic lymphocytic leukemia (CLL)\n",
      "        Intermediate- or high-risk (RAI stage I-IV) disease Evidence of active disease required by\n",
      "        at least one of the following for intermediate-risk CLL: One of the following B symptoms:\n",
      "        Weight loss of 10% or more in previous 6 months Extreme fatigue Fever over 100 F without\n",
      "        evidence of infection Night sweats Massive (more than 6 cm below left costal margin) or\n",
      "        progressive splenomegaly Massive (more than 10 cm in longest diameter) or progressive\n",
      "        lymphadenopathy Progressive lymphocytosis with more than 50% increase over 2-month period\n",
      "        or anticipated doubling time of less than 12 months Progressive bone marrow failure as\n",
      "        manifested by development or worsening of anemia and/or thrombocytopenia Autoimmune anemia\n",
      "        and/or thrombocytopenia poorly responsive to corticosteroids Biopsy proven low-,\n",
      "        intermediate-, or high-grade non-Hodgkin's lymphoma Transformed lymphoma allowed\n",
      "        Measurable disease required Re-treatment on this study allowed if disease relapsed after a\n",
      "        complete remission\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: ANC at least 1,500/mm3 (at least 1,000/mm3 in CLL\n",
      "        patients with at least 30% marrow involvement) Platelets at least 100,000/mm3 (at least\n",
      "        50,000/mm3 in CLL patients with at least 30% marrow involvement) Hepatic: Bilirubin less\n",
      "        than 1.5 mg/dL Transaminases less than 2.5 times normal Renal: Creatinine no greater than\n",
      "        1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No history of\n",
      "        impaired cardiac status, e.g.: Severe coronary artery disease Cardiomyopathy Uncontrolled\n",
      "        congestive heart failure Arrhythmia Other: No known AIDS or HIV infection No second\n",
      "        malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer In situ\n",
      "        cervical cancer Not pregnant or nursing Effective contraception required of fertile\n",
      "        patients during and for 2 months after study\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent therapy Biologic therapy: Not specified\n",
      "        Chemotherapy: See Disease Characteristics At least 4 weeks since chemotherapy (8 weeks\n",
      "        since nitrosoureas or mitomycin) and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since radiotherapy and recovered Surgery: Not specified\n",
      "        Other: No prior bone marrow transplant\n",
      "2124\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary or recurrent desmoid tumor\n",
      "        Unresectable and symptomatic or progressive disease OR Disease for which a mutilating\n",
      "        surgery would be required for complete resection Bidimensionally measurable or clinically\n",
      "        evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over (no prepubertal patients) Performance status:\n",
      "        0-2 Life expectancy: More than 2 months Hematopoietic: Absolute granulocyte count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL\n",
      "        Transaminases no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no\n",
      "        greater than 3 times ULN Renal: Not specified Cardiovascular: No history of deep vein\n",
      "        thrombosis Other: Not pregnant Fertile patients must use effective barrier contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: No concurrent dexamethasone for antiemesis No other concurrent hormonal\n",
      "        therapy, including hormonal contraceptives Radiotherapy: Not specified Surgery: See\n",
      "        Disease Characteristics\n",
      "2131\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven carcinoid tumor with radiologically confirmed metastatic\n",
      "             disease\n",
      "          -  Recurrence after surgery or radiotherapy allowed\n",
      "          -  Must meet at least 1 of the following conditions:\n",
      "               -  Symptomatic carcinoid syndrome not controlled\n",
      "               -  Other systemic symptoms (e.g., weight loss, anorexia)\n",
      "               -  24 hour urinary 5-hydroxyindole acetic acid (5-HIAA) 100 mg or greater\n",
      "               -  Bone metastases\n",
      "               -  Carcinoid heart disease\n",
      "               -  Carcinoid asthma\n",
      "          -  Measurable disease or 24-hour urinary 5-HIAA 50 mg or greater required\n",
      "          -  No known brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 3.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  See Disease Characteristics\n",
      "        Pulmonary:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  No concurrent infection (no fever for at least 3 days prior to treatment unless fever\n",
      "             due to tumor)\n",
      "          -  No significant medical or psychiatric illness that would preclude study or informed\n",
      "             consent\n",
      "          -  No other malignancy within the past 5 years except basal cell or squamous cell skin\n",
      "             cancer or curatively treated stage I carcinoma of the cervix\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior interferon therapy\n",
      "        Chemotherapy:\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior endocrine therapy allowed\n",
      "          -  Concurrent octreotide allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Prior surgery allowed\n",
      "        Other:\n",
      "          -  No prior fluorinated pyrimidine\n",
      "2132\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of refractory or relapsed ovarian epithelial cancer\n",
      "               -  Must have failed prior regimen containing cisplatin or carboplatin\n",
      "          -  Bidimensionally measurable or evaluable disease\n",
      "               -  Serial CA-125 antigen titers or cytologically positive pleural effusion and/or\n",
      "                  ascites acceptable as evaluable disease\n",
      "          -  Autologous bone marrow harvest of greater than 1.2 x 10 to the eighth nucleated\n",
      "             cells/kg required before study entry\n",
      "          -  No evidence of tumor at marrow harvest sites by bilateral bone marrow aspirates and\n",
      "             biopsies, pelvic x-ray, and bone scan\n",
      "          -  CNS involvement allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 65\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,500/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Hemoglobin greater than 10.0 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  SGOT and SGPT less than 2 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "          -  No prior hemorrhagic cystitis\n",
      "        Cardiovascular:\n",
      "          -  LVEF greater than 45% by MUGA scan\n",
      "        Other:\n",
      "          -  No hearing loss in voice tones\n",
      "          -  No active infection\n",
      "          -  No psychological contraindication to study treatment\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  HIV negative\n",
      "          -  General medical condition must allow general anesthesia\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior bone marrow transplantation\n",
      "          -  More than 4 weeks since other prior biologic therapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or\n",
      "             mitomycin) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  More than 4 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2135\n",
      "DISEASE CHARACTERISTICS: Newly diagnosed oligodendroglioma or oligoastrocytoma (with at\n",
      "        least 25% oligodendral elements) Low-grade oligodendroastrocytoma or oligodendroglioma\n",
      "        that is recurrent after surgery without radiotherapy is allowed Prior partial or gross\n",
      "        total resection of tumor (or biopsy only in case of no further surgical option) required\n",
      "        At least 3 of the following histologic anaplastic features: High cellularity Endothelial\n",
      "        abnormalities Nuclear abnormalities Necrosis Mitoses\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 69 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.4 mg/dL Renal: Creatinine no greater than 1.3 mg/dL\n",
      "        Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception No active or uncontrolled infection No other disease,\n",
      "        including malignancy, that would preclude study No neurologic or psychiatric disturbance\n",
      "        that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No\n",
      "        prior radiotherapy to the skull Surgery: See Disease Characteristics\n",
      "2136\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically diagnosed primary systemic amyloidosis based on the following:\n",
      "               -  Deposition of fibrillary protein with Congo red positive stain or characteristic\n",
      "                  electron microscopic appearance\n",
      "               -  Monoclonal light chain protein (Bence-Jones protein) in serum or urine or\n",
      "                  immunohistochemical studies\n",
      "               -  Evidence of tissue involvement other than carpal tunnel syndrome\n",
      "               -  Diagnostic histologic material available for central pathology review\n",
      "                    -  Confirmation of tissue diagnosis at all sites of organ dysfunction\n",
      "                       encouraged\n",
      "          -  No senile, secondary, localized, dialysis-related, or familial amyloidosis\n",
      "          -  No known therapy-related myelodysplasia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Adult\n",
      "        Performance status:\n",
      "          -  SWOG 0-4\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No NYHA class IV status\n",
      "        Other:\n",
      "          -  No uncontrolled diabetes\n",
      "          -  No active peptic ulcer disease\n",
      "          -  No medical condition that precludes high-dose steroids\n",
      "          -  No second malignancy within 5 years except:\n",
      "          -  Adequately treated nonmelanomatous skin cancer\n",
      "          -  In situ cervical cancer\n",
      "          -  Adequately treated stage I/II cancer in complete remission\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of fertile patients\n",
      "          -  Blood/body fluid analyses within 14 days prior to registration\n",
      "          -  Imaging/exams for tumor measurement within 28 days prior to registration\n",
      "          -  Other screening exams within 42 days prior to registration\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior interferon alfa\n",
      "        Chemotherapy\n",
      "          -  Prior melphalan allowed, but recovered from effects\n",
      "          -  At least 4 weeks since cytotoxic therapy and recovered\n",
      "        Endocrine therapy\n",
      "          -  Prior prednisone allowed, but recovered from effects\n",
      "          -  At least 4 weeks since prior glucocorticoids\n",
      "          -  No prior dexamethasone\n",
      "          -  No planned or concurrent dexamethasone or other therapy for primary systemic\n",
      "             amyloidosis\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2137\n",
      "DISEASE CHARACTERISTICS: Histologically proven melanoma that is metastatic No tumor\n",
      "        replacement of 25% or more of liver on CT or MRI No involvement of the CNS or a major\n",
      "        nerve Measurable disease required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80%-100% Life\n",
      "        expectancy: More than 3 months Hematopoietic: No coagulopathy (i.e., platelets less than\n",
      "        80,000) Hepatic: Bilirubin normal Renal: Creatinine normal Cardiovascular: No abnormal\n",
      "        cardiac stress test in patients over 50 years of age or with possible cardiac disease\n",
      "        suggested by history, physical exam, or EKG Pulmonary: FEV1 or VC greater than 65% of\n",
      "        predicted in patients with significant smoking history or with suspected pulmonary disease\n",
      "        by history, physical exam, or x-ray Other: No site of ongoing bleeding No systemic\n",
      "        infection No HIV antibody No HBsAg No requirement for steroids No psychiatric disease that\n",
      "        precludes informed consent or protocol treatment No second malignancy except: Basal cell\n",
      "        skin carcinoma Carcinoma in situ of the cervix No pregnant or nursing women Negative\n",
      "        pregnancy test required of fertile women Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior interleukin-2 At least 28 days since treatment for\n",
      "        melanoma\n",
      "2139\n",
      "DISEASE CHARACTERISTICS: Diagnosis of intermediate- or high-grade soft tissue sarcoma of\n",
      "        the extremity amenable to limb-sparing procedure or amputation Buttocks or shoulder\n",
      "        lesions allowed if an artery is available for cannulation No metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine clearance at least 60\n",
      "        mL/min Cardiovascular: Ejection fraction at least 50% by MUGA scan No history of\n",
      "        congestive heart failure or severe angina pectoris Other: No other prior malignancy except\n",
      "        basal cell skin cancer or carcinoma in situ of the cervix Not pregnant Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        See Disease Characteristics\n",
      "2147\n",
      "DISEASE CHARACTERISTICS: Adenocarcinoma of the colon documented by colonoscopy or barium\n",
      "        enema Tumor either considered resectable or totally resected within 24 hours prior to\n",
      "        study No dual primary tumors Randomization within 2 weeks prior to surgery or within 24\n",
      "        hours after surgery required Patients randomized after surgery must meet the following\n",
      "        criteria: Complete resection performed with no evidence of residual disease or distant\n",
      "        metastases Distal margin of tumor above the peritoneal reflection in area of rectum No\n",
      "        free perforation Intestinal obstruction allowed Preliminary or complementary colostomy\n",
      "        allowed Concurrent registration for E-3293 strongly recommended\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than\n",
      "        2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Other: No prior nonmalignant\n",
      "        systemic disease that would preclude use of chemotherapy No second malignancy within 5\n",
      "        years except: Superficial nonmelanomatous skin cancer Carcinoma in situ of the cervix Not\n",
      "        pregnant or nursing Fertile patients must use adequate contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        fluorouracil No other prior or concurrent chemotherapy for this malignancy Endocrine\n",
      "        therapy: Not specified Radiotherapy: No prior or concurrent radiotherapy for this\n",
      "        malignancy Surgery: See Disease Characteristics\n",
      "2149\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic melanoma that is deemed grossly surgically\n",
      "             resectable\n",
      "               -  Multiple resected sites or metastatic melanoma of unknown primary allowed\n",
      "                  provided all known disease can be grossly resected\n",
      "               -  Recurrence in iliac lymph nodes after inguinal lymph dissection allowed\n",
      "          -  No metastatic disease beyond the lesions planned for resection\n",
      "               -  Confirmed by CT scan of chest, abdomen, pelvis, and CT or MRI of brain within 42\n",
      "                  days of study\n",
      "          -  Concurrent registration on protocol SWOG-9431 required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other malignancy within the past 5 years except adequately treated basal cell or\n",
      "             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated\n",
      "             stage I or II cancer from which patient is currently disease free\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior immunotherapy in the adjuvant or metastatic setting allowed\n",
      "        Chemotherapy:\n",
      "          -  Prior chemotherapy in the adjuvant or metastatic setting allowed\n",
      "        Endocrine therapy:\n",
      "          -  Prior hormonal therapy in the adjuvant or metastatic setting allowed\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy in the adjuvant or metastatic setting allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 14 days since prior surgery in the adjuvant or metastatic setting\n",
      "        Other:\n",
      "          -  Recovered from prior therapy\n",
      "2150\n",
      "Inclusion Criteria:\n",
      "          -  Histologically documented non-small cell carcinoma\n",
      "          -  Completely resected T2N0M0 Stage I NSCLC as defined by the International Staging\n",
      "             System\n",
      "          -  Surgery shall consist of a lobectomy or pneumonectomy with resection of associated N1\n",
      "             lymph nodes (either by thoracotomy or thoracoscopy)\n",
      "          -  Patients must be randomized within 4 to 8 weeks from the date of complete surgical\n",
      "             resection\n",
      "          -  No prior chemotherapy or radiation for non-small cell lung cancer\n",
      "          -  Performance status of 0 or 1\n",
      "          -  Women must be non-pregnant and non-lactating; patients of childbearing potential must\n",
      "             agree to use an effective form of contraception while on study\n",
      "          -  Patients must have no history of previous or concomitant malignancy, other than\n",
      "             curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell\n",
      "             carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or\n",
      "             other cancer for which the patient has bee disease free for five years\n",
      "          -  Granulocytes >= 1,800/ul\n",
      "          -  Platelets >= 100,000/ul\n",
      "          -  Bilirubin < 1.5 mg/dl\n",
      "          -  SGOT (AST) < 2.0 x ULN\n",
      "2152\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed cancer not amenable to cure or long-term control by surgery,\n",
      "             radiotherapy, chemotherapy, or hormonal manipulations, including the following tumor\n",
      "             types:\n",
      "               -  Colon cancer\n",
      "               -  Lung cancer\n",
      "               -  Renal cancer\n",
      "               -  Breast cancer\n",
      "               -  Pancreatic cancer\n",
      "          -  Metastatic disease or subclinical disease at high risk of recurrence\n",
      "          -  No brain metastases unresponsive to irradiation or surgery\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-2 OR\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No prior or concurrent significant cardiovascular disease\n",
      "        Pulmonary:\n",
      "          -  No prior or concurrent pulmonary disease\n",
      "        Other:\n",
      "          -  No prior or concurrent autoimmune disease\n",
      "          -  No other prior or concurrent major medical illness\n",
      "          -  HIV negative\n",
      "          -  No clinical evidence of AIDS\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior hormonal therapy\n",
      "          -  No concurrent chronic steroid therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2153\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed ependymoma that is recurrent after\n",
      "        radiotherapy Histologic confirmation of recurrence encouraged but not required in patients\n",
      "        with pure ependymoma at diagnosis and unequivocal radiologic evidence of recurrence\n",
      "        Histologic confirmation of recurrence required in patients with mixed histology at\n",
      "        diagnosis Ependymoma at least 80% of histology No subependymoma Measurable or evaluable\n",
      "        disease on imaging exam\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Hematopoietic: WBC\n",
      "        at least 3,500 Platelets at least 130,000 Hepatic: Bilirubin no greater than 0.3 mg/dL\n",
      "        above normal Renal: Creatinine no greater than 0.3 mg/dL above normal Cardiovascular: No\n",
      "        NYHA class III/IV status Other: No uncontrolled infection No pregnant or nursing women\n",
      "        Negative pregnancy test required of fertile women Effective contraception required of\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cisplatin\n",
      "        or etoposide At least 4 weeks since chemotherapy (6 weeks since nitrosoureas) Endocrine\n",
      "        therapy: Steroid dose stable for at least 1 week prior to entry if indicator lesion in CNS\n",
      "        Radiotherapy: See Disease Characteristics At least 4 weeks since radiotherapy Surgery: Not\n",
      "        specified\n",
      "2154\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven resectable stage II or III adenocarcinoma of the stomach\n",
      "          -  No evidence of locally inoperable or distant metastases on chest x-ray and any\n",
      "             combination of abdominal ultrasound, CT scan, or laparoscopy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  WHO 0-1\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No clinical evidence of uncontrolled angina pectoris, cardiac failure, or significant\n",
      "             uncontrolled cardiac arrhythmia\n",
      "        Other:\n",
      "          -  No medical contraindication to study therapy\n",
      "          -  No other prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of\n",
      "             the cervix\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2155\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced breast cancer not eligible for\n",
      "        (or patient refuses participation in) a higher priority phase III SWOG study Local stage\n",
      "        IIIB/IV disease, i.e.: Inflammatory Fixed to chest wall Fixed to axillary lymph nodes\n",
      "        Recurrent disease Metastatic disease Disease stable or responsive to standard dose\n",
      "        systemic chemotherapy Measurable or evaluable disease required except: Unevaluable stage\n",
      "        IV disease (beyond draining lymph nodes) eligible following surgical resection,\n",
      "        radiotherapy, or chemotherapy Less than 30% bone marrow involvement on aspiration and\n",
      "        biopsy No active brain metastases CT or MRI required unless asymptomatic and no history of\n",
      "        brain metastases No large symptomatic pleural effusion\n",
      "        PATIENT CHARACTERISTICS: Age: Under 65 Performance status: SWOG 0 or 1 Hematopoietic:\n",
      "        Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 2.0 mg/dL ALT/AST no\n",
      "        greater than 2 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: Left ventricular ejection fraction at least\n",
      "        45% on MUGA No angina No history of myocardial infarction Exercise stress test without\n",
      "        definite ischemia required for: History suggestive of coronary disease Diabetes mellitus\n",
      "        Hypertension Age over 50 Pulmonary: FEV1 greater than 60% of predicted or greater than 2.0\n",
      "        liters DLCO greater than 60% of predicted Other: No prior hemorrhagic cystitis No active\n",
      "        systemic infection No active CNS disease (e.g., seizures) HIV negative No second\n",
      "        malignancy within 2 years except: Localized nonmelanomatous skin cancer Carcinoma in situ\n",
      "        of the cervix Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since chemotherapy and recovered No more than 2 different\n",
      "        prior chemotherapy regimens for metastatic disease No prior mitomycin or nitrosourea\n",
      "        Lifetime cumulative doxorubicin dose less than 350 mg per square meter Endocrine therapy:\n",
      "        Not specified Radiotherapy: At least 2 weeks since radiotherapy and recovered Surgery: At\n",
      "        least 3 weeks since major surgery and recovered\n",
      "2156\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic cancer of any type Measurable\n",
      "        or evaluable disease required, i.e.: Bidimensionally measurable lesions on physical exam,\n",
      "        x-ray, CT, MRI, or other radiologic procedure Any lesion apparent on radiologic exam that\n",
      "        is not measurable in 2 perpendicular diameters Previously irradiated lesions acceptable\n",
      "        provided subsequent progression is documented No active brain metastases Previously\n",
      "        treated brain metastases allowed provided measurable/evaluable disease exists outside the\n",
      "        CNS\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:\n",
      "        (within 14 days prior to entry) WBC at least 3,000 Platelets at least 100,000 Hematocrit\n",
      "        at least 30% (may be transfused) Hepatic: (within 14 days prior to entry) Bilirubin less\n",
      "        than 2.0 mg/dl PT and PTT normal Renal: (within 14 days prior to entry) Creatinine less\n",
      "        than 2.0 mg/dl Cardiovascular: No MI within 6 months No medication for arrhythmia No\n",
      "        medication for CHF Hypertension that is stable off medication allowed Pulmonary: pO2 at\n",
      "        least 60 mm Hg in patients with primary lung cancer or symptomatic pulmonary disease\n",
      "        Reasonable respiratory reserve No dyspnea at rest No requirement for supplemental oxygen\n",
      "        Other: No familial history of malignant hyperthermia No chronic underlying\n",
      "        immunodeficiency disease No HIV seropositivity No active infection requiring antibiotic\n",
      "        therapy No other serious intercurrent illness No concurrent malignancy No pregnant or\n",
      "        nursing women Adequate contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent therapy with other anticancer agents No concurrent\n",
      "        immunosuppressive agents (e.g., cyclosporin) Biologic therapy: Prior interferon alpha\n",
      "        allowed Chemotherapy: At least 4 weeks since systemic chemotherapy with recovery required\n",
      "        Endocrine therapy: No concurrent corticosteroids Radiotherapy: At least 4 weeks since\n",
      "        radiotherapy Surgery: Adequate recovery required Other: No prior organ allograft\n",
      "2158\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer Newly\n",
      "        diagnosed or progressive metastatic disease with at least 1 metastatic target lesion No\n",
      "        known clinical brain or leptomeningeal metastasis Phase I entry: Measurable and/or\n",
      "        evaluable disease with an indicator lesion outside prior radiotherapy field Phase II\n",
      "        entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator\n",
      "        lesion outside prior radiotherapy field At least 1 x 1 cm on chest x-ray At least 2 x 2 cm\n",
      "        on CT scan or ultrasound Skin lesion or node at least 1 x 1 cm No bone-only lesion Hormone\n",
      "        receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Hematopoietic: Absolute granulocyte count at least 2,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no\n",
      "        greater than the upper limit of normal (ULN) AST/ALT no greater than 1.5 times ULN\n",
      "        Alkaline phosphatase no greater than 2.5 times ULN (no greater than 5.0 times ULN if\n",
      "        AST/ALT normal) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: Left\n",
      "        ventricular ejection fraction at least 50% at rest by MUGA or echocardiogram No congestive\n",
      "        heart failure No angina pectoris (even if controlled) No myocardial infarction within the\n",
      "        past year No uncontrolled arrhythmia No uncontrolled hypertension Other: No active\n",
      "        infection No grade 2 or greater symptomatic peripheral neuropathy No significant\n",
      "        neurologic or psychiatric disorder, including dementia or seizures No peptic ulcer,\n",
      "        unstable diabetes mellitus, or other contraindication to dexamethasone No prior malignancy\n",
      "        except nonmelanomatous skin cancer or excised carcinoma in situ of the cervix Not pregnant\n",
      "        or nursing Fertile patients must use effective contraception Geographically accessible\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent supportive colony-stimulating\n",
      "        factors (e.g., filgrastim (G -CSF)) (Prophylactic treatment during the second step of\n",
      "        phase I allowed) Chemotherapy: Phase I patients: At least 12 months since prior adjuvant\n",
      "        chemotherapy Prior neoadjuvant chemotherapy allowed Prior cumulative dose of doxorubicin\n",
      "        no greater than 300 mg/m2 Prior cumulative dose of epirubicin no greater than 500 mg/m2 If\n",
      "        epirubicin dose level at least 90 mg/m2: Prior cumulative dose of doxorubicin no greater\n",
      "        than 200 mg/m2 Prior cumulative dose of epirubicin no greater than 300 mg/m2 Phase II\n",
      "        patients: (closed as of 03/27/2000) No prior neoadjuvant or adjuvant chemotherapy regimen\n",
      "        other than cyclophosphamide, methotrexate, and fluorouracil, or doxorubicin and\n",
      "        cyclophosphamide given for a maximum of 4 courses All patients: No prior chemotherapy for\n",
      "        metastatic disease No prior taxanes Endocrine therapy: Prior hormonal therapy in the\n",
      "        adjuvant and/or metastatic setting allowed if subsequent disease progression No more than\n",
      "        2 prior hormonal therapy regimens for metastatic disease No concurrent corticosteroids\n",
      "        (except for premedication or hypersensitivity reaction) Radiotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior radiotherapy (unless single fractions for\n",
      "        palliation) Concurrent local palliative radiotherapy for control of bone pain or for other\n",
      "        reasons with no curative intent allowed Concurrent whole-brain radiotherapy for brain\n",
      "        metastasis allowed No concurrent radiotherapy to sole measurable lesion Surgery: Not\n",
      "        specified Other: No other concurrent investigational drugs or anticancer therapy No\n",
      "        concurrent preventive IV antibiotics\n",
      "2160\n",
      "DISEASE CHARACTERISTICS: Cytologically confirmed unilateral malignant pleural effusion or\n",
      "        exudative effusion with positive biopsy from any tumor type No chylous effusion Drainage\n",
      "        of effusion with chest tube or soft catheter required Lung re-expansion demonstrated on\n",
      "        chest x-ray Continuing drainage less than 250 mL/24 hours (or equivalent measured over 4\n",
      "        hours)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:\n",
      "        (within 2 weeks prior to entry) WBC greater than 2,000 Platelets greater than 50,000\n",
      "        Hepatic: Not specified Renal: (within 2 weeks prior to entry) Creatinine less than 2.5\n",
      "        mg/dL OR Creatinine clearance greater than 40 mL/min Other: No pregnant or nursing women\n",
      "        Adequate contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior sclerosing agents on the affected side No prior\n",
      "        intrapleural therapy No change in systemic therapy for at least 2 weeks prior to\n",
      "        randomization Biologic therapy: Not specified Chemotherapy: No prior systemic bleomycin\n",
      "        Systemic chemotherapy allowed after pleurodesis Endocrine therapy: Hormone therapy allowed\n",
      "        after pleurodesis Radiotherapy: No significant radiotherapy to affected hemithorax\n",
      "        Irradiation of painful bone lesions allowed on the affected side if field does not include\n",
      "        a significant portion of the pleura Surgery: See Disease Characteristics No prior\n",
      "        thoracoscopic lysis of adhesions on the affected side\n",
      "2161\n",
      "DISEASE CHARACTERISTICS: Histopathologically proven non-small cell lung cancer that is\n",
      "        incurable by surgery or radiotherapy Brain metastases allowed Demonstrated resistance to\n",
      "        prior chemotherapy required by 1 of the following: Tumor growth or recurrence while on\n",
      "        treatment Failure of tumor to shrink over 3 consecutive courses of treatment Measurable or\n",
      "        evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Greater than 12 weeks Hematopoietic: ANC at least 1,500 Platelets at least 100,000\n",
      "        Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.5 mg/dL (26 micromoles/L)\n",
      "        AST/ALT less than 1.5 times normal Renal: Creatinine less than 1.6 mg/dL (150\n",
      "        micromoles/L) Cardiovascular: No uncontrolled hypertension or other cardiac disease No\n",
      "        myocardial infarction within 6 months Other: No uncontrolled diabetes No active abuse of\n",
      "        ethanol No allergies to study medication No active infection or other serious medical\n",
      "        condition that precludes protocol treatment No dementia or significantly altered mental\n",
      "        status that precludes informed consent No prior melanoma or malignancy of the following\n",
      "        sites: Breast Kidney Thyroid Salivary glands Endometrium No other second malignancy within\n",
      "        5 years except: Nonmelanomatous skin cancer Carcinoma in situ of cervix No pregnant or\n",
      "        nursing women Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Recovery from any treatment-limiting toxicity required Biologic\n",
      "        therapy: Not specified Chemotherapy: At least 3 weeks since myelosuppressive chemotherapy\n",
      "        (6 weeks since nitrosoureas, mitomycin, or high-dose carboplatin) Endocrine therapy: Not\n",
      "        specified Radiotherapy: At least 3 weeks since radiotherapy unless to a limb or limited\n",
      "        treatment area Surgery: Not specified\n",
      "2162\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and\n",
      "        neck considered incurable by surgery or radiotherapy Newly diagnosed extensive\n",
      "        locoregional disease or distant metastases Locoregionally recurrent or persistent disease,\n",
      "        or distant metastases occurring after initial surgery or radiotherapy No nasopharyngeal\n",
      "        carcinoma No history of brain metastases Measurable or evaluable disease Documented\n",
      "        progressive disease or biopsy-proven residual carcinoma required if sole measurable site\n",
      "        previously irradiated\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Hematopoietic:\n",
      "        ANC at least 1,500/mm3 Hemoglobin at least 10 g/dL (transfusion allowed) Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL AST/ALT no greater than twice normal Alkaline phosphatase no\n",
      "        greater than twice normal Renal: Creatinine no greater than 1.2 mg/dL OR Creatinine\n",
      "        clearance at least 50 mL/min Calcium normal No history of hypercalcemia Cardiovascular: No\n",
      "        congestive heart failure No serious arrhythmia requiring medication No myocardial\n",
      "        infarction within 6 months No medications known to alter cardiac conduction (i.e.,\n",
      "        lanoxin, beta or calcium channel blockers) Other: No significant detectable or occult\n",
      "        infection Complete evaluation required if elevated WBC (12,000 or greater) or fever (101.6\n",
      "        F or higher) No hypersensitivity to E. coli-derived proteins No allergy to drugs utilizing\n",
      "        Cremophor No other malignancy within 3 years except curatively treated nonmelanomatous\n",
      "        skin cancer or carcinoma in situ of the cervix Not pregnant Negative pregnancy test\n",
      "        Fertile patients must use effective contraception Must complete quality of life and pain\n",
      "        assessments at required intervals\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for recurrent disease At least 12 months since induction or neoadjuvant\n",
      "        chemotherapy with paclitaxel or fluorouracil (6 months since cisplatin) Endocrine therapy:\n",
      "        Not specified Radiotherapy: See Disease Characteristics Surgery: Recovered from major\n",
      "        surgery\n",
      "2164\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven CNS germ cell tumor of 1 of the following subtypes:\n",
      "               -  CNS germinoma\n",
      "               -  Immature teratoma\n",
      "               -  Embryonal cell carcinoma\n",
      "               -  Yolk sac tumor\n",
      "               -  Endodermal sinus tumor\n",
      "               -  Choriocarcinoma OR\n",
      "          -  Pineal or suprasellar mass associated with elevated CSF alpha fetoprotein or\n",
      "             beta-human chorionic gonadotropin allowed\n",
      "          -  Patients 18 years and over with localized pure germinomas ineligible\n",
      "          -  Evaluable CT or MRI of brain and/or spinal cord required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  3 and over\n",
      "        Hematopoietic:\n",
      "          -  Age 18 and over:\n",
      "               -  WBC at least 4,000/mm^3\n",
      "               -  Platelet count at least 100,000/mm^3\n",
      "          -  Under age 18:\n",
      "               -  Absolute neutrophil count at least 1,000/mm^3\n",
      "               -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 0.3 mg/dL above upper limit of normal for age\n",
      "        Other:\n",
      "          -  No uncontrolled infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for CNS germ cell tumor\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed except as antiemetics\n",
      "        Radiotherapy:\n",
      "          -  No prior cranial or spinal radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2167\n",
      "DISEASE CHARACTERISTICS: Pathologically confirmed myeloid malignancies as follows: Acute\n",
      "        myelogenous leukemia that is relapsed or refractory after at least 2 courses of standard\n",
      "        induction chemotherapy Accelerated or myeloblastic chronic myelogenous leukemia Refractory\n",
      "        anemia with excess blasts (RAEB) RAEB in transformation Chronic myelomonocytic leukemia\n",
      "        More than 25% of bone marrow blasts positive for the CD33 antigen Clear signs of active\n",
      "        leukemia following recovery from prior therapy required No rapidly accelerating blast\n",
      "        count No clinically unstable disease No active CNS leukemia\n",
      "        PATIENT CHARACTERISTICS: Age: Over 16 Performance status: Karnofsky 60%-100% Life\n",
      "        expectancy: At least 6 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 2.5\n",
      "        mg/dL AST less than 3 times normal Alkaline phosphatase less than 3 times normal Renal:\n",
      "        Creatinine less than 2.0 mg/dL Cardiovascular: No NYHA class III/IV status Pulmonary: No\n",
      "        clinically significant pulmonary disease Other: No serious infection uncontrolled by\n",
      "        antibiotics No pregnant or nursing women Negative pregnancy test required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from prior therapy Biologic therapy: No detectable\n",
      "        antibodies to M195 from prior monoclonal antibody M195 or HuM195 Chemotherapy: At least 2\n",
      "        days since hydroxyurea At least 3 weeks since other chemotherapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: At least 3 weeks since radiotherapy Surgery: Not specified\n",
      "2168\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven mycosis fungoides/Sezary syndrome Stage I-IV\n",
      "        disease No CNS involvement At least 1 measurable lesion required (skin, lymph nodes,\n",
      "        visceral lesion, or peripheral blood counts)\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-3 Hematopoietic: WBC at\n",
      "        least 3,000/mm3 Platelet count at least 75,000/mm3 Hepatic: Bilirubin no more than 2.0\n",
      "        mg/dL Transaminases no more than 2 x normal Alkaline phosphatase no more than 2 x normal\n",
      "        Renal: Creatinine no more than 2.0 mg/dL Other: No active systemic infection No\n",
      "        significant organ failure uncontrolled with medication No pregnant or lactating women\n",
      "        Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior systemic therapy\n",
      "        Chemotherapy: At least 4 weeks since prior topical chemotherapeutics or systemic therapy\n",
      "        Endocrine therapy: At least 4 weeks since prior topical (including steroid) therapy or\n",
      "        systemic therapy Radiotherapy: Not specified Surgery: Not specified\n",
      "2169\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage I-V kidney cancer of one of the following histologies:\n",
      "               -  Wilms' tumor, favorable histology\n",
      "               -  Wilms' tumor, focal or diffuse anaplastic\n",
      "               -  Clear cell sarcoma\n",
      "               -  Rhabdoid tumor\n",
      "                    -  (The rhabdoid tumor stratum closed to accrual effective 07/13/2001)\n",
      "          -  Prior nephrectomy or biopsy required\n",
      "               -  Prior bilateral biopsy (preferably open) with bilateral staging and pathologic\n",
      "                  evaluation required for bilateral tumor\n",
      "          -  Must begin study therapy within 5 days after nephrectomy (unless medically\n",
      "             contraindicated)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 16\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2170\n",
      "DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the breast that is\n",
      "        potentially curable Prior treatment with one of the following therapies required:\n",
      "        Segmental mastectomy (lumpectomy) followed by radiotherapy Chest wall irradiation allowed\n",
      "        only in patients with T4 dermal involvement on pathologic diagnosis Further excision or\n",
      "        boost radiotherapy to the tumor bed recommended if microscopic disease found at mastectomy\n",
      "        margins Total mastectomy Chest wall irradiation required if microscopic disease found at\n",
      "        mastectomy margins Clinical stage T1-3a N0-2 M0 disease prior to surgery The following T4\n",
      "        features exclude: Chest wall extension Edema (including peau d'orange) Skin ulceration\n",
      "        Satellite skin nodules confined to same breast Inflammatory carcinoma Pathologic stage\n",
      "        T1-4 NX-2 M0 disease following surgery Eligible T4 tumors are those with dermal\n",
      "        involvement on pathology assessment only Pathologic assessment of axillary lymph nodes\n",
      "        required May be omitted in patients with clinical N0 status provided other entry criteria\n",
      "        are met No bilateral breast cancer without complete resection of both sides Hormone\n",
      "        receptor status: Estrogen and progesterone receptor status determined from primary tumor\n",
      "        when possible by quantitative biochemical methods or immunohistochemistry Results recorded\n",
      "        as positive or negative if immunohistochemistry used Unknown status does not exclude\n",
      "        provided other entry criteria are met\n",
      "        PATIENT CHARACTERISTICS: Age: Postmenopausal Sex: Women only Menopausal status:\n",
      "        Postmenopausal by one or more of the following: Amenorrhea lasting more than 1 year in\n",
      "        women under 50 years of age with no prior hysterectomy No menses for 6 months prior to\n",
      "        breast surgery in women 50 years of age and over with no prior hysterectomy Documented\n",
      "        oophorectomy prior to breast cancer diagnosis Luteinizing hormone and follicle-stimulating\n",
      "        hormone values diagnostic of postmenopausal status by local laboratory criteria Women 50\n",
      "        years of age and over with prior hysterectomy Performance status: ECOG 0-2 Life\n",
      "        expectancy: At least 5 years Hematopoietic: WBC at least 3,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: (unless metastatic disease ruled out by radiologic exam) AST or ALT\n",
      "        less than twice normal Alkaline phosphatase less than twice normal Renal: Not specified\n",
      "        Other: No symptomatic gallbladder disease or cholecystitis No intercurrent illness that\n",
      "        reduces life expectancy to less than 5 years No other major medical or psychiatric illness\n",
      "        that precludes study treatment or follow-up No second malignancy within 5 years except:\n",
      "        Adequately treated basal cell skin carcinoma Adequately treated cancer of the cervix,\n",
      "        endometrium, colon, or thyroid Able and willing to complete quality-of-life questionnaires\n",
      "        in English or French Illiteracy, loss of sight, or other inability to complete\n",
      "        questionnaires does not exclude Accessible for treatment and follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: Prior\n",
      "        or concurrent adjuvant chemotherapy allowed at investigator's discretion Recommended\n",
      "        regimens: CMF (cyclophosphamide/methotrexate/fluorouracil) CEF\n",
      "        (cyclophosphamide/etoposide/fluorouracil) AC (doxorubicin/cyclophosphamide) Choice of\n",
      "        adjuvant chemotherapy regimen defined prior to randomization if given concurrently with\n",
      "        protocol therapy Endocrine therapy: No estrogen, progestins, or androgen therapy for a\n",
      "        period of more than 30 days following pathologic diagnosis of breast cancer Prior\n",
      "        tamoxifen allowed All hormonal therapy discontinued prior to randomization Radiotherapy:\n",
      "        See Disease Characteristics Surgery: See Disease Characteristics\n",
      "2173\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung\n",
      "        cancer Stage IIIA/B disease No malignant pleural effusions Minimal residual disease after\n",
      "        one or a combination of the following: Incomplete surgical resection i.e., macroscopic\n",
      "        residual disease at completion of surgery Radical radiotherapy with no evidence of disease\n",
      "        progression at entry Documented complete or partial tumor response following at least 2\n",
      "        courses of cytotoxic chemotherapy No evidence of disease progression during or following\n",
      "        prior therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:\n",
      "        Absolute neutrophil count greater than 500/mm3 Platelet count greater than 50,000/mm3\n",
      "        Hepatic: Bilirubin less than 2.0 times upper limit of normal (ULN) AST/ALT no greater than\n",
      "        3.0 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No acute illness\n",
      "        within 1 week of start of study No other illness that would significantly interfere with\n",
      "        study outcome No major medical illness that precludes prolonged marimastat administration\n",
      "        No second malignancy within 5 years except: Adequately treated basal cell carcinoma of the\n",
      "        skin In situ carcinoma of the cervix Not pregnant or nursing Medically approved method of\n",
      "        contraception required of fertile women Willing and able to tolerate and comply with study\n",
      "        requirements\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No prior marimastat, batimastat, bleomycin, or busulphan No more than 1\n",
      "        cytotoxic chemotherapy regimen for non-small cell lung cancer Endocrine therapy: Not\n",
      "        specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics\n",
      "        Other: At least 4 weeks since any investigational drug therapies\n",
      "2174\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Acute myeloid leukemia (AML) in one of the following categories:\n",
      "          -  First relapse if initial CR less than 6 months\n",
      "          -  Refractory to first or second induction with daunomycin, cytarabine, and thioguanine\n",
      "             (DAT) or other anthracycline-containing regimens\n",
      "          -  Relapse following bone marrow transplantation provided good trilineage engraftment\n",
      "             followed transplant and greater than 6 months since transplant\n",
      "          -  Presentation with secondary AML or AML evolving from myelodysplastic syndrome --Acute\n",
      "             lymphocytic leukemia in one of the following categories:\n",
      "          -  In second or subsequent relapse or failed second or later induction attempts\n",
      "             regardless of prior remissions\n",
      "          -  Relapsed following bone marrow transplantation provided good trilineage engraftment\n",
      "             followed transplant and greater than 6 months since transplant\n",
      "          -  No isolated CNS or extramedullary relapse\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Under 22 at diagnosis\n",
      "          -  Performance status: Karnofsky 50-100% (ECOG 0-2)\n",
      "          -  Lansky 40-100% (in patients under 12 years of age)\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  ALT less than twice normal\n",
      "          -  Creatinine normal for age (within 2 standard deviations) OR glomular filtration rate\n",
      "             at least 70 mL/min\n",
      "          -  Albumin at least 3 g/dL\n",
      "          -  Ejection fraction greater than 50% at rest or with 5% increase with exercise OR\n",
      "             shortening fraction greater than 27% by echocardiogram\n",
      "          -  No history of clinical heart failure\n",
      "          -  No uncontrolled infection\n",
      "          -  No anticonvulsant therapy\n",
      "          -  No history of allergic reactions or anaphylaxis to etoposide not remediable by\n",
      "             premedication\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Third percentile weight for height\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since chemotherapy and recovered\n",
      "          -  Prior cumulative anthracycline dose no greater than 360 mg per square meter\n",
      "          -  Hydroxyurea therapy allowed just prior to study for rapidly rising blast count\n",
      "2175\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Multiple myeloma of any stage confirmed by:\n",
      "               -  Bone marrow plasmacytosis with at least 10% plasma cells, sheets of plasma\n",
      "                  cells, or biopsy proven plasmacytosis\n",
      "               -  Myeloma (M) protein in serum and/or urine\n",
      "          -  Measurable disease by at least one of the following:\n",
      "               -  Serum M-component at least 1.0 g/dL by electrophoresis\n",
      "                    -  Baseline measurement by nephelometry also, if used to follow response\n",
      "               -  Urine M-protein excretion greater than 200 mg/24 hours by electrophoresis\n",
      "          -  The following are not considered measurable but are followed for response:\n",
      "               -  Lytic bone lesions\n",
      "               -  Bone marrow plasmacytosis\n",
      "               -  Anemia\n",
      "               -  Serum beta 2-microglobulin\n",
      "          -  Objective evidence of progression by at least one of the following:\n",
      "               -  Increased serum M-protein (by electrophoresis unless M-spike less than 1.5 g/dL)\n",
      "                    -  At least 50% above lowest remission level or by at least 2 g/dL\n",
      "                    -  To more than 1.0 g/dL if sole protein indication of relapse\n",
      "                    -  Nephelometry may be used instead of electrophoresis\n",
      "               -  Increased urine M-protein\n",
      "                    -  To 50% above lowest level OR by 2 g/24 hours\n",
      "                    -  To greater than 200 mg/24 hours\n",
      "               -  Definite new lytic bone lesions or at least a 50% increase in size of existing\n",
      "                  lesions (discussion with ECOG Study Chairman required if sole indication of\n",
      "                  progression)\n",
      "               -  Increase in serum or urine M-protein by 25% to under 50% (as above) plus one of\n",
      "                  the following:\n",
      "                    -  Serum calcium greater than 12 mg/dL without other cause\n",
      "                    -  Hemoglobin decreased by more than 2.0 g/dL not attributed to chemotherapy,\n",
      "                       interferon therapy, or a myelodysplastic syndrome\n",
      "                         -  Less than 11 g/dL in men\n",
      "                         -  Less than 10 g/dL in women\n",
      "                    -  At least a 50% increase in bone marrow plasmacytosis\n",
      "          -  Failure of prior cytotoxic therapy defined by one of the following:\n",
      "               -  Never responded\n",
      "               -  Relapsed within 2 months of last treatment\n",
      "               -  Relapsed 2-12 months after last treatment following initial response\n",
      "          -  Adequate prior chemotherapy required, e.g.:\n",
      "               -  At least 2 courses of combination chemotherapy (e.g., VBMCP, VBAP, MP)\n",
      "                    -  Prior vincristine, doxorubicin, and dexamethasone (VAD) allowed\n",
      "                         -  No demonstrated resistance to VAD\n",
      "                         -  At least 3 months since prior VAD\n",
      "                    -  Cumulative doxorubicin dose no more than 250 mg/m2\n",
      "                    -  Prior autologous peripheral blood stem cell transplant allowed if performed\n",
      "                       prior to development of drug resistance\n",
      "                         -  No prior allogeneic transplant\n",
      "          -  No smoldering myeloma, localized plasmacytoma, or monoclonal gammopathy of\n",
      "             undetermined significance (MGUS)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-3\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  AST less than 1.5 times ULN\n",
      "          -  No chronic or active hepatitis or cirrhosis\n",
      "        Renal:\n",
      "          -  Creatinine less than 3.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Ejection fraction at least 50%\n",
      "          -  No history of congestive heart failure\n",
      "          -  No overt angina despite medication\n",
      "          -  No myocardial infarction within 2 months\n",
      "          -  No poorly controlled hypertension (i.e., pressure 200/110 or higher despite\n",
      "             medication)\n",
      "          -  No arrhythmia requiring therapy (i.e., sustained atrial or ventricular arrhythmia or\n",
      "             multifocal premature ventricular contraction)\n",
      "               -  Digoxin to control ventricular rate of atrial fibrillation that has been chronic\n",
      "                  for more than 1 month allowed\n",
      "        Neurologic:\n",
      "          -  No peripheral neuropathy with weakness\n",
      "          -  No cerebellar disease with ataxia\n",
      "        Gastrointestinal:\n",
      "          -  Adequate gastrointestinal function to allow absorption of PSC 833\n",
      "          -  No active peptic ulcer\n",
      "        Other:\n",
      "          -  No hypersensitivity to PSC 833 or cyclosporine\n",
      "          -  No active infection\n",
      "          -  HIV negative\n",
      "          -  No uncontrolled diabetes mellitus\n",
      "          -  No second malignancy within the past 5 years except curatively treated\n",
      "             nonmelanomatous skin cancer, carcinoma in situ of the cervix, or other localized\n",
      "             cancer treated with surgery alone\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No other serious medical problem unless sufficiently stabilized\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior biologic therapy (e.g., interferon) allowed\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since other prior chemotherapy (including plicamycin)\n",
      "        Endocrine therapy:\n",
      "          -  At least 2 weeks since high dose steroids (at least 100 mg/m2/day of prednisone or at\n",
      "             least 40 mg/day of dexamethasone (including steroids for hypercalcemia)\n",
      "        Radiotherapy:\n",
      "          -  At least 2 weeks since prior radiotherapy except limited radiotherapy to a single\n",
      "             bone lesion\n",
      "        Surgery:\n",
      "          -  At least 4 weeks since prior major surgery\n",
      "        Other:\n",
      "          -  No concurrent anticoagulants\n",
      "          -  No concurrent drugs known to modulate cyclosporine blood concentrations\n",
      "2176\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed mantle cell lymphoma (MCL) requiring\n",
      "        therapy NCCTG pathology review required - Repeat biopsy is required for previously treated\n",
      "        patients with previously biopsy proven MCL who relapse after achieving a partial or\n",
      "        complete remission - Rebiopsy is not required for patients with: Progression of previously\n",
      "        biopsy proven MCL who have not received therapy since the diagnostic biopsy OR Previously\n",
      "        biopsy proven MCL who progress or achieve less than a partial remission following initial\n",
      "        therapy Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin normal AST no greater than 3 times normal (5 times\n",
      "        normal with liver involvement) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular:\n",
      "        No uncontrolled hypertension No unstable angina No active congestive heart failure No\n",
      "        myocardial infarction within 6 months No serious uncontrolled arrhythmia Other: No active\n",
      "        or uncontrolled infection No HIV antibody No medical or psychiatric condition that\n",
      "        precludes participation No malignancy in the past 5 years, except carcinoma in situ of the\n",
      "        cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer\n",
      "        that is in remission following a radical retropubic prostatectomy or radiation therapy No\n",
      "        pregnant or nursing women Negative pregnancy test required of fertile women within 7 days\n",
      "        prior to entry Effective contraception required of fertile patients throughout study and\n",
      "        at least 30 days thereafter\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from any reversible acute toxic effects of previous\n",
      "        therapy Biologic therapy: Not specified Chemotherapy: At least 4 weeks since chemotherapy\n",
      "        (8 weeks since nitrosoureas or mitomycin) No prior fludarabine, pentostatin, or cladribine\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to greater than 25%\n",
      "        of bone marrow Surgery: Not specified\n",
      "2179\n",
      "DISEASE CHARACTERISTICS: One of the following incompletely staged malignancies: Ovarian\n",
      "        cancer of any cell type Primary fallopian tube carcinoma Primary peritoneal carcinoma No\n",
      "        clinical evidence of metastases to abdominal organs, the adnexa, or retroperitoneal lymph\n",
      "        nodes on CT with contrast or at prior abdominal surgery No metastases on chest x-ray No\n",
      "        contraindications to laparoscopy, i.e.: No bowel obstruction No ileus No peritonitis No\n",
      "        excessive obesity as indicated by a Quetelet Index over 35 (weight in kg/height in sqm) No\n",
      "        diaphragmatic hernia on chest x-ray No grade 2 heart toxicity\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Performance status: GOG 0 or 1 Hematopoietic: WBC at\n",
      "        least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no more than 1.5\n",
      "        mg/dL AST no more than 3 times normal Renal: Creatinine no more than 2.0 mg/dL Other: No\n",
      "        second malignancy except nonmelanomatous skin cancer Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or\n",
      "        concomitant chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior or\n",
      "        concomitant abdominal or pelvic radiotherapy Surgery: No prior retroperitoneal surgery No\n",
      "        more than 10 weeks since initial abdominal surgery\n",
      "2180\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologic evidence of one of the following malignancies that has failed conventional\n",
      "             therapy:\n",
      "               -  Acute lymphoblastic leukemia\n",
      "               -  Non-Hodgkin's lymphoma with bone marrow involvement\n",
      "               -  Osteogenic sarcoma\n",
      "          -  In vitro transport resistance to methotrexate demonstrated by bone marrow aspirate\n",
      "             assay\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  21 and under at diagnosis\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  Granulocytopenia allowed with bone marrow involvement\n",
      "          -  Thrombocytopenia allowed with bone marrow involvement\n",
      "          -  Anemia allowed with bone marrow involvement\n",
      "        Hepatic:\n",
      "          -  (unless due to disease)\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  AST no greater than 100\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Other:\n",
      "          -  No other serious medical illness\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior bone marrow transplantation allowed\n",
      "        Chemotherapy:\n",
      "          -  At least 1 week since prior intrathecal treatment\n",
      "          -  At least 2 weeks since prior systemic chemotherapy and recovered\n",
      "               -  At least 10 days for rapidly proliferating leukemia (i.e., WBC greater than\n",
      "                  50,000)\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy allowed and recovered\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2182\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed acute lymphoblastic leukemia (ALL)\n",
      "               -  More than 25% lymphoblasts in bone marrow\n",
      "                    -  Patients with myeloid antigen expression AND unequivocal lymphoid\n",
      "                       immunophenotype are eligible\n",
      "          -  Philadelphia (Ph) chromosome status determined by cytogenetics, fluorescence in situ\n",
      "             hybridization (FISH), and/or RNA analysis\n",
      "               -  Patients determined to be Ph chromosome negative by cytogenetics, but positive\n",
      "                  for BCR-ABL by FISH or polymerase chain reaction are considered Ph chromosome\n",
      "                  positive\n",
      "               -  Patients with Ph chromosome-positive disease may be up to age 65\n",
      "          -  No myelodysplasia or other antecedent hematologic disorder\n",
      "          -  Patients age 50 and under must be HLA typed during induction therapy of study\n",
      "             treatment OR provide a written explanation for not undergoing HLA typing\n",
      "               -  A and B typing required\n",
      "               -  C and DR typing done if feasible\n",
      "          -  Allogeneic stem cell transplantation patients must meet the following criteria:\n",
      "               -  Appropriate HLA histocompatible donor available\n",
      "                    -  Ph chromosome-negative patients must have HLA identical sibling\n",
      "                    -  Ph chromosome-positive patients must have HLA identical, HLA-matched\n",
      "                       unrelated, or haploidentical related donor\n",
      "          -  Postinduction therapy:\n",
      "               -  CSF negative for leukemia\n",
      "               -  No occult or overt leukemic meningitis\n",
      "               -  Documented complete remission\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to 65\n",
      "        Performance status:\n",
      "          -  Induction therapy:\n",
      "               -  Not specified\n",
      "          -  Postinduction therapy:\n",
      "               -  0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Induction therapy:\n",
      "               -  Direct bilirubin ≤ 2.0 mg/dL\n",
      "          -  Postinduction therapy:\n",
      "               -  Direct bilirubin < 2.0 mg/dL\n",
      "               -  SGPT or SGOT < 3 times normal\n",
      "        Renal:\n",
      "          -  Induction therapy:\n",
      "               -  Creatinine < 2 mg/dL\n",
      "          -  Postinduction therapy:\n",
      "               -  Creatinine ≤ 2 mg/dL\n",
      "               -  Creatinine clearance ≥ 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Induction and postinduction therapy:\n",
      "               -  No significant cardiac disease requiring digoxin and/or diuretics\n",
      "               -  No major ventricular dysrhythmia requiring medication\n",
      "               -  No ischemic heart disease requiring medication\n",
      "          -  Postinduction therapy:\n",
      "               -  Cardiac ejection fraction ≥ 50% for patients under consideration for\n",
      "                  transplantation\n",
      "        Pulmonary:\n",
      "          -  Induction therapy:\n",
      "               -  Not specified\n",
      "          -  Postinduction therapy:\n",
      "               -  FEV_1 ≥ 60% of predicted for patients under consideration for transplantation\n",
      "               -  DLCO ≥ 50% of predicted for patients under consideration for transplantation\n",
      "        Other:\n",
      "          -  Induction and postinduction therapy:\n",
      "               -  HIV negative\n",
      "               -  No concurrent organ damage or other medical problem (e.g., psychiatric disorder\n",
      "                  or drug abuse) that would preclude study therapy\n",
      "               -  Not pregnant\n",
      "          -  Postinduction therapy:\n",
      "               -  No persistent infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent umbilical cord allogeneic transplantation\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Prior corticosteroids for ALL allowed\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Induction and postinduction therapy:\n",
      "               -  No other prior therapy for ALL\n",
      "          -  Postinduction therapy:\n",
      "               -  No concurrent antibiotics\n",
      "2187\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Malignant solid tumor or lymphoma refractory to standard therapy or for which no\n",
      "             therapy of proven benefit exists\n",
      "          -  No leukemia\n",
      "          -  Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: Karnofsky 70-100%\n",
      "          -  Life expectancy: At least 3 months\n",
      "          -  WBC at least 3,500/mm3\n",
      "          -  Absolute neutrophil count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST/ALT less than twice normal (unless due to disease)\n",
      "          -  PT and PTT normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  No history of congestive heart failure requiring medical therapy\n",
      "          -  No clinically significant or life threatening cardiac arrhythmia\n",
      "          -  No history of significant pulmonary disease or lymphangitic lung disease\n",
      "          -  No hypersensitivity to cyclosporine or cremophore\n",
      "          -  No history of manifest or latent porphyria or hypersensitivity to barbiturates (for\n",
      "             parts of study using phenobarbital)\n",
      "          -  No history of inflammatory bowel disease requiring therapy\n",
      "          -  No chronic diarrhea syndrome or paralytic ileus\n",
      "          -  No medical or psychiatric condition that precludes informed consent\n",
      "          -  Not pregnant\n",
      "          -  Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since prior biologic therapy\n",
      "          -  At least 2 weeks since prior colony stimulating factors\n",
      "          -  At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas or\n",
      "             mitomycin)\n",
      "          -  No prior bleomycin or irinotecan\n",
      "          -  At least 4 weeks since prior radiotherapy to greater than 25% of bone marrow\n",
      "          -  Minimum time interval between prior therapy and eligibility shortened by 2 weeks when\n",
      "             phenobarbital is administered\n",
      "          -  Concurrent use of medications that affect the central nervous or cardiovascular\n",
      "             systems (e.g., anticonvulsants, calcium channel blockers, oral contraceptives) must\n",
      "             be approved by the Principal Investigator\n",
      "2188\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage II or IIIA breast cancer with at\n",
      "        least 4 positive axillary nodes Definitive resection required, preferably within 4 weeks\n",
      "        prior to entry No overt residual axillary nodal carcinoma after surgery Hormone receptor\n",
      "        status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0 or 1 Hematopoietic: Absolute neutrophil count greater than\n",
      "        1,500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL PT and\n",
      "        aPTT normal Hepatic: Bilirubin normal (unless benign congenital hyperbilirubinemia) Normal\n",
      "        liver biopsy required in patients with active hepatitis B or C Renal: Creatinine normal\n",
      "        Cardiovascular: No active heart disease Normal wall motion on MUGA or echocardiogram\n",
      "        Other: Adequate nutritional status (i.e., more than 1,000 calories/day orally) HIV\n",
      "        negative No serious medical or psychiatric disease No second malignancy except: Basal cell\n",
      "        skin cancer Carinoma in situ of the cervix Not pregnant Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: At least 2 weeks since major surgery\n",
      "2191\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma that has failed\n",
      "        standard local modalities for local disease and/or effective systemic therapy for\n",
      "        metastatic disease, or for which other forms of systemic therapy have been refused\n",
      "        Eligible sites include but are not limited to: Uterine cervix Head and neck Skin Esophagus\n",
      "        Lung Penis Measurable or evaluable disease required Measurable disease defined as\n",
      "        previously unirradiated disease reproducibly measurable in 2 dimensions by physical exam,\n",
      "        x-ray, CT, MRI, or other radiologic procedure Documented progressive disease in a\n",
      "        previously irradiated site is accepted as measurable Evaluable disease includes: Any\n",
      "        visible radiologic disease not measurable in 2 perpendicular diameters Elevated squamous\n",
      "        cell carcinoma antigen (SCCA) No active brain metastases Previously treated brain\n",
      "        metastases that have responded to therapy do not exclude, but CNS disease is not\n",
      "        considered measurable or evaluable\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        at least 3,000 Platelets at least 100,000 Hct at least 30% Hepatic: Bilirubin less than\n",
      "        2.0 mg/dl PT normal PTT normal Renal: Creatinine less than 2.0 mg/dl Cardiovascular: No MI\n",
      "        within 6 months No CHF requiring medication No arrhythmia requiring medication Pulmonary:\n",
      "        Reasonable respiratory reserve required No requirement for supplemental oxygen No dyspnea\n",
      "        at rest Other: No chronic underlying immunodeficiency disease No HIV positivity No\n",
      "        pregnant patients (negative pregnancy test required) Adequate birth control required of\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concomitant immunosuppressive drugs, e.g.,\n",
      "        cyclosporin Chemotherapy: At least 3 weeks since prior systemic chemotherapy with recovery\n",
      "        Endocrine therapy: No concomitant corticosteroids Radiotherapy: No prior radiotherapy to\n",
      "        measurable site unless disease progression is documented Surgery: Not specified\n",
      "2192\n",
      "DISEASE CHARACTERISTICS: Histologically proven or unequivocal radiologic evidence of\n",
      "        non-Hodgkin's lymphoma that has relapsed or is refractory after first-line chemotherapy\n",
      "        Unequivocal radiologic evidence of relapse defined as the presence of enlarged (at least 2\n",
      "        cm diameter) lymph nodes by CT scan or lymphangiogram Biopsy of accessible lymph nodes to\n",
      "        confirm relapse encouraged Low-, intermediate-, or high-grade disease Normal bilateral\n",
      "        bone marrow biopsy at time of bone marrow collection required (cellularity at least 20%\n",
      "        and no histologic evidence of tumor) History of marrow involvement allowed if present\n",
      "        marrow is histologically normal No disease progression in a previously irradiated site A\n",
      "        new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The\n",
      "        terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of\n",
      "        \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former\n",
      "        terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: CALGB 0-2 Karnofsky 70-100%\n",
      "        Life expectancy: More than 2 months Hematopoietic: Neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 3 times normal SGOT and\n",
      "        SGPT less than 3 times normal Alkaline phosphatase less than 3 times normal Hepatitis B\n",
      "        surface antigen negative Renal: Creatinine normal Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular: Cardiac ejection fraction normal by MUGA scan No uncontrolled or severe\n",
      "        cardiovascular disease, including the following: Myocardial infarction within the past 6\n",
      "        months Congestive heart failure Symptomatic angina (despite optimal medical management)\n",
      "        Life-threatening arrhythmia or hypertension Pulmonary: Pulmonary function tests (DLCO and\n",
      "        spirometry) greater than 60% predicted Other: HIV negative No serious organ dysfunction\n",
      "        (unless caused by lymphoma) No active bacterial, viral, or fungal infection No active\n",
      "        peptic ulcer disease No uncontrolled diabetes mellitus No other malignancy except\n",
      "        curatively treated carcinoma in situ of the cervix or basal cell or squamous cell skin\n",
      "        cancer No other serious medical or psychiatric illness that would preclude study Not\n",
      "        pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Prior nitrosourea allowed if cumulative dose no more than 600 mg/m2 Prior\n",
      "        bleomycin allowed if cumulative dose no more than 300 units/m2 Prior doxorubicin allowed\n",
      "        if cumulative dose no more than 450 mg/m2 No prior high-dose etoposide (more than 1,800\n",
      "        mg/m2) No prior high-dose cyclophosphamide (more than 100 mg/kg) No chemotherapy within 4\n",
      "        weeks (no melphalan, nitrosourea, or mitomycin within 6 weeks) prior to bone marrow\n",
      "        collection No prior salvage therapy Endocrine therapy: Not specified Radiotherapy: See\n",
      "        Disease Characteristics No prior radiotherapy to liver or lung Prior other radiotherapy\n",
      "        allowed if doses do not exceed the following limits: 1,400 cGy to the mediastinum 1,400\n",
      "        cGy to the whole abdomen 4,000 cGy to the CNS Surgery: Not specified\n",
      "2193\n",
      "DISEASE CHARACTERISTICS: Primary or secondary acute nonlymphocytic leukemia and acute\n",
      "        lymphocytic leukemia in one of the following states: First or greater remission Early\n",
      "        relapse Chronic myelogenous leukemia (CML) in one of the following states: First or\n",
      "        greater chronic phase Treatment on this protocol is preferred to total body irradiation\n",
      "        containing protocols for patients under 40 with CML in stable first chronic phase who are\n",
      "        otherwise eligible for allogeneic bone marrow transplantation Accelerated phase Myeloid or\n",
      "        lymphoid blast crisis Myelodysplastic syndromes of the following types: Refractory anemia\n",
      "        Refractory anemia with ringed sideroblasts Refractory anemia with excess blasts Chronic\n",
      "        myelomonocytic leukemia Multiple myeloma Non-Hodgkin's lymphoma HLA identical bone marrow\n",
      "        donor available Unable to undergo total body irradiation because of one of the following\n",
      "        reasons: Under age 2 (CNS still growing and at high risk of permanent radiation injury)\n",
      "        Prior high dose radiotherapy to the brain, lungs, heart, liver, or abdomen In relapse\n",
      "        following allogeneic or autologous transplant using total body irradiation for ablation,\n",
      "        but eligible for a second transplant No current CNS involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 50 and under (patients aged 51-55 accrued on a case-by-case\n",
      "        basis after discussion and approval by the BMT service) Performance status: Karnofsky\n",
      "        70-100% Life expectancy: Greater than 8 weeks Hematopoietic: Not specified Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL AST no greater than 3 times normal Neither value increasing\n",
      "        for at least 2-4 weeks prior to transplant Renal: Creatinine less than 2 times normal and\n",
      "        not rising for at least 2-4 weeks prior to transplant OR Creatinine clearance greater than\n",
      "        80 mL/min Cardiovascular: Left ventricular ejection fraction at least 50% Cardiac function\n",
      "        good Pulmonary: No severe restrictive lung disease No chronic obstructive pulmonary\n",
      "        disease Other: No active viral or bacterial infection at transplant No coexisting medical\n",
      "        problem that would significantly increase the risk of the transplant procedure Not\n",
      "        pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Prior therapy allowed, including prior bone marrow transplant\n",
      "2197\n",
      "DISEASE CHARACTERISTICS: Documented relapsed or refractory germ cell cancer of the\n",
      "        following sites of origin: Testes Ovary Retroperitoneum Mediastinum Other sites Any stage\n",
      "        of disease allowed Any histologic subtype allowed Seminoma only allowed if ineligible for\n",
      "        radiotherapy Failed to achieve complete remission (CR) following at least 3 courses of a\n",
      "        standard platinum-containing regimen or experienced clear relapse following CR obtained\n",
      "        with such a regimen Absence of tumor markers in the presence of stable residual masses\n",
      "        after initial treatment may be allowed (surgical biopsy should be performed; if medically\n",
      "        safe, to confirm persistence of disease and rule out mature teratoma or fibrosis) Prior\n",
      "        CNS involvement allowed in the absence of gross residual CNS tumor following definitive\n",
      "        local therapy (surgery plus radiotherapy) No gross tumor involvement on bone marrow biopsy\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 60 Performance status: Karnofsky 80-100%\n",
      "        Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 2 times normal Albumin greater\n",
      "        than 3.0 mg/dL Renal: Creatinine less than 1.8 mg/dL Cardiovascular: LVEF at least 50% No\n",
      "        other serious cardiac disease that would preclude transplantation Pulmonary: DLCO, FEV1,\n",
      "        and FVC at least 50% predicted pO2 at least 70 mm Hg on room air Other: HIV negative No\n",
      "        other concurrent serious psychiatric, neurologic, neoplastic, immunologic, or other\n",
      "        medical problem that would preclude transplantation Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics\n",
      "        No prior chest irradiation Surgery: See Disease Characteristics\n",
      "2204\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed neoplasm that is recurrent in the\n",
      "        subarachnoid space Biopsy of recurrent lesion required if original diagnosis made more\n",
      "        than 2 years prior to entry and CSF cytology negative Radiographic evidence of measurable\n",
      "        lesion in the leptomeninges (by myelography, CT, or MRI) or cytologic evidence of\n",
      "        malignancy in the CSF Any type of neoplasm eligible provided tumor cells (tissue or CSF\n",
      "        preparation) bind significantly to intact monoclonal antibody Me1-14 IgG2a or to Me1-14\n",
      "        F(ab')2 Patency of subarachnoid pathways demonstrated by isotopic intraventricular flow\n",
      "        PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%\n",
      "        Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: AST less than 1.5 times upper limit of normal (ULN) Alkaline\n",
      "        phosphatase less than 1.5 times ULN Renal: Creatinine less than 1.2 mg/dL Other: No\n",
      "        allergy to iodine Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior antineoplastic chemotherapy unless unequivocal evidence of tumor progression\n",
      "        No concurrent systemic chemotherapy Endocrine therapy: Corticosteroids allowed if at\n",
      "        lowest possible dose and stable for at least 10 days prior to entry Radiotherapy: At least\n",
      "        3 months since prior radiotherapy to site of measurable disease unless unequivocal\n",
      "        evidence of disease progression Surgery: Not specified\n",
      "2207\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven invasive squamous cell carcinoma of the true vocal cord\n",
      "               -  Stage II (T2a/b N0) disease with bulk of tumor present on vocal cord (i.e., the\n",
      "                  epicenter) with extension to adjacent areas\n",
      "          -  No verrucal carcinoma or adenocarcinoma\n",
      "          -  No extension to pre-epiglottic space or pyriform sinus\n",
      "          -  No fixed cord or cartilage invasion\n",
      "          -  No evidence of adenopathy, including any of the following:\n",
      "               -  Nodes larger than 1 cm by radiography\n",
      "               -  Nodes containing a low central density consistent with necrosis by radiography\n",
      "               -  Clinically palpable nodes larger than 1 cm and firm in consistency\n",
      "          -  No recurrent or persistent disease\n",
      "          -  No evidence or suspicion of distant metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the mid-neck or larynx\n",
      "        Surgery:\n",
      "          -  No prior complete stripping or laser excision of all gross disease\n",
      "2208\n",
      "DISEASE CHARACTERISTICS: Neuroblastoma histologically confirmed at initial diagnosis or\n",
      "        demonstration of malignant, small, round cell tumor with elevated catecholamine\n",
      "        metabolites Refractory to conventional therapy and other higher priority therapy\n",
      "        PATIENT CHARACTERISTICS: Age: No greater than 21 at diagnosis Performance status: 0-2 Life\n",
      "        expectancy: At least 2 months Hematopoietic: Cytopenias from marrow involvement eligible\n",
      "        with study chairman approval ANC at least 1,000 Platelets at least 100,000 (transfusion\n",
      "        independent) Counts between 70,000-100,000 allowed provided: Autologous bone marrow or\n",
      "        peripheral stem cells available for rescue Study chairman approves entry Hemoglobin at\n",
      "        least 8 g/dL (may transfuse) Hepatic: Bilirubin no greater than 1.5 times normal AST/ALT\n",
      "        less than 2.5 times normal Renal: Creatinine no greater than 1.5 times normal OR\n",
      "        Creatinine clearance or radioisotope GFR at least 70 mL/min per 1.73 square meters\n",
      "        Pulmonary: No history of dyspnea at rest No exercise intolerance Other: No active\n",
      "        infection requiring hospitalization No pregnant or nursing women Negative pregnancy test\n",
      "        required of fertile women Effective contraception required of fertile patients during and\n",
      "        for 2 months after study Patients unable to receive blood products due to religious\n",
      "        reasons may receive buthionine sulfoximine alone\n",
      "        PRIOR CONCURRENT THERAPY: At least 6 months since myeloablative therapy with bone marrow\n",
      "        transplantation Recovered from toxic effects of prior therapy Biologic therapy: Not\n",
      "        specified Chemotherapy: At least 3 weeks since chemotherapy (6 weeks since mitomycin or\n",
      "        nitrosourea) Endocrine therapy: Not specified Radiotherapy: At least 6 weeks since\n",
      "        radiotherapy to any extremity site or significant marrow-containing compartment At least 6\n",
      "        months since the following: More than 24 Gy craniospinal irradiation Total abdominopelvic\n",
      "        plus lung irradiation Mantle plus Y-port irradiation Total-body irradiation No palliative\n",
      "        radiotherapy to bony lesions within 1 month after entry Surgery: Not specified\n",
      "2210\n",
      "DISEASE CHARACTERISTICS: Metastatic cancer considered incurable by standard therapy and\n",
      "        for which no higher priority protocol is available Locally progressive primary brain\n",
      "        tumors (e.g., astrocytoma, glioma) are also eligible Brain metastases allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-4 (poor performance\n",
      "        status brain tumor patients specifically eligible) Life expectancy: At least 2 months\n",
      "        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: No\n",
      "        history of adult asthma No emphysema No pulmonary insufficiency No pulmonary edema Other:\n",
      "        No AIDS or positive HIV serology No pregnant women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified\n",
      "2211\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed invasive (stage II-IV) carcinoma of the\n",
      "        breast 8 or more positive axillary nodes required for stage II disease\n",
      "        Chemotherapy-responsive disease required of patients with measurable or evaluable disease\n",
      "        Partial or complete response to 3 courses of standard\n",
      "        cyclophosphamide/doxorubicin/fluorouracil (CAF) or, for patients who have had CAF,\n",
      "        cyclophosphamide/methotrexate/fluorouracil (CMF) 3-month course of standard\n",
      "        mitomycin/vinblastine or paclitaxel acceptable in patients clearly resistant to CAF or CMF\n",
      "        Visceral response despite progression in bone will be considered on an individual basis\n",
      "        Patients with no evidence of disease may be entered without evidence of a chemotherapy\n",
      "        response Resectable disease must be surgically removed prior to transplantation Hormone\n",
      "        receptor status: If estrogen-receptor positive, prior failure with at least 1 hormonal\n",
      "        manipulation required unless patient is premenopausal or has rapidly progressing visceral\n",
      "        disease No more than 20% of marrow involved with tumor\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 60 Sex: Women only Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 80%-100% Hematopoietic: WBC at least 4,000/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL AST less than 2 times\n",
      "        normal Albumin at least 3.0 g/dL Renal: Creatinine less than 1.8 mg/dL BUN less than 20\n",
      "        mg/dL Cardiovascular: Left ventricular ejection fraction at least 55% Pulmonary: DLCO,\n",
      "        FEV1, and FVC at least 50% of predicted pO2 at least 70 mm Hg on room air Other: No\n",
      "        serious psychiatric, neurologic, or medical illness that would compromise the safety of a\n",
      "        bone marrow transplant Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: See Disease Characteristics Radiotherapy: No prior\n",
      "        chest irradiation other than to locally involved lymph nodes Surgery: See Disease\n",
      "        Characteristics\n",
      "2212\n",
      "DISEASE CHARACTERISTICS: Primary central nervous system non-Hodgkin's lymphoma (PCNSL)\n",
      "        Clinically diagnosed intracranial space-occupying lesion Pathology consistent with\n",
      "        non-Hodgkin's lymphoma and reviewed by NCCTG Biopsy optional if characteristic history,\n",
      "        pathognomonic neuroimaging, and cytology are consistent with malignant lymphocytes from\n",
      "        vitrectomy, CSF, or both No occult systemic lymphoma or prior lymphoma No post-transplant\n",
      "        lymphoproliferative disorder Disease measurable or evaluable on postoperative\n",
      "        contrast-enhanced CT or MRI Postoperative therapy must start within 6 weeks of definitive\n",
      "        diagnosis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-3 Hematopoietic: WBC at\n",
      "        least 4,000/mm3 Platelet count at least 120,000/mm3 Hepatic: Bilirubin no greater than 2\n",
      "        times normal AST no greater than 2 times normal Renal: Creatinine no greater than 1.5\n",
      "        times normal Cardiovascular: No heart failure No uncontrolled arrhythmia Pulmonary: No\n",
      "        severe pulmonary failure Other: No serious uncontrolled infection No active bleeding No\n",
      "        AIDS or HIV-positive serology No prior organ transplant No pregnant or nursing women\n",
      "        Negative pregnancy test required of fertile women Adequate contraception required of\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Corticosteroids allowed if dose fixed or decreasing for at\n",
      "        least 1 week prior to baseline scan Radiotherapy: No prior radiotherapy Surgery: Not\n",
      "        specified\n",
      "2213\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Clinically and histologically proven diagnosis of 1 of the following:\n",
      "               -  Mycosis fungoides (MF) meeting 1 of the following conditions:\n",
      "                    -  Stage IIB disease that has failed psoralen ultraviolet A (PUVA) light\n",
      "                       therapy and topical chemotherapy (mechlorethamine and/or carmustine)\n",
      "                    -  Stage III disease with generalized erythroderma\n",
      "                    -  Stage IV disease with biopsy proven nodal or visceral involvement\n",
      "               -  Sezary syndrome\n",
      "                    -  Stage III MF with a minimum of 20% Sezary cells (based on total WBC)\n",
      "          -  No clinically significant ascites or pleural effusion\n",
      "               -  Clinically significant pleural effusion defined as shortness of breath with\n",
      "                  oxygen saturation less than 90%\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 80\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  At least 16 weeks\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 11.5 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.5 times normal\n",
      "          -  SGOT less than 2.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  No nephrotic syndrome\n",
      "        Cardiovascular:\n",
      "          -  No history of myocardial infarction or congestive heart failure\n",
      "          -  No symptomatic coronary artery disease\n",
      "          -  No clinically manifest hypotension\n",
      "          -  No severe hypertension\n",
      "          -  No arrhythmia on electrocardiogram\n",
      "          -  No edema\n",
      "          -  No contraindication to pressor agents\n",
      "        Pulmonary:\n",
      "          -  See Disease Characteristics\n",
      "          -  No dyspnea at rest or severe exertional dyspnea\n",
      "        Neurologic:\n",
      "          -  No significant CNS dysfunction, including any of the following:\n",
      "               -  Seizure disorder\n",
      "               -  Active cerebrovascular disease\n",
      "               -  Dementia or delirium\n",
      "        Other:\n",
      "          -  No autoimmune disease, including psoriasis\n",
      "          -  No uncontrolled peptic ulcer disease\n",
      "          -  No uncontrolled infection\n",
      "          -  No history of adverse reaction to interleukin-2\n",
      "          -  HIV and HTLV-I negative\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior systemic or topical chemotherapy (6 weeks since prior\n",
      "             mitomycin or nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  At least 1 week since prior corticosteroids\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No prior organ allograft\n",
      "          -  At least 3 weeks since other prior major surgery\n",
      "        Other:\n",
      "          -  At least 4 weeks since prior immunosuppressive therapy\n",
      "          -  At least 2 weeks since prior phototherapy (ultraviolet B [UVB] or PUVA light therapy)\n",
      "          -  No concurrent phototherapy (UVB or PUVA light therapy)\n",
      "2215\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage T1-3, pN1, M0 carcinoma of the breast\n",
      "        considered suitable for adjuvant treatment with endocrine therapy alone Estrogen receptor\n",
      "        at least 10 fmol/mg cytosol protein or positive on immunohistochemical assay Potentially\n",
      "        curative resection within 6 weeks of entry by one of the following: Total mastectomy with\n",
      "        negative margins Breast-conserving procedure (lumpectomy or quadrantectomy) for tumors\n",
      "        less than 5 cm Adequate re-resection or mastectomy within 4 weeks of initial surgery\n",
      "        required if margins are positive after initial surgery Axillary clearance (not sampling)\n",
      "        required at surgery, with at least 1 node positive upon histopathologic examination of at\n",
      "        least 8 nodes Suspicious manifestations of metastatic disease (e.g., hot spots on bone\n",
      "        scan, skeletal pain of unknown cause) must be proven benign No bilateral breast cancer Any\n",
      "        mass in contralateral breast must be proven benign by biopsy\n",
      "        PATIENT CHARACTERISTICS: Age: 70 and under Sex: Women only Menopausal status:\n",
      "        Peri/postmenopausal, i.e.: More than 6 months since last normal menstrual period (LNMP)\n",
      "        with no prior hysterectomy and no hormone replacement therapy (HRT) Prior hysterectomy and\n",
      "        no HRT and either age greater than 55 or age 55 or less with postmenopausal LH, FSH, and\n",
      "        E2 levels On HRT and either age 50 or greater or LNMP more than 6 months prior to starting\n",
      "        HRT Performance status: Not specified Hematopoietic: WBC greater than 4,000 Platelets\n",
      "        greater than 100,000 Hepatic: Bilirubin less than 1.1 mg/dL (20 micromoles/L) AST less\n",
      "        than 60 IU/L Renal: Creatinine less than 1.3 mg/dL (120 micromoles/L) Other: No\n",
      "        nonmalignant systemic disease that would preclude protocol therapy or prolonged follow-up\n",
      "        No psychiatric or addictive disorder that would preclude informed consent No prior or\n",
      "        concurrent second malignancy except: Nonmelanomatous skin cancer Adequately treated in\n",
      "        situ carcinoma of the cervix Geographically accessible for follow-up\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for breast cancer other than potentially\n",
      "        curative surgery (see Disease Characteristics)\n",
      "2217\n",
      "DISEASE CHARACTERISTICS: Suspected gastric lymphoma or documented gastric lymphoma of\n",
      "        mucosa-associated lymphoid tissue (MALT) that is stage IE Gastric MALT lymphoma with\n",
      "        perigastric lymph nodes identified on endoscopic ultrasound eligible at MDACC and Houston\n",
      "        VA Medical Center only No indication for expeditious treatment with chemotherapy,\n",
      "        radiotherapy, or surgery based on clinical condition, underlying illness, or tumor stage\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Not specified Hematopoietic:\n",
      "        Not specified Hepatic: Not specified Renal: Not specified Other: No contraindication to\n",
      "        endoscopy or biopsy No pregnant or nursing women Adequate contraception required of\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent chemotherapy or radiotherapy\n",
      "2221\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage I, invasive breast cancer\n",
      "          -  Hormone receptor status:\n",
      "               -  Estrogen receptor positive\n",
      "               -  Progesterone receptor positive or negative\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  65 to 80\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Postmenopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life Expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No serious disease that would preclude surgery\n",
      "          -  No other prior or concurrent malignancy except basal cell carcinoma or carcinoma in\n",
      "             situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Not specified\n",
      "2222\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed gastric cancer that is either metastatic\n",
      "        or locally advanced and inoperable Bidimensionally measurable disease No CNS metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 75 and under Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Granulocyte count at least 2,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.7 mg/dL Renal: Creatinine no greater than\n",
      "        1.3 mg/dL Creatinine clearance greater than 60 mL/min Cardiovascular: No myocardial\n",
      "        infarction within past 12 months No coronary heart disease requiring drug therapy\n",
      "        Congestive heart failure or arrhythmia treatable with standard medication allowed Other:\n",
      "        No active infection No history of severe mental disorder No other malignancy within past\n",
      "        10 years except carcinoma in situ of the cervix or nonmelanoma skin cancer Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        Not specified\n",
      "2225\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed myelodysplastic syndrome: Refractory anemia (RA), refractory\n",
      "             anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB)\n",
      "             or chronic myelomonocytic leukemia (CMML)\n",
      "          -  No patients with refractory anemia with excess blasts in transformation (RAEB-t)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100\n",
      "        Hematopoietic:\n",
      "          -  Platelet count greater than 20,000\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.6 mg/dL\n",
      "          -  SGOT less than 150 U/L\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No symptoms of coronary artery disease, congestive heart failure, edema, clinically\n",
      "             manifest hypotension, presence of cardiac arrhythmias on EKG, or severe hypertension\n",
      "        Pulmonary:\n",
      "          -  No significant pleural effusion, dyspnea at rest or severe exertional dyspnea\n",
      "        Other:\n",
      "          -  No patients with nephrotic syndrome\n",
      "          -  No uncontrolled infections or active peptic ulcer disease\n",
      "          -  No serious intercurrent medical illness\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required of all patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunosuppressive therapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 2 weeks since corticosteroid therapy\n",
      "          -  At least 4 weeks since other endocrine therapy\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2226\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed intermediate- or high-grade non-\n",
      "        Hodgkin's lymphoma of the following histologies: Follicular, predominantly large cell\n",
      "        Diffuse small cleaved cell Diffuse mixed, small and large cell Diffuse large cell Large\n",
      "        cell, immunoblastic Lymphoblastic Small noncleaved cell Disease has relapsed following or\n",
      "        is resistant to primary anthracycline-containing combination chemotherapy Objective\n",
      "        response to salvage DHAP chemotherapy required Ineligible for bone marrow transplantation\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 64 Performance status: Zubrod 0 or 1 Hematopoietic:\n",
      "        ANC at least 1,500 Platelets at least 140,000 Hb at least 10 g/dl Hepatic: Bilirubin less\n",
      "        than 1.5 mg/dl (26 micromoles/liter) SGOT less than 4 x normal Renal: Creatinine less than\n",
      "        1.5 mg/dl (133 micromoles/liter) Cardiovascular: LVEF greater than 50% No life-threatening\n",
      "        arrhythmia by EKG No uncontrolled hypertension Pulmonary: FEV, FVC, and DLCO greater than\n",
      "        50% of predicted Other: No uncontrolled diabetes No other uncontrolled medical condition\n",
      "        No history of second malignancy except: Nonmelanomatous skin cancer Carcinoma in situ\n",
      "        Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior\n",
      "        anthracycline-containing combination chemotherapy required Prior salvage DHAP chemotherapy\n",
      "        required Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "2227\n",
      "DISEASE CHARACTERISTICS: Histologically proven low-grade non-Hodgkin's lymphoma of the\n",
      "        following subtypes: Follicular, predominantly small cleaved cell Follicular mixed (small\n",
      "        cleaved and large cell) Previously treated on Protocol CLB 8691 or previously untreated\n",
      "        Previously untreated patients with Stage IV disease (Ann Arbor classification) must meet\n",
      "        the following conditions: Documented bone marrow involvement Lymph node biopsy must not\n",
      "        show higher grade lymphoma At least 1 additional risk factor as follows: At least 2\n",
      "        extranodal sites Nodes or nodal group at least 5 cm Male Previously treated patients must\n",
      "        have progressed or relapsed on Protocol CLB-8691 Recurrence should be documented by biopsy\n",
      "        if possible Bidimensionally measurable disease by physical exam, radiograph, CT, or MRI\n",
      "        (sonography and barium studies alone not acceptable) Measurable liver disease defined as:\n",
      "        Mass greater than 3.5 cm on CT, MRI, or ultrasound OR Histologically documented\n",
      "        lymphomatous hepatomegaly more than 5 cm below the costal margin The following disease\n",
      "        manifestations are not considered measurable: Ascites or pleural effusion Bony disease\n",
      "        (lytic lesions on x-ray should be documented and followed) CNS lesions Bone marrow\n",
      "        involvement No lymphomatous involvement (including CNS lymphoma) requiring immediate\n",
      "        radiotherapy A new classification scheme for adult non-Hodgkin's lymphoma has been adopted\n",
      "        by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "        terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol\n",
      "        uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to physiologic 55 Patients over 55 are eligible only if\n",
      "        study chairperson agrees that the patient can tolerate intensive chemotherapy Performance\n",
      "        status: Zubrod 0-1 Life expectancy: More than 2 years Hematopoietic: Granulocyte count at\n",
      "        least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic:\n",
      "        Bilirubin less than 1.5 times normal Renal: Creatinine less than 1.5 times normal\n",
      "        Cardiovascular: LVEF at least 50% No acute changes or arrhythmias on ECG No cardiomegaly\n",
      "        on chest x-ray or physical exam No uncontrolled or severe cardiovascular disease,\n",
      "        including myocardial infarction within the past 6 months or congestive heart failure (CHF)\n",
      "        No active cardiac problems, including compensated CHF or angina Other: HIV negative No\n",
      "        other malignancy within the past 5 years except curatively treated basal cell skin cancer\n",
      "        or carcinoma in situ of the cervix No active uncontrolled bacterial, viral, or fungal\n",
      "        infection No other serious medical illness that would limit survival to less than 2 years\n",
      "        No psychiatric condition that would preclude informed consent or compliance No\n",
      "        uncontrolled duodenal ulcer Not pregnant Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interferon only on Protocol CLB-8691\n",
      "        allowed Chemotherapy: Prior oral cyclophosphamide only on Protocol CLB-8691 allowed No\n",
      "        concurrent chemotherapy Endocrine therapy: No chronic steroids for other health problems\n",
      "        No concurrent steroids for any condition including documented CNS metastases, adrenal\n",
      "        failure, or septic shock Nonsteroidal hormonal drugs for nondisease related problems\n",
      "        allowed (e.g., insulin for diabetes) Radiotherapy: See Disease Characteristics No prior\n",
      "        radiotherapy No concurrent palliative radiotherapy Surgery: At least 2 weeks since prior\n",
      "        major surgery Other: No other prior therapy\n",
      "2230\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven Hodgkin's disease, subclassified according to the\n",
      "        Rye system Clinical Stages IA, IEA, IIA, and IIEA according to modified Ann Arbor system\n",
      "        Staging laparotomy not allowed Completely resected disease allowed Residual disease, if\n",
      "        present, must be bidimensionally measurable No mediastinal mass greater than 1/3 the\n",
      "        maximum chest diameter No infradiaphragmatic presentation No pericardial E lesions (small\n",
      "        pericardial effusions in the absence of nodular pericardial disease allowed) Concurrent\n",
      "        registration on protocol SWOG-9208 (quality-of-life study) required unless patient does\n",
      "        not understand or read English\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: SWOG 0-2 Hematopoietic: AGC\n",
      "        at least 2,000 Platelets within normal limits Hepatic: Bilirubin within normal limits\n",
      "        Renal: Creatinine within normal limits Cardiovascular: LVEF normal No serious EKG\n",
      "        abnormality Pulmonary: No serious pulmonary condition Other: No serious medical condition\n",
      "        other than Hodgkin's disease No known AIDS or HIV-associated complex No second malignancy\n",
      "        within 5 years except: Adequately treated nonmelanomatous skin cancer Adequately treated\n",
      "        in situ carcinoma of the cervix No pregnant or lactating women Adequate contraception\n",
      "        required of fertile patients Blood/body fluid analyses to determine eligibility completed\n",
      "        within 14 days prior to registration; imaging studies for tumor measurement completed\n",
      "        within 28 days prior to registration; screening exams other than blood/body fluid\n",
      "        analyses, and imaging studies of nonmeasurable disease or uninvolved organs completed\n",
      "        within 42 days prior to registration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No\n",
      "        prior chemotherapy for any reason Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy for any reason Surgery: No staging laparotomy\n",
      "2232\n",
      "DISEASE CHARACTERISTICS: Histologically proven, progressive, recurrent or metastatic\n",
      "        breast cancer in patients over 70 years of age Measurable or evaluable disease required,\n",
      "        including: Lesions of the mediastinum, retroperitoneum, or liver at least 3 cm in diameter\n",
      "        on CT scan or ultrasound The following are not considered measurable or evaluable:\n",
      "        Lymphedema Hilar enlargement Pleural effusion Ascites Bone marrow infiltration\n",
      "        Osteoblastic skeletal lesion No CNS metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Over 70 Sex: Not specified Menopausal status: Postmenopausal\n",
      "        Performance status: WHO 0-2 Hematopoietic: WBC at least 3,000 Platelets at least 100,000\n",
      "        Hepatic: Bilirubin less than 1.4 mg/dL (25 micromoles/L) Renal: Creatinine clearance\n",
      "        (calculated) greater than 50 mL/min in patients weighing at least 45 kg and measured\n",
      "        creatinine clearance at least 50 mL/min in patients weighing less than 45 kg\n",
      "        Cardiovascular: No congestive heart failure No myocardial infarction within 6 months No\n",
      "        severe arrhythmia No complete bundle branch block Other: No active uncontrolled infection\n",
      "        No mental disorders that may preclude patient follow-up No second malignancy except:\n",
      "        Adequately treated basal cell carcinoma of the skin Adequately treated in situ carcinoma\n",
      "        of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for advanced disease At least 1 year since prior adjuvant chemotherapy\n",
      "        Endocrine therapy: At least 4 weeks since prior estrogens, androgens, and progestins\n",
      "        Tamoxifen or aminoglutethimide allowed with no waiting period if disease progresses\n",
      "        Recovery from prior hormonal therapy for metastatic disease required Radiotherapy: Prior\n",
      "        radiotherapy allowed provided: Evaluable disease exists outside of treatment field No\n",
      "        greater than 50% of bone marrow was irradiated Surgery: Not specified\n",
      "2236\n",
      "DISEASE CHARACTERISTICS: Acute leukemias in the following categories: Histologically\n",
      "        documented ANLL in first remission (CR1) or second remission (CR2) Pediatric ANLL patients\n",
      "        in CR1 eligible provided they are not enrolled on protocol CCG-2891 ALL in CR1 presenting\n",
      "        with at least 1 of the following high-risk features: WBC at presentation greater than\n",
      "        50,000/mm3 (200,000/mm3 in pediatric patients) Hypoploidy as measured by flow cytometry\n",
      "        Pseudodiploidy with translocations t(9;22), t(4;11), and t(8;14) CR not achieved until\n",
      "        after 4 weeks of induction therapy ALL in CR2 that has relapsed in the bone marrow\n",
      "        following a first remission regardless of time of relapse Acute biphenotypic leukemia\n",
      "        (mixed myeloid and lymphoid lineage at presentation) in CR1 or CR2, i.e., patients\n",
      "        classified as lymphoblastic or myeloblastic based on FAB morphology and histochemistry\n",
      "        features Adult acute undifferentiated leukemia (no evidence of lymphoid or myeloid\n",
      "        differentiation) and in CR1 or CR2 Patients in this category are analyzed separately CR\n",
      "        defined as no evidence of leukemia at time of transplantation as documented by\n",
      "        normocellular bone marrow aspirate containing no more than 5% blasts no more than 2 weeks\n",
      "        prior to cytoreduction Normal diagnostic LP or Ommaya reservoir tap required no more than\n",
      "        2 weeks prior to start of cytoreduction in all ALL patients and in ANLL patients at risk\n",
      "        for CNS disease No extramedullary disease at time of transplantation HLA-identical,\n",
      "        MLC-compatible related donor required Donor must be healthy and willing to undergo general\n",
      "        anesthesia and donation procedure For T-cell depletion, donor should be able to have a\n",
      "        volume of 15 ml/kg patient body weight harvested safely\n",
      "        PATIENT CHARACTERISTICS: Age: Any age (5 to 55 to be eligible for randomization)\n",
      "        Performance status: Karnofsky (or Lansky) 70-100% Life expectancy: Greater than 8 weeks\n",
      "        Hematopoietic: See Disease Characteristics Hepatic: Bilirubin less than 1.5 mg/dl SGOT no\n",
      "        greater than 3 times upper limit of normal (ULN) (both parameters stable for at least 4\n",
      "        weeks prior to transplantation) Renal: Creatinine less than 2 times ULN and stable for at\n",
      "        least 4 weeks prior to transplantation OR Creatinine clearance at least 70 mL/min\n",
      "        Cardiovascular: Fractional shortening greater than 28% on echocardiogram (23-28% if FS\n",
      "        increases as a response to stress on supine bicycle ergometer) LVEF at least 50% on\n",
      "        echocardiogram or MUGA Other: In good clinical condition at time of transplantation with\n",
      "        no medical problems that would significantly increase the risk of the procedure No\n",
      "        infection at time of transplantation Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2238\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven non-small cell lung cancer\n",
      "          -  Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard\n",
      "             radiotherapy indications)\n",
      "          -  Measurable or evaluable disease\n",
      "          -  Measurable disease defined as bidimensionally measurable lesion on physical exam or\n",
      "             radiograph (CT or MRI acceptable)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: 0-2\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  WBC at least 4,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST less than 3 times normal\n",
      "          -  Alkaline phosphatase less than 3 times normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No more than 1 prior chemotherapy regimen allowed\n",
      "          -  At least 4 weeks since prior chemotherapy and recovered\n",
      "          -  No prior radiotherapy\n",
      "          -  Recovered from toxic effects of any prior therapy\n",
      "2242\n",
      "DISEASE CHARACTERISTICS: Operable, clinical Stage I/II breast cancer (T1-3, N0-1, M0) No\n",
      "        evidence of distant metastases on x-ray of chest, spine, and pelvis Bone scan evidence\n",
      "        alone of secondary mass allowed unless considered unequivocal evidence of metastasis No\n",
      "        primary carcinoma fixed to underlying muscle or chest wall No deeply fixed axillary nodes\n",
      "        No ulceration, skin infiltration, or peau d'orange involving more than 1/3 of breast No\n",
      "        bilateral tumors Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Under 50 Sex: Women only Menopausal status: Any status\n",
      "        Performance status: Not specified Life expectancy: No limits on life expectancy due to\n",
      "        intercurrent illness Hematopoietic: WBC at least 3,000 Platelets at least 90,000\n",
      "        Hemoglobin at least 10 g/dL Hepatic: Normal liver function required Renal: Normal kidney\n",
      "        function required Other: Fit for surgery No prior treatment for other malignancies except:\n",
      "        Nonmelanomatous skin cancer Cone-biopsied in situ carcinoma of the cervix English-speaking\n",
      "        patients eligible for quality-of-life assessments\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Chemotherapy for\n",
      "        high-risk patients allowed at the discretion of the clinician Endocrine therapy: At least\n",
      "        6 weeks since prior hormonal therapy No concomitant hormonal therapy including oral\n",
      "        contraceptives (patients must discontinue the pill for 2 years) Radiotherapy: Not\n",
      "        specified Surgery: Not specified\n",
      "2243\n",
      "DISEASE CHARACTERISTICS: Histologically documented metastatic breast or endometrial\n",
      "        carcinoma or mesothelioma not amenable to surgical and/or radiotherapeutic cure or\n",
      "        long-term control Measurable soft tissue, bony, or visceral lesions required Indicator\n",
      "        lesions other than blastic bony metastases and pleural effusions required for breast\n",
      "        cancer Hormone receptor status (breast cancer): Estrogen-receptor-positive and/or\n",
      "        progesterone-receptor-positive\n",
      "        PATIENT CHARACTERISTICS: Age: At least 18 Sex (breast cancer): Not specified Menopausal\n",
      "        status (breast cancer): Any status Performance status: Not specified Life expectancy: At\n",
      "        least 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since therapy Chemotherapy:\n",
      "        At least 4 weeks since therapy Endocrine therapy: Breast cancer: At least disease\n",
      "        stabilization achieved following tamoxifen or other hormonal manipulation if such\n",
      "        treatment given previously At least 4 weeks since therapy Nonbreast cancer patients may be\n",
      "        entered immediately after conventional doses of megestrol or other hormones Radiotherapy:\n",
      "        At least 4 weeks since therapy Concomitant radiotherapy to nonindicator lesions allowed\n",
      "        Surgery: At least 4 weeks since therapy\n",
      "2245\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven, previously untreated, squamous cell carcinoma of\n",
      "        the glottic and supraglottic larynx that would normally require total laryngectomy Stage\n",
      "        III/IV disease (excluding T1 and M1) Endoscopic tumor staging required within 4 weeks of\n",
      "        entry Tumors must be considered resectable and potentially curable with conventional\n",
      "        surgery and radiotherapy T4 disease limited to: Up to 1 cm invasion of the base of tongue\n",
      "        Questionable cartilage invasion on CT (clinically T3) Measurable disease required No\n",
      "        synchronous primary tumors No subglottic tumors\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: (obtained within 3 weeks of entry) WBC at least 3,500 Platelets at least\n",
      "        100,000 Hepatic: Not specified Renal: (obtained within 2 weeks of entry) Creatinine\n",
      "        clearance at least 50 mL/min (measured or calculated) Serum calcium normal Cardiovascular:\n",
      "        Status adequate to tolerate all protocol therapy Pulmonary: Status adequate to tolerate\n",
      "        all protocol therapy Other: Nutritional status adequate to tolerate all protocol therapy\n",
      "        Mental status adequate to follow instructions and keep appointments No second malignancy\n",
      "        except nonmelanomatous skin cancer (Patients who have been disease-free for at least 3\n",
      "        years following treatment for a prior cancer may be eligible at the discretion of the\n",
      "        protocol chairman) Negative pregnancy test required of fertile women Effective\n",
      "        contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior therapy Chemotherapy: No prior\n",
      "        therapy Endocrine therapy: No prior therapy Radiotherapy: No prior radiotherapy to the\n",
      "        head and neck Surgery: No prior therapy\n",
      "2253\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven adenocarcinoma of the exocrine pancreas\n",
      "             excluding periampullary cancer\n",
      "          -  Resectable malignancy must be located in a region that can be encompassed by a\n",
      "             radiation port of 20 x 20 cm\n",
      "          -  No evidence of extranodal metastatic disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Bilateral renal function as demonstrated by excretory urogram (IVP) or abdominal CT\n",
      "             scan with contrast OR\n",
      "          -  Greater than 2/3 of one functioning kidney must be shielded during radiation therapy\n",
      "        Other:\n",
      "          -  Must have adequate oral nutrition (greater than 1200 calories daily)\n",
      "          -  Greater than 5 years since prior malignancy except:\n",
      "               -  Squamous cell skin cancer\n",
      "               -  Basal cell skin cancer\n",
      "               -  In situ cervical cancer\n",
      "          -  Not pregnant or lactating\n",
      "          -  Patients of reproductive potential must use effective birth control\n",
      "          -  No cystic neoplasms of the pancreas\n",
      "          -  No islet cell, periampullary or cholangiocarcinoma\n",
      "          -  No Federal Medical Center inmates\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for this disease\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiation therapy for this disease\n",
      "          -  No prior radiation therapy to the abdomen\n",
      "        Surgery:\n",
      "          -  Celiotomy and standardized exploration for resectability required\n",
      "2254\n",
      "DISEASE CHARACTERISTICS: - Acute lymphocytic leukemia (ALL) with documented\n",
      "        chemosensitivity (complete response [CR], partial response [PR], or minor response [MR])\n",
      "        in first or second remission, first or second relapse, or high risk ALL with Ph positive\n",
      "        9/22 translocation; OR - Acute myelogenous leukemia (AML) with documented chemosensitivity\n",
      "        (CR, PR, or MR) in first or second remission, or first or second relapse; OR - Chronic\n",
      "        myelogenous leukemia (CML), chronic or accelerated, that is not in blast crisis; OR -\n",
      "        Hodgkin's disease or non-Hodgkin's lymphoma with documented chemosensitivity in first or\n",
      "        second relapse Consenting human lymphocyte antigen (HLA)-identical related donor required\n",
      "        No active central nervous system (CNS) or skin leukemia involvement No disease that\n",
      "        requires additional mediastinal radiation\n",
      "        PATIENT CHARACTERISTICS: Age: 18-55 Performance status: Karnofsky 70-100% Life expectancy:\n",
      "        Greater than 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 times\n",
      "        normal serum glutamate oxalo-acetate transaminase (SGOT) less than 2 times normal Renal:\n",
      "        Creatinine less than 1.5 times normal Cardiovascular: Left ventricular ejection fraction\n",
      "        at rest at least 40% or within normal range Pulmonary: diffusing capacity of the lung for\n",
      "        carbon monoxide (DLCO) greater than 45% of predicted or within normal range Other: HIV\n",
      "        negative At least 2 weeks since any active infection requiring intravenous treatment with\n",
      "        antifungal, antibacterial or antiviral agents with the exception of coagulase negative\n",
      "        staphylococcal line infection No coexisting medical problems that would significantly\n",
      "        increase the risk of the transplant procedure Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: No more that 2 prior therapy regimens Biologic therapy: No prior\n",
      "        autologous or allogeneic bone marrow or peripheral blood stem cell transplant\n",
      "        Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Prior radiation\n",
      "        therapy subject to dose requirements Surgery: Not specified Other: At least 2 weeks since\n",
      "        intravenous treatment with antifungal, antibacterial or antiviral agents, except for\n",
      "        treatment of coagulase negative staphylococcal infection of an IV or central line\n",
      "2255\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Microscopically confirmed solid tumor or lymphoma not potentially curable by\n",
      "             conventional surgery or radiotherapy\n",
      "          -  Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60\n",
      "             Gy, including pulmonary and esophageal tumors\n",
      "          -  No metastatic disease more effectively treated by systemic chemotherapy\n",
      "          -  No history of brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0 or 1\n",
      "          -  WBC at least 4,000\n",
      "          -  ANC at least 1,500\n",
      "          -  Platelets at least 100,000\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Calcium no greater than 11.0 mg/dL\n",
      "          -  No pregnant or nursing women\n",
      "          -  Pregnancy test required, as appropriate\n",
      "          -  Effective contraception required of fertile patient\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and\n",
      "             recovered\n",
      "          -  At least 4 weeks since radiotherapy and recovered\n",
      "2256\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, early stage, unilateral invasive breast\n",
      "        cancer of TNM stages T0 - T3, N0-1, M0, i.e., Histologically proven axillary node\n",
      "        metastases OR Lymph node negative Not locally advanced If supraclavicular node is enlarged\n",
      "        or suspicious of metastasis, negative biopsy for supraclavicular node metastases required\n",
      "        No evidence of any other metastases clinically or on routine staging investigations No\n",
      "        past history of pure in situ carcinoma in either breast Primary tumor is completely\n",
      "        excised\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Performance status: Not specified\n",
      "        Hematopoietic: Neutrophil count greater than 2,000/mm3 Platelet count greater than\n",
      "        100,000/mm3 No evidence of sepsis Hepatic: Adequate hepatic function Bilirubin normal\n",
      "        AST/ALT normal Renal: Adequate renal function Creatinine less than 1.2 mg/dL\n",
      "        Cardiovascular: No clinically significant cardiovascular disease Other: No prior or\n",
      "        concurrent other malignancy except adequately treated basal or squamous cell carcinoma of\n",
      "        the skin or in situ carcinoma of the cervix Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Prior tamoxifen allowed Radiotherapy: No prior\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "2257\n",
      "DISEASE CHARACTERISTICS: See General Eligibility Criteria\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: WHO 0-2 Life Expectancy: At\n",
      "        least 3 months Hematopoietic: ANC at least 2,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL Liver function tests no greater than 2 times\n",
      "        upper limit of normal (ULN) (unless related to liver metastases, then no greater than 5\n",
      "        times ULN) Renal: Creatinine no greater than 1.4 mg/dL Creatinine clearance at least 60\n",
      "        mL/min Cardiovascular: LVEF greater than 50% (measured by MUGA scan) Other: Not pregnant\n",
      "        or nursing Effective contraceptive method must be used during study No active bacterial\n",
      "        infections No other nonmaliganant diseases No history of alcoholism or drug abuse No\n",
      "        psychosis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy within 4 weeks of study\n",
      "        Concurrent use of growth factors is allowed in cases of febrile neutropenia (prophylactic\n",
      "        use not allowed) Chemotherapy: No prior chemotherapy within 4 weeks of study No prior\n",
      "        nitrosoureas, mitomycin, or high dose carboplatin within 6 weeks of study Endocrine\n",
      "        therapy: No concurrent corticosteroids (unless approved by clinical investigator)\n",
      "        Radiotherapy: No prior radiotherapy within 4 weeks of study No prior extensive\n",
      "        radiotherapy within 6 weeks of study Surgery: Not specified Other: No prior experimental\n",
      "        therapy No prior anthracyclines or anthracenediones\n",
      "2258\n",
      "DISEASE CHARACTERISTICS: Histologically proven non-Hodgkin's lymphoma of the central\n",
      "        nervous system (CNS) including leptomeninges and the spinal cord No Burkitt's lymphoma or\n",
      "        low grade T-cell lymphoma Must have at least 1 measurable lesion No AIDS-related primary\n",
      "        central nervous system lymphoma (PCNSL) No disease confined to the eye without other\n",
      "        localization in the CNS\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 60 Performance status: Karnofsky 40-100% Neurological\n",
      "        functional status 0-3 Life expectancy: Not specified Hematopoietic: Not specified Hepatic:\n",
      "        No serious impairment of hepatic function Renal: No serious impairment of renal function\n",
      "        Creatinine no greater than 1.5 mg/dL OR Creatinine clearance no less than 50 mL/min\n",
      "        Cardiovascular: No serious impairment of cardiac function Other: HIV negative No\n",
      "        congenital or acquired immunodeficiency syndrome No prior/concurrent systemic lymphoma No\n",
      "        prior malignancy except: Adequately treated non-melanoma skin cancer Carcinoma in situ of\n",
      "        the cervix uteri Not pregnant No severe uncontrolled infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent treatment with immunosuppressive\n",
      "        drug Chemotherapy: No prior chemotherapy Endocrine therapy: Corticosteroid use for less\n",
      "        than 3 weeks allowed Radiotherapy: Not specified Surgery: No prior organ transplantation\n",
      "2259\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of one of the following malignancies:\n",
      "               -  Acute lymphoblastic leukemia (ALL) of B- or T-cell lineage\n",
      "               -  Philadelphia chromosome-positive ALL eligible\n",
      "               -  Lymphoblastic lymphoma\n",
      "               -  Chronic myelogenous leukemia in lymphoid blast crisis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 20-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  Glucocorticoids for higher bilirubin allowed prior to entry, at principal\n",
      "             investigator's discretion\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Glucocorticoids or renal radiotherapy for higher creatinine allowed prior to entry,\n",
      "             at principal investigator's discretion\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular ejection fraction at least 50%\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior biologic therapy\n",
      "        Chemotherapy\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy\n",
      "          -  No prior endocrine therapy\n",
      "        Radiotherapy\n",
      "          -  No prior radiotherapy\n",
      "        Surgery\n",
      "          -  No prior surgery\n",
      "2263\n",
      "DISEASE CHARACTERISTICS: Histologically proven locally advanced breast cancer Unresected\n",
      "        T3 or T4 lesion, OR Unresected T2 lesion if patient considered appropriate candidate for\n",
      "        neoadjuvant chemotherapy to enhance breast conservation Hormone receptor status: Not\n",
      "        specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Hematopoietic: WBC at least 3,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal Renal: Creatinine no\n",
      "        greater than 1.5 times normal Cardiovascular: LVEF at least 50% (baseline MUGA) No history\n",
      "        of uncontrolled congestive heart failure At least 6 months since prior myocardial\n",
      "        infarction No unstable angina No uncontrolled hypertension Neurologic: No peripheral\n",
      "        neuropathy Other: Not pregnant or nursing No psychosis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic\n",
      "        therapy Endocrine therapy: No prior hormonal therapy for breast cancer Prior estrogen\n",
      "        replacement therapy allowed No concurrent steroid therapy Radiotherapy: Not specified\n",
      "        Surgery: See Disease Characteristics Other: No concurrent treatment for serious infection\n",
      "        (bacterial, viral, or fungal)\n",
      "2264\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Chronic neuropathic pain with diagnosis of cancer or AIDS\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  SGOT no greater than 2 times upper limit of normal (ULN)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No clinical history of infarction or angina\n",
      "          -  No advanced heart failure\n",
      "          -  No sick sinus syndrome, intraventricular conduction disease, second or third degree\n",
      "             AV block or arrhythmias requiring treatment (exception may be granted by cardiac\n",
      "             consult)\n",
      "          -  No focal wall motion abnormalities\n",
      "          -  Ejection fraction at least 40%\n",
      "          -  Systolic blood pressure at least 90 mm Hg\n",
      "        Other:\n",
      "          -  Must be able to take oral medication\n",
      "          -  No known allergy or adverse reaction to flecainide, mexilitene or any other type I\n",
      "             antiarrhythmic drug\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 2 weeks since prior chemotherapy that may cause neuropathy\n",
      "        Endocrine therapy:\n",
      "          -  At least 2 weeks since prior corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No tricyclic antidepressant treatment within past 2 weeks\n",
      "          -  No concurrent use of flecainide, mexiletene or any other type I antiarrhythmic drug\n",
      "2265\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid\n",
      "             cancer, or adrenal cancer with clinical, radiological, or histologic evidence of\n",
      "             incurability\n",
      "          -  Patients with thyroid cancer must have failed radioactive iodine\n",
      "          -  Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  65 and under\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm3\n",
      "          -  Platelet count at least 140,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.47 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular ejection fraction at least 50% by MUGA scan\n",
      "          -  No congestive heart failure\n",
      "          -  No severe, uncontrolled hypertension\n",
      "          -  No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG\n",
      "        Other:\n",
      "          -  No allergy to study medications\n",
      "          -  No uncontrolled infection\n",
      "          -  No active abuse of ethanol that would preclude treatment\n",
      "          -  No other prior or concurrent malignancy\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No more than 1 prior chemotherapy regimen\n",
      "          -  No prior anthracycline or cisplatin\n",
      "          -  At least 3 weeks since other prior chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy to more than 25% of bone marrow\n",
      "          -  At least 3 weeks since other prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2266\n",
      "DISEASE CHARACTERISTICS: Pathologically confirmed acute promyelocytic leukemia in one of\n",
      "        the following categories: First complete remission following induction retinoids First\n",
      "        complete remission following induction chemotherapy and not eligible for additional\n",
      "        consolidation chemotherapy Second or subsequent remission following induction retinoids or\n",
      "        chemotherapy Clinically complete remission following consolidation chemotherapy and:\n",
      "        Detectable minimal residual disease by reverse transcription-polymerase chain reaction\n",
      "        (RT-PCR) assay Not eligible for bone marrow transplant Molecular remission (i.e., negative\n",
      "        RT-PCR assay) with subsequent evidence of early molecular relapse (i.e., normal peripheral\n",
      "        blood counts, normal bone marrow morphology, and positive RT-PCR assay)\n",
      "        PATIENT CHARACTERISTICS: Age: 12 and over Performance status: Not specified Life\n",
      "        expectancy: Greater than 4 weeks Hematopoietic: See Disease Characteristics Hepatic:\n",
      "        Bilirubin no greater than 2.5 mg/dL AST no greater than 4 times normal Alkaline\n",
      "        phosphatase no greater than 4 times normal Renal: Creatinine no greater than 2.5 mg/dL\n",
      "        Cardiovascular: (Patients receiving idarubicin and cytarabine only) No history of cardiac\n",
      "        disease OR Left ventricular ejection fraction greater than 50% by MUGA or echocardiogram\n",
      "        Other: No uncontrolled serious infection HIV negative No active second malignancy except\n",
      "        basal cell carcinoma Not pregnant or nursing Negative pregnancy test Fertile women must\n",
      "        use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        See Disease Characteristics Retinoid therapy to continue until 30 days past complete\n",
      "        remission No other concurrent chemotherapy At least 3 weeks since any cytotoxic\n",
      "        chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 3 weeks\n",
      "        since any radiotherapy and recovered No concurrent radiotherapy Surgery: Not specified\n",
      "2268\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed carcinoma of the colon or rectum with\n",
      "        radiologically confirmed metastases or clinically confirmed incurability No hepatic or CNS\n",
      "        metastases Progression following fluorouracil (5-FU) alone or with a modulator (e.g.,\n",
      "        leucovorin, PALA, levamisole, interferon) Measurable disease outside prior radiotherapy\n",
      "        fields The following are not considered measurable: Pleural effusion or ascites\n",
      "        Osteoblastic lesions or evidence of disease on bone scan alone Progressive irradiated\n",
      "        lesions alone Bone marrow involvement Brain metastases Malignant hepatomegaly by physical\n",
      "        exam alone Chemical markers (e.g., CEA)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 16 weeks Hematopoietic: Absolute neutrophil count at least 1,800/mm3 Platelet\n",
      "        count at least 125,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL Other: No concurrent infection Afebrile for at least 3 days\n",
      "        prior to treatment unless fever due to tumor No known HIV infection No other medical\n",
      "        condition that precludes protocol participation No second malignancy within 5 years\n",
      "        except: Nonmelanomatous skin cancer Curatively treated in situ cervical carcinoma No\n",
      "        pregnant or nursing women Negative pregnancy test required of fertile women Effective\n",
      "        contraception required of fertile women Blood/body fluid analyses within 7 days prior to\n",
      "        registration Imaging/exams for tumor measurement within 21 days prior to registration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior mouse-based vaccines or monoclonal\n",
      "        antibodies Chemotherapy: At least 2 weeks since prior 5-FU or at least 1 week past the AGC\n",
      "        nadir, whichever is later No other prior chemotherapy except irinotecan Endocrine therapy:\n",
      "        Not specified Radiotherapy: At least 6 months since radiotherapy Surgery: Not specified\n",
      "2269\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or metastatic primary colorectal\n",
      "        carcinoma Must have measurable disease (evaluable disease acceptable in Phase I)\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance Status: ECOG 0-3 Life Expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 150,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL OR 3.0 mg/dL in patients with liver\n",
      "        metastases Liver enzymes no greater than 3.0 times upper limit of normal (in patients with\n",
      "        liver metastases) Renal: Not specified Other: Not pregnant or lactating Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy\n",
      "        for metastatic disease allowed Prior treatment with 5-FU allowed Prior treatment with\n",
      "        irinotecan allowed Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since\n",
      "        prior radiotherapy (measurable disease must be located outside the prior radiotherapy\n",
      "        portal) Surgery: Not specified Other: Prior treatment with folinic acid allowed\n",
      "2273\n",
      "DISEASE CHARACTERISTICS: Histologically proven nasopharyngeal carcinoma (excluding\n",
      "        adenocarcinoma), stage III or IV with no evidence of distant metastatic disease (M0) No\n",
      "        lung, bone, or liver metastases as proven within 42 days of registration by: -CT scan or\n",
      "        nucleotide study of the chest or chest x-ray -liver and bone scan if alkaline phosphatase\n",
      "        is greater than the institutional upper limit of normal (ULN), or if clinically indicated\n",
      "        -liver scan if SGOT is greater than the institutional ULN\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: SWOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at\n",
      "        least 75,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.6 mg/dL AND/OR\n",
      "        Creatinine clearance at least 50 mL/minute Other: Not pregnant or nursing Women/men of\n",
      "        reproductive potential must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No previous\n",
      "        chemotherapy to the primary site or nodes Endocrine therapy: Not specified Radiotherapy:\n",
      "        No previous radiotherapy (except for nonmelanomatous skin cancer outside of the radiation\n",
      "        therapy treatment volume) Surgery: No previous surgery to the primary site or nodes\n",
      "2274\n",
      "DISEASE CHARACTERISTICS: Histologically proven unresectable primary hepatocellular\n",
      "        carcinoma No major vessel involvement Disease must be confined to the liver (no\n",
      "        extrahepatic disease) Patients have no more than 3 tumors, with no tumor exceeding 7 cm in\n",
      "        diameter, and the sum total tumor volume less than 200 cm3\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky 40-100% Life\n",
      "        Expectancy: At least 4 months Hematopoietic: Hemoglobin at least 10 g/dL Platelet count at\n",
      "        least 75,000/mm3 Absolute granulocyte count at least 1,000/mm3 PT within 3 seconds of\n",
      "        institutional norm Hepatic: SGPT no greater than 3 times upper limit of normal (ULN) SGOT\n",
      "        no greater than 3 times ULN Child-Pugh grade A or B Albumin at least 25 g/L Bilirubin no\n",
      "        greater than 2.98 mg/dL Absent or easily controlled ascites not requiring routine or\n",
      "        intermittent paracentesis Alkaline phosphatase no greater than 2.5 times ULN Renal:\n",
      "        Creatinine no greater than 1.3 times ULN OR Creatinine clearance at least 45 mL/min\n",
      "        Cardiovascular: No coronary artery disease No New York Heart Association class III or\n",
      "        greater cardiac symptoms Other: Not pregnant or nursing No medical or psychiatric\n",
      "        condition compromising informed consent No obesity or tumor location that would limit\n",
      "        adequate tumor imaging No history of bleeding from liver tumor(s) or gastroesophageal\n",
      "        bleeding No known hypersensitivity to cisplatin, bovine collagen, epinephrine, sulfites or\n",
      "        radiographic contrast agents No history of encephalopathy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for hepatocellular\n",
      "        carcinoma No concurrent immunomodulating agents Chemotherapy: No prior or concurrent\n",
      "        chemotherapy for hepatocellular carcinoma No concurrent cytotoxic agents Endocrine\n",
      "        therapy: No prior endocrine therapy for hepatocellular carcinoma Radiotherapy: No prior\n",
      "        radiotherapy for hepatocellular carcinoma Surgery: Prior surgical resection of the liver\n",
      "        allowed Other: No concurrent use of aspirin, nonsteroidal anti-inflammatory agents,\n",
      "        anticoagulants including warfarin sodium (Coumadin), and epinephrine containing\n",
      "        medications including topical anesthetics such as bupivacaine HCl No prior investigational\n",
      "        agents within 4 weeks of study No concurrent use of probenecid or thiazides Concurrent use\n",
      "        of analgesics and antiemetics is allowed Concurrent use of topical and other local\n",
      "        anesthetics, locoregional nerve blocks, and systemic agents is allowed\n",
      "2275\n",
      "Inclusion Criteria:\n",
      "          -  REGISTRATION # 1\n",
      "          -  All patients must have biopsy proven diagnosis of low, intermediate or high grade\n",
      "             malignant non-Hodgkin's lymphoma; transformed lymphomas are eligible\n",
      "          -  Patients with histologic diagnosis of working formulation A (malignant lymphoma small\n",
      "             lymphocytic) or working formulation I (malignant lymphoma, lymphoblastic) are not\n",
      "             eligible\n",
      "          -  Patients must have relapsed after achieving a complete or partial response to prior\n",
      "             therapy, or have never responded to prior therapy\n",
      "          -  Patients must have debulking (salvage) chemotherapy to determine if the disease is\n",
      "             sensitive to chemotherapy; the sole exception to this requirement is for patients\n",
      "             with intermediate or high grade lymphoma (working formulation D - H or J) whose\n",
      "             disease did not respond to, or progressed during, INITIAL chemotherapy\n",
      "          -  Prior therapy is required; concurrent therapy is NOT permitted\n",
      "               -  Patients with low grade lymphoma (working formulation B or C) must have received\n",
      "                  at least two prior chemotherapy regimens; if the patient has had one or more CR,\n",
      "                  then the most recent CR must have been less than one year in duration\n",
      "               -  Patients with intermediate or high grade non-Hodgkin's lymphoma (working\n",
      "                  formulation D - H or J) must have received at least one prior chemotherapy\n",
      "                  regimen\n",
      "               -  NOTE: Debulking chemotherapy given only to determine sensitivity is not\n",
      "                  considered in the calculation of number of prior regimens\n",
      "          -  Patients must have a bone marrow aspirate and biopsy obtained within 42 days of stem\n",
      "             cell collection or within 42 days prior to registration\n",
      "          -  Patients with a history of seizures or central nervous system involvement by lymphoma\n",
      "             are NOT eligible\n",
      "          -  Only patients with a normal cardiac history and physical exam or in lieu of this, an\n",
      "             institutionally normal ejection fraction as measured by either ECHO or MUGA scan are\n",
      "             eligible; specifically, there should be: no EKG evidence of active cardiac disease\n",
      "             (i.e., arrhythmias, ischemia), no history of congestive heart failure (CHF), no\n",
      "             history of myocardial infarction or ischemia, no history of arrhythmia (other than\n",
      "             bradycardia treated by pacing), no current cardiac medications for the control of CHF\n",
      "             or arrhythmias, no S3 gallop rhythm, or peripheral edema, and no chest X-ray findings\n",
      "             compatible with CHF; EKG must be performed within 42 days prior to registration\n",
      "          -  All patients must have a pretreatment serum creatinine of =< 1.5 times the\n",
      "             institutional upper limit of normal measured after completion of prior therapy and\n",
      "             within 28 days prior to registration\n",
      "          -  Patients must have adequate pulmonary function as measured by a DLCO >= 65% of\n",
      "             predicted or FEV1 >= 65% of predicted measured after completion of prior therapy and\n",
      "             within 120 days prior to registration\n",
      "          -  Patients must have adequate hepatic function as measured by a bilirubin of =< 1.5 x\n",
      "             the institutional upper limit of normal and SGOT or SGPT =< 2 x the institutional\n",
      "             upper limit of normal, measured after completion of prior therapy and within 28 days\n",
      "             prior to registration\n",
      "          -  Patients who have undergone previous bone marrow transplantation or autologous\n",
      "             peripheral blood stem cell transplantation are NOT eligible\n",
      "          -  Patients who have undergone previous therapy with interleukin-2 are NOT eligible\n",
      "          -  Patients must have recovered from the nadir resulting from the last cancer therapy;\n",
      "             this will generally be at least four weeks from prior radiation or chemotherapy, and\n",
      "             six weeks from nitrosoureas\n",
      "          -  Patients must have a Southwest Oncology Group performance status of 0 or 1\n",
      "          -  Patients must have a CT scan of the chest, abdomen and pelvis performed within 28\n",
      "             days prior to registration and at least 21 days after the completion of prior\n",
      "             chemotherapy (excluding mobilization therapy)\n",
      "          -  Patients must have LDH performed within 28 days prior to registration and at least 21\n",
      "             days after completion of prior chemotherapy (excluding mobilization therapy)\n",
      "          -  Patients must have undergone an adequate collection of peripheral blood stem cells\n",
      "             (PBSC) according to accepted procedures at each individual institution\n",
      "          -  Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis\n",
      "             with cyclophosphamide are not eligible\n",
      "          -  Patients who have received prior involved field irradiation prohibiting the use of\n",
      "             TBI are not eligible\n",
      "          -  Patients must be negative for antibody to HIV and this test must have been performed\n",
      "             within 42 days prior to registration; patients must not have an autoimmune disease or\n",
      "             have had a prior allogeneic (from someone else) organ or tissue transplant\n",
      "          -  If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next\n",
      "             working day; in calculating days of tests and measurements, the day a test or\n",
      "             measurement is done is considered day 0; therefore, if a test is done on a Monday,\n",
      "             the Monday four weeks later would be considered day 28; this allows for efficient\n",
      "             patient scheduling without exceeding the guidelines\n",
      "          -  No prior malignancy is allowed except for adequately treated basal cell (or squamous\n",
      "             cell) skin cancer, in situ cervical cancer or other cancer for which the patient has\n",
      "             been disease-free for five years\n",
      "          -  Pregnant or nursing women may not participate; women or men of reproductive potential\n",
      "             may not participate unless they have agreed to use an effective contraceptive method\n",
      "          -  Patients must be informed of the investigational nature of this study and must sign\n",
      "             and give written informed consent in accordance with institutional and federal\n",
      "             guidelines\n",
      "          -  At the time of patient registration, the treating institution's name and ID number\n",
      "             must be provided to the statistical center in order to ensure that the current\n",
      "             (within 365 days) date of institutional review board approval for this study has been\n",
      "             entered into the database\n",
      "          -  REGISTRATION # 2 (RANDOMIZATION)\n",
      "          -  Patients who are less than 28 days or more than 80 days after PBSCT will not be\n",
      "             registered for randomization\n",
      "          -  Patients known to be ineligible for registration step #1 may not be registered to\n",
      "             registration step #2\n",
      "          -  Restaging radiographic studies are not required between PBSCT and registration #2\n",
      "             (randomization), however, patients with known active recurrent or progressive disease\n",
      "             are not eligible for randomization\n",
      "          -  ANC > 500 mm^3\n",
      "          -  Platelet count supportable to > 20,000/mm^3 with no more than one transfusion per day\n",
      "          -  The patient must be free of active bacterial, fungal or viral infection, afebrile,\n",
      "             off antibiotics, antifungal and antiviral agents (with the exception of prophylactic\n",
      "             therapy) for three consecutive days\n",
      "          -  Bilirubin =< 2 times the institutional upper limit of normal; test must be completed\n",
      "             within 7 days prior to registration\n",
      "          -  SGOT or SGPT =< 2 times the institutional upper limit of normal; test must be\n",
      "             completed within 7 days prior to registration\n",
      "          -  Alkaline phosphatase =< 2 times the institutional upper limit of normal; test must be\n",
      "             completed within 7 days prior to registration\n",
      "          -  Creatinine =< 1.5 times the institutional upper limit of normal; test must be\n",
      "             completed within 7 days prior to registration\n",
      "          -  The patient must have =< grade 1 cardiac, pulmonary, CNS, renal, hepatic, GI toxicity\n",
      "             and < grade 3 mucosal toxicity according to the Southwest Oncology Group Toxicity\n",
      "             Criteria\n",
      "          -  The patient must have received no amphotericin B, corticosteroids, pentoxifylline, or\n",
      "             growth factors for at least 72 hours prior to registration\n",
      "          -  The patient must have a current Southwest Oncology Group performance status of 0-2\n",
      "          -  Patients must have an EKG with no active cardiac disease and a chest x-ray with no\n",
      "             active pulmonary disease; these tests must be completed within 7 days prior to\n",
      "             registration\n",
      "          -  Patients must not have an autoimmune disease or have had a prior allogeneic (from\n",
      "             someone else) organ or tissue transplant\n",
      "2276\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed adenocarcinoma of the breast of the\n",
      "        following stages: Stage II/IIIA disease with 4 or more involved axillary lymph nodes Stage\n",
      "        IIIB Inflammatory No bone marrow involvement documented on bone marrow aspiration and\n",
      "        biopsy Prior breast cancer allowed Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Sex: Women only Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 70%-100% Hematopoietic: Not specified Hepatic: Bilirubin no\n",
      "        greater than 2.0 mg/dL Renal: Creatinine clearance at least 60 mL/min Cardiovascular: Left\n",
      "        ventricular ejection fraction at least 50% by MUGA No abnormal cardiac conduction\n",
      "        documented as second- or third-degree heart block or bundle branch block Pulmonary: DLCO\n",
      "        at least 60% of predicted Other: Not HIV positive No history of second malignancy within 5\n",
      "        years except: Nonmelanomatous skin cancer In situ carcinoma of the cervix No pregnant\n",
      "        women\n",
      "        PRIOR CONCURRENT THERAPY: At least 3 courses of induction therapy required, with regimen\n",
      "        at the discretion of the investigator No disease progression during induction\n",
      "2277\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III or IV breast, ovarian, or\n",
      "        nonsmall cell lung cancer (NSCLC): Adenocarcinoma No progressive disease May have\n",
      "        comlpeted at least 1 standard chemotherapy regimen Confirmed HER-2/neu protein\n",
      "        overexpression in tumor (either primary tumor or metastasis)\n",
      "        PATIENT CHARACTERISTICS: Age: Pre or postmenopausal Performance status: Not specified Life\n",
      "        expectancy: At least 12 months Hematopoietic: WBC greater than 3,500/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less\n",
      "        than 1.5 mg/dL Creatinine clearance greater than 60 mL/min Other: No anergy (positive\n",
      "        delayed type hypersensitivity response required to two or more common recall antigens)\n",
      "        Female patients must be nonfertile Male patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 1 month since cytotoxic chemotherapy Endocrine therapy: At least\n",
      "        1 month since corticosteroid therapy Concurrent hormone therapy allowed Radiotherapy:\n",
      "        Concurrent radiation therapy for local control of disease allowed (except as initial\n",
      "        therapy for NSCLC) Surgery: Not specified\n",
      "2278\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven squamous cell carcinoma of the oral cavity or oropharynx\n",
      "               -  Operable, primary, unilateral, stage T2-4, N0-3, M0 disease\n",
      "               -  No high probability of bilateral lymphatic spread (requirement for bilateral\n",
      "                  neck dissection)\n",
      "          -  No tumor involvement of the following sites:\n",
      "               -  Pterygopalatine fossa\n",
      "               -  Carotid artery\n",
      "               -  Maxillary sinus\n",
      "               -  Facial skin\n",
      "               -  Anterior floor of the mouth\n",
      "               -  Base of the tongue infiltrating more than 1 cm\n",
      "          -  Measurable or evaluable disease by physical exam and/or noninvasive imaging\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  75 and under\n",
      "        Performance status:\n",
      "          -  ECOG 0-2 OR\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  More than 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm3\n",
      "          -  Platelet count at least 60,000/mm3\n",
      "          -  Hematocrit at least 30%\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  Hepatitis B surface antigen negative\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No coronary artery disease\n",
      "          -  No serious arrhythmia\n",
      "          -  No evidence of prior myocardial infarction on ECG (stress test required if in doubt)\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No autoimmune disease\n",
      "          -  No contraindications to pressor agents\n",
      "          -  No serious infection requiring antibiotics\n",
      "          -  No other concurrent primary malignancy\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior or other concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No prior or concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior or concurrent hormonal therapy\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior major organ allografts\n",
      "        Other:\n",
      "          -  No other prior therapy\n",
      "          -  No other concurrent investigational drugs, agents, or devices\n",
      "          -  No concurrent nonsteroidal antiinflammatory drugs, ranitidine, cimetidine, or\n",
      "             coumarin\n",
      "2279\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed solid tumor for which no standard\n",
      "        treatment exists (including surgery, radiotherapy, or systemic agents) No primary CNS\n",
      "        malignancy No CNS metastases Only disease that can be sequentially biopsied is eligible\n",
      "        for determination of the biochemical modulating dose that decreases AGT in tumor tissue\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        greater than 4,000/mm3 Absolute neutrophil count greater than 2,000/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 3 times\n",
      "        normal Prothrombin time less than upper limit of normal Renal: Creatinine no greater than\n",
      "        1.5 mg/dL OR Creatinine clearance at least 60 mL/min Calcium normal Electrolytes normal\n",
      "        Other: Diabetes controlled by diet or insulin allowed Not pregnant Fertile patients must\n",
      "        use effective contraception during and for 2 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since chemotherapy (6 weeks since mitomycin) and recovered No prior nitrosoureas Endocrine\n",
      "        therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified\n",
      "2280\n",
      "DISEASE CHARACTERISTICS: See General Eligibility Criteria\n",
      "        PATIENT CHARACTERISTICS: Age: 35 to 70 Sex: Women only Menopausal status: Pre-, peri-, or\n",
      "        postmenopausal Performance status: Not specified Life expectancy: At least 10 years\n",
      "        Cardiovascular: No prior deep vein thrombosis Pulmonary: No prior pulmonary embolus Other:\n",
      "        Psychologically and physically able to undertake therapy for 5 years No other medical\n",
      "        condition more serious than risk of breast cancer No prior cancer except: Nonmelanomatous\n",
      "        skin cancer In situ cancer of the cervix No pregnant women Effective nonhormonal\n",
      "        contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Hormone replacement therapy for menopausal symptoms allowed at\n",
      "        lowest effective dose Not currently on tamoxifen Not currently on anticoagulants\n",
      "2282\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed surgically incurable metastatic malignant melanoma\n",
      "          -  Measurable disease\n",
      "          -  No active brain metastases or edema\n",
      "          -  No leptomeningeal disease\n",
      "          -  No ocular melanoma\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT less than 3 times the upper limit of normal unless due to liver metastases\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 75 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure\n",
      "          -  No symptoms of coronary artery disease\n",
      "          -  No serious cardiac arrhythmias\n",
      "          -  No prior myocardial infarction on EKG\n",
      "          -  Normal cardiac stress test required for the following:\n",
      "               -  Over 50 years of age\n",
      "               -  Abnormal EKG\n",
      "               -  Prior history of cardiac disease\n",
      "        Pulmonary:\n",
      "          -  No symptomatic pulmonary disease\n",
      "          -  FEV1 greater than 2.0 L OR at least 75% predicted if over 50 years of age or with\n",
      "             history of pulmonary symptoms\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No significant infection\n",
      "          -  HIV negative\n",
      "          -  No other prior malignancy within the past 5 years except basal cell or squamous cell\n",
      "             skin cancer or carcinoma in situ of the cervix\n",
      "          -  No organ allografts\n",
      "          -  No significant disease other than malignancy\n",
      "          -  No seizure disorder\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior interleukin-2 therapy for metastatic disease\n",
      "          -  At least 4 weeks since prior vaccine therapy\n",
      "          -  At least 4 weeks since prior adjuvant immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for disease\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  No prior radiation therapy to measurable disease site unless disease is clearly\n",
      "             progressive\n",
      "          -  At least 4 weeks since prior radiation therapy for local control or palliation and\n",
      "             recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior systemic therapy for metastatic disease\n",
      "          -  At least 3 months since definitive therapy for brain metastases\n",
      "2283\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven small cell lung cancer\n",
      "        Complete response (CR) or partial response (PR) following first line chemotherapy required\n",
      "        Chest x-ray showing CR or PR required. No documented prior brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing Effective contraception use by men or women of reproductive\n",
      "        potential No prior malignancies within 5 years except: Adequately treated nonmelanomatous\n",
      "        skin cancer Adequately treated carcinoma in situ of the cervix No other concurrent\n",
      "        malignancies No prior diagnosis of breast cancer, melanoma, or hypernephroma No major\n",
      "        medical illness that would preclude prolonged administration of marimastat or required\n",
      "        follow up No active peptic ulceration or symptoms suggestive of this diagnosis No grade 3\n",
      "        or 4 musculoskeletal disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior\n",
      "        induction combination chemotherapy regimen required Must be completed prior to\n",
      "        randomization Hematologically recovered before randomization Minimum of 4 cycles required\n",
      "        No change in regimen due to progression No chemotherapy within 28 days prior to\n",
      "        randomization if thoracic radiation is given prior to or concurrent with chemotherapy No\n",
      "        prior marimastat Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy allowed\n",
      "        Must be completed prior to randomization Last dose of radiation treatment must be within\n",
      "        7-14 days prior to randomization if thoracic radiation and/or prophylactic cranial\n",
      "        irradiation is given after completion of chemotherapy If severe esophagitis precludes\n",
      "        administration of oral medication, randomization may be within 21 days after radiation\n",
      "        therapy Surgery: No surgery within 2 weeks prior to randomization Prior complete resection\n",
      "        of tumor allowed Other: No other investigational agents within 4 weeks prior to study, and\n",
      "        none planned No concurrent coumarin anticoagulants and no coumarin anticoagulants within 4\n",
      "        weeks prior to randomization No concurrent antitumor treatment\n",
      "2285\n",
      "DISEASE CHARACTERISTICS: Biopsy proven relapsed malignant melanoma that has failed prior\n",
      "        standard regimen for metastatic disease Must have HLA-matched or related bone marrow donor\n",
      "        (5- or 6-antigen match) No history of CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 44 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Not specified Hepatic: SGOT and SGPT less than 1.5 times\n",
      "        upper limit of normal Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.5 mg/dL\n",
      "        AND/OR Creatinine clearance greater than 75 mL/min Cardiovascular: No history of cardiac\n",
      "        disease No symptomatic cardiac disease Ejection fraction greater than 50% Pulmonary: FEV1\n",
      "        greater than 50% predicted (greater than 75% if received thoracic irradiation) DLCO\n",
      "        greater than 50% predicted Other: Not pregnant Fertile women must use effective\n",
      "        contraception HIV negative No active bacterial, fungal, or viral infection Hepatitis B\n",
      "        negative\n",
      "        PRIOR CONCURRENT THERAPY: At least 1 prior standard regimen for metastatic disease\n",
      "2286\n",
      "DISEASE CHARACTERISTICS: Histologically proven locally advanced (surgically unresectable)\n",
      "        or metastatic squamous cell of the esophagus or carcinoma of the stomach Patients with\n",
      "        tumor extension below the GE junction into the proximal stomach must have the bulk of the\n",
      "        tumor involve the esophagus or GE junction Bidimensionally measurable or evaluable disease\n",
      "        No CNS metastases or carcinomatous meningitis No bone metastases (Closed to adenocarcinoma\n",
      "        of the esophagus as of 05/1998)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky 60-100% Life\n",
      "        Expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no\n",
      "        greater than 3 times upper limit of normal (ULN)(no greater than 5 times ULN if liver\n",
      "        metastases present) Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No\n",
      "        unstable angina No New York Heart Association class III or IV cardiac disease Pulmonary:\n",
      "        No interstitial pulmonary fibrosis Other: Not pregnant or nursing Negative pregnancy test\n",
      "        No active or uncontrolled infection No prior malignancy for at least 5 years, except:\n",
      "        Nonmelanoma skin cancer Carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered No prior radiation to the pelvis Surgery: Not specified\n",
      "2289\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of Wilms' tumor\n",
      "               -  Eligible subtypes:\n",
      "                    -  Favorable histologies\n",
      "                    -  Anaplastic histologies\n",
      "                    -  Clear cell sarcoma of the kidney\n",
      "                    -  Rhabdoid tumor of the kidney\n",
      "          -  Relapsed disease after entry on protocol NWTS-5 (NWTS-Q9401)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  21 and under at original diagnosis\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  At least 4 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT or SGPT less than 2.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times normal OR\n",
      "          -  Creatinine clearance or GFR at least 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Shortening fraction at least 27% by echocardiogram OR\n",
      "          -  Ejection fraction greater than 50% by echocardiogram or MUGA scan\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  At least 2 weeks since prior chemotherapy and recovered\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  No prior therapy for relapsed Wilms' tumor\n",
      "          -  Recovered from the toxic effects of any other prior therapy\n",
      "2290\n",
      "DISEASE CHARACTERISTICS: TdT positive acute lymphocytic leukemia or blastic chronic\n",
      "        myelogenous leukemia Failed at least one standard treatment\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky greater than 70%\n",
      "        Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Bilirubin no\n",
      "        greater than 2.0 mg/dL Transaminases no greater than 2.5 times normal Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Creatinine clearance greater than 60 mL/min Cardiovascular:\n",
      "        Ejection fraction greater than 40% Other: Not pregnant or nursing No serious concurrent\n",
      "        illness\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks\n",
      "        since chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 3 weeks since radiation therapy Surgery: Not specified\n",
      "2291\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven metastatic or locally advanced, inoperable adenocarcinoma of\n",
      "             the breast\n",
      "               -  Clinically evident metastases (e.g., clearly malignant lesions on chest x-ray or\n",
      "                  CT or abdominal CT do not require histologic confirmation)\n",
      "               -  Hot spots on bone scan not shown to be malignant on plain x-rays are not\n",
      "                  adequate evidence of malignant disease in the absence of other lesions\n",
      "          -  Must meet 1 of the following conditions:\n",
      "               -  Disease progression after 1 prior chemotherapy regimen for locally advanced or\n",
      "                  metastatic disease (which may or may not have followed a separate adjuvant\n",
      "                  regimen using chemotherapy or hormonal therapy)\n",
      "               -  Locally advanced or metastatic disease during or after 1 adjuvant or neoadjuvant\n",
      "                  chemotherapy regimen\n",
      "               -  One of the above chemotherapy regimens must have contained an anthracycline\n",
      "                  (e.g., doxorubicin, but not mitoxantrone)\n",
      "               -  Single drug substitution (e.g., methotrexate for doxorubicin) during prior\n",
      "                  combination chemotherapy allowed\n",
      "          -  Bidimensionally measurable\n",
      "          -  No clinical or radiographic evidence of brain or leptomeningeal disease\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100% OR\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 2,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  SGOT no greater than 2.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  No uncontrolled hypercalcemia\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No history of arrhythmia requiring treatment\n",
      "          -  No heart block\n",
      "          -  No clinical evidence of congestive heart failure\n",
      "          -  No unstable angina (e.g., new onset, crescendo, or rest angina)\n",
      "          -  Stable exertional angina allowed\n",
      "        Other:\n",
      "          -  No current symptomatic grade 2 or greater peripheral neuropathy\n",
      "          -  No history of hypersensitivity to products containing Cremophor EL (e.g.,\n",
      "             cyclosporine or teniposide) or Polysorbate 80 (e.g., IV etoposide)\n",
      "          -  No serious infection\n",
      "          -  No significant psychiatric disease that would preclude study\n",
      "          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or\n",
      "             completely excised carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior bone marrow or stem cell transplantation\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior chemotherapy (2 weeks for oral cyclophosphamide or 6\n",
      "             weeks for nitrosoureas or mitomycin)\n",
      "          -  No prior high-dose chemotherapy given with ablative intent\n",
      "          -  No prior taxoids\n",
      "          -  No other concurrent antineoplastic therapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Prior hormonal therapy as adjuvant therapy or for metastatic disease allowed\n",
      "          -  At least 1 week since prior hormonal therapy\n",
      "          -  No concurrent corticosteroids except:\n",
      "               -  Prophylaxis or treatment for acute hypersensitivity reactions\n",
      "               -  Chronic therapy (more than 6 months) at low doses (20 mg/day or less of\n",
      "                  methylprednisolone or equivalent)\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy to major bone marrow areas\n",
      "          -  No prior high-dose radiotherapy given with ablative intent\n",
      "          -  No concurrent radiotherapy except limited palliative radiotherapy (e.g., for a\n",
      "             solitary rib fracture) during objective response\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  More than 2 weeks since prior surgery except simple biopsy or placement of venous\n",
      "             access device\n",
      "        Other:\n",
      "          -  At least 4 weeks since prior investigational drugs\n",
      "          -  Concurrent medications known to alter cardiac conduction (e.g., digoxin, beta\n",
      "             blockers, or calcium channel blockers) allowed\n",
      "          -  No concurrent ketoconazole\n",
      "          -  No concurrent bisphosphonates unless initiated more than 3 months before\n",
      "             randomization\n",
      "          -  No concurrent experimental drug or therapy\n",
      "2292\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Pathologically documented Epstein-Barr virus (EBV) antigen-positive at risk or with\n",
      "             lymphoproliferative disease, lymphoma, or other EBV-associated malignancy\n",
      "          -  Immunocompromised as a consequence of:\n",
      "               -  Genetic or acquired immunodeficiency (including AIDS)\n",
      "               -  Allogeneic bone marrow or organ transplant\n",
      "          -  Normal lymphocyte donor related to patient or, for organ allografts, to organ*:\n",
      "               -  Immunocompetent\n",
      "               -  HLA compatible\n",
      "               -  EBV seropositive\n",
      "               -  HIV negative\n",
      "               -  Organ donors at least HLA haplotype-identical with the lymphoma NOTE: *However,\n",
      "                  if the HSCT donor is EBV seronegative or not available (e.g., a cord blood\n",
      "                  transplant), EBV-specific T-cells generated from a normal seropositive related\n",
      "                  or unrelated donor matched for at least 2 HLA alleles may be used.\n",
      "               -  Patients who develop other EBV-associated malignancies without pre-existing\n",
      "                  immune deficiency, including: EBV+ Hodgkin's and Non-Hodgkin's disease, EBV+\n",
      "                  nasopharyngeal carcinoma, EBV+hemophagocytic lymphohistiocytosis, or EBV+\n",
      "                  leiomyosarcoma. Normal, EBV specific T-cells from third party seropositive\n",
      "                  donors who are HLA compatible in at least 2 HLA alleles shared by the patient\n",
      "                  will be used. Selection of T cells known to be restricted by an HLA allele\n",
      "                  shared by the patient will be given priority.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  No moribund patients\n",
      "        Life expectancy:\n",
      "          -  At least 9 weeks\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Pregnant women eligible\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2293\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed non small cell lung cancer ineligible\n",
      "        for higher priority protocols Sputum cytology acceptable Stage IIIB/IV Must have\n",
      "        measurable or evaluable disease Lesion outside prior radiotherapy fields Cytology-positive\n",
      "        pleural effusion and ascites are neither measurable nor evaluable No brain metastases on\n",
      "        CT\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute granulocyte count greater than 2,000/mm3 Platelet\n",
      "        count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine\n",
      "        less than 1.5 mg/dL Other: No pregnant or nursing women Negative pregnancy test required\n",
      "        of fertile women Effective contraception required of fertile patients Blood/body fluid\n",
      "        analyses within 7 days prior to registration Imaging/exams for tumor measurement within 28\n",
      "        days prior to registration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior adjuvant\n",
      "        or neoadjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: At\n",
      "        least 4 weeks since radiotherapy and recovered AND Progressive disease outside of\n",
      "        radiation port Surgery: Recovered from any prior surgery\n",
      "2294\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer Bidimensionally\n",
      "        measurable disease of any of the following types required: Bidimensionally measurable lung\n",
      "        lesions on chest X-ray, CT scan, or MRI Palpable and quantifiable lymph nodes at least 2 x\n",
      "        2 cm Abdominal mass at least 2 x 2 cm quantifiable by CT scan Bidimensionally measurable\n",
      "        liver metastases at least 2 x 2 cm Palpable hepatomegaly if liver edge is clearly defined\n",
      "        and extends at least 5 cm below the costal margin of the xiphoid process Unacceptable as\n",
      "        measurable disease: Diffuse lung infiltration or unidimensionally measurable hilar lesions\n",
      "        Pelvic mass of indefinite dimension Bone metastases Pleural effusion or ascites No brain\n",
      "        metastases Must have failed or progressed on prior therapy or relapsed less than 12 months\n",
      "        after therapy discontinuation Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: SWOG 0-2 Life expectancy: At least 6 months Hematopoietic: Granulocyte\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT no greater than\n",
      "        2.5 times upper limit of normal Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No\n",
      "        history of congestive heart failure, myocardial infarction within past 6 months,\n",
      "        ventricular arrhythmia, or ischemic heart disease requiring medication If necessary,\n",
      "        ejection fraction at least 50% by MUGA Other: Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception No other prior malignancies in past\n",
      "        5 years other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ\n",
      "        of the cervix No other serious illnesses or active infections No seizure disorder\n",
      "        requiring anticonvulsant therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        See Disease Characteristics No more than 2 prior chemotherapy regimens for metastatic\n",
      "        disease One prior adjuvant chemotherapy regimen for metastatic disease allowed At least 4\n",
      "        weeks since prior chemotherapy No other concurrent chemotherapy Endocrine therapy: One\n",
      "        prior regimen of hormonal therapy for metastatic disease allowed At least 3 weeks since\n",
      "        prior hormonal therapy and recovered No concurrent hormonal or corticosteroid therapy\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy to less than 25% bone marrow No\n",
      "        concurrent radiotherapy Surgery: At least 4 weeks since prior surgery and recovered No\n",
      "        concurrent surgery Other: At least 4 weeks since any prior treatment directed at the tumor\n",
      "        and recovered No other concurrent anticancer or investigational therapy No concurrent\n",
      "        participation on another therapeutic clinical trial\n",
      "2295\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage IIIB breast cancer with dermal/epidermal invasion or\n",
      "             clinical features of inflammation, erythema, pain or hypersensitivity, edema, or\n",
      "             thickening of the skin\n",
      "          -  Diagnosis within the past 6 months\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  60 and under\n",
      "        Performance status:\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT or SGPT no greater than 1.5 times the upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "          -  Creatinine clearance at least 80 mL/min\n",
      "          -  No history of hemorrhagic cystitis\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular fraction at least 55% on MUGA scan\n",
      "          -  No previous valvular heart disease or arrhythmia\n",
      "        Pulmonary:\n",
      "          -  FEV_1 at least 60% predicted\n",
      "          -  Room air pO_2 greater than 85 mmHg\n",
      "          -  Room air pCO_2 no greater than 43 mmHg\n",
      "          -  DLCO at least 60% of the lower limit of predicted value\n",
      "        Other:\n",
      "          -  No history of malignant disease in the past 5 years, except for squamous or basal\n",
      "             cell skin cancer and stage I or in situ cervical cancer\n",
      "          -  No organic CNS dysfunction\n",
      "          -  Not pregnant\n",
      "          -  No known and potentially disabling psychosocial history\n",
      "          -  Not positive for hepatitis B or HIV\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Stratum 1:\n",
      "               -  No more than one cycle of chemotherapy\n",
      "          -  Stratum 2:\n",
      "               -  No greater than 225 mg/m^2 doxorubicin and no greater than 250 mg/m^2 paclitaxel\n",
      "                  during previous chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiation to the left chest wall\n",
      "        Surgery:\n",
      "          -  Modified radical mastectomy allowed\n",
      "2296\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed Stage III (T1-2 N2-3 M0, T3 N2 M0, or T4\n",
      "        N0-3 M0) non-small cell lung cancer Must be candidates for either a resection with\n",
      "        curative intent or definitive thoracic irradiation following induction chemotherapy No\n",
      "        malignant pericardial or pleural effusions or superior vena cava syndrome Must have\n",
      "        measurable or evaluable indicator lesions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100%\n",
      "        Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 160,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.0 mg/dL SGOT and/or SGPT no greater than 1.5 times the upper\n",
      "        limit of normal Alkaline phosphatase no greater than 5 times the upper limit of normal\n",
      "        Renal: Creatinine clearance at least 65 mL/min Cardiovascular: Must have stable heart\n",
      "        rhythm No unstable angina No myocardial infarction within 6 months No clinical evidence of\n",
      "        congestive heart failure Neurologic: Must have normal auditory function No symptoms of\n",
      "        peripheral neuropathy Other: No prior malignancy except non-melanoma skin cancer or in\n",
      "        situ carcinoma of the cervix Not pregnant Adequate contraception required of all fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy\n",
      "        Surgery: Not specified\n",
      "2297\n",
      "DISEASE CHARACTERISTICS: Histologic or cytologic confirmation of malignant solid tumor\n",
      "        including, but not limited to: Breast cancer Prostate cancer Colon cancer Adrenocortical\n",
      "        tumors No CNS metastases No conventional therapy for cure or palliation available\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: aPTT and PT no greater than upper limit of normal (ULN)\n",
      "        Bilirubin no greater than 1.5 times ULN AST no greater than 2 times ULN Albumin at least\n",
      "        3.0 g/dL Renal: Creatinine clearance at least 50 mL/min Sodium and potassium normal\n",
      "        Cardiovascular: Ejection fraction normal if prior doxorubicin therapy No New York Heart\n",
      "        Association class III or IV heart disease No history of significant cardiac arrhythmia No\n",
      "        history of congestive heart failure Neurologic: No seizure disorder No grade 2 or greater\n",
      "        peripheral neuropathy Other: Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception No insulin-dependent diabetes mellitus No\n",
      "        uncontrolled infection No chronic debilitating disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        or immunotherapy No concurrent immunotherapy No concurrent filgrastim (G-CSF) or\n",
      "        sargramostim (GM-CSF) Chemotherapy: More than 4 weeks since prior chemotherapy (6 weeks\n",
      "        for mitomycin or nitrosoureas) and recovered Prior doxorubicin allowed if total dose less\n",
      "        than 300 mg/m2 No other concurrent chemotherapy No more than 2 prior chemotherapy regimens\n",
      "        for metastatic disease Endocrine therapy: No current steroid use of greater than 1.5 mg\n",
      "        dexamethasone (or equivalent) per day Radiotherapy: At least 4 weeks since prior radiation\n",
      "        therapy No radiation therapy to greater than 25% of bone marrow No concurrent radiotherapy\n",
      "        Surgery: At least 4 weeks since prior major surgery\n",
      "2298\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable or metastatic cancer\n",
      "        Confirmed by biopsy or fine needle aspiration Tumors must predominantly involve the lung\n",
      "        Measurable or evaluable disease No lymphomas or leukemias No AIDS associate Kaposi's\n",
      "        Sarcoma No uncontrolled brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy: At\n",
      "        least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count within normal limits\n",
      "        Hepatic: Bilirubin no greater than 2 times normal Renal: Creatinine no greater than 2.0\n",
      "        mg/dL Cardiovascular: Adequate cardiovascular system with NYHA Class 0 or I No\n",
      "        uncontrolled cardiac arrhythmias Pulmonary: FEV1 at least 65% of predicted FVC at least\n",
      "        65% of predicted No asthma or bronchial obstruction that would prevent the delivery of\n",
      "        IL-2 to all lobes of the lung Other: HIV negative No medical or psychological criteria\n",
      "        that would make patient unable to tolerate the treatment Not pregnant or nursing Adequate\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interleukin-2 Prior biologic response\n",
      "        therapy allowed No chronic use of immunosuppressive medicines Chemotherapy: Prior\n",
      "        chemotherapy allowed Endocrine therapy: No chronic steroid use Prior hormonal therapy\n",
      "        allowed Radiotherapy: No prior or concurrent radiotherapy except as palliative to areas of\n",
      "        painful metastases outside the lung Surgery: Not specified\n",
      "2299\n",
      "DISEASE CHARACTERISTICS: See General Eligibility Criteria\n",
      "        PATIENT CHARACTERISTICS: Age: 19 to 64 Performance Status: Zubrod 0-3 Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin less than 2 mg/dL SGOT and SGPT less than 3 times normal\n",
      "        Alkaline phosphatase less than 3 times normal Renal: Creatinine clearance at least 60\n",
      "        mL/min Cardiovascular: Cardiac ejection fraction at least 50% Pulmonary: No history of\n",
      "        severe chronic obstructive lung disease No history of recurrent pulmonary emboli Other:\n",
      "        Not pregnant or nursing Effective contraception should be practiced by fertile patients No\n",
      "        history of diabetes mellitus complicated by ketoacidosis No history of depression or\n",
      "        psychosis No history of autoimmune disorders No concurrent thyroid disorders unable to be\n",
      "        maintained on replacement therapy No prior hypersensitivity to interferon alfa-2b\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 12\n",
      "        months of prior alkylator therapy Endocrine Therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified\n",
      "2302\n",
      "DISEASE CHARACTERISTICS: Histologically proven, resected, stage I or II pancreatic\n",
      "        adenocarcinoma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3000/mm3 Lymphocyte count at least\n",
      "        700/mm3 Platelet count at least 100,000/mm3 Hepatic: Not specified Renal: Creatinine no\n",
      "        greater than 2.0 mg/dL Cardiovascular: No clinically significant heart disease Other: No\n",
      "        other serious illness No active infections requiring antibiotics within past 2 weeks Not\n",
      "        pregnant or nursing Fertile patients must use effective birth control No known\n",
      "        immunodeficiency No active bleeding\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: No concurrent corticosteroids Radiotherapy: No prior\n",
      "        radiation therapy Surgery: Must undergo Whipple procedure or distal pancreatectomy at\n",
      "        Memorial Hospital Must not have undergone splenectomy Other: No investigational treatment\n",
      "        within 2 months of surgery No immunosuppressive therapies\n",
      "2304\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Curatively treated carcinoma of the breast\n",
      "          -  Currently taking adjuvant tamoxifen\n",
      "               -  Must be substantial uncertainty as to whether or not to continue tamoxifen\n",
      "                  (i.e., no clear indication or definite contraindication to further treatment\n",
      "                  with tamoxifen)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  No contraindications to receiving tamoxifen\n",
      "          -  No other serious medical problems\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior biologic therapy allowed\n",
      "        Chemotherapy:\n",
      "          -  Prior chemotherapy allowed\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  Prior surgery allowed\n",
      "2305\n",
      "DISEASE CHARACTERISTICS: Previously untreated large cell lymphoma, including the following\n",
      "        histologic designations: Rappaport classification Diffuse histiocytic Mixed\n",
      "        lymphocytic-histiocytic Working Formulation classification Diffuse large cell, cleaved\n",
      "        and/or noncleaved Immunoblastic Diffuse, mixed small and large cell Lukes-Collins\n",
      "        classification Diffuse large cleaved Diffuse large noncleaved Immunoblastic T or B cell\n",
      "        True histiocytic Updated Kiel classification Cytocentric large cell\n",
      "        Centroblastic-centrocytic T-zone Lymphoepithelioid cell (Lennert's) Immunoblastic T or B\n",
      "        cell Large cell anaplastic Pleomorphic Centroblastic-centrocytic, diffuse Malignant\n",
      "        histiocytosis Murphy stage III/IV HIV-associated lymphoma eligible Any degree of bone\n",
      "        marrow involvement eligible CNS disease eligible (such patients not randomized)\n",
      "        PATIENT CHARACTERISTICS: Age: Under 22 Performance status: Not specified Hepatic: Not\n",
      "        specified Renal: Not specified Other: Not pregnant or nursing Adequate contraception\n",
      "        required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy\n",
      "2306\n",
      "DISEASE CHARACTERISTICS: Diagnostically proven intermediate, advanced, or high risk\n",
      "        chronic lymphocytic leukemia of the B cells with marrow tumor reduced by prior therapy\n",
      "        Marrow tumor content no greater than 30% of total nucleated cells Patients age 50 and\n",
      "        under who have high risk disease are eligible Patients age 65 and under who have\n",
      "        intermediate or high risk disease that has failed at least 1 therapy including an\n",
      "        alkylating agent or fludarabine are eligible No history of transformation to aggressive\n",
      "        lymphoma (Richter's syndrome)\n",
      "        PATIENT CHARACTERISTICS: Age: 17 to 65 Performance status: Karnofsky 70%-100% Life\n",
      "        expectancy: Not severely limited by illness other than leukemia Hematopoietic: Absolute\n",
      "        neutrophil count greater than 2,000/mm3 (no growth factor support) Platelet count greater\n",
      "        than 120,000/mm3 (unless documented active autoimmune thrombocytopenia) Hemoglobin greater\n",
      "        than 10 g/dL (unless documented active autoimmune anemia) No coexisting myelodysplasia\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine clearance at least 50\n",
      "        mL/min Cardiovascular: No cardiac disease that would limit ability to receive\n",
      "        cytoreductive therapy and compromise survival Pulmonary: No pulmonary disease that would\n",
      "        limit ability to receive cytoreductive therapy and compromise survival Other: No HIV\n",
      "        antibody Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior radiation therapy to chest\n",
      "        or abdomen greater than 2,000 Gy\n",
      "2308\n",
      "DISEASE CHARACTERISTICS: Histologically proven advanced, recurrent, or inoperable ovarian\n",
      "        epithelial cancer Previously treated with 1 platinum-containing chemotherapy regimen\n",
      "        Bidimensionally measurable or reproducibly measurable disease in 2 dimensions on CT scan\n",
      "        (The measurable disease stratum closed to accrual effective 08/1998) OR Evaluable but\n",
      "        radiographically nonmeasurable disease with CA-125 more than 50 units/mL on 2 measurements\n",
      "        at least 1 week apart\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT and SGPT no greater\n",
      "        than 3 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR\n",
      "        Creatinine clearance at least 60 mL/min Cardiovascular: No myocardial infarction,\n",
      "        congestive heart failure, or other significant cardiac disease within the past 6 months No\n",
      "        uncontrolled hypertension Other: No significant active infection (e.g., pneumonia,\n",
      "        peritonitis, or wound abscess) No uncontrolled metabolic disease (e.g., diabetes mellitus\n",
      "        or hypothyroidism) No asthma (even if controlled with medication) No other serious\n",
      "        concurrent illness No dementia or altered mental status that would preclude informed\n",
      "        consent No other malignancy except curatively treated nonmelanomatous skin cancer or\n",
      "        carcinoma in situ of the cervix Not pregnant Negative pregnancy test Fertile patients must\n",
      "        use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: See\n",
      "        Disease Characteristics No more than 1 prior chemotherapy regimen No other concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy\n",
      "        Surgery: See Disease Characteristics Other: At least 4 weeks since prior investigational\n",
      "        agents\n",
      "2309\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed colorectal carcinoma At least grade 2\n",
      "        diarrhea as a consequence of chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Concurrent enrollment into SWOG-9420 protocol allowed No sensitivity to octreotide\n",
      "        acetate or loperamide hydrochloride Eligible if less than 24 hours since prior loperamide\n",
      "        or octreotide and no resolution of diarrhea Not pregnant or lactating Effective\n",
      "        contraception required of fertile patients Not HIV positive No idiopathic ulcerative\n",
      "        colitis or Crohn's disease, acute stool culture positive bacterial colitis,\n",
      "        pseudomembranous colitis, short bowel syndrome, enteroenteric fistulae, chronic\n",
      "        pancreatitis, ischemic bowel disease, or gastrointestinal disorders known to cause\n",
      "        diarrhea Absence of definitive culture results required\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy\n",
      "        with a fluoropyrimidine alone or in combination with an accepted modulating agent\n",
      "        (leucovorin, levamisole, methotrexate, interferon, PALA, or hydroxyurea) required Prior\n",
      "        chemotherapy with uracil mustard and tegafur (UFT) allowed No concurrent chemotherapy\n",
      "        allowed during study Endocrine therapy: Not specified Radiotherapy: No whole pelvic or\n",
      "        abdominal radiation therapy allowed Surgery: No colectomy, coloanal anastamosis,\n",
      "        abdominoperineal resection, or colostomy allowed Other: No antidiarrheal agents (e.g.,\n",
      "        diphenoxylate hydrochloride, elixir paregoric, opium tincture or tincture of belladonna,\n",
      "        or kaolin) during study No cyclosporine allowed\n",
      "2310\n",
      "DISEASE CHARACTERISTICS: Histologically proven liposarcoma that is incurable by standard\n",
      "        surgery Measurable or evaluable disease required No active CNS involvement or\n",
      "        leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT less than 5 times\n",
      "        upper normal limit Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No poorly\n",
      "        controlled atrial arrhythmias, angina pectoris, or myocardial infarction within past 6\n",
      "        months No symptomatic congestive heart failure, percutaneous transluminal coronary\n",
      "        angioplasty, or coronary artery bypass graft within past 3 months Other: Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception No known active retroviral\n",
      "        disease\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from toxic effects of all prior therapy No concurrent\n",
      "        cytotoxic therapy Biologic therapy: Not specified Chemotherapy: Prior chemotherapy allowed\n",
      "        Endocrine therapy: No concurrent hormonal therapy Radiotherapy: Prior radiation therapy\n",
      "        for metastatic disease allowed No radiotherapy to sole site of measurable disease within\n",
      "        past 6 months Surgery: Not specified\n",
      "2312\n",
      "DISEASE CHARACTERISTICS: Histologically proven, untreated, locally advanced breast cancer;\n",
      "        stage IIB (T3 N0), IIIA, or IIIB Measurable disease Not inflammatory breast cancer or\n",
      "        other stage IIB (T2 N1) No distant metastases except for positive ipsilateral\n",
      "        supraclavicular nodes\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:\n",
      "        Not pregnant Fertile patients must use effective contraception during and 6 months after\n",
      "        treatment Medically and psychologically stable\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy of any type\n",
      "2313\n",
      "DISEASE CHARACTERISTICS: Histologically proven resectable stage II or III adenocarcinoma\n",
      "        of the colon Caudal margin of the primary tumor must lie above the peritoneal reflection\n",
      "        Must have pathologic confirmation of either N1-3 (stage III), or if N0, must have T3-T4\n",
      "        (stage II) with bowel obstruction or perforation Obstruction documented as: At least 75%\n",
      "        colon or small bowel obstruction on x-ray and/or endoscopy Significant bowel dilatation\n",
      "        surgically documented Significant obstruction described in the pathology report\n",
      "        Perforation documented by gross operative/pathologic evidence of a colon wall defect with\n",
      "        associated abscess or peritonitis Complete en bloc resection by laparotomy required No\n",
      "        laparoscopic colectomy without prior surgery on protocol SWOG-9411 No gross or microscopic\n",
      "        residual disease No distant peritoneal metastases (stage IV) even if grossly resectable No\n",
      "        requirement to open the pelvic peritoneum to define the extent of disease No extrapelvic\n",
      "        nodal metastasis unless resected en bloc with the primary tumor No distant metastases No\n",
      "        other diagnosis of stage II-III colon cancer within the past 5 years May have undergone\n",
      "        complete surgical resection at least 5 years prior to study Completely resected prior or\n",
      "        synchronous stage 0-I colon cancer eligible\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0-2 Hematopoietic: WBC (white\n",
      "        blood cell) at least 3,500/mm3 Platelet count at least within the lower limit of normal\n",
      "        Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST (angiotensin\n",
      "        sensitivity test) no greater than 2 times ULN Alkaline phosphatase no greater than 2 times\n",
      "        ULN Renal: Creatinine no greater than 2 times ULN Other: No organic brain syndrome,\n",
      "        Alzheimer's disease, or other altered mental status No second malignancy within 5 years\n",
      "        except: Adequately treated nonmelanomatous skin cancer Adequately treated carcinoma in\n",
      "        situ of the cervix Not pregnant or nursing Negative pregnancy test Effective contraception\n",
      "        required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        fluorouracil or other chemotherapy for cancer No concurrent chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: No prior or concurrent radiotherapy for cancer\n",
      "        Surgery: Complete en bloc resection required (see Disease Characteristics)\n",
      "2314\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed embryonal (EMB) rhabdomyosarcoma (RMS) or botryoid or\n",
      "             spindle cell variants of EMB RMS or embryonal ectomesenchymoma meeting 1 of the\n",
      "             following criteria:\n",
      "               -  Stage 1, no clinical group IV: Tumor in favorable site (orbit, head and neck\n",
      "                  [excluding parameningeal], genitourinary [not bladder/prostate], or biliary\n",
      "                  tract) and no metastatic disease\n",
      "               -  Stage 2 or 3, clinical group I or II: Tumor in unfavorable site\n",
      "                  (bladder/prostate, extremity, cranial parameningeal, trunk, retroperitoneum,\n",
      "                  pelvis, perineal/perianal, intrathoracic, gastrointestinal, or liver), no gross\n",
      "                  residual disease after initial surgery, and no metastatic disease\n",
      "          -  Must have ipsilateral lymph node dissection if age 10 or over with primary\n",
      "             paratesticular cancer OR under age 10 with clinically positive regional lymph nodes\n",
      "          -  Low risk of recurrence\n",
      "          -  Previously untreated disease\n",
      "          -  No alveolar RMS or undifferentiated sarcoma\n",
      "          -  No intermediate-risk disease\n",
      "          -  No metastatic disease at diagnosis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 50\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin elevation secondary to biliary or hepatic primaries allowed\n",
      "        Renal:\n",
      "          -  Creatinine elevation secondary to tumor obstruction allowed\n",
      "        Other:\n",
      "          -  No uncontrolled infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2315\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Unilateral carcinoma of the breast that has not been previously treated with standard\n",
      "             therapies\n",
      "          -  Tumor greater than 2 cm in its maximum diameter as assessed by mammography, except:\n",
      "               -  No locally advanced disease, i.e., no tumor with direct extension to the chest\n",
      "                  wall or skin\n",
      "               -  No metastatic disease\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 70\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 80-100%\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 2,000/mm^3\n",
      "          -  Platelet count at least 150,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin within upper limits of normal (ULN)\n",
      "          -  Alkaline phosphatase no greater than 1.5 times ULN\n",
      "          -  AST no greater than 1.5 times ULN\n",
      "          -  No chronic active hepatitis\n",
      "        Renal:\n",
      "          -  Creatinine within ULN\n",
      "        Cardiovascular:\n",
      "          -  No prior atrial or ventricular arrhythmias\n",
      "          -  No history of congestive heart failure\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No uncontrolled hypertension\n",
      "        Neurologic:\n",
      "          -  No pre-existing motor or sensory neuropathy greater than grade 1\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No active infection\n",
      "          -  No history of second malignancy except adequately treated basal cell skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior endocrine therapy\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No prior surgery\n",
      "          -  No prior surgical biopsy of breast nodule\n",
      "2316\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage IV or recurrent squamous cell,\n",
      "        adenosquamous, or adenocarcinoma of the uterine cervix including: Lung, liver, lymph node,\n",
      "        or skin metastases OR Retroperitoneal disease OR Other advanced measurable disease OR\n",
      "        Positive paraaortic lymph nodes Measurable disease that is beyond the scope of\n",
      "        conventional radiation therapy or surgery, or recurrent after radiation therapy or surgery\n",
      "        Measurable, recurrent disease within a previously irradiated field must have increased in\n",
      "        size by 100% on at least 2 successive scans, MRI, or physical examinations\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times\n",
      "        the upper limit of normal (ULN) AST and ALT no greater than 2 times ULN Renal: Creatinine\n",
      "        no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: No New\n",
      "        York Heart Association class III/IV heart disease No uncontrolled congestive heart failure\n",
      "        or angina Pulmonary: No chronic obstructive pulmonary disease Gastrointestinal: No\n",
      "        evidence of active gastrointestinal bleeding No active peptic ulcer disease No\n",
      "        inflammatory bowel disease Other: Normal diet required No known active infections HIV\n",
      "        negative AIDS-related complex (ARC) negative No substance abuse or psychiatric problems No\n",
      "        evidence of autoimmune disease No other prior invasive malignancy except resected basal\n",
      "        cell or squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: 1 prior biologic therapy allowed At least 4\n",
      "        weeks since prior biologic therapy Chemotherapy: 1 prior adjuvant chemotherapy regimen\n",
      "        allowed 1 prior chemotherapy regimen for advanced disease allowed At least 4 weeks since\n",
      "        prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent steroid\n",
      "        therapy No concurrent megestrol acetate Radiotherapy: See Disease Characteristics No\n",
      "        concurrent radiotherapy Surgery: See Disease Characteristics At least 2 weeks since prior\n",
      "        surgery\n",
      "2317\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer\n",
      "        of any type Selected stage IIIA/B disease (T3-4, N0-1, M0) with superior sulcus\n",
      "        involvement, including: Apical tumor without rib or vertebral body involvement, with\n",
      "        Pancoast syndrome Superior sulcus tumor with involvement of the chest wall (T3) and\n",
      "        usually ribs 1 and 2 by CT or MRI, with or without Pancoast syndrome Superior sulcus tumor\n",
      "        with involvement of vertebral body or subclavian vessels (T4) by CT or MRI, with or\n",
      "        without Pancoast syndrome Pancoast syndrome defined: Arm or shoulder pain Neurologic\n",
      "        findings corresponding to C8 and T1 roots or the inferior trunk of the brachial plexus,\n",
      "        with or without Horner's syndrome Single primary lesion that is measurable or evaluable by\n",
      "        chest x-ray or CT required Pleural effusions allowed only if: Transudate with negative\n",
      "        cytology on 2 separate thoracenteses if present before mediastinoscopy or exploratory\n",
      "        thoracotomy Transudate or exudate with negative cytology on a single thoracentesis if\n",
      "        present only after preregistration exploratory or staging thoracotomy OR Present on CT but\n",
      "        not chest x-ray AND considered too small to tap under CT or ultrasound guidance\n",
      "        Thoracoscopy to assess pleural metastases strongly recommended No mediastinal or\n",
      "        supraclavicular nodal involvement (N2-3) established by mediastinoscopy, mediastinotomy,\n",
      "        thoracoscopy, or thoracotomy No documented single- or multi-level ipsilateral or\n",
      "        contralateral mediastinal nodes whether or not enlarged nodes visible on chest x-ray or CT\n",
      "        AP window nodes (level 5) causing vocal cord paralysis considered N2 disease in patients\n",
      "        with a distinct primary tumor in the left upper lobe Paralysis documented by indirect\n",
      "        laryngoscopy No evidence of distant metastases on the following: Chest CT, preferably with\n",
      "        contrast Thoracic spine MRI strongly recommended if CT suggests vertebral body invasion\n",
      "        Abdominal CT including liver and adrenals, preferably with contrast Biopsy or aspiration\n",
      "        cytology required to confirm diagnosis of any CT or MRI abnormality MRI and ultrasound\n",
      "        sufficient to diagnose benign cysts or hemangiomas Brain CT or MRI with contrast Bone scan\n",
      "        with x-rays or MRI, and/or aspiration cytology of any abnormality (unless related to chest\n",
      "        wall extension of primary) No pericardial effusions or superior vena cava syndrome Patient\n",
      "        considered candidate for potential pulmonary resection by attending thoracic surgeon\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0-2 Albumin at least 0.85\n",
      "        times normal and no greater than 10% tumor-related weight loss required in patients with\n",
      "        performance status 2 Hematopoietic: WBC at least 4,000 Platelets at least normal Hepatic:\n",
      "        (unless abnormality due to documented benign disease) Bilirubin no greater than 1.5 times\n",
      "        normal ALT or AST no greater than 1.5 times normal Renal: Creatinine clearance\n",
      "        (calculated) at least 50 mL/min Cardiovascular: No poorly controlled disease, e.g.:\n",
      "        Myocardial infarction within 3 months Active angina Arrhythmia Clinically evident\n",
      "        congestive heart failure Pulmonary: FEV1 at least 2.0 liters OR Predicted postresection\n",
      "        FEV1 greater than 800 mL based on quantitative lung V/Q scan DLCO at least 50% of\n",
      "        predicted (corrected for hemoglobin) and recommended if pneumonectomy planned Other: No\n",
      "        symptomatic peripheral neuropathy No peptic ulcer disease unless medically controlled\n",
      "        Acceptance of potential worsening of any existing clinical hearing loss No second\n",
      "        malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer\n",
      "        Adequately treated in situ cervical cancer No pregnant or nursing women Effective\n",
      "        contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy for lung cancer Prior\n",
      "        exploratory thoracotomy allowed only for diagnostic or staging purposes\n",
      "2319\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed acute lymphocytic leukemia FAB class\n",
      "        L1-L2 Mixed immunophenotypic markers with no cytochemical myeloid markers allowed No\n",
      "        non-Hodgkin's lymphoma No chronic myelogenous leukemia in blast crisis Concurrent\n",
      "        registration on the cytogenetics protocol SWOG-9007 required\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: SWOG 0-3 Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin no greater than 2 times normal (unless elevation due to\n",
      "        leukemia) AST no greater than 3 times normal (unless elevation due to leukemia) No chronic\n",
      "        liver disease Renal: Creatinine no greater than 2 times normal Cardiovascular: Left\n",
      "        ventricular ejection fraction at least 50% by MUGA or echocardiogram No symptomatic\n",
      "        congestive heart failure No symptomatic coronary artery disease No cardiomyopathy No\n",
      "        uncontrolled arrhythmia Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: No prior remission induction chemotherapy for acute lymphocytic\n",
      "        leukemia\n",
      "2320\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following\n",
      "        sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk\n",
      "        factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or\n",
      "        more regional lymph nodes Microscopically positive mucosal margins Complete resection of\n",
      "        all visible and palpable disease Therapy must begin within 8 weeks of tumor-related\n",
      "        surgery Bilateral resections may or may not be performed simultaneously Eligibility window\n",
      "        begins with first definitive surgery Neck dissection not required for T4 N0, truly midline\n",
      "        supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or\n",
      "        concurrent head and neck tumors No evidence of distant metastasis Concurrent registration\n",
      "        on Fixed Tumor Repository Study allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal:\n",
      "        Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol\n",
      "        therapy No second malignancy within 5 years No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head\n",
      "        and neck region Surgery: See Disease Characteristics\n",
      "2321\n",
      "DISEASE CHARACTERISTICS: Chronic myelogenous leukemia in chronic phase Molecular evidence\n",
      "        of BCR/ABL rearrangement OR Presence of Philadelphia chromosome Eligibility for allogeneic\n",
      "        bone marrow transplantation does not exclude\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Performance status: WHO 0-2 Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin less than twice normal No severe hepatic problem Renal:\n",
      "        Creatinine less than twice normal No severe renal problem Cardiovascular: No severe\n",
      "        cardiovascular problem Other: No contraindication to interferon therapy No history of\n",
      "        severe depression No pregnant women Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy Prior therapeutic or back-up leukapheresis\n",
      "        allowed Hydroxyurea may be started up to 4 weeks prior to entry\n",
      "2324\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of chronic myelogenous leukemia in blast crisis\n",
      "               -  Bone marrow blasts at least 20% OR\n",
      "               -  Bone marrow blasts plus promyelocytes at least 50%\n",
      "          -  Ineligible for higher priority protocols\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 and over\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  LVEF greater than 50% by MUGA scan or echocardiogram\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  Prior therapy for blast crisis allowed\n",
      "2325\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed sarcomas in the following categories:\n",
      "        Soft tissue sarcoma (STS) High-grade STS of the extremities Primary extending to fascia or\n",
      "        locally recurrent At least 10 cm in greatest dimension or multifocal on surgical pathology\n",
      "        Primary site controlled by surgery and/or radiotherapy High-grade truncal or head and neck\n",
      "        sarcoma At least 10 cm in greatest dimension or any size with no surgical options for\n",
      "        clear margins Primary site controlled by surgery and/or radiotherapy Locally recurrent\n",
      "        disease in CR or PR after surgery, chemotherapy, or radiotherapy Metastatic STS in CR or\n",
      "        PR after surgery, chemotherapy, or radiotherapy Osteosarcoma (OS) Extremity OS after\n",
      "        neoadjuvant chemotherapy and surgical resection provided: Less than 50% necrosis in the\n",
      "        surgical specimen LDH or alkaline phosphatase greater than 2 times normal at presentation\n",
      "        Axial OS in CR or PR after chemotherapy and/or surgery Primary or recurrent metastatic OS\n",
      "        in CR or PR after chemotherapy, surgery, and/or radiotherapy Ewing's sarcoma or primitive\n",
      "        neuroectodermal tumor Primary site in CR or PR after chemotherapy, radiotherapy, or\n",
      "        surgery Rib, pelvic, or axial skeleton primary Bulky tumor (at least 10 cm in greatest\n",
      "        diameter) Primary or recurrent metastatic disease in CR or PR after surgery, chemotherapy,\n",
      "        or radiotherapy Rhabdomyosarcoma Gross residual disease after primary treatment with\n",
      "        surgery, chemotherapy, and radiotherapy Primary group IV or recurrent metastatic disease\n",
      "        in CR or PR after chemotherapy and radiotherapy with or without surgery No brain\n",
      "        metastasis No histologically confirmed bone marrow metastasis Prior metastases allowed\n",
      "        with clearing of bone marrow at entry No contraindication to collection of mobilized stem\n",
      "        cells or, if needed, autologous bone marrow\n",
      "        PATIENT CHARACTERISTICS: Age: 10 to 55 Performance status: Karnofsky 80-100%\n",
      "        Hematopoietic: Absolute neutrophil count greater than 2,000/mm3 Platelet count greater\n",
      "        than 150,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: See Disease Characteristics\n",
      "        Bilirubin less than 1.5 mg/dL AST and ALT less than 3 times normal Hepatitis B surface\n",
      "        antigen negative Negative hepatitis C antigen test required in patients with hepatitis C\n",
      "        antibody Renal: Creatinine less than 1.4 mg/dL Creatinine clearance greater than 75 mL/min\n",
      "        Cardiovascular: LVEF at least 55% by MUGA or echocardiogram No history of significant\n",
      "        cardiac disease Pulmonary: FEV1 greater than 2 liters PaO2 greater than 70 mm Hg on room\n",
      "        air PaCO2 less than 42 mm Hg on room air DLCO greater than 60% predicted Other: No hearing\n",
      "        loss of greater than 40 decibels HIV negative No organic or psychiatric CNS dysfunction\n",
      "        that would preclude study No other medical or psychosocial problems that would place\n",
      "        patient at unacceptable risk No history of other malignancy except nonmelanoma skin cancer\n",
      "        or carcinoma in situ of the cervix Not pregnant Negative pregnancy test Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: More than 2 weeks since treatment to control primary or\n",
      "        recurrent tumor Biologic therapy: Not specified Chemotherapy: See Disease Characteristics\n",
      "        No more than 2 prior chemotherapy regimens (including adjuvant therapy) Prior cumulative\n",
      "        cisplatin dose less than 400 mg/m2 Prior cumulative doxorubicin dose less than 240 mg/m2\n",
      "        Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior\n",
      "        radiotherapy to more than 20% of the bone marrow-containing axial skeleton No prior\n",
      "        radiotherapy to the left chest wall Surgery: See Disease Characteristics\n",
      "2326\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage IV breast carcinoma that is\n",
      "        considered incurable by standard treatment Ongoing objective response to prior induction\n",
      "        chemotherapy required No brain metastasis Hormone receptor status: Estrogen and\n",
      "        progesterone receptor status known\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Not specified Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 90-100% Life expectancy: More than 3 months Hematopoietic:\n",
      "        Absolute neutrophil count greater than 1,500/mm3 Platelet count greater than 100,000/mm3\n",
      "        Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than 1.5 times upper limit of\n",
      "        normal (unless due to benign congenital hyperbilirubinemia) PT and aPTT normal Liver\n",
      "        biopsy normal if serologic evidence of active hepatitis B or C Renal: Creatinine no\n",
      "        greater than 1.2 mg/dL Cardiovascular: No active heart disease LVEF at least 50% and no\n",
      "        abnormal wall motion by MUGA scan Pulmonary: DLCO normal Other: Nutritional status\n",
      "        adequate (more than 1,000 calories/day orally) HIV negative No other active serious\n",
      "        medical or psychiatric disease No other prior malignancy except basal cell skin cancer or\n",
      "        carcinoma in situ of the cervix uteri Not pregnant Negative pregnancy test Fertile\n",
      "        patients must use effective barrier contraception during and for up to 2 years after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior mitomycin\n",
      "        or nitrosourea No prior anthracycline greater than 500/m2 unless previously received\n",
      "        dexrazoxane At least 4 weeks since other prior chemotherapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: No prior radiotherapy to pelvis or brain Surgery: At least 2 weeks\n",
      "        since prior major surgery\n",
      "2328\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed transitional cell carcinoma, squamous\n",
      "        cell, or adenocarcinoma of the renal pelvis, ureter, bladder, or urethra Progressing\n",
      "        regional or metastatic disease after one prior systemic or intra- arterial chemotherapy\n",
      "        regimen Bidimensionally measurable disease, e. g.: Pulmonary nodules Palpable lymph nodes\n",
      "        Cutaneous or subcutaneous nodules Mediastinal tumor or hepatic metastases if clearly\n",
      "        measurable on CT No prior radiotherapy to indicator lesion unless documented progression\n",
      "        since completion of radiotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Hematopoietic:\n",
      "        (within 2 weeks prior to entry) WBC at least 4,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: (within 2 weeks prior to entry) Bilirubin no greater than 2.0 mg/dL AST no\n",
      "        greater than twice normal Renal: (within 2 weeks prior to entry) Creatinine no greater\n",
      "        than 1.5 mg/dL OR Creatinine clearance greater than 40 mL/min Other: No active unresolved\n",
      "        infection No concurrent parenteral antibiotics At least 7 days since parenteral\n",
      "        antibiotics No history of prior malignancy within 5 years except: Curatively treated\n",
      "        nonmelanomatous skin cancer In situ cancer of the cervix Not pregnant or nursing Adequate\n",
      "        contraception required of fertile patients Physically and medically able to take oral\n",
      "        medications\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: One prior systemic biological response\n",
      "        modifier therapy allowed At least 3 weeks since biologic response modifier therapy and\n",
      "        recovered Chemotherapy: See Disease Characteristics At least 3 weeks since chemotherapy\n",
      "        and recovered Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since\n",
      "        radiotherapy Surgery: At least 3 weeks since major surgery and recovered\n",
      "2329\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma or adenocarcinoma\n",
      "        of the esophagus No cancer of the cardia Stage T1, T2, T3, or T4 No tumor greater than 7\n",
      "        cm No tumor with diameter greater than 3 cm No involved nodes located more than 3 cm from\n",
      "        tumor Supraclavicular nodal involvement eligible with cervical esophageal tumor No\n",
      "        metastasis Patient ineligible for surgery because of one of the following: Condition that\n",
      "        contraindicates surgery Refusal of surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 74 Performance status: 0-2 Hematopoietic: WBC at least\n",
      "        2,000/mm3 Polymorphonuclear lymphocyte count at least 1,500/mm3 Platelet count at least\n",
      "        80,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Not specified Renal: Creatinine less than\n",
      "        2.8 mg/dL Cardiovascular: No angina pectoris No history of myocardial infarction No\n",
      "        contraindication to therapy on EKG No other cardiac contraindication to chemotherapy\n",
      "        Other: No peripheral neuropathy No second malignancy except basal cell skin cancer,\n",
      "        carcinoma in situ of the cervix, or other carcinoma in remission for at least 2 years Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic: Not specified Chemotherapy: Not specified Endocrine\n",
      "        therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics\n",
      "        Other: No prior laser therapy No prior electrocoagulation No prior cryotherapy No prior\n",
      "        sclerosing injection\n",
      "2330\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven primary squamous cell or adenocarcinoma of the\n",
      "        esophagus Clinical Stage T1-4, Nx, M0 disease required Disease entirely confined to the\n",
      "        esophagus and periesophageal soft tissue with no tumor extension within 2 cm proximal to\n",
      "        the stomach No biopsy-proven invasion of the tracheal-bronchial tree or\n",
      "        tracheal-esophageal (TE) fistula Bronchoscopy of tracheal-bronchial tree required for\n",
      "        lesions less than 30 cm from the incisors to exclude TE fistula Negative liver biopsy\n",
      "        required if liver CT suggestive of metastatic disease Negative biopsy required for\n",
      "        enlarged (1.5 cm or greater) retroperitoneal or celiac nodes seen on CT Negative biopsy of\n",
      "        clinically or radiographically positive supraclavicular nodes required with cervical\n",
      "        primaries No recurrent disease No multiple carcinomas of the esophagus\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: WBC at least 4,000 Platelets at least 150,000 Hb at least 10 g/dL Hepatic:\n",
      "        Not specified Renal: Creatinine normal OR Creatinine clearance at least 65 mL/min\n",
      "        Nutrition: Recommended oral intake requirements (by mouth or tube feeding): More than 1.5\n",
      "        x Basal Energy Expenditure (BEE) measured by Harris- Benedict equation OR More than 1,000\n",
      "        calories/sqm of body surface area (BSA) Intravenous hyperalimentation (recommended if\n",
      "        inadequate oral intake): 1.75-2.25 x BEE OR 1,200-1,600 calories/sqm BSA Upper limits may\n",
      "        be waived for hypermetabolic patients Other: No second malignancy within 5 years except:\n",
      "        Curable nonmelanomatous skin cancer Cervical cancer in situ No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent growth factor\n",
      "        administration Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior chest irradiation Surgery: No prior resection\n",
      "2331\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven renal cell cancer that is metastatic\n",
      "               -  No greater than 50% estimated hepatic replacement by tumor on CT or MRI\n",
      "               -  No symptomatic involvement of the CNS or a major nerve\n",
      "          -  Measurable disease required\n",
      "          -  Ineligible for treatment with low-dose interleukin-2 on another CMC protocol\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 50%-100%\n",
      "        Life expectancy:\n",
      "          -  More than 3 months\n",
      "        Hematopoietic:\n",
      "          -  No coagulopathy (i.e., platelet count less than 80,000/mm3)\n",
      "        Hepatic:\n",
      "          -  AST and ALT no greater than 5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 4.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No symptomatic angina\n",
      "          -  No untreated coronary artery disease\n",
      "          -  No refractory arrhythmia\n",
      "          -  No abnormal left ventricular function\n",
      "        Pulmonary:\n",
      "          -  No dyspnea on minimal exertion\n",
      "        Other:\n",
      "          -  No site of ongoing bleeding\n",
      "          -  No systemic infection\n",
      "          -  No HIV antibody\n",
      "          -  No HBsAg\n",
      "          -  No requirement for steroids\n",
      "          -  No psychiatric disease that precludes informed consent or protocol treatment\n",
      "          -  No second malignancy except:\n",
      "               -  Basal cell skin carcinoma\n",
      "               -  Carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior interleukin-2\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  At least 28 days since prior treatment for renal cell cancer\n",
      "2332\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed advanced carcinomas of the following types:\n",
      "               -  Breast carcinoma that is ineligible for or patient has refused participation in\n",
      "                  a higher priority protocol in the following categories:\n",
      "                    -  Stage II disease with at least 10 involved lymph nodes and no evidence of\n",
      "                       disease (NED) following surgery\n",
      "                    -  Stage III disease rendered surgically NED with or without radiotherapy\n",
      "                    -  Stage IV disease following partial response (PR) or complete response (CR)\n",
      "                       to surgery, chemotherapy, or radiotherapy\n",
      "                         -  Prior high dose chemotherapy allowed at discretion of investigator\n",
      "                         -  No chemoresistant disease rendered surgically NED\n",
      "                    -  Locoregionally recurrent disease within 2 years of breast conservation with\n",
      "                       or without chemotherapy\n",
      "          -  Stage III/IV ovarian cancer\n",
      "               -  PR/CR following debulking surgery and/or chemotherapy\n",
      "               -  Ineligible for or refused participation in higher priority protocols\n",
      "          -  Primary soft tissue sarcoma with high-grade disease greater than 10 cm or that is\n",
      "             metastatic\n",
      "               -  Rendered surgically NED or achieved PR/CR on any chemotherapeutic or\n",
      "                  immunotherapeutic regimen\n",
      "               -  Ineligible for or refused participation in higher priority protocols\n",
      "          -  Malignant melanoma in the following categories:\n",
      "               -  Ulcerative primary tumor with any number of completely resected metastatic lymph\n",
      "                  nodes\n",
      "               -  Stage II disease with more than 4 involved nodes rendered NED\n",
      "               -  Stage III disease rendered surgically NED or achieved PR/CR on any\n",
      "                  chemotherapeutic or immunotherapeutic regimen\n",
      "          -  Osteosarcoma that is ineligible for or refused participation in higher priority\n",
      "             protocols\n",
      "               -  Resected primary with less than 50% tumor necrosis on pathologic review\n",
      "               -  Metastatic disease rendered surgically NED or PR/CR on any chemotherapeutic,\n",
      "                  radiotherapeutic, or immunotherapeutic regimen\n",
      "          -  The following diseases rendered surgically NED or that achieved PR/CR on any\n",
      "             chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen also eligible:\n",
      "               -  Small cell bone carcinoma\n",
      "               -  Metastatic Ewing's sarcoma\n",
      "               -  Metastatic gastrointestinal malignancy\n",
      "               -  Recurrent Wilms' tumor\n",
      "          -  No CNS metastases\n",
      "          -  No current histologically confirmed bone marrow metastases\n",
      "               -  Prior bone metastases with resolution at time of entry permitted\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Physiologic 18 to 55\n",
      "        Performance status:\n",
      "          -  Karnofsky 80%-100%\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,500/mm3\n",
      "          -  Platelet count greater than 120,000/mm3\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  AST/ALT less than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.4 mg/dL\n",
      "          -  Creatinine clearance at least 70 mL/min\n",
      "          -  No history of hemorrhagic cystitis\n",
      "        Cardiovascular:\n",
      "          -  Ejection fraction at least 55% by MUGA\n",
      "          -  No significant cardiac disease\n",
      "        Pulmonary:\n",
      "          -  FEV1 greater than 2 L\n",
      "          -  pO2 (room air) greater than 70 mm Hg\n",
      "          -  pCO2 (room air) less than 42 mm Hg\n",
      "          -  DLCO greater than 60% of predicted\n",
      "        Other:\n",
      "          -  No potentially disabling psychosocial history\n",
      "          -  No organic or functional CNS dysfunction or other medical problem that would present\n",
      "             party at undue risk\n",
      "          -  HIV negative\n",
      "          -  Hepatitis B surface antigen negative\n",
      "          -  No hearing loss greater than 40 decibels\n",
      "          -  No contraindication to the following procedures:\n",
      "               -  Collection by apheresis of up to 16 x 10 to the 8th mononuclear cells mobilized\n",
      "                  by G-CSF\n",
      "               -  Collection of autologous bone marrow, if needed\n",
      "          -  No second malignancy except:\n",
      "               -  Nonmelanomatous skin cancer\n",
      "               -  Carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No more than 3 prior chemotherapy regimens (excluding adjuvant therapy)\n",
      "          -  No more than 200 mg per square meter of prior cisplatin\n",
      "          -  No more than 800 mg per square meter of prior carboplatin\n",
      "          -  No prior exposure to greater than 1,000 mg per square meter of \"24-hour paclitaxel\n",
      "             equivalents\" (using a 1:1.3 ratio between paclitaxel doses given by 24-hour infusion\n",
      "             and by 3-hour infusion)\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to more than 20% of bone marrow\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2335\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed melanoma that is metastatic and unresectable\n",
      "          -  Measurable, progressive disease (by physical exam and/or noninvasive imaging)\n",
      "               -  No prior irradiation of indicator lesions\n",
      "          -  No CNS metastases (confirmed by CT or MRI)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 70\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No serious hepatic disease\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.65 mg/dL\n",
      "          -  No serious renal disease\n",
      "        Cardiovascular:\n",
      "          -  No serious cardiac disease\n",
      "        Pulmonary:\n",
      "          -  No serious pulmonary disease\n",
      "        Other:\n",
      "          -  No organ allograft\n",
      "          -  No autoimmune disease\n",
      "          -  No uncontrolled infection\n",
      "          -  No active peptic ulcer\n",
      "          -  No hyper or hypothyroidism\n",
      "          -  No requirement for corticosteroids\n",
      "          -  No second malignancy except basal cell skin carcinoma or carcinoma in situ of the\n",
      "             cervix\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy with interleukin-2\n",
      "          -  No prior interferon alfa in combination with cisplatin or dacarbazine\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy with cisplatin in combination with dacarbazine\n",
      "          -  More than 3 months since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2338\n",
      "DISEASE CHARACTERISTICS: Histologically and cytologically proven chronic myelogenous\n",
      "        leukemia Accelerated phase OR Chronic phase No hypocellular marrow (less than 25%\n",
      "        cellularity) No patients under age 55 with a HLA-matched sibling donor\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: 0-1 Hematopoietic: Granulocyte\n",
      "        count greater than 1,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin\n",
      "        less than 1.5 mg/dL AST less than 3 times normal Renal: Creatinine less than 2.0 mg/dL\n",
      "        Creatinine clearance greater than 60 mL/min Cardiovascular: Left ventricular ejection\n",
      "        fraction normal No significant cardiac disease requiring digoxin, diuretics,\n",
      "        antiarrhythmics, or antianginal medications Pulmonary: PFTs normal DLCO normal Other: No\n",
      "        persistent infection requiring antibiotics No concurrent organ damage or medical problem\n",
      "        that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior interferon\n",
      "        therapy Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified\n",
      "2339\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed colorectal carcinoma or radiologically confirmed colorectal\n",
      "             carcinoma in a synchronous metastasis\n",
      "          -  Intrahepatic metastases required\n",
      "               -  No more than 15 metastases involving no more than 60% of functioning liver\n",
      "          -  No extrahepatic disease unless:\n",
      "               -  Resectable anastomotic or locally recurrent tumor\n",
      "               -  Resectable mesenteric lymph node involvement in patients undergoing initial\n",
      "                  resection of primary colorectal carcinoma\n",
      "               -  Disease extension from liver metastasis amenable to en bloc resection (e.g.,\n",
      "                  diaphragm wall, kidney, abdominal wall)\n",
      "          -  No biopsy-proven chronic active hepatitis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Physiologic 18 to 70\n",
      "        Performance status:\n",
      "          -  Karnofsky 60%-100%\n",
      "        Hematopoietic:\n",
      "          -  AGC at least 1,500\n",
      "          -  Platelets at least 100,000\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL (unless reversibly obstructed by metastasis)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Other:\n",
      "          -  No second malignancy within 5 years except adequately treated:\n",
      "               -  Nonmelanomatous skin cancer\n",
      "               -  In situ bladder cancer\n",
      "               -  In situ cervical cancer\n",
      "               -  No pregnant women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Prior mitomycin or nitrosoureas allowed\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the liver\n",
      "          -  At least 3 weeks since radiotherapy and recovered\n",
      "          -  Prior pelvic radiotherapy allowed\n",
      "          -  No planned concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2341\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven glandular breast cancer\n",
      "        Metastatic or locoregionally relapsed disease for which curative surgery and/or\n",
      "        radiotherapy is not feasible Histologic/cytologic confirmation of metastasis as feasible\n",
      "        Progression required within the month prior to entry, whether or not it occurs on hormonal\n",
      "        therapy No clinically detectable cerebral or meningeal involvement Measurable lesion\n",
      "        required, including soft tissue site, lymphadenopathy, or visceral site The following are\n",
      "        not considered measurable: Bony sites of involvement Ascites Pulmonary lymphangitic\n",
      "        carcinomatosis Skin lesions Pathologic CEA or CA 15.3 levels Laboratory changes Pleural\n",
      "        effusion Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Under 60 Sex: Women only Menopausal status: Not specified\n",
      "        Performance status: WHO 0-2 Life expectancy: Greater than 3 months Hematopoietic: ANC at\n",
      "        least 2,000 Platelets at least 100,000 Hepatic: Bilirubin no greater than 2.0 mg/dL (35\n",
      "        micromoles/L) Renal: Creatinine no greater than 1.3 mg/dL (130 micromoles/L)\n",
      "        Cardiovascular: No congestive heart failure, even if stable No coronary artery disease No\n",
      "        myocardial infarction within 6 months Ventricular ejection fraction (resting) normal by\n",
      "        isotopic scan or echocardiogram No evidence of cardiac disease on EKG Other: No active\n",
      "        infection No second malignancy except: In situ cervical carcinoma Basal cell skin\n",
      "        carcinoma No pregnant women No psychological, familial, social, or geographical\n",
      "        contraindication to regular follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        palliative chemotherapy At least 1 year since adjuvant chemotherapy Maximum prior\n",
      "        cumulative anthracycline doses as follows: Epirubicin no greater than 450 mg per square\n",
      "        meter Doxorubicin no greater than 300 mg per square meter Pirarubicin no greater than 300\n",
      "        mg per square meter Mitoxantrone no greater than 60 mg per square meter Endocrine therapy:\n",
      "        Prior hormonal therapy allowed See Disease Characteristics Radiotherapy: At least 6 weeks\n",
      "        since radiotherapy to more than one third of hematopoietic regions Surgery: Not specified\n",
      "2342\n",
      "DISEASE CHARACTERISTICS: Acute myelogenous leukemia (AML) in the following categories:\n",
      "        Refractory to initial standard therapy consisting of idarubicin/cytarabine and\n",
      "        amsacrin/cytarabine (on protocol HOVON 29) First or subsequent relapse following complete\n",
      "        response to standard chemotherapy (on protocols HOVON 4/4A or 11 or any other protocol) At\n",
      "        least 6 months between mitoxantrone/etoposide and relapse No myelodysplasia\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:\n",
      "        Not applicable Hepatic: Bilirubin no greater than 2 x normal Alkaline phosphatase no\n",
      "        greater than 2 x normal Renal: Creatinine no greater than 1.7 mg/dl (150 micromoles/liter)\n",
      "        OR Creatinine clearance at least 60 ml/min Cardiovascular: No uncontrolled hypertension No\n",
      "        other severe cardiac disease Pulmonary: No severe pulmonary disease Other: No known\n",
      "        intolerance to any study drug No uncontrolled severe infection Not HIV seropositive No\n",
      "        severe neurologic or metabolic disease No concomitant malignancy except: Nonmelanomatous\n",
      "        skin cancer In situ cervical carcinoma No pregnant women\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2343\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven unresectable adenocarcinoma of the pancreas limited to the\n",
      "             head, body, or tail of the pancreas\n",
      "               -  Diameter no greater than 5 cm\n",
      "               -  Volume no greater than 66 mL\n",
      "          -  No ascites (with or without tumor cells)\n",
      "          -  No endoscopically proven tumor penetration of duodenum or stomach\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL (transfusion allowed)\n",
      "        Hepatic:\n",
      "          -  No hepatic disease\n",
      "          -  At least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis\n",
      "             suspected\n",
      "          -  No vascular occlusion of portal system\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  BUN no greater than 25 mg/dL\n",
      "        Other:\n",
      "          -  No Crohn's disease, ulcerative colitis, or other inflammatory bowel disease\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  If prior chemotherapy, test dose of colloidal phosphorous P32 administered prior to\n",
      "             attempted treatment\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to pancreas, liver, or upper gastrointestinal tract\n",
      "        Surgery:\n",
      "          -  No complete surgical resection\n",
      "          -  No splenectomy\n",
      "2344\n",
      "DISEASE CHARACTERISTICS: Multiple myeloma of any stage that has failed 1 or 2 prior\n",
      "        regimens (chemotherapy, biologic therapy, or both, or bone marrow transplantation)\n",
      "        Evidence of disease progression required Ineligible for known treatment of higher\n",
      "        potential efficacy One of the following protein criteria required: Quantifiable\n",
      "        M-components of IgG, IgA, IgD, or IgE Urinary kappa or lambda light chain (Bence-Jones\n",
      "        protein) excretion Re-treatment on this protocol allowed if disease relapsed after a\n",
      "        complete remission\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet\n",
      "        count greater than 50,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Transaminases less\n",
      "        than 2.5 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance\n",
      "        at least 60 mL/min Cardiovascular: No history of impaired cardiac status, e.g.: Severe\n",
      "        coronary artery disease Cardiomyopathy Congestive heart failure Arrhythmia Other: No known\n",
      "        AIDS or HIV infection No second malignancy within 5 years except: Adequately treated\n",
      "        nonmelanomatous skin cancer Carcinoma in situ of the cervix No pregnant or nursing women\n",
      "        Effective contraception required of fertile patients during and for 2 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics At least 4 weeks since chemotherapy (8 weeks since mitomycin or\n",
      "        nitrosoureas) and recovered Endocrine therapy: No concurrent steroids Radiotherapy: At\n",
      "        least 4 weeks since radiotherapy and recovered Surgery: Not specified\n",
      "2345\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed salivary gland carcinoma that is\n",
      "        metastatic or recurrent, including the following types: Mucoepidermoid carcinoma\n",
      "        Adenocarcinoma Pathology review required Measurable disease required Lesion in a\n",
      "        previously irradiated field must be progressing and biopsy- proven\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        at least 3,000/mm3 ANC at least 1,500/mm3 Platelet count at least 100,000/mm3 Hb at least\n",
      "        10 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 2.0\n",
      "        mg/dL Cardiovascular: No MI within the past 6 months No CHF No unstable arrhythmia No\n",
      "        current antiarrhythmic, inotropic, or antianginal medication Other: No history of allergy\n",
      "        to Cremophor No prior malignancy within 5 years except: Curatively treated nonmelanomatous\n",
      "        skin cancer Curatively treated in-situ cancer of the cervix No concurrent malignancy Not\n",
      "        pregnant or nursing Effective contraception strongly advised for fertile patients\n",
      "        Blood/body fluid analyses to determine eligibility and imaging studies and scans/x-rays\n",
      "        for tumor measurement completed within 14 days prior to registration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological response modifier therapy\n",
      "        allowed Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy:\n",
      "        Prior radiotherapy allowed with recovery Surgery: Prior surgery allowed with recovery\n",
      "2347\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant melanoma definitively resected\n",
      "        within 12 weeks prior to entry One of the following categories: Stage II disease (greater\n",
      "        than 4 mm Breslow thickness) Stage III disease (regional lymph node involvement) Recurrent\n",
      "        non-nodal superficial regional disease (local or in transit) Recurrent regional nodal\n",
      "        involvement\n",
      "        PATIENT CHARACTERISTICS: Able to tolerate interferon No second malignancy except\n",
      "        curatively treated: Carcinoma of the cervix Nonmelanomatous skin cancer No pregnant or\n",
      "        nursing women\n",
      "        PRIOR CONCURRENT THERAPY: No prior immunosuppressive therapy, including systemic steroids\n",
      "        No prior biologic therapy Recovered from surgery\n",
      "2351\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Recurrent or metastatic breast or prostate cancer\n",
      "          -  \"Pain worst\" score of 4 or greater on the Brief Pain Inventory\n",
      "          -  No prior enrollment on this study (patients treated during the run-in period are\n",
      "             ineligible for randomization)\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No major psychiatric illness, including the following DSM-III-R diagnoses:\n",
      "               -  Bipolar disorder\n",
      "               -  Schizophrenia\n",
      "               -  Major depression\n",
      "               -  Multiple personality disorder\n",
      "               -  Psychotic disorder\n",
      "               -  Dementia\n",
      "               -  Outpatient status required\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 28 days since prior palliative radiotherapy to major site(s) of pain\n",
      "        Surgery:\n",
      "          -  Greater than 30 days since prior surgery\n",
      "2352\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Pathologic\n",
      "        stage T1-3, N1-2, M0 No clinical or pathologic T4 disease No primary tumor fixed to chest\n",
      "        wall No axillary nodes fixed to chest wall or neurovascular bundle No preoperative arm\n",
      "        edema No clinical skin involvement (microscopic focal dermal invasion or dermal lymphatic\n",
      "        involvement eligible) No clinical N2 disease Modified radical mastectomy or lumpectomy\n",
      "        required prior to entry Sentinel node biopsy allowed Randomization required within 12\n",
      "        weeks from definitive surgery Surgery dated from mastectomy or axillary dissection for\n",
      "        lumpectomy No positive deep mastectomy margins Radiotherapy planned within 12 weeks\n",
      "        following axillary node dissection for lumpectomy patients Synchronous bilateral breast\n",
      "        cancer eligible If tumor is at least 2 cm, then nodes not involved If no tumor is at least\n",
      "        2 cm, then at least 1 node must be involved Both invasive primaries receptor-positive\n",
      "        Previously treated, noninvasive breast cancer eligible No prior invasive breast cancer No\n",
      "        adenoid cystic, squamous, or sarcomatous histology Hormone receptor status: Estrogen- or\n",
      "        progesterone-receptor positive, i.e.: At least 10 fmole/mg cytosol protein by\n",
      "        ligand-binding assay OR Receptor positive by immunocytochemistry\n",
      "        PATIENT CHARACTERISTICS: Age: 65 and over OR Postmenopausal and ineligible/inappropriate\n",
      "        for or declined other active node positive adjuvant studies Sex: Female Menopausal status:\n",
      "        Postmenopausal, defined as: At least 1 year since last menstrual period Hysterectomized\n",
      "        with bilateral oophorectomy Hysterectomized with 1 or both ovaries remaining and either:\n",
      "        Over 60 FSH in postmenopausal range Not surgically castrated, under 60, and on HRT FSH\n",
      "        elevated 2 weeks after HRT discontinued Performance status: Not specified Life expectancy:\n",
      "        At least 7 years except for breast cancer Hematopoietic: WBC greater than 3,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no\n",
      "        greater than 1.5 mg/dL AST less than 2 times normal Renal: Creatinine no greater than 2.0\n",
      "        mg/dL BUN no greater than 25.0 mg/dL Other: No extensive macular degeneration on exam\n",
      "        within 1 year of entry, e.g.: No exudative or atrophic macular lesions that reduce\n",
      "        corrected vision to less than 20/40 Health adequate for protocol treatment No nutritional\n",
      "        supplementation except single daily multivitamin No other vitamin A supplements\n",
      "        Gynecologic exam within the past year required of women who retain a uterus No second\n",
      "        malignancy within the past 10 years except: Inactive nonmelanomatous skin cancer Carcinoma\n",
      "        in situ of the cervix Prior noninvasive contralateral breast cancer\n",
      "        PRIOR CONCURRENT THERAPY: No prior chemotherapy or hormonal therapy for breast cancer\n",
      "        except: Up to 1 month of tamoxifen if started by a non participating physician At least 2\n",
      "        weeks since hormone replacement therapy No concurrent megestrol\n",
      "2353\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of supratentorial or infratentorial brain tumor\n",
      "               -  Localized, non-disseminated\n",
      "               -  Primary tumor or solitary metastasis\n",
      "               -  Recurrent or progressive\n",
      "               -  Unresectable\n",
      "               -  Negative CSF\n",
      "          -  Must have failed standard therapy including radiotherapy\n",
      "          -  Measurable disease as evidenced by CT scan or MRI\n",
      "               -  Single or multiple masses accessible to light administration\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  3 to 70\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  May transfuse platelets\n",
      "        Hepatic:\n",
      "          -  PT and PTT normal\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior brachytherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  No other concurrent antitumor therapy\n",
      "2354\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unilateral adenocarcinoma of the breast\n",
      "          -  Stage I/II/III (Tx, T0-3, N0-2) disease in one of the following categories or\n",
      "             multifocal tumors if one of the foci is in agreement with the following:\n",
      "               -  Centrally or medially located with any lymph node status\n",
      "                    -  Central location defined as underlying the areola\n",
      "                    -  Medial location defined as at least partial involvement of upper or lower\n",
      "                       medial quadrant of breast\n",
      "               -  Externally located with axillary node involvement\n",
      "          -  Prior mastectomy or breast-conserving surgery and axillary dissection required\n",
      "               -  Sentinel node procedure as axillary intervention without further axillary\n",
      "                  surgery is allowed\n",
      "               -  No prior internal mammary chain dissection\n",
      "               -  No upper inner lesion treated with breast-conserving surgery that precludes\n",
      "                  sparing of internal mammary lymph node chain from radiotherapy volume\n",
      "                    -  Decision at radiation oncologist's discretion\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  75 and under\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No prior cardiac disease\n",
      "        Other:\n",
      "          -  No prior malignancy except adequately treated nonmelanomatous skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  Concurrent enrollment in other randomized trials allowed\n",
      "2355\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed, stage IV adenocarcinoma of the breast\n",
      "        Previously untreated or prior adjuvant chemotherapy only CR or PR following 3-5 courses of\n",
      "        induction chemotherapy for current diagnosis with one of the following:\n",
      "        Cyclophosphamide/doxorubicin Cyclophosphamide/methotrexate/fluorouracil\n",
      "        Cyclophosphamide/mitoxantrone No active CNS metastases on CT or MRI Hormone receptor\n",
      "        status: Any status\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Sex: Women Menopausal status: Pre- or\n",
      "        postmenopausal Performance status: ECOG 0-2 Hematopoietic: WBC greater than 3,000\n",
      "        Platelets greater than 100,000 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal:\n",
      "        Creatinine clearance greater than 60 mL/min Cardiovascular: Left ventricular ejection\n",
      "        fraction greater than 50% on MUGA or echocardiogram No abnormal cardiac conduction on EKG,\n",
      "        i.e.: No second- or third-degree heart block No bundle-branch block No arrhythmia except:\n",
      "        Supraventricular sinus tachycardia Occasional premature atrial or ventricular contractions\n",
      "        Pulmonary: DLCO greater than 60% of predicted Other: No preexisting peripheral neuropathy\n",
      "        No HIV antibody No history of second malignancy within 5 years except: Nonmelanomatous\n",
      "        skin cancer Cervical carcinoma in situ No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Hematologically\n",
      "        recovered from prior chemotherapy Endocrine therapy: Failure on 1 prior hormonal regimen\n",
      "        required for ER-positive disease (greater than 10 femtomoles) unless visceral metastatic\n",
      "        crisis requires immediate chemotherapy Radiotherapy: Not specified Surgery: Not specified\n",
      "2357\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following diagnoses:\n",
      "               -  Histologically proven recurrent non-Hodgkin's lymphoma\n",
      "                    -  Previously in complete remission (CR)\n",
      "               -  Refractory or recurrent intermediate-grade lymphoma (IGL) or high-grade\n",
      "                  immunoblastic lymphoma (IBL) meeting 1 of the following conditions:\n",
      "                    -  In partial remission (PR) or CR to and currently enrolled on the MSKCC\n",
      "                       standard dose salvage regimen with ifosfamide, carboplatin, and etoposide\n",
      "                       (ICE)\n",
      "                    -  In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses\n",
      "                       of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of\n",
      "                       cyclophosphamide, mechlorethamine, vincristine, procarbazine, and\n",
      "                       prednisone (C-MOPP))\n",
      "                         -  No prior ifosfamide\n",
      "               -  Low-grade lymphoma\n",
      "                    -  In second or greater remission or chemosensitive relapse\n",
      "                    -  No HLA identical sibling donor available\n",
      "               -  IGL or IBL\n",
      "                    -  In first CR\n",
      "                    -  Poor prognosis, defined by age-adjusted international index of 3 or 4 based\n",
      "                       on lactic dehydrogenase, number of extranodal sites, stage, and performance\n",
      "                       status\n",
      "          -  Adequate bone marrow cellularity\n",
      "          -  No lymphoblastic or small noncleaved cell lymphoma\n",
      "          -  Ineligible for total body irradiation (TBI) phase of study if prior radiotherapy dose\n",
      "             precludes the use of TBI NOTE: A new classification scheme for adult non-Hodgkin's\n",
      "             lymphoma has been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\"\n",
      "             lymphoma will replace the former terminology of \"low\", \"intermediate\", or \"high\"\n",
      "             grade lymphoma.However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Physiologic 18 to 65\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL (if no history of Gilbert's disease)\n",
      "          -  No chronic active or persistent hepatitis\n",
      "          -  Hepatitis B positivity allowed provided that the following conditions are met:\n",
      "               -  Bilirubin same as above*\n",
      "               -  SGPT no greater than 500 IU/L*\n",
      "               -  Alkaline phosphatase no greater than 2 times normal* NOTE: * In the absence of\n",
      "                  liver involvement by lymphoma\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  No history of chronic renal insufficiency\n",
      "        Cardiovascular:\n",
      "          -  LVEF at least 50% by echocardiogram or MUGA scan\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No unstable angina\n",
      "          -  No arrhythmia other than chronic atrial fibrillation\n",
      "        Pulmonary:\n",
      "          -  DLCO at least 50% predicted (corrected for hemoglobin and alveolar ventilation)\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No uncontrolled infection\n",
      "          -  No other malignancy within the past 5 years except curatively treated basal cell skin\n",
      "             cancer or carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2361\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Newly diagnosed acute promyelocytic leukemia\n",
      "          -  Must have promyelocyte-retinoic acid receptor alpha transcript at disease\n",
      "             presentation\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 to 74\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 3 times upper limit of normal (ULN)\n",
      "          -  AST no greater than 3 times ULN\n",
      "          -  Alkaline phosphatase no greater than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No cardiac contraindication to anthracycline chemotherapy\n",
      "        Other:\n",
      "          -  No active serious infection not controlled by antibiotics\n",
      "          -  No severe concurrent psychiatric disease\n",
      "          -  No other malignancy except basal cell carcinoma\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No concurrent cytotoxic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior corticosteroids for leukemia allowed\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antileukemic therapy\n",
      "2362\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed acute lymphocytic leukemia that is\n",
      "        relapsed after or refractory to induction therapy 1 or 2 prior inductions allowed, but\n",
      "        refractory to only 1 regimen CNS involvement allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-3 Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin no greater than 1.5 times normal (unless directly\n",
      "        attributable to leukemia) Renal: Creatinine no greater than 1.5 times normal (unless\n",
      "        directly attributable to leukemia) Cardiovascular: No uncontrolled or severe\n",
      "        cardiovascular disease including: Myocardial infarction within 6 months Congestive heart\n",
      "        failure Other: No uncontrolled duodenal ulcer No uncontrolled infection No second\n",
      "        malignancy within 5 years except curatively treated: In situ cervical cancer Basal cell\n",
      "        skin cancer No other serious medical illness that would limit survival to under 2 years No\n",
      "        psychiatric illness that would prevent informed consent or compliance No pregnant or\n",
      "        nursing women Adequate contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2363\n",
      "DISEASE CHARACTERISTICS: Colonic adenoma(s) of at least 10 mm completely resected within\n",
      "        18 months prior to randomization or suspected adenomatous polyp(s) Colonoscopy with\n",
      "        submission of at least 7 rectosigmoid biopsies required at entry No benign hyperplastic\n",
      "        polyps or polyps less than 10 mm to be eligible for treatment No polyposis coli (i.e.,\n",
      "        more than 100 polyps in colon) No history of invasive colorectal cancer\n",
      "        PATIENT CHARACTERISTICS: Age: 21 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Platelet count greater than 100,000/mm3 Hemoglobin greater\n",
      "        than 10 g/dL No untreated pernicious anemia Hepatic: Bilirubin less than 2 mg/dL ALT less\n",
      "        than 2 times normal Alkaline phosphatase less than 2 times normal PT normal Renal: Not\n",
      "        specified Gastrointestinal: No intestinal malabsorption No inflammatory bowel disease\n",
      "        Other: No seizure within the past year No poor medical risk No other malignancy within\n",
      "        past 5 years except basal cell cancer, superficial skin cancer, or carcinoma in situ of\n",
      "        the cervix No vitamin B12 deficiency (less than 200 pg/mL) Not pregnant or nursing Fertile\n",
      "        patients must use effective barrier contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        methotrexate Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See\n",
      "        Disease Characteristics No prior small bowel resection Other: No concurrent\n",
      "        anticonvulsants No concurrent drugs that markedly interfere with folate absorption or\n",
      "        metabolism (e.g., sulfasalazine and phenytoin) No concurrent vitamins during and for 2\n",
      "        years after beginning of study\n",
      "2368\n",
      "DISEASE CHARACTERISTICS: Confirmed diagnosis of active multiple myeloma Refractory (less\n",
      "        than a partial response) to or relapsed after standard chemotherapy Myeloma protein\n",
      "        present for response evaluation Nonsecretory myeloma eligible if plasmacytosis greater\n",
      "        than 30% OR Pathologic diagnosis of Castleman's disease Multicentric or symptomatic\n",
      "        disease requiring therapy Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 1 year Hematopoietic: Absolute granulocyte count greater than 1,500/mm3 Platelet\n",
      "        count greater than 100,000/mm3 Hepatic: Bilirubin normal SGOT no greater than 2 times\n",
      "        upper limit of normal PT and PTT normal No coagulopathy Renal: Creatinine less than 1.5\n",
      "        mg/dL OR Creatinine clearance greater than 70 mL/min Calcium no greater than 12 mg/dL\n",
      "        Other: No severe psychiatric disorder that would preclude informed consent No known\n",
      "        seizure disorder No peripheral neuropathy or POEMS (polyneuropathy, organomegaly,\n",
      "        endocrinopathy, monoclonal gammopathy, and skin changes) syndrome No uncontrolled or\n",
      "        brittle diabetes mellitus HIV negative No other active medical illness that would preclude\n",
      "        study No other malignancy within the past 5 years except nonmelanomatous skin cancer or\n",
      "        stage IA cervical carcinoma Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception during and for 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (6\n",
      "        weeks since prior mitomycin or nitrosoureas) Endocrine therapy: At least 4 weeks since\n",
      "        prior glucocorticoids (e.g., prednisone, dexamethasone) Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy No prior radiotherapy to more than 20% of bone marrow Surgery: At\n",
      "        least 4 weeks since prior surgery Other: Recovered from the toxic effects of prior therapy\n",
      "        No other concurrent therapy\n",
      "2369\n",
      "DISEASE CHARACTERISTICS: Histologically proven lymphoproliferation following organ\n",
      "        (kidney, liver, or heart) allograft Bidimensionally measurable disease If all disease\n",
      "        removed at biopsy, eligible only if recurrence is bidimensionally measurable Group 1\n",
      "        (clinically urgent disease): Histologically proven involvement of the allograft OR\n",
      "        Histologically proven bone marrow involvement OR Liver involvement with hepatic\n",
      "        insufficiency Bilirubin greater than upper limit of normal (ULN) OR SGOT or SGPT at least\n",
      "        2 times ULN OR Clinical hepatic encephalopathy OR LDH at least 3 times ULN OR Systemic\n",
      "        sepsis OR Locally urgent lesions Tonsillar enlargement that threatens airway Superior vena\n",
      "        cava syndrome Bilateral hydronephrosis Postobstructive pneumonia OR Small noncleaved\n",
      "        lymphocytic lymphoma (i.e., adult Burkitt's lymphoma) Group 2: All other patients No CNS\n",
      "        disease only\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Not specified Hematopoietic:\n",
      "        Not specified Hepatic: See Disease Characteristics Renal: Not specified Cardiovascular:\n",
      "        See Disease Characteristics Pulmonary: See Disease Characteristics Other: No known AIDS,\n",
      "        HIV-associated complex, or positive HIV antibody No other malignancy within past 5 years,\n",
      "        except: Adequately treated basal or squamous cell skin cancer Adequately treated stage I\n",
      "        or II cancer or other noninvasive cancers Carcinoma in situ of the cervix Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interferon for lymphoma No prior bone\n",
      "        marrow transplantation Chemotherapy: No prior chemotherapy for lymphoma Endocrine therapy:\n",
      "        Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other:\n",
      "        Intra-aortic balloon pump allowed only for heart failure caused by acute rejection or\n",
      "        lymphomatous involvement\n",
      "2370\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  De novo or secondary acute myeloid leukemia of any morphologic type\n",
      "               -  Acute promyelocytic leukemia also entered on MRC ATRA trial\n",
      "               -  No blastic transformation of chronic myeloid leukemia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to physiologic 59\n",
      "          -  Patients for whom intensive therapy is considered inappropriate may be entered on\n",
      "             protocol MRC-LEUK-AML11 or its successor\n",
      "        Performance status:\n",
      "          -  Any status\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent active malignancy\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  No prior cytotoxic chemotherapy for leukemia\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2372\n",
      "DISEASE CHARACTERISTICS: Recurrent brain tumor based on one of the following: Tissue\n",
      "        diagnosis if there was a prior diagnosis of astrocytoma or oligodendroglioma or if there\n",
      "        is a question of radiation necrosis from prior interstitial brachytherapy Metabolic\n",
      "        activity in excess of normal cortex measured by 18-fluorodeoxyglucose uptake on PET One of\n",
      "        the following histologic types required: Glioblastoma multiforme Anaplastic astrocytoma\n",
      "        Anaplastic oligodendroglioma Anaplastic mixed glioma Tumor progression required, i.e.: 28%\n",
      "        increase in contrast-enhancing area or 50% increase in contrast- enhancing volume over at\n",
      "        least 4 weeks Measurable disease required No history, surgical findings, or radiographic\n",
      "        signs of intratumoral hemorrhage\n",
      "        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: Karnofsky 50%-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000 Platelets at least 75,000\n",
      "        Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 3 times normal No history of\n",
      "        bleeding disorder No hepatic disease resulting in hospitalization Renal: Creatinine less\n",
      "        than 1.5 mg/dL No renal disease resulting in hospitalization Cardiovascular: No ongoing\n",
      "        anticoagulation for deep vein thrombosis (DVT) No residual symptoms from DVT after\n",
      "        discontinuation of anticoagulation No cardiac disease resulting in hospitalization\n",
      "        Pulmonary: No pulmonary disease resulting in hospitalization Other: No peripheral\n",
      "        neuropathy of any etiology HIV negative No pregnant or nursing women Adequate\n",
      "        contraception required during and for 12 months following protocol therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for glioblastoma multiforme No more than 1 prior chemotherapy regimen for\n",
      "        anaplastic astrocytoma, malignant oligodendroglioma, or malignant mixed glioma At least 4\n",
      "        weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin) Endocrine therapy: Not\n",
      "        specified Radiotherapy: Completion of 1 course of conventional external radiotherapy\n",
      "        required At least 4 weeks since radiotherapy Surgery: Decompressive surgery for clinically\n",
      "        suspected increased intracranial pressure performed prior to entry\n",
      "2374\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of recurrent medulloblastoma or CNS germ cell tumor\n",
      "               -  Histologic review of the primary intracranial or spinal cord tumor required\n",
      "                    -  Biopsy and reduction of tumor bulk prior to study encouraged but not\n",
      "                       required\n",
      "          -  No more than 1 prior primary therapy (radiotherapy or chemoradiotherapy) and/or 1\n",
      "             prior salvage therapy\n",
      "               -  Patients with progression on salvage therapy ineligible\n",
      "          -  Minimal residual disease (tumor bulk no more than 1.5 cm) or in second clinical\n",
      "             complete remission (CR)\n",
      "          -  Bone marrow infiltration with or without mass lesions or isolated abnormal CSF\n",
      "             cytology as the only manifestation of recurrent disease allowed if a clinical CR is\n",
      "             first achieved with conventional therapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  2 to 25\n",
      "        Performance status:\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy:\n",
      "          -  More than 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGPT less than 80 IU\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  LVEF normal\n",
      "        Other:\n",
      "          -  No infection\n",
      "          -  Able to tolerate vigorous hydration\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Prior cyclophosphamide or ifosfamide allowed\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent dexamethasone as an antiemetic\n",
      "          -  Other concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Pretransplantation radiotherapy boost allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Pretransplantation surgery allowed\n",
      "        Other:\n",
      "          -  At least 4 weeks since prior therapy except corticosteroids\n",
      "2375\n",
      "Inclusion Criteria:\n",
      "          -  Diagnosis of stage I or IIA, grade I-III endometrial adenocarcinoma or uterine\n",
      "             sarcoma\n",
      "          -  Must be considered a candidate for surgery\n",
      "          -  No contraindication to laparoscopy\n",
      "          -  No clinical or chest x-ray evidence of metastasis beyond the uterine corpus or\n",
      "             macroscopic involvement of the endocervix\n",
      "          -  Performance status - GOG 0-3\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT no greater than 3 times normal\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Prior malignancy allowed if no current evidence of disease\n",
      "          -  Not pregnant\n",
      "          -  No prior pelvic or abdominal radiotherapy\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior retroperitoneal surgery\n",
      "2376\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and\n",
      "        neck that is recurrent or refractory following at least 1 course of therapy Primary or\n",
      "        metastatic tumors involving skin, nodes (palpable and biopsy- proven), subcutaneous\n",
      "        tissue, or muscle allowed No involvement of major artery or any visceral organ Measurable\n",
      "        lesions accessible for direct intratumoral injection with no immediate risk of hemorrhage\n",
      "        or embolization Most troublesome tumor (identified by the investigator) at least 0.5 cc\n",
      "        and no greater than 20 cc Smaller tumors eligible for treatment but not for efficacy\n",
      "        assessment An improvable primary treatment goal (palliative or preventive) for most\n",
      "        troublesome tumor must be identified by the investigator prior to enrollment If multiple\n",
      "        tumors qualify as most troublesome and share the primary physician-selected treatment\n",
      "        goal, the largest tumor is selected Patient may also select a most troublesome tumor and 1\n",
      "        palliative treatment goal for that tumor (need not match the physician-selected tumor or\n",
      "        goal) No fibrotic lesions (e.g., previously irradiated lesion with no subsequent disease\n",
      "        progression) No tumors involving or threatening to invade the carotid or other major\n",
      "        vessel\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Life\n",
      "        expectancy: At least 6 months Hematopoietic: Absolute granulocyte count greater than\n",
      "        1,000/mm3 Platelet count greater than 75,000/mm3 Hepatic: Not specified Renal: Creatinine\n",
      "        no greater than 1.5 times normal Cardiovascular: No NYHA class III/IV status No history of\n",
      "        arrhythmia that would increase risk of treatment Other: No hypersensitivity to cisplatin,\n",
      "        bovine collagen, epinephrine, or sulfites No significant history of extracranial carotid\n",
      "        vascular disease from atherosclerosis, radiation therapy or previous carotid artery\n",
      "        surgery No uncontrolled local infection at treatment sites No medical or psychiatric\n",
      "        condition that would preclude informed consent No pregnant or nursing women Adequate\n",
      "        contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: More than 28 days since any antineoplastic therapy or therapy\n",
      "        with investigational agents Fully recovered from side effects of prior treatment\n",
      "2377\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven invasive adenocarcinoma of\n",
      "        the breast Fine-needle aspiration is acceptable Core or Tru-cut biopsies are preferable No\n",
      "        more than 63 days between initial diagnosis and randomization Tumor palpable on clinical\n",
      "        exam and confined to the breast and ipsilateral axilla If clinically negative axillary\n",
      "        nodes (N0): primary tumor greater than 1 cm (T1c-T3) If clinically positive axillary nodes\n",
      "        (N1): any size primary tumor (T1-3) No N2 disease, i.e., ipsilateral nodes clinically\n",
      "        fixed to one another or to other structures No skeletal pain unless: Bone scan and/or\n",
      "        roentgenologic exam negative for metastatic disease Suspicious findings confirmed as\n",
      "        benign by x-ray, MRI, or biopsy No ulceration, erythema, skin infiltration (complete\n",
      "        fixation), or peau d'orange, or skin edema of any magnitude Tethering or dimpling of skin\n",
      "        or nipple inversion allowed No bilateral malignancy Suspicious contralateral mass proven\n",
      "        benign on biopsy allowed None of the following unless proven benign on biopsy: Suspicious\n",
      "        palpable nodes in contralateral axilla Palpable supraclavicular or infraclavicular nodes\n",
      "        Hormone receptor status: Any status\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Not specified Life expectancy: At least 10 years (exclusive of cancer\n",
      "        diagnosis) Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin normal AST/ALT normal Alkaline phosphatase normal Renal: Creatinine\n",
      "        normal Cardiovascular: No active cardiac disease that would preclude doxorubicin, e.g.:\n",
      "        Documented myocardial infarction History of congestive heart failure Angina pectoris\n",
      "        requiring medication Valvular disease with documented cardiac function compromise\n",
      "        Arrhythmia associated with heart failure or cardiac dysfunction Poorly controlled\n",
      "        hypertension, i.e., diastolic blood pressure greater than 100 mm Hg Cardiomegaly on chest\n",
      "        x-ray or ventricular hypertrophy on EKG unless left ventricular ejection fraction at least\n",
      "        45% by MUGA Other: No other malignancy within the past 10 years except: Segmentally\n",
      "        resected lobular carcinoma in situ of the ipsilateral or contralateral breast Effectively\n",
      "        treated nonmelanomatous skin cancer Surgically treated carcinoma in situ of the cervix No\n",
      "        systemic disease that would preclude therapy No psychiatric or addictive disorder that\n",
      "        would preclude informed consent Geographically accessible for follow-up Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for breast cancer No prior anthracyclines for\n",
      "        any malignancy No concurrent sex hormones (e.g., birth control pills or ovarian\n",
      "        replacement therapy)\n",
      "2378\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Women registered on Arm I, II, III, or IV of protocol SWOG-8897 who have completed at\n",
      "             least 1 course of assigned chemotherapy\n",
      "               -  Completion of tamoxifen therapy not required\n",
      "               -  Registration to current study required between 5.25-8 years or 10-11 years after\n",
      "                  randomization to protocol SWOG-8897\n",
      "          -  Patients must be diagnosed disease-free with no prior recurrence after registration\n",
      "             on protocol SWOG-8897\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Pre- and postmenopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life Expectancy:\n",
      "          -  At least 5 years\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Pregnant or nursing women not eligible for nuclear medicine (MUGA) portion of study\n",
      "          -  Fertile patients must use effective contraception during and for 1 month after MUGA\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior chemotherapy for second primary malignancy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for second primary malignancy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2379\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid tumor that is refractory to standard\n",
      "        therapy or for which no standard therapy exists Eligible tumors, include, but are not\n",
      "        limited to, the following: Breast Ovarian Head and neck Non-small cell lung cancer\n",
      "        Abnormal liver function Control patients with normal liver function are enrolled Brain\n",
      "        metastases allowed if controlled by radiotherapy or surgery and neurologic status\n",
      "        currently stable Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Not specified Menopausal status: Not\n",
      "        specified Performance status: Karnofsky 50-100% Life expectancy: At least 1 month\n",
      "        Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 9 g/dL OR Hematocrit at least 35% Hepatic: See Disease Characteristics\n",
      "        No active acute hepatitis Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: No concurrent cardiovascular disease that is\n",
      "        poorly controlled with currently available treatment or of such severity as to preclude\n",
      "        study Pulmonary: No concurrent pulmonary disease that is poorly controlled with currently\n",
      "        available treatment or of such severity as to preclude study Other: No other concurrent\n",
      "        illness (e.g., CNS disease) that is poorly controlled with currently available treatment\n",
      "        or of such severity as to preclude study No severe infection requiring treatment Not\n",
      "        pregnant Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or\n",
      "        nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior radiotherapy and recovered No prior\n",
      "        radiotherapy to more than 25% of bone marrow Surgery: See Disease Characteristics\n",
      "        Recovered from major surgery\n",
      "2380\n",
      "DISEASE CHARACTERISTICS: Multiple myeloma confirmed by bone marrow plasmacytosis and with\n",
      "        measurable M-component in the serum or urine by immunoelectrophoresis or immunofixation No\n",
      "        Stage I myeloma No smoldering multiple myeloma Refractory to or in first relapse following\n",
      "        an initial response to VAD (vincristine/doxorubicin/dexamethasone), with relapse defined\n",
      "        as any of the following: 50% increase above the lowest remission level of serum or urine\n",
      "        M-protein while on therapy 25-50% increase above the lowest remission level of serum or\n",
      "        urine M-protein associated with either: Hypercalcemia (greater than 11 mg/dl) Hb decrease\n",
      "        of 2 g/dl attributable to increasing marrow plasmacytosis Appearance of new lytic lesions\n",
      "        Calcium no greater than 11 mg/dl No myeloma meningitis No plasma cell leukemia\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        greater than 500 (after G-CSF) Platelets greater than 25,000 Hepatic: Bilirubin no greater\n",
      "        than 2.0 mg/dl Renal: Creatinine no greater than 2.0 mg/dl Cardiovascular: No NYHA class\n",
      "        II-IV disease Pulmonary: DLCO at least 50% of predicted FVC at least 75% of predicted FEV1\n",
      "        at least 60% of predicted Other: No uncontrolled infection No active fungal infection No\n",
      "        fever No prior malignancy within 5 years except: Basal cell skin cancer In situ carcinoma\n",
      "        of the cervix No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological response modifiers allowed\n",
      "        Chemotherapy: No time limit between cytotoxic therapy and protocol treatment Prior\n",
      "        cumulative melphalan dose less than 300 mg Endocrine therapy: Corticosteroids for\n",
      "        hypercalcemia allowed Radiotherapy: Prior radiotherapy allowed Prior pelvic radiotherapy\n",
      "        allowed, but patients with such therapy are unlikely to have adequate PBSC harvested\n",
      "        Surgery: Not specified\n",
      "2381\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, advanced stages IIB/III/IV cutaneous\n",
      "        T-cell lymphoma Measurable or evaluable disease required Measurable disease includes: Skin\n",
      "        disease evaluated by clinical assessment grid method Lesion measurable on imaging (i.e.,\n",
      "        CT measurement of lymph nodes) Pure osteolytic lesion Unidimensional lesion for which a\n",
      "        normal measurement is available (e.g., mediastinal width on x-ray) Evaluable disease\n",
      "        defined as malignant disease evident on physical or radiographic exam but not measurable\n",
      "        by ruler or caliper, i.e.: Pelvic masses Confluent multinodular lung metastases Skin\n",
      "        metastases CNS metastases eligible if stable for at least 4 weeks following completion of\n",
      "        surgery or radiotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: ANC at least 1,500 Platelets at least 100,000 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL AST less than 3 times normal Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Other: No contraindication to indwelling central venous catheter No\n",
      "        active infection including HIV No other medical condition that would preclude protocol\n",
      "        compliance No pregnant or nursing women Adequate contraception required of fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological therapy allowed Chemotherapy:\n",
      "        Prior systemic chemotherapy allowed Patients with more than 1 prior regimen analyzed\n",
      "        separately At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)\n",
      "        Endocrine therapy: Not specified Radiotherapy: Prior skin irradiation allowed At least 4\n",
      "        weeks since wide-field radiotherapy Surgery: Fully recovered from prior surgery Other:\n",
      "        Prior topical therapy allowed Prior PUVA allowed\n",
      "2382\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed diagnosis of one of the following malignancies:\n",
      "               -  Hodgkin's lymphoma\n",
      "               -  Acute myelogenous leukemia\n",
      "               -  Chronic myelogenous leukemia\n",
      "          -  Failed standard therapy or in chronic phase if on standard therapy\n",
      "          -  At least 30% of malignant cells reactive with anti-Tac as determined by\n",
      "             immunofluorescence studies\n",
      "               -  All Hodgkin's lymphoma patients eligible due to 100% Tac-positivity of\n",
      "                  Reed-Sternberg cells\n",
      "          -  Measurable disease\n",
      "          -  No symptomatic CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  0-2\n",
      "        Life expectancy:\n",
      "          -  Greater than 2 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 3 times normal\n",
      "          -  No significant hepatic disease\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 3 times normal\n",
      "          -  No significant renal disease\n",
      "        Cardiovascular:\n",
      "          -  No significant cardiovascular disease\n",
      "        Pulmonary:\n",
      "          -  No significant pulmonary disease\n",
      "        Other:\n",
      "          -  No significant endocrine, rheumatologic, or allergic disease\n",
      "          -  No HIV-I antibody\n",
      "          -  No active disease due to any of the following:\n",
      "          -  Cytomegalovirus Herpes simplex virus I/II\n",
      "          -  Hepatitis B or C Tuberculosis\n",
      "          -  Negative pregnancy test required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior murine anti-Tac monoclonal antibody\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Concurrent treatment allowed for complications of primary disease\n",
      "2383\n",
      "DISEASE CHARACTERISTICS: Scheduled to receive a first course of highly emetogenic single\n",
      "        day cancer chemotherapy regimens including: Cisplatin at least 50 mg/m2 Carboplatin at\n",
      "        least 300 mg/m2 Dacarbazine at least 500 mg/m2 Doxorubicin at least 40 mg/m2 Epirubicin at\n",
      "        least 60 mg/m2 Ifosfamide at least 1200 mg/m2 Cyclophosphamide at least 600 mg/m2\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Must be able to complete diary card (fluent in German, French, or\n",
      "        Italian) No severe concurrent illness No other etiologies that cause vomiting, including:\n",
      "        Gastrointestinal obstruction Hypercalcemia CNS metastases No active peptic ulceration No\n",
      "        prior gastrointestinal bleeding due to peptic ulcer No moderate to severe nausea or any\n",
      "        vomiting in the 24 hours prior to chemotherapy Not pregnant or lactating\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months\n",
      "        since prior chemotherapy Concurrent etoposide and fluorouracil allowed (days 1-5) No\n",
      "        chemotherapy before day 0 of study Endocrine therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified Other: No other concurrent antiemetics No concurrent high\n",
      "        dose benzodiazepines No concurrent psychotropic agents\n",
      "2388\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IIIA or IIIB non-small cell lung cancer that is\n",
      "             unicentric and inoperable, including the following cellular types:\n",
      "               -  Squamous cell carcinoma\n",
      "               -  Adenocarcinoma\n",
      "               -  Bronchoalveolar carcinoma\n",
      "               -  Large cell anaplastic carcinoma\n",
      "               -  Non-small cell lung cancer not otherwise specified\n",
      "          -  Tumors may be multifocal if all of disease is believed to be result of direct spread\n",
      "          -  Disease must be fully accessible by radiotherapy ports for the entire prescribed dose\n",
      "          -  No supraclavicular nodes or diffuse pleural involvement\n",
      "          -  No contralateral hilar disease or an exudative, bloody, or cytologically malignant\n",
      "             effusion\n",
      "          -  Measurable disease required for phase II of this study\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 1 year\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  BUN no greater than 1.5 times normal\n",
      "          -  Creatinine no greater than 1.5 times normal\n",
      "        Pulmonary:\n",
      "          -  FEV1 no greater than 1 liter except if tumor has negatively impacted\n",
      "          -  pulmonary function\n",
      "        Other:\n",
      "          -  No other serious medical or psychiatric illness\n",
      "          -  No prior lung cancer except if free of disease for more than 3 years\n",
      "          -  No other prior malignancy except nonmelanoma skin cancer or if free of\n",
      "          -  disease for more than 1 year\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior thoracic radiotherapy\n",
      "          -  Concurrent radiotherapy to other anatomic sites allowed\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2390\n",
      "DISEASE CHARACTERISTICS: Histologically documented metastatic adenocarcinoma of the breast\n",
      "        Concurrent intraductal or lobular carcinoma in situ allowed Bilateral disease allowed\n",
      "        Measurable or evaluable recurrent metastatic disease (Stage IIIB or IV) documented by\n",
      "        radiograph, CT scan, nuclear medicine scan, or physical exam Tumor must be clinically\n",
      "        chemosensitive as documented by a reduction in tumor burden No clinical evidence of brain\n",
      "        metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet\n",
      "        count at least 50,000/mm3 Hemoglobin at least 8 g/dL Hepatic: Bilirubin less than 1.5\n",
      "        times normal Hepatitis B surface antigen negative Renal: Creatinine less than 1.8 mg/dL\n",
      "        Creatinine clearance normal Blood urea nitrogen (BUN) less than 1.5 times normal\n",
      "        Cardiovascular: Ejection fraction at least 45% by MUGA No uncontrolled or significant\n",
      "        cardiovascular disease including myocardial infarction (less than 1 year) or congestive\n",
      "        heart failure Pulmonary: PFT-FEV1 at least 60% of predicted DLCO and FVC at least 60% of\n",
      "        predicted Other: Not pregnant Negative pregnancy test HIV negative No serious medical or\n",
      "        psychiatric illness No prior or concurrent malignancy, other than curatively treated\n",
      "        carcinoma in situ of the cervix or basal cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent hormonal therapy for\n",
      "        breast cancer\n",
      "2392\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed multiple myeloma or other B-cell malignancy including\n",
      "             non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, or amyloidosis\n",
      "               -  Non-Hodgkin's lymphoma with T-cell immunophenotypes included\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3 (unless due to disease)\n",
      "          -  Platelet count at least 100,000/mm^3 (unless due to disease)\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  LVEF at least 40%\n",
      "        Pulmonary:\n",
      "          -  DLCO or FVC and FEV1 at least 50% of predicted unless due to restriction from volume\n",
      "             loss secondary to disease\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No overt infection or unexplained fever requiring broad spectrum antibiotics\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 2 weeks since prior biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  At least 2 weeks since other prior chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  At least 2 weeks since prior endocrine therapy\n",
      "          -  Concurrent steroids allowed\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2393\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic, locally recurrent, or\n",
      "        surgically unresectable colorectal carcinoma Measurable disease No CNS metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2.5\n",
      "        times normal (5 times normal if known liver metastases) Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Other: No severe concurrent infection Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1\n",
      "        prior chemotherapy regimen Prior fluorouracil-based regimen for advanced colorectal cancer\n",
      "        allowed Prior fluorouracil with radiotherapy not considered therapy for advanced disease\n",
      "        At least 4 weeks since prior chemotherapy (8 weeks for mitomycin or nitrosoureas) and\n",
      "        recovered Endocrine therapy: No concurrent steroids except for antiemesis or as\n",
      "        replacement therapy Radiotherapy: See Chemotherapy No prior radiotherapy to more than 30%\n",
      "        of bone marrow Surgery: See Disease Characteristics At least 4 weeks since prior surgery\n",
      "        unless fully recovered Other: No concurrent vitamin supplements containing folic acid No\n",
      "        other concurrent anticancer therapy\n",
      "2395\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following diagnoses:\n",
      "               -  Acute myeloid leukemia (AML) (FAB M0-M7)\n",
      "               -  Secondary AML in first relapse (Secondary AML stratum closed as of 04/02/02)\n",
      "               -  AML in primary induction failure (Refractory AML stratum closed as of 04/03/01)\n",
      "               -  Myelodysplastic syndromes (MDS) (not related to Down syndrome) (MDS stratum\n",
      "                  closed as of 04/03/01)\n",
      "          -  Extramedullary disease allowed\n",
      "          -  Relapse more than 6 months after allogeneic or autologous bone marrow transplantation\n",
      "             allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 21 at diagnosis\n",
      "        Performance status:\n",
      "          -  Karnofsky 50-100% (over 10 years)\n",
      "          -  Lansky 50-100% (10 years and under)\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  ALT less than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 2 times normal\n",
      "        Cardiovascular:\n",
      "          -  Shortening fraction greater than 29%\n",
      "          -  Ejection fraction greater than 55% with normal wall motion\n",
      "        Other:\n",
      "          -  No uncontrolled infection\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy:\n",
      "          -  At least 12 weeks since prior idarubicin and recovered\n",
      "          -  At least 2 weeks since other prior chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2396\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed atypical endometrial hyperplasia with recommended treatment\n",
      "             with either:\n",
      "               -  An immediate hysterectomy (Part A) OR\n",
      "               -  A three-month delay prior to hysterectomy and a randomized choice of treatment\n",
      "                  with oral medroxyprogesterone acetate (Provera) or medroxyprogesterone acetate\n",
      "                  suspension (Depo-Provera) during the 3 months (Part B with arms I and II)\n",
      "          -  Diagnosed by dilation and curettage, Novak curettage, Vabra aspirate or Pipelle\n",
      "             endometrial biopsy\n",
      "          -  No recognized endometrial carcinoma\n",
      "          -  Must not be considered inoperable\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  GOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT no greater than 3 times normal\n",
      "          -  Alkaline phosphatase no greater than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2 times normal\n",
      "        Cardiovascular\n",
      "          -  No prior thrombophlebitis or thromboembolic phenomena\n",
      "          -  No prior cerebrovascular disorders\n",
      "        Other:\n",
      "          -  No prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ\n",
      "             of the uterine cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2398\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed supratentorial * grade I/II glioma,\n",
      "        including: Diffuse fibrillary astrocytoma No pilocytic astrocytoma No mixed tumor with\n",
      "        ependymoma elements * Supratentorial sites include: Frontal, temporal, parietal, or\n",
      "        occipital lobes Thalamus, basal ganglia, or midbrain Lateral or third ventricles Pons,\n",
      "        medulla, or optic chiasm tumors allowed only if secondary to eligible tumor More than 1\n",
      "        separate tumor allowed Diagnosis based on surgical biopsy or subtotal resection Measurable\n",
      "        or evaluable disease on T2-weighted MRI required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        greater than 3,500/mm3 Platelet count greater than 130,000/mm3 Hemoglobin greater than 9\n",
      "        g/dL Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) AST less than 2\n",
      "        times ULN Alkaline phosphatase less than 2 times ULN Renal: Creatinine less than 1.5 times\n",
      "        ULN Other: No active or uncontrolled infection No second malignancy within 3 years except:\n",
      "        Nonmelanomatous skin cancer In situ cervical cancer No pregnant or nursing women Negative\n",
      "        pregnancy test required within 7 days prior to entry Effective contraception required of\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: At least 1 week since prior steroids OR Stable steroid\n",
      "        dose for at least 1 week prior to study Radiotherapy: No prior cranial or head and neck\n",
      "        irradiation Surgery: See Disease Characteristics\n",
      "2399\n",
      "DISEASE CHARACTERISTICS: Histologically proven advanced or metastatic soft tissue sarcoma\n",
      "        including the following: Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma\n",
      "        Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma\n",
      "        including haemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Mixed mesodermal\n",
      "        tumor of the uterus Measurable disease with evidence of progression in prior 6 weeks No\n",
      "        symptomatic or known CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: WHO 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC at least 3000/mm3 Neutrophil count greater than 2,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater 1.75 mg/dL Albumin at\n",
      "        least 25 g/L Renal: Creatinine clearance greater than 70 mL/min Cardiovascular: No history\n",
      "        of uncontrolled cardiovascular disease Other: Fertile women must use effective\n",
      "        contraception No other severe medical illness including psychosis No prior primary\n",
      "        malignant tumor except: Adequately treated carcinoma in situ of the cervix Basal cell\n",
      "        carcinoma\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No radiotherapy to the sole\n",
      "        index lesion Surgery: Not specified\n",
      "2400\n",
      "DISEASE CHARACTERISTICS: Previously untreated follicular stage III or IV non-Hodgkin's\n",
      "        lymphoma At least one measurable mass\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: WHO 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Alkaline phosphatase and bilirubin less\n",
      "        than 2.5 times upper limit of normal (ULN) (unless clearly related to NHL) Renal:\n",
      "        Creatinine and BUN less than 2.5 times ULN (unless clearly related to NHL) Cardiovascular:\n",
      "        No severe cardiac disease (e.g. severe heart failure requiring treatment or cardiac\n",
      "        ejection fraction less than 45%) Neurologic: No neurologic disease Pulmonary: No pulmonary\n",
      "        disease Other: Not pregnant No prior malignancies except nonmelanoma skin cancer or\n",
      "        carcinoma in situ of the cervix Not HIV positive No psychiatric or metabolic disease\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent immunotherapeutic\n",
      "        drugs, chemotherapy, or radiotherapy\n",
      "2401\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or persistent multiple myeloma at least 6 months\n",
      "             following allogeneic bone marrow transplantation (BMT) from an HLA identical sibling\n",
      "          -  Must meet one of following criteria to be considered persistent, recurrent, or\n",
      "             progressive disease:\n",
      "               -  Residual detectable disease 6-12 months after BMT, as determined by the M\n",
      "                  protein level or bone marrow involvement, without further evidence of clinical\n",
      "                  or laboratory improvement on 2 consecutive measurements 4 weeks apart\n",
      "               -  Complete response not achieved 12 or more months after BMT and there is no\n",
      "                  evidence of progressive improvement\n",
      "               -  At least 25% increase of serum paraprotein (greater than 1.0 g/dL) as measured\n",
      "                  on two occasions or a 50% increase in urinary light chain excretion (greater\n",
      "                  than 150 mg/day) as measured on 2 occasions\n",
      "               -  A 10% increase in plasma cells in the bone marrow\n",
      "          -  Disease in complete response but with recurrence of M protein and 10% point increase\n",
      "             in myeloma cells in the marrow allowed\n",
      "          -  No lytic lesions alone or new soft tissue plasmacytoma as sole evidence of\n",
      "             progression\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  More than 4 weeks\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Must have received prior allogeneic bone marrow transplantation from an HLA A;B;DR\n",
      "             genotypically matched sibling donor\n",
      "          -  No concurrent interferon therapy for relapsed disease\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since cyclosporine, methotrexate, azathioprine, or other graft\n",
      "             versus host disease (GVHD) prophylaxis/treatment without evidence of flare of GVHD\n",
      "          -  At least 4 weeks since prior chemotherapy for relapsed disease\n",
      "        Endocrine therapy:\n",
      "          -  Must be receiving a dose no greater than 0.25 mg/kg prednisone for at least 4 weeks\n",
      "             prior to registration without flare of GVHD\n",
      "          -  No prior prednisone dose greater than 0.25 mg/kg in the past 4 weeks\n",
      "          -  Must receive concurrent prednisone of a dose no greater than 0.25 mg/kg\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  Concurrent palliative radiotherapy allowed if evidence of other evaluable disease\n",
      "             other than irradiated bony sites\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2403\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed Hodgkin's disease, non-Hodgkin's lymphoma, or leukemia in\n",
      "             one of the following categories:\n",
      "               -  Adult T-cell leukemia or lymphoma (ATL)\n",
      "                    -  No smoldering ATL\n",
      "                    -  No limitation on prior therapy\n",
      "               -  Cutaneous T-cell lymphoma (CTCL)\n",
      "                    -  Stages IB-III and failed at least 1 standard therapy\n",
      "                    -  Stage IV regardless of prior therapy\n",
      "               -  Stages I-IV peripheral T-cell lymphoma\n",
      "                    -  Relapsed after standard chemotherapy\n",
      "                    -  Ineligible for or refused salvage chemotherapy or bone marrow\n",
      "                       transplantation (BMT)\n",
      "               -  B-cell non-Hodgkin's lymphoma (NHL) of any histology\n",
      "                    -  Indolent stages II-IV NHL\n",
      "                         -  Failed at least 1 standard therapy\n",
      "                         -  Disease symptomatic and requiring treatment\n",
      "                    -  Aggressive NHL\n",
      "                         -  Relapsed after standard chemotherapy\n",
      "                         -  Ineligible for or refused salvage chemotherapy or BMT\n",
      "               -  Chronic lymphocytic leukemia (CLL)\n",
      "                    -  Rai stages III and IV or Binet stage C\n",
      "                    -  Failed standard therapy and at least 1 salvage chemotherapy\n",
      "               -  Primary B-cell prolymphocytic leukemia or prolymphocytic transformation of CLL\n",
      "                    -  Failed standard therapy and at least 1 salvage chemotherapy\n",
      "               -  Hairy cell leukemia\n",
      "                    -  Failed standard and salvage chemotherapy\n",
      "                    -  Ineligible for or refused further salvage chemotherapy or BMT\n",
      "               -  Acute myelogenous leukemia\n",
      "                    -  Failed standard chemotherapy\n",
      "                    -  Ineligible for or refused salvage chemotherapy or BMT\n",
      "               -  Stages II-IV Hodgkin's disease\n",
      "                    -  Failed standard chemotherapy\n",
      "                    -  Ineligible for curative salvage radiotherapy or chemotherapy\n",
      "                    -  Ineligible for or refused BMT\n",
      "               -  Patients with leukemias or lymphomas not easily classified in above categories\n",
      "                  who have failed standard therapy and are ineligible for or have refused bone\n",
      "                  marrow transplant\n",
      "          -  Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the following:\n",
      "               -  Greater than 10% of malignant cells reactive with anti-Tac by\n",
      "                  immunohistochemistry\n",
      "               -  Greater than 10% of malignant cells from a particular site positive by FACS\n",
      "               -  Greater than 400 IL2Ra sites per malignant cell by radiolabeled anti-Tac binding\n",
      "               -  Soluble IL2Ra level greater than 1,000 U/mL (normal geometric mean 235, with 95%\n",
      "                  confidence levels of 112-502 U)\n",
      "               -  Hodgkin's disease with measurable disease not amenable to biopsy\n",
      "          -  No CNS disease requiring treatment\n",
      "               -  Malignant cells in CSF allowed if judged not to represent clinically significant\n",
      "                  leukemic or lymphomatous meningitis (as in CSF contamination by blood)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 50-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 2 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm3*\n",
      "          -  Platelet count greater than 50,000/mm3* NOTE: *nonleukemic patients\n",
      "        Hepatic:\n",
      "          -  AST and ALT less than 5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL OR\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "        Pulmonary:\n",
      "          -  FEV1, TLC, and DLCO greater than 50% of predicted if pulmonary or mediastinal\n",
      "             involvement with tumor greater than one third of total thoracic diameter\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Serum must neutralize no more than 75% LMB-2 in tissue culture\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior interferon\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior cytotoxic chemotherapy\n",
      "          -  At least 3 weeks since prior retinoids\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent corticosteroids unless begun at least 3 weeks prior to entry and dose\n",
      "             not increased during 3 weeks prior to entry\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior whole-body electron beam radiotherapy\n",
      "          -  Other radiotherapy allowed within 3 weeks of entry provided less than 10% of marrow\n",
      "             irradiated and measurable disease exists outside radiation port\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since any prior systemic therapy\n",
      "          -  No other concurrent investigational agents\n",
      "2404\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory non-Hodgkin's\n",
      "        lymphoma or Hodgkin's disease requiring salvage chemotherapy Prior treatment with at least\n",
      "        3 courses of first line chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        Greater than 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 50,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.5\n",
      "        mg/dL Creatinine clearance at least 40 mL/min Cardiovascular: No symptomatic congestive\n",
      "        heart failure (class III or more as defined by American Heart Association) Electrolytes:\n",
      "        Potassium at least 3.4 meq/L Magnesium at least 1.4 meq/L Other: Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior high dose\n",
      "        chemotherapy with stem cell transplant At least 3 courses of first line chemotherapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified\n",
      "2405\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III or IV squamous cell carcinoma of\n",
      "        the head and neck that is surgically unresectable and not curable by radiation therapy\n",
      "        Upper aerodigestive tract only Unresectable or recurrent disease following initial therapy\n",
      "        with surgery and/or radiation Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 times\n",
      "        institutional normal Transaminases no greater than 3 times institutional normal Renal:\n",
      "        Creatinine clearance greater than 40 mL/min Cardiovascular: Adequate cardiac function No\n",
      "        heart failure Pulmonary: Adequate pulmonary function not requiring supplemental oxygen\n",
      "        Other: Not pregnant Fertile patients must use adequate contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: Prior radiation therapy allowed Surgery:\n",
      "        Prior surgery allowed\n",
      "2406\n",
      "DISEASE CHARACTERISTICS: See General Eligibility Criteria\n",
      "        PATIENT CHARACTERISTICS: Age: 13 and over Performance status: Not specified Hematopoietic:\n",
      "        Not specified Hepatic: Not specified Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular: No cardiac disease No clinically significant cardiac abnormality No\n",
      "        ischemia No recent injury on EKG Other: No intolerance or unresponsiveness to rapamycin No\n",
      "        hypersensitivity to macrolide antibiotics, e.g., erythromycin, azithromycin,\n",
      "        clarithromycin No requirement for medications that may significantly affect rapamycin\n",
      "        metabolism, i.e.: Carbamazepine Ketoconazole Primidone Cimetidine Nicardipine Rifampin\n",
      "        Diltiazem Phenobarbital Valproic acid Erythromycin Phenytoin Verapamil No uncontrolled\n",
      "        systemic infection No pregnant or nursing women Negative pregnancy test required of\n",
      "        fertile women Effective contraception required of fertile patients during and for 3 months\n",
      "        after study Able to tolerate less than 400 mL of liquid oral intake\n",
      "        PRIOR CONCURRENT THERAPY: At least 1 week since any investigational drug\n",
      "2409\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the pancreas\n",
      "               -  Stage T1-4, N0-1 (stage I-IVA)\n",
      "               -  No M1 or NX staging\n",
      "               -  Primary tumor of the pancreas (pancreatic head, neck, uncinate process, or\n",
      "                  body/tail) and maximum diameter/dimension and tumor status at surgical margin\n",
      "                  known\n",
      "          -  Prior potentially curative gross resection within 3-8 weeks before study\n",
      "          -  No non-adenocarcinomas, adenosquamous carcinomas, islet cell carcinomas,\n",
      "             cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile\n",
      "             duct carcinoma, or ampullary carcinoma\n",
      "          -  No recurrent disease\n",
      "          -  Post-resection CA-19-9 level required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT no greater than 5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Other:\n",
      "          -  No significant nausea or vomiting\n",
      "          -  No prior malignancy within the past 5 years except nonmelanomatous skin cancer or\n",
      "             carcinoma in situ of the cervix\n",
      "          -  Able to maintain adequate nutrition (at least 1,500 calories/day)\n",
      "               -  Feeding tube allowed\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2411\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian epithelial\n",
      "        carcinoma including the following cellular diagnoses: Serous adenocarcinoma Mucinous\n",
      "        adenocarcinoma Endometrioid adenocarcinoma Clear cell adenocarcinoma Undifferentiated\n",
      "        carcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner's Tumor\n",
      "        Stage III (optimal or suboptimal) must be surgically reassessed OR Stage III (suboptimal)\n",
      "        or stage IV clinically reassessed after induction chemotherapy For stage III surgical\n",
      "        reassessment: No more than 12 weeks between end of chemotherapy and reassessment surgery\n",
      "        AND No more than 6 weeks between reassessment surgery and randomization Patients treated\n",
      "        on protocol GOG-158 are eligible At least a partial response to chemotherapy as defined\n",
      "        as: Microscopic disease documented at reassessment surgery for patients optimally debulked\n",
      "        (disease no greater than 1 cm) after primary surgery Suboptimally debulked disease\n",
      "        (greater than 1 cm) after primary surgery and 1 of the following: Negative reassessment\n",
      "        laparotomy Only microscopic disease at reassessment surgery Gross residual disease no\n",
      "        greater than 1 cm at reassessment surgery prior to debulking Clinical complete response to\n",
      "        induction chemotherapy including: - suboptimal disease Stage III or IV AND - either an\n",
      "        abnormal CT or elevated CA-125 prior to induction chemotherapy and both are within normal\n",
      "        limits following induction chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: Under 66 Performance status: GOG 0 or 1 Hematopoietic:\n",
      "        Absolute granulocyte count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL AST no greater than 3 times normal Renal: Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: Left ventricular ejection fraction at least\n",
      "        45% by MUGA No congestive heart failure Pulmonary: FEV1 and FVC at least 60% Other: Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No prior malignancy in the past 5 years except adequately treated\n",
      "        nonmelanomatous skin cancer, carcinoma in situ of the cervix, or any other cancer whose\n",
      "        prior treatment does not contraindicate this study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 and no more than 6 prior platinum-based combination\n",
      "        chemotherapy courses (i.e., cisplatin or carboplatin) required Endocrine therapy: Not\n",
      "        specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No prior\n",
      "        anthracyclines\n",
      "2412\n",
      "DISEASE CHARACTERISTICS: Histologically proven inoperable, metastatic, or recurrent renal\n",
      "        cell carcinoma Measurable or evaluable disease No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Neutrophil count greater than 1,500/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: Liver enzymes less than 3 (5 if known liver metastases)\n",
      "        times institutional normal Renal: Creatinine less than 1.5 mg/dL Cardiovascular: Adequate\n",
      "        cardiac function No unstable angina No significant coronary artery disease No heart\n",
      "        failure with New York Heart Association classification III or IV Pulmonary: No evidence of\n",
      "        pulmonary disease (documented normal DLCO and PFT) Other: No prior malignancy except:\n",
      "        Nonmelanoma skin cancer Carcinoma in situ of any kind No pregnant or lactating Fertile\n",
      "        patients must use adequate contraception Normal thyroid functions as evidenced by normal\n",
      "        T4 and TSH\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior biologic therapy At least\n",
      "        4 weeks since prior biologic therapy Chemotherapy: No more than 1 prior chemotherapy At\n",
      "        least 4 weeks since prior chemotherapy Endocrine therapy: No more than 1 prior hormonal\n",
      "        therapy At least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since\n",
      "        prior radiation therapy No prior radiation therapy if entire tumor was within radiation\n",
      "        field Surgery: Not specified\n",
      "2415\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed stage II/III multiple myeloma (or have\n",
      "        greater than normal beta-2-microglobulin) meeting the Salmon and Durie criteria Stage I\n",
      "        multiple myeloma must have had prior chemotherapy before undergoing transplantation\n",
      "        PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than\n",
      "        2 mg/dL Renal: Creatinine clearance at least 50 mg/min Cardiovascular: Left ventricular\n",
      "        ejection fraction at least 41% Other: Not pregnant HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2416\n",
      "DISEASE CHARACTERISTICS: Patients must be undergoing surgical resection of a colorectal\n",
      "        primary adenocarcinoma Metastatic colorectal cancer to liver (hepatic metastases) allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: No known or suspected allergy to isosulfan blue Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2417\n",
      "DISEASE CHARACTERISTICS: Pathologically confirmed acute myeloid leukemia Not in first\n",
      "        complete remission with translocations t(8;21) unless failed first line induction therapy\n",
      "        Not in first complete remission with translocations t(15;17) or 16q abnormality unless:\n",
      "        Failed first line induction therapy OR Molecular evidence of disease Pathologically\n",
      "        confirmed acute lymphoblastic lymphoma (ALL) Not in first complete remission OR High risk\n",
      "        ALL in first complete remission defined as: Hypodiploidy OR Pseudodiploidy with\n",
      "        translocations t(9,22), t(4;11), or t(8;14) OR Elevated WBC at presentation Greater than\n",
      "        100,000/mm3 if 6-12 months old Greater than 50,000/mm3 if 10-20 years old Greater than\n",
      "        20,000/mm3 if 21 or over OR Failed to achieve complete remission after 4 weeks of\n",
      "        induction therapy Pathologically confirmed chronic myelogenous leukemia (CML) not in blast\n",
      "        crisis Pathologically confirmed undifferentiated leukemia or biphenotypic leukemia\n",
      "        Pathologically confirmed juvenile CML with or without either 7q- or infantile monosomy 7\n",
      "        Leukocytosis with absolute monocytosis greater than 450 microliters AND Immature myeloid\n",
      "        cells in peripheral blood circulation Less than 25% marrow blasts Myelodysplastic\n",
      "        syndromes: Refractory anemia (RA) RA with ringed sideroblasts RA with excess blasts (RAEB)\n",
      "        RAEB in transformation Chronic myelomonocytic leukemia Pathologically confirmed stage IV\n",
      "        lymphoblastic lymphoma No active CNS or skin leukemic involvement No consenting suitably\n",
      "        HLA-matched related donor available Consenting unrelated donor available\n",
      "        PATIENT CHARACTERISTICS: Age: 55 and under Performance status: Karnofsky 70-100% OR Lansky\n",
      "        60-100% Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic:\n",
      "        Bilirubin less than 2.5 mg/dL SGOT less than 3 times upper limit of normal Renal:\n",
      "        Creatinine within normal range OR Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: Asymptomatic OR Left ventricular ejection fraction at rest greater than\n",
      "        40% and improves with exercise Pulmonary: Asymptomatic OR DLCO greater than 45% Other: Not\n",
      "        pregnant or lactating HIV negative No uncontrolled viral, bacterial, or fungal infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior autologous or allogeneic bone marrow\n",
      "        transplant Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified\n",
      "        Radiotherapy: No concurrent mediastinal radiation No prior radiation therapy that would\n",
      "        preclude total body irradiation Surgery: Not specified\n",
      "2418\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian cancer that is\n",
      "        refractory to an initial chemotherapy regimen that included a platinum agent plus\n",
      "        paclitaxel - Epithelial ovarian cancer - Primary carcinoma of the peritoneum - Fallopian\n",
      "        tube cancer Initial response to platinum and paclitaxel must have been one of the\n",
      "        following: Progression or stable disease Response that lasted less than 3 months Response\n",
      "        that lasted at least 3 months, but when retreated with both agents (in combination or as\n",
      "        single agents) disease was refractory Measurable or evaluable disease Evaluable disease is\n",
      "        defined by: CA-125 at least 100 units/mL AND CA-125 level must have at least doubled from\n",
      "        baseline determination\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal\n",
      "        (ULN) AST or ALT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular: No New York Heart Association Class III or IV heart disease No myocardial\n",
      "        infarction within last 6 months No congestive heart failure No unstable angina No\n",
      "        clinically significant pericardial effusion or arrhythmia Neurology: No current peripheral\n",
      "        neuropathy of any etiology that is greater than grade 1 Other: No active serious infection\n",
      "        or other serious underlying medical condition No prior significant allergic reactions to\n",
      "        drugs containing Cremophor, such as teniposide, cyclosporin, or vitamin K Not pregnant or\n",
      "        nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since immunotherapy No\n",
      "        concurrent immunotherapy Chemotherapy: Prior paclitaxel treatment must have been\n",
      "        administered on a 3 week or greater schedule No other prior chemotherapy besides platinum\n",
      "        and paclitaxel At least 3 weeks since acceptable chemotherapy Endocrine therapy: At least\n",
      "        3 weeks since hormonal therapy No concurrent hormonal therapy Radiotherapy: At least 3\n",
      "        weeks since radiotherapy No prior radiation to greater than 30% of bone marrow Surgery: At\n",
      "        least 3 weeks since major surgery\n",
      "2419\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed soft tissue sarcoma of an extremity or\n",
      "        the body wall that is a primary or a postoperatively recurrent tumor Biopsy required\n",
      "        within 2 months prior to entry Grade II or III tumor, including AJCC stages IIB and IIIB\n",
      "        lesions at least 8 cm in diameter No more than 4 chest lesions that are no greater than 3\n",
      "        mm in diameter on preoperative CT The following histologies are excluded: Angiosarcoma of\n",
      "        the scalp or face Chondrosarcoma Extraosseous Ewing's sarcoma Head and neck sarcoma\n",
      "        Kaposi's sarcoma Osteosarcoma Primitive neuroectodermal tumor Rhabdomyosarcoma Patients on\n",
      "        this study are also eligible for Frozen Tumor Repository study (protocol RTOG-9308)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80%-100%\n",
      "        Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 150,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL SGOT no greater than 50 U Renal: Creatinine no greater\n",
      "        than 1.5 mg/dL Cardiovascular: No congestive heart failure (CHF) within 6 months No\n",
      "        myocardial infarction (MI) within 6 months No New York Heart Association class II-IV heart\n",
      "        disease Left ventricular ejection fraction at least 50% by MUGA or echocardiogram If\n",
      "        history of CHF or MI, criterion must be met within past 6 months Other: No\n",
      "        contraindication to surgery No uncontrolled bacterial, viral, or fungal infection No\n",
      "        serious medical or psychiatric illness that precludes informed consent or limits survival\n",
      "        to less than 2 years No second malignancy within 5 years except: Surgically treated in\n",
      "        situ cervical cancer Nonmelanomatous skin cancer Not pregnant or nursing Negative\n",
      "        pregnancy test required of fertile women within 7 days prior to entry Effective\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No\n",
      "        prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy\n",
      "        Surgery: See Disease Characteristics\n",
      "2420\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant glioma - Recurrent\n",
      "        glioblastoma - Anaplastic astrocytoma - Mixed anaplastic glioma For recurrent\n",
      "        glioblastoma: Required documented progression must include an increase in tumor size of at\n",
      "        least 25% or appearance of new lesion For anaplastic astrocytoma or mixed anaplastic\n",
      "        glioma: Must have measurable, contrast enhancing disease on postoperative CT or MRI scan\n",
      "        No postoperative radiation or chemotherapy If patients have received prior brachytherapy\n",
      "        or stereotactic radiosurgery, they must have confirmation of true progressive disease\n",
      "        rather than radiation necrosis by PET scanning or biopsy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count\n",
      "        at least 1,800/mm3 Platelet count at least 125,000/mm3 Hemoglobin at least 9 g/dL\n",
      "        (transfusion allowed) Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 2.0 times\n",
      "        upper limit of normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance\n",
      "        greater than 70 mL/min Cardiovascular: No uncontrolled arrhythmias or conduction defects\n",
      "        No unstable or newly diagnosed angina pectoris No New York Heart Association class II-IV\n",
      "        heart disease No congestive heart failure No major problems with edema (e.g., severe\n",
      "        Cushing's syndrome, residual leg swelling from deep-vein thrombosis) No recent coronary\n",
      "        artery disease No poorly controlled hypertension (diastolic greater than 110 mmHg and\n",
      "        systolic greater than 180 mmHg) Pulmonary: DLCO greater than 80% of expected value Other:\n",
      "        HIV negative No major psychiatric illness No other prior malignancy except adequately\n",
      "        treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately\n",
      "        treated stage I or II cancer from which the patient is currently in complete remission, or\n",
      "        any other cancer from which the patient has been free of disease for 5 years Not pregnant\n",
      "        or nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No prior nitrosourea or temozolomide No more than 1 prior chemotherapy regimen allowed for\n",
      "        patients with glioblastoma At least 6 weeks since mitomycin or procarbazine and recovered\n",
      "        At least 4 weeks since other prior chemotherapy and recovered No other concurrent\n",
      "        chemotherapy Endocrine therapy: If receiving steroids, must be on a stable steroid dose\n",
      "        for at least 72 hours prior to study No other concurrent endocrine therapy Radiotherapy:\n",
      "        At least 6 weeks since radiotherapy No greater than 10-20% of marrow irradiated in prior\n",
      "        radiotherapy No other concurrent radiotherapy Surgery: Surgery allowed\n",
      "2421\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck (including nasopharynx) that is considered incurable with surgery or radiation\n",
      "        therapy Bidimensionally measurable disease Patients whose only site of measurable disease\n",
      "        is within a previous radiation port must have documented progressive disease or\n",
      "        biopsy-proven recurrence after the completion of radiotherapy No uncontrolled CNS\n",
      "        metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Hematopoietic:\n",
      "        Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR\n",
      "        Creatinine clearance at least 60 mL/min Calcium normal No history of hypercalcemia\n",
      "        Cardiovascular: No history of ventricular arrhythmias or symptomatic bradyarrhythmia\n",
      "        Other: No significant detectable infection Not pregnant or nursing No other active\n",
      "        malignancies Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interleukin-2, interferons, and\n",
      "        monoclonal antibodies allowed Recovered from prior therapy Chemotherapy: Prior paclitaxel\n",
      "        infusion no greater than 24 hours for recurrent or metastatic disease required Endocrine\n",
      "        therapy: Not specified Radiotherapy: Recovered from prior radiotherapy Surgery: Recovered\n",
      "        from any prior major surgery\n",
      "2423\n",
      "DISEASE CHARACTERISTICS: One of the following histologically documented hematologic\n",
      "        malignancies: Acute myelogenous leukemia Failed or relapsed following conventional dose\n",
      "        chemotherapy (e.g., doxorubicin, cytarabine) or high dose cytarabine (HD ARA-C) Chronic\n",
      "        myelogenous leukemia in blast crisis that has failed at least 1 conventional antileukemic\n",
      "        regimen Acute lymphoblastic leukemia (ALL) that is relapsed following or initially\n",
      "        refractory to conventional therapy Failed at least 1 salvage regimen for ALL Disease\n",
      "        refractory to conventional HD ARA-C allowed Primarily refractory or relapsed Hodgkin's or\n",
      "        non-Hodgkin's lymphoma Failed at least 1 conventional second or third generation regimen\n",
      "        (e.g., ProMACE-CytaBOM) Refractory multiple myeloma Not eligible for protocols of higher\n",
      "        priority and no alternative forms of therapy available that offer a reasonable chance of\n",
      "        palliation or cure\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% Life\n",
      "        expectancy: At least 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 3\n",
      "        mg/dL Renal: Creatinine clearance at least 40 mL/min Pulmonary: Pulse oximetry greater\n",
      "        than 88% in patients with a history of pulmonary disease Other: No major concurrent\n",
      "        disease that renders patient a poor medical risk No uncontrolled infection Disease related\n",
      "        fever allowed at investigator's discretion No mental incapacity that precludes informed\n",
      "        consent No incarcerated patients Not pregnant Effective contraception required of fertile\n",
      "        women\n",
      "        PRIOR CONCURRENT THERAPY: Not specified Biologic therapy: Not specified Chemotherapy: At\n",
      "        least 3 weeks since prior chemotherapy (24 hours since hydroxyurea) and recovered\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to 30% or more of\n",
      "        bone marrow At least 4 weeks since prior radiotherapy and recovered Surgery: Not specified\n",
      "2424\n",
      "DISEASE CHARACTERISTICS: Histologically proven glioblastoma multiforme or anaplastic\n",
      "        astrocytoma Prior surgical resection and radiotherapy completed approximately 1 month\n",
      "        prior to study\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 OR Karnofsky 70-100%\n",
      "        Life expectancy: Not specified Hematopoietic: WBC greater than 2000/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: No active infection with hepatitis B Renal: Not\n",
      "        specified Other: Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        during and for 1 month after study No active collagen vascular or autoimmune disease No\n",
      "        prior severe reaction to any blood product No other prior malignancy within the past 5\n",
      "        years except adequately treated squamous cell or basal cell skin cancer, carcinoma in situ\n",
      "        or the cervix, or stage I or II cancer in complete remission Not immunologically\n",
      "        compromised due to chronic conditions Not allergic by standard skin testing HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy with\n",
      "        immunomodulatory effects (e.g., interleukin-2, interferon alfa) Chemotherapy: No prior or\n",
      "        concurrent local or systemic chemotherapy Endocrine therapy: At least 1 week since prior\n",
      "        corticosteroid therapy No concurrent corticosteroid therapy Radiotherapy: See Disease\n",
      "        Characteristics Surgery: See Disease Characteristics Other: No concurrent\n",
      "        antiproliferatives or immunosuppressants\n",
      "2426\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and\n",
      "        neck or its variants (lymphoepithelioma, undifferentiated epidermoid carcinoma, etc.)\n",
      "        Previously untreated Stage III or IV (M0) No exophytic T3 N0 tumors or T1 N1 lesions May\n",
      "        be entered after initial induction therapy Evaluable disease Must have received therapy\n",
      "        with one of the following induction regimens, except as modified for toxicity: - Cisplatin\n",
      "        at least 80 mg/m2/cycle and fluorouracil at least 1000 mg/m2/day for at least 4 days every\n",
      "        4 weeks - Carboplatin at least 300 mg/m2/cycle and fluorouracil at least 1000 mg/m2/day\n",
      "        for at least 4 days every 4 weeks - Cisplatin at least 25 mg/m2/day over 5 days,\n",
      "        fluorouracil at least 800 mg/m2/day on days 2-5 and leucovorin at least 500 mg/m2/day over\n",
      "        5 days, every 4 weeks\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: WBC at least 4,000/mm3 Absolute neutrophil count\n",
      "        normal Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusions\n",
      "        permitted, if not used solely for achieving the eligibility criteria) Hepatic: SGOT less\n",
      "        than 1.5 times upper limit of normal (ULN) Total bilirubin and SGOT no greater than 2\n",
      "        times ULN as an isolated value Alkaline phosphatase less than 2.5 times ULN Alkaline\n",
      "        phosphatase no greater than 2.5 times ULN as an isolated value Renal: Not specified\n",
      "        Cardiovascular: No acute cardiac dysrhythmias or unstable cardiac conditions such as\n",
      "        angina Neurology: No peripheral neuropathy greater than grade 1 Nutritional status:\n",
      "        Adequate and nutritionally balanced enteral intake (at least 1,800 kcal/day) No\n",
      "        intravenous alimentation as primary source of calories No weight loss of greater than 20%\n",
      "        of body weight in past 3 months Other: No prior allergy to polysorbate 80 No other serious\n",
      "        illness or medical condition No persistent diarrhea No other prior or concurrent\n",
      "        malignancy, unless disease free for at least 5 years, except: Limited basal cell carcinoma\n",
      "        of the skin Squamous cell carcinoma of the skin Carcinoma in situ of the cervix Not\n",
      "        pregnant or nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy within 5 years other than described in Disease Characteristics No greater\n",
      "        than 3 cycles of prior chemotherapy as described in Disease Characteristics Endocrine\n",
      "        therapy: Prior hormone therapy allowed Radiotherapy: No prior radiotherapy for squamous\n",
      "        cell cancer of the head and neck Surgery: May have undergone surgery as the sole treatment\n",
      "        for disease 2 or more years prior to study\n",
      "2428\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed measurable stage IIIB or IV non-small\n",
      "        cell lung cancer No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC at least 3500/mm3 Granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT and\n",
      "        SGPT no greater than 2.5 times upper limit of normal (ULN) Alkaline phosphatase no greater\n",
      "        than 2.5 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at\n",
      "        least 60 mL/min Calcium and electrolytes normal Other: No other malignancy within past 5\n",
      "        years except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix\n",
      "        Not pregnant or nursing No active infections or other serious medical conditions\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 2 weeks since prior\n",
      "        radiotherapy No prior radiotherapy to site(s) of measurable disease Surgery: At least 3\n",
      "        weeks since any prior surgery\n",
      "2430\n",
      "Inclusion Criteria:\n",
      "          -  TCC of the bladder which is muscle-invasive and has demonstrated resistance to\n",
      "             platinum-based chemotherapy, or tumor stage T1 that has either failed BCG or has\n",
      "             concomitant CIS\n",
      "          -  Patients will be eligible if they are if they are inappropriate for cystectomy\n",
      "             because of metastatic disease or are medically unfit for surgery, or if they have\n",
      "             refused cystectomy\n",
      "          -  Patients without muscle invasion (TI) must have concomitant carcinoma in situ (CIS)\n",
      "             or have recurrent/persistent tumor following at least 1 course of intravesical\n",
      "             bacillus Calmette-guerin (BCG) immunotherapy\n",
      "          -  Patients who have receive BCG and have only CIS are also eligible if the lesions are\n",
      "             sufficient raised and demarcated to be measurable (must be approved by Dr. Dinney)\n",
      "          -  Patients must have negative adenoviral culture of urine prior to treatment; patients\n",
      "             may be registered if the culture is negative after 14 days\n",
      "          -  Local-regional disease will be defined as those patients who have evidence of locally\n",
      "             unresectable disease by examination under anesthesia (pelvic sidewall fixation,\n",
      "             invasion of central genitalia, or nodal involvement\n",
      "               -  Pelvic nodal involvement will be biopsy documented; patients in the nodal\n",
      "                  category will include those with either mediastinal, para-aortic, or\n",
      "                  supraclavicular involvement\n",
      "          -  Distant visceral disease will include those patients with documented of distant\n",
      "             visceral sites (lung, bone, liver); a biopsy will not be required in the patients\n",
      "             with characteristic radiographic evidence of metastases\n",
      "          -  Patients with muscle invasion must have failed to respond to CDDP-based chemotherapy\n",
      "             or have recurrent/persistent tumor after chemotherapy; patients who are not\n",
      "             candidates for CDDP-based chemotherapy because of poor cardiac function, renal\n",
      "             function, or performance status are also eligible\n",
      "          -  Expected survival > 12 weeks\n",
      "          -  Bidimensionally measurable disease; vigorous transurethral resection should be\n",
      "             avoided prior to study\n",
      "          -  Zubrod performance status less than or equal to 2\n",
      "          -  Patients have voluntarily signed an informed consent in accordance with institutional\n",
      "             policies\n",
      "          -  Negative pregnancy test if female and of childbearing potential (non-childbearing is\n",
      "             defined as greater than one year postmenopausal or surgically sterilized); females\n",
      "             and males must agree to use barriers method of birth control while on study\n",
      "          -  Negative serology for human immunodeficiency virus\n",
      "        \n",
      "2432\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of previously untreated intermediate-grade or immunoblastic lymphoma\n",
      "               -  Tumor score of 3 or greater, defined by the presence of 3 or more of the\n",
      "                  following criteria :\n",
      "                    -  Ann Arbor stage III or IV disease\n",
      "                    -  B symptoms (fever, sweats, and weight loss greater than 10%)\n",
      "                    -  At least 1 tumor mass greater than 7 cm or mediastinal mass visible on\n",
      "                       plain chest x-ray\n",
      "                    -  Beta-2 microglobulin at least 3.0\n",
      "                    -  Lactic dehydrogenase at least 1.1 times the upper limit of normal\n",
      "          -  T- and B-cell lymphomas allowed if intermediate grade or immunoblastic\n",
      "          -  Divergent histologies, including bone marrow involvement, allowed\n",
      "          -  CNS involvement allowed NOTE: A new classification scheme for adult non-Hodgkin's\n",
      "             lymphoma has been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\"\n",
      "             lymphoma will replace the former terminology of \"low\", \"intermediate\", or \"high\"\n",
      "             grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to 59\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL (unless elevation due to lymphoma)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL (unless elevation due to lymphoma)\n",
      "        Cardiovascular:\n",
      "          -  LVEF greater than 50% by echocardiogram if over age 45\n",
      "          -  No congestive heart failure, angina, history of myocardial infarction, or arrhythmia\n",
      "             unless cleared by principal investigator after cardiology consultation\n",
      "        Pulmonary:\n",
      "          -  No history of chronic obstructive or restrictive lung disease\n",
      "          -  Pulmonary consultation required for smokers or patients with questionable lung\n",
      "             function\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No prior malignancy with poor prognosis (less than 90% probability of surviving for 5\n",
      "             years)\n",
      "          -  No geographic, economic, emotional, or social condition that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior biologic therapy\n",
      "        Chemotherapy\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy\n",
      "          -  No prior endocrine therapy\n",
      "        Radiotherapy\n",
      "          -  No prior radiotherapy\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2435\n",
      "DISEASE CHARACTERISTICS: Histologically proven plateau phase multiple myeloma at original\n",
      "        diagnosis: Bone marrow plasmacytosis with greater than 10% plasma cells, sheets of plasma\n",
      "        cells, or biopsy proven plasmacytoma Must be in stable plateau phase requiring objective\n",
      "        response, no evidence of continuing improvement by any criteria, and less than 20%\n",
      "        variation in M protein at least 4 weeks prior to study Must have at least one of the\n",
      "        following at original diagnosis: M protein in serum or urine X-ray evidence of osteolytic\n",
      "        lesion Measurable or evaluable M protein Serum M protein greater than 1.0 g/dL Urine M\n",
      "        protein greater than 200 mg/24 hours M protein less than these values will be considered\n",
      "        evaluable (serum less than 1 g/dL or urine less than 200 mg/24 hours) Nonsecretory\n",
      "        patients are ineligible\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 2,500/mm3 Absolute neutrophil count at least\n",
      "        1,250/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper\n",
      "        limit of normal (ULN) SGOT less than 1.5 times ULN Renal: Creatinine clearance at least 50\n",
      "        mL/min Cardiovascular: No New York Heart Association class III or IV congestive heart\n",
      "        failure Other: Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        No uncontrolled peptic ulcer disease No inflammatory bowel disease No history of\n",
      "        significant autoimmune disease (rheumatoid arthritis or systemic lupus erythematosus)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 60 days since prior biologic response\n",
      "        modifiers At least 60 days since prior bone marrow transplantation Chemotherapy: At least\n",
      "        60 days since prior chemotherapy Endocrine therapy: No concurrent corticosteroids\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "2437\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the pancreas that is\n",
      "        locoregionally active or metastatic and not amenable to cure or long-term control by\n",
      "        surgery, radiotherapy, or chemotherapy No brain metastases refractory to irradiation or\n",
      "        surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 OR Karnofsky\n",
      "        60-100% Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Not\n",
      "        specified Renal: Not specified Cardiovascular: No prior or concurrent significant\n",
      "        cardiovascular disease Pulmonary: No prior or concurrent significant pulmonary disease\n",
      "        Other: No AIDS HIV negative No prior or concurrent autoimmune disease No other concurrent\n",
      "        major medical illness Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: No concurrent\n",
      "        chronic steroid therapy Radiotherapy: See Disease Characteristics At least 4 weeks since\n",
      "        prior radiotherapy Surgery: See Disease Characteristics Other: At least 4 weeks since\n",
      "        other prior therapy\n",
      "2438\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant solid tumor Refractory\n",
      "        disease; not curable by surgery, radiation therapy, or standard chemotherapy Measurable or\n",
      "        evaluable disease required by evidence of radiographic abnormalities, abnormal physical\n",
      "        exam, or elevated tumor markers at least 3 times above normal No brain metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute granulocyte\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater\n",
      "        than 1.8 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater\n",
      "        than 60 mL/min Other: No medical or psychiatric conditions Not pregnant Adequate\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior topotecan\n",
      "        or ifosfamide At least 4 weeks since myelosuppressive chemotherapy At least 6 weeks since\n",
      "        nitrosourea or mitomycin Must have recovered from prior therapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: No prior radiation therapy to pelvis At least 4 weeks since\n",
      "        radiation therapy to major bone marrow containing areas Surgery: Must not have an option\n",
      "        of surgery for this disease\n",
      "2439\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unresectable hepatocellular carcinoma (HCC) or highly\n",
      "             suspicious for HCC based on CT scan and elevated alfafetoprotein\n",
      "          -  Measurable disease by abdominal CT scan Accessible (peripheral) lesions\n",
      "          -  No metastatic disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  Platelet count at least 60,000/mm3\n",
      "          -  Absolute neutrophil count greater than 1,500/mm3\n",
      "          -  Prothrombin time of no greater than 16 seconds after administration of fresh frozen\n",
      "             plasma\n",
      "          -  Bilirubin no greater than 3.0 mg/dL\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Child's class A or B cirrhosis eligible\n",
      "          -  No uncontrolled infection Not pregnant or breast feeding\n",
      "          -  No unstable or severe intercurrent medical condition\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  At least 4 weeks since prior radiation therapy\n",
      "          -  No prior hepatic transplantation\n",
      "          -  No more than 1 prior systemic regimen for hepatocellular carcinoma allowed\n",
      "          -  No concurrent therapy with other investigational agents\n",
      "          -  No prior gene therapy\n",
      "          -  No prior intralesional therapy\n",
      "2443\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven advanced metastatic\n",
      "        carcinoma of the breast Bidimensionally measurable disease No brain or leptomeningeal\n",
      "        disease\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Hemoglobin at least 10 g/dL Neutrophil count at least\n",
      "        2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 11.7\n",
      "        mg/dL AST/ALT no greater than 2 times upper limit of normal (5 times upper limit of normal\n",
      "        in presence of liver metastases) Renal: Creatinine no greater than 1.7 mg/dL\n",
      "        Cardiovascular: No concurrent treatment for congestive cardiac failure Cardiac function\n",
      "        within normal limits by MUGA or ECHO scan, if prior anthracycline therapy Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception No concurrent\n",
      "        nonmalignant systemic disease No active uncontrolled infection No prior history of\n",
      "        malignant disease except: Squamous cell carcinoma of the skin Curatively treated carcinoma\n",
      "        in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunological therapy\n",
      "        Chemotherapy: At least 1 prior chemotherapy regimen for advanced disease (including\n",
      "        adjuvant therapy), but not more than 2 prior regimens At least 4 weeks since prior\n",
      "        chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered Cumulative dose of prior\n",
      "        epirubicin no greater than 450 mg/m2 Cumulative dose of prior doxorubicin no greater than\n",
      "        240 mg/m2 No concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Low\n",
      "        dose steroid therapy allowed if dose established at least 4 weeks prior to study\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Surgery: Not\n",
      "        specified Other: No concurrent experimental therapy\n",
      "2445\n",
      "DISEASE CHARACTERISTICS: Refractory or recurrent advanced malignancy following known\n",
      "        standard effective therapy or advanced malignancy for which no standard effective therapy\n",
      "        exists Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 2 months Hematopoietic: Absolute neutrophil count at least 1800/mm3 Hematocrit at\n",
      "        least 30 mg/dL Platelet count at least 50,000/mm3 Hepatic: Bilirubin no greater than 1.5\n",
      "        times normal unless due to disease, then less than 3.5 times normal Transaminases less\n",
      "        than 3 times upper limit of normal (ULN) (less than 5 times ULN if due to liver\n",
      "        metastases) Renal: Creatinine no greater than 2.5 times normal Cardiovascular: No severe\n",
      "        cardiac abnormalities Must have adequate venous access No history of sustained ventricular\n",
      "        arrhythmia or unexplained syncope Pulmonary: No severe pulmonary abnormalities Other: Not\n",
      "        pregnant or nursing Effective contraception required of fertile female patients No serious\n",
      "        concurrent medical or psychiatric illness Adequate nutrition No human antimouse antibodies\n",
      "        PRIOR CONCURRENT THERAPY: At least 4 weeks since prior anticancer therapy and recovered If\n",
      "        there was disease progression during therapy, at least 2 weeks since prior anticancer\n",
      "        therapy and recovered Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        chemotherapy Endocrine therapy: Concurrent topical steroids used in the chronic management\n",
      "        of cutaneous T cell lymphoma allowed No other concurrent hormone therapy Radiotherapy: No\n",
      "        concurrent palliative radiotherapy Surgery: Not specified\n",
      "2446\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage III or IV squamous cell head and neck cancer\n",
      "               -  T3-4, N0-3, M0\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance Status:\n",
      "          -  ECOG 0-2\n",
      "        Life Expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 3.0 mg/dL\n",
      "          -  SGOT no greater than 3 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 3.0 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent beta-adrenergic blocking agents\n",
      "2447\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven recurrent or refractory pediatric solid tumor\n",
      "          -  Bone marrow metastases allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  1 to 30\n",
      "        Performance status:\n",
      "          -  0-2\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3 (transfusion independent)\n",
      "          -  Hemoglobin at least 10 g/dL (RBC transfusion allowed)\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT no greater than 2.5 times normal\n",
      "        Renal:\n",
      "          -  Adequate renal function as defined by one of the following:\n",
      "               -  GFR by creatinine clearance\n",
      "               -  Radioisotope GFR\n",
      "               -  Iothalamate at least 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Adequate cardiac function as defined by one of the following:\n",
      "               -  Ejection fraction at least 55% by MUGA\n",
      "               -  Fractional shortening at least 28% by echocardiogram\n",
      "        Neurologic:\n",
      "          -  Adequate CNS function as defined by:\n",
      "               -  Seizure disorder, if present, controlled by anticonvulsants\n",
      "               -  CNS toxicity no greater than grade 2\n",
      "        Other:\n",
      "          -  No uncontrolled infections\n",
      "          -  Not pregnant or nursing\n",
      "          -  No allergy to platinum compounds\n",
      "          -  No history of allergy to etoposide (unless mobilization phase not required)\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Recovered from prior immunotherapy\n",
      "          -  At least 1 week since prior cytokines\n",
      "          -  At least 3 months since prior bone marrow or peripheral blood stem cell\n",
      "             transplantation\n",
      "          -  No concurrent immunomodulator\n",
      "          -  No concurrent cytokines\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered\n",
      "          -  No prior thiotepa\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Recovered from prior radiotherapy\n",
      "          -  At least 6 months since prior total body irradiation conditioning\n",
      "          -  No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2448\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed pelvic cancer Planned therapy is to\n",
      "        undergo continuous definitive or adjuvant external beam pelvic radiation therapy with or\n",
      "        without fluorouracil (5-FU) plus or minus levamisole No split course radiation therapy\n",
      "        Planned course of radiation therapy must also meet the following criteria: - Entire pelvis\n",
      "        must be encompassed by the planned radiotherapy fields - Total planned dose to the central\n",
      "        axis midplane or isocenter for the whole pelvic field must be between 4500-5350 cGy -\n",
      "        Treatment must be given 4-5 times per week on a one-treatment-per-day basis No stool\n",
      "        incontinence or stool frequency of 7 or more per day prior to initiation of radiation\n",
      "        therapy Must be entered on study before the second radiation therapy fraction No current\n",
      "        or prior metastases beyond pelvic regional lymph nodes Must have functioning rectum No\n",
      "        planned perineal irradiation No anal cancer No active intraluminal gastrointestinal (GI)\n",
      "        tumors Patients with completely resectioned GI tumors who also receive adjuvant treatment\n",
      "        are eligible\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine less\n",
      "        than 2 times upper limit of normal Other: No known allergy to glutamine No history of\n",
      "        inflammatory bowel disease No other medical condition that may interfere with treatment\n",
      "        Not pregnant or nursing Adequate contraception is required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        leucovorin or other chemotherapy agents, except 5-FU with or without levamisole Endocrine\n",
      "        therapy: Not specified Radiotherapy: See Disease Characteristics No prior pelvic\n",
      "        radiotherapy No brachytherapy prior to completion of all external beam radiotherapy\n",
      "        Surgery: No abdominal-perineal resection, Hartmann procedure, or other surgical procedure\n",
      "        that has left patient without a functioning rectum\n",
      "2449\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed malignant pleural or peritoneal mesothelioma\n",
      "               -  Measurable or evaluable disease\n",
      "          -  CALGB groups 1-4\n",
      "          -  No CNS metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  21 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,500/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGOT no greater than 2 times upper limit of normal\n",
      "          -  Bilirubin no greater than 2 mg/dL\n",
      "          -  PT and PTT normal\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "        Cardiovascular:\n",
      "          -  No symptomatic New York Heart Association class II-IV cardiovascular disease\n",
      "          -  No congestive heart failure\n",
      "          -  No angina pectoris\n",
      "          -  No cardiac arrhythmias\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No cerebrovascular disease\n",
      "        Metabolic:\n",
      "          -  No serum calcium, phosphate, electrolyte, or other metabolic abnormalities, such as\n",
      "             metabolic acidosis\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No serious infection\n",
      "          -  No uncontrolled psychosis or neurologic disease (e.g., seizure disorders)\n",
      "          -  No uncontrolled diabetes mellitus\n",
      "          -  No other primary malignancy within the past 5 years except nonmelanoma skin cancer\n",
      "          -  No senility or emotional instability\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No more than one prior systemic chemotherapy regimen\n",
      "          -  No prior doxorubicin\n",
      "          -  At least 6 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy for progressive or recurrent disease allowed except myocardium\n",
      "             radiotherapy\n",
      "        Surgery:\n",
      "          -  Prior surgical resection allowed\n",
      "2450\n",
      "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated\n",
      "        clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than\n",
      "        10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life\n",
      "        expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal:\n",
      "        Not specified Other: No history of phenylketonuria Negative serum pregnancy test required\n",
      "        of fertile women Adequate contraception required of fertile women during and for 6 months\n",
      "        after the study\n",
      "        PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area\n",
      "2451\n",
      "DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) in second complete\n",
      "        remission (CR) for 30 days to less than 1 year before study entry Second CR defined by the\n",
      "        following: Neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Normal\n",
      "        bone marrow morphology with no excess blasts (greater than 5%) No myelodysplasia No\n",
      "        extramedullary or CNS leukemia Initial diagnosis of de novo AML (M0-M7) No prior\n",
      "        myelodysplasia No myeloproliferative disease No secondary AML Cytogenetics not required No\n",
      "        cytogenetic evidence of persistent leukemia if cytogenetics performed\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 69 Hematopoietic: See Disease Characteristics\n",
      "        Granulocyte count at least 1,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than\n",
      "        3 times normal Alkaline phosphatase less than 3 times normal No cirrhosis or chronic\n",
      "        hepatitis Biopsy required if chronic liver disease suspected (history of alcohol abuse or\n",
      "        possible hepatitis) Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow/stem cell transplantation\n",
      "        Chemotherapy: Prior non-ablative chemotherapy at initial diagnosis, during initial\n",
      "        remission, or as reinduction therapy (to produce current second remission) allowed At\n",
      "        least 4 weeks since hospital discharge after reinduction therapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: Not specified Surgery: Not specified Other: No prior\n",
      "        post-remission therapy for second remission\n",
      "2452\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Newly diagnosed chronic myelogenous leukemia in chronic phase\n",
      "          -  Philadelphia chromosome- or bcr/abl-positive\n",
      "               -  Cytogenetic negativity (analyzed separately) allowed if at least 1 of the\n",
      "                  following criteria is met:\n",
      "                    -  Malaise with decreased performance status\n",
      "                    -  Weight loss of more than 10% within the past 6 months\n",
      "                    -  Fever more than 38.5 C for 5 consecutive days\n",
      "                    -  Symptomatic splenomegaly\n",
      "                    -  Leukocyte count greater than 50,000/mm^3\n",
      "                    -  Platelet count greater than 1,000,000/mm^3\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  See Disease Characteristics\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other medical condition that would reduce life expectancy\n",
      "          -  No other uncontrolled malignancy\n",
      "          -  Not pregnant\n",
      "          -  No other contraindication to study therapy\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior interferon\n",
      "        Chemotherapy:\n",
      "          -  No prior cytotoxic therapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2456\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant melanoma that is metastatic\n",
      "        (any pT, any N, M1 by AJCC staging) Measurable disease by physical exam or noninvasive\n",
      "        radiologic procedure No concurrent or prior diagnosis of ocular melanoma No CNS metastases\n",
      "        No patients who can be rendered NED by surgery unless patient declines surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy:\n",
      "        At least 4 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL AST or ALT no\n",
      "        greater than 3 times normal No evidence of hepatic failure No active hepatitis Renal:\n",
      "        Creatinine clearance at least 40 mL/min Cardiovascular: No myocardial infarction within 6\n",
      "        months No decompensating congestive heart failure No unstable angina No current\n",
      "        symptomatic arrhythmia Other: No known HIV antibody No thyroid abnormality uncontrollable\n",
      "        by medication No medical, sociological, or psychological impediment to study compliance No\n",
      "        pre-existing psychiatric condition (especially depression) or history of severe\n",
      "        psychiatric disorder No autoimmune disease (e.g., systemic lupus erythematosus, multiple\n",
      "        sclerosis, ankylosing spondylitis) No concurrent malignancy except nonmelanomatous skin\n",
      "        cancer Not pregnant or nursing Negative pregnancy test Effective contraception required of\n",
      "        fertile women No history of egg allergies\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since interferon alfa or\n",
      "        melanoma vaccine No prior immunotherapy for metastatic disease No concurrent cytokines or\n",
      "        levamisole Chemotherapy: No prior chemotherapy for metastatic disease At least 4 months\n",
      "        since adjuvant therapy No concurrent chemotherapy Endocrine therapy: At least 1 week since\n",
      "        corticosteroids No concurrent immunosuppressives (e.g., azathioprine or cyclosporine)\n",
      "        Radiotherapy: Prior radiotherapy for metastatic disease allowed Surgery: See Disease\n",
      "        Characteristics Prior surgery for metastatic disease allowed\n",
      "2458\n",
      "DISEASE CHARACTERISTICS: Histologic or cytologic confirmation of metastatic breast cancer\n",
      "        with two exceptions: -New or enlarging pulmonary nodules demonstrable on two chest\n",
      "        radiographs taken at least one month apart OR -Multiple characteristic lytic bone\n",
      "        metastasis or liver metastases Measurable indicator lesion Measurable metastatic disease\n",
      "        must be bidimensionally measurable except in the case of hepatomegaly that may be\n",
      "        unidimensionally measurable Patients receiving bisphosphonates must have a measurable\n",
      "        disease other than bone No CNS metastases unless controlled with prior surgery and/or\n",
      "        radiotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: WBC at least 3500/mm3 or absolute neutrophil count at\n",
      "        least 2000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 0.3\n",
      "        mg/dL above upper limit of normal limit (ULN) AST no greater than 3 times ULN Renal:\n",
      "        Creatinine no greater than 0.3 mg/dL above ULN Cardiovascular: No New York Heart\n",
      "        Association class III or IV heart disease Other: Physician-estimated oral caloric intake\n",
      "        of at least 1200 calories per day No uncontrolled infection or chronic debilitating\n",
      "        disease Not pregnant or nursing Women of childbearing potential must use adequate\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Must have\n",
      "        previously received 1 but no more than 2 chemotherapy regimens At least 1 prior regimen\n",
      "        administered for metastatic disease At least 1 prior regimen containing an anthracycline\n",
      "        or paclitaxel At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 3 weeks since prior radiotherapy No prior strontium 89 radiotherapy\n",
      "        Prior radiotherapy must have been to less than 25% of bone marrow Surgery: At least 4\n",
      "        weeks since any major surgery\n",
      "2459\n",
      "DISEASE CHARACTERISTICS: Biopsy proven glioblastoma multiforme or anaplastic astrocytoma\n",
      "        Central pathologic review at Dartmouth-Hitchcock Medical Center, including assay for tumor\n",
      "        p53 expression No anaplastic oligodendroglioma No mixed oligodendroastrocytoma Recurrent\n",
      "        or progressive disease following radiotherapy documented by CT or MRI within 2 weeks of\n",
      "        entry\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: WBC at least 3,000 ANC at least 1,500 Platelets at least 100,000 Hepatic:\n",
      "        Bilirubin no greater than 1.0 mg/dL AST/ALT no greater than 2.5 times normal Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Other: No documented sensitivity to E. coli-derived\n",
      "        products No major medical or psychiatric illness that would interfere with therapy or\n",
      "        compliance with scheduled follow-up No pregnant or nursing women Adequate contraception\n",
      "        required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior taxanes or topoisomerase I inhibitors At least 4 weeks\n",
      "        since chemotherapy (6 weeks since nitrosoureas) At least 4 weeks since radiotherapy\n",
      "2461\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven stage II or III pancreatic\n",
      "        adenocarcinoma Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell\n",
      "        carcinoma Adenosquamous carcinoma Undifferentiated (anaplastic) carcinoma Mixed\n",
      "        ductal-endocrine carcinoma Well differentiated adenocarcinoma Moderately well or poorly\n",
      "        differentiated adenocarcinoma Undifferentiated ductal carcinoma Must have unresectable and\n",
      "        localized disease Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception Loss of\n",
      "        no greater than 15% of actual body weight Oral intake of greater than 1,200 calories per\n",
      "        day No other malignancy within the past 5 years except adequately treated basal or\n",
      "        squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer\n",
      "        that is currently in complete remission\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic\n",
      "        chemotherapy for pancreatic cancer Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiation therapy for pancreatic cancer Surgery: At least 2 weeks since prior surgical\n",
      "        bypass procedure and recovered\n",
      "2463\n",
      "DISEASE CHARACTERISTICS: Histologically proven breast carcinoma in one of the following\n",
      "        categories: 10 or more involved axillary nodes 5 or more involved axillary nodes and\n",
      "        either: Primary tumor estrogen receptor (ER)-negative (less than 10 femtomoles per\n",
      "        milligram of cytosol protein) T3 tumor (regardless of ER status) Total mastectomy or\n",
      "        breast-conserving procedure (lumpectomy or quadrantectomy) required within 6 weeks prior\n",
      "        to randomization Tumor confined to breast and axillary nodes (T1a-c, T2, or T3, N1-2, M0\n",
      "        by the UICC staging system) The following conditions exclude entry: Satellite skin nodules\n",
      "        distant from the primary tumor Supraclavicular node involvement Inoperable, matted\n",
      "        axillary nodes Fixation of primary tumor to chest wall (excluding pectoralis major)\n",
      "        Bilateral breast cancer (any mass in opposite breast unless biopsy-proven benign) Hot\n",
      "        spots on bone scintigram (unless confirmed to be benign) Skeletal pain of unknown cause\n",
      "        Hormone receptor status: ER status determination preferred, but not required\n",
      "        PATIENT CHARACTERISTICS: Age: 16-65 Sex: Women only Menopausal status: Any status\n",
      "        Performance status: ECOG 0-2 Hematopoietic: WBC at least 4,000 Platelets at least 100,000\n",
      "        Hepatic: Bilirubin no greater than 1.1 mg/dL (20 micromoles/L) AST no greater than twice\n",
      "        normal Renal: Creatinine no greater than 1.3 mg/dL (120 micromoles/L) Cardiovascular: Left\n",
      "        ventricular ejection fraction greater than 50% by MUGA Other: No second malignancy except:\n",
      "        Basal cell carcinoma Adequately treated carcinoma in situ of the cervix No significant\n",
      "        nonmalignant disease that would preclude participation No psychiatric or addictive\n",
      "        disorder that would compromise informed consent or participation No pregnant or nursing\n",
      "        women Adequate contraception strongly advised for fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for breast cancer other than surgery (see\n",
      "        Disease Characteristics)\n",
      "2465\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma (NHL) and\n",
      "             mantle cell lymphoma with clinical or pathological evidence of recurrent disease\n",
      "          -  Measurable or evaluable disease\n",
      "          -  CNS metastases not requiring intravenous steroid therapy allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: CALGB 0-2\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  Absolute neutrophil count at least 1500/mm3 (unless due to bone marrow involvement by\n",
      "             lymphoma)\n",
      "          -  Platelet count at least 100,000/mm3 (unless due to bone marrow involvement by\n",
      "             lymphoma)\n",
      "          -  At least 7 days since platelet transfusion\n",
      "          -  Hemoglobin at least 9.0 g/dL\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  Transaminases no greater than 2.5 times upper limit of normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min\n",
      "          -  No significant uncontrolled medical or psychiatric illness\n",
      "          -  No active serious infection\n",
      "          -  Not pregnant or lactating\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Central venous catheter required prior to study entry\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No more than 1 prior chemotherapy regimen\n",
      "          -  At least 4 weeks since prior chemotherapy and recovered from all toxic effects Prior\n",
      "             chemotherapy must contain anthracycline if intermediate or high-grade NHL other than\n",
      "             mantle cell\n",
      "          -  No concurrent treatment with other chemotherapeutic or investigational antineoplastic\n",
      "             drugs\n",
      "          -  At least 4 weeks since prior radiation therapy and recovered (Site of only measurable\n",
      "             disease must not be located within prior radiation therapy port)\n",
      "          -  No concurrent radiation therapy to any lesion\n",
      "2466\n",
      "DISEASE CHARACTERISTICS: Histologically proven myelodysplastic syndrome Less than 30%\n",
      "        blasts in bone marrow\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Zubrod 0-2 Karnofsky 60-100%\n",
      "        ECOG 0-2 Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL Renal:\n",
      "        Creatinine no greater than 2 mg/dL Cardiovascular: No New York Heart Association Class IV\n",
      "        disease No antihypertensive medication within 24 hours of amifostine administration Other:\n",
      "        Not pregnant or nursing Effective contraceptive method must be used during study No\n",
      "        medical illness No psychosis Eligible patients with an HLA compatible donor are referred\n",
      "        to bone marrow transplantation\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy within 4 weeks of study and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "2467\n",
      "DISEASE CHARACTERISTICS: One of the following hematologic malignancies that is ineligible\n",
      "        for higher priority protocols and confirmed at Memorial Hospital: Acute myelogenous\n",
      "        leukemia Accelerated or blastic phase (greater than 10% blasts in marrow) chronic\n",
      "        myelogenous leukemia Poor-risk myelodysplastic syndrome, defined as: Refractory anemia\n",
      "        with excess blasts (RAEB) with at least 10% marrow blasts and cytopenia requiring therapy\n",
      "        RAEB in transformation Chronic myelomonocytic leukemia No acute promyelocytic leukemia\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:\n",
      "        Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL Transaminases no greater than 3\n",
      "        times normal Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance greater\n",
      "        than 60 mL/min Cardiovascular: No cardiomyopathy No symptomatic congestive heart failure\n",
      "        Other: No concurrent active malignancy No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy except biologic agent alone or hydroxyurea\n",
      "2469\n",
      "DISEASE CHARACTERISTICS: Acute myelogenous leukemia, either de novo or secondary (evolving\n",
      "        from myelodysplastic syndrome, myeloproliferative syndrome, or previous treatment for\n",
      "        malignancies other than leukemia) OR Refractory anemia with excess blasts in\n",
      "        transformation Patient is at least 60 years old and at least one of the following is true:\n",
      "        Failed one induction attempt or First or greater relapse OR Patient is 18-59 years old\n",
      "        without an acceptable allogeneic donor and no autologous marrow for transplant and at\n",
      "        least one of the following is true: Failed 2 separate induction attempts, or Second or\n",
      "        greater relapse, or Resistant relapse, or Relapsed post transplant Prior treatment with\n",
      "        anthracyclines or mitoxantrone required Cumulative daunorubicin dose less than 400/m2\n",
      "        required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% (50% if\n",
      "        hospitalized) Hematopoietic: Not specified Hepatic: Total direct bilirubin no greater than\n",
      "        2.0 mg/dL SGOT and SGPT no greater than 3 x normal Alkaline phosphatase no greater than 3\n",
      "        x normal No active hepatitis Renal: Not specified Cardiovascular: No myocardial infarction\n",
      "        within last 6 months No congestive heart failure Ejection fraction greater than 50%\n",
      "        (measured by MUGA or 2-D Echo) Pulmonary: No severe chronic obstructive pulmonary disease\n",
      "        Other: No active infection or antimicrobiologically stabilized infection Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "2471\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed progressive or recurrent stage IV\n",
      "        non-small cell lung cancer (NSCLC) Patient with brain metastases on CT or MRI scan are\n",
      "        included Symptomatic cases must have had brain radiotherapy at least one month prior to\n",
      "        registration Patients without brain metastases: At least one target lesion Bidimensionally\n",
      "        measurable Not previously irradiated\n",
      "        PATIENT CHARACTERISTICS: Age: Under 70 Performance status: WHO 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute neutrophil count greater than 2,000/mm3 WBC greater than\n",
      "        3,500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.46\n",
      "        mg/dL Transaminases less than 2 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.70 mg/dL Creatinine clearance greater than 60 mL/min Other: No prior or concurrent\n",
      "        malignancies at other sites with the exception of adequately treated in situ carcinoma of\n",
      "        the cervix or basal and squamous carcinoma of the skin Not pregnant or nursing Negative\n",
      "        pregnancy test 24 hours prior to commencing temozolomide\n",
      "        PRIOR CONCURRENT THERAPY: No other investigational drugs allowed during this study\n",
      "        Biologic therapy: Prior biologic therapy allowed No concurrent biologic therapy allowed No\n",
      "        concurrent growth factor to induce neutrophil increase No concurrent erythropoietin\n",
      "        Chemotherapy: No prior chemotherapy for metastatic disease At least 3 months since any\n",
      "        neoadjuvant and adjuvant treatment, and induction chemotherapy preceding radical\n",
      "        radiotherapy Endocrine therapy: See Protocol Outline Concurrent steroids should be\n",
      "        maintained on the lowest dose possible Radiotherapy: Prior radiotherapy allowed Concurrent\n",
      "        local radiotherapy to nonbrain lesions allowed Concurrent palliative radiation therapy of\n",
      "        bone lesions permitted No concurrent radiation to target lesions No concurrent brain\n",
      "        radiotherapy Surgery: Prior surgery allowed\n",
      "2472\n",
      "DISEASE CHARACTERISTICS: Newly diagnosed chronic myelogenous leukemia in chronic phase\n",
      "        Philadelphia chromosome and/or BCR/ABL positive Initial diagnosis within 6 months of\n",
      "        randomization No clinical or laboratory evidence of acceleration or blastic disease No\n",
      "        contraindication to peripheral blood cell stem cell collection prior to treatment\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: No major organ impairment Not pregnant Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interferon alfa Chemotherapy: Prior\n",
      "        hydroxyurea allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:\n",
      "        Not specified\n",
      "2473\n",
      "DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease No more than 5 weeks\n",
      "        since diagnostic biopsy No B symptoms Clinical/pathologic stages (all histologies) as\n",
      "        follows: Stage IA/IIA with mediastinal mass less than one third of chest diameter Stage\n",
      "        IIIA limited to spleen or splenic, celiac, or portal nodes and lesions no larger than 6 cm\n",
      "        Surgical staging required if: Clinical and imaging findings equivocal Tanner stage IV/V\n",
      "        for whom radiotherapy is planned Concurrent registration on protocols POG-8828 (late\n",
      "        effects study) and POG- 8829 (epidemiology study) required\n",
      "        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified\n",
      "        Hematopoietic: No hematopoietic disease Hepatic: No liver disease Renal: No renal disease\n",
      "        Other: No severe organ or system damage or failure No pregnant or nursing women\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy\n",
      "2475\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid tumors that are refractory or\n",
      "        recurrent -No CNS primary or metastatic disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky at least 60%\n",
      "        Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST and\n",
      "        ALT no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 1.5\n",
      "        mg/dL Cardiovascular: At least 6 months since prior cardiac arrhythmias, myocardial\n",
      "        infarction, or congestive heart failure Other: Not pregnant or nursing Effective\n",
      "        contraceptive method must be used for 2 months after study completion Not HIV positive No\n",
      "        uncontrolled or serious infection No pre-existing grade 3 or greater neurotoxicity Must be\n",
      "        mentally capable of understanding the explanation of the study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or\n",
      "        mitomycin) Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy Surgery: Not specified Other: No presence of toxic effects from prior therapy\n",
      "2477\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed GD2 positive tumors which include:\n",
      "               -  High risk neuroblastoma (stage IV, or N-myc amplified, or localized\n",
      "                  neuroblastoma multiply recurrent)\n",
      "               -  Recurrent or metastatic osteosarcoma\n",
      "               -  Recurrent or metastatic GD2 positive sarcomas\n",
      "          -  If free of disease, patient must be fully recovered from toxic effects or\n",
      "             complications of prior treatments (chemotherapy or surgery)\n",
      "               -  No greater than 6 months since last chemotherapy or surgery before first\n",
      "                  injection of A1G4\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  At least 6 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 500/mm^3\n",
      "          -  Absolute leukocyte count greater than 500/mm^3\n",
      "          -  Peripheral T-cell phytohemagglutinin activation (PHA) at least 50% of normal\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No significant heart disease (NYHA class III or IV)\n",
      "        Other:\n",
      "          -  No other serious intercurrent illnesses\n",
      "          -  No active infections requiring antibiotics\n",
      "          -  No active bleeding\n",
      "          -  No primary immunodeficiency\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent antibiotics\n",
      "          -  No prior mouse antibodies and detectable human antimouse antibody (HAMA) titer\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 6 weeks since nitrosoureas\n",
      "          -  At least 4 weeks since other systemic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent nonsteroidal anti-inflammatory agents\n",
      "          -  No concurrent corticosteroid\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since radiotherapy\n",
      "          -  No prior radiation therapy to the spleen\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No splenectomy\n",
      "2479\n",
      "DISEASE CHARACTERISTICS: Diagnosis of xeroderma pigmentosum confirmed by unscheduled DNA\n",
      "        synthesis assay At least one histologically confirmed actinic keratosis All actinic\n",
      "        keratoses removed prior to treatment No associated syndromes, e.g., Cockayne's syndrome or\n",
      "        trichothiodystrophy\n",
      "        PATIENT CHARACTERISTICS: Age: 1.66 to 60 Other: Good general health and mental capacity No\n",
      "        illegal drug use No pregnant or nursing women Negative pregnancy test required of fertile\n",
      "        women Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2481\n",
      "DISEASE CHARACTERISTICS: Patient immunocompromised as the result of any of the following:\n",
      "        Allogeneic bone marrow/peripheral stem cell transplant Autologous bone marrow/peripheral\n",
      "        stem cell transplant Hematological malignancy (including lymphoma) Aplastic anemia and\n",
      "        myelodysplastic syndromes (currently on immunosuppressive treatment) Solid organ\n",
      "        transplantation (other than lung) Other solid organ malignancy (after cytotoxic\n",
      "        chemotherapy) HIV/AIDS High dose prolonged corticosteroid therapy (at least 20 mg/day of\n",
      "        prednisolone or equivalent for more than 3 weeks) or prolonged therapy with other\n",
      "        immunosuppressive agents (e.g., azathioprine, methotrexate) Diagnosis of either definite\n",
      "        or probable acute invasive aspergillosis Fungal infection represents a new episode of\n",
      "        acute invasive aspergillosis Patients with the following are ineligible: Aspergilloma or\n",
      "        allergic bronchopulmonary aspergillosis Chronic invasive aspergillosis Sarcoidosis CMV\n",
      "        pneumonia\n",
      "        PATIENT CHARACTERISTICS: Age: 12 and over Life expectancy: At least 72 hours\n",
      "        Hematopoietic: Not specified Hepatic: Bilirubin no greater than 5 times upper limit of\n",
      "        normal (ULN) SGOT/SGPT no greater than 5 times ULN Alkaline phosphatase no greater than 5\n",
      "        times ULN Renal: Creatinine no greater than 2.5 mg/dL Other: No history of\n",
      "        hypersensitivity or intolerance to azole antifungal agents including miconazole,\n",
      "        ketoconazole, fluconazole, or itraconazole No history of hypersensitivity or severe\n",
      "        intolerance to conventional or lipid formulations of amphotericin B Not pregnant or\n",
      "        nursing Fertile women must use effective contraception Negative pregnancy test No prior\n",
      "        participation on this trial Not on artificial ventilation and unlikely to be extubated\n",
      "        within 24 hours No condition that could affect patient safety, preclude evaluation of\n",
      "        response, or make study completion unlikely\n",
      "        PRIOR CONCURRENT THERAPY: At least 8 weeks since prior systemic treatment with\n",
      "        amphotericin B or itraconazole At least 2 weeks since prior systemic antifungal therapy\n",
      "        for more than 96 hours at doses greater than 0.5 mg/kg/day for conventional or lipid\n",
      "        formulations of amphotericin B or greater than 200 mg/day of itraconazole No concurrent\n",
      "        drugs that are metabolized primarily by hepatic cytochrome P-450 enzymes or which induce\n",
      "        or inhibit these enzymes, such as terfenadine, loratidine, astemizole, midazolam,\n",
      "        triazolam, cisapride, rifampin, rifabutin, barbiturates, carbamazepine, coumarins,\n",
      "        sulfonylureas, nivarapine, erythromycin, ritonavir, delaviridine, omeprazole, and\n",
      "        phenytoin At least 2 weeks since prior rifampin, rifabutin, carbamazepine, or barbiturates\n",
      "        for more than 3 days No concurrent investigational drugs other than cytotoxics,\n",
      "        antiretroviral agents, or therapies for AIDS-related opportunistic infection No concurrent\n",
      "        filgrastim (G-CSF) or sargramostim (GM-CSF) other than for treatment of granulocytopenia\n",
      "        No concurrent white blood cell transfusions No concurrent systemic antifungal agents\n",
      "        active against Aspergillus spp. (e.g., itraconazole, lipid formulations of amphotericin B,\n",
      "        or flucytosine)\n",
      "2482\n",
      "DISEASE CHARACTERISTICS: Acute leukemia past first remission or induction failure Chronic\n",
      "        myelogenous leukemia in accelerated phase or blast crisis\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Life expectancy not severely limited by concurrent illness Hematopoietic: Not specified\n",
      "        Hepatic: No evidence of chronic active hepatitis or cirrhosis Bilirubin no greater than 2\n",
      "        times upper limit of normal SGPT no greater than 4 times upper limit of normal Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Cardiovascular: Left ventricular ejection fraction at\n",
      "        least 50% No uncontrolled arrhythmias or symptomatic cardiac disease Pulmonary: FEV1, FVC,\n",
      "        and DLCO at least 50% No symptomatic pulmonary disease Other: Related donor who is\n",
      "        HLA-identical required No effusion or ascites greater than 1 L prior to drainage HIV\n",
      "        negative Not pregnant No active CNS disease\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2484\n",
      "Inclusion Criteria:\n",
      "        Women age 18 to 55 years who had regular menstrual cycles of 21- to 35-days duration and\n",
      "        pathologic stages I to II breast cancer, in whom all gross disease—including ductal\n",
      "        carcinoma in situ—was surgically removed either in a one-stage or two-stage procedure.\n",
      "        Surgical treatment consisted of an open biopsy followed by a mastectomy or\n",
      "        breast-conserving surgery with or without sentinel node biopsy and/or axillary nodal\n",
      "        dissection.\n",
      "        Fine needle aspirates and core or stereotactic needle biopsies were allowed before the\n",
      "        definitive procedure. Chemotherapy and/or radiotherapy were allowed in accordance with\n",
      "        internationally accepted criteria, as per investigator's discretion.\n",
      "        Eligibility required serum be drawn within 1 calendar day of the lumpectomy/mastectomy for\n",
      "        women who underwent a one-stage procedure and within 1 calendar day of each stage for\n",
      "        women who underwent a two-stage procedure.\n",
      "        \n",
      "2487\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histopathologically proven metastatic melanoma\n",
      "               -  No CNS metastases\n",
      "          -  HLA-A2 positive\n",
      "          -  Bidimensionally measurable disease by palpation on clinical exam or radiographic\n",
      "             imaging (x-ray, CT scan, or MRI)\n",
      "          -  Surgically accessible site for tumor cell procurement (skin, subcutaneous nodule, or\n",
      "             superficial node) and patient clinically eligible for such surgery\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age\n",
      "          -  18 to 75\n",
      "        Performance status\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy\n",
      "          -  More than 16 weeks\n",
      "        Hematopoietic\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Absolute neutrophil count greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Hematocrit greater than 30%\n",
      "        Hepatic\n",
      "          -  Bilirubin no greater than 1.6 mg/dL\n",
      "          -  SGOT no greater than 150 IU (or no greater than 3 times normal)\n",
      "          -  Prothrombin time no greater than 1.5 times control\n",
      "        Renal\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Calcium no greater than 12 mg/dL\n",
      "        Cardiovascular\n",
      "          -  No congestive heart failure\n",
      "          -  No clinically significant hypotension\n",
      "          -  No symptoms of coronary artery disease\n",
      "          -  No arrhythmia on EKG requiring drug therapy\n",
      "        Pulmonary\n",
      "          -  No severe chronic obstructive pulmonary disease\n",
      "          -  FEV_1 at least 1.0 L\n",
      "          -  DLCO at least 45% of predicted\n",
      "        Other\n",
      "          -  No active infection or oral temperature greater than 38.2 degrees C within 72 hours\n",
      "             of study\n",
      "          -  No systemic infection requiring chronic maintenance or suppressive therapy\n",
      "          -  HIV negative\n",
      "          -  No history of seizures\n",
      "          -  No retinitis or choroiditis\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use adequate contraception\n",
      "          -  Peripheral blood samples available weekly for 4 consecutive weeks\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  At least 4 weeks since other prior immunotherapy\n",
      "        Chemotherapy\n",
      "          -  1 or 2 courses of cytoreductive chemotherapy allowed for bulky disease\n",
      "          -  At least 4 weeks since prior standard or investigational chemotherapy\n",
      "        Endocrine therapy\n",
      "          -  At least 4 weeks since prior steroid therapy\n",
      "        Radiotherapy\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  At least 4 weeks since other prior investigational drug therapy and recovered\n",
      "2488\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven grade II or III soft tissue sarcoma of one of following\n",
      "             high-risk groups:\n",
      "               -  Grade II/III primary tumor with lesion size of at least 5 cm, deep, and\n",
      "                  extracompartmental (S1)\n",
      "               -  Local recurrence of primary tumor (S2)\n",
      "               -  Inadequate surgical excision of S1 or S2 (S3)\n",
      "          -  Disease recurrence after prior surgery allowed\n",
      "          -  The following histological types are eligible:\n",
      "               -  Malignant fibrous histiocytoma\n",
      "               -  Liposarcoma (round cell and pleomorphic)\n",
      "               -  Leiomyosarcoma\n",
      "               -  Fibrosarcoma\n",
      "               -  Rhabdomyosarcoma\n",
      "               -  Synovial sarcoma\n",
      "               -  Malignant paraganglioma\n",
      "               -  Neurofibrosarcoma (malignant schwannoma)\n",
      "               -  Extraskeletal Ewing's sarcoma\n",
      "               -  Extraskeletal osteosarcoma\n",
      "               -  Malignant peripheral neuroectodermal tumors\n",
      "               -  Mesenchymal chondrosarcoma\n",
      "               -  Angiosarcoma\n",
      "               -  Miscellaneous sarcoma\n",
      "               -  Unclassified sarcoma\n",
      "          -  No distant metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 70\n",
      "        Performance status:\n",
      "          -  WHO 0-2 OR\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  No bleeding disorder\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.25 times upper limit of normal\n",
      "          -  No severe hepatic dysfunction\n",
      "        Renal:\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "          -  No chronic renal failure\n",
      "        Cardiovascular:\n",
      "          -  No documented existing cardiac failure\n",
      "          -  No manifest heart failure (New York Heart Association class III or IV)\n",
      "          -  Left ventricular ejection fraction no more than 10% below institutional normal\n",
      "        Other:\n",
      "          -  No other prior or concurrent malignancy except adequately treated basal cell skin\n",
      "             cancer or carcinoma in situ of the cervix\n",
      "          -  No other severe disease\n",
      "          -  No severe cerebrovascular disease\n",
      "          -  No extremely obese patients\n",
      "          -  No prior metallic implants relevant to the regional hyperthermia field\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy (except to disease recurrence outside study irradiation field)\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior mutilative surgery\n",
      "2489\n",
      "DISEASE CHARACTERISTICS: Microscopically confirmed adenocarcinoma of the stomach or\n",
      "        gastroesophageal junction Reviewed by Department of Pathology of participating institution\n",
      "        Stage II-IV (T2, N1-2, M0 or T3-4, any N, M0) by physical exam, CT, and laparoscopy\n",
      "        Potentially curable by surgery Suspected sites of metastasis proven M0 prior to entry\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: WBC at least 4,000 Platelets at least 150,000 Hepatic: Bilirubin less than\n",
      "        2 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than\n",
      "        50 mL/min BUN no greater than 30 mg/dL Cardiovascular: No NYHA class III/IV status No\n",
      "        active angina No myocardial infarction within 6 months No significant ventricular\n",
      "        arrhythmia requiring medication No clinically significant conduction system abnormality\n",
      "        Other: No serious intercurrent infection No nonmalignant medical illness that is\n",
      "        uncontrolled or precludes study participation No psychiatric disorder that precludes\n",
      "        informed consent No clinically significant auditory impairment No second malignancy within\n",
      "        5 years except: Basal cell skin cancer Carcinoma in situ of the cervix No pregnant or\n",
      "        nursing women Negative pregnancy test required of fertile women Effective contraception\n",
      "        required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy\n",
      "2490\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed Kaposi's sarcoma requiring chemotherapy and/or currently\n",
      "             being treated with paclitaxel\n",
      "          -  Serologic diagnosis of HIV infection documented by a positive ELISA and confirmed\n",
      "             with a Western Blot or other federally approved HIV diagnostic test\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm ^3(with or without the use of\n",
      "             colony-stimulating factors)\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  AST no greater than 2.5 times ULN\n",
      "          -  Alkaline phosphatase no greater than 2.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Neurologic:\n",
      "          -  No greater than grade 2 peripheral neuropathy\n",
      "          -  No neuropsychiatric history or altered mental status that would preclude study\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No other prior or concurrent malignancy except curatively treated carcinoma in situ\n",
      "             of the cervix or basal cell or squamous cell skin cancer\n",
      "          -  No sensitivity to E. coli-derived proteins\n",
      "          -  No active untreated infection\n",
      "          -  No new infectious complications requiring a change in antibiotics within the past 2\n",
      "             weeks\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 1 week since prior radiotherapy\n",
      "          -  No prior radiotherapy to marker lesions\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 2 weeks since prior systemic treatment for Kaposi's sarcoma\n",
      "          -  At least 2 weeks since prior nonapproved FDA investigational agents except available\n",
      "             Investigational New Drugs that are antiretroviral agents\n",
      "          -  Concurrent maintenance therapy for opportunistic infections allowed\n",
      "          -  Concurrent commercially available antiretroviral therapy allowed\n",
      "2491\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant glioma, including: Anaplastic\n",
      "        astrocytoma Glioblastoma Evidence of recurrence by MRI and positron emission tomography\n",
      "        despite primary treatment that included radiotherapy with or without chemotherapy\n",
      "        Stereotactically accessible tumor Solitary tumor preferred Largest tumor surgically\n",
      "        accessible for debulking if multifocal disease Not adjacent to optic chiasm or brain stem\n",
      "        No subependymal spread No herniation or marked midline shift Consent for autopsy required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100%\n",
      "        Hematopoietic: Hematologic parameters normal Hepatic: Hepatic parameters normal (less than\n",
      "        twice normal if on anticonvulsants) Renal: Renal parameters normal Cardiovascular: No\n",
      "        congestive heart failure No angina Other: No medical contraindication to neurosurgery and\n",
      "        fluid injection into brain No serious uncontrolled infection Negative pregnancy test\n",
      "        required of fertile women prior to entry Adequate contraception required of fertile women\n",
      "        during and for 3 months after treatment\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics\n",
      "        At least 2 months since radiotherapy Surgery: Not specified\n",
      "2492\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically verified (at original diagnosis) solid tumor that is relapsed or\n",
      "             refractory The following histologies are eligible:\n",
      "          -  Sarcomas: Rhabdomyosarcoma Ewing's sarcoma, Peripheral neuroectodermal tumor (PNET),\n",
      "             Osteosarcoma, Other soft tissue sarcomas\n",
      "          -  Brain tumors: Ependymoma Primitive neuroectodermal tumor (PNET), High grade\n",
      "             astrocytoma, Brain stem glioma (histologic verification not required), Neuroblastoma\n",
      "          -  Measurable disease that can be followed clinically or radiologically required\n",
      "          -  The following not considered measurable: Bone lesions measured by bone scan or bone\n",
      "             marrow involvement\n",
      "          -  Central nervous system disease documented by cerebrospinal fluid cytology\n",
      "          -  Pleural effusion\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 21 and under at original diagnosis\n",
      "          -  Performance status: 0-3\n",
      "          -  Life expectancy: Greater than 2 months\n",
      "          -  In the absence of marrow involvement:\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3 (transfusion independent)\n",
      "          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)\n",
      "          -  With bone marrow involvement:\n",
      "          -  Absolute neutrophil count at least 750/mm3\n",
      "          -  Red cell and platelet support possible\n",
      "          -  Bilirubin normal\n",
      "          -  ALT/AST less than 1.5 times normal\n",
      "          -  Alkaline phosphatase less than 2.5 times normal\n",
      "          -  Creatinine no greater than 1.5 times normal OR creatinine clearance or radioisotope\n",
      "             glomerular filtration rate at least 60 mL/min\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Prior bone marrow transplantation allowed:\n",
      "          -  Must have stable engraftment without need for significant blood product support or\n",
      "             cytokine therapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "          -  No prior paclitaxel or docetaxel At least 2 weeks since chemotherapy (4 weeks since\n",
      "             nitrosoureas)\n",
      "          -  No other concurrent cancer chemotherapy\n",
      "          -  Concurrent corticosteroids allowed for intracranial pressure in brain tumor patients\n",
      "             provided patient has been stable for at least 4 weeks\n",
      "          -  Corticosteroids allowed as pretreatment for docetaxel\n",
      "          -  At least 2 months since extensive radiotherapy, defined as:\n",
      "          -  Craniospinal Volume greater than 50% of abdominopelvic cavity\n",
      "          -  Volume greater than one third of lung volume\n",
      "          -  No concurrent radiotherapy\n",
      "          -  No more than 2 prior therapies and fully recovered\n",
      "2493\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast that is\n",
      "        recurrent or metastatic No CNS metastases Bidimensionally measurable disease required\n",
      "        Patients with bone sites only are not eligible Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Women only Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Hematopoietic: Platelet count at least 100,000/mm3 Absolute\n",
      "        granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST less\n",
      "        than 2.5 times upper limit of normal Renal: Creatinine no greater than twice upper limit\n",
      "        of normal Other: No allergy to cyclosporine or to drugs formulated with Cremophor (e.g.,\n",
      "        some anesthetics and muscle relaxants) No active unresolved infection More than 7 days\n",
      "        since parenteral antibiotics No second malignancy within 5 years except: In situ cervical\n",
      "        cancer Nonmelanomatous skin cancer No pregnant or nursing women Adequate contraception\n",
      "        required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior\n",
      "        anthracyclines or medical contraindication to anthracycline therapy required No prior\n",
      "        paclitaxel or taxotere No more than 1 prior regimen for metastatic or recurrent disease\n",
      "        Adjuvant chemotherapy within 6 months of diagnosis of metastatic disease considered\n",
      "        therapy for advanced disease At least 3 weeks since chemotherapy Endocrine therapy: At\n",
      "        least 3 weeks since hormonal therapy for metastases Radiotherapy: Not specified Surgery:\n",
      "        Not specified Other: No concurrent treatment with any of the following agents proven to\n",
      "        affect blood levels of cyclosporine: Diltiazem Nicardipine Verapamil Fluconazole\n",
      "        Itraconazole Ketoconazole Clarithromycin Erythromycin Methylprednisolone Prednisolone\n",
      "        Allopurinol Bromocriptine Danazol Metoclopramide Nafcillin Rifampin Carbamazepine\n",
      "        Phenobarbital Phenytoin Octreotide Ticlopidine\n",
      "2494\n",
      "DISEASE CHARACTERISTICS: Diagnosis of colorectal cancer for which postoperative\n",
      "        radiotherapy to the pelvis is indicated\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: WBC at least 4,000/mm3 Absolute granulocyte count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        ALT no greater than 1.25 times upper limit of normal (ULN) (no greater than 5 times ULN if\n",
      "        elevation secondary to malignancy) Alkaline phosphatase no greater than 1.25 times ULN (no\n",
      "        greater than 5 times ULN if elevation secondary to malignancy) Renal: Creatinine normal OR\n",
      "        Creatinine clearance normal or greater than 60 mL/min Other: No medical or psychiatric\n",
      "        condition that would preclude study No prior malignancy except: Appropriately treated\n",
      "        localized epithelial skin or cervical cancer Remote history of other cured malignancy (at\n",
      "        the discretion of the sponsor) Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent antineoplastic biological\n",
      "        response modifiers Chemotherapy: No prior systemic chemotherapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: See Disease Characteristics No prior radiotherapy to the pelvis\n",
      "        Surgery: See Disease Characteristics Other: No other concurrent investigational drugs No\n",
      "        other concurrent antineoplastic therapy No concurrent halogenated antiviral agent (e.g.,\n",
      "        sorivudine)\n",
      "2496\n",
      "DISEASE CHARACTERISTICS: Biopsy proven non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)\n",
      "        Evaluable residual tumor after initial biopsy or excision required Registration required\n",
      "        within 42 days of definitive diagnosis Grade II/III, unresectable or metastatic disease\n",
      "        The following histologies exclude: Angiofibroma of the nasopharynx Mesothelioma Desmoid\n",
      "        tumor Peripheral neuroepithelioma Desmoplastic small cell tumor Rhabdomyosarcoma\n",
      "        Extraosseous Ewing's sarcoma Undifferentiated sarcoma Kaposi's sarcoma Grade 1 NRSTS,\n",
      "        including: Angiomatoid malignant fibrous histiocytoma Dermatofibrosarcoma protuberans\n",
      "        Myxoid and well-differentiated liposarcoma Well-differentiated and infantile\n",
      "        hemangiopericytoma Well-differentiated malignant peripheral nerve sheath tumor\n",
      "        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified\n",
      "        Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine normal for age No\n",
      "        hydronephrosis Cardiovascular: Shortening fraction greater than 28% Other: No HIV\n",
      "        infection Not pregnant or nursing Effective contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy No prior nephrectomy\n",
      "        (surgical correction of hydronephrosis allowed)\n",
      "2497\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary intracranial or extraneural\n",
      "        neoplasm with leptomeningeal metastases At least 30% of malignant cells in the\n",
      "        cerebrospinal fluid, primary tumor, or metastatic tumor must react with the B3 mouse\n",
      "        monoclonal antibody\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% Life\n",
      "        expectancy: Not specified Hematopoietic: ANC greater than 1000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.2\n",
      "        mg/dL Pulmonary: DLCO at least 60 Other: No neutralizing antibodies to Pseudomonas\n",
      "        exotoxin Not pregnant or nursing Not allergic to penicillin\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No chemotherapy\n",
      "        within past 4 weeks (6 weeks for nitrosoureas) unless there is evidence of disease\n",
      "        progression in CNS No concurrent chemotherapy Endocrine therapy: Patients receiving\n",
      "        corticosteroids must be on stable dose for 10 days prior to entry Radiotherapy: No\n",
      "        radiotherapy to disease site within past 3 months unless there is evidence of disease\n",
      "        progression in CNS No concurrent radiotherapy Surgery: Not specified\n",
      "2498\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Biopsy proven squamous cell carcinoma of the following head and neck sites:\n",
      "        Hypopharynx Oral cavity Larynx Oropharynx Nasal cavity Unknown primary Paranasal sinus\n",
      "        Histologically proven poorly-differentiated carcinoma of the following head and neck\n",
      "        sites:\n",
      "        Hypopharynx Oral cavity Larynx Oropharynx Nasal cavity Paranasal sinus Stage III/IV (T0-4\n",
      "        N1-3 M0-2) disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        WBC at least 3,000/mm3 Bilirubin no greater than 2.0 mg/dL AST no greater than 100 U/L\n",
      "        Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min (patients in\n",
      "        Group N2-N3) No second malignancy within 5 years except curatively treated nonmelanomatous\n",
      "        skin carcinoma No prior RT or chemotherapy, except prior radiotherapy to primary tumor\n",
      "        allowed Not pregnant or nursing. Negative pregnancy test required Effective contraception\n",
      "        required of fertile women Subjects with unknown primary cancers who had metastatic\n",
      "        cervical lymph nodes are eligible Signed informed consent previously approved by the\n",
      "        Institutional Review Board.\n",
      "2499\n",
      "DISEASE CHARACTERISTICS: Acute leukemia, myelodysplastic syndromes or chronic myelogenous\n",
      "        leukemia (CML) in accelerated phase or blast crisis and relapsed within 1 year after\n",
      "        allogeneic bone marrow transplantation Must not be candidates for second course of high\n",
      "        dose chemoradiotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 60 and under Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3 mg/dL Renal:\n",
      "        Creatinine less than 2 mg/dL Cardiovascular: Greater than 40% ejection fraction per MUGA\n",
      "        scan or ECHO Other: Not pregnant No serious intercurrent illness No active CNS disease\n",
      "        Must be ineligible for protocols of higher priority No active acute graft vs host disease\n",
      "        (GVHD) greater than grade 2 or extensive chronic GVHD No active uncontrolled infection\n",
      "        Original marrow donor must undergo filgrastim primed peripheral blood stem cell collection\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2501\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed Mullerian carcinoma\n",
      "        (ovarian epithelial or peritoneal carcinoma) (closed to accrual as of 8/23/01) OR\n",
      "        Gastrointestinal cancer with abdominal carcinomatosis OR Peritoneal mesothelioma (closed\n",
      "        to accrual as of 8/23/01) Must have received an adequate course of any platinum-based\n",
      "        chemotherapy regimen for ovarian cancer with evidence of intraabdominal disease Must have\n",
      "        received an adequate course of fluorouracil-based treatment for metastatic colon cancer\n",
      "        Intact primary gastrointestinal tumor allowed if not at risk of obstruction and/or\n",
      "        bleeding Abdominal lesions must be less than 10 cm Extraperitoneal lesions must be less\n",
      "        than 2 cm No hepatic disease No clinically significant pleural effusion (controlled by\n",
      "        pleurodesis allowed) No brain metastases No significant adhesions or symptoms of\n",
      "        obstruction\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL (transfusion allowed) Lymphocyte count at\n",
      "        least 800/mm3 Hepatic: See Disease Characteristics Bilirubin no greater than 1.5 mg/dL\n",
      "        SGOT or SGPT less than 2.5 times upper limit of normal Albumin at least 3.5 g/dL Hepatitis\n",
      "        B and C negative Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No\n",
      "        significant heart disease Other: Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception Loss of no more than 10% of body weight over a 4\n",
      "        month period No overt autoimmune disease No active ulcer disease No prior inflammatory\n",
      "        bowel disease (e.g., Crohn's disease or ulcerative colitis)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent immunotherapy\n",
      "        Chemotherapy: At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or\n",
      "        nitrosoureas) and recovered No concurrent chemotherapy Endocrine therapy: No chronic\n",
      "        steroid therapy Radiotherapy: At least 3 months since prior localized radiotherapy (e.g.,\n",
      "        pelvic or small field) and recovered No radiotherapy to whole abdomen No concurrent\n",
      "        radiotherapy Surgery: Recovered from prior surgery At least 3 weeks since prior major\n",
      "        abdominal surgery At least 2 weeks since prior laparoscopy\n",
      "2502\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer\n",
      "        Metastatic disease and/or axillary node or chest wall recurrence following mastectomy\n",
      "        diagnosed at least 3 months since prior adjuvant chemotherapy Radiologic scans required No\n",
      "        inflammatory carcinoma of the breast without metastases (i.e. T4d M0) No previously\n",
      "        untreated inflammatory carcinoma of the breast (T4d) No recurrent breast cancer diagnosed\n",
      "        less than 3 months since prior adjuvant chemotherapy No history or evidence of CNS (brain\n",
      "        or leptomeningeal) metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 60 Sex: Female Performance status: ECOG 0-2 Menopausal\n",
      "        status: Not specified Life expectancy: Not specified Hematopoietic: Hemoglobin at least\n",
      "        100 g/L Granulocyte count at least 1500/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        AST and/or ALT no greater than 3 times upper limit of normal OR AST and/or ALT no greater\n",
      "        than 5 times upper limit of normal, if liver metastases Bilirubin no greater than 1.5\n",
      "        times upper limit of normal Renal: Serum creatinine no greater than 2 times upper limit of\n",
      "        normal Cardiovascular: No history of congestive heart failure OR At least 1 year since\n",
      "        prior myocardial infarction LVEF at least 45% or normal (ECHO or MUGA are acceptable)\n",
      "        Other: No prior or concurrent malignancies allowed, except adequately treated squamous or\n",
      "        basal cell carcinoma of the skin or in situ carcinoma of the cervix, or cancer treated\n",
      "        more than 5 years ago and presumed cured Not HIV positive No clinical evidence of AIDS Not\n",
      "        pregnant or nursing Effective contraception required of fertile patients No major medical\n",
      "        illness precluding safe administration of planned treatment or required follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic response modifier\n",
      "        therapy Chemotherapy: No prior chemotherapy for metastatic or recurrent breast cancer\n",
      "        Induction chemotherapy required Endocrine therapy: Prior hormonal therapy allowed No\n",
      "        concurrent hormonal therapy Radiotherapy: Concurrent radiotherapy allowed for pain control\n",
      "        or to solitary bone or soft tissue sites Surgery: Prior oophorectomy allowed See Disease\n",
      "        Characteristics\n",
      "2503\n",
      "Inclusion Criteria:\n",
      "          -  Stage IV colorectal adenocarcinoma, excluding brain metastases\n",
      "          -  Histological confirmation of colorectal adenocarcinoma\n",
      "          -  Previously untreated patients\n",
      "          -  Previously treated patients\n",
      "               -  For the Phase I trial, no limitations\n",
      "               -  For the Phase II trial, previous treated limited to adjuvant radiation and/or\n",
      "                  chemotherapy which is completed at least 12 months before documentation of\n",
      "                  metastatic disease; patients may not have received chemotherapy for metastatic\n",
      "                  disease\n",
      "          -  For the Phase I trial, patients may have measurable disease or unmeasurable disease;\n",
      "             for the Phase II trial, patients must have measurable disease in at least two\n",
      "             dimensions on x-rays, CT scan or MRI\n",
      "          -  Expected survival of at least 16 weeks\n",
      "          -  Performance status of >= 70% (Karnofsky)\n",
      "          -  WBC >= 3000 uL\n",
      "          -  Platelet count >= 100,000/uL\n",
      "          -  Bilirubin =< 2 x ULN\n",
      "          -  Creatinine =< 2 x ULN\n",
      "          -  Not pregnant and not lactating; women of child bearing age must have negative\n",
      "             pregnancy test (beta-hcg)\n",
      "          -  No allergies to interferon-gamma or E.coli derived products\n",
      "          -  No serious medical intercurrent medical illnesses, including Class III or IV\n",
      "             cardiovascular disease; patient may not be dependent on immunosuppressive drugs\n",
      "             including corticosteroids, and may not receive these drugs for the entire duration of\n",
      "             the study\n",
      "          -  No diarrhea, and with adequate oral intake\n",
      "          -  Patients of child-bearing age and potential must agree to use adequate birth control\n",
      "             other than oral contraceptives for the entire duration of the study\n",
      "          -  No previous or concurrent malignancy except inactive nonmelanoma skin cancer, in situ\n",
      "             carcinoma of the cervix, grade 1 bladder cancer, or other cancers if the patient has\n",
      "             been disease free for >= 5 years\n",
      "          -  Patients must be oriented and rational, and aware of the investigational nature of\n",
      "             the study\n",
      "2504\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed solid malignancy or lymphoma for which no effective therapy\n",
      "             exists\n",
      "          -  Measurable or evaluable disease\n",
      "          -  No CNS metastasis unless stable for at least 4 weeks following surgery and/or\n",
      "             radiotherapy and no requirement for anticonvulsants\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: At least 3 months\n",
      "          -  ANC at least 1,500\n",
      "          -  Platelets at least 100,000\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  AST less than 2.5 times normal\n",
      "          -  Creatinine clearance at least 50 mL/min\n",
      "          -  No concurrent cholesterol-lowering agents\n",
      "          -  No active infection (including HIV)\n",
      "          -  No concomitant medical condition that precludes study compliance\n",
      "          -  No pregnant or nursing women\n",
      "          -  Adequate contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)\n",
      "          -  At least 4 weeks since wide-field radiotherapy\n",
      "          -  Fully recovered from prior surgery\n",
      "2505\n",
      "DISEASE CHARACTERISTICS: Cutaneous melanoma in one of the following categories: T4, N0, M0\n",
      "        Deep primary tumor with Breslow depth greater than 4.0 cm Tx, N1, M0 Primary tumor with\n",
      "        regional lymph node metastases found at lymphadenectomy but clinically undetectable Tx,\n",
      "        N2, M0 Clinically apparent regional lymph node metastases (synchronous or metachronous)\n",
      "        confirmed by lymphadenectomy Definitive surgical resection and lymphadenectomy with\n",
      "        pathologically confirmed adequate surgical margins required Minimum 2 cm margin for\n",
      "        primary lesions with Breslow depth greater than 2 mm Distal interphalangeal amputation\n",
      "        required for subungual melanomas No primary melanoma originating apart from the skin No\n",
      "        multiple in transit metastases in an extremity No lymph node involvement outside the\n",
      "        operative area resected by radical neck, axillary lymph node, or ilioinguinal dissection\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 75 Performance status: ECOG 0 or 1 Hematopoietic: WBC\n",
      "        at least 4,000 Platelets at least 125,000 Hemoglobin at least 9.8 g/dL (6.1 mmol/L)\n",
      "        Hepatic: Bilirubin no greater than 2 times normal AST no greater than 2 times normal\n",
      "        Renal: Creatinine no greater than 1.6 mg/dL (140 micromoles/L) Cardiovascular: No\n",
      "        ventricular or supraventricular arrhythmia requiring treatment No congestive heart failure\n",
      "        (NYHA class 3/4 status) Other: No uncontrolled infection No requirement for ongoing\n",
      "        steroids, NSAIDs, or other immunomodulators No organic brain syndrome or significant\n",
      "        impairment of basal cognitive function No psychiatric disorder that would preclude study\n",
      "        participation or would be exacerbated by study therapy (e.g., depression) No second\n",
      "        malignancy except: In situ cervical cancer Nonmelanomatous skin cancer No pregnant or\n",
      "        nursing women\n",
      "        PRIOR CONCURRENT THERAPY: No prior treatment on this protocol for patients with recurrent\n",
      "        melanoma at regional lymph nodes No preoperative infusion or perfusion therapy Biologic\n",
      "        therapy: No prior adjuvant immunotherapy Chemotherapy: No prior adjuvant systemic\n",
      "        chemotherapy No prior anthracyclines Endocrine therapy: Not specified Radiotherapy: No\n",
      "        prior adjuvant radiotherapy Surgery: See Disease Characteristics\n",
      "2506\n",
      "DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the breast with at least\n",
      "        4 involved axillary and/or intramammary lymph nodes No known T4, N3, or M1 disease Dermal\n",
      "        lymphatic involvement without clinical inflammatory changes (edema, peau d'orange,\n",
      "        erythema) allowed Must have undergone breast conserving surgery or modified radical\n",
      "        mastectomy plus axillary lymph node dissection Surgical margins negative for invasive or\n",
      "        noninvasive ductal carcinoma At least 10 nodes sampled No more than 12 weeks since\n",
      "        definitive surgery Synchronous bilateral breast carcinoma allowed if: Diagnosed within 4\n",
      "        weeks of initial histologic diagnosis One breast meets the eligibility criteria Other\n",
      "        breast has fewer than 10 involved nodes and is not N3 or T4 Both breasts treated by\n",
      "        modified radical mastectomy or breast conserving surgery with axillary node dissection\n",
      "        Concurrent registration on S9719 Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Sex: Female Menopausal status: Any status Performance\n",
      "        status: SWOG 0 or 1 Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at\n",
      "        least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5\n",
      "        times upper limit of normal (ULN) SGOT no greater than 1.5 times ULN Hepatitis C status\n",
      "        required Renal: Creatinine clearance at least 60 mL/min Cardiovascular: Left ventricular\n",
      "        ejection fraction at rest at least 45% by MUGA No EKG abnormalities unless cleared by a\n",
      "        cardiologist No uncontrolled or significant cardiac disease No congestive heart failure No\n",
      "        second or third degree heart block or other serious cardiac conduction abnormality No\n",
      "        atrial or ventricular arrhythmia No requirement for medication known to affect cardiac\n",
      "        conduction unless: Given for reasons other than heart failure or arrhythmia Cleared by a\n",
      "        cardiologist Pulmonary: FVC and FEV1 at least 60% predicted DLCO at least 60% predicted\n",
      "        Other: HIV negative Hepatitis B surface antigen status required No serious medical or\n",
      "        psychiatric illness that would preclude informed consent or study participation No second\n",
      "        malignancy within the past 5 years except adequately treated basal cell or squamous cell\n",
      "        skin cancer, carcinoma in situ of the cervix, or intraductal or lobular carcinoma of the\n",
      "        breast (diagnosed at any time) Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: No prior hormonal therapy for breast cancer Radiotherapy:\n",
      "        No prior radiotherapy to the breast Surgery: See Disease Characteristics\n",
      "2507\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven persistent or recurrent ovarian epithelial, fallopian tube, or\n",
      "             primary peritoneal cancer following at least 3 courses of initial standard platinum\n",
      "             based chemotherapy OR have radiologic evidence of recurrence with a CA125 greater\n",
      "             than 100\n",
      "          -  Initial stage IV disease having a complete response following platinum based therapy\n",
      "             allowed\n",
      "          -  No brain metastases\n",
      "          -  Not eligible for other high priority national or institutional study\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Greater than 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3000/mm3\n",
      "          -  Absolute neutrophil count greater than 1500/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times normal\n",
      "          -  SGOT or SGPT less than 1.5 times normal\n",
      "          -  PT/PTT within normal limits\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times normal\n",
      "          -  Creatinine less than 1.5 times normal\n",
      "          -  Creatinine clearance greater than 55 mL/min\n",
      "        Cardiovascular:\n",
      "          -  LVEF at least 45%\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  HIV negative\n",
      "          -  No prior malignancy other than curatively treated carcinoma in situ of the cervix,\n",
      "             nonmelanoma skin cancer, or breast cancer if the risk of recurrence is sufficiently\n",
      "             low\n",
      "          -  No serious illness that would prevent treatment\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent acetaminophen\n",
      "2510\n",
      "DISEASE CHARACTERISTICS: Histologically proven melanoma that is considered surgically\n",
      "        incurable Dermal, subcutaneous, or lymph node metastases required At least 3 lesions\n",
      "        evaluable and accessible for injection and biopsy One lesion at least 10 mm in diameter No\n",
      "        leukemia or lymphoma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 6 months Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 times\n",
      "        upper limit of normal (ULN) SGOT no greater than 3 times ULN Alkaline phosphatase no\n",
      "        greater than 3 times ULN Renal: Creatinine no greater than 3 times ULN Immunologic:\n",
      "        Clinical evidence of immune response required within 4 days of smallpox vaccination At\n",
      "        least 1 positive cutaneous delayed-type hypersensitivity response to 1 of the following:\n",
      "        Microbial recall antigens Dinitrofluorobenzene after sensitization Purified protein\n",
      "        derivative of tuberculin following BCG vaccination No altered immunocompetence (e.g.,\n",
      "        immune deficiency disease or immunosuppressive therapy) in patient or household contacts\n",
      "        No allergy to any of the following: Polymyxin B sulfate Streptomycin sulfate\n",
      "        Chlortetracycline hydrochloride Neomycin sulfate No history of eczema or other exfoliative\n",
      "        skin conditions in patient or household contacts HIV negative Other: No other malignancy\n",
      "        within the past 3 years except superficial squamous cell or basal cell skin cancer or\n",
      "        carcinoma in situ of the cervix or prostate Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 8 weeks\n",
      "        since prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent or\n",
      "        imminent steroid therapy Radiotherapy: At least 8 weeks since prior radiotherapy No\n",
      "        concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior\n",
      "        surgery\n",
      "2512\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Primary amyloidosis diagnosed by appropriate amyloid stains or electromicroscopy of\n",
      "             abdominal fat, bone marrow, or other target tissues\n",
      "               -  Pathology reviewed by Temple University\n",
      "          -  Amyloidosis secondary to any stage of multiple myeloma allowed provided plasma cell\n",
      "             concentration in bone marrow is less than 15%\n",
      "          -  No amyloidosis secondary to rheumatoid arthritis or chronic infection\n",
      "          -  No familial amyloidosis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 to 65\n",
      "        Performance status:\n",
      "          -  Karnofsky 80-100%\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Liver function tests less than twice normal\n",
      "          -  No active liver disease\n",
      "        Renal:\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "          -  Nephrotic syndrome allowed\n",
      "        Cardiovascular:\n",
      "          -  Cardiac evaluation required in patients with left ventricular ejection fraction less\n",
      "             than 45% by echocardiogram or MUGA\n",
      "          -  No poorly controlled hypertension\n",
      "        Pulmonary:\n",
      "          -  FEV_1 and DLCO greater than 50% of predicted, or pulmonary evaluation required\n",
      "          -  No chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  No history of serious coagulopathy, hemorrhage, or bleeding\n",
      "          -  No active infection\n",
      "          -  No other serious comorbid disease (e.g., poorly controlled diabetes)\n",
      "          -  No pregnant women\n",
      "          -  Adequate contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  More than 12 monthly cycles of prior alkylating agent chemotherapy discouraged\n",
      "        Endocrine therapy:\n",
      "          -  Corticosteroids discontinued at least 6 weeks prior to transplantation\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2513\n",
      "DISEASE CHARACTERISTICS: Female patients with Stage II, III or IV breast carcinoma in\n",
      "        remission, and not eligible for protocols of higher priority (DM89-102) Stage II breast\n",
      "        cancer must have spread to at least 10 axillary nodes; patients with fewer than 10 nodes\n",
      "        must have extranodal extensions Patients with greater than 75% positive nodes for tumor\n",
      "        are eligible No bone marrow involvement with tumor by standard histopathological exam of\n",
      "        bilateral iliac marrow biopsies 2 weeks prior to study Prior normalization of markers\n",
      "        needed in patients with elevated tumor markers (e.g., CEA) Metastatic disease patients\n",
      "        must have documentation verifying at least 50% reduction of all sites of disease, except\n",
      "        bone Stable bone metastases measured via bone scan are eligible Responsive disease but\n",
      "        with large tumor burden should enter high risk BMT protocols (93-090)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: Zubrod 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater than\n",
      "        100,000/mm3 No hematopoietic growth factor treatments Hepatic: Bilirubin, SGOT, and SGPT\n",
      "        less than 2 times normal Renal: Estimated creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: Normal ejection fraction Pulmonary: DLCO greater than 50% of predicted\n",
      "        Other: Not HIV positive Not pregnant 2 weeks prior to study No comorbid condition placing\n",
      "        patient at high risk for complications No prior active infections No history of untreated\n",
      "        central nervous system (CNS) disease No allergic response to eggs or murine protein\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent involvement in any other clinical trial that\n",
      "        effects engraftment Biologic therapy: No growth factors within 1 week Chemotherapy: No\n",
      "        more than 2 chemotherapy regimens allowed after relapse for metastatic disease\n",
      "        Chemotherapy responsive disease prior to study Stage II/III disease receiving neoadjuvant\n",
      "        chemotherapy allowed with at least 4 positive nodes at mastectomy No partial response to\n",
      "        chemotherapy less than 50% of any site except bone No prior chemotherapy treatment with\n",
      "        carmustine Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:\n",
      "        Mastectomy allowed\n",
      "2514\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant solid tumor for which there\n",
      "        are no therapeutic options that are potentially curative or have been demonstrated to\n",
      "        increase survival No primary or metastatic CNS malignancy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin normal SGOT no\n",
      "        greater than 2.5 times upper limit of normal Renal: Creatinine normal OR Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: No atrial or ventricular arrhythmia requiring\n",
      "        medication No ischemic event within the past 6 months Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No active\n",
      "        infection No other active malignancy except curatively treated carcinoma in situ of the\n",
      "        cervix or basal cell skin cancer No other serious concurrent medical illness No history of\n",
      "        seizure disorder requiring active therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered Endocrine\n",
      "        therapy: Not specified Radiotherapy: No prior radiotherapy to more than 10% of bone marrow\n",
      "        No prior electron-beam radiotherapy At least 4 weeks since other prior radiotherapy\n",
      "        Surgery: Prior surgery allowed Other: Recovered from prior therapy\n",
      "2516\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven adenocarcinoma of the breast that is\n",
      "             metastatic and progressive or locally recurrent and inoperable\n",
      "          -  At least one bidimensionally measurable or evaluable lesion\n",
      "               -  Lytic bone lesions on x-ray/CT scan, surrounded by calcified bone, and at least\n",
      "                  1 cm\n",
      "               -  Bidimensionally measurable extraosseous disease required for patients on\n",
      "                  bisphosphonates\n",
      "               -  The following are not considered evaluable:\n",
      "                    -  Previously irradiated lesions\n",
      "                    -  Lymphangitic spread\n",
      "                    -  Ascites\n",
      "                    -  Blastic bone lesions\n",
      "                    -  Pleural effusions\n",
      "          -  No rapidly progressive disease for which hormonal therapy is not indicated\n",
      "          -  No massive visceral disease (i.e., more than one third of any organ)\n",
      "          -  No brain metastases\n",
      "          -  Hormone receptor status:\n",
      "               -  Estrogen receptor positive or progesterone receptor positive, defined by 1 of\n",
      "                  the following:\n",
      "                    -  At least 10 femtomoles H3-estrogen or at least 20 femtomoles\n",
      "                    -  H3 progesterone binding per mg of cytosol protein by DCC or sucrose density\n",
      "                       method\n",
      "                    -  At least 0.10 femtomoles H3-estrogen or at least 0.20 femtomoles\n",
      "                    -  H3-progesterone binding per mg of DNA by IF/EIA technique\n",
      "                    -  Positive immunohistochemistry noted on pathology report\n",
      "               -  Unknown receptor status eligible provided:\n",
      "                    -  Disease-free interval of at least 2 years since adjuvant therapy or initial\n",
      "                       surgery (if no adjuvant therapy), including most recently treated tumor in\n",
      "                       bilateral breast cancer if status unknown in one primary tumor\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Postmenopausal by 1 of the following:\n",
      "               -  Natural menopause and more than 1 year since last menstrual period (LMP)\n",
      "               -  Radiation-induced oophorectomy and more than 1 year since LMP\n",
      "               -  Chemotherapy induced menopause if:\n",
      "                    -  At least 1 year since LMP (+ 1 year post-tamoxifen)\n",
      "                    -  Serum FSH and LH and plasma estradiol levels in postmenopausal range\n",
      "                    -  LHRH-induced amenorrhea\n",
      "               -  Surgical castration\n",
      "                    -  Patients under age 56 with prior hysterectomy and 1 or both ovaries intact\n",
      "                       or tamoxifen-induced amenorrhea with at least 12 months since prior\n",
      "                       tamoxifen must have postmenopausal serum FSH and LH and plasma estradiol\n",
      "                       concentrations\n",
      "        Performance status:\n",
      "          -  ECOG (WHO) 0-2\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT/SGPT less than 2.5 times ULN (less than 5 times ULN with liver metastases)\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No deep venous thrombosis\n",
      "        Other:\n",
      "          -  No mental incapacitation\n",
      "          -  No severe concurrent disease\n",
      "          -  No prior or concurrent malignancy except curatively treated carcinoma in situ of the\n",
      "             cervix or basal cell or squamous cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since chemotherapy for metastatic disease and recovered\n",
      "          -  No more than 1 prior chemotherapy regimen for metastatic disease\n",
      "          -  Prior adjuvant chemotherapy allowed if disease free for at least 6 months\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior hormonal therapy for advanced disease (e.g., tamoxifen or LHRH agonists)\n",
      "          -  Prior adjuvant tamoxifen allowed if disease free for at least 6 months\n",
      "          -  No other concurrent hormonal therapy, including steroids\n",
      "        Radiotherapy:\n",
      "          -  Recovered from toxic effects of prior radiotherapy\n",
      "          -  Concurrent palliative radiotherapy, including whole brain irradiation, allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior ovariectomy for advanced disease\n",
      "        Other:\n",
      "          -  No other concurrent investigational drugs\n",
      "          -  Concurrent bisphosphonates allowed if short term (7 days) for hypercalcemia due to\n",
      "             suspect tumor flare or if on prior bisphosphonates with bidimensionally measurable\n",
      "             extraosseous lesion\n",
      "2517\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed indolent non-Hodgkin's lymphoma (NHL) of\n",
      "        1 of the following types: Diffuse small lymphocytic cell Follicular small cleaved cell\n",
      "        Follicular mixed small and large cleaved cell Mantle cell lymphoma/leukemia (intermediate\n",
      "        differentiated lymphoma) Preferentially treated on protocol NCCTG-958053 when available\n",
      "        Monocytoid B-cell Mucosa-associated lymphoid tissue (MALT) Lymphoplasmacytic lymphoma\n",
      "        (Waldenstrom's macroglobulinemia) Histology documented by lymph node (or other mass) or\n",
      "        bone marrow biopsy within 6 months prior to entry Relapsed after cytotoxic chemotherapy\n",
      "        regimens At least 1 measurable lesion by palpation, chest x-ray, CT, or MRI, e.g.: Lymph\n",
      "        node at least 1.5 x 1.5 cm by palpation Spleen at least 3 cm below left costal margin The\n",
      "        following exclude: CNS involvement by positive CSF cytology or CT/MRI B- or T-cell chronic\n",
      "        lymphocytic leukemia Hairy cell leukemia Mycosis fungoides Aggressive lymphoma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:\n",
      "        Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Total bilirubin no greater than 2 times normal OR Direct bilirubin no greater than 1.0\n",
      "        mg/dL above normal Renal: Creatinine no greater than 2.0 times normal Cardiovascular: No\n",
      "        uncontrolled congestive heart failure No uncontrolled hypertension No uncontrolled angina\n",
      "        pectoris Other: No uncontrolled or active infection No AIDS or HIV antibody No second\n",
      "        malignancy within 5 years except: Carcinoma in situ of the cervix Resected nonmelanomatous\n",
      "        skin cancer Prostate cancer in remission following radical retropubic prostatectomy or\n",
      "        radiotherapy Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior therapy Biologic therapy:\n",
      "        See Disease Characteristics No concurrent interferon Chemotherapy: See Disease\n",
      "        Characteristics No prior purine nucleoside analogues (e.g., fludarabine, pentostatin, or\n",
      "        2- chlorodeoxyadenosine) At least 3 weeks since prior chemotherapy (6 weeks since\n",
      "        nitrosoureas) No other concurrent cytotoxic chemotherapy Endocrine therapy: No prior\n",
      "        octreotide for lymphoma No concurrent corticosteriods except for Addison's disease\n",
      "        Radiotherapy: Not specified Surgery: Not specified Other: No other concurrent\n",
      "        investigational drugs\n",
      "2518\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary amyloidosis Must have presence\n",
      "        of paraprotein in serum or urine determined by immunoelectrophoresis/immunofixation No\n",
      "        primary amyloidosis manifested only by carpal tunnel syndrome or purpura No history of\n",
      "        secondary, familial, or localized amyloidosis No evidence of overt multiple myeloma: Lytic\n",
      "        bone disease or pathological fractures OR At least 30% plasma cells in bone marrow\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute granulocyte count at least 1000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Alkaline phosphatase no\n",
      "        greater than 1000 u/L or less than 4 times upper limit of normal Renal: Creatinine no\n",
      "        greater than 2.0 mg/dL Cardiovascular: Confirmed by echocardiogram: Ejection fraction at\n",
      "        least 50% Interventricular septal thickness no greater than 15 mm No New York Heart\n",
      "        Association classification II-IV Pulmonary: DLCO at least 50% FVC at least 60% FEV1 at\n",
      "        least 55% Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception No active infection No other malignancy within the past 5 years\n",
      "        except surgically treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or\n",
      "        indolent prostate cancer No known sensitivity to E. coli derivatives\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interferon allowed Chemotherapy: At\n",
      "        least 4 weeks since prior melphalan Lifetime cumulative dose of melphalan no greater than\n",
      "        150 mg No greater than 2 prior courses of chemotherapy Endocrine therapy: Prior\n",
      "        dexamethasone allowed Radiotherapy: Not specified Surgery: Not specified\n",
      "2519\n",
      "Inclusion Criteria:\n",
      "          -  Serologic diagnosis of HIV infection as documented by a positive ELISA and confirmed\n",
      "             with a western blot, other federally approved HIV diagnostic test, or HIV viral load\n",
      "             measurement\n",
      "          -  Biopsy-proven, measurable Kaposi's sarcoma with any of the following:\n",
      "               -  Progressive cutaneous disease\n",
      "               -  Symptomatic oropharyngeal or conjunctival lesions\n",
      "               -  Any visceral involvement\n",
      "               -  Tumor-related lymphedema\n",
      "               -  Tumor-related ulceration or pain\n",
      "               -  NOTE: All patients must have measurable disease; baseline measurements must be\n",
      "                  obtained < 4 weeks prior to registration\n",
      "          -  ECOG performance status 0-2\n",
      "          -  ANC >= 1000/mm³ (with or without the use of colony-stimulating factors)\n",
      "          -  Platelet count >= 50,000/mm³\n",
      "          -  Hemoglobin >= 8 gm/dL\n",
      "          -  Bilirubin < 1.5 x the upper limit of normal (unless elevation is due to Crixivan\n",
      "             administration with isolated elevation in conjugated bilirubin)\n",
      "          -  SGOT or SGPT =< 5 x the upper limit of normal\n",
      "          -  Creatinine =< 2.1 mg/dl\n",
      "          -  Women must not be pregnant or lactating due to potential toxicity of therapy\n",
      "          -  Women of childbearing potential and sexually active men must be advised to use an\n",
      "             accepted and effective method of contraception due to potential toxicity of therapy\n",
      "          -  No prior systemic cytotoxic chemotherapy for Kaposi's sarcoma\n",
      "          -  Prior radiation therapy must have been discontinued >= 7 days prior to randomization\n",
      "             and must NOT have been delivered to marker lesions; (NOTE: Radiation therapy will not\n",
      "             be permitted during study treatment)\n",
      "          -  No active, untreated infection (no new opportunistic infectious complications within\n",
      "             the previous week requiring a change in antibiotics); maintenance therapy for\n",
      "             opportunistic infections will be allowed\n",
      "          -  No prior or concomitant malignancy other than curatively treated carcinoma in situ of\n",
      "             the cervix or basal/squamous cell carcinoma of the skin\n",
      "          -  No neuropsychiatric history or altered mental status that might prevent informed\n",
      "             consent or affect the ability of the patient to comply with the study\n",
      "          -  Institutions must ask patients to participate in the quality of life portion of the\n",
      "             protocol; however, patients may decline participation in this component of the study\n",
      "             and still be eligible; the reason for refusal or inability to complete the QOL\n",
      "             assessments must be documented in the Assessment Compliance Form (#596)\n",
      "          -  Must not be known to be sensitive to E. coli derived proteins\n",
      "          -  No history of cardiac insufficiency (NY Heart Association status >= 2)\n",
      "          -  Patients must be on stable (no change in drugs or doses) antiretroviral therapy for\n",
      "             greater than 14 days prior to study; a combination regimen is required; ideally this\n",
      "             will be a protease inhibitor containing triple therapy regimen\n",
      "          -  Patients must give signed, written informed consent\n",
      "2520\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed localized adenocarcinoma of the pancreas\n",
      "             that is considered unresectable\n",
      "          -  Measurable or evaluable disease\n",
      "          -  No metastatic disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 2,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 3.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Other:\n",
      "          -  No serious concurrent systemic disorder\n",
      "          -  No active infection or uncontrolled infection\n",
      "          -  Not pregnant\n",
      "          -  Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 1 month since any prior investigational agent\n",
      "2522\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable, incompletely resected with\n",
      "        gross residual disease, or locally recurrent large bowel carcinoma confined to a site\n",
      "        within the abdomen or pelvis All disease must be encompassable within a single\n",
      "        radiotherapy port No evidence of uncontrolled metastatic disease outside of the planned\n",
      "        radiotherapy port\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Not specified\n",
      "        Cardiovascular: No history of significant myocardial disease No New York Heart Association\n",
      "        class III or IV disease No unstable angina No myocardial infarction in the past 4 months\n",
      "        Other: No significant infection or other coexistent medical condition that would preclude\n",
      "        protocol therapy Maintain an adequate oral nutrition intake (at least 1,200 calories\n",
      "        estimated per day) No greater than 6 bowel movements per day prior to treatment No\n",
      "        significant nausea or emesis on optimal antiemetic therapy Not pregnant or nursing\n",
      "        Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        irinotecan Endocrine therapy: Not specified Radiotherapy: No prior abdominal or pelvic\n",
      "        radiotherapy Surgery: At least 3 weeks since laparotomy or laparoscopic procedure with or\n",
      "        without resection\n",
      "2523\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed advanced transitional cell urothelial cancer\n",
      "               -  Clinical Stage IV: T any, N1-3, M0; T any, N any, M1; or cT4, Nx, M0 (bladder\n",
      "                  tumors)\n",
      "               -  Pathological Stage III or IV bladder cancer: T any, N1-3, M0; T3b, N0, M0; T4,\n",
      "                  N0, M0; and T4, Nx, M0\n",
      "               -  Pathological Stage III or IV urothelial cancer of the renal pelvis or ureter: T\n",
      "                  any, N1-3, M0; T3, N0, M0; T4, N0, M0; and surgery has been performed within 10\n",
      "                  weeks of initiation of therapy\n",
      "          -  Impaired renal function (See Renal function tests)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100% OR\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 150,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times normal\n",
      "          -  Alkaline phosphatase less than 2 times normal\n",
      "          -  SGOT less than 2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine greater than 1.5 mg/dL but no greater than 2.5 mg/dL OR\n",
      "          -  Creatinine clearance 30-59 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Normal cardiac function by history, physical examination, and chest radiograph OR\n",
      "          -  If prior cardiac disease, left ventricular ejection fraction must be at least 50% by\n",
      "             radionuclide ventriculogram or echocardiogram\n",
      "          -  No serious cardiac arrhythmias; including first, second, and third degree heart block\n",
      "          -  No New York Heart Association class III or IV heart disease\n",
      "        Other:\n",
      "          -  No uncontrolled infection\n",
      "          -  No other active cancer, except nonmelanomatous skin cancer and in situ carcinoma of\n",
      "             the cervix curatively treated\n",
      "          -  Not pregnant\n",
      "          -  Effective barrier contraception required for all fertile patients during and for 6\n",
      "             months after therapy (encouraged to continue for 2 years or longer)\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior systemic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the bladder\n",
      "          -  At least 4 weeks since any other prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2524\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic, locally recurrent, or\n",
      "        unresectable squamous cell carcinoma or adenocarcinoma of the esophagus The bulk of the\n",
      "        tumor must involve the esophagus or gastroesophageal (GE) junction (for tumors extending\n",
      "        between the GE junction into the proximal stomach) Gastric cancers with only minor GE\n",
      "        junction or distal esophagus involvement are not eligible Measurable or evaluable disease\n",
      "        No prior treatment for metastatic disease No brain metastases No osseous metastases as\n",
      "        only site of disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL AST or ALT no greater than\n",
      "        2 times upper limit of normal (ULN) Renal: Creatinine no greater than 2 times ULN Calcium\n",
      "        no greater than 12 mg/dL Cardiovascular: No New York Heart Association class III/IV heart\n",
      "        disease No myocardial infarction within 6 months of study No congestive heart failure No\n",
      "        unstable angina No clinically significant pericardial effusion or arrhythmia Neurologic:\n",
      "        No concurrent peripheral neuropathy greater than grade 1 Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No active\n",
      "        serious infection or medical illness No history of hypersensitivity to drugs containing\n",
      "        Cremophor (teniposide, cyclosporine, or vitamin K) No invasive malignancies within 5\n",
      "        years, except: Curatively treated basal or squamous cell carcinoma of the skin Curatively\n",
      "        treated carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy within 4 weeks of study\n",
      "        No concurrent immunotherapy Chemotherapy: No more than 1 prior chemotherapy regimen or\n",
      "        chemotherapy/radiation therapy given in a neoadjuvant or adjuvant setting No prior\n",
      "        chemotherapy within 4 weeks of study No concurrent chemotherapy Endocrine therapy: No\n",
      "        prior hormonal therapy within 4 weeks of study Concurrent megestrol (Megace) allowed No\n",
      "        other concurrent hormonal therapy Radiotherapy: No prior radiotherapy within 4 weeks of\n",
      "        study No prior radiation to greater than 30% of bone marrow No more than 1 prior\n",
      "        chemotherapy/radiation therapy regimen given in a neoadjuvant or adjuvant setting No\n",
      "        concurrent radiotherapy Surgery: No prior surgery within 2 weeks of study Other: No prior\n",
      "        parenteral antibiotics within 1 week of study\n",
      "2525\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory head and neck\n",
      "        cancer Measurable or evaluable disease At least one prior chemotherapy regimen for\n",
      "        recurrent or metastatic disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL AST or ALT no greater than\n",
      "        2 times upper limit of normal (ULN) Renal: Creatinine no greater than 2 times ULN Calcium\n",
      "        within normal limits Cardiovascular: No New York Heart Association class III-IV heart\n",
      "        disease No myocardial infarction within 6 months No congestive heart failure No unstable\n",
      "        angina No clinically significant pericardial effusions or arrhythmias Neurologic: No\n",
      "        peripheral neuropathy greater than grade 1 Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraceptive method Negative pregnancy test No active infection or\n",
      "        serious underlying medical condition No history of hypersensitivity to drugs containing\n",
      "        Cremophor (teniposide, cyclosporine, or vitamin K) No prior invasive malignancies within\n",
      "        the past 2 years, except: Curatively treated basal or squamous cell carcinoma of the skin\n",
      "        Carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior immunotherapy No\n",
      "        concurrent immunotherapy Chemotherapy: See Disease Characteristics At least 5 weeks since\n",
      "        prior nitrosoureas, melphalan, or mitomycin At least 3 weeks since other prior\n",
      "        chemotherapy Prior taxane therapy allowed only if administered on a 3 week or greater\n",
      "        schedule No concurrent chemotherapy Endocrine therapy: At least 3 weeks since prior\n",
      "        hormonal therapy Concurrent megestrol (Megace) allowed No other concurrent hormonal\n",
      "        therapy Radiotherapy: At least 3 weeks since prior radiotherapy No prior radiotherapy to\n",
      "        greater than 30% of bone marrow No concurrent radiotherapy Surgery: At least 3 weeks since\n",
      "        major surgery Other: At least 1 week since prior parenteral antibiotics\n",
      "2527\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically documented extensive stage small\n",
      "        cell carcinoma of the bronchus Measurable or evaluable disease No pleural effusions, bone\n",
      "        scan abnormalities, or bone marrow biopsies as only evidence of disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-1 Hematopoietic:\n",
      "        Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL SGOT less than 2 times normal Renal: Serum creatinine no\n",
      "        greater than 1.5 mg/dL Cardiovascular: No cardiac disease Pulmonary: No interstitial\n",
      "        pneumonia No fibroid lung Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception No psychiatric illness No malabsorption disorder No uncontrolled\n",
      "        infection No uncontrolled diabetes mellitus No prior or concurrent malignancy within the\n",
      "        past 5 years except carcinoma in situ of the cervix or basal cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for small cell lung cancer No other concurrent chemotherapy Endocrine\n",
      "        therapy: No chronic steroid therapy (except steroids for adrenal failure or hormones for\n",
      "        non-disease related conditions) Radiotherapy: No prior pelvic or mediastinal radiotherapy\n",
      "        Surgery: Not specified Other: No concurrent anticonvulsants\n",
      "2528\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic (stage IV) or locally advanced\n",
      "        (stage IIIB) adenocarcinoma of the breast. Bidimensionally measurable disease. No active\n",
      "        central nervous system (CNS) metastases. Brain metastases must be controlled for at least\n",
      "        3 months and have other sites of measurable disease. No carcinomatous meningitis. No\n",
      "        lymphangitic lung metastases as the only site of metastatic disease. Hormone receptor\n",
      "        status: Any estrogen or progesterone receptor status.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over. Sex: Female. Menopausal status: Not specified.\n",
      "        Performance status: Eastern Cooperative Oncology Group (ECOG) score range 0-2. Life\n",
      "        expectancy: At least 6 months. Hematopoietic: Absolute neutrophil count at least\n",
      "        2,000/mm3. Platelet count at least 100,000/mm3. Hepatic: serum glutamic oxaloacetic\n",
      "        transaminase (SGOT) and/or serum glutamic pyruvic transaminase (SGPT) no greater than 2.5\n",
      "        times upper limit of normal (ULN). Alkaline phosphatase no greater than 5 times ULN.\n",
      "        Bilirubin no greater than ULN. No SGOT and/or SGPT greater than 1.5 times ULN if\n",
      "        concomitant with alkaline phosphatase greater than 2.5 times ULN. Renal: Calcium no\n",
      "        greater than 1.2 times ULN. Creatinine no greater than 1.5 times ULN. Cardiovascular:left\n",
      "        ventricular ejection fraction (LVEF) at least institutional lower limit of normal on\n",
      "        multiple gated acquisition scan (MUGA) or echocardiogram. No myocardial infarction within\n",
      "        6 months. No angina pectoris requiring antianginal medication. No history of congestive\n",
      "        heart failure. No cardiac arrhythmias requiring medication. No vascular disease with\n",
      "        documented cardiac function compromise No uncontrolled hypertension (diastolic greater\n",
      "        than 100 mm Hg). Other: Not pregnant or nursing. Fertile patients must use effective\n",
      "        barrier contraception. No diabetics with fasting blood sugar greater than 200 mg/dL. No\n",
      "        peripheral neuropathy greater than grade 1. No psychosis or addictive disorders. No known\n",
      "        hypersensitivity to E. coli-derived drugs.\n",
      "        PRIOR CONCURRENT THERAPY: Chemotherapy: No prior chemotherapy for metastatic breast cancer\n",
      "        or non-breast cancer. At least 12 months since nontaxane containing adjuvant chemotherapy\n",
      "        for primary tumor (in patients with metastatic disease). Prior adjuvant chemotherapy with\n",
      "        anthracycline containing regimens allowed (provided total doxorubicin dose did not exceed\n",
      "        240 mg/m2). Endocrine therapy: At least 4 weeks since adjuvant hormone or hormone therapy\n",
      "        for metastatic disease (at least 2 weeks for rapidly progressive disease). No concurrent\n",
      "        hormonal birth control. Radiotherapy: At least 4 weeks since prior radiotherapy. Prior\n",
      "        breast radiotherapy following lumpectomy allowed. No radiotherapy to greater than 30% of\n",
      "        bone marrow. No prior left chest wall radiotherapy with anthracycline containing adjuvant\n",
      "        chemotherapy. Surgery: Not specified.\n",
      "2529\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following histologically proven diagnoses:\n",
      "               -  Primary invasive adenocarcinoma of the unilateral or bilateral breast\n",
      "                    -  Stage I, IIA, or IIB (T1-3, N0-1, M0)\n",
      "                    -  No recurrent invasive breast cancer\n",
      "               -  Ductal carcinoma in situ (DCIS)\n",
      "               -  Lobular carcinoma in situ (LCIS) with microinvasion\n",
      "               -  Paget's disease of the nipple\n",
      "          -  No sarcoma, lymphoma, or apocrine, adenocystic, or squamous cell cancer of the breast\n",
      "          -  Currently free of breast cancer (no evidence of disease)\n",
      "               -  No evidence of distant disease on chest x-ray or chest CT scan and mammogram of\n",
      "                  the opposite breast within the past year\n",
      "          -  Prior definitive local treatment of primary lesion (mastectomy or breast-sparing\n",
      "             procedure with radiotherapy) and either axillary node or sentinel node biopsy\n",
      "               -  Surgical margins clear of both infiltrating carcinoma (any type) and DCIS\n",
      "                    -  No gross or microscopically positive margins except:\n",
      "                         -  Invasive cancer or DCIS at the focal margin treated with definitive\n",
      "                            radiotherapy\n",
      "                         -  Gross or LCIS at the final margin\n",
      "               -  Biopsy requirement waived for DCIS or LCIS with minimal microinvasion\n",
      "          -  Patients with breast-sparing procedure must have received or be planning to receive\n",
      "             radiotherapy at start of tamoxifen treatment\n",
      "          -  No endometrial simple or cystic hyperplasia, proliferative changes, complex\n",
      "             (adenomatous) or atypical hyperplasia, or carcinoma\n",
      "          -  Patients must be planning one of the following:\n",
      "               -  Starting adjuvant tamoxifen for five years OR\n",
      "               -  Started tamoxifen within 28 days prior to study and planning to receive adjuvant\n",
      "                  tamoxifen for five years\n",
      "          -  Hormone receptor status:\n",
      "               -  Candidate for adjuvant tamoxifen therapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Adult\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Postmenopausal defined as:\n",
      "               -  At least 1 year since last menstrual period\n",
      "               -  At least 2 months since bilateral oophorectomy prior to breast cancer diagnosis\n",
      "               -  4-12 months since last menstrual period and FSH elevated to postmenopausal range\n",
      "               -  Postmenopausal estrogen therapy and 55 years of age or older\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Fertile patients must use effective contraception during and for at least 2 months\n",
      "             after study\n",
      "          -  No other malignancy within the past 5 years except adequately treated basal cell or\n",
      "             squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer\n",
      "             currently in complete remission\n",
      "          -  No concurrent nonmalignant-related illness that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Adjuvant chemotherapy allowed\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior hormonal treatment for breast cancer (except tamoxifen)\n",
      "          -  No concurrent postmenopausal estrogen therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior or concurrent hysterectomy\n",
      "        Other:\n",
      "          -  No prior or current participation in an adjuvant intergroup trial\n",
      "2530\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed nonhematologic malignancy Refractory\n",
      "        disease or disease for which no effective standard therapy exists HER2 overexpression in\n",
      "        tumor tissue Measurable or evaluable disease No CNS metastases Hormone receptor status:\n",
      "        Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: CALGB 0-1 Life expectancy: At least 3 months Hematopoietic: Absolute granulocyte\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater\n",
      "        than 1.5 times normal SGOT no greater than 5 times normal Alkaline phosphatase no greater\n",
      "        than 5 times normal Renal: BUN no greater than 1.5 times normal Creatinine no greater than\n",
      "        1.5 times normal Cardiovascular: No uncontrolled or severe cardiac disease LVEF at least\n",
      "        45% by MUGA or echocardiogram Other: HIV negative No immunologic disease (e.g., autoimmune\n",
      "        disease) Negative viral hepatitis antibodies No psychiatric conditions which would prevent\n",
      "        compliance with treatment Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No active uncontrolled bacterial, viral, or fungal infection Prior or\n",
      "        concurrent malignancy allowed\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interleukin-2 (IL-2) and/or herceptin\n",
      "        allowed No concurrent immunosuppressive drugs or other immunomodulators (other than IL-2)\n",
      "        Chemotherapy: At least 6 weeks since nitrosoureas, melphalan, or mitomycin More than 4\n",
      "        weeks since other chemotherapy Endocrine therapy: No concurrent corticosteroids\n",
      "        Radiotherapy: More than 4 weeks since prior radiotherapy Surgery: At least 4 weeks since\n",
      "        major surgery\n",
      "2533\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignancy with no alternate treatments\n",
      "        available Measurable or evaluable progressive disease Somatostatin receptors present on\n",
      "        tumor and uptake demonstrated on diagnostic scan with OctreoScan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil\n",
      "        count at least 1,500/mm3 Hepatic: Total bilirubin no greater than 2.0 mg/dL Renal:\n",
      "        Creatinine clearance at least 40 mL/min Other: No active infections Not HIV positive No\n",
      "        coexisting medical condition Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: Not\n",
      "        specified Radiotherapy: At least 4 weeks since prior wide field radiation therapy Surgery:\n",
      "        Recovery from prior surgery\n",
      "2534\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adrenocortical carcinoma in Stage III or\n",
      "        IV and incurable by surgery Bidimensionally measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Hematopoietic: WBC\n",
      "        at least 4,000/mm3 Absolute granulocyte count at least 2,000/mm3 Platelet count at least\n",
      "        150,000/mm3 Prothrombin time and partial thromboplastin time no greater than upper limit\n",
      "        of normal (ULN) Hepatic: SGOT and alkaline phosphatase no greater than 2 times ULN Renal:\n",
      "        Creatinine clearance at least 50 mL/min Serum creatinine no greater than ULN Other: No\n",
      "        second malignancy within 5 years except adequately treated basal cell or squamous cell\n",
      "        carcinoma of the skin,in situ carcinoma of the cervix, or other cancer for which patient\n",
      "        has been disease free for 5 years Not pregnant or nursing Effective contraception required\n",
      "        of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy At least 4\n",
      "        weeks since prior biologic therapy (one regimen only) Chemotherapy: No concurrent\n",
      "        chemotherapy At least 4 weeks since prior mitotane No other prior chemotherapy allowed\n",
      "        Endocrine therapy: At least 6 weeks since prior hormonal therapy No concurrent hormonal\n",
      "        therapy Radiotherapy: At least 4 weeks since prior radiation therapy (to less than 25% of\n",
      "        bone marrow) No concurrent radiation therapy Surgery: Prior surgery allowed in relapsed\n",
      "        patients with no other prior treatment\n",
      "2535\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven cancer No brain or other\n",
      "        CNS metastases (including prior treated metastases)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: No grade 3 or greater hepatic\n",
      "        dysfunction Renal: No hypercalcemia Cardiovascular: No uncontrolled hypotension Other: Not\n",
      "        pregnant or nursing Effective contraceptive method must be used by fertile patients No\n",
      "        psychosis No severe concurrent illness other than neoplasia No epileptic seizures during\n",
      "        the previous year, migraines, gastrointestinal obstructions, or other causes of vomiting\n",
      "        No prior or concurrent amifostine contraindications No prior known contraindications or\n",
      "        sensitivity to dexamethasone, granisetron, ondansetron, prochlorperazine, diphenhydramine,\n",
      "        cimetidine, or magnesium\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: No prior estrogen within 24 hours of amifostine therapy Radiotherapy:\n",
      "        Not specified Surgery: Not specified Other: No prior alcohol, disulphiram, tetracycline,\n",
      "        or erythromycin within 24 hours of amifostine therapy No prior antiemetics such as\n",
      "        benzodiazepines, antipsychotics, anticonvulsants, or antihistamines within 24 hours of\n",
      "        amifostine therapy\n",
      "2536\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven recurrent primary malignant glioma\n",
      "               -  Measurable recurrent or residual primary central nervous system neoplasm\n",
      "                  confirmed by MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance Status:\n",
      "          -  Karnofsky at least 60%\n",
      "        Hematopoietic:\n",
      "          -  Hematocrit greater than 29%\n",
      "          -  ANC greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 125,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGOT less than 1.5 times upper limit of normal (ULN)\n",
      "          -  Bilirubin less than 1.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  BUN less than 25 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Effective contraceptive method must be used for the duration of the study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy within 6 weeks of study\n",
      "          -  No prior topotecan or carmustine treatment failure\n",
      "          -  No more than 1 prior chemotherapy regimen\n",
      "        Endocrine therapy:\n",
      "          -  Patients taking corticosteroids must be on stable dose for at least 2 weeks prior to\n",
      "             study and the dose should not escalate over entry level\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy within 6 weeks of study\n",
      "        Surgery:\n",
      "          -  No prior surgical resection within 3 weeks of study\n",
      "        Other:\n",
      "          -  No concurrent medication that may interfere with study results\n",
      "2537\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed diagnosis of carcinoma\n",
      "          -  Stage II-III (T2, T3, N0 or T1-3, N1) carcinoma of head and neck, including: oral\n",
      "             cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus\n",
      "          -  No N2 or N3\n",
      "          -  Measurable disease is not required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Zubrod 0-3\n",
      "        Life expectancy:\n",
      "          -  Anticipated survival is 3-4 years (median)\n",
      "        Hematopoietic:\n",
      "          -  WBC count at least 3.5/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  Not specified\n",
      "        Pulmonary:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No infection or severe medical illness\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No prior surgery\n",
      "2538\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia,\n",
      "             or multiple myeloma\n",
      "               -  Low grade, intermediate grade, or high grade (diffuse large cell immunoblastic\n",
      "                  only) NHL OR\n",
      "          -  Histologically confirmed Hodgkin's disease with prior chemotherapy\n",
      "          -  Evaluable lesion\n",
      "          -  Must be scheduled for at least 1 myelosuppressive cytotoxic regimen (experimental\n",
      "             chemotherapy regimens allowed) for at least 4-6 months\n",
      "          -  No anemia predominantly due to factors other than cancer or chemotherapy (i.e.,iron\n",
      "             or folate deficiencies, hemolysis, or gastrointestinal bleeding) NOTE: A new\n",
      "             classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The\n",
      "             terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  At least 6 months\n",
      "        Hematopoietic:\n",
      "          -  Transferrin saturation at least 20%\n",
      "          -  Ferritin at least 50 ng/mL OR\n",
      "          -  Adequate iron stores in bone marrow\n",
      "          -  If transferrin saturation is less than 20% or ferritin is less than 50 ng/mL,\n",
      "             investigator may utilize bone marrow evaluation results to determine whether iron\n",
      "             stores are adequate\n",
      "          -  Hemoglobin at least 10.0 g/dL\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No active, unresolved infection\n",
      "          -  No hypersensitivity to mammalian cell derived products\n",
      "          -  Must be able to read and understand English at a 6th grade level consistent with\n",
      "             comprehending the quality of life questionnaires\n",
      "          -  No other malignancy within past 5 years, except basal cell skin cancer or carcinoma\n",
      "             in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent epoetin alfa independent of protocol\n",
      "          -  No concurrent interferons and interleukins (occasional short term use may be\n",
      "             permitted on a case by case basis)\n",
      "          -  No prior peripheral blood stem cell transplantation\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 2 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior total lymphoid, extensive abdominal, or inverted Y radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 30 days since prior nonchemotherapy experimental agents\n",
      "2539\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed colorectal cancer\n",
      "          -  Must be suitable for elective surgical resection by right hemicolectomy, left\n",
      "             hemicolectomy, sigmoid colectomy, anterior resection or abdomino-perineal resection\n",
      "          -  No adenocarcinoma of the transverse colon\n",
      "          -  No synchronous multiple adenocarcinomas\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Pulmonary:\n",
      "          -  No contraindication to pneumoperitoneum such as severe cardio-respiratory disease\n",
      "        Other:\n",
      "          -  No acute intestinal obstruction\n",
      "          -  No prior malignancy within the past 5 years, except basal cell carcinoma, carcinoma\n",
      "             in situ of the cervix, or prostate cancer\n",
      "          -  Not pregnant\n",
      "          -  No gastrointestinal disease that requires surgical intervention, e.g., Crohn's\n",
      "             disease, chronic ulcerative disease, familial polyposis\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "          -  Adjuvant chemotherapy allowed\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Preoperative radiotherapy must be administered before randomization into this trial\n",
      "          -  Adjuvant radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2540\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage II-IV low-grade, mantle cell, or\n",
      "        follicular B-cell lymphoma Stage I disease is eligible only if radiotherapy is not\n",
      "        considered feasible due to location of disease or previous radiation treatments No chronic\n",
      "        lymphocytic lymphoma No small lymphocytic lymphoma with lymphocyte count greater than\n",
      "        5,000/mm3 Must be either first-line therapy or no more than 4 relapses after standard\n",
      "        therapies, including chemotherapy, radiotherapy, autologous bone marrow transplantation,\n",
      "        and/or immunotherapy Eligible if refractory to first treatment with a standard therapy\n",
      "        Patients refractory to autologous bone marrow transplantation (ABMT) or relapsed after\n",
      "        ABMT are eligible Patients with low-grade or follicular lymphoma must have failed at least\n",
      "        one chemotherapy regimen Patients with mantle cell lymphoma are eligible even if no prior\n",
      "        treatment Bidimensionally measurable disease Demonstrable monoclonal CD20-positive B-cell\n",
      "        population in lymph nodes or bone marrow No prior diagnosis of intermediate or high-grade\n",
      "        non-Hodgkin's lymphoma No CNS, pericardial, pleural, or peritoneal involvement by lymphoma\n",
      "        No AIDS-related lymphoma No pleural effusion No ascites A new classification scheme for\n",
      "        adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n",
      "        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n",
      "        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 4 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 75,000/mm3 Hemoglobin at least 8.0 g/dL Hepatic: Bilirubin no greater than 2.0\n",
      "        mg/dL Alkaline phosphatase no greater than 2 times upper limit of normal (ULN) SGOT no\n",
      "        greater than 2 times ULN Renal: Creatinine clearance at least 65 mL/min Cardiovascular:\n",
      "        See Disease Characteristics No pericardial effusion No New York Heart Association class\n",
      "        III or IV heart disease No myocardial infarction within the past 6 months Other: No\n",
      "        active, uncontrolled bacterial, viral, or fungal infection No active opportunistic\n",
      "        infection No active inflammatory arthritis (excluding degenerative joint disease) No known\n",
      "        hypersensitivity to interleukin-2 No history of an autoimmune disorder No history of\n",
      "        seizure disorder No other primary malignancy in the past 5 years except squamous cell or\n",
      "        basal cell carcinoma of the skin or carcinoma in situ of the cervix Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior\n",
      "        radioimmunotherapy At least 6 months since prior autologous bone marrow transplantation\n",
      "        and recovered At least 4 weeks since prior colony-stimulating factors or epoetin alfa At\n",
      "        least 3 weeks since prior immunotherapy and recovered No concurrent hematopoietic growth\n",
      "        factors Chemotherapy: See Disease Characteristics At least 3 weeks since prior\n",
      "        chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered Endocrine therapy: At\n",
      "        least 3 weeks since prior corticosteroids No corticosteroids during or for 8 weeks after\n",
      "        study Radiotherapy: See Disease Characteristics See Biologic therapy At least 3 weeks\n",
      "        since prior radiotherapy and recovered Surgery: Not a recipient of an allogeneic organ\n",
      "        transplantation, unless organ is no longer functional At least 4 weeks since any prior\n",
      "        major surgery (except diagnostic surgery) and recovered\n",
      "2542\n",
      "DISEASE CHARACTERISTICS: Malignant or suspected lesions of the head and neck that are\n",
      "        scheduled for excisional biopsy Lesions no greater than 2 cm in diameter in the mouth,\n",
      "        oropharynx, hypopharynx or larynx Suspected severe dysplasia, carcinoma in situ and/or\n",
      "        invasive carcinoma of the head and neck\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC greater than 3500/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: SGOT and SGPT no greater than 2 times upper limit of normal\n",
      "        Alkaline phosphatase no greater than 2 times upper limit of normal Bilirubin no greater\n",
      "        than 2 mg/dL Renal: Creatinine no greater than 2.5 mg/dL Other: No known hypersensitivity\n",
      "        to porphyrins Not pregnant Fertile patients must use effective birth control\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2544\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable stage II, IIIA, or IIIB\n",
      "        non-small cell lung cancer No distant metastases No prior complete (or gross subtotal)\n",
      "        tumor resection No post-resection intrathoracic tumor recurrence Pleural effusion seen on\n",
      "        a chest x-ray allowed only if appearing after thoracotomy or other invasive thoracic\n",
      "        procedure (pleural effusion acceptable if seen only on CT scan, not on chest x-ray) Must\n",
      "        be ineligible or refused participation in protocol RTOG-9309\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 2,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 8.0 g/dL Hepatic: Bilirubin no\n",
      "        greater than 1.5 mg/dL* SGOT no greater than 1.5 times upper limit of normal* * Unless due\n",
      "        to documented benign disease Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular:\n",
      "        No myocardial infarction within the past 6 months No symptomatic heart disease, including\n",
      "        angina, congestive heart failure, or uncontrolled arrhythmias Other: No weight loss of\n",
      "        greater than 5% in 3 months prior to diagnosis No other prior or concurrent invasive\n",
      "        malignancy within the past 3 years except nonmelanomatous skin cancer Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic or neck\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "2545\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent or progressive epithelial\n",
      "        ovarian cancer defined as: A serial rise in CA 125 over a minimum of 3 samples to a level\n",
      "        greater than 50% of the upper limit of normal OR Measurable or evaluable disease Disease\n",
      "        progression following paclitaxel given by 3 or 24 hour infusion within the past 6 months\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky at least 60% Life\n",
      "        expectancy: Not specified Hematopoietic: AGC at least 1500/uL Platelet count at least\n",
      "        100,000/uL Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than\n",
      "        2.0 mg/dL Other: No active or uncontrolled infections No history of grade 3-4 peripheral\n",
      "        neuropathy of any etiology No previously developed severe hypersensitivity reactions to\n",
      "        paclitaxel Not pregnant or lactating Patients of childbearing potential must use effective\n",
      "        method of contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior platinum\n",
      "        based chemotherapy required Complete recovery from the myelosuppressive effects of prior\n",
      "        chemotherapy for a minimum of 3 weeks At least one prior regimen of paclitaxel by 3 or 24\n",
      "        hour infusion within 6 months prior to study, with no intervening chemotherapy Endocrine\n",
      "        therapy: No hormone therapy within 3 weeks of entry onto protocol Radiotherapy: No prior\n",
      "        radiation therapy to major bone marrow ares within 4 weeks of entry onto protocol Surgery:\n",
      "        Not specified\n",
      "2546\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent or progressive brain tumors\n",
      "        including the following: Anaplastic astrocytoma and glioblastoma multiforme Brain stem\n",
      "        glioma Medulloblastoma or primitive neuroectodermal tumors present in supratentorial or\n",
      "        posterior fossa locations Ependymoma Low grade gliomas Other Measurable or evaluable\n",
      "        disease by CT or MRI OR Histologically confirmed previously untreated glial tumors\n",
      "        including: Brain stem glioma Glioblastoma multiforme Measurable disease after surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 2 to 21 Performance status: Karnofsky 50-100% (over 10 years\n",
      "        of age) Lansky 50-100% (under 10 years of age) Life expectancy: At least 8 weeks\n",
      "        Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater\n",
      "        than 50,000/mm3 Hemoglobin greater than 7.0 g/dL Transfusion support allowed after bone\n",
      "        marrow transplantation or extensive radiation Hepatic: Bilirubin less than 1.5 mg/dL SGPT\n",
      "        less than 2 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine\n",
      "        clearance greater than 60 mL/min Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception during and for 6 months after study No significant systemic\n",
      "        illness including infections No amino acidurias or organic acidemias\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Recovered from all prior immunotherapy No\n",
      "        concurrent prophylactic hematopoietic growth factors Chemotherapy: At least 3 weeks since\n",
      "        prior myelosuppressive chemotherapy (6 weeks for nitrosourea) and recovered No other\n",
      "        concurrent cancer chemotherapy Endocrine therapy: Stable or decreasing dosage of\n",
      "        dexamethasone for intracranial pressure within 2 weeks of study entry No concurrent\n",
      "        dexamethasone used as an antiemetic Radiotherapy: At least 8 weeks since prior\n",
      "        radiotherapy to evaluable lesions and recovered Surgery: At least 4 months since prior\n",
      "        radiosurgery Other: No other concurrent investigational agents\n",
      "2547\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed refractory malignancies for which no effective therapy is\n",
      "             currently available\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "        Hepatic:\n",
      "          -  Total bilirubin no greater than 2.0 mg/dL\n",
      "          -  No chronic active hepatitis\n",
      "        Renal:\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular ejection fraction greater than 45%\n",
      "        Pulmonary:\n",
      "          -  DLCO greater than 60% of predicted\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No active infection\n",
      "          -  No concurrent medical condition that would preclude therapy\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or\n",
      "             mitomycin)\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No radiotherapy to greater than 30% of bone marrow\n",
      "          -  No wide field radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from any prior surgery\n",
      "2548\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed B-cell non-Hodgkin's lymphoma (low,\n",
      "        intermediate, or high grade categories) A new classification scheme for adult\n",
      "        non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n",
      "        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n",
      "        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: BUN no greater\n",
      "        than 1.5 times upper limit of normal (ULN) Creatinine no greater than 1.5 times ULN Other:\n",
      "        No known allergies to mouse proteins No second primary malignancy within past 5 years\n",
      "        other than adequately treated in situ carcinoma of the cervix or uterus, or basal or\n",
      "        squamous cell carcinoma of the skin Not pregnant or nursing Effective contraception\n",
      "        required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior exposure to mouse antibodies other\n",
      "        than technetium Tc 99m LL2 monoclonal antibody Chemotherapy: Not specified Endocrine\n",
      "        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: At least\n",
      "        1 month since any other prior investigational therapy No concurrent participation in\n",
      "        another protocol involving medical devices or investigational agents\n",
      "2549\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV squamous cell\n",
      "        (epidermoid) carcinoma of head and neck limited to the oral cavity, oropharynx,\n",
      "        hypopharynx, or larynx No distant metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 6 months Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet\n",
      "        count at least 75,000/mm3 No known bleeding disorder Hepatic: Bilirubin no greater than 2\n",
      "        times normal No end stage liver disease PT and PTT no greater than 1.5 times normal Renal:\n",
      "        Creatinine less than 2 times normal No end stage renal disease Cardiovascular: No unstable\n",
      "        angina Pulmonary: No severe oxygen dependent chronic obstructive pulmonary disease Other:\n",
      "        No other malignancy known to be active within the past 5 years except basal or squamous\n",
      "        cell skin cancer outside the planned radiation portals or carcinoma in situ of the cervix\n",
      "        No other life threatening illness Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for head and neck cancer Endocrine therapy: Not specified Radiotherapy: No\n",
      "        prior radiotherapy for head and neck cancer Surgery: No prior surgery (other than biopsy)\n",
      "        for head and neck cancer\n",
      "2550\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed colon, lung, prostate, or invasive breast cancer\n",
      "               -  No ductal or lobular carcinoma in situ of the breast only\n",
      "          -  Patient and natural full sibling must have (or have had) cancer of the same type\n",
      "          -  Participants in E-3Y92 not eligible\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2551\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed malignancy that is metastatic or unresectable and for which\n",
      "             standard curative or palliative measures do not exist or are no longer effective\n",
      "          -  Advanced measurable or evaluable disease that is clearly progressive\n",
      "          -  No brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0-1 Karnofsky 80-100%\n",
      "          -  Life expectancy: At least 3 months\n",
      "          -  WBC greater than 4,000/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT/SGPT less than 2 times normal\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  No congestive heart failure\n",
      "          -  No coronary artery disease\n",
      "          -  No serious cardiac arrhythmias\n",
      "          -  No evidence of prior myocardial infarction on EKG\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Not HIV positive\n",
      "          -  No seizure disorders\n",
      "          -  No active infection that requires antibiotic therapy\n",
      "          -  No significant medical disease other than the malignancy\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No more than 2 prior biological response modifier treatment regimen\n",
      "          -  No immunotherapy within the past 4 weeks\n",
      "          -  No prior interleukin-12\n",
      "          -  No more than 2 prior chemotherapy regimens\n",
      "          -  At least 4 weeks since chemotherapy and recovered\n",
      "          -  At least 6 weeks since nitrosoureas or mitomycin and recovered\n",
      "          -  No concurrent chemotherapy\n",
      "          -  At least 4 weeks since hormone therapy and recovered\n",
      "          -  No concurrent hormone therapy\n",
      "          -  No concurrent corticosteroids\n",
      "          -  At least 4 weeks since radiotherapy and recovered\n",
      "          -  No concurrent radiotherapy\n",
      "          -  No organ allografts\n",
      "          -  At least 2 weeks since intravenous antibiotics\n",
      "2554\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid malignant tumors (carcinoma or\n",
      "        sarcoma) Not eligible for any known treatment or regimen of higher potential efficacy No\n",
      "        history of CNS tumors or prior CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/mL SGOT/SGPT no greater\n",
      "        than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/mL OR\n",
      "        Creatinine clearance at least 60 mL/min Cardiovascular: At least 6 months since any acute\n",
      "        myocardial infarction No congestive heart failure No New York Heart Association class III\n",
      "        or IV heart disease No clinically significant cardiac arrhythmias Pulmonary: Not specified\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception No\n",
      "        gastrointestinal bleeding or bleeding tendency\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (at least 6 weeks since nitrosoureas or mitomycin) and recovered\n",
      "        No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy and recovered No concurrent radiotherapy Surgery: Not specified\n",
      "        Other: No prior systemic retinoid therapy\n",
      "2555\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast with\n",
      "        progressing locoregional or metastatic disease Measurable or evaluable indicator lesion No\n",
      "        uncontrolled CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 0.3 mg/dL above upper limit\n",
      "        of normal (ULN) AST no greater than 3 times ULN Renal: Creatinine no greater than 1.0\n",
      "        mg/dL above ULN Cardiovascular: No New York Heart Association class III or IV heart\n",
      "        disease Other: No uncontrolled infection No chronic debilitating disease Not pregnant or\n",
      "        lactating Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since chemotherapy No more than 2 prior chemotherapy regimens for metastatic disease No\n",
      "        more than 1 prior chemotherapy regimen in the adjuvant setting At least 1 prior regimen\n",
      "        containing taxane or doxorubicin for metastatic disease or in the adjuvant setting\n",
      "        Endocrine therapy: Not specified Radiotherapy: No radiotherapy to greater than 25% of bone\n",
      "        marrow No prior treatment with strontium 89 Surgery: At least 4 weeks since major surgery\n",
      "        Other: No concurrent metoclopramide\n",
      "2556\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma of the ovary,\n",
      "        fallopian tube, or peritoneum At least 3 prior courses of standard platinum-paclitaxel\n",
      "        regimen Patients with taxane allergy may enter this study after 3 courses of platinum\n",
      "        based treatment CA125 at least 35 measured within 30 days of commencement of treatment\n",
      "        Measurable disease not required No CNS metastases, carcinomatous meningitis or\n",
      "        interstitial pulmonary fibrosis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL Calcium less than 12.0 mg/dL Cardiovascular: No unstable angina\n",
      "        No New York Heart Association grade III or IV cardiac disease Pulmonary: See Disease\n",
      "        Characteristics Other: No active or uncontrolled infection No history of seizures No known\n",
      "        Gilbert's Disease No medical or psychiatric conditions that makes patient a poor risk for\n",
      "        participation in this study Not pregnant or lactating Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior\n",
      "        irinotecan or topotecan Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy to the pelvis Surgery: At least 4 weeks since prior surgery and recovered\n",
      "        Other: No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis\n",
      "2557\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed transitional cell carcinoma of the bladder of the following\n",
      "             types:\n",
      "               -  Multiple (not greater than 10), resectable, T1 or Ta, grade G1-G3\n",
      "               -  Solitary T1 GIII tumor\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  85 and under\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Values used to evaluate function may not exceed two times the upper limit of normal\n",
      "        Renal:\n",
      "          -  Values used to evaluate function may not exceed two times the upper limit of normal\n",
      "        Other:\n",
      "          -  No second malignancy except basal cell skin carcinoma\n",
      "          -  Not pregnant or nursing\n",
      "          -  No uncontrollable urinary tract infection\n",
      "          -  No active tuberculosis\n",
      "          -  No HIV antibody\n",
      "          -  No leukemia\n",
      "          -  No Hodgkin's disease\n",
      "          -  No transplant recipients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior treatment with BCG\n",
      "        Chemotherapy:\n",
      "          -  No cytostatic agents within the past 3 months\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2558\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary, stage 0 carcinoma in situ (CIS)\n",
      "        in conjunction with Barrett's esophagus or severe dysplasia in Barrett's esophagus who are\n",
      "        medically unsuitable for or have refused surgery Previously biopsied Barrett's mucosa with\n",
      "        areas of severe dysplasia and/or CIS\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky greater than 50%\n",
      "        Life expectancy: Not specified Hematopoietic: WBC at least 2,000/mm3 Platelet count at\n",
      "        least 50,000/mm3 Hepatic: No porphyria or hypersensitivity to porphyrins Bilirubin no\n",
      "        greater than 3.0 mg/dL Alkaline phosphatase no greater than 3 times ULN SGOT no greater\n",
      "        than 3 times ULN PT no greater than 1.5 times the upper limit of normal (ULN) Renal:\n",
      "        Creatinine no greater than 3.0 mg/dL Other: No contraindication to endoscopy Not pregnant\n",
      "        or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        chemotherapy At least 1 month since prior chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No concurrent radiation therapy No concurrent laser therapy At least 1 month\n",
      "        since prior radiation therapy At least 1 month since prior laser therapy Surgery: Not\n",
      "        specified\n",
      "2559\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III or IV cutaneous or ocular\n",
      "        melanoma that can be completely resected or rendered free of disease but is at high risk\n",
      "        of recurrence OR Recurrent disease following interferon alfa or ineligible for or refused\n",
      "        interferon alfa HLA-A2 positive Tumor tissue must be available for analysis of\n",
      "        gp100/tyrosinase expression Detectable expression of one or the other antigen not required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Absolute granulocyte count at least 1,500/mm3 Hemoglobin at least 9 g/dL Hepatic:\n",
      "        Bilirubin no greater than 2 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: No major cardiovascular illness Pulmonary: No\n",
      "        major respiratory illness (e.g., pneumonia) Gastrointestinal: No major gastrointestinal\n",
      "        illness Other: Not pregnant or nursing No major systemic infection (e.g., sepsis) No\n",
      "        coagulation or bleeding disorder HIV negative Hepatitis B surface antigen negative\n",
      "        Hepatitis C surface antigen negative No history of uveitis or autoimmune inflammatory eye\n",
      "        disease No active autoimmune disease Not allergic to Montanide ISA-51 No active second\n",
      "        malignancy within the past 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 1 month\n",
      "        since prior biologic therapy Chemotherapy: At least 1 month since prior chemotherapy,\n",
      "        including adjuvant therapy Endocrine therapy: At least 1 month since prior endocrine\n",
      "        therapy No concurrent steroid therapy Radiotherapy: At least 1 month since prior\n",
      "        radiotherapy Surgery: See Disease Characteristics At least 1 month since prior surgery\n",
      "2560\n",
      "DISEASE CHARACTERISTICS: Histologically proven acute myelogenous leukemia by bone marrow\n",
      "        aspirate or biopsy Clear evidence of relapse or residual disease with greater than 5%\n",
      "        blasts on bone marrow examination or greater than 30% peripheral blasts No active CNS\n",
      "        leukemia Not eligible for potentially curative allogeneic or autologous bone marrow\n",
      "        transplantation without further surgery Must have failed to achieve a complete remission\n",
      "        with conventional chemotherapy (cytarabine based) or have relapsed within 12 months after\n",
      "        initial remission\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 6 weeks Hematopoietic: See Disease Characteristics Hepatic: Bilirubin less than 1.6\n",
      "        mg/dL (unless due to disease) Renal: Creatinine less than 1.6 mg/dL (unless due to\n",
      "        disease) No prior hemorrhagic cystitis Other: Not pregnant Fertile patients must use\n",
      "        effective contraception No active uncontrolled infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics Recovered from prior chemotherapy No other concurrent chemotherapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: Must have recovered from prior radiotherapy\n",
      "        Surgery: Not specified\n",
      "2562\n",
      "DISEASE CHARACTERISTICS: Histologically proven acute leukemia of any histologic type that\n",
      "        is refractory to known effective therapy\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 50-100% Life\n",
      "        expectancy: At least 6 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater\n",
      "        than 1.5 mg/dL ALT no greater than 5 times upper limit of normal Renal: Creatinine normal\n",
      "        for age Cardiovascular: No unstable angina No uncontrolled arrhythmia Pulmonary: No third\n",
      "        space effusion Other: No severe uncontrolled infection Adequate nutritional status At\n",
      "        least third percentile for weight Normal total serum protein Normal albumin/globulin ratio\n",
      "        No serious concurrent physical or mental illness Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior bone marrow\n",
      "        transplantation Recovered from prior biologic therapy No concurrent anticancer biologic\n",
      "        therapy Chemotherapy: Recovered from prior chemotherapy No concurrent anticancer\n",
      "        chemotherapy Endocrine therapy: Recovered from prior endocrine therapy No concurrent\n",
      "        anticancer endocrine therapy No concurrent dexamethasone or other steroids as antiemetic\n",
      "        agents Radiotherapy: No concurrent anticancer radiotherapy Surgery: Not specified Other:\n",
      "        No concurrent dairy products for 2-4 hours before, during, or 2-4 hours after study drug\n",
      "        No concurrent trimethoprim-sulfamethoxazole or dapsone as prophylaxis for Pneumocystis\n",
      "        infection No concurrent multivitamins containing folic acid\n",
      "2563\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable stage III or stage IV\n",
      "        melanoma Patients who are disease free following surgical resection or chemotherapy for\n",
      "        stage III or IV disease also eligible HLA-A201 positive\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 5 months Hematopoietic: WBC at least 3,500/mm3 Platelet count at\n",
      "        least 75,000/mm3 LDH no greater than 2 times upper limit of normal No active bleeding\n",
      "        Hepatic: Albumin at least 3.5 mg/dL Renal: Not specified Other: Not pregnant or less than\n",
      "        3 months postpartum Fertile patients must use effective contraception No serious\n",
      "        underlying medical conditions No known immunodeficiency No active infection No retinal or\n",
      "        choroidal eye disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and\n",
      "        recovered No prior tyrosinase or gp100 peptides No prior Montanide ISA-51 No prior\n",
      "        melanoma protein vaccine or melanoma whole cell vaccines No other concurrent immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No concurrent\n",
      "        chemotherapy Endocrine therapy: At least 2 weeks since prior systemic steroids and\n",
      "        recovered No concurrent systemic steroids Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered No prior radiotherapy to the spleen No concurrent radiotherapy\n",
      "        Surgery: Recovered from any prior surgery No prior splenectomy Other: At least 1 week\n",
      "        since prior antiinflammatory drugs and recovered At least 1 week since prior\n",
      "        antihistamines and recovered No concurrent antiinflammatory drugs No concurrent\n",
      "        antihistamines No concurrent antimicrobial drugs\n",
      "2564\n",
      "DISEASE CHARACTERISTICS: Histologically proven myelodysplastic syndrome Refractory anemia\n",
      "        (RA) RA with ringed sideroblasts (RARS) RA with excess blasts (RAEB) RAEB in\n",
      "        transformation Chronic myelomonocytic leukemia (CMML) RA and RARS: Platelet count less\n",
      "        than 50,000/mm3 CMML: If WBC greater than 10,000/mm3, then must have at least 8% monocytes\n",
      "        in the blood or marrow\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater\n",
      "        than 2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No New York\n",
      "        Heart Association class III or IV heart disease Other: No active or uncontrolled infection\n",
      "        Not pregnant or nursing Fertile patients must use effective contraception No other active\n",
      "        cancer except skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than one\n",
      "        prior chemotherapy regimen for myelodysplastic syndromes At least 3 weeks since\n",
      "        chemotherapy and recovered No prior high-dose cytarabine (at least 0.5 g/m2 for at least 4\n",
      "        doses) Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified\n",
      "2565\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed locally advanced carcinoma of the\n",
      "        uterine cervix, vagina, or bladder or other pelvic malignancy for which whole pelvic\n",
      "        radiation therapy is planned Metastatic disease is permitted\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: CALGB 0-2 Hematopoietic: WBC at\n",
      "        least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin within normal\n",
      "        limits Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: No unstable angina or\n",
      "        myocardial infarction in previous 6 months Other: Not pregnant No significant concomitant\n",
      "        illness, uncontrolled infection, or cirrhosis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior whole pelvic\n",
      "        radiation therapy Surgery: Not specified\n",
      "2567\n",
      "DISEASE CHARACTERISTICS: Histologically proven advanced malignancy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet\n",
      "        count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL SGOT less than 3\n",
      "        times upper limit of normal (ULN) (less than 5 times ULN if due to hepatic metastases) LDH\n",
      "        less than 3 times ULN (less than 5 times ULN if due to hepatic metastases) Alkaline\n",
      "        phosphatase less than 3 times ULN (less than 5 times ULN if due to hepatic metastases)\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL Other: No active infection requiring systemic\n",
      "        therapy within 1 week prior to entry No significant concurrent illness No history of\n",
      "        bleeding disorder or clotting factor deficiency No dementia or altered mental status that\n",
      "        would prohibit informed consent Not pregnant or nursing Effective contraception strongly\n",
      "        advised for fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent colony stimulating factors\n",
      "        during topotecan infusion Chemotherapy: At least 3 weeks since prior chemotherapy No more\n",
      "        than 3 prior chemotherapy regimens Endocrine therapy: Not specified Radiotherapy: At least\n",
      "        3 weeks since prior radiotherapy Surgery: Not specified\n",
      "2569\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed previously untreated nodular or diffuse mantle cell lymphoma\n",
      "             or their blastic variant\n",
      "          -  No CNS involvement\n",
      "          -  Not a candidate for stem cell transplantation or refuses one\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 and over\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3*\n",
      "          -  Platelet count greater than 100,000/mm^3* NOTE: * Unless lymphoma involvement\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL (unless lymphoma involvement)\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL (unless lymphoma involvement)\n",
      "        Cardiovascular:\n",
      "          -  Cardiac ejection fraction at least 50% (for patients over age 40)\n",
      "        Other:\n",
      "          -  Must be willing to receive blood transfusion\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  HIV negative\n",
      "          -  No other co-morbid medical or psychiatric illness that would preclude treatment\n",
      "          -  No prior or concurrent malignancy with poor prognosis (less than 90% probability of\n",
      "             survival at 5 years)\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "2570\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced colorectal cancer Must have\n",
      "        unresectable (Stage IV) disease or have failed or refused conventional chemotherapy\n",
      "        Measurable disease by conventional imaging methods Liver involvement no greater than 50%\n",
      "        No CNS involvement Not positive for human antimouse antibody titer\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Platelet count at\n",
      "        least 150,000/mm3 Prothrombin time less than 1.3 times control Hepatic: Bilirubin no\n",
      "        greater than 1 mg/dL Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No\n",
      "        significant cardiac disease (New York Heart Association class II/IV heart disease) Other:\n",
      "        No serious infection requiring treatment with antibiotics No other serious illness Not\n",
      "        pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior mouse monoclonal antibody or antibody\n",
      "        fragment, chimeric or humanized antibody, or constructs derived from antibodies At least 4\n",
      "        weeks since prior immunotherapy Chemotherapy: No prior mitomycin/radiotherapy combination\n",
      "        At least 4 weeks since prior chemotherapy Endocrine therapy: No concurrent steroids or\n",
      "        other antiinflammatory agents Radiotherapy: No prior radiotherapy/mitomycin combination\n",
      "        Surgery: Not specified\n",
      "2571\n",
      "DISEASE CHARACTERISTICS: Eligible patients must have no evidence of disease in addition to\n",
      "        1 of the following features: Stage I, II, or III breast cancer and have received adjuvant\n",
      "        chemotherapy and remain clinically free of identifiable disease, but have rising CA15.3\n",
      "        (BR2729) or CEA levels Stage III breast cancer and have completed adjuvant therapy no more\n",
      "        than 24 months ago Recurrence in the ipsilateral axilla following a lumpectomy/axillary\n",
      "        dissection or modified radical mastectomy Recurrence in the ipsilateral breast following a\n",
      "        lumpectomy/axillary dissection Stage II breast cancer with at least 4 positive axillary\n",
      "        lymph nodes at 24 months following completion of adjuvant therapy Patients with isolated\n",
      "        elevation of the CEA level must have a colonoscopy to rule out colon carcinoma A\n",
      "        colonoscopy within the past 5 years is acceptable if there is no strong family history of\n",
      "        colon carcinoma, colonic polyps, or inflammatory bowel disease Hormone receptor status:\n",
      "        Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Premenopausal or\n",
      "        postmenopausal Performance status: Karnofsky 90-100% Life expectancy: Not specified\n",
      "        Hematopoietic: Lymphocyte count at least 500/mm3 WBC count at least 3,000/mm3 Hepatic:\n",
      "        Aspartate aminotransferase no greater than 1.5 times upper limit of normal (ULN) Alkaline\n",
      "        phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular: No New York Heart Association class III or IV cardiac disease Other: Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No other concurrent active cancers except basal cell or squamous cell\n",
      "        carcinomas of the skin No history of a seafood allergy No known history of\n",
      "        immunodeficiency or autoimmune disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: No concurrent\n",
      "        steroids Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 4 weeks\n",
      "        since prior surgery\n",
      "2574\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically documented metastatic or\n",
      "        previously irradiated recurrent locoregional squamous cell or mucoepidermoid carcinoma of\n",
      "        the head and neck Unresectable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Karnofsky\n",
      "        70-100% Life expectancy: Greater than 4 months Hematopoietic: WBC at least 3000/mm3\n",
      "        Platelet count at least 100,000/mm3 Granulocyte count at least 1500/mm3 Hepatic: Bilirubin\n",
      "        no greater than 2.5 times normal SGOT and SGPT no greater than 2.5 times upper limit of\n",
      "        normal Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min\n",
      "        Other: No other significant infection No other medical or psychiatric illness Not pregnant\n",
      "        or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 1 month\n",
      "        since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 3 months\n",
      "        since prior radiotherapy (patients with recurrent disease) to head and neck region\n",
      "        Surgery: Not speciified Other: At least 24 hours since antihypertensive medication\n",
      "2580\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced sarcoma that is metastatic or\n",
      "        incurable surgically Evaluable or measurable disease Must be refractory to all known forms\n",
      "        of effective therapy No CNS tumor involvement No major liver involvement (more than 33%\n",
      "        replacement of liver by tumor)\n",
      "        PATIENT CHARACTERISTICS: Age: 18-65 Performance status: ECOG 0-2 Life expectancy: At least\n",
      "        12 weeks Hematopoietic: WBC greater than 3,000/mm3 Absolute granulocyte count at least\n",
      "        1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Alkaline phosphatase no greater than 3 times normal SGOT no greater than 3 times normal\n",
      "        Protein no less than 15% below lower limit of normal Renal: BUN less than 30 mg/dL\n",
      "        Creatinine less than 1.5 mg/dL OR Creatinine clearance no less than 60 mL/min Calcium no\n",
      "        greater than 11.0 mg/dL Sodium 130-150 mmol/L Potassium 3.0-5.0 mmol/L Cardiovascular: No\n",
      "        organic heart disease - coronary artery disease - history of angina - history of\n",
      "        dysrhythmia requiring ongoing medical intervention - uncontrolled hypertension - patients\n",
      "        that require beta blockers - congestive heart failure Neurologic: No tumor involvement of\n",
      "        CNS No moderate or severe peripheral neuropathy No history of severe emotional instability\n",
      "        by psychiatric history Pulmonary: FEV1 at least 60% of predicted Maximum voluntary volume\n",
      "        at least 60% of predicted Partial pressure of oxygen at least 60 OR Oxygen saturation at\n",
      "        least 90% Other: No history of secondary primary cancer which conceivably could be active\n",
      "        No active nonmalignant gastric and/or duodenal ulcer No serious infection requiring\n",
      "        hospitalization within the previous 14 days No history of hepatitis related to general\n",
      "        anesthesia No history of allergy to lidocaine or related compound No development of\n",
      "        malignant hyperthermia after general anesthesia No unexplained persistent fever Not\n",
      "        pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 8 weeks\n",
      "        since nitrosoureas (e.g., CCNU, BCNU, mitomycin) At least 4 weeks since any other\n",
      "        chemotherapy Recovered from all toxic effects Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior irradiation of more than 25% of the marrow Surgery: Not specified\n",
      "        Other: No concurrent nonsteroidal anti-inflammatory agents or aspirin\n",
      "2581\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of relapsed chronic lymphocytic leukemia\n",
      "               -  Intermediate- or high-risk (stage I-IV) disease\n",
      "          -  Intermediate-risk patients must have active disease, defined by at least 1 of the\n",
      "             following criteria:\n",
      "               -  Presence of any 1 of the following disease-related B symptoms:\n",
      "                    -  10% or more loss of body weight within the past 6 months\n",
      "                    -  Extreme fatigue\n",
      "                    -  Fever greater than 100 degrees Fahrenheit without evidence of infection\n",
      "                    -  Night sweats\n",
      "               -  Massive (greater than 6 cm below left costal margin) or progressive splenomegaly\n",
      "               -  Massive (greater than 10 cm in longest diameter) or progressive lymphadenopathy\n",
      "               -  Progressive lymphocytosis with an increase of more than 50% over a 2-month\n",
      "                  period or anticipated doubling time of less than 12 months\n",
      "               -  Progressive bone marrow failure as manifested by the development or worsening of\n",
      "                  anemia and/or thrombocytopenia\n",
      "               -  Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids\n",
      "          -  Failed 1-2 prior front-line regimens\n",
      "          -  Failed prior fludarabine\n",
      "          -  Ineligible for any known treatment of higher potential efficacy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "          -  Absolute neutrophil count at least 1,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Transaminases less than 2.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No history of severe coronary artery disease, cardiomyopathy, uncontrolled congestive\n",
      "             heart failure, or arrhythmias\n",
      "        Neurologic:\n",
      "          -  No prior drug-related neurotoxicity\n",
      "          -  No other neurologic disorder\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective barrier or non-hormonal contraception during and\n",
      "             for 2 months after study participation\n",
      "          -  No HIV infection\n",
      "          -  No AIDS\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior bone marrow transplantation\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (8 weeks for mitomycin or nitrosoureas) and\n",
      "             recovered\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No concurrent steroids\n",
      "          -  No concurrent hormonal contraceptives\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent therapy\n",
      "2582\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed Stage IIIB and IV adenocarcinoma of the\n",
      "        breast Stage II-IIIA adenocarcinoma of the breast with poor risk features (including\n",
      "        poorly differentiated histology, high mitotic rate, hormone receptor negative, high S\n",
      "        phase) with at least three involved axillary lymph nodes, estimated five year relapse free\n",
      "        survival rate less than 50%, and does not qualify for higher priority protocol treatments\n",
      "        No central nervous system involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Greater than 2 months Hematopoietic: Platelet count greater than 75,000/mm3\n",
      "        Neutrophils greater than 1500/mm3 Hepatic: Serum bilirubin, alkaline phosphatase, and SGOT\n",
      "        or SGPT less than 3 times upper limit of normal, unless due to disease Renal: Serum\n",
      "        creatinine less than 1.5 times upper limit of normal Creatinine clearance at least 60\n",
      "        mL.min Cardiovascular: Ventricular ejection fraction at least 45% No uncontrolled or\n",
      "        severe cardiovascular disease, including recent myocardial infarction, congestive heart\n",
      "        failure, angina, life threatening arrhythmia, or hypertension Pulmonary: DLCO and\n",
      "        spirometry at least 50% of predicted Other: Not HIV positive Not HBsAG positive Not\n",
      "        pregnant Must have functioning central venous catheter No active infection No uncontrolled\n",
      "        diabetes mellitus No other prior malignancy except for adequately treated basal cell or\n",
      "        squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II\n",
      "        cancer from which the patient is currently in complete remission, or any other cancer from\n",
      "        which the patient has been disease free for at least 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior hematopoietic progenitor cell support\n",
      "        Chemotherapy: No prior dose intensive therapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "2583\n",
      "DISEASE CHARACTERISTICS: Metastatic breast cancer within 2 years of an adjuvant\n",
      "        anthracycline based chemotherapy for advanced disease, or failure of one prior\n",
      "        anthracycline based chemotherapeutic regimen for advanced breast cancer Exception: When\n",
      "        anthracyclines are contraindicated, metastatic disease within 2 years of any adjuvant\n",
      "        cytotoxic regimen, or failure of one prior cytotoxic chemotherapeutic regimen for advanced\n",
      "        breast cancer also qualifies Evaluable or measurable disease in at least one nonirradiated\n",
      "        area No CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin at least 8.0\n",
      "        g/dL Absolute neutrophil count at least 1500/mm3 Hepatic: Total serum bilirubin no greater\n",
      "        than 1.5 mg/dL No history of chronic active hepatitis or cirrhosis SGOT and/or SGPT no\n",
      "        greater than 2 times the upper limit of normal Renal: Serum creatinine no greater than 2.0\n",
      "        mg/dL Other: Not HIV positive Not pregnant or nursing Effective contraceptive required of\n",
      "        fertile patients No uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or\n",
      "        bowel obstruction No history of a second malignancy with the exception of non-melanoma\n",
      "        skin cancer or carcinoma in situ of the cervix No known hypersensitivity to ingredients of\n",
      "        the study medication or cyclosporine No neurologic problems requiring treatment No\n",
      "        treatment with drugs within 48 hours that are known to interact with cyclosporine\n",
      "        PRIOR CONCURRENT THERAPY: At least 4 weeks since any investigational therapy Biologic\n",
      "        therapy: No concurrent antibiotics, e.g. clarithromycin, erythromycin, nafcillin,\n",
      "        rifampin, itraconazole, ketoconazole, or fluconazole (no greater than 200 mg/day allowed)\n",
      "        Chemotherapy: No prior paclitaxel At least 6 weeks since nitrosoureas At least 4 weeks\n",
      "        since other myelosuppressive chemotherapy Endocrine therapy: At least 2 weeks since\n",
      "        hormone therapy No concurrent danazol Radiotherapy: At least 3 weeks since radiation\n",
      "        therapy Surgery: Must be recovered from previous surgery Other: No concurrent calcium\n",
      "        channel blockers, e.g. diltiazem, nicardipine, and verapamil No concurrent\n",
      "        anticonvulsants, e.g. carbamazepine, phenobarbital, and phenytoin No concurrent\n",
      "        bromocriptine\n",
      "2584\n",
      "DISEASE CHARACTERISTICS: Histologically proven Stage IIIB or IV bronchioloalveolar\n",
      "        non-small cell lung carcinoma -incompletely resected or unresectable -tumors may be\n",
      "        multifocal or diffuse -measurable or evaluable disease required No prior brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: SWOG 0-2 Life Expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than institutional upper limit of\n",
      "        normal (ULN) SGOT no greater than 2 times ULN Renal: Creatinine no greater than\n",
      "        institutional ULN OR creatinine clearance at least 50 mL/min Other: Not pregnant or\n",
      "        nursing Effective contraceptive method used while on study No prior malignancies allowed,\n",
      "        except: basal or squamous cell skin cancer in situ cervical cancer Stage I or II cancer\n",
      "        which is in remission Any cancer from which patients have been disease free for 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for lung cancer\n",
      "        Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No\n",
      "        prior radiation therapy (including palliative radiotherapy) Surgery: Prior surgery is\n",
      "        allowed\n",
      "2585\n",
      "DISEASE CHARACTERISTICS: Pathologically proven incurable advanced solid tumor refractory\n",
      "        to standard therapy or for which no standard therapy exists No known brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 OR Karnofsky\n",
      "        70-100% Life expectancy: Not specified Hematopoietic: WBC at least 4,000/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST less than 1.25\n",
      "        times normal Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No significant\n",
      "        cardiac disease Other: No significant metabolic disorder No significant infection Not\n",
      "        pregnant or nursing Effective contraception must be used by fertile women\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks\n",
      "        (6 weeks for nitrosourea) since prior chemotherapy and recovered Endocrine therapy: Not\n",
      "        specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery:\n",
      "        Not specified\n",
      "2586\n",
      "DISEASE CHARACTERISTICS: Histologically proven advanced pancreatic cancer with metastatic\n",
      "        disease Bidimensionally measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte\n",
      "        count at least 1,500/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than 2.0\n",
      "        mg/dL SGOT, SGPT and alkaline phosphatase less than 3 times upper limit of normal Serum\n",
      "        albumin at least 3.0 g/dL Renal: Serum creatinine no greater than 1.5 mg/dL Other: Not\n",
      "        eligible for higher priority protocol No prior malignancy within 5 years except adequately\n",
      "        treated basal cell carcinoma of the skin or carcinoma in situ of the cervix Not pregnant\n",
      "        or nursing Fertile patients must use effective birth control No underlying medical\n",
      "        condition precluding treatment\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent\n",
      "        radiotherapy No prior radiotherapy to only site(s) of measurable disease Fully recovered\n",
      "        from therapy Surgery: Fully recovered from prior surgery\n",
      "2587\n",
      "DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian\n",
      "        tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis\n",
      "        from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have\n",
      "        ascites and tumor accessible by laparoscopic or percutaneous biopsy Immunohistochemical\n",
      "        evidence of p53 gene mutation in the ascitic fluid cell block or primary tumor biopsy or\n",
      "        other documented mutation\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Life expectancy: At least 3 months Performance\n",
      "        status: Karnofsky 60-100% Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count\n",
      "        at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5\n",
      "        mg/dL AST/ALT less than 1.5 times the upper limit of normal (ULN) Alkaline phosphatase\n",
      "        less than 1.5 times ULN Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance\n",
      "        greater than 50 mL/min Other: Ability to tolerate paired paracenteses or biopsies\n",
      "        (percutaneous or laparoscopic) HIV negative No adenoviral infections determined by ELISA\n",
      "        screening No uncontrolled serious bacterial, viral, fungal or parasitic infection No known\n",
      "        or suspected hypersensitivity to study drug or any excipient used in formulation or\n",
      "        delivery system No underlying medical condition that would obscure interpretation of\n",
      "        adverse events Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        for at least 1 month before, during, and 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior biologic therapy\n",
      "        and recovered Chemotherapy: At least 3 months since local intraperitoneal antitumor\n",
      "        therapy directed against peritoneal carcinomatosis and recovered At least 1 month since\n",
      "        systemic chemotherapy for ovarian, fallopian tube, or peritoneal cancer or an unapproved\n",
      "        indication and recovered Endocrine therapy: At least 3 months since any systemic\n",
      "        corticosteroid therapy Radiotherapy: At least 1 year since prior total abdominal\n",
      "        radiotherapy Surgery: Not specified Other: At least 3 months since prior investigational\n",
      "        therapy and recovered At least 3 months since prior immunosuppressive therapy\n",
      "2588\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed refractory anemia, refractory anemia\n",
      "        with excess blasts, refractory anemia with excess blasts in transformation, refractory\n",
      "        anemia with ringed sideroblasts, or chronic myelomonocytic leukemia with significant\n",
      "        cytopenias of at least 4 weeks duration No more than 1 prior treatment for disease Not\n",
      "        eligible for allogeneic bone marrow transplantation if less than 60 years of age\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: Hematocrit less than 26% (or requiring transfusion) for\n",
      "        at least 4 weeks Absolute neutrophil count less than 1000/mm3 for at least 4 weeks\n",
      "        Platelet count less than 50/mm3 for at least 4 weeks Hepatic: Bilirubin less than 1.5\n",
      "        mg/dL Transaminase less than 2.5 times upper limit of normal Renal: Creatinine less than\n",
      "        1.5 mg/dL Creatinine clearance of at least 60 mL/min Other: Not pregnant or lactating\n",
      "        Fertile patients must use effective contraception while on study and for 100 days\n",
      "        afterwards No uncontrolled or life-threatening infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No concurrent\n",
      "        treatment with growth factors Chemotherapy: At least 4 weeks since prior chemotherapy (8\n",
      "        weeks for mitomycin or nitrosourea) and recovered Endocrine therapy: No concurrent use of\n",
      "        steroids Radiotherapy: At least 4 weeks since prior radiation therapy and recovered\n",
      "        Surgery: Not specified\n",
      "2589\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL)\n",
      "               -  Diffuse large B-cell lymphoma\n",
      "               -  Primary mediastinal large B-cell lymphoma\n",
      "               -  Anaplastic large cell lymphoma (B-cell, T-cell, or null-cell type)\n",
      "          -  At least two of the following risk factors:\n",
      "               -  Stage III or IV\n",
      "               -  LDH greater than upper limit of normal (ULN)\n",
      "               -  ECOG 2, 3, or 4\n",
      "          -  No CNS involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 60\n",
      "        Performance status:\n",
      "          -  See Disease Characteristics\n",
      "          -  ECOG 0-4\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  No hepatitis B or C\n",
      "          -  AST or ALT no greater than 2 times ULN*\n",
      "          -  Bilirubin no greater than 2.34 mg/dL* NOTE: *Unless due to tumor involvement\n",
      "        Renal:\n",
      "          -  Creatinine clearance at least 60 mL/min (unless due to tumor involvement)\n",
      "        Cardiovascular:\n",
      "          -  No significant heart failure\n",
      "          -  LVEF normal\n",
      "          -  No active angina pectoris\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No major ventricular arrhythmia\n",
      "        Pulmonary:\n",
      "          -  No significant lung disorder\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No severe active acute or chronic infection\n",
      "          -  No severe psychoses\n",
      "          -  No prior or concurrent malignancy except adequately treated carcinoma in situ of the\n",
      "             cervix or nonmelanomatous skin cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for NHL (except emergency therapy, but no more than 1 course of\n",
      "             standard chemotherapy)\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for NHL (except emergency therapy of no greater than 600 cGy\n",
      "             radiation)\n",
      "          -  No concurrent prophylactic radiotherapy to the brain\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2590\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed primary invasive breast carcinoma resected\n",
      "             at time of original diagnosis\n",
      "               -  No ductal carcinoma in situ\n",
      "          -  Axillary lymph node negative, positive, or unknown\n",
      "          -  No evidence of metastases\n",
      "          -  No localized or distant breast cancer recurrence\n",
      "          -  Not registered on protocol NCCTG-893052, any other IBCSG protocol, or protocol\n",
      "             SWOG-S9623\n",
      "          -  Hormone receptor status:\n",
      "               -  Estrogen or progesterone receptor positive as defined by tumor receptor content\n",
      "                  at least 10 fmol/mg protein or receptor positive by ERICA or PgRICA\n",
      "               -  Unknown status allowed if effort to determine status has been made by\n",
      "                  immunocytochemistry\n",
      "          -  No contralateral breast cancer\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Postmenopausal\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Postmenopausal defined by one of the following:\n",
      "               -  Age 50 or over at start of adjuvant tamoxifen\n",
      "               -  Under age 50 and considered postmenopausal by treating physician at start of\n",
      "                  adjuvant tamoxifen\n",
      "               -  Under age 50 at start of adjuvant tamoxifen and had bilateral oophorectomy\n",
      "                  (surgical or radiation)\n",
      "               -  Under age 50 and premenopausal at start of adjuvant tamoxifen, but became\n",
      "                  amenorrheic during tamoxifen and remained amenorrheic for at least 1 year\n",
      "               -  Considered postmenopausal by physician with LH/FSH levels under the treatment\n",
      "                  center's postmenopausal limits\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 5 years\n",
      "        Hematopoietic:\n",
      "          -  WBC ≥ 3,000/mm^3 OR\n",
      "          -  Granulocyte count ≥ 1,500/mm^3\n",
      "          -  Platelet count ≥ 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  AST and/or ALT < 2 times upper limit of normal (ULN) (unless imaging examinations\n",
      "             have ruled out metastatic disease)\n",
      "          -  Alkaline phosphatase < 2 times ULN (unless imaging examinations have ruled out\n",
      "             metastatic disease)\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent medical or psychiatric condition that would preclude study\n",
      "             participation\n",
      "          -  No other malignancy within the past 5 years except adequately treated superficial\n",
      "             squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n",
      "          -  Able to swallow study drug\n",
      "          -  Adequate oral intake\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Prior adjuvant chemotherapy allowed\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Completed at least 4.5 but no more than 6 years of adjuvant tamoxifen after resection\n",
      "          -  Completed at least 4.5-6 years of adjuvant aromatase inhibitor as initial therapy or\n",
      "             after tamoxifen\n",
      "          -  No more than 3 months since prior adjuvant tamoxifen\n",
      "          -  No concurrent hormone replacement therapy (e.g., megestrol)\n",
      "          -  No concurrent selective estrogen-receptor modulators (e.g., raloxifene or idoxifene)\n",
      "          -  Concurrent intermittent vaginal estrogens (e.g., Estring) allowed if other local\n",
      "             measures for intractable vaginal atrophy are insufficient\n",
      "          -  No other concurrent aromatase inhibitors\n",
      "          -  No more than 2 years since prior aromatase inhibitor therapy (re-randomization)\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  At least 1 month since prior investigational drugs\n",
      "          -  Prior treatment on a clinical trial for breast cancer allowed if permission has been\n",
      "             obtained from the sponsors of the original study for their patient to participate on\n",
      "             MA.17/JMA.17/BIG-97-01\n",
      "          -  No prior placebo on core protocol\n",
      "          -  No concurrent anticancer therapy\n",
      "          -  Concurrent thyroid medication, calcium, vitamin D, and bisphosphonates allowed\n",
      "2594\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed Stage I, IIA or IIB invasive\n",
      "        adenocarcinoma of the breast with T1-3, pN0 and M0 classification Must have undergone\n",
      "        total mastectomy or lumpectomy followed by an axillary dissection or sentinel node\n",
      "        resection if participating in NSABP B-32 Histologically negative axillary lymph nodes OR\n",
      "        Histologically negative sentinel lymph nodes if participating in NSABP B-32 Lumpectomy and\n",
      "        axillary dissection acceptable only if margins of resected specimen are histologically\n",
      "        free of invasive tumor or ductal carcinoma in situ and other dominant masses within the\n",
      "        ipsilateral breast remnant are histologically confirmed to be benign Additional operation\n",
      "        after resection is allowed in order to obtain clear margins No bilateral malignancy of the\n",
      "        breast ER positive tumors as defined by at least one of the following: At least 10 fmol/mg\n",
      "        cytosol protein by either dextran-coated charcoal or sucrose density gradient methods\n",
      "        Positive or not definitely negative results by the enzyme immunoassay method (EIA) or by\n",
      "        immunocytochemical assay No more than 63 days from time of initial cytologic or histologic\n",
      "        diagnosis of breast cancer till randomization No bone metastases (confirmation must be\n",
      "        made for those with skeletal pain) Tumor must be no greater than 5 cm in its greatest\n",
      "        dimension for patients who are treated by lumpectomy and axillary dissection Hormone\n",
      "        receptor status: Estrogen receptor positive\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Menopausal status: Not specified\n",
      "        Life expectancy: At least 10 years (excluding diagnosis of cancer) Performance status: Not\n",
      "        specified Hematopoietic: WBC at least 4,000/mm3 Platelet count postoperative at least\n",
      "        100,000/mm3 Hepatic: Bilirubin normal SGOT/SGPT normal Renal: Creatinine normal\n",
      "        Cardiovascular: No cardiac disease that would preclude the use of doxorubicin (for\n",
      "        patients who are to receive adjuvant chemotherapy in this study), including: Myocardial\n",
      "        infarction Angina pectoris that requires antianginal medication History of congestive\n",
      "        heart failure Arrhythmia associated with concurrent heart failure or cardiac dysfunction\n",
      "        Valvular disease with cardiac compromise Cardiomegaly or ventricular hypertrophy unless\n",
      "        left ventricular function is within normal limits Poorly controlled hypertension Other: No\n",
      "        prior invasive breast cancer or ductal carcimoma in situ No systemic disease that would\n",
      "        preclude patients from any part of study No history of symptomatic gallbladder or biliary\n",
      "        tract disease unless patient has undergone cholecystectomy No ulceration, erythema,\n",
      "        infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or\n",
      "        skin edema of any magnitude No prior nonbreast malignancies in past 10 years except:\n",
      "        Squamous or basal cell carcinoma of the skin that has been effectively treated Carcinoma\n",
      "        in situ of the cervix that has been treated by operation only Lobular carcinoma in situ of\n",
      "        the ipsilateral or contralateral breast treated by segmented resection only No psychiatric\n",
      "        or addictive disorders Not pregnant or nursing Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for breast cancer\n",
      "        Chemotherapy: No prior chemotherapy for breast cancer No prior anthracycline therapy for\n",
      "        patients who are to receive adjuvant chemotherapy in this study Endocrine therapy: No\n",
      "        prior endocrine therapy for breast cancer Must discontinue any sex hormonal therapy before\n",
      "        prior to and during study Radiotherapy: No prior radiotherapy for breast cancer No breast\n",
      "        radiation therapy before randomization for patients who receive lumpectomy Surgery: See\n",
      "        Disease Characteristics At least 2 weeks since last surgical procedure Other: No\n",
      "        concurrent cyclosporine therapy No concurrent heparin or warfarin anticoagulation therapy\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2596\n",
      "Inclusion Criteria:\n",
      "          -  Patients with biopsy proven B-cell malignancies [e.g. chronic lymphocytic leukemia\n",
      "             (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM)]; HIV-associated lymphomas\n",
      "             and acute leukemias are not eligible\n",
      "          -  Performance status: ECOG 0, 1, or 2\n",
      "          -  Life expectancy of at least 12 weeks\n",
      "          -  Patients with aggressive NHL will be enrolled after having failed all possible\n",
      "             therapy with curative intent\n",
      "          -  Patients with CLL must have failed an alkylating agent-containing regimen as well as\n",
      "             fludarabine chemotherapy\n",
      "          -  Patients with multiple myeloma must have received at least one prior chemotherapy\n",
      "             regimen and not be eligible for a dose intensification treatment approach\n",
      "          -  At least 4 weeks must have elapsed since prior large-field radiation therapy\n",
      "          -  Patients must have been off previous anti-cancer therapy for at least 3 weeks (6\n",
      "             weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity\n",
      "          -  Prior vincristine therapy is allowed\n",
      "          -  Sexually active men and women must use an accepted and effective method of\n",
      "             contraception\n",
      "          -  In women of child-bearing age, a pregnancy test may be done at the discretion of the\n",
      "             investigator\n",
      "          -  Must have given written informed consent\n",
      "        \n",
      "2597\n",
      "DISEASE CHARACTERISTICS: Histologically proven CIS and/or unresectable/residual\n",
      "        superficial bladder tumor (pTa G1-G3 to pT1 G1-G3) -confirmed by biopsy, bladder mapping,\n",
      "        or positive cytology Cystoscopic examination and bladder mapping must be performed within\n",
      "        6 weeks of study\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky of 60 to 100% Life\n",
      "        Expectancy: Not specified Hematopoietic: Hemoglobin greater than 11 g/dL WBC greater than\n",
      "        4500/mm3 Neutrophils greater than 1500/mm3 Platelet count greater than 100,000/mm3\n",
      "        Hepatic: Bilirubin, AST, and ALT no greater than 2.5 x normal Renal: Creatinine no greater\n",
      "        than 2.5 x normal Cardiovascular: No concurrent cardiovascular disease Other: No active\n",
      "        infection requiring concurrent therapy Not pregnant or nursing No upper renal tract\n",
      "        disease No concurrent malignancy except for basal or squamous cell skin cancer or\n",
      "        noninvasive cancer of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No intravesical BCG within 3 months prior to\n",
      "        study entry Prior BCG therapy is required for CIS patients (if not contraindicated)\n",
      "        Chemotherapy: No prior intravesical chemotherapy within 4 weeks prior to study No prior\n",
      "        systemic anticancer therapy within 4 months prior to study No prior paclitaxel therapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy within 4 months prior\n",
      "        to study Surgery: Not specified Other: No hypersensitivity reactions to products\n",
      "        containing cremophor\n",
      "2600\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast with\n",
      "        previous manifestations of progressing regional or metastatic cancer Received one prior\n",
      "        systemic chemotherapy regimen for the treatment of metastases, which meets all of the\n",
      "        following criteria: Included either doxorubicin, a taxane (i.e., paclitaxel or docetaxel),\n",
      "        or both 6-8 courses were given If weekly taxane therapy received, at least 12 doses were\n",
      "        given Recovered from all related toxic effects (except alopecia and/or neuropathy) 3-6\n",
      "        weeks have elapsed since last course of chemotherapy was given No more than 40 weeks have\n",
      "        elapsed since the first dose of chemotherapy for metastases No current or prior history of\n",
      "        brain metastases Responding or stable disease since the initiation of systemic\n",
      "        chemotherapy (i.e., no disease progression) required No prior enrollment on ECOG trials\n",
      "        for metastatic disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal Status: Not specified\n",
      "        Performance status: ECOG 0 or 1 Hematopoietic: Granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no\n",
      "        greater 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Other:\n",
      "        Not pregnant or nursing Negative pregnancy test required if pre- or peri-menopausal (i.e.,\n",
      "        last menstrual period within one year prior to study) Pre- or peri-menopausal sexually\n",
      "        active women must use effective contraception No other invasive malignancy within last 5\n",
      "        years except curatively treated basal or squamous cell carcinoma of the skin or carcinoma\n",
      "        in situ of the cervix No history of rheumatoid arthritis, osteoarthritis, symptomatic\n",
      "        osteoarthritis requiring therapy, or other inflammatory arthritis At least 5 years since\n",
      "        prior invasive malignancies except: Curatively treated basal cell or squamous cell\n",
      "        carcinoma of the skin Carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No prior\n",
      "        trastuzumab Chemotherapy: See Disease Characteristics No concurrent chemotherapy No prior\n",
      "        marimastat or batimastat Endocrine therapy: Prior and/or concurrent hormonal therapy for\n",
      "        breast cancer allowed Concurrent hormonal therapy allowed Radiotherapy: No concurrent\n",
      "        radiotherapy Surgery: No prior organ allograft Other: At least 4 weeks since other\n",
      "        investigational agents No concurrent bisphosphonate therapy unless it was initiated prior\n",
      "        to the study No concurrent immunosuppressive therapy Patients receiving anticoagulant\n",
      "        therapy must be carefully monitored\n",
      "2602\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed malignant solid tumor that is refractory to conventional\n",
      "             therapy or recurrent neuroblastoma treated with myeloablative therapy and autologous\n",
      "             stem cell transplant in second complete or partial response\n",
      "          -  Bone marrow metastases with granulocytopenia, anemia, and/or thrombocytopenia are\n",
      "             eligible\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Under 21 at diagnosis\n",
      "          -  Performance status: CCG 0-2\n",
      "          -  Life expectancy: At least 2 months\n",
      "          -  Absolute neutrophil count at least 750/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "          -  Hemoglobin at least 7.0 g/dL\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT and SGPT less than 2.5 times normal\n",
      "          -  Creatinine no greater than 1.5 g/dL OR creatinine clearance at least 50 mL/min OR\n",
      "             radioisotope GFR at least 50 mL/min\n",
      "          -  Seizure disorders controlled with anticonvulsants allowed\n",
      "          -  No CNS toxicity greater than grade 2\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 1 month since prior autologous stem cell transplantation\n",
      "          -  No prior allogeneic transplantation\n",
      "          -  At least 2 weeks since prior chemotherapy (4 weeks for nitrosourea) and recovered\n",
      "          -  No other concurrent chemotherapy\n",
      "          -  No concurrent immunomodulating agents (including steroids)\n",
      "          -  Concurrent corticosteroid therapy for increased intracranial pressure allowed\n",
      "          -  Concurrent dexamethasone for CNS tumor allowed\n",
      "          -  At least 2 weeks since prior radiotherapy\n",
      "          -  Concurrent radiotherapy to localized lesions allowed\n",
      "          -  At least 2 weeks since prior retinoids Prior isotretinoin or 9-cis-retinoic acid\n",
      "             allowed\n",
      "2603\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, locally advanced, metastatic or\n",
      "        recurrent adenocarcinoma of the stomach or gastroesophageal junction Measurable disease\n",
      "        CNS metastases allowed provided that patient has other sites of measurable disease, is\n",
      "        neurologically stable, and is receiving no concurrent anticonvulsant therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3500/mm3 Absolute neutrophil count at least\n",
      "        1500/mm3 Platelet count at least 100,000/mm3 (no platelet transfusion within 7 days)\n",
      "        Hemoglobin at least 9 g/dL Hepatic: Total bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminases no greater than 2.5 times upper limit of normal (ULN) (no greater than 5\n",
      "        times ULN if liver metastases) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine\n",
      "        clearance at least 60 mL/min Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception No concurrent uncontrolled medical or\n",
      "        psychiatric condition No active uncontrolled infection No prior malignant disease within\n",
      "        the past 5 years except curatively treated non-melanoma skin cancer and carcinoma in situ\n",
      "        of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic growth factors\n",
      "        Chemotherapy: One prior adjuvant or neoadjuvant 5-FU-based chemotherapy regimen allowed At\n",
      "        least 4 weeks since prior adjuvant or neoadjuvant chemotherapy (6 weeks if nitrosoureas or\n",
      "        mitomycin) and recovered No prior therapy with a topoisomerase I inhibitor No other\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: One prior\n",
      "        radiotherapy regimen allowed No prior radiation therapy to only site of measurable disease\n",
      "        At least 4 weeks since prior radiation therapy and recovered No concurrent palliative\n",
      "        radiation therapy Surgery: Not specified Other: See Disease Characteristics No other\n",
      "        concurrent investigational antineoplastic therapy\n",
      "2604\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven medulloblastoma or supratentorial primitive neuroectodermal\n",
      "             tumor\n",
      "          -  Average-risk group:\n",
      "               -  Localized tumor with no overt evidence of invasion beyond the posterior fossa\n",
      "               -  Less than 1.5 cm2 residual tumor/imaging abnormality\n",
      "               -  No CNS or extraneural metastasis (confirmed by bone scan)\n",
      "               -  Brain stem invasion allowed if above criteria met\n",
      "          -  High-risk group:\n",
      "               -  Metastatic disease within the neuraxis (subarachnoid dissemination) OR greater\n",
      "                  than 1.5 cm^2 residual disease at the primary site after surgery\n",
      "          -  No bone involvement by bone scan\n",
      "          -  Must begin study within 28 days of definitive surgery\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age\n",
      "          -  3 to 20 at diagnosis\n",
      "        Performance status\n",
      "          -  ECOG 0-3 (except patients with posterior fossa syndrome)\n",
      "        Life expectancy\n",
      "          -  Not specified\n",
      "        Hematopoietic\n",
      "          -  WBC greater than 3,000/mm^3\n",
      "          -  Absolute neutrophil count greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "        Hepatic\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGPT less than 1.5 times normal\n",
      "        Renal\n",
      "          -  Creatinine less than 1.2 mg/dL OR\n",
      "          -  Creatinine clearance greater than 70 mL/min\n",
      "        Other\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  HIV negative\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy\n",
      "          -  Prior corticosteroids allowed\n",
      "        Radiotherapy\n",
      "          -  No prior radiotherapy\n",
      "        Surgery\n",
      "          -  See Disease Characteristics\n",
      "2606\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced melanoma beyond hope of\n",
      "        surgical cure or metastatic disease Tumors must be refractory to all known forms of\n",
      "        effective therapy No CNS tumor involvement No major liver involvement (more than 33%\n",
      "        replacement of liver by tumor)\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC greater than 3,000/mm3 Absolute granulocyte count at\n",
      "        least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5\n",
      "        mg/dL Alkaline phosphatase no greater than 3 times normal SGOT no greater than 3 times\n",
      "        normal Protein no less than 15% below lower limit of normal Renal: BUN less than 30 mg/dL\n",
      "        Creatinine less than 1.5 mg/dL OR Creatinine clearance no less than 60 mL/min Calcium no\n",
      "        greater than 11.0 mg/dL Sodium 130-150 mEq/L Potassium 3.0-5.0 mg/dL Cardiovascular: No\n",
      "        organic heart disease, including: - coronary artery disease - history of angina - history\n",
      "        of dysrhythmia requiring ongoing medical intervention - uncontrolled hypertension -\n",
      "        patients requiring beta blockers Neurologic: No moderate or severe peripheral neuropathy\n",
      "        No history of severe emotional instability by psychiatric history Pulmonary: FEV1 at least\n",
      "        60% of predicted Maximum voluntary volume at least 60% of predicted Partial pressure of\n",
      "        oxygen at least 60 OR Oxygen saturation at least 90% Other: No history of secondary\n",
      "        primary cancer which conceivably could be active No active nonmalignant gastric and/or\n",
      "        duodenal ulcer No serious infection requiring hospitalization within the previous 14 days\n",
      "        No history of hepatitis related to general anesthesia No history of allergy to lidocaine\n",
      "        or related compounds No development of malignant hyperthermia after general anesthesia No\n",
      "        unexplained persistent fever Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since biologic therapy\n",
      "        Chemotherapy: At least 8 weeks since nitrosoureas (e.g., lomustine, carmustine, mitomycin)\n",
      "        At least 4 weeks since any other chemotherapy Recovered from all toxic effects No\n",
      "        concurrent chemotherapy Endocrine therapy: At least 4 weeks since endocrine therapy No\n",
      "        concurrent hormonal therapy Radiotherapy: At least 4 weeks since radiotherapy No prior\n",
      "        irradiation of more than 25% of the marrow Surgery: Not specified Other: No concurrent\n",
      "        nonsteroidal antiinflammatory agents or aspirin\n",
      "2608\n",
      "Inclusion Criteria:\n",
      "          -  Patients must have Stage III-IV (Ann Arbor classification) low-grade Non-Hodgkin's\n",
      "             lymphoma\n",
      "          -  Baseline measurements and evaluations must be obtained within 4 weeks prior to\n",
      "             registration; all areas of disease (evaluable and measurable) should be recorded and\n",
      "             mapped out in order to assess response and uniformity of response to therapy; must\n",
      "             have at least one objective MEASURABLE disease parameter\n",
      "               -  Radiographic findings are acceptable providing that clear-cut measurement can be\n",
      "                  made\n",
      "               -  Abnormalities on scans may be used to document the presence of disease for\n",
      "                  staging purposes; a clearly defined, bidimensionally measurable defect or mass\n",
      "                  measuring at least 2 cm in diameter on a radionuclide or a CT scan will be\n",
      "                  acceptable as measurable disease\n",
      "               -  An enlarged spleen extending at least 2 cm below the costal margin will\n",
      "                  constitute measurable disease providing that no explanation other than\n",
      "                  lymphomatous involvement is likely; for an enlarged liver to constitute the only\n",
      "                  evident measurable disease parameter, liver biopsy proof of lymphoma in the\n",
      "                  liver is required\n",
      "          -  Patients must have a tissue diagnosis of low-grade malignant lymphoma obtained within\n",
      "             12 months prior to registration (according to the International Working Formulation)\n",
      "             as below:\n",
      "               -  ML- small lymphocytic (Category A)\n",
      "               -  ML-follicular-small cleaved (Category B)\n",
      "               -  ML-follicular-mixed small cleaved and large cell (Category C)\n",
      "          -  Patients having both diffuse and follicular architectural elements will be considered\n",
      "             eligible if the histology is predominantly follicular (i.e. >= 50% of the\n",
      "             cross-sectional area); if the interval since tissue diagnosis of low-grade malignant\n",
      "             lymphoma is > 12 months, diagnostic confirmation using either FNA or nodal biopsy is\n",
      "             required to confirm that the histology remains in one of the eligible categories\n",
      "          -  Women of child bearing potential and sexually active males are strongly advised to\n",
      "             use an accepted and effective method of birth control\n",
      "          -  No prior chemotherapy, radiotherapy, or immunotherapy\n",
      "          -  No active, uncontrolled infections (afebrile for > 48 hours off antibiotics)\n",
      "          -  No evidence of a previous or concurrent malignancy, with the exception of 1) treated\n",
      "             carcinoma in situ of the cervix, 2) treated squamous cell or basal cell skin cancer\n",
      "             OR 3) any other surgically cured malignancy from which the patient has been disease\n",
      "             free for at least 5 years\n",
      "          -  ECOG performance status 0-1\n",
      "          -  WBC > 3000/mm^3\n",
      "          -  Plts > 100,000/mm^3\n",
      "          -  Creatinine =< 1.5 mg/dl\n",
      "          -  Bilirubin < 2.0 mg/dl\n",
      "          -  LFTs =< 5x ULN (SGOT and Alkaline Phosphate)\n",
      "          -  These lab values must be obtained within 4 weeks prior to protocol entry; patients\n",
      "             with documented marrow involvement at the time of registration are not required to\n",
      "             meet the hematologic parameters above\n",
      "          -  Patient must give signed informed consent\n",
      "2610\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent primary malignant glioma\n",
      "        Measurable recurrent or residual primary central nervous system neoplasm confirmed by MRI\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky 60-100%\n",
      "        Hematopoietic: Hematocrit greater than 29% Absolute neutrophil count greater than\n",
      "        1,500/mm3 Platelet count greater than 125,000/mm3 Hepatic: SGOT less than 1.5 times upper\n",
      "        limit of normal (ULN) Bilirubin less than 1.5 times ULN Renal: Creatinine less than 1.5\n",
      "        mg/dL BUN less than 25 mg/dL Pulmonary: DLCO at least 60% Other: Not pregnant Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since prior chemotherapy No prior irinotecan or carmustine treatment failure No more than\n",
      "        1 prior chemotherapy regimen Endocrine therapy: Patients taking corticosteroids must be on\n",
      "        a stable dose for at least 1 week prior to study and the dose should not escalate over\n",
      "        entry dose level Radiotherapy: At least 6 weeks since prior radiotherapy Surgery: At least\n",
      "        3 weeks since prior surgical resection Other: No concurrent medication that may interfere\n",
      "        with study results\n",
      "2612\n",
      "DISEASE CHARACTERISTICS: Histologically proven, previously untreated, low grade gastric\n",
      "        lymphoma Clinical stage I and II1 No bulky disease No high grade component (grade 5 and 4,\n",
      "        if monoclonality proven, allowed) Documented presence/absence of H. pylori infection\n",
      "        Measurable and/or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:\n",
      "        Not pregnant or lactating Fertile patients must use effective contraception No prior or\n",
      "        concurrent malignancies unless: At least 1 year remission Low risk or recurrence No prior\n",
      "        gastric malignancy No nonmalignant disease causing poor medical risk No allergy to\n",
      "        omeprazole\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the abdomen\n",
      "        Surgery: No prior gastric surgery except simple closure of perforated ulcer with or\n",
      "        without wedge excision of the ulcer Other: No prior therapy for gastric lymphoma At least\n",
      "        30 days since experimental therapy No other concurrent experimental therapy At least 30\n",
      "        days since antibiotics with activity against H. pylori\n",
      "2613\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Must be undergoing a diagnostic/therapeutic craniotomy for biopsy/resection of\n",
      "             recurrent or newly diagnosed (or presumed) cerebral anaplastic astrocytoma or\n",
      "             glioblastoma multiforme\n",
      "               -  Patients undergoing stereotactic biopsy or partial resection are eligible\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2 OR\n",
      "          -  Karnofsky 60-100%\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm3\n",
      "          -  Absolute neutrophil count at least 1,800/mm3\n",
      "          -  Platelet count at least 125,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT less than 2 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance greater than 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No cardiovascular illnesses that cannot be adequately controlled with\n",
      "          -  appropriate therapy or would increase risk, e.g.:\n",
      "          -  Severe cardiac disease such as uncontrolled arrhythmias or conduction\n",
      "          -  defects\n",
      "          -  Major problems with edema (e.g., residual leg swelling from deep venous\n",
      "          -  thrombosis)\n",
      "          -  Recent coronary artery disease\n",
      "          -  Poorly controlled hypertension (systolic pressure greater than 180 mm Hg,\n",
      "          -  diastolic pressure greater than 110 mm Hg)\n",
      "        Other:\n",
      "          -  No other medical illnesses that cannot be adequately controlled with\n",
      "          -  appropriate therapy or would increase risk, e.g.:\n",
      "          -  Major problems with edema (e.g., Cushing's syndrome)\n",
      "          -  Major psychiatric illness\n",
      "          -  No other malignancy requiring active therapy\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must us effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Must have failed or received no prior treatment with a nitrosourea,\n",
      "          -  procarbazine, or temozolomide\n",
      "          -  No prior O6-benzylguanine\n",
      "          -  At least 4 weeks since prior chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 6 weeks since prior radiotherapy\n",
      "          -  No prior radiotherapy to greater than 10-20% of bone marrow\n",
      "        Other:\n",
      "          -  No concurrent therapy for any other malignancy\n",
      "          -  At least 2 weeks since other prior investigational drug\n",
      "2615\n",
      "DISEASE CHARACTERISTICS: AIDS-related Kaposi's sarcoma that requires systemic chemotherapy\n",
      "        One or more of the following (Kaposi's sarcoma- or AIDS-associated): Edema that impairs\n",
      "        functional activity Symptomatic, evaluable pulmonary Kaposi's sarcoma documented within 3\n",
      "        months before study Symptomatic, evaluable GI Kaposi's sarcoma documented within 3 months\n",
      "        before study Moderate or severe pain despite the use of analgesics Lesion(s) that patient\n",
      "        feels are disfiguring and impair patient's self-image or daily activities At least 5\n",
      "        bidimensionally measurable monocutaneous lesions\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 40-100% Life\n",
      "        expectancy: At least 120 days Hematopoietic: Neutrophil count at least 1,200 cells/mm3\n",
      "        Platelet count at least 75,000 cells/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Creatinine\n",
      "        less than 2 times upper limit of normal (ULN) Bilirubin less than 2 times ULN Renal: Not\n",
      "        specified Cardiovascular: Cardiac ejection fraction at least 50% No histopathological\n",
      "        evidence of antracycline-induced cardiomyopathy Pulmonary: No significant non-Kaposi's\n",
      "        sarcoma associated pulmonary insufficiency (defined as oxygen saturation less than 90%)\n",
      "        Other: Not pregnant or nursing Fertile women must be using medically proven method of\n",
      "        birth control No opportunistic infection in the past 4 weeks No other active malignancies\n",
      "        except basal or squamous cell carcinoma of the skin or in situ cervical or anal carcinoma\n",
      "        No neuropsychiatric history or altered mental status that prevents informed consent or\n",
      "        compliance with protocol requirements\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 14 days\n",
      "        since prior anti-Kaposi's sarcoma therapy No prior Doxil or DaunoXome No concurrent\n",
      "        cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent\n",
      "        radiation therapy Surgery: Not specified Other: Antiviral therapy allowed Colony\n",
      "        stimulating factors allowed Erythropoietin allowed Prophylactic therapy, maintenance\n",
      "        therapy and treatment for HIV-associated opportunistic infections allowed\n",
      "2616\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the stomach or\n",
      "        gastroesophageal junction beyond the scope of surgical resection Must have measurable\n",
      "        disease in either one or two dimensions either radiographically or by physical examination\n",
      "        Measurable disease must be documented outside of a prior radiation portal Evaluable\n",
      "        disease only not allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC greater than 4,000/mm3 Absolute neutrophil count greater\n",
      "        than 1,500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than\n",
      "        upper limit of normal (ULN) SGOT no greater than 1.5 times ULN Alkaline phosphatase no\n",
      "        greater than 5 times ULN Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No New York\n",
      "        Heart Association class III or IV heart disease No chronic or unstable angina No\n",
      "        uncontrolled congestive heart failure No arrhythmia No chronic angina No myocardial\n",
      "        infarction in the past 1 year If history of atherosclerotic heart disease, prior cardiac\n",
      "        catheterization or thallium stress test must not suggest coronary artery disease\n",
      "        Neurology: No symptomatic peripheral neuropathy greater than grade 2 No cerebellar disease\n",
      "        No seizure disorder No organic mental syndrome No major psychoaffective disorder\n",
      "        Pulmonary: No chronic obstructive pulmonary disease No chronic bronchitis, emphysema,\n",
      "        sarcoid, or bronchiectasis Other: No poorly controlled diabetes mellitus No psychiatric\n",
      "        illness No active infections, including AIDS, ARC, or HIV positive No history of\n",
      "        hypersensitivity to products containing Polysorbate 80 No history of uncontrolled alcohol\n",
      "        or drug abuse No uncontrolled hypercalcemia No other prior malignancy within the past 5\n",
      "        years other than nonmelanomatous skin cancer or cervical carcinoma in situ Not pregnant or\n",
      "        nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        prior systemic chemotherapy Endocrine therapy: No chronic use of steroids No concurrent\n",
      "        hormonal therapy (except birth control pills) Radiotherapy: At least 1 month since prior\n",
      "        radiotherapy No concurrent palliative radiotherapy (arm I patients) Surgery: Must have\n",
      "        fully recovered from surgery Other: At least 4 weeks since other investigational agents\n",
      "        and recovered from all toxic effects No chronic use of aspirin, nonsteroidal\n",
      "        antiinflammatory agents, antianginal medications, or extraordinary antihypertensive\n",
      "        regimens\n",
      "2617\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed esophageal or non-small cell lung\n",
      "        carcinoma Esophageal cancer: Biopsy proven esophageal carcinoma considered acceptable for\n",
      "        curative esophageal resection Lung cancer: Stages IA-IIIB, T(any)N(any)M0 disease without\n",
      "        pleural effusion, which constitutes locally advanced lung cancer Must be candidates for\n",
      "        induction chemotherapy followed by surgical resection\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 4,000/mm3 Platelet count at least\n",
      "        160,000/mm3 Hepatic: Bilirubin no greater than 1.0 mg/dL Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Creatinine clearance greater than 65 mL/min Other: Not pregnant Adequate\n",
      "        contraception required of all fertile female patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: No\n",
      "        prior surgical mediastinal staging such as prior mediastinoscopy or Chamberlain procedures\n",
      "        See Disease Characteristics\n",
      "2618\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid malignant tumors with convincing\n",
      "        clinical, radiographic or isotopic evidence of dissemination Biopsy proof required in all\n",
      "        doubtful cases Must not be eligible for any known regimens or treatments of higher\n",
      "        potential efficacy\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: ECOG 0-2 Life Expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT and SGPT no\n",
      "        greater than 2 times normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: No history of acute myocardial infarction\n",
      "        within the past 6 months No clinically significant cardiac arrhythmias No New York Heart\n",
      "        Association class III or IV disease Other: HIV negative No GI bleeding or bleeding\n",
      "        tendency Not pregnant or nursing Effective contraception required for fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Must have recovered from prior biologic\n",
      "        therapy Chemotherapy: At least 4 weeks since prior chemotherapy and recovered At least 6\n",
      "        weeks since prior nitrosourea or mitomycin Endocrine therapy: Not specified Radiotherapy:\n",
      "        At least 4 weeks since prior radiotherapy and recovered Surgery: Not specified\n",
      "2619\n",
      "DISEASE CHARACTERISTICS: Stage III (nonresectable) and IV melanoma, or any other advanced\n",
      "        metastatic malignancy for which all standard therapy has failed Must have at least two\n",
      "        cutaneous, mucosal or lymph nodal lesions that can be biopsied or one lesion large enough\n",
      "        to be biopsied twice\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Hemoglobin at least 9.0 g/dL Platelet count at least\n",
      "        100,000/mm3 WBC at least 3500/mm3 Absolute granulocyte count at least 1500/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL SGOT and SGPT less than 2.5 times normal Renal:\n",
      "        Creatinine no greater than 1.8 mg/dL Other: Not pregnant Not HIV or hepatitis BsAg\n",
      "        positive No major systemic infections No coagulation disorders No major illness of\n",
      "        cardiovascular or respiratory systems No symptomatic CNS disease or evidence of cerebral\n",
      "        edema\n",
      "        PRIOR CONCURRENT THERAPY: No therapy for cancer within the past month\n",
      "2620\n",
      "Inclusion Criteria:\n",
      "          -  Previously treated non-Hodgkin's lymphoma (all histologies except lymphoblastic and\n",
      "             Burkitt's lymphoma) or Hodgkin's disease\n",
      "          -  Maximum of 4 previous treatment regimens\n",
      "          -  Measurable disease\n",
      "          -  No CNS involvement\n",
      "          -  Performance status - Zubrod 0-1\n",
      "          -  Performance status - Karnofsky 80-100%\n",
      "          -  At least 12 weeks\n",
      "          -  Platelet count at least 75,000/mm^3\n",
      "          -  Absolute neutrophil count greater than 1500/mm^3\n",
      "          -  Lymphocyte count greater than 500/mm^3\n",
      "          -  Hemoglobin at least 8.0 g/dL\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT/SGPT less than 2 times normal\n",
      "          -  Creatinine no greater than 1.6 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  No severe cardiovascular disease including active ischemic heart disease, congestive\n",
      "             heart failure, or major arrhythmias\n",
      "          -  No severe pulmonary disease including dyspnea with moderate to severe exertion\n",
      "          -  HIV negative\n",
      "          -  No active infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use adequate contraception\n",
      "          -  No clinically significant autoimmune disease (e.g. rheumatoid arthritis)\n",
      "          -  No clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer\n",
      "          -  No prior allogeneic bone marrow or stem cell transplant\n",
      "          -  At least 3 weeks since prior biologic therapy for lymphoma\n",
      "          -  At least 3 weeks since prior chemotherapy for lymphoma\n",
      "          -  No concurrent steroid therapy\n",
      "          -  At least 3 weeks since prior endocrine therapy for lymphoma\n",
      "          -  At least 3 weeks since prior radiotherapy for lymphoma\n",
      "          -  At least 2 weeks since prior surgery\n",
      "2621\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic melanoma Patient must express\n",
      "        HLA-A2 (a human leukocyte antigen) Tumor must express MAGE-3 or Melan-A by polymerase\n",
      "        chain reaction (PCR) analysis No untreated brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70%-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no\n",
      "        greater 1.5 times upper limit of normal (ULN) SGPT no greater than 2 times ULN Renal:\n",
      "        Calcium no greater than 11 mg/dL Creatinine no greater than 1.5 times ULN Cardiovascular:\n",
      "        No significant cardiovascular disease or cardiac arrhythmia requiring medical intervention\n",
      "        Other: Hepatitis B surface antigen negative HIV negative No serious concurrent infection\n",
      "        No clinically significant autoimmune disease No active gastrointestinal bleeding or\n",
      "        uncontrolled peptic ulcer disease No history of inflammatory bowel disease No psychiatric\n",
      "        illness that may interfere with compliance in study Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunosuppressive drugs At least\n",
      "        4 weeks since biologic therapy Chemotherapy: At least 2 weeks since chemotherapy Endocrine\n",
      "        therapy: No concurrent systemic corticosteroids (except physiologic replacement doses)\n",
      "        Radiotherapy: At least 2 weeks since radiotherapy Surgery: At least 2 weeks since surgery\n",
      "2622\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven bronchoalveolar carcinoma (BAC) based on these criteria:\n",
      "               -  Absence of primary adenocarcinoma elsewhere\n",
      "               -  Absence of a demonstrable central bronchogenic origin\n",
      "               -  A peripheral location in the lung parenchyma\n",
      "               -  Intact interstitial framework of the lung\n",
      "               -  A histological appearance setting it apart from other tumors, with a\n",
      "                  characteristic pattern of growth: cuboidal or cylindrical cells lining up the\n",
      "                  alveolar septa with preservation of basic pulmonary architecture\n",
      "          -  Must be unresectable Stage IIIB, IV, or recurrent BAC\n",
      "          -  Evidence of multinodular lesions involving the lungs bilaterally or unilaterally (in\n",
      "             the latter the lesions must involve more than one lobe)\n",
      "          -  At least one target lesion bidimensionally measurable that has not undergone prior\n",
      "             irradiation\n",
      "          -  No CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 75 (inclusive)\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Greater than 3 months\n",
      "        Hematopoietic:\n",
      "          -  ANC at least 1,500/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2 times upper limit of normal\n",
      "          -  SGOT, SGPT, and alkaline phosphatase less than 2 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 times upper limit of normal\n",
      "        Cardiovascular:\n",
      "          -  No history of ischemic or congestive heart disease\n",
      "          -  No arrhythmia requiring chronic cardiopulmonary medications\n",
      "          -  No history of clinically or electrographically documented myocardial infarction\n",
      "        Other:\n",
      "          -  No preexisting motor or other serious sensory neurotoxicity\n",
      "          -  No active or prior second primary cancer except basal cell carcinoma of the skin or\n",
      "             carcinoma in situ of the cervix\n",
      "          -  No clinical evidence of uncontrolled infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test 72 hours prior to start of study medication\n",
      "          -  Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since radiotherapy\n",
      "          -  Must have at least one bidimensional lesion outside the irradiated fields\n",
      "        Surgery:\n",
      "          -  Fully recovered from any prior major surgery\n",
      "2623\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Unequivocal diagnosis of metastatic breast cancer\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No uncontrolled CNS metastases\n",
      "          -  No disease that is evaluable only, including blastic bone disease, malignant ascites,\n",
      "             and malignant pleural effusion\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  SWOG 0-2 OR\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 18 weeks\n",
      "        Hematopoietic:\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "          -  PT and PTT within normal limits\n",
      "          -  Neutrophil count at least 2,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.2 mg/dL\n",
      "          -  Transaminases no greater than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.6 mg/dL OR\n",
      "          -  Creatinine clearance at least 70 mL/min\n",
      "        Other:\n",
      "          -  No active infections requiring antibiotics\n",
      "          -  No viral hepatitis allowed\n",
      "          -  Seronegative for hepatitis B or C\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 2 months following\n",
      "             study participation\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  2 prior chemotherapy regimens for metastatic disease allowed as adjuvant therapy or\n",
      "             for advanced disease (may include high dose chemotherapy with stem cell support)\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  At least 6 weeks since prior nitrosourea or mitomycin therapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  2 prior hormonal therapy regimens for metastatic disease as adjuvant therapy or for\n",
      "             advanced diseases allowed\n",
      "          -  At least 2 weeks since prior hormonal therapy (at least 4 weeks in case of disease\n",
      "             progression while receiving hormonal therapy after initial response)\n",
      "          -  No concurrent hormonal therapy except oral contraceptives\n",
      "          -  No concurrent use of steroids except for management of severe or life- threatening\n",
      "             toxic effects arising from bryostatin 1\n",
      "        Radiotherapy:\n",
      "          -  At least 2 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent use of drugs known to interfere with platelet function, such as aspirin\n",
      "             or NSAIDs (including ibuprofen)\n",
      "          -  No concurrent use of anticoagulants\n",
      "          -  At least 2 weeks since prior use of aspirin\n",
      "          -  At least 2 days since prior use of NSAIDS\n",
      "          -  Concurrent use of acetaminophen to control pain is allowed\n",
      "          -  If acetaminophen inadequate for pain control, concurrent use of oral narcotics such\n",
      "             as codeine or oxycodone is allowed\n",
      "2624\n",
      "DISEASE CHARACTERISTICS: Cytologically proven small, noncleaved cell non-Hodgkin's\n",
      "        lymphoma, Burkitt's lymphoma, non-Burkitt's lymphoma, or B cell acute lymphoblastic\n",
      "        leukemia (B-ALL) Stage III or IV B-ALL - must have FAB L3 morphology and have been\n",
      "        registered on POG-9400\n",
      "        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: HIV antibody positive allowed Not pregnant or lactating\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No\n",
      "        prior chemotherapy Endocrine therapy: Prior emergency steroid therapy may be allowed\n",
      "        Radiotherapy: Prior emergency radiotherapy may be allowed Surgery: Prior surgery allowed\n",
      "        Other: No concurrent dexamethasone as an anti-emetic\n",
      "2625\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the oral cavity,\n",
      "        oropharynx, hypopharynx, or larynx No distant metastatic disease No previous or concurrent\n",
      "        head and neck primaries No lip, nasopharynx, or salivary gland lesions No recurrent tumors\n",
      "        Stage IV disease comprised of T4 NO-3 lesions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky greater than 60\n",
      "        Life Expectancy: Not specified Hematopoietic: ANC greater than 2,000 Platelet count\n",
      "        greater than 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50\n",
      "        mL/min Cardiovascular: Not specified Other: Not pregnant or nursing No adverse medical\n",
      "        illnesses No imaging studies performed greater than one month preregistration No\n",
      "        laboratory studies greater than 2 weeks preregistration No other malignancies, except for\n",
      "        basal or squamous cell of the skin, within the past 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the\n",
      "        head and neck Surgery: No prior surgery to study site other than a biopsy Other: Protocol\n",
      "        treatment must begin within 8 weeks of biopsy\n",
      "2626\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven tumors:\n",
      "               -  Unresectable meningioma\n",
      "               -  Atypical meningioma\n",
      "               -  Malignant meningioma\n",
      "               -  Angioblastic meningioma\n",
      "               -  Hemangiopericytoma\n",
      "          -  Recurrent or progressive, unresectable tumor after failing radiation therapy or\n",
      "             refused radiation therapy following 2 surgeries\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky at least 60%\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  AGC at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGPT less than 2.0 times normal\n",
      "          -  Alkaline phosphatase less than 2.0 times normal\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times normal OR\n",
      "          -  Creatinine less than 1.5 times normal\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  No diseases that obscure toxicity or dangerously alter drug metabolism\n",
      "          -  No serious intercurrent medical illness\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use adequate contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  Prior chemotherapy allowed and recovered from all myelotoxicity secondary to the\n",
      "             therapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior hormonal therapy allowed\n",
      "          -  No concurrent hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2628\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven low or intermediate grade ductal carcinoma in situ (DCIS) of\n",
      "             the breast\n",
      "               -  No greater than 2.5 cm in the greatest dimension\n",
      "          -  OR\n",
      "          -  Histologically proven high-grade DCIS of the breast\n",
      "               -  No greater than 1 cm in greatest dimension\n",
      "          -  Region of DCIS must be at least 2.5 mm in greatest dimension (mammographic estimate\n",
      "             of size allowed where pathologic measurement is impossible)\n",
      "          -  DCIS must be non-palpable; detected by a mammogram or found incidentally by a breast\n",
      "             biopsy\n",
      "          -  Pathologically confirmed negative margins of at least 3 mm\n",
      "          -  Breast must be suitable for breast conserving therapy\n",
      "               -  Proper tumor size versus breast size\n",
      "               -  No carcinoma or suspicious mammogram findings in other breast sites\n",
      "          -  No prior in situ or invasive breast cancer\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Greater than 5 years\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other invasive malignancies within the past 10 years except nonmelanomatous skin\n",
      "             cancer or carcinoma in situ of the cervix\n",
      "          -  No known HIV infection\n",
      "          -  No Paget's nipple disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Adjuvant tamoxifen allowed\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to breast\n",
      "          -  No adjuvant radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2629\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Malignant solid tumors\n",
      "          -  Must have failed conventional treatment or for whom conventional therapy is not\n",
      "             available\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  Intraocular retinoblastomas may be measured by direct visualization\n",
      "               -  Germ cell tumors may be measured by tumor markers\n",
      "          -  No known bone marrow involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Any age\n",
      "        Performance status:\n",
      "          -  Lansky 60-100% for patients 16 and under\n",
      "          -  Karnofsky 60-100% for patients over 16\n",
      "        Life expectancy:\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,000/mm^3\n",
      "          -  Platelet count at least 75,000/mm^3\n",
      "          -  If parameters not met, must have adequate stem cell yield\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times the upper limit of normal (ULN)\n",
      "          -  SGOT and SGPT no greater than 2.5 times the ULN (unless liver involvement by tumor)\n",
      "        Renal:\n",
      "          -  Creatinine within normal limits OR\n",
      "          -  Creatinine clearance at least 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Fractional shortening greater than 28% on echocardiogram OR\n",
      "          -  Ejection fraction at least 55% on RNCA prior to first cycle of thiotepa\n",
      "        Pulmonary:\n",
      "          -  DLCO greater than 55% of predicted (only required if there is clinical evidence of\n",
      "             pulmonary dysfunction)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior bone marrow or peripheral blood stem cell rescue allowed\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy if absolute neutrophil count is less than\n",
      "             1,000/mm^3 or platelet count is less than 75,000/mm^3, and recovered (i.e. adequate\n",
      "             stem cells collected to predict hematopoietic recovery)\n",
      "          -  No concurrent chemotherapy except for dexamethasone for antiedema effects\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent use of corticosteroids used solely as antiemetics\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since radiotherapy if absolute neutrophil count is less than\n",
      "             1,000/mm^3 or platelet count is less than 75,000/mm^3, and recovered (i.e. adequate\n",
      "             stem cells collected to predict hematopoietic recovery)\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2630\n",
      "DISEASE CHARACTERISTICS: Documented HIV antibody positive Histologically confirmed, by\n",
      "        biopsy, non-Hodgkin's lymphoma that is in complete remission or stable/partial remission\n",
      "        for a minimal period of one month And/or Histologically confirmed, by biopsy, Kaposi's\n",
      "        sarcoma without stable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100%\n",
      "        Hematopoietic: Absolute neutrophil count at least 500/mm3 Platelet count greater than\n",
      "        25,000/mm3 (unless secondary to lymphoma) Hepatic: Transaminases less than 5 times upper\n",
      "        limit of normal AND Bilirubin less than 2.0, unless secondary to lymphoma Renal:\n",
      "        Creatinine less than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Dose reduction\n",
      "        of 21% if creatinine clearance 10-50 mL/min Dose reduction of 50% if creatinine clearance\n",
      "        less than 10 mL/min Cardiovascular: No active cardiac arrhythmia or angina Pulmonary: Must\n",
      "        exclude Pneumocystis carinii pneumonia if there is any suspicion of infection Other: No\n",
      "        uncontrolled infections Not pregnant or nursing Adequate contraception for fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Patients with\n",
      "        concurrent antiretroviral therapy should be on a stable dose of that therapy for at least\n",
      "        one month prior to entry No concurrent cytotoxic chemotherapy Endocrine therapy: No\n",
      "        concurrent hormone therapy Radiotherapy: No concurrent radiotherapy Surgery: Not specified\n",
      "2631\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non hematologic\n",
      "        malignancy refractory to standard therapy, or for which no known effective therapies exist\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute\n",
      "        neutrophil count at least 2,000/mm3 Absolute lymphocyte count at least 1,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL Transaminase no greater than 2.5 times upper limit of\n",
      "        normal Renal: Creatinine no greater than 1.4 mg/dL Cardiovascular: No myocardial\n",
      "        infarction within 6 months No current, uncontrolled cardiac arrhythmias Other: No history\n",
      "        of anaphylactic reactions Not pregnant Fertile patients must use effective contraception\n",
      "        No serious uncontrolled, concurrent medical disorder\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior paclitaxel\n",
      "        allowed No prior irinotecan At least 4 weeks since prior chemotherapy Endocrine therapy:\n",
      "        No concurrent steroids Radiotherapy: At least 4 weeks since prior radiotherapy Surgery:\n",
      "        Not specified\n",
      "2633\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven metastatic breast cancer\n",
      "               -  Stage IV disease patients who have either been treated to maximal response or\n",
      "                  who have had high dose chemotherapy or a marrow ablative regimen (if they meet\n",
      "                  immunologic criteria and have not received more than 2 chemotherapy regimens for\n",
      "                  treatment of metastatic disease)\n",
      "               -  Patients with advanced stage disease who:\n",
      "                    -  Received at least 1 standard chemotherapy regimen, but no more than 2, for\n",
      "                       treatment of metastatic disease\n",
      "                    -  Refused chemotherapy\n",
      "                    -  Refused or progressed despite hormonal therapy\n",
      "          -  Measurable or evaluable disease\n",
      "          -  Positive or negative for HLA-A2\n",
      "          -  Must have superficial inguinal or axillary lymph nodes that are free of tumor\n",
      "             involvement and are surgically accessible\n",
      "          -  No symptomatic or acutely life threatening tumor that is judged likely to require\n",
      "             intervention with alternative modalities within 3 months\n",
      "          -  No brain metastases\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0 or 1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  BUN less than 25 mg/dL\n",
      "          -  Creatinine less than 1.8 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No ischemic or congestive cardiac disease requiring chronic medication\n",
      "          -  No New York Heart Association class III or IV heart disease\n",
      "          -  No evidence of ischemic change or ventricular ectopy (greater than 4/min) on\n",
      "             electrocardiogram (EKG)\n",
      "          -  No evidence of type II arterial-ventricular block\n",
      "          -  No evidence of current cardiac disease by stress test and EKG\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No active infection requiring treatment\n",
      "          -  No psychiatric illness\n",
      "          -  No history of seizure disorder\n",
      "          -  No other prior malignancy within the past 10 years except squamous cell or basal cell\n",
      "             skin cancer or carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior specific or nonspecific immunotherapy, unless there is\n",
      "             obvious progression of metastatic disease, and recovered\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy, unless there is obvious progression of\n",
      "             metastatic disease, and recovered\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior steroids, unless there is obvious progression of\n",
      "             metastatic disease, and recovered\n",
      "        Radiotherapy:\n",
      "          -  Concurrent radiotherapy allowed for local control of disease\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2634\n",
      "DISEASE CHARACTERISTICS: Histologically proven carcinoma of the breast with metastases No\n",
      "        CNS metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Menopausal status: Not specified Sex: Female\n",
      "        Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) SGOT\n",
      "        and SGPT no greater than 2 times ULN (no greater than 5 times ULN with liver metastases)\n",
      "        Renal: Not specified Cardiovascular: Ejection fraction within normal range No history of\n",
      "        cardiac disease including myocardial infarction, cardiac failure and angina Other: Not\n",
      "        pregnant No prior or concurrent malignancy that is likely to interfere with protocol\n",
      "        treatments or comparisons\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy other than adjuvant No prior high dose adjuvant chemotherapy requiring\n",
      "        transplantation Cumulative dose of doxorubicin no greater than 300 mg/m2 permitted\n",
      "        Cumulative dose of epirubicin no greater than 400 mg/m2 permitted At least 6 months since\n",
      "        prior anthracyclines Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:\n",
      "        Not specified\n",
      "2637\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed locally recurrent or metastatic\n",
      "        nasopharyngeal carcinoma that is not curable with resection or radiation therapy\n",
      "        Bidimensionally measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count greater than 1500/mm3 Platelet\n",
      "        count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine\n",
      "        less than 3.0 mg/dL Other: No active infections Serum calcium within institutional normal\n",
      "        range No history of hypercalcemia Prior malignancy other than nasopharyngeal carcinoma\n",
      "        allowed No concurrent malignancy Not pregnant or lactating Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed Chemotherapy:\n",
      "        No prior chemotherapy for metastatic or recurrent disease Prior induction or adjuvant\n",
      "        chemotherapy concurrent with radiation therapy allowed No prior treatment with paclitaxel\n",
      "        Endocrine therapy: Not specified Radiotherapy: See Chemotherapy Surgery: Not specified\n",
      "2638\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed locally advanced\n",
      "        adenocarcinoma or squamous cell carcinoma of the esophagus Evidence of disease extension\n",
      "        into or through the wall of the esophagus (T2- T4) and/or regional nodal metastases (N1)\n",
      "        Patients with distant metastatic disease or who cannot undergo resection may also be\n",
      "        treated on the phase I portion of this trial but are not eligible for the modified phase\n",
      "        II portion Patients entered in the modified phase II portion of the trial must have\n",
      "        evaluable (measurable in one dimension) or measurable disease at the primary site\n",
      "        PATIENT CHARACTERISTICS: Age: 18 or over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 2 months for those with metastatic disease or 2 years for those with locally\n",
      "        advanced disease Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 2.0 mg/dl Renal:\n",
      "        Creatinine clearance at least 60 mL/min Serum creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular: No history of refractory congestive heart failure or cardiomyopathy Other:\n",
      "        Not pregnant No other malignancy within 5 years except: Curatively treated carcinoma in\n",
      "        situ of the cervix Basal cell carcinoma of the skin\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        More than 1 week since major surgery\n",
      "2640\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically documented solid tumor that is\n",
      "        refractory to conventional therapy or for which no conventional treatment exists No\n",
      "        primary or secondary brain tumor No CNS disease or treatment-related CNS dysfunction No\n",
      "        bone metastases involving 4 or more sites\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 8 weeks Hematopoietic: Absolute neutrophil count greater than 1,500 Platelet count\n",
      "        greater than 100,000 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Other: No active infection No history of egg protein allergy No\n",
      "        prior gastric or small intestine resection or clinical evidence of malabsorption No\n",
      "        history of medical, neurologic, or psychiatric disorder No concomitant medical problem\n",
      "        unrelated to the malignancy that precludes study compliance or increases treatment risk No\n",
      "        pregnant women Adequate contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        more than 4 courses of combination chemotherapy that included an alkylating agent,\n",
      "        cisplatin, or carboplatin (applies once grade 1 or worse myelosuppression is reported on\n",
      "        this study) No prior mitomycin or nitrosoureas At least 28 days since chemotherapy No\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy to wide ports involving pelvis or 20% of bone marrow At least 28 days since\n",
      "        large-field radiotherapy No concurrent radiotherapy Surgery: At least 14 days since major\n",
      "        surgery Other: No bone marrow transplantation\n",
      "2641\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven untreated stage Ib or IIa cervical carcinoma, squamous or\n",
      "             adenocarcinoma suitable for surgical excision\n",
      "               -  No CNS metastases\n",
      "          -  Circulating CD4+ lymphocyte count at least 400\n",
      "          -  Proven absence of hepatitis B and C antibodies\n",
      "          -  Previous exposure to vaccinia from smallpox vaccination, as well as no previous\n",
      "             exposure, is allowed\n",
      "          -  Reaction to 2 or more antigens on Pasteur Merieux CMI test required\n",
      "          -  Ability to collaborate planned follow-up required\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  19 and over\n",
      "        Performance status:\n",
      "          -  WHO/ECOG no greater than 2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,000 (3,000 x 10 to the ninth/L)\n",
      "          -  Platelet count greater than 120,000 (120 x 10 to the ninth/L)\n",
      "          -  No bleeding disorder\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times normal\n",
      "          -  AST and ALT less than 1.5 times normal\n",
      "          -  Prothrombin or partial thromboplastin time no greater than 2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.3 mg/dL (120 micromoles/L)\n",
      "        Other:\n",
      "          -  No ongoing infection\n",
      "          -  No HIV antibody\n",
      "          -  No serious medical or psychiatric illness\n",
      "          -  No second malignancy within 5 years except for curatively treated basal cell skin\n",
      "             cancer which required surgery, hormone therapy, immunotherapy or chemotherapy\n",
      "          -  Not pregnant or nursing\n",
      "          -  Adequate contraception required\n",
      "          -  Patient or her household contacts must not have any of the following:\n",
      "               -  Chronic steroid therapy\n",
      "               -  Renal or other allograft\n",
      "               -  Known immunodeficiency\n",
      "               -  Eczema\n",
      "               -  Children under 5 years old\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2643\n",
      "DISEASE CHARACTERISTICS: Histologically proven EBV-associated primary CNS lymphoma HIV\n",
      "        infection confirmed by a positive ELISA and Western blot\n",
      "        PATIENT CHARACTERISTICS: Age: Open to children and adults of any age Performance Status:\n",
      "        Karnofsky at least 50% Life Expectancy: At least 4 weeks Hematopoietic: Hemoglobin at\n",
      "        least 6.9 gm/dL ANC at least 500/mm3 Platelet count at least 50,000/mm3 Hepatic: Bilirubin\n",
      "        no greater than 1.5 x upper limit of normal (ULN) (1.5 to 2.5 x ULN if receiving\n",
      "        indinavir) Renal: Creatinine no greater than 1.5 x ULN Cardiovascular: Not specified\n",
      "        Other: Not pregnant or nursing Contraception required in fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other:\n",
      "        Prior or concurrent antiretroviral therapy allowed No prior EBV-associated primary CNS\n",
      "        lymphoma therapy within 1 week of study\n",
      "2644\n",
      "DISEASE CHARACTERISTICS: Histologically proven unresectable (including incomplete\n",
      "        resections) or locally recurrent pancreatic or gastric cancer No evidence of metastases\n",
      "        outside of the planned radiation field No cystadenocarcinoma of the pancreas or pancreatic\n",
      "        tumors of neuroendocrine origin\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin within normal limits Alkaline phosphatase no\n",
      "        greater than 3.0 times upper limit of normal (ULN) AST no greater than 3.0 times ULN\n",
      "        Renal: Creatinine no greater than 1.3 times ULN Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No significant infection or medical illness No\n",
      "        significant nausea or vomiting At least 1200 calories per day of oral nutrition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent biologic therapy\n",
      "        Chemotherapy: No prior or concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior radiotherapy (except focal fields for skin cancer that do not\n",
      "        overlap with planned radiotherapy fields) Surgery: At least 21 days since laparotomy\n",
      "        surgery\n",
      "2645\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed single primary\n",
      "        bronchogenic non-small cell lung cancer (NSCLC) Stage IIIA (T1-2 N2 M0; T3 N0-2 M0) or\n",
      "        IIIB (T4 or N3 M0, excluding malignant pleural effusion) Following NSCLC cellular types\n",
      "        are eligible: adenocarcinoma large cell carcinoma squamous cell carcinoma unspecified\n",
      "        Histology or cytology from involved mediastinal or supraclavicular nodes are sufficient\n",
      "        for diagnosis if a separate primary lesion of the lung parenchyma is clearly evident on\n",
      "        radiographs Radiographic evidence of mediastinal lymph nodes of at least 1.5 cm in the\n",
      "        largest diameter is sufficient to stage N2 or N3 If the largest mediastinal nodes are less\n",
      "        than 1.5 cm in diameter and this is the basis for stage III disease, then at least one of\n",
      "        the nodes has to be proven positive cytologically or histologically No bronchioloalveolar\n",
      "        carcinoma or stage IIIB tumor involving the superior sulcus Patients must meet at least\n",
      "        one of the following conditions: - FEV1 less than 2 liters and predicted FEV1 of the\n",
      "        contralateral lung no greater than 800 mL based on the quantitative split function testing\n",
      "        - Creatinine clearance less than 50 mL/min - Significant clinical hearing loss and\n",
      "        unwilling to accept the potential for worsening due to cisplatin - Controlled congestive\n",
      "        heart failure that, in the opinion of the investigator, may become decompensated due to\n",
      "        excessive hydration prior to cisplatin administration - SWOG performance status 2 and\n",
      "        either albumin less than 0.85 times upper limit of normal or weight loss of greater than\n",
      "        10% due to tumor Measurable or evaluable disease Patients with pleural effusion are\n",
      "        eligible only if: - pleural fluid must be a transudate with negative cytology if present\n",
      "        before mediastinoscopy or exploratory thoracotomy - pleural fluid can be either transudate\n",
      "        or exudate with negative cytology if present only after exploratory or staging thoracotomy\n",
      "        but not before - in any case, pleural effusion is present only on CT scan but not on\n",
      "        decubitus chest x-ray, and it is deemed too small to tap under either CT or ultrasound\n",
      "        guidance\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least\n",
      "        1,200/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times\n",
      "        upper limit of normal SGOT no greater than 1.5 times upper limit of normal Renal:\n",
      "        Creatinine clearance at least 20 mL/min Cardiovascular: No unstable congestive heart\n",
      "        failure No active angina No unstable cardiac arrhythmias Pulmonary: FEV1 at least 1.0\n",
      "        liter Also See Disease Characteristics Other: No uncontrolled peptic ulcer disease No\n",
      "        active infection No prior malignancy except adequately treated basal cell or squamous cell\n",
      "        skin cancer, in situ cervical cancer, or other cancer for which the patient has been\n",
      "        disease free for 5 years Not pregnant or nursing Adequate contraception required of all\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiation for lung\n",
      "        cancer Surgery: No prior surgery for lung cancer\n",
      "2647\n",
      "DISEASE CHARACTERISTICS: Invasive transitional cell carcinoma of the bladder that is\n",
      "        clinical stage T2-3a N0 M0 by cystoscopy Cystoscopy performed at Memorial Sloan-Kettering\n",
      "        Cancer Center (MSKCC) No multifocal carcinoma in situ No obstructive uropathy or palpable\n",
      "        mass Pathologic confirmation of histology and no more than 20% positive expression of\n",
      "        nuclear p53, as follows: On study following transurethral resection of the bladder (TURB)\n",
      "        OR At TURB performed within 6 weeks of entry as part of initial staging\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100%\n",
      "        Hematopoietic: WBC at least 3,500 Platelets greater than 150,000 Hepatic: Bilirubin less\n",
      "        than 2.0 mg/dL Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than\n",
      "        60 mL/min per 1.73 square meters Cardiovascular: No NYHA class III/IV status Other: No\n",
      "        concomitant malignancy other than basal cell skin carcinoma Negative pregnancy test\n",
      "        required of fertile women Adequate contraception required of fertile women\n",
      "        PRIOR CONCURRENT THERAPY: No prior systemic chemotherapy No prior bladder irradiation\n",
      "2648\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed malignancy (solid tumor or lymphoma)\n",
      "          -  No history of brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  WBC at least 4,000/mm3\n",
      "          -  Absolute neutrophil count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Creatinine normal\n",
      "          -  No history of seizure disorder Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas and mitomycin)\n",
      "             and recovered\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "2649\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven phyllodes tumors of the breast with borderline or malignant\n",
      "             grade, defined as 1 of the following:\n",
      "               -  Borderline, defined as 5-9 mitoses/10 high power fields (HPF), pushing or\n",
      "                  infiltrating margins, 2+ atypia\n",
      "               -  Malignant, defined as 10 or more mitoses/10 HPF, predominantly infiltrating\n",
      "                  margins, usually 3+ atypia with occasional 2+ atypia\n",
      "          -  Must have been excised with breast-conserving resection\n",
      "               -  No positive margins\n",
      "          -  Local recurrence of a previously excised phyllodes tumor allowed if the recurrence is\n",
      "             in the area of the prior excision\n",
      "          -  No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  No prior radiotherapy to the ipsilateral breast\n",
      "        Surgery\n",
      "          -  See Disease Characteristics\n",
      "2650\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed (except if medically contraindicated) brain stem glioma that\n",
      "             is unlikely to respond to existing therapy and for which no curative therapy exists\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concomitant disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at\n",
      "             least 1 week before study entry)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2651\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed (except if medically contraindicated) incurable primitive\n",
      "             neuroectodermal tumor\n",
      "               -  Evidence of progressive or recurrent tumor by MRI or CT scan performed within 2\n",
      "                  weeks prior to study entry\n",
      "          -  Must have received and failed prior standard therapy\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic insufficiency\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No severe heart disease\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concomitant disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on a stable dose for\n",
      "             at least 1 week prior to study entry)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston treatment\n",
      "2652\n",
      "Inclusion Criteria:\n",
      "          -  Histologically or cytologically proven acute leukemia (M3 marrow) that is refractory\n",
      "             to conventional therapy or for which no effective therapy exists\n",
      "          -  No CNS leukemia\n",
      "          -  No solid tumors\n",
      "          -  Performance status: Karnofsky 50-100% OR Lansky at least 50 (for infants)\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGPT less than 5 times normal\n",
      "          -  Normal creatinine for age OR GFR at least 70 mL/min\n",
      "          -  No significant systemic illness such as infection\n",
      "          -  No significant third space fluid collection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Recovered from acute toxic effects of prior immunotherapy\n",
      "          -  At least 6 months since prior bone marrow transplant with no evidence of\n",
      "             graft-versus-host disease\n",
      "          -  At least 10 days since prior biologic therapy\n",
      "          -  At least 1 week since prior growth factors\n",
      "          -  At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)\n",
      "             and recovered\n",
      "          -  No concurrent steroids\n",
      "          -  Recovered from acute toxic effects of all prior radiotherapy\n",
      "          -  At least 2 weeks since prior local palliative radiotherapy (small port)\n",
      "          -  At least 6 months since prior substantial bone marrow radiation\n",
      "          -  No other concurrent anticancer therapy or investigational agents\n",
      "          -  No concurrent nonsteroidal anti-inflammatory agents\n",
      "2653\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed incurable oligodendroglioma that progressed\n",
      "             during or is recurrent or residual after initial therapy, including radiotherapy\n",
      "             and/or chemotherapy\n",
      "          -  Evidence of tumor by gadolinium-enhanced MRI, CT scan, or positron-emission\n",
      "             tomography\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "          -  Must have received and failed prior standard therapy (i.e., radiotherapy,\n",
      "             chemotherapy, immunotherapy, or cytodifferentiating agent)\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from any prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2654\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable primary mixed glioma that is progressive,\n",
      "             persistent, or recurrent following initial standard therapy, including radiation\n",
      "             therapy\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/mL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/mL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No known chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "          -  No severe chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No other severe medical illness\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy (unless there is evidence of disease\n",
      "             progression)\n",
      "        Surgery:\n",
      "          -  Fully recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2656\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed intraabdominal cancer\n",
      "          -  Diffuse abdominal carcinomatosis Chemotherapy refractory advanced stage ovarian\n",
      "             cancer\n",
      "          -  Measurable disease\n",
      "          -  Residual, recurrent, or metastatic disease beyond the scope of standard curative\n",
      "             therapy\n",
      "          -  Extension of disease to sites distant to the peritoneal cavity allowed\n",
      "             Retroperitoneal lymphadenopathy allowed as long as there is evaluable intraabdominal\n",
      "             disease\n",
      "          -  No history of progressive brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: Karnofsky 70-100%\n",
      "          -  Hemoglobin greater than 9 g/dL\n",
      "          -  WBC greater than 3,000/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  ALT less than 100 U/L\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "          -  Normal electrocardiogram\n",
      "          -  No recent history of cardiac ischemia\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Hepatitis B negative\n",
      "          -  No evidence of clinical immunodeficiency syndromes or immunodeficiency associated\n",
      "             diseases\n",
      "          -  No history of autoimmune disease\n",
      "          -  No concurrent major illness\n",
      "          -  No serious infection requiring intravenous antibiotics\n",
      "          -  No active peptic ulcer disease\n",
      "          -  Must have free flow of fluid into the peritoneal space\n",
      "          -  No leakage from the catheter exit site\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 3 weeks since prior biologic therapy (6 weeks for interleukin-2)\n",
      "          -  No prior recombinant human interleukin-12\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "          -  No concurrent systemic chemotherapy\n",
      "          -  No concurrent systemic corticosteroids\n",
      "          -  No prior radiation therapy to the whole abdomen\n",
      "          -  No concurrent radiotherapy\n",
      "          -  At least 3 weeks since prior exposure to any investigational drug\n",
      "          -  No concurrent investigational drug\n",
      "2657\n",
      "Inclusion Criteria:\n",
      "          -  Histologically confirmed adenocarcinoma of the female breast which is inoperable,\n",
      "             recurrent or metastatic\n",
      "          -  HER-2/neu status must be known at the time of protocol registration; HER-2/neu\n",
      "             assessment will be based on FISH analysis of either the primary tumor or a metastatic\n",
      "             site; a scoring of 0 or 1+ by immunohistochemistry (IHC) is considered negative; 2+\n",
      "             is considered negative unless confirmed by FISH positivity, in which case it should\n",
      "             be considered positive; 3+ by IHC is considered positive; for centers using FISH\n",
      "             only, a positive FISH assay by itself is sufficient to determine HER-2 positivity\n",
      "          -  Patients with the following prior therapy are eligible:\n",
      "               -  Patients with 0-1 prior chemotherapy regimens for metastatic or locally advanced\n",
      "                  breast cancer, with the following exception: no prior taxane for\n",
      "                  metastatic/locally advanced breast cancer\n",
      "               -  Patients with 0-1 prior chemotherapy regimens in the adjuvant setting; if\n",
      "                  adjuvant regimen included a taxane, patient must have been disease free for at\n",
      "                  least 12 months from completion of adjuvant therapy until relapse\n",
      "               -  Patients must be > 2 weeks from prior surgery, other than simple biopsy or\n",
      "                  placement of venous access device; patients must be > 4 weeks from prior\n",
      "                  chemotherapy; patients must be >6 weeks from nitrosoureas, melphalan, or\n",
      "                  mitomycin\n",
      "                    -  Patients must be > 4 weeks from prior hormonal therapy unless tumor\n",
      "                       measurements document clear progression while on treatment; if progression\n",
      "                       is documented and toxicity from hormonal regimen has resolved, patients may\n",
      "                       be placed on study > 1 week from prior hormonal therapy\n",
      "          -  Prior Herceptin therapy is not allowed\n",
      "          -  Patients with central nervous system metastases are eligible only if the patient has\n",
      "             completed cranial irradiation at least 6 months prior, is currently asymptomatic, and\n",
      "             is not currently receiving corticosteroids for this condition; patients with\n",
      "             leptomeningeal carcinoma (carcinomatous meningitis) are not eligible\n",
      "          -  MESURABLE DISEASE: Any mass reproducibly measurable in two perpendicular dimensions,\n",
      "             examples include:\n",
      "               -  Pulmonary nodules\n",
      "               -  Hepatic lesions\n",
      "               -  Skin nodules (if two measurements can be assigned)\n",
      "               -  Lymph nodes\n",
      "          -  The following lesions do not qualify as measurable:\n",
      "               -  Central nervous system (CNS) lesions\n",
      "               -  Bone disease only; lytic lesions should be documented and followed\n",
      "               -  Lymphangitic pulmonary metastases (patients with lymphangitic metastases are\n",
      "                  eligible if there are other sites of metastatic disease which can be measured)\n",
      "               -  Lesions which have been irradiated unless there is definite documentation of\n",
      "                  progression since radiotherapy\n",
      "          -  A baseline assessment of left ventricular ejection fraction within 8 weeks of\n",
      "             registration is required (echocardiogram or resting multi gated acquisition scan\n",
      "             [MUGA] (radionuclide cineangiography [RNCA]) nuclear scintigraphy); patients with a\n",
      "             left ventricular ejection fraction (LVEF) < 45% are ineligible\n",
      "          -  Granulocytes >= 1500/ul\n",
      "          -  Platelet count >= 100,000/ul\n",
      "          -  Creatinine =< 2.0 mg/dl\n",
      "          -  Bilirubin within institutional normal limits\n",
      "          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])\n",
      "2659\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignancy that is stage IV and/or at\n",
      "        high risk of recurrence despite standard treatment Stage IV malignancy that is surgically\n",
      "        rendered free of macroscopic tumor allowed if current available treatment is not likely to\n",
      "        offer a survival advantage or result in significant palliation If at high risk for\n",
      "        recurrence, must have an estimated recurrence rate of at least 75% following definitive\n",
      "        therapy, such as: Postresection of pancreatic cancer Gastric cancer with regional lymph\n",
      "        node involvement Node positive stage II or stage III esophageal cancer Stage IIIA or IIIB\n",
      "        non-small cell lung cancer Breast cancer with at least 10 positive axillary nodes Must\n",
      "        have low tumor burden or no evidence of disease Must have evidence of prior vaccinia (for\n",
      "        smallpox immunization) Must have CEA expressing type tumor or a serum CEA elevation of 10\n",
      "        or greater during course of disease No CNS metastases Hormone receptor status: Not\n",
      "        specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: ECOG 0-1 Life expectancy: At least 6 months Hematopoietic: Absolute granulocyte\n",
      "        count at least 1,500/mm3 WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT and SGPT no\n",
      "        greater than 4 times ULN Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine\n",
      "        clearance at least 50 mL/min Other: HIV negative No uncontrolled seizure disorders,\n",
      "        encephalitis, or multiple sclerosis No history of allergy or untoward reaction to prior\n",
      "        vaccination with vaccinia virus No other prior or concurrent diagnosis of altered immune\n",
      "        function, including eczema, atopic dermatitis, or any autoimmune disease such as systemic\n",
      "        lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's\n",
      "        syndrome, Addison's disease, Hashimoto's thyroiditis, or active Graves' disease Must be\n",
      "        maintaining a reasonable state of nutrition, consistent with weight maintenance No\n",
      "        frequent vomiting or severe anorexia Must be able to avoid close contact with children 3\n",
      "        years or younger, pregnant women, individuals with eczema or history of eczema or other\n",
      "        open skin conditions, or immunosuppressed individuals for at least 2 weeks after each\n",
      "        vaccination No serious concurrent medical illnesses including inflammatory bowel disease,\n",
      "        Crohn's disease, ulcerative colitis, or active diverticulitis Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception during and for\n",
      "        at least 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Must have recovered from toxic effects of all prior therapy\n",
      "        Biologic therapy: Prior vaccinia immunization required No concurrent biologic therapy No\n",
      "        concurrent immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks\n",
      "        since prior nitrosoureas or mitomycin) No concurrent chemotherapy Endocrine therapy:\n",
      "        Physiologic replacement of steroids allowed No concurrent hormonal therapy Radiotherapy:\n",
      "        No prior radiotherapy to more than 50% of all nodal groups Surgery: At least 3 weeks since\n",
      "        any prior major surgery\n",
      "2660\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage II, III, or IV high-grade non-Hodgkin's lymphoma that has\n",
      "             not responded to, or has relapsed after a standard primary chemotherapy regimen plus\n",
      "             at least 1 standard second-line salvage chemotherapy regimen NOTE: A new\n",
      "             classification scheme for adult non-Hodgkin's lymphoma has been adoptedby PDQ. The\n",
      "             terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection requiring treatment\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agent\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior dexamethasone, prednisone, or other corticosteroids\n",
      "          -  No concurrent corticosteroid\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No concurrent antibiotics, antifungals, or antivirals\n",
      "2661\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage II, III, or IV mantle cell lymphoma that is not curable\n",
      "             by surgery, radiotherapy, and/or chemotherapy\n",
      "          -  Measurable tumor of greater than 2 cm in largest diameter for lymph nodes located in\n",
      "             head, neck, axillary, inguinal, and femoral areas (at least 1 cm for other areas)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2000/mm^3\n",
      "          -  Platelet count greater than 20,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections requiring treatment\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agent\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior corticosteroids (e.g., dexamethasone or prednisone)\n",
      "          -  No concurrent dexamethasone, prednisone, or other corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No concurrent antibiotics, antifungals, or antivirals\n",
      "2662\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed intermediate or high grade non-Hodgkin's\n",
      "        lymphoma, acute myelogenous leukemia, or acute lymphocytic leukemia that is refractory to\n",
      "        or relapsed after prior therapy Must be HIV seropositive confirmed by Western blot Must\n",
      "        have a 6/6 HLA matched sibling donor or 6/6, 5/6, or 4/6 HLA matched umbilical cord blood\n",
      "        (UCB) from the New York Blood Center's Unrelated UCB Bank that is not homozygous for the\n",
      "        CCR-5 mutation No active primary CNS lymphoma or chronic CNS infection No history of AIDS\n",
      "        defining opportunistic infection or active invasive aspergillus infection A new\n",
      "        classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The\n",
      "        terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of\n",
      "        \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former\n",
      "        terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 55 Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 6 months (unless due to hematologic malignancy) Hematopoietic:\n",
      "        Peripheral CD4 count greater than 100/mm3 Hepatic: Transaminases no greater than 4 times\n",
      "        normal Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Creatinine clearance at least 60 mL/min Cardiovascular: No myocardial infarction within\n",
      "        the past 6 months Normal cardiac function (LVEF greater than 40%) Pulmonary: FVC and FEV1\n",
      "        greater than 70% of predicted DLCO at least 60% of predicted Other: No other malignancy\n",
      "        except nonmelanoma skin cancer or carcinoma in situ of the cervix within the past 5 years\n",
      "        Not pregnant (must have negative pregnancy test within 2 weeks of therapy)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow, peripheral blood stem\n",
      "        cell, or umbilical cord blood transplant Chemotherapy: Cumulative lifetime dose of\n",
      "        doxorubicin no greater than 450 mg/m2 (or equivalent dose of mitoxantrone or daunorubicin)\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other:\n",
      "        No concurrent involvement in any other clinical trial that may affect hematologic\n",
      "        engraftment\n",
      "2663\n",
      "DISEASE CHARACTERISTICS: Histologically proven oral cavity and/or oropharyngeal squamous\n",
      "        cell carcinoma Radiation volume to encompass at least 50% of parotid glands and have at\n",
      "        least 50 Gy delivered to that volume via external beam No salivary gland malignancies or\n",
      "        diseases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: Karnofsky 60-100% Life\n",
      "        Expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Not pregnant or nursing Effective contraceptive method must be used\n",
      "        during study No pilocarpine allergy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head or neck\n",
      "        Surgery: Not specified Other: No concurrent adrenergic antagonists, cholinergic drugs,\n",
      "        anti-cholinergics, or tricyclics\n",
      "2664\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven high-risk renal cell carcinoma that has been completely\n",
      "             resected within the past 12 weeks\n",
      "               -  T3b (N0); N1 (T1-3b); T3c or T4 (N0-1); N2 or N3 (T1-4) disease OR\n",
      "               -  M1 disease resected to no evaluable disease\n",
      "          -  Postoperative radiographic evaluation must reveal no evidence of detectable residual\n",
      "             disease\n",
      "          -  No ascites or pleural effusions\n",
      "          -  No detectable metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age\n",
      "          -  16 and over\n",
      "        Performance status\n",
      "          -  ECOG 0-1 OR\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy\n",
      "          -  Not specified\n",
      "        Hematopoietic\n",
      "          -  WBC at least 4,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "        Renal\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular\n",
      "          -  No congestive heart failure\n",
      "          -  No symptoms of coronary artery disease\n",
      "          -  No serious cardiac arrhythmias\n",
      "          -  No prior myocardial infarction\n",
      "          -  Normal cardiac stress test required if over age 40\n",
      "        Pulmonary\n",
      "          -  FEV1 greater than 2.0 liters or at least 75% predicted for height and age\n",
      "          -  No chronic obstructive pulmonary disease\n",
      "        Other\n",
      "          -  HIV negative\n",
      "          -  No significant detectable infection\n",
      "          -  No other significant medical disease\n",
      "          -  No other invasive malignancy within the past 5 years except surgically cured\n",
      "             nonmelanomatous skin cancer or carcinoma in situ or stage I carcinoma of the cervix\n",
      "          -  No contraindication to pressor agents\n",
      "          -  No seizure disorder\n",
      "          -  No psychiatric illness that would preclude informed consent\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  No prior interleukin-2 for renal cell carcinoma\n",
      "        Chemotherapy\n",
      "          -  No prior systemic chemotherapy for renal cell carcinoma\n",
      "        Endocrine therapy\n",
      "          -  No concurrent steroids\n",
      "        Radiotherapy\n",
      "          -  Prior locoregional radiotherapy to solitary resectable metastases allowed\n",
      "        Surgery\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior surgical resection\n",
      "          -  No prior organ allografts\n",
      "        Other\n",
      "          -  No other prior systemic therapy for renal cell carcinoma\n",
      "2665\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable neuroendocrine tumor that is unlikely to respond\n",
      "             to existing therapy, meeting 1 of the following criteria:\n",
      "          -  Metastatic disease\n",
      "          -  Disease that is not curable with surgery or radiotherapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No concurrent nonmalignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2666\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable primitive neuroectodermal tumors outside the\n",
      "             central nervous system that are unlikely to respond to existing therapy, meeting 1 of\n",
      "             the following criteria:\n",
      "               -  Metastatic disease\n",
      "               -  Progressive, recurrent, or refractory disease after initial therapy, including\n",
      "                  surgery, chemotherapy, and/or radiotherapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2667\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable glioblastoma multiforme that has progressed,\n",
      "             recurred, or persisted following completion of initial standard therapy (including\n",
      "             radiotherapy and/or chemotherapy)\n",
      "               -  Measurable disease by MRI or CT scan\n",
      "          -  Brain stem tumor is excluded\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  No liver failure\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit\n",
      "        Renal:\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., severe COPD)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use adequate contraception during and for 4 weeks after study\n",
      "          -  No active infection\n",
      "          -  No other serious medical or psychiatric conditions\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since chemotherapy (unless radiologically proven progression)\n",
      "          -  At least 6 weeks since nitrosoureas\n",
      "        Endocrine therapy:\n",
      "          -  Corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since radiotherapy (unless radiologically proven progression)\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2668\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed incurable primary malignant brain tumor\n",
      "             that has progressed during or is recurrent after prior initial therapy, including\n",
      "             radiotherapy\n",
      "               -  Failed prior standard therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Hematological function normal\n",
      "          -  WBC at least 2000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No liver failure\n",
      "          -  No evidence of hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No evidence of renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No chronic heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as severe chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No medical or psychiatric illness that would preclude study treatment\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy, except in patients with disease\n",
      "             progression during initial therapy\n",
      "          -  At least 6 weeks since prior nitrosoureas, except in patients with disease\n",
      "             progression during initial therapy\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy, except in patients with disease\n",
      "             progression during initial therapy\n",
      "        Surgery:\n",
      "          -  At least 4 weeks since prior surgery, except in patients with disease progression\n",
      "             during initial therapy\n",
      "        Other:\n",
      "          -  Recovered from prior therapy\n",
      "          -  Cytodifferentiating agents allowed\n",
      "2669\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent metastatic Ewing's sarcoma,\n",
      "        peripheral primitive neuroectodermal tumor (PNET) or Clinical Group IV rhabdomyosarcoma\n",
      "        Complete remission or very good partial remission (at least 50% reduction in measurable\n",
      "        tumor burden) following initial chemotherapy with or without surgery No primary CNS PNET\n",
      "        PATIENT CHARACTERISTICS: Age: Under 50 Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Greater than 3 months Hematopoietic: Granulocyte count at least 1,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal:\n",
      "        Creatinine clearance greater than 50% of normal Pulmonary: LVEF greater than 41% Other:\n",
      "        HIV negative Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: No prior dose limiting\n",
      "        irradiation to any organ site Surgery: See Disease Characteristics\n",
      "2670\n",
      "1. Required Tumor Parameters\n",
      "             1.1 Patients with operable, histologically confirmed adenocarcinoma of the female\n",
      "             breast and positive lymph nodes. Node positivity may be determined by either an\n",
      "             axillary node dissection or a positive sentinel node finding by immunohistochemistry\n",
      "             or histology. This includes any patient with one or more positive lymph nodes whose\n",
      "             tumors are T0, T1, 2 or 3 and N1, N2, MO. Patients with metaplastic carcinoma are\n",
      "             eligible. Bilateral disease does not exclude patients from entry.\n",
      "             1.2 Tumors that are locally advanced at diagnosis are not eligible. This is left to\n",
      "             investigator judgment. Patients with tumors fixed to the chest wall, peau d'orange\n",
      "             skin changes, skin ulcerations, or clinical inflammatory changes (T4 disease) are\n",
      "             excluded from this study. Dermal lymphatic involvement noted on pathology without\n",
      "             clinical inflammatory changes will not exclude a patient from this study.\n",
      "             1.3 Patients with any ERP/PgR status are eligible.\n",
      "          2. Prior treatment:\n",
      "             2.1 <84 days from mastectomy or within 84 days of axillary dissection if the\n",
      "             patient's most extensive breast surgery was a breast sparing procedure.\n",
      "             2.2 Surgical resection margins - All tumor should be removed by either a modified\n",
      "             radical mastectomy or a segmental mastectomy. Node dissection: patients may have had\n",
      "             either an axillary node dissection or sentinel lymph node biopsy before beginning\n",
      "             treatment on protocol.\n",
      "               -  Mastectomy: There should be no evidence of gross or microscopic tumor at the\n",
      "                  surgical resection margins noted in the final surgery or pathology reports for\n",
      "                  patients who have had a modified radical mastectomy. Patients with close margins\n",
      "                  (tumor < 1 mm from margin) are eligible.\n",
      "               -  Segmental mastectomy (lumpectomy): Although clear margins are preferable, DCIS\n",
      "                  or LCIS at the surgical resection margin will not render a patient who has\n",
      "                  undergone a segmental mastectomy ineligible for this study. Invasive tumor at\n",
      "                  the final resection margin will render a patient ineligible.\n",
      "             2.3 No prior chemotherapy.\n",
      "             2.4 No prior radiation therapy for this malignancy. Patients who received radiation\n",
      "             to the breast for DCIS are eligible. Patients who have had segmental mastectomy will\n",
      "             be treated with radiotherapy according to standard procedures in the treating\n",
      "             physician's institution after completion of all chemotherapy. Patients who have had\n",
      "             modified radical mastectomy may also receive radiotherapy at the discretion of the\n",
      "             treating physician according to institutional guidelines.\n",
      "             2.5 Patients may receive up to four weeks of tamoxifen therapy for this malignancy\n",
      "             and still be eligible for study entry. Patients who received tamoxifen for purposes\n",
      "             of chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications\n",
      "             (including previous breast cancer) are eligible. Tamoxifen therapy should be\n",
      "             discontinued before the patient is enrolled on this study.\n",
      "          3. Age > 18. There is no upper age limit for enrollment on this study.\n",
      "          4. Required initial laboratory data:\n",
      "               -  Granulocyte count > 1000/mm3\n",
      "               -  Platelet count > 100,000/mm3\n",
      "               -  Bilirubin within upper limits of normal\n",
      "2671\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed resectable adenocarcinoma of the breast\n",
      "        Histologically positive lymph nodes (1 to 3) OR Lymph node negative and high risk disease\n",
      "        Tumor greater than 1.0 cm diameter May have undergone an axillary dissection with at least\n",
      "        6 nodes removed and examined or a sentinel node biopsy Patients who are positive by\n",
      "        sentinel node biopsy will receive an axillary dissection No locally advanced or\n",
      "        inflammatory or metastatic breast cancer Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Not specified Life expectancy: Not specified Hematopoietic: Neutrophil\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Adequate hepatic\n",
      "        function Bilirubin no greater than upper limit of normal Renal: Adequate renal function\n",
      "        Cardiovascular: Adequate cardiac function Normal MUGA or echocardiogram Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective barrier method contraception At\n",
      "        least 5 years since prior invasive malignancies, except basal cell or squamous cell\n",
      "        carcinoma of the skin or carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for this malignancy Endocrine therapy: No concurrent tamoxifen Up to 4 weeks\n",
      "        of tamoxifen treatment for this malignancy allowed Radiotherapy: No prior radiotherapy for\n",
      "        this malignancy Prior radiotherapy to the breast for ductal carcinoma in situ allowed\n",
      "        Surgery: Tumor should be removed by either a modified radical mastectomy and/or a\n",
      "        segmental mastectomy plus axillary lymph node dissection or sentinel node biopsy before\n",
      "        beginning treatment on protocol No greater than 84 days since last surgical procedure that\n",
      "        constitutes or completes definitive surgical therapy (mastectomy; axillary\n",
      "        dissection/sentinel node biopsy; or resection of primary site to obtain a negative margin\n",
      "2672\n",
      "Disease Characteristics:\n",
      "          -  Histologically confirmed stage I, II, or III adenocarcinoma of the pancreas Resected\n",
      "             with no gross residual disease At least 50% of tumor cells must be CEA positive and\n",
      "             stain with at least moderate intensity HLA-A2 positive\n",
      "        Patient Characteristics:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: Karnofsky 70-100%\n",
      "          -  Life expectancy: Greater than 6 months\n",
      "          -  Hematopoietic: Absolute neutrophil count at least 1000/mm3\n",
      "          -  Hepatic: Bilirubin less than 2.0 mg/dL SGOT and alkaline phosphatase less than 4\n",
      "             times the upper limit of normal No hepatic failure\n",
      "          -  Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min\n",
      "          -  Cardiovascular: No New York Heart Association class III or IV heart disease\n",
      "          -  Pulmonary: No concurrent asthma or chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  No other malignancy except nonmelanoma skin cancer or controlled superficial bladder\n",
      "             cancer within the past 5 years.\n",
      "          -  No history of autoimmune diseases such as inflammatory bowel disease, systemic lupus\n",
      "             erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis, or multiple\n",
      "             sclerosis\n",
      "          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral\n",
      "             hepatitis\n",
      "          -  No active infectious enteritis or eosinophilic enteritis Not pregnant or nursing\n",
      "             Fertile patients must use effective contraception\n",
      "        Prior Therapy:\n",
      "          -  Biologic therapy: At least 4 weeks since immunotherapy. No other concurrent\n",
      "             immunotherapy\n",
      "          -  Chemotherapy: At least 4 weeks since chemotherapy and recovered. No concurrent\n",
      "             chemotherapy\n",
      "          -  Endocrine therapy: No concurrent corticosteroid or immunosuppressive therapy. At\n",
      "             least 6 weeks since steroid therapy\n",
      "          -  Radiotherapy: At least 4 weeks since radiotherapy and recovered\n",
      "          -  Surgery: Recovered from prior surgery\n",
      "2673\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent or persistent ovarian\n",
      "        epithelial cancer or primary peritoneal carcinoma Progressive disease on platinum-based\n",
      "        treatment alone or in combination Two prior treatment regimens allowed only if other\n",
      "        regimen was paclitaxel OR recurrence within 6 months of chemotherapy Measurable disease\n",
      "        Not eligible for a higher priority GOG protocol\n",
      "        PATIENT CHARACTERISTICS: Age: 13 and over Performance status: GOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN) Alkaline phosphatase no\n",
      "        greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 mg/dL Other: No\n",
      "        significant infection Not pregnant Fertile patients must use effective contraception At\n",
      "        least 5 years since prior malignancy; no prior chemotherapy or radiotherapy for that\n",
      "        malignancy No concurrent malignancy other than non-melanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy and\n",
      "        recovered No prior treatment with aminocamptothecin Endocrine therapy: At least 4 weeks\n",
      "        since prior endocrine therapy Radiotherapy: At least 4 weeks since prior radiotherapy and\n",
      "        recovered No prior radiotherapy to site(s) of measurable disease used on this trial No\n",
      "        prior radiotherapy to more than 25% of marrow-bearing areas Surgery: At least 4 weeks\n",
      "        since prior surgery\n",
      "2675\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or progressive Waldenstrom's macroglobulinemia\n",
      "             that is unlikely to respond to existing therapy, including surgery, radiotherapy, and\n",
      "             chemotherapy\n",
      "               -  Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan\n",
      "               -  Must have received and failed at least one standard first-line therapy (e.g.,\n",
      "                  corticosteroid/alkylator combination)\n",
      "          -  Biochemical evidence of Waldenstrom's macroglobulinemia\n",
      "               -  Abnormal proteins in serum and urine\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No active infection\n",
      "          -  No non-malignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agent\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks (6 weeks since nitrosoureas) since prior chemotherapy\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplastons\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "2676\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable neuroblastoma that is unlikely to respond to\n",
      "             existing therapy, meeting 1 of the following criteria:\n",
      "               -  Metastatic disease\n",
      "               -  Progressive, recurrent, or persistent disease after initial therapy, including\n",
      "                  surgery, chemotherapy, and/or radiotherapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2677\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent primary low grade glioma including:\n",
      "               -  Fibrillary astrocytoma\n",
      "               -  Oligodendroglioma\n",
      "               -  Mixed glioma\n",
      "          -  Evidence of measurable enhancing or non-enhancing CNS neoplasm on MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Hematocrit greater than 29%\n",
      "          -  Absolute neutrophil count greater than 1500/mm^3\n",
      "          -  Platelet count greater than 125,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGOT less than 1.5 times upper limit of normal (ULN)\n",
      "          -  Bilirubin less than 1.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  BUN less than 25 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy unless disease progression\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed (must be on stable dose for 1 week prior to study)\n",
      "          -  No concurrent immunosuppressive agents\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy unless disease progression\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent medication that may interfere with study\n",
      "2678\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed colorectal carcinoma Inoperable advanced\n",
      "        recurrent or metastatic disease Measurable disease outside previously irradiated area No\n",
      "        CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 74 Performance status: WHO 0-1 Life expectancy: More\n",
      "        than 12 weeks Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater than\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.25 times upper limit of normal (ULN) SGOT less\n",
      "        than 1.25 times ULN Albumin greater than 3.5 g/dL Renal: Creatinine clearance greater than\n",
      "        70 mL/min Cardiovascular: No history of congestive heart failure, myocardial infarction\n",
      "        within the past 6 months, active ischemic heart disease, or uncontrolled hypertension\n",
      "        Other: No weight loss more than 10% in the last 2 months No other prior malignancy except\n",
      "        curatively treated carcinoma in situ of the cervix or non-melanoma skin cancer No history\n",
      "        of alcohol abuse No uncontrolled medical or psychiatric disease Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent filgrastim (G-CSF) Chemotherapy:\n",
      "        No prior chemotherapy for advanced disease Recovered from prior adjuvant therapy No other\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease\n",
      "        Characteristics No prior radiotherapy for advanced disease Surgery: See Disease\n",
      "        Characteristics Other: No other concurrent therapy\n",
      "2679\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary brain glioma Astrocytoma\n",
      "        Gliosarcoma Oligodendroglioma Oligoastrocytoma Tumor progression by CT scan or MRI\n",
      "        following radiotherapy Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        AST no greater than 3 times upper limit of normal No prior Gilbert's syndrome Renal:\n",
      "        Creatinine no greater than 2.0 mg/dL Cardiovascular: No history of myocardial infarction\n",
      "        within 6 months No congestive heart failure requiring therapy Other: No concurrent active\n",
      "        second malignancy No uncontrolled infection No other severe concurrent disease Not\n",
      "        pregnant or lactating Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1\n",
      "        prior adjuvant chemotherapy regimen and 1 for recurrence (Gliadel is considered 1 regimen)\n",
      "        At least 4 weeks since prior chemotherapy At least 6 weeks since prior nitrosoureas No\n",
      "        prior irinotecan, topotecan, or aminocamptothecin Endocrine therapy: At least 2 weeks on\n",
      "        fixed dose of corticosteroids (or no corticosteroids) prior to baseline scan Radiotherapy:\n",
      "        At least 8 weeks since prior radiotherapy Surgery: No surgical resection between last\n",
      "        radiotherapy or chemotherapy and study therapy, unless unequivocal tumor growth since\n",
      "        surgery\n",
      "2680\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the colon\n",
      "        or rectum Bidimensionally measurable lesions Sentinel lesions outside the field of any\n",
      "        prior radiation therapy No confirmed or suspected brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-1 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: No active\n",
      "        congestive heart failure No uncontrolled angina At least 6 months since prior myocardial\n",
      "        infarction No uncontrolled hypertension Other: Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception No concurrent serious infection No\n",
      "        other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in\n",
      "        situ of the cervix No overt psychosis or mental disability No life threatening illness\n",
      "        (unrelated to tumor)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No prior chemotherapy for metastatic disease At least 6 months since prior adjuvant\n",
      "        chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiation therapy\n",
      "        and recovered No concurrent radiotherapy Surgery: At least 4 weeks since prior major\n",
      "        surgery and recovered No concurrent surgery Other: At least 28 days since prior\n",
      "        administration of any investigational drug No other concurrent anticancer therapy\n",
      "2681\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed residual, recurrent, or metastatic malignant melanoma or\n",
      "             other advanced malignancies\n",
      "          -  Must have failed standard curative and/or palliative therapies\n",
      "          -  No brain or central nervous system metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 13 and over\n",
      "          -  Performance status: Karnofsky 70-100%\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  Absolute neutrophil count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL (may be\n",
      "             posttransfusion or may receive erythropoietin)\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT and SGPT no greater than 2 times ULN\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  Calcium no greater than 11 mg/dL (may receive agents to decrease calcium)\n",
      "          -  No significant cardiovascular disease\n",
      "          -  No cardiac arrhythmia requiring drug or device intervention\n",
      "          -  No history of significant peripheral neuropathy\n",
      "          -  No significant central nervous system disease\n",
      "          -  HIV negative Hepatitis B surface antigen negative\n",
      "          -  No concurrent serious infection requiring intravenous antibiotic therapy\n",
      "          -  No clinically significant autoimmune disease (i.e., rheumatoid arthritis)\n",
      "          -  No clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer\n",
      "             disease\n",
      "          -  No history of inflammatory bowel disease\n",
      "          -  No other major illness that substantially increases the risk associated with\n",
      "             participation in this study\n",
      "          -  Not pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 4 weeks since prior biologic therapy\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  No concurrent systemic corticosteroids\n",
      "          -  At least 2 weeks since prior local radiotherapy\n",
      "          -  At least 2 weeks since surgery Other: At least 4 weeks since prior investigational\n",
      "             drug\n",
      "2682\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unifocal or multifocal supratentorial WHO grade II\n",
      "             astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma,\n",
      "             or oligoastrocytoma\n",
      "          -  Patients with neurofibromatosis are eligible\n",
      "          -  No other low-grade histologies, including:\n",
      "               -  Pilocytic astrocytoma\n",
      "               -  Subependymal giant cell astrocytoma of tuberous sclerosis\n",
      "               -  Subependymoma\n",
      "               -  Pleomorphic xanthoastrocytoma\n",
      "               -  Presence of a neuronal element such as ganglioglioma\n",
      "               -  Dysneuroembryoplastic epithelial tumor\n",
      "          -  No presence of any high-grade glioma, including:\n",
      "               -  Anaplastic astrocytoma\n",
      "               -  Glioblastoma multiforme\n",
      "               -  Anaplastic oligodendroglioma\n",
      "               -  Anaplastic oligoastrocytoma\n",
      "          -  No tumors in nonsupratentorial or other locations including optic chiasm, optic\n",
      "             nerve(s), pons, medulla, cerebellum, or spinal cord\n",
      "          -  No evidence of spread to spinal meninges or noncontiguous cranial meninges (i.e.,\n",
      "             leptomeningeal gliomatosis)\n",
      "          -  No gliomatosis cerebri\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Hematopoietic:\n",
      "          -  For high-risk patients:\n",
      "               -  Granulocyte count at least 1,500/mm^3\n",
      "               -  Platelet count normal\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 times normal\n",
      "          -  SGOT or SGPT no greater than 4 times normal\n",
      "          -  Alkaline phosphatase no greater than 2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2 times normal\n",
      "        Pulmonary:\n",
      "          -  No chronic lung disease (unless DLCO at least 60%)\n",
      "        Neurological:\n",
      "          -  Neurologic function score no greater than 3\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or\n",
      "             nonmelanoma skin cancer\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the head or neck (unless brain is clearly excluded, such as\n",
      "             radiotherapy for localized vocal cord cancer)\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2683\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent, persistent or metastatic cervical carcinoma\n",
      "             (squamous or adenocarcinoma), with no potentially curative standard treatment\n",
      "          -  Measurable disease or evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to physiological 60\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Greater than 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3000/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times normal\n",
      "          -  SGOT/SGPT less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times normal\n",
      "          -  Creatinine less than 1.5 times normal\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "        Other:\n",
      "          -  Ineligible for other high priority national or institutional study\n",
      "          -  Not pregnant or nursing\n",
      "          -  HIV negative\n",
      "          -  No prior malignancy except nonmelanoma skin cancer\n",
      "          -  No serious medical or psychiatric illness preventing treatment or informed consent\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Greater than 4 weeks since prior chemotherapy\n",
      "          -  No greater than 2 prior chemotherapy regimens\n",
      "          -  No prior taxane or camptothecin\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy except that required for nondisease related conditions\n",
      "             (e.g., insulin for diabetes)\n",
      "        Radiotherapy:\n",
      "          -  Greater than 4 weeks since prior radiation therapy\n",
      "          -  No concurrent radiation therapy\n",
      "        Surgery:\n",
      "          -  Greater than 4 weeks since prior surgery\n",
      "2684\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed newly diagnosed supratentorial primary malignant brain tumor\n",
      "          -  No infratentorial tumors, infiltrating tumors, tumors with subependymal spread, or\n",
      "             multifocal tumors\n",
      "          -  Candidate for surgical resection\n",
      "          -  Prior external beam radiotherapy to site of measurable disease or resection site in\n",
      "             the nervous system required\n",
      "          -  Presence of tenascin in the tumor demonstrated by immunohistology with either a\n",
      "             polyclonal rabbit antitenascin antibody or monoclonal antibody 81C6\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 50-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Alkaline phosphatase less than 1.5 times normal\n",
      "          -  Lactic dehydrogenase less than 1.5 times normal\n",
      "          -  SGOT less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No iodine allergies\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed, but must be on stable dose for at least 10 days\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2685\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the colon that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "          -  Metastatic or unresectable disease\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal failure\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple\n",
      "             tumors may be admitted earlier)\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2686\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable primary malignant brain tumor that has progressed,\n",
      "             recurred, or persisted after initial therapy\n",
      "               -  Must have failed prior standard therapy\n",
      "          -  No brain stem glioma\n",
      "          -  Evidence of tumor by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 1,500/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic failure\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Recovered from prior endocrine therapy\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy (unless clear radiological evidence of\n",
      "             progression) and recovered\n",
      "        Surgery:\n",
      "          -  At least 4 weeks since prior surgery (unless clear radiological evidence of\n",
      "             progression) and recovered\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2687\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed (unless medically contraindicated) visual pathway glioma\n",
      "             that is unlikely to respond to existing therapy and for which no curative therapy\n",
      "             exists\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm3\n",
      "          -  Platelet count greater than 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas)\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at\n",
      "             least 1 week prior to study)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2688\n",
      "DISEASE CHARACTERISTICS: Histologically proven cervical intraepithelial dysplasia, grade\n",
      "        CIN II, or CIN I by repeat cytology No invasive carcinoma by Pap smear No positive\n",
      "        endocervical curettage\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 55 (premenopausal) Performance status: Not specified\n",
      "        Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal:\n",
      "        Not specified Other: No concurrent beta carotene supplements Not pregnant or nursing No\n",
      "        prior malignancy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: At least 6 months\n",
      "        since prior cauterization, cryosurgery, laser, or conization of the cervix\n",
      "2689\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory leukemia, lymphoma,\n",
      "        or other solid tumor that has overt meningeal involvement Definition of meningeal disease:\n",
      "        Leukemia/lymphoma: CSF cell count at least 5/mm3 and evidence of blast cells on cytospin\n",
      "        preparation or cytology Solid tumors: Presence of tumor cells on cytospin preparation or\n",
      "        cytology OR evidence of meningeal disease on CT or MRI scan No bone marrow disease\n",
      "        PATIENT CHARACTERISTICS: Age: 1 to 21 Performance Status: ECOG 0-2 Life Expectancy: At\n",
      "        least 8 weeks Hematopoietic: Platelet count greater than 40,000/mm3 Hepatic: Bilirubin\n",
      "        less than 2.0 mg/dL ALT less than 5 times upper limit of normal Renal: Creatinine less\n",
      "        than 1.5 mg/dL Other: Not pregnant or nursing Negative pregnancy test Effective\n",
      "        contraceptive method used by fertile patients No uncontrolled illness or infection (except\n",
      "        for HIV positive patients) No obstructive hydrocephalus or compartmentalization of the CSF\n",
      "        flow\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No acute toxic effects from prior\n",
      "        immunotherapy No prior allogeneic or autologous bone marrow transplantations within 3\n",
      "        months of study Chemotherapy: No prior systemic CNS directed chemotherapy within 3 weeks\n",
      "        of study No prior nitrosourea within 6 weeks of study No prior intrathecal chemotherapy\n",
      "        within 1 week of study No acute toxic effects from prior chemotherapy No prior DTC 101\n",
      "        Concurrent systemic chemotherapy for management of primary cancer allowed Concurrent\n",
      "        dexamethasone with systemic chemotherapy regimen allowed No concurrent chemotherapy for\n",
      "        leptomeningeal disease No concurrent high dose methotrexate, high dose cytarabine,\n",
      "        mercaptopurine, thiotepa, fluorouracil, and topotecan Endocrine therapy: Concurrent\n",
      "        prednisone therapy with systemic chemotherapy allowed Radiotherapy: No prior craniospinal\n",
      "        irradiation within 8 weeks of study No acute toxic effects from prior radiotherapy\n",
      "        Concurrent local radiation therapy allowed No concurrent whole brain or craniospinal\n",
      "        radiotherapy Surgery: Not specified Other: At least 2 weeks since investigational drugs\n",
      "        and recovered No other concurrent investigational drugs Concurrent antibiotic therapy\n",
      "        allowed\n",
      "2690\n",
      "DISEASE CHARACTERISTICS: Histologically proven multiple myeloma with greater than 12\n",
      "        months of prior therapy Bone marrow plasmacytosis at least 30% or protein criteria present\n",
      "        No obvious myelodysplastic changes in the bone marrow No CNS disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: SWOG 0-2 (3-4 acceptable if\n",
      "        based solely on bone pain) Life expectancy: Not specified Hematopoietic: CD34+ at least\n",
      "        4,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT or SGPT no greater than 4\n",
      "        times upper limit of normal No active or chronic hepatitis or liver cirrhosis Renal:\n",
      "        Creatinine no greater than 3.0 mg/dL Cardiovascular: LVEF greater than 50% Pulmonary: FEV1\n",
      "        or FVC at least 50% of predicted DLCO at least 50% of predicted Patients unable to\n",
      "        complete pulmonary function tests must have a CT scan of the chest and acceptable arterial\n",
      "        blood gases of PO2 greater than 70 Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception HIV negative No active infection\n",
      "        requiring IV antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy Endocrine therapy: Prior steroid therapy allowed Radiotherapy: At\n",
      "        least 4 weeks since prior radiotherapy Surgery: Not specified\n",
      "2691\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed low grade follicular lymphoma, mantle\n",
      "        cell lymphoma, or chronic lymphocytic leukemia with no greater than 12 months of prior\n",
      "        standard therapy Follicular lymphoma Must have poor prognosis disease defined as any of\n",
      "        the following: Any nodal or extranodal tumor mass with a diameter more than 7 cm\n",
      "        Involvement of at least 3 nodal sites, each of which has a diameter greater than 3 cm\n",
      "        Systemic symptoms Substantial splenic involvement no greater than 5 cm below left costal\n",
      "        margin Serous effusions (ascites, pleural or pericardial effusions) Orbital or epidural\n",
      "        involvement Ureteral compression Leukemia presentation (at least 500/microliter) Increased\n",
      "        LDH level Greater than 20% bone marrow involvement Mantle cell lymphoma No mantle zone\n",
      "        morphology Chronic lymphocytic leukemia Must have either anemia (hemoglobin less than 10\n",
      "        g/dL), thrombocytopenia (less than 100,000/mm3), cytogenetic abnormalities including +12\n",
      "        and 11q, elevated LDH levels, labeling index at least 2%, systemic symptoms, or\n",
      "        hepatosplenomegaly No active CNS disease A new classification scheme for adult\n",
      "        non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n",
      "        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n",
      "        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: SWOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: At least 4,000/g CD34+ peripheral blood stem cells available See\n",
      "        Disease Characteristics Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminases no\n",
      "        greater than 4 times upper limit of normal No active chronic hepatitis or liver cirrhosis\n",
      "        Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Left ventricular ejection\n",
      "        fraction at least 50% Pulmonary: FEV1, FVC, and DLCO at least 50% of predicted Other: HIV\n",
      "        negative No active infection requiring intravenous antibiotics Not pregnant or nursing\n",
      "        Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy Endocrine therapy: Prior corticosteroids allowed Radiotherapy: At\n",
      "        least 4 weeks since prior local radiotherapy Surgery: Not specified\n",
      "2692\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of unknown primary that is unlikely to\n",
      "             respond to existing therapy, including surgery, radiotherapy, and chemotherapy\n",
      "               -  Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2693\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic or recurrent squamous cell\n",
      "        carcinoma of the oral cavity, lip, hypopharynx, oropharynx, nasopharynx, paranasal\n",
      "        sinuses, nasal cavity, nostril, or larynx that is not curable by surgery or radiation\n",
      "        therapy Must have one or more measurable indicator lesions Bone metastases, brain\n",
      "        metastases, elevated enzyme levels and lesions on radionuclide scans are not acceptable as\n",
      "        the sole parameters of measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Transaminases (SGOT/SGPT) less\n",
      "        than 2.5 times upper limit of normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine\n",
      "        clearance at least 50 mL/min Cardiovascular: No unstable cardiac rhythm Other: No active\n",
      "        infection requiring antibiotics No concurrent medical condition that makes participation\n",
      "        in this study medically unsafe No other prior malignancy in the last 2 years except basal\n",
      "        or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or\n",
      "        metachronous/synchronous epidermoid/squamous cell cancers of the head and neck Not\n",
      "        pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior\n",
      "        chemotherapy regimen as part of a locoregional treatment (e.g., induction/concomitant)\n",
      "        allowed, either as primary treatment or as therapy for locoregional relapse, if relapse\n",
      "        occurred more than 6 months later No other prior chemotherapy Prior chemoprevention agents\n",
      "        (e.g., cisretinoic acid or other vitamin analogues) allowed Endocrine therapy: Not\n",
      "        specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        radiotherapy No prior radiotherapy to more than 50% of bone marrow-bearing bones Surgery:\n",
      "        See Disease Characteristics\n",
      "2694\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed cancer of the head and neck that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "               -  Metastatic disease OR incurable with surgery or radiation\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "               -  Tumor must be at least 2 cm for the lymph nodes located in the head, neck,\n",
      "                  axillary, inguinal or femoral areas and at least 0.5 cm for other areas\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  16 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 2.5 mg/dL\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., severe chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No other serious medical or psychiatric conditions\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic therapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy (unless multiple tumors) and recovered\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "2695\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage I-IV primary central nervous system lymphoma for which\n",
      "             no curative therapy exists\n",
      "          -  Measurable tumor by MRI or CT scan\n",
      "          -  Tumor must be greater than 2 cm in largest diameter\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic insufficiency\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No cardiac insufficiency\n",
      "          -  No hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for at least 4 weeks\n",
      "             after study participation\n",
      "          -  No serious infection requiring antibiotics, antifungals, or antivirals\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents (e.g., interferon or interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agent\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "          -  Must be on stable dose for at least 4 weeks prior to study entry\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplastons\n",
      "2697\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage II, III, or IV low grade non-Hodgkin's lymphoma that is\n",
      "             unlikely to respond to existing therapy or for which no established therapy exists\n",
      "             NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted\n",
      "             by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the\n",
      "             former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 20,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious active infections\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents (e.g., interferon, interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior corticosteroids\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent antineoplastic agents\n",
      "          -  No concurrent antibiotics, antifungals, or antivirals\n",
      "2698\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV adenocarcinoma or transitional cell carcinoma of\n",
      "             the kidney that is unlikely to respond to existing therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be more than 2 cm for lymph nodes in head, neck, axillary, inguinal, or\n",
      "             femoral areas and at least 0.5 cm for other locations\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/mL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No known chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  Not a high medical or psychiatric risk\n",
      "          -  No concurrent nonmalignant systemic disease that would preclude therapy\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "2699\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed low-grade astrocytoma that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at\n",
      "             least 1 week prior to study entry)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2700\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed rhabdoid tumor of the central nervous system that is\n",
      "             unlikely to respond to existing therapy and for which no curative therapy exists\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No severe heart disease\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concomitant disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on a stable dose for\n",
      "             at least 1 week before study entry)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston treatment\n",
      "2701\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV breast cancer that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "               -  Must have failed prior standard therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal,\n",
      "             or femoral areas and at least 0.5 cm in other locations\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal Status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin nor greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious medical or psychiatric disorders\n",
      "          -  No active infections\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy, except in patients with disease\n",
      "             progression during or after initial therapy\n",
      "          -  Recovery from prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas), except in\n",
      "             patients with disease progression during or after initial therapy\n",
      "          -  Recovery from prior chemotherapy\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  At least 12 weeks since prior hormonal therapy, except in patients with disease\n",
      "             progression during and after initial therapy\n",
      "          -  Concurrent corticosteroids allowed\n",
      "          -  Recovery from prior hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple\n",
      "             tumors who have received radiotherapy to some, but not all, tumors may be admitted\n",
      "             earlier than 8 weeks)\n",
      "        Surgery:\n",
      "          -  Recovered from any prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2702\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV breast cancer that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "          -  Failed prior standard therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary, inguinal,\n",
      "             or femoral areas and at least 0.5 cm in other locations\n",
      "          -  Hormone receptor status:\n",
      "          -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal Status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal failure\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious medical or psychiatric disorders\n",
      "          -  No active infections\n",
      "          -  No other serious concurrent disease\n",
      "          -  No serious malabsorption syndromes\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Recovered from prior immunotherapy\n",
      "          -  At least 4 weeks since prior immunotherapy, except in patients with disease\n",
      "             progression during or after initial therapy\n",
      "        Chemotherapy:\n",
      "          -  Recovered from prior chemotherapy\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas), except in\n",
      "             patients with disease progression during or after initial therapy\n",
      "        Endocrine therapy:\n",
      "          -  Recovered from prior hormonal therapy\n",
      "          -  At least 12 weeks since prior hormonal therapy, except in patients with disease\n",
      "             progression during and after initial therapy\n",
      "          -  Concurrent corticosteroids for peritumoral edema allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "          -  Patients with multiple tumors who have received radiotherapy to some, but not all,\n",
      "             tumors may be admitted earlier than 8 weeks\n",
      "        Surgery:\n",
      "          -  Recovered from any prior surgery\n",
      "          -  No prior extensive stomach or intestinal surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent therapy for metastatic breast cancer\n",
      "2704\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed primary liver cancer that is unlikely to respond to existing\n",
      "             therapy and for which no curative therapy exists\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  14 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 3 mg/dL\n",
      "          -  SGOT/SGPT no greater than 10 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high doses of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No known chronic heart failure\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high doses of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception for 4 weeks before study, during\n",
      "             study, and for 4 weeks after study\n",
      "          -  No serious medical or psychiatric disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent steroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "2705\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV adenocarcinoma of the pancreas that is unlikely to\n",
      "             respond to existing therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  Not a high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2706\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage II, III, or IV intermediate-grade non-Hodgkin's lymphoma\n",
      "             that has not responded to or has relapsed after a standard primary chemotherapy\n",
      "             regimen plus at least 1 standard second-line salvage chemotherapy regimen NOTE: A new\n",
      "             classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The\n",
      "             terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious infection requiring treatment\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior dexamethasone, prednisone, or other corticosteroids\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Prior cytodifferentiation therapy allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No concurrent antibiotics, antifungals, or antivirals\n",
      "2707\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven incurable and/or metastatic carcinoma of the small intestine\n",
      "             that is unlikely to respond to existing therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be greater than 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No known chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  Not high medical or psychiatric risk\n",
      "          -  No concurrent nonmalignant systemic disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2708\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed AIDS-related\n",
      "        non-Hodgkin's lymphoma of the intermediate or high grade histologic types Anaplastic large\n",
      "        cell lymphoma allowed Must be HIV positive Must have at least one objective measurable or\n",
      "        evaluable disease parameter No parenchymal CNS involvement by lymphoma (meningeal lymphoma\n",
      "        allowed) A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by\n",
      "        PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "        terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol\n",
      "        uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: (Except patients with lymphomatous marrow involvement)\n",
      "        Absolute neutrophil count at least 1000/mm3 Platelet count at least 50,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 5.0 mg/dL Renal: Creatinine less than 3.0 mg/dL Cardiovascular:\n",
      "        Patients with history of heart disease, evidence of congestive heart failure, radiographic\n",
      "        evidence of cardiomegaly, or electrocardiographic evidence of a prior myocardial\n",
      "        infarction must have LVEF at least at lower limit of normal Neurologic: No grade 3 or\n",
      "        greater peripheral neuropathy Other: No prior or concurrent malignancy other than Kaposi's\n",
      "        sarcoma, curatively treated basal cell or squamous cell carcinoma of the skin, or\n",
      "        curatively treated carcinoma in situ of the cervix Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No history of sensitivity to E. coli-derived\n",
      "        proteins\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 5 days since interferon therapy\n",
      "        Chemotherapy: No prior cytotoxic chemotherapy except for mucocutaneous Kaposi's sarcoma At\n",
      "        least 12 months since cytotoxic chemotherapy for Kaposi's sarcoma Endocrine therapy: Prior\n",
      "        steroids allowed No concurrent steroid therapy greater than 5 mg prednisone (or\n",
      "        equivalent) per day Radiotherapy: No prior radiotherapy except for mucocutaneous Kaposi's\n",
      "        sarcoma Surgery: Not specified Other: No concurrent zidovudine (AZT) Concurrent\n",
      "        antiretroviral medications other than AZT allowed\n",
      "2711\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed invasive ovarian epithelial carcinoma or\n",
      "        primary peritoneal carcinoma at time of initial laparotomy No histologically confirmed\n",
      "        noninvasive ovarian malignancy or low malignant potential tumor or carcinomatosis from\n",
      "        other nonovarian or peritoneal sites At least three courses of first-line combination\n",
      "        chemotherapy (platinum and paclitaxel) with either persistent or recurrent disease If no\n",
      "        treatment with first-line paclitaxel, salvage paclitaxel failure must be documented prior\n",
      "        to eligibility Ascites that is cytologically positive for adenocarcinoma or gross evidence\n",
      "        of recurrent disease with ascites, or gross recurrent disease with abdominopelvic washing\n",
      "        cytologically positive for adenocarcinoma Adequate peritoneal distribution by Technetium\n",
      "        99 scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy:\n",
      "        Greater than 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at\n",
      "        least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5\n",
      "        mg/dL SGOT/SGPT no greater than 2.5 times normal No active hepatitis or chronic liver\n",
      "        failure Renal: Creatinine no greater than 2 mg/dL Other: Not HIV positive No concurrent\n",
      "        immunosuppressive disorders No active systemic infections or active peritonitis\n",
      "        Geographically available for follow-up Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior viral based gene therapy treatments\n",
      "        or p53 directed vaccines No other prior gene therapy Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since chemotherapy No concurrent chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: At least 4 weeks since radiotherapy No concurrent\n",
      "        radiotherapy Surgery: At least 4 weeks since surgery, including surgery for a perforated\n",
      "        bowel, bowel anastamosis, colostomy, or ileostomy\n",
      "2712\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or stage IV squamous cell lung cancer unlikely to\n",
      "             have a curative response to existing standard regimens\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  At least 2 cm in diameter\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious active infections\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2713\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or extensive stage small cell lung cancer unlikely\n",
      "             to have a curative response to existing standard regimens\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  At least 2 cm in diameter\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infections\n",
      "          -  No other concurrent serious disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2715\n",
      "DISEASE CHARACTERISTICS: Histologically proven hematologic malignancies or solid tumors\n",
      "        Undergone high-dose chemotherapy or chemoradiotherapy with autologous bone marrow and/or\n",
      "        peripheral blood stem cell transplantation Confirmation of complete remission is required\n",
      "        for acute leukemia No significant CNS disease No clinically significant ascites or pleural\n",
      "        effusions Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Not specified Menopausal status: Not\n",
      "        specified Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic:\n",
      "        Absolute neutrophil count at least 1,000/mm3 Hemoglobin at least 9 g/dL (transfusion\n",
      "        allowed) Platelet count at least 50,000/mm3 (transfusion independent) No clinically\n",
      "        significant coagulopathy (unless due to cancer and resolved) Hepatic: Bilirubin no greater\n",
      "        than 2 mg/dL SGOT no greater than 2 times upper limit of normal No chronic or acute\n",
      "        hepatitis Hepatitis B surface antigen negative Renal: Creatinine no greater than 2 mg/dL\n",
      "        No symptomatic hypercalcemia Calcium less than 12 mg/dL Cardiovascular: No uncontrolled\n",
      "        angina No arrhythmias requiring drug or device therapy No symptomatic congestive heart\n",
      "        failure Pulmonary: No clinically significant pulmonary dysfunction Metabolic: No\n",
      "        uncontrolled diabetes mellitus No untreated hyper or hypothyroidism No Cushing's disease\n",
      "        Gastrointestinal: No clinically significant gastrointestinal hemorrhages No uncontrolled\n",
      "        peptic ulcer disease No history of inflammatory bowel disease Other: Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception No\n",
      "        serious infection requiring IV antibiotics No psychosis No clinically significant\n",
      "        autoimmune disease HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent\n",
      "        biologic therapy Chemotherapy: See Disease Characteristics Endocrine therapy: At least 3\n",
      "        weeks since prior corticosteroids No concurrent systemic corticosteroids (other than\n",
      "        replacement doses) Radiotherapy: See Disease Characteristics Surgery: Not specified Other:\n",
      "        No other concurrent investigational agents\n",
      "2716\n",
      "DISEASE CHARACTERISTICS: Incurable, solid tumors in patients who are not candidates for\n",
      "        effective systemic therapy Progressive disease defined as a 25% increase in diameter of\n",
      "        measurable lesions or appearance of new lesions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Greater than 16 weeks Hematopoietic: WBC at least 4000/mm3 Platelet count at least\n",
      "        125,000/mm3 Hemoglobin at least 8 g/dL Hepatic: Bilirubin within normal limits SGOT no\n",
      "        greater than 1.5 times normal (2.5 times normal with disease involvement) Alkaline\n",
      "        phosphatase no greater than 2.5 times normal PT or PTT less than 1.5 times normal Renal:\n",
      "        Creatinine no greater than 1.5 times normal Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular: No history of congestive heart failure, active ischemic heart disease, or\n",
      "        uncontrolled hypertension No myocardial infarction within the past 6 months Other: Not\n",
      "        pregnant or nursing (negative pregnancy test required) Fertile patients must use effective\n",
      "        contraception No weight loss of 10% or more in the past 3 months No frequent vomiting No\n",
      "        severe anorexia\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed No concurrent\n",
      "        immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for\n",
      "        mitomycin or nitrosoureas) and recovered No greater than 300 mg/m2 cumulative dose of\n",
      "        doxorubicin No concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior\n",
      "        hormone therapy No concurrent anticancer hormone therapy Concurrent corticosteroids\n",
      "        allowed Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No\n",
      "        concurrent radiotherapy Surgery: Not specified Other: At least 4 weeks since prior\n",
      "        investigational drug therapy No other concurrent investigational therapy\n",
      "2717\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable anaplastic astrocytoma that has progressed,\n",
      "             recurred, or persisted after completion of standard therapy (including radiation\n",
      "             therapy)\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "          -  Must have received prior standard therapy (i.e., radiation therapy, chemotherapy,\n",
      "             immunotherapy, or cytodifferentiating agent)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease such as severe chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No active infection\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Fully recovered from any prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2718\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed low-grade astrocytoma that has progressed,\n",
      "             recurred, or persisted after initial therapy, including radiotherapy\n",
      "          -  Previously treated with at least 1 prior standard therapy (e.g., radiotherapy,\n",
      "             chemotherapy, immunotherapy, or cytodifferentiating agent)\n",
      "               -  Must have failed standard therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  Tumor must be at least 5 mm\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  More than 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No chronic heart failure\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No other concurrent serious disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Must recover from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplastons\n",
      "2719\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV mesothelioma that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "               -  Evidence of disease by CT scan or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  1 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  Hepatic function adequate\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  Not at high medical or psychiatric risk\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy (or less if multiple tumors) and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2720\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed soft tissue sarcoma that is unlikely to respond to existing\n",
      "             therapy, including surgery, radiotherapy, and chemotherapy\n",
      "               -  Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No nonmalignant systemic disease\n",
      "          -  Not high medical or psychiatric risk\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2721\n",
      "DISEASE CHARACTERISTICS: Histologically proven newly diagnosed or previously treated\n",
      "        multiple myeloma At least one chemotherapy regimen and no more than four regimens\n",
      "        Pancytopenia related to multiple myeloma allowed At least 50% plasma cells in the bone\n",
      "        marrow Splenomegaly OR Plasma cell leukemia No solitary bone or solitary extramedullary\n",
      "        plasmacytoma\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        At least 3 months Hematopoietic: WBC at least 2,500/mm3 OR neutrophil count at least\n",
      "        1,000/mm3 (previously treated patients with platelet count at least 75,000/mm3 must have a\n",
      "        neutrophil count of greater than 500/mm3) Platelet count at least 75,000/mm3 (previously\n",
      "        treated patients must have platelet count at least 45,000/mm3) Thrombocytopenia related to\n",
      "        idiopathic thrombocytopenic purpura or B12 or folate deficiency allowed Hepatic: Bilirubin\n",
      "        no greater than upper limit of normal (ULN) ALT or AST no greater than 2 times ULN (unless\n",
      "        greater than 1/3 of liver is involved by tumor, in which case ALT or AST must be no\n",
      "        greater than 5 times ULN) Renal: Not specified Cardiovascular: LVEF at least 50% by MUGA\n",
      "        scan or echocardiogram No New York Heart Association class II or greater cardiac disease\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception No prior\n",
      "        malignancies within 5 years, except: Adequately treated basal or squamous cell skin cancer\n",
      "        Adequately treated carcinoma in situ of the cervix No uncontrollable physical, mental, or\n",
      "        emotional disorders No history of hypersensitivity to doxorubicin HCL or liposomal or\n",
      "        PEGylated formulations of other drugs No active infection requiring IV antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Patients who have\n",
      "        previously failed treatment with doxorubicin HCl liposome, vincristine, and dexamethasone\n",
      "        (VAD) are allowed if anthracycline therapy has been at least 6 months, and prior\n",
      "        anthracycline exposure no greater than 300 mg/m2 No other concurrent chemotherapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy allowed Concurrent\n",
      "        radiotherapy to control pain or prevent fractures allowed Surgery: Prior surgery allowed\n",
      "        if recovered\n",
      "2722\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the colon that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Metastatic or unresectable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal failure\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No serious malabsorption syndromes\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple\n",
      "             tumors may be admitted earlier)\n",
      "        Surgery:\n",
      "          -  No prior extensive stomach or intestinal surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent anticancer therapy\n",
      "2723\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the esophagus that is unlikely to respond\n",
      "             to existing therapy and for which no curative therapy exists\n",
      "          -  Meets 1 of the following criteria:\n",
      "               -  Metastatic disease\n",
      "               -  Not curable with surgery or radiotherapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  No hepatic failure\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/ml\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic or congestive heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as severe chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No medical illness, psychiatric illness, or non-malignant systemic disease that would\n",
      "             preclude study treatment\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent steroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy (except in patients with multiple tumors\n",
      "             who have received radiotherapy to some of their tumors) and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "2724\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic breast cancer that expresses carcinoembryonic\n",
      "             antigen (CEA)\n",
      "               -  At least 25% of the tumor cells must stain positive for CEA with at least\n",
      "                  moderate intensity\n",
      "          -  Must have achieved either partial response or complete response after high dose\n",
      "             chemotherapy and peripheral blood stem cell transplant\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 6 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1000/mm^3\n",
      "          -  Absolute lymphocyte count at least 1000/mm^3\n",
      "          -  Hemoglobin at least 9 mg/dL\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  No serious ongoing chronic or acute hepatic disease\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No serious ongoing chronic or acute cardiac disease (New York Heart Association class\n",
      "             III or IV)\n",
      "        Pulmonary:\n",
      "          -  No serious ongoing chronic or acute pulmonary illness such as asthma, chronic\n",
      "             obstructive pulmonary disease, or radiation or drug induced pneumonitis\n",
      "        Other:\n",
      "          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled\n",
      "             superficial bladder cancer within the past 5 years\n",
      "          -  No history of autoimmune disease such as inflammatory bowel disease, systemic lupus\n",
      "             erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple\n",
      "             sclerosis\n",
      "          -  No inflammatory bowel condition such as active infectious enteritis or eosinophilic\n",
      "             enteritis\n",
      "          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral\n",
      "             hepatitis\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since steroids\n",
      "          -  No concurrent steroid therapy\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent immunosuppressive agents such as azathioprine or cyclosporine A\n",
      "2725\n",
      "DISEASE CHARACTERISTICS: Must have a columnar lined esophagus that meets the following\n",
      "        criteria: Specialized intestinal metaplasia Nondysplastic or low grade dysplasia Extends a\n",
      "        minimum of 1 cm above the gastroesophageal junction\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater\n",
      "        than 120,000/mm3 Hemoglobin greater than 12 g/dL Prothrombin time less than 3 seconds\n",
      "        beyond control Partial thromboplastin time less than 10 seconds beyond control Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL Transaminases less than 1.5 times normal Renal: Creatinine\n",
      "        less than 1.5 mg/dL Urinalysis: less than 1+ protein, 0-3 urinary casts, 0-5 white blood\n",
      "        cells and red blood cells Cardiovascular: No severe dyspnea at rest, orthopnea, edema,\n",
      "        history of congestive heart failure requiring continued treatment, or unstable angina\n",
      "        Neurologic: No severe degenerative neurologic disease Pulmonary: No requirement of\n",
      "        supplemental oxygen for exertion or rest Other: No prior malignancy within 5 years No\n",
      "        active rheumatoid arthritis, lupus or other rheumatologic autoimmune disease (no less than\n",
      "        2 years of quiescence if inactive) No history of abnormal wound healing No history of\n",
      "        esophageal varices or variceal bleeding Not pregnant or nursing Negative pregnancy test\n",
      "        Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No regular, scheduled use of antiinflammatory medications,\n",
      "        steroids, or anticoagulants No nutritional supplements other than two multivitamins per\n",
      "        day or four single nutrient vitamin supplements per day\n",
      "2726\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or stage IV bronchoalveolar cell lung cancer\n",
      "             unlikely to have a curative response to existing standard regimens\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  At least 2 cm in diameter\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections\n",
      "          -  No other concurrent serious disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2727\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed (except brain stem locations) brain tumor that is unlikely\n",
      "             to respond to existing therapy and for which no curative therapy exists\n",
      "          -  Evidence of tumor by gadolinium-enhanced MRI, CT scan, or positron emission\n",
      "             tomography\n",
      "          -  Tumor must be at least 5 mm\n",
      "          -  Ineligible for other BRI brain tumor protocols\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on a stable dose for\n",
      "             at least 1 week prior to study entry)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Must recover from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2728\n",
      "DISEASE CHARACTERISTICS: Patients with HLA identical family donors and any one of the\n",
      "        following conditions documented by marrow aspiration and biopsy: -Acute leukemia\n",
      "        refractory to induction treatment or after 1 or more relapses -Acute myeloid leukemia with\n",
      "        t(9;22), -5/5q-, -7/7q-, and 11q23 involvement in first remission (not M4 or M5) -Acute\n",
      "        lymphocytic leukemia with t(9;22) or t(4;11) in first remission -Myelodysplastic syndrome\n",
      "        with greater than 5% bone marrow blasts -Chronic myeloid leukemia in accelerated phase or\n",
      "        nonlymphoid blast crisis -Myeloma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma,\n",
      "        or Hodgkin's disease refractory to 2 lines of standard treatment or progression on\n",
      "        standard treatment No evidence of active extramedullary disease\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Greater than 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than\n",
      "        2.0 mg/dL SGOT no greater than 4 times upper limit of normal and not increasing for 2-4\n",
      "        weeks prior to transplant Renal: Creatinine less than 2 times normal and not increasing\n",
      "        for 2-4 weeks prior to transplant OR Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: LVEF greater than 50% by MUGA Pulmonary: DLCO greater than 50% Other: Not\n",
      "        HIV positive Not pregnant or nursing Fertile patients must use effective contraceptive\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2729\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, incurable solid tumor that is\n",
      "        unresectable or has distant metastasis for which a more effective therapy does not exist\n",
      "        No active CNS metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 8 weeks Hematopoietic: WBC at least 3000/mm3 Absolute neutrophil count at least\n",
      "        1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL\n",
      "        Transaminases no greater than 2.5 times normal PT and PTT no greater than 1.25 times upper\n",
      "        limit of normal Renal: Creatinine no greater than 1.4 mg/dL Creatinine clearance at least\n",
      "        60 mL/min Cardiovascular: No myocardial infarction within past 6 months No congestive\n",
      "        heart failure or serious arrhythmias requiring treatment Other: No greater than grade 2\n",
      "        neuropathy (including hearing loss) No frequent vomiting or severe anorexia No recent loss\n",
      "        of greater than 10% of body weight Not pregnant or nursing Fertile patients must use\n",
      "        effective birth control during and for at least 6 months after study No serious concurrent\n",
      "        medical illness that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and\n",
      "        recovered from toxic effects No concurrent immunotherapy Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (at least 6 weeks since prior mitomycin or nitrosoureas) and\n",
      "        recovered No other concurrent chemotherapy Endocrine therapy: Concurrent hormonal therapy\n",
      "        allowed if patient has progressive disease while receiving hormonal therapy for at least\n",
      "        three months Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No\n",
      "        concurrent radiation therapy Surgery: At least 21 days since prior major surgery Other:\n",
      "        Any drugs that affect hepatic or renal function must be given as a stable dose and should\n",
      "        not be initiated after patient enters study\n",
      "2730\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed (except if medically contraindicated) severe pediatric brain\n",
      "             tumor that is unlikely to respond to existing therapy and for which no curative\n",
      "             therapy exists\n",
      "               -  Histology requirement may be waived for brain stem tumors\n",
      "          -  Measurable tumor by MRI or CT scan\n",
      "               -  Tumor must be at least 5 mm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No history of heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at\n",
      "             least 1 week before study entry)\n",
      "        Radiation therapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from any prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2731\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Must meet one of the following criteria:\n",
      "               -  Histologically confirmed primary invasive squamous carcinoma or adenocarcinoma\n",
      "                  of the cervix\n",
      "               -  History of cervical cancer suspected of being recurrent\n",
      "               -  Known diagnosis of recurrent cervical cancer being considered for pelvic\n",
      "                  exenteration\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No insulin-dependent diabetes mellitus\n",
      "          -  No active serious infection not controlled by antibiotics\n",
      "          -  Must tolerate being in the scanner for the duration of the study\n",
      "          -  Not mentally retarded\n",
      "          -  No prisoners\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2732\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory solid tumors\n",
      "        including, but not limited to: Pancreatic cancer Bladder cancer Colon cancer Head and neck\n",
      "        cancer Lung cancer Measurable disease or a measurable tumor marker (not based solely on\n",
      "        cytopathological data) No primary or active metastatic CNS disease (assessed by edema or 2\n",
      "        radiologic imaging techniques at least 4 weeks apart)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Hemoglobin at least 9.0 g/dL Platelet count at least 100,000/mm3 PT or PTT no greater than\n",
      "        1.2 times upper limit of normal (ULN) Hepatic: Bilirubin no greater than 1.5 time ULN ALT\n",
      "        or AST no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal:\n",
      "        Creatinine no greater than 1.5 times ULN Cardiovascular: No grade 3 cardiac dysrhythmias\n",
      "        No atrial fibrillation No prior myocardial infarction No history of unstable angina No\n",
      "        history of congestive heart failure LVEF greater than 50% in patients with prior\n",
      "        cumulative anthracycline dose less than 450 mg/m2 of doxorubicin Other: HIV negative Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        double-barrier contraception for at least 2 weeks before, throughout, and at least 2 weeks\n",
      "        after the study Permanent central venous catheter in place No history of illicit drug or\n",
      "        alcohol abuse within the past 5 years No emotional or psychiatric disorders No known\n",
      "        significant drug allergies or serious adverse experiences with marketed or investigational\n",
      "        drugs No allergy to latex Normal serum electrolytes No other serious medical disorders No\n",
      "        active infections No history of significant retinal disorder or disease No history of\n",
      "        seizure disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunologic\n",
      "        therapy No concurrent immunologic therapy Chemotherapy: At least 4 weeks since prior\n",
      "        chemotherapy At least 6 weeks since prior mitomycin or nitrosoureas No prior high dose\n",
      "        chemotherapy with stem cell rescue No other concurrent chemotherapy No prior anthracycline\n",
      "        dose exceeding the equivalent of greater than 45O mg/m2 of doxorubicin Endocrine therapy:\n",
      "        At least 4 weeks since prior endocrine therapy (including steroids) No concurrent\n",
      "        endocrine therapy Radiotherapy: At least 4 weeks since prior radiotherapy No prior\n",
      "        radiation to greater than 25% of total bone marrow No concurrent radiotherapy Surgery: At\n",
      "        least 4 weeks since prior surgery No concurrent surgery Other: At least 30 days since\n",
      "        prior investigational agents No concurrent medications with dysrhythmic potential\n",
      "        including, but not limited to: terfenadine, astemizole, cisapride, diphenhydramine,\n",
      "        quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, tricyclic\n",
      "        antidepressants, haloperidol, risperidone, and indapamine No concurrent rifampin,\n",
      "        phenobarbital, phenytoin, or other inducers of CYP3A No concurrent triazolam, alprazolam,\n",
      "        midazolam, or other CYP3A metabolized benzodiazepines No concurrent HMG-CoA reductase\n",
      "        inhibitors (except fluvastatin) No concurrent anticoagulant therapy (low dose warfarin\n",
      "        therapy to maintain catheter patency allowed)\n",
      "2733\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic colon cancer expressing\n",
      "        carcinoembryonic antigen (CEA) At least 50% of tumor cells must express CEA with at least\n",
      "        moderate intensity Resectable hepatic metastases or other site of metastatic colon cancer\n",
      "        that is resectable (e.g., lung metastases)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 6 months Hematopoietic: Absolute neutrophil count at least 1000/mm3\n",
      "        Absolute lymphocyte count at least 1000/mm3 Hemoglobin at least 9 mg/dL Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL No hepatic disease Renal:\n",
      "        Creatinine less than 2.5 mg/dL Cardiovascular: No ongoing cardiac disease No New York\n",
      "        Heart Association class III or IV heart disease Pulmonary: No ongoing pulmonary disease\n",
      "        such as: Asthma Chronic obstructive pulmonary disease (COPD) Active radiation- or\n",
      "        drug-induced pneumonitis Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception No history of autoimmune disease such as but not limited to:\n",
      "        Inflammatory bowel disease Systemic lupus erythematosus Ankylosing spondylitis Scleroderma\n",
      "        Type I diabetes Multiple sclerosis No other serious ongoing chronic or acute illness No\n",
      "        medical or psychological impediment to study compliance No concurrent or prior second\n",
      "        malignancy except: Nonmelanoma skin cancer Controlled superficial bladder cancer within\n",
      "        the last 5 years No active or chronic infection including: Urinary tract infection HIV\n",
      "        Viral hepatitis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        concurrent chemotherapy Endocrine therapy: No concurrent corticosteroids No concurrent\n",
      "        hormone therapy Radiotherapy: No concurrent radiation therapy Surgery: No specified Other:\n",
      "        No immunosuppressives such as: Azathioprine Cyclosporine A\n",
      "2736\n",
      "DISEASE CHARACTERISTICS: Phase I: Histologically proven advanced, primary, or malignant\n",
      "        solid tumors that are refractory to standard therapy or for which no curative therapy\n",
      "        exists Androgen-independent prostate cancer Head and neck cancers Breast cancer Non-small\n",
      "        cell lung cancer Colorectal cancer Ovarian cancer Esophageal cancer Bladder cancer Kidney\n",
      "        cancer Other solid tumors Metastatic disease should not require palliative treatment\n",
      "        within 4 weeks of enrollment Phase II: Histologically proven androgen-independent prostate\n",
      "        cancer Serum testosterone less than 30 ng/mL Failed at least one prior chemotherapy\n",
      "        regimen Progressive Minimum of 3 rising PSA values from baseline obtained at least 1 week\n",
      "        apart OR Two rising PSA values more than one month apart AND At least 25% increase over\n",
      "        range of values AND PSA at least 4 ng/mL No active CNS or epidural tumor Hormone receptor\n",
      "        status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Not specified Menopausal status: Not\n",
      "        specified Performance status: Karnofsky 60-100% Life expectancy: At least 6 months\n",
      "        Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than 100,000/mm3 Hepatic:\n",
      "        Bilirubin less than 2.0 mg/dL SGOT less than 3 times the upper limit of normal Prothrombin\n",
      "        time less than 14 seconds Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance\n",
      "        greater than 60 mL/min Cardiovascular: No New York Heart Association class III or IV\n",
      "        cardiac disease Pulmonary: No severe debilitating pulmonary disease Other: Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception No active infection No other\n",
      "        severe medical problems\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: At\n",
      "        least 4 weeks since prior chemotherapy and recovered Endocrine therapy: Concurrent medical\n",
      "        therapy (i.e., gonadotropin releasing hormone analogs or diethylstilbestrol) to maintain\n",
      "        castrate levels of serum testosterone allowed No other concurrent hormonal therapy\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Concurrent\n",
      "        radiotherapy to localized sites of disease not being evaluated in study allowed Surgery:\n",
      "        Not specified Other: At least 4 weeks since prior investigational anticancer therapy and\n",
      "        recovered No concurrent intravenous antibiotics\n",
      "2737\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced refractory cancer Must meet one\n",
      "        of the following criteria: - Failed at least 1 regimen of radiotherapy, chemotherapy, or\n",
      "        immunotherapy and not a candidate for a regimen of higher efficacy - Refractory to\n",
      "        existing standard therapy and not candidate for a regimen of higher efficacy - Advanced\n",
      "        malignancy for which there is no standard chemotherapy available No known brain metastases\n",
      "        or leptomeningeal involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Greater than 3 months Hematopoietic: Absolute neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Prothrombin time at least 30% of control\n",
      "        Partial thromboplastin time at least 30% of control Hepatic: Bilirubin less than 2 mg/dL\n",
      "        ALT and AST no greater than 2 times normal Alkaline phosphatase no greater than 2 times\n",
      "        normal Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular: No New York Heart Association class III or IV heart disease No myocardial\n",
      "        infarction in the past 6 months Other: No immunodeficiency syndrome (acquired or\n",
      "        congenital) No uncontrolled infection No significant comorbidity that may compromise\n",
      "        participation in this study Not pregnant Effective contraception required of all fertile\n",
      "        patients during and until 3 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks\n",
      "        since prior immunotherapy No concurrent immunotherapy or biologic response modifier\n",
      "        therapy Chemotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent corticosteroids\n",
      "        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No\n",
      "        concurrent radiotherapy Surgery: At least 3 weeks since any prior major surgery Other: No\n",
      "        organ allograft At least 30 days since any prior investigational agents No concurrent\n",
      "        nonsteroidal antiinflammatory agents or aspirin No concurrent alternative therapies (i.e.,\n",
      "        herbal medicines, high doses of vitamins) No other concurrent investigational agents\n",
      "2738\n",
      "DISEASE CHARACTERISTICS: Must be enrolled in SWOG-9623 at time of registration to this\n",
      "        study, but must not have started treatment Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Adult Sex: Female Menopausal status: Not specified\n",
      "        Performance status: See Disease Characteristics Life expectancy: SWOG 0 or 1\n",
      "        Hematopoietic: See Disease Characteristics Hepatic: See Disease Characteristics Renal: See\n",
      "        Disease Characteristics\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2740\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed, previously untreated stage IIIa (T1-2 N2 M0) non-small cell\n",
      "             lung cancer\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Total bilirubin no greater than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine clearance at least 55 mL/min\n",
      "        Other:\n",
      "          -  Not HIV positive\n",
      "          -  No active infections\n",
      "          -  Not pregnant or lactating\n",
      "          -  Effective contraception required of fertile patients during study participation\n",
      "          -  No coexisting medical condition\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiation therapy\n",
      "          -  No concurrent radiation therapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent use of investigational agents during study participation\n",
      "2741\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic breast, ovarian, endometrial, or cervical\n",
      "             carcinoma\n",
      "          -  Measurable and evaluable disease\n",
      "          -  No brain metastases\n",
      "          -  No hepatic involvement greater than 80%\n",
      "          -  No lung involvement greater than 30%\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute granulocyte count greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 90,000/mm^3\n",
      "          -  Normal bone marrow cellularity on bone marrow biopsy\n",
      "          -  Thrombin time less than 17 sec\n",
      "          -  Fibrinogen greater than 200 mg/dL\n",
      "          -  FSP less than 40\n",
      "          -  No coagulopathy\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  SGPT less than 2 times normal\n",
      "          -  PT less than 14 sec\n",
      "          -  PTT less than 35 sec\n",
      "        Renal:\n",
      "          -  BUN less than 25 mg/dL\n",
      "          -  Creatinine clearance at least 45 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Normal cardiovascular system\n",
      "          -  Resting ventricular ejection fraction greater than 40%\n",
      "          -  No prior myocardial infarction\n",
      "          -  No symptomatic coronary artery disease\n",
      "          -  No unstable blood pressure\n",
      "          -  No thromboembolic disease\n",
      "        Neurologic:\n",
      "          -  No seizures or other CNS disorders\n",
      "          -  Negative computerized tomographic scan of brain\n",
      "        Pulmonary:\n",
      "          -  FEV_1 greater than 70% of predicted\n",
      "          -  Arterial pressure of oxygen greater than 60 mmHg on room air with appropriate\n",
      "             pressure of carbon dioxide and pH values\n",
      "          -  No history of cardiopulmonary or respiratory disease\n",
      "        Other:\n",
      "          -  No other serious concurrent medical illness\n",
      "          -  No diabetes mellitus\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Prior chemotherapy allowed\n",
      "        Endocrine therapy:\n",
      "          -  No adrenal corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent cardiac glycosides, antianginal therapy, or antiarrhythmics\n",
      "          -  No concurrent vasodilators, anticoagulants, thrombolytic agents, or aspirin\n",
      "2744\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV epithelial ovarian\n",
      "        cancer that is refractory to platinum therapy or has relapsed within 12 months after\n",
      "        platinum therapy Minimal residual disease by laparotomy Must have adequate number of\n",
      "        peripheral stem cells collected No intraabdominal, pelvic disease, or other disease\n",
      "        greater than 1 cm No brain metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 2 times the upper limit of normal (ULN) Serum\n",
      "        transaminases less than 2 times ULN Renal: Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: Cardiac ejection fraction at least 45% No active angina No uncontrolled\n",
      "        hypertension Pulmonary: FEV1, vital capacity, and diffusion capacity greater than 50% of\n",
      "        predicted Other: Not HIV positive No active hepatitis B or C infection Not pregnant No\n",
      "        concurrent malignancy except basal cell or squamous cell carcinoma of the skin No serious\n",
      "        medical conditions such as uncontrolled diabetes mellitus\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No immunotherapy within the past 4 weeks No\n",
      "        concurrent immunotherapy Chemotherapy: No chemotherapy within the past 4 weeks No\n",
      "        mitomycin within the past 6 weeks No other concurrent chemotherapy No prior anthracycline\n",
      "        therapy greater than 200 mg/m2 Endocrine therapy: Not specified Radiotherapy: No\n",
      "        radiotherapy within the past 4 weeks No concurrent radiotherapy No prior radiotherapy to\n",
      "        the whole abdomen Surgery: Prior surgery allowed\n",
      "2745\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed renal cell carcinoma, melanoma, or sarcoma with 1-3 newly\n",
      "             diagnosed intraparenchymal brain metastases based on contrast-enhanced MRI (CT scan\n",
      "             acceptable if patients have a medical contraindication to MRI)\n",
      "          -  No lesion greater than 4.0 cm in diameter and, if multiple lesions are present, no\n",
      "             more than one greater than 3.0 cm in diameter\n",
      "          -  No limitation on the extent of extracranial metastatic disease\n",
      "          -  No metastases in the brain stem, midbrain, pons, or medulla\n",
      "          -  No leptomeningeal metastases documented by MRI or CSF evaluation\n",
      "          -  No metastases within 10 mm of optic nerve or chiasm\n",
      "          -  No history of multiple liver metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "          -  Hemoglobin greater than 8 g/dL\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No major medical illness\n",
      "          -  No psychoses\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Prior chemotherapy allowed\n",
      "          -  Systemic chemotherapy may be continued at the discretion of investigator after\n",
      "             completion of radiosurgery\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior cranial radiotherapy\n",
      "          -  Prior or concurrent radiotherapy to noncranial sites allowed\n",
      "        Surgery:\n",
      "          -  No prior surgical resection for brain metastases\n",
      "          -  Prior stereotactic biopsy for diagnostic purposes allowed\n",
      "2748\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary refractory or relapsed acute\n",
      "        myelocytic leukemia (AML) or acute lymphocytic leukemia (ALL), chronic myelogenous\n",
      "        leukemia (CML) in blast crisis, or refractory or relapsed lymphoblastic lymphoma Priority\n",
      "        is given to patients previously treated with conventional high dose cytarabine regimen\n",
      "        without bryostatin 1 Eligible if previously failed a conventional high dose cytarabine\n",
      "        regimen or if underwent subsequent high dose therapy with bone marrow/stem cell\n",
      "        transplantation with curative intent\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over (must be 60 or under if receiving higher dose of\n",
      "        cytarabine) Performance status: Karnofsky 60-100% Life expectancy: Not specified\n",
      "        Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL (bilirubin no\n",
      "        greater than 3.0 mg/dL and conjugated bilirubin no greater than 0.5 mg/dL if Gilbert's\n",
      "        disease and predominantly unconjugated hyperbilirubinemia present) AST no greater than 2.5\n",
      "        times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN\n",
      "        Renal: Creatinine clearance at least 40 mL/min (at least 60 mL/min if receiving higher\n",
      "        dose of cytarabine) Pulmonary: No clinically significant pulmonary disease Other: Not\n",
      "        pregnant No patients who are poor medical risks because of nonmalignant systemic disease\n",
      "        No serious, active, uncontrolled infection No prior or concurrent medical status that\n",
      "        would make assessing cortical or cerebellar neurologic toxicity difficult\n",
      "        PRIOR CONCURRENT THERAPY: Recovery from the major toxic effects of prior therapy required\n",
      "        Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics At\n",
      "        least 24 hours since prior chemotherapy with hydroxyurea At least 3 weeks since other\n",
      "        prior systemic chemotherapy No prior clinically significant cerebellar toxicity due to\n",
      "        cytarabine Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "2749\n",
      "DISEASE CHARACTERISTICS: Histologically proven persistent or platinum refractory stage\n",
      "        III/IV ovarian cancer\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than\n",
      "        1.5 mg/mL, unless history of Gilbert's disease SGOT or SGPT no greater than 2 times upper\n",
      "        limit of normal Renal: Creatinine clearance at least 50 mg/mL No history of hemorrhagic\n",
      "        cystitis Cardiovascular: No history of coronary artery disease No poorly controlled\n",
      "        arrhythmia or myocardial infarction Left ventricle ejection fraction at least 50%\n",
      "        Pulmonary: Diffusion capacity at least 50% Other: Not pregnant HIV negative No second\n",
      "        malignancy in the last 5 years except basal carcinoma of the skin\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No history of\n",
      "        allergy to any chemotherapy drugs Endocrine therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified\n",
      "2750\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent or refractory\n",
      "        carcinoma of the endometrium or fallopian tubes or sarcomas of gynecologic origin\n",
      "        including mixed mesodermal sarcomas Documented recurrence or persistence of disease after\n",
      "        appropriate surgical and/or radiation therapy Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Platelet count at least 50,000/mm3 Granulocyte\n",
      "        count at least 1,000/mm3 Hepatic: SGOT and SGPT no greater than 3 times upper limit of\n",
      "        normal (ULN) Bilirubin no greater than 3 times ULN Renal: Creatinine less than 2.5 mg/dL\n",
      "        Cardiovascular: MUGA at least lower limit of normal Normal ejection fraction and/or stable\n",
      "        cardiac status Other: No medical or social factors that would interfere with compliance\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No serious concurrent illness requiring immediate therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months\n",
      "        since prior combined modality or adjuvant chemotherapy Prior doxorubicin allowed if\n",
      "        cumulative dose is recorded Endocrine therapy: Not specified Radiotherapy: No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: At least 30 days since prior noncytotoxic\n",
      "        experimental antiemetic or antifungal investigational drugs\n",
      "2751\n",
      "DISEASE CHARACTERISTICS: Primary, previously untreated, histologically confirmed invasive\n",
      "        squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix\n",
      "        stage IIB, IIIB, or IVA Negative para-aortic lymph nodes determined by lymphangiogram, CT,\n",
      "        MRI, or lymphadenectomy (excluding suspicious para-aortic lymph nodes) Para-aortic\n",
      "        lymphadenectomy must be performed extraperitoneally or by laparoscopy No histologically\n",
      "        confirmed cancer involving the para-aortic lymph nodes, intraperitoneal disease, or\n",
      "        positive peritoneal cytology No recurrent invasive carcinoma of the uterine cervix,\n",
      "        regardless of previous treatment or cervix cancers other than squamous cell,\n",
      "        adenosquamous, or adenocarcinoma No carcinoma of the cervical stump\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: GOG 0-3 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 times normal SGOT and alkaline phosphatase no\n",
      "        greater than 3 times normal Renal: Creatinine no greater than 2.0 mg/dL Other: No\n",
      "        septicemia or severe infection Not pregnant Negative pregnancy test Effective\n",
      "        contraception required of fertile patients No other invasive malignancy unless disease\n",
      "        free for at least 5 years and no prior cancer treatment that contraindicated this protocol\n",
      "        therapy No concomitant malignancy other than nonmelanomatous skin cancer Must complete\n",
      "        smoking history questionnaire and provide urine specimen for cotinine analysis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy to\n",
      "        the pelvis Surgery: No prior hysterectomy\n",
      "2752\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant glioma that is progressive or\n",
      "        recurrent following radiation therapy or chemotherapy Anaplastic astrocytoma Glioblastoma\n",
      "        multiforme Low grade glioma that has progressed to biopsy proven high grade glioma is\n",
      "        eligible if the progression occurred after radiotherapy with or without chemotherapy\n",
      "        Measurable progression or recurrence by serial MR or CT imaging\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Greater than 2 months Hematopoietic: Absolute neutrophil count 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminases no greater than 4 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.7 mg/dL Cardiovascular: No uncontrolled hypertension No angina pectoris No evidence\n",
      "        of uncontrolled cardiac dysrhythmia Other: No serious infection or other medical illness\n",
      "        No other prior or concurrent malignancy within 5 years except curatively treated basal or\n",
      "        squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast Not\n",
      "        pregnant or nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        topoisomerase 1 inhibitor (topotecan, irinotecan, 9- aminocamptothecin) No more that 1\n",
      "        prior chemotherapy regimen At least 6 weeks since nitrosourea and recovered At least 3\n",
      "        weeks since any other chemotherapy and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 3 months since completion of most recent course of radiotherapy and\n",
      "        recovered Surgery: Not specified Other: No concurrent investigational agents At least 14\n",
      "        days since prior valproic acid No concurrent valproic acid\n",
      "2754\n",
      "DISEASE CHARACTERISTICS: Mammogram highly suspicious for ductal carcinoma in situ or early\n",
      "        invasive carcinoma Branching or linear microcalcifications clustered or distributed\n",
      "        segmentally in the breast without an associated palpable or mammographic mass Palpable\n",
      "        thickening or nipple discharge allowed At least 5 mm area of calcification or contain\n",
      "        enough calcium for core biopsies Small palpable carcinoma (T1 or T2) with no palpable\n",
      "        axillary lymph nodes (N0) No definitive local therapy Atypical hyperplasia (ductal or\n",
      "        lobular) and/or carcinoma on initial diagnostic biopsy Hormone receptor status: Not\n",
      "        specified\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute\n",
      "        granulocyte count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular: No uncontrolled congestive heart failure Other: Fasting serum\n",
      "        triglycerides less than 400 mg/dL Fertile patients must use effective contraception during\n",
      "        and for one year after completing fenretinide therapy No concurrent serious illness or\n",
      "        infection, e.g., septicemia No prior thromboembolic disease No prior degenerative retinal\n",
      "        disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 5 years\n",
      "        since prior chemotherapy Endocrine therapy: At least 12 months since prior tamoxifen\n",
      "        therapy No concurrent estrogen therapy At least 3 months since prior anabolic steroids\n",
      "        Radiotherapy: No prior radiotherapy to the chest or breast Surgery: See Disease\n",
      "        Characteristics Other: No vitamin A supplementation greater than 25,000 IU At least 12\n",
      "        months since prior retinoid therapy\n",
      "2755\n",
      "DISEASE CHARACTERISTICS: Healthy women and men\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: No chronic liver disease\n",
      "        Renal: No chronic renal disease Cardiovascular: No chronic cardiovascular disease\n",
      "        Pulmonary: No chronic pulmonary disease Other: No known allergy to soy proteins No\n",
      "        consumption of soy protein within past week\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No antibiotics within past 3 months\n",
      "        Chemotherapy: Not specified Endocrine therapy: No oral contraceptive or hormone\n",
      "        replacement therapy Radiotherapy: Not specified Surgery: Not specified Other: No\n",
      "        medication likely to affect gastrointestinal, liver, or kidney function\n",
      "2756\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed B-cell non-Hodgkin's lymphoma (low,\n",
      "        intermediate, or high grade categories) Must have been treated with chemotherapy and/or\n",
      "        radiotherapy with evidence of minimal residual disease by conventional diagnostic\n",
      "        modalities A new classification scheme for adult non-Hodgkin's lymphoma has been adopted\n",
      "        by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "        terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol\n",
      "        uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: BUN no greater\n",
      "        than 1.5 times upper limit of normal (ULN) Creatinine no greater than 1.5 times ULN Other:\n",
      "        No known allergies to mouse proteins No second primary malignancy within past 5 years\n",
      "        other than adequately treated in situ carcinoma of the cervix or uterus, or basal or\n",
      "        squamous cell carcinoma of the skin Not pregnant or nursing Effective contraception\n",
      "        required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior exposure to mouse antibodies other\n",
      "        than LymphoScan Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics Surgery: Not specified Other: At least 1 month\n",
      "        since any other prior investigational therapy No concurrent participation in another\n",
      "        protocol involving medical devices or investigational agents\n",
      "2757\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV melanoma or stage III melanoma not potentially\n",
      "             curable by surgery\n",
      "          -  Phase I: (closed to accrual 3/7/2001) measurable or evaluable disease required\n",
      "          -  Phase II: At least 2 measurable subcutaneous or cutaneous metastases that are\n",
      "             accessible for biopsy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  No active bleeding\n",
      "        Hepatic:\n",
      "          -  AST less than 1.5 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase less than 1.5 times ULN\n",
      "          -  PT/PTT within normal range\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Pulmonary:\n",
      "          -  No interstitial lung disease or unexplained interstitial infiltrates on chest x-ray\n",
      "          -  No chronic obstructive pulmonary disease\n",
      "          -  No asthma requiring treatment\n",
      "        Other:\n",
      "          -  No active infection requiring antimicrobial drugs\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective barrier contraception\n",
      "          -  No allergies to acetaminophen or acetylcysteine\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin)\n",
      "          -  No prior nitrosoureas\n",
      "          -  No prior hepatic perfusions with chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent oral contraceptives\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent vitamin, mineral, or garlic supplements\n",
      "          -  At least 7 days since prior garlic or alcohol\n",
      "          -  No concurrent treatment with medications known to affect P450 hepatic enzymes\n",
      "          -  No concurrent treatment with calcium channel blockers\n",
      "2758\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory non-small cell lung\n",
      "        cancer At least one prior systemic therapy OR prior radiation therapy Must have measurable\n",
      "        disease Previously irradiated sites of disease are not considered evaluable unless there\n",
      "        is radiologic documentation of progression\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        At least 3 months Hematopoietic: WBC at least 3,000/mm3 Hemoglobin greater than 10 g/dL\n",
      "        Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal:\n",
      "        Creatinine less than 2.0 mg/dL Cardiovascular: No prior history of myocardial infarction\n",
      "        within previous 6 months No uncompensated congestive heart failure No primary (not due to\n",
      "        electrolytes or drugs) cardiac arrhythmias besides premature ventricular contractions\n",
      "        Pulmonary: No dyspnea at rest or need for supplemental oxygen Patients with symptomatic\n",
      "        lung disease or extensive lung metastases must have oxygen saturation greater than 90%\n",
      "        Other: Not pregnant or nursing Negative pregnancy test Patients with elevated temperatures\n",
      "        greater than 100.5 F must have no occult infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent cyclosporin Chemotherapy: At\n",
      "        least 3 weeks since chemotherapy and recovered No concurrent methotrexate See Disease\n",
      "        Characteristics Endocrine therapy: No concurrent systemic corticosteroids Radiotherapy: At\n",
      "        least 3 weeks since radiotherapy See Disease Characteristics Surgery: Not specified\n",
      "2759\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed CD33 positive acute myeloid leukemia\n",
      "        (AML) in first relapse At least 6 months of complete remission No CNS leukemia No AML\n",
      "        secondary to exposure to chemotherapy or toxins\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC less than 30,000/mm3 at time of CMA-676 administration\n",
      "        Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular: No severe cardiac disease Pulmonary: No severe pulmonary disease Other:\n",
      "        Not pregnant or nursing Fertile patients must use an effective method of contraception Not\n",
      "        known to be HIV positive No prior myelodysplastic syndrome No other active malignancy No\n",
      "        uncontrolled infections Able to obtain bone marrow aspirate\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation No prior\n",
      "        anti-CD33 antibody therapy Chemotherapy: No prior chemotherapy for AML in first relapse\n",
      "        except hydroxyurea At least 24 hours since prior hydroxyurea Endocrine therapy: Not\n",
      "        specified Radiotherapy: Not specified Surgery: Not specified Other: At least 4 weeks since\n",
      "        prior investigational agents\n",
      "2760\n",
      "DISEASE CHARACTERISTICS: Histologically proven advanced myelodysplastic syndrome (MDS),\n",
      "        including: Refractory anemia Refractory anemia with ringed sideroblasts Refractory anemia\n",
      "        with excess blasts Refractory anemia with excess blasts in transformation MDS with at\n",
      "        least bicytopenia No chronic myelomonocytic leukemia No acute leukemia\n",
      "        PATIENT CHARACTERISTICS: Age: 17 and over Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        Greater than 6 months Hematopoietic: Hemoglobin less than 8.5 g/dL Absolute granulocyte\n",
      "        count less than 1,000 g/dL Platelet count less than 70,000/mm3 Hepatic: No major hepatic\n",
      "        problems Renal: No major renal problems Cardiovascular: No major cardiac disease Other:\n",
      "        Prior transfusion of blood products is allowed Not pregnant Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior cytokine therapy is allowed\n",
      "        Chemotherapy: No prior chemotherapy Endocrine therapy: Prior steroid therapy is allowed\n",
      "        Radiotherapy: Not specified Surgery: Not specified Other: Prior leucovorin calcium and\n",
      "        pyridoxine allowed\n",
      "2761\n",
      "DISEASE CHARACTERISTICS: Suspicious mammographic finding or palpable abnormality OR\n",
      "        Suspicious clinical or ultrasound finding without associated benign mammographic features\n",
      "        May have more than one suspicious lesion based on mammography or clinical exam if an index\n",
      "        lesion is present Mammogram within 2 months prior to MRI scan and copy of films required\n",
      "        of all patients 30 years of age and over Eligibility maintained if patient meets above\n",
      "        criteria and has had: Breast implant Prior benign excisional or core biopsy at least 6\n",
      "        months prior to study Fine needle aspiration performed at any time Cancer in the\n",
      "        contralateral breast No history of prior breast cancer in the study breast No benign\n",
      "        excisional or core biopsy of the affected breast within the last 6 months\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 79 Sex: Women Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Cardiovascular: No implanted pacemaker Other: No implanted ferromagnetic device\n",
      "        No ferromagnetic aneurysm clip No severe claustrophobia No ocular metal fragments No\n",
      "        schrapnel injury No difficulty lying prone No poor venous access No impaired\n",
      "        decision-making abilities Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Not specified\n",
      "2763\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic, recurrent, or refractory\n",
      "        epithelial endometrial carcinoma Must be one of the following histologic types:\n",
      "        Endometrioid adenocarcinoma Villoglandular Secretory Ciliated Endometrioid adenocarcinoma\n",
      "        with squamous differentiation Serous carcinoma Clear cell carcinoma Mucinous carcinoma\n",
      "        Squamous carcinoma Mixed types of carcinoma Undifferentiated carcinoma Must not be\n",
      "        amenable to surgery or radiotherapy Documented evidence of progression at site if the only\n",
      "        site of measurable disease has been irradiated Metastatic sites need not be biopsied\n",
      "        Measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal\n",
      "        (ULN) SGOT no greater than 2 times ULN Renal: Creatinine no greater than 2.0 mg/dL\n",
      "        Creatinine clearance at least 25 mL/min Other: At least 5 years since other prior\n",
      "        malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in\n",
      "        situ of the cervix, or adequately treated stage I or II cancer in complete remission Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No more than 1\n",
      "        prior biologic therapy regimen Chemotherapy: No concurrent chemotherapy No prior taxane\n",
      "        for any reason No more than 2 prior chemotherapy courses used for the sole purpose of\n",
      "        radiosensitization during primary definitive therapy allowed No other prior chemotherapy\n",
      "        Endocrine therapy: No concurrent hormonal therapy Prior hormonal or other endocrine\n",
      "        therapy allowed Radiotherapy: No concurrent radiotherapy except to sites of bone\n",
      "        metastases for palliative control of pain Prior radiotherapy to no more than 30% of bone\n",
      "        marrow allowed At least 4 weeks since radiotherapy and recovered Surgery: Prior surgery\n",
      "        allowed Must have recovered from surgery and any complication therefrom\n",
      "2766\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed central nervous system cancer including:\n",
      "               -  Medulloblastoma with either local residual disease of greater than 1 cm^2 on MRI\n",
      "                  following resection or evidence of metastases (M1-4)\n",
      "               -  Other primitive neuroectodermal tumors\n",
      "               -  Ependymoma with evidence of subarachnoid metastases\n",
      "          -  Must have less than 1 cm of midline shift or no acute elevated intercranial pressure\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Platelet count greater than 125,000/mm^3\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "          -  No preexisting hematologic condition that would increase toxicity or limit ability to\n",
      "             comply with evaluations and follow-up\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2 times upper limit of normal (ULN)\n",
      "          -  SGOT less than 2 times ULN\n",
      "          -  Alkaline phosphatase less than 2 times ULN\n",
      "          -  No preexisting hepatic condition that would increase toxicity or limit ability to\n",
      "             comply with evaluations and follow-up\n",
      "        Renal:\n",
      "          -  Creatinine greater than 70 mL/min\n",
      "          -  No preexisting renal condition that would increase toxicity or limit ability to\n",
      "             comply with evaluations and follow-up\n",
      "        Pulmonary:\n",
      "          -  No history of significant pulmonary disease or, if there is preexisting pulmonary\n",
      "             disease, then DLCO greater than 60% of predicted\n",
      "          -  No preexisting pulmonary condition that would increase toxicity or limit ability to\n",
      "             comply with evaluations and follow-up\n",
      "        Other:\n",
      "          -  No preexisting psychiatric condition that would increase toxicity or limit ability to\n",
      "             comply with evaluations and follow-up\n",
      "          -  No prior or concurrent malignancies within the past 5 years except curatively treated\n",
      "             carcinoma in situ of the cervix or basal cell or squamous cell skin cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No increasing doses of steroids for intracranial disease within 3 days of\n",
      "             registration\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  10-28 days since prior surgical resection OR\n",
      "          -  At least 5 days since prior biopsy\n",
      "2767\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic breast cancer Adequate\n",
      "        peripheral blood stem cells harvested and stored\n",
      "        PATIENT CHARACTERISTICS: Age: 21-65 Sex: Female Performance status: 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 mg/dL SGOT and\n",
      "        SGPT normal Renal: Creatinine less than 1.5 mg/dL Cardiovascular: Ejection fraction of at\n",
      "        least 50% No symptomatic coronary artery disease Pulmonary: FEV1 and DLCO greater than 50%\n",
      "        of predicted Other: Not pregnant Not HIV positive Not hepatitis B surface antigen positive\n",
      "        No uncontrolled infection No other prior malignancy within 5 years except: Curatively\n",
      "        treated in situ adenocarcinoma of the cervix Curatively treated nonmelanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior therapy Biologic therapy:\n",
      "        Not specified Chemotherapy: No prior chemotherapy for metastatic disease Prior adjuvant\n",
      "        chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy\n",
      "        for metastatic disease Surgery: Not specified\n",
      "2768\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma or adenocarcinoma\n",
      "        of the thoracic esophagus (adenocarcinoma stratum closed) Locally advanced and surgically\n",
      "        resectable (T2-4 N0-1 M0) T1 N1 tumors are eligible, T1 N0 tumors and in situ carcinoma\n",
      "        are not eligible No cervical esophageal tumors No brain, pulmonary, liver, bone, lymph\n",
      "        node (cervical or supraclavicular) or other distant metastases No positive cytology of the\n",
      "        pleura, pericardium, or peritoneum No invasion of the tracheobronchial tree or presence of\n",
      "        tracheoesophageal fistula\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1500/mm3\n",
      "        Platelet count at least 150,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Calcium no greater than 12 mg/dL Cardiovascular: No\n",
      "        New York Heart Association class III/IV heart disease No history of active angina No\n",
      "        myocardial infarction within 6 months No history of significant ventricular arrhythmia\n",
      "        requiring medication No history of clinically significant conduction system abnormality\n",
      "        Pulmonary: FEV1 at least 1.2 L Other: Not pregnant or nursing Negative pregnancy test No\n",
      "        serious concurrent infections or uncontrolled nonmalignant medical illnesses No psychosis\n",
      "        No clinically significant hearing loss No recurrent laryngeal nerve or phrenic nerve\n",
      "        paralysis No concurrent active malignancy except nonmelanomatous skin cancer or carcinoma\n",
      "        in situ of the cervix Prior malignancies without evidence of disease for at least 5 years\n",
      "        allowed\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        prior chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior radiotherapy No other concurrent radiotherapy Surgery: Not\n",
      "        specified\n",
      "2769\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed high risk malignancy including:\n",
      "               -  Acute nonlymphocytic leukemia (ANLL) after induction failure, or in first\n",
      "                  complete remission with high risk features including stem cell or biphenotypic\n",
      "                  classification (acute myeloid leukemia (AML) M0), erythroleukemia (AML M6),\n",
      "                  acute megakaryocytic leukemia (AML M7), cytogenic markers indicative of poor\n",
      "                  prognosis, or failure to achieve complete remission after standard induction\n",
      "                  therapy\n",
      "               -  Acute lymphocytic leukemia (ALL) or ANLL in second or subsequent remission\n",
      "               -  Chronic myeloid leukemia (CML) in chronic phase\n",
      "                    -  CML with accelerated phase or blast crisis are eligible after reinduction\n",
      "                       chemotherapy converts disease to chronic phase\n",
      "               -  High risk ALL in first complete remission\n",
      "               -  Myelodysplastic syndrome with evidence of evolution to acute myeloid leukemia\n",
      "                    -  Refractory anemia with excess blasts\n",
      "                    -  Refractory anemia with excess blasts in transformation\n",
      "               -  Non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after\n",
      "                  autologous stem cell transplantation\n",
      "          -  Must also meet all the following conditions:\n",
      "               -  No HLA-ABC/DR identical related bone marrow or UCB donor\n",
      "               -  No 5/6 antigen matched related bone marrow or UCB donor\n",
      "               -  Condition precludes waiting to search and find a donor in the National Marrow\n",
      "                  Donor Registry\n",
      "          -  Must have an available serologic matched umbilical cord blood unit in the New York\n",
      "             Blood Center's Placental Blood Project\n",
      "          -  No active CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 55 at time of umbilical cord blood transplantation\n",
      "        Performance status:\n",
      "          -  Zubrod 0-1\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  For patients with ALL or ANLL in remission, CML in chronic phase, or NHL without\n",
      "             marrow involvement who elect to undergo autologous peripheral blood stem cell\n",
      "             collection and storage:\n",
      "               -  WBC at least 3,000/mm^3\n",
      "               -  Absolute neutrophil count at least 1,000/mm^3\n",
      "               -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "          -  ALT/AST no greater than 4 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Creatinine clearance at least 50 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Normal cardiac function by echocardiogram or radionuclide scan (shortening fraction\n",
      "             or ejection fraction at least 80% of normal value for age)\n",
      "        Pulmonary:\n",
      "          -  FVC and FEV_1 at least 60% of predicted for age\n",
      "          -  For adults:\n",
      "               -  DLCO at least 60% of predicted\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No active infections at time of autologous stem cell harvest or pretransplant\n",
      "             cytoreduction\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior autologous stem cell transplantation allowed\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2771\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven anaplastic oligodendroglioma OR\n",
      "          -  Histologically proven anaplastic mixed glioma (oligoastrocytoma) provided there is an\n",
      "             unequivocal and substantial (at least 25%) oligodendroglial element\n",
      "          -  No systemic or leptomeningeal metastases (excluding contiguous leptomeninges)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age\n",
      "          -  18 and over\n",
      "        Performance status\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy\n",
      "          -  Not specified\n",
      "        Hematopoietic\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) OR\n",
      "          -  SGOT no greater than 2 times ULN\n",
      "        Renal\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular\n",
      "          -  LVEF at least 50%\n",
      "        Pulmonary\n",
      "          -  DLCO at least 50% of predicted\n",
      "        Other\n",
      "          -  No other serious illness that would preclude study therapy\n",
      "          -  No other concurrent malignancy except basal cell skin cancer or carcinoma in situ of\n",
      "             the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  No prior systemic chemotherapy\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  No prior cranial radiotherapy\n",
      "        Surgery\n",
      "          -  Prior complete or partial resection, open biopsy, or stereotactic biopsy allowed\n",
      "2776\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically diagnosed:\n",
      "               -  Acute myeloid leukemia in first, second, or third complete remission or first or\n",
      "                  second early relapse\n",
      "               -  Acute lymphoblastic leukemia in first, second, or third complete remission or\n",
      "                  first or second early relapse\n",
      "               -  Hodgkin's lymphoma in second or third remission or first, second, or third\n",
      "                  relapse, or refractory\n",
      "               -  Non-Hodgkin's lymphoma in second or third remission or first, second, or third\n",
      "                  relapse, or refractory\n",
      "               -  Multiple myeloma and plasma cell leukemia in second or third remission or first,\n",
      "                  second, or third relapse, or refractory\n",
      "               -  Myelodysplastic syndrome deemed suitable for allogeneic bone marrow\n",
      "                  transplantation\n",
      "          -  No symptoms or signs of CNS involvement and CNS is disease free on lumbar puncture\n",
      "             and brain CT scan\n",
      "          -  No active meningeal cancer\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  4 to 55 (4 to 60 if donor is identical twin)\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  SGOT/SGPT less than 3 times normal\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.1 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min (no greater than 1.5 times normal for\n",
      "             children under 40 kg)\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No uncontrolled congestive heart failure\n",
      "          -  No active angina pectoris requiring nitrates\n",
      "          -  At least 6 months since prior myocardial infarction\n",
      "          -  No major ventricular arrhythmia\n",
      "          -  Left ventricular ejection fraction at least 45% on MUGA\n",
      "        Pulmonary:\n",
      "          -  No severe or symptomatic restrictive or obstructive lung disease\n",
      "          -  FEV_1 greater than 50% of predicted\n",
      "          -  DLCO greater than 50% of predicted\n",
      "        Neurologic:\n",
      "          -  No severe central or peripheral neurologic abnormality\n",
      "        Other:\n",
      "          -  Must have HLA-A,B,C,D/DR identical sibling age 4 to 65, in good health\n",
      "          -  No insulin-dependent diabetes mellitus\n",
      "          -  No major thyroid or major adrenal dysfunction\n",
      "          -  No active infection\n",
      "          -  No other active malignancy\n",
      "          -  Not pregnant\n",
      "          -  HIV negative\n",
      "          -  HTLV-I and HTLV-II negative\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No excessive anthracycline exposure, unless endomyocardial biopsy shows less than\n",
      "             grade 2 drug effect and cardiac scan shows at least 50% ejection fraction\n",
      "          -  At least 1 year since prior autologous bone marrow or peripheral blood progenitor\n",
      "             cell transplant or allogeneic bone marrow transplant\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks since prior chemotherapy\n",
      "          -  No prior excessive carmustine and bleomycin\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent nitroglycerin for angina pectoris\n",
      "          -  No concurrent anti-arrhythmic drugs for major ventricular dysrhythmias\n",
      "2777\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage IIIA non-small cell lung cancer\n",
      "        that has been completely resected by lobectomy, bilobectomy, pneumonectomy, or sleeve\n",
      "        lobectomy through any incision (thoracoscopic or video assisted resection is acceptable)\n",
      "        No known residual disease present Involvement in N2 nodes must have been determined only\n",
      "        at the time of surgical exploration or by postoperative pathologic diagnosis All grossly\n",
      "        involved nodes must be removed at surgery No positive mediastinoscopy (if lymph nodes on\n",
      "        CT scan are greater than 1.5 cm in diameter, mediastinoscopy is required)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ZUBROD 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT no greater than upper limit of\n",
      "        normal Renal: Creatinine clearance at least 20 mL/min Other: Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent growth factors Chemotherapy: No\n",
      "        prior chemotherapy for non-small cell lung cancer No other concurrent chemotherapy\n",
      "        Endocrine therapy: No concurrent hormone therapy except: Steroids for adrenal failure\n",
      "        Hormones for nondisease related conditions Dexamethasone as an antiemetic Radiation\n",
      "        therapy: No prior radiotherapy for non-small cell lung cancer Surgery: See Disease\n",
      "        Characteristics\n",
      "2778\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer Measurable or\n",
      "        evaluable disease Must be ineligible for other high priority national or institutional\n",
      "        study No visible metastases on brain CT or MRI (unless single lesion amenable to surgical\n",
      "        resection) Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Life expectancy: More than 2 months Hematopoietic: WBC\n",
      "        greater than 3,000/mm3 Platelet count greater than 100,000/mm3 No prior clotting disorder\n",
      "        unless therapeutically anticoagulated Hepatic: Bilirubin less than the upper limit of\n",
      "        normal SGOT or SGPT less than 1.5 times normal Renal: BUN less than 1.5 times normal\n",
      "        Creatinine less than 1.5 times normal Cardiovascular: No prior thromboembolism unless\n",
      "        therapeutically anticoagulated Other: No symptomatic ascites, pleural effusion or\n",
      "        peripheral edema No serious medical or psychiatric illness No prior malignancy other than\n",
      "        curatively treated carcinoma in situ of the cervix or skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (2 weeks if weekly regimen) Any number of prior chemotherapy\n",
      "        regimens allowed Endocrine therapy: Any number of prior hormonal therapy regimens allowed\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 1 week since\n",
      "        prior surgery\n",
      "2779\n",
      "DISEASE CHARACTERISTICS: Healthy postmenopausal female between the ages of 50 and 69 with\n",
      "        diet of greater than 32% of total calories from fat and less than 15 grams of fiber\n",
      "        PATIENT CHARACTERISTICS: Age: 50 to 69 Sex: Female Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: At least 2 years since menopause In general good health Increased body\n",
      "        fat (125%-175% of ideal body weight) Increased upper body fat (waist-to-hip circumference\n",
      "        ratio greater than 0.85) Serum estradiol greater than 13 picograms per milliliter\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent medication that can interfere with blood test\n",
      "        results No hormone replacement therapy or thyroid hormones\n",
      "2782\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic renal cell carcinoma or melanoma\n",
      "        Measurable or evaluable disease No active brain metastases Previously treated CNS\n",
      "        metastases responding to therapy are eligible, but CNS cannot be the site of evaluable\n",
      "        disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        Not specified Hematopoietic: Hematocrit at least 25 WBC at least 3,000/mm3 Platelet count\n",
      "        at least 100,000/mm3 PT and PTT within normal limits Hepatic: Bilirubin less than 2.0\n",
      "        mg/dL Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No myocardial infarction\n",
      "        within 6 months No medication for congestive heart failure or cardiac arrhythmias No\n",
      "        hypertension (unless blood pressure is stable off medication) Pulmonary: Must have\n",
      "        reasonable respiratory reserves and not require supplemental oxygen No dyspnea at rest\n",
      "        Oxygen saturation must be greater than 90% for patients with risk of respiratory symptoms\n",
      "        Other: Not HIV positive Not positive for hepatitis B antigen No chronic underlying\n",
      "        immunodeficiency No concurrent active infection requiring antibiotic therapy Not pregnant\n",
      "        or nursing No concurrent serious illness No family history of malignant hyperthermia No\n",
      "        hypersensitivity to interferon alfa-2b and interleukin-2\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interleukin-2 and interferon alfa-2b\n",
      "        in combination therapy Chemotherapy: No prior systemic chemotherapy within 4 weeks of\n",
      "        study and recovered Endocrine therapy: No concurrent corticosteroid therapy Radiotherapy:\n",
      "        No prior radiotherapy within 4 weeks of interleukin-2 therapy No prior stereotactic\n",
      "        radiosurgery or gamma knife therapy within 1 week of interleukin-2 therapy Surgery: No\n",
      "        prior organ allograft transplantation Must be recovered from prior surgery Other: No\n",
      "        concurrent cyclosporin therapy No concurrent treatment with other anticancer agents\n",
      "2783\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignant solid tumor that has failed prior\n",
      "        conventional chemotherapy or for which no established therapy exists Recurrent or\n",
      "        metastatic gastrointestinal adenocarcinoma with no prior therapy eligible No evidence of\n",
      "        CNS metastases (brain or leptomeningeal disease)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.8 mg/dL SGOT and\n",
      "        SGPT less than 3 times upper limit of normal (ULN) Alkaline phosphatase less than 3 times\n",
      "        ULN (5 times ULN for metastatic disease) Renal: Creatinine no greater than 1.8 mg/dL OR\n",
      "        Creatinine clearance at least 60 mL/min Cardiovascular: No congestive heart failure Other:\n",
      "        No uncontrolled diabetes Not pregnant or nursing Negative pregnancy test No other serious\n",
      "        medical illness (e.g. clinically active infectious process) No psychiatric illness\n",
      "        precluding study No ascites or pleural effusion\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy and recovered No more than 1 prior adjuvant chemotherapy regimen\n",
      "        No more than 1 prior chemotherapy regimen for recurrent or metastatic disease No prior\n",
      "        irinotecan or raltitrexed At least 8 weeks since prior nitrosourea or mitomycin and\n",
      "        recovered Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered Prior radiotherapy limited to no greater than 25% of bone\n",
      "        marrow Surgery: Not specified\n",
      "2784\n",
      "DISEASE CHARACTERISTICS: Histologically proven renal cell carcinoma Clinical presentation\n",
      "        consistent with metastatic renal cell carcinoma Bidimensionally measurable disease No CNS\n",
      "        tumor involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 6 weeks Hematopoietic: WBC at least 3,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Prothrombin time less than 1.3 times control Hepatic: Serum bilirubin no\n",
      "        greater than 1 mg/dL Renal: Serum creatinine no greater than 2 mg/dL Cardiovascular: No\n",
      "        New York Heart Association Class III/IV Other: No serious infection or illness Not\n",
      "        pregnant or lactating Effective contraception required of fertile patients No\n",
      "        hypercalcemia greater than 12.5 mg/dL or symptomatic\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 6 weeks since prior chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No significant prior radiation therapy to the entire pelvis and/or\n",
      "        lumbosacral spine Surgery: Not specified Other: No concurrent antibiotics\n",
      "2785\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed diagnosis of severe aplastic anemia based on bone marrow\n",
      "             cellularity of less than 20%\n",
      "          -  Must meet at least two of the following criteria:\n",
      "               -  Granulocyte count less than 500/mm^3\n",
      "               -  Platelet count less than 20,000/mm^3\n",
      "               -  Reticulocyte count less than 50,000/mm^3\n",
      "          -  Following etiologies eligible:\n",
      "               -  Fanconi's anemia\n",
      "               -  Hypoplastic leukemia\n",
      "               -  Monosomy 7\n",
      "               -  Drug exposure (chloramphenicol, NSAIDS)\n",
      "               -  Viral exposure (EBV, hepatitis, parvovirus, HIV)\n",
      "               -  Nutritional deficiencies\n",
      "               -  Thymoma\n",
      "               -  Paroxysmal nocturnal hemoglobinuria\n",
      "               -  Amegakaryocytic thrombocytopenia OR\n",
      "          -  Histologically confirmed myelodysplastic syndrome (MDS) that is refractory to medical\n",
      "             management or with cytogenic abnormalities predictive of transformation into acute\n",
      "             leukemia, including 5q-, 7q-, monosomy 7, or trisomy 8\n",
      "          -  The following etiologies only are eligible:\n",
      "               -  Refractory anemia\n",
      "               -  Refractory anemia with ringed sideroblasts\n",
      "               -  De novo primary MDS\n",
      "               -  Therapy-related secondary MDS OR\n",
      "          -  Confirmed diagnosis of inherited hematopoietic disorder that is refractory to medical\n",
      "             management\n",
      "          -  Following etiologies eligible:\n",
      "               -  Severe combined immunodeficiency\n",
      "               -  Familial erythrophagocytic lymphohistiocytosis\n",
      "               -  Wiskott-Aldrich syndrome\n",
      "               -  Kostmann's syndrome (infantile histiocytosis)\n",
      "               -  Chronic granulomatous disease\n",
      "               -  Leukocytic adhesion deficiency\n",
      "               -  Chediak-Higashi syndrome\n",
      "               -  Paroxysmal nocturnal hemoglobinuria\n",
      "               -  Fanconi's anemia\n",
      "               -  Dyskeratosis congenita\n",
      "               -  Diamond-Blackfan anemia\n",
      "               -  Amegakaryocytic thrombocytopenia\n",
      "               -  Osteopetrosis\n",
      "               -  Gaucher's disease\n",
      "               -  Lesch-Nyhan syndrome\n",
      "               -  Mucopolysaccharidoses\n",
      "               -  Lipodoses\n",
      "          -  Autologous or haploidentical related peripheral blood stem cells available as backup\n",
      "          -  Serologically matched umbilical cord blood unit available in the New York Blood\n",
      "             Center's Placental Blood Project, or other acceptable umbilical cord blood registry\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  55 and under\n",
      "        Performance status:\n",
      "          -  Zubrod 0-1\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  ALT/AST no greater than 4 times normal\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Creatinine clearance at least 50 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Normal cardiac function by echocardiogram or radionuclide scan\n",
      "          -  Shortening fraction or ejection fraction at least 80% normal for age\n",
      "          -  Non-Fanconi patients with acquired or congenital cardiomyopathy may receive melphalan\n",
      "             as a substitute for cyclophosphamide\n",
      "        Pulmonary:\n",
      "          -  FVC and FEV_1 at least 60% of predicted for age\n",
      "          -  DLCO at least 60% of predicted in adult patients\n",
      "        Other:\n",
      "          -  No active concurrent malignancy\n",
      "          -  No active infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  HIV negative\n",
      "          -  Must have an available serologic matched Umbilical Cord Blood Unit (UCBU) in the New\n",
      "             York Blood Center's Placental Blood Project, or other acceptable Umbilical Cord Blood\n",
      "             (UCB) registry\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No concurrent cytotoxic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent immunosuppressive medications\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2788\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent, persistent, or progressive\n",
      "        glioblastoma multiforme or anaplastic astrocytoma diagnosed by biopsy/resection Evaluable\n",
      "        residual disease by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: SGOT no greater than 2.5 times upper limit of\n",
      "        normal Bilirubin within normal limits Renal: Creatinine no greater than 1.5 mg/dL OR\n",
      "        Creatinine clearance greater than 60 mL/min BUN no greater than 25 mg/dL Pulmonary: DLCO\n",
      "        greater than 80% predicted Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraceptive method during and for 2 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks since prior nitrosourea, procarbazine, or mitomycin) and\n",
      "        recovered Endocrine therapy: Concurrent corticosteroid therapy must be stable for at least\n",
      "        1 week prior to study, if clinically possible Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered Surgery: Not specified\n",
      "2789\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent adult solid tumors Must have\n",
      "        measurable or evaluable disease No known bone marrow metastasis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Women Performance Status: Zubrod 0-2 Life\n",
      "        Expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than\n",
      "        2.0 times upper limit of normal Renal: Creatinine no greater than 1.5 times upper limit of\n",
      "        normal Other: Concurrently active secondary malignancies are allowed\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        paclitaxel therapy No more than 1 prior chemotherapy regimen for metastatic disease At\n",
      "        least 4 weeks since chemotherapy Greater than 6 weeks since nitrosoureas, melphalan, or\n",
      "        mitomycin Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since\n",
      "        radiotherapy No prior whole pelvic radiation Surgery: At least 4 weeks since major surgery\n",
      "2791\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic or unresectable malignant\n",
      "        disease Prior brain metastases with no residual signs or symptoms or medications allowed\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) AST/ALT no\n",
      "        greater than 2.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception No concurrent condition that would preclude study No\n",
      "        psychological, familial, sociological, or geographical condition that might compromise\n",
      "        medical follow up No neuropathy greater than grade 1, including hearing loss\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks\n",
      "        since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)and recovered Prior\n",
      "        cisplatin allowed Endocrine therapy: Not specified Radiotherapy: At least 2 weeks since\n",
      "        prior radiotherapy Prior radiotherapy for brain metastases allowed Surgery: Not specified\n",
      "2793\n",
      "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma (with\n",
      "        at least 25% oligodendroglial elements) Recurrent or progressive disease following both\n",
      "        radiotherapy and procarbazine/lomustine/vincristine chemotherapy (or other\n",
      "        nitrosoureas-based chemotherapy) Contrast enhancing, measurable disease (at least one\n",
      "        lesion measuring at least 1 cm) by CT or MRI required Within 2 weeks prior to study\n",
      "        treatment Within 3 days following concurrent surgery for the recurrence Steroid doses\n",
      "        stable or decreasing for at least 2 weeks prior to scan No extracranial disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18-69 Performance status: WHO 0-2 Life expectancy: At least\n",
      "        3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal\n",
      "        (ULN) Alkaline phosphatase no greater than 2 times ULN AST/ALT no greater than 2 times ULN\n",
      "        Renal: Creatinine no greater than 1.25 times ULN Creatinine clearance at least 60 mL/min\n",
      "        Other: Not pregnant or lactating Effective contraception required of fertile women No\n",
      "        diseases interfering with follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No more than one prior chemotherapy regimen At least 4 weeks since prior\n",
      "        chemotherapy Prior nitrosourea required At least 6 weeks since nitrosourea Endocrine\n",
      "        therapy: Not specified Radiotherapy: See Disease Characteristics More than 3 months since\n",
      "        radiotherapy Surgery: Not specified Other: No concurrent treatment with other\n",
      "        investigational agents or other antitumor agents\n",
      "2794\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven advanced cancer not amenable to curative\n",
      "             therapy (solid tumors and hematologic malignancies eligible except primary and\n",
      "             metastatic brain tumors)\n",
      "          -  Cachexia (weight loss at least 2 percent within a one month period)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance Status:\n",
      "          -  CALBG 0-2\n",
      "        Life Expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Granulocytes greater than 1,000/mm3\n",
      "          -  Platelet count greater than 75,000/mm3\n",
      "          -  Hemoglobin greater than 8 mg/dL\n",
      "        Hepatic:\n",
      "          -  AST less than 3 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase less than 3 times ULN\n",
      "          -  Bilirubin less than 1.5 times ULN\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times ULN\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure requiring diuretics within less than 6 months\n",
      "          -  No uncontrolled or severe cardiovascular disease within less than 6 months\n",
      "          -  No myocardial infarction within less than 6 months\n",
      "        Other:\n",
      "          -  Not pregnant nor contemplating pregnancy during study\n",
      "          -  Negative pregnancy test\n",
      "          -  No uncontrolled hypercalcemia\n",
      "          -  No metabolic disorders (hyperthyroidism)\n",
      "          -  No poorly controlled diabetes\n",
      "          -  No peripheral edema or ascites requiring diuretics\n",
      "          -  No enteric fistulas, with tracheobronchial fistulas or with aspiration\n",
      "          -  No esophageal or bowel obstruction that would preclude eating\n",
      "          -  Free T4 within normal range\n",
      "          -  No serious medical illness\n",
      "          -  No psychosis\n",
      "          -  No uncontrolled bacterial, viral, or fungal infections\n",
      "          -  No active uncontrolled duodenal ulcers\n",
      "          -  Above laboratory values required unless bone marrow, liver, kidney, or splenic\n",
      "             involvement by tumor is documented\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Prior and concurrent chemotherapy allowed\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent steroids such as dronabinol or megestrol acetate (except for adrenal\n",
      "             failure)\n",
      "        Radiotherapy:\n",
      "          -  No prior or concurrent radiotherapy to abdomen or pelvis\n",
      "        Surgery:\n",
      "          -  Greater than 3 weeks since major surgery\n",
      "          -  Greater than 1 week since minor surgery\n",
      "        Other:\n",
      "          -  No concurrent diuretics\n",
      "2795\n",
      "DISEASE CHARACTERISTICS: Histologically proven ovarian epithelial cancer or primary\n",
      "        peritoneal carcinoma No tumors of low malignant potential Chemotherapy sensitive disease\n",
      "        Relapse greater than 6 months after complete response to chemotherapy Partial response to\n",
      "        most recent chemotherapy No more than 3 prior chemotherapy regimens Evidence of refractory\n",
      "        or recurrent disease other than elevated CA-125 after primary surgery or chemotherapy;\n",
      "        persistent disease need not be still present No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 65 and under Performance status: GOG 0 or 1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC greater than 2500/mm3 Platelet count greater than\n",
      "        100,000/mm3 Hepatic: Bilirubin normal Renal: Creatinine clearance at least 50 mL/min\n",
      "        Cardiovascular: Normal radionuclide cardiac scan with ejection fraction greater than 45%\n",
      "        OR Normal left ventricular function by echocardiogram OR Cardiac clearance by Cardiology\n",
      "        service Pulmonary: DLCO greater than 50% predicted Other: Not pregnant Hepatitis B and C\n",
      "        negative HIV-1 negative\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2796\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced adenocarcinoma of the stomach\n",
      "        or gastroesophageal junction beyond hope of surgical cure and not considered a candidate\n",
      "        for potentially curative chemotherapy/radiation therapy Measurable or evaluable disease\n",
      "        Tumor must be accessible for biopsy No known central nervous system metastases or\n",
      "        carcinomatous meningitis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 150,000/mm3 Hemoglobin at least 9.0 mg/dL (transfusion allowed) Hepatic:\n",
      "        Bilirubin no greater than upper limit of normal (ULN), regardless of liver involvement\n",
      "        secondary to tumor AST no greater than 3 times ULN Renal: Creatinine no greater than 1.5\n",
      "        times ULN Cardiovascular: No unstable angina No uncontrolled high blood pressure No active\n",
      "        congestive heart failure No myocardial infarction in the last 6 months No serious\n",
      "        uncontrolled cardiac arrhythmia No New York Heart Association Class III or IV heart\n",
      "        disease Pulmonary: No interstitial pneumonia or extensive and symptomatic interstitial\n",
      "        fibrosis of the lung No pleural effusion or ascites, which cause respiratory compromise\n",
      "        (at least Grade 2 dyspnea) Other: No active or uncontrolled infection No prior malignancy,\n",
      "        except for adequately treated basal cell or squamous cell skin cancer, adequately treated\n",
      "        noninvasive carcinomas, or other cancer from which the patient has been disease free for\n",
      "        at least 5 years Not pregnant or nursing Adequate contraception required of all fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for gastric or gastroesophageal junction cancer No prior irinotecan (CPT-11)\n",
      "        or other camptothecin Endocrine therapy: Not specified Radiotherapy: No prior abdominal or\n",
      "        pelvic radiotherapy No prior radiotherapy to greater than 25% of bone marrow No prior\n",
      "        radiotherapy to measurable or evaluable indicator lesions At least 4 weeks since major\n",
      "        radiotherapy (chest radiotherapy) Surgery: At least 3 weeks since major surgery and\n",
      "        recovered At least 2 weeks since minor surgery and recovered Other: No other concurrent\n",
      "        investigational agents\n",
      "2798\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent superficial bladder cancer defined as papillary\n",
      "             transitional cell carcinoma (stage Ta/T1) and/or carcinoma in situ (stage Tis) of the\n",
      "             urinary bladder\n",
      "               -  No evidence of invasion of the underlying muscle (stage T2) at baseline\n",
      "          -  Must meet 1 of the following criteria:\n",
      "               -  Failure of at least 2 prior courses of intravesical therapy, 1 of which must\n",
      "                  have been a course of BCG\n",
      "               -  Recurrent or persistent disease within 6 months after failing a 6-week course of\n",
      "                  BCG followed by maintenance therapy\n",
      "               -  Inability or ineligibility to complete 1 course of intravesical therapy with\n",
      "                  BCG, and failure of 2 prior courses of intravesical therapy with an alternative\n",
      "                  agent\n",
      "          -  Diagnosis must have been made no more than 24 months after completion of prior\n",
      "             treatment with intravesical immunotherapy or chemotherapy\n",
      "          -  If carcinoma in situ is current or previous diagnosis, the biopsies must be obtained\n",
      "             from at least 4 sites (bladder mapping)\n",
      "          -  If prostatic urothelial biopsy discloses carcinoma in situ, transurethral prostatic\n",
      "             resection must be carried out prior to study\n",
      "          -  Papillary disease must have undergone complete transurethral resection (TURBT) within\n",
      "             28 days before study\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2 times upper limit of normal (ULN)\n",
      "          -  SGOT and SGPT less than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "        Other:\n",
      "          -  Normal upper tract (ureter and renal pelvic) evaluation within 6 months\n",
      "          -  No known sensitivity to anthracyclines or to Cremophor EL\n",
      "          -  HIV negative\n",
      "          -  No known AIDS or HIV-1 associated complex\n",
      "          -  No other significant concurrent illness\n",
      "          -  No other prior malignancy within the past 3 years except superficial bladder cancer,\n",
      "             adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of\n",
      "             the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No concurrent biological response modifier therapy\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Prior oral bropirimine for bladder cancer allowed\n",
      "          -  No prior AD 32 for bladder cancer\n",
      "          -  No other intravenously administered systemic chemotherapy for bladder cancer\n",
      "          -  No concurrent chemotherapy for any other malignancy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2799\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable stage IIIA or IIIB\n",
      "        non-small cell carcinoma of the lung Adenocarcinoma Squamous cell carcinoma Anaplastic\n",
      "        large cell carcinoma Stage IIIA patients must not be candidates for resection after\n",
      "        neoadjuvant therapy (unresectable T3N1 or T1-3 primary tumors with metastasis limited to\n",
      "        the ipsilateral mediastinal and subcarinal lymph nodes) Mediastinotomy or thoracoscopy\n",
      "        required for potentially resectable IIIa disease when ipsilateral mediastinal lymph nodes\n",
      "        are less than 2 cm Stage IIIB patients must not have significant pleural effusion (seen on\n",
      "        CT scan only OR does not reaccumulate after one thoracentesis and is cytologically\n",
      "        negative) Metastases to contralateral mediastinal or supraclavicular nodes allowed\n",
      "        Measurable or evaluable disease No distant metastasis or significant pleural effusion\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Granulocyte count at least 1,500/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less\n",
      "        than 1.5 mg/dL SGOT no greater than 2 times normal No liver disease with significant\n",
      "        hepatic insufficiency Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance\n",
      "        at least 50 mL/min Cardiovascular: No cardiac arrhythmia or end stage congestive heart\n",
      "        failure Neurologic: No preexisting clinically significant peripheral neuropathy No organic\n",
      "        brain syndrome Other: No history of prior or concurrent malignancy in the past 5 years\n",
      "        except: Surgically cured basal cell carcinoma of the skin Carcinoma in situ of the cervix\n",
      "        Not pregnant Fertile patients must use effective contraception during and for 2 weeks\n",
      "        after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic radiotherapy\n",
      "        Surgery: Not specified\n",
      "2800\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or radiographically proven primary, recurrent, or refractory malignant\n",
      "             gliomas (glioblastoma, anaplastic astrocytoma, and mixed anaplastic glioma)\n",
      "               -  Must be a candidate for neurosurgical biopsy or tumor debulking\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance Status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life Expectancy:\n",
      "          -  Greater than 4 months\n",
      "        Hematopoietic:\n",
      "          -  Granulocytes greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "          -  PT and PTT within normal limits\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure\n",
      "          -  No coronary artery disease\n",
      "          -  No serious cardiac arrhythmias\n",
      "          -  No prior myocardial infarction\n",
      "        Pulmonary:\n",
      "          -  No major pulmonary problems\n",
      "        Other:\n",
      "          -  No history of neurologic disease (except related to brain tumor)\n",
      "          -  No psychosis\n",
      "          -  No impaired cognitive function\n",
      "          -  No significant concurrent medical illness\n",
      "          -  No active infection requiring antibiotic therapy\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Adequate peripheral veins to permit leukapheresis, or placement of indwelling central\n",
      "             vascular access device\n",
      "          -  No hepatitis B or C\n",
      "          -  HIV negative\n",
      "          -  No prior autoimmune disease\n",
      "          -  Allergy to gentamicin is allowed\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 6 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine) and recovered\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Reduction or elimination of corticosteroids\n",
      "          -  Not greater than 0.15 mg/kg/day dexamethasone equivalent\n",
      "        Radiotherapy:\n",
      "          -  At least 6 weeks since prior radiotherapy and recovered\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Prior surgery is allowed\n",
      "        Other:\n",
      "          -  Concurrent therapy with acetaminophen, anticonvulsant agents, and headache pain\n",
      "             medications is allowed\n",
      "2801\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary, locally advanced (at least 10\n",
      "        axillary lymph node metastases or T4 or N2, M0 disease), or stage IV breast cancer\n",
      "        Patients with at least 10 axillary node metastases and no distant metastases receive\n",
      "        adjuvant chemotherapy with a doxorubicin containing regimen Patients with T4 or N2, M0\n",
      "        disease and no prior chemotherapy receive neoadjuvant or induction chemotherapy prior to\n",
      "        salvage mastectomy (patients must show partial remission based on tumor palpation)\n",
      "        Patients with stage IV breast cancer receive induction chemotherapy with doxorubicin\n",
      "        (unless relapsed less than 1 year following therapy or metastatic disease progression\n",
      "        observed or greater than 300 mg/m2 previously taken, then may receive induction\n",
      "        chemotherapy with paclitaxel regimen) Stage IV cancer patients must have at least a\n",
      "        partial remission following induction chemotherapy Stage IV cancer patients should have\n",
      "        minimal metastatic disease (chest wall recurrence or bone only); patients with more\n",
      "        extensive and/or visceral metastases must have near complete remission following induction\n",
      "        chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 70 Performance Status: SWOG 0-1 Karnofsky 80-100% Life\n",
      "        Expectancy: At least 2 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 times upper limit of\n",
      "        normal (ULN) (unless tumor related) SGOT and SGPT less than 2.0 times ULN (unless tumor\n",
      "        related) Alkaline phosphatase less than 2.0 times ULN (unless tumor related) Renal:\n",
      "        Creatinine within institutional normal limits Cardiovascular: Cardiac ventricular ejection\n",
      "        fraction (MUGA) or echocardiogram within normal limits prior to high dose chemotherapy No\n",
      "        uncontrolled or severe cardiovascular disease No myocardial infarction within 6 months No\n",
      "        congestive heart failure No symptomatic angina No life threatening arrhythmias No\n",
      "        hypertension Pulmonary: Pulmonary function tests greater than 75% predicted normal Room\n",
      "        air arterial blood gases within normal limits Other: Not HIV positive Not hepatitis B\n",
      "        surface antigen positive Not hepatitis C antibody positive No serious organ dysfunction\n",
      "        (unless caused by breast cancer) No active bacterial, viral, or fungal infections No\n",
      "        active peptic ulcers No uncontrolled diabetes Not pregnant Effective contraceptive method\n",
      "        must be used during study Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2802\n",
      "DISEASE CHARACTERISTICS: Histologically diagnosed childhood malignancy that had prior\n",
      "        anthracycline therapy Echocardiographic evidence of reduced fractional shortening, reduced\n",
      "        contractility, or increased afterload, or any combination At least 6 months oncologic\n",
      "        disease free\n",
      "        PATIENT CHARACTERISTICS: Age: At least 8 at study entry and less than 22 at diagnosis\n",
      "        Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not\n",
      "        specified Hepatic: Not specified Renal: No history of renal disease No known renal artery\n",
      "        stenosis Cardiovascular: No congenital cardiovascular malformations No active congestive\n",
      "        heart failure not attributable to sepsis or renal failure No medication for heart\n",
      "        condition No history of symptomatic arrhythmia antedating anthracycline therapy No\n",
      "        constrictive pericarditis No uncontrolled hypertension Pulmonary: No primary valvular or\n",
      "        outflow tract obstruction Other: Not pregnant or lactating Must use adequate contraception\n",
      "        No reaction or intolerance to ACE inhibitors\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 1 year\n",
      "        since prior cumulative anthracycline therapy of at least 200 mg/m2 No prior amsacrine\n",
      "        therapy Endocrine therapy: Not specified Radiotherapy: No prior mediastinal, spinal, or\n",
      "        total body irradiation that included the heart Surgery: Not specified Other: No concurrent\n",
      "        angiotensin converting enzyme (ACE)inhibitor treatment No concurrent treatment with other\n",
      "        investigational drug No oncologic therapy within past 6 months\n",
      "2803\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III/IV ovarian or non-small cell lung\n",
      "        cancer\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 3.0 mg/dL Renal: Creatinine no\n",
      "        greater than 2 mg/dL Other: Not pregnant or nursing No history of platinum, paclitaxel or\n",
      "        amifostine hypersensitivity Prior myelosuppressive events allowed No clinically\n",
      "        significant ascites\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy within 1 month of study Endocrine therapy: Not specified Radiotherapy: No\n",
      "        prior radiation therapy within 1 month of study Surgery: Not specified\n",
      "2804\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory solid tumors\n",
      "        Evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 4 months Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hemoglobin at least 8 g/dL Hepatic: Bilirubin less than 1.5 g/dL\n",
      "        Alkaline phosphatase less than 3 times upper limit of normal (ULN) AST less than 3 times\n",
      "        ULN Renal: Calcium greater than 8 mg/dL Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular: No active congestive heart failure Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No grade 2 neuropathy No intolerability for\n",
      "        hydration\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed Chemotherapy:\n",
      "        No more than 3 prior failed chemotherapy regimens Prior paclitaxel as a radiosensitizer\n",
      "        allowed No prior weekly paclitaxel infusion failure Prior platinum or paclitaxel therapy\n",
      "        allowed Endocrine therapy: Prior endocrine therapy allowed Radiotherapy: Prior\n",
      "        radiotherapy allowed Surgery: Prior surgery allowed Other: No concurrent dilantin therapy\n",
      "        No antihypertensive/diuretics within 24 hours prior to chemotherapy\n",
      "2808\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically and/or cytologically confirmed T cell or pre-B cell non-Hodgkin's\n",
      "             lymphoma\n",
      "               -  Lymphoblastic or peripheral T cell\n",
      "               -  Stage I, II, III, or IV\n",
      "          -  No anaplastic lymphoma, large cell lymphoma, or small noncleaved cell lymphoma\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and under\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior malignancy\n",
      "          -  No chronic medical or psychological condition\n",
      "          -  No congenital immunodeficiency\n",
      "          -  HIV and HTLV negative\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  No prior organ transplant\n",
      "2810\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven stage I or IIA invasive\n",
      "        breast cancer T0, T1, or T2 (no greater than 3 cm), N0 Noninflammatory Nonmetastatic No\n",
      "        ductal carcinoma in situ Eligible for breast-conserving surgery Hormone receptor status:\n",
      "        Positive or negative\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Pre- and\n",
      "        postmenopausal Performance status: Not specified Life expectancy: Not specified\n",
      "        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not\n",
      "        pregnant No allergy or sensitivity to radiopharmaceuticals or patent blue V dye\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No\n",
      "        prior neoadjuvant chemotherapy Endocrine therapy: No prior endocrine therapy Radiotherapy:\n",
      "        No prior neoadjuvant radiotherapy Surgery: No prior breast surgical biopsy or axillary\n",
      "        surgery\n",
      "2811\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically diagnosed advanced (high grade) childhood medulloblastoma\n",
      "          -  Residual disease of at least 1.5 cm2 in size on MRI or CT scan OR\n",
      "          -  Evidence of CNS or extraneural metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  3 to 21\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGPT less than 5 times normal\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.7 mg/dL OR\n",
      "          -  Creatinine clearance greater than 70 mL/min\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2812\n",
      "PROTOCOL ENTRY CRITERIA:\n",
      "        --Disease Characteristics--\n",
      "          -  Histologically confirmed stage III or IV melanoma 1 or more metastatic tumors for\n",
      "             which surgery is not deemed to be a curative option\n",
      "          -  Dacarbazine is indicated as first line chemotherapy\n",
      "          -  At least 1 measurable tumor at least 1 cm2 but no greater than 100 cm2\n",
      "          -  No history of brain metastases\n",
      "        --Prior/Concurrent Therapy--\n",
      "          -  Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "          -  Chemotherapy: See Disease Characteristics; No prior chemotherapy\n",
      "          -  Endocrine therapy: No concurrent immunosuppressive drugs\n",
      "          -  Radiotherapy: At least 4 weeks since prior radiotherapy\n",
      "          -  Surgery: At least 2 weeks since prior major surgery\n",
      "          -  Other: No other concurrent anticancer drug therapy or experimental therapy\n",
      "        --Patient Characteristics--\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: Karnofsky 80-100%\n",
      "          -  Life expectancy: At least 24 weeks\n",
      "          -  Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3;\n",
      "             Hemoglobin at least 9 g/dL\n",
      "          -  Hepatic: Bilirubin no greater than 2.0 mg/dL; SGOT/SGPT less than 3 times upper limit\n",
      "             of normal (ULN); PT/PTT normal; Albumin normal; LDH no greater than 2 times ULN\n",
      "          -  Renal: Creatinine no greater than 2.0 mg/dL\n",
      "          -  Cardiovascular: No uncontrolled hypertension; No New York Heart Association class III\n",
      "             or IV disease\n",
      "          -  Other: HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile\n",
      "             patients must use effective contraception; No active autoimmune disease; No active\n",
      "             infection requiring parenteral antibiotics; No uncontrolled diabetes mellitus; No\n",
      "             other prior malignancy within the past 5 years except skin cancer or stage 0-II\n",
      "             cervical cancer; No significant psychiatric disorders\n",
      "2813\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one of the following: -\n",
      "        Severe aplastic anemia with bone marrow cellularity less than 20% and at least 2 of the\n",
      "        following criteria: Granulocyte count less than 500/mm3 Platelet count less than\n",
      "        20,000/mm3 Reticulocyte count less than 50,000/mm3 Etiologies may be Fanconi's anemia,\n",
      "        hypoplastic leukemia, monosomy 7, drug exposure (chloramphenicol, NSAIDS), viral exposure\n",
      "        (EBV, hepatitis, parvovirus, HIV), nutritional deficiencies, thymoma, paroxysmal nocturnal\n",
      "        hemoglobinuria, and amegakaryocytic thrombocytopenia - Myelodysplastic syndrome (MDS) that\n",
      "        is refractory to medical management or with cytogenetic abnormalities predictive of\n",
      "        transformation into acute leukemia, including 5q-, 7q-, monosomy 7, and trisomy 8 De novo\n",
      "        primary or therapy-related secondary MDS Refractory anemia or refractory anemia with\n",
      "        ringed sideroblasts only - Inherited hematopoietic disorders that are refractory to\n",
      "        medical management Severe combined immunodeficiency Familial erythrophagocytic\n",
      "        lymphohistiocytosis Wiskott-Aldrich syndrome Kostmann's syndrome (infantile\n",
      "        agranulocytosis) Chronic granulomatous disease Leukocyte adhesion deficiency\n",
      "        Chediak-Higashi syndrome Paroxysmal nocturnal hemoglobinuria Fanconi's anemia Dyskeratosis\n",
      "        congenita Diamond-Blackfan anemia Amegakaryocytic thrombocytopenia Osteopetrosis Gaucher's\n",
      "        disease Lesch-Nyhan syndrome Mucopolysaccharidoses Lipidoses Must also meet all the\n",
      "        following conditions: No HLA-ABC/DR identical related bone marrow or UCB donor No 5/6\n",
      "        antigen matched related bone marrow or UCB donor Condition precludes waiting to search and\n",
      "        find a donor in the National Marrow Donor Registry Must have backup autologous or\n",
      "        haploidentical related marrow Must have available serologic match umbilical cord blood\n",
      "        unit in the New York Blood Center's Placental Blood Project\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-1 OR Karnofsky or\n",
      "        Lansky 80-100% Life expectancy: At least 3 months Hematopoietic: See Disease\n",
      "        Characteristics Hepatic: Bilirubin no greater than 2.0 mg/dL ALT/AST no greater than 4\n",
      "        times normal Renal: Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 50\n",
      "        mL/min Cardiovascular: Shortening fraction or ejection fraction at least 80% of normal for\n",
      "        age Pulmonary: FVC and FEV1 at least 60% predicted for age Adults: DLCO at least 60%\n",
      "        predicted Other: No active concurrent malignancy No active infections at time of backup\n",
      "        bone marrow harvest or pretransplant cytoreduction Not pregnant or nursing Negative\n",
      "        pregnancy test HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        cytotoxic chemotherapy Endocrine therapy: No concurrent immunosuppressive medications\n",
      "        Radiotherapy: No concurrent radiotherapy Surgery: Not specified\n",
      "2814\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary malignant gliomas including the\n",
      "        following: Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic\n",
      "        oligodendroglioma Anaplastic infiltrating glioma Mixed malignant gliomas Must show\n",
      "        evidence of tumor recurrence or progression on at least 2 serial enhanced MRI scans Must\n",
      "        have measurably enhancing residual disease on MRI or CT scan of brain\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Greater than 8 weeks Hematopoietic: Absolute granulocyte count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGPT less than 2 times\n",
      "        institutional normal Alkaline phosphatase less than 2 times institutional normal Bilirubin\n",
      "        less than 1.5 mg/dL Renal: BUN less than 1.5 times institutional normal OR Creatinine less\n",
      "        than 1.5 times institutional normal Other: No active infection Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception 1 month before, during, and 1 month\n",
      "        after study No other disease that will obscure toxicity or alter drug metabolism No other\n",
      "        concurrent medical illness\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        procarbazine No prior isotretinoin At least 4 weeks since prior chemotherapy (6 weeks for\n",
      "        nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: Prior\n",
      "        radiotherapy allowed Surgery: Not specified Other: No concurrent tetracyclines\n",
      "2815\n",
      "DISEASE CHARACTERISTICS: Histologically proven progressive or recurrent primary malignant\n",
      "        glioma Phase I (excluding group A patients): No more than 2 prior chemotherapy regimens,\n",
      "        including 1 prior adjuvant therapy and 1 prior regimen for recurrent or progressive tumor,\n",
      "        or 2 prior regimens for progressive tumor Phase II and/or group A patients: No more than 1\n",
      "        prior chemotherapy regimen, either as adjuvant or for recurrent disease Measurable disease\n",
      "        by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no greater\n",
      "        than 3 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular: No uncontrolled hypertension No unstable angina No symptomatic congestive\n",
      "        heart failure No myocardial infarction within 6 months No serious uncontrolled cardiac\n",
      "        arrhythmia Other: Not pregnant or nursing Negative pregnancy test Fertile patients must\n",
      "        use effective contraception No severe nonmalignant systemic disease or active infection No\n",
      "        concurrent alcoholism or drug abuse No psychosis HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No concurrent\n",
      "        sargramostim (GM-CSF) Chemotherapy: See Disease Characteristics At least 4 weeks since\n",
      "        prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or suramin) No prior irinotecan,\n",
      "        topotecan, or other topotecan 1 inhibitors No other concurrent chemotherapy Endocrine\n",
      "        therapy: Stable or decreasing dosage of corticosteroids within 72 hours of study entry\n",
      "        (phase II only) No other concurrent immunosuppressive agents No concurrent hormonal\n",
      "        therapy Radiotherapy: At least 4 weeks since prior radiotherapy Patients with prior\n",
      "        interstitial brachytherapy or stereotactic radiosurgery must have confirmation of\n",
      "        progressive disease No concurrent radiotherapy Surgery: At least 3 weeks since prior\n",
      "        resection Other: Acute toxic effects (excluding neurotoxicity or alopecia) of any prior\n",
      "        therapy must be resolved No concurrent valproic acid as a single agent Concurrent\n",
      "        enzyme-inducing antiepileptic drugs (EIAED) with or without steroids are allowed No\n",
      "        concurrent investigational drugs\n",
      "2816\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage IIA or stage IIB resectable cutaneous\n",
      "        melanoma rendered disease free Clinically uninvolved lymph nodes by physical examination\n",
      "        OR Pathologically uninvolved lymph nodes or sentinel lymph nodes after either complete\n",
      "        node dissection or selective lymphadenectomy, respectively No evidence of metastatic\n",
      "        disease within 28 days prior to definitive surgery HLA-A2 positive\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Hematopoietic: No\n",
      "        coagulation disorders No significant hematologic abnormality Hepatic: Bilirubin no greater\n",
      "        than 2.0 mg/dL No significant liver abnormality Renal: Creatinine no greater than 2.0\n",
      "        mg/dL No significant kidney abnormality Cardiovascular: No major medical illness of the\n",
      "        cardiovascular system Pulmonary: No major medical illness of the respiratory system Other:\n",
      "        No known allergic reaction to Montanide ISA-51 or sargramostim (GM-CSF) No major systemic\n",
      "        infections Not pregnant or nursing HIV negative Hepatitis B surface antigen negative\n",
      "        Hepatitis C antibody negative No prior uveitis or autoimmune inflammatory eye disease No\n",
      "        active autoimmune disease No other malignancy within past 5 years\n",
      "        PRIOR CONCURRENT THERAPY: At least 1 month since prior adjuvant therapy or any other\n",
      "        therapy for cancer Biologic therapy: Not specified Chemotherapy: Not specified Endocrine\n",
      "        therapy: No concurrent steroid therapy Radiotherapy: At least 1 month since prior\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "2817\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV indolent B-cell lymphoma\n",
      "        Diffuse small cleaved cell lymphoma Follicular small cleaved cell lymphoma Follicular\n",
      "        mixed cell lymphoma Follicular large cell lymphoma At least 1 lymph node or visceral\n",
      "        lesion at least 2 cm in diameter\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Lymphocyte count less than 5,000/mm3 Hepatic: Not specified\n",
      "        Renal: Not specified Other: No active infection No concurrent life threatening disease Not\n",
      "        pregnant Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma\n",
      "2818\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic renal cell carcinoma\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No active brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  More than 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  No coagulation disorders\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT and SGPT less than 112.5 IU/L each or less than 2.5 times upper limit of normal\n",
      "          -  No clinically significant hepatic disease, including autoimmune hepatitis\n",
      "        Renal:\n",
      "          -  Creatinine less than 2 mg/dL OR\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "          -  No clinically significant renal disease\n",
      "        Cardiovascular:\n",
      "          -  No clinically significant cardiac disease\n",
      "          -  No thrombophlebitis\n",
      "        Pulmonary:\n",
      "          -  No severe debilitating pulmonary disease\n",
      "          -  No pulmonary embolism\n",
      "        Other:\n",
      "          -  No history of diabetes mellitus prone to ketoacidosis\n",
      "          -  No known hypersensitivity to retinoids or retinoic acid derivatives or to interferon\n",
      "             or any component of the injection for this study\n",
      "          -  No thyroid abnormalities that hinder maintaining thyroid function at the normal range\n",
      "          -  No severe infection\n",
      "          -  No severe malnutrition\n",
      "          -  No clinically significant retinal abnormalities\n",
      "          -  No pre-existing psychiatric condition, especially depression or a history of severe\n",
      "             psychiatric disorder\n",
      "          -  No other concurrent malignancy except nonmelanoma skin cancer or curatively treated\n",
      "             carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use 2 effective methods of contraception during and for 1 month\n",
      "             after study participation\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No more than 1 prior biological response modifier therapy or immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No more than 1 prior chemotherapy regimen\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent steroids\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  At least 4 weeks since prior major surgery\n",
      "        Other:\n",
      "          -  No prior retinoid therapy\n",
      "2819\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven unresectable solid tumors (e.g., lung, breast, head and neck,\n",
      "             bladder)\n",
      "          -  Clinically suitable for treatment with single agent docetaxel\n",
      "          -  Caucasian (at least 2 generations originating in any of the original peoples of\n",
      "             Europe, North Africa, or the Middle East) OR\n",
      "          -  African American (at least 2 generations originating in any of the black racial\n",
      "             groups of Africa)\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than upper limit of normal (ULN)\n",
      "          -  AST no greater than 1.5 times ULN AND\n",
      "          -  Alkaline phosphatase no greater than 2.5 times ULN\n",
      "        Renal:\n",
      "          -  BUN no greater than 1.5 times ULN\n",
      "          -  Creatinine no greater 1.5 times ULN\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior bone marrow transplantation\n",
      "        Chemotherapy:\n",
      "          -  No prior docetaxel\n",
      "          -  Prior paclitaxel allowed\n",
      "          -  1 or 2 prior chemotherapy regimens allowed\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormones for disease related conditions\n",
      "          -  Concurrent steroids for adrenal failure allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 2 weeks since prior radiotherapy\n",
      "          -  Palliative radiotherapy allowed except whole brain irradiation for CNS disease\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 48 hours since prior or concurrent ethanol (CYP3A enzyme inducer) or\n",
      "             grapefruit juice (CYP3A enzyme inhibitor)\n",
      "          -  At least 7 days since prior or concurrent CYP450 inducing drugs:\n",
      "               -  Antiseizure medications: phenobarbital, phenytoin, carbamazepine, or lamotrigine\n",
      "               -  Anti-TB therapy: rifampin, isoniazid, or sulfinpyrazone\n",
      "          -  At least 7 days since prior or concurrent CYP450 3A inhibiting drugs:\n",
      "               -  Macrolides: erythromycin, clarithromycin, azithromycin, or roxithromycin\n",
      "               -  Azoles: ketoconazole, fluconazole, or itraconazole\n",
      "               -  Other antibiotics: metronidazole or chloramphenicol\n",
      "               -  Anti-HIV drugs: ritonavir, indinavir, nelfinavir, or delavirdine\n",
      "               -  Immunosuppressive agents: cyclosporine\n",
      "               -  Antidepressant agent: nefazodone\n",
      "2820\n",
      "Inclusion Criteria:\n",
      "          -  Histologically confirmed tumor or highly suspicious cancerous mass based on imaging\n",
      "             and clinical signs but not indicative of a direct biopsy/cellular diagnosis preceding\n",
      "             surgery\n",
      "          -  Must have a clinical condition or physiologic status which demonstrates that the\n",
      "             appropriate or standard initial therapy for the tumor is surgical biopsy or resection\n",
      "          -  Performance status - ECOG 0-2\n",
      "          -  Life expectancy not specified\n",
      "          -  WBC greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "          -  No significant cardiac disease that would preclude the safe use of general anesthesia\n",
      "          -  No significant pulmonary disease that would preclude the safe use of general\n",
      "             anesthesia\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 1 month after study\n",
      "          -  No history of grade III or IV peripheral neuropathy\n",
      "          -  See Disease Characteristics\n",
      "2821\n",
      "DISEASE CHARACTERISTICS: Histologically proven poor prognosis acute myeloid leukemia\n",
      "        (AML), myelodysplastic syndrome (MDS), or recurrent/refractory acute lymphocytic leukemia,\n",
      "        including: Myelodysplastic syndrome (MDS) stages B and C Refractory anemia, refractory\n",
      "        anemia with ringed sideroblasts, or refractory anemia with excess blasts (between 5% and\n",
      "        20% myeloblasts) MDS with increased erythroblasts or monocytoblasts of no greater than 20%\n",
      "        MDS in transformation (between 20% to 30% myeloblasts) or acute nonlymphoblastic leukemia\n",
      "        (at least 30% myeloblasts) Chronic myelomonocytic leukemia Poor prognosis refractory or\n",
      "        recurrent acute myeloid leukemia after complete response Secondary or therapy related AML\n",
      "        or MDS AML blastic crisis of chronic myelogenous leukemia or other myeloproliferative\n",
      "        disorders such as polycythemia vera, essential thrombocytopenia, or agnogenic myeloid\n",
      "        metaplasia\n",
      "        PATIENT CHARACTERISTICS: Age: 19 to 90 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT\n",
      "        or SGPT less than 2.0 times upper limit of normal Renal: Normal serum creatinine\n",
      "        Cardiovascular: No congestive heart failure No symptomatic ischemic heart disease Other:\n",
      "        Not pregnant or nursing Fertile patients must use effective contraception HIV negative No\n",
      "        uncontrolled infection No poorly controlled diseases (e.g., diabetes, systemic lupus\n",
      "        erythematosus) No history of psychiatric disorders No other malignancies within the past 5\n",
      "        years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of\n",
      "        the cervix No concurrent severe medical problems No history of allergic reaction to\n",
      "        topotecan and its derivatives\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent immunotherapy\n",
      "        Chemotherapy: No prior topotecan At least 4 weeks since prior chemotherapy No other\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: No other investigational drugs within 30 days\n",
      "        of study No other concurrent investigational therapy except for basal cell skin cancer\n",
      "2822\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage I, II, III, or IV low- or\n",
      "        intermediate-grade B-cell non-Hodgkin's lymphoma Small lymphocytic Follicular small\n",
      "        cleaved cell Follicular mixed cell Follicular large cell Marginal Diffuse large B-cell\n",
      "        Lymphoplasmacytoid Patients with small lymphocytic lymphoma must have an absolute\n",
      "        lymphocyte count less than 10,000/mm3 At least one bidimensionally measurable site At\n",
      "        least 1.5 cm in its greatest dimension Not in field of prior radiotherapy Progressive\n",
      "        disease after at least one prior treatment regimen for lymphoma A new classification\n",
      "        scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of\n",
      "        \"indolent\" or \"aggressive\" lymphoma will replace the former terminology of \"low\",\n",
      "        \"intermediate\", or \"high\" grade lymphoma. However, this protocol uses the former\n",
      "        terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: See Disease Characteristics Absolute neutrophil count at\n",
      "        least 1000/mm3 Platelet count at least 50,000/mm3 Hemoglobin at least 8 g/dL Hepatic:\n",
      "        Bilirubin no greater than 1.5 times upper limit of normal (ULN) ALT or AST no greater than\n",
      "        2 times ULN Albumin greater than 3.0 g/dL No hepatitis B or C infection Renal: Creatinine\n",
      "        no greater than ULN Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception HIV negative No active infection requiring anti-infective therapy No other\n",
      "        prior invasive malignancy within past 5 years, except: Curatively treated basal cell or\n",
      "        squamous cell skin cancer Carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior stem cell transplantation allowed At\n",
      "        least 4 weeks since prior biologic therapy No other concurrent immunotherapy Chemotherapy:\n",
      "        At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: At\n",
      "        least 4 weeks since prior endocrine therapy No concurrent hormonal therapy (except\n",
      "        contraceptives and replacement steroids) No concurrent corticosteroids Radiotherapy: See\n",
      "        Disease Characteristics At least 4 weeks since prior radiotherapy for localized disease No\n",
      "        concurrent radiotherapy Surgery: Not specified Other: No other concurrent experimental\n",
      "        medications (including approved drugs tested in an investigational setting)\n",
      "2823\n",
      "DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the esophagus,\n",
      "        gastroesophageal junction or cardia T2N1, T3 any N, T4 any N, and negative margins\n",
      "        Proximal and distal margins of resection must be negative No metastases Must be within\n",
      "        4-12 weeks from date of surgery and clinically without evidence of local-regional or\n",
      "        distant recurrence\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 120,000/mm3 Hepatic: SGOT no greater than 2 times upper limit of normal (ULN)\n",
      "        Bilirubin no greater than 2 times ULN Renal: Creatinine within institutional normal limits\n",
      "        Cardiovascular: No New York Heart Association class III or IV heart disease No symptomatic\n",
      "        coronary artery disease No myocardial infarction within 6 months No clinically significant\n",
      "        conduction system abnormalities such as second or third degree heart block or bundle\n",
      "        branch block Neurologic: No symptomatic peripheral neuropathy No psychosis Other: Not\n",
      "        pregnant or nursing Effective contraceptive method must be used by fertile patients No\n",
      "        significant hearing loss No concurrent uncontrolled infection or medical illness No\n",
      "        concurrent malignancies within 3 years, except: Nonmelanoma skin cancer Carcinoma in situ\n",
      "        of the cervix No history of allergy to drugs containing cremophor No hypersensitivity to\n",
      "        E. coli derived proteins\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        prior chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior radiotherapy No concurrent radiotherapy Surgery: See Disease\n",
      "        Characteristics\n",
      "2824\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignant glioma: Anaplastic astrocytoma\n",
      "        Anaplastic oligodendroglioma Glioblastoma multiforme Unifocal disease Progressive or\n",
      "        recurrent disease following radiation therapy and/or chemotherapy Must be eligible for\n",
      "        surgical resection of the tumor mass No unresectable leptomeningeal spread or ventricular\n",
      "        invasion outside the radiation treatment volume No exophytic ventricular tumors Must have\n",
      "        a maximal cross-sectional diameter enhancing tumor greater than 2.0 cm but not greater\n",
      "        than 5.0 cm by preoperative MRI Ratio of major axes of the tumor should not exceed 1.5 No\n",
      "        marked edema by preoperative MRI or CT that cannot be corrected by tumor resection\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified\n",
      "        Renal: Not specified Cardiovascular: No uncontrolled hypertension, angina pectoris, or\n",
      "        uncontrolled cardiac dysrhythmia Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception No serious concurrent infection or other medical illness No prior\n",
      "        or concurrent malignancy within 5 years except for curatively treated carcinoma in situ of\n",
      "        the cervix or basal cell carcinoma of the skin\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        See Disease Characteristics No concurrent chemotherapy At least 4 weeks since prior\n",
      "        chemotherapy (6 weeks since nitrosoureas) and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics At least 3 months since prior radiotherapy and\n",
      "        recovered Surgery: See Disease Characteristics Other: At least 4 weeks since prior use of\n",
      "        medical device No concurrent investigational agents\n",
      "2825\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage IIIB with metastatic pleural\n",
      "        effusion or metastatic stage IV non-small cell lung cancer Large cell Adenocarcinoma\n",
      "        Squamous cell Bronchioalveolar carcinoma Undifferentiated No small cell or carcinoid\n",
      "        histologies At least 1 bidimensionally measurable or evaluable indicator lesion Measurable\n",
      "        or evaluable indicator lesion(s) must be completely outside the radiation portal or there\n",
      "        must be proof of disease progression No current CNS metastases at study entry No meningeal\n",
      "        carcinomatosis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Greater than 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT\n",
      "        and/or SGPT no greater than 2.5 times ULN if alkaline phosphatase less than ULN, OR\n",
      "        alkaline phosphatase no greater than 4 times ULN if SGOT and/or SGPT less than ULN Renal:\n",
      "        Creatinine clearance at least 50 mL/min Other: No concurrent illness that would effect\n",
      "        assessment of this study Not pregnant or nursing Effective contraception required of all\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic\n",
      "        chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics Prior radiotherapy for non-small cell lung\n",
      "        cancer allowed Radiotherapy for new brain metastases (other than leptomeningeal disease)\n",
      "        is allowed during study, but chemotherapy is stopped during and for 2 weeks following\n",
      "        radiotherapy Concurrent radiotherapy to other sites allowed if there is no objective\n",
      "        criteria for disease progression Surgery: Not specified Other: No other concurrent\n",
      "        experimental drug\n",
      "2826\n",
      "DISEASE CHARACTERISTICS: Histologically proven high risk Ewing's family of tumors: Ewing's\n",
      "        sarcoma of bone Extraosseous Ewing's sarcoma Peripheral neuroepithelioma Must have one of\n",
      "        the following characteristics: Metastatic disease at diagnosis Primary tumor of the\n",
      "        humerus, femur, or trunk Bulky (greater than 8 cm) tumor Elevated LDH prior to biopsy (at\n",
      "        least 900 IU/mL)\n",
      "        PATIENT CHARACTERISTICS: Age: 3 to 60 Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 500/mm3 Platelet count at least\n",
      "        75,000/mm3 Hemoglobin at least 8 g/dL (transfusion allowed) Hepatic: Bilirubin no greater\n",
      "        than 1.5 mg/dL SGOT or SGPT no greater than 3 times normal Renal: BUN less than 30 mg/dL\n",
      "        Creatinine no greater than 1.5 times normal for age OR Creatinine clearance at least 70\n",
      "        mL/min Cardiovascular: Ejection fraction at least 50% OR Fractional shortening at least\n",
      "        29% Other: Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "2827\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent, advanced, or metastatic\n",
      "        endometrial cancer not amenable to curative surgery or radiotherapy Patients should have\n",
      "        previously undergone radical surgery (minimum of total abdominal hysterectomy and\n",
      "        bisalpingoophorectomy), radical radiotherapy, or not be candidate for such procedures\n",
      "        Bidimensionally measurable disease by x-ray, CT scan, MRI, or physical exam No papillary\n",
      "        serous or clear cell carcinomas of the endometrium Hormone receptor status: Estrogen\n",
      "        receptor positive and/or progesterone receptor positive Unknown receptor status patients\n",
      "        allowed provided (1) original tumor was well- or moderately-well differentiated (2) had\n",
      "        endometrioid histology\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Menopausal\n",
      "        status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count\n",
      "        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL\n",
      "        (transfusion-independent) Prothrombin time or activated partial thromboplastin time no\n",
      "        greater than 1.25 times upper limit of normal (ULN) Hepatic: Bilirubin no greater than 1.5\n",
      "        times normal ALT or AST no greater than 2.5 times ULN (ALT and AST no greater than 5 times\n",
      "        ULN in the presence of liver metastases) Renal: Creatinine no greater than 1.5 ULN Other:\n",
      "        No other primary malignancy within the past 5 years except adequately treated\n",
      "        nonmelanomatous cancer of the skin or carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for recurrent or metastatic endometrial cancer At least 1 year since prior\n",
      "        adjuvant chemotherapy Endocrine therapy: No prior antiestrogen therapy for any stage of\n",
      "        endometrial cancer At least 12 months from time of diagnosis since prior raloxifene Prior\n",
      "        progesterone treatment allowed Radiotherapy: See Disease Characteristics At least 2 weeks\n",
      "        since prior radiotherapy and recovered Surgery: See Disease Characteristics\n",
      "2828\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV bladder carcinoma that is unlikely to respond to\n",
      "             existing therapy and for which no curative therapy exists or stage IV newly\n",
      "             diagnosed, incurable bladder carcinoma\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located\n",
      "             in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the\n",
      "             largest diameter for other localizations\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from any prior operative procedure\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2829\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV adrenal gland carcinoma that is unlikely to respond\n",
      "             to existing therapy and for which no curative therapy exists\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located\n",
      "             in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the\n",
      "             largest diameter for other localizations\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other concurrent serious disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from any prior operative procedure\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2830\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven breast, lung, colorectal,\n",
      "        or prostate cancer that has failed prior chemotherapy or hormone therapy No active CNS\n",
      "        metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3500/mm3\n",
      "        Platelet count at least 150,000/mm3 Fibrinogen above lower limits of normal Hepatic:\n",
      "        Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3\n",
      "        times ULN Prothrombin time no greater than 1.5 times ULN Active partial thromboplastin\n",
      "        time no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other:\n",
      "        No history of heparin associated thrombocytopenia At least 1 year since prior\n",
      "        thromboembolic phenomenon such as deep venous thrombosis, pulmonary embolus, or clotted\n",
      "        catheter No prior intolerance of unfractionated or low molecular weight heparin\n",
      "        PRIOR CONCURRENT THERAPY: No concurrent anticoagulation therapy No concurrent enrollment\n",
      "        on systemic or radiation therapy study (therapy off study allowed)\n",
      "2831\n",
      "DISEASE CHARACTERISTICS:\n",
      "        -Histologically confirmed stage IV melanoma Must be MHC Class I HLA-A2.1\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: ECOG 0-1\n",
      "          -  Life expectancy: At least 2 months\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  INR no greater than 1.5 mg/dL\n",
      "          -  No coagulopathies including thrombocytopenia\n",
      "          -  Partial thromboplastin time no greater than 50 seconds\n",
      "          -  No major cardiac illness\n",
      "          -  No major respiratory illness\n",
      "          -  No active systemic infection or other illness\n",
      "          -  No peripheral vascular disease\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of all fertile patients during and for one month\n",
      "             after completion of treatment\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 30 days since prior immunotherapy\n",
      "          -  No concurrent immunotherapy\n",
      "          -  At least 30 days since prior chemotherapy\n",
      "          -  No concurrent chemotherapy\n",
      "          -  At least 30 days since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "2833\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed solid tumor that is refractory to conventional therapy or\n",
      "             for which no effective therapy is known\n",
      "          -  Brain tumors eligible Brainstem gliomas may waive histological verification\n",
      "             requirement\n",
      "          -  Neurologic deficits associated with CNS malignancies must be stable for a minimum of\n",
      "             4 weeks prior to study\n",
      "          -  No leukemia Stratum 2\n",
      "          -  No marrow involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 21 and under\n",
      "          -  Performance status: Karnofsky or Lansky 50-100%\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Platelet count at least 75,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGPT less than 5 times normal\n",
      "          -  Creatinine normal for age OR creatinine clearance at least 70 mL/min\n",
      "          -  Shortening fraction at least 27% of normal OR ejection fraction greater than 50% of\n",
      "             normal\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test required\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No concurrent anticancer therapy\n",
      "          -  At least 6 months since bone marrow transplant and no evidence of graft versus host\n",
      "             disease\n",
      "          -  At least 1 week since growth factors\n",
      "          -  No concurrent granulocyte colony-stimulating factor\n",
      "          -  Recovered from prior immunotherapy\n",
      "          -  Stratum 2: No prior bone marrow transplantation (with or without total body\n",
      "             irradiation)\n",
      "          -  At least 6 weeks since prior nitrosourea\n",
      "          -  At least 2 weeks since other prior myelosuppressive chemotherapy\n",
      "          -  Dexamethasone must be a stable or decreasing dose for 2 weeks prior to study\n",
      "          -  Recovered from prior chemotherapy\n",
      "          -  Stratum 2: No more than 2 prior chemotherapy regimens\n",
      "          -  At least 2 weeks since local palliative radiotherapy (small port)\n",
      "          -  At least 6 months since prior substantial bone marrow radiation (e.g., cross-\n",
      "             sectional radiotherapy [greater than 24 Gy], total body irradiation, hemi- pelvic\n",
      "             radiotherapy)\n",
      "          -  Recovered from prior radiotherapy\n",
      "          -  Stratum 2: No prior central axis radiation\n",
      "2836\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unresectable non-small cell lung cancer with a growth\n",
      "             pattern allowing access to the majority of tumor cells via the airway (e.g.,\n",
      "             bronchioloalveolar or papillary adenocarcinoma)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Prothrombin time and partial thromboplastin time normal\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No New York Heart Association class III or IV heart disease\n",
      "        Pulmonary:\n",
      "          -  Room air oxygen saturation greater than 90%\n",
      "          -  FEV1 greater than 1.0 L pCO2 less than 50\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No active systemic viral, bacterial, or fungal infections requiring treatment\n",
      "          -  No concurrent illness requiring hospitalization or intravenous medication\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior adenovirus gene therapy\n",
      "          -  At least 2 weeks since any systemic biologic therapy including prior biologic\n",
      "             response modifiers and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 2 weeks since any prior systemic chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Recovered from any prior endocrine therapy\n",
      "        Radiotherapy:\n",
      "          -  Recovered from any prior radiotherapy\n",
      "        Surgery:\n",
      "          -  At least 2 weeks since any surgical procedure requiring anesthesia\n",
      "          -  At least 4 weeks since prior surgical resection of lung tissues\n",
      "        Other:\n",
      "          -  No other concurrent therapy\n",
      "2837\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage 0 and I (Ta, T1 or Tis) resected\n",
      "        transitional cell carcinoma of the bladder No advanced disease or muscle invasion No\n",
      "        history of transitional cell carcinoma of the prostate\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Greater than 3 years Hematopoietic: WBC at least 3500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times\n",
      "        upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN SGOT no\n",
      "        greater than 3 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception At least 5 years\n",
      "        since prior malignancy except nonmetastatic squamous cell or basal cell carcinoma of the\n",
      "        skin No history of drug interactions which could affect therapy No immunodeficiency\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior intravesical BCG required (if T1 or Tis\n",
      "        pathology and negative cytology PAB) Chemotherapy: Not specified Endocrine therapy: Not\n",
      "        specified Radiotherapy: No prior radiotherapy to the pelvis Surgery: Not specified Other:\n",
      "        Intravesical therapy within 30 days allowed At least 30 days since greater than 2\n",
      "        multivitamins daily\n",
      "2841\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or metastatic malignant disease\n",
      "        not amenable to curative surgery, radiotherapy, conventional chemotherapy, or\n",
      "        investigational therapy of higher priority Priority given to patients with lung cancer or\n",
      "        cancers with tumors easily available for biopsy No CNS disease unless stable post\n",
      "        radiation\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        At least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Creatinine clearance at least 50 mL/min Cardiovascular: Systolic blood pressure\n",
      "        at least 90 mm Hg No severe heart decompensation No clinically significant cardiac\n",
      "        arrhythmia on EKG No inability to tolerate bradycardia Other: No active, uncontrolled\n",
      "        infection No nonmalignant systemic disease Not pregnant or nursing Effective contraception\n",
      "        required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immune stimulating agents\n",
      "        Chemotherapy: At least 3 weeks since chemotherapy (6 weeks since nitrosourea or mitomycin)\n",
      "        and recovered No prior paclitaxel or carboplatin No concurrent chemotherapy Endocrine\n",
      "        therapy: No concurrent hormone therapy Radiotherapy: At least 3 weeks since radiotherapy\n",
      "        to major bone marrow bearing areas and recovered Concurrent radiotherapy allowed for vital\n",
      "        indications or pain relief Surgery: At least 3 weeks since surgery\n",
      "2842\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed carcinoma of the liver or bile ducts\n",
      "        including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer Measurable\n",
      "        or evaluable disease by CT scan (ascites, pleural effusions, and bone metastases are not\n",
      "        considered evaluable)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin less than 3 mg/dL No severe cirrhosis Renal: Creatinine no greater than\n",
      "        3.0 mg/dL Cardiovascular: Left ventricular cardiac ejection fraction at least 45% Other:\n",
      "        No allergy to egg or egg products Not pregnant or nursing Effective contraception required\n",
      "        of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        doxorubicin At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: Prior radiotherapy allowed Surgery: Not specified\n",
      "2843\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic and/or recurrent renal cell\n",
      "        carcinoma Bidimensionally measurable disease required (outside any prior radiation fields)\n",
      "        No untreated brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        No other serious illness No serious active infection requiring therapy HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No prior vinca alkaloid No other concurrent chemotherapy Endocrine therapy: No concurrent\n",
      "        hormone therapy No concurrent corticosteroids (topical or inhaled corticosteroids allowed)\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy Less than 25% of bone marrow\n",
      "        irradiated No concurrent radiotherapy Surgery: At least 3 weeks since prior surgery Other:\n",
      "        No other concurrent investigational drugs\n",
      "2845\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III or IV, recurrent or refractory,\n",
      "        indolent B cell non-Hodgkin's lymphoma of the following types: Working Group Formulation A\n",
      "        (small cell lymphocytic) Working Group Formulation B, C, and D (follicular) Must have\n",
      "        relapsed after prior chemotherapy At least 1 lymph node or visceral lesion at least 2 cm\n",
      "        in diameter\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Lymphocyte count less than 5,000/mm3 Hepatic: Not specified\n",
      "        Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No active infection HIV negative No hepatitis B or C No concurrent life\n",
      "        threatening condition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy for\n",
      "        lymphoma (e.g., rituximab) Chemotherapy: See Disease Characteristics Endocrine therapy: No\n",
      "        other concurrent corticosteroids and/or epinephrine (unless anaphylactic shock)\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "2849\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the\n",
      "        pancreas Bidimensionally measurable lesions with sentinel lesions outside field of any\n",
      "        prior radiation therapy No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-1 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL Cardiovascular: No active congestive heart failure No\n",
      "        uncontrolled angina At least 6 months since prior myocardial infarction No uncontrolled\n",
      "        hypertension Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No concurrent serious infection At least 5 years since prior malignancy\n",
      "        except the following: Nonmelanoma skin cancer Carcinoma in situ of the cervix No overt\n",
      "        psychosis or mental disability\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No prior chemotherapy for metastatic disease At least 6 months since prior adjuvant\n",
      "        chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See\n",
      "        Disease Characteristics At least 6 months since prior adjuvant chemoradiation to disease\n",
      "        At least 2 weeks since prior radiotherapy and recovered No concurrent radiotherapy\n",
      "        Surgery: At least 4 weeks since prior surgery and recovered No concurrent surgery Other:\n",
      "        At least 4 weeks since prior investigational drug (including analgesics or antiemetics) No\n",
      "        other concurrent anticancer therapy\n",
      "2850\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumor Must be refractory\n",
      "        to standard therapy or no standard therapy exists No CNS metastases or CNS primary\n",
      "        malignancy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count\n",
      "        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than\n",
      "        1.5 mg/dL SGOT and SGPT no greater than 2.5 times upper limit of normal Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular:\n",
      "        No history of cardiac arrhythmias No congestive heart failure No myocardial infarction in\n",
      "        the last 6 months Neurologic: No grade 3 or greater neurotoxicity Other: HIV negative No\n",
      "        serious or uncontrolled infection Not pregnant Adequate contraception required of all\n",
      "        fertile patients during study and until 2 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and\n",
      "        recovered Chemotherapy: At least 6 weeks since prior nitrosoureas or mitomycin At least 4\n",
      "        weeks since other prior chemotherapy Must have recovered from prior chemotherapy Endocrine\n",
      "        therapy: Must have recovered from prior endocrine therapy Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy and recovered Surgery: Not specified\n",
      "2852\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed, anaplastic astrocytoma\n",
      "        No oligodendrogliomas or oligoastrocytomas\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3500/mm3 Platelet count at least 130,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater\n",
      "        than 2 times ULN Renal: Creatinine no greater than 0.5 mg/dL Other: Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception No uncontrolled infection No\n",
      "        concurrent malignant disease or major medical problem except superficial skin cancers\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 5 years\n",
      "        since prior chemotherapy Endocrine therapy: Concurrent corticosteroids allowed\n",
      "        Radiotherapy: At least 5 years since prior radiotherapy Surgery: Not specified\n",
      "2853\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic or unresectable carcinoma of the\n",
      "        kidney No CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 4 months Hematopoietic: WBC at least 3,500/mm3 Granulocyte count at least\n",
      "        2,500/mm3 Platelet count at least 100,000/mm3 PT no greater than 1.3 times upper limit of\n",
      "        normal (ULN) Hematocrit at least 28% Hepatic: Bilirubin less than 2.0 mg/dL SGOT no\n",
      "        greater than 1.25 times ULN (unless due to tumor) Renal: Creatinine less than 2.0 mg/dL\n",
      "        Calcium less than 12 mg/dL Proteinuria no greater than 2.0 by dipstick Cardiovascular: No\n",
      "        active angina No uncontrolled congestive heart failure No uncontrolled arrhythmias No\n",
      "        myocardial infarction within 6 months Pulmonary: No significant pulmonary disease (RA pO2\n",
      "        less than 60 or pCO2 greater than 50) Other: Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception HIV negative No active infection No daily emesis or inability\n",
      "        to tolerate solid foods No prior or concurrent second malignancy within 2 years, except:\n",
      "        Nonmelanoma skin cancer Carcinoma in situ of the cervix No sever diarrhea (greater than 4\n",
      "        watery stools per day) No active pelvic inflammatory disease No inflammatory bowel disease\n",
      "        No uncontrolled seizure disorders No personal or family history of malignant hyperthermia\n",
      "        No recent thromboembolism or any condition requiring concurrent anticoagulation\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent biologic therapy\n",
      "        Chemotherapy: No prior gemcitabine No prior fluorouracil other than adjuvant fluorouracil\n",
      "        received at least 1 year prior to study No other concurrent chemotherapy Endocrine\n",
      "        therapy: Concurrent corticosteroids not allowed (except for nausea or vomiting)\n",
      "        Radiotherapy: At least 14 days since prior radiation to axial skeleton No concurrent\n",
      "        radiotherapy (except to local lesions) Surgery: At least 14 days since prior exploration\n",
      "        and biopsy At least 21 days since prior resection with anastomosis No major organ\n",
      "        allograft Other: No concurrent barbiturates No concurrent oral anticoagulants No other\n",
      "        concurrent investigational drugs or devices\n",
      "2854\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumor Relapsed from or\n",
      "        resistant to at least 1 course of standard anticancer therapy AND/OR Lack of standard\n",
      "        therapy that is known to be beneficial in the underlying disease\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-3 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine\n",
      "        no greater than 2.5 times ULN Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception during and for at least 4 months\n",
      "        following study No active serious infections that are not controlled by antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics No other concurrent chemotherapy Endocrine therapy: See Disease\n",
      "        Characteristics Radiotherapy: See Disease Characteristics No concurrent radiotherapy\n",
      "        Surgery: See Disease Characteristics Other: No other concurrent investigational agents\n",
      "2855\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced malignancy involving the\n",
      "        peritoneal cavity, excluding leukemia and lymphoma Patients with ovarian cancer must have\n",
      "        received prior standard therapy Predominantly small tumor metastases less than 1.0 cm in\n",
      "        diameter including: Ovarian cancer with epithelial histology Other gynecological tumors\n",
      "        Breast cancer Gastric cancer Colorectal cancer Appendiceal cancer Pancreatic cancer\n",
      "        Unknown primary cancer Other malignancies with predominantly intraperitoneal manifestation\n",
      "        No extensive intraperitoneal adhesions that cannot be easily lysed laparoscopically or by\n",
      "        laparotomy No symptomatic disease outside the peritoneal cavity Asymptomatic disease\n",
      "        outside the peritoneum considered (e.g., bone lesions)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL AST no greater than 2 times upper\n",
      "        limit of normal Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and/or\n",
      "        mitomycin) Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "2856\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following histologically confirmed diseases for which no curative\n",
      "             surgical, radiotherapy, or chemotherapy programs are available and standard therapy\n",
      "             offers, at best, a modest clinical benefit\n",
      "               -  Solid tumors\n",
      "               -  Gliomas\n",
      "               -  Non-Hodgkin's lymphoma\n",
      "          -  Primary and metastatic CNS malignancies are eligible\n",
      "          -  Evaluable or measurable disease\n",
      "          -  CD34 count at least 2.0 cells/μL\n",
      "          -  No bone marrow involvement\n",
      "               -  Histologically negative bone marrow biopsy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 70\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 8.5 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST and ALT less than 2.5 times normal\n",
      "          -  Prothrombin time less than 1.2 times normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No acute cardiac disease by EKG\n",
      "        Pulmonary:\n",
      "          -  No symptomatic pulmonary disease\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No other severe comorbid conditions\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 2 months after study\n",
      "             completion\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Chemotherapy\n",
      "          -  No prior hematopoietic stem cell transplantation\n",
      "        Chemotherapy:\n",
      "          -  No prior high-dose chemotherapy\n",
      "          -  Prior adjuvant chemotherapy allowed\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to 25% or more of bone marrow\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 4 weeks since prior myelosuppressive therapy\n",
      "2857\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed clearly progressive metastatic or unresectable melanoma\n",
      "          -  Must be HLA-A2.1 positive\n",
      "          -  Measurable disease\n",
      "          -  No active brain metastases, leptomeningeal disease, or seizure disorder\n",
      "               -  More than 4 months since prior definitive therapy (surgery or radiotherapy) for\n",
      "                  brain metastases and must not have evidence of disease on brain CT scan or MRI\n",
      "          -  No ascites or pleural effusions\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1 OR\n",
      "          -  Karnofsky 80-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No congestive heart failure\n",
      "          -  No symptoms of coronary artery disease\n",
      "          -  No serious cardiac arrhythmias\n",
      "          -  No evidence of prior myocardial infarction on EKG\n",
      "          -  Normal cardiac stress test required for all patients over 40 years\n",
      "        Pulmonary:\n",
      "          -  FEV_1 greater than 2.0 liters or at least 75% of predicted\n",
      "          -  No chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No significant systemic infection\n",
      "          -  No contraindication to use of pressor agents\n",
      "          -  No history of major psychiatric illness\n",
      "          -  No other major illness that would significantly increase the risk of immunotherapy\n",
      "          -  No other active malignancy except surgically cured nonmelanoma skin cancer or\n",
      "             carcinoma in situ or stage I carcinoma of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior interleukin-2\n",
      "          -  At least 4 weeks since prior vaccine therapy or other cytokine therapy\n",
      "        Chemotherapy:\n",
      "          -  One prior chemotherapy regimen allowed\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine or lomustine) and\n",
      "             recovered\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent steroids\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy to areas of measurable disease unless there has been clearly\n",
      "             progressive disease in this site or there is measurable disease outside of areas of\n",
      "             prior radiation\n",
      "          -  At least 2 weeks since prior radiotherapy for local control or palliative therapy and\n",
      "             recovered\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior major surgery\n",
      "          -  No prior organ allografts\n",
      "        Other:\n",
      "          -  No antihypertensive therapy within 24 hours prior to interleukin-2\n",
      "2858\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed non-small cell lung cancer, ovarian\n",
      "             carcinoma, squamous cell carcinoma of the head and neck, tumor types for which no\n",
      "             standard treatment exists, or tumor types that have failed standard therapy\n",
      "          -  Paclitaxel and cisplatin combination therapy must be an appropriate option in\n",
      "             treating disease\n",
      "          -  No potentially curable type of cancer (e.g., newly diagnosed testicular cancer)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 6 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 4,000/mm^3\n",
      "          -  Absolute neutrophil count greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  SGOT and SGPT normal\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No evidence of congestive heart failure\n",
      "          -  No uncontrolled moderate to severe hypertension\n",
      "          -  Includes patients with persistent elevated systolic blood pressures of greater than\n",
      "             170 mm Hg and diastolic blood pressures of greater than 100 mm Hg for more than 1\n",
      "             month while under medical treatment\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  No perceived or actual clinical risk of cisplatin induced toxicity that exceeds the\n",
      "             clinical benefit of using cisplatin therapy\n",
      "          -  No known history of severe hypersensitivity to polyoxyl 35 castor oil vehicle\n",
      "          -  No severe medical problems unrelated to malignancy that would interfere with\n",
      "             compliance in this study\n",
      "          -  Not pregnant\n",
      "          -  Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent colony stimulating factors except for febrile neutropenia\n",
      "          -  No concurrent aminoglycoside therapy except for febrile neutropenia or other life\n",
      "             threatening infections\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior nitrosoureas or mitomycin\n",
      "          -  At least 3 weeks since other prior chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to measurable disease\n",
      "        Surgery:\n",
      "          -  At least 2 weeks since prior major surgery\n",
      "        Other:\n",
      "          -  No other concurrent investigational agents\n",
      "2859\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed newly diagnosed or recurrent supratentorial primary or\n",
      "             metastatic malignant brain tumor\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  Candidate for surgical resection\n",
      "               -  Extension of tumor no more than 1.0 cm beyond the margin of the surgical cavity\n",
      "          -  Demonstrated reactivity of tumor cells with tenascin by immunohistology with either a\n",
      "             polyclonal rabbit antibody or the monoclonal mouse antibody\n",
      "          -  No infratentorial tumors, diffusely infiltrating tumors, tumors with subependymal\n",
      "             spread, or multifocal tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 50-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Alkaline phosphatase less than 1.5 times normal\n",
      "          -  SGOT less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior chemotherapy, unless unequivocal evidence of progression\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed, but must be on stable dose for at least 1 week\n",
      "        Radiotherapy:\n",
      "          -  At least 3 months since prior radiotherapy to site of measurable disease in the CNS\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2860\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed neoplasm that is metastatic in the cerebrospinal fluid or\n",
      "             leptomeningeal/subarachnoid space\n",
      "               -  Cytologic diagnosis of malignancy in the cerebrospinal fluid or neuroimaging\n",
      "                  evidence of leptomeningeal tumor by MRI\n",
      "          -  Must have a recurrent or refractory leptomeningeal tumor\n",
      "               -  Leptomeningeal tumors of leukemia, lymphoma, and all germ cell tumors must have\n",
      "                  also failed initial treatment or be recurrent\n",
      "          -  No evidence of obstructive hydrocephalus or complete block of the spinal\n",
      "             cerebrospinal fluid pathways on prestudy technetium Tc 99m albumin or indium In 111\n",
      "             DTPA flow study\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.5 mg/dL\n",
      "          -  SGOT or SGPT less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  BUN less than 30 mg/dL\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Calcium within normal limits\n",
      "        Neurological:\n",
      "          -  Neurological examination stable\n",
      "          -  No rapidly progressing or deteriorating neurological deficits\n",
      "        Other:\n",
      "          -  No active infectious process\n",
      "          -  Magnesium, phosphorus, potassium, chloride, and bicarbonate normal\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior nitrosoureas or mitomycin\n",
      "          -  At least 4 weeks since any other prior chemotherapy\n",
      "          -  At least 3 weeks since prior intrathecal chemotherapy\n",
      "          -  No other concurrent intrathecal chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  For patients on corticosteroids:\n",
      "               -  Must be on a stable dose of corticosteroids for at least 1 week\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy to the CNS\n",
      "          -  At least 4 weeks since any other prior radiotherapy\n",
      "          -  No concurrent radiotherapy to the CNS\n",
      "        Surgery:\n",
      "          -  At least 3 weeks since prior surgery\n",
      "        Other:\n",
      "          -  No concurrent medication that may interfere with study results (e.g.,\n",
      "             immunosuppressive agents other than corticosteroids)\n",
      "2861\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed primary squamous, basaloid, or cloacogenic carcinoma of the\n",
      "             anal canal, other than carcinoma in situ\n",
      "               -  T2-4, Any N, M0 (stage II or III)\n",
      "          -  No local or regional recurrence after local excision or abdominal peritoneal\n",
      "             resection\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,800/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.4 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 80 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No uncompensated heart disease\n",
      "          -  No uncontrolled high blood pressure\n",
      "        Other:\n",
      "          -  No AIDS\n",
      "          -  No active systemic infection\n",
      "          -  No uncontrolled diabetes\n",
      "          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer\n",
      "          -  No mental condition that would preclude study participation\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior epoetin alfa allowed in lieu of blood transfusions\n",
      "        Chemotherapy:\n",
      "          -  At least 5 years since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 5 years since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No prior surgery of anal canal except for biopsy of study site\n",
      "2862\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid tumor with parenchymal brain\n",
      "        metastasis Solitary metastasis eligible only if refused surgery or surgical resection\n",
      "        deemed inappropriate No leptomeningeal metastases or subarachnoid spread of tumor No small\n",
      "        cell lung cancer, germ cell tumors, lymphoma, or leukemia No liver metastases, unless from\n",
      "        breast cancer No more than 1 site of extracranial metastases (multiple bone or lung\n",
      "        metastases count as one site), unless from breast cancer Hormone receptor status: Not\n",
      "        specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Absolute\n",
      "        neutrophil count at least 1,500/mm3 Platelet count at least 50,000/mm3 Hepatic: Bilirubin\n",
      "        no greater than 2 times upper limit of normal (ULN) AST and ALT no greater than 2 times\n",
      "        ULN Renal: Creatinine no greater than 2.0 mg/mL Other: No history of porphyria No history\n",
      "        of G6PD deficiency HIV negative No other major medical illnesses No major psychiatric\n",
      "        impairment Not pregnant or nursing Negative pregnancy test\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No chemotherapy\n",
      "        during and for 2 weeks after gadolinium texaphyrin therapy Endocrine therapy: Concurrent\n",
      "        hormonal therapy allowed Radiotherapy: No prior cranial radiation, including prior\n",
      "        stereotactic radiosurgery No plan for radiosurgery or radiation boost following whole\n",
      "        brain radiotherapy Concurrent radiotherapy allowed to other sites, except kidneys and\n",
      "        liver Surgery: No prior subtotal or total resection of brain metastases (except biopsies)\n",
      "2863\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic or locally unresectable\n",
      "        malignancy Patient may be responding to therapy: Stage IIIC/IV or recurrent/refractory\n",
      "        ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols)\n",
      "        Recurrent or refractory germ cell carcinoma Extensive disease small cell lung cancer in\n",
      "        partial or complete remission Stage IIIB non-small cell lung cancer responding to\n",
      "        chemotherapy Sarcomas in or near complete remission after induction chemotherapy\n",
      "        Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary Other tumors\n",
      "        without curative or first line therapy (not eligible for phase II or III studies) No\n",
      "        active brain or bone marrow metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 55 Performance status: PS 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT less than\n",
      "        2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Creatinine clearance at\n",
      "        least 60 mL/min Cardiovascular: No uncontrolled or severe cardiovascular disease No\n",
      "        myocardial infarction within 6 months No congestive heart failure Other: Not pregnant No\n",
      "        other serious medical or psychological illnesses No active uncontrolled bacterial, viral,\n",
      "        or fungal infection No active duodenal ulcer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Greater than 3\n",
      "        weeks since prior chemotherapy See Disease Characteristics No other concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: Greater than 1 week since\n",
      "        prior radiotherapy No concurrent radiotherapy Surgery: Greater than 1 week since prior\n",
      "        surgery (except for biopsies) Other: No barbiturates, dilantin, or cimetidine within 3\n",
      "        weeks of high dose chemotherapy No antihypertensive medications within 24 hours prior to\n",
      "        amifostine administration\n",
      "2864\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic refractory ovarian epithelial\n",
      "        cancer OR primary peritoneal cancer provided the clinical and pathological features of the\n",
      "        tumor are similar to primary ovarian epithelial carcinoma Patients must have received\n",
      "        prior chemotherapy including at least one platinum analogue and one taxane analogue unless\n",
      "        patient is poor candidate for these treatments due to neuropathy, nephropathy, or\n",
      "        hypersensitivity (to Taxol only) Bidimensionally measurable disease by x-ray, CT scan,\n",
      "        MRI, or physical exam Ascites not considered measurable or evaluable Hormone receptor\n",
      "        status: Estrogen receptor status must be known or tissue must be available for analysis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Sex:\n",
      "        Female Menopausal status: Not specified Life expectancy: At least 24 weeks Hematopoietic:\n",
      "        Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at\n",
      "        least 9 g/dL (transfusion-independent) Prothrombin time or activated partial\n",
      "        thromboplastin time no greater than 1.25 times upper limit of normal (ULN) Hepatic:\n",
      "        Bilirubin no greater than 1.5 times normal ALT or AST no greater than 2.5 times ULN (ALT\n",
      "        and AST no greater than 5 times ULN in the presence of liver metastases) Renal: Creatinine\n",
      "        no greater than 1.5 ULN Other: No other malignancy within the past 5 years except\n",
      "        adequately treated nonmelanomatous cancer of the skin or carcinoma in situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No more than 2 prior chemotherapy regimens (including repeated drug\n",
      "        combinations) for patients with potentially platinum-sensitive disease No more than 3\n",
      "        prior chemotherapy regimens (including repeated drug combinations) for patients with\n",
      "        platinum resistant disease At least 6 weeks since mitomycin or nitrosoureas At least 3\n",
      "        weeks since other prior chemotherapy Recovered from prior chemotherapy Endocrine therapy:\n",
      "        At least 3 weeks since hormone replacement therapy No prior hormonal therapy for ovarian\n",
      "        cancer Radiotherapy: At least 2 weeks since prior radiotherapy and recovered Surgery: Not\n",
      "        specified\n",
      "2865\n",
      "DISEASE CHARACTERISTICS: Histologically newly diagnosed early B-cell or B-precursor or\n",
      "        B-progenitor acute lymphocytic leukemia Prior registration on POG-9400, stratum 6 for\n",
      "        induction therapy Average prognosis (neither very good nor very poor)\n",
      "        PATIENT CHARACTERISTICS: Age: Children Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy other than on POG-9400\n",
      "2866\n",
      "DISEASE CHARACTERISTICS: Primary or therapy-related myelodysplastic syndrome: Refractory\n",
      "        anemia with excess blasts Refractory anemia with excess blasts in transformation Chronic\n",
      "        myelomonocytic leukemia Refractory anemia, refractory anemia with ringed sideroblasts, or\n",
      "        refractory cytopenia with multilineage dysplasia These patients must also have one of the\n",
      "        following criteria: Greater than 4 units of RBCs transfused within the past 3 months OR\n",
      "        Platelet count less than 50,000/mm3 OR Neutrophil count less than 1,000/mm3 AND a recent\n",
      "        infection requiring antibiotics\n",
      "        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than\n",
      "        1.5 mg/dL SGOT no greater than 2 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception Free of any evidence of prior cancer for at least 12 months\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior interferon No\n",
      "        prior hematopoietic growth factors or cytokines except epoetin alfa No concurrent epoetin\n",
      "        alfa Chemotherapy: No prior topotecan No prior chemotherapy for this disease At least 12\n",
      "        months since prior chemotherapy for another disease No other concurrent chemotherapy\n",
      "        Endocrine therapy: At least 1 month since prior corticosteroids No concurrent hormonal\n",
      "        therapy for disease-related conditions Concurrent steroids for adrenal failure allowed No\n",
      "        concurrent dexamethasone and other steroidal antiemetics Radiotherapy: No prior\n",
      "        radiotherapy for this disease At least 12 months since prior radiotherapy for another\n",
      "        disease Surgery: Not specified Other: No prior cytotoxic therapy (including low-dose\n",
      "        antimetabolites) for this disease At least 1 month since prior retinoids\n",
      "2867\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Intermediate- or high-risk chronic lymphocytic leukemia (CLL) as defined by the\n",
      "             three-stage Rai system\n",
      "               -  Rai intermediate disease must be active disease (including weight loss, fatigue,\n",
      "                  fevers, evidence of progressive marrow failure, splenomegaly, progressive\n",
      "                  lymphadenopathy, and progressive lymphocytosis with a rapid doubling time)\n",
      "          -  Other low-grade B-cell neoplasms, including small lymphocytic lymphoma (and its\n",
      "             variants), Waldenstrom's macroglobulinemia, and follicular lymphoma allowed\n",
      "          -  Autoimmune hemolytic anemia or autoimmune thrombocytopenia allowed regardless of\n",
      "             disease stage\n",
      "          -  B-cells demonstrated by immunophenotypic (or immunohistochemical) analysis of the\n",
      "             malignant lymphocytes\n",
      "          -  Must be previously treated\n",
      "          -  For CLL, absolute lymphocytosis in the blood at least 5,000 lymphocytes/mm^3 OR\n",
      "          -  Bone marrow lymphocytosis at least 30% of all nucleated cells\n",
      "          -  No Rai intermediate-risk disease that meets the criteria of Montserrat \"smoldering\n",
      "             leukemia\" NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been\n",
      "             adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace\n",
      "             the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However,\n",
      "             this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  More than 4 weeks\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Other:\n",
      "          -  No active infections requiring systemic antibiotics\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior biologic therapy\n",
      "          -  Concurrent intravenous immunoglobulin allowed\n",
      "          -  Concurrent epoetin alfa allowed\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent prednisone therapy allowed as long as dose is stable or decreasing over\n",
      "             the past 4 weeks\n",
      "          -  No increase in prednisone therapy while on study\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2870\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven ipsilateral malignant pleural mesothelioma\n",
      "          -  No contralateral thoracic or intra-abdominal involvement\n",
      "          -  No distant metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0 or 1\n",
      "          -  Life expectancy: Not specified\n",
      "          -  Hematopoietic:\n",
      "               -  Absolute neutrophil count greater than 2,000/mm3\n",
      "               -  Platelet count greater than 100,000/mm3\n",
      "               -  No symptomatic anemia requiring transfusion\n",
      "          -  Hepatic:\n",
      "               -  Bilirubin less than 2.0 mg/dL\n",
      "               -  No autoimmune hepatitis\n",
      "               -  No history of decompensated liver disease; e.g. esophageal varices\n",
      "               -  Ascites\n",
      "               -  Albumin at least 2.5 mg/dL\n",
      "               -  Increasing prothrombin time of at least 2.0\n",
      "          -  Renal: Creatinine no greater than 1.5 mg/dL\n",
      "          -  Cardiovascular:\n",
      "               -  No symptomatic or debilitating cardiovascular disease,\n",
      "               -  No concurrent thrombophlebitic or embolic disorders\n",
      "          -  Pulmonary:\n",
      "               -  No symptomatic or debilitating pulmonary disease,\n",
      "               -  Pretreatment diffusion capacity greater than 30% of predicted normal\n",
      "               -  Projected post-treatment FEV1 at least 1.0 L\n",
      "          -  Other:\n",
      "               -  No prior malignancy within 3 years, except nonmelanomatous skin cancer\n",
      "               -  Carcinoma in situ of the cervix\n",
      "               -  Ductal carcinoma in situ of the breast\n",
      "               -  Not pregnant\n",
      "               -  Fertile patients must use effective contraception\n",
      "               -  No history of hypersensitivity to interferon or any component of the injection\n",
      "               -  No uncontrolled diabetes (blood sugars consistently at least 300 mg/dL)\n",
      "               -  No insulin dependent diabetes mellitus with history of ketoacidosis within 1\n",
      "                  year\n",
      "               -  No psychosis\n",
      "               -  No uncontrolled thyroid abnormalities\n",
      "               -  No active infection requiring intravenous antibiotics\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Biologic therapy: No prior biologic therapy\n",
      "          -  Chemotherapy: No prior chemotherapy\n",
      "          -  Endocrine therapy: Not specified\n",
      "          -  Radiotherapy: No prior radiotherapy\n",
      "          -  Surgery:\n",
      "               -  No prior debulking surgery\n",
      "               -  No prior chest tube drainage with sclerosis if tumor resectable\n",
      "               -  Prior thoracentesis allowed\n",
      "2871\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven gallbladder or bile duct\n",
      "        carcinoma with metastatic or recurrent disease deemed unresectable and not considered a\n",
      "        candidate for potentially curative therapy Measurable or evaluable disease No known active\n",
      "        CNS disease Closed to bile duct carcinoma as of July 1999\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: SGOT no greater than 5 times upper limit of normal (ULN)\n",
      "        Bilirubin no greater than 1.5 mg/dL OR Bilirubin no greater than 2 times ULN in patients\n",
      "        with biliary stents or percutaneous biliary catheters Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Cardiovascular: No New York Heart Association class III or IV heart disease\n",
      "        Other: Nutritional intake at least 1200 kcal/day No uncontrolled infection or chronic\n",
      "        debilitating disease Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No uncontrolled seizure disorder No prior malignancy within 5 years except\n",
      "        adequately treated basal cell/squamous cell carcinomas and adequately treated noninvasive\n",
      "        carcinomas\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biological therapy or immunotherapy\n",
      "        for recurrent or metastatic disease No concurrent biologic therapy Chemotherapy: No prior\n",
      "        chemotherapy for recurrent or metastatic disease Prior adjuvant chemotherapy allowed if\n",
      "        used as a radiation sensitizer for completely resected disease No other concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for\n",
      "        recurrent or metastatic disease Prior adjuvant radiotherapy allowed if used as a radiation\n",
      "        sensitizer for completely resected disease No radiotherapy to greater than 25% of bone\n",
      "        marrow No radiotherapy within the past 4 weeks No concurrent radiotherapy Concurrent CNS\n",
      "        radiation allowed Surgery: No post abdominal exploration (with or without resection)\n",
      "        within the past 4 weeks Other: No concurrent medication for other medical conditions\n",
      "        except for: Analgesics Chronic treatments for preexisting conditions Agents required for\n",
      "        life-threatening medical conditions No laxatives\n",
      "2872\n",
      "DISEASE CHARACTERISTICS: Histologically proven extensive stage small cell lung cancer\n",
      "        Extends beyond hemithorax and supraclavicular lymph nodes Pleural effusions allowed\n",
      "        Bidimensionally measurable disease Bone marrow metastases allowed No symptomatic CNS\n",
      "        metastases or carcinomatous meningitis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal Renal: Creatinine less\n",
      "        than 1.24 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No cardiac\n",
      "        insufficiency No uncontrolled cardiac disease LVEF greater than 50% OR ECHO greater than\n",
      "        30% Other: Not pregnant Fertile patients must use effective contraception No psychoses No\n",
      "        active infection No loss of weight greater than 10% during the last 3 months No other\n",
      "        malignancy except nonmelanomatous skin cancer or stage I cervical cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent immunotherapy\n",
      "        Chemotherapy: No prior or other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior or concurrent radiotherapy Surgery: No prior or concurrent surgery\n",
      "2873\n",
      "DISEASE CHARACTERISTICS: Histologically proven previously untreated locally advanced or\n",
      "        inflammatory breast cancer Potentially operable disease Tumor at least 3 cm in diameter No\n",
      "        metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Absolute\n",
      "        neutrophil count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin\n",
      "        greater than 9 g/dL Hepatic: PT and aPTT normal Bilirubin normal (except in patients with\n",
      "        benign congenital hyperbilirubinemia) AST/ALT no greater than 1.5 times upper limit of\n",
      "        normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN No active hepatitis B or C\n",
      "        Liver biopsy normal (if positive serology for hepatitis B or C) Renal: Creatinine normal\n",
      "        Cardiovascular: Adequate cardiac function No active cardiac disease Other: Not pregnant\n",
      "        Fertile patients must use effective contraception No other serious medical or psychiatric\n",
      "        disease No prior or concurrent malignancy except basal cell skin cancer or carcinoma in\n",
      "        situ of the cervix HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease\n",
      "        Characteristics Other: No prior therapy for breast cancer\n",
      "2875\n",
      "DISEASE CHARACTERISTICS: Microscopically confirmed metastatic breast cancer Must be\n",
      "        refractory or have recurred after at least 1 systemic chemotherapy regimen Estrogen\n",
      "        receptor positive tumors must have failed or recurred after hormonal therapy At least 1\n",
      "        site of measurable disease required Previously radiated lesions are not considered\n",
      "        measurable unless there is evidence of disease progression after completion of radiation\n",
      "        therapy No known brain metastases Hormone receptor status: Unspecified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: Zubrod 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 4000/mm3\n",
      "        Platelet count at least 100,000/mm3 Absolute neutrophil count at least 1500/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2 times normal Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL BUN no greater than 30 mg/dL Other: Effective birth control must\n",
      "        be used by fertile patients (barrier method preferred) Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior treatment Biologic\n",
      "        therapy: No immunologic therapy within the past 2 weeks Chemotherapy: No chemotherapy\n",
      "        within the past 4 weeks (6 weeks for mitomycin or nitrosoureas) See Disease\n",
      "        Characteristics Endocrine therapy: No hormonal therapy within the past 2 weeks See Disease\n",
      "        Characteristics Radiotherapy: No radiotherapy within the past 4 weeks See Disease\n",
      "        Characteristics Surgery: Not specified Other: No concurrent cholesterol lowering agents,\n",
      "        supplemental vitamins, or other antioxidants\n",
      "2876\n",
      "DISEASE CHARACTERISTICS: Histologically documented malignant melanoma in node(s) meeting\n",
      "        one or more of the following criteria: 1 or more lymph nodes found to contain metastatic\n",
      "        melanoma with gross evidence of extracapsular nodal extension Nodal recurrence at the site\n",
      "        of previous lymphadenectomy All gross cancer removed with negative margins Prior node\n",
      "        biopsy allowed if complete nodal dissection performed Parotid involvement outside a node\n",
      "        allowed No distant metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 125,000/mm3\n",
      "        Hematocrit at least 33% Hepatic: AST no greater than 2 times upper limit of normal (ULN)\n",
      "        LDH no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Bilirubin\n",
      "        no greater than 2 times ULN If LDH or alkaline phosphatase are above normal, CT or MRI of\n",
      "        liver required Renal: Creatinine no greater than 1.8 mg/dL BUN no greater than 33 mg/dL\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception No other\n",
      "        prior or concurrent malignancies within 2 years, except any carcinoma in situ, lobular\n",
      "        carcinoma of the breast in situ, carcinoma in situ of the cervix, atypical melanocytic\n",
      "        hyperplasia or Clark I melanoma in situ, or basal or squamous cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interferon Chemotherapy: Not\n",
      "        specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the head\n",
      "        and neck, axillary, or inguinal areas Surgery: See Disease Characteristics Recovered from\n",
      "        prior surgery\n",
      "2878\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Newly diagnosed acute myeloid leukemia (AML)\n",
      "               -  M0-M2, M4-M7\n",
      "               -  Histologically proven by bone marrow aspirate and biopsy (requirement may be\n",
      "                  waived for patients with overt leukemia in the peripheral blood)\n",
      "               -  M3 (acute promyelocytic leukemia) patients excluded unless already treated with\n",
      "                  trans retinoic acid\n",
      "          -  Evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  SGOT/SGPT no greater than 2.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Ejection fraction at least 50%\n",
      "          -  Must be able to stop taking antihypertensive medication 24 hours prior to cytarabine\n",
      "             administration\n",
      "        Other:\n",
      "          -  No preexisting severe organ dysfunction\n",
      "          -  No history of underlying medical or psychiatric illness that may impair the patient's\n",
      "             ability to participate in the study\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior cytotoxic therapy for AML\n",
      "          -  No prior amifostine\n",
      "          -  At least 1 month since chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 1 month since radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2879\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage III or IV\n",
      "        melanoma gp100 positive tumor cells and/or tyrosinase positive tumor cells HLA type A1,\n",
      "        A2, or A3 Measurable disease May have up to 3 brain metastases if all are less than 2 cm\n",
      "        in diameter and are asymptomatic, and there is no mass effect or they have been treated\n",
      "        successfully by surgical excision or by gamma knife radiation therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 79 Performance status: ECOG 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count\n",
      "        greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin no greater than\n",
      "        2.5 times upper limit of normal (ULN) AST and ALT no greater than 2.5 times ULN Alkaline\n",
      "        phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular: No New York Heart Association class II, III, or IV heart disease Other: No\n",
      "        known or suspected allergy to any component of the vaccine No medical condition that would\n",
      "        preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior growth factors\n",
      "        At least 3 months since prior agents with putative immunomodulating activity (except\n",
      "        nonsteroidal antiinflammatory agents) At least 1 year since other prior melanoma\n",
      "        vaccinations Chemotherapy: At least 3 months since prior chemotherapy No concurrent\n",
      "        chemotherapy Endocrine therapy: At least 3 months since prior corticosteroids No\n",
      "        concurrent corticosteroids Radiotherapy: At least 3 months since prior radiotherapy No\n",
      "        concurrent radiotherapy Surgery: See Disease Characteristics Other: At least 3 months\n",
      "        since other prior investigational drugs or therapy At least 3 months since prior allergy\n",
      "        desensitization injections At least 14 days since completion of acute treatment for a\n",
      "        serious infection No concurrent allergy desensitization injections\n",
      "2880\n",
      "DISEASE CHARACTERISTICS: Metastatic breast cancer that is accessible for biopsy or\n",
      "        aspiration Bidimensionally measurable disease with at least one diameter greater than 1 cm\n",
      "        documented on x-ray or photograph, or a palpable lesion No brain metastases or\n",
      "        carcinomatous meningitis Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female Menopausal status: Not\n",
      "        specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic:\n",
      "        Absolute neutrophil count greater than 1,500/mm3 Platelet count greater than 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT no greater than 3 times upper limit of\n",
      "        normal (ULN) (no greater than 5 times ULN if metastatic to liver) Renal: Creatinine no\n",
      "        greater than 2.0 mg/dL Calcium no greater than 12 mg/dL Cardiovascular: No myocardial\n",
      "        infarction within 3 months prior to study No unstable angina or symptomatic congestive\n",
      "        heart failure Other: No active or uncontrolled infection Not HIV positive No psychoses Not\n",
      "        pregnant or nursing Effective contraception required of fertile women No second malignancy\n",
      "        within past 5 years except: Adequately treated basal or squamous cell carcinoma of the\n",
      "        skin In situ cancer of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Prior paclitaxel permitted if patient had disease-free interval of greater\n",
      "        than 1 year Prior taxotere permitted Endocrine therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified\n",
      "2881\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck (SCCHN) Recurrent disease documented by histology or cytology (excluding\n",
      "        endolaryngeal recurrence) following first line therapy with curative intent, such as:\n",
      "        Radiation (at least 5000 cGy by standard methodology) and/or Surgery (definitive resection\n",
      "        with postoperative radiation as indicated) Lesions accessible to intratumoral injections\n",
      "        Bidimensionally measurable disease The sum of the products of the bidirectional\n",
      "        measurements for all bidimensionally measurable lesions must be not greater than 30 cm2\n",
      "        The sum of the longest diameters of all measurable lesions must be not greater than 10 cm\n",
      "        No CNS metastasis Tumor tissue from biopsy of primary or recurrent tumor must be available\n",
      "        to determine p53 mutation status\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Greater than 12 weeks Hematopoietic: Platelet count at least 100,000/mm3\n",
      "        Absolute neutrophil count at least 2,000/mm3 Hepatic: Total bilirubin no greater than\n",
      "        upper limit of normal (ULN) AST/SGOT and/or ALT/SGPT no greater than 1.5 times ULN\n",
      "        Alkaline phosphatase no greater than 5 times ULN Renal: Not specified Other: Not pregnant\n",
      "        or nursing Barrier contraception required during treatment Negative for HIV 1, HIV 2,\n",
      "        hepatitis B, and hepatitis C At least 2 years since prior malignancy, other than SCCHN No\n",
      "        contact with former tissue or organ transplant recipients or persons with severe\n",
      "        immunodeficiency disease within 28 days following final dose of study drug No serious\n",
      "        concurrent medical conditions No active uncontrolled infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunostimulating drugs No prior\n",
      "        autologous or allogeneic organ or tissue transplant Chemotherapy: At least 4 weeks since\n",
      "        prior chemotherapy At least 6 weeks since nitrosourea or mitomycin No other concurrent\n",
      "        chemotherapy Endocrine therapy: No concurrent nontopical corticosteroids unless chronic\n",
      "        (at least 6 months) at low doses (no greater than 10 mg of oral prednisone) Radiotherapy:\n",
      "        See Disease Characteristics At least 4 weeks since radiotherapy to measurable disease\n",
      "        sites, unless progressive disease No concurrent radiotherapy to disease sites receiving\n",
      "        study drug injections Surgery: See Disease Characteristics No concurrent surgery to\n",
      "        disease sites receiving study drug injections Other: No concurrent high dose steroids At\n",
      "        least 4 weeks since experimental therapy No concurrent other experimental drugs or therapy\n",
      "        No prior gene therapy using adenoviral vectors\n",
      "2882\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed intermediate or high grade B-cell\n",
      "        non-Hodgkin's lymphoma that meets one of the following criteria: - Relapsed or progressed\n",
      "        following at least 1 course of standard therapy - Developed from a low grade lymphoma\n",
      "        regardless of remission status - In first complete response with 3 or more of the\n",
      "        following pretreatment criteria met at the time of original diagnosis: Stage III/IV\n",
      "        disease Two or more extranodal sites of disease Lactate dehydrogenase greater than 1.2\n",
      "        times normal Performance status 2-4 (at time of diagnosis) Dimension of the largest tumor\n",
      "        at least 10 cm No myelodysplasia A new classification scheme for adult non-Hodgkin's\n",
      "        lymphoma has been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma\n",
      "        will replace the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma.\n",
      "        However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: See Disease Characteristics\n",
      "        ECOG 0-2 (ECOG 3-4 acceptable if based solely on pain) Life expectancy: Not specified\n",
      "        Hematopoietic: CD34 cells at least 1,000/g Hepatic: See Disease Characteristics Bilirubin\n",
      "        no greater than 1.5 mg/dL Transaminases no greater than 4 times upper limit of normal No\n",
      "        active chronic hepatitis or liver cirrhosis Renal: Creatinine no greater than 3.0 mg/dL\n",
      "        Cardiovascular: No evidence for clinically significant functional impairment Left\n",
      "        ventricular ejection fraction at least 45% Patients with lower ejection fractions may be\n",
      "        included if a formal cardiological evaluation reveals no evidence for clinically\n",
      "        significant functional impairment Pulmonary: FEV1, FVC, and DLCO at least 50% of predicted\n",
      "        If unable to complete pulmonary function tests due to bone pain or fracture, must have a\n",
      "        high resolution CT scan of the chest and acceptable blood arterial gases defined as PO2\n",
      "        greater than 70 Other: HIV negative No active infection that is unresponsive to\n",
      "        intravenous antibiotics Not pregnant or nursing Effective contraception required of all\n",
      "        fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2883\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven newly diagnosed or recurrent primary intracranial WHO grade III\n",
      "             or IV glioma\n",
      "          -  Reactivity of tumor cells with 81C6 demonstrated by immunohistology with either a\n",
      "             polyclonal rabbit antibody or the monoclonal mouse antibody\n",
      "          -  Radiographic evidence of a single lesion by MRI or CT scan\n",
      "               -  No greater than 2 to 5 cm\n",
      "          -  No cerebral herniation syndrome\n",
      "          -  Midline brain shift less than 0.5 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Hemoglobin greater than 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Alkaline phosphatase less than 1.5 times normal\n",
      "          -  SGOT less than 1.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No allergies to iodine or local anesthetics\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent autologous bone marrow transplant\n",
      "        Chemotherapy:\n",
      "          -  No more than 1 prior conventional or phase II chemotherapy regimen\n",
      "          -  No prior phase I chemotherapy regimens\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  No concurrent systemic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Corticosteroids allowed but must be on stable dose for at least 1 week\n",
      "        Radiotherapy:\n",
      "          -  At least 3 months since radiotherapy to site of measurable disease in the nervous\n",
      "             system, unless evidence of progression\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2884\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent supratentorial glioblastoma multiforme, anaplastic\n",
      "             astrocytoma, or gliosarcoma\n",
      "          -  Must be able to undergo surgical resection\n",
      "          -  At least 1 bidimensionally measurable lesion documented on Gd-MRI within 72 hours\n",
      "             after surgical implantation of Gliadel wafers\n",
      "          -  Not requiring immediate radiotherapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 125,000/mm^3\n",
      "          -  Hematocrit at least 29%\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT or SGPT less than 2.5 times ULN\n",
      "          -  Alkaline phosphatase less than 2 times ULN\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times ULN\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "        Neurological:\n",
      "          -  Must be neurologically stable\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "               -  No AIDS-related illness\n",
      "          -  No nonmalignant systemic disease that would make patient a poor medical risk\n",
      "          -  No acute infection requiring intravenous antibiotics\n",
      "          -  Not pregnant or nursing\n",
      "               -  Negative pregnancy test 24 hours prior to study\n",
      "          -  Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior irinotecan\n",
      "          -  At least 6 weeks since chemotherapy unless there is unequivocal evidence of tumor\n",
      "             progression after chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 1 week of nonincreasing dose of steroids prior to study\n",
      "        Radiotherapy:\n",
      "          -  At least 6 weeks since radiotherapy unless there is unequivocal evidence of tumor\n",
      "             progression after radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2885\n",
      "DISEASE CHARACTERISTICS: Histologically proven cervical, vaginal, or endometrial carcinoma\n",
      "        for which abdominal radical hysterectomy (Rutledge-Piver II or III type) and pelvic node\n",
      "        dissection is indicated The following are excluded: Extensive intraoperative\n",
      "        retroperitoneal blood loss (more than 3000 mL) Excessive postsurgical hemorrhage or oozing\n",
      "        of the wound area requiring postoperative drainage Concurrent urinary or bowel\n",
      "        injury/deviation or surgical procedures for urinary incontinence (Burch etc.) Application\n",
      "        of prophylactic abdominal mesh for subsequent radiotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        neoadjuvant chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "2886\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed ependymoma that is unlikely to respond to existing therapy\n",
      "             and for which no curative therapy exists\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "          -  Tumor must be at least 5 mm\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm3\n",
      "          -  Platelet count greater than 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal failure\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas)\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at\n",
      "             least 1 week prior to study)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "2887\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignancy that is refractory to\n",
      "        standard therapy or for which no standard therapy exists Low grade lymphoproliferative\n",
      "        disorder defined as: Chronic lymphocytic leukemia/small lymphocytic lymphoma Waldenstrom's\n",
      "        macroglobulinemia Follicular lymphoma (small cleaved, mixed, and large cell) Mantle cell\n",
      "        lymphoma Prolymphocytic leukemia (T and B type) Cutaneous T cell non-Hodgkin's lymphoma\n",
      "        Marginal zone lymphoma and variants Hairy cell leukemia variants MALT lymphomas Patients\n",
      "        with low grade lymphoproliferative disorders must have received at least 1 or more\n",
      "        treatment regimens and must not be eligible for potentially curative treatments (i.e.,\n",
      "        bone marrow transplantation) No HTLV-1 associated lymphomas, Burkitt's or small\n",
      "        non-cleaved lymphomas, transplant related lymphoproliferative disorders, Hodgkin's\n",
      "        disease, diffuse large cell lymphoma, or multiple myeloma No primary brain tumors or\n",
      "        history of brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet\n",
      "        count greater than 100,000/mm3 Hemoglobin at least 8.0 g/dL Hepatic: Bilirubin no greater\n",
      "        than 1.2 mg/dL AST/ALT less than 2.5 times upper limit of normal Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No\n",
      "        history of unstable or newly diagnosed angina pectoris No myocardial infarction within the\n",
      "        last 6 months No New York Heart Association class II-IV congestive heart failure\n",
      "        Neurologic: No grade 2 or greater peripheral neuropathy Pulmonary: No grade 2 or greater\n",
      "        pulmonary toxicity (dyspnea on significant exertion) Other: HIV negative No autoimmune\n",
      "        hemolytic anemia Must be able to have a central venous access catheter No active\n",
      "        infections requiring oral or intravenous antibiotics No medical or psychiatric problems\n",
      "        unrelated to the malignancy that may limit compliance with study, expose patient to undue\n",
      "        risk, or confound toxicity assessment Not pregnant or nursing Adequate contraception is\n",
      "        required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior platelet or red\n",
      "        blood cell transfusions Chemotherapy: At least 6 weeks since nitrosoureas or mitomycin At\n",
      "        least 4 weeks since other chemotherapy No investigational or standard chemotherapy for at\n",
      "        least 2 months after completion of last dose of UCN-01 Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since radiotherapy Surgery: At least 4 weeks since major\n",
      "        surgery Other: No concurrent anticonvulsant medications\n",
      "2888\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck considered incurable with surgery or radiation therapy Bidimensionally measurable\n",
      "        disease or readily evaluable disease by either physical exam or radiography Biopsy proven\n",
      "        recurrence following completion of radiotherapy required if only site of measurable\n",
      "        disease is within a previous radiation port\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 2000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Neurologic: Peripheral\n",
      "        sensory neuropathy no greater than grade 1 Other: No significant active infection\n",
      "        (patients with WBC of 12,000/mm3 or greater, or fever of 100.6 degrees F or higher, must\n",
      "        be evaluated to rule out occult infection) Not pregnant or nursing Effective contraception\n",
      "        required of fertile patients No active second malignancy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy (interleukin-2,\n",
      "        interferon, monoclonal antibodies, and/or retinoids) permitted Recovered from prior\n",
      "        biologic therapy Chemotherapy: No more than one prior chemotherapy regimen for advanced or\n",
      "        relapsed disease No chemotherapy within 4 weeks prior to study Prior neoadjuvant or\n",
      "        radiosensitizing chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Prior\n",
      "        radiotherapy permitted Recovered from prior radiotherapy Surgery: Recovered from major\n",
      "        surgery\n",
      "2889\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven limited stage small cell\n",
      "        lung cancer (SCLC) Must have completed adequate first-line combined modality treatment\n",
      "        comprising at least 4-6 courses of a 2-drug chemotherapy regimen and chest radiotherapy No\n",
      "        evidence of disease progression or relapse Disease response (complete or partial) after\n",
      "        treatment\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC greater that 3,000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: AST less than 1.5 times upper limit of normal Hepatitis B\n",
      "        negative Renal: Not specified Cardiovascular: Adequate cardiac function Other: HIV\n",
      "        negative Not pregnant or nursing Fertile patients must use effective contraception No\n",
      "        prior malignancy within 5 years except adequately treated nonmelanomatous skin cancer or\n",
      "        carcinoma in situ of the cervix No history of tuberculosis No grade 3 local skin toxicity\n",
      "        reaction (ulceration) to 5 IU or greater of PPD test No active infections requiring\n",
      "        systemic antibiotics, antiviral, or antifungal treatments No serious unstable chronic\n",
      "        illnesses No psychological, familial, sociological, or geographical condition that would\n",
      "        preclude study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior therapy with proteins of murine\n",
      "        origin At least one month since prior immunotherapy No other concurrent immunotherapy\n",
      "        Chemotherapy: See Disease Characteristics No concurrent chemotherapy Endocrine therapy: No\n",
      "        concurrent chronic use of systemic corticosteroids Radiotherapy: See Disease\n",
      "        Characteristics No concurrent radiotherapy including prophylactic cranial irradiation No\n",
      "        prior spleen radiotherapy Surgery: No prior surgery for SCLC No prior splenectomy Other:\n",
      "        No prior second-line therapy for SCLC At least one month since prior investigational\n",
      "        agents No concurrent chronic use of systemic antihistamines or nonsteroidal\n",
      "        anti-inflammatory drugs No concurrent immunosuppressive therapy\n",
      "2890\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic melanoma involving cervical,\n",
      "        axillary, inguinal, groin, or iliac lymph nodes All gross disease is resected at the time\n",
      "        of surgical lymphadenectomy No distant metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 6 months Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin at least 8\n",
      "        g/dL Hepatic: Bilirubin no greater than 1.4 mg/dL AST or ALT no greater than 1.5 times\n",
      "        normal No active hepatitis Renal: Creatinine no greater than 1.4 mg/dL Cardiovascular: No\n",
      "        congestive heart failure, unstable angina, or current symptomatic arrhythmias Other: HIV\n",
      "        negative No autoimmune diseases (e.g., lupus erythematosus, multiple sclerosis, or\n",
      "        ankylosing spondylitis) No condition that would be considered as a contraindication for\n",
      "        surgery Not pregnant or nursing Adequate contraception required for all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: At least 4 weeks since prior therapy for melanoma Biologic\n",
      "        therapy: At least 3 months since prior interferon therapy Chemotherapy: No active\n",
      "        immunosuppression due to prior chemotherapy Endocrine therapy: No active immunosuppression\n",
      "        due to steroid therapy Radiotherapy: Not specified Surgery: Not specified\n",
      "2891\n",
      "DISEASE CHARACTERISTICS: Histologically proven multiple myeloma Pancytopenia related to\n",
      "        multiple myeloma allowed Failed or progressed after at least 2 chemotherapy or biologic\n",
      "        therapy regimens\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Platelet count at least 50,000/mm3 Absolute\n",
      "        neutrophil count at least 750/mm3 Hepatic: SGOT/SGPT less than 3 times upper limit of\n",
      "        normal Bilirubin less than 5.0 mg/dL Renal: Not specified Other: No active infection\n",
      "        requiring intravenous antibiotics Not HIV positive Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics May have failed\n",
      "        prior bone marrow transplant No other concurrent colony stimulating factors Concurrent\n",
      "        immunoglobulin allowed Chemotherapy: See Disease Characteristics Concurrent pamidronate\n",
      "        allowed Endocrine therapy: Not specified Radiotherapy: Concurrent standard radiation\n",
      "        therapy to treat extra-skeletal and/or skeletal tumor sites allowed Surgery: Not specified\n",
      "        Other: Concurrent epoetin alfa for anemia allowed\n",
      "2893\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed hematologic malignancies and adult solid\n",
      "        tumors, including: Non-Hodgkin's lymphoma Lung cancer Hodgkin's disease Ovarian cancer\n",
      "        Breast cancer No refractory disease (less than partial response to induction chemotherapy)\n",
      "        No CNS metastases No unilateral bone marrow biopsy within 6 months of study showing at\n",
      "        least 20% involvement by fibrosis tumors Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Menopausal status: Not specified Performance\n",
      "        Status: ECOG 0-2 Life expectancy: At least 16 weeks Hematopoietic: Absolute neutrophil\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT or SGPT no\n",
      "        greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 2 mg/dL\n",
      "        Other: HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must\n",
      "        use effective contraception No underlying medical or psychiatric conditions No concurrent\n",
      "        active infection No prior malignancies except nonmelanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior myeloid growth\n",
      "        factor Chemotherapy: At least 4 weeks since prior chemotherapy No more than 1 prior\n",
      "        chemotherapy regimen (excluding adjuvant chemotherapy) Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since pelvic, para-aortic, inverted Y, cranial, spinal, or\n",
      "        mediastinal radiation Surgery: At least 2 weeks since major surgery Other: No\n",
      "        antihypertensive medication within 24 hours of amifostine administration\n",
      "2895\n",
      "DISEASE CHARACTERISTICS: Histologically proven oral mucosal intraepithelial neoplasia\n",
      "        Stage II: moderate dysplasia, keratosis with atypia Stage III: severe keratinizing or\n",
      "        nonkeratinizing dysplasia No myelodysplastic syndrome No retinopathies\n",
      "        PATIENT CHARACTERISTICS: See General Eligibility Criteria\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No concurrent chemotherapy Endocrine therapy: No concurrent endocrine therapy\n",
      "        Radiotherapy: No concurrent radiotherapy Surgery: Prior surgical ablation of prior\n",
      "        dysplastic sites allowed Other: At least 2 months since prior therapy toxicities Patient\n",
      "        Characteristics-- Age: Not specified Performance Status: SWOG 0-1 Life Expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception at least 1 month before, during, and at least 2 months after study\n",
      "2898\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignancy or condition of the following\n",
      "        types: Acute myelogenous leukemia (not M5 or M6) or lymphocytic leukemia in first or\n",
      "        greater remission or early relapse OR Chronic myelogenous leukemia OR Myelodysplastic\n",
      "        syndrome OR Aggressive or refractory non-Hodgkin's lymphoma OR Aggressive or refractory\n",
      "        Hodgkin's disease OR Multiple myeloma at early relapse or after conventional chemotherapy\n",
      "        to reduce tumor mass OR High risk chronic lymphocytic leukemia OR Aplastic anemia\n",
      "        HLA-matched or 1 antigen mismatched (related or unrelated) available as donor\n",
      "        PATIENT CHARACTERISTICS: Age: 50 and under Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Greater than 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than\n",
      "        2 mg/dL SGOT less than 4 times upper limit of normal (ULN) Renal: Creatinine less than 2\n",
      "        times ULN OR Creatinine clearance greater than 60 mL/min Cardiovascular: LVEF at least 50%\n",
      "        by MUGA Pulmonary: DLCO at least 50% Other: HIV negative No active extramedullary disease\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "2899\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven, newly diagnosed, supratentorial malignant glioblastoma\n",
      "             multiforme not requiring immediate radiation therapy\n",
      "          -  At least 1 bidimensionally measurable lesion\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT and SGPT less than 2.5 times ULN\n",
      "          -  Alkaline phosphatase less than 2 times ULN\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times ULN\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "        Other:\n",
      "          -  Must be neurologically stable\n",
      "          -  No systemic disease\n",
      "          -  No acute infection requiring intravenous antibiotics\n",
      "          -  No frequent vomiting\n",
      "          -  No other medical condition that would interfere with oral medication intake such as\n",
      "             partial bowel obstruction\n",
      "          -  No prior or concurrent malignancies except:\n",
      "               -  Surgically cured carcinoma in situ of the cervix\n",
      "               -  Basal or squamous cell carcinoma of the skin\n",
      "          -  HIV negative\n",
      "          -  No AIDS-related illness\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior biologic therapy\n",
      "          -  No concurrent biologic therapy (growth factors or erythropoietin)\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent steroid allowed (must be on stable dose for at least 1 week prior to\n",
      "             study)\n",
      "        Radiotherapy:\n",
      "          -  No prior radiation therapy\n",
      "          -  No prior interstitial brachytherapy\n",
      "          -  No prior radiosurgery to the brain\n",
      "          -  Not requiring immediate radiation therapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from any effects of prior surgery\n",
      "          -  At least 2 weeks since prior surgical resection\n",
      "        Other:\n",
      "          -  No other concurrent investigational drugs\n",
      "2900\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed supratentorial anaplastic\n",
      "        oligodendroglioma or anaplastic oligoastrocytoma not requiring immediate radiotherapy\n",
      "        Newly diagnosed, progressive, or recurrent disease Bidimensionally measurable disease At\n",
      "        least 1.5 cm2 by MRI\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: More than 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.5\n",
      "        times upper limit of normal (ULN) SGOT/SGPT less than 2.5 times ULN Alkaline phosphatase\n",
      "        less than 2 times ULN Renal: BUN less than 1.5 times ULN Creatinine less than 1.5 times\n",
      "        ULN Other: Neurologically stable No nonmalignant systemic disease No acute infection\n",
      "        treated with intravenous antibiotics No frequent vomiting No medical condition (e.g.,\n",
      "        partial bowel obstruction) that would interfere with oral medication intake No other prior\n",
      "        or concurrent malignancy except surgically cured carcinoma in situ of the cervix or basal\n",
      "        cell or squamous cell carcinoma of the skin No AIDS-related illness HIV negative Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior biologic therapy No\n",
      "        concurrent biologic therapy No concurrent growth factors (e.g., epoetin alfa)\n",
      "        Chemotherapy: No more than 1 prior chemotherapy regimen No other concurrent chemotherapy\n",
      "        Endocrine therapy: Must be on stable dose of steroids for at least 1 week prior to study\n",
      "        Concurrent steroids allowed Radiotherapy: See Disease Characteristics No concurrent\n",
      "        radiotherapy Surgery: At least 2 weeks since prior surgical resection (newly diagnosed\n",
      "        patients must be enrolled within 28 days of surgery or biopsy) Recovered from prior major\n",
      "        surgery Other: No other concurrent investigational drugs\n",
      "2903\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV non-small cell lung cancer that cannot be cured\n",
      "             with existing therapeutic regimens\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "               -  Tumor must be at least 2 cm for the lymph nodes located in the head, neck,\n",
      "                  axillary, inguinal or femoral areas and at least 0.5 cm for other areas\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., severe chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No other serious medical or psychiatric conditions\n",
      "          -  No active infection\n",
      "          -  No serious malabsorption syndromes\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy (less than 8 weeks if multiple tumors are\n",
      "             involved) and recovered\n",
      "        Surgery:\n",
      "          -  No prior extensive stomach or intestinal surgery\n",
      "          -  Recovered from any prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplaston treatment\n",
      "          -  No other concurrent treatment for metastatic lung cancer\n",
      "2904\n",
      "DISEASE CHARACTERISTICS: Histologically or serologically confirmed metastatic germ cell\n",
      "        neoplasm (gonadal or extragonadal primary) that cannot be cured with either surgery or\n",
      "        chemotherapy Seminomas, nonseminomas, or ovarian germ cell tumors allowed If\n",
      "        histologically confirmed, requires one or more of the following: Metastatic lesions on\n",
      "        chest x-ray or CT scan Rising serum HCG or AFP If only evidence of progressive disease,\n",
      "        then two additional consecutive determinations must exhibit serologic progression Only\n",
      "        eligible if alternative causes for increased serum levels are absent Failed initial\n",
      "        cisplatin combination chemotherapy (generally bleomycin/etoposide/cisplatin,\n",
      "        cisplatin/etoposide, cisplatin/vinblastine, or similar regimens) Failed and demonstrated\n",
      "        progressive disease following the administration of at least one \"salvage\" regimen for\n",
      "        advanced germ cell neoplasms Failed no more than three prior regimens defined as: 25%\n",
      "        increase in the product of perpendicular diameters of measurable tumor masses during prior\n",
      "        therapy, new lesions OR Increasing AFP or HCG Disease progression during initial induction\n",
      "        chemotherapy or with primary mediastinal nonseminomatous germ cell tumors can be treated\n",
      "        with paclitaxel plus gemcitabine as second-line therapy (initial salvage chemotherapy)\n",
      "        PATIENT CHARACTERISTICS: Age: 15 and over Performance status: ECOG 0-2 Hematopoietic: WBC\n",
      "        at least 4,000/mm3 Platelet count at least 100,000/mm3 Hepatic: SGOT no greater than 4\n",
      "        times normal Bilirubin no greater than 2 mg/dL Renal: Creatinine no greater than 2.5 mg/dL\n",
      "        Other: No active uncontrolled infection Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 3 weeks since prior chemotherapy and recovered Endocrine therapy:\n",
      "        Not specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered\n",
      "        Surgery: At least 3 weeks since major surgery and recovered Other: At least 1 week since\n",
      "        prior intravenous antibiotics No concurrent intravenous antibiotics\n",
      "2906\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically diagnosed lung cancer including\n",
      "        the following: Relapsed limited stage small cell lung cancer (SCLC) Limited stage SCLC\n",
      "        responding to conventional radiotherapy Extensive stage SCLC Stage IIIB and IV non-small\n",
      "        cell lung cancer (NSCLC) Stages II-IIIA NSCLC who are unable or unwilling to undergo\n",
      "        surgery but are acceptable candidates for high dose chemotherapy Cryopreserved peripheral\n",
      "        blood stem cells with CD34 count greater than 2000/mm3 No untreated or uncontrolled brain\n",
      "        metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5\n",
      "        times normal SGOT less than 1.5 times normal Renal: Creatinine clearance greater than 50\n",
      "        mL/min Pulmonary: Left ventricular ejection fraction greater than 45% DLCO greater than\n",
      "        40% Other: Not pregnant or lactating No medical or psychiatric illness preventing informed\n",
      "        consent or intensive treatment\n",
      "        PRIOR CONCURRENT THERAPY: Concurrent chemotherapy allowed if no evidence of disease\n",
      "        progression\n",
      "2907\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the breast\n",
      "        Must have failed at least one but no more than two prior therapies for metastatic breast\n",
      "        cancer, including endocrine and chemotherapy Relapsing while receiving or within 6 months\n",
      "        of completing adjuvant chemotherapy Disease progression during or subsequent to the most\n",
      "        recent therapy Measurable and evaluable disease Bone is an evaluable site only No CNS\n",
      "        metastases Hormone receptor status: Estrogen receptor negative, positive, or unknown\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any status\n",
      "        Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute\n",
      "        neutrophil count greater than 1,500/mm3 Platelet count greater than 100,000/mm3 Hepatic:\n",
      "        Bilirubin no greater than 1.5 mg/dL AST/ALT less than 3 times upper limit of normal PTT\n",
      "        within normal limits Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No active\n",
      "        congestive heart failure No poorly controlled hypertension At least 3 months since prior\n",
      "        myocardial infarction Other: No history of other malignant neoplasms, except curatively\n",
      "        treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the\n",
      "        cervix Not pregnant or nursing Negative pregnancy test, documented sterilization, or\n",
      "        postmenopausal status Fertile patients must use effective contraception No uncontrolled\n",
      "        nonmalignant systemic diseases (including active peptic ulcer and poorly controlled\n",
      "        diabetes mellitus) No underlying disease state associated with active bleeding No\n",
      "        unexplained abnormality of prothrombin time (e.g., warfarin therapy)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 28 days since prior chemotherapy Endocrine therapy: See Disease\n",
      "        Characteristics At least 28 days since prior hormonal therapy Radiotherapy: Not specified\n",
      "        Surgery: At least 2 weeks since major surgery Other: At least 28 days since prior use of\n",
      "        other investigational drugs No therapeutic anticoagulation with heparin\n",
      "2908\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV melanoma that is recurrent or progressing and\n",
      "             unlikely to respond to existing therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  Tumor must be at least 2 cm in the lymph nodes in the head, neck, axillary,\n",
      "                  inguinal, or femoral areas and at least 0.5 cm in other locations\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times the upper limit of normal\n",
      "          -  No hepatic insufficiency\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious medical or psychiatric disorders\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple\n",
      "             tumors who have received radiotherapy to some, but not all, tumors may be admitted\n",
      "             earlier than 8 weeks)\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2909\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically and biochemically confirmed recurrent or progressing multiple myeloma\n",
      "             that is unlikely to respond to existing therapy, including surgery, radiotherapy, and\n",
      "             chemotherapy\n",
      "               -  At least one standard first line therapy failure\n",
      "          -  No localized plasmacytoma or plasmacytosis limited to the bone marrow\n",
      "          -  Evidence of tumor by MRI or CT scan\n",
      "          -  Presence of myeloma proteins in serum and urine, including Bence-Jones proteins\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic insufficiency\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal problems\n",
      "          -  No renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No serious medical or psychiatric disorders\n",
      "          -  No active infections\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered (patients with multiple\n",
      "             tumors who have received radiotherapy to some, but not all, tumors may be admitted\n",
      "             earlier than 8 weeks)\n",
      "        Surgery:\n",
      "          -  Must be recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2913\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed glioblastoma multiforme\n",
      "          -  Tumor subtotally resected or biopsied\n",
      "               -  Radiologic evidence of residual or recurrent tumor by gadolinium-enhanced MRI,\n",
      "                  CT scan, or positron-emission tomography\n",
      "          -  No brain stem tumor\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  More than 4 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 1,500/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic:\n",
      "          -  No hepatic failure\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that would contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from any prior surgery\n",
      "2915\n",
      "-  Histologically or cytologically proven metastatic colorectal cancer\n",
      "          -  Prior surgery required\n",
      "          -  No prior treatment for metastatic disease\n",
      "          -  Disease progression while on fluorouracil adjuvant therapy\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: SWOG 0-2\n",
      "          -  Hematopoietic: Platelet count at least 100,000/mm3, Absolute granulocyte count at\n",
      "             least 1,500/mm3\n",
      "          -  Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT or SGPT\n",
      "             no greater than 3 times ULN (no greater than 5 times ULN if liver involvement)\n",
      "          -  Renal: Creatinine clearance at least 50 mL/min\n",
      "          -  Other: Must be able to swallow and retain oral medications No nutritional support by\n",
      "             gastrostomy feeding tube or parenteral support No intractable vomiting or nausea\n",
      "          -  Patients with history of prior malignancy must be currently disease free and off all\n",
      "             therapy for that malignancy\n",
      "          -  Not pregnant or nursing Fertile patients must use effective contraception\n",
      "          -  Biologic therapy: No concurrent immunotherapy Chemotherapy; At least 3 weeks since\n",
      "             prior chemotherapy and recovered; No concurrent flucytosine; No other concurrent\n",
      "             chemotherapy\n",
      "          -  Endocrine therapy: No concurrent hormonal therapy\n",
      "          -  Radiotherapy: Prior adjuvant pelvic radiation or radiation to one area of recurrence\n",
      "             allowed At least 4 weeks since prior radiotherapy and recovered Total area of bone\n",
      "             marrow irradiation must not exceed 25% No concurrent radiotherapy\n",
      "          -  Surgery: At least 2 weeks since prior surgery for colorectal cancer and recovered No\n",
      "             prior resection of the stomach or small intestine\n",
      "          -  Other: No other concurrent anticancer therapy\n",
      "2916\n",
      "DISEASE CHARACTERISTICS: Histologically proven multiple myeloma with no greater than 12\n",
      "        months of prior therapy Bone marrow plasmacytosis at least 30% or protein criteria present\n",
      "        No obvious myelodysplastic changes in the bone marrow No CNS disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: SWOG 0-2 (3-4 acceptable if\n",
      "        based solely on bone pain) Life expectancy: Not specified Hematopoietic: CD34+ at least 4\n",
      "        million/kg Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT or SGPT no greater than 4\n",
      "        times upper limit of normal No active chronic hepatitis or liver cirrhosis Renal:\n",
      "        Creatinine no greater than 3.0 mg/dL Cardiovascular: LVEF greater than 50% Pulmonary: FEV1\n",
      "        or FVC at least 50% of predicted DLCO at least 50% of predicted Patients unable to\n",
      "        complete pulmonary function tests must have a CT scan of the chest and acceptable arterial\n",
      "        blood gases of PO2 greater than 70 Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception HIV negative No active infection\n",
      "        requiring IV antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy Endocrine therapy: Prior steroid therapy allowed Radiotherapy: At\n",
      "        least 4 weeks since prior radiotherapy Surgery: Not specified\n",
      "2917\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed progressive, primary, intracranial, supratentorial,\n",
      "             low-grade glioma including:\n",
      "               -  Astrocytoma\n",
      "               -  Oligodendroglioma\n",
      "               -  Mixed glioma\n",
      "               -  Optic pathway glioma*\n",
      "               -  Pontine glioma* NOTE: *Biopsy not required\n",
      "          -  Patients with optic pathway glioma must also meet the following criteria:\n",
      "               -  Progressive loss of vision as defined by doubling of octaves\n",
      "               -  Visual acuity loss not explained by other causes\n",
      "               -  Increase in proptosis of greater than 3 mm\n",
      "               -  Increase in diameter of optic nerve of at least 2 mm on neuroimaging\n",
      "               -  Increase in distribution of tumor involving optic tracts or optic radiations as\n",
      "                  indicated by CT scan or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  4 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  More than 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT and SGPT less than 2.5 times ULN\n",
      "          -  Alkaline phosphatase less than 2 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "          -  BUN less than 1.5 times ULN\n",
      "        Other:\n",
      "          -  Must be neurologically stable\n",
      "          -  No systemic disease\n",
      "          -  No acute infection requiring IV antibiotics\n",
      "          -  No frequent vomiting\n",
      "          -  No other medical condition that would interfere with oral medication (e.g., partial\n",
      "             bowel obstruction)\n",
      "          -  No other prior or concurrent malignancies except:\n",
      "               -  Surgically cured carcinoma in situ of the cervix\n",
      "               -  Basal or squamous cell skin cancer\n",
      "          -  HIV negative\n",
      "          -  No AIDS-related illness\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent biologic therapy (growth factors or epoetin alfa)\n",
      "        Chemotherapy:\n",
      "          -  At least 6 weeks since prior chemotherapy unless evidence of disease progression\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 6 weeks since prior radiotherapy unless evidence of disease progression\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  At least 3 weeks since prior surgery unless evidence of disease progression\n",
      "          -  Recovered from all prior surgery\n",
      "        Other:\n",
      "          -  No other concurrent investigational drugs\n",
      "2918\n",
      "DISEASE CHARACTERISTICS: Previously established diagnosis of acute myelogenous leukemia:\n",
      "        Failure to achieve a complete remission with initial induction regimen First relapse\n",
      "        within 1 year of initial complete remission Failure to achieve complete remission with one\n",
      "        or two courses of reinduction therapy at first relapse Second relapse after no more than\n",
      "        two different induction regimens Chemotherapy-related leukemia with unfavorable\n",
      "        cytogenetics No active CNS leukemia Not eligible for allogeneic bone marrow transplant\n",
      "        from related donor\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 74 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 4 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than upper limit\n",
      "        of normal (ULN) (unless elevation due to AML) Renal: Creatinine no greater than 0.3 mg/dL\n",
      "        above ULN Cardiovascular: No myocardial infarction within the past 3 months No congestive\n",
      "        heart failure No poorly controlled cardiac arrhythmia Other: Not pregnant or nursing\n",
      "        Fertile patients must use adequate contraception No psychosis No active systemic\n",
      "        infections\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Recovered from the\n",
      "        toxic effects of previous chemotherapy At least 3 days since hydroxyurea Endocrine\n",
      "        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior\n",
      "        or concurrent aminoglycosides or amphotericin B within past 7 days\n",
      "2919\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven CD20 positive follicular (closed to accrual 9/18/00) or mantle\n",
      "             cell lymphoma\n",
      "               -  Untreated \"de novo\" disease OR\n",
      "               -  Chemotherapy resistant disease OR\n",
      "               -  Relapsing disease\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No symptomatic CNS disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n",
      "          -  No hepatitis B or C\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2 times ULN\n",
      "        Cardiovascular:\n",
      "          -  Ejection fraction at least 50%\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No active opportunistic infections\n",
      "          -  HIV negative\n",
      "          -  No prior malignancy within 5 years except adequately treated carcinoma in situ of the\n",
      "             cervix or localized nonmelanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior antibody based therapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas) and\n",
      "             recovered\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior corticosteroids, unless chronic dose no greater than 20\n",
      "             mg/day for nonlymphoma related condition\n",
      "          -  No other concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2920\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Stratum A (less than 3 months since prior therapy) closed to accrual effective\n",
      "             06/20/2000)\n",
      "          -  Histologically or cytologically confirmed recurrent or refractory small cell lung\n",
      "             cancer\n",
      "               -  Only 1 prior regimen allowed (an alternating regimen with\n",
      "                  cyclophosphamide/doxorubicin/vincristine and etoposide/cisplatin is acceptable)\n",
      "          -  No mixed histology\n",
      "          -  Measurable or evaluable disease that has not been in the field of prior radiotherapy\n",
      "          -  No uncontrolled CNS metastases (treated CNS metastases eligible)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 2,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Total bilirubin no greater than 1.5 times upper limit of normal (ULN) OR\n",
      "          -  Direct bilirubin normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No unstable angina pectoris\n",
      "          -  No uncontrolled congestive heart failure\n",
      "          -  No myocardial infarction within the past 3 months\n",
      "        Other:\n",
      "          -  No uncontrolled infections\n",
      "          -  No other concurrent malignancy except skin cancer or localized prostate cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior topoisomerase I inhibitor (e.g., topotecan or irinotecan) or taxane (e.g.,\n",
      "             paclitaxel or docetaxel)\n",
      "          -  At least 3 months since other prior chemotherapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 2 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  At least 3 weeks since any prior major surgery\n",
      "2921\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable meningioma that has progressed or recurred\n",
      "             following surgical resection and radiotherapy\n",
      "               -  Evidence of tumor by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  WBC at least 2000/mm3\n",
      "          -  Platelet count at least 50,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No active infection\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "          -  At least 4 weeks since prior therapy with mifepristone and recovered\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2922\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven adenocarcinoma of the stomach that is unlikely to respond to\n",
      "             existing therapy, including surgery, radiotherapy, and chemotherapy\n",
      "               -  Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No known chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  Not a high medical or psychiatric risk\n",
      "          -  No concurrent nonmalignant systemic disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2924\n",
      "DISEASE CHARACTERISTICS: On interferon alfa-2b treatment for at least 8 weeks Dose must be\n",
      "        stable for 2 weeks prior to and during study Fatigue level at least 4 on the Symptom and\n",
      "        Fatigue Self Evaluation Form (0 none, 10 worst possible)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: More than 4 weeks Hematopoietic: Hematocrit at least 30% Hepatic: Not\n",
      "        specified Renal: Creatinine no greater than 2.0 mg/dL Other: No history of any of the\n",
      "        following: Chronic use of anticonvulsants Seizure disorder Motor tics Glaucoma Family\n",
      "        history or diagnosis of Tourette's disorder No allergic reaction or hypersensitivity to\n",
      "        methylphenidate Cognitively able to participate Not incarcerated Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No monoamine oxidase inhibitors\n",
      "        within 2 months\n",
      "2925\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed colorectal cancer\n",
      "        Unresectable disease Measurable disease No uncontrolled brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal\n",
      "        (ULN) AST no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN\n",
      "        Other: No active infection Not pregnant or nursing Negative pregnancy test for\n",
      "        premenopausal women Fertile patients must use effective contraception No concurrent\n",
      "        uncontrolled systemic disorders No prior malignant disease within the past year except in\n",
      "        situ carcinoma of the cervix or curatively treated basal cell carcinoma of the skin No\n",
      "        history of allergy to bryostatin 1 or its vehicle\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: Only\n",
      "        one prior chemotherapy regimen in the adjuvant or metastatic setting allowed At least 3\n",
      "        weeks since prior chemotherapy (6 weeks for nitrosoureas) No other concurrent chemotherapy\n",
      "        Endocrine therapy: No concurrent hormonal therapy (except contraceptives, appetite\n",
      "        stimulants and replacement steroids) Radiotherapy: At least 3 weeks since prior\n",
      "        radiotherapy No concurrent radiation therapy No concurrent palliative radiation therapy to\n",
      "        only site of measurable disease Surgery: Not specified Other: At least 1 month since prior\n",
      "        use of any other investigational agent No concurrent use of experimental medications\n",
      "2926\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven incurable stage IV carcinoma of the uterine cervix and/or vulva\n",
      "             that is unlikely to respond to existing therapy\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "          -  Tumor must be at least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No known chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease, such as chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Not a high medical or psychiatric risk\n",
      "          -  No concurrent nonmalignant systemic disease\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  At least 1 month since prior tamoxifen if no progression\n",
      "               -  May enter study immediately if evidence of progression\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplastons\n",
      "          -  No other concurrent antineoplastic agents\n",
      "2927\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of the colon metastatic to the liver that\n",
      "             expresses carcinoembryonic antigen (CEA) after resection with curative intent\n",
      "               -  At least 50% of the tumor cells must stain positive for CEA with at least\n",
      "                  moderate intensity\n",
      "          -  No gross residual disease after surgery\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Greater than 6 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1000/mm 3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  No chronic or acute hepatic disease\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No chronic or acute cardiac disease (New York Heart Association class III or IV)\n",
      "        Pulmonary:\n",
      "          -  No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary\n",
      "             disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled\n",
      "             superficial bladder cancer within the past 5 years\n",
      "          -  No history of autoimmune disease such as inflammatory bowel disease, systemic lupus\n",
      "             erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis\n",
      "          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral\n",
      "             hepatitis\n",
      "          -  No active infectious enteritis or eosinophilic enteritis\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No other concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No concurrent chemotherapy\n",
      "          -  At least 6 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent steroid therapy (or any other immunosuppressives)\n",
      "          -  At least 6 weeks since prior steroid therapy\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "          -  At least 6 weeks since prior radiotherapy\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "2928\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma\n",
      "               -  First relapse requires histologic confirmation of relapse\n",
      "          -  No CNS metastases\n",
      "          -  No lymphomatous meningitis\n",
      "          -  Measurable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15-75\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Unless due to lymphoma:\n",
      "               -  Platelet count at least 100,000/mm^3\n",
      "               -  Absolute granulocyte count at least 1,500/mm^3\n",
      "               -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN\n",
      "             if liver involvement)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Baseline calcium less than 12 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within 6 months\n",
      "          -  No congestive heart failure requiring therapy\n",
      "        Other:\n",
      "          -  No history of seizures\n",
      "          -  No uncontrolled diabetes mellitus (i.e., random blood sugar of at least 250 mg)\n",
      "          -  No other concurrent severe disease\n",
      "          -  No uncontrolled infection\n",
      "          -  HIV negative\n",
      "          -  No psychoses\n",
      "          -  No prior malignancy except for adequately treated basal cell or squamous cell skin\n",
      "             cancer or in situ cancer of the cervix unless surgically treated and disease free for\n",
      "             at least 5 years\n",
      "          -  Not pregnant or lactating\n",
      "          -  Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior bone marrow transplantation\n",
      "        Chemotherapy:\n",
      "          -  No more than 2 prior chemotherapy regimens for treatment of lymphoma\n",
      "          -  No prior irinotecan, topotecan or aminocamptothecin\n",
      "          -  At least 3 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy\n",
      "          -  Radiotherapy that is not a part of a combined-modality therapy is counted as a\n",
      "             regimen (see Chemotherapy)\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No phenytoin, phenobarbital, or other antiepileptic prophylaxis\n",
      "2932\n",
      "DISEASE CHARACTERISTICS: Cytologically confirmed early chronic phase chronic myelogenous\n",
      "        leukemia (CML) Diagnosed within 12 months Philadelphia chromosome positive OR bcr positive\n",
      "        No late chronic phase, accelerated phase, or blastic phase CML\n",
      "        PATIENT CHARACTERISTICS: Age: 12 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 mg/dL Renal:\n",
      "        Creatinine less than 2 mg/dL Cardiovascular: No severe heart disease Other: No psychoses\n",
      "        Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Less than 1 month of prior interferon alfa\n",
      "        Chemotherapy: Less than 1 month of prior cytarabine Prior hydroxyurea allowed Endocrine\n",
      "        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified\n",
      "2933\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven refractory or recurrent nonhematologic\n",
      "             malignancies\n",
      "          -  Measurable or evaluable disease by radiographic or clinical examination\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance Status: Karnofsky 70-100%\n",
      "          -  Absolute neutrophil count at least 2,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 2.5 times upper limit of normal\n",
      "          -  Albumin at least 3 g/dL\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 60 mL/min\n",
      "          -  No concurrent neurotoxicities greater than grade 1 from previous chemotherapy\n",
      "          -  No concurrent neuropathy greater than grade 1\n",
      "          -  Not pregnant\n",
      "          -  Effective contraceptive method must be used by fertile patients during and up to 2\n",
      "             months after study\n",
      "          -  No serious uncontrolled medical illness\n",
      "          -  No history of active inflammatory bowel disease, ileus, or other chronic\n",
      "             malabsorption syndromes\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No concurrent isoniazid\n",
      "          -  No concurrent rifampin\n",
      "          -  At least 4 weeks since chemotherapy\n",
      "          -  At least 6 weeks since nitrosoureas therapy\n",
      "          -  At least 3 months since suramin therapy\n",
      "          -  No prior carboxyamidotriazole\n",
      "          -  No concurrent steroids (except dose required for adrenal insufficiency)\n",
      "          -  No concurrent tamoxifen\n",
      "          -  No prior radiotherapy within 4 weeks of study\n",
      "          -  No prior total gastrectomy or total ileocolectomy\n",
      "          -  No concurrent therapy with H2 antagonists, barbiturates, calcium channel blockers,\n",
      "             terfenadine, astemizole, cisapride, digitoxin, quinidine, amiodarone, carbamazepine,\n",
      "             imipramine, or antacids\n",
      "          -  No concurrent erythromycin\n",
      "2934\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent stage IV adenocarcinoma of the\n",
      "        colon and rectum No CNS metastases Bidimensionally measurable lesion (at least 2 cm in\n",
      "        dimension) or evaluable disease (as malignant ascites or bone metastases) as documented by\n",
      "        CT or MRI Must be outside prior radiotherapy field\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: WHO 0-2 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: Absolute neutrophil count greater than 1,500/mm3\n",
      "        Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times\n",
      "        normal Alkaline phosphatase no greater than 3 times normal SGOT/SGPT no greater than 3\n",
      "        times normal Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No uncontrolled\n",
      "        congestive heart failure or angina pectoris in the past 6 months No hypertension or\n",
      "        arrhythmia in the past 6 months Neurologic: No peripheral neuropathy No significant\n",
      "        neurologic or psychiatric disorder Other: No complete or partial obstruction of the bowel\n",
      "        No serious nonmalignant disease No active infection No second malignancy except in situ\n",
      "        cervical carcinoma or nonmelanomatous skin carcinoma No chronic diarrhea Not pregnant or\n",
      "        nursing Fertile women must use adequate contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy for metastatic disease\n",
      "        Chemotherapy: No prior chemotherapy for metastatic disease At least 6 months since prior\n",
      "        adjuvant chemotherapy with no disease progression or after metastatic liver resection No\n",
      "        prior chemotherapy with oxaliplatin or irinotecan Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 2 weeks since prior radiotherapy Surgery: At least 2 weeks since\n",
      "        surgery Other: At least 30 days since use of investigational agent\n",
      "2936\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven non-Hodgkin's disease that has failed both prior high-dose\n",
      "             chemotherapy and bone marrow transplantation\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 20,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents (e.g., interferon or interleukin-2)\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior corticosteroids\n",
      "          -  No concurrent corticosteroids\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent antineoplastic agents\n",
      "          -  No concurrent antibiotics, antifungals, or antivirals\n",
      "2937\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed invasive, recurrent, or metastatic\n",
      "        thymoma or thymic carcinoma not amenable to potentially curative therapy Must have\n",
      "        extensive disease defined as: - distant disease - pleural disease with or without\n",
      "        mediastinal involvement - recurrent progressive disease in site of previous radiotherapy\n",
      "        Measurable disease with at least one bidimensionally measurable lesion Must have\n",
      "        octreotide scan prestudy that demonstrates activity in the area of measurable disease\n",
      "        within 6 months prior to registration\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal: Creatinine no greater than 3.0 mg/dL Other: No diabetes mellitus or any other\n",
      "        complications to high dose corticosteroid therapy No acute concurrent complications such\n",
      "        as infections Other prior malignancy(ies) must have been curatively treated and\n",
      "        demonstrate no evidence of recurrence Not pregnant or nursing Negative pregnancy test\n",
      "        Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy\n",
      "        allowed if disease progression is demonstrated prior to study entry Endocrine therapy:\n",
      "        Prior or concurrent corticosteroids for myasthenia gravis allowed Radiotherapy: Prior\n",
      "        radiotherapy allowed Surgery: No postsurgical complications\n",
      "2939\n",
      "DISEASE CHARACTERISTICS: Histologically proven refractory or recurrent supratentorial\n",
      "        glioblastoma multiforme Bidimensionally measurable, enhancing residual disease by\n",
      "        T1-weighted gadolinium-enhanced MRI required within 15 days prior to treatment Stable dose\n",
      "        of corticosteroids required for at least 7 days prior to scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 75,000/mm3 Hemoglobin at least 9 g/dL without blood transfusions\n",
      "        for 15 days prior to treatment Hepatic: AST/SGOT no greater than 3 times upper limit of\n",
      "        normal (ULN) Bilirubin less than 1.5 times ULN Renal: Creatinine no greater than 2 mg/dL\n",
      "        OR Creatinine clearance at least 40 mL/min Other: Not allergic to etoposide Effective\n",
      "        contraception required of fertile patients Negative serum pregnancy test required of\n",
      "        fertile women No other acute or chronic medical or psychiatric condition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        leflunomide (SU101) therapy No more than one prior single-agent or combination systemic\n",
      "        chemotherapy regimen for initial disease Radiosensitizer(s) concurrent with radiotherapy\n",
      "        allowed in addition to chemotherapy for primary disease At least 6 weeks since nitrosourea\n",
      "        or mitomycin At least 2 weeks since vincristine No prior single-agent procarbazine At\n",
      "        least 4 weeks since other chemotherapy No concurrent chemotherapy agents Endocrine\n",
      "        therapy: No concurrent hormone therapy (except medroxyprogesterone acetate for appetite\n",
      "        stimulation) Less than 4 weeks of prior hormonal therapy (tamoxifen or retinoids) if\n",
      "        failed one prior chemotherapy regimen Radiotherapy: Prior conventional radiotherapy for\n",
      "        initial disease required No more than one prior course of radiotherapy At least 8 weeks\n",
      "        since radiotherapy No prior interstitial radiotherapy No concurrent radiotherapy Surgery:\n",
      "        Maximally feasible resection for initial disease required No more than two resections\n",
      "        permitted At least 1 week since surgery and/or biopsy for disease No prior interstitial\n",
      "        radiotherapy or implanted BCNU-wafers No concurrent surgery (including resection,\n",
      "        stereotactic surgery or interstitial implants) Other: No concurrent investigational agent\n",
      "        At least 4 weeks since prior investigational agent At least 1 week since cholestyramine or\n",
      "        monoamine oxidase inhibitors\n",
      "2940\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage IV adenocarcinoma of the lung that is unlikely to\n",
      "             respond to existing therapy and for which no curative therapy exists\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  No hepatic insufficiency\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No chronic heart disease that would preclude study treatment\n",
      "          -  No history of chronic heart failure\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No lung disease that would preclude study treatment\n",
      "          -  No serious lung disease (e.g., severe chronic obstructive pulmonary disease)\n",
      "        Neurologic:\n",
      "          -  No neurological disease that would preclude study treatment\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No gastrointestinal or psychiatric disease that would preclude study treatment\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulatory agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agents\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "2941\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed large cell, undifferentiated, or poorly differentiated stage\n",
      "             IV lung cancer unlikely to have a curative response to existing standard regimens\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "               -  At least 2 cm in diameter\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No history of other cardiovascular conditions that contraindicate high dosages of\n",
      "             sodium\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections\n",
      "          -  No other concurrent serious disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agent\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic agent\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  Prior cytodifferentiating agent allowed\n",
      "2942\n",
      "DISEASE CHARACTERISTICS: Histologically proven B-cell chronic lymphocytic leukemia Stage I\n",
      "        or II with evidence of active disease as defined by: Massive or progressive splenomegaly\n",
      "        and/or lymphadenopathy Weight loss of greater than 10% within 6 months CALGB grade 2 or 3\n",
      "        fatigue Fevers of greater than 100.5 C or night sweats for over 2 weeks and no evidence of\n",
      "        infection Progressive lymphocytosis Stage III or IV Patient registration on CALGB 9665\n",
      "        required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-3 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine no\n",
      "        greater than 1.5 times upper limit of normal Other: No medical condition requiring chronic\n",
      "        use of oral corticosteroids Direct antiglobulin test or direct Coombs test negative Not\n",
      "        pregnant Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic: No prior biologic therapy for disease No concurrent\n",
      "        erythropoietin Chemotherapy: No concurrent chemotherapy No prior chemotherapy for disease\n",
      "        Endocrine: No concurrent chronic oral corticosteroids No prior corticosteroids for\n",
      "        autoimmune complications developing since diagnosis No concurrent hormone therapy for\n",
      "        disease related conditions No concurrent dexamethasone or other corticosteroid-based\n",
      "        antiemetics Radiotherapy: No concurrent palliative radiotherapy Surgery: Not specified\n",
      "        Other: No prophylactic therapy for viral, bacterial, or fungal infections\n",
      "2943\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven recurrent or unresectable:\n",
      "          -  Malignant meningioma\n",
      "          -  Intracranial hemangiopericytoma\n",
      "          -  Primary central nervous system sarcoma, including:\n",
      "          -  Fibrosarcoma\n",
      "          -  Rhabdomyosarcoma\n",
      "          -  Chondrosarcoma\n",
      "          -  Leiomyosarcoma\n",
      "          -  Measurable or evaluable disease on CT or MRI scan\n",
      "          -  Persistent disease following biopsy or incomplete resection OR\n",
      "          -  Recurrent disease following complete resection\n",
      "          -  No benign meningioma\n",
      "          -  No prior or current systemic sarcoma\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Absolute granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 3 months\n",
      "          -  No active angina\n",
      "          -  No unstable heart rhythms\n",
      "          -  No congestive heart failure\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No allergy to study drugs\n",
      "          -  No serious concurrent medical or psychiatric illness\n",
      "          -  No uncontrolled peptic ulcer disease\n",
      "          -  No prior malignancy within past 5 years except adequately treated:\n",
      "          -  Basal or squamous cell carcinoma of the skin\n",
      "          -  Carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Effective contraception required of fertile patients\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Recovered from toxic effects of prior therapy and/or from postoperative complications\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior ifosfamide\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy (except estrogen replacement therapy)\n",
      "          -  Corticosteroids allowed if dose is stable or decreasing\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  Progressive disease following radiation required\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2944\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed acute myelogenous leukemia (AML), acute\n",
      "        lymphoblastic leukemia (ALL) of B-cell or T-cell type, or blast crisis of chronic\n",
      "        myelogenous leukemia (CML) Must fulfill one of the following criteria: - Newly diagnosed,\n",
      "        previously untreated AML or ALL in elderly patients (65 75) - First or subsequent relapse\n",
      "        of AML or ALL after standard chemotherapy, autologous or allogeneic bone marrow\n",
      "        transplantation, or high-dose treatment with peripheral blood stem cell support - AML or\n",
      "        ALL that is refractory to standard chemotherapy (no complete remission achieved after 2\n",
      "        courses of conventional induction chemotherapy) - CML in blast crisis of any subtype\n",
      "        (i.e., myelogenous or lymphoblastic) with or without previously known chronic phase No\n",
      "        leukemic involvement of the central nervous system\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: WHO 0-3 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.25 times upper limit\n",
      "        of normal (ULN) Renal: Creatinine less than 1.25 times ULN Cardiovascular: No history of\n",
      "        atrial or ventricular arrhythmias No history of congestive heart failure, even if\n",
      "        medically controlled No history of documented myocardial infarction Neurologic: No motor\n",
      "        or sensory neuropathy grade 2 or more No dementia or significantly altered mental status\n",
      "        Other: HIV negative No active infection or other serious underlying medical condition No\n",
      "        prior allergic reaction to a drug containing Cremophor EL No complete bowel obstruction\n",
      "        Not pregnant or nursing Adequate contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No required concurrent cytoreductive treatment\n",
      "        in addition to paclitaxel No concurrent growth factors or cytokine No concurrent\n",
      "        immunotherapeutic drugs Chemotherapy: No prior paclitaxel or related compounds for a\n",
      "        malignancy other that leukemia No required concurrent cytoreductive treatment in addition\n",
      "        to paclitaxel Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "2945\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage 0, I, or II B-cell chronic\n",
      "        lymphocytic leukemia Stable disease that would otherwise be observed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 1 year Hematopoietic: Absolute lymphocyte count greater than 5,000/mm3 Mature\n",
      "        lymphocytes with less than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts Bone\n",
      "        marrow with at least 30% lymphocytes Hepatic: No cirrhosis Renal: Not specified\n",
      "        Cardiovascular: No history of unstable cardiac arrhythmia No active congestive heart\n",
      "        failure Other: No history of uncontrolled seizure disorder Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No other\n",
      "        concurrent condition that would make life expectancy less than 1 year\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent interferon alfa Chemotherapy: No\n",
      "        prior chemotherapy No concurrent chemotherapy Endocrine therapy: At least 3 months since\n",
      "        prior corticosteroids No concurrent corticosteroids Radiotherapy: Not specified Surgery:\n",
      "        Not specified\n",
      "2946\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed persistent, recurrent, or refractory\n",
      "        endometrial carcinoma who have failed prior first line chemotherapy Bidimensionally\n",
      "        measurable disease by physical exam or medical imaging techniques (sonography acceptable\n",
      "        if lesion(s) are clearly defined and measurable in two dimensions) Ascites and pleural\n",
      "        effusions are not measurable\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy:\n",
      "        At least 2 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Granulocyte count at least 1,500/mm3 Hemoglobin at least 8 g/dL Hepatic:\n",
      "        Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3\n",
      "        times ULN Alkaline phosphatase no greater than 3 times ULN Renal: Creatinine no greater\n",
      "        than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients\n",
      "        must use effective contraception No significant infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy and recovered Endocrine therapy:\n",
      "        Not specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered\n",
      "        Surgery: At least 4 weeks since prior surgery and recovered Other: At least 4 weeks since\n",
      "        any prior therapy directed at malignant endometrial tumor(s) At least 4 weeks since prior\n",
      "        folate-containing vitamins No concurrent folate-containing vitamins No other concurrent\n",
      "        anticancer therapy\n",
      "2947\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed melanoma metastatic to regional lymph\n",
      "        nodes with a clinically palpable mass Must have clinical evidence of the following:\n",
      "        Metastases in 1 nodal site All other nodes microscopically negative No intransit\n",
      "        metastases No extranodal extension OR Metastases in more than 1 nodal site More than 1\n",
      "        positive lymph node in a single site Intransit metastases Extranodal extension Must have\n",
      "        undergone complete resection of tumor, measuring at least 2 cm in diameter, within the\n",
      "        past 6 weeks No distant metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: At least 6 months Hematopoietic: Hematocrit at least 30% WBC at least\n",
      "        3,000/mm3 Hepatic: Hepatitis B and C negative Renal: Not specified Other: Not pregnant or\n",
      "        nursing No active serious infection No active autoimmune disease HIV negative No other\n",
      "        malignancy within the last 5 years except squamous cell carcinoma of the skin, carcinoma\n",
      "        in situ of the cervix, superficial bladder carcinoma, early stage prostate cancer, or\n",
      "        noninvasive melanoma No active severe depression or psychiatric disorder with psychotic\n",
      "        symptoms No uncontrolled thyroid abnormalities\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since prior cytotoxic drugs (except for isolated limb perfusion) Endocrine therapy: No\n",
      "        concurrent systemic corticosteroids Radiotherapy: At least 6 months since prior\n",
      "        radiotherapy Surgery: See Disease Characteristics Other: At least 30 days since prior\n",
      "        investigational drugs\n",
      "2950\n",
      "DISEASE CHARACTERISTICS:\n",
      "        Part I:\n",
      "          -  Histologically proven advanced solid tumors that are refractory or for which no\n",
      "             curative therapy exists\n",
      "          -  No CNS metastases, peritumoral edema, or symptomatic brain metastases (part I)\n",
      "          -  Measurable or evaluable disease\n",
      "        Part II:\n",
      "          -  Histologically proven recurrent gliomas or brain metastases for which no curative\n",
      "             therapy exists\n",
      "          -  Receiving anticonvulsants\n",
      "          -  Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  AST or ALT less than 3 times upper limit of normal (ULN) (less than 5 times ULN if\n",
      "             liver metastases)\n",
      "        Renal:\n",
      "          -  Creatinine less than 2 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No unstable angina\n",
      "          -  No myocardial infarction within past 6 months\n",
      "          -  No maintenance therapy for life-threatening arrhythmias\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  HIV negative\n",
      "          -  No active infection or other serious concurrent illness\n",
      "          -  Triglycerides no greater than 300 mg/dL\n",
      "          -  Cholesterol no greater than 350 mg/dL\n",
      "          -  No known hypersensitivity to macrolide antibiotics (e.g., clarithromycin,\n",
      "             erythromycin, or azithromycin)\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas and mitomycin)\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids used to reduce edema in patients with primary or\n",
      "             metastatic CNS tumors allowed\n",
      "          -  No concurrent hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 1 month since prior investigational agents\n",
      "          -  At least 3 weeks since prior immunosuppressive therapy\n",
      "          -  No concurrent anticonvulsant therapy (part I)\n",
      "          -  No concurrent immunosuppressive therapy (e.g., terfenadine, cisapride, astemizole,\n",
      "             pimozide)\n",
      "          -  No known agents that inhibit or induce cytochrome p450\n",
      "2951\n",
      "DISEASE CHARACTERISTICS: Histologically, cytologically, or clinically confirmed\n",
      "        unresectable, stage IV, or recurrent soft tissue sarcoma No Ewing's sarcoma, Kaposi's\n",
      "        sarcoma, bone sarcomas, mesotheliomas, or primitive neuroectodermal tumors Bidimensionally\n",
      "        measurable disease by x-ray, CT scan or MRI, or physical examination No CNS metastases No\n",
      "        more than 2 prior chemotherapy regimens for advanced, recurrent, or metastatic disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Greater than 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin\n",
      "        greater than 10.0 g/dL WBC at least 3,500/mm3 OR Absolute neutrophil count at least\n",
      "        1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "        SGOT/SGPT no greater than 1.5 times ULN Alkaline phosphatase less than 2 times ULN Renal:\n",
      "        Calcium less than ULN Creatinine or BUN less than 1.5 times ULN OR Creatinine clearance\n",
      "        greater than 60 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception No other malignancy within the past 5 years\n",
      "        except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of\n",
      "        the cervix, or fully excised and/or treated stage I cancer currently in complete remission\n",
      "        No nonmalignant systemic disease rendering patient a poor medical risk No acute infection\n",
      "        requiring IV antibiotics HIV negative No AIDS-related illness No frequent vomiting or\n",
      "        medical condition that could interfere with oral medication intake (e.g., partial bowel\n",
      "        obstruction)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic response modifier treatment\n",
      "        allowed At least 4 weeks since prior immunotherapy At least 4 weeks since prior biologic\n",
      "        therapy No concurrent epoetin alfa Chemotherapy: See Disease Characteristics Prior\n",
      "        dacarbazine allowed At least 4 weeks since prior chemotherapy No other concurrent\n",
      "        chemotherapy Endocrine therapy: No concurrent hormonal therapy for malignancy\n",
      "        Radiotherapy: At least 3 weeks since prior radiotherapy and recovered No prior\n",
      "        radiotherapy to areas of measurable disease unless there is clear progression or there is\n",
      "        measurable disease outside the area of prior radiation No concurrent radiotherapy Surgery:\n",
      "        At least 4 weeks since prior surgery and recovered Other: No other concurrent\n",
      "        investigational drugs\n",
      "2952\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent or stage IV\n",
      "        (metastatic or locally advanced) unresectable soft tissue sarcoma Patients with soft\n",
      "        tissue Ewing's sarcoma, Kaposi's sarcoma, sarcoma of the bone, and mesothelioma are not\n",
      "        eligible Must have failed at least one, but no more than two, prior chemotherapy regimens,\n",
      "        one of which contained doxorubicin either as adjuvant therapy or first-line therapy for\n",
      "        metastatic disease Bidimensionally measurable disease on x-ray, MRI or CT scan, or\n",
      "        physical exam (outside of previously irradiated area) No CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Platelet count at least lower limit of normal WBC at least\n",
      "        3,500/mm3 OR Absolute neutrophil count at least 1,750/mm3 Hepatic: Bilirubin no greater\n",
      "        than 1.5 mg/dL AST no greater than 3 times upper limit of normal (ULN) (no greater than 5\n",
      "        times ULN with liver tumor involvement) Renal: Creatinine less than ULN OR Creatinine\n",
      "        clearance greater than 60 mL/min Calcium less than ULN Cardiovascular: No myocardial\n",
      "        infarction within past 6 months No congestive heart failure requiring therapy Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception No physical, mental,\n",
      "        or emotional disorders No other prior malignancy within the past 5 years, except:\n",
      "        Adequately treated basal or squamous cell skin cancer Carcinoma in situ of the cervix\n",
      "        Adequately treated stage I or II cancer in complete remission No active or uncontrolled\n",
      "        infection HIV negative No known Gilbert's syndrome No uncontrolled diabetes (random blood\n",
      "        sugar at least 200 mg)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic response modifier therapy\n",
      "        allowed Chemotherapy: See Disease Characteristics No prior irinotecan or topotecan No\n",
      "        other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy\n",
      "        Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy and\n",
      "        recovered No concurrent radiotherapy Surgery: At least 4 weeks since prior surgery and\n",
      "        recovered\n",
      "2953\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Newly diagnosed or recurrent (at least 2 occurrences within 12 months) Ta, multifocal\n",
      "             Ta (at least 2 visible tumors), or stage T1 bladder cancer\n",
      "               -  No carcinoma in situ (Tis) only\n",
      "               -  No T2 or greater tumors\n",
      "          -  No evidence of upper tract (ureter or renal pelvic) transitional cell carcinoma based\n",
      "             on intravenous pyelogram performed within 4 months of the TURB\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,500/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No prior malignancy within the past 5 years except adequately treated basal cell or\n",
      "             squamous cell skin cancer, carcinoma in situ of the cervix, or superficial\n",
      "             transitional cell carcinoma of the bladder\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent biological response modifiers\n",
      "        Chemotherapy:\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2954\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage III or IV\n",
      "        unresectable adenocarcinoma of the exocrine pancreas Must have been treated with 1 prior\n",
      "        gemcitabine regimen, and have documented disease progression either during or within 6\n",
      "        months after completion of therapy Measurable or evaluable disease outside of previously\n",
      "        irradiated area No islet cell tumors or lymphoma of the pancreas No significant CNS\n",
      "        disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL\n",
      "        Hepatic: Bilirubin no greater than 2 mg/dL AST or ALT no greater than 2 times upper limit\n",
      "        of normal (ULN) (no greater than 5 times ULN if liver metastases) Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Cardiovascular: No atrial or ventricular arrhythmias requiring\n",
      "        medication No atrial fibrillation (with or without medication) No ischemic event within\n",
      "        past 6 months No history of congestive heart failure Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception No significant psychiatric disorders No\n",
      "        active infection No other prior malignancies within past 5 years, except: Basal or\n",
      "        squamous cell skin cancer Carcinoma in situ of the cervix No concurrent serious systemic\n",
      "        disorder\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy No concurrent\n",
      "        immunotherapy Chemotherapy: At least 4 weeks since prior gemcitabine therapy and recovered\n",
      "        No other prior chemotherapy (except fluorouracil as a radiation enhancing agent) No other\n",
      "        concurrent chemotherapy Endocrine therapy: No prior hormonal therapy No concurrent\n",
      "        hormonal therapy (except contraceptives, hormone replacement, or megestrol acetate)\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: At least 4 weeks since prior investigational\n",
      "        agents\n",
      "2955\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed aggressive non-Hodgkin's lymphoma requiring chemotherapy\n",
      "          -  Stage II, III, or IV\n",
      "               -  B cell:\n",
      "                    -  Centroblastic\n",
      "                    -  Immunoblastic\n",
      "                    -  Large cell anaplastic\n",
      "                    -  Non-Burkitt lymphoblastic\n",
      "               -  T cell:\n",
      "                    -  Pleomorphic medium cell\n",
      "                    -  Pleomorphic large cell\n",
      "                    -  Immunoblastic\n",
      "                    -  Large cell anaplastic\n",
      "                    -  Lymphoblastic\n",
      "                         -  No Burkitt (L3) subtype\n",
      "                         -  No large mediastinal mass OR\n",
      "          -  Stage I, II, III, or IV\n",
      "               -  Bulk disease greater than 10 cm\n",
      "               -  Nodal or extranodal site\n",
      "          -  No primary localized gut lymphoma\n",
      "          -  No CNS involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  15 to 65\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  No concurrent bone marrow dysplastic syndromes\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 times ULN\n",
      "        Other:\n",
      "          -  No other malignancy except skin cancer or stage I cervical cancer\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2956\n",
      "DISEASE CHARACTERISTICS: Leukemia, lymphoma, or Hodgkin's disease OR Stem cell\n",
      "        transplantation or bone marrow transplantation (allogenic or autologous) for a neoplastic\n",
      "        disease Absolute granulocyte count no greater than 1,000/mm3 anticipated to fall below\n",
      "        500/mm3 within 24-48 hours, and expected to last for longer than 7 days from onset of\n",
      "        fever Fever (i.e., oral or axillary temperature at least 38.5 degrees C or 101.3 degrees F\n",
      "        once, or at least 38 degrees C or 100.4 degrees F on two or more occasions separated at\n",
      "        least by 1 hour during a 12 hour period) Presumed infection\n",
      "        PATIENT CHARACTERISTICS: Age: 2 and over Performance status: Not moribund or comatose for\n",
      "        any reason with little hope of recovery Life expectancy: At least 48 hours Hematopoietic:\n",
      "        See Disease Characteristics Hepatic: No hepatic stupor or coma Renal: Adults: No renal\n",
      "        failure requiring hemodialysis or peritoneal dialysis OR Creatinine no greater than 2.25\n",
      "        mg/dL OR Creatinine clearance at least 40 mL/min Children: No renal impairment (i.e.,\n",
      "        creatinine greater than upper limit of normal) Pulmonary: No lung infiltrate Other: No\n",
      "        known allergy to piperacillin, tazobactam, or vancomycin No history of immediate or\n",
      "        accelerated reaction to beta-lactam antibiotics No prior inclusion in this study No\n",
      "        catheter related infection No known HIV infection Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not\n",
      "        specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified Other: At least 4 days since prior intravenous antibacterial agents Oral\n",
      "        antibiotics for prophylaxis of bacterial infection allowed At least 30 days since prior\n",
      "        treatment with any other investigational antibiotic No other concurrent antibiotics except\n",
      "        trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia\n",
      "2957\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven CNS tumor that is refractory to conventional\n",
      "             therapy or for which no effective therapy is known\n",
      "          -  Histological requirement may be waived for brainstem and optic gliomas\n",
      "          -  Stratum 2: No bone marrow involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 21 and under\n",
      "          -  Performance status: Karnofsky 50-100% OR Lansky 50-100%\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Absolute neutrophil count at least 1500/mm3\n",
      "          -  Platelet count at least 100,000/mm3 (stratum 2: at least 125,000/mm3)\n",
      "          -  Hemoglobin at least 8 g/dL\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 2.5 times normal\n",
      "          -  Creatinine or GFR normal for age\n",
      "          -  If required, DLCO must be 80% of normal and patient old enough to cooperate for DLCO\n",
      "             test\n",
      "          -  Neurologic deficits must be stable for at least 2 weeks prior to study\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 7 days since prior biologic therapy or immunotherapy and recovered\n",
      "          -  At least 6 months since prior bone marrow transplant (stratum 1 only)\n",
      "          -  At least 7 days since prior growth factors\n",
      "          -  No concurrent filgrastim (G-CSF) prophylaxis\n",
      "          -  Stratum 2: No prior bone marrow transplantation\n",
      "          -  At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)\n",
      "             and recovered\n",
      "          -  Stratum 2: No greater than 2 prior chemotherapy regimens\n",
      "          -  No prior nitrosourea therapy\n",
      "          -  If receiving dexamethasone, must be on stable or decreasing dose for at least 2 weeks\n",
      "             prior to study\n",
      "          -  At least 2 weeks since prior local palliative radiotherapy (small port)\n",
      "          -  At least 6 months since prior substantial bone marrow radiation, total body\n",
      "             irradiation, hemipelvic radiotherapy, or total abdominal/pelvic/chest or mantle/Y\n",
      "             ports radiotherapy\n",
      "          -  Recovered from prior radiotherapy\n",
      "          -  Stratum 2: No prior central axis radiation\n",
      "          -  No other concurrent anticancer or investigational agents\n",
      "2958\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed neuroblastoma or melanoma at original diagnosis\n",
      "               -  Refractory to chemotherapy or recurrence after prior multiagent chemotherapy\n",
      "               -  Measurable or evaluable (detectable by bone scan) metastatic disease OR\n",
      "               -  No evidence of disease if complete response to prior surgical resection,\n",
      "                  radiotherapy, and/or chemotherapy OR\n",
      "          -  Histologically confirmed tumor expressing GD2 antigen at original diagnosis or\n",
      "             relapse\n",
      "               -  Refractory to standard treatment\n",
      "               -  Measurable or evaluable disease by clinical assessments or laboratory markers OR\n",
      "               -  No evidence of disease after prior surgical resection of metastatic, recurrent\n",
      "                  disease\n",
      "               -  Histologically confirmed recurrent osteogenic sarcoma after prior chemotherapy\n",
      "                  allowed\n",
      "               -  Soft tissue sarcoma allowed\n",
      "          -  No primary CNS tumors\n",
      "          -  Prior CNS metastases allowed, provided:\n",
      "               -  Disease previously treated\n",
      "               -  Disease clinically stable for 4 weeks before study\n",
      "               -  At least 4 weeks since prior steroids for CNS metastases\n",
      "          -  No clinically detectable pleural effusions or ascites\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  21 and under\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100% for children over age 10\n",
      "          -  Lansky 60-100% for children age 10 and under\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3\n",
      "          -  Platelet count at least 75,000/mm^3 (transfusion allowed)\n",
      "          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  ALT or AST no greater than 2.5 times normal\n",
      "          -  Hepatitis B surface antigen negative\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Shortening fraction at least 27% by echocardiogram OR\n",
      "          -  Ejection fraction more than 50% by MUGA scan\n",
      "          -  No congestive heart failure\n",
      "          -  No uncontrolled cardiac rhythm disturbance\n",
      "        Pulmonary:\n",
      "          -  FEV_1 and FVC more than 60% of predicted OR\n",
      "          -  No dyspnea at rest\n",
      "          -  No exercise intolerance\n",
      "          -  Oxygen saturation more than 94% by pulse oximetry on room air\n",
      "        Neurologic:\n",
      "          -  No seizure disorders requiring antiseizure medications\n",
      "          -  No significant neurologic deficit or grade 2 or greater objective peripheral\n",
      "             neuropathy\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  HIV negative\n",
      "          -  No significant concurrent illnesses unrelated to cancer or its treatment\n",
      "          -  No significant psychiatric disabilities\n",
      "          -  No uncontrolled active infections\n",
      "          -  No uncontrolled active peptic ulcer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 1 week since prior growth factors\n",
      "          -  At least 1 week since prior immunomodulatory therapy\n",
      "          -  Prior monoclonal antibodies allowed if no detectable antibody to hu14.18\n",
      "          -  Prior autologous bone marrow transplantation (BMT) or stem cell transplantation (SCT)\n",
      "             allowed\n",
      "          -  Prior autologous BMT or SCT with monoclonal antibody-purged specimens allowed\n",
      "          -  No concurrent growth factors\n",
      "          -  No concurrent interferon\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or\n",
      "             melphalan)\n",
      "          -  No concurrent palliative chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 2 weeks since prior glucocorticoids, except for life-threatening symptoms\n",
      "          -  No concurrent corticosteroids\n",
      "          -  No concurrent glucocorticoids, except for life-threatening symptoms\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 3 weeks since prior radiotherapy\n",
      "          -  No concurrent palliative radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy)\n",
      "          -  No prior organ allografts\n",
      "          -  No concurrent palliative surgery\n",
      "        Other:\n",
      "          -  Recovered from prior therapy\n",
      "          -  At least 1 week since prior tretinoin\n",
      "          -  At least 3 weeks since prior immunosuppressive therapy\n",
      "          -  No other concurrent immunosuppressive drugs\n",
      "2959\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of one of the following cancers and undergoing high dose chemotherapy with\n",
      "             autologous stem cell rescue (ASCR):\n",
      "               -  Metastatic breast cancer\n",
      "               -  Multiple myeloma\n",
      "               -  Hodgkin's disease\n",
      "               -  Recurrent or refractory low, intermediate, or high grade non-Hodgkin's lymphoma\n",
      "               -  Acute myelogenous leukemia beyond first remission\n",
      "               -  Acute lymphoblastic leukemia beyond first remission\n",
      "               -  Ovarian cancer\n",
      "               -  Refractory malignancy and measurable or evaluable disease (at time of ASCR)\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.\n",
      "             The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2960\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed myelodysplatic syndrome (MDS), diagnosed\n",
      "        at least 3 months prior to study enrollment, with one of the following subtypes:\n",
      "        Refractory anemia with excess blasts (RAEB) RAEB in transformation (RAEB-T) Chronic\n",
      "        myelomonocytic leukemia (CMML) CMML with leukocytosis not controlled by hydroxyurea\n",
      "        eligible in absence of neutropenia No treatment- or mutagen-related MDS One or more\n",
      "        cytopenias required: Untransfused hemoglobin less than 10 g/dL and/or\n",
      "        transfusion-dependent (requiring at least four units of red blood cells in prior 12 weeks)\n",
      "        Platelet count no greater than 50,000/mm3 or absolute neutrophil count less than 1,000/mm3\n",
      "        No myelosclerosis occupying more than 30% of marrow\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 3 months Hematopoietic: See Disease Characteristics No hereditary\n",
      "        hemolytic disorders Transferrin saturation greater than 20% Ferritin at least 50 ng/mL\n",
      "        Hepatic: Bilirubin less than 3 mg/dL AST/ALT and LDH less than 2 times upper limit of\n",
      "        normal Renal: Creatinine less than 2 mg/dL Cardiovascular: No significant cardiovascular\n",
      "        disorders (unrelated to MDS) No uncontrolled hypertension Pulmonary: No significant\n",
      "        pulmonary disorders (unrelated to MDS) Neurologic: No significant neurologic disorders\n",
      "        (unrelated to MDS) No history of epilepsy Metabolic: No significant endocrine disorders\n",
      "        (unrelated to MDS) Other: Not pregnant or nursing No significant gastrointestinal diseases\n",
      "        (unrelated to MDS) or GI blood loss No significant genitourinary system diseases\n",
      "        (unrelated to MDS) No active infection requiring IV antibiotic therapy No other serious\n",
      "        illness or medical condition Not HIV positive Not hepatitis B surface antigen positive No\n",
      "        iron, vitamin B12, or folate deficiencies No autoimmune disease No prior or concurrent\n",
      "        malignancy within 2 years except in situ carcinoma of the cervix or basal cell or squamous\n",
      "        cell carcinoma of the skin\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent hematopoietic stimulants\n",
      "        Chemotherapy: See Disease Characteristics At least 35 days since prior chemotherapy\n",
      "        Endocrine therapy: No concurrent androgen therapy No concurrent corticosteroids\n",
      "        Radiotherapy: Not specified Surgery: Not specified Other: At least 35 days since any\n",
      "        previous therapy for MDS (other than transfusion) No participation in any other\n",
      "        experimental clinical trial within 35 days of entry into current trial\n",
      "2961\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of chronic lymphocytic leukemia (CLL) of any stage as defined by the\n",
      "             following:\n",
      "               -  Peripheral blood absolute lymphocyte count greater than 5,000/mm^3 within 14\n",
      "                  days prior to study\n",
      "               -  Lymphocytes must be small to moderate size with no more than 55% prolymphocytes,\n",
      "                  atypical lymphocytes, or lymphoblasts morphologically\n",
      "               -  Phenotypically characterized as B-CLL\n",
      "          -  Must have one of the following characteristics indicating need for chemotherapy:\n",
      "               -  Progressive marrow failure (hemoglobin less than 10 g/dL and/or platelet count\n",
      "                  less than 100,000/mm^3)\n",
      "               -  Progressive lymphocytosis with an increase of more than 50% over a 2 month\n",
      "                  period or anticipated doubling time of less than 6 months\n",
      "               -  Massive (i.e., greater than 6 cm below left costal margin) or progressive\n",
      "                  splenomegaly\n",
      "               -  Massive nodes or clusters (i.e., greater than 10 cm in longest diameter) or\n",
      "                  progressive adenopathy\n",
      "               -  At least 10% weight loss within 6 months of study\n",
      "               -  Extreme fatigue\n",
      "               -  Fevers greater than 100.5 degrees F for 2 weeks without evidence of infection\n",
      "               -  Night sweats without evidence of infection\n",
      "          -  No autoimmune anemia or autoimmune thrombocytopenia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 mg/dL unless secondary to tumor\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "          -  Creatinine clearance at least 40 mL/min if creatinine is greater than 1.5 mg/dL\n",
      "        Other:\n",
      "          -  No other prior or concurrent malignancy within the past 2 years except basal cell\n",
      "             carcinoma of the skin or carcinoma in situ of the cervix\n",
      "          -  No active infection requiring oral or intravenous antibiotics\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior cytotoxic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior steroid treatment for CLL\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "2962\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven solid malignancy for which\n",
      "        no curative therapy exists Glioblastoma eligible if following criteria are met: Stable\n",
      "        performance status Stable symptoms At least 4 weeks on stable dose of dexamethasone CNS\n",
      "        metastases allowed if no progression or no new edema present Measurable or evaluable\n",
      "        disease No acute or chronic leukemia or multiple myeloma No known bone marrow involvement\n",
      "        with tumor\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count greater than 1500/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than\n",
      "        2.0 mg/dL SGOT or SGPT no greater than 3 times upper limit of normal (ULN) (5 times ULN if\n",
      "        due to liver metastases) Renal: Creatinine no greater than 1.5 mg/dL Other: No\n",
      "        malabsorption syndrome due to prior surgery, gastrointestinal disease, or other unknown\n",
      "        reason No concurrent nonmalignant systemic disease No active uncontrolled infection No\n",
      "        frequent vomiting or medical condition that could interfere with oral medication uptake\n",
      "        (e.g., partial bowel obstruction, bowel resection, partial intestinal bypass, external\n",
      "        biliary diversion) No prior or concurrent malignancies at other sites except carcinoma in\n",
      "        situ of the cervix or adequately treated basal or squamous cell skin cancer HIV negative\n",
      "        No AIDS-related illness Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        and recovered No prior allogeneic, syngeneic, or autologous bone marrow transplantation No\n",
      "        prior peripheral blood stem cell transplantation No concurrent biologic therapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or\n",
      "        mitomycin) and recovered No concurrent chemotherapy Endocrine therapy: See Disease\n",
      "        Characteristics Radiotherapy: At least 4 weeks since prior radiotherapy to at least 25% of\n",
      "        bone marrow (including pelvic irradiation) and recovered No concurrent radiotherapy\n",
      "        Surgery: Prior major gastrointestinal surgery allowed (e.g., Whipple procedure) Other: At\n",
      "        least 4 weeks since any prior investigational therapy At least 24 hours since prior\n",
      "        alcohol consumption\n",
      "2963\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed surgically resectable\n",
      "        solid tumor\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: CALGB 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times\n",
      "        upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN Other: Not\n",
      "        pregnant or nursing Medically cleared for surgery No active medical or psychiatric disease\n",
      "        that would prevent compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        Not specified\n",
      "2964\n",
      "DISEASE CHARACTERISTICS: Stage Ta (any grade) transitional cell carcinoma of the bladder\n",
      "        on basis of cystoscopy Recurrent disease no greater than T1 Must not be at high risk for\n",
      "        upper tract (ureter or renal pelvic) transitional cell cancers\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception No other\n",
      "        prior malignancy in the past 5 years except adequately treated basal cell or squamous cell\n",
      "        skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer\n",
      "        in complete remission No allergies to fluoroquinolones If allergic to penicillin or\n",
      "        cephalosporin, must be able to take co-trimoxazole\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 28 days\n",
      "        since prior intravesical therapy and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 28 days since prior radiotherapy and recovered Surgery: Not\n",
      "        specified Other: At least 3 months prior to cystoscopy since prior fluoroquinolones No\n",
      "        concurrent fluoroquinolones No concurrent hemodialysis or peritoneal dialysis No\n",
      "        concurrent probenecid or theophylline No concurrent antacids containing aluminum,\n",
      "        magnesium or calcium, products containing iron or zinc, caffeine, cyclosporine, or\n",
      "        warfarin\n",
      "2965\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor refractory to\n",
      "        conventional cytotoxic anticancer therapy or for which no curative therapy exists\n",
      "        Measurable or evaluable disease No active, progressive brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than 1.5\n",
      "        mg/dL SGOT/SGPT no greater than 3 times upper limit of normal No nonmalignant hepatic\n",
      "        disease Renal: Creatinine no greater than 2.0 mg/dL Potassium and magnesium at least lower\n",
      "        limit of normal (LLN) Calcium at least LLN Cardiovascular: QTc interval on echocardiogram\n",
      "        less than 450 milliseconds No myocardial infarction within past 6 months No uncontrolled\n",
      "        congestive heart failure No unstable angina No active cardiomyopathy No unstable\n",
      "        ventricular arrhythmia No uncontrolled hypertension Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception Must have functional central venous access\n",
      "        device or percutaneous intravenous catheter No known hypersensitivity to intoplicine or\n",
      "        its analogs No active alcoholism or drug addiction No uncontrolled, unstable psychotic\n",
      "        disorders No serious infections No underlying medical conditions that may be aggravated by\n",
      "        treatment\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks\n",
      "        since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered No other\n",
      "        concurrent antineoplastic therapy Endocrine therapy: Not specified Radiotherapy: At least\n",
      "        3 weeks since prior radiotherapy (except short courses (no greater than 5 fractions) of\n",
      "        nonmyelosuppressive, palliative radiotherapy) and recovered No concurrent radiotherapy\n",
      "        Surgery: Not specified Other: At least 3 weeks since prior investigational therapy No\n",
      "        other concurrent investigational therapy\n",
      "2967\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory, metastatic breast\n",
      "        cancer Patients previously treated for metastatic disease must show response to last\n",
      "        standard dose chemotherapy regimen within 60 days of study entry OR Patients with no\n",
      "        evidence of disease (e.g., resected skin lesions) must show no evidence of progression or\n",
      "        bone disease No CNS metastases No disease progression following prior platinum or\n",
      "        paclitaxel based regimens Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Sex: Not specified Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute\n",
      "        neutrophil count at least 1,500/mm3 Platelet count at least 90,000/mm3 No prior inability\n",
      "        to mobilize adequate peripheral blood progenitor cells for high dose therapy Hepatic:\n",
      "        Bilirubin no greater than 1.8 mg/dL Transaminases stable and no greater than 3 times upper\n",
      "        limit of normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: LVEF within\n",
      "        normal limits No significant cardiovascular disease No coronary artery disease No\n",
      "        arrhythmias No congestive heart failure Other: Not pregnant or nursing Negative pregnancy\n",
      "        test required of fertile women Effective contraception required of fertile patients Not\n",
      "        HIV positive No nonmalignant disease precluding protocol treatment No sensitivity to E.\n",
      "        coli-derived drug preparations No prior participation in this study No greater than grade\n",
      "        I neurotoxicity\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior cellular support for high dose\n",
      "        chemotherapy Chemotherapy: See Disease Characteristics No more than 6 prior courses of\n",
      "        chemotherapy for metastatic disease At least 3 weeks since prior chemotherapy and\n",
      "        recovered No prior high dose chemotherapy with cellular support Endocrine therapy: No\n",
      "        concurrent steroid therapy Concurrent hormonal therapy allowed Radiotherapy: At least 3\n",
      "        weeks since prior radiotherapy and recovered No prior extensive pelvic radiation Surgery:\n",
      "        Not specified Other: Recovered from acute toxic effects of any prior therapy No concurrent\n",
      "        anticoagulation therapy\n",
      "2968\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed solid tumor that is not amenable to any\n",
      "        standard curative therapy or is refractory to conventional therapy Tumor suitable for MRI\n",
      "        or PET imaging No active brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 4 months Hematopoietic: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.17 mg/dL ALT or AST less than 2\n",
      "        times upper limit of normal (ULN) Alkaline phosphatase less than 2 times ULN (unless due\n",
      "        to liver or bone metastases) Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No\n",
      "        ischemic heart disease Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception at least 4 weeks before, during, and for 4 weeks after the study No other\n",
      "        serious medical condition or serious infection within past 28 days No other active\n",
      "        concurrent malignancies, except: Carcinoma in situ of the cervix Adequately treated basal\n",
      "        or squamous cell carcinoma of the skin No autoimmune disorders No inflammatory bowel\n",
      "        disease No diabetes\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since prior nitrosoureas or mitomycin and recovered Endocrine therapy: Concurrent steroid\n",
      "        use allowed Radiotherapy: At least 6 weeks since prior radiotherapy (except radiotherapy\n",
      "        to small isolated fields not including significant areas of bone marrow) and recovered No\n",
      "        prior radiotherapy to tumor site(s) that will be imaged by MRI/PET scanning or used to\n",
      "        assess tumor response Surgery: No concurrent open surgery Other: At least 4 weeks since\n",
      "        all other prior anticancer therapies and recovered No concurrent heparin or warfarin\n",
      "        Concurrent NSAIDs allowed\n",
      "2969\n",
      "1. Any other serious illnesses which would limit survival to <2 years, or psychiatric\n",
      "             condition which would prevent compliance with treatment or informed consent.\n",
      "          2. Uncontrolled or severe cardiovascular disease.\n",
      "          3. History of pancreatitis or overt coagulopathy (prior cerebrovascular accident or\n",
      "             hemorrhage, transient ischemic attack or deep venous thrombosis).\n",
      "          4. Elevations in bilirubin, creatinine, or amylase that may suggest impaired hepatic,\n",
      "             renal, or pancreatic function must be considered as potentially serious obstacles for\n",
      "             safe tolerance of the therapy prescribed in this protocol.\n",
      "          5. Prior use of the agents administered in this protocol for other non-malignant disease\n",
      "             may reduce the likelihood of beneficial outcome, and should also be considered prior\n",
      "             to enrolling patients.\n",
      "          6. Treatment under this protocol would expose an unborn child to significant risks.\n",
      "             Women and men of reproductive potential should agree to use an effective means of\n",
      "             birth control.\n",
      "          7. Unequivocal histologic diagnosis of Acute Lymphoblastic leukemia (ALL), FAB L1-or L2\n",
      "             or Acute Undifferentiated Leukemia (AUL).\n",
      "          8. Age ≥ 15 years\n",
      "          9. Prior Treatment: No prior treatment for leukemia, with three permissible exceptions:\n",
      "             i. emergency leukapheresis; ii. emergency treatment for hyperleukocytosis with\n",
      "             hydroxyurea; iii. cranial RT for CNS leukostasis (one dose only).\n",
      "2970\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed anaplastic astrocytoma or anaplastic\n",
      "        oligoastrocytoma in first relapse Recurrence or progression at least 6 months from initial\n",
      "        diagnosis Must have received maximally feasible surgical resection and fractionated\n",
      "        external beam radiotherapy Must have received no more than 1 prior systemic cytotoxic\n",
      "        chemotherapy regimen for initial disease Bidimensionally measurable disease by MRI scan\n",
      "        (stable dose of corticosteroids for at least 7 days prior to scan)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 75,000/mm3 Hemoglobin at least 9 g/dL Hepatic: AST no greater than\n",
      "        3 times upper limit of normal (ULN) Bilirubin less than 1.5 times ULN Renal: Creatinine no\n",
      "        greater than 2 mg/dL OR Creatinine clearance at least 40 mL/min Other: Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception during\n",
      "        and for 3 months after the study No known allergy to etoposide No other acute or chronic\n",
      "        medical illness or psychiatric disorder\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior epoetin alfa,\n",
      "        filgrastim (G-CSF), or sargramostim (GM-CSF) and recovered No concurrent immunotherapy\n",
      "        Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (2\n",
      "        weeks since vincristine; 6 weeks since nitrosoureas or mitomycin) and recovered No prior\n",
      "        leflunomide (SU101) therapy No other concurrent chemotherapy Endocrine therapy: No\n",
      "        concurrent hormonal therapy (except medroxyprogesterone acetate for appetite stimulation)\n",
      "        Radiotherapy: See Disease Characteristics No more than 1 prior course of radiotherapy At\n",
      "        least 8 weeks since prior radiotherapy and recovered No prior interstitial radiotherapy or\n",
      "        implanted carmustine wafers Prior radiosensitizer(s) concurrent with radiotherapy or used\n",
      "        as neoadjuvant therapy allowed No concurrent radiotherapy Surgery: See Disease\n",
      "        Characteristics No more than 2 prior surgical resections At least 1 week since prior\n",
      "        surgery or biopsy for anaplastic astrocytoma No concurrent surgery (including resection,\n",
      "        stereotactic surgery, or interstitial implants) Other: At least 4 weeks since prior\n",
      "        investigational agents No other concurrent investigational agents\n",
      "2972\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven breast cancer Must be\n",
      "        enrolled no later than 40 weeks from the start of first line chemotherapy for metastatic\n",
      "        disease High dose chemotherapy with bone marrow transplantation or stem cell rescue as\n",
      "        part of first line therapy is allowed Either no evidence of disease or nonprogressive\n",
      "        disease following first line chemotherapy Patients receiving concurrent hormonal therapy\n",
      "        are eligible Patients with bone metastases as the only site of disease are eligible No\n",
      "        known brain metastases (patients with stable brain metastases for greater than 6 months\n",
      "        may be allowed if not on concurrent corticosteroids) No locoregional disease as the only\n",
      "        evidence of metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Neutrophil\n",
      "        count at least 1,000/mm3 Platelet count at least 75,000/mm3 Hemoglobin at least 9 g/dL\n",
      "        Hepatic: SGOT or SGPT no greater than 2.0 times upper limit of normal (ULN) (less than 5\n",
      "        times ULN with liver metastases) Bilirubin no greater than 2.0 times ULN Renal: Creatinine\n",
      "        no greater than 2.0 times ULN Cardiovascular: No significant cardiac disease No myocardial\n",
      "        infarction within 1 year of study No uncontrolled arrhythmias No uncontrolled hypertension\n",
      "        No congestive heart failure Pulmonary: Not specified Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception Negative pregnancy test No prior\n",
      "        malignancies within the past 5 years, except: Curatively treated nonmelanoma skin cancer\n",
      "        Carcinoma in situ of the cervix No autoimmune disease (e.g., systemic lupus erythematosus,\n",
      "        ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis,\n",
      "        rheumatoid arthritis) No immunodeficiency disease (cellular immunodeficiencies,\n",
      "        hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital\n",
      "        immunodeficiencies) Controlled Type II diabetes allowed No clinically significant active\n",
      "        infection No known allergy to shellfish No known allergy to soy beans and/or soy products\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior interferons,\n",
      "        tumor necrosis factor, other cytokines or biologic response modifiers, BCG vaccines, or\n",
      "        therapeutic monoclonal antibodies Chemotherapy: See Disease Characteristics Must have\n",
      "        completed first line chemotherapy for metastatic disease At least 3 weeks since prior\n",
      "        chemotherapy Endocrine therapy: No concurrent corticosteroid, cyclosporine, or\n",
      "        adrenocorticotropic hormone therapy Radiotherapy: At least 3 weeks since radiation therapy\n",
      "        Surgery: At least 4 weeks since prior surgery requiring general anesthetic No splenectomy\n",
      "        Other: At least 4 weeks since other investigational drugs Concurrent bisphosphonate\n",
      "        therapy allowed provided therapy was initiated more than 3 weeks prior to study\n",
      "2973\n",
      "DISEASE CHARACTERISTICS: Immunologically diagnosed Waldenstrom's macroglobulinemia (WM)\n",
      "        Evaluable quantifiable IgM One of the following criteria must be met: 1) Patient\n",
      "        demonstrates clinical symptoms such as fatigue, dizziness, visual inacuity, or hemorrhagic\n",
      "        manifestations of WM with anemia, hyperviscosity, thrombocytopenia, or coagulopathies 2)\n",
      "        Advanced tumor mass present involving ONE of the following: Extensive lymphadenopathy\n",
      "        (greater than 2 cm) Hepato or splenomegaly palpable on clinical examination Marked bone\n",
      "        marrow infiltration greater than 50% 3) Progressive disease; i.e., increase in IgM\n",
      "        concentration by at least 50%, and/or a drop of greater than 2 g/dL in hemoglobin (in the\n",
      "        absence of gastrointestinal bleeding), and/or a greater than 50,000/mm3 decrease in\n",
      "        platelets\n",
      "        PATIENT CHARACTERISTICS: Age: Under 70 Performance status: SWOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not\n",
      "        specified Cardiovascular: At least 6 months since myocardial infarction No congestive\n",
      "        heart failure No arrhythmia refractory to therapy Ejection fraction within normal range by\n",
      "        MUGA or ECHO Pulmonary: FEV1 at least 50% of predicted DLCO at least 50% of predicted\n",
      "        Other: Not pregnant or nursing Effective contraception required of fertile patients No\n",
      "        significant comorbid condition No uncontrolled life-threatening infection No uncontrolled\n",
      "        diabetes No other malignancy within past 5 years except adequately treated basal or\n",
      "        squamous cell skin cancer, carcinoma in situ of the cervix or adequately treated stage I\n",
      "        or II cancer currently in remission HIV negative Hepatitis B surface antigen negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 4\n",
      "        weeks since radiotherapy and recovered Surgery: Not specified\n",
      "2974\n",
      "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with\n",
      "        at least 25% oligodendroglial elements Recurrent or progressive disease following\n",
      "        radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT\n",
      "        scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits\n",
      "        from the present recurrence No new neurological deficits interfering with daily activities\n",
      "        No tumor causing midline shift or brain stem compression due to which a rapid\n",
      "        deterioration is to be expected in case of no response No signs of increased intracranial\n",
      "        pressure No extracranial disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN)\n",
      "        AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN\n",
      "        Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN\n",
      "        Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception No other malignant or nonmalignant diseases interfering\n",
      "        with follow-up No psychological, familial, sociological, or geographical condition\n",
      "        potentially hampering compliance with the study and follow-up\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics\n",
      "        Surgery: Not specified Other: No other concurrent investigational drugs No other\n",
      "        concurrent antitumor agents\n",
      "2975\n",
      "DISEASE CHARACTERISTICS: Pathologically proven advanced solid tumors for which no standard\n",
      "        therapy exists or that has progressed or recurred following prior therapy Measurable or\n",
      "        evaluable disease No hematological malignancies (e.g., leukemia or lymphoma) No known\n",
      "        brain or leptomeningeal disease, unless lesions were previously irradiated, currently not\n",
      "        being treated with corticosteroids, and have no clinical symptoms\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin less than 1.5 mg/dL AST\n",
      "        or ALT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if\n",
      "        due to tumor) PT and aPTT no greater than 1.5 times ULN Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: No unstable atrial or\n",
      "        ventricular arrhythmias that require medication No ischemic events within 6 months Other:\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No psychiatric disorders No history of seizure disorders No other severe\n",
      "        concurrent disease No history of ulcers or abnormalities that would interfere with\n",
      "        carbendazim absorption No history of hypersensitivity to PEG-formulated medications\n",
      "        (including cyclosporine or etoposide)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin) and recovered No\n",
      "        concurrent cytotoxic therapy Endocrine therapy: Not specified Radiotherapy: At least 4\n",
      "        weeks since prior radiotherapy Surgery: No prior gastrointestinal surgery that would\n",
      "        interfere with carbendazim absorption Other: No concurrent use of phenytoin,\n",
      "        phenobarbital, valproic acid, or other antiepileptic prophylaxis No concurrent scheduled\n",
      "        antacids, such as H2 blockers (e.g., cimetidine or ranitidine) or hydrogen pump inhibitors\n",
      "        (e.g., omeprazole), or cisapride\n",
      "2979\n",
      "DISEASE CHARACTERISTICS: Histologically proven unresectable primary or metastatic\n",
      "        hepatocellular carcinoma Measurable disease by CT or MRI scan No tense ascites Brain\n",
      "        metastases allowed with proper treatment\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Zubrod\n",
      "        0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Albumin at least 3 g/dL Alkaline phosphatase no greater than 3 times upper limit of normal\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No significant infection Peripheral neurologic\n",
      "        toxicity limited to paresthesia and decreased vibratory sense without motor weakness\n",
      "        allowed Constipation managed with laxatives without evidence of bowel obstruction allowed\n",
      "        No psychological disorders including delirium, confusion, suicidal ideation, or untreated\n",
      "        depression\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: Prior palliative radiotherapy\n",
      "        allowed At least 3 weeks since prior radiotherapy and recovered Surgery: Recovered from\n",
      "        any prior surgery\n",
      "2980\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced,\n",
      "        unresectable carcinoma of the biliary tree or pancreas Metastatic disease allowed on a\n",
      "        case by case basis provided the following criteria exists: Minimal or low volume disease\n",
      "        Need for palliative radiotherapy to primary tumor with or without motexafin gadolinium No\n",
      "        requirement for systemic therapy Measurable disease in at least 2 dimensions No ascites\n",
      "        requiring therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 No history of glucose-6-phosphate dehydrogenase deficiency Hepatic:\n",
      "        Bilirubin no greater than 2.0 mg/dL AST and ALT less than 3 times upper limit of normal\n",
      "        Renal: Creatinine no greater than 1.6 mg/dL Other: Not pregnant or nursing Negative\n",
      "        pregnancy test Fertile patients must use effective contraception No history of porphyria\n",
      "        No active infection No physical or psychological illness that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No\n",
      "        prior radiotherapy to primary site of tumor Surgery: See Disease Characteristics At least\n",
      "        3 weeks since prior major surgery Other: At least 4 weeks since prior investigational\n",
      "        drugs No other concurrent investigational antineoplastic drugs\n",
      "2981\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage IV breast cancer presenting as\n",
      "        primary metastatic disease or with recurrence after an initial diagnosis of localized\n",
      "        disease Enrollment in protocol for high dose chemotherapy with stem cell rescue using the\n",
      "        \"STAMP V\" regimen (cyclophosphamide, thiotepa, and carboplatin) No enrollment in research\n",
      "        transplant protocol whose primary endpoint is response duration or recovery time from\n",
      "        toxic effects No brain or CNS metastases Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 80-100% Life expectancy: At least 6 months Hematopoietic:\n",
      "        WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater\n",
      "        than 1.5 times normal SGOT no greater than 2.5 times normal Renal: Creatinine no greater\n",
      "        than 1.8 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Systolic ejection\n",
      "        fraction at least 50% No significant cardiovascular disease or cardiac arrhythmia\n",
      "        requiring drug or device intervention Pulmonary: DLCO and FEV1 greater than 50%\n",
      "        Neurologic: No significant peripheral neuropathy or CNS disease Other: Fertile patients\n",
      "        must use effective contraception Not pregnant or lactating Not HIV positive No concurrent\n",
      "        active infections requiring IV antibiotic therapy No significant gastrointestinal bleeding\n",
      "        or uncontrolled peptic ulcer disease No history of inflammatory bowel disease No\n",
      "        clinically significant autoimmune disease No other serious illness or medical condition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics No concurrent chemotherapy Endocrine therapy: No concurrent\n",
      "        corticosteroids Radiotherapy: No concurrent radiotherapy Surgery: Not specified Other: At\n",
      "        least 4 weeks since any investigational drugs No concurrent investigational drugs\n",
      "2982\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent ovarian cancer Failed or relapsed\n",
      "        after cytoreductive surgery followed by a platinum-based chemotherapy regimen Measurable\n",
      "        or evaluable disease Recurrent disease manifested by isolated increased levels of CA-125\n",
      "        and no other evaluable disease eligible if CA-125 is at least 100\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) ALT\n",
      "        and/or AST no greater than 2.5 times ULN Renal: Creatinine no greater than 2 times ULN\n",
      "        Neurological: No evidence of moderate peripheral neuropathy greater than grade 1 Other:\n",
      "        Not pregnant Fertile patients must use effective contraception No medical, social, or\n",
      "        psychological factors interfering with compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior IM-862 No concurrent biologic therapy\n",
      "        (e.g., interleukin-2 and interferons) Chemotherapy: See Disease Characteristics Recovered\n",
      "        from prior chemotherapy No concurrent antineoplastic cytotoxic agents Endocrine therapy:\n",
      "        Not specified Radiotherapy: Recovered from prior radiotherapy Surgery: See Disease\n",
      "        Characteristics Recovered from prior surgery Other: No other concurrent investigational\n",
      "        drugs\n",
      "2983\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited stage small\n",
      "        cell lung cancer Includes disease restricted to one hemithorax with regional lymph node\n",
      "        metastases, including hilar, ipsilateral and contralateral mediastinal lymph nodes\n",
      "        Clinically suspected or confirmed supraclavicular lymph node metastases and pleural\n",
      "        effusions that are visible on plain chest radiographs, whether cytologically positive or\n",
      "        not, are not eligible Unidimensionally or bidimensionally measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 2 times upper limit of\n",
      "        normal (ULN) Renal: Creatinine no greater than ULN Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No concurrent active second malignancy except\n",
      "        nonmelanoma skin cancer (i.e., completed therapy and considered to be at less than 30%\n",
      "        risk of relapse)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for small cell lung cancer No other concurrent chemotherapy Endocrine\n",
      "        therapy: No concurrent steroids except for adrenal failure No concurrent hormones except\n",
      "        for nondisease related conditions (e.g., insulin for diabetes) No concurrent dexamethasone\n",
      "        except for intermittent use as an antiemetic or as an adjunct to prophylactic cranial\n",
      "        irradiation Radiotherapy: No prior mediastinal radiotherapy Surgery: Not specified\n",
      "2984\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed low grade (grade 1 or 2), superficial\n",
      "        (stage Ta or T1) transitional cell carcinoma (TCC) of the bladder Newly diagnosed or\n",
      "        recurrent All visible tumor must have been resected within the past 12 weeks Standard\n",
      "        clinical management determined to be expectant observation without further surgery,\n",
      "        intravesical therapy, or systemic therapy No prior upper tract TCC No history of grade 3\n",
      "        TCC, carcinoma in situ including severe dysplasia, non-TCC histology, or TCC greater than\n",
      "        or equal to T2 No involvement of upper urinary tract prior to or at the time of initial\n",
      "        tumor resection Abdominal CT scan, IVP, or retrograde pyelogram within the past 3 months\n",
      "        to rule out upper urinary tract tumor\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception No prior malignancy within the past 5 years and no concurrent\n",
      "        malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix No\n",
      "        clinically significant hearing loss (i.e., hearing loss effects everyday life and/or wears\n",
      "        a hearing aide) No other significant medical or psychiatric condition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior growth factors No\n",
      "        concurrent growth factors Chemotherapy: No prior systemic chemotherapy for bladder cancer\n",
      "        No concurrent intravesical therapy At least 4 weeks since prior chemotherapy No concurrent\n",
      "        chemotherapy Endocrine therapy: At least 4 weeks since prior high dose steroids or\n",
      "        prednisone No concurrent high dose steroids No concurrent prednisone or its equivalent in\n",
      "        excess of 10 mg/day Radiotherapy: No prior radiotherapy for bladder cancer At least 4\n",
      "        weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease\n",
      "        Characteristics Other: At least 4 weeks since prior carbamazepine or experimental drugs No\n",
      "        concurrent carbamazepine or experimental drugs\n",
      "2987\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or locally\n",
      "        advanced solid tumors that have failed standard therapy or for which no standard therapy\n",
      "        exists Measurable or evaluable disease No active, symptomatic brain metastases No\n",
      "        leukemia, lymphoma, or multiple myeloma No significant pleural or peritoneal effusions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than 1.5\n",
      "        times upper limit of normal (ULN) AST and ALT no greater than 3 times ULN (no greater than\n",
      "        5 times ULN if due to liver disease) Albumin at least 2.0 g/dL Renal: Not specified Other:\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception during and for 3 months after study No active infection or serious\n",
      "        concurrent systemic disorders No second primary malignancy in the past 5 years except\n",
      "        carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin No\n",
      "        body surface area greater than 3 m2\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No concurrent\n",
      "        routine use of filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered No other\n",
      "        concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy (except\n",
      "        contraceptives and corticosteroids) Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy (including wide field pelvic radiation) No concurrent radiotherapy Surgery:\n",
      "        Not specified Other: At least 4 weeks since prior investigational agents Concurrent\n",
      "        warfarin and heparin allowed No aspirin and other nonsteroidal antiinflammatory 2 days\n",
      "        before, the day of, and 2 days after LY231514 administration (5 days for long-acting\n",
      "        agents) No concurrent nonsteroidal antiinflammatory drugs or salicylates with a long\n",
      "        half-life e.g., naproxen, piroxicam, diflunisal, or nabumetone) No other concurrent\n",
      "        experimental medications No concurrent dialysis\n",
      "2988\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven metastatic pancreatic cancer with overexpression of HER2/neu\n",
      "          -  Patients in whom there is inadequate tissue to evaluate for HER2/neu overexpression\n",
      "             but who have elevated serum HER2/neu antigen levels are eligible\n",
      "          -  Radiographically measurable disease\n",
      "               -  May have metastatic disease in which primary lesion is measurable but metastatic\n",
      "                  lesions are not measurable\n",
      "               -  Ascites is not measurable\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 3.0 mg/dL\n",
      "               -  Greater than 3 times normal if increase in bilirubin is due to biliary\n",
      "                  obstruction from tumor as long as biliary system is stented or bypassed and\n",
      "                  bilirubin, SGOT, or SGPT is stable or decreasing\n",
      "          -  SGOT no greater than 3 times normal\n",
      "               -  No greater than 5 times normal if liver metastases present OR\n",
      "               -  Greater than 5 times normal if increase in SGOT or SGPT is due to biliary\n",
      "                  obstruction from tumor as long as biliary system is stented or bypassed and\n",
      "                  biliary SGOT or SGPT is stable or decreasing\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No unstable angina\n",
      "          -  No prior congestive heart failure\n",
      "          -  No prior myocardial infarction\n",
      "          -  LVEF at least 45% by MUGA or echocardiogram\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior trastuzumab\n",
      "          -  No concurrent growth factors\n",
      "        Chemotherapy:\n",
      "          -  No prior anthracyclines\n",
      "          -  No prior gemcitabine except prior low dose (no greater than 300 mg/m2/week)\n",
      "             gemcitabine with radiotherapy\n",
      "          -  At least 6 months since prior adjuvant therapy\n",
      "          -  More than 2 weeks since other prior chemotherapy\n",
      "          -  No other concurrent cytotoxic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Chemotherapy\n",
      "          -  More than 2 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent investigational agents\n",
      "2989\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced or\n",
      "        metastatic or solid tumors refractory to standard therapy or for which no standard therapy\n",
      "        exists (surgery, radiotherapy, and/or chemotherapy) Measurable or evaluable disease by\n",
      "        medical photograph, plain x-ray, CT, MRI, palpation, or serum tumor markers at least 2\n",
      "        times upper limit of normal No asymptomatic brain metastases No leukemia, lymphoma, or\n",
      "        multiple myeloma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL No coagulation disorders Hepatic:\n",
      "        Bilirubin normal AST and ALT no greater than 3 times upper limit of normal (ULN) (no\n",
      "        greater than 5 times ULN if liver involvement) Renal: Creatinine less than 1.5 mg/dL\n",
      "        Creatinine clearance at least 45 mL/min Cardiovascular: No cardiac conduction\n",
      "        abnormalities Other: Not pregnant or nursing Negative pregnancy test Fertile patients must\n",
      "        use effective contraception No active infection No concurrent serious systemic disorders\n",
      "        No concurrent or recent (within past 6 months) small bowel obstruction, symptoms of small\n",
      "        bowel obstruction, or any other gastrointestinal disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No concurrent\n",
      "        filgrastim (G-CSF) Chemotherapy: See Disease Characteristics At least 3 weeks since prior\n",
      "        chemotherapy and recovered No prior SR-45023A No other concurrent chemotherapy Endocrine\n",
      "        therapy: No concurrent hormonal cancer therapy (except contraception, hormone replacement\n",
      "        therapy, and corticosteroids) Radiotherapy: See Disease Characteristics Prior radiotherapy\n",
      "        allowed to less than 25% of the bone marrow and recovered No prior radiotherapy to the\n",
      "        whole pelvis No concurrent radiotherapy Surgery: See Disease Characteristics Other: At\n",
      "        least 4 weeks since prior investigational agents No other concurrent investigational\n",
      "        agents No concurrent anticoagulation therapy (e.g., Coumadin or heparin) No concurrent\n",
      "        digoxin, beta blockers, or calcium channel blockers\n",
      "2990\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic adenocarcinoma of the breast\n",
      "          -  Measurable disease outside previously irradiated area or occurred/progressed after\n",
      "             completion of radiotherapy\n",
      "          -  Must have received 1 or 2 prior chemotherapy regimens for metastatic disease\n",
      "               -  More than 3 prior regimens allowed\n",
      "          -  No active brain metastases or meningeal breast cancer involvement\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Sex:\n",
      "          -  Male or female\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT or SGPT no greater than 3 times ULN (5 times ULN for liver metastases)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No history of myocardial infarction or unstable angina within the past 6 months\n",
      "          -  No uncontrolled congestive heart failure\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Prior diagnosis of cancer allowed (must be off cancer therapy and have no evidence of\n",
      "             disease)\n",
      "          -  No history of retinopathy and/or macular degeneration\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Chemotherapy:\n",
      "          -  No prior irofulven\n",
      "2991\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed colorectal adenocarcinoma\n",
      "          -  Primary colorectal tumor must have been previously resected\n",
      "          -  Potentially completely resectable hepatic metastases (or removable by cryoresection)\n",
      "             without current evidence of other metastatic disease\n",
      "          -  No extrahepatic sites of disease\n",
      "          -  No ascites or hepatic encephalopathy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  No active infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the liver\n",
      "          -  At least 4 weeks since prior radiotherapy to the pelvis\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "2992\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced and/or\n",
      "        metastatic solid tumors for which no standard therapy is available No known CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: Hemoglobin at least 9 g/dL WBC at least\n",
      "        3,000/mm3 Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) ALT and/or AST no\n",
      "        greater than 2.5 times ULN (no greater than 4.0 times ULN if liver or bone metastasis\n",
      "        present) Alkaline phosphatase no greater than 2.5 times ULN (no greater than 4.0 times ULN\n",
      "        if liver or bone metastasis present) Renal: Creatinine no greater than 1.5 times ULN OR\n",
      "        Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception No history of other serious medical conditions\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks since mitomycin or\n",
      "        nitrosoureas) Endocrine therapy: At least 4 weeks since prior hormonal therapy Concurrent\n",
      "        antiandrogen therapy allowed Radiotherapy: At least 4 weeks since prior extended field\n",
      "        radiotherapy Surgery: Not specified\n",
      "2993\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven hairy cell leukemia (HCL)\n",
      "               -  Classic HCL\n",
      "                    -  Hairy cells in the bone marrow and/or peripheral blood which co-express\n",
      "                       CD20/CD25 or CD20/CD11c, and/or which are positive for tartrate resistant\n",
      "                       acid phophatase (TRAP)\n",
      "               -  Prolymphocytic HCL variant\n",
      "                    -  Lymphoid cells in the bone marrow and/or peripheral blood with morphology\n",
      "                       intermediate between typical hairy cells and prolymphocytes, which\n",
      "                       co-express CD20/CD11c but lack CD25 expression, and which are negative for\n",
      "                       TRAP\n",
      "          -  Progressive or recurrent disease after prior treatment with cladribine\n",
      "               -  Greater than 1 month since standard dose cladribine OR\n",
      "               -  Greater than 3 months since low dose cladribine\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.3 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No serious cardiac disease\n",
      "        Other:\n",
      "          -  No acute or chronic infection\n",
      "          -  HIV negative\n",
      "          -  No psychosis\n",
      "          -  Not pregnant or nursing\n",
      "          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or\n",
      "             basal cell or squamous cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Recovered from prior therapy\n",
      "          -  No concurrent cytoreductive therapy\n",
      "2994\n",
      "DISEASE CHARACTERISTICS: Histologically proven supratentorial grade IV astrocytoma\n",
      "        (glioblastoma multiforme)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 2 months Hematopoietic: WBC at least 3000/mm3 Absolute neutrophil\n",
      "        count at least 1500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10.0 g/dL\n",
      "        No serious blood dyscrasias Hepatic: Bilirubin no greater than 2.0 mg/dL AST and ALT no\n",
      "        greater than 4 times upper limit of normal (ULN) Albumin at least 3.0 g/dL PT and PTT no\n",
      "        greater than 1.5 times ULN No liver failure Renal: Creatinine no greater than 1.7 mg/dL OR\n",
      "        BUN no greater than 40 mg/dL No renal failure Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No serious infection No concurrent serious\n",
      "        medical illness No allergy to penicillin or history of serious reaction to penicillamine\n",
      "        No prior malignancy within the past 5 years except curatively treated carcinoma in situ or\n",
      "        basal cell skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy for brain tumor No\n",
      "        prior biologic therapy for brain tumor, including: Immunotoxins Immunoconjugates Antisense\n",
      "        Peptide receptor antagonists Interferons Interleukins Tumor infiltrating lymphocytes\n",
      "        Lymphokine activated killer cells Gene therapy No concurrent growth factors (e.g.,\n",
      "        filgrastim or epoetin alfa) Chemotherapy: No prior chemotherapy for brain tumor Endocrine\n",
      "        therapy: Must be on stable corticosteroid regimen for at least 1 week (at least 5 days) No\n",
      "        other prior hormonal therapy for brain tumor Radiotherapy: No prior radiotherapy for brain\n",
      "        tumor Surgery: Recovered from prior surgery Other: No concurrent investigational agents No\n",
      "        concurrent gold compounds (auronofin, gold sodium thiomalate) No concurrent herbal dietary\n",
      "        supplements\n",
      "2995\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer No CNS\n",
      "        metastases No rapidly progressing visceral disease Previously irradiated lesions(s) may be\n",
      "        designated as measurable indicator tumor(s) only if more than 6 months since radiotherapy,\n",
      "        patient has no other measurable disease regrowth, and bidimensionally measurable regrowth\n",
      "        is documented within 2 months prior to study Stratum 1 (hormonal): Must be hormone\n",
      "        receptor positive (ER or PR) Prior hormonal therapy only allowed for metastatic disease\n",
      "        Must have progressed on last hormonal regimen Must have at least one bidimensionally\n",
      "        measurable tumor Stratum 2 (chemotherapy): Hormone receptor positive or negative Must have\n",
      "        progressed on or after prior chemotherapy (1-2 regimens) for metastatic disease (bone\n",
      "        marrow transplant counts as 2 regimens) Prior hormonal therapy allowed Must have at least\n",
      "        one bidimensionally measurable tumor Stratum 3 (tamoxifen): Must be hormone receptor\n",
      "        positive (ER or PR) and progressing on tamoxifen No symptomatic visceral metastasis if on\n",
      "        adjuvant tamoxifen at time of systemic recurrence Must have at least one bidimensionally\n",
      "        measurable tumor, or lytic bone lesion which measures at least one cm in diameter Hormone\n",
      "        receptor status: See above\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Menopausal status: Not specified Performance status:\n",
      "        ECOG 0-2 OR Karnofsky 60-100% Life expectancy: At least 3 months Hematopoietic: WBC at\n",
      "        least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Fasting triglycerides within normal range Hepatic: Bilirubin no greater than\n",
      "        1.5 times upper limit of normal (ULN) SGOT and/or SGPT no greater than 2.5 times ULN\n",
      "        Concurrent medication with drugs that significantly alter hepatic metabolism (e.g.,\n",
      "        phenobarbital, phenytoin, oral azole antifungals) allowed only if dosage stable Renal:\n",
      "        Creatinine less than 2 times ULN OR Creatinine clearance greater than 40 mL/min Concurrent\n",
      "        medication with drugs that significantly alter renal metabolism (e.g., probenecid) allowed\n",
      "        only if dosage stable Other: At least 5 years since any other prior invasive malignancy\n",
      "        except basal cell and squamous cell carcinoma of the skin No serious concurrent illness\n",
      "        that would prevent compliance No history of or clinically significant risk factors for\n",
      "        developing pancreatitis Fasting triglycerides within normal range Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior monoclonal antibody HER2 therapy for\n",
      "        metastatic disease allowed only if combined with chemotherapy or hormonal therapy and\n",
      "        treatment failed No concurrent immunotherapy Chemotherapy: See Disease Characteristics At\n",
      "        least 4 weeks since prior cytotoxic chemotherapy (at least 6 weeks since prior mitomycin\n",
      "        or nitrosourea) No prior retinoid therapy for breast cancer At least 3 months since any\n",
      "        other prior retinoid therapy except topical application for dermatological indications No\n",
      "        concurrent chemotherapy Endocrine therapy: See Disease Characteristics At least 2 weeks\n",
      "        since prior non-FDA approved hormonal therapy No other concurrent hormonal therapy except\n",
      "        chronic low dose hormone replacement therapy or low dose corticosteroids for noncancer\n",
      "        indication Radiotherapy: See Disease Characteristics Prior radiotherapy allowed Concurrent\n",
      "        radiotherapy allowed only to non-indicator tumor(s) that do not represent new disease or\n",
      "        disease progression Surgery: Prior surgery allowed Other: At least one month since prior\n",
      "        investigational therapy (except hormonal) No other concurrent investigational therapy\n",
      "        Concurrent medication with drugs that significantly alter hepatic metabolism (e.g.,\n",
      "        phenobarbital, phenytoin, oral azole antifungals) allowed only if dosage stable No more\n",
      "        than 15,000 IU of vitamin A consumed daily\n",
      "2996\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumors for which no\n",
      "        standard therapy exists or that is persistent or recurrent following prior therapy\n",
      "        Measurable or evaluable disease No hematologic malignancies (e.g., leukemia or lymphoma)\n",
      "        No known brain or leptomeningeal disease (unless lesions have been irradiated, are\n",
      "        currently untreated with corticosteroids, and have no clinical symptoms)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Karnofsky 70-100%\n",
      "        Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic:\n",
      "        Bilirubin less than 1.5 times upper limit of normal (ULN) AST and ALT less than 3 times\n",
      "        ULN Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min\n",
      "        Calcium no greater than 12 mg/dL Cardiovascular: No myocardial infarction within 6 months\n",
      "        No congestive heart failure requiring therapy No unstable angina Other: Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception No\n",
      "        active infection No other concurrent severe disease No psychiatric disorders No history of\n",
      "        seizure disorders No uncontrolled diabetes (blood sugar no greater than 200 mg/dL)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        and recovered Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No\n",
      "        prior mitomycin, irinotecan, or nitrosoureas No more than 6 courses of chemotherapy\n",
      "        containing an alkylating agent No more than 4 courses of carboplatin Endocrine therapy: At\n",
      "        least 4 weeks since prior endocrine therapy and recovered Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy and recovered No prior radiotherapy to more than 20% of bone\n",
      "        marrow No prior whole pelvis radiotherapy Surgery: Not specified Other: No concurrent\n",
      "        phenytoin, phenobarbital, valproic acid, or other antiepileptic prophylaxis No concurrent\n",
      "        warfarin\n",
      "2997\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven pediatric malignancy,\n",
      "        except when there is appearance consistent with brainstem tumor on MRI, a tumor marker\n",
      "        positive for germ cell tumor, or ophthalmologic diagnosis of intraocular retinoblastoma\n",
      "        Failed conventional treatment or conventional therapy is not available Measurable disease\n",
      "        by MRI, CT scan, biochemical tumor markers, cytology, or bone marrow examination\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Lansky 60-100% OR\n",
      "        Karnofsky 60-100% Life expectancy: At least 6 weeks Hematopoietic: Absolute neutrophil\n",
      "        count at least 750/mm3 (between 300-750/mm3, if due to bone marrow infiltration by\n",
      "        malignancy) Platelet count at least 75,000/mm3 (between 20,000-75,000/mm3, if due to bone\n",
      "        marrow infiltration by malignancy) Hepatic: Bilirubin less than 2.0 mg/dL ALT less than 3\n",
      "        times upper limit of normal (ULN) Renal: Creatinine less than 2 times ULN OR Creatinine\n",
      "        clearance at least 70 mL/min Neurologic: No peripheral neuropathy grade 3 or 4 No seizure\n",
      "        disorder in patients without CNS malignancies Other: Not pregnant or nursing Negative\n",
      "        pregnancy tests during study and for 1 month after final dose of thalidomide Fertile\n",
      "        patients must use effective contraception during and for at least 1 month after study\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No limit on the number of prior\n",
      "        agents or regimens received Biologic therapy: Prior bone marrow transplantation allowed\n",
      "        Chemotherapy: Recovered from prior chemotherapy No prior thalidomide Endocrine therapy:\n",
      "        Not specified Radiotherapy: Not specified Surgery: At least 4 weeks since prior major\n",
      "        surgery (2 weeks for minor surgery, excluding central venous catheter placement\n",
      "        procedures)\n",
      "2998\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer\n",
      "        Squamous cell lung cancer Large cell lung cancer Adenocarcinoma lung cancer Mixture of\n",
      "        above Locally advanced disease for which the patient declined aggressive treatment or that\n",
      "        is unsuitable for aggressive curative treatment due to at least one of the following:\n",
      "        Performance status of ECOG 2 or 3 Otherwise unexplained weight loss greater than 10% in\n",
      "        the last 6 months Bulky disease that cannot be irradiated safely to high doses Inability\n",
      "        to tolerate chemotherapy Cytologically positive pleural effusion OR Clinically or\n",
      "        radiologically proven metastatic disease for which palliative chemotherapy is not planned\n",
      "        in the first 38 days after radiotherapy No more than one brain metastasis allowed One of\n",
      "        the following symptoms identified as the index symptom: Loss of appetite Nausea Vomiting\n",
      "        Cough Coughing up blood Chest pain Shortness of breath Difficulty swallowing Fatigue Must\n",
      "        have symptoms related to intrathoracic lung cancer that are amenable to radiation\n",
      "        palliation\n",
      "        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-3 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Other: Fluent in English or French No loss of sight or other inability to\n",
      "        complete questionnaires or diary Not pregnant No concurrent terminal illness No other\n",
      "        active malignancy that is causing symptoms or is expected to progress in the next 3 months\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 30 days\n",
      "        since prior chemotherapy and failed No planned chemotherapy within 38 days after study\n",
      "        treatment Endocrine therapy: Not specified Radiotherapy: No planned laser therapy within\n",
      "        38 days after study treatment Surgery: At least 30 days since prior surgery and failed\n",
      "        Other: No planned photodynamic therapy or sclerotherapy within 38 days after study\n",
      "        treatment\n",
      "2999\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Pathologically proven advanced cancer for which no curative therapy exists\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "          -  Hemoglobin greater than 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  SGOT and SGPT no greater than 2 times upper limit of normal (ULN) (no greater than 5\n",
      "             times ULN if liver metastases present)\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "        Other:\n",
      "          -  Unassisted oral or enteral intake sufficient to maintain a reasonable state of\n",
      "             nutrition\n",
      "          -  No concurrent medical condition that is likely to interfere with study participation\n",
      "          -  No active visual disturbances that require intervention beyond corrective lenses\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior bone marrow transplantation\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
      "          -  No prior high dose chemotherapy with bone marrow or stem cell rescue\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormone therapy (except megestrol acetate)\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  No prior radiotherapy to 25% or more of bone marrow\n",
      "          -  No concurrent radiotherapy (except palliative radiotherapy within the first 28 days\n",
      "             of the study)\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 30 days since prior investigational therapy\n",
      "          -  No concurrent investigational therapy\n",
      "3000\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic melanoma Measurable disease\n",
      "        HLA-A2 01 phenotype No active CNS or hepatic metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Normal CD4 and CD8 T cell numbers by flow\n",
      "        cytometry Lactic dehydrogenase less than 2 times normal Hepatic: No viral hepatitis Renal:\n",
      "        Not specified Cardiovascular: No prior venous thrombosis, angina pectoris, or congestive\n",
      "        heart failure Pulmonary: No prior asthma Immunologic: Positive intradermal skin test for\n",
      "        mumps, histoplasmosis, or streptokinase antigen Immunoglobulin levels normal No prior\n",
      "        autoimmune disease (lupus erythematosus, rheumatoid arthritis, or thyroiditis) No allergy\n",
      "        to tetanus toxoid or influenza vaccine No sensitivity to E. coli drug preparations Other:\n",
      "        Not pregnant or nursing Fertile patients must use effective contraception HIV negative No\n",
      "        active infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior interferon At\n",
      "        least 8 weeks since prior interleukin-2 Chemotherapy: No more than 3 prior courses of\n",
      "        cytotoxic chemotherapy At least 8 weeks since prior chemotherapy Endocrine therapy: No\n",
      "        concurrent corticosteroids Radiotherapy: Not specified Surgery: Not specified Other: No\n",
      "        other concurrent immunosuppressive agents\n",
      "3001\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of one of the following:\n",
      "               -  Severe aplastic anemia as defined by either of the following:\n",
      "                    -  Marrow cellularity (< 25% [or 25-50% cellularity with < 30% of remaining\n",
      "                       cells hematopoietic in origin])\n",
      "                    -  At least 2 of the following abnormal peripheral blood counts:\n",
      "                         -  Reticulocyte count < 1% (corrected for hematocrit)\n",
      "                         -  Platelet count < 20,000/mm^3\n",
      "                         -  Neutrophil count < 500/mm^3\n",
      "               -  Histologically confirmed hematologic malignancy, including any of the following:\n",
      "                    -  Acute leukemia\n",
      "                         -  Resistant or recurrent disease after combination chemotherapy with at\n",
      "                            least one standard regimen OR in first remission and at high risk of\n",
      "                            relapse\n",
      "                         -  Acute myeloid leukemia (AML) (antecedent myelodysplastic syndromes\n",
      "                            [MDS], secondary AML, or high-risk cytogenetic abnormalities)\n",
      "                         -  Acute lymphoblastic leukemia (ALL) (high-risk cytogenetic\n",
      "                            abnormalities)\n",
      "                    -  Chronic myeloid leukemia (CML)\n",
      "                         -  Chronic phase, accelerated phase, or blast phase\n",
      "                    -  Myeloproliferative disorders or MDS, including any of the following:\n",
      "                         -  Myelofibrosis\n",
      "                         -  Polycythemia vera*\n",
      "                         -  Essential thrombocythemia*\n",
      "                         -  Refractory anemia\n",
      "                         -  Refractory anemia with excess blasts\n",
      "                         -  Refractory anemia with excess blasts in transformation\n",
      "                         -  Chronic myelomonocytic leukemia NOTE: * Only if transformed to AML or\n",
      "                            MDS\n",
      "                    -  Lymphoproliferative disease\n",
      "                         -  Recurrent or persistent, symptomatic disease after first-line\n",
      "                            chemotherapy, including any of the following:\n",
      "                              -  Chronic lymphocytic leukemia (CLL) (≥ 20% marrow involvement)\n",
      "                              -  Waldenstrom macroglobulinemia\n",
      "                              -  Low-grade non-Hodgkin lymphoma\n",
      "                    -  Intermediate or high-grade non-Hodgkin lymphoma, meeting 1 of the following\n",
      "                       criteria:\n",
      "                         -  Resistant or recurrent disease after combination chemotherapy with one\n",
      "                            standard regimen\n",
      "                         -  Lymphoblastic lymphoma or small noncleaved cell lymphoma in first\n",
      "                            remission and at high risk of relapse\n",
      "                         -  CNS disease\n",
      "                         -  Bone marrow disease and LDH greater than 300\n",
      "               -  Solid tumor that would otherwise be treated on RPCI-DS-9115 (or equivalent\n",
      "                  autologous stem transplant protocol) AND has a syngeneic donor\n",
      "          -  Autologous bone marrow transplant not possible (or desirable) due to 1 of the\n",
      "             following:\n",
      "               -  History of marrow tumor\n",
      "               -  Inadequate marrow dose\n",
      "               -  Abnormal marrow histology or function prior to storage\n",
      "               -  Thrombocytopenia or leukopenia\n",
      "               -  Marrow cellularity < 20%\n",
      "          -  Histocompatible donor identified\n",
      "               -  Well-matched donor, as defined by 1 of the following:\n",
      "                    -  Family member matched for 5 or 6 HLA specificities (A, B, DR)*\n",
      "                    -  Unrelated donor meeting compatibility criteria of the National Marrow Donor\n",
      "                       Program (matched for HLA A, B, and DRB1 antigens)*\n",
      "                    -  Identical twin sibling\n",
      "               -  If a compatible cord blood donor is identified and there is no suitable\n",
      "                  unrelated donor available, patient may receive cord blood transplant NOTE:\n",
      "                  *Patients ≤ 25 years of age may be singly mismatched at the A or B loci\n",
      "        NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by\n",
      "        PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "        terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol\n",
      "        uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  4 to 70\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2 OR\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Bilirubin < 3 times normal (unless due to disease)\n",
      "          -  Alkaline phosphatase < 3 times normal (unless due to disease)\n",
      "          -  SGOT < 3 times normal (unless due to disease)\n",
      "          -  Hepatitis B surface antigen negative\n",
      "          -  No severe hepatic disease that would preclude study participation\n",
      "        Renal:\n",
      "          -  Creatinine normal\n",
      "          -  Creatinine clearance ≥ 50 mL/min\n",
      "          -  No severe renal disease that would preclude study participation\n",
      "        Cardiovascular:\n",
      "          -  Cardiac ventricular ejection fraction ≥ 50% by MUGA or echocardiogram\n",
      "          -  No uncontrolled or severe cardiovascular disease (e.g., myocardial infarction,\n",
      "             congestive heart failure, symptomatic angina, life threatening arrhythmia, or\n",
      "             hypertension within the past 6 months)\n",
      "        Pulmonary:\n",
      "          -  DLCO or DLVA ≥ 50% predicted (corrected for hemoglobin or alveolar ventilation)\n",
      "        Other:\n",
      "          -  No serious concurrent medical or psychiatric illness\n",
      "          -  No other serious organ dysfunction (unless due to underlying disease), including the\n",
      "             following:\n",
      "               -  Uncontrolled bacterial, viral, or fungal infection\n",
      "               -  Uncontrolled peptic ulcer disease\n",
      "               -  Uncontrolled diabetes mellitus\n",
      "          -  HIV negative\n",
      "          -  Cytomegalovirus status known\n",
      "          -  Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  Pretransplant cytoreductive chemotherapy allowed for patients with relapsed or\n",
      "             refractory disease\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not eligible for total-body irradiation if prior radiotherapy exceeded the following\n",
      "             limits:\n",
      "               -  Mediastinum: 3,600 cGy\n",
      "               -  Heart: 3,600 cGy\n",
      "               -  Whole lungs: 1,200 cGy\n",
      "               -  Small bowel: 3,600 cGy\n",
      "               -  Kidneys: 1,200 cGy\n",
      "               -  Whole liver: 1,600 cGy\n",
      "               -  Cranial spinal: 3,600 cGy\n",
      "               -  Brain: 4,000 cGy\n",
      "               -  Retina: 4,000 cGy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "3003\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic breast cancer\n",
      "          -  At least 1 line of prior chemotherapy for metastatic disease (adjuvant or neoadjuvant\n",
      "             chemotherapy is considered first line if completed less than one year prior to\n",
      "             palliative chemotherapy)\n",
      "          -  No cerebral metastases\n",
      "          -  Hormonal receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm ^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)\n",
      "          -  AST/ALT no greater than 2.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.58 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No clinically significant cardiac insufficiency or ischemic disease\n",
      "        Pulmonary:\n",
      "          -  No bronchoconstriction other than pulmonary lymphangitis\n",
      "        Other:\n",
      "          -  No serious chronic disease\n",
      "          -  No bowel obstruction\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent immunotherapy\n",
      "          -  No concurrent prophylactic growth factor\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy\n",
      "          -  No prior high-dose chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormonal therapy\n",
      "          -  No concurrent steroid therapy except in an emergency\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy (for primary tumor or axillary or mammary\n",
      "             chain treatment only)\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent antitumor therapy\n",
      "3005\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck that is incurable with surgery or radiotherapy No nasopharyngeal primaries Measurable\n",
      "        or evaluable disease Newly diagnosed with extensive, incurable local regional disease AND\n",
      "        distant metastases OR Local regional recurrence/persistence or distant metastases after\n",
      "        surgery or radiotherapy Persistent or progressive disease after radiotherapy must be\n",
      "        histologically proven at least 8 weeks after therapy No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusion allowed) Hepatic: Bilirubin\n",
      "        no greater than 1.5 mg/dL SGOT and SGPT no greater than 2 times upper limit of normal\n",
      "        (ULN) Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine no greater than\n",
      "        1.2 mg/dL OR Creatinine clearance at least 50 mL/min Calcium no greater than ULN No\n",
      "        history of hypercalcemia Other: No active infection No other concurrent malignancy within\n",
      "        past 2 years except curatively treated basal cell or squamous cell skin cancer or\n",
      "        carcinoma in situ of the cervix No known hypersensitivity to murine proteins Not pregnant\n",
      "        or nursing Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior chimeric antibody or kinase inhibitor\n",
      "        for recurrent or metastatic disease No more than 1 prior biotherapy regimen for recurrent\n",
      "        or metastatic disease Chemotherapy: At least 3 months since prior induction or adjuvant\n",
      "        chemotherapy concurrent with radiotherapy No prior chemotherapy for recurrent disease\n",
      "        Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4\n",
      "        weeks since prior radiotherapy Surgery: See Disease Characteristics Recovered from prior\n",
      "        major surgery\n",
      "3006\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic adenocarcinoma of the breast\n",
      "        Tumor tissue positive for staining with DF3 (CA27-29) and/or DF3-P OR Elevated serum\n",
      "        CA15-3 (CA27-29) May have received no prior treatment or any number of prior regimens for\n",
      "        metastatic disease Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance\n",
      "        status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: WBC greater than\n",
      "        2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL\n",
      "        SGPT less than 4 times upper limit of normal Renal: Creatinine less than 2.0 mg/dL\n",
      "        Immunologic: At least normal delayed type hypersensitivity At least normal CD4:CD8 ratio\n",
      "        (greater than 1) At least normal lymphocyte proliferation to concanavalin A At least\n",
      "        normal immunoglobulin levels No evidence of altered immune responsiveness or autoimmune\n",
      "        syndromes (scleroderma, systemic lupus erythematosus, etc.) If no antivaccinia antibodies,\n",
      "        then must have physician certification of prior vaccinia immunization OR patient\n",
      "        recollection and appropriate vaccination site scar Other: HIV negative No prior or\n",
      "        concurrent extensive skin disorders (e.g., eczema, extensive psoriasis, burns, impetigo,\n",
      "        disseminated zoster) No other serious medical condition that would preclude study\n",
      "        participation No active infection requiring antibiotics Must be able to avoid close\n",
      "        contact with children under 3 years old, pregnant women, individuals with eczema or other\n",
      "        skin conditions, and immunosuppressed people for 2 weeks after each vaccination No\n",
      "        seizures, encephalitis, or multiple sclerosis No allergy to eggs Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior vaccinia virus exposure required No\n",
      "        other concurrent biologic therapy Chemotherapy: See Disease Characteristics At least 3\n",
      "        weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy:\n",
      "        At least 3 weeks since prior hormonal therapy No concurrent steroids or hormonal therapy\n",
      "        Radiotherapy: At least 3 weeks since prior radiotherapy No concurrent radiotherapy\n",
      "        Surgery: No prior splenectomy Other: At least 3 days since prior antibiotics\n",
      "3010\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven metastatic solid tumors\n",
      "        that are refractory to standard therapies or for which no potentially effective therapy\n",
      "        exists No leukemia, lymphoma, or multiple myeloma Measurable or evaluable disease No\n",
      "        pleural or peritoneal effusions No symptomatic brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin normal AST and ALT no\n",
      "        greater than 3 times normal (no greater than 5 times normal if liver involvement present)\n",
      "        Albumin at least 2.5 g/dL Renal: Creatinine clearance at least 45 mL/min Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception during and for 3\n",
      "        months after study No active infection No concurrent serious systemic disorders Body\n",
      "        surface area no greater than 3.0 m2\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: At\n",
      "        least 3 weeks since prior chemotherapy and recovered No prior LY231514 or irinotecan No\n",
      "        greater than 6 prior courses of a regimen containing an alkylating agent (except low dose\n",
      "        cisplatin) No greater than 4 prior courses of a carboplatin-containing regimen No prior\n",
      "        mitomycin No other concurrent chemotherapy Endocrine therapy: No concurrent hormone\n",
      "        therapy (except contraceptives or corticosteroids) Radiotherapy: No prior radiotherapy to\n",
      "        25% or more of the bone marrow No prior radiotherapy to the whole pelvis Recovered from\n",
      "        any prior radiotherapy No concurrent radiotherapy Surgery: Not specified Other: At least 4\n",
      "        weeks since any prior investigational agents No concurrent experimental medications No\n",
      "        aspirin or other nonsteroidal antiinflammatory agents for 2 days prior, the day of, and 2\n",
      "        days after the dose of LY231514 (5 days prior to LY231514 for long acting agents such as\n",
      "        piroxicam)\n",
      "3011\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic cutaneous or ocular melanoma that is chemotherapy\n",
      "             naive\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No pleural effusions or ascites\n",
      "          -  No untreated CNS metastases\n",
      "          -  Stable brain metastases by CT or MRI scan\n",
      "               -  At least 4 weeks since prior steroid therapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase no greater than 2.5 times ULN (unless due to hepatic metastases)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No active infection\n",
      "          -  No known hypersensitivity to E.coli derived proteins\n",
      "          -  No other serious medical problems\n",
      "          -  No more than 1 primary malignancy within past 5 years, other than:\n",
      "               -  Nonmelanomatous skin cancer\n",
      "               -  Carcinoma in situ of the cervix\n",
      "          -  No history of spinal cord compression\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior biologic therapy allowed (e.g., interleukin-2, interferon alfa, or vaccine\n",
      "             therapy)\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  Prior radiotherapy for primary ocular melanoma, brain metastases, or to metastatic\n",
      "             sites encompassing less than 25% of the bone marrow allowed\n",
      "          -  No other prior radiotherapy\n",
      "        Surgery:\n",
      "          -  At least 2 weeks since prior surgery and recovered\n",
      "3012\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic gastrointestinal carcinoma\n",
      "        Measurable disease No CNS metastases No obstruction or partial obstruction of GI tract No\n",
      "        obstruction of genitourinary tract\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 125,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No uncontrolled high blood\n",
      "        pressure, unstable angina, active congestive heart failure, myocardial infarction within\n",
      "        prior 6 months, or serious uncontrolled cardiac arrhythmia Neurological: No concurrent\n",
      "        symptomatic peripheral sensory neuropathy Other: No active or uncontrolled infection Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        cisplatin, oxaliplatin, nitrosoureas, or mitomycin C 1 or 2 prior chemotherapy regimens\n",
      "        allowed (including irinotecan) Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiation therapy to whole pelvis, 30% or greater of bone marrow, and site of measurable\n",
      "        disease At least 4 weeks since prior radiation therapy and recovered Surgery: Not\n",
      "        specified\n",
      "3014\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed glioblastoma multiforme\n",
      "        requiring radical radiotherapy No anaplastic astrocytoma or low-grade astrocytoma Able to\n",
      "        start radiotherapy within 5 weeks of definitive surgery (unless delay due to cause other\n",
      "        than medical illness or poor performance status)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: See Disease Characteristics\n",
      "        Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3\n",
      "        Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: AST and\n",
      "        ALT no greater than 2 times upper limit of normal (ULN) Bilirubin no greater than 2 mg/dL\n",
      "        PT and aPTT no greater than 1.5 times ULN Renal: Creatinine less than 1.5 mg/dL\n",
      "        Cardiovascular: No severe cardiac disease Pulmonary: No severe lung disease Other: No\n",
      "        other significant life-threatening disease No other active malignancy No known\n",
      "        glucose-6-phosphate dehydrogenase deficiency No known porphyria Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No biologic therapy for at least 4 weeks after\n",
      "        study completion No immunotherapy for at least 4 weeks after study completion\n",
      "        Chemotherapy: No chemotherapy for at least 4 weeks after study completion Endocrine\n",
      "        therapy: Concurrent steroids allowed Radiotherapy: See Disease Characteristics No prior\n",
      "        radiotherapy for this disease or other brain tumor No prior radiotherapy to face, head, or\n",
      "        neck Surgery: See Disease Characteristics Recovered from prior surgery or postoperative\n",
      "        complication Other: At least 48 hours since prior MRI scan with contrast No concurrent MRI\n",
      "        scans with contrast No other concurrent experimental drug\n",
      "3015\n",
      "DISEASE CHARACTERISTICS: At diagnosis: Histologically confirmed unilateral adenocarcinoma\n",
      "        of the breast that was considered operable Must have had adequate therapy for primary\n",
      "        disease including chemotherapy/ovarian ablation if appropriate and local postoperative\n",
      "        radiotherapy if the patient received conservative (breast preserving) surgery Must have\n",
      "        remained disease-free after therapy for primary disease Must have been receiving tamoxifen\n",
      "        for minimum of 2 years and maximum of 3 years 1 month with no more than 1 month break at\n",
      "        any one time No inflammatory breast cancer, histologically positive supraclavicular nodes,\n",
      "        or ulceration/infiltration or skin metastases No evidence of local relapse or distant\n",
      "        metastasis (on chest x-ray, scintigraphic bone scanning and liver ultrasonography/CT\n",
      "        scanning) at any time Hormone receptor status: Estrogen receptor positive or unknown\n",
      "        PATIENT CHARACTERISTICS: Age: Postmenopausal as defined below Sex: Female Menopausal\n",
      "        status: Postmenopausal as defined by: 55 years of age and over, and amenorrhea for greater\n",
      "        than 2 years OR Radiation menopause (at least 3 months previously) or surgical\n",
      "        oophorectomy OR Natural amenorrhea for at least 1 year at breast cancer diagnosis\n",
      "        Performance status: Not specified Life expectancy: Not specified Hematopoietic: WBC at\n",
      "        least 4,000/mm3 Hemoglobin normal Hepatic: SGOT no greater than 2.5 times upper limit of\n",
      "        normal (ULN) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No\n",
      "        significant cardiac disorder Other: No significant skeletal or endocrine disorders No\n",
      "        clinical evidence of severe osteoporosis and/or history of osteoporotic fracture No other\n",
      "        prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix No\n",
      "        psychiatric or addictive disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Prior or concurrent bisphosphonates allowed Adjuvant or neoadjuvant\n",
      "        chemotherapy for primary disease allowed Endocrine therapy: At least 4 weeks since prior\n",
      "        hormone replacement therapy (oral, topical, or vaginal) Prior low-dose progestins for\n",
      "        relief of menopausal symptoms (up to 6 months duration) allowed No concurrent progestins\n",
      "        No concurrent systemic corticosteroids for a prolonged period (i.e., greater than 2 weeks)\n",
      "        No concurrent selective estrogen receptor modulators Radiotherapy: See Disease\n",
      "        Characteristics Surgery: See Disease Characteristics Other: Prior participation and\n",
      "        completion of therapy on another clinical study of systemic therapy (e.g., comparison of\n",
      "        chemotherapy schedules) allowed No concurrent warfarin Concurrent treatment for other\n",
      "        diseases allowed only when clinically indicated\n",
      "3017\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven stage IB2, IIA, IIB, IIIB, or IVA invasive carcinoma of the\n",
      "             uterine cervix\n",
      "               -  Any cell type\n",
      "          -  No metastases to para-aortic lymph nodes, scalene nodes, or to other organs outside\n",
      "             the radiation field at time of original staging\n",
      "          -  Study entry required within 8 weeks of diagnosis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  GOG 0-2\n",
      "        Life expectancy:\n",
      "          -  More than 6 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT no greater than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "          -  No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal\n",
      "             transplantation) that would require modification of radiation fields\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  No septicemia or severe infection\n",
      "          -  No other invasive malignancy within the past 3 years except nonmelanomatous skin\n",
      "             cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for this or any prior malignancy\n",
      "        Endocrine therapy:\n",
      "          -  No prior endocrine therapy\n",
      "        Radiotherapy:\n",
      "          -  No prior pelvic or abdominal radiotherapy for this malignancy\n",
      "          -  No prior radiotherapy for any other prior malignancy\n",
      "          -  No more than 1 month interval between surgery and radiotherapy\n",
      "        Surgery:\n",
      "          -  See Radiotherapy\n",
      "        Other:\n",
      "          -  No other prior therapy for this malignancy\n",
      "          -  Stent or nephrostomy tube required if ureteral obstruction present\n",
      "3019\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed renal cell carcinoma and evidence of\n",
      "        metastatic disease Bidimensionally measurable disease No active brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute\n",
      "        neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin\n",
      "        within normal range ALT/AST no greater than 2.5 times upper limit of normal (ULN) Renal:\n",
      "        Creatinine within 1.5 times ULN AND Creatinine clearance at least 50 mL/min Other: Not\n",
      "        pregnant or lactating Fertile patients must use effective contraception No prior\n",
      "        malignancy within 5 years and at low risk for recurrence Must have undergone potentially\n",
      "        curative therapy for prior malignancy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since biological therapy and\n",
      "        recovered Chemotherapy: No prior cytotoxic chemotherapy Endocrine therapy: At least 4\n",
      "        weeks since hormone therapy and recovered Radiotherapy: At least 4 weeks since\n",
      "        radiotherapy Surgery: At least 4 weeks since major surgery\n",
      "3020\n",
      "DISEASE CHARACTERISTICS: Radiological diagnosis of probable high grade glioma, or biopsy\n",
      "        proven high grade glioma, undergoing neurosurgery (biopsy or tumor resection) with\n",
      "        interactive MRI guided control Must have an enhancing cerebral lesion No radiological\n",
      "        diagnosis of metastases due to multiple lesions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 50-100% while on\n",
      "        steroids Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Granulocyte\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Prothrombin time no greater\n",
      "        than 1.5 times upper limit of normal (ULN) Active partial thromboplastin time no greater\n",
      "        than 1.5 times ULN Hepatic: Bilirubin no greater than 2 mg/dL AST and ALT no greater than\n",
      "        2 times ULN Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No severe cardiac\n",
      "        disease Pulmonary: No severe pulmonary disease Other: No other significant life\n",
      "        threatening disease No known glucose-6-phosphate dehydrogenase deficiency or porphyria No\n",
      "        other active malignancy No intractable seizures Not pregnant or nursing Effective\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: Concurrent steroids allowed Radiotherapy: Concurrent radiotherapy\n",
      "        allowed Surgery: See Disease Characteristics Other: At least 48 hours since prior MRI scan\n",
      "        with contrast No concurrent active agent or investigational drug No concurrent use of\n",
      "        other study treatment Concurrent antiseizure medication allowed\n",
      "3022\n",
      "DISEASE CHARACTERISTICS: Surgically debulked stage III or IV ovarian epithelial cancer\n",
      "        Must be able to obtain adequate number of viable cells from excised tumor mass Must have\n",
      "        received 6 courses of combination chemotherapy comprised of either paclitaxel and\n",
      "        cisplatin OR paclitaxel and carboplatin Must be clinically tumor free following completion\n",
      "        of chemotherapy (i.e., no metastasis by physical examination and CT of the abdomen and\n",
      "        pelvis and serum CA-125 less than 35 IU/L) Not on a Phase III GOG protocol\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0 or 1 Hematopoietic:\n",
      "        Hematocrit at least 25% WBC at least 3,000/mm3 Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing No active infections HIV negative Hepatitis B surface\n",
      "        antigen negative Hepatitis C antibody negative No active autoimmune disease No prior\n",
      "        invasive malignancy within the past 5 years except nonmelanomatous skin cancer, carcinoma\n",
      "        in situ of the cervix, or superficial bladder cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics 4-12 weeks since prior chemotherapy Endocrine therapy: No concurrent\n",
      "        systemic corticosteroids Radiotherapy: At least 6 months since prior major field\n",
      "        radiotherapy Surgery: See Disease Characteristics\n",
      "3024\n",
      "Inclusion Criteria:\n",
      "          -  Cytologically confirmed atypical glandular cells of undetermined significance (AGUS)\n",
      "          -  Must be scheduled to undergo complete histologic examination of the cervix by cone\n",
      "             biopsy using loop electrosurgical excision procedure with an endocervical curettage,\n",
      "             excisional cone biopsy with or without endocervical curettage, or hysterectomy within\n",
      "             6 months of the initial cytologic diagnosis of AGUS\n",
      "          -  No history of endometrial hyperplasia\n",
      "          -  No history of cancer of the endometrium, vagina, or cervix\n",
      "          -  HIV negative\n",
      "          -  No pregnant patients who are at high risk for excessive bleeding or preterm labor if\n",
      "             a cone biopsy is performed\n",
      "          -  No prior cytotoxic chemotherapy for vaginal and/or cervical cancer\n",
      "          -  No prior radiotherapy to the vagina or cervix\n",
      "          -  No concurrent radiotherapy to the vagina or cervix\n",
      "          -  No prior hysterectomy\n",
      "3025\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung\n",
      "        cancer, including: Squamous cell carcinoma Adenocarcinoma (including bronchoalveolar cell)\n",
      "        Large cell anaplastic carcinoma (including giant and clear cell carcinomas) Inoperable or\n",
      "        unresectable stage IIIA or IIIB disease of the following stage groupings: T1 N2 M0 or T2\n",
      "        N2 M0 T3 N2 M0 and T4 N0-2 M0 eligible if staging is based on closeness to the carina or\n",
      "        invasion of the mediastinum or chest wall Patients with contralateral mediastinal disease\n",
      "        (N3) or tumors adjacent to but not invading a vertebral body are eligible if all gross\n",
      "        disease can be encompassed in the study radiation boost field Patients with a transudate,\n",
      "        cytologically negative, nonbloody pleural effusion are eligible if the tumor can be\n",
      "        encompassed within a reasonable field of radiotherapy Measurable or evaluable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALBG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte\n",
      "        count at least 1,500/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 2 times\n",
      "        upper limit of normal Renal: Creatinine clearance at least 20 mL/min Other: Not pregnant\n",
      "        or nursing Effective contraception required of fertile patients No active second\n",
      "        malignancy except nonmelanomatous skin cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy No other concurrent chemotherapy Endocrine therapy: No concurrent hormones\n",
      "        except for steroids administered for adrenal failure or septic shock, or hormones\n",
      "        administered for non-disease-related conditions (e.g., insulin for diabetes)\n",
      "        Glucocorticosteroids permitted as antiemetics Radiotherapy: No prior radiotherapy Surgery:\n",
      "        At least 2 weeks since exploratory thoracotomy\n",
      "3029\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Solid organ recipient (kidney, liver, heart, lung, or pancreas) receiving\n",
      "             immunosuppressive agents (e.g., prednisone, other corticosteroid, azathioprine,\n",
      "             cyclosporine, tacrolimus, mycophenolate mofetil)\n",
      "          -  At least 6 months since transplant\n",
      "          -  At least 2 prior (same event or separate events) basal cell carcinomas (BCC) or\n",
      "             squamous cell carcinomas (SCC) resected\n",
      "               -  All visible BCC and SCC resected\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Life expectancy:\n",
      "          -  Greater than 2 years\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3400/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 10.0 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase no greater than 3 times ULN\n",
      "          -  SGOT no greater than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use two effective forms of birth control for at least 1 month\n",
      "             before, during, and at least 3 years after study\n",
      "          -  No history of oral retinoid intolerance\n",
      "          -  No significant, uncontrolled hyperlipidemia\n",
      "          -  No other significant medical condition or threatened allograft rejection state where\n",
      "             retinoid use would be contraindicated\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Other:\n",
      "          -  At least 1 year since prior retinoids\n",
      "          -  No concurrent oral vitamin A supplements, topical retinoids, or other potentially\n",
      "             irritating skin preparations\n",
      "          -  No alcohol during and for 2 months after study\n",
      "3030\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic adenocarcinoma of the breast\n",
      "          -  Strong overexpression of HER-2 by immunohistochemistry (3+)\n",
      "               -  0-2+ tumors allowed if demonstrate amplification by FISH\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  Brain metastasis must not represent sole site of disease\n",
      "          -  No untreated brain metastasis receiving radiotherapy\n",
      "          -  Previously treated brain metastases in continued response to radiotherapy and/or\n",
      "             surgery for at least 2 months allowed\n",
      "          -  Hormone receptor status:\n",
      "               -  Positive or negative\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver\n",
      "             metastases present)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No congestive heart failure or unstable angina\n",
      "          -  No clinically significant pericardial effusion or arrhythmia\n",
      "        Other:\n",
      "          -  No other invasive malignancy within the past 5 years except curatively treated basal\n",
      "             cell or squamous cell skin cancer or carcinoma in situ of the cervix\n",
      "          -  No active uncontrolled infection\n",
      "          -  No prior allergic reaction to Cremophor EL, anesthetics, or muscle relaxants\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent filgrastim (G-CSF)\n",
      "        Chemotherapy:\n",
      "          -  Prior adjuvant chemotherapy allowed\n",
      "          -  Prior taxane therapy allowed\n",
      "          -  No prior cisplatin or carboplatin\n",
      "          -  No prior chemotherapy for metastatic disease\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy to more than 25% of marrow\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior surgery and recovered\n",
      "        Other:\n",
      "          -  At least 7 days since prior parenteral antibiotics\n",
      "3033\n",
      "DISEASE CHARACTERISTICS: Transitional cell carcinoma of the bladder with biopsy proven\n",
      "        muscle invasion suitable for resection leaving no residual visible or palpable tumor mass\n",
      "        Unifocal No greater than 5 cm Stages II and III (T2-T3a, N0-NX, M0) No prior treatment for\n",
      "        bladder cancer other than endoscopic resection, intravesical chemotherapy, or intravesical\n",
      "        immunotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 120,000/mm3\n",
      "        Hepatic: Bilirubin normal SGOT/SGPT normal Renal: GFR at least 50 mL/min Cardiovascular:\n",
      "        Normal cardiac function (i.e., no New York Heart Association class II-IV) Other: Normal\n",
      "        auditory function No second primary malignant tumor except basal cell carcinoma of the\n",
      "        skin Fit for cisplatin containing combination chemotherapy, radical radiotherapy, or\n",
      "        cystectomy No active infections Not pregnant or nursing No concurrent illness that\n",
      "        significantly affects clinical assessments\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics No prior systemic chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior radiotherapy to the bladder Surgery: See Disease Characteristics No\n",
      "        prior partial cystectomy Prior transurethral resection of the bladder allowed\n",
      "3034\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed primary melanoma of cutaneous origin\n",
      "               -  Stage II (T3 N0 M0 1.5-4.0 mm Breslow depth)\n",
      "                    -  Clinically negative regional lymph node pathologic status unknown OR\n",
      "                    -  Histologically negative regional lymph nodes\n",
      "               -  Stage III (T4 N0 M0)\n",
      "                    -  Greater than 4.0 mm Breslow depth OR\n",
      "               -  Stage III (T1-4 N1)\n",
      "                    -  One lymph node positive microscopically\n",
      "          -  Patients must meet at least 1 of the following criteria:\n",
      "               -  T_2b N_0 - primary melanoma 1.01-2.0 mm with ulceration, node negative\n",
      "               -  T_3a-b N_0 - primary melanoma 2.01-4.0 mm with and without ulceration, node\n",
      "                  negative\n",
      "               -  T_4a-b N_0 - primary melanoma > 4.0 mm with or without ulceration, node negative\n",
      "               -  T_1-a N_1a-2a (microscopic) - primary melanoma of any thickness with\n",
      "                  microscopically positive lymph node (any number)\n",
      "          -  Patients with a positive sentinel node should undergo complete lymphadenectomy of the\n",
      "             nodal basin prior to study\n",
      "          -  Must complete all primary therapy (wide excision with or without lymphadenectomy) and\n",
      "             be randomized in this study within 84 days of wide excision\n",
      "          -  Must have undergone an adequate wide excision of the primary lesion\n",
      "          -  No clinical, radiological/laboratory, or pathological evidence of incompletely\n",
      "             resected melanoma or any distant metastatic disease\n",
      "          -  No clinically palpable lymphadenopathy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 125,000/mm^3\n",
      "          -  Hematocrit at least 30%\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 times upper limit of normal (ULN)\n",
      "          -  AST, LDH, and alkaline phosphatase no greater than 2 times ULN\n",
      "          -  If lactate dehydrogenase or alkaline phosphatase is above normal, a contrast-enhanced\n",
      "             CT scan or MRI of the liver is required to document the absence of tumor\n",
      "        Renal:\n",
      "          -  BUN no greater than 33 mg/dL OR\n",
      "          -  Creatinine no greater than 1.8 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No history of active ischemic heart disease\n",
      "          -  No cerebrovascular disease\n",
      "          -  No congestive heart failure (New York Heart Association class III or IV heart\n",
      "             disease)\n",
      "        Other:\n",
      "          -  No other history of invasive melanoma\n",
      "          -  No autoimmune disorders or conditions of immunosuppression\n",
      "          -  No other concurrent or prior malignancies within the past 5 years except:\n",
      "               -  Cancer in situ\n",
      "               -  Lobular carcinoma in situ of the breast\n",
      "               -  Carcinoma in situ of the cervix\n",
      "               -  Atypical melanocytic hyperplasia or Clark 1 melanoma in situ\n",
      "               -  Basal or squamous cell skin cancer\n",
      "          -  No evidence of organic brain syndrome or significant impairment of basal cognitive\n",
      "             function or any psychiatric disorder that would preclude study participation\n",
      "          -  No other significant medical or surgical condition, or any medication or treatment\n",
      "             regimens, that would interfere with study participation\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy including tumor vaccines, interferon, interleukins,\n",
      "             levamisole, or other biologic response modifiers for melanoma\n",
      "        Chemotherapy:\n",
      "          -  No prior or concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent systemic corticosteroids including oral steroids (i.e., prednisone,\n",
      "             dexamethasone), topical steroid creams or ointments, or any steroid-containing\n",
      "             inhalers\n",
      "        Radiotherapy:\n",
      "          -  No prior or concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  No other concurrent immunosuppressive medications\n",
      "3037\n",
      "DISEASE CHARACTERISTICS: Newly diagnosed high risk acute myeloid leukemia (AML) defined\n",
      "        as: AML after myelodysplastic syndrome; refractory anemia with excess blasts in\n",
      "        transformation or \"AML in evolution\" also eligible AML following a chronic\n",
      "        myeloproliferative disorder (except chronic myelogenous leukemia) Therapy related AML or\n",
      "        AML following exposure to a known hematopoietic toxin Relapsed AML Age 70 or older OR AML\n",
      "        in first relapse defined as: AML in first relapse without treatment on protocol AML-9801\n",
      "        Relapsed following standard chemotherapy Previously treated on AML-9701 and relapsed after\n",
      "        at least 6 months of remission OR Chronic myelogenous leukemia (CML) in blast crisis\n",
      "        defined as: 20% or more blast cells in the bone marrow or peripheral blood Pure lymphoid\n",
      "        blastic crisis eligible if resistant to an acute lymphocytic leukemia type treatment\n",
      "        regimen or relapsed after initial response to such a treatment\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3\n",
      "        mg/dL SGOT/SGPT no greater than 2.5 times upper limit of normal Renal: Creatinine less\n",
      "        than 3 mg/dL Cardiovascular: No overt congestive heart failure or uncontrollable\n",
      "        ventricular arrhythmias No uncontrollable hypertension Neurologic: No cerebellar\n",
      "        dysfunction Other: Not pregnant or nursing Negative pregnancy test Fertile patients must\n",
      "        use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "3039\n",
      "DISEASE CHARACTERISTICS: Must have a 6 antigen HLA identical related donor and one of the\n",
      "        following diseases: -Acute myelogenous leukemia in high risk first complete remission or\n",
      "        second or greater complete remission -Acute lymphocytic leukemia in high risk first\n",
      "        complete remission or second or greater remission -Chronic myelogenous leukemia in chronic\n",
      "        phase -Indolent non-Hodgkin's lymphoma (NHL) or aggressive NHL in complete or partial\n",
      "        remission, not eligible for autologous bone marrow transplant (ABMT) -Multiple myeloma in\n",
      "        complete or partial response -Myelodysplastic syndrome -Stage III or IV chronic\n",
      "        lymphocytic leukemia -Hodgkin's disease after first complete remission Patients must also\n",
      "        have one of the following high risk features: -Age 55-70 -Age 18-54 must have one of the\n",
      "        following conditions: LVEF 35-44% FEV1 or FVC 40-49% Bilirubin 2.1-3.0 mg/dL, AST 71-175,\n",
      "        or ALT 81-200 Creatinine 2.1-3.0 mg/dL Disease recurrence less than 1 year after ABMT\n",
      "        Between 18 to 24 months of prior chemotherapy (12 to 24 months for multiple myeloma)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3.1 mg/dL Renal:\n",
      "        Creatinine less than 3.1 mg/dL Cardiovascular: LVEF at least 35% Pulmonary: FEV1 and FVC\n",
      "        at least 40% of predicted (60% for patients who have received thoracic or mantle\n",
      "        radiotherapy) Other: Not pregnant Fertile patients must use effective contraception Not\n",
      "        HIV positive\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "3040\n",
      "DISEASE CHARACTERISTICS: Confirmed diagnosis of primary tumor and/or recurrence that has a\n",
      "        low curative potential using other therapies, including but not limited to: Acute leukemia\n",
      "        Myeloma Breast cancer Ovarian cancer Hodgkin's disease Non-Hodgkin's lymphoma\n",
      "        Neuroblastoma Ewing's sarcoma In the absence of recurrence, malignancies for which an\n",
      "        autotransplant regimen is considered a reasonable therapeutic alternative are also\n",
      "        considered Greater than 25% of bone marrow normal cellularity and less than 10% of volume\n",
      "        composed of tumor cells No active brain metastases or carcinomatous meningitis (controlled\n",
      "        CNS metastases eligible)\n",
      "        PATIENT CHARACTERISTICS: Age: 14 to 70 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC greater than 3000/mm3 Absolute neutrophil count greater than\n",
      "        1500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin, SGOT, and SGPT less\n",
      "        than 2 times normal Renal: Creatinine clearance greater than 60 mL/min Cardiovascular:\n",
      "        LVEF at least 45% Pulmonary: DLCO at least 50% FEV1 at least 60% Other: Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception HIV, HTLV-1, and HTLV-2 negative\n",
      "        Hepatitis B and C negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No more than 1 prior autologous peripheral\n",
      "        blood stem cell transplant Chemotherapy: Cumulative anthracycline or equivalent dose no\n",
      "        greater than 450 mg/m2 Endocrine therapy: Not specified Radiotherapy: Not specified\n",
      "        Surgery: Not specified Other: Recovered from prior therapy No antihypertensives during and\n",
      "        24 hours prior to amifostine administration\n",
      "3042\n",
      "DISEASE CHARACTERISTICS: Histologically proven solid tumors or lymphoma refractory to\n",
      "        standard therapy or for which no standard therapy exists Brain metastases allowed if\n",
      "        following criteria met: Asymptomatic Received prior therapy for brain metastases Stable\n",
      "        for at least 2 months No concurrent steroid therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic and Renal: Albumin at least 2.5 g/dL Prothrombin time less than 1.6\n",
      "        For patients without prior pelvic radiotherapy: AST at least 3 times upper limit of normal\n",
      "        (ULN) OR Bilirubin 1.0 - 7.0 mg/dL with any AST OR Creatinine 1.6 - 5.0 mg/dL For patients\n",
      "        with prior pelvic radiotherapy: AST less than 3 times ULN AND Bilirubin less than 1.0\n",
      "        mg/dL AND Creatinine less than 1.6 mg/dL Other: Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent colony stimulating factors\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (at least 6 weeks since melphalan\n",
      "        or mitomycin) At least 3 months since suramin No prior nitrosoureas or irinotecan\n",
      "        Endocrine therapy: No concurrent steroids (except as antiemetic for chemotherapy)\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 4 weeks since\n",
      "        major surgery Other: No concurrent medications known to affect hepatic or renal function\n",
      "        (e.g., antiseizure medication or nonsteroidal antiinflammatory drugs)\n",
      "3043\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignancy including: - Pediatric acute\n",
      "        lymphocytic leukemia (ALL) in first complete remission with high risk features including\n",
      "        presence of t(4;11) or t(9;22), or extreme hyperleukocytosis (initial WBC greater than 500\n",
      "        K/mL), or failure to achieve a complete remission after standard induction therapy - Adult\n",
      "        ALL or acute nonlymphoblastic leukemia (ANLL) in first complete remission with t(8;14)\n",
      "        translocation or failure to achieve complete remission after standard induction therapy -\n",
      "        ALL or ANLL in second or subsequent remission - Chronic myelogenous leukemia in chronic or\n",
      "        accelerated phase - Myelodysplastic syndrome with evidence of evolution to acute myeloid\n",
      "        leukemia Refractory anemia with excess blasts Refractory anemia with excess blasts in\n",
      "        transformation Chronic myelomonocytic leukemia - T-lymphoblastic non-Hodgkin's lymphoma in\n",
      "        second or subsequent remission - Stage IV neuroblastoma Must also meet all the following\n",
      "        conditions: No HLA-ABC/DR identical related bone marrow or UCB donor No 5/6 antigen\n",
      "        matched related bone marrow or UCB donor Condition precludes waiting to search and find a\n",
      "        donor in the National Marrow Donor Registry Must have an available serologic matched\n",
      "        umbilical cord blood unit in the New York Blood Center's Placental Blood Project No active\n",
      "        CNS disease Not eligible for COBLT study (Transplantation of Banked Umbilicial Cord Blood\n",
      "        Cells for Use in Clinical Research on Transplantation of Umbilical Cord Blood Stem and\n",
      "        Progenitor Cells)\n",
      "        PATIENT CHARACTERISTICS: Age: Under 55 at time of umbilical cord blood transplantation\n",
      "        Performance status: Zubrod 0-1 Lansky 80-100% Karnofsky 80-100% Life expectancy: At least\n",
      "        3 months Hematopoietic: Adequate hematologic status at time of back-up bone marrow\n",
      "        harvest: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,000/mm3 Platelet\n",
      "        count at least 100,000/mm3 Hepatic: ALT/AST no greater than 4 times normal Bilirubin no\n",
      "        greater than 2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Creatinine clearance at\n",
      "        least 50 mL/min Cardiovascular: Normal cardiac function by echocardiogram or radionuclide\n",
      "        scan (shortening fraction or ejection fraction at least 80% of normal value for age)\n",
      "        Pulmonary: FVC and FEV1 at least 60% of predicted for age For adults: DLCO at least 60% of\n",
      "        predicted Other: No active infections at time of back-up bone marrow harvest or\n",
      "        pretransplant reduction Not pregnant or nursing Negative pregnancy test Fertile patients\n",
      "        must use effective contraception HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "3044\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven recurrent or refractory solid tumors\n",
      "          -  No leukemia\n",
      "          -  Patients with brain tumors are not eligible until the first 2 patients at each dose\n",
      "             level are evaluable for toxicity\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 21 and under\n",
      "          -  Performance status: Karnofsky 50-100% Lansky play scale 50-100% (for infants)\n",
      "          -  Life expectancy: At least 8 weeks\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "          -  Platelet count at least 75,000/mm3\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  SGPT less than 5 times upper limit of normal\n",
      "          -  Creatinine normal for age OR GFR at least 70 mL/min\n",
      "          -  Cardiac shortening fraction at least 27% OR institutional normal OR cardiac ejection\n",
      "             fraction greater than 50% OR institutional normal\n",
      "          -  Neurologic deficits in patients with CNS tumors must be stable for at least 2 weeks\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 6 months after the\n",
      "             study\n",
      "          -  No uncontrolled infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 1 week since prior growth factor therapy and recovered\n",
      "          -  At least 6 months since prior bone marrow transplantation and no evidence of graft\n",
      "             versus host disease\n",
      "          -  At least 2 weeks since prior myelosuppressive chemotherapy and recovered\n",
      "          -  At least 6 weeks since prior nitrosourea and recovered\n",
      "          -  At least 2 weeks on stable dexamethasone for patients with CNS tumors\n",
      "          -  No concurrent chemotherapy\n",
      "          -  At least 2 weeks since prior palliative radiotherapy (small port)\n",
      "          -  At least 6 months since prior substantial bone marrow radiation\n",
      "          -  At least 6 months since total abdominal, pelvic, chest, mantle, and Y ports\n",
      "             radiotherapy\n",
      "          -  No other concurrent anticancer therapy or investigational agents\n",
      "3046\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Individuals at average risk (Parts A and B) or above average risk (Part A only) for\n",
      "             development of colon cancer\n",
      "               -  Average risk individuals defined as:\n",
      "                    -  No history of colon adenomas\n",
      "                    -  No strong family history of colon polyps or cancer\n",
      "               -  Above average risk individuals defined as:\n",
      "                    -  History of one or more sporadic adenomatous polyps at least 0.5 cm in size\n",
      "                       (either tubular, tubulovillous, or villous adenomas)\n",
      "                    -  Have had polypectomy or refused this procedure\n",
      "                    -  No significant family history of adenomatous polyps, colon cancer, or\n",
      "                       hereditary nonpolyposis colorectal cancer or other hereditary colon cancer\n",
      "                       syndrome\n",
      "                    -  Polyps should not have had a focus of adenocarcinoma within them\n",
      "          -  No history of gastrointestinal cancer outside of the large bowel\n",
      "          -  No other gastrointestinal mucosal epithelial disease (e.g., Barrett's esophagus,\n",
      "             chronic or recurrent peptic ulcer disease, celiac sprue, or other disorders of\n",
      "             nutrient absorption)\n",
      "          -  No significant asymptomatic lesions on flexible sigmoidoscopy, such as inflammation,\n",
      "             premalignancy or malignancy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  No platelet or coagulation abnormalities\n",
      "          -  No personal or family history of a bleeding disorder\n",
      "          -  Hematopoietic concentration must not be due to significant acute or chronic disorder\n",
      "        Hepatic:\n",
      "          -  No liver disease\n",
      "        Renal:\n",
      "          -  No renal insufficiency\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No chronic congestive heart failure\n",
      "          -  No history of endocarditis\n",
      "          -  No history of rheumatic fever\n",
      "          -  No cardiac valve prostheses\n",
      "          -  No mitral valve prolapse that requires antibiotic prophylaxis\n",
      "        Other:\n",
      "          -  HIV negative\n",
      "          -  No gout\n",
      "          -  No pancreatitis\n",
      "          -  No other chronic viral infection\n",
      "          -  No significant acute or uncontrolled chronic medical illness\n",
      "          -  Generally non-smoking (no more than 4 cigarettes per week, i.e., not daily smokers)\n",
      "          -  Must abstain from smoking for at least 1 month prior to enrolling in the study\n",
      "          -  No alcohol consumption of greater than 2 glasses of wine or beer per day\n",
      "          -  Normal weight (90-120% of optimum body weight) and body habitus\n",
      "          -  No change in weight within 5-10% of body weight within the past year\n",
      "          -  No history of inflammatory bowel disease (either ulcerative colitis or Crohn's\n",
      "             disease )\n",
      "          -  No hearing or equilibrium disorders\n",
      "          -  No other prior malignancy except resected carcinoma in situ of the cervix or\n",
      "             nonmelanoma skin cancer\n",
      "          -  No allergies to sulindac or tartrazine dyes or prior severe adverse reactions to\n",
      "             nonsteroidal antiinflammatory drugs (asthma, gastrointestinal bleeding, or renal\n",
      "             insufficiency)\n",
      "          -  No potential allergy to curcumin, quercetin, or rutin\n",
      "          -  No gastrointestinal bleeding\n",
      "          -  Not institutionalized, mentally disabled, or incarcerated\n",
      "          -  No unusually high intake of stored micronutrients or high doses of supplemental\n",
      "             calcium or folate\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent coumadin\n",
      "          -  No chronic use of nonsteroidal antiinflammatory drugs (unless they can be stopped for\n",
      "             3 months)\n",
      "          -  No other putative colon cancer chemoprevention agents (unless they can be stopped for\n",
      "             3 months)\n",
      "3049\n",
      "DISEASE CHARACTERISTICS: Histologically proven hematologic cancer, including acute or\n",
      "        chronic leukemia, malignant lymphoma, or multiple myeloma Exclude acute promyelocytic\n",
      "        leukemia (M3) Relapse from or resistance to at least one course of standard anticancer\n",
      "        therapy and lack of alternative therapy that has proven to be curative in the underlying\n",
      "        disease\n",
      "        PATIENT CHARACTERISTICS: Age: 17 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.5 mg/dL\n",
      "        Renal: Creatinine no greater than 2.5 mg/dL Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception during and for at least 4 months after study No\n",
      "        history of grand mal seizures (other than infantile febrile seizures) No active serious\n",
      "        infections that are not controlled by antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: No other concurrent investigational agents\n",
      "3050\n",
      "Inclusion Criteria:\n",
      "          -  Histologically diagnosed intermediate risk (stage I or II) or high risk (stage III or\n",
      "             IV) refractory B-cell chronic lymphocytic leukemia\n",
      "          -  Intermediate risk group must have evidence of active disease as shown by at least one\n",
      "             of the following:\n",
      "               -  Massive or progressive splenomegaly and/or lymphadenopathy\n",
      "               -  Weight loss of greater than 10% in the last 6 months\n",
      "               -  CALGB grade 2-4 fatigue\n",
      "               -  Fevers greater than 100.5 degree Fahrenheit OR night sweats for greater than2\n",
      "                  weeks without evidence of infection\n",
      "               -  Progressive lymphocytosis with an increase greater than 50% over a 2 month\n",
      "                  period or an anticipated doubling time of less than 6 months\n",
      "          -  Refractory to fludarabine treatment OR relapsed within 6 months of fludarabine\n",
      "          -  Lymphocytosis greater than 5000/mm3 at some time during disease\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No more than 1 prior nonradiolabeled antibody treatment (e.g., Campath-1H or\n",
      "             rituximab)\n",
      "          -  At least 1, but no more than 3, prior chemotherapy regimens\n",
      "          -  At least 1 prior chemotherapy regimen comprising fludarabine\n",
      "          -  No other concurrent chemotherapy\n",
      "          -  No concurrent chronic use of oral corticosteroids\n",
      "          -  No concurrent hormone therapy except for non-disease related conditions\n",
      "          -  No concurrent dexamethasone or other corticosteroid-based antiemetics\n",
      "          -  No concurrent palliative radiotherapy\n",
      "3051\n",
      "DISEASE CHARACTERISTICS: Histologically proven locally advanced or metastatic breast\n",
      "        cancer and meeting one of the following criteria: No prior systemic therapy OR Relapsed\n",
      "        more than 12 months after stopping adjuvant tamoxifen (tamoxifen- sensitive) OR Relapsed\n",
      "        while receiving adjuvant tamoxifen for more than 12 months (tamoxifen-refractory) OR\n",
      "        Disease progression while receiving tamoxifen as first-line treatment for metastatic\n",
      "        breast cancer (tamoxifen-refractory) Evaluable or bidimensionally measurable disease No\n",
      "        rapid disease progression requiring chemotherapy Brain metastases allowed if stable for at\n",
      "        least 6 months after surgery or radiotherapy, with no increase in corticosteroids Hormone\n",
      "        receptor status: Estrogen receptor positive AND/OR Progesterone receptor positive OR\n",
      "        Unknown status allowed if over 50 years old\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: ECOG 0-1 Life expectancy: At least 24 weeks Hematopoietic: Granulocyte\n",
      "        count at least 1500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL,\n",
      "        transfusion independent Hepatic: Bilirubin no greater than 1.5 times normal PT/PTT no\n",
      "        greater than 1.25 times upper limit of normal (ULN) ALT/AST no greater than 2.5 times ULN\n",
      "        Renal: Creatinine less than 1.5 times ULN Calcium no greater than 11 mg/dL No\n",
      "        hypercalcemia Other: Not pregnant or nursing Fertile patients must use approved\n",
      "        nonhormonal contraceptive during and for 3 months after study No known predisposition to\n",
      "        thromboembolic disorder At least 5 years since other primary malignancy except: Adequately\n",
      "        treated nonmelanomatous skin cancer Carcinoma in situ of the cervix No serious concurrent\n",
      "        systemic disorders incompatible with study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Concurrent\n",
      "        hematopoietic growth factor allowed Chemotherapy: No prior chemotherapy for metastatic\n",
      "        breast cancer No concurrent chemotherapy Endocrine therapy: No prior hormonal therapy for\n",
      "        metastatic breast cancer (except tamoxifen) No concurrent supplemental estrogen or\n",
      "        progesterone At least 3 weeks since prior estrogen replacement therapy No other concurrent\n",
      "        hormone therapy Radiotherapy: At least 2 weeks since prior radiotherapy Surgery: Not\n",
      "        specified Other: At least 4 weeks since prior use of other investigational agents\n",
      "        Concurrent bisphosphonate therapy allowed No other concurrent investigational agent\n",
      "3052\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven recurrent or refractory\n",
      "        non-small cell lung cancer Squamous cell Adenocarcinoma (including bronchoalveolar cell)\n",
      "        Large cell anaplastic (giant and clear cell carcinomas) Measurable disease (not bone\n",
      "        disease only, pleural or pericardial effusions, or irradiated lesions, unless progression\n",
      "        is documented after radiotherapy) No CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater 1.5 mg/dL SGOT no greater than 2 times upper\n",
      "        limit of normal (ULN) Renal: Creatinine no greater than ULN Cardiovascular: No active\n",
      "        cardiac disease No unstable angina No myocardial infarction within 6 months No congestive\n",
      "        heart failure No inability to tolerate hypotension Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception HIV negative No uncontrolled diabetes mellitus\n",
      "        No psychiatric disorders No concurrent secondary malignancies except nonmelanomatous skin\n",
      "        cancer or patients with less than a 30% risk of relapse\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks since mitomycin) At least 1 prior chemotherapy agent or\n",
      "        combination, including adjuvant or neoadjuvant therapy for non-small cell lung cancer No\n",
      "        more than 1 prior chemotherapy agent or combination for metastatic or recurrent disease No\n",
      "        prior HMAF No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal\n",
      "        therapy except for nondisease related conditions Radiotherapy: See Disease Characteristics\n",
      "        At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy Surgery:\n",
      "        Not specified\n",
      "3053\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed residual or relapsed Hodgkin's lymphoma following\n",
      "             conventional dose standard chemotherapy\n",
      "          -  Presence of the following prognostic factors are allowed:\n",
      "               -  B symptoms (fever, weight loss, night sweats)\n",
      "               -  Extranodal disease\n",
      "               -  Complete remission of less than 1 year duration\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease\n",
      "          -  No chronic active or persistent hepatitis\n",
      "        Renal:\n",
      "          -  No history of chronic renal insufficiency\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No unstable angina\n",
      "          -  No significant cardiac arrhythmias other than chronic atrial fibrillation\n",
      "          -  Ejection fraction at least 50%\n",
      "        Pulmonary:\n",
      "          -  DLCO at least 50%\n",
      "        Other:\n",
      "          -  No uncontrolled infection\n",
      "          -  HIV negative\n",
      "          -  At least 5 years since prior malignancy except:\n",
      "               -  Curatively treated cutaneous basal cell carcinoma\n",
      "               -  Carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile women must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Must have failed conventional dose standard chemotherapy\n",
      "3054\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed previously untreated acute myelogenous\n",
      "        leukemia (AML) FAB M1, M2, M4, M5, M6, or M7 No AML secondary to chemotherapy, radiation\n",
      "        therapy, or toxic agents No history of myelodysplastic syndromes If possible, patient\n",
      "        should be enrolled on protocol RUSH-CYL-9003\n",
      "        PATIENT CHARACTERISTICS: Age: 70 and under Performance status: 0-3 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin greater than 2.0 mg/dL and no\n",
      "        greater than 3.0 mg/dL allowed with 50% reduction in drug doses Renal: Creatinine less\n",
      "        than 3.0 mg/dL Cardiovascular: No overt congestive heart failure No uncontrollable\n",
      "        ventricular arrhythmias No uncontrollable hypertension If cardiac ejection fraction is\n",
      "        less than 45% of predicted, an echocardiogram and a cardiac consult must be obtained to\n",
      "        ascertain cardiac tolerance of anthracycline therapy Neurological: No cerebellar\n",
      "        dysfunction Other: Fever, infection, or other complications of disease allowed Not\n",
      "        pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior interferon At\n",
      "        least 2 weeks since prior hematopoietic growth factors (including erythropoietin)\n",
      "        Chemotherapy: At least 2 weeks since prior chemotherapy Endocrine therapy: At least 2\n",
      "        weeks since prior steroids Radiotherapy: Not specified Surgery: Not specified Other: At\n",
      "        least 2 weeks since prior retinoids\n",
      "3055\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven previously untreated invasive carcinoma of the uterine cervix\n",
      "               -  Squamous cell carcinoma\n",
      "               -  Adenosquamous carcinoma\n",
      "               -  Adenocarcinoma\n",
      "          -  TNM classification stage IIIB or IVA (FIGO classification stage IB, IIA, IIB, IIIA,\n",
      "             IIIB, or IVA)\n",
      "          -  Cytologically or histologically proven metastases to the para-aortic lymph nodes\n",
      "          -  No more than 8 weeks since diagnosis\n",
      "          -  No metastases to scalene nodes, intraperitoneal metastases, or metastases to other\n",
      "             organs outside the radiation field at the time of original clinical and surgical\n",
      "             staging\n",
      "               -  Negative CT scan of the chest\n",
      "          -  Patients with ureteral obstruction must be treated with stent or nephrostomy tube\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  GOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 6 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times normal\n",
      "          -  SGOT no greater than 3 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 2.0 mg/dL\n",
      "          -  No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal\n",
      "             transplantation) requiring modification of radiation fields\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  No septicemia or severe infection\n",
      "          -  No other invasive malignancy within the past 3 years except nonmelanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior cytotoxic chemotherapy for this or other malignancy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy for this or other malignancy\n",
      "          -  No prior radiotherapy to pelvis or abdomen\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other prior therapy for this malignancy\n",
      "3057\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven locally advanced and/or\n",
      "        unresectable adenocarcinoma of the pancreas No metastatic disease No completely resected\n",
      "        pancreatic cancer\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% OR ECOG\n",
      "        0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Renal: Creatinine no greater than\n",
      "        1.5 mg/dL Cardiovascular: No congestive heart failure No New York Heart Association class\n",
      "        III and IV heart disease Other: Not pregnant No concurrent medical problems that would\n",
      "        increase the side effects or morbidity of chemoradiation No concurrent medical condition\n",
      "        that would make patient ineligible to receive external beam radiation such as: Crohn's\n",
      "        disease Inflammatory bowel disease No active infection requiring systemic antibiotics\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        gemcitabine No prior chemotherapy for pancreatic cancer Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior radiotherapy to the pancreas Surgery: Not specified\n",
      "3059\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed breast carcinoma that has been completely excised\n",
      "               -  Clinically relapse free\n",
      "          -  Must have completed at least two years of adjuvant therapy with tamoxifen for early\n",
      "             breast cancer AND have no clear indication for or against receiving further tamoxifen\n",
      "          -  No significant endometrial hyperplasia\n",
      "          -  No patients with negligibly low risk of breast cancer death\n",
      "          -  Hormone receptor status:\n",
      "               -  Any status allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Any status allowed\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other life threatening disease\n",
      "          -  No retinopathy\n",
      "          -  No psychiatric disorder or other condition that would preclude study compliance\n",
      "          -  No serious toxicity (e.g., depression) thought to be due to tamoxifen\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  Any primary treatment allowed\n",
      "3060\n",
      "1. Patients with histologically documented untreated squamous cell carcinoma or\n",
      "             adenocarcinoma of the thoracic esophagus (below 20 cm) or gastroesophageal junction\n",
      "             and with less than 2cmdistal spread into the gastric cardia eligible for C9781.\n",
      "          2. There could be no evidence of distant metastatic disease by history and physical\n",
      "             examination; upper endoscopy with biopsy, computed tomography (CT) of the chest and\n",
      "             upper abdomen, and pulmonary function studies were all required.\n",
      "          3. Tumors had to be considered surgically resectable (T1-3, NX), including regional\n",
      "             thoracic lymph node (N1) metastases.\n",
      "          4. Patients with supraclavicular lymph nodes measuring ≤1.5 cm by CT (not palpable) were\n",
      "             eligible, as were patients with lymph node metastases to levels 15 to 20\n",
      "             (predominantly celiac axis and paracardial nodes) ≤ 1.5 cm by CT.\n",
      "          5. Patients could not have previously received chemotherapy or radiation therapy for\n",
      "             this tumor or any radiation therapy that would overlap the radiation fields required\n",
      "             for this malignancy. Patients with previous malignancies were eligible if more than 5\n",
      "             years had elapsed from diagnosis without evidence of tumor recurrence.\n",
      "          6. There could be no other serious illness that would limit survival to less than 2\n",
      "             years, or psychiatric condition that would prevent compliance with treatment or\n",
      "             informed consent.\n",
      "          7. Patients with uncontrolled or severe cardiovascular disease, pulmonary disease, or\n",
      "             active infections were excluded, as were pregnant patients.\n",
      "3063\n",
      "DISEASE CHARACTERISTICS: Diagnosis of refractory chronic lymphocytic leukemia Evidence of\n",
      "        active disease after fludarabine or alkylator therapy Must meet one or more of the\n",
      "        following criteria for active disease: Minimum of one of the following disease-related\n",
      "        symptoms: Weight loss of 10% or more within the previous 6 months Extreme fatigue (e.g.,\n",
      "        unable to work or perform usual activities) Fevers greater than 100.5 degrees F for 2\n",
      "        weeks or more without evidence of infection Night sweats without evidence of infection\n",
      "        Evidence of progressive marrow failure manifested by the development or worsening of\n",
      "        autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroid\n",
      "        therapy Massive (e.g., greater than 6 cm below the left costal margin) or progressive\n",
      "        splenomegaly Massive nodes or clusters (e.g., greater than 10 cm in longest diameter) or\n",
      "        progressive lymphadenopathy Progressive lymphocytosis with an increase of more than 50%\n",
      "        over a 2-month period or an anticipated doubling time of less than 6 months Ineligible if\n",
      "        marked hypogammaglobulinemia or development of monoclonal protein in the absence of the\n",
      "        above criteria for active disease Must have one of the following resulting from prior\n",
      "        fludarabine or alkylator-containing therapy: Disease progression during therapy Failure to\n",
      "        respond or obtained less than a partial response to therapy Disease progression within 6\n",
      "        months of the last course of therapy after an initial response Failure to respond or\n",
      "        disease progression allowed at any time after the final dose if alkylator agent was not\n",
      "        the most recent therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: See Disease Characteristics Hepatic: See\n",
      "        Disease Characteristics Bilirubin no greater than 2 times upper limit of normal No liver\n",
      "        dysfunction due to organ infiltration by lymphocytes Renal: Creatinine clearance at least\n",
      "        50 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception during and for up to 28 days after study No neurotoxicity of grade\n",
      "        2 or higher No history of significant neurologic toxicity (grade 2 or greater motor or\n",
      "        sensory impairment) due to prior chemotherapy or radiotherapy No history of seizure\n",
      "        disorder No active infection No other malignancy within the past 2 years (except\n",
      "        adequately treated non- melanomatous skin cancer or carcinoma in situ) that would preclude\n",
      "        study No systemic nonmalignant comorbid disease that would preclude study No\n",
      "        psychological, sociological, or geographical condition that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow or peripheral blood stem\n",
      "        cell transplantation Recovered from prior immunotherapy At least 4 weeks since prior\n",
      "        biologic therapy and recovered Concurrent growth factors allowed Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or\n",
      "        mitomycin) and recovered No prior 506U78 therapy No other concurrent chemotherapy\n",
      "        Endocrine therapy: See Disease Characteristics No concurrent corticosteroid therapy\n",
      "        greater than 10 mg/day of prednisone equivalent No concurrent corticosteroids as\n",
      "        antiemetics Concurrent hormone replacement therapy or oral contraceptives allowed\n",
      "        Concurrent hydrocortisone as prophylaxis or treatment of transfusion reactions allowed\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: No other concurrent anticancer agents\n",
      "3064\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous or adenosquamous carcinoma of\n",
      "        the cervix that is metastatic, recurrent, or refractory Any stage disease treated with\n",
      "        prior radical surgery and/or definitive radiotherapy that has locally recurred and is no\n",
      "        longer amenable to surgery or radiotherapy OR Metastatic disease that is not amenable to\n",
      "        surgery or radiation therapy Measurable disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Not specified Renal: Creatinine no greater than 1.5 times upper limit of normal\n",
      "        Other: No history of allergic reaction to mannitol Not pregnant or nursing Negative\n",
      "        pregnancy test Fertile patients must use effective contraception during and for 3 months\n",
      "        after study No other prior malignancy except: Adequately treated basal cell or squamous\n",
      "        cell skin cancer In situ cervical cancer Adequately treated stage I or II cancer from\n",
      "        which the patient is currently in complete remission Any other cancer from which the\n",
      "        patient has been disease free for 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent colony stimulating factor\n",
      "        therapy Chemotherapy: Prior chemotherapy (hydroxyurea, fluorouracil, metronidazole,\n",
      "        cisplatin, or other platinum agent) allowed as a radiosensitizing agent only No other\n",
      "        concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease\n",
      "        Characteristics Prior radiotherapy allowed to less than 30% of the bone marrow only\n",
      "        Recovered from toxic effects No concurrent radiotherapy Surgery: See Disease\n",
      "        Characteristics Prior surgery allowed Recovered from effects of prior surgery Other: No\n",
      "        prior systemic therapy for this disease\n",
      "3065\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent anaplastic oligodendroglioma or\n",
      "        anaplastic mixed oligoastrocytoma following primary surgery and radiation therapy Tumors\n",
      "        for anaplastic mixed oligoastrocytoma must contain at least 25% oligodendroglial elements\n",
      "        Tumors must be clinically aggressive for patients with only 1 anaplastic feature Prior low\n",
      "        grade oligodendrogliomas or oligoastrocytomas undergoing repeat biopsy following clinical\n",
      "        or radiological progression are eligible Bidimensionally measurable and progressive\n",
      "        lesions by CT or MRI\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Not specified Renal: Creatinine normal Other: Not pregnant\n",
      "        or nursing Fertile patients must use effective contraception No prior malignancies except\n",
      "        curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer No other\n",
      "        serious illness or medical condition No active uncontrolled infection No history of\n",
      "        neurologic or psychiatric disorder\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n",
      "        since chemotherapy No more than 1 prior chemotherapy regimen No prior camptothecin\n",
      "        derivatives Endocrine therapy: At least 2 weeks on stable steroid therapy, if necessary\n",
      "        Radiotherapy: At least 2 months since prior radiotherapy No prior radiation therapy for\n",
      "        recurrent disease Surgery: At least 6 weeks since prior surgery (except biopsy only) Prior\n",
      "        surgery for recurrent disease allowed (including stereotactic biopsy or partial resection)\n",
      "        Other: No concurrent experimental drugs or anticancer therapy\n",
      "3066\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian epithelial\n",
      "        cancer who have undergone surgical debulking Stage III patients must have greater than 1\n",
      "        cm residual mass after surgery Must have had no more than 1 course of platinum based\n",
      "        chemotherapy No CNS disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: SWOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminases no greater than 4 times upper limit of normal No active chronic hepatitis or\n",
      "        liver cirrhosis Renal: Creatinine no greater than 3.0 mg/dL Cardiovascular: LVEF at least\n",
      "        50% Pulmonary: FVC, FEV1, and corrected DLCO at least 50% of predicted If unable to\n",
      "        complete pulmonary function tests due to pain related to the recent surgery, patient must\n",
      "        have a high resolution CT scan of the chest and acceptable arterial blood gases (PO2 at\n",
      "        least 70) Other: HIV negative No active infection requiring intravenous antibiotics Not\n",
      "        pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See\n",
      "        Disease Characteristics\n",
      "3068\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed B cell low grade non-Hodgkin's lymphoma\n",
      "        Stage II, III or IV Measurable disease No chronic lymphatic leukemia, prolymphocytic\n",
      "        leukemia and hairy cell leukemia, angioimmunoblastic lymphadenopathy, mycosis fungoides,\n",
      "        Sezary's syndrome and T-zone lymphoma, plasmacytoma, T cell lymphomas, or centroblastic\n",
      "        lymphoma No CNS disease A new classification scheme for adult non-Hodgkin's lymphoma has\n",
      "        been adopted by PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace\n",
      "        the former terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "        protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 15 to 70 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Granulocyte count at least 2,000/mm3 Platelet count at least\n",
      "        150,000/mm3 Hepatic: Bilirubin no greater than 1.96 mg/dL AST/ALT no greater than 2 times\n",
      "        upper limit of normal Renal: Creatinine no greater than 1.65 mg/dL OR Creatinine clearance\n",
      "        no greater than 40 mL/min Cardiovascular: No history of myocardial infarction in the past\n",
      "        12 months No severe or uncontrolled cardiac failure Other: No history of malignant disease\n",
      "        except basal cell carcinoma or carcinoma in situ of the cervix No active peptic\n",
      "        ulceration, significant dyspepsia, or history of hematemesis or melena No concurrent\n",
      "        medical or psychological condition that may preclude study participation Not pregnant\n",
      "        Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No prior extensive radiotherapy for any malignant disease Prior radiotherapy\n",
      "        for localized disease that subsequently relapses permitted Surgery: Not specified\n",
      "3069\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed malignancy Malignant lymphoma -\n",
      "        Non-Hodgkin's lymphoma Intermediate and high grade (aggressive) histology with primary\n",
      "        refractory disease or relapsed following standard therapy - Hodgkin's disease Relapsed or\n",
      "        refractory after 2 regimens of curative therapy - No CNS disease that has not responded to\n",
      "        standard therapy prior to bone marrow transplantation Breast cancer Stage IV disease,\n",
      "        refractory, or relapsed after doxorubicin based first line therapy Ovarian cancer Primary\n",
      "        refractory disease or relapsed after first line chemotherapy Testicular cancer Relapsed or\n",
      "        refractory disease after 2 regimens of chemotherapy Other malignancies Recurrent or\n",
      "        refractory to standard chemotherapy regimens, but with documented responses to a minimum\n",
      "        of 2 courses of a docetaxel based chemotherapy Must not be greater than 60 days past\n",
      "        completion of adjuvant or induction therapy Prior history of cerebrospinal fluid (CSF)\n",
      "        tumor involvement without symptoms or signs allowed provided the CSF is now free of\n",
      "        disease on lumbar puncture and CT scan of the brain No active leptomeningeal involvement\n",
      "        or brain metastases No severe symptomatic CNS disease Hormone receptor status: Not\n",
      "        specified\n",
      "        NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by\n",
      "        PDQ. The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "        terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this protocol\n",
      "        uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 65 and under Menopausal status: Not specified Performance\n",
      "        status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Not specified\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2.5 times\n",
      "        normal No history of severe hepatic dysfunction Renal: Creatinine no greater than 2.0\n",
      "        mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: Ejection fraction at\n",
      "        least 50% No major heart disease No angina pectoris No major ventricular dysrhythmias\n",
      "        Hypertension or congestive heart failure that is controlled with medications allowed\n",
      "        Pulmonary: DLCO at least 60% of normal No symptomatic obstructive or restrictive disease\n",
      "        Other: HIV negative No uncompensated major thyroid or adrenal dysfunction No\n",
      "        insulin-dependent diabetes mellitus No active infections No significant skin breakdown\n",
      "        from tumor or other disease Must have been seen and evaluated by a dentist for teeth\n",
      "        cleaning and potential sources of infection No other prior malignancy except nonmelanoma\n",
      "        skin cancer Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No prior total dose of doxorubicin or daunorubicin of 450 mg/m2 or greater\n",
      "        unless an endomyocardial biopsy shows less than grade 2 drug effect Endocrine therapy: Not\n",
      "        specified Radiotherapy: No prior pelvic irradiation Surgery: Not specified Other: No\n",
      "        concurrent nitroglycerin or antiarrhythmic drugs\n",
      "3070\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced Hodgkin's disease requiring\n",
      "        systemic therapy Stage IA or IIA disease with bulky disease or more than three sites of\n",
      "        involvement are also eligible\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified\n",
      "        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other\n",
      "        active malignancy within 5 years HIV negative Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for Hodgkin's disease Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy for Hodgkin's disease Surgery: Not specified\n",
      "3071\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed glioblastoma multiforme with areas of necrosis as diagnosed\n",
      "             by surgical biopsy or subtotal excision\n",
      "               -  Supratentorial tumor\n",
      "          -  Gross measurable residual disease\n",
      "          -  No well-differentiated or anaplastic astrocytoma, multifocal glioma, or recurrent\n",
      "             glioblastoma multiforme\n",
      "          -  Therapy must begin within 5 weeks after surgery but within 1 week after registration\n",
      "          -  CT or MRI scan preoperatively and MRI postoperatively prior to initiation of\n",
      "             radiotherapy\n",
      "               -  If undergoing a stereotactic-guided needle biopsy, not required to repeat MRI\n",
      "                  after procedure if the prebiopsy MRI is suitable for treatment planning\n",
      "          -  Prior complete surgical resection of tumor allowed\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2 mg/dL\n",
      "          -  SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamic oxaloacetic\n",
      "             transaminase) no greater than 2 times normal\n",
      "        Renal:\n",
      "          -  BUN (blood urea nitrogen) no greater than 30 mg/dL\n",
      "          -  Creatinine no greater than 1.8 mg/dL\n",
      "        Pulmonary:\n",
      "          -  Normal chest x-ray OR\n",
      "          -  DLCO (carbon monoxide diffusing capacity) at least 60% predicted\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or\n",
      "             bladder, ductal carcinoma in situ of the breast, or nonmelanomatous skin cancer\n",
      "          -  Neurologic functional status 0-3\n",
      "          -  No major medical illness or psychiatric impairments that would preclude study\n",
      "             participation\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior systemic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to head or neck\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "3072\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed transitional cell carcinoma of the\n",
      "        urothelium (renal pelvis, ureter, bladder, or urethra) or mixed histologies containing a\n",
      "        component of transitional cell carcinoma of the urothelium with manifestations of\n",
      "        progressing regional or metastatic cancer Clinically unsuspected organ-confined prostate\n",
      "        cancer found during cystoprostatectomy allowed Evaluable or measurable disease No\n",
      "        significant pericardial or pleural effusion or edema No significant ascites No CNS\n",
      "        metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: AST no greater than 2 times upper limit of normal Bilirubin no\n",
      "        greater than 1.5 mg/dL Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No\n",
      "        history of severe cardiovascular disease (American Heart Association class III or IV),\n",
      "        uncontrolled congestive heart failure, or cardiac dysrhythmias Other: Prior malignancy\n",
      "        allowed if curatively treated with no evidence of recurrence No active infection requiring\n",
      "        parenteral antibiotics Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior systemic biologic response modifier\n",
      "        therapy No concurrent filgrastim (G-CSF) within 24 hours prior to and after study\n",
      "        chemotherapy administration Chemotherapy: No prior systemic chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: No prior pelvic radiotherapy as a component of\n",
      "        bladder-sparing therapy or as an adjuvant for locally advanced disease with positive\n",
      "        margins No concurrent local radiotherapy for pain control or life-threatening situations\n",
      "        Surgery: See Disease Characteristics\n",
      "3076\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic or incurable, locally\n",
      "        advanced squamous cell carcinoma of the esophagus Measurable disease outside of a\n",
      "        previously radiated field required\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin normal SGOT no greater than 2 times upper limit of\n",
      "        normal Renal: Creatinine normal Cardiovascular: No congestive heart failure or angina\n",
      "        pectoris, even if medically controlled No prior myocardial infarction within the past year\n",
      "        No clinically significant conduction system abnormalities, such as 2nd or 3rd degree heart\n",
      "        block or bundle branch block Pulmonary: Not specified Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception No active infections or medical\n",
      "        illnesses that are uncontrolled No second malignancy other than previously treated\n",
      "        nonmelanoma skin cancer or carcinoma in situ of the cervix or a prior malignancy from\n",
      "        which patient has been disease free for past 3 years Caloric intake greater than 1500\n",
      "        calories/day Fluid intake greater than 1500 mL/day\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy Surgery: Not specified\n",
      "3079\n",
      "DISEASE CHARACTERISTICS: Histologically proven breast cancer including: Stage IV\n",
      "        metastatic disease with current partial or complete response to prior induction\n",
      "        chemotherapy High risk primary disease with less than 60% chance of progression free\n",
      "        survival at 3 years Stage II tumors with 10 or more axillary node involvement Stage IIIA\n",
      "        or IIIB tumors No bone marrow metastases No CNS metastases No more than 10 bone metastases\n",
      "        Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 59 and under Menopausal status: Not specified Performance\n",
      "        status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Neutrophil count\n",
      "        greater than 2,000/mm3 Platelet count greater than 150,000/mm3 Hemoglobin greater than 9\n",
      "        g/dL (blood transfusions allowed) Hepatic: Bilirubin no greater than 1.2 mg/dL SGOT or\n",
      "        SGPT less than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.2 mg/dL\n",
      "        Creatinine clearance at least 80 mL/min No prior hemorrhagic cystitis Cardiovascular:\n",
      "        Ejection fraction at least 55% by MUGA No prior valvular heart disease or arrhythmia\n",
      "        Pulmonary: DLCO at least 60% lower limit of predicted pCO2 no greater than 43 mmHg on room\n",
      "        air pO2 greater than 85 mmHg on room air FEV 1 at least 2 liters Other: No other prior\n",
      "        malignancy except basal or squamous cell skin cancer, or carcinoma in situ or stage I\n",
      "        carcinoma of the cervix Not pregnant HIV negative Hepatitis B negative No prior history of\n",
      "        disabling psychosocial disorder No other CNS dysfunction\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy No more than 2 prior\n",
      "        chemotherapy regimens for metastatic disease Prior total doxorubicin dose no greater than\n",
      "        180 mg/m2 Prior total paclitaxel dose no greater than 750 mg/m2 Endocrine therapy: At\n",
      "        least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy No prior radiotherapy to the left chest wall No prior radiotherapy to greater\n",
      "        than 20% of bone marrow (excluding syngeneic transplantation candidates) Surgery: Not\n",
      "        specified\n",
      "3080\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven malignancies refractory to conventional\n",
      "             treatment or for which no standard therapy exists\n",
      "          -  Primary brain tumor or brain metastases allowed if stable symptoms within 2 weeks\n",
      "             prior to study and able to give informed consent\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 75\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 10.0 g/dL\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.0 mg/dL\n",
      "          -  AST and ALT no greater than 2.5 times upper limit of normal if due to liver\n",
      "             metastases\n",
      "          -  No chronic liver disease\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.47 mg/dL OR\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No angina requiring treatment within the past 6 months\n",
      "          -  No uncompensated coronary artery disease by electrocardiogram or physical examination\n",
      "          -  No prior transient ischemic attacks, stroke, or peripheral vascular disease\n",
      "          -  LVEF at least 45%\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "          -  No allergy to egg products\n",
      "          -  No nonmalignant systemic disease that would increase risk\n",
      "          -  No active uncontrolled infection\n",
      "          -  No diabetes mellitus with evidence of severe peripheral vascular disease or diabetic\n",
      "             ulcers\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)\n",
      "             and recovered\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since other prior endocrine therapy and recovered\n",
      "          -  Concurrent corticosteroids for symptom control allowed if no change in dose\n",
      "             requirement within 2 weeks prior to study\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy (except for palliative reasons) and\n",
      "             recovered\n",
      "          -  Concurrent radiotherapy allowed for control of bone pain or as indicated\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent investigational treatment\n",
      "          -  No concurrent treatment with drugs interfering with hepatic CYP3A4 metabolism (e.g.,\n",
      "             grapefruit juice or warfarin)\n",
      "3081\n",
      "DISEASE CHARACTERISTICS: Histologically proven non-Hodgkin's lymphoma or Hodgkin's disease\n",
      "        Diffuse small cell (i.e., chronic lymphocytic leukemia, small lymphocytic, immunocytoma)\n",
      "        Follicular Mantle cell Peripheral T cell Diffuse large B cell Leukemic (i.e.,\n",
      "        lymphoblastic, Burkitt's) First relapse or first progression after responding to a salvage\n",
      "        regimen and high dose chemotherapy with autologous stem cell transplantation (second\n",
      "        remission) Response of greater than 50% of tumor mass decrease observed at time of\n",
      "        progression Prior high dose chemotherapy plus autologous stem cell transplantation as\n",
      "        first line therapy allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 64 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminase no greater than 3.0 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.7 mg/dL Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No other prior or concurrent malignancies except curatively treated (by\n",
      "        radiotherapy or surgery) basal cell skin cancer or carcinoma in situ\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No other\n",
      "        concurrent immunotherapy No concurrent hematopoietic growth factors Chemotherapy: See\n",
      "        Disease Characteristics No concurrent chemotherapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: No concurrent radiotherapy Surgery: Not specified\n",
      "3082\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage II or III (T2-4a, Nx or N0, M0) primary carcinoma of\n",
      "             the bladder with muscle invasion\n",
      "               -  Resectable disease\n",
      "               -  Prostatic urethral involvement with transitional cell carcinoma allowed, if\n",
      "                  completely resected and no evidence of stromal invasion\n",
      "               -  No tumor-related hydronephrosis\n",
      "          -  Positive lymph node must be evaluated by lymphadenectomy or percutaneous needle\n",
      "             biopsy\n",
      "               -  No nodal metastases\n",
      "          -  No distant metastases\n",
      "          -  No more than 6 weeks since prior transurethral resection of the bladder tumor\n",
      "               -  Functioning bladder\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Adult\n",
      "        Performance status:\n",
      "          -  Zubrod 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "          -  White blood cell (WBC) count of at least 4,000/mm^3\n",
      "          -  Absolute neutrophil count at least 1,800/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Other:\n",
      "          -  No other prior or concurrent malignancy within the past 5 years except curatively\n",
      "             treated nonmelanoma skin cancer, stage I prostate cancer, or carcinoma in situ of the\n",
      "             cervix\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Medically operable\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior systemic chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior pelvic radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "        Other:\n",
      "          -  No concurrent potential nephrotoxic or ototoxic drugs (e.g., aminoglycosides)\n",
      "3083\n",
      "DISEASE CHARACTERISTICS: Diagnosis of any of the following: Chronic myelogenous leukemia\n",
      "        (CML) in first chronic phase Myelodysplastic syndrome Refractory anemia with excess blasts\n",
      "        (RAEB) RAEB in transformation Secondary leukemias untreated or in complete remission 1\n",
      "        (CR1) Acute myeloid leukemia in complete remission 2 (CR2) Acute lymphocytic leukemia\n",
      "        (ALL) in CR2 High-risk acute leukemia in CR1 Ph+ ALL in CR1 or consolidation after\n",
      "        induction chemotherapy Must qualify for allogeneic bone marrow transplantation (BMT) No\n",
      "        HLA-matched, sibling donor for BMT available No current CNS disease No history of more\n",
      "        than 2 episodes of active CNS disease\n",
      "        PATIENT CHARACTERISTICS: Age: 19 to 55 Performance status: ECOG 0 or 1 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL\n",
      "        Renal: Creatinine no greater than 2 mg/dL Cardiovascular: LVEF at least 45% No active\n",
      "        congestive heart failure, arrhythmia, or angina pectoris No myocardial infarction within\n",
      "        the past 12 months Pulmonary: FEV1 and FVC at least 50% predicted (75% predicted if\n",
      "        received prior thoracic or mantle radiotherapy) Other: No active serious infection (e.g.,\n",
      "        mucormycosis, uncontrolled aspergillosis, or tuberculosis) HIV negative Not pregnant\n",
      "        Fertile patients must use effective contraception No concurrent debilitating medical or\n",
      "        psychiatric illness that would preclude compliance No prior malignancy except curatively\n",
      "        treated skin cancer or carcinoma of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior\n",
      "        autologous or allogeneic bone marrow transplantation No prior transfusions from donor\n",
      "        Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy:\n",
      "        Not specified Surgery: Not specified\n",
      "3086\n",
      "Inclusion Criteria:\n",
      "          -  Histologically confirmed, locally advanced, non-metastatic primary T3 or T4 primary\n",
      "             adenocarcinoma of the rectum\n",
      "          -  No evidence of tumor outside of the pelvis including liver metastases, peritoneal\n",
      "             seeding, or metastatic inguinal lymphadenopathy\n",
      "          -  No intra-operative radiotherapy (IORT) or brachytherapy will be allowed\n",
      "          -  The distal border of the tumor must be at or below the peritoneal reflection, defined\n",
      "             as within 12 centimeters of anal verge by proctoscopic examination\n",
      "          -  Transmural penetration of tumor through the muscularis propria must be demonstrated\n",
      "             by either of the following:\n",
      "               -  CT scan plus endorectal ultrasound or\n",
      "               -  MRI\n",
      "          -  Tumors must be defined prospectively by the surgeon as clinically resectable or not;\n",
      "             clinically resectable tumors will be defined by the surgeon as mobile and completely\n",
      "             resectable with negative margins based on the routine examination of the\n",
      "             non-anesthetized patient; before pre-op treatment, the surgeon should estimate and\n",
      "             record the type of resection anticipated: APR, LAR, or LAR/coloanal anastomosis\n",
      "          -  The tumor may be clinically fixed or initially not completely resectable, clinical\n",
      "             stage T4, N0-2, M0 based on the presence of at least one of the following criteria:\n",
      "               -  Clinically fixed tumors on rectal examination with tumor adherent to the pelvic\n",
      "                  sidewall or sacrum\n",
      "               -  Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the\n",
      "                  lack of clear tissue plane will be considered evidence of fixation\n",
      "               -  Hydronephrosis on CT scan or IVP or ureteric or bladder invasion as documented\n",
      "                  by cystoscopy and cytology or biopsy, or invasion into prostate\n",
      "               -  Vaginal or uterine involvement\n",
      "          -  ECOG performance status 0-2 and surgical evaluation confirms the patient's medical\n",
      "             condition would tolerate the proposed surgical procedure\n",
      "          -  Caloric intake should be >= 1500 kilocalories/d\n",
      "          -  WBC >= 3500/uL\n",
      "          -  Platelets >= 100,000/uL\n",
      "          -  Serum creatinine =< 2.0 mg/dL\n",
      "          -  Serum bilirubin less than 2.0 mg/dL\n",
      "          -  Alk Phos =< 2 x ULN\n",
      "          -  SGOT =< 2 x ULN\n",
      "          -  CEA should be determined prior to initiation of therapy\n",
      "          -  Absence of clinical evidence of high-grade (lumen diameter < 1cm) large bowel\n",
      "             obstruction, unless diverting colostomy has been performed\n",
      "          -  Pregnant or lactating women are not eligible\n",
      "          -  Women of childbearing potential and sexually active males are strongly advised to use\n",
      "             an accepted and effective method of contraception\n",
      "          -  No prior chemotherapy or pelvic irradiation therapy\n",
      "          -  No previous or concurrent malignancy is allowed, except:\n",
      "               -  Nonmelanoma skin cancer or in situ cervical cancer\n",
      "               -  Treated non-pelvic cancer from which the patient has been continuously disease\n",
      "                  free more than five years\n",
      "          -  No active inflammatory bowel disease or other serious medical illness which might\n",
      "             limit the ability of the patient to receive protocol therapy\n",
      "3088\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic stage IV/clinical group IV rhabdomyosarcoma,\n",
      "             undifferentiated sarcoma, or ectomesenchymoma\n",
      "               -  No metastatic embryonal tumors in patients under 10 years of age, regardless of\n",
      "                  primary site\n",
      "               -  Metastatic tumors of parameningeal sites eligible\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No positive cerebrospinal fluid cytology or multiple intracranial metastases\n",
      "          -  Patients presenting with the following are only eligible for continuation therapy and\n",
      "             may not receive irinotecan/vincristine upfront window therapy:\n",
      "               -  Evidence of base of skull erosion or skull metastatic disease that displaces or\n",
      "                  indents the dura, compresses the brain parenchyma, or causes evidence of cranial\n",
      "                  nerve palsy\n",
      "               -  Tumor that touches or displaces the spinal cord\n",
      "               -  Evidence of intracranial primary tumor extension\n",
      "               -  Tumors that could cause potentially life-threatening complications (e.g., renal,\n",
      "                  airway) with progression due to location and/or growth rate\n",
      "               -  Requires emergency radiotherapy\n",
      "               -  Lab values are consistent with disseminated intravascular coagulation\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Under 50 (alveolar rhabdomyosarcoma, undifferentiated sarcoma, and ectomesenchymoma\n",
      "             patients)\n",
      "          -  10 to 49 (embryonal histology patients)\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "          -  Absolute neutrophil count greater than 1,000/mm^3*\n",
      "          -  Platelet count greater than 150,000/mm^3* NOTE: *Unless there is tumor involvement of\n",
      "             bone marrow\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  PT, PTT, and fibrinogen less than 1.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.2 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior steroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  No more than 42 days since prior initial surgical procedure, including biopsy for\n",
      "             diagnosis\n",
      "3089\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignancy for which no curative therapy\n",
      "        exists At least 1 bidimensionally measurable lesion No acute or chronic leukemia or\n",
      "        multiple myeloma No active CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG-WHO 0-2 Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count greater than\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic:\n",
      "        Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 3 times upper limit of\n",
      "        normal (ULN) (5 times ULN if elevations due to liver metastasis) Renal: Creatinine no\n",
      "        greater than 1.5 times ULN Cardiovascular: No prior or concurrent QTc interval\n",
      "        prolongation greater than 500 m/sec, unless approved by cardiology consult prior to study\n",
      "        Other: No malabsorption syndrome due to surgery, prior disease, or other unknown reason No\n",
      "        frequent vomiting or other medical condition that could interfere with oral medicine\n",
      "        intake (e.g., partial bowel obstruction, external biliary diversion) No concurrent\n",
      "        nonmalignant systemic disease making patient a poor risk for study No active uncontrolled\n",
      "        infection Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        and recovered No prior allogeneic, syngeneic, or autologous bone marrow transplantation No\n",
      "        prior peripheral blood stem cell transplantation No concurrent biologic therapy\n",
      "        Chemotherapy: No more than 2 prior chemotherapy regimens At least 4 weeks since prior\n",
      "        chemotherapy (6 weeks since mitomycin or nitrosoureas) and recovered No other concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered No prior wide field radiation (radiotherapy to at least 25% of\n",
      "        bone marrow, including pelvic irradiation) No concurrent radiotherapy Surgery: Prior major\n",
      "        gastrointestinal surgery allowed if recovered Other: At least 4 weeks since other prior\n",
      "        investigational therapy and recovered\n",
      "3090\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor that is not\n",
      "        amenable to standard therapy Measurable or evaluable disease No brain involvement or\n",
      "        leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Liver function tests no\n",
      "        greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN if liver\n",
      "        metastases present) Renal: Creatinine no greater than 1.4 mg/dL Creatinine clearance at\n",
      "        least 60 mL/min Cardiovascular: LVEF at least 50% (by MUGA) Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception No active infections No other\n",
      "        nonmalignant disease that precludes study No history of alcoholism, drug addiction, or\n",
      "        psychotic disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas,\n",
      "        mitomycin, and high dose carboplatin) No other concurrent antitumor drugs Endocrine\n",
      "        therapy: No concurrent corticosteroids Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy (6 weeks for extensive radiotherapy) No concurrent radiotherapy Surgery: Not\n",
      "        specified Other: No prior anthracyclines or anthracenediones No other concurrent\n",
      "        investigational drugs\n",
      "3092\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor not\n",
      "        amenable to standard therapy No brain tumor involvement or leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin less than 1.5 mg/dL\n",
      "        Transaminases and alkaline phosphatase no greater than 2.5 times upper limit of normal\n",
      "        (ULN) (no greater than 5 times ULN for liver metastases) Renal: Creatinine no greater than\n",
      "        1.4 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active bacterial infections\n",
      "        (e.g., abscess or fistula) No other nonmalignant disease that precludes protocol therapy\n",
      "        No history of alcoholism, drug addiction, or psychotic disorders that would prevent\n",
      "        compliance No glaucoma Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy: At least 4 weeks since prior anticancer hormonal therapy Radiotherapy:\n",
      "        At least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy) No\n",
      "        concurrent radiotherapy except for localized palliation Surgery: Not specified Other: No\n",
      "        other concurrent investigational drugs or antitumor drugs No sulphonylureas or\n",
      "        anti-arrhythmic agents\n",
      "3093\n",
      "DISEASE CHARACTERISTICS: Anemic: Hemoglobin in males less than 11.5 g/dL; hemoglobin in\n",
      "        females less than 10.0 g/dL No anemia secondary to B12, folic acid, or iron deficiency No\n",
      "        anemia secondary to gastrointestinal bleed or hemolysis No anemia secondary to a primary\n",
      "        or chemotherapy-induced myelodysplastic syndrome No anemia secondary to acute lymphocytic\n",
      "        leukemia Histologically confirmed advanced malignancy Lung Breast Other Currently\n",
      "        receiving myelosuppressive, cytotoxic chemotherapy for advanced cancer No patients\n",
      "        receiving adjuvant therapy for cancer that has been surgically removed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 4 months Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal:\n",
      "        Not specified Cardiovascular: No uncontrolled hypertension (systolic at least 180,\n",
      "        diastolic at least 100) Other: Normal or elevated ferritin No known hypersensitivity to\n",
      "        epoetin alfa Must be able to reliably take oral medication Must be alert and mentally\n",
      "        competent Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 year since prior epoetin alfa At\n",
      "        least 2 weeks since prior red blood cell transfusions No concurrent peripheral blood stem\n",
      "        cell or bone marrow transplantation Chemotherapy: See Disease Characteristics Endocrine\n",
      "        therapy: Not specified Radiotherapy: Concurrent radiotherapy allowed Surgery: See Disease\n",
      "        Characteristics\n",
      "3094\n",
      "DISEASE CHARACTERISTICS: Clinically dysplastic nevi with a personal history of cutaneous\n",
      "        melanoma and/or a family history of cutaneous melanoma in two or more blood relatives\n",
      "        (blood relatives include first, second, or third degree relatives from the same blood\n",
      "        line) Clinically dysplastic nevi defined as: At least 4 mm in diameter and flatness\n",
      "        (either a component or throughout) with at least 1 of the following: Variable pigmentation\n",
      "        Irregular or asymmetrical outline Indistinct border Must have at least 10 or more large\n",
      "        (diameter at least 4 mm) clinically dysplastic nevi on the trunk or extremities (excluding\n",
      "        head, pubic area, breasts in women, hands, and/or below the knees) No stage III or IV\n",
      "        melanoma Patients with history of melanoma who received adjuvant therapy must be more than\n",
      "        1 year from completion of therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC greater than 3,500/mm3 Platelet count greater than\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL AST less than 2 times normal Alkaline\n",
      "        phosphatase less than 2 times normal Renal: Creatinine less than 2.0 mg/dL Cardiovascular:\n",
      "        No symptomatic arteriosclerotic coronary artery disease No history of coronary artery\n",
      "        disease Other: Fasting triglyceride level less than 210 mg/dL Fasting cholesterol level\n",
      "        less than 350 mg/dL No nonmalignant disease that would preclude administration of\n",
      "        retinoids No psychiatric conditions that would preclude study compliance Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception during\n",
      "        and for 6 months after study\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics Biologic therapy: Not specified\n",
      "        Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified\n",
      "        Surgery: No prior coronary bypass surgery Other: No prior systemic retinoids No concurrent\n",
      "        vitamin (except a daily multivitamin) or dietary supplement No concurrent systemic therapy\n",
      "        for hyperlipidemia\n",
      "3095\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory acute leukemia\n",
      "        (myeloid or lymphoid), blast crisis chronic myeloid leukemia, myelodysplasia, lymphoma, or\n",
      "        myeloma of all FAB subtypes\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 6 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL\n",
      "        (except for leukemic infiltration dysfunction) Alkaline phosphatase less than 2 times\n",
      "        upper limit of normal (except for leukemic infiltration dysfunction) Renal: Creatinine no\n",
      "        greater than 2.0 mg/dL Other: No active infection Not pregnant Fertile patients must use\n",
      "        effective contraception No history of seizure disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 2 weeks\n",
      "        since prior chemotherapy (except hydroxyurea) No other concurrent chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: Not specified\n",
      "        Other: No other concurrent investigational agents Concurrent antibiotic therapy allowed\n",
      "        for stable patients\n",
      "3096\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed serous papillary carcinoma of the ovary\n",
      "               -  Recurrent or refractory disease following at least one regimen including\n",
      "                  paclitaxel, cisplatin, or carboplatin\n",
      "          -  Measurable disease outside of irradiated field\n",
      "          -  No CNS metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 16 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,800/mm^3\n",
      "          -  Platelet count at least 125,000/mm^3\n",
      "          -  No history of thrombosis or thromboembolic events\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.0 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 2 months after study\n",
      "          -  No other concurrent second malignancy or prior malignancy within past 5 years, except\n",
      "             basal or squamous cell skin cancer or curatively treated stage I carcinoma of the\n",
      "             cervix\n",
      "          -  No concurrent infection\n",
      "          -  At least 3 days since prior fever (unless due to tumor)\n",
      "          -  No other concurrent severe medical illness\n",
      "          -  No HIV positivity\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior tamoxifen or antiestrogen therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 6 months since prior radiotherapy\n",
      "          -  No concurrent radiotherapy except to symptomatic or potentially disabling bone lesion\n",
      "             accompanied by other measurable disease\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent anticoagulants\n",
      "          -  No other concurrent therapeutic trials\n",
      "3098\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck Metastatic disease at diagnosis OR Persistent, metastatic or recurrent disease\n",
      "        following surgery and/or radiotherapy No newly diagnosed nonmetastatic disease\n",
      "        Bidimensionally measurable disease Demonstrated progressive disease if only measurable\n",
      "        site is within a previous radiotherapy port\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times\n",
      "        upper limit of normal (ULN) SGOT or SGPT no greater than 1.5 times ULN Alkaline\n",
      "        phosphatase no greater than 2.5 times ULN Renal: Calcium no greater than upper limit of\n",
      "        normal (ULN) Creatinine no greater than 1.5 times ULN OR Creatinine clearance at least 60\n",
      "        mL/min Other: Not pregnant or nursing Fertile patients must use effective contraception No\n",
      "        other prior malignancy within the past 5 years except adequately treated basal cell or\n",
      "        squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or any adequately\n",
      "        treated stage I or II cancer that is currently in complete remission No neuropathy sensory\n",
      "        greater than grade 1 No history of hypersensitivity reaction to Polysorbate 80\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        No prior carboplatin or cisplatin No prior chemotherapy for recurrent disease No other\n",
      "        concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy (except oral\n",
      "        contraceptives or treatment for osteoporosis) Radiotherapy: See Disease Characteristics At\n",
      "        least 28 days since prior radiotherapy and recovered No concurrent radiotherapy Surgery:\n",
      "        See Disease Characteristics At least 28 days since prior surgery and recovered\n",
      "3099\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed incurable high-grade glioma, glioblastoma multiforme, or\n",
      "             anaplastic astrocytoma that is refractory or recurrent, or with residual tumor after\n",
      "             standard therapy, including radiotherapy\n",
      "               -  Evidence of tumor by gadolinium-enhanced MRI or contrast-enhanced CT scan\n",
      "          -  No brain stem tumor\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  6 months to 17 years\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 1,500/mm^3\n",
      "          -  Platelet count greater than 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal insufficiency\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No serious active infections or fever\n",
      "          -  No other serious concurrent disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "          -  No concurrent antineoplastic therapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior antineoplaston therapy\n",
      "3100\n",
      "DISEASE CHARACTERISTICS: Histologically proven primary stage I (T2, N0), II, or IIIA\n",
      "        non-small cell lung cancer (NSCLC) curatively resected by pneumonectomy, lobectomy, or\n",
      "        wedge resection OR Stage I or II mesothelioma Measurable disease Lesions must be at least\n",
      "        3 cm in diameter\n",
      "        PATIENT CHARACTERISTICS: Age: 20 to 70 Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: No other malignancy except nonmelanoma skin cancer No history of severe allergies\n",
      "        No history of autoimmune disease Not pregnant\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n",
      "        Endocrine therapy: No concurrent glucocorticoids Radiotherapy: Not specified Surgery: See\n",
      "        Disease Characteristics Other: No concurrent nonsteroidal antiinflammatory drugs\n",
      "3101\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic renal cell carcinoma\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  Clear evidence of progression if only site of measurable disease is within previous\n",
      "             radiation port\n",
      "          -  Previously irradiated brain metastases allowed, if not life threatening, symptoms\n",
      "             controlled for 3 months, and not requiring corticosteroids\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0-1\n",
      "          -  Life expectancy: Greater than 3 months\n",
      "          -  WBC at least 3,000/mm3\n",
      "          -  Platelet count at least 100,00/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  Creatinine no greater than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception for 1 month before, during, and for\n",
      "             3 months after study\n",
      "          -  No active bacterial or viral infection\n",
      "          -  No serious underlying medical condition that would interfere with compliance\n",
      "          -  No other malignancy within the past 5 years except basal cell carcinoma of the skin\n",
      "          -  No dementia or altered mental status that would prevent informed consent\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No more than 1 prior therapy with biologic response modifiers\n",
      "          -  No prior chemotherapy for advanced disease\n",
      "          -  No other concurrent chemotherapy\n",
      "          -  No concurrent steriods (except topical use)\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "          -  At least 4 weeks since major surgery (including nephrectomy)\n",
      "          -  No other concurrent experimental agents\n",
      "3102\n",
      "DISEASE CHARACTERISTICS: Histologically proven recurrent glioblastoma or anaplastic\n",
      "        astrocytoma Stereotactically accessible, enhancing mass no greater than 50 mL total volume\n",
      "        by MRI No significant mass effect Recent craniotomy allowed No anaplastic\n",
      "        oligodendroglioma No tumors of the brainstem, cerebellum, or both hemispheres No diffuse\n",
      "        subependymal or CSF disease If on stable or increasing dose of steroid, must have evidence\n",
      "        of increasing contrast enhancement by MRI or CT scan Prior external beam radiotherapy\n",
      "        required\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 1500/mm3\n",
      "        Platelet count greater than 100,000/mm3 Hemoglobin greater than 9.5 g/dL Hepatic:\n",
      "        Bilirubin less than 2 mg/dL AST and ALT less than 2 times upper limit of normal (ULN)\n",
      "        PT/PTT no greater than ULN Renal: Creatinine less than 2 mg/dL Other: Not pregnant\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No systemic\n",
      "        diseases to cause unacceptable anesthetic/operative risk No active infection requiring\n",
      "        treatment No unexplained febrile illness\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent blood or platelet transfusions\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: See Disease\n",
      "        Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        radiotherapy Surgery: See Disease Characteristics Medically able to undergo surgery Other:\n",
      "        No other concurrent investigational agents\n",
      "3103\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed diagnosis of any cancer\n",
      "        other than breast cancer, multiple myeloma, or prostate cancer Objective evidence of bone\n",
      "        metastases discovered within 6 weeks of study entry (patients who at screening present\n",
      "        with an ECOG score of 2) No study entry restrictions for bone metastases for patients with\n",
      "        an ECOG of 0 and 1 No symptomatic brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.5 mg/dL\n",
      "        for liver metastases Renal: Creatinine no greater than 3.0 mg/dL Calcium at least 8.0\n",
      "        mg/dL but less than 12.0 mg/dL Cardiovascular: No history of severe cardiovascular disease\n",
      "        within past 6 months (e.g., congestive heart failure) No hypertension refractory to\n",
      "        treatment No symptomatic coronary artery disease Other: Not pregnant or nursing Negative\n",
      "        pregnancy test Fertile patients must use effective contraception No history of\n",
      "        noncompliance to medical regimen\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Concurrent biologic response modifier\n",
      "        therapies allowed Concurrent marketed cytokine or colony stimulating factor therapies\n",
      "        allowed Chemotherapy: Concurrent marketed chemotherapy agents allowed (including open\n",
      "        label cooperative trials or for supportive care) Endocrine therapy: Concurrent hormonal\n",
      "        agents and steroid therapies allowed Concurrent corticosteroid therapy allowed (for\n",
      "        chemotherapy induced nausea/vomiting or spinal compression) Radiotherapy: Concurrent\n",
      "        radiotherapy to treat extraskeletal and/or skeletal tumor sites allowed Surgery: Prior\n",
      "        surgery to treat or prevent pathological fracture or spinal cord compression allowed\n",
      "        Other: At least 30 days since other prior investigational drugs No concurrent\n",
      "        bisphosphonate agent At least 30 days since prior bisphosphonate agent (single exposure\n",
      "        allowed within prior 12 months)\n",
      "3105\n",
      "DISEASE CHARACTERISTICS: Any of the following diagnoses eligible: Acute myelogenous\n",
      "        leukemia beyond first complete remission Acute lymphoblastic leukemia Chemotherapy\n",
      "        resistant non-Hodgkin's lymphoma Chemotherapy resistant Hodgkin's disease Multiple myeloma\n",
      "        Primary refractory acute leukemia Secondary leukemia Chronic myelomonocytic leukemia No\n",
      "        chronic myelogenous leukemia, aplastic anemia, or myelofibrosis HLA identical related\n",
      "        donor required\n",
      "        PATIENT CHARACTERISTICS: Age: 0.5 to 65 Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: See Disease Characterisitics Hepatic: Bilirubin less than 2.5\n",
      "        mg/dL (unless Gilbert's syndrome present) Renal: Creatinine no greater than 2 mg/dL\n",
      "        Cardiovascular: No active congestive heart failure, arrhythmia, or angina pectoris No\n",
      "        myocardial infarction within past 12 months Pulmonary: No requirement for oxygen Other:\n",
      "        Afebrile for greater than 48 hours No active, serious infection (e.g., sepsis,\n",
      "        mucormycosis, or uncontrolled aspergillosis) No debilitating medical or psychiatric\n",
      "        illness that would preclude compliance Not pregnant Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplant Chemotherapy:\n",
      "        See Disease Characteristics Endocrine therapy: No concurrent corticosteroids Radiotherapy:\n",
      "        Not specified Surgery: Not specified\n",
      "3106\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven adenocarcinoma of the stomach\n",
      "               -  Stage IB, II, IIIA, IIIB, and IV (T2-3, any N, M0)\n",
      "                    -  No lymph node metastases outside the field of resection (e.g.,\n",
      "                       supraclavicular, mediastinal, or paraaortic nodes)\n",
      "               -  Potentially resectable\n",
      "               -  May involve the gastroesophageal junction, but bulk of tumor must be in the\n",
      "                  stomach\n",
      "               -  No distant metastases\n",
      "               -  No pleural or pericardial effusion\n",
      "          -  No peritoneal disease diagnosed by laparoscopy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Zubrod 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 16 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute granulocyte count greater than 2,000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No New York Heart Association class III or IV heart disease\n",
      "          -  No hypertension\n",
      "        Neurologic:\n",
      "          -  No cerebrovascular disease\n",
      "          -  No diabetic neuropathy\n",
      "          -  No mental status abnormalities\n",
      "        Other:\n",
      "          -  No uncontrolled diabetes\n",
      "          -  No infection\n",
      "          -  No other malignancies within past 5 years except resected squamous cell or basal cell\n",
      "             skin cancer\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to stomach\n",
      "        Surgery:\n",
      "          -  No prior surgery to stomach\n",
      "3108\n",
      "DISEASE CHARACTERISTICS: Histologically proven prostate cancer limited to the prostate\n",
      "        (including seminal vesicle and/or local lymph node involvement) with elevated PSA (greater\n",
      "        than 2 ng/ml) following surgery or rising PSA following radiotherapy Negative bone scan\n",
      "        and CT scan of abdomen and pelvis No PSA progression during chemotherapy, hormonal therapy\n",
      "        (including steroids), or neoadjuvant or adjuvant androgen ablation therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 6 months Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: SGOT and SGPT no greater than 2 times upper limit of normal Bilirubin no greater\n",
      "        than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at\n",
      "        least 50 mL/min Cardiovascular: Not specified Pulmonary: Not specified Other: No active\n",
      "        untreated infection No known infection with HIV No concurrent medical conditions that\n",
      "        would prevent compliance No history or evidence of active eczema or psoriasis or other\n",
      "        contraindications to vaccinia virus administration (i.e., allergy) No significant allergy\n",
      "        or hypersensitivity to eggs No evidence of immunosuppression Must be able to avoid contact\n",
      "        with high risk individuals (immunosuppressed patients, children under 3, pregnant women,\n",
      "        or patients with a history of or active eczema or other exfoliative diseases) for 7-10\n",
      "        days after immunization (household contacts must not be high risk) Fertile patients must\n",
      "        use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 6 months since prior chemotherapy and recovered Endocrine\n",
      "        therapy: See Disease Characteristics At least 6 months since prior hormonal therapy\n",
      "        (including steroids) and recovered Radiotherapy: See Disease Characteristics At least 3\n",
      "        months since prior radiotherapy of prostate and recovered Surgery: See Disease\n",
      "        Characteristics At least 3 months since prior prostate surgery and recovered Other: Prior\n",
      "        vaccinia immunization required OR Patient recollection of immunization and appropriate\n",
      "        vaccination site scar\n",
      "3109\n",
      "Inclusion Criteria:\n",
      "          -  Histologically proven solid tumor or lymphoma\n",
      "               -  Responded to irinotecan OR no existing curative therapy\n",
      "          -  No leukemia\n",
      "          -  Measurable or evaluable disease\n",
      "          -  Performance status - Karnofsky 70-100%\n",
      "          -  WBC at least 3500/mm^3\n",
      "          -  Absolute neutrophil count at least 1500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Bilirubin normal\n",
      "          -  SGOT/SGPT less than 5 times upper limit of normal (unless due to disease)\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No inflammatory bowel disease requiring therapy\n",
      "          -  No chronic diarrhea syndrome or paralytic ileus\n",
      "          -  At least 2 weeks since prior colony stimulating factor\n",
      "          -  At least 4 weeks since prior biologic therapy\n",
      "          -  No concurrent biologic therapy\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n",
      "          -  No other concurrent chemotherapy\n",
      "          -  At least 4 weeks since prior radiotherapy to greater than 25% of bone marrow\n",
      "          -  No concurrent palliative radiotherapy\n",
      "          -  No prior transplant\n",
      "          -  No concurrent substrates of UGT1A1 enzyme\n",
      "          -  No concurrent inducers or inhibitors of UGT1A1 enzyme activity\n",
      "3110\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage II breast cancer with 1 of the\n",
      "        following: Estrogen receptor negative with at least 4 positive nodes OR Estrogen receptor\n",
      "        positive with at least 6 positive nodes OR Histologically proven stage IIIA breast cancer\n",
      "        Must have already received 4-7 courses of conventional chemotherapy with a doxorubicin\n",
      "        based regimen (which may include paclitaxel or docetaxel) No greater than 60 days since\n",
      "        induction chemotherapy Prior definitive surgical treatment of primary lesion (modified\n",
      "        radical mastectomy or breast conserving procedure plus axillary node dissection) Margins\n",
      "        free of tumor Hormone receptor status: Estrogen and progesterone receptor status known\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 65 Menopausal status: Not specified Performance\n",
      "        status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Not specified\n",
      "        Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 2 times normal\n",
      "        Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular: Left ventricular ejection fraction at least 50% if any of the following:\n",
      "        Symptoms of congestive heart failure Abnormal cardiac exam Prior doxorubicin dose greater\n",
      "        than 400 mg/m2 Pulmonary: No significant pulmonary disease (DLCO less than 60% predicted)\n",
      "        Other: Not pregnant Negative pregnancy test HIV negative No significant active infection\n",
      "        No other severe disease that would severely limit life expectancy No other malignancy\n",
      "        within past 5 years unless: Chance of survival for greater than 5 years is 90% AND Treated\n",
      "        with surgery only (no chemotherapy or radiotherapy)\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No greater than 1 prior chemotherapy regimen (no greater than 7 prior\n",
      "        courses) Endocrine therapy: No concurrent tamoxifen Radiotherapy: Not specified Surgery:\n",
      "        See Disease Characteristics Other: No other concurrent experimental agents\n",
      "3111\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed ovarian epithelial, peritoneal, or tubal\n",
      "        cancer Epithelial cell types Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous\n",
      "        adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial\n",
      "        carcinoma Transitional cell Malignant Brenner's tumor Adenocarcinoma not otherwise\n",
      "        specified Measurable or evaluable disease No brain or leptomeningeal metastases No\n",
      "        symptomatic bowel involvement of ovarian cancer Not eligible for higher priority GOG phase\n",
      "        II or III study\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal SGOT/SGPT/GGT no\n",
      "        greater than 3 times normal Alkaline phosphatase no greater than 3 times normal No acute\n",
      "        hepatitis Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance greater than\n",
      "        50 mL/min Other: No septicemia or severe infection Body surface area at least 1 m2\n",
      "        Adequate intestinal function (i.e., does not require IV hydration or nutritional support)\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception 3 months prior to and during study No other malignancies within the past 5\n",
      "        years except curatively treated skin cancer No other severe medical problems that would\n",
      "        prevent compliance No condition of the GI tract that would affect GI absorption and\n",
      "        motility No severe gastrointestinal bleeding\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No\n",
      "        prior topotecan, other camptothecin analogs, or etoposide At least 1 prior\n",
      "        cisplatin/paclitaxel based regimen At least 3 weeks since prior chemotherapy and recovered\n",
      "        No more than 2 prior cytotoxic chemotherapy regimens No other concurrent chemotherapy\n",
      "        Endocrine therapy: No concurrent hormonal therapy for cancer Radiotherapy: At least 3\n",
      "        weeks since prior radiotherapy to no more than 10% of the bone marrow and recovered No\n",
      "        concurrent radiotherapy Surgery: Not specified Other: At least 28 days or 5 half lives\n",
      "        since prior investigational drugs (including cytotoxic drugs) No concurrent metoclopramide\n",
      "        or cisapride for maintaining gastric motility or emptying No chronic H2 antagonists,\n",
      "        proton pump inhibitors, or antacids for gastritis, gastroesophageal reflux disease, or\n",
      "        gastric or duodenal ulcers Intermittent antacids allowed, if no antacids 6 hours prior to\n",
      "        and 90 minutes after topotecan\n",
      "3112\n",
      "Inclusion:\n",
      "          -  Phenotypic studies from peripheral blood showing CD3+, CD57+ cells greater than\n",
      "             400/mm3 or CD8+ cells greater than 650/mm3 within eight weeks prior to registration\n",
      "          -  Evidence for clonal T-cell receptor gene rearrangement within one year prior to\n",
      "             registration\n",
      "          -  At least one of the following: Severe neutropenia less than 500/mm3, neutropenia\n",
      "             associated with recurrent infections, symptomatic anemia, or transfusion-dependent\n",
      "             anemia\n",
      "          -  Bilirubin ≤ 2.0 mg/dl, SGOT(AST) ≤ 1.5 times normal, and Creatinine ≤ 2.0 mg/dl\n",
      "             within 4 weeks prior to registration\n",
      "          -  ECOG performance status of 0-2\n",
      "          -  At least 18 years of age\n",
      "          -  Written informed consent\n",
      "        Exclusion:\n",
      "          -  Prior therapy with oral MTX or oral Cy\n",
      "          -  Previous or concurrent malignancies except inactive non-melanoma skin cancer, in situ\n",
      "             carcinoma of the cervix, or other cancer if the patient has been disease free for\n",
      "             over 5 years\n",
      "          -  Pregnant or breast-feeding for female patients\n",
      "          -  Serious medical illness, other than that treated by the study, which would limit\n",
      "             survival to less than 2 years, or psychiatric condition which would prevent informed\n",
      "             consent\n",
      "        Note: to be eligible for step 2 of this study, patients were required to have no response\n",
      "        after at least 4 months of methotrexate treatment.\n",
      "3113\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignant melanoma at primary or any\n",
      "        metastatic site Bidimensionally measurable disease by MRI scan Must have 1-6 enhancing\n",
      "        brain metastases If at least 2 lesions are present, only 1 lesion may be greater than 3 cm\n",
      "        in maximum diameter\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic response modifier or\n",
      "        immunotherapy Chemotherapy: No concurrent chemotherapy with whole brain radiotherapy Prior\n",
      "        systemic chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        stereotactic or conventional radiotherapy to any field of the brain Surgery: Prior\n",
      "        surgical resection of brain metastases allowed (provided 1 or 2 measurable brain\n",
      "        metastases remain)\n",
      "3114\n",
      "Inclusion Criteria:\n",
      "          -  Histologically proven disease of any of the following types:\n",
      "               -  Non metastatic alveolar rhabdomyosarcoma\n",
      "                    -  Stage I, II, or III; Clinical Group I, II, or III\n",
      "               -  Stage II or III, Clinical Group III embryonal rhabdomyosarcoma\n",
      "                    -  Botryoid\n",
      "                    -  Spindle cell\n",
      "               -  Under 10 years, stage IV, Clinical Group IV embryonal rhabdomyosarcoma\n",
      "                    -  Botryoid\n",
      "                    -  Spindle cell\n",
      "               -  Undifferentiated sarcoma\n",
      "                    -  Stage I, II, or III; Clinical Group I, II, or III\n",
      "               -  Ectomesenchymoma\n",
      "                    -  Stage I, II, or III; Clinical Group I, II, or III, with alveolar features\n",
      "                    -  Under 10 years, Stage IV, Clinical Group IV, with embryonal features\n",
      "          -  No more than 6 weeks since initial surgical procedure (e.g., biopsy) giving the\n",
      "             definitive diagnosis\n",
      "          -  No parameningeal rhabdomyosarcoma with positive CSF cytology or multiple intracranial\n",
      "             metastases\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  Creatinine normal* for age\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No prior chemotherapy\n",
      "          -  Prior steroids allowed\n",
      "          -  No prior radiotherapy\n",
      "          -  See Disease Characteristics\n",
      "3116\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor that is\n",
      "        refractory to conventional treatment or for which no curative or standard palliative\n",
      "        treatment exists No brain involvement or leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG/WHO 0-2 Life\n",
      "        expectancy: At least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Lymphocyte count at least 600/mm3 Hepatic: Bilirubin less than 1.5 mg/dL\n",
      "        AST and ALT no greater than 2.5 times upper limit of normal No liver cirrhosis Hepatitis B\n",
      "        surface antigen negative Renal: Creatinine no greater than 1.4 mg/dL OR Creatinine\n",
      "        clearance at least 60 mL/min Cardiovascular: No New York Heart Association class III or IV\n",
      "        heart disease Immunologic: No immunodeficiency No autoimmune disease Other: Not pregnant\n",
      "        or nursing Negative pregnancy test Fertile patients must use effective contraception No\n",
      "        active infection No nonmalignant disease incompatible with study No prior alcoholism, drug\n",
      "        addiction, or psychotic disorders unless suitable for adequate follow up No cerebroside\n",
      "        metabolite abnormalities (e.g., Gaucher's disease) HIV negative\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No\n",
      "        concurrent cytokines Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for\n",
      "        nitrosoureas, mitomycin, and high dose chemotherapy) Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy (6 weeks for extensive\n",
      "        radiotherapy) No concurrent radiotherapy Surgery: Not specified Other: No other concurrent\n",
      "        investigational or antitumor drugs\n",
      "3117\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed solid tumors, including but not limited\n",
      "        to breast, gastrointestinal, and unknown primary cancer that is refractory to standard\n",
      "        therapy or for which no standard therapy exists No known bone marrow involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 OR\n",
      "        WBC at least 3,500/mm3 AND Platelet count at least 100,000/mm3 Hepatic: Bilirubin no\n",
      "        greater than 1.5 mg/dL No known Gilbert's syndrome No other significant hepatic disease\n",
      "        requiring medication Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No\n",
      "        significant cardiac disease requiring medication Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No other significant medical condition\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior colony\n",
      "        stimulating factor and other cytokines active on bone marrow Chemotherapy: At least 4\n",
      "        weeks since prior chemotherapy (6 weeks since mitomycin or nitrosoureas) No prior or\n",
      "        concurrent irinotecan and fluorouracil therapy Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent radiotherapy\n",
      "        Surgery: Recovered from prior major surgery\n",
      "3118\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed renal cell carcinoma considered\n",
      "        incurable by surgery and not amenable to radiation therapy with curative intent Locally\n",
      "        advanced disease OR Locally recurrent disease OR Metastatic disease No transitional cell\n",
      "        carcinoma Measurable disease No CNS metastases or carcinomatous meningitis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least\n",
      "        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: AST less than 3 times upper limit\n",
      "        of normal (ULN) Bilirubin normal Renal: Creatinine less than 1.5 times ULN Cardiovascular:\n",
      "        No New York Heart Association class III or IV heart disease Metabolic: Oral intake at\n",
      "        least 1,200 calories per day Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception No uncontrolled infection No known\n",
      "        seizure disorder No other malignancy within the past 5 years except nonmelanoma skin\n",
      "        cancer or carcinoma in situ of the cervix No other medical or psychiatric condition that\n",
      "        would interfere with compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        No concurrent immunomodulating agents Chemotherapy: No prior chemotherapy for renal cell\n",
      "        carcinoma No other concurrent cytostatic or cytotoxic therapy Endocrine therapy: At least\n",
      "        4 weeks since prior hormonal therapy No concurrent hormonal agents Radiotherapy: See\n",
      "        Disease Characteristics At least 3 weeks since prior radiotherapy No prior radiotherapy to\n",
      "        greater than 15% of bone marrow No concurrent radiotherapy Surgery: See Disease\n",
      "        Characteristics\n",
      "3121\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed solid tumor that is not amenable to\n",
      "             standard therapy\n",
      "          -  No brain involvement or leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  WHO 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 mg/dL\n",
      "          -  Liver function tests no greater than 2.5 times upper limit of normal (ULN) (no\n",
      "             greater than 5 times ULN if liver metastases present)\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.4 mg/dL OR\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No active bacterial infections (e.g., abscess or fistulae)\n",
      "          -  No other nonmalignant disease that precludes protocol therapy\n",
      "          -  No history of alcoholism, drug addiction, or psychotic disorders that preclude\n",
      "             participation\n",
      "          -  No glaucoma\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "          -  No other concurrent antitumor drugs\n",
      "        Endocrine therapy:\n",
      "          -  At least 4 weeks since prior anticancer hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy)\n",
      "          -  No concurrent radiotherapy (except localized palliative radiotherapy)\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent sulfonylurea agent for diabetes or antiarrhythmic agents\n",
      "          -  No other concurrent investigational drugs\n",
      "3122\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven melanoma that is\n",
      "        unresectable and regionally metastatic, or widely disseminated OR Histologically or\n",
      "        cytologically proven non-small cell lung cancer (NSCLC) that is locally advanced,\n",
      "        unresectable, or metastatic Stage IIIA, IIIB, or IV Evidence of disease progression prior\n",
      "        to study At least 1 bidimensionally measurable lesion The following are NOT considered\n",
      "        measurable: previously irradiated lesions, ascites, pleural effusion, bone metastases,\n",
      "        brain metastases, leptomeningeal disease, or an abdominal mass that can be palpated but\n",
      "        not measured Melanoma patients whose only manifestation of disease is 1 of the following\n",
      "        are NOT eligible: Lymphedema Pleural effusion Ascites CNS metastases Bone marrow\n",
      "        infiltration Osteoblastic bone lesions\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 No abnormal clotting tests Hepatic: Bilirubin no greater than 2.0 mg/dL AST\n",
      "        and ALT no greater than 2 times upper limit of normal (ULN) (5 times ULN if due to liver\n",
      "        metastases) Renal: Creatinine no greater than 1.6 mg/dL OR Creatinine clearance at least\n",
      "        60 mL/min Urinary protein less than 0.3 g/dL Cardiovascular: No superior vena cava\n",
      "        obstruction in NSCLC unless successfully treated at least 2 months prior to study Other:\n",
      "        No underlying disease state associated with active bleeding No prior or concurrent\n",
      "        malignancies at other sites except adequately treated cone biopsied carcinoma in situ of\n",
      "        the cervix uteri or basal cell or squamous cell skin cancer No nonmalignant systemic\n",
      "        disease making patient poor risk for study No active uncontrolled infection Not pregnant\n",
      "        or nursing Negative pregnancy test Fertile patients must use effective contraception\n",
      "        during and for 3 weeks after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        (including interferon or interleukin-2) for melanoma patients No other concurrent\n",
      "        anticancer immunotherapy Chemotherapy: No prior chemotherapy for melanoma patients except\n",
      "        adjuvant or local chemotherapy (extracorporeal circulation) At least 4 weeks since prior\n",
      "        adjuvant or local chemotherapy if presence of measurable lesions outside the treated limb\n",
      "        (6 months if no presence of measurable lesions outside the treated limb) No prior\n",
      "        chemotherapy for NSCLC except platinum compounds used as radiosensitizer At least 4 weeks\n",
      "        since prior platinum compounds No other concurrent anticancer chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Concurrent\n",
      "        radiotherapy allowed for bone pain or other reasons No irradiation of all evaluable\n",
      "        lesions Surgery: See Disease Characteristics Other: At least 4 weeks since other prior\n",
      "        investigational drugs No other concurrent investigational drugs No concurrent\n",
      "        anticoagulants except heparin used to prevent occlusion of IV lines during week(s) off\n",
      "        treatment\n",
      "3126\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  One of the following diagnoses:\n",
      "               -  Acute myeloid leukemia (AML), with or without myelodysplastic syndromes\n",
      "                    -  Not in first complete remission (CR)* with translocations t(8;21) and inv\n",
      "                       (16) unless failure of first-line induction therapy\n",
      "                    -  Not in first CR* with translocations t(15;17) abnormality unless:\n",
      "                         -  Failure of first-line induction therapy OR\n",
      "                         -  Molecular evidence of persistent disease\n",
      "                    -  Not in first CR with Down syndrome\n",
      "                    -  Patients with third or greater medullary relapse or refractory disease\n",
      "                       (other than primary induction failures) receive busulfan/melphalan\n",
      "                       conditioning regimen NOTE: * CR defined by no greater than 5% blasts in\n",
      "                       marrow\n",
      "               -  Acute lymphocytic leukemia (ALL)\n",
      "                    -  Not in first CR OR\n",
      "                    -  High-risk ALL in first CR, with high risk defined as one of the following:\n",
      "                         -  Hypoploidy (no greater than 44 chromosomes)\n",
      "                         -  Pseudodiploidy with translocations or molecular evidence of t(9;22),\n",
      "                            11q23, or t(8;14) (except B-cell ALL) with or without MLL gene\n",
      "                            arrangement\n",
      "                         -  Elevated WBC at presentation\n",
      "                              -  Age 6-12 months: greater than 100,000/mm^3\n",
      "                              -  Age 10-17 years: greater than 200,000/mm^3\n",
      "                              -  Age 18: greater than 20,000/mm^3\n",
      "                         -  Failed to achieve CR after 4 weeks of induction therapy\n",
      "                    -  Patients with B-ALL must not be in first CR, must meet at least one of the\n",
      "                       high-risk criteria specified above, or must not meet any of the following\n",
      "                       criteria:\n",
      "                         -  Translocation t(8;14)\n",
      "                         -  Blasts have surface immunoglobulins\n",
      "                         -  CD10 positive\n",
      "                    -  Patients with third or greater medullary relapse or refractory disease\n",
      "                       (other than primary induction failures) receive busulfan/melphalan\n",
      "                       conditioning regimen\n",
      "               -  Chronic myelogenous leukemia, meeting criteria for 1 of the following:\n",
      "                    -  Accelerated phase\n",
      "                    -  Chronic phase if 1 year from diagnosis without a matched unrelated bone\n",
      "                       marrow donor AND unresponsive to or unable to tolerate interferon\n",
      "                    -  Blast crisis, defined as greater than 30% promyelocytes plus blasts in bone\n",
      "                       marrow\n",
      "                         -  Patients receive busulfan/melphalan conditioning regimen\n",
      "               -  Acute undifferentiated leukemia (AUL), infant leukemia, or biphenotypic leukemia\n",
      "                    -  Patients with third or greater medullary relapse or refractory disease\n",
      "                       (other than primary induction failures) receive busulfan/melphalan\n",
      "                       conditioning regimen\n",
      "               -  Juvenile myelomonocytic leukemia meeting the following criteria:\n",
      "                    -  No Philadelphia chromosome\n",
      "                    -  Bone marrow blasts less than 30%\n",
      "                    -  Peripheral blood monocytes greater than 1,000/mm^3\n",
      "                    -  At least 2 of the following:\n",
      "                         -  Peripheral blood spontaneous growth and/or sargramostim (GM-CSF)\n",
      "                            hypersensitivity\n",
      "                         -  Increased hemoglobin F for age\n",
      "                         -  Clonal abnormalities (e.g., monosomy 7 or RAS mutations)\n",
      "                         -  Peripheral blood with myeloid precursors\n",
      "                         -  WBC greater than 10,000/mm^3\n",
      "               -  Myelodysplastic syndromes defined by the following:\n",
      "                    -  Refractory anemia (RA)\n",
      "                    -  RA with ringed sideroblasts\n",
      "                    -  RA with excess blasts (RAEB)\n",
      "                    -  RAEB in transformation\n",
      "                    -  Chronic myelomonocytic leukemia\n",
      "               -  Paroxysmal nocturnal hemoglobinuria\n",
      "               -  Hodgkin's lymphoma or non-Hodgkin's lymphoma beyond first CR or primary\n",
      "                  induction failures AND chemosensitive (greater than 50% reduction in tumor mass\n",
      "                  size)\n",
      "               -  Inborn error of metabolism including, but not limited to, Hurler's syndrome,\n",
      "                  adrenoleukodystrophy (ALD), Maroteaux-Lamy syndrome, globoid cell\n",
      "                  leukodystrophy, metachromatic leukodystrophy, fucosidosis, or mannosidosis\n",
      "                    -  For ALD patients over age 5, IQ must be at least 80\n",
      "                    -  For all other patients over age 5, IQ must be at least 70\n",
      "                    -  For all patients age 5 and under, developmental quotient or clinical\n",
      "                       neurodevelopmental examination should demonstrate potential for\n",
      "                       stabilization at a level of functioning where continuous life support\n",
      "                       (e.g., mechanical ventilation) would not be predicted to be required in the\n",
      "                       year after transplantation\n",
      "               -  Combined immune deficiencies including, but not limited to:\n",
      "                    -  Severe combined immunodeficiency (SCID) requiring cytoreduction\n",
      "                    -  Wiskott-Aldrich syndrome\n",
      "                    -  Leukocyte adhesion defect\n",
      "                    -  Chediak-Higashi disease\n",
      "                    -  X-linked lymphoproliferative disease\n",
      "                    -  Adenosine deaminase deficiency\n",
      "                    -  Purine nucleoside phosphorylase deficiency\n",
      "                    -  X-linked SCID\n",
      "                    -  Common variable immune deficiency\n",
      "                    -  Nezelof's syndrome\n",
      "                    -  Cartilage hair hypoplasia\n",
      "          -  No dyskeratosis congenita\n",
      "          -  No ALL, AML, AUL, or biphenotypic leukemia in third or higher medullary relapse or\n",
      "             refractory disease other than primary induction failure\n",
      "          -  No primary myelofibrosis or myelofibrosis grade 3 or worse\n",
      "          -  No active CNS leukemia involvement (CSF with WBC greater than 5/mm^3 and malignant\n",
      "             cells on cytospin)\n",
      "          -  No consenting 5/6 or 6/6 HLA-matched related donor available\n",
      "          -  3-6/6 HLA-matched unrelated umbilical cord blood donor available\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  See Disease Characteristics\n",
      "          -  18 and under\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%, if age 16 to 18\n",
      "          -  Lansky 50-100%, if under age 16\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.5 mg/dL\n",
      "          -  SGOT less than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine normal for age OR\n",
      "          -  Creatinine clearance or glomerular filtration rate greater than 50% lower limit of\n",
      "             normal for age\n",
      "        Cardiovascular:\n",
      "          -  If symptomatic:\n",
      "               -  LVEF greater than 40% (or shortening fraction greater than 26%) and improves\n",
      "                  with exercise OR\n",
      "               -  Shortening fraction greater than 26%\n",
      "        Pulmonary:\n",
      "          -  If symptomatic:\n",
      "               -  DLCO, FEV_1, and FEC greater than 45% predicted OR\n",
      "               -  Oxygen saturation greater than 85% on room air\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  HIV negative\n",
      "          -  No uncontrolled viral, bacterial, or fungal infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 1 year since prior allogeneic stem cell transplantation (SCT) with\n",
      "             cytoreductive preparative therapy\n",
      "          -  At least 6 months since prior autologous SCT\n",
      "          -  No concurrent thrombopoietic growth factors\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  See Biologic therapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "3127\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited or extensive\n",
      "        stage small cell lung cancer (SCLC) Disease recurring at least 90 days following\n",
      "        completion of first line chemotherapy Partial or complete response to first line therapy\n",
      "        Must have at least one bidimensionally measurable non CNS lesion May be within a prior\n",
      "        radiation port if at least 6 weeks since prior radiotherapy and progressing Brain and/or\n",
      "        leptomeningeal metastases allowed if asymptomatic and not requiring corticosteroids\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 2 months Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL (after transfusion, if\n",
      "        needed) Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2 times\n",
      "        upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)\n",
      "        Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver\n",
      "        metastases present) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at\n",
      "        least 60 mL/min Other: No active uncontrolled infection No other malignancies within the\n",
      "        past 5 years except curatively treated basal or squamous cell skin cancer, carcinoma in\n",
      "        situ of the cervix, or stage I low grade prostate cancer No other severe medical\n",
      "        conditions that would preclude study or cause exposure to extreme risk or decreased life\n",
      "        expectancy No uncontrolled emesis No active peptic ulcer, diabetes mellitus, chronic\n",
      "        gastritis, significant ascites, or other gastrointestinal (GI) conditions (e.g., removal\n",
      "        of a portion of the stomach or recent GI obstruction) that would alter absorption or GI\n",
      "        motility No history of allergic reactions to compounds chemically related to topotecan Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception for 3 months prior to, during, and at least 4 weeks after the study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No\n",
      "        concurrent immunotherapy for SCLC Chemotherapy: See Disease Characteristics No prior\n",
      "        topotecan Only one prior chemotherapy regimen allowed No other concurrent chemotherapy for\n",
      "        SCLC Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease\n",
      "        Characteristics At least 24 hours since prior radiotherapy No concurrent radiotherapy for\n",
      "        SCLC Surgery: At least 4 weeks since prior surgery Other: At least 30 days or five half\n",
      "        lives since other prior investigational drugs No prior drugs (e.g., cisapride) that would\n",
      "        alter absorption or GI motility No other concurrent investigational therapy for SCLC\n",
      "3129\n",
      "DISEASE CHARACTERISTICS: Cytologically confirmed acute myeloid leukemia (AML) in first\n",
      "        complete remission (CR) or subsequent CR Less than 5% blasts in normal bone marrow Less\n",
      "        than 3 months since last dose of chemotherapy OR Less than 6 months since achieving CR\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 OR Karnofsky 70-100%\n",
      "        Life expectancy: Greater than 3 months Hematopoietic: WBC at least 1,500/mm3 Platelet\n",
      "        count at least 75,000/mm3 Hepatic: PTT normal Bilirubin no greater than 2 times upper\n",
      "        limit of normal (ULN) SGOT and SGPT no greater than 2 times ULN Renal: Creatinine no\n",
      "        greater than 1.5 times ULN Cardiovascular: No class III or IV heart disease No\n",
      "        hypotension, severe hypertension, or serious or uncontrolled cardiac dysrhythmia (e.g.,\n",
      "        ventricular arrhythmias) No acute myocardial infarction within the past 12 months No\n",
      "        active uncontrolled angina pectoris No symptomatic arteriosclerotic blood vessel disease\n",
      "        Pulmonary: No history of asthma within the past 5 years Other: No other active\n",
      "        malignancies except localized basal or squamous cell skin cancer or carcinoma in situ of\n",
      "        the cervix HIV negative No prior or active peptic or esophageal ulcer disease No history\n",
      "        of hypersensitivity to histamine or histamine products, or severe allergies Not pregnant\n",
      "        or nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior autologous stem cell transplantation\n",
      "        allowed No prior allogeneic stem cell transplantation No other concurrent immunomodulating\n",
      "        agents Chemotherapy: See Disease Characteristics Prior induction or consolidation therapy\n",
      "        allowed No concurrent chemotherapy Endocrine therapy: At least 24 hours since prior\n",
      "        corticosteroids No concurrent steroids Radiotherapy: Not specified Surgery: Not specified\n",
      "        Other: No concurrent alternative therapy (e.g., laetrile, Brudzinski's treatment, etc.)\n",
      "3130\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor not amenable\n",
      "        to standard treatment No symptomatic brain involvement or leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Other liver function tests no\n",
      "        greater than 2 times upper limit of normal (unless related to liver metastases) Renal:\n",
      "        Creatinine no greater than 1.4 mg/dL Other: Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception during and for 3 months after study\n",
      "        No active bacterial infections No nonmalignant disease that would be incompatible with\n",
      "        study No prior alcoholism, drug addiction, or psychotic disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n",
      "        Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy\n",
      "        (6 weeks for extensive radiotherapy) No concurrent radiotherapy Surgery: Not specified\n",
      "        Other: No other concurrent investigational or antitumor drugs\n",
      "3131\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed refractory metastatic breast cancer Must\n",
      "        have either relapsed or failed to achieve complete remission after combination\n",
      "        chemotherapy with or without stem cell or marrow transplantation No CNS disease No\n",
      "        generalized or total mass liver involvement greater than 25% volume No pulmonary\n",
      "        metastasis involving greater than 25% of lung volume Tumor markers and evidence of\n",
      "        metastatic disease by physical exam or radiography required for patients with bone disease\n",
      "        only Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to physiologic age of 55 Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic:\n",
      "        Absolute granulocyte count at least 2000/mm3 Platelet count at least 150,000/mm3 Arterial\n",
      "        blood gases within normal limits for age and sex Hepatic: See Disease Characteristics\n",
      "        Bilirubin no greater than 1.3 mg/dL Renal: Creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular: LVEF at least 50% by MUGA Pulmonary: FEV1 and FVC at least 65% of\n",
      "        predicted Corrected diffusing capacity at least 60% Other: Adequate venous access Able to\n",
      "        tolerate apheresis, filgrastim (G-CSF), and cyclosporine Human anti-mouse antibody (HAMA)\n",
      "        negative No other primary malignant neoplasm except curatively treated basal cell\n",
      "        carcinoma or surgically cured carcinoma in situ of the cervix Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent\n",
      "        chemotherapy At least 1 year since prior high dose intensive marrow toxic therapy\n",
      "        requiring stem cells or bone marrow transplantation No pulmonary toxicity due to prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy No concurrent radiotherapy No prior radiotherapy to greater than 25% of total\n",
      "        skeleton Surgery: Not specified\n",
      "3132\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed primary myelodysplastic syndrome (MDS)\n",
      "        with greater than 10% bone marrow blasts Refractory anemia with excess blasts (RAEB) OR\n",
      "        RAEB in transformation No chronic myelomonocytic leukemia No secondary MDS after prior\n",
      "        chemotherapy except if treatment was for acute myeloid leukemia No allogeneic bone marrow\n",
      "        transplantation planned\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Hemoglobin no greater than 10 g/dL OR transfusion\n",
      "        requirement of at least 3 packs of RBCs per month OR Platelet count less than 50,000/mm3\n",
      "        OR Absolute neutrophil count less than 1,000/mm3 No disseminated intravascular coagulation\n",
      "        defined as fibrinogen less than 100 mg/dL AND prolonged PT, PTT, or thrombin time AND\n",
      "        platelet count less than 25,000/mm3 without transfusion Hepatic: Bilirubin no greater than\n",
      "        2.0 mg/dL Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) (unless\n",
      "        due to underlying disease or Gilbert's syndrome) SGPT and SGOT no greater than 4 times ULN\n",
      "        (unless due to underlying disease or Gilbert's syndrome) Renal: Creatinine no greater than\n",
      "        2.0 mg/dL Cardiovascular: No uncontrolled hypertension No congestive heart failure,\n",
      "        cardiac arrhythmia, or angina pectoris No history of myocardial infarction within the past\n",
      "        6 months No other significant cardiovascular disease LVEF within normal range by MUGA or\n",
      "        echocardiogram No active ischemia Pulmonary: No pulmonary dysfunction Other: No central or\n",
      "        peripheral neuropathy No uncontrolled or unstable diabetes No other significant organ\n",
      "        system dysfunction HIV negative No prior malignancy except basal cell carcinoma or\n",
      "        carcinoma in situ of the uterus No active, uncontrolled infection Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception during and for 3 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 2 months\n",
      "        since prior biologic therapy (e.g., hematopoietic growth factors or biological response\n",
      "        modifiers) Chemotherapy: See Disease Characteristics At least 2 months since prior\n",
      "        chemotherapy Endocrine therapy: At least 2 months since prior endocrine therapy\n",
      "        Radiotherapy: At least 2 months since prior radiotherapy Concurrent radiotherapy allowed\n",
      "        Surgery: At least 2 months since prior surgery Other: No other concurrent investigational\n",
      "        drugs\n",
      "3133\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed malignancy refractory to existing\n",
      "             chemotherapy or for which no standard therapy exists\n",
      "          -  Evaluable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Greater than 3 months\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1,500/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  Hemoglobin greater than 8.0 mg/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 2.0 mg/dL\n",
      "          -  AST less than 3.0 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Other:\n",
      "          -  No active infection requiring antibiotics\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective barrier contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks since prior systemic cytotoxic chemotherapy (including fluorouracil)\n",
      "             and recovered\n",
      "          -  No prior gemcitabine\n",
      "        Endocrine therapy:\n",
      "          -  Prior hormonal therapy allowed\n",
      "          -  No concurrent hormonal contraception\n",
      "        Radiotherapy:\n",
      "          -  At least 3 weeks since prior radiotherapy to large areas of active bone marrow and\n",
      "             recovered\n",
      "        Surgery:\n",
      "          -  Prior major surgery allowed and recovered\n",
      "        Other:\n",
      "          -  No prior or concurrent antiviral nucleosides\n",
      "3134\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Cytologically proven myelodysplastic syndrome (MDS) of one of the following types:\n",
      "               -  Refractory anemia with excess blasts (RAEB)\n",
      "               -  RAEB in transformation\n",
      "               -  Chronic myelomonocytic leukemia\n",
      "               -  MDS with multiple chromosomal abnormalities\n",
      "               -  MDS with life threatening cytopenias in at least 2 cell lines\n",
      "                    -  Platelet count < 30,000/mm^3 OR\n",
      "                    -  Absolute neutrophil count no greater than 1,000/mm^3 OR\n",
      "                    -  Anemia requiring transfusion support\n",
      "               -  Leukemia out of MDS (meet any of above requirements, but greater than 30% blasts\n",
      "                  in marrow)\n",
      "          -  No acute leukemia\n",
      "          -  Medically eligible for bone marrow transplant according to standard operating\n",
      "             procedure of the Sidney Kimmel Cancer Center at Johns Hopkins Blood and Bone Marrow\n",
      "             Transplant\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 65\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior acute allergic reactions to sargramostim (GM-CSF)\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "3135\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Diagnosis of 1 of the following:\n",
      "               -  Acute myeloid leukemia (AML) beyond first remission OR with primary refractory\n",
      "                  disease\n",
      "               -  AML that has transformed from myelodysplastic syndromes, if induction\n",
      "                  chemotherapy not recommended\n",
      "          -  Documented CD45 expression in patients with relapsed disease\n",
      "               -  Not needed for patients in remission\n",
      "          -  Circulating blast count less than 10,000/mm^3 (may be controlled with hydroxyurea or\n",
      "             similar agent)\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age\n",
      "          -  2 to 55\n",
      "        Performance status\n",
      "          -  Not specified\n",
      "        Life expectancy\n",
      "          -  More than 60 days\n",
      "        Hematopoietic\n",
      "          -  See Disease Characteristics\n",
      "        Hepatic\n",
      "          -  Bilirubin less than 1.5 mg/dL (unless bilirubin is determined by the gastroenterology\n",
      "             service to be predominantly unconjugated [indirect] as the result of possible\n",
      "             hemolysis)\n",
      "          -  AST less than 1.5 times upper limit of normal (ULN)\n",
      "        Renal\n",
      "          -  Creatinine less than 2.0 mg/dL OR less than 1.5 times ULN for age\n",
      "        Other\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No major infection\n",
      "          -  No circulating antibodies to mouse immunoglobulins\n",
      "          -  HIV negative\n",
      "          -  Able to tolerate diagnostic or therapeutic procedures (e.g., radiation isolation)\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  Not specified\n",
      "        Chemotherapy\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  No radiotherapy to maximum tolerated levels to any normal organ\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "3136\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignant melanoma that is surgically or\n",
      "        medically incurable Measurable or evaluable metastatic disease OR No evidence of disease\n",
      "        following surgical resection of a distant metastasis OR Surgical resection of at least 2\n",
      "        local or regional recurrences, at least 1 of which had evidence of lymph node involvement\n",
      "        Each recurrence at least 1 month apart\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy:\n",
      "        Greater than 3 months Hematopoietic: WBC at least 3500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hemoglobin at least 10.0 g/dL Hepatic: Bilirubin less than 2.0 mg/dL SGOT less\n",
      "        than 3 times normal Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant Fertile\n",
      "        patients must use effective contraception HIV negative No active infections requiring\n",
      "        antibiotic, antiviral, or antifungal therapy No other active malignancy No concurrent\n",
      "        significant illnesses\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior immunotherapy\n",
      "        Chemotherapy: At least 1 month since prior chemotherapy No more than 2 prior chemotherapy\n",
      "        regimens for melanoma Endocrine therapy: At least 1 month since prior steroids (except\n",
      "        intermittent use as antiemetic or as topical agent) No concurrent steroids Radiotherapy:\n",
      "        At least 1 month since prior radiotherapy No prior radiotherapy to vaccine site Surgery:\n",
      "        No prior organ allografts\n",
      "3137\n",
      "DISEASE CHARACTERISTICS: Histologically proven small cell lung cancer Good prognosis on\n",
      "        the Manchester scale, with no more than 2 of the following high risk factors: Karnofsky\n",
      "        less than 60% Hyponatremia (low sodium) Alkaline phosphatase at least 1.5 times upper\n",
      "        limit of normal (ULN) LDH greater than ULN No symptomatic CNS metastases requiring\n",
      "        corticosteroids\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: See Disease Characteristics\n",
      "        Life expectancy: Not specified Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet\n",
      "        count at least 125,000/mm3 Hepatic: See Disease Characteristics Bilirubin less than 1.25\n",
      "        times upper limit of normal (ULN) SGOT/SGPT less than 1.25 times ULN Renal: Creatinine\n",
      "        less than ULN Cardiovascular: LVEF at least 50% No myocardial infarction within 5 years No\n",
      "        uncontrolled cardiac disease Pulmonary: No severe chronic obstructive pulmonary disease\n",
      "        Other: No neurological symptoms greater than grade 2 No severe psychoses No other\n",
      "        concurrent medical problems No active infection HIV negative No allergy to E. coli derived\n",
      "        products No prior malignancy within 5 years except basal cell skin cancer, carcinoma in\n",
      "        situ of the cervix, or lung or respiratory cancer in remission Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior antineoplastic therapy\n",
      "3139\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed follicular or diffuse large cell,\n",
      "        diffuse mixed, or immunoblastic non-Hodgkin's lymphoma (working formulation D, F, G, or H)\n",
      "        First relapse from a complete response or complete response unconfirmed after a front line\n",
      "        chemotherapy regimen (e.g., CHOP-like regimen) Second relapse from partial response after\n",
      "        2-4 courses of second line standard dose chemotherapy (e.g., MINE, EPOCH, or\n",
      "        platinum-containing regimens) No more than 1 salvage treatment regimen No CNS involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Transaminases no greater than 2 times upper limit of normal\n",
      "        Bilirubin no greater than 2 mg/dL (unless due to biopsy proven lymphoma) No chronic viral\n",
      "        hepatitis Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60\n",
      "        mL/min No overt renal insufficiency Cardiovascular: LVEF at least 45% No congestive heart\n",
      "        failure (New York Heart Association class III or IV) No myocardial infarction within past\n",
      "        6 months No uncontrolled hypertension (diastolic blood pressure greater than 115 mmHg) No\n",
      "        unstable angina No coronary angioplasty within past 6 months No uncontrolled atrial or\n",
      "        ventricular cardiac arrhythmias Pulmonary: DLCO and FEV1 at least 45% of predicted No\n",
      "        severe pulmonary disease No seasonal or recurrent asthma within past 10 years No asthmatic\n",
      "        symptoms (e.g., wheezing) related to current respiratory tract infection No concurrent\n",
      "        symptoms of bronchoconstriction No anaphylactic/anaphylactoid-type event manifested by\n",
      "        disseminated urticaria, laryngeal edema, and/or bronchospasm Other: Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception HIV\n",
      "        negative No prior malignancy within the past 5 years except carcinoma in situ of the\n",
      "        cervix or basal cell or squamous cell skin cancer No severe medical or psychiatric illness\n",
      "        (including severe depression) No active peptic ulcer disease No poorly controlled diabetes\n",
      "        No allergy to insect vemons No active history of angioedema or recurrent urticaria (an\n",
      "        isolated episode of urticaria is allowed) No active infection No fever greater than 38.2\n",
      "        degrees C (except fevers due to B symptoms) No allergy to E. coli derived products\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 week since prior hematopoietic\n",
      "        growth factors Chemotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to\n",
      "        relapsed sites of vital organs (except as part of initial treatment) At least 4 weeks\n",
      "        since prior palliative radiotherapy to bulky nodes Surgery: At least 2 weeks since prior\n",
      "        major surgery Other: No other concurrent investigational drugs No concurrent beta\n",
      "        adrenergic blocking agents\n",
      "3140\n",
      "DISEASE CHARACTERISTICS: Histologically proven myelodysplastic syndrome (MDS) with 1 of\n",
      "        the following classifications: Refractory anemia Refractory anemia with ringed\n",
      "        sideroblasts Refractory anemia with excess blasts Chronic myelomonocytic leukemia History\n",
      "        of MDS, received chemotherapy for acute leukemia within past 12 months, and now in\n",
      "        remission Myelodysplastic disease must be stable (not anticipated to require chemotherapy\n",
      "        for at least 4 months) Must have 1 of the following N-, K-, or H-ras peptide mutations:\n",
      "        Progenitor cells contain aspartic acid, valine, or serine substitution at codon 12, OR\n",
      "        Aspartic acid or arginine substitution at codon 13\n",
      "        PATIENT CHARACTERISTICS: Age: Over 17 Performance status: ECOG 0 or 1 Life expectancy:\n",
      "        Greater than 5 months Hematopoietic: WBC at least 1,500/mm3 Platelet count at least\n",
      "        50,000/mm3 Hepatic: Not specified Renal: Not specified Cardiovascular: No New York Heart\n",
      "        Association class III or IV heart disease Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception No other medical condition that might prevent completion\n",
      "        of study or prevent immunological response to study regimen No other concurrent serious\n",
      "        medical illness No active bleeding\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: No concurrent immunosuppressive drugs including\n",
      "        systemic steroids or antiinflammatory drugs Radiotherapy: No prior irradiation of spleen\n",
      "        Surgery: No prior splenectomy\n",
      "3141\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed melanoma that is surgically incurable\n",
      "          -  At least one dermal, subcutaneous or lymph node metastasis that is evaluable for\n",
      "             local response and accessible for injection\n",
      "          -  If only one accessible lesion is available, it must be at least 2 cm\n",
      "          -  If two or more accessible lesions exist, then none of them are required to be at\n",
      "             least 2 cm\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Life expectancy: Greater than 3 months\n",
      "          -  Leukocyte count at least 3,000/mm3\n",
      "          -  Platelet count at least 120,000/mm3\n",
      "          -  SGOT and alkaline phosphatase less than 5 times normal\n",
      "          -  Bilirubin less than 1.5 mg/dL (unless secondary to hepatic metastasis)\n",
      "          -  BUN less than 40 mg/dL\n",
      "          -  Creatinine less than 2.5 mg/dL\n",
      "          -  No evidence of congestive heart failure, unstable angina, or serious cardiac\n",
      "             arrhythmias\n",
      "          -  Not positive for hepatitis B virus\n",
      "          -  Not positive for HIV\n",
      "          -  No history of allergy to vaccinia virus\n",
      "          -  No evidence of other primary tumors except for basal cell carcinoma, squamous cell\n",
      "             skin carcinoma, or carcinoma in situ of the cervix\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No underlying immunodeficiency disorder\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 30 days since prior biologic therapy (e.g., interferon or IL-2)\n",
      "          -  At least 30 days since prior chemotherapy\n",
      "          -  No concurrent steroids\n",
      "          -  At least 30 days since prior radiotherapy\n",
      "          -  Prior radiotherapy to no greater than 50% of nodal groups\n",
      "          -  No prior splenectomy\n",
      "          -  No concurrent drugs which affect immune function (e.g., glucocorticoids or\n",
      "             cimetidine)\n",
      "3143\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven recurrent or metastatic soft tissue sarcoma\n",
      "          -  No rhabdomyosarcoma, Ewing's sarcoma, chondrosarcoma, osteogenic sarcoma,\n",
      "             mesothelioma, or Kaposi's sarcoma Bidimensionally measurable disease other than\n",
      "             previously irradiated disease site(s) even if there has been progression within the\n",
      "             radiation field\n",
      "          -  Pulmonary nodule(s) at least 1 x 1 cm No brain metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: ECOG 0 or 1\n",
      "          -  Absolute neutrophil count at least 2,000/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST and ALT less than 1.5 times upper limit of normal (ULN) (3 times ULN if liver\n",
      "             metastases present)\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 3 months after study\n",
      "          -  No uncontrolled infection\n",
      "          -  No history of prior malignancy within the past 5 years except basal cell or squamous\n",
      "             cell skin cancer, carcinoma in situ of the cervix, or any other malignancy in\n",
      "             complete remission\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No more than 1 prior chemotherapy regimen in the adjuvant setting\n",
      "          -  No prior chemotherapy for metastatic disease\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)\n",
      "          -  At least 4 weeks since prior radiotherapy\n",
      "          -  Recovered from prior surgery\n",
      "3144\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed stage III or IV epithelial or germ cell ovarian cancer that\n",
      "             is unlikely to respond to existing therapy and for which no curative therapy exists\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 2,000/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT/SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/mL\n",
      "          -  No renal insufficiency\n",
      "          -  No history of renal conditions that contraindicate high dosages of sodium\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No history of congestive heart failure\n",
      "          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n",
      "        Pulmonary:\n",
      "          -  No serious lung disease (e.g., chronic obstructive pulmonary disease)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception for 4 weeks before, during, and for\n",
      "             4 weeks after study participation\n",
      "          -  No active infection\n",
      "          -  No concurrent serious systemic disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids allowed (e.g., dexamethasone or methylprednisone)\n",
      "        Radiotherapy:\n",
      "          -  At least 8 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "        Other:\n",
      "          -  Prior cytodifferentiating agents allowed\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent antineoplastic agents\n",
      "3146\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the pancreas\n",
      "        Locoregional and not amenable to surgery based on 1 or more of the following: Size of\n",
      "        pancreatic tumor greater than 5 cm Lymph nodes bulky, greater than 2 cm, but within\n",
      "        radiation port Vascular involvement or impingement of major vessels (e.g., superior\n",
      "        mesenteric artery, superior mesenteric vein, portal vein, hepatic artery) Involvement of\n",
      "        colon (head lesions) or involvement of adrenal, kidney, or colon (tail lesions) Patients\n",
      "        must be registered and begin treatment within 42 days of surgical staging No metastatic\n",
      "        disease or nodal disease outside of radiation port documented by CT scan or MRI and chest\n",
      "        x-ray\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Albumin greater than 3 g/dL Bilirubin less than 2.0 mg/dL Renal:\n",
      "        Creatinine less than 2.0 mg/dL Calcium normal Other: No prior or concurrent malignancy\n",
      "        within the past 5 years except inactive nonmelanoma skin cancer, carcinoma in situ of the\n",
      "        cervix, or other curatively treated cancers Not pregnant or nursing Negative pregnancy\n",
      "        test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for carcinoma of the\n",
      "        pancreas Chemotherapy: No prior chemotherapy for carcinoma of the pancreas No other\n",
      "        concurrent chemotherapy Endocrine therapy: No prior endocrine therapy for carcinoma of the\n",
      "        pancreas No concurrent hormone therapy (except for nondisease-related conditions)\n",
      "        Radiotherapy: No prior radiation therapy for carcinoma of the pancreas No prior abdominal\n",
      "        radiation therapy Surgery: See Disease Characteristics No prior surgery for carcinoma of\n",
      "        the pancreas\n",
      "3148\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic and/or recurrent renal cell\n",
      "        carcinoma Bidimensionally measurable disease No concurrent brain metastases Patients with\n",
      "        prior brain metastases who have undergone radiation and/or surgery, with stable response,\n",
      "        confirmed by MRI, and off corticosteroids are eligible\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified\n",
      "        Other: Not pregnant or nursing Fertile patients must use effective contraception No other\n",
      "        serious illness or active infection requiring antibiotics Not HIV positive No active\n",
      "        substance abuse\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 months since prior interleukin-2\n",
      "        therapy At least 6 months since prior interferon alfa therapy At least 1 month since other\n",
      "        prior biologic therapy No other concurrent biologic therapy (e.g., filgrastim or\n",
      "        sargramostim) Chemotherapy: At least 6 months since prior fluorouracil therapy At least 1\n",
      "        month since prior chemotherapy No other concurrent chemotherapy Endocrine therapy: At\n",
      "        least 1 month since prior endocrine therapy No concurrent hormone therapy No concurrent\n",
      "        corticosteroids except if inhaled or topical Radiotherapy: At least 1 month since prior\n",
      "        radiotherapy (to less than 25% of the bone marrow only, and there must be measurable\n",
      "        disease outside of radiation field) No concurrent radiotherapy Surgery: At least 3 weeks\n",
      "        since prior surgery Other: No concurrent ongoing therapy with investigational drugs\n",
      "3149\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed stage IIIB or IV\n",
      "        advanced primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma,\n",
      "        squamous cell carcinoma, or unspecified) or recurrent non-small cell lung cancer after\n",
      "        previous surgery and/or radiotherapy Stage IIIB: T4 lesion due to malignant pleural\n",
      "        effusion, OR multiple lesions in a single lobe containing a T3 or T4 primary, OR lesions\n",
      "        in multiple lobes of the ipsilateral lung for which one such lesion is T3 or T4 Any N M0\n",
      "        Stage IV: Any T, Any N, M1 Measurable or evaluable disease Measurable or evaluable disease\n",
      "        must be outside of the prior radiotherapy port or prior surgical resection area No brain\n",
      "        metastases No bronchoalveolar carcinoma or stage IIIB tumor involving the superior sulcus\n",
      "        (pancoast tumors)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine no\n",
      "        greater than 2 times upper limit of normal AND Creatinine clearance at least 50 mL/min\n",
      "        Other: No prior malignancy in the past 5 years except adequately treated basal cell or\n",
      "        squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I\n",
      "        or II cancer from which the patient is currently in complete remission Not pregnant or\n",
      "        nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for non-small cell\n",
      "        lung cancer No concurrent biologic therapy to measurable or evaluable lesions\n",
      "        Chemotherapy: No prior systemic chemotherapy for non-small cell lung cancer Endocrine\n",
      "        therapy: No concurrent hormonal therapy to measurable or evaluable lesions Radiotherapy:\n",
      "        At least 3 weeks since prior radiotherapy and recovered No concurrent radiotherapy to\n",
      "        measurable lesions Palliative radiation to small field nonmeasurable sites of disease\n",
      "        (painful bony metastases) allowed Surgery: At least 3 weeks since surgery (thoracic or\n",
      "        other major surgeries) and recovered\n",
      "3150\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed diagnosis of T-cell acute lymphoblastic leukemia (ALL) or\n",
      "             lymphoblastic lymphoma (LBL)\n",
      "          -  Leukemia or lymphoma cells should express at least two of the following cell surface\n",
      "             antigens: CD1a, CD2, CD3 (surface or cytoplasmic), CD4, CD5, CD7, and CD8\n",
      "          -  Leukemia cells should be negative for myeloperoxidase or Sudan Black B If the only T\n",
      "             cell markers present are CD4 and CD7, the leukemic cells should be demonstrated to\n",
      "             lack the myeloid markers CD33 and/or CD13\n",
      "          -  Refractory to at least one induction treatment regimen or in first or later relapse\n",
      "             after achieving a complete remission\n",
      "          -  No CNS leukemia or lymphoma requiring intrathecal or craniospinal radiotherapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 16 and over\n",
      "          -  Bilirubin no greater than 2 times upper limit of normal (unless due to leukemia)\n",
      "          -  Creatinine clearance at least 50 mL/min (unless due to leukemia)\n",
      "          -  No neurologic toxicity of grade 3 or greater during prior treatment of ALL/LBL\n",
      "          -  No preexisting neuropathy of grade 2 or greater regardless of causality\n",
      "          -  No history of seizure disorder\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  No concurrent erythropoietin\n",
      "          -  No other concurrent chemotherapy\n",
      "          -  No concurrent dexamethasone or other steroidal antiemetics\n",
      "          -  No concurrent hormone therapy, except for non-disease-related conditions\n",
      "3151\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IIIB/IV nonsmall\n",
      "        cell lung cancer eligible for first line chemotherapy Measurable disease (must be outside\n",
      "        radiation port or proof of progressive disease) Metastatic CNS disease allowed if treated\n",
      "        and stable for at least 21 days prior to study\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Greater than 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin at\n",
      "        least 10 g/dL Absolute neutrophil count at least 1500/mm3 Hepatic: Bilirubin no greater\n",
      "        than upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN AST no\n",
      "        greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular:\n",
      "        At least 3 months since prior myocardial infarction No uncontrolled congestive heart\n",
      "        failure No uncontrolled arrhythmias Other: Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception Peripheral neuropathy less than grade 2 No history of\n",
      "        hypersensitivity to products containing polysorbate 80 No other significant medical\n",
      "        condition No meningeal carcinomatosis No weight loss of greater than 10% within past 3\n",
      "        months due to disease\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy to pelvis, spine, or long bones and recovered No prior radiotherapy to at\n",
      "        least 30% of bone marrow Surgery: Greater than 4 weeks since prior major surgery Other: At\n",
      "        least 3 weeks since prior investigational drugs\n",
      "3152\n",
      "DISEASE CHARACTERISTICS: Suspected ovarian cancer OR Recurrence of ovarian cancer\n",
      "        Scheduled for exploratory surgery\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3000/mm3 Granulocyte count at least 1500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no\n",
      "        greater than 2.0 mg/dL SGPT and SGOT no greater than 2 times upper limit of normal (ULN)\n",
      "        Alkaline phosphatase no greater than 2 times ULN No acute hepatitis Renal: Creatinine no\n",
      "        greater than 1.4 mg/dL BUN no greater than 1.5 times ULN No known or suspected kidney\n",
      "        disease Cardiovascular: No history of congestive heart failure No unstable angina No\n",
      "        myocardial infarction within 6 months Other: Not pregnant or nursing No septicemia or\n",
      "        severe infection No medical condition that would preclude the administration of large\n",
      "        fluid volumes over a short period of time\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 months\n",
      "        since prior cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: At least\n",
      "        3 months since prior radiotherapy Surgery: See Disease Characteristics Other: At least 2\n",
      "        days since prior folic acid supplements At least 5 days since nonsteroidal\n",
      "        antiinflammatory medications\n",
      "3153\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage II or stage III\n",
      "        pancreatic adenocarcinoma that is considered resectable Lesions should be amenable to\n",
      "        surgery with curative intent Bidimensionally measurable or evaluable disease No evidence\n",
      "        of metastatic disease No clinically detectable third space fluid collections (e.g.,\n",
      "        ascites or effusions)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 9.5 g/dL Hepatic: Bilirubin no greater than 4 times upper limit of\n",
      "        normal (ULN) PTT no greater than 1.5 times control (unless on anticoagulants) Renal:\n",
      "        Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception No concurrent serious systemic disorders incompatible\n",
      "        with study No active infection No second primary malignancy, previously untreated with\n",
      "        curative intent or presently active, that would preclude curative resection of the\n",
      "        pancreas\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for pancreatic carcinoma Endocrine therapy: Not specified Radiotherapy: No\n",
      "        prior radiotherapy for pancreatic carcinoma Surgery: See Disease Characteristics Other: At\n",
      "        least 1 month since prior investigational agents At least 72 hours since prior\n",
      "        anticoagulant therapy, cholesterol-lowering agents (e.g., lovastatin), high dosage\n",
      "        vitamins, or antioxidants No concurrent anticoagulants except for the sole purpose of\n",
      "        central line patency maintenance No other concurrent investigational agents\n",
      "3154\n",
      "DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma of the head and\n",
      "        neck, including: Stage III or IV: oral cavity, paranasal sinus, hypopharynx, oropharynx,\n",
      "        larynx, and nasopharynx OR Unknown primary carcinoma of the head and neck with greater\n",
      "        than N1 disease if no planned neck dissection Evaluable disease No metastases below\n",
      "        clavicle by clinical or radiographic diagnosis All hypopharynx and nasopharynx patients\n",
      "        with N3 disease undergo a CT scan of the chest\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Platelet count at least 130,000/mm3 WBC at least 3,400/mm3\n",
      "        Hemoglobin greater than 10.0 g/dL (transfusion allowed) Hepatic: Not specified Renal:\n",
      "        Creatinine no greater than 1.4 mg/dL Cardiovascular: No active heart disease No myocardial\n",
      "        infarction within past 6 months No uncontrolled congestive heart failure No uncontrolled\n",
      "        angina Cardiac ejection fraction at least 50% by MUGA scan for patients under 65 without\n",
      "        antecedent heart disease, at least 55% for patients over 65 and/or with antecedent heart\n",
      "        disease Pulmonary: FEV greater than 60% of predicted Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the\n",
      "        treatment field Surgery: Eligible for PEG gastrostomy Other: At least 24 hours since prior\n",
      "        antihypertensive and diuretic medications (prior to amifostine and chemotherapy regimens)\n",
      "3155\n",
      "DISEASE CHARACTERISTICS: Primary operable stage I (tumors at least 1 cm), stage II, and\n",
      "        stage IIIA invasive breast carcinoma Treatment within the past 4 years by total mastectomy\n",
      "        and axillary dissection, or breast sparing surgical removal of cancer with clear\n",
      "        macroscopic margins and axillary dissection followed by adjuvant breast radiation No\n",
      "        evidence of recurrent disease or new breast cancer since completion of initial local\n",
      "        treatment confirmed within the past 6 months by physician evaluation, except stage I\n",
      "        mastectomy, for which physician evaluation can be within 1 year prior to randomization\n",
      "        Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 70 at time of diagnosis Sex: Female Menopausal status:\n",
      "        Not specified Performance status: Not specified Life expectancy: At least 10 years\n",
      "        (excluding breast cancer) Hematopoietic: Not specified Hepatic: No cirrhosis Renal: Not\n",
      "        specified Other: Not pregnant Accessible geographically and by telephone Able to\n",
      "        communicate dietary data via 24-hour food recall Able to commit to the intervention\n",
      "        schedule No comorbidity requiring a specific diet or taking a medication which\n",
      "        contraindicates consuming a high fiber diet (e.g., systemic scleroderma, other digestive\n",
      "        malabsorption syndromes, and insulin dependent diabetes) No other primary or recurrent\n",
      "        invasive cancer within the past 10 years except nonmelanoma skin cancer or carcinoma in\n",
      "        situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        chemotherapy Endocrine therapy: No concurrent estrogen replacement therapy, including\n",
      "        vaginal estrogen creams Radiotherapy: See Disease Characteristics Surgery: See Disease\n",
      "        Characteristics Other: No concurrent enrollment in another clinical trial that has dietary\n",
      "        restrictions or endpoints similar to this study\n",
      "3156\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven advanced solid tumors that\n",
      "        have failed standard therapy or for which no curative therapy exists No leukemia,\n",
      "        lymphoma, or multiple myeloma No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin normal\n",
      "        SGOT/SGPT no greater than 3 times upper limit of normal (ULN) PT/PTT less than ULN OR\n",
      "        International normalized ratio (INR) less than 1.1 Renal: Creatinine no greater than 2.0\n",
      "        mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No clear evidence of\n",
      "        acute ischemic heart disease on EKG No history of myocardial infarction within past 6\n",
      "        months No history of angina No peripheral vascular disorder Neurologic: No active seizure\n",
      "        disorder Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception No evidence of hematemesis, melena, or hematochezia No history of\n",
      "        inflammatory bowel disease, autoimmune disease, or bleeding disorders No Type I diabetes\n",
      "        mellitus or Type II diabetes with peripheral vascular disorders No active infections or\n",
      "        any serious concurrent systemic disorders incompatible with study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks for mitomycin and nitrosoureas) and recovered No other\n",
      "        concurrent cytotoxic therapy Endocrine therapy: Not specified Radiotherapy: At least 4\n",
      "        weeks since prior radiotherapy and recovered Surgery: At least 6 weeks since prior major\n",
      "        surgery Other: At least 4 weeks since any other prior investigational agent No concurrent\n",
      "        anticonvulsant therapy No concurrent aspirin greater than 100 mg per day, heparin, or\n",
      "        nonsteroidal antiinflammatory medication No concurrent calcium channel blockers,\n",
      "        antiarrhythmias, or anti-angina therapy Concurrent beta-blocking agents for hypertension\n",
      "        or anxiety allowed\n",
      "3157\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  HIV-infected patients with histologically or cytologically proven intermediate grade\n",
      "             large cell lymphoma; high grade large cell immunoblastic lymphoma; or high grade\n",
      "             small noncleaved cell lymphoma who have either failed to respond to or relapsed\n",
      "             following first line combination chemotherapy\n",
      "          -  Bidimensionally measurable disease\n",
      "          -  No CNS lymphoma (parenchymal brain or spinal cord tumor)\n",
      "          -  No meningeal lymphoma\n",
      "          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.\n",
      "             The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 to 70\n",
      "          -  Performance status: Karnofsky 60-100%\n",
      "          -  Absolute neutrophil count at least 1,000/mm3\n",
      "          -  Platelet count greater than 75,000/mm3\n",
      "          -  Hematologic criteria not applicable if abnormal functions are attributable to\n",
      "             lymphomatous infiltration of bone marrow or liver\n",
      "          -  Bilirubin less than 2.0 mg/dL, except in patients receiving indinavir who have\n",
      "             isolated hyperbilirubinemia\n",
      "          -  Transaminases less than 5 times upper limit of normal\n",
      "          -  Hepatic criteria not applicable if abnormal functions are attributable to\n",
      "             lymphomatous infiltration of bone marrow or liver\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or\n",
      "             nonmetastatic nonmelanomatous skin cancer\n",
      "          -  No acute active opportunistic infection requiring antibiotic treatment Patients with\n",
      "             Mycobacterium avium complex allowed\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  At least 2 weeks since prior immunomodulating agents\n",
      "          -  Concurrent filgrastim (G-CSF) allowed\n",
      "          -  Concurrent epoetin alfa allowed\n",
      "          -  Concurrent antibiotics may be given if clinically indicated during study\n",
      "          -  No more than 2 prior standard treatment regimens for non-Hodgkin's lymphoma\n",
      "          -  No concurrent systemic corticosteroids\n",
      "          -  Concurrent topical and/or oral antifungal agents permitted\n",
      "3158\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed technically resectable metastatic\n",
      "        colorectal cancer that is high risk for relapse Must meet one of the following criteria:\n",
      "        Metastatic colorectal cancer confined to liver plus portal lymph nodes Recurrent\n",
      "        metastatic colorectal cancer confined to liver after first hepatic resection Metastatic\n",
      "        colorectal cancer confined to lung plus liver Metastatic colorectal cancer confined to\n",
      "        liver with MSKCC risk factor score greater than 4 Metastatic colorectal cancer confined to\n",
      "        lung, with either greater than 1 nodule and/or less than 3 years disease free survival\n",
      "        Metastatic colorectal cancer confined to ovary Metastatic colorectal cancer confined to a\n",
      "        single intraabdominal lymph node Must have failed fluorouracil-based chemotherapy for\n",
      "        metastatic disease, received fluorouracil-based chemotherapy in adjuvant setting, have\n",
      "        tumor with measured thymidylate synthase level greater than 4.0, or have lung metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 2.0 mg/dL\n",
      "        Cardiovascular: No myocardial infarction in the last 6 months Other: No other prior\n",
      "        malignancy in the past 5 years except adequately treated basal cell or squamous cell skin\n",
      "        cancer or carcinoma in situ of the cervix No active or uncontrolled infection No\n",
      "        psychiatric or other disorders No other concurrent disease that would preclude entry into\n",
      "        this study Not pregnant or nursing Effective contraception required of all fertile\n",
      "        patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics No prior irinotecan or other camptothecins Endocrine therapy: Not\n",
      "        specified Radiotherapy: Not specified Surgery: See Disease Characteristics\n",
      "3159\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced non-small cell lung cancer that\n",
      "        is progressive within 2 months prior to study entry Stage IIIB due to malignant pleural\n",
      "        effusion or supraclavicular lymph node involvement only Stage IV At least 1\n",
      "        bidimensionally or unidimensionally measurable target lesion Brain metastases or\n",
      "        leptomeningeal disease that have been treated with radiotherapy, is stable without\n",
      "        medications (e.g., steroids), and asymptomatic are allowed\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: WHO 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at\n",
      "        least 100,000/mm3 Prothrombin time less than 1.5 times normal Hepatic: Bilirubin no\n",
      "        greater than 1.25 times upper limit of normal (ULN) (no greater than 2.5 times ULN if due\n",
      "        to liver metastases) AST or ALT less than 3 times ULN (no greater than 5 times ULN if due\n",
      "        to liver metastases) Renal: Creatinine clearance at least 60 mL/min Cardiovascular: No\n",
      "        uncontrolled cardiac disease, sign of cardiac failure, or rhythm disturbances requiring\n",
      "        medication No myocardial infarction in the past 3 months Neurological: No preexisting\n",
      "        motor or sensory neurotoxicity of grade 2 or greater Other: No active uncontrolled\n",
      "        infection Not a poor medical risk due to nonmalignant disease No secondary primary\n",
      "        malignancy in the past 5 years (excluding melanoma, breast cancer, and hypernephroma)\n",
      "        except carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the\n",
      "        skin No psychological condition that might hamper compliance in this study Not pregnant\n",
      "        Effective contraception required of all fertile patients during and for 3 months after\n",
      "        study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No\n",
      "        concurrent colony stimulating factor except for secondary prophylaxis in case of infection\n",
      "        and severe neutropenia No concurrent immunotherapy Chemotherapy: No prior chemotherapy for\n",
      "        advanced disease, including intracavitary chemotherapy At least 1 year since prior\n",
      "        neoadjuvant or adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy: See\n",
      "        Disease Characteristics No concurrent hormonal agents (except corticosteroids for\n",
      "        antiemetic prophylaxis) Radiotherapy: Prior radiotherapy should not include all target\n",
      "        lesions for evaluation At least 4 weeks since prior radiotherapy Concurrent palliative\n",
      "        radiotherapy allowed if indicator lesion is outside of radiation field Surgery: Not\n",
      "        specified\n",
      "3160\n",
      "DISEASE CHARACTERISTICS: Polyclonal or monoclonal B-cell lymphoproliferative disorder\n",
      "        while under pharmacologic immune suppression for control of either allograft rejection or\n",
      "        autoimmune disease Measurable disease as defined by one of the following: At least 1 tumor\n",
      "        mass measuring 1.0 cm in largest dimension Greater than 25% marrow involvement\n",
      "        Quantifiable extranodal disease Expression of CD20 antigen confirmed by biopsy or fine\n",
      "        needle aspirate Progression of disease or stable disease following reduction of\n",
      "        immunosuppressive medication and antiviral therapy Inability to further reduce\n",
      "        immunosuppressive medication\n",
      "        PATIENT CHARACTERISTICS: Age: 3 to 70 Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3\n",
      "        Platelet count at least 50,000/mm3 Hepatic: Not specified Renal: Not specified\n",
      "        Cardiovascular: No congestive heart failure Pulmonary: No pneumonitis Other: Not pregnant\n",
      "        or nursing Negative pregnancy test Fertile patients must use effective contraception\n",
      "        during and for 3 months after study No serious nonmalignant disease No active uncontrolled\n",
      "        bacterial, viral, or fungal infections\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks for nitrosoureas) No concurrent chemotherapy Endocrine\n",
      "        therapy: At least 2 weeks since change in dosing and type of immunosuppressive drugs\n",
      "        unless due to progression of disease Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy No concurrent radiotherapy Surgery: At least 4 weeks since prior major\n",
      "        surgery (except diagnostic surgery) Other: At least 30 days or 5 half-lives since other\n",
      "        prior investigational drugs or whichever is longer\n",
      "3162\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven metastatic renal cell carcinoma not amenable to complete\n",
      "             surgical resection and progressive despite immunotherapy\n",
      "          -  Bidimensionally evaluable clinically or radiographically\n",
      "          -  HLA 6/6 or 5/6 matched family donor available\n",
      "          -  No CNS metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 to 80\n",
      "        Performance status:\n",
      "          -  ECOG 0 or 1\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 4 mg/dL\n",
      "          -  Transaminases no greater than 3 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No malignancy-associated hypercalcemia (< 2.5 mmol/L)\n",
      "        Cardiovascular:\n",
      "          -  Left ventricular ejection fraction greater than 40%\n",
      "        Pulmonary:\n",
      "          -  DLCO greater than 65% of predicted\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  HIV negative\n",
      "          -  No major organ dysfunction that would preclude transplantation\n",
      "          -  No other malignancies except basal cell or squamous cell skin cancer\n",
      "          -  No psychiatric disorder or mental deficiency that would preclude study participation\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy\n",
      "          -  See Disease Characteristics\n",
      "        Chemotherapy\n",
      "          -  Not specified\n",
      "        Endocrine therapy\n",
      "          -  Not specified\n",
      "        Radiotherapy\n",
      "          -  Not specified\n",
      "        Surgery\n",
      "          -  Not specified\n",
      "        Other\n",
      "          -  At least 1 month since prior treatment for renal cell carcinoma\n",
      "3166\n",
      "DISEASE CHARACTERISTICS: Histologically proven cervical dysplasia (cervical\n",
      "        intraepithelial neoplasia II or III) Lesions must be delineated after colposcopic biopsy\n",
      "        No pap smears suspicious for invasive carcinoma No positive endocervical curettage\n",
      "        PATIENT CHARACTERISTICS: Age: Over 14 Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n",
      "        specified Immunologic: No proliferative skin disorder (e.g., psoriasis) No diagnosed\n",
      "        autoimmune disorders No allergy to tretinoin or latex Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception (except\n",
      "        intrauterine device) during and for 3 months after study Normal diet with adequate protein\n",
      "        and carbohydrate intake No in-utero exposure to diethylstilbesterol No prior malignancy No\n",
      "        prior toxic shock syndrome\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 1 week\n",
      "        since prior tretinoin No prior retinoids (greater than 25,000 IU vitamin A or equivalent\n",
      "        for at least 3 months) No other tretinoin during or for 3 months after study Endocrine\n",
      "        therapy: No concurrent regular steroids Radiotherapy: Not specified Surgery: See Disease\n",
      "        Characteristics Other: No concurrent regular anticoagulant medication No concurrent\n",
      "        nutritional supplements other than 2 multivitamins per day\n",
      "3167\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed locally advanced, unresectable\n",
      "        pancreatic or periampullary adenocarcinoma Patients may have evidence of hepatic or other\n",
      "        intra-abdominal or systemic metastases if they have dominant symptomatology from the\n",
      "        locally unresectable component of disease Prior treatment with 1 chemotherapy regimen\n",
      "        required Palliative bypass procedures without resection allowed Bidimensionally measurable\n",
      "        disease on CT or MRI scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count\n",
      "        at least 1,500/mm3 Platelet count at least 150,000/mm3 Hemoglobin at least 8.5 g/dL No\n",
      "        history of G6PD deficiency Hepatic: SGOT or SGPT less than 2 times upper limit of normal\n",
      "        (ULN) Alkaline phosphatase less than 2 times ULN Bilirubin no greater than 2.0 mg/dL\n",
      "        (elevated values must be falling or stable for at least 1 week prior to therapy) Renal:\n",
      "        Creatinine no greater than 2.0 mg/dL (no clinical indication of compromised kidney) Other:\n",
      "        Not pregnant or nursing Fertile patients must use effective contraception No second\n",
      "        malignancy within the past 5 years, except: Resected superficial nonmelanomatous skin\n",
      "        cancer Carcinoma in situ of the cervix No uncontrolled or serious medical conditions No\n",
      "        active peptic ulcers No weight loss greater than 5% of ideal body weight within 30 days\n",
      "        prior to study No uncontrolled nausea and vomiting No claustrophobia\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n",
      "        No concurrent experimental biologic therapy Chemotherapy: See Disease Characteristics\n",
      "        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy compromising the\n",
      "        delivery of radiation on this study No prior radiotherapy to areas within the planned\n",
      "        field of treatment Surgery: At least 4 weeks since prior gastrointestinal surgery Other:\n",
      "        At least 4 weeks since prior experimental drugs No other concurrent experimental drugs\n",
      "3168\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  History of stage 0-II breast cancer with no more than 4 involved axillary nodes if\n",
      "             nodal status and number of nodes investigated is known\n",
      "          -  No current evidence of disease\n",
      "          -  Hormone receptor status:\n",
      "               -  Positive, negative, or unknown\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Menopausal or perimenopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  No active liver disease\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Cardiovascular:\n",
      "          -  No prior or concurrent deep vein thrombosis\n",
      "          -  No hereditary traits for deep vein thrombosis\n",
      "          -  No prior or concurrent cerebral stroke\n",
      "          -  No prior or concurrent coronary disease\n",
      "        Other:\n",
      "          -  No prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix\n",
      "          -  No porphyria\n",
      "          -  No other serious disease that would prevent compliance or greatly limit life\n",
      "             expectancy\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior hormone replacement therapy (HRT) allowed if stopped no more than 4 weeks after\n",
      "             breast cancer diagnosis and at least 3 months prior to study\n",
      "          -  No prior HRT initiated after breast cancer diagnosis\n",
      "          -  No concurrent hormonal therapy for breast cancer except tamoxifen or toremifene\n",
      "        Radiotherapy:\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No prior randomization into trials comparing effects of chemotherapy and bilateral\n",
      "             oophorectomy in premenopausal women\n",
      "3170\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III, stage IV, or recurrent renal\n",
      "        cell carcinoma Measurable disease No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil\n",
      "        count at least 1500/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than\n",
      "        1.5 mg/dL ALT and AST no greater than 2.5 times the institutional normal values Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must\n",
      "        use effective contraception No uncontrolled systemic infection No other prior or\n",
      "        concurrent malignancies except nonmelanoma skin cancer, carcinoma in situ of the cervix,\n",
      "        or ductal carcinoma in situ of the breast that have been curatively treated No evidence of\n",
      "        delirium, confusion, suicidal ideation, or untreated depression\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 30 days since prior cytokines and\n",
      "        recovered No more than 1 prior treatment with cytokines (interleukin-2 or interferons)\n",
      "        Chemotherapy: No prior cytotoxic chemotherapy No prior aminocamptothecin No other\n",
      "        concurrent antineoplastic agents Endocrine therapy: At least 30 days since prior hormone\n",
      "        therapy and recovered No more than 1 prior hormone therapy (tamoxifen or\n",
      "        medroxyprogesterone) Radiotherapy: Prior radiotherapy allowed if indicator lesion and\n",
      "        greater than 15% of marrow producing bone have not been irradiated Surgery: Recovered from\n",
      "        prior surgery Other: At least 30 days since other investigational agents No concurrent\n",
      "        investigational agents\n",
      "3171\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed locally advanced, locally recurrent, or\n",
      "             metastatic colorectal adenocarcinoma not curable by surgery or radiotherapy\n",
      "               -  Histological or cytological requirement waived in patients who developed\n",
      "                  radiological or clinical evidence of metastatic cancer after a prior surgical\n",
      "                  resection unless:\n",
      "                    -  More than 5 years has elapsed since primary surgery OR\n",
      "                    -  Primary cancer was stage I or II\n",
      "          -  Site of primary lesion must be or have been confirmed endoscopically, radiologically,\n",
      "             or surgically to be or have been in the large bowel\n",
      "          -  Measurable or evaluable disease\n",
      "          -  No CNS metastases or carcinomatous meningitis\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 9.0 g/dL (transfusion allowed)\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  AST no greater than 5 times upper limit of normal (ULN)\n",
      "          -  Alkaline phosphatase no greater than 5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No uncontrolled hypertension\n",
      "          -  No unstable angina\n",
      "          -  No symptomatic congestive heart failure\n",
      "          -  No myocardial infarction within the past 6 months\n",
      "          -  No serious uncontrolled arrhythmia\n",
      "          -  No New York Heart Association class III or IV cardiac disease\n",
      "        Pulmonary:\n",
      "          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the\n",
      "             lung\n",
      "          -  No pleural effusion or ascites that cause respiratory compromise (grade 2 or worse\n",
      "             dyspnea)\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No active or uncontrolled infection\n",
      "          -  No symptomatic sensory peripheral neuropathy\n",
      "          -  No known allergy to platinum compounds\n",
      "          -  No history of gastrointestinal bleeding unless it is determined to be acceptable by\n",
      "             the enrolling physician\n",
      "          -  No other prior or concurrent malignancy within the past 3 years except nonmelanoma\n",
      "             skin cancer, carcinoma in situ of the uterine cervix, or other resected malignant\n",
      "             tumor with less than a 10% probability of tumor relapse within 3 years of diagnosis\n",
      "          -  No medical or psychiatric conditions that would preclude study\n",
      "          -  No colonic or small bowel disorders with uncontrolled symptoms of more than 3 loose\n",
      "             stools per day\n",
      "          -  Colostomy or ileostomy allowed at investigator's discretion\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Prior adjuvant immunotherapy for resected stage II-IV disease allowed if adjuvant\n",
      "             therapy concluded at least 1 year before documentation of recurrent disease\n",
      "          -  No concurrent sargramostim (GM-CSF)\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for advanced colorectal cancer\n",
      "          -  No prior standard adjuvant chemotherapy for rectal cancer\n",
      "          -  Prior adjuvant fluorouracil for resected stage II-IV disease allowed if adjuvant\n",
      "             therapy concluded at least 1 year before documentation of recurrent disease\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior major radiotherapy (e.g., chest or bone palliative\n",
      "             radiotherapy)\n",
      "          -  No prior radiotherapy to more than 15% of bone marrow\n",
      "          -  No prior standard adjuvant radiotherapy for rectal cancer\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior major surgery (e.g., laparotomy) (2 weeks for minor\n",
      "             surgery) and recovered\n",
      "          -  Insertion of a vascular access device not considered major or minor surgery\n",
      "        Other:\n",
      "          -  No other concurrent investigational agents\n",
      "3172\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically proven HIV-associated B cell non-Hodgkin's lymphoma,\n",
      "             including:\n",
      "          -  Diffuse large B cell lymphoma\n",
      "          -  Intermediate grade diffuse large cell lymphoma\n",
      "          -  High grade large cell immunoblastic lymphoma\n",
      "          -  Burkitt's lymphoma\n",
      "          -  High grade B cell lymphoma, Burkitt's like (small noncleaved lymphoma)\n",
      "          -  No primary CNS lymphoma (parenchymal brain or spinal cord tumor)\n",
      "          -  Evaluable disease HIV documentation may be serologic (ELISA or western blot),\n",
      "             culture, or quantitative PCR or bDNA assay Tumors must be CD20 positive (greater than\n",
      "             50% cells express CD20)\n",
      "          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.\n",
      "             The terminology of \"indolent\" or \"aggressive\" lymphoma will replace the former\n",
      "             terminology of \"low\", \"intermediate\", or \"high\" grade lymphoma. However, this\n",
      "             protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: Karnofsky 70-100%\n",
      "          -  Absolute neutrophil count greater than 1,000/mm3*\n",
      "          -  Platelet count greater than 75,000/mm3*\n",
      "             * Unless cytopenias are secondary to lymphoma\n",
      "          -  Bilirubin less than 2.0 mg/dL (unless secondary to hepatic infiltration with lymphoma\n",
      "             or isolated hyperbilirubinemia associated with the use of indinavir)\n",
      "          -  SGOT or SGPT less than 7 times upper limit of normal\n",
      "          -  Creatinine less than 2.0 mg/dL (unless due to lymphoma)\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No acute, active HIV-associated opportunistic infection requiring antibiotics\n",
      "          -  Mycobacterium avium complex allowed\n",
      "          -  No concurrent malignancy except carcinoma in situ of the cervix, nonmetastatic\n",
      "             nonmelanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Prior or concurrent epoetin alfa or filgrastim (G-CSF) allowed\n",
      "          -  No prior colony stimulating factor therapy within 24 hours prior to chemotherapy\n",
      "          -  No prior chemotherapy for HIV-associated non-Hodgkin's lymphoma\n",
      "          -  At least 1 year since prior cyclophosphamide or doxorubicin\n",
      "          -  No prior radiotherapy for HIV-associated non-Hodgkin's lymphoma\n",
      "          -  Chronic therapy with myelosuppressive agents allowed\n",
      "          -  Concurrent antiretroviral therapy, antifungal medications, and antibiotics allowed\n",
      "3173\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed unresectable stage IV colon or rectal\n",
      "        cancer that has failed conventional chemotherapy for advanced disease or refused other\n",
      "        treatment Measurable disease No liver involvement of greater than 50% No clinical evidence\n",
      "        of CNS tumor involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: At least 14 weeks Hematopoietic: WBC at least 3,5000/mm3 Platelet count at\n",
      "        least 150,000/mm3 Hepatic: Bilirubin no greater than 1.0 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL Cardiovascular: No clinically significant cardiac disease (New York\n",
      "        Heart Association class III/IV heart disease) Other: No positive human antimouse antibody\n",
      "        titer No serious infection requiring treatment with antibiotics No other serious illness\n",
      "        Not pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior mouse monoclonal antibody or antibody\n",
      "        fragment, or chimeric or humanized antibody At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: No prior carmustine, fluorouracil, vincristine, and streptozocin At least 4\n",
      "        weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4\n",
      "        weeks since prior radiotherapy Surgery: Not specified\n",
      "3174\n",
      "PROTOCOL ENTRY CRITERIA:\n",
      "        --Disease Characteristics-- Histologically confirmed metastatic melanoma not amenable to\n",
      "        complete surgical resection and progressive despite immunotherapy and/or chemotherapy\n",
      "        Bidimensionally evaluable clinically or radiographically HLA 6/6 or 5/6 matched sibling\n",
      "        donor available No CNS metastases --Prior/Concurrent Therapy-- See Disease Characteristics\n",
      "        At least 30 days since prior treatment for melanoma --Patient Characteristics-- Age: 18 to\n",
      "        60 Performance status: ECOG 0-1 Life expectancy: At least 3 months Hematopoietic: Not\n",
      "        specified Hepatic: Bilirubin no greater than 4 mg/dL Transaminases no greater than 3 times\n",
      "        upper limit of normal Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: Left\n",
      "        ventricular ejection fraction greater than 40% Pulmonary: DLCO greater than 65% of\n",
      "        predicted Other: HIV negative No major organ dysfunction precluding transplantation No\n",
      "        other malignancies except basal cell or squamous cell skin cancer No psychiatric disorder\n",
      "        or mental deficiency that would preclude study Not pregnant or nursing\n",
      "3175\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed invasive adenocarcinoma of the breast\n",
      "               -  Confined to the breast and ipsilateral axilla on clinical exam\n",
      "                    -  Stage I, II, or IIIA (cT1-3, N0-1, M0)\n",
      "          -  At least one axillary lymph node with evidence of tumor on histologic exam\n",
      "               -  Sentinel node biopsy allowed if followed by axillary dissection\n",
      "               -  No suspicious palpable nodes in the contralateral axilla or palpable\n",
      "                  supraclavicular or infraclavicular nodes, unless proven on biopsy to not be\n",
      "                  involved with tumor\n",
      "          -  No bilateral malignancy or mass in the opposite breast, unless mass is histologically\n",
      "             proven to be benign\n",
      "          -  Must have undergone either a prior total mastectomy and axillary dissection (modified\n",
      "             radical mastectomy) OR\n",
      "          -  Prior lumpectomy and axillary dissection\n",
      "               -  Patients must receive radiotherapy after randomization (not before) AND after\n",
      "                  chemotherapy\n",
      "               -  Margins must be clear\n",
      "               -  No ipsilateral lymph nodes that are fixed to one another or to other structures\n",
      "                  (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are\n",
      "                  considered axillary nodes)\n",
      "               -  No histologically evident invasive tumor or ductal carcinoma in situ\n",
      "               -  No diffuse tumors by mammography that would not be surgically amenable to\n",
      "                  lumpectomy\n",
      "               -  No other dominant mass in the ipsilateral breast remnant unless one of the\n",
      "                  following is true:\n",
      "                    -  Histologically benign\n",
      "                    -  Surgically removed with clear margins if malignant\n",
      "          -  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete\n",
      "             fixation), peau d'orange, or skin edema of any magnitude\n",
      "               -  Tethering or dimpling of the skin or nipple inversion allowed\n",
      "          -  No metastatic disease\n",
      "               -  Skeletal pain allowed if bone scan negative for metastases\n",
      "          -  Hormone receptor status:\n",
      "               -  Estrogen and progesterone status determined\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  greater than or equal to 18 years\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  At least 10 years, excluding diagnosis of cancer\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the\n",
      "             investigator, this represents an ethnic or racial variation)\n",
      "          -  Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper\n",
      "             limit of normal (ULN), significant underlying hematologic disorders must be excluded\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than ULN\n",
      "          -  Alkaline phosphatase less than 2.5 times ULN*\n",
      "          -  SGOT less than 1.5 times ULN*\n",
      "          -  No nonmalignant systemic hepatic disease that would preclude study participation\n",
      "             NOTE: *Alkaline phosphatase and SGOT cannot both be greater than ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than normal\n",
      "          -  No nonmalignant systemic renal disease that would preclude study participation\n",
      "        Cardiovascular:\n",
      "          -  No nonmalignant systemic cardiovascular disease that would preclude study\n",
      "             participation\n",
      "          -  LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram\n",
      "          -  No active cardiac disease that would preclude use of doxorubicin or docetaxel,\n",
      "             including the following:\n",
      "               -  Any prior myocardial infarction\n",
      "               -  Angina pectoris requiring anti-anginal medication\n",
      "               -  History of congestive heart failure\n",
      "               -  Cardiac arrhythmia requiring medication\n",
      "               -  Severe conduction abnormality\n",
      "               -  Valvular disease with documented cardiac function compromise\n",
      "               -  Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at\n",
      "                  least LLN\n",
      "               -  Poorly controlled hypertension (diastolic greater than 100 mm/Hg)\n",
      "               -  Hypertension well controlled by medication allowed\n",
      "        Other:\n",
      "          -  No grade 2 or greater peripheral neuropathy\n",
      "          -  No other prior malignancy within the past 5 years except:\n",
      "               -  Effectively treated squamous cell or basal cell skin cancer\n",
      "               -  Surgically treated carcinoma in situ of the cervix\n",
      "               -  Segmentally resected lobular carcinoma in situ of the ipsilateral or\n",
      "                  contralateral breast\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective barrier contraception\n",
      "          -  No nonmalignant systemic disease that would preclude study participation\n",
      "          -  No diabetes with morning fasting blood glucose of 200 mg/dL or greater\n",
      "          -  No psychiatric or addictive disorders that would preclude informed consent\n",
      "          -  No contraindication to corticosteroids that would preclude study participation\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy for breast cancer\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for breast cancer\n",
      "          -  No prior anthracyclines or taxanes\n",
      "          -  No other concurrent investigational chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No prior hormonal therapy for breast cancer\n",
      "          -  No concurrent hormonal birth control methods or other hormonal therapy\n",
      "          -  No concurrent raloxifene, including for osteoporosis\n",
      "          -  Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or\n",
      "             conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator\n",
      "             applied vaginally 3 times a week) allowed\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy for this malignancy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy,\n",
      "             mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy\n",
      "             margins)\n",
      "        Other:\n",
      "          -  No prior systemic therapy for this malignancy\n",
      "          -  No concurrent medications that alter cardiac conduction (e.g., digitalis, beta\n",
      "             blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive\n",
      "             heart failure (allowed if administered for other reasons [e.g., hypertension])\n",
      "          -  Concurrent bisphosphonates allowed\n",
      "3176\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV mantle cell lymphoma\n",
      "        (diffuse, nodular, mantle zone, or blastic variants)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: Not specified Hepatic: No chronic active or\n",
      "        persistent hepatitis Bilirubin less than 2 mg/dL (unless history of Gilbert's disease)\n",
      "        Renal: No history of chronic renal insufficiency Creatinine less than 1.5 mg/dL OR\n",
      "        Creatinine clearance greater than 60 mL/min Cardiovascular: At least 6 months since\n",
      "        myocardial infarction No unstable angina No cardiac arrhythmias other than chronic atrial\n",
      "        fibrillation LVEF at least 50% Pulmonary: DLCO at least 50% Other: No medical illness that\n",
      "        would preclude study treatment No uncontrolled infection No history of malignancy, other\n",
      "        than curatively treated basal cell skin cancer or carcinoma in situ of the cervix Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception Not HIV positive\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy\n",
      "3177\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced or metastatic\n",
      "        renal cell carcinoma Bidimensionally measurable lesions that have not been irradiated\n",
      "        Minimum indicator lesion size: Liver, soft tissue, or other masses - one diameter at least\n",
      "        20 mm (evaluable only radiographically) Lung - one diameter at least 10 mm by x-ray or CT\n",
      "        scan Skin lesions and lymph nodes - one diameter at least 10 mm by clinical measurement No\n",
      "        clinical or radiologic evidence of CNS metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3000/mm3 Neutrophil count at least\n",
      "        1500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (red cell\n",
      "        transfusions allowed) Hepatic: Bilirubin no greater than 1.5 times the upper limit of\n",
      "        normal (ULN) (except for patients with Gilbert's syndrome) ALT and/or AST no greater than\n",
      "        2.5 times ULN (no greater than 4 times ULN with liver metastases) Alkaline phosphatase no\n",
      "        greater than 2.5 times ULN (no greater than 4 times ULN with liver metastases) Renal:\n",
      "        Creatinine no greater than 1.5 times ULN Cardiovascular: No history of severe cardiac\n",
      "        disease: New York Heart Association class II (if not due to cancer), III, or IV Myocardial\n",
      "        infarction within the past 6 months Ventricular tachyarrhythmias requiring ongoing\n",
      "        treatment Unstable angina Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception No other prior or concurrent malignancy except basal cell\n",
      "        carcinoma of the skin, carcinoma in situ of the cervix, or any other malignancy from which\n",
      "        the patient has been disease free for at least 2 years No history of medically significant\n",
      "        psychiatric disease, especially depression No history or evidence of retinopathy No\n",
      "        seizure disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent immunotherapy, biologic\n",
      "        response modifiers, cytokines, monoclonal antibodies, antitumor vaccines, or any other\n",
      "        systemic therapy Chemotherapy: No prior or concurrent chemotherapy Endocrine therapy: No\n",
      "        prior or concurrent hormone therapy Hormone replacement after adrenalectomy is allowed\n",
      "        Radiotherapy: Prior radiotherapy allowed No concurrent radiotherapy Surgery: Prior\n",
      "        nephrectomy allowed Other: No other concurrent investigational drugs No concurrent\n",
      "        anticonvulsant therapy\n",
      "3178\n",
      "DISEASE CHARACTERISTICS: Histologically proven, newly diagnosed multiple myeloma Eligible\n",
      "        if pancytopenia related to multiple myeloma At least 50% plasma cells in the bone marrow\n",
      "        OR Splenomegaly OR Plasma cell leukemia No solitary extramedullary plasmacytoma or plasma\n",
      "        cell dyscrasia\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        At least 3 months Hematopoietic: If less than 50% plasma cells in bone marrow: WBC at\n",
      "        least 2,500/mm3 OR Absolute neutrophil count at least 1,000/mm3 (greater than 500/mm3 if\n",
      "        platelet count at least 75,000/mm3) Platelet count greater than 45,000/mm3\n",
      "        (thrombocytopenia related to idiopathic thrombocytopenic purpura or vitamin B12 or folate\n",
      "        deficiency allowed) Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN)\n",
      "        ALT or AST less than 2 times ULN (if greater than one third of liver involved, then no\n",
      "        greater than 5 times ULN) No severe hepatic disease Renal: Creatinine no greater than 2.0\n",
      "        mg/dL Other: No severe infection requiring intravenous antibiotics Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception No prior malignancy within 5 years\n",
      "        except for treated basal cell or squamous cell skin cancer, or carcinoma in situ of the\n",
      "        cervix No Type I hypersensitivity or anaphylactic reactions to murine proteins or to any\n",
      "        component of rituximab\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation\n",
      "        Concurrent sargramostim (GM-CSF) allowed for severe, symptomatic neutropenia Chemotherapy:\n",
      "        At least 4 weeks since investigational drugs Endocrine therapy: Not specified\n",
      "        Radiotherapy: Not specified Surgery: Not specified Other: No concurrent use of\n",
      "        investigational drugs or devices Concurrent epoetin alfa allowed for anemia Plasmapheresis\n",
      "        allowed at study onset to treat renal failure\n",
      "3179\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed completely resected T1 or Ta papillary\n",
      "        tumors of the urinary bladder TaG2 greater than 2 relapses in 2 years TaG3 unifocal or\n",
      "        multifocal Unifocal primary T1G2-3 after a histological tumor-free second resection If\n",
      "        multiple/multifocal, worst stage and grade AND/OR Histologically and cytologically\n",
      "        confirmed primary or secondary carcinoma in situ of the urinary bladder No persistent T1\n",
      "        disease in second resection No contracted bladder (bladder capacity less than 80 mL) or\n",
      "        bladder irritation within past 5 years No urothelial carcinoma of the upper urinary tract\n",
      "        or the urethra\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 90 Performance status: WHO 0-1 Life expectancy: Not\n",
      "        specified Hematopoietic: Not specified Hepatic: Liver function no greater than 1.5 times\n",
      "        upper limit of normal (ULN) Renal: Renal function no greater than 1.5 times ULN Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception No other concurrent\n",
      "        malignancies except basocellular carcinoma No congenital or acquired immunosuppression\n",
      "        (e.g., HIV, leukemia, lymphoma, transplant recipient) No uncontrollable or untreated\n",
      "        urinary tract infection No chronic recurring bacterial cystitis\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior BCG therapy Chemotherapy: At least 3\n",
      "        months since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 5\n",
      "        years since prior radiotherapy to the bladder Surgery: See Disease Characteristics Other:\n",
      "        No prior tuberculostatic therapy No concurrent local antiseptics or antibiotics\n",
      "3180\n",
      "DISEASE CHARACTERISTICS: Newly diagnosed B-cell precursor acute lymphocytic leukemia No L3\n",
      "        morphology Very poor prognosis CNS 3 (blasts and WBC greater than 5 microliters) OR Must\n",
      "        meet all of the following criteria: No simultaneous trisomy 4 and 10 DNA index no greater\n",
      "        than 1.16 (if FISH 4 and 10 unsatisfactory) No TEL-AML1 [t(12;21)] Meets at least 1 of the\n",
      "        following: Has MLL (11q23) and/or BCR-ABL [t(9;22)] WBC greater than 100,000/mm3 Age over\n",
      "        12 (boys) or 16 (girls) OR Boys Girls WBC 8 12 greater than 80,000/mm3 9 13 greater than\n",
      "        60,000/mm3 10 14 greater than 40,000/mm3 11 15 greater than 20,000/mm3 Concurrent\n",
      "        registration on stratum 6 of POG-9400 before 11/15/1999 OR Concurrent registration on\n",
      "        stratum 4 of POG-9900 after 11/15/1999 Concurrent registration on POG-9201, POG-9705, or\n",
      "        POG-9806 unless ineligible\n",
      "        PATIENT CHARACTERISTICS: Age: Children Performance status: Not specified Life expectancy:\n",
      "        Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not\n",
      "        specified\n",
      "        PRIOR CONCURRENT THERAPY: See Disease Characteristics\n",
      "3181\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage III or IV renal cancer that has been\n",
      "        completely resected and is at high risk for recurrence, including at least one of the\n",
      "        following: Tumor invades adrenal gland or perinephric tissues but not beyond Gerota's\n",
      "        fascia (T3a) OR Tumor extending into renal vein, vena cava (T3b) OR Tumor grossly extends\n",
      "        into vena cava above diaphragm (T3c) OR Tumor invades beyond Gerota's fascia (T4) OR Any\n",
      "        lymph node involvement totally resected (N1-3) OR Completely resected metastases of all\n",
      "        sites No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hemoglobin at least 9 g/dL Hepatic: Bilirubin less than 3 times upper limit of normal\n",
      "        (ULN) AST or ALT less than 3 times ULN Renal: Creatinine no greater than 1.9 mg/dL\n",
      "        Cardiovascular: No prior myocardial infarction within 6 months No LVEF less than 35% No\n",
      "        primary cardiac arrhythmias beyond occasional PVCs No angina No uncontrolled congestive\n",
      "        heart failure No cerebrovascular accident Pulmonary: No dyspnea at rest or requirement for\n",
      "        supplemental oxygen Oxygen saturation greater than 90% for patients with symptomatic lung\n",
      "        disease Other: Not pregnant or nursing Negative pregnancy test Fetile patients must use\n",
      "        effective contraception Temperatures greater than 100.5 degrees F must have occult\n",
      "        infection excluded No psychiatric disorders\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent\n",
      "        cyclosporine or methotrexate Endocrine therapy: At least 3 weeks since prior\n",
      "        corticosteroids No concurrent corticosteroids Radiotherapy: Not specified Surgery: At\n",
      "        least 2 weeks since prior surgery Other: At least 3 weeks since prior immunosuppressive\n",
      "        medications No concurrent immunosuppressive medications\n",
      "3182\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed previously untreated ovarian cancer, fallopian tube\n",
      "             carcinoma, papillary serous cancer of the uterus, or primary peritoneal carcinoma\n",
      "               -  Suboptimally debulked stage III or suboptimally or optimally debulked stage IV\n",
      "          -  Measurable or evaluable disease\n",
      "               -  CNS lesions, lytic bone lesions, and radiated lesions (unless there is\n",
      "                  documented progression after radiotherapy) are not considered measurable\n",
      "               -  CA 125 levels above 49 units/mL in the absence of cirrhosis or nonmalignant\n",
      "                  gross ascites are considered evaluable\n",
      "          -  Ineligible for other high-priority national or institutional study\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  More than 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,000/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT and/or SGPT less than 2.5 times ULN OR\n",
      "          -  SGOT and/or SGPT no greater than 2.5 times ULN if alkaline phosphatase no greater\n",
      "             than ULN OR\n",
      "          -  Alkaline phosphatase no greater than 4 times ULN if SGOT and/or SGPT no greater than\n",
      "             ULN\n",
      "          -  No SGOT and/or SGPT greater than 1.5 times ULN with alkaline phosphatase greater than\n",
      "             2.5 times ULN\n",
      "          -  Alkaline phosphatase less than 350 U/L\n",
      "        Renal:\n",
      "          -  BUN less than 1.5 times normal\n",
      "          -  Creatinine less than 1.5 times ULN\n",
      "        Other:\n",
      "          -  No other malignancy within the past 5 years except curatively treated carcinoma in\n",
      "             situ of the cervix or skin cancer\n",
      "          -  No other serious medical or psychiatric illness\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  No concurrent hormone therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "3184\n",
      "DISEASE CHARACTERISTICS: Histologically proven (except for brain stem tumors) malignancy\n",
      "        that has\n",
      "        failed or relapsed after standard first-line antineoplastic therapy\n",
      "          -  Sarcoma (soft tissue and bone)\n",
      "          -  Kidney tumors\n",
      "          -  Brain tumors\n",
      "          -  Other solid tumors (gonadal and germ cell tumors, malignant melanoma,\n",
      "          -  retinoblastoma, liver tumors, and miscellaneous tumors) Must have had recurrence\n",
      "             within the past 4 weeks\n",
      "        No bone marrow involvement\n",
      "        No prior or concurrent myelogenous leukemia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  1 to 21\n",
      "        Performance status:\n",
      "          -  Lansky or Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count greater than 1000/mm3\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  No grade III or IV thrombosis\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.5 times upper limit of normal (ULN)\n",
      "          -  SGOT or SGPT less than 2.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine clearance or glomerular filtration rate at least 70 mL/min\n",
      "        Cardiovascular:\n",
      "          -  Ejection fraction normal\n",
      "          -  No evidence of arrhythmias requiring therapy\n",
      "          -  Fractional shortening greater than 28%\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 10 days since prior colony-stimulating factor therapy and recovered\n",
      "          -  At least 30 days since prior epoetin alfa\n",
      "          -  No other concurrent cytokines, including epoetin alfa\n",
      "        Chemotherapy:\n",
      "          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and\n",
      "          -  recovered\n",
      "          -  At least 3 months since therapy with etoposide, carboplatin, or ifosfamide\n",
      "          -  that is identical to study treatment\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Concurrent radiotherapy allowed after third course of therapy\n",
      "          -  No prior cranial/spinal radiotherapy\n",
      "          -  No prior radiotherapy to greater than 50% of bone marrow\n",
      "        Surgery:\n",
      "          -  Concurrent surgery allowed after the second course of therapy\n",
      "        Other:\n",
      "          -  No concurrent investigational agents\n",
      "          -  No concurrent lithium, aspirin, coumadin, or heparin\n",
      "3185\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed adenocarcinoma of any differentiation grade\n",
      "               -  Excludes the following \"treatable\" conditions:\n",
      "                    -  Axillary node involvement\n",
      "                    -  Peritonitis carcinomatosis\n",
      "                    -  Blastic bone metastases and/or elevated PSA\n",
      "                    -  Squamous cell cancer with cervical or inguinal presentation\n",
      "                    -  Poorly differentiated carcinoma\n",
      "                         -  Neuroendocrine tumors OR\n",
      "                         -  Tumors located in the mediastinum, retroperitoneum, or nodes\n",
      "          -  At least one measurable metastatic site\n",
      "          -  No brain or meningeal metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Hematopoietic:\n",
      "          -  Leukocyte count at least 4,000/mm3\n",
      "          -  Thrombocyte count at least 100,000/mm3\n",
      "        Hepatic:\n",
      "          -  Bilirubin less than 1.4 mg/dL\n",
      "          -  AST and ALT less than 3 times upper limit of normal\n",
      "          -  No cirrhosis of the liver\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.7 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  At least 3 months since myocardial infarction\n",
      "          -  No congestive heart failure, tachydysrhythmia, or unstable angina pectoris\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  No active infection\n",
      "          -  No other serious illness or medical condition\n",
      "          -  No current or prior malignancy except nonmelanomatous skin cancer or carcinoma in\n",
      "             situ of the cervix\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy (no greater than 25% of bone marrow)\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "3186\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma or poorly differentiated\n",
      "        carcinoma of the pancreas Metastatic disease with at least 1 bidimensionally measurable\n",
      "        lesion OR Locally advanced disease that is either recurrent or not amenable to surgery\n",
      "        Measurable disease outside of prior radiation port or disease progression within the port\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count at\n",
      "        least 125,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT no\n",
      "        greater than 2.5 times ULN (less than 3 times ULN if liver metastases) Renal: Creatinine\n",
      "        no greater than ULN Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for metastatic disease At least 1 year since prior adjuvant chemotherapy\n",
      "        Prior chemoradiotherapy as initial therapy allowed Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics See Chemotherapy At least 4 weeks since prior\n",
      "        radiotherapy Surgery: Not specified\n",
      "3188\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the oral\n",
      "        cavity, nasopharynx, oropharynx, hypopharynx, or larynx Previously untreated Stage III or\n",
      "        IV No distant metastatic disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: SGOT and SGPT no greater than 2.5 times upper limit of normal Renal:\n",
      "        Creatinine no greater than 2.0 mg/dL Creatinine clearance greater than 61 mL/min Other: No\n",
      "        history of any underlying medical or psychiatric illness Not pregnant or nursing Effective\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: No prior therapy for head and neck cancer Biologic therapy: Not\n",
      "        specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not\n",
      "        specified Surgery: Not specified Other: At least 24 hours since prior antihypertensive\n",
      "        medication\n",
      "3189\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed follicular non-Hodgkin's lymphoma No\n",
      "        prior treatment Bulky stage II, stage III, or stage IV Must express cluster of\n",
      "        differentiation antigen 20 (CD20) antigen Bidimensionally measurable disease No Central\n",
      "        Nervous System (CNS) involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Granulocyte count at least 1500/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Not specified Renal: Not specified Cardiovascular: No arrhythmias\n",
      "        (except sinus arrhythmia or infrequent premature ventricular contractions) No history of\n",
      "        impaired cardiac status (severe coronary artery disease, cardiomyopathy, congestive heart\n",
      "        failure, or serious arrhythmia Ejection fraction at least normal Other: HIV negative No\n",
      "        prior malignancy within past 5 years except adequately treated basal cell or squamous cell\n",
      "        skin cancer or carcinoma in situ of the cervix No pregnant or nursing Fertile patients\n",
      "        must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibodies Chemotherapy:\n",
      "        No prior chemotherapy for lymphoma Endocrine therapy: Not specified Radiotherapy: No prior\n",
      "        radiotherapy for lymphoma Surgery: Not specified\n",
      "3190\n",
      "DISEASE CHARACTERISTICS: Cytogenetically or molecularly proven chronic phase chronic\n",
      "        myeloid leukemia (CML) that is Philadelphia chromosome positive OR Philadelphia chromosome\n",
      "        negative with evidence of the BCR-ABL rearrangement or evidence of the P120 protein On\n",
      "        interferon alfa therapy less than 6 months In complete hematologic response, defined as:\n",
      "        WBC less than 10,000/mm3 Platelet count less than 450,000/mm3 Less than 5% circulating\n",
      "        blasts No signs and symptoms of disease, including progressive splenomegaly\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not\n",
      "        specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use\n",
      "        effective contraception No history of intolerance to sargramostim (GM-CSF) Must be able to\n",
      "        perform self injection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interferon alfa required Chemotherapy:\n",
      "        Prior hydroxyurea and cytarabine allowed Endocrine therapy: Not specified Radiotherapy:\n",
      "        Not specified Surgery: Not specified Other: No other concurrent myelosuppressive drug\n",
      "        therapy\n",
      "3191\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic, locally advanced, or\n",
      "        recurrent cancer of the liver (hepatoma), bile duct, or gallbladder (cholangiocarcinoma)\n",
      "        Bidimensionally measurable disease The following are not considered measurable lesions:\n",
      "        Lesions seen on colonoscopic examination or barium studies Bone metastases CNS lesions\n",
      "        CEA, CA19-9, or AFP levels Ascites No CNS disease only No symptomatic brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CALGB 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 OR Platelet count at least 75,000/mm3 in patients with\n",
      "        clinically documented sequestration or hemodilution unrelated to primary bone marrow\n",
      "        insufficiency Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminases no greater than 5 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No significant\n",
      "        underlying medical or psychiatric illness No active infections No other malignancy within\n",
      "        the past 5 years except curatively treated nonmelanoma skin cancer and carcinoma in situ\n",
      "        of the cervix\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for advanced or metastatic hepatobiliary cancer No other concurrent\n",
      "        chemotherapy No concurrent investigational antineoplastic drugs Endocrine therapy: Not\n",
      "        specified Radiotherapy: No prior radiotherapy to only site of measurable disease At least\n",
      "        6 weeks since prior radiotherapy and recovered No concurrent radiotherapy to any lesion\n",
      "        Surgery: Not specified\n",
      "3192\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histological confirmation of invasive, early stage breast cancer\n",
      "          -  Prior complete excision of tumor required (wide local excision or mastectomy)\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Pre-, peri-, or post-menopausal\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Adequate bone marrow function\n",
      "        Hepatic:\n",
      "          -  Adequate hepatic function\n",
      "        Renal:\n",
      "          -  Adequate renal function\n",
      "        Other:\n",
      "          -  No prior cancer except for basal cell carcinoma or carcinoma in situ\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent hormone therapy allowed\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy\n",
      "          -  Concurrent radiotherapy allowed\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No more than 6 weeks since prior surgery to the breast\n",
      "3193\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed recurrent or new primary squamous cell carcinoma of the head\n",
      "             and neck occurring in a previously irradiated field\n",
      "          -  Pathologic stage of recurrence must be rT3-4 and/or rN2-3\n",
      "          -  The following sites are eligible:\n",
      "               -  Oral cavity, oropharynx, or hypopharynx: Any rT2-4 and/or clinical rN+\n",
      "               -  Larynx: Any rT4, rT3 with perineural invasion, or any rT with clinical rN+\n",
      "               -  Any site: Positive margin(s), at least 2 nodes or ECS\n",
      "          -  No primary tumor of the nasopharynx\n",
      "          -  Must be eligible for or have undergone complete resection which leaves behind no\n",
      "             gross residual disease\n",
      "          -  Must have prior head and neck irradiation of 45-75 Gy\n",
      "          -  Lifetime spinal cord radiotherapy dose no greater than 50 Gy\n",
      "          -  No ongoing RTOG late morbidity of grade 3 or greater (unless correctable by surgery)\n",
      "          -  No active acute radiation mucositis from previous radiotherapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 70-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm^3\n",
      "          -  Hemoglobin at least 9 g/dL (transfusion allowed)\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGOT or SGPT no greater than 3 times upper limit of normal\n",
      "          -  Bilirubin no greater than 2 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction, unstable angina, coronary heart failure, or uncontrolled\n",
      "             arrhythmias within past 6 months\n",
      "          -  No severe cerebrovascular disease or hypotension not caused by antihypertensive\n",
      "             medication\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No allergy to cisplatin, fluorouracil, or amifostine\n",
      "          -  No uncontrolled insulin-dependent diabetes mellitus or other medical condition\n",
      "             interfering with wound healing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy for tumor recurrence (except adjuvant chemotherapy)\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 6 months since prior radiotherapy\n",
      "          -  Prior radiotherapy treatment records must be available\n",
      "        Surgery:\n",
      "          -  No prior salvage surgery consisting of partial laryngectomy\n",
      "3194\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed advanced, incurable, squamous cell\n",
      "        carcinoma of the head and neck Recurrent disease in a previously irradiated field must be\n",
      "        biopsy proven or documented unequivocally by physical exam or radiograph(s) Measurable or\n",
      "        evaluable disease Patients with ECOG performance status of 0-1 must be ineligible for\n",
      "        protocol E-1395 and unable to tolerate cisplatin-based therapy for 1 or more of the\n",
      "        following reasons: Hearing loss that precludes cisplatin Unable to handle a fluid load\n",
      "        necessitated by cisplatin-based treatment, due to underlying cardiac or pulmonary disease\n",
      "        Mild renal insufficiency (creatinine 1.6-2.0 mg/dL) or creatinine clearance of 40-60\n",
      "        mL/min that would make cisplatin treatment difficult, if not dangerous History of brain\n",
      "        metastases allowed if disease has stabilized or improved after radiation and/or craniotomy\n",
      "        No history of carcinomatous meningitis\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 (See Disease\n",
      "        Characteristics) Life expectancy: Not specified Hematopoietic: Absolute neutrophil count\n",
      "        at least 1,800/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than\n",
      "        1.5 mg/dL SGOT and SGPT no greater than 5 times upper limit of normal Renal: See Disease\n",
      "        Characteristics Creatinine no greater than 2.0 mg/dL No evidence of symptomatic\n",
      "        hypercalcemia Cardiovascular: See Disease Characteristics No active angina or uncontrolled\n",
      "        arrhythmias Metabolic: No uncontrolled diabetes; no random blood sugar at least 300 mg/dL\n",
      "        Neurological: No evidence of ongoing grade 2 or greater peripheral sensory neuropathy\n",
      "        Pulmonary: See Disease Characteristics Other: No other concurrent, active, invasive\n",
      "        malignancies No significant detectable infection Not pregnant or nursing Effective\n",
      "        contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy except in the adjuvant, neoadjuvant, or radiosensitizing setting No prior\n",
      "        chemotherapy for recurrent or persistent disease after definitive local therapy At least 6\n",
      "        months since prior methotrexate or paclitaxel Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy\n",
      "        Surgery: See Disease Characteristics Recovered from prior surgery\n",
      "3196\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed head and neck squamous cell cancer (excluding nasopharynx\n",
      "             and salivary glands) on biopsy of the primary lesion or the neck mass\n",
      "          -  Stage III or IV disease\n",
      "               -  No evidence of distant or systemic metastases\n",
      "          -  Resectable disease\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-1\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3000/mm^3\n",
      "          -  Platelet count greater than 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  SGOT less than 2 times upper limit of normal\n",
      "          -  Bilirubin less than 1.4 mg/dL\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.6 mg/dL\n",
      "        Other:\n",
      "          -  No prior or concurrent primary malignancies\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior radiotherapy to the head and neck\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior surgery (other than biopsy)\n",
      "3197\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic ovarian epithelial cancer that is platinum- and\n",
      "             paclitaxel resistant as defined by: Disease progression while on first-line regimen\n",
      "             containing both a platinum drug and paclitaxel OR Tumor progression within 6 months\n",
      "             of completion of platinum-based therapy (either as first- or second-line) or\n",
      "             paclitaxel-based therapy (either as first- or second-line)\n",
      "          -  Refractory or recurrent ovarian epithelial cancer as defined by: Lesions of any\n",
      "             diameter\n",
      "          -  Nonmeasurable disease (with CA-125 at least 35)\n",
      "          -  Ascites and/or pleural effusions allowed\n",
      "          -  No borderline or low malignant potential tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: 18 and over\n",
      "          -  Performance status: Zubrod 0-2\n",
      "          -  Life expectancy: At least 12 weeks\n",
      "          -  WBC at least 3,000/mm3\n",
      "          -  Granulocyte count at least 1,500/mm3\n",
      "          -  Platelet count at least 100,000/mm3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL PT/PTT normal\n",
      "          -  Creatinine no greater than 1.4 mg/dL\n",
      "          -  No active, unresolved upper respiratory infections\n",
      "          -  Not HIV positive\n",
      "          -  At least 5 years since prior malignancy, except nonmelanomatous skin cancer\n",
      "          -  Willing and able to undergo placement of Tenckhoff catheter in the peritoneal cavity\n",
      "             for sampling of ascites or peritoneal fluid\n",
      "          -  No concurrent serious medical illness\n",
      "          -  No untreated gastrointestinal obstruction\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  May have failed an unlimited number of prior chemotherapy regimens\n",
      "          -  At least 30 days since prior chemotherapy\n",
      "          -  No prior radiotherapy to the pelvis or abdomen\n",
      "          -  Eligible for laparoscopy\n",
      "3198\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unresectable primary, recurrent, or residual benign\n",
      "             meningioma\n",
      "          -  Measurable disease by CT scan or MRI\n",
      "          -  Must have disease progression within the past 10 years OR progressive neurologic\n",
      "             deficit within the past 6 months\n",
      "          -  Must have undergone prior radiotherapy with subsequent disease progression OR refused\n",
      "             radiotherapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  SWOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 4,000/mm^3\n",
      "          -  Platelet count at least lower limit of normal\n",
      "        Hepatic:\n",
      "          -  Not specified\n",
      "        Renal:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No other malignancy within the past 5 years except adequately treated basal or\n",
      "             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated\n",
      "             stage I or II cancer in complete remission\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  No prior cytotoxic chemotherapy for meningioma\n",
      "          -  Prior mifepristone allowed\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent glucocorticoids and hormone replacement therapy allowed if stable dose\n",
      "             maintained for at least 72 hours prior to CT scan or MRI\n",
      "          -  No concurrent antitumor hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 6 months since prior radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "3199\n",
      "Inclusion Criteria:\n",
      "          -  Histologically proven locally advanced melanoma of an extremity\n",
      "               -  One or more evaluable in-transit metastases\n",
      "               -  All disease within the perfusion field of the extremity (with no local resection\n",
      "                  options short of amputation)\n",
      "               -  Disease outside of perfusion field (with no local resection options short of\n",
      "                  amputation) if all the following are true:\n",
      "                    -  High tumor burden (more than 10 lesions or any single lesion greater than 3\n",
      "                       cm)\n",
      "                    -  Presence of pain, edema, skin breakdown, or decreased mobility\n",
      "                    -  Greater than 80% of known tumor is within extremity perfusion field\n",
      "                    -  Life expectancy more than 6 months\n",
      "                    -  No brain metastases\n",
      "          -  At least 1 bidimensionally measurable lesion\n",
      "          -  Patients who received prior prophylactic isolated limb perfusion (ILP) must have 1 of\n",
      "             the following:\n",
      "               -  Disease-free interval for at least 6 months after prior ILP with melphalan\n",
      "               -  Disease-free interval for at least 3 months after prior ILP with an agent other\n",
      "                  than melphalan\n",
      "          -  Patients who received prior therapeutic ILP must have 1 of the following:\n",
      "               -  Partial response of at least 3 months duration after prior ILP with melphalan\n",
      "               -  Stable response or disease progression after ILP without melphalan (performed at\n",
      "                  least 3 months prior to study)\n",
      "          -  Performance status - ECOG 0-2\n",
      "          -  Performance status - Zubrod 0-2\n",
      "          -  See Disease Characteristics\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  WBC greater than 2,500/mm^3\n",
      "          -  Hemoglobin greater than 9 g/dL\n",
      "          -  Bilirubin less than 1.25 times ULN\n",
      "          -  AST and ALT less than 2 times ULN\n",
      "          -  Alkaline phosphatase less than 2 times ULN\n",
      "          -  Coagulation studies normal or within 1 second of upper limit of normal (ULN)\n",
      "          -  Creatinine less than 1.5 mg/dL\n",
      "          -  Creatinine clearance greater than 50 mL/min\n",
      "          -  Calcium less than 12 mg/dL\n",
      "          -  No severe peripheral vascular disease (claudication or other ischemic peripheral\n",
      "             vascular disease [e.g., venous thrombosis or occlusive peripheral arterial disease])\n",
      "          -  No New York Heart Association class II-IV heart disease (congestive heart failure)\n",
      "          -  No uncontrolled or life-threatening cardiac arrhythmia\n",
      "          -  No myocardial infarction within the past year\n",
      "          -  No unstable angina\n",
      "          -  No symptomatic cerebral or carotid artery disease\n",
      "          -  No pulmonary embolism within the past year\n",
      "          -  Other prior malignancy allowed if completed curative therapy, disease-free for at\n",
      "             least 5 years, and at low risk for recurrence\n",
      "          -  No active peptic ulcer disease within the past year\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No known melphalan hypersensitivity\n",
      "          -  No known hypersensitivity to any component of tumor necrosis factor alpha formulation\n",
      "          -  No contraindications to ionotropic agents (e.g., dopamine or neosynephrine)\n",
      "          -  No concurrent infections uncontrolled with antibiotics\n",
      "          -  HIV negative\n",
      "          -  At least 1 month since prior biologic therapy\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 1 month since prior chemotherapy\n",
      "          -  At least 4 months since prior isolated limb perfusion\n",
      "          -  At least 1 month since prior radiotherapy\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 12 months since prior coronary artery surgery or angioplasty\n",
      "3200\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed advanced breast cancer that is refractory or unlikely to\n",
      "             respond to hormonal therapy AND failed at least 1 prior chemotherapy regimen\n",
      "          -  Symptomatic lymphangitic pulmonary dissemination allowed\n",
      "          -  Extensive visceral metastasis allowed\n",
      "          -  Patients who are refractory or who have failed to respond after at least 8 weeks of\n",
      "             methotrexate or a methotrexate-containing regimen are not eligible\n",
      "          -  Measurable disease\n",
      "          -  No bone metastases\n",
      "          -  Hormone receptor status:\n",
      "          -  Estrogen receptor negative\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Postmenopausal\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Postmenopausal\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,000/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT no greater than 2 times normal\n",
      "          -  Blood ammonia normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  BUN less than 60 mg/dL\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "          -  No chronic renal failure\n",
      "        Cardiovascular:\n",
      "          -  No severe heart disease\n",
      "        Pulmonary:\n",
      "          -  No severe lung disease\n",
      "        Other:\n",
      "          -  No serious active infections or fever\n",
      "          -  No other concurrent serious disease\n",
      "          -  No prior or concurrent secondary malignancies within the past 2 years\n",
      "          -  Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "          -  No concurrent biologic therapy for metastatic breast cancer\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior cytotoxic chemotherapy and recovered\n",
      "          -  No other concurrent chemotherapy for metastatic breast cancer\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior hormonal therapy and recovered\n",
      "          -  No concurrent hormonal therapy for metastatic breast cancer\n",
      "        Radiotherapy:\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "          -  No concurrent radiotherapy for metastatic breast cancer\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  At least 4 weeks since prior participation in experimental clinical trials\n",
      "          -  No prior antineoplaston A10 therapy\n",
      "          -  No other concurrent treatment for metastatic breast cancer\n",
      "          -  No concurrent salicylates, nonsteroidal anti-inflammatory drugs, phenylbutazone,\n",
      "             phenytoin, and sulfonamides\n",
      "3201\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed limited stage small cell lung cancer\n",
      "        Primary tumor must be evaluable radiographically\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-1 Life expectancy: At\n",
      "        least 3 months Hematopoietic: WBC greater than 4,000/mm3 Platelet count greater than\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT and SGPT less than 2 times normal\n",
      "        Renal: Creatinine less than 1.5 mg/dL Other: No concurrent active infection No prior\n",
      "        malignancy except squamous or basal cell carcinoma of the skin or carcinoma in situ of the\n",
      "        cervix Not pregnant or nursing Effective contraception required of all fertile patients\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:\n",
      "        Not specified\n",
      "3202\n",
      "DISEASE CHARACTERISTICS: Histologically proven unresectable Merkel cell carcinoma\n",
      "        Local-regional OR Metastatic Bidimensionally measurable disease If all known sites\n",
      "        previously irradiated, disease must be progressive CNS metastases allowed if not only site\n",
      "        of measurable disease No pleural effusions or ascites\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Absolute granulocyte count at least 1500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Not specified Renal: Not specified Other: Not pregnant or\n",
      "        nursing Fertile patients must use effective contraception No other prior malignancy within\n",
      "        5 years except: Adequately treated basal cell or squamous cell skin cancer Adequately\n",
      "        treated stage I or II cancer In situ cervical cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy or immunotherapy No\n",
      "        concurrent immunotherapy Chemotherapy: No prior chemotherapy for metastatic disease At\n",
      "        least 4 weeks since prior adjuvant chemotherapy No prior adjuvant cyclophosphamide,\n",
      "        methotrexate, or fluorouracil No other concurrent chemotherapy Endocrine therapy: No\n",
      "        concurrent hormone therapy Radiotherapy: See Disease Characteristics At least 14 days\n",
      "        since prior radiotherapy Surgery: At least 2 weeks since prior surgery\n",
      "3204\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically or cytologically confirmed anaplastic astrocytoma\n",
      "               -  Tumor subtotally resected or biopsied\n",
      "          -  Radiologic evidence of residual or recurrent tumor by gadolinium-enhanced MRI, CT\n",
      "             scan, or positron-emission tomography\n",
      "          -  No brain stem tumors\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  More than 2 months\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 1,500/mm^3\n",
      "          -  Platelet count at least 50,000/mm^3\n",
      "          -  Hemoglobin at least 10 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 2.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 5 times upper limit of normal\n",
      "          -  No hepatic failure\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.5 mg/dL\n",
      "          -  No renal failure\n",
      "        Cardiovascular:\n",
      "          -  No prior congestive heart failure\n",
      "          -  No coronary artery disease\n",
      "          -  No myocardial infarction within the past year\n",
      "          -  No angina requiring medication\n",
      "          -  No uncontrolled hypertension\n",
      "        Pulmonary:\n",
      "          -  No moderate to severe chronic obstructive pulmonary disease\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception during and for 4 weeks after study\n",
      "             participation\n",
      "          -  No active infection\n",
      "          -  No other concurrent serious disease\n",
      "          -  No other prior malignancy except carcinoma in situ of the cervix or superficial\n",
      "             nonmelanoma skin cancer\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No prior immunotherapy\n",
      "          -  No concurrent immunomodulating agents\n",
      "        Chemotherapy:\n",
      "          -  No prior myelosuppressive chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Concurrent corticosteroids for cerebral edema allowed\n",
      "        Radiotherapy:\n",
      "          -  No prior myelosuppressive radiotherapy\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "          -  Recovered from any prior surgery\n",
      "        Other:\n",
      "          -  No prior cytodifferentiating agents\n",
      "          -  No prior antineoplaston therapy\n",
      "          -  No other concurrent antineoplastic agents\n",
      "3205\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed metastatic or locally recurrent\n",
      "        adenocarcinoma of the colon or rectum Bidimensionally measurable disease Lesions seen on\n",
      "        colonoscopic examination or barium studies, bone metastases, CNS lesions, CEA levels and\n",
      "        ascites are not considered measurable No CNS disease only CNS metastases with other sites\n",
      "        of measurable disease allowed provided appropriate therapy for CNS metastases has been\n",
      "        administered and patient is neurologically stable and does not require intravenous steroid\n",
      "        or anticonvulsant therapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Zubrod 0-2 Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil\n",
      "        count at least 1,500/mm3 Platelet count at least 100,000/mm3 (no platelet transfusion\n",
      "        within 7 days) Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL\n",
      "        Transaminases no greater than 2.5 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing\n",
      "        Negative pregnancy test Fertile patients must use effective contraception No significant\n",
      "        uncontrolled medical or psychiatric illness No serious active infection No other active\n",
      "        malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix unless\n",
      "        adequately treated and less than 30% risk of relapse\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic use of growth\n",
      "        factors except for documented febrile neutropenia or sepsis Chemotherapy: At least 12\n",
      "        months since prior fluorouracil based adjuvant or neoadjuvant chemotherapy No more than 1\n",
      "        prior regimen No prior chemotherapy for advanced metastatic colorectal cancer No other\n",
      "        concurrent chemotherapy No concurrent investigational antineoplastic drugs Endocrine\n",
      "        therapy: See Disease Characteristics Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered No prior radiotherapy to the only site of measurable disease No\n",
      "        concurrent radiotherapy Surgery: Not specified Other: See Disease Characteristics At least\n",
      "        30 days since prior investigational drug\n",
      "3207\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent or metastatic breast cancer\n",
      "        Bidimensionally measurable disease No bone scan abnormalities alone Lytic lesions allowed\n",
      "        in conjunction with bone scan abnormalities No pure blastic bone metastases No pleural or\n",
      "        peritoneal effusions No previously irradiated lesions Resected disease not allowed No\n",
      "        brain metastases or leptomeningeal disease Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified\n",
      "        Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic:\n",
      "        Granulocyte count at least 1500/mm3 Hemoglobin at least 8.0 g/dL Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 2.0 mg/dL\n",
      "        Calcium no greater than 11.0 mg/dL Cardiovascular: No history of arrhythmias No history of\n",
      "        other significant cardiac diseases No New York Heart Association class III or IV cardiac\n",
      "        function Left ventricular ejection fraction at least 50% Pulmonary: No symptomatic\n",
      "        lymphangitic pulmonary metastases Other: Not pregnant Negative pregnancy test No history\n",
      "        of other malignancy except: Carcinoma in situ of the cervix Curatively treated nonmelanoma\n",
      "        skin cancer No severe infection No severe malnutrition No other serious medical illness No\n",
      "        history of grade 3-4 peripheral neuropathy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and\n",
      "        mitomycin) and recovered No more than 3 prior chemotherapy regimens as\n",
      "        adjuvant/neoadjuvant therapy or for disease At least 1 year since prior paclitaxel or\n",
      "        docetaxel Prior anthracycline (doxorubicin or epirubicin) or mitoxantrone-based regimen\n",
      "        allowed as adjuvant therapy or for advanced disease No other concurrent chemotherapy\n",
      "        Endocrine therapy: At least 3 weeks since prior exogenous hormonal therapy for stage IV\n",
      "        disease and/or as adjuvant therapy Radiotherapy: No radiotherapy to greater than 50% of\n",
      "        marrow At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherepy\n",
      "        to the only measurable lesion Surgery: At least 2-3 weeks since prior surgery and\n",
      "        recovered No concurrent surgery to the only measurable lesion Other: No concurrent\n",
      "        nonprotocol treatment\n",
      "3208\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed metastatic breast cancer\n",
      "          -  Bidimensionally measurable disease\n",
      "               -  No bone scan abnormalities alone\n",
      "               -  Lytic lesions in conjunction with bone scan abnormalities allowed\n",
      "               -  No pure blastic bone metastases\n",
      "               -  No pleural or peritoneal effusions\n",
      "               -  No previously irradiated lesions\n",
      "          -  Must have received 2-4 prior chemotherapy regimens, including paclitaxel and\n",
      "             doxorubicin, for breast cancer\n",
      "          -  Brain metastases allowed if other measurable disease exists\n",
      "               -  No uncontrolled or life threatening brain lesions\n",
      "          -  No carcinomatous meningitis\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Female\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Granulocyte count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  AST/ALT no greater than 5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Calcium no greater than 11.0 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  Negative pregnancy test\n",
      "          -  No history of other malignancy except carcinoma in situ of the cervix or curatively\n",
      "             treated nonmelanoma skin cancer\n",
      "          -  No other serious medical illnesses, including severe infection and severe\n",
      "             malnutrition\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)\n",
      "             and recovered\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  Prior hormonal therapies for stage IV disease and/or adjuvant therapy allowed\n",
      "          -  At least 3 weeks since prior hormonal therapy\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior radiotherapy to greater than 30% of the marrow bearing bone\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "          -  No concurrent radiotherapy to the only measurable lesion\n",
      "        Surgery:\n",
      "          -  Recovered from prior surgery\n",
      "          -  No concurrent surgery to the only measurable lesion\n",
      "        Other:\n",
      "          -  No concurrent nonprotocol treatment\n",
      "3209\n",
      "DISEASE CHARACTERISTICS: Histologically proven stage II, III, or IV pancreatic cancer that\n",
      "        is unresectable No symptomatic third space fluid collection (e.g., ascites, pleural\n",
      "        effusion)\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: At least 3 months Hematopoietic: WBC at least 3,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hematocrit at least 33% Hemoglobin at least 10.5 g/dL Hepatic: Bilirubin\n",
      "        no greater than 3.0 mg/dL SGOT or SGPT no greater than 3 times upper limit of normal\n",
      "        Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No history of myocardial\n",
      "        infarction within past 3 months No congestive heart failure Other: HIV negative No other\n",
      "        prior malignancy except basal cell skin cancer No persistent fever greater than 102\n",
      "        degrees F (39 degrees C) unless caused by the pancreatic cancer Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy (e.g., interferons,\n",
      "        interleukins) Chemotherapy: No prior chemotherapy Endocrine therapy: No concurrent\n",
      "        systemic steroids Radiotherapy: No prior radiotherapy Surgery: At least 30 days since\n",
      "        prior surgery Decompressive surgery and endoscopic stenting (including expandable wire\n",
      "        stents) allowed to relieve symptoms of disease Other: At least 30 days since prior\n",
      "        investigational therapy Palliative care to relieve symptoms of disease allowed, including\n",
      "        pain management and celiac block by endoscopic ultrasonography or percutaneously\n",
      "3210\n",
      "DISEASE CHARACTERISTICS: Current smokers with 20+ packs per year history of smoking OR\n",
      "        Former smokers who discontinued smoking 1 year prior to registration (less than 5\n",
      "        cigarettes in the prior year) and had a 20+ packs per year history prior to discontinuing\n",
      "        smoking\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater\n",
      "        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 40 IU/mL OR SGPT\n",
      "        less than IU/mL Renal: Not specified Other: Fasting triglycerides less than 320 mg/dL No\n",
      "        prior malignancy in the past 5 years except nonmelanoma skin cancer or noninvasive\n",
      "        cervical cancer No history of malabsorption syndrome Not pregnant Effective contraception\n",
      "        required of all fertile persons\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        isotretinoin Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified Other: No prior warfarin or its derivatives At least 3 months since megadose\n",
      "        vitamin A (greater than 25,000 IU/day) or beta-carotene greater than 30 mg/day or\n",
      "        alpha-tocopherol at least 400 IU daily No concurrent megadose vitamin A (greater than\n",
      "        25,000 IU/day), beta-carotene greater than 30 mg/day, alpha-tocopherol at least 400 IU\n",
      "        daily, or other daily supplements and tonics\n",
      "3211\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed newly diagnosed or recurrent supratentorial glioblastoma or\n",
      "             malignant astrocytoma\n",
      "               -  Grade 3 or 4 astrocytoma as defined by the Daumas-Duport classification\n",
      "          -  Suitable for radical resection on the basis of imaging studies\n",
      "          -  Patients with recurrent disease must have failed surgery and radiotherapy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100% for newly diagnosed tumor\n",
      "          -  Karnofsky 70-100% for recurrent tumor\n",
      "        Life expectancy:\n",
      "          -  At least 3 months\n",
      "        Hematopoietic:\n",
      "          -  Recurrent tumor:\n",
      "               -  WBC at least 2,000/mm^3\n",
      "               -  Platelet count at least 80,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Recurrent tumor:\n",
      "               -  PT/PTT no greater than 1.5 times upper limit of normal (ULN)\n",
      "               -  Bilirubin and LFTs less than 2 times ULN\n",
      "               -  Alkaline phosphatase no greater than 3 times ULN\n",
      "               -  GGT no greater than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2 mg/dL\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  Not specified\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "          -  No prior cranial radiotherapy for newly diagnosed tumor\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "3213\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Pathologically confirmed recurrent malignant glioma for which surgery is indicated\n",
      "          -  Unilateral, supratentorial, solitary lesion at least 1.0 cm in diameter on\n",
      "             contrast-enhanced CT or MRI\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin, AST, ALT, and alkaline phosphatase less than 2.5 times normal\n",
      "        Renal:\n",
      "          -  Creatinine less than 1.5 times normal\n",
      "          -  BUN less than 2.5 times normal\n",
      "          -  Protein no greater than 3 g/dL\n",
      "          -  No gross hematuria\n",
      "        Other:\n",
      "          -  No hypersensitivity to nitrosoureas\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No concurrent life threatening disease\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent immunotherapy during first 8 weeks of study\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since chemotherapy (6 weeks since nitrosoureas)\n",
      "          -  No concurrent chemotherapy during first 8 weeks of study\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Prior definitive external-beam radiotherapy (i.e., at least 5,000 cGy) required\n",
      "          -  No concurrent radiotherapy or brachytherapy during first 4 weeks of study\n",
      "        Surgery:\n",
      "          -  Prior cytoreductive surgery for supratentorial brain tumor required\n",
      "          -  Biopsy alone not sufficient\n",
      "        Other:\n",
      "          -  No concurrent investigational therapy during first 8 weeks of study\n",
      "3214\n",
      "DISEASE CHARACTERISTICS: Histologically proven malignant primary glioma Glioblastoma\n",
      "        multiforme Anaplastic oligodendroglioma Gliosarcoma Mixed malignant glioma Anaplastic\n",
      "        astrocytoma Clear evidence of tumor recurrence or progression by CT or MRI within 2 weeks\n",
      "        prior to study after failing prior best surgical resection and radiation Surgically\n",
      "        accessible tumor for which resection is indicated Tumors greater than 2.0 cm in diameter\n",
      "        Tumor not extending into the ventricular system\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 No evidence of bleeding diatheses Hepatic: SGPT no\n",
      "        greater than 2 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2\n",
      "        times ULN Bilirubin less than 1.5 mg/dL Renal: BUN less than 1.5 times ULN OR Creatinine\n",
      "        less than 1.5 times ULN Cardiovascular: Not specified Pulmonary: Not specified Other: No\n",
      "        active uncontrolled infection Must be afebrile (less than 38.0 degrees Celsius) No other\n",
      "        unstable or serious medical conditions HIV negative Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy\n",
      "        allowed (at least 2 weeks since prior vincristine, 3 weeks since prior procarbazine, and 6\n",
      "        weeks since prior nitrosoureas) and recovered Endocrine therapy: Not specified\n",
      "        Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy\n",
      "        Surgery: See Disease Characteristics Other: No prior or concurrent anticoagulants\n",
      "3215\n",
      "Inclusion Criteria:\n",
      "          -  Patients must have histologically confirmed supratentorial grade IV astrocytoma\n",
      "             (glioblastoma multiforme)\n",
      "          -  Patients must have measurable or non-measurable tumor on the post operative,\n",
      "             pretreatment MRI/CT scan (within two weeks of starting treatment)\n",
      "          -  Patients must not have received prior radiation therapy, chemotherapy, hormonal\n",
      "             therapy, immunotherapy or therapy with biologic agents (including immunotoxins,\n",
      "             immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins,\n",
      "             TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid\n",
      "             therapy is allowed\n",
      "          -  Patients must have recovered from the immediate post-operative period and be\n",
      "             maintained on a stable steroid regimen (no increase for the last five days)\n",
      "          -  Absolute neutrophil count >= 1500/mm^3\n",
      "          -  Platelets >= 100,000/mm^3\n",
      "          -  Hemoglobin concentration >= 9.0 g/dl\n",
      "          -  Creatinine =< 1.7mg/dL\n",
      "          -  Total bilirubin =< 1.2 mg/dl\n",
      "          -  Transaminases =< 2 times above the upper limits of the institutional normal\n",
      "          -  Estimated life expectancy greater than 2 months\n",
      "          -  Patients must give informed consent and understand the investigational nature of this\n",
      "             study and its potential risks and benefits\n",
      "          -  Patients, if female and of childbearing potential must have a negative serum beta-hCG\n",
      "             test and must not be breast feeding; all patients with the potential for pregnancy\n",
      "             should be counseled and requested to follow acceptable birth control methods to avoid\n",
      "             conception\n",
      "          -  Patients must have a Karnofsky performance status of >= 60%\n",
      "          -  No other serious concurrent infection or other medical illness should be present\n",
      "             which would jeopardize the ability of the patient to receive the drug outlined in\n",
      "             this protocol with reasonable safety\n",
      "          -  Patients must have no concurrent malignancy except curatively treated basal or\n",
      "             squamous cell carcinoma of the skin or carcinoma in situ; patients with prior\n",
      "             malignancies must be disease-free for >= five years\n",
      "        \n",
      "3217\n",
      "DISEASE CHARACTERISTICS: Diagnosis of unresectable malignant primary or metastatic liver\n",
      "        tumors Tumors are deemed unresectable based on the following factors: 1-10 liver tumors\n",
      "        Bilobar liver tumors Location of 1 or more lesions near a major intrahepatic vascular\n",
      "        structure (hepatic vein, portal vein, vena cava) Severe cirrhosis to preclude a major\n",
      "        liver resection No unresectable extrahepatic disease Prior failure of other therapeutic\n",
      "        modalities allowed No more than moderate ascites No hepatic encephalopathy\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: Zubrod 0-1 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Not specified Hepatic: No severe liver dysfunction (Child's\n",
      "        Class C) Bilirubin no greater than 3.0 mg/dL Albumin no greater than 3.0 mg/dL PT no\n",
      "        greater than 50% above normal Renal: No renal dysfunction Creatinine less than 2.0 mg/dL\n",
      "        Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No altered mental status No active infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks\n",
      "        since prior radiotherapy Surgery: See Disease Characteristics\n",
      "3218\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven relapsed or refractory hematologic malignancy or bone marrow\n",
      "             disorder for which there is no standard curative therapy, including, but not limited\n",
      "             to:\n",
      "               -  Myelodysplasia\n",
      "               -  Multiple myeloma\n",
      "               -  Myeloproliferative syndrome\n",
      "               -  Chronic lymphocytic leukemia\n",
      "               -  Aplastic anemia\n",
      "               -  Non-Hodgkin's lymphoma\n",
      "               -  Acute leukemia\n",
      "               -  Hodgkin's lymphoma\n",
      "               -  Chronic myelogenous leukemia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Over 18\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  Greater than 1 month\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n",
      "          -  AST no greater than 3 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 2.0 mg/dL\n",
      "        Cardiovascular:\n",
      "          -  Cardiac ejection fraction greater than 40%\n",
      "        Pulmonary:\n",
      "          -  FEV_1 greater than 50% predicted\n",
      "        Other:\n",
      "          -  No active infection\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 10 weeks after study\n",
      "             participation\n",
      "          -  No uncontrolled psychiatric or medical illness\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Greater than 3 weeks since prior biologic therapy\n",
      "        Chemotherapy:\n",
      "          -  Greater than 3 weeks since prior chemotherapy and recovered\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  Not specified\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No other concurrent investigational agents\n",
      "3219\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed solid tumor that is refractory to standard therapy or for\n",
      "             which no standard therapy exists\n",
      "          -  Measurable or evaluable disease\n",
      "          -  No CNS metastasis or primary CNS malignancy\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  WBC greater than 3,500/mm^3\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT and SGPT no greater than 2.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No history of coronary artery disease documented by prior myocardial infarction,\n",
      "             angiography, or coronary-artery bypass grafting\n",
      "          -  No cardiac arrhythmias or congestive heart failure within the past 6 months\n",
      "          -  Stable atrial fibrillation on standard treatment allowed at discretion of\n",
      "             investigator\n",
      "        Pulmonary:\n",
      "          -  DLCO at least 60% of predicted\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 2 months after study\n",
      "          -  No active serious or uncontrolled infection\n",
      "          -  HIV negative\n",
      "          -  No diabetes\n",
      "          -  No other medical condition that would preclude study\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  See Disease Characteristics\n",
      "        Biologic therapy:\n",
      "          -  At least 4 weeks since prior immunotherapy and recovered\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)\n",
      "             and recovered\n",
      "          -  Prior fluorouracil allowed\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior mediastinal radiotherapy\n",
      "          -  At least 4 weeks since prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  Not specified\n",
      "        Other:\n",
      "          -  No concurrent anticonvulsant medications\n",
      "3220\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed B-cell malignancy,\n",
      "        including B-cell non-Hodgkin's lymphoma or B-cell chronic lymphocytic leukemia, that has\n",
      "        failed at least one regimen of standard chemotherapy At least 1 confirmed tumor site by\n",
      "        radiolabeled LL2 IgG No greater than 25% bone or bone marrow involvement No brain\n",
      "        metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% ECOG 0-2\n",
      "        Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Granulocyte count\n",
      "        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than\n",
      "        2 mg/dL AST and alkaline phosphatase less than 1.5 times upper limit of normal (ULN)\n",
      "        (except for bone involvement) Renal: Creatinine less than 1.5 times ULN Other: Not\n",
      "        pregnant Fertile patients must use effective contraception during and for 3-6 months after\n",
      "        study HIV negative No severe anorexia, nausea, or vomiting No other significant concurrent\n",
      "        medical condition that would interfere with compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior murine monoclonal antibody therapy\n",
      "        allowed (if unreactive to yttrium Y 90-labeled humanized anti-CD22 monoclonal antibody LL2\n",
      "        by HPLC or ELISA test) Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine\n",
      "        therapy: At least 2 weeks since prior corticosteroids (except for adrenal insufficiency)\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy to the index lesion No prior\n",
      "        extensive radiotherapy to greater than 25% of bone marrow (except total body irradiation\n",
      "        as part of bone marrow or stem cell transplantation regimen with engraftment of functional\n",
      "        marrow (i.e., producing normal peripheral blood counts) No prior maximum tolerated dose\n",
      "        levels of radiotherapy to critical organs (e.g., lung, liver, or kidney) Surgery: At least\n",
      "        4 weeks since prior major surgery Other: No other concurrent investigational agents\n",
      "3221\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed transitional cell carcinoma of the\n",
      "        bladder or mixed histologies containing a component of transitional cell carcinoma Must\n",
      "        have undergone radical cystectomy and pelvic lymph node dissection within 12 weeks prior\n",
      "        to randomization No evidence of distant metastatic disease on pre- or postoperative\n",
      "        radiographic scans No positive surgical margins in the cystectomy specimen and no known\n",
      "        macroscopic residual disease left at time of cystectomy No bladder sparing surgery May\n",
      "        have undergone continent urinary diversion or neobladder procedure but must have recovered\n",
      "        completely from the effects of surgery Must have muscle-invasive disease on final\n",
      "        pathologic staging and have a primary tumor stage of pT4, any N, M0, or any pT, N+, M0, or\n",
      "        pT3b, any N, any M, and following a pelvic lymph node dissection have a pathologic nodal\n",
      "        stage of pN0 (only if pT3b or pT4), pN1, or pN2 Clinically unsuspected organ confined\n",
      "        prostate cancer found during cystoprostatectomy allowed\n",
      "        PATIENT CHARACTERISTICS: Age: Any age Performance status: ECOG 0-2 Life expectancy: Not\n",
      "        specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater\n",
      "        than 2 times ULN Renal: Creatinine no greater than 1.7 mg/dL OR Creatinine clearance at\n",
      "        least 60 mL/min Cardiovascular: No second degree atrioventricular block or bundle branch\n",
      "        block Other: No history of prior malignancy in the past 5 years except basal or squamous\n",
      "        cell carcinoma of the skin or carcinoma in situ of the cervix No active infection\n",
      "        requiring antibiotics No history of allergic reaction to drugs utilizing the vehicle\n",
      "        Cremophor Not pregnant or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Recovered from all prior therapies Biologic therapy: No prior\n",
      "        biologic response modifier therapy No filgrastim (G-CSF) 24 hours pre- or\n",
      "        post-chemotherapy administration Chemotherapy: No prior systemic chemotherapy Endocrine\n",
      "        therapy: Not specified Radiotherapy: No prior radiotherapy as a component of bladder\n",
      "        sparing therapy No prior adjuvant radiotherapy for locally advanced disease with positive\n",
      "        margins Surgery: See Disease Characteristics Other: Prior intravesical therapy for\n",
      "        superficial bladder cancer allowed and recovered\n",
      "3222\n",
      "DISEASE CHARACTERISTICS: Histologically proven glioblastoma multiforme, anaplastic\n",
      "        astrocytoma, or anaplastic mixed glioma Progressive or recurrent disease following\n",
      "        radiotherapy (54-64 Gy) and/or chemotherapy Tumor recurrence must have anatomic\n",
      "        characteristics that allow safe and reasonable surgical intervention Measurable disease by\n",
      "        serial MR or CT imaging No Li-Fraumeni syndrome or known germline defect in p53 gene No\n",
      "        radiographically or surgically proven gliomatosis cerebri No tumors requiring immediate\n",
      "        excision due to impending neurologic decline\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count\n",
      "        at least 1,000/mm3 Platelet count at least 100,000/mm3 Hematocrit at least 25% Hepatic:\n",
      "        Bilirubin less than 1.5 mg/dL SGOT and SGPT less than 2.5 times upper limit of normal\n",
      "        (ULN) PT or PTT no greater than ULN Renal: Creatinine no greater than 1.7 mg/dL\n",
      "        Cardiovascular: No uncontrolled hypertension No uncontrolled or unstable angina pectoris\n",
      "        No uncontrolled cardiac dysrhythmia Other: Not pregnant or nursing Negative pregnancy test\n",
      "        Fertile patients must use effective contraception during and for 6 months after study HIV\n",
      "        negative No other active malignancy within the past 5 years except curatively treated\n",
      "        basal or squamous cell skin cancer or carcinoma in situ of the cervix No uncontrolled or\n",
      "        serious concurrent infection or other serious medical illness that would preclude study\n",
      "        therapy No viral syndrome diagnosed within 2 weeks prior to study No other underlying\n",
      "        medical condition that would increase risk of study or obscure interpretation of adverse\n",
      "        results No active adenoviral infection\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy\n",
      "        and recovered No concurrent biologic therapy Chemotherapy: See Disease Characteristics No\n",
      "        more than 1 prior chemotherapy regimen At least 3 weeks since prior chemotherapy (6 weeks\n",
      "        for nitrosoureas) and recovered No prior interstitial chemotherapy such as Gliadel wafer\n",
      "        implantation for present brain tumor No concurrent chemotherapy Endocrine therapy: At\n",
      "        least 3 weeks since prior hormonal therapy and recovered No concurrent hormonal therapy\n",
      "        Radiotherapy: See Disease Characteristics No prior brachytherapy for present brain tumor\n",
      "        At least 3 months since other prior radiotherapy and recovered No concurrent radiotherapy\n",
      "        Surgery: See Disease Characteristics No prior radiosurgery for present brain tumor At\n",
      "        least 3 weeks since other prior oncologic surgery No other concurrent oncologic surgery\n",
      "        Other: No other concurrent investigational drugs\n",
      "3223\n",
      "Inclusion Criteria:\n",
      "          1. Patients must have cytologic or histologic proof of large (>5 mc), Grade III,\n",
      "             resectable soft tissue sarcoma of the extremity or trunk (AJCC Stage IIIB). Patients\n",
      "             with The American Joint Committee on Cancer (AJCC) Stage IIB tumors (Grade II)\n",
      "             greater than 8 cms will also be eligible.\n",
      "          2. Patients may have measurable or non-measurable disease (C/P pre-referral excision).\n",
      "          3. Patients may have had prior doxorubicin (up to a total doxorubicin dose of 450\n",
      "             mg/m2).\n",
      "          4. Patients may have a prior history of malignancy (at the discretion of the Principal\n",
      "             Investigator).\n",
      "          5. Patients must have Karnofsky Point Scale (P.S.)> of >70 or Xubrod P.S. of 0 or 1.\n",
      "          6. Patients must have: Absolute neutrophil count (ANC) > 1,500 cells/mm; platelet count\n",
      "             > 100,000 platelets/ml; serum creatinine <1.8 mg/dl, aspartate aminotransferase (AST\n",
      "             or SGOT) and alanine aminotransferase (ALT or SGPT) < 3 times normal, total bilirubin\n",
      "             < 1.5mg/dl; for patients with cumulative Adriamycin 450 mg/M2, EF >50%.\n",
      "          7. Women of childbearing potential must not be pregnant or breast feeding and must\n",
      "             practice adequate contraception.\n",
      "        \n",
      "3224\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  High-risk neuroblastoma by:\n",
      "               -  Histopathology OR\n",
      "               -  Bone marrow involvement plus elevated urinary catecholamines\n",
      "          -  Prior tumor progression on standard chemotherapy and poor long-term prognosis as\n",
      "             indicated by 1 or more of the following:\n",
      "               -  N-myc amplification in tumor cells\n",
      "               -  Diploid chromosomal content plus lp loss of heterozygosity in tumor cells\n",
      "               -  Distant skeletal metastases\n",
      "               -  Unresectable primary tumor infiltrating across the midline\n",
      "               -  More than 10% tumor cells in bone marrow\n",
      "               -  Less than 30% chance of long-term progression-free survival\n",
      "          -  Evaluable (microscopic marrow metastasis, elevated tumor markers, abnormal bone scan\n",
      "             or MIBG or PET scan) but not measurable (CT scan, MRI) disease documented at least 4\n",
      "             weeks after completion of prior systemic therapy\n",
      "          -  No rapidly progressive disease as defined by 1 or more of the following:\n",
      "               -  Serum lactic dehydrogenase greater than 1.5 times upper limit of normal due to\n",
      "                  tumor\n",
      "               -  An opiate requirement for pain from tumor\n",
      "               -  Greater than 25% increase in tumor by successive imaging studies\n",
      "               -  Life expectancy less than 8 weeks\n",
      "          -  Second or subsequent remission after chemotherapy and/or radiotherapy allowed\n",
      "             provided there is less than 30% chance of survival\n",
      "          -  No prior myelodysplastic syndromes or leukemia\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  Not specified\n",
      "        Life expectancy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 8 weeks\n",
      "        Hematopoietic:\n",
      "          -  Not specified\n",
      "        Hepatic:\n",
      "          -  No grade 3 or worse liver toxicity\n",
      "        Renal:\n",
      "          -  No grade 3 or worse renal toxicity\n",
      "          -  Creatinine clearance at least 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No grade 3 or worse cardiac toxicity\n",
      "        Pulmonary:\n",
      "          -  No grade 3 or worse pulmonary toxicity\n",
      "        Other:\n",
      "          -  Not pregnant\n",
      "          -  No grade 3 or worse gastrointestinal toxicity\n",
      "          -  No grade 3 or worse neurologic system toxicity\n",
      "          -  No grade 4 hearing deficit\n",
      "          -  No active life-threatening infection\n",
      "          -  No prior exposure to mouse antibodies and human anti-mouse antibody greater than\n",
      "             1,000 ELISA units/mL\n",
      "          -  No allergy to mouse proteins\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  Not specified\n",
      "        Chemotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  See Disease Characteristics\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "3225\n",
      "Inclusion Criteria:\n",
      "          -  Diagnosis of ovarian epithelial carcinoma\n",
      "          -  Previously treated with an adequate course of platinum based chemotherapy\n",
      "          -  Evidence of intraabdominal disease\n",
      "          -  No significant adhesions\n",
      "          -  Performance status - Zubrod 0-2\n",
      "          -  Lymphocyte count at least 500/mm^3\n",
      "          -  Bilirubin no greater than 1.5 mg/dL\n",
      "          -  SGOT less than 2.5 times upper limit of normal\n",
      "          -  Creatinine no greater than 1.5 mg/dL\n",
      "          -  No major disorder of the cardiovascular system\n",
      "          -  No major disorder of the pulmonary system\n",
      "          -  Not pregnant or nursing\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  Successful placement of peritoneal catheter\n",
      "          -  No overt autoimmune disease\n",
      "          -  No concurrent chronic steroid therapy\n",
      "          -  No prior radiotherapy\n",
      "          -  Prior surgery allowed\n",
      "          -  Recovered from prior therapy\n",
      "3228\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed carcinoma located in the pelvis that is\n",
      "        unresectable, incompletely resected, or locally recurrent Must be biopsy-proven or have\n",
      "        radiological progression All disease must be encompassable within standard pelvic\n",
      "        radiotherapy fields No evidence of metastatic disease outside of the planned radiotherapy\n",
      "        field\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n",
      "        Hepatic: Not specified Renal: Creatinine clearance at least 30 mL/min Other: Must maintain\n",
      "        adequate oral nutrition (i.e., at least 1200 calories estimated intake per day) No\n",
      "        significant infection or other concurrent medical condition that would preclude study No\n",
      "        significant nausea or vomiting No malabsorption secondary to short-gut syndrome, Crohn's\n",
      "        disease, or sprue No patients with more than 6 bowel movements per day or baseline no\n",
      "        greater than grade 3 diarrhea for patients with colostomy Not pregnant or nursing Negative\n",
      "        pregnancy test Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n",
      "        chemotherapy for metastatic cancer At least 6 months since prior adjuvant chemotherapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior\n",
      "        radiotherapy Surgery: At least 21 days since prior laparotomy or laparoscopic procedure\n",
      "        with or without resection Other: No concurrent sorivudine or chemically related analogues\n",
      "        (e.g., brivudine)\n",
      "3229\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumors\n",
      "        refractory to conventional anticancer therapy, or for which no effective therapy exists\n",
      "        Measurable or evaluable disease No active brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL ALT and AST no greater\n",
      "        than 2.5 times upper limit of normal (ULN) Renal: Creatinine less than 1.5 times ULN\n",
      "        Cardiovascular: No uncontrolled or significant cardiovascular disease No myocardial\n",
      "        infarction within past 6 months No congestive heart failure (with or without therapy) No\n",
      "        history of atrial or ventricular arrhythmias No history of second or third degree heart\n",
      "        block Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n",
      "        effective contraception No serious uncontrolled medical disorder or active infection No\n",
      "        known hypersensitivity to drugs containing Cremophor EL No concurrent neurologic toxicity\n",
      "        No dementia or altered mental status\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas,\n",
      "        mitomycin, or carboplatin) Prior taxane therapy allowed No other concurrent chemotherapy\n",
      "        Endocrine therapy: At least 1 week since prior steroid therapy No concurrent hormonal\n",
      "        therapy Radiotherapy: At least 4 weeks since prior wide field radiotherapy (involving at\n",
      "        least 30% of the bone marrow) No concurrent radiotherapy Surgery: Not specified Other: No\n",
      "        other concurrent experimental anticancer medications\n",
      "3232\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or recurrent\n",
      "        nonhematologic malignancy that is not amenable to or has failed standard therapy\n",
      "        Measurable or evaluable disease No uncontrolled brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 8 weeks Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count at least\n",
      "        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no greater than 5 times\n",
      "        upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at\n",
      "        least 60 mL/min Pulmonary: No respiratory failure Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception No active infection or other concurrent severe\n",
      "        medical illness that would interfere with compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n",
      "        since prior chemotherapy (6 weeks since nitrosoureas) and recovered No prior cisplatin or\n",
      "        gemcitabine Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered No concurrent radiotherapy Surgery: Not specified\n",
      "3233\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed epithelial cancer of\n",
      "        the exocrine pancreas Metastatic disease Previously untreated disease or progressive\n",
      "        disease after first-line chemotherapy Bidimensionally measurable disease Indicator lesion\n",
      "        must be outside of any prior radiation port No brain metastases No islet cell tumors,\n",
      "        lymphoma, or sarcoma of the pancreas\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT/SGPT no greater\n",
      "        than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present) Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Cardiovascular: No active congestive heart failure No\n",
      "        uncontrolled angina No myocardial infarction within the past 6 months Other: Not pregnant\n",
      "        or nursing Negative pregnancy test Fertile patients must use effective contraception No\n",
      "        concurrent serious infection No history of other malignancy within the past 5 years except\n",
      "        nonmelanoma skin cancer or carcinoma in situ of the cervix No overt psychosis, mental\n",
      "        disability, or incompetence No other life threatening illness\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy No prophylactic\n",
      "        colony stimulating factors to prevent neutropenia Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy and recovered No other\n",
      "        concurrent cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: See\n",
      "        Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No\n",
      "        concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery and recovered\n",
      "        No concurrent surgery Other: No other concurrent anticancer treatment At least 28 days\n",
      "        since other prior investigational drugs, including analgesics or antiemetics No other\n",
      "        investigational drugs during and for 28 days after study No concurrent drugs that induce\n",
      "        or inhibit CYP3A enzyme\n",
      "3235\n",
      "DISEASE CHARACTERISTICS: Histologically proven hematologic malignancy for which there is\n",
      "        no standard curative therapy, including, but not limited to: Low grade non-Hodgkin's\n",
      "        lymphoma (NHL) Mantle cell lymphoma Chronic lymphocytic leukemia (stage II-IV)\n",
      "        Myelodysplastic syndrome, including: Refractory anemia (RA) with ringed sideroblasts RA\n",
      "        with excess blasts (RAEB) RAEB in transformation Chronic myelomonocytic leukemia Multiple\n",
      "        myeloma OR Histologically proven hematologic malignancy that has failed 1 prior therapy OR\n",
      "        is at high risk for relapse, including, but not limited to: Intermediate grade NHL High\n",
      "        grade NHL Hodgkin's disease Acute lymphoblastic lymphoma Acute myelogenous leukemia OR\n",
      "        Histologically proven chronic myelogenous leukemia in chronic or accelerated phase, with\n",
      "        the following risk factors that preclude eligibility for standard allogeneic peripheral\n",
      "        blood stem cell transplantation: Older age Poor performance status Healthy, partially\n",
      "        related HLA 5/6 or 6/6 serologic match donor available A new classification scheme for\n",
      "        adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of \"indolent\" or\n",
      "        \"aggressive\" lymphoma will replace the former terminology of \"low\", \"intermediate\", or\n",
      "        \"high\" grade lymphoma. However, this protocol uses the former terminology.\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 60 or physiologic 70 Performance status: Karnofsky 0-2\n",
      "        Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than\n",
      "        2.0 mg/dL SGOT and SGPT less than 2 times normal No active hepatitis Renal: Creatinine\n",
      "        less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min Cardiovascular:\n",
      "        Ejection fraction greater than 45% OR Cardiac clearance Pulmonary: DLCO at least 50%\n",
      "        predicted Other: No active infection HIV-1, HIV-2, and HTLV-1 negative Not pregnant or\n",
      "        nursing\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "3236\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV metastatic melanoma\n",
      "        Unresectable disease for which no other therapy exists Measurable or evaluable disease by\n",
      "        clinical or radiographic evaluation Metastatic tumor tissue expressing both gp100 and\n",
      "        MART-1 No uncontrolled or progressive CNS involvement\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n",
      "        Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 No\n",
      "        clinically significant hematologic disorder Hepatic: Bilirubin less than 2.0 mg/dL No\n",
      "        clinically significant hepatic disease Hepatitis B surface antigen negative Renal:\n",
      "        Creatinine less than 2.0 mg/dL No clinically significant renal disease Cardiovascular: No\n",
      "        clinically significant cardiac disease Other: Not pregnant or nursing Fertile patients\n",
      "        must use effective contraception Negative pregnancy test HIV-1 and HIV-2 negative HTLV-1\n",
      "        negative No significant psychiatric disorder that would prevent compliance No underlying\n",
      "        condition that would preclude study therapy No autoimmune disease or other major immune\n",
      "        system illness No active infection requiring parenteral antibiotic therapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy with vaccines directed\n",
      "        at MART-1 or gp100 melanoma antigens Prior interleukin-2 or interferon therapy allowed\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No concurrent\n",
      "        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy and recovered Surgery: At least 4 weeks since prior surgery (except study\n",
      "        biopsies) and recovered Other: At least 4 weeks since prior experimental therapy and\n",
      "        recovered At least 4 weeks since prior immunosuppressive drugs and recovered No other\n",
      "        concurrent experimental therapy or anti-cancer drugs No concurrent immunosuppressive\n",
      "        therapy\n",
      "3237\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed unresectable advanced solid tumor for which no standard\n",
      "             therapy exists that is potentially curative or definitely capable of extending life\n",
      "             expectancy\n",
      "               -  Biopsy confirmation of recurrent tumors required, unless sole site of disease is\n",
      "                  inaccessible bony and/or pulmonary metastases\n",
      "          -  Eligible solid tumors include, but not are limited to, prostate cancer, breast\n",
      "             cancer, or melanoma\n",
      "          -  No lymphoma\n",
      "          -  No CNS metastases\n",
      "               -  Patients with primary brain tumors are eligible if they are not receiving\n",
      "                  antiepileptic medication(s) but are receiving stable doses of corticosteroids\n",
      "          -  Hormone receptor status:\n",
      "               -  Not specified\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Sex:\n",
      "          -  Not specified\n",
      "        Menopausal status:\n",
      "          -  Not specified\n",
      "        Performance status:\n",
      "          -  ECOG 0-2\n",
      "        Life expectancy:\n",
      "          -  See Disease Characteristics\n",
      "          -  At least 12 weeks\n",
      "        Hematopoietic:\n",
      "          -  WBC at least 3,500/mm^3\n",
      "          -  Absolute neutrophil count at least 1,700/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "          -  Hemoglobin at least 8 g/dL\n",
      "        Hepatic:\n",
      "          -  Bilirubin within upper limit of normal (ULN)\n",
      "          -  AST and ALT no greater than 2.5 times ULN\n",
      "          -  Alkaline phosphatase no greater than 2.5 times ULN\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 times ULN\n",
      "        Cardiovascular:\n",
      "          -  No New York Heart Association class III or IV heart disease\n",
      "          -  No history of angina\n",
      "        Neurologic:\n",
      "          -  No grade 2 or greater peripheral neuropathy\n",
      "          -  No seizure disorder\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception\n",
      "          -  No uncontrolled infection\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  More than 4 weeks since prior immunotherapy\n",
      "          -  More than 4 weeks since prior biologic therapy\n",
      "          -  No concurrent immunotherapy\n",
      "        Chemotherapy:\n",
      "          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas)\n",
      "             and recovered\n",
      "          -  No other concurrent chemotherapy\n",
      "        Endocrine therapy:\n",
      "          -  See Disease Characteristics\n",
      "        Radiotherapy:\n",
      "          -  More than 4 weeks since prior radiotherapy\n",
      "          -  No prior radiotherapy to more than 25% of bone marrow\n",
      "          -  No concurrent radiotherapy\n",
      "        Surgery:\n",
      "          -  See Disease Characteristics\n",
      "3238\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven metastatic or recurrent\n",
      "        colorectal or pancreatic cancer for which no curative surgery exists Failed at least 1\n",
      "        regimen of standard fluorouracil based chemotherapy for metastatic colorectal cancer or\n",
      "        gemcitabine for pancreatic cancer Autologous peripheral blood stem cells (PBSC) or bone\n",
      "        marrow available Diffuse bone marrow involvement allowed if: Autologous bone marrow or\n",
      "        PBSC with no greater than 5% tumor involvement available Tumor site at least 2.0 cm in\n",
      "        diameter confirmed by pretherapy indium In 111 monoclonal antibody MN-14 imaging and CT\n",
      "        scan\n",
      "        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Karnofsky 70-100% ECOG 0-2 Life\n",
      "        expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at\n",
      "        least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2\n",
      "        mg/dL SGOT no greater than 2.0 times upper limit of normal (ULN) Renal: Creatinine no\n",
      "        greater than ULN Other: No severe anorexia, nausea, or vomiting No concurrent significant\n",
      "        medical complications that would preclude compliance Not pregnant Fertile patients must\n",
      "        use effective contraception during and for 3 months after study No allergy to 90Y-hMN-14\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior murine monoclonal antibody allowed\n",
      "        Chemotherapy: No prior irinotecan At least 4 weeks since prior chemotherapy and recovered\n",
      "        (8 weeks since nitrosourea, mitomycin or 90Y-hMN-14) Endocrine therapy: Not specified\n",
      "        Radiotherapy: At least 4 weeks since prior radiotherapy to index lesion and recovered No\n",
      "        prior radiotherapy to greater than 25% of red marrow (pelvic field radiation as adjuvant\n",
      "        therapy for rectal cancer allowed) No prior radiotherapy to maximum tolerated dose to any\n",
      "        critical organ (e.g., lung, liver, or kidney) Surgery: At least 4 weeks since major\n",
      "        surgery\n",
      "3239\n",
      "DISEASE CHARACTERISTICS: Refractory stage IV breast cancer Received high dose chemotherapy\n",
      "        (HDC) with autologous or syngeneic peripheral blood stem cell transplantation (PBSCT) OR\n",
      "        Stage IV breast cancer Failed to achieve complete response to HDC with autologous or\n",
      "        syngeneic PBSCT at initial restaging following HDC No enrollment on protocol FHCRC-976,\n",
      "        unless evidence of no response or progressive disease at initial restaging following\n",
      "        transplantation Hormone receptor status: Not specified\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Menopausal status: Not specified Performance\n",
      "        status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Platelet count at\n",
      "        least 50,000/mm3 (untransfused) Absolute neutrophil count greater than 1,000/mm3 (without\n",
      "        filgrastim (G-CSF) support) Hepatic: Bilirubin no greater than 2.5 times upper limit of\n",
      "        normal (ULN) SGOT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0\n",
      "        mg/dL Cardiovascular: LVEF greater than 40% No poorly controlled arrhythmias No prior\n",
      "        coronary artery disease No congestive heart failure within last year No myocardial\n",
      "        infarction within past 2 years Other: No active infection No grade 3 regimen related\n",
      "        toxicity according to Bearman model No allergy to paclitaxel, trastuzumab, or benzyl\n",
      "        alcohol No grade 3 peripheral neuropathy with last chemotherapy HIV negative Not pregnant\n",
      "        or nursing Fertile patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n",
      "        Disease Characteristics Endocrine therapy: Concurrent antihormonal therapy (tamoxifen or\n",
      "        anastrozole) allowed as clinically indicated for hormone receptor positive disease\n",
      "        Radiotherapy: Not specified Surgery: Not specified\n",
      "3240\n",
      "DISEASE CHARACTERISTICS: B-cell chronic lymphocytic leukemia or multiple myeloma in\n",
      "        remission that was previously treated with chemotherapy without disease progression\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: Lymphocyte count less than 10,000/mm3 Hepatic: Not specified\n",
      "        Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective\n",
      "        contraception No active infection or other concurrent lifethreatening disease Medical\n",
      "        condition satisfactory for treatment with chemotherapy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not\n",
      "        specified\n",
      "3241\n",
      "DISEASE CHARACTERISTICS: Pathologically confirmed malignant pleural mesothelioma Free\n",
      "        flowing pleural effusion\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 12 weeks Hematopoietic: WBC greater than 4,000/mm3 Granulocyte count greater than\n",
      "        1,500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.5\n",
      "        mg/dL SGPT no greater than 1.5 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 1.5 mg/dL Cardiovascular: No unstable angina No clinical evidence of congestive heart\n",
      "        failure Pulmonary: No postobstructive pneumonia Other: Fertile patients must use effective\n",
      "        contraception Not pregnant or nursing No serious concurrent infection No prior\n",
      "        malignancies except basal cell or squamous cell skin carcinomas, stage I colon, cervical,\n",
      "        breast, prostate, head and neck, or lung cancer, as long as there has been no evidence of\n",
      "        tumor occurrence within the past 5 years\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy\n",
      "        No concurrent immunotherapy Chemotherapy: No prior chemotherapy No concurrent chemotherapy\n",
      "        Endocrine therapy: At least 3 weeks since prior hormonal therapy No concurrent hormonal\n",
      "        therapy Radiotherapy: No prior chest radiotherapy At least 3 weeks since other prior\n",
      "        radiotherapy No concurrent radiotherapy Surgery: Prior pleurodesis or chest surgery on the\n",
      "        same side of the effusion is allowed as long as there is a free flowing pleural effusion\n",
      "        without loculation At least 2 weeks since major surgery other than biopsy Other: At least\n",
      "        3 weeks since use of any other investigational medication No concurrent use of any other\n",
      "        investigational medications\n",
      "3242\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically confirmed epithelial breast cancer\n",
      "          -  At least 3 cutaneous or subcutaneous lesions required\n",
      "          -  Measurable disease that includes, but is not limited to, cutaneous or subcutaneous\n",
      "             metastases\n",
      "        PATIENT CHARACTERISTICS:\n",
      "          -  Age: Over 18\n",
      "          -  Performance status: ECOG 0-2\n",
      "          -  Absolute granulocyte count at least 1,500/mm3\n",
      "          -  Hemoglobin greater than 8 g/dL\n",
      "          -  Platelet count greater than 100,000/mm3\n",
      "          -  Bilirubin less than 2 mg/dL\n",
      "          -  PT/PTT within normal range\n",
      "          -  SGOT/SGPT less than 2 times upper limit of normal\n",
      "          -  Creatinine less than 1.8 mg/dL\n",
      "          -  Not pregnant\n",
      "          -  Fertile patients must use effective contraception during and for 3 months after\n",
      "             therapy\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "          -  Concurrent cytotoxic chemotherapy allowed, if stable and responding\n",
      "          -  At least 4 weeks since prior chemotherapy, if starting a new regimen\n",
      "          -  At least 4 weeks since radiotherapy\n",
      "          -  Prior adjuvant radiotherapy to the chest wall allowed\n",
      "          -  At least 6 months since radiotherapy to lesions that are to be injected\n",
      "          -  Recovered from prior therapy\n",
      "3243\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced or\n",
      "        metastatic solid tumors refractory to standard therapy or for which no standard therapy\n",
      "        exists (surgery, radiotherapy, and/or chemotherapy) Measurable or evaluable disease by\n",
      "        medical photograph, plain x-ray, CT, MRI, palpation, or serum tumor markers at least 2\n",
      "        times upper limit of normal No symptomatic, progressive brain metastases by CT or MRI scan\n",
      "        No cerebral edema No leukemia or multiple myeloma\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hemoglobin at least 9.0 g/dL No coagulation disorders Hepatic:\n",
      "        Bilirubin normal AST and ALT no greater than 3 times upper limit of normal (ULN) (no\n",
      "        greater than 5 times ULN if liver involvement) PT or INR, and PTT normal Renal: Creatinine\n",
      "        no greater than 1.5 mg/dL Cardiovascular: No cardiac conduction abnormalities Other: Not\n",
      "        pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No active or uncontrolled infection No other concurrent severe disease No\n",
      "        known hypersensitivity to SR-45023A analogs No concurrent or recent (within past 6 months)\n",
      "        small bowel obstruction, symptoms of small bowel obstruction, or any other\n",
      "        gastrointestinal disease impacting absorption of study drug No psychiatric disorders or\n",
      "        geographic distance that would prevent compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: See\n",
      "        Disease Characteristics At least 4 weeks since prior chemotherapy (6 weeks since\n",
      "        carboplatin, mitomycin, or nitrosoureas) and recovered No prior SR-45023A No other\n",
      "        concurrent chemotherapy Endocrine therapy: No concurrent steroid therapy for brain disease\n",
      "        No concurrent hormonal cancer therapy (except contraception, hormone replacement therapy,\n",
      "        or corticosteroids) Radiotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        radiotherapy and recovered No concurrent radiotherapy (except symptomatic radiotherapy for\n",
      "        pathologic fractures) Surgery: At least 4 weeks since prior surgery and recovered Other:\n",
      "        At least 4 weeks since prior investigational agents No other concurrent investigational\n",
      "        agents No concurrent anticoagulation therapy (e.g., heparin) except low dose warfarin for\n",
      "        central venous catheter patency No concurrent digoxin, beta blockers, or calcium channel\n",
      "        blockers No concurrent H2 histamine inhibitors (e.g., ranitidine, famotidine, or\n",
      "        cimetidine), proton pump inhibitors (e.g., omeprazole or lansoprazole), or other drugs\n",
      "        that might interfere with study drug absorption\n",
      "3244\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent, metastatic, or unresectable\n",
      "        ovarian, tubal, or peritoneal carcinoma that is refractory to platinum, taxane, and\n",
      "        topotecan Must have received at least 1 prior chemotherapy regimen Resistance to platinum,\n",
      "        taxane, and topotecan is defined as the following: Progressive disease while on\n",
      "        chemotherapy OR Relapse within six months of completing chemotherapy OR Failure to achieve\n",
      "        complete response after six courses of chemotherapy No recurrent or metastatic disease\n",
      "        amenable to attempted curative therapy with surgery and/or radiotherapy Measurable disease\n",
      "        No brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At\n",
      "        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count\n",
      "        at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT or SGPT no greater\n",
      "        than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present) Renal:\n",
      "        Creatinine no greater than 1.5 mg/dL Cardiovascular: No active congestive heart failure No\n",
      "        uncontrolled angina No myocardial infarction within past 6 months Other: Not pregnant or\n",
      "        nursing Negative pregnancy test Fertile patients must use effective contraception No\n",
      "        concurrent serious infection No psychiatric disorder or mental disability No other\n",
      "        malignancy within past 5 years, except: Nonmelanomatous skin cancer Carcinoma in situ of\n",
      "        the cervix No other life threatening illness No history of camptothecin derivative allergy\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        See Disease Characteristics At least 4 weeks since prior chemotherapy (6 weeks for\n",
      "        nitrosoureas or mitomycin) No other concurrent chemotherapy Endocrine therapy: Not\n",
      "        specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4\n",
      "        weeks since prior surgery No concurrent surgery Other: At least 4 weeks since other prior\n",
      "        investigational drugs No other concurrent investigational drugs and for 4 weeks after\n",
      "        study treatment\n",
      "3245\n",
      "DISEASE CHARACTERISTICS:\n",
      "          -  Histologically proven high grade glioma that is progressive or recurrent following\n",
      "             radiotherapy or chemotherapy\n",
      "               -  Anaplastic astrocytoma\n",
      "               -  Anaplastic oligodendroglioma\n",
      "               -  Glioblastoma multiforme\n",
      "          -  Prior low grade glioma that has progressed to high grade glioma following\n",
      "             radiotherapy and/or chemotherapy allowed\n",
      "          -  Measurable disease by MRI or CT scan\n",
      "        PATIENT CHARACTERISTICS:\n",
      "        Age:\n",
      "          -  18 and over\n",
      "        Performance status:\n",
      "          -  Karnofsky 60-100%\n",
      "        Life expectancy:\n",
      "          -  Not specified\n",
      "        Hematopoietic:\n",
      "          -  Absolute neutrophil count at least 1,500/mm^3\n",
      "          -  Platelet count at least 100,000/mm^3\n",
      "        Hepatic:\n",
      "          -  Bilirubin normal\n",
      "          -  SGOT or SGPT no greater than 2.5 times upper limit of normal\n",
      "        Renal:\n",
      "          -  Creatinine no greater than 1.5 mg/dL OR\n",
      "          -  Creatinine clearance greater than 60 mL/min\n",
      "        Cardiovascular:\n",
      "          -  No myocardial infarction, stroke, or congestive heart failure within the past 3\n",
      "             months\n",
      "        Other:\n",
      "          -  Not pregnant or nursing\n",
      "          -  Negative pregnancy test\n",
      "          -  Fertile patients must use effective contraception during and for 1 month after study\n",
      "          -  No serious active infection or medical illness that would preclude compliance\n",
      "          -  HIV negative\n",
      "          -  No history of gastrointestinal disorders that would interfere with absorption of\n",
      "             study drug\n",
      "          -  No other malignancy within the past 5 years except curatively treated carcinoma in\n",
      "             situ of the cervix or breast, or basal cell or squamous cell skin cancer\n",
      "          -  No hypersensitivity to tetracyclines or its derivatives\n",
      "        PRIOR CONCURRENT THERAPY:\n",
      "        Biologic therapy:\n",
      "          -  No concurrent filgrastim (G-CSF)\n",
      "        Chemotherapy:\n",
      "          -  At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas) and\n",
      "             recovered\n",
      "          -  No more than 2 prior chemotherapy regimens\n",
      "        Endocrine therapy:\n",
      "          -  Not specified\n",
      "        Radiotherapy:\n",
      "          -  No prior large field radiotherapy (greater than 20% of total bone marrow)\n",
      "          -  At least 3 months since other prior radiotherapy and recovered\n",
      "        Surgery:\n",
      "          -  No prior major upper gastrointestinal surgery\n",
      "          -  At least 14 days since other prior major surgery\n",
      "        Other:\n",
      "          -  No other concurrent investigational agents\n",
      "          -  No prolonged sun exposure\n",
      "3246\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed colorectal cancer metastatic to the\n",
      "        liver No preoperative or intraoperative evidence of extrahepatic metastasis including\n",
      "        clinical, radiographic, gross or microscopic evidence Tumors must be no more than 4 cm in\n",
      "        diameter No more than 6 total tumors May have failed prior systemic chemotherapy Failure\n",
      "        of 1 prior intra-arterial regimen excluding floxuridine, fluorouracil, or another\n",
      "        fluoropyrimidine allowed if liver enzymes recovered No evidence of cirrhosis No gross\n",
      "        ascites\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy:\n",
      "        At least 16 weeks Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at\n",
      "        least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no\n",
      "        greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No active\n",
      "        duodenal or gastric ulcers Not pregnant or nursing Negative pregnancy test Fertile\n",
      "        patients must use effective contraception\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n",
      "        Characteristics At least 4 weeks since prior chemotherapy (6-8 weeks since nitrosoureas or\n",
      "        mitomycin) Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior\n",
      "        radiotherapy No prior radiotherapy to the liver Surgery: Not specified\n",
      "3247\n",
      "DISEASE CHARACTERISTICS: One of the following hematologic malignancies: Advanced\n",
      "        myelodysplastic syndromes Refractory anemia with excess blasts Refractory anemia with\n",
      "        excess blasts in transformation Chronic myelomonocytic leukemia Refractory acute myeloid\n",
      "        leukemia (AML) First salvage with primary refractory AML or first complete response (CR)\n",
      "        no greater than 12 months in duration or at least second salvage therapy Once maximum\n",
      "        tolerated dose is determined, intermediate AML prognosis (first CR duration greater than\n",
      "        12 months but less than 24 months) eligible Refractory acute lymphocytic leukemia\n",
      "        Refractory or transformed chronic lymphocytic leukemia Chronic myelogenous leukemia in\n",
      "        blastic phase No CNS disease\n",
      "        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:\n",
      "        Not specified Hematopoietic: No specified Hepatic: Bilirubin no greater than 2.0 mg/dL\n",
      "        SGOT or SGPT no greater than 2.0 times upper limit of normal Renal: Creatinine no greater\n",
      "        than 2.0 mg/dL Cardiovascular: No active congestive heart failure No uncontrolled angina\n",
      "        No myocardial infarction within the past 6 months Other: Not pregnant or nursing Fertile\n",
      "        patients must use effective contraception Negative pregnancy test No concurrent grade 4\n",
      "        infection No psychiatric disorder or mental disability No other life threatening illness\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:\n",
      "        At least 30 days since prior cytotoxic therapy and recovered No concurrent chemotherapy\n",
      "        Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy to greater than\n",
      "        25% of skeleton Surgery: No concurrent surgery Other: At least 3 weeks since prior\n",
      "        investigational drugs (including analgesics or antiemetics) Recovered from toxic effects\n",
      "        of any prior therapy\n",
      "3248\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically proven medullary thyroid\n",
      "        carcinoma Unresectable local-regional disease OR Distant metastases Autologous peripheral\n",
      "        blood stem cells (PBSC) or bone marrow available Diffuse bone/marrow involvement allowed\n",
      "        if: Autologous bone marrow or PBSC with no greater than 5% tumor involvement available\n",
      "        Radiation dose to marrow no greater than 3000 cGy until 6 patients have been treated\n",
      "        safely at that dose level At least 1 site confirmed by CT targeted by pretherapy indium In\n",
      "        111 monoclonal antibody MN-14 imaging\n",
      "        PATIENT CHARACTERISTICS: Age: 16 to 80 Performance status: Karnofsky 60-100% ECOG 0-2 Life\n",
      "        expectancy: At least 3 months Hematopoietic: WBC at least 3000/mm3 Granulocyte count at\n",
      "        least 1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2\n",
      "        mg/dL Renal: Creatinine less than 1.5 times upper limit of normal Cardiovascular: Ejection\n",
      "        fraction at least 50% Other: No severe anorexia, nausea, or vomiting No concurrent\n",
      "        significant medical complications that would preclude compliance Not pregnant Fertile\n",
      "        patients must use effective contraception during and for 3 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since biologic therapy\n",
      "        Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No greater than 240\n",
      "        mg/m2 doxorubicin total for combination therapy with doxorubicin but no greater than 550\n",
      "        mg/m2 doxorubicin if radioimmunotherapy alone No prior failure on doxorubicin therapy for\n",
      "        combination therapy but not radioimmunotherapy alone Endocrine therapy: Prior synthroid\n",
      "        (T4) allowed Radiotherapy: See Disease Characteristics At least 4 weeks since prior\n",
      "        radiotherapy to index lesion and recovered No prior radiotherapy to greater than 35% of\n",
      "        red marrow Surgery: At least 4 weeks since prior major surgery\n",
      "3249\n",
      "Inclusion Criteria:\n",
      "          -  Histologically documented malignancy, which is either metastatic or inoperable, for\n",
      "             which there is no known curative or standard palliative therapy, or all standard\n",
      "             therapeutic approaches have failed\n",
      "          -  Patients with leukemia or primary CNS malignancies are excluded; patients with\n",
      "             metastatic disease to the CNS, who are not receiving anticonvulsants, including\n",
      "             phenytoin, carbamazepine, phenobarbital, primidone, and felbamate, and who have\n",
      "             reasonable expectation of surviving long enough to receive two cycles of therapy, are\n",
      "             eligible\n",
      "          -  Life expectancy of 2 months or longer\n",
      "          -  ECOG performance status of 0-2\n",
      "          -  Pretreatment laboratory data, obtained within 14 days of study entry, must meet the\n",
      "             following criteria:\n",
      "          -  ANC >= 1,500 /mm^3\n",
      "          -  Platelets >= 100,000 /mm^3\n",
      "          -  SGOT =< 2.5-times upper limit of normal\n",
      "          -  SGPT =< 2.5-times upper limit of normal\n",
      "          -  Total bilirubin =< upper limit of normal\n",
      "          -  Creatinine =< 1.5 mg/dl\n",
      "          -  Creatinine CL >= 60 ml/min (measured 24hr) if creatinine > 1.5 mg/dl\n",
      "          -  DLCO >= 80% predicted\n",
      "          -  At least 4 weeks since last receiving radiotherapy or chemotherapy and complete\n",
      "             recovery from previous treatment related toxicity\n",
      "          -  No prior treatment with a nitrosourea or with bleomycin\n",
      "          -  No enzyme inducing anticonvulsant agents\n",
      "          -  At least 2 weeks since major surgery\n",
      "          -  Patients must not have uncontrolled serious medical or psychiatric illness\n",
      "          -  Women of childbearing potential must not be lactating or pregnant, because of the\n",
      "             proven teratogenicity of other agents of this class; a negative pregnancy test has to\n",
      "             be obtained within 2 weeks of entry; both fertile males and females must use adequate\n",
      "             contraception upon entry into the study\n",
      "          -  Patients must have given signed informed consent\n",
      "3250\n",
      "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent or refractory\n",
      "        B-cell malignancy that has failed at least one standard therapy Stage II to IV\n",
      "        non-Hodgkin's lymphoma B-cell chronic lymphocytic leukemia, hairy cell leukemia, or\n",
      "        Waldenstrom's macroglobulinemia allowed if: Autologous bone marrow or peripheral blood\n",
      "        stem cells (PBSC) with no greater than 5% tumor involvement available Estimated radiation\n",
      "        dose to marrow no greater than 3,000 cGy (bone marrow involvement of greater than 25% is\n",
      "        allowed provided stem cell contamination and predicted marrow radiation doses are below\n",
      "        the above cited cut off values) At least 1 confirmed site of tumor targeted by pretherapy\n",
      "        indium In 111 humanized LL2 Autologous peripheral blood stem cells (PBSC) or bone marrow\n",
      "        available No active brain metastases\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 70-100%\n",
      "        Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Granulocyte count\n",
      "        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2\n",
      "        mg/dL Renal: Creatinine less than 1.5 times upper limit of normal Cardiovascular: Cardiac\n",
      "        ejection fraction greater than 50% Pulmonary: DLCO greater than 60% predicted Forced vital\n",
      "        capacity greater than 60% predicted Other: No severe anorexia, nausea, or vomiting HIV\n",
      "        negative No prisoners No concurrent significant medical complication that would preclude\n",
      "        study compliance Not pregnant Negative pregnancy test Fertile patients must use effective\n",
      "        contraception during and for 3 months after study\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior low dose radioimmunotherapy allowed\n",
      "        Chemotherapy: No prior high dose chemotherapy with PBSC rescue At least 4 weeks since\n",
      "        prior chemotherapy and recovered Endocrine therapy: At least 2 weeks since prior\n",
      "        corticosteroids and recovered Radiotherapy: Prior low dose radioimmunotherapy allowed\n",
      "        Prior radiotherapy to less than 35% of red marrow allowed At least 4 weeks since prior\n",
      "        radiotherapy to index lesion Surgery: At least 4 weeks since major surgery\n",
      "3251\n",
      "DISEASE CHARACTERISTICS: Histologically proven metastatic, refractory solid tumors for\n",
      "        which no curative therapy exists No more than 2 prior chemotherapy regimens for metastatic\n",
      "        disease No prior high dose chemotherapy regimen requiring bone marrow transplantation or\n",
      "        peripheral blood stem cell transplantation No hematologic malignancies No brain or\n",
      "        leptomeningeal disease\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life\n",
      "        expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 2,000/mm3\n",
      "        Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal (no greater than 1.5 times\n",
      "        upper limit of normal (ULN) if liver metastases present) SGOT and SGPT normal (no greater\n",
      "        than 5 times ULN if liver metastases present) Hepatitis B negative Renal: Creatinine less\n",
      "        than 1.5 mg/dL EDTA clearance greater than 60 mL/min Other: Not pregnant or nursing\n",
      "        Fertile patients must use effective contraception during and for 6 months after study No\n",
      "        severe concurrent nonmalignant disease that would preclude protocol therapy HIV negative\n",
      "        No AIDS related illness No mental incapacity\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks\n",
      "        since prior immunotherapy and recovered No concurrent biological response modifier therapy\n",
      "        or immunotherapy No concurrent prophylactic growth factors Chemotherapy: See Disease\n",
      "        Characteristics No prior camptothecins (e.g., irinotecan or topotecan) At least 4 weeks\n",
      "        since other prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered No\n",
      "        other concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal\n",
      "        therapy and recovered No concurrent corticosteroids used as anticancer therapy No other\n",
      "        concurrent hormonal therapy Radiotherapy: No prior radiotherapy to greater than 25% of\n",
      "        bone marrow At least 4 weeks since other prior radiotherapy and recovered No concurrent\n",
      "        radiotherapy Surgery: Not specified Other: No concurrent investigational drug or\n",
      "        participation in other clinical study\n",
      "3253\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed, aggressive (stage\n",
      "        II-IV) B-cell non-Hodgkin's lymphoma, including but not limited to: Mantle cell Diffuse\n",
      "        large cell Diffuse mixed cell Anaplastic large cell (B-cell type) Diffuse small cleaved\n",
      "        cell Marginal zone lymphoma No prior T-cell lymphoma CD20 positive\n",
      "        PATIENT CHARACTERISTICS: Age: 19 and over Performance status: WHO 0-2 Karnofsky 70-100%\n",
      "        Life expectancy: At least 6 months Hematopoietic: Absolute neutrophil count greater than\n",
      "        1,000/mm3 (unless due to non-Hodgkin's lymphoma (NHL) bone marrow involvement) Hepatic:\n",
      "        Unless due to NHL: Bilirubin less than 3.0 mg/dL Alkaline phosphatase less than 3 times\n",
      "        upper limit of normal (ULN) SGOT less than 3 times ULN Renal: Not specified Other: Not\n",
      "        pregnant or nursing Fertile patients must use effective contraception HIV negative No\n",
      "        other serious disease or medical condition that would interfere with compliance\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No other\n",
      "        concurrent chemotherapy Endocrine therapy: No concurrent corticosteroids (unless for\n",
      "        prevention of nausea or vomiting) Nonsteroidal hormones for nonlymphoma related conditions\n",
      "        allowed (e.g., insulin for diabetes) Radiotherapy: No concurrent radiotherapy Surgery: Not\n",
      "        specified Other: No other concurrent investigational agents\n",
      "3254\n",
      "DISEASE CHARACTERISTICS: Histologically confirmed recurrent malignant glioma, including:\n",
      "        Glioblastoma Gliosarcoma High grade glioma Anaplastic astrocytoma Anaplastic mixed\n",
      "        oligoastrocytoma Anaplastic oligodendroglioma Must have evidence of tumor recurrence or\n",
      "        progression on gadolinium enhanced MRI or CT scan following radiotherapy with or without\n",
      "        chemotherapy\n",
      "        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life\n",
      "        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n",
      "        Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less\n",
      "        than 1.5 times upper limit of normal (ULN) SGOT and SGPT less than 3 times ULN Alkaline\n",
      "        phosphatase less than 2 times ULN Renal: Creatinine less than 1.5 times ULN BUN less than\n",
      "        1.5 times ULN Other: No nonmalignant systemic disease that would cause patient to be a\n",
      "        poor medical risk No acute infection requiring intravenous antibiotics No psychological\n",
      "        disorder that would interfere with study compliance HIV negative No AIDS-related illness\n",
      "        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective\n",
      "        contraception No frequent vomiting or medical condition that would interfere with oral\n",
      "        medication intake (e.g., partial bowel obstruction) No prior or concurrent malignancy,\n",
      "        except: Surgically cured carcinoma in situ of the cervix Basal or squamous cell skin\n",
      "        cancer\n",
      "        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy At\n",
      "        least 4 weeks since prior biologic therapy Chemotherapy: See Disease Characteristics At\n",
      "        least 4 weeks since prior chemotherapy No prior temozolomide or dacarbazine Endocrine\n",
      "        therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since\n",
      "        prior external beam radiotherapy At least 8 weeks since prior stereotactic radiosurgery\n",
      "        Surgery: At least 2 weeks since prior brain biopsy, craniotomy, or other surgery"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "IOPub data rate exceeded.\n",
      "The notebook server will temporarily stop sending output\n",
      "to the client in order to avoid crashing it.\n",
      "To change this limit, set the config variable\n",
      "`--NotebookApp.iopub_data_rate_limit`.\n",
      "\n",
      "Current values:\n",
      "NotebookApp.iopub_data_rate_limit=1000000.0 (bytes/sec)\n",
      "NotebookApp.rate_limit_window=3.0 (secs)\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for i,row in df.iterrows():\n",
    "    if i > 20:\n",
    "        if row['ic_mentions_female'] == 1:\n",
    "            print(i)\n",
    "            print(row['inclusion'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "health_nlp_py35",
   "language": "python",
   "name": "health_nlp_py35"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
